<SEC-DOCUMENT>0001047469-15-005184.txt : 20150603
<SEC-HEADER>0001047469-15-005184.hdr.sgml : 20150603
<ACCEPTANCE-DATETIME>20150602203555
ACCESSION NUMBER:		0001047469-15-005184
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20150603
DATE AS OF CHANGE:		20150602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-204144
		FILM NUMBER:		15908566

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>a2224803zs-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg15201_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fa15201_index_to_financial_statements">  INDEX TO FINANCIAL STATEMENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>As Filed with the Securities and Exchange Commission on June&nbsp;2, 2015

  </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B>


Registration No.&nbsp;333-204144


 </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>


Amendment No.1<BR>
to<BR>  </B></FONT><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 26-3687168</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>One Kendall Square<BR>
Bldg. 1400E, Suite B14202<BR>
Cambridge, Massachusetts 02139<BR>
(617)&nbsp;349-1971</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Jill C. Milne, Ph.D.<BR>
President and Chief Executive Officer<BR>
Catabasis Pharmaceuticals,&nbsp;Inc.<BR>
One Kendall Square<BR>
Bldg. 1400E, Suite B14202<BR>
Cambridge, Massachusetts 02139<BR>
(617)&nbsp;349-1971</B></FONT><FONT SIZE=1><BR>
(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="46%" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Steven D. Singer, Esq.<BR>
Rosemary G. Reilly, Esq.<BR>
Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP<BR>
60 State Street<BR>
Boston, MA 02109<BR>
Telephone: (617)&nbsp;526-6000<BR>
Fax: (627)&nbsp;526-5000</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Divakar Gupta<BR>
Darren DeStefano<BR>
Brent B. Siler<BR>
Cooley&nbsp;LLP<BR>
1114 Avenue of the Americas<BR>
New York, NY 10036-7798<BR>
Telephone: (212)&nbsp;479-6000<BR>
Fax: (212)&nbsp;479-6275</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after this Registration Statement is declared effective.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="116pt" style="font-family:times;"></TD>
<TD WIDTH="8%" style="font-family:times;"></TD>
<TD WIDTH="89pt" style="font-family:times;"></TD>
<TD WIDTH="8%" style="font-family:times;"></TD>
<TD WIDTH="126pt" style="font-family:times;"></TD>
<TD WIDTH="8%" style="font-family:times;"></TD>
<TD WIDTH="136pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Smaller reporting company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or
until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=422869,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]BA15201A.;32',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=6>


<!-- COMMAND=ADD_TXTHEX,"" -->


</FONT><FONT COLOR="#FF4040" SIZE=2>The information in this preliminary prospectus is not complete and may be changed. We may not
sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is
not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">

<FONT SIZE=2><B>









<!-- COMMAND=ADD_TXTHEX,"" -->


 </B></FONT><FONT COLOR="#FF4040" SIZE=2><B>SUBJECT TO COMPLETION, DATED JUNE&nbsp;2, 2015</B></FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="157pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g664220.jpg" ALT="LOGO" WIDTH="243" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=6><B>Catabasis Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Common Stock<BR>
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is the initial public offering of our common stock. We are selling&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering. We
currently
expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted the underwriters an option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock to cover over-allotments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have applied to list our common stock on The NASDAQ Global Market under the symbol "CATB." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our common stock involves risks. See "Risk Factors" beginning on page&nbsp;10.  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company" under applicable Securities and Exchange Commission rules and will be eligible for reduced public company
disclosure requirements. See "Summary&#151;Implications of Being an Emerging Growth Company." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this
prospects. Any representation to the contrary is a criminal offense. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Public Offering Price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Underwriting Discount(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Proceeds to Catabasis Pharmaceuticals,&nbsp;Inc. (before expenses)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
refer you to "Underwriting" beginning on page 164 for additional information regarding underwriter compensation.

 </FONT></DD></DL>


 </DIV>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters expect to deliver the shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 through the book-entry facilities of The Depository Trust Company. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<P style="font-family:times;"><FONT SIZE=4><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="38%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=4><B>Citigroup</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4><B> Cowen and Company</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=4><B> Oppenheimer&nbsp;&amp;&nbsp;Co.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4><B><BR>&nbsp;</B></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=4><B> Wedbush&nbsp;PacGrow</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=left style="font-family:times;"><font> </FONT> <FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=270590,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]BC15201A.;47',USER='LPALLES',CD=';2-JUN-2015;10:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG15201A_main_toc"></A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>We are responsible for the information contained in this prospectus. We have not authorized anyone to provide you with different
information, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and
the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus
is accurate as of any date other than the date on the front of this prospectus.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg15201_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG15201_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca15201_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Summary</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca15201_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg15201_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg15201_risk_factors"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#co15201_special_note_regarding_forward__spe02700"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements and Industry
Data</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#co15201_special_note_regarding_forward__spe02700"><FONT SIZE=2>51</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#co15201_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#co15201_use_of_proceeds"><FONT SIZE=2>53</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#co15201_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#co15201_dividend_policy"><FONT SIZE=2>54</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#co15201_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#co15201_capitalization"><FONT SIZE=2>55</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cq15201_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cq15201_dilution"><FONT SIZE=2>57</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cs15201_selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cs15201_selected_financial_data"><FONT SIZE=2>60</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cy15201_management_s_discussion_and_an__man03466"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cy15201_management_s_discussion_and_an__man03466"><FONT SIZE=2>61</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc15201_business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc15201_business"><FONT SIZE=2>77</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dm15201_management"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dm15201_management"><FONT SIZE=2>126</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#do15201_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#do15201_executive_compensation"><FONT SIZE=2>133</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq15201_transactions_with_related_persons"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transactions with Related Persons</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq15201_transactions_with_related_persons"><FONT SIZE=2>145</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq15201_principal_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq15201_principal_stockholders"><FONT SIZE=2>148</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds15201_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds15201_description_of_capital_stock"><FONT SIZE=2>152</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds15201_shares_eligible_for_future_sale"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds15201_shares_eligible_for_future_sale"><FONT SIZE=2>157</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#aa1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income and Estate Tax Considerations for Non-U.S. Holders of Common Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#aa1"><FONT SIZE=2>160</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dw15201_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dw15201_underwriting"><FONT SIZE=2>164</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dw15201_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dw15201_legal_matters"><FONT SIZE=2>171</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dw15201_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dw15201_experts"><FONT SIZE=2>171</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dw15201_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dw15201_where_you_can_find_more_information"><FONT SIZE=2>171</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#fa15201_index_to_financial_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#fa15201_index_to_financial_statements"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=132317,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]BG15201A.;27',USER='CHE108069',CD=';2-JUN-2015;03:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca15201_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca15201_summary"> </A>
<A NAME="toc_ca15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights, and is qualified in its entirety by, the more detailed information and financial
statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire
prospectus, especially our financial statements and the notes thereto appearing at the end of this prospectus and the "Risk Factors" section of this prospectus, before deciding to invest in our common
stock.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to "Catabasis," "the company," "we," "us" and "our" refer
to Catabasis Pharmaceuticals,&nbsp;Inc.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_overview"> </A>
<A NAME="toc_ca15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by
simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each
with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Our initial
focus is on treatments for rare diseases. We are also developing other product candidates for the treatment of serious lipid disorders. We target therapeutic areas and specific diseases with
significant unmet medical need where we believe we will have a competitive advantage. We seek to develop therapies that modulate multiple targets in the disease pathway. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_our_product_candidates"> </A>
<A NAME="toc_ca15201_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Candidates    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied our SMART linker technology platform to build a development pipeline that includes three clinical-stage product
candidates and multiple programs in preclinical development. The following chart summarizes key information regarding our product candidates. We hold worldwide rights to all of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g589761.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="330">
  </B></FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=191506,FOLIO='1',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<A NAME="page_ca15201_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004 is an oral small molecule that we believe has the potential to be a disease-modifying therapy for the treatment of Duchenne
muscular dystrophy, or DMD, that may be able to regenerate muscle in boys regardless of the underlying dystrophin mutation. DMD is an ultimately fatal genetic disorder involving progressive muscle
degeneration. CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid, or DHA, a naturally occurring unsaturated
fatty acid with anti-inflammatory properties. We designed CAT-1004 to enhance the activity of salicylate and DHA in modulating the NF-<FONT FACE="SYMBOL">k</FONT>B pathway at multiple
points. NF-<FONT FACE="SYMBOL">k</FONT>B, or nuclear factor kappa-light-chain-enhancer of activated B cells, is a protein that coordinates cellular response to damage, stress and
inflammation and plays an important role in muscle health. We believe that CAT-1004 modulates the disease pathway in DMD by inhibiting activated NF-<FONT FACE="SYMBOL">k</FONT>B and
reducing the movement of activated NF-<FONT FACE="SYMBOL">k</FONT>B to the nucleus of the cell. Activated NF-<FONT FACE="SYMBOL">k</FONT>B drives muscle degeneration and
suppresses muscle regeneration. Chronic activation of NF-<FONT FACE="SYMBOL">k</FONT>B has been reported in multiple skeletal muscle disorders, including muscular dystrophies, atrophy and
inflammatory myopathies. In animal models of DMD, CAT-1004 inhibited activated NF-<FONT FACE="SYMBOL">k</FONT>B, reduced muscle inflammation and degeneration and increased muscle
regeneration. In Phase&nbsp;1 clinical trials in adults, CAT-1004 inhibited activated NF-<FONT FACE="SYMBOL">k</FONT>B and was well tolerated with no observed safety concerns. We plan to
initiate patient enrollment in a Phase&nbsp;1/2 clinical trial of CAT-1004 in boys with DMD in June 2015. Subject to patient enrollment, we expect to report top-line Phase&nbsp;2 data in late
2016. If the results from our Phase&nbsp;1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase&nbsp;3
pivotal clinical trial of CAT-1004 in 2017 and seek marketing approval based on this Phase 3 trial.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMD
is a rare pediatric disorder caused by various mutations in the dystrophin gene that result in a lack of functional dystrophin in muscle fibers, leading to inexorable muscle
weakness. DMD occurs almost exclusively in males, occurring in approximately 1 in 3,500 live male births. Based on this incidence rate, we estimate that DMD affects a total of approximately 15,000
patients in the United States and approximately 19,000 patients in the European Union. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no therapies approved for the treatment of DMD in the United States. Corticosteroid therapy is often prescribed to treat the inflammation underlying DMD and to delay loss of
ambulation. While corticosteroids have demonstrated efficacy in DMD patients, corticosteroids also can cause significant complications due to systemic toxicities, including growth suppression,
reduction in bone strength and compromise of the immune system. A number of companies are developing therapies to treat DMD in patients with specific mutations in the dystrophin gene. Based on the
prevalence of the specific mutations that the three most advanced of these product candidates are designed to address, these product candidates would be expected to be effective in an aggregate of
approximately 26% of DMD patients. We believe that DMD patients, including those treated with these dystrophin therapies, will continue to require treatments to reduce muscle inflammation and enhance
muscle regeneration. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on its mechanism of action in suppressing activated NF-<FONT FACE="SYMBOL">k</FONT>B, we believe that CAT-1004 has the potential to combine reduction of inflammation and
muscle degeneration with positive effects on muscle regeneration, all of which may allow patients to retain muscle function longer. In addition, we believe that CAT-1004 has the potential to be
effective in all DMD patients, regardless of the underlying mutation, and provide significant benefit to patients both as monotherapy and when used in combination with other therapies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2000 Series  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our two other clinical-stage product candidates, CAT-2054 and CAT-2003, are members of our CAT-2000 series of molecules. We applied our
SMART linker technology to engineer these molecules as SMART linker conjugates of the omega-3 fatty acid eicosapentaenoic acid, or EPA, and nicotinic </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=905432,FOLIO='2',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<A NAME="page_ca15201_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:times;"><FONT SIZE=2>acid
to modulate the Sterol Regulatory Element Binding Protein, or SREBP, pathway. EPA is a naturally occurring unsaturated fatty acid that has anti-inflammatory properties and beneficial effects on
triglycerides. Nicotinic acid, which is also known as vitamin B3, is a naturally occurring essential vitamin that has beneficial lipid effects at high doses. Because we used different SMART linkers
for CAT-2054 and CAT-2003, they possess different pharmacokinetic and biodistribution characteristics. CAT-2003, our first generation product candidate in the CAT-2000 series, is an orally
administered molecule that modulates the SREBP pathway predominately in the intestine. CAT-2054, our second generation product candidate in the CAT-2000 series, is an orally administered molecule that
modulates the SREBP pathway predominately in the liver. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP
is a master regulator of lipid metabolism, the processing of fats, triglycerides and cholesterol by the body, and controls the metabolism of both low density lipoprotein
cholesterol, or LDL-C, and triglycerides. We believe that the CAT-2000 product candidates modulate the disease pathway by inhibiting the maturation of the SREBP protein, thereby reducing its activity
and reducing the production of proteins involved in lipid metabolism. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have focused our initial development efforts for the CAT-2000 series on lipid disorders such as hypercholesterolemia and hypertriglyceridemia because these disorders have clear
short-term efficacy biomarkers, enabling us to rapidly and efficiently demonstrate proof of concept for our technology. In the CAT-2000 series, our development priority is CAT-2054 for the treatment
of hypercholesterolemia, or elevated LDL-C, given what we believe is an attractive potential commercial opportunity in hypercholesterolemia and other SREBP-related metabolic disorders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are initially developing CAT-2054 for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient. Hypercholesterolemia is a disease that increases
the risk of cardiovascular events. By modulating the SREBP pathway, CAT-2054 may inhibit production of important cholesterol metabolism proteins, such as proprotein convertase subtilisin
kexin&nbsp;9, or PCSK9; 3-hydroxy-3-methyl-glutaryl-CoA reductase, or HMG-CoA reductase; adenosine triphosphate citrate lyase, or ATP citrate lyase; as well as Niemann-Pick C1-like 1, or NPC1L1. In
a clinical trial of our first generation SREBP modulator CAT-2003, we observed statistically significant reductions in LDL-C, suggesting an impact of SREBP modulation on cholesterol metabolism.
Because the liver is the primary regulator of cholesterol metabolism, we specifically designed the SMART linker in CAT-2054 to deliver more of the intact conjugate to the liver than CAT-2003. We
believe that CAT-2054, if approved, has the potential to be the first therapy to simultaneously modulate cholesterol synthesis, clearance and absorption. In January 2015, we initiated a Phase&nbsp;1
clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. Preliminary data are available for the full range of doses tested in the single and multiple
ascending dose portions of the trial. If the final results of this
clinical trial are positive, we intend to initiate a Phase&nbsp;2a clinical trial in patients with hypercholesterolemia in the fourth quarter of 2015 and would expect to report Phase&nbsp;2a data
in mid-2016. If the results of the planned Phase&nbsp;2a clinical trial are positive, we intend to initiate a Phase&nbsp;2b clinical trial of CAT-2054 in the fourth quarter of 2016. We intend to
seek to commercialize CAT-2054 through one or more collaborations.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypercholesterolemia
is a major risk factor for cardiovascular disease, a leading cause of mortality and morbidity in the United States. Hypercholesterolemia is a complex disease
involving redundant biological pathways that are tightly regulated and have built-in feedback mechanisms. Current treatment guidelines recognize lowering of LDL-C as a primary target for reducing the
risk of cardiovascular disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
of the lipid-lowering therapies currently available or in development target proteins in the SREBP pathway to lower LDL-C. Despite the availability of these drugs, many patients
are unable to achieve their LDL-C goals. A 2011 report of the Centers for Disease Control and Prevention estimated that, of the 34&nbsp;million adults in the United States receiving treatment for
high LDL-C, 11&nbsp;million had </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=46939,FOLIO='3',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<A NAME="page_ca15201_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;"><FONT SIZE=2>uncontrolled
LDL-C. Directly reducing active SREBP may have a significant benefit on LDL-C levels in circulation. SREBP modulators may work synergistically with inhibitors of proteins that are
downstream of SREBP such as PCSK9, HMG-CoA reductase and ATP citrate lyase. In addition, SREBP modulators may substantially reduce feedback mechanisms that are activated by other classes of LDL-C
lowering drugs, such as statins and ezetimibe. We believe that CAT-2054, if approved, has the potential to be the first therapy to simultaneously modulate cholesterol synthesis, clearance and
absorption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003
is our first generation product candidate in the CAT-2000 series. We engineered CAT-2003 as an orally administered SMART linker conjugate of EPA and nicotinic acid to modulate
the SREBP pathway. We designed CAT-2003 to target triglyceride levels in the blood. We have studied CAT-2003 for the treatment of multifactorial chylomicronemia syndrome, or MFC, and refractory severe
hypertriglyceridemia, or rSHTG, diseases with niche patient populations with elevated triglycerides or
hypertriglyceridemia. We have completed three Phase&nbsp;2a trials with CAT-2003 in patient populations with hypertriglyceridemia. While we have chosen to prioritize CAT-2054 over CAT-2003, we
believe that the clinical trial data for CAT-2003 support the utility of our SMART linker technology and the potential to treat lipid and metabolic disorders by modulating the SREBP pathway. We intend
to pursue collaborations to conduct exploratory evaluation of CAT-2003 in other serious diseases that involve alterations in the SREBP pathway, such as nonalcoholic steatohepatitis and hepatocellular
carcinoma, either to develop CAT-2003 as a product candidate or to support our development efforts for CAT-2054. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-4001  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-4001, our most advanced preclinical product candidate, is a SMART linker conjugate of monomethyl fumarate and DHA. CAT-4001 is a
small molecule that activates the Nrf2 pathway and inhibits activated NF-<FONT FACE="SYMBOL">k</FONT>B. Nrf2, or Nuclear factor (erythroid-derived 2)-like 2, is a gene transcription factor,
a protein that works inside of cells to control the expression of genes, that controls the body's response to cellular stress and oxidative damage. We believe that CAT-4001 modulates the disease
pathway by enhancing the movement of Nrf2 to the nucleus of the cells and inhibits NF-<FONT FACE="SYMBOL">k</FONT>B by reducing the movement of activated
NF-<FONT FACE="SYMBOL">k</FONT>B to the nucleus of the cells. We are exploring CAT-4001 as a potential treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and
amyotrophic lateral sclerosis, or ALS, two diseases of the central nervous system in which the Nrf2 and NF-<FONT FACE="SYMBOL">k</FONT>B pathways have been implicated. We plan to conduct
additional preclinical evaluation of CAT-4001 in 2015, and if the results are positive we intend to advance CAT-4001 into investigational new drug application enabling studies in 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_smart_linker_technology_platform"> </A>
<A NAME="toc_ca15201_4"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


SMART Linker Technology Platform    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have developed our SMART linker technology platform to create molecules that simultaneously modulate multiple biological targets
within one or more related disease pathways. The linkers used in our technology platform are small chemicals designed to join two separate bioactives into a single conjugate molecule. In systemic
circulation, our SMART linker conjugates are stable and inactive, potentially reducing off-target toxicities and side-effects. The conjugates are designed to be cleaved by specific enzymes exclusively
within cells in order to release the two bioactives inside the cells. By releasing the bioactive components of the conjugate molecule only inside cells, the SMART linker allows the bioactives to reach
their targets more efficiently and have greater efficacy than if the bioactives were dosed independently or in combination. The stability of our SMART linker conjugates outside of cells and the
release of the bioactives exclusively within cells are differentiating features of our SMART linker technology platform. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=644464,FOLIO='4',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<A NAME="page_ca15201_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe our SMART linker technology platform has the potential to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> enhance activity on disease pathways through modulation of multiple biological targets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improve efficacy by matching the pharmacokinetics and tissue distribution of the component bioactives; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improve safety and tolerability by releasing the component bioactives only within cells. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_our_strategy"> </A>
<A NAME="toc_ca15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our objective is to apply our proprietary SMART linker technology platform to discover, develop and commercialize novel, bi-functional
therapeutics, with an initial focus on rare diseases and serious lipid disorders, either on our own or through collaborations. To achieve our goals, we are pursuing the following
strategies:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> complete the development of CAT-1004 through registration for DMD; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advance the development of CAT-2054; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advance the development of CAT-4001; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue to apply our SMART linker technology platform; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain flexibility in commercializing and maximizing the value of our development programs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_risks_associated_with_our_business"> </A>
<A NAME="toc_ca15201_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Associated with Our Business    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are
discussed more fully in the "Risk Factors" section of this prospectus immediately following this prospectus summary. These risks include the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have incurred significant losses since inception and expect to incur significant and increasing losses for at least the next
several years. We may never achieve or maintain profitability. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or
eliminate our product development programs or commercialization efforts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our approach to the discovery and development of product candidates based on our SMART linker technology platform is unproven, and we
do not know whether we will be able to develop any products of commercial value. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We are dependent on the successful development and commercialization of our most advanced product candidates. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our SMART linker technology platform may fail to help us discover and develop additional potential product candidates. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail
to compete effectively. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If we are unable to obtain and maintain sufficient patent protection for our product candidates, or if the scope of the patent
protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize our product candidates successfully may be
adversely affected. </FONT></DD></DL>
</UL>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1026379,FOLIO='5',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<A NAME="page_ca15201_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_our_corporate_information"> </A>
<A NAME="toc_ca15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Corporate Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated under the laws of the State of Delaware on June&nbsp;26, 2008 under the name Catabasis
Pharmaceuticals,&nbsp;Inc. Our executive offices are located at One Kendall Square, Bldg.&nbsp;1400E, Suite&nbsp;B14202, Cambridge, Massachusetts 02139, and our telephone number is
(617)&nbsp;349-1971. Our website address is www.catabasis.com. The information contained on, or that can be
accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ca15201_implications_of_being_an_emerging_growth_company"> </A>
<A NAME="toc_ca15201_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of Being an Emerging Growth Company    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a company with less than $1&nbsp;billion of revenue during our last fiscal year, we qualify as an "emerging growth company" as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we
are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. In particular, in
this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an
emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=299703,FOLIO='6',FILE='DISK122:[14ZDH1.14ZDH15201]CA15201A.;46',USER='LPALLES',CD=';2-JUN-2015;12:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc15201_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc15201_the_offering"> </A>
<A NAME="toc_cc15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding immediately following this offering</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Over-allotment option</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our
ongoing development of CAT-1004 and CAT-2054, as well as for working capital and other general corporate purposes. See the "Use of Proceeds" section in this prospectus for a more complete description of the intended use of proceeds from this
offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus for a discussion of factors to consider carefully before
deciding to invest in shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposed NASDAQ Global Market symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"CATB"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="15%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering is based on 6,659,760 shares of our common stock outstanding as of April&nbsp;30, 2015 and 116,030,239
additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 763,538 shares of our common stock issuable upon the exercise of warrants outstanding as of April&nbsp;30, 2015, at a
weighted-average exercise price of $0.47 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 19,002,857 shares of our common stock issuable upon the exercise of stock options outstanding as of April&nbsp;30, 2015, at a
weighted-average exercise price of $0.43 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 331,922 shares of our common stock available for future issuance as of April&nbsp;30, 2015 under our amended and restated 2008
equity incentive plan; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 13,727,495 and 2,343,236 additional shares of our common stock that will become available for future issuance in connection with this
offering under our 2015 stock incentive plan and our 2015 employee stock purchase plan, respectively.

</FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, all information in this prospectus assumes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise of the outstanding options or warrants described above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise by the underwriters of their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of our common stock to cover
over-allotments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 116,030,239 shares of our common stock
upon the closing of this offering; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the automatic conversion of warrants to purchase 315,688 shares of preferred stock into warrants to purchase 315,688 shares of common
stock upon the closing of this offering and the related reclassification of our warrant liability to stockholders' (deficit) equity; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the restatement of our certificate of incorporation and the amendment and restatement of our bylaws upon the closing of this offering. </FONT></DD></DL>
</UL>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=993122,FOLIO='7',FILE='DISK122:[14ZDH1.14ZDH15201]CC15201A.;39',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ce15201_1_8"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ce15201_summary_financial_information"> </A>
<A NAME="toc_ce15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following summary financial data together with our financial statements and the related
notes appearing at the end of this prospectus and the "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of this prospectus.
We have derived the statement of operations data for the years
ended December&nbsp;31, 2013 and 2014 and the balance sheet data as of December&nbsp;31, 2014 from our audited financial statements appearing at the end of this prospectus. The statement of
operations data for the three months ended March&nbsp;31, 2014 and 2015 and the balance sheet data as of March&nbsp;31, 2015 have been derived from our unaudited financial statements appearing at
the end of this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited financial data reflects all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of the financial information as of and for the periods presented. Our historical results are not necessarily indicative of
results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full
year.</I></FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share and per share data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,686</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,096</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,616</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,373</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(149</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:36pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,870,362</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,446,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,085,910</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,355,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108,413,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111,350,589</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;2 in the notes to our financial statements appearing at the end of this prospectus for a description of the method used to calculate basic and diluted net loss per share
and unaudited pro forma basic and diluted net loss per share. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=634929,FOLIO='8',FILE='DISK122:[14ZDH1.14ZDH15201]CE15201A.;43',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ce15201_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth summary balance sheet data as of March&nbsp;31, 2015:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into 116,030,239
shares of our common stock, and (ii) the conversion of our outstanding warrants to purchase 315,688 shares of preferred stock into warrants to purchase 315,688 shares of common stock, resulting in the
reclassification of our warrant liability to stockholders' (deficit) equity, upon the closing of this offering; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock in this
offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of March&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma<BR>
As Adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes payable, net of current portion and discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(81,880</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(81,880</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(79,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=207600,FOLIO='9',FILE='DISK122:[14ZDH1.14ZDH15201]CE15201A.;43',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cg15201_1_10"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cg15201_risk_factors"> </A>
<A NAME="toc_cg15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock,
you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end
of this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks actually occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose
all or part of your investment.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg15201_risks_related_to_our_financial__ris02844"> </A>
<A NAME="toc_cg15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Additional Capital    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred significant losses since inception and expect to incur significant and increasing
losses for at least the next several years. We may never achieve or maintain profitability.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred significant annual net operating losses in every year since our inception. We expect to continue to incur significant
and increasing operating losses for at least the next several years. Our net losses were $18.1&nbsp;million and $21.9&nbsp;million for the years ended December&nbsp;31, 2013 and 2014,
respectively, and $6.5&nbsp;million for the three months ended March&nbsp;31, 2015. As of March&nbsp;31, 2015, we had an accumulated deficit of $81.9&nbsp;million. We have not generated any
revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We have financed our operations to date
primarily through private placements of our preferred stock and a debt financing, and have devoted substantially all of our financial resources and efforts to research and development, including
preclinical studies and our clinical development programs. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will
continue to have, an adverse effect on our stockholders' (deficit) equity and working capital.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that our expenses will increase substantially if and as we:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continue to develop and conduct clinical trials with respect to our product candidates CAT-1004 and CAT-2054, including a planned
Phase&nbsp;1/2 clinical trial of CAT-1004 for which we plan to initiate patient enrollment in June 2015 and an ongoing Phase&nbsp;1 clinical trial of CAT-2054 that we initiated in January 2015; </FONT> <FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiate and continue research and preclinical and clinical development efforts for our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek to identify and develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which
we may obtain marketing approval, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the manufacture of larger quantities of product candidates for clinical development and potentially commercialization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain, expand and protect our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hire and retain additional personnel, such as clinical, quality control and scientific personnel; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including personnel to support our product development
and help us comply with our obligations as a public company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add equipment and physical infrastructure to support our research and development programs. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=974724,FOLIO='10',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future
collaborator is, able to obtain marketing approval for, and successfully commercialize, one or more of our product candidates. This will require our, or any of our future collaborators', success in a
range of challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those
products for which we, or any of our future collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance
or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of increased expenses, and if or when we might
achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators does, we may never generate revenues that are large enough
for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain
profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product
candidates or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a limited operating history and no history of commercializing pharmaceutical products, which
may make it difficult to evaluate the prospects for our future viability.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We began operations in 2008. Our operations to date have been limited to financing and staffing our company and developing our
technology and conducting preclinical research and early-stage clinical trials for our product candidates. We have not yet demonstrated an ability to successfully conduct pivotal clinical trials,
obtain marketing approvals, manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development,
especially clinical-stage biopharmaceutical companies such as ours. Predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a
history of successfully developing and commercializing pharmaceutical products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need substantial additional funding. If we are unable to raise capital when needed, we could
be forced to delay, reduce or eliminate our product development programs or commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive
and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new
research and preclinical development efforts for and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we may incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the
responsibility of a future collaborator. Furthermore, following the completion of this offering, we expect to incur significant additional costs associated with operating as a public company.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced
to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to use the net proceeds of this offering primarily to fund our ongoing research and development efforts. We will be required to expend significant funds in order to advance the
development of CAT-1004 and CAT-2054, as well as our other product candidates. In addition, while we may seek one or more collaborators for future development of our product candidates, and, in
particular, expect that we would conduct any large Phase&nbsp;3 clinical trial of CAT-2054 for the treatment </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=215246,FOLIO='11',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
hypercholesterolemia in collaboration with one or more partners that would pay most of the associated costs, we may not be able to enter into a collaboration for any of our product candidates on
suitable terms or at all. In any event, the net proceeds of this offering and our existing cash and cash equivalents will not be sufficient to fund all of the efforts that we plan to undertake or to
fund the completion of development of any of our product candidates. Accordingly, we will be required to obtain further funding through public or private equity offerings, debt financings,
collaborations and licensing arrangements or other sources. With the exception of our credit facility with MidCap Financial Trust, or MidCap, Flexpoint MCLS SPV LLC, or Flexpoint, and Square 1 Bank,
or Square 1, we do not have any committed external source of funds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adequate
additional financing may not be available to us on acceptable terms, or at all. Further, our ability to obtain additional debt financing may be limited by covenants we have made
under our loan and security agreement with MidCap, Flexpoint and Square 1, including our negative pledge with respect to intellectual property in favor of MidCap, Flexpoint and Square 1, as well as
our pledge to MidCap, Flexpoint and Square 1 of substantially all of our assets, other than our intellectual property,
as collateral. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of March&nbsp;31, 2015, will enable us to fund our operating expenses, debt
service and capital expenditure requirements at least through 2016. Our estimate as to how long we expect the net proceeds from this offering, together with our existing cash and cash equivalents, to
be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances,
some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future
funding requirements, both short-term and long-term, will depend on many factors, including:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, our product
candidates and potential product candidates, including current and future clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to identify a collaborator for CAT-2054 and the terms and timing of any collaboration agreement that we may establish for
the development and commercialization of CAT-2054; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to enter into and the terms and timing of any additional collaborations, licensing or other arrangements that we may
establish; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and characteristics of future product candidates that we pursue and their development requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the outcome, timing and costs of seeking regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs
are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to receipt of marketing approval, revenue, if any, received from commercial sales of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and
defending against intellectual property related claims; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of operating as a public company. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=498078,FOLIO='12',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The audit opinion on our financial statements contains a going concern explanatory paragraph.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on our cash balances, recurring losses, net capital deficiency and debt outstanding as of December&nbsp;31, 2014 and our
projected spending in 2015, which raise substantial doubt about our ability to continue as a going concern, the audit opinion on our audited financial
statements as of and for the year ended December&nbsp;31, 2014 contains a going concern explanatory paragraph. If we are unable to obtain sufficient capital in this offering, our business, financial
condition and results of operations will be materially and adversely affected and we will need to obtain alternative financing or significantly modify our operational plans to continue as a going
concern. If we are unable to continue as a going concern, we might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than
the values reflected in our financial statements. Additionally, amounts due under our credit facility may become immediately due and payable upon the occurrence of a material adverse change, as
defined under the loan agreement. Further, even if we successfully complete and receive the net proceeds from this offering, given our planned expenditures for the next several years, including,
without limitation, expenditures in connection with our clinical trials of CAT-1004 and CAT-2054, our independent registered public accounting firm may conclude, in connection with the audit of our
financial statements for fiscal year 2015 or any other subsequent period that there is substantial doubt regarding our ability to continue as a going concern. In addition, the inclusion of a going
concern explanatory paragraph by our auditors, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to
raise new capital or to enter into critical contractual relations with third parties. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our stockholders, including purchasers of common
stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent that we
raise additional capital through the sale of common stock, convertible securities or other equity securities, our existing stockholders' ownership interest may be substantially diluted, and the terms
of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. Additional debt financing, if
available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring
additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. For example, our debt facility
with MidCap, Flexpoint and Square 1 contains restrictive covenants that, among other things and subject to certain exceptions, prohibit us from transferring any of our material assets, exclusively
licensing our intellectual property (subject to certain exceptions), merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring
additional indebtedness, creating any lien on our property, making investments in third parties or redeeming stock or paying dividends. Future debt securities or other financing arrangements could
contain similar or more restrictive negative covenants. In addition, securing additional financing could require a substantial amount of time and attention from our management and may divert a
disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management's ability to oversee the development of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to
delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=153760,FOLIO='13',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our existing and any future indebtedness could adversely affect our ability to operate our business.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2015, we had $10.0&nbsp;million of outstanding borrowings under our credit facility with MidCap, Flexpoint and
Square&nbsp;1. We currently make monthly interest payments and, beginning in October 2015, will be required to repay principal and interest on these borrowings in monthly installments through
October 2018. Subject to the restrictions in this existing credit facility, we could in the future incur additional indebtedness beyond our borrowings from MidCap, Flexpoint and Square&nbsp;1.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
outstanding indebtedness, including any additional indebtedness beyond our borrowings from MidCap, Flexpoint and Square&nbsp;1, combined with our other financial obligations and
contractual commitments could have significant adverse consequences, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requiring us to dedicate a portion of our cash resources to the payment of interest and principal, reducing money available to fund
working capital, capital expenditures, product development and other general corporate purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increasing our vulnerability to adverse changes in general economic, industry and market conditions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity
financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to satisfy our current and future debt service obligations with our existing cash and cash equivalents. However, we may not have sufficient funds, and may be unable to arrange
for additional financing, to pay the amounts due under our existing debt instruments. Failure to make payments or comply with other covenants under our existing debt instruments could result in an
event of default and acceleration of amounts due. Under our loan and security agreement with MidCap, Flexpoint and Square 1, the occurrence of an event that would reasonably be expected to have a
material adverse effect on our business, operations, assets or condition is an event of default. If an event of default occurs and the lenders accelerate the amounts due, we may not be able to make
accelerated payments, and the lenders could seek to enforce security interests in the collateral securing such indebtedness, which includes substantially all of our assets other than our intellectual
property. In addition, the covenants under our credit facility, the pledge of our assets as collateral and the negative pledge with respect to our intellectual property could limit our ability to
obtain additional debt financing.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg15201_risks_related_to_the_discovery__ris03675"> </A>
<A NAME="toc_cg15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the Discovery, Development and Commercialization of Our Product Candidates    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our approach to the discovery and development of product candidates based on our SMART linker
technology platform is unproven, and we do not know whether we will be able to develop any products of commercial value.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are focused on discovering and developing novel bi-functional small molecule drugs by applying our SMART linker technology platform.
While we believe that applying our SMART linker technology platform may potentially enable drug research and clinical development that is more efficient than conventional small molecule drug research
and development, this approach is
unproven. We have not yet succeeded and may never succeed in demonstrating efficacy and safety for any of our product candidates in later stage clinical trials or in obtaining marketing approval
thereafter. For example, although we have discovered and evaluated numerous compounds using our SMART linker technology platform, we have not yet advanced a compound into Phase&nbsp;3 clinical
development and no product created using the SMART linker technology platform has ever been approved for sale. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=667368,FOLIO='14',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent on the success of our product candidates CAT-1004 and CAT-2054. If we are unable to
complete the clinical development of, obtain marketing approval for or successfully commercialize at least one of these product candidates, either alone or with a collaborator, or if we experience
significant delays in doing so, our business could be substantially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no products approved for sale and are investing a significant portion of our efforts and financial resources in the
development of CAT-1004 for the treatment of Duchenne muscular dystrophy, or DMD, and CAT-2054 for the treatment of hypercholesterolemia. Our prospects are substantially dependent on our ability, or
that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize at least one of these product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
success of CAT-1004 and CAT-2054 will depend on several factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful completion of our ongoing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiation and successful enrollment and completion of additional clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration, or FDA, or any comparable
foreign regulatory authority for marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timely receipt of marketing approvals from applicable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of our future collaborators, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent of any required post-marketing approval commitments to applicable regulatory authorities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of supply arrangements with third-party raw materials suppliers and manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of arrangements with third-party manufacturers to obtain finished drug products that are appropriately packaged for
sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> protection of our rights in our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful launch of commercial sales following any marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a continued acceptable safety profile following any marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commercial acceptance by patients, the medical community and third-party payors following any marketing approval;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to compete with other therapies, including, in the case of CAT-1004, therapies targeting dystrophin, utrophin and
myostatin and inflammatory mediators. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the
manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and successfully commercialize at least one of CAT-1004 or CAT-2054,
on our own or with any future collaborator, or experience delays as a result of any of these factors or otherwise, our business could be substantially harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our SMART linker technology platform may fail to help us discover and develop additional potential
product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A significant portion of the research that we are conducting involves the development of new compounds using our SMART linker
technology platform. The drug discovery that we are conducting using our SMART linker technology platform may not be successful in creating compounds that have commercial value or therapeutic utility.
Our SMART linker technology platform may initially show </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=420245,FOLIO='15',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>promise
in identifying potential product candidates, yet fail to yield viable product candidates for clinical development or commercialization for a number of reasons,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compounds created through our SMART linker technology platform may not demonstrate improved efficacy, safety or tolerability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that
they are unlikely to receive marketing approval and achieve market acceptance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a potential product candidate may not be capable of being produced at an acceptable cost. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
research programs to identify new product candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new
product candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop product candidates and obtain product revenues in future
periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have never obtained marketing approval for a product candidate and we may be unable to obtain, or
may be delayed in obtaining, marketing approval for any of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive
review any new drug applications, or NDAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our
product candidates. If the FDA does not accept or approve our NDAs for either of our most advanced product candidates, it may require that we conduct additional clinical, nonclinical or manufacturing
validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or application that we
submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be
considered sufficient by the FDA to approve our NDAs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining
profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Results of preclinical studies and early clinical trials may not be predictive of results of future
clinical trials.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in
late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine
whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in
designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying
interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing
approval for the product candidates. Even if we, or any future collaborators, believe that the results of clinical trials for our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=668792,FOLIO='16',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>product
candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including
changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and
the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and
commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we are developing CAT-1004 for the treatment of DMD, a disease for which regulatory
authorities have not issued definitive guidance as to how to measure and demonstrate efficacy, there is increased risk that the outcome of our clinical trials will not be satisfactory for marketing
approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is currently no approved therapy for DMD in the United States. In addition, there has been limited historical clinical trial
experience for the development of drugs to treat the underlying cause of DMD. As a result, the design and conduct of clinical trials for this disease, particularly for drugs to address the underlying
cause of this disease, is subject to increased risk. In particular, regulatory authorities in the United States and European Union have not issued definitive guidance as to how to measure and
demonstrate efficacy. We anticipate that the primary endpoint in our Phase&nbsp;1/2 clinical trial of CAT-1004 for the treatment of DMD will be change in muscle inflammation as measured by magnetic
resonance imaging, or MRI, of leg muscles. MRI markers of leg muscle inflammation have been observed to increase with age but decrease with initiation of steroid therapy. We intend to include as
exploratory endpoints the timed function tests best suited for this age group, specifically the 10 meter walk/run, time to stand and 4-stair climb tests. However, due to the age and development stage
of the patients we intend to enroll in this clinical trial, these endpoints may not be sufficiently sensitive to demonstrate efficacy over the period of the trial. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may expend our limited resources to pursue a particular product candidate or indication and fail
to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific
indications that we identify as most likely to succeed, in terms of both their potential for marketing approval and commercialization. As a result, we may forego or delay pursuit of opportunities with
other product candidates or for other indications that may prove to have greater commercial potential. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and
development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target
market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights to the product candidate. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical drug development involves a lengthy and expensive process with an uncertain outcome.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be
conducted as planned or completed on schedule, or at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure
to demonstrate efficacy in a clinical trial or across a broad population of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=863372,FOLIO='17',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>patients,
the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the
FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. For example, our IND for CAT-2003 was placed on partial clinical hold by
the FDA in November 2012 because of the need for additional nonclinical work to support potential expansion of dosing and duration of our proposed Phase&nbsp;1 multiple ascending dose trial.
Although the partial clinical hold was removed in July 2013, it is possible that any of our development programs may be placed on full or partial clinical hold by regulatory authorities at any point,
which would delay and
possibly prevent further development of our product candidates. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during
clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the
same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail
to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the risk of failure inherent in drug development, certain of the compounds that we are developing and may develop in the future using our SMART linker technology platform
may be particularly susceptible to failure to the extent they are based on compounds that others have previously studied or tested, but did not progress in development due to safety, tolerability or
efficacy concerns or otherwise. Our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to
market any of our product candidates would significantly harm our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy
to the FDA and other comparable foreign regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development
and commercialization of these product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United
States without obtaining marketing approval from the FDA. Comparable foreign regulatory authorities, such as the European Medicines Agency, or the EMA, impose similar restrictions. We, and any future
collaborators, may never receive such approvals. We, and any future collaborators, must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our
product candidates in humans before we, or they, will be able to obtain these approvals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We have not previously submitted an NDA to
the FDA or similar drug approval filings to comparable foreign regulatory authorities for any of our product candidates. Any inability to complete preclinical and clinical development successfully
could result in additional costs to us, or any future collaborators, and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties.
Moreover, if (1)&nbsp;we, or any future collaborators, are required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we, or they
contemplate, (2)&nbsp;we, or any future collaborators, are unable to successfully complete clinical trials of our product candidates or other testing, (3)&nbsp;the results of these trials or tests
are unfavorable, uncertain or are only modestly favorable, or (4)&nbsp;there are unacceptable safety concerns associated with our product candidates, we, or any future collaborators,
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be delayed in obtaining marketing approval for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> not obtain marketing approval at all; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=21,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=783492,FOLIO='18',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain approval for indications or patient populations that are not as broad as intended or desired; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including
boxed warnings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be subject to additional post-marketing testing or other requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be required to remove the product from the market after obtaining marketing approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our
product candidates may be identified during development that could delay or prevent their marketing approval or limit their use.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us, any
future collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more
restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. For example, in our clinical trials of CAT-2003 we observed gastrointestinal
tolerability issues, including nausea, diarrhea and vomiting, and in some cases these adverse events led to dose reductions or discontinuations. If any of our product candidates is associated with
adverse events or undesirable side effects or has properties that are unexpected, we, or any future collaborators, may need to abandon development or limit development of that product candidate to
certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that
initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we, or any future collaborators, experience any of a number of possible unforeseen events in
connection with clinical trials of our product candidates, potential marketing approval or commercialization of our product candidates could be delayed or prevented.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, or any future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay
or prevent marketing approval or commercialization of our product candidates, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical trials of our product candidates may produce unfavorable or inconclusive results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon
product development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of patients required for clinical trials of our product candidates may be larger than we, or any future collaborators,
anticipate, patient enrollment in these clinical trials may be slower than we, or any future collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we,
or any future collaborators, anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of planned clinical trials of our product candidates may be greater than we anticipate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our third-party contractors or those of any future collaborators, including those manufacturing our product candidates or components
or ingredients thereof or conducting clinical trials on our behalf or on behalf of any future collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us
or any future collaborators in a timely manner or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulators or institutional review boards may not authorize us, any future collaborators or our or their investigators to commence a
clinical trial or conduct a clinical trial at a prospective trial site; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=22,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=677637,FOLIO='19',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or
clinical trial protocols with prospective trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical
trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial's duration; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may have to delay, suspend or terminate clinical trials of our product candidates for various
reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, such as the
delay we experienced in one of our Phase&nbsp;2 clinical trials of CAT-2003 while we reformulated CAT-2003 in a coated capsule and evaluated its tolerability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulators or institutional review boards may require that we, or any future collaborators, or our or their investigators suspend or
terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable
health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar drug or drug
candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our, or any future collaborators', clinical trial designs or
our or their interpretation of data from preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes
or facilities of third-party manufacturers with which we, or any future collaborators, enter into agreements for clinical and commercial supplies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of
our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
rendering our clinical data insufficient to obtain marketing approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
development costs for us, or any future collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required
to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin
as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we, or any future
collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any future collaborators, to bring products to market before we, or
any future collaborators, do and impair our ability, or the ability of any future collaborators, to successfully commercialize our product candidates and may harm our business and results of
operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we, or any future collaborators, experience delays or difficulties in the enrollment of patients
in clinical trials, our or their receipt of necessary regulatory approvals could be delayed or prevented.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, or any future collaborators, may not be able to initiate or continue clinical trials for any of our product candidates if we, or
they, are unable to locate and enroll a sufficient number of eligible patients to participate in clinical trials as required by the FDA or comparable foreign regulatory </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=23,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=279369,FOLIO='20',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_cg15201_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>authorities,
such as the EMA. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the size and nature of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the severity of the disease under investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the proximity of patients to clinical sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the eligibility criteria for the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the design of the clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> efforts to facilitate timely enrollment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> competing clinical trials; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinicians' and patients' perceptions as to the potential advantages and risks of the drug being studied in relation to other
available therapies, including any new drugs that may be approved for the indications we are investigating. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
particular, the successful completion of our clinical development program for CAT-1004 for the treatment of DMD is dependent upon our ability to enroll a sufficient number of patients
with DMD. DMD is a rare disease with a small patient population. Further, there are only a limited number of specialist physicians that regularly treat patients with DMD and major clinical centers
that support DMD treatment are concentrated in a few geographic regions. In addition, other companies are conducting clinical trials and have announced plans for future clinical trials that are
seeking, or are likely to seek, to enroll patients with DMD and patients are generally only able to enroll in a single trial at a time. The small population of patients, competition for these patients
and the limited trial sites may make it difficult for us to enroll enough patients to complete our clinical trials for CAT-1004 in a timely and cost-effective manner. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The clinical trials that we conduct may also have inclusion criteria that further limit the population of patients that we are able to enroll. For example, for the Phase&nbsp;1/2
clinical trial of CAT-1004 for which we expect to initiate patient enrollment in June 2015, we plan to enroll only ambulatory boys between ages four and seven who have not used steroids for at least
six months prior to the trial. These inclusion criteria could present challenges to enrollment because steroid therapy for DMD is often initiated in this age range.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
inability, or the inability of any future collaborators, to enroll a sufficient number of patients for our, or their, clinical trials could result in significant delays or may
require us or them to abandon one or more clinical trials altogether. Enrollment delays in our, or their, clinical trials may result in increased development costs for our product candidates, delay or
halt the development of and approval processes for our product candidates and jeopardize our, or any future collaborators', ability to commence sales of and generate revenues from our product
candidates, which could cause the value of our company to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=24,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=803796,FOLIO='21',FILE='DISK122:[14ZDH1.14ZDH15201]CG15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ci15201_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If any of our product candidates receives marketing approval and we, or others, later discover that
the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could
be compromised.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual
positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the drug is less effective than
previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may withdraw their approval of the drug or seize the drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional
clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require the addition of labeling statements, such as a "black box" warning or a contraindication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side
effects for distribution to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, could be sued and held liable for harm caused to patients; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the drug may become less competitive; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if one of our product candidates receives marketing approval, it may fail to achieve the degree
of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be
smaller than we estimate.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never commercialized a product. Even if one of our product candidates is approved by the appropriate regulatory authorities for
marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, physicians are often
reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that
they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our
product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance
of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the efficacy and safety of the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential advantages of the product compared to alternative treatments; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=102109,FOLIO='22',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ci15201_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prevalence and severity of any side effects; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the clinical indications for which the product is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations or warnings, including distribution or use restrictions, contained in the product's approved labeling; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the product's convenience and ease of administration compared to alternative treatments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the willingness of the target patient population to try, and of physicians to prescribe, the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the strength of sales, marketing and distribution support; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approval of other new products for the same indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the standard of care for the targeted indications for the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of market introduction of our approved products as well as competitive products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> availability and amount of reimbursement from government payors, managed care plans and other third-party payors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> adverse publicity about the product or favorable publicity about competitive products; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential product liability claims. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
potential market opportunities for our product candidates are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions,
including industry knowledge and publications, third-party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of
significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions
proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to establish sales, marketing and distribution capabilities or enter into sales,
marketing and distribution arrangements with third parties, we may not be successful in commercializing any product candidates that we develop if and when those product candidates are approved.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a sales, marketing or distribution infrastructure and have no experience in the sale, marketing or distribution of
pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. We plan to use
a combination of focused in-house sales and marketing capabilities and third-party collaboration, licensing and distribution arrangements to sell any of our products that receive marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
generally plan to seek to retain full commercialization rights in the United States and Canada for products that we can commercialize with a specialized sales force and to retain
co-promotion or similar rights in the United States and Canada when feasible in indications requiring a larger commercial infrastructure. The development of sales, marketing and distribution
capabilities will require substantial resources, will be time-consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish
marketing and distribution capabilities is delayed or does not occur for any reason, we could have prematurely or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=424012,FOLIO='23',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ci15201_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>unnecessarily
incurred these commercialization costs. This may be costly, and our investment could be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not
be able to hire or retain a sales force in the United States or Canada that is sufficient in size or has adequate expertise in the medical markets that we plan to target. If we are unable to establish
or retain a sales force and marketing and distribution capabilities, our operating results may be adversely affected. If a potential partner has development or commercialization expertise that we
believe is particularly relevant to one of our products, then we may seek to collaborate with that potential partner even if we believe we could otherwise develop and commercialize the product
independently. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to collaborate with third parties for commercialization in the United States and Canada of any products that require a large sales, marketing and product distribution
infrastructure. We also plan to commercialize our product candidates outside the United States and Canada through collaboration, licensing and distribution arrangements with third parties. As a result
of entering into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues may be lower, perhaps
substantially lower, than if we were to directly market and sell products in those markets. Furthermore, we may be unsuccessful in entering into the necessary arrangements with third parties or may be
unable to do so on terms that are favorable to us. In addition, we may have little or no control over such third parties, and any of them may fail to devote the necessary resources and attention to
sell and market our products effectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not establish sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing any of our
product candidates that receive marketing approval. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face substantial competition from other pharmaceutical and biotechnology companies, and our
operating results may suffer if we fail to compete effectively.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new drug products is highly competitive. We expect that we, and any future collaborators, will
face significant competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect to any of our product candidates that we, or
they, may seek to develop or commercialize in the future. Specifically, there are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing
the development of product candidates for the treatment of the key indications of our most advanced programs, including DMD, severe hypertriglyceridemia and hypercholesterolemia. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are initially developing CAT-1004 for the treatment of DMD. While there are currently no therapies approved for the treatment of DMD in the United States, corticosteroid therapy is
often prescribed to treat the inflammation underlying DMD and to delay loss of ambulation. In addition, a number of companies are developing therapies to treat DMD, one of which is already on the
market in Europe and others are in the process of registration or late stage clinical development, including Eli Lilly, BioMarin Pharmaceuticals, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta
Therapeutics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are initially developing CAT-2054 for the treatment of hypercholesterolemia. There are many widely available products, including statins and cholesterol absorption inhibitors,
approved for the treatment of patients with hypercholesterolemia. The market and development pipeline for cholesterol regulating therapies is especially large and competitive. If CAT-2054 is approved
for the treatment of hypercholesterolemia, either as monotherapy or in combination therapies, it will face intense competition from current approved therapies as well as a number of therapeutic
approaches in
development, including PCSK9 inhibitors being developed by Sanofi/Regeneron Pharmaceuticals, Amgen, Eli Lilly and Pfizer; cholesterol ester transfer protein inhibitors, including those being </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=218696,FOLIO='24',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ci15201_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>developed
by Merck and Eli Lilly; and other alternative therapies being developed by a range of competitors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, have fewer or more tolerable side effects or are less costly
than any product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects,
are more convenient or are less expensive than any products that we, or any future collaborators, may develop. Our competitors also may obtain FDA or other marketing approval for their products before
we, or any future collaborators, are able to obtain approval for ours, which could result in our competitors establishing a strong market position before we, or any future collaborators, are able to
enter the market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
of our existing and potential future competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even
more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial
sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or comparable foreign regulatory authorities approve generic versions of any of our
products that receive marketing approval, or such authorities do not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our
products could be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA is approved, the product covered thereby becomes a "reference-listed drug" in the FDA's publication, "Approved Drug
Products with Therapeutic Equivalence Evaluations." Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in
the United States. In support of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage
form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is
absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic
products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug may
be typically lost to the generic product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and
Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. Specifically, in cases where such exclusivity has been
granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering the
reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed
drug. It is unclear whether the FDA will treat the active ingredients in our product candidates as NCEs and, therefore, afford them five years of NCE data exclusivity if they are approved. If any
product we develop does not receive five years of NCE </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=541980,FOLIO='25',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ci15201_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>exclusivity,
the FDA may approve generic versions of such product three years after its date of approval. Manufacturers may seek to launch these generic products following the expiration of the
applicable marketing exclusivity period, even if we still have patent protection for our product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition
that our products may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially
limit our ability to obtain a return on the investments we have made in those product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we, or any future collaborators, are able to commercialize any product candidate that we, or
they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the
costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not
available, or reimbursement is available only to limited levels, we, or any future collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided,
the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their
investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly
from payor to payor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products
vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or
product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a
result, we, or any future collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product,
possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or
the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore,
our ability, and the ability of any future collaborators, to commercialize any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and
related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused
on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement
for particular medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably. These payors may not view our products, if any, as
cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a
competitive basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated
product revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and
profitability will suffer. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=371556,FOLIO='26',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<A NAME="page_ci15201_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA
or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may
also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We
cannot be sure that coverage will be available for any product candidate that we, or any future collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further,
the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower
prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or
any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Product liability lawsuits against us could divert our resources, cause us to incur substantial
liabilities and limit commercialization of any products that we may develop.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability claims as a result of the clinical testing of our product candidates despite obtaining
appropriate informed consents from our clinical trial participants. We will face an even greater risk if we or any future collaborators commercially sell any product that we may or they may develop.
For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties.
Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to
limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for our product candidates or products that we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant costs to defend resulting litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to trial participants or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced resources of our management to pursue our business strategy; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability to commercialize any products that we may develop. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we maintain general liability insurance of $2.0&nbsp;million in the aggregate and clinical trial liability insurance of $3.0&nbsp;million in the aggregate, this insurance
may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to
increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are
unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and
commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=30,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=79006,FOLIO='27',FILE='DISK122:[14ZDH1.14ZDH15201]CI15201A.;34',USER='CHE108062',CD=';2-JUN-2015;02:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ck15201_1_28"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck15201_risks_related_to_our_dependence_on_third_parties"> </A>
<A NAME="toc_ck15201_1"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Dependence on Third Parties    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to seek to establish collaborations and, if we are not able to establish them on
commercially reasonable terms, we may have to alter our development and commercialization plans.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to
fund expenses. We expect to seek one or more collaborators for the development and commercialization of one or more of our product candidates. For example, conducting pivotal Phase&nbsp;3 clinical
trials of CAT-2054 in patients with hypercholesterolemia will likely involve significant cost and we expect that we would conduct any large Phase&nbsp;3 clinical trial of CAT-2054 in patients with
hypercholesterolemia in collaboration with one or more partners. Likely collaborators may include large and mid-size pharmaceutical companies, regional
and national pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain marketing approval for CAT-1004 and other product candidates from foreign regulatory
authorities, we intend to enter into strategic relationships with international biotechnology or pharmaceutical companies for the commercialization of CAT-1004 and other product candidates outside of
the United States and Canada. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of
the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Those factors may include the
potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory
authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the
potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a
collaboration could be more attractive than the one with us for our product candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations are complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large pharmaceutical
companies that have resulted in a reduced number of potential future collaborators. In addition, our loan and security agreement with MidCap, Flexpoint and Square 1 contains, and any collaboration
agreements that we enter into in the future may contain, restrictions on our ability to enter into potential collaborations or to otherwise develop specified compounds.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product
candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope
of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund
development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we
may not be able to further develop our product candidates or bring them to market and generate product revenue. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we enter into collaborations with third parties for the development and commercialization of our
product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to enter into collaborations for the development and commercialization of certain of our product candidates. If we enter into
such collaborations, we will
have limited control over the amount and timing of resources that our collaborators will dedicate to the development or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=779847,FOLIO='28',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>commercialization
of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators' abilities to successfully perform the functions assigned
to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations,
prior to or upon the expiration of the agreed upon terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations
involving our product candidates pose a number of risks, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not perform their obligations as expected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew
development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding or external factors, such as an acquisition, that divert
resources or create competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a
product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and
distribution of such product or products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of
development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product
candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a
way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential
liability; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or
commercialization of the applicable product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in
a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our
business could be significantly harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as contract research
organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to conduct clinical
trials of any other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative
arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new contract research organization begins work. As a result, delays </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=32,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=210752,FOLIO='29',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>would
likely occur, which could materially impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
our reliance on these third parties for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our studies
is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards. For example, notwithstanding the obligations of a contract research organization for a trial of one
of our product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover,
the FDA requires us to comply with standards, commonly referred to as current Good Clinical Practices, or cGCPs, for conducting, recording and reporting the results of clinical trials to assure that
data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these cGCPs through periodic inspections of
trial sponsors, principal investigators, clinical trial sites and institutional review boards. If we or our third-party contractors fail to comply with applicable cGCPs, the clinical data generated in
our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the marketing approval process.
We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. We are also required to register clinical trials and post the results of completed
clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we
cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities,
including our
competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these
third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may
not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully
commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase
and our ability to generate revenues could be impaired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical
development or marketing approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We contract with third parties for the manufacture and distribution of our product candidates for
clinical trials and expect to continue to do so in connection with our future development and commercialization efforts. This reliance on third parties increases the risk that we will not have
sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no manufacturing facilities and limited personnel with manufacturing experience. We rely on contract manufacturers to
produce both drug substance and drug product required for our clinical trials. We plan to continue to rely upon contract manufacturers, and, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=33,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=362204,FOLIO='30',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>potentially
collaboration partners, to manufacture commercial quantities of our products, if approved. Reliance on such third-party contractors entails risks,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing delays if our third-party contractors give greater priority to the supply of other products over our product candidates
or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible breach by the third-party contractors of our agreements with them; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the failure of third-party contractors to comply with applicable regulatory requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or
placebo not being properly identified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of
drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible misappropriation of our proprietary information, including our trade secrets and know-how. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently rely, and expect to continue to rely, on a small number of third-party contract manufacturers to supply the majority of our active pharmaceutical ingredient and required
finished product for our preclinical studies and clinical trials. We do not have long-term agreements with any of these third parties. If any of our existing manufacturers should become unavailable to
us for any reason, we may incur some delay in identifying or qualifying replacements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations, delay our clinical trials and, if our products are approved for sale, result in
lost sales. Additionally, we rely on third parties to supply the raw materials needed to manufacture our product candidates. Any reliance on suppliers may involve several risks, including a potential
inability to obtain critical materials and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to future contract manufacture caused by
problems at suppliers could delay shipment of our product candidates, increase our cost of goods sold and result in lost sales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are approved by any regulatory agency, we plan to enter into agreements with third-party contract manufacturers for the commercial production and
distribution of those products. It may be difficult for us to reach agreement with a contract manufacturer on satisfactory terms or in a timely manner. In addition, we may face competition for access
to manufacturing facilities as there are a limited number of contract manufacturers operating under current good manufacturing practices, or cGMPs, that are capable of manufacturing our product
candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-party
manufacturers are required to comply with cGMPs and similar regulatory requirements outside the United States. Facilities used by our third-party manufacturers must be
approved by the FDA after we submit an NDA and before potential approval of the product candidate. Similar regulations apply to manufacturers of our product candidates for use or sale in foreign
countries. We do not control the manufacturing process and are completely dependent on our third-party manufacturers for compliance with the applicable regulatory requirements for the manufacture of
our product candidates. If our manufacturers cannot successfully manufacture material that conforms to our specifications or the strict regulatory requirements of the FDA and any applicable foreign
regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=34,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=645703,FOLIO='31',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>these
facilities are not approved for commercial manufacture, we may need to find alternative manufacturing facilities, which could result in delays in obtaining approval for the applicable product
candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our manufacturers are subject to ongoing periodic inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory
requirements both prior to and following the receipt of marketing approval for any of our product candidates. Some of these inspections may be unannounced. Failure by any of our manufacturers to
comply with applicable cGMPs or other regulatory requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of
approvals, operating restrictions, interruptions in supply and criminal prosecutions, any of which could adversely affect supplies of our product candidates and significantly harm our business,
financial condition and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize
any products that receive marketing approval on a timely and competitive basis. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck15201_risks_related_to_our_intellectual_property"> </A>
<A NAME="toc_ck15201_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Intellectual Property    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain and maintain sufficient patent protection for our product candidates, or
if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to commercialize our product
candidates successfully may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our proprietary product candidates. If we do not adequately protect our intellectual property, competitors may be able to erode or negate any competitive advantage we may have, which could
harm our business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States and abroad related to our novel product candidates that
are important to our business. The patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and
pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly
involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications.
Assuming the other requirements for patentability are met, currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the
United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot be
certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in
the courts or patent </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=35,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=364247,FOLIO='32',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>offices
in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in
post-grant review procedures, oppositions, derivations, reexaminations, inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent
rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In
addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
pending and future patent applications may not result in patents being issued which protect our product candidates, in whole or in part, or which effectively prevent others from
commercializing competitive products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow
the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example,
European patent law restricts the patentability of methods of treatment of the human body more than United States law does. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or
otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. Our
competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any
approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or
assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or
unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable
patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect the confidentiality of our trade secrets, the value of our technology
could be materially adversely affected and our business would be harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we have obtained composition of matter patents with respect to our most advanced product candidates, we also rely on trade secret
protection for certain aspects of technology platform, including certain aspects of our SMART linker technology platform. We seek to protect these trade secrets, in part, by entering into
non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, contract manufacturers, suppliers and other
third parties. We also enter into confidentiality and invention or patent assignment agreements with employees and certain consultants. Any party with whom we have executed such an agreement may
breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, if any of our trade secrets were to be lawfully
obtained or independently developed by a competitor, we would have no right to prevent such third-party, or those to whom they communicate such technology or information, from using that technology or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=36,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=585188,FOLIO='33',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>information
to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our business and competitive position could be harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
which could be expensive, time consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized
use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert
against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid
or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or
unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is
upheld, the court will construe the patent's claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do
not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may
curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position,
business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party
against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an
adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient
financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of
such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are sued for infringing intellectual property rights of third parties, such litigation could
be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates and use our
SMART linker technology platform without infringing the intellectual property and other proprietary rights of third parties. Third parties have U.S. and non-U.S. issued patents and pending patent
applications relating to compounds and methods of use for the treatment of DMD and hypercholesterolemia, the key indications for our priority programs. If any third-party patents or patent
applications are found to cover our product candidates or their methods of use, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not
be available on commercially reasonable terms, or at all.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=37,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=458027,FOLIO='34',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>adversarial
proceedings regarding intellectual property rights with respect to our products candidates, including interference proceedings before the U.S. Patent and Trademark Office. Third parties
may assert infringement claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be
adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us,
which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for
patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid
or unenforceable, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to
overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and
scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient resources to bring
these actions to a successful conclusion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are found to infringe a third-party's intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the
infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or
marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be
non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys' fees
if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which
could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes to the patent law in the United States and other jurisdictions could diminish the value of
patents in general, thereby impairing our ability to protect our products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent
reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law in September 2011, could increase those
uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine
prior art and provide more efficient and cost-effective avenues for
competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a "first to file" system. The first-to-file provisions, however, only
became effective in March 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its
implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our collaboration partners'
patent applications and the enforcement or defense of our or our collaboration partners' issued patents, all of which could harm our business, results of operations and financial condition. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of
patent owners </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=38,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=181399,FOLIO='35',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>in
certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to
enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations
governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the
lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the
patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that
could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and
failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely
affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to enforce our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively
expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained
patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as
strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other
intellectual property rights may not be effective or sufficient to prevent them from so competing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of
some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered
significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing
countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our
other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able
to prevent third parties from practicing our inventions in certain countries outside the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained
patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop
infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=39,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500437,FOLIO='36',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<A NAME="page_ck15201_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceedings
to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of
our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts
in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Patent term may be inadequate to protect our competitive position on our products for an adequate
amount of time.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are
prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the
patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the
United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our
patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims by third parties asserting that our employees or we have misappropriated
their intellectual property, or claiming ownership of what we regard as our own intellectual property.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our employees and our licensors' employees, including our senior management, were previously employed at universities or at
other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including each member of our senior management, executed proprietary
rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other
proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such
third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such
intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by
or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights. Even if we are
successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=40,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=62002,FOLIO='37',FILE='DISK122:[14ZDH1.14ZDH15201]CK15201A.;17',USER='HYUNG',CD=';2-JUN-2015;11:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cm15201_1_38"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cm15201_risks_related_to_regulatory_ap__ris02920"> </A>
<A NAME="toc_cm15201_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Regulatory Approval and Other Legal Compliance Matters    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we complete the necessary preclinical and clinical studies, the marketing approval process
is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we
cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject
to extensive regulation by the FDA and comparable foreign regulatory authorities, which regulations differ from country to country. We, and any future collaborators, are not permitted to market our
product candidates in the United States
or in other countries until we, or they, receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in
various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product
candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval
of an NDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can
vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes
in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process
and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations
of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any future collaborators to generate revenue from the particular
product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to obtain marketing approval in international jurisdictions would prevent our product
candidates from being marketed abroad.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market and sell our products in the European Union and many other jurisdictions, we, and any future collaborators, must
obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to
obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with
obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that
country. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by
regulatory authorities in other
countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=954338,FOLIO='38',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug
exclusivity for our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a
patient population of fewer than 200,000 individuals annually in the United States. While we have obtained orphan drug designation from the FDA for CAT-1004 for the treatment of DMD, we, or any future
collaborators, may seek orphan drug designations for other product candidates or in other jurisdictions and may be unable to obtain such designations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product
candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such
designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable
exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug
designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs
can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is
clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the
terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and
extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain
marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product's approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses for which they are not approved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, manufacturers of approved products and those manufacturers' facilities are required to comply with extensive FDA requirements, including ensuring that quality control and
manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and
reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure
compliance with cGMPs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our and their contract
manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=546616,FOLIO='39',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our
products withdrawn by regulatory authorities and our, or any future collaborators', ability to market any future products could be limited, which could adversely affect our ability to achieve or
sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any of our product candidates for which we, or any future collaborators, obtain marketing approval
in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply
with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future, as well as the
manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements of and
review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements,
requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and
recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions
of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies,
including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the
approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers' communications regarding off-label use and if we, or any
future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or
enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to
investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with
regulatory requirements, may yield various results, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on such products, manufacturers or manufacturing processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the labeling or marketing of a product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on product distribution or use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requirements to conduct post-marketing studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning letters or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of the products from the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to approve pending applications or supplements to approved applications that we submit; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recall of products; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=43,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=600768,FOLIO='40',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on coverage by third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, restitution or disgorgement of profits or revenues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of marketing approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to permit the import or export of products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted and future legislation may increase the difficulty and cost for us and any future
collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our
ability, or the ability of any future collaborators, to
profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that will be adopted in the future, may result
in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, became law in 2010
and includes the following provisions of potential importance to our product candidates:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of federal healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government
investigative powers and enhanced penalties for noncompliance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off
negotiated prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> extension of manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of eligibility criteria for Medicaid programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to
report financial arrangements with physicians and teaching hospitals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things,
created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=44,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=134606,FOLIO='41',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>with
recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction
to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in
effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare
funding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure
whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product
candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us and
any future collaborators to more stringent product labeling and post-marketing testing and other requirements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with customers and third-party payors, among others, will be subject to applicable
anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and
diminished profits and future earnings.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any products for which
we obtain marketing approval. Our arrangements with third-party payors and customers, if any, will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws
and regulations may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. These include
the following: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Kickback Statute.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The federal healthcare Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly
and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase,
order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;False Claims Laws.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The federal false claims laws impose criminal and civil penalties against individuals or entities for, among other
things,
knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or
avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HIPAA.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for,
among other
things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and
Clinical Health Act and its implementing regulations,
also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health
information; </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=45,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=992152,FOLIO='42',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transparency Requirements.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Federal laws require applicable manufacturers of covered drugs, biologics, devices and supplies to report
payments and
other transfers of value to physicians and teaching hospitals and ownership and investment interests by physicians; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Analogous State and Foreign Laws.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and
false claims
laws, which may be broader in scope, can apply to our business activities, including sales or marketing arrangements, and claims involving healthcare items or services and are generally broad and are
enforced by many different federal and state agencies as well as through private actions. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value
to physicians and other healthcare providers or marketing expenditures. State laws also govern the privacy and security of health information in some circumstances, many of which differ from each
other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our
operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to comply with environmental, health and safety laws and regulations, we could become
subject to fines or penalties or incur costs that could significantly harm our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and
the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials,
including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot
completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could
be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to
comply with such laws and regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this
insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and
regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to
comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=46,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1036115,FOLIO='43',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governments outside the United States tend to impose strict price controls, which may adversely
affect our revenues, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental
control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing
approval in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of
our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially
harmed. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cm15201_risks_related_to_emplo__cm102212"> </A>
<A NAME="toc_cm15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Employee Matters and Managing Growth    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain our Chief Executive Officer and to attract,
retain and motivate qualified personnel.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on the pharmaceutical research and development and business development expertise of Jill C. Milne, our
President and Chief Executive Officer. Although we have entered into an employment agreement with Dr.&nbsp;Milne, this agreement does not prevent her from terminating her employment with us at any
time. In the future, we may be dependent on other members of our management, scientific and development team. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to compete in the highly competitive biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and
medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. If we lose one or more of our executive officers or other key employees, our ability to
implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time
because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully.
Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants
and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue
to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to grow our organization, and as a result, we may encounter difficulties in managing our
growth, which could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
drug manufacturing, regulatory affairs and sales, marketing and distribution. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial
systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a disproportionate amount of its attention to managing these growth
activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the
expansion of our operations or identify, recruit and train additional qualified personnel. Our inability to manage the expansion of our operations effectively may result in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=47,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500778,FOLIO='44',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>weaknesses
in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage
our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful
commercialization of our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cm15201_risks_related_to_our_common_stock_and_this_offering"> </A>
<A NAME="toc_cm15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Common Stock and This Offering    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


No public market for our common stock currently exists, and an active trading market for our common
stock may not develop.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock
will be determined through negotiations with the underwriters. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following
this offering. Although we intend to list our common stock on The NASDAQ Global Market, an active trading market for our shares may never develop or, if developed, be maintained following this
offering. If an active market for our common stock does not develop or is not maintained, it may be difficult for you to sell shares you purchase in this offering without depressing the market price
for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies
or technologies by using our shares as consideration. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase shares of common stock in this offering, you will suffer immediate dilution in the
book value of your investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial public offering price of our common stock is substantially higher than the net tangible book value per share of our common
stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering.
Based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, you will experience
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our pro forma net tangible book value per share after giving effect to this offering and the assumed initial public
offering price. Purchasers of common stock in this offering will have contributed approximately&nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate price paid by all purchasers of our stock and will own approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock outstanding after this offering, excluding any shares of our common stock that they may have acquired prior to this offering. Furthermore, if the underwriters
exercise their over-allotment option or our previously issued options and warrants to acquire common stock at prices below the assumed initial public offering price are exercised, you will experience
further dilution. For a further description of the dilution that you will experience immediately after this offering, see "Dilution." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock is likely to be highly volatile, which could result in substantial
losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price is likely to be highly volatile. The stock market in general and the market for smaller pharmaceutical and
biotechnology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the
initial public offering price and you may lose some or all of your investment. The market price for our common stock may be influenced by many factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success of existing or new competitive products or technologies; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=48,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=736778,FOLIO='45',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and results of clinical trials of CAT-1004, CAT-2054 and any of our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commencement or termination of collaborations for our development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure or discontinuation of any of our development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> results of clinical trials of product candidates of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory or legal developments in the United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the level of expenses related to any of our product candidates or clinical development programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of our efforts to develop additional product candidates or products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales of our common stock by us, our insiders or other stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in estimates or recommendations by securities analysts, if any, that cover our stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> general economic, industry and market conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the other factors described in this "Risk Factors" section. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
in the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially
relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion
of management's attention and resources, which could harm our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in the use of the net proceeds from this offering and may not use them
effectively.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could
significantly harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this
offering in a manner that does not produce income or that loses value. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company," and the reduced disclosure requirements applicable to emerging
growth companies may make our common stock less attractive to investors.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an
emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=49,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=130208,FOLIO='46',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>certain
disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation
requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or SOX Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, reduced disclosure
obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. In this prospectus, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We
cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less
active trading market for our common stock and our stock price may be more volatile. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows
an
emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur increased costs as a result of operating as a public company, and our management will
be required to devote substantial time to new compliance initiatives and corporate governance practices.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a public company, and particularly after we are no longer an "emerging growth company," we will incur significant legal, accounting
and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ
Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial
controls and corporate governance practices. We expect that we will need to hire additional accounting, finance and other personnel in connection with our becoming, and our efforts to comply with the
requirements of being, a public company and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These
requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us
as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified
members of our board of directors. We are currently evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs.
These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new
guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and
governance practices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to SOX Section&nbsp;404 we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an
Annual Report on Form&nbsp;10-K with the Securities and Exchange Commission, or the SEC, after we become a public company. However, while we remain an emerging growth company, we will not be
required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404
within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=50,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=646072,FOLIO='47',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>which
is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and
document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and
implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed
timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an
adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A significant portion of our total outstanding shares is restricted from immediate resale but may be
sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.  </I></B></FONT></P>


<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the
perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering and giving effect to
the conversion of all outstanding shares of our preferred stock into 116,030,239 shares of our common stock upon the closing of this offering, we will
have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
outstanding based on the 6,659,760 shares of our common stock outstanding as of April&nbsp;30, 2015. Of these shares, the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold by us in
this offering may be resold in the
public market immediately, unless purchased by our affiliates. The remaining 122,689,999 shares are currently restricted under securities laws or as a result of lock-up or other agreements, but will
be able to be sold after this offering as described in the "Shares Eligible for Future Sale" section of this prospectus. Moreover, after this offering, holders of an aggregate of 116,030,239 shares of
our common stock, along with the holders of warrants to purchase 315,688 shares of common stock, will have rights, subject to conditions, to require us to file registration statements covering their
shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all 39,755,270 shares of common stock that we may issue
under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates
and the lock-up agreements described in the "Underwriting" section of this prospectus.

 </FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not anticipate paying any cash dividends on our capital stock in the foreseeable future,
accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to
finance the operation, development and growth of our business. Furthermore, the terms of our credit facility with MidCap, Flexpoint and Square 1 preclude us from paying dividends, and any future debt
agreements may also preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


After this offering, our executive officers, directors and principal stockholders, if they choose to
act together, will continue to have the ability to control all matters submitted to stockholders for approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing, our executive officers and directors, combined with our stockholders who owned more than 5% of our outstanding common
stock before this offering and their affiliates will, in the aggregate, beneficially own shares representing approximately&nbsp;&nbsp;&nbsp;&nbsp;% of our capital stock. As a result, if these stockholders were
to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to
act together, would control the election of directors and approval of any merger, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=51,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=304907,FOLIO='48',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>consolidation
or sale of all or substantially all of our assets. This concentration of ownership control may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delay, defer or prevent a change in control; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> entrench our management or the board of directors; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Provisions in our corporate charter documents and under Delaware law could make an acquisition of
us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our corporate charter and our bylaws that will become effective upon the closing of this offering may discourage, delay
or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These
provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because
our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish a classified board of directors such that all members of the board are not elected at one time; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> allow the authorized number of our directors to be changed only by resolution of our board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit the manner in which stockholders can remove directors from the board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be
acted on at stockholder meetings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by
written consent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit who may call a special meeting of stockholder meetings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison
pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or
repeal certain provisions of our charter or bylaws. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State of Delaware, which prohibits a
person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess
of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us,
whether or not it is desired by, or beneficial to, our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=52,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=704542,FOLIO='49',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cm15201_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our certificate of incorporation that will become effective upon the closing of this offering
designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and
exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors and officers.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation that will become effective upon the closing of this offering provides that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District
of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware
or our certificate of incorporation or bylaws, or any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit the ability of our
stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our
directors and officers. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our share price and trading volume could decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock will likely depend, in part, on the research and reports that securities or industry analysts
publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts
downgrade our stock or change their opinion of our stock, our share price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports
on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=53,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=157046,FOLIO='50',FILE='DISK122:[14ZDH1.14ZDH15201]CM15201A.;26',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_co15201_1_51"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="co15201_special_note_regarding_forward__spe02700"> </A>
<A NAME="toc_co15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects,
plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
forward-looking statements include, among other things, statements about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to identify, develop and commercialize novel small molecule drugs based on our SMART linker technology platform; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to have up to three product candidates in clinical trials in 2015; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ongoing and planned clinical trials for our product candidates, whether conducted by us or by any future collaborators, including the
timing of initiation of these trials and of the anticipated results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to enter into collaborations for the development and commercialization of product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential benefits of any future collaboration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to receive research and development funding and achieve anticipated milestones under our collaborations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our commercialization, marketing and manufacturing capabilities and strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our intellectual property position and strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to identify additional products or product candidates with significant commercial potential; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations related to the use of proceeds from this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments relating to our competitors and our industry; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of government laws and regulations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary
statements
included in this prospectus, particularly in the "Risk Factors" section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=868624,FOLIO='51',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<A NAME="page_co15201_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding
that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=330766,FOLIO='52',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<A NAME="page_co15201_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="co15201_use_of_proceeds"> </A>
<A NAME="toc_co15201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds from our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering will be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth
on the cover
page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their over-allotment
option, we estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price
range set forth on the cover
page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the
cover
page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as
set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed
initial public offering price per share and after deducting estimated underwriting discounts and commissions.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2015, we had cash and cash equivalents of approximately $24.3&nbsp;million. We currently estimate that we will use the net proceeds from this offering, together
with our cash and cash equivalents, as follows:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the clinical development of CAT-1004; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the clinical development of CAT-2054; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the remainder for other product candidates, working capital and other general corporate purposes. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
expected use of the net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions. The
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of and results
from clinical trials, any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain broad discretion
over the allocation of the net proceeds from this offering. We have no current agreements, commitments or understandings for any material acquisitions or licenses of any products, businesses or
technologies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our planned use of the net proceeds from this offering and our existing cash and cash equivalents, we estimate that such funds will be sufficient to enable us to complete our
planned Phase&nbsp;1/2 clinical trial of CAT-1004 and our planned Phase&nbsp;2 development of CAT-2054, and to fund our operating expenses, debt service and capital expenditure requirements at
least through 2016. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not expect that the
net proceeds from this offering and our existing cash and cash equivalents will be sufficient to enable us to fund the completion of development of any of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing instruments and U.S. government securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=269130,FOLIO='53',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<A NAME="page_co15201_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="co15201_dividend_policy"> </A>
<A NAME="toc_co15201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any,
to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. In addition, our ability to pay cash dividends
on our common stock is prohibited by the covenants of our credit facility with MidCap Financial Trust, Flexpoint MCLS SPV LLC and Square 1 Bank. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=986567,FOLIO='54',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<A NAME="page_co15201_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="co15201_capitalization"> </A>
<A NAME="toc_co15201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our capitalization as of March&nbsp;31, 2015:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis; </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma basis to give effect to (i)&nbsp;the conversion of all outstanding shares of our preferred stock into 116,030,239
shares of our common stock, (ii)&nbsp;the conversion of our outstanding warrants to purchase 315,688 shares of preferred stock into warrants to purchase 315,688 shares of common stock, resulting in
the reclassification of our warrant liability to stockholders' (deficit) equity, and (iii)&nbsp;the filing and effectiveness of our restated certificate of incorporation, all upon the closing of
this offering; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
stock in this
offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
capitalization following the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. You should read
this table together with our financial statements and the related notes appearing at the end of this prospectus and the sections of this prospectus titled "Selected Financial Data" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations." </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of March&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma As<BR>
Adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share and per share&nbsp;data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Notes payable, net of current portion and discount</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, par value $0.001 per share; 68,837,703 shares authorized, issued and outstanding, actual; no
shares authorized, issued or outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, par value $0.001 per share; 56,026,590 shares authorized, 47,192,536 shares issued and
outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
44,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock, par value $0.001 per share; no shares authorized, issued or outstanding actual; 5,000,000 shares authorized, no shares
issued or outstanding pro forma and pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, par value $0.001 per share; 155,000,000 shares authorized, 6,659,760 shares issued and outstanding, actual; 150,000,000
shares authorized, pro forma and pro forma as adjusted; 122,689,999 shares issued and outstanding, pro forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding,
pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
95,245</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(79,201</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,487</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,638</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,638</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price
range set forth on the cover
page of this prospectus, would increase or decrease the pro forma as adjusted amount of additional paid-in-capital, total stockholders'


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=990850,FOLIO='55',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<A NAME="page_co15201_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and
after
deducting estimated underwriting discounts and commissions. An increase or decrease of 1,000,000&nbsp;shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would increase or decrease the pro forma as adjusted amount of additional paid-in-capital, total stockholders' equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in
the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table above does not include:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 763,538 shares of our common stock issuable upon the exercise of warrants outstanding as March&nbsp;31, 2015, at a weighted-average
exercise price of $0.47 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 17,839,736 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2015, at a
weighted-average exercise price of $0.40 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1,495,043 shares of our common stock available for future issuance as of March&nbsp;31, 2015 under our amended and restated 2008
equity incentive plan; and </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 13,727,495 and 2,343,236 additional shares of our common stock that will become available for future issuance in connection with this
offering under our 2015 stock incentive plan and our 2015 employee stock purchase plan, respectively.

</FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=233457,FOLIO='56',FILE='DISK122:[14ZDH1.14ZDH15201]CO15201A.;60',USER='DPERRY',CD=';2-JUN-2015;16:34' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cq15201_1_57"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cq15201_dilution"> </A>
<A NAME="toc_cq15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our historical net tangible book value (deficit) as of March&nbsp;31, 2015 was $(80.7)&nbsp;million, or $(12.12) per share of our common stock. Our historical net tangible book value
(deficit) is the amount of our total tangible assets less our total liabilities and preferred stock, which is not included within our stockholders' (deficit) equity. Historical net tangible book value
(deficit) per share represents historical net tangible book value (deficit) divided by the 6,659,760 shares of our common stock outstanding as of March&nbsp;31, 2015.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pro forma net tangible book value as of March&nbsp;31, 2015 was $12.0&nbsp;million, or $0.10 per share of our common stock. Pro forma net tangible book value represents the
amount of our total tangible assets less our total liabilities, after giving effect to (i) the automatic conversion of all outstanding shares of
our preferred stock into an aggregate of 116,030,239 shares of our common stock upon the closing of this offering, and (ii) the conversion of warrants to purchase 315,688 shares of preferred stock
into warrants to purchase 315,688 shares of common stock resulting in the reclassification of our warrant liability to stockholders' (deficit) equity. Pro forma net tangible book value per share
represents pro forma net tangible book value divided by the total number of shares outstanding as of March&nbsp;31, 2015, after giving effect to the automatic conversion of all outstanding shares of
our preferred stock into an aggregate of 116,030,239 shares of our common stock upon the closing of this offering.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>



&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After giving effect to our issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
which is the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us, our pro forma as adjusted net tangible book value as of March&nbsp;31, 2015 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents
an immediate
increase in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in pro forma as adjusted net
tangible book
value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share
after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis:

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assumed initial public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value (deficit) per share as of March&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase per share attributable to the conversion of outstanding preferred stock and the reclassification of the warrant liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of March&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on
the cover page of
this prospectus, would increase or decrease our pro forma as adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, our pro forma as adjusted net tangible book value per share after this
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and dilution per share to new investors purchasing shares in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us,

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=611962,FOLIO='57',FILE='DISK122:[14ZDH1.14ZDH15201]CQ15201A.;45',USER='HYUNG',CD=';2-JUN-2015;11:33' -->
<A NAME="page_cq15201_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. An increase or decrease of 1,000,000 shares in the number of
shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, decrease or increase the dilution per share to new investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, assuming no change
in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the underwriters exercise their over-allotment option in full, the pro forma as adjusted net tangible book value will increase to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing an immediate
increase to existing stockholders of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new investors. If any shares are issued upon exercise of
outstanding options or
outstanding warrants, you will experience further dilution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes, on a pro forma as adjusted basis as of March&nbsp;31, 2015, after giving effect to the conversion of all of our outstanding preferred stock into common
stock, the differences between the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by new
investors purchasing shares of common stock in this offering. The calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the
estimated price range set forth on the cover page of this prospectus, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us:

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total Consideration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Existing stockholders</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,689,999</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>93,124,554</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
$1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of
this prospectus, would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total
consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in
the case of a decrease, would decrease the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming that the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by
new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage
points, assuming no change in the assumed initial public offering price. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares purchased from us by existing stockholders is based on 122,689,999 shares of our common stock outstanding as of March&nbsp;31, 2015, after giving effect to the
automatic conversion of all of our outstanding shares of preferred stock into 116,030,239 shares of common stock upon the closing of this offering, and
excludes:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 763,538 shares of our common stock issuable upon the exercise of warrants outstanding as of March&nbsp;31, 2015 at a
weighted-average exercise price of $0.47 per share; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 17,839,736 shares of our common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2015, at a
weighted-average exercise price of $0.40 per share;

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=316753,FOLIO='58',FILE='DISK122:[14ZDH1.14ZDH15201]CQ15201A.;45',USER='HYUNG',CD=';2-JUN-2015;11:33' -->
<A NAME="page_cq15201_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1,495,043 additional shares of our common stock available for future issuance as of March&nbsp;31, 2015 under our amended and
restated 2008 equity incentive plan; and </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 13,727,495 and 2,343,236 additional shares of our common stock that will become available for future issuance in connection with this
offering under our 2015 stock incentive plan and our 2015 employee stock purchase plan, respectively.

</FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the underwriters exercise their over-allotment option in full, the following will occur:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the percentage of shares of our common stock held by existing stockholders will decrease to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of
shares of our common stock outstanding after this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of our common stock held by new investors will increase to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number
of shares of our common stock outstanding after this offering. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=62,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=764558,FOLIO='59',FILE='DISK122:[14ZDH1.14ZDH15201]CQ15201A.;45',USER='HYUNG',CD=';2-JUN-2015;11:33' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cs15201_1_60"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cs15201_selected_financial_data"> </A>
<A NAME="toc_cs15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should read the following selected financial data together with our financial statements and the related notes appearing at the end
of this prospectus and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this prospectus. We have derived the statement of operations data for the
years ended December&nbsp;31, 2013 and 2014 and the balance sheet data as of December&nbsp;31, 2013 and 2014 from our audited financial statements appearing at the end of this prospectus. The
statement of operations data for the three months ended March&nbsp;31, 2014 and 2015 and the balance sheet data as of March&nbsp;31, 2015 have been derived from our unaudited financial statements
appearing at the end of this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited financial data reflects all
adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information as of and for the periods presented. Our historical results are not
necessarily indicative of results that should be expected in any future period, and our results for any interim period are not necessarily indicative of results that should be expected for any full
year.

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share and per share data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,686</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,096</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,616</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,373</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(149</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:36pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,870,362</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,446,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,085,910</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,355,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108,413,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111,350,589</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
Note&nbsp;2 in the notes to our financial statements appearing at the end of this prospectus for a description of the method used to calculate basic and diluted net loss per share
and unaudited pro&nbsp;forma basic and diluted net loss per share. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,964</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,234</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes payable, net of current portion and discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>92,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(53,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(75,380</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(81,880</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(52,184</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(73,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(79,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=549594,FOLIO='60',FILE='DISK122:[14ZDH1.14ZDH15201]CS15201A.;28',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cy15201_1_61"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cy15201_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_cy15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS OF<BR>  FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations
together with our financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or
set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You
should review the "Risk Factors" section of this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cy15201_overview"> </A>
<A NAME="toc_cy15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by
simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each
with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Our initial
focus is on treatments for rare diseases, such as Duchenne muscular dystrophy, or DMD. We are also developing other product candidates for the treatment of serious lipid disorders. We target
therapeutic areas and specific diseases with significant unmet medical need where we believe we will have a competitive advantage. We seek to develop therapies that modulate multiple targets in the
disease pathway. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied our SMART linker technology platform to build a development pipeline that includes three clinical-stage product candidates and multiple programs in preclinical
development. Our drug candidates are small molecules. CAT-1004 is an oral small molecule that we believe has the potential to be a disease-modifying therapy for the treatment of DMD that may be able
to regenerate muscle in boys regardless of the underlying dystrophin mutation. DMD is an ultimately fatal genetic disorder involving progressive muscle degeneration. Our two other clinical-stage
product candidates, CAT-2054 and CAT-2003, are members of our CAT-2000 series of molecules. We are initially developing CAT-2054 for the treatment of patients with hypercholesterolemia, or elevated
low density lipoprotein cholesterol, or LDL-C, levels, for whom existing treatments are insufficient. Hypercholesterolemia is a disease that increases the risk of cardiovascular events. In
January&nbsp;2015, we initiated a Phase&nbsp;1 clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. Preliminary data are available for the full
range of doses tested in the single and multiple ascending dose portions of the trial. We have completed three Phase&nbsp;2a trials of CAT-2003 in patient populations with elevated triglycerides or
hypertriglyceridemia. CAT-4001 is in preclinical studies and is being developed for the treatment of severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral
sclerosis, two diseases of the central nervous system in which the Nrf2 and NF-<FONT FACE="SYMBOL">k</FONT>B pathways have been implicated.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
our inception in June 2008, we have devoted substantially all of our resources to developing our proprietary platform technology, identifying potential product candidates,
undertaking preclinical studies and conducting clinical trials for our three clinical-stage compounds, building our intellectual property portfolio, organizing and staffing our company, business
planning, raising capital, and providing general and administrative support for these operations. To date, we have financed our operations primarily through private placements of our preferred stock
and a debt financing. From our inception through March&nbsp;31, 2015, we have raised an aggregate of $103.1&nbsp;million, of which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=906638,FOLIO='61',FILE='DISK122:[14ZDH1.14ZDH15201]CY15201A.;58',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cy15201_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>$92.9&nbsp;million
consisted of gross proceeds from private placements of preferred stock and $10.0&nbsp;million consisted of gross proceeds from a secured debt financing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not generated any revenue to date. We have incurred significant annual net operating losses in every year since our inception and expect to incur a net operating loss in 2015 and
continue to incur net operating losses for the foreseeable future. Our net losses were $18.1&nbsp;million and $21.9&nbsp;million for the years ended December&nbsp;31, 2013 and 2014,
respectively, and $6.5&nbsp;million for the three months ended March&nbsp;31, 2015. As of March&nbsp;31, 2015, we had an accumulated deficit of $81.9&nbsp;million. We expect to continue to
incur significant expenses and increasing operating losses for the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our
expenses will increase significantly if and as we continue to develop and conduct clinical trials with respect to CAT-1004 and our CAT-2054 product candidates; initiate and continue research,
preclinical and clinical development efforts for our other product candidates and potential product candidates; maintain, expand and protect our intellectual property portfolio; establish a commercial
infrastructure to support the marketing and sale of certain of our product candidates; and hire additional personnel, such as clinical, regulatory, quality control and scientific personnel. In
addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cy15201_financial_operations_overview"> </A>
<A NAME="toc_cy15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financial Operations Overview    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have not generated any revenue from product sales or any other source and do not expect to generate any revenue from the
sale of products in the near future. In the future, we will seek to generate revenue primarily from a combination of product sales and collaborations with strategic partners. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery
efforts, and the development of our product candidates, which include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> employee-related expenses including salaries, benefits and stock-based compensation expense; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical
trials and research and development and preclinical activities on our behalf; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of consultants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of lab supplies and acquiring, developing and manufacturing preclinical study materials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other
supplies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities
are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summarizes our most advanced current research and development programs: </FONT></P>



<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CAT-1004 is an orally administered SMART linker conjugate of salicylate and the omega-3 fatty acid docosahexaenoic acid, or DHA, that
we designed to enhance the activity of salicylate and DHA in modulating the NF-<FONT FACE="SYMBOL">k</FONT>B pathway at multiple points. NF-<FONT FACE="SYMBOL">k</FONT>B, or
nuclear factor kappa-light-chain-enhancer of activated B cells, is a protein that coordinates cellular response to damage, stress and inflammation and plays an important role in muscle health. We plan
to initiate patient enrollment in a Phase&nbsp;1/2 clinical trial of CAT-1004 for the treatment of DMD in June 2015 and, subject to patient enrollment, expect to report top-line Phase&nbsp;2 data
in late 2016. If the results from our Phase&nbsp;1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month
Phase&nbsp;3 pivotal clinical trial of CAT-1004 in 2017 and seek marketing approval based on this Phase&nbsp;3 trial.

</FONT></DD></DL>
</UL>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=788234,FOLIO='62',FILE='DISK122:[14ZDH1.14ZDH15201]CY15201A.;58',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cy15201_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CAT-2054 is an orally administered SMART linker conjugate of the omega-3 fatty acid eicosapentaenoic acid, or EPA, and nicotinic acid,
designed to modulate the SREBP pathway in the liver. SREBP is a master regulator of lipid metabolism and controls levels of both LDL-C and triglycerides. We are initially developing CAT-2054 to treat
patients with hypercholesterolemia for whom existing treatments are insufficient. In January 2015, we initiated a Phase&nbsp;1 clinical trial to assess the safety, tolerability and pharmacokinetics
of CAT-2054 in healthy volunteers. Preliminary data are available for the full range of doses tested in the single and multiple ascending dose portions of the trial. If the final results of this
clinical trial are positive, we intend to initiate a Phase&nbsp;2a clinical trial of CAT-2054 for the treatment of hypercholesterolemia in the fourth quarter of 2015 and would expect to report
Phase&nbsp;2a data in mid-2016. If the results of the planned Phase&nbsp;2a clinical trial are positive, we intend to initiate a Phase&nbsp;2b clinical trial of CAT-2054 in the fourth quarter of
2016. </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CAT-2003 is an orally administered SMART linker conjugate of EPA and nicotinic acid that we designed to modulate the SREBP pathway. We
have completed three Phase&nbsp;2a trials of CAT-2003 in patient populations with elevated triglycerides or hypertriglyceridemia. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
research and development programs include our CAT-4001 development program and activities related to exploratory efforts, target validation and lead optimization for our early
stage programs and our proprietary platform technology. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program,
but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs. We record our research and development expenses net of
any research and development tax incentives we are entitled to receive from government authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our research and development expenses by program: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> CAT-1004</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>879</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>777</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAT-2054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
652</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
3,208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
478</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
1,033</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAT-2003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
6,727</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
3,807</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
607</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
351</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other research and platform programs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
1,276</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
468</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs not directly allocated to programs:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employee expenses including cash compensation, benefits and share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,575</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,172</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Facilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>754</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consultants and professional expenses, including share-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>217</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>476</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>120</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total costs not directly allocated to programs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,827</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,691</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,987</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,686</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,096</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,616</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
successful development of our product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will
be necessary to complete the remainder of the development of these product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from CAT-1004, CAT-2054 or
any of our other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=895621,FOLIO='63',FILE='DISK122:[14ZDH1.14ZDH15201]CY15201A.;58',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cy15201_1_64"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>current
or potential product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainties
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing an appropriate safety profile with investigational new drug application, or IND, enabling toxicology studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful enrollment in, and completion of clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> receipt of marketing approvals from applicable regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a continued acceptable safety profile of the products following approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the
development of that product candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in
earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the
foreseeable future as our product candidate development programs progress. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through
commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many
of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical
development programs and plans. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for
personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development
expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, potential commercialization of our
product candidates and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside
consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company including expenses related to services associated with
maintaining compliance with exchange listing and Securities and Exchange Commission requirements, insurance costs and investor relations costs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cy15201_critical_accounting_policies_and_estimates"> </A>
<A NAME="toc_cy15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies and Estimates    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have
prepared in accordance with United States generally accepted </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=67,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=93473,FOLIO='64',FILE='DISK122:[14ZDH1.14ZDH15201]CY15201A.;58',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_cy15201_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>accounting
principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and
judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus, we believe that the following
accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves
reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we
have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met.
We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and
circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued
research and development expenses include the costs incurred for services performed by CROs in connection with research and development activities for which we have not yet been invoiced. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on
our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to
our CROs will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will
be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or
prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ
from the actual status and timing of services performed, it could result in us reporting expense amounts that are too high or too low in any particular period. To date, there have been no material
differences between our estimates of such expenses and the amounts actually incurred. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We measure stock-based awards granted to employees and members of the board of directors at fair value on the date of grant and
recognize the corresponding stock-based compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective
award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=68,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=478125,FOLIO='65',FILE='DISK122:[14ZDH1.14ZDH15201]CY15201A.;58',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da15201_1_66"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We measure other stock-based awards granted to non-employees at fair value as the awards vest and recognize the resulting value as expense during the period the
related services are rendered. At the end of each financial reporting period prior to completion of the service, we re-measure the unvested portion of these awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. We historically have been a private company and lack company-specific historical and
implied volatility information. Therefore, we estimate our expected volatility based on the historical volatility of a representative group of publicly traded biopharmaceutical companies and expect to
continue to do so until we have adequate historical data regarding the volatility of our traded stock price. We determine the expected term of our options utilizing the "simplified" method for awards
that qualify as "plain-vanilla" options, while we determine the expected term of other nonemployee options based on the contractual term of the options. We determine the risk-free interest rate by
reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We assume an expected dividend yield of
zero because we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimated the fair value of stock options granted using the Black-Scholes option-pricing model based on the assumptions noted in the following table: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92&nbsp;-&nbsp;2.03%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.71&nbsp;-&nbsp;3.01%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.96&nbsp;-&nbsp;3.01%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.54&nbsp;-&nbsp;2.11%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.0&nbsp;-&nbsp;81.5%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.2&nbsp;-&nbsp;83.4%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.2 - 82.8%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76.5&nbsp;-&nbsp;84.0%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
assumptions represented our best estimates, but the estimates involve inherent uncertainties and the application of our judgment. As a result, if factors change and we use
significantly different assumptions or estimates, our stock-based compensation expense could be materially different. We recognize stock-based compensation expense for only the portion of awards that
are expected to vest.
In developing a forfeiture rate estimate for pre-vesting forfeitures, we have considered our historical experience of actual forfeitures. If our future actual forfeiture rate is materially different
from our estimate, our stock-based compensation expense could be significantly different from what we have recorded in the prior periods. However, estimates will not be necessary to determine the fair
value of new awards once our common stock begins to be publicly traded. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the classification of our stock-based compensation expense recognized in our statements of operations: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended<BR>
March&nbsp;31, 2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>168</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>897</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuations of Common Stock  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors determines the fair value of our common stock on each date of grant, with input from management. Due to the
absence of a public trading market for our common stock, our

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=184653,FOLIO='66',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_67"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


board of directors' determination of the fair value of our common stock has historically been performed using methodologies, approaches and assumptions consistent with the American Institute of
Certified Public Accountants Audit and Accounting Practice Aid Series: </FONT><FONT SIZE=2><I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I></FONT><FONT SIZE=2>. We
performed contemporaneous valuations, with the assistance of a third-party specialist, as of October&nbsp;31, 2013, December&nbsp;31, 2014 and March 17,&nbsp;2015. For financial reporting
purposes, we also performed common stock valuations retrospectively, with the assistance of a third-party specialist, as of April&nbsp;1, 2014 and August&nbsp;28, 2014. Our board of directors has
considered various objective and subjective factors, along with input from management, to determine its best estimate of the fair value of our common stock as of each grant date, including the
following:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to our
common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress of our research and development programs, including the status of clinical trials for our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our stage of development and business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our financial condition, including cash on hand and borrowings under our credit facility; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our historical and forecasted performance and operating results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the composition of, and changes to, our management team and board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of an active public market for our common stock and our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the likelihood of achieving a liquidity event such as a sale of our company or an initial public offering, or IPO, given prevailing
market conditions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the analysis of initial public offerings and the market performance of similar companies in the biopharmaceutical industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external market conditions affecting the biopharmaceutical industry; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> trends within the biopharmaceutical industry. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
the dates of our contemporaneous valuations have not always coincided with the dates of our stock-based compensation grants. In determining the exercise prices of the
options granted, our board of directors considered, among other things, the most recent contemporaneous or retrospective valuations of our common stock and our assessment of additional objective and
subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent contemporaneous valuation, or if
available the most recent retrospective valuation, and the grant dates included, when available, the prices paid in recent transactions involving our equity securities, as well as our stage of
development, our operating and financial performance and current business conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are significant judgments and estimates inherent in the determination of the fair value of our common stock, including the contemporaneous and retrospective valuations. These
judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event and the determinations of the appropriate valuation
methods. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per common share could have been significantly different. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Valuation Methodologies  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock valuations were prepared using a hybrid of the option-pricing method, or OPM, and the probability-weighted expected
return method, or PWERM. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=70,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=910088,FOLIO='67',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OPM.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The OPM treats each class of common stock and preferred stock as call options on the total equity value of a company, with
exercise prices based
on the value thresholds at which the allocation among the various holders of a company's securities changes. Under this method, the common stock has value only if the funds available for distribution
to stockholders exceed the value of the preferred stock liquidation preference at the time of a liquidity event, such as a strategic sale, merger or IPO. The common stock is modeled as a call option
on the underlying equity value at a predetermined exercise price. In the model, the exercise price is based on a comparison with the total equity value rather than, as in the case of a regular call
option, a comparison with a per share stock price. Thus, common stock is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately
after the preferred stock liquidation preference is paid. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
OPM uses the Black-Scholes option-pricing model to price the call options. This model defines the securities' fair values as functions of the current fair value of a company and uses
assumptions such as the anticipated timing of a potential liquidity event and the estimated volatility of the equity securities. The aggregate value of the common stock derived from the OPM is then
divided by the number of shares of common stock outstanding to arrive at the per share value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
used the OPM backsolve approach to estimate enterprise value under the OPM. The OPM backsolve approach uses the OPM to calculate the implied equity value based on recent sales of the
company's securities. For the OPM, we based our assumed volatility factor on the historical trading volatility of our publicly traded peer companies. At each valuation date, we determined the
appropriate volatility to be used, considering such factors as our expected time to a liquidity event and our stage of development. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
derive the fair value of our common stock using the OPM, we calculated the proceeds to the common stockholders based on the preferences and priorities of the preferred and common
stock. We then applied a discount for lack of marketability to the common stock to account for the lack of access to an active public market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PWERM.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values
for the
company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available
as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and
probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability is then applied to the common stock to account for the lack of access to an active
public market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
our common stock valuations as of October&nbsp;31, 2013, April&nbsp;1, 2014, August&nbsp;28, 2014, December&nbsp;31, 2014 and March&nbsp;17, 2015, we used a hybrid of the
OPM and PWERM and considered two types of future event scenarios: an IPO and a sale transaction. We valued the IPO scenario using the OPM backsolve approach for the October&nbsp;31, 2013 valuation.
We used the guideline public company method, which includes comparisons to publicly traded companies in our industry that recently completed IPOs, for the April&nbsp;1, 2014, August&nbsp;28, 2014,
December&nbsp;31, 2014 and March 17, 2015 valuations. We valued the sale scenario using the OPM backsolve approach. Our board of directors determined the relative probability of each type of future
event scenario based on an analysis of market conditions at the time, including then-current IPO valuations of similarly situated companies, and expectations as to the timing and likely prospects of
the future-event scenarios. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
derive the fair value of the common stock for each scenario using the hybrid PWERM and OPM, we calculated the proceeds to the common stockholders based on the preferences and
priorities of the preferred and common stock. We then applied a discount for lack of marketability to the common stock to account for the lack of access to an active public market. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=71,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=260633,FOLIO='68',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_69"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Option Grants  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes by grant date the number of shares of common stock subject to options granted between January&nbsp;1,
2014 and May&nbsp;31, 2015, the per share exercise price of the options, the fair value of the common stock underlying the options on the date of grant and the per share estimated fair value of the
options. For financial reporting purposes, the value of the April&nbsp;1, 2014 valuation has been applied retrospectively to our March&nbsp;19, 2014 option grants and the value of the
October&nbsp;28, 2014 valuation has been applied retrospectively to our August&nbsp;28, 2014, October&nbsp;21, 2014 and November&nbsp;5, 2014 option grants.

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:40pt;"><FONT SIZE=1><B>Grant Date

<!-- COMMAND=ADD_SCROPPEDRULE,40pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Common<BR>
Shares<BR>
Underlying<BR>
Options<BR>
Granted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Share<BR>
Exercise Price<BR>
of Options(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value of<BR>
Common Stock<BR>
on Grant<BR>
Date(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Retrospective<BR>
Fair Value<BR>
Per Share<BR>
on Grant<BR>
Date(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;19, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,581,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>August&nbsp;28, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>727,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>October&nbsp;21, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>700,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>November&nbsp;5, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>February&nbsp;12, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,769,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March 26, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>941,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>April 30, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,210,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.86</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the determination by our board of directors of the fair value of our common stock on the date of grant, taking into consideration the various
objective and subjective factors described above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
fair value of common stock at the grant date was adjusted in connection with a retrospective fair value assessment for financial reporting purposes. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


JOBS Act  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the JOBS Act
provides that an "emerging growth company," or EGC, can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result,
we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC, we intend
to rely on certain of these exemptions, including exemptions from the requirement to provide an auditor's attestation report on our system of internal controls over financial reporting pursuant to
Section&nbsp;404(b) of the Sarbanes-Oxley Act and from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to
the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an EGC until the earlier of: the last
day of the fiscal year in which we have total annual gross revenues of $1&nbsp;billion or more; the last day of the fiscal year following the fifth anniversary of the date of the completion of this
offering; the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or the date on which we are deemed to be a large accelerated filer under
the rules of the Securities and Exchange Commission. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=72,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=328109,FOLIO='69',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_70"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>




<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da15201_results_of_operations"> </A>
<A NAME="toc_da15201_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations

    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of Three Months Ended March&nbsp;31, 2014 and 2015

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the three months ended March&nbsp;31, 2014 and 2015, together with the
dollar increase or decrease in those items:

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,096</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,616</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,373</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>371</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,891</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,891</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,031</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses increased by $1.5&nbsp;million to $4.6&nbsp;million for the three months ended March&nbsp;31,
2015 from $3.1&nbsp;million for the three months ended March&nbsp;31, 2014, an increase of 49%. The increase in research and development expenses was partially attributable to a net increase of
$1.2&nbsp;million in direct program costs, reflecting an increase of $0.8&nbsp;million for CAT-1004 driven by activities in preparation for the start of a Phase&nbsp;1/2 clinical trial, an
increase of $0.5&nbsp;million for CAT-2054 driven by the start of a Phase&nbsp;1 clinical trial, and an increase of $0.6&nbsp;million in our general research and platform programs, which were
partially offset by a decrease of $0.3&nbsp;million in CAT-2003 clinical trial, manufacturing and preclinical development costs due to the completion of two Phase&nbsp;2 clinical trials in late
2013 and early 2014. In addition, the costs related to internal research and development increased by $0.3&nbsp;million, primarily attributable to increased research and development employee
headcount.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses

 </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses increased by $0.4&nbsp;million to $1.7&nbsp;million for the three months ended March&nbsp;31,
2015 from $1.4&nbsp;million for the three months ended March&nbsp;31, 2014, an increase of 21%. The increase in general and administrative expenses was primarily attributable to increased employee
costs of $0.2&nbsp;million associated with hiring additional senior personnel, and an increase of $0.2&nbsp;million in consulting expense primarily due to recruiting for two senior business
development positions.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Expense

 </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense consists of interest expense, which increased by $0.1&nbsp;million for the three months ended March&nbsp;31, 2015 due
to the interest expense on our credit facility which we entered into in August 2014.

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=73,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=843949,FOLIO='70',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of Years Ended December&nbsp;31, 2013 and 2014

 </I></B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the years ended December&nbsp;31, 2013 and 2014, together with the
dollar change in those items: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,994</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,692</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,870 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,681</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,562 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(21,681</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(203</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18,118</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(21,884</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses increased by $1.7&nbsp;million to $15.7&nbsp;million for the year ended December&nbsp;31, 2014
from $14.0&nbsp;million for the year ended December&nbsp;31, 2013, an increase of 12%. The increase in research and development expenses was partially attributable to a net increase of
$1.0&nbsp;million in direct program costs, reflecting an increase of $2.6&nbsp;million for CAT-2054 manufacturing and preclinical development costs associated with IND-enabling studies, an
increase of $0.6&nbsp;million in our general research and platform programs and an increase of $0.8&nbsp;million for CAT-1004 manufacturing and preclinical development costs, which were partially
offset by a decrease of $3.0&nbsp;million in CAT-2003 clinical trial, manufacturing and preclinical development costs due to the completion of two Phase&nbsp;2 clinical trials in late 2013 and
early 2014. In addition, the costs related to internal research and development increased by $0.7&nbsp;million, primarily attributable to stock-based compensation expense. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and Administrative Expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses increased by $1.9&nbsp;million to $6.0&nbsp;million for the year ended December&nbsp;31, 2014
from $4.1&nbsp;million for the year ended December&nbsp;31, 2013, an increase of 46%. The increase in general and administrative expenses was primarily attributable to increased employee costs of
$0.7&nbsp;million and increased professional and consulting fees of $0.9&nbsp;million. The $0.7&nbsp;million increase in employee costs consisted of an increase of $0.6&nbsp;million in
salaries and benefits and an increase of $0.3&nbsp;million in stock-based compensation expense, partially offset by a decrease of $0.2&nbsp;million in travel expense. The increase in employee
costs was primarily due to the hiring of additional members of our management team. The $0.9&nbsp;million increase in professional and consulting fees primarily consisted of an increase of
$0.4&nbsp;million in intellectual property legal fees and an increase of $0.4&nbsp;million in consulting expense associated with market studies for our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense consists primarily of interest expense, which increased by $0.2&nbsp;million for the year ended December&nbsp;31,
2014, due to the interest expense on our credit facility which we entered into in August 2014. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=74,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=470866,FOLIO='71',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_72"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da15201_liquidity_and_capital_resources"> </A>
<A NAME="toc_da15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sources of Liquidity  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From our inception through March&nbsp;31, 2015, we have raised an aggregate of $103.1&nbsp;million, of which $92.9&nbsp;million
consisted of gross proceeds from private placements of preferred stock and $10.0&nbsp;million consisted of gross proceeds from a secured debt financing. As of March&nbsp;31, 2015, we had
$24.3&nbsp;million in cash and cash equivalents.

</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;27, 2014, we entered into a loan and security agreement with MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and Square 1 Bank. On March&nbsp;31, 2015, we entered
into an amendment to the Credit Facility, as amended, the Credit Facility. The Credit Facility provides for initial borrowings of $5.0&nbsp;million and additional borrowings of up to
$20.0&nbsp;million. Concurrently with entering into the Credit Facility in August 2014, we borrowed $5.0&nbsp;million under a term loan under the Credit Facility and we issued to the lenders
warrants to purchase an aggregate of 157,844 shares of our series&nbsp;B preferred stock (157,844 shares of common stock on an as-converted basis) at an exercise price of $0.9503 per share.
Concurrently with the amendment to the Credit Facility, we drew down an additional $5.0&nbsp;million under our term loan under the Credit Facility and we issued to the lenders
warrants to purchase an aggregate of 157,844 shares of our series&nbsp;B preferred stock (157,844 shares of common stock on an as-converted basis) at an exercise price of $0.9503 per share. An
additional $5.0&nbsp;million was available to us under the Credit Facility until May&nbsp;31, 2015, subject to our completion of a series&nbsp;B preferred stock financing meeting certain
conditions, including gross proceeds to us of at least $8.0&nbsp;million, and our issuance of warrants to purchase shares of our stock equal in value to 3% of the amount drawn. However, none of this
$5.0 million was drawn. The remaining $10.0&nbsp;million will be available to us until July&nbsp;31, 2015, subject to the completion of an initial public offering with net cash proceeds to us of
at least $50.0&nbsp;million, and our issuance of warrants to purchase shares of our common stock equal in value to 3% of the amount drawn. All borrowings under the Credit Facility are due on
October&nbsp;1, 2018 and are collateralized by substantially all of our personal property, other than our intellectual property.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no financial covenants associated with the Credit Facility; however, there are negative covenants that prohibit us from transferring any of our material assets, exclusively
licensing our intellectual property (subject to certain exceptions), merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring
additional indebtedness, creating any lien on our property, making investments in third parties or redeeming stock or paying dividends. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Facility also includes events of default, the occurrence and continuation of any of which provides the lenders the right to exercise remedies against us and the collateral
securing the loans under the Credit Facility, including cash. These events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the occurrence of a
material adverse event, which includes a material adverse change in our business, operations or conditions (financial or otherwise) or a material impairment of the prospect of repayment of any portion
of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against us in an amount greater than $250,000. The occurrence of a material adverse change could
result in acceleration of payment of the debt. At March&nbsp;31, 2015, we concluded that the likelihood of the acceleration of the debt was remote, as a material adverse change had not occurred and
was unlikely to occur.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are obligated to make monthly interest-only payments on any term loans borrowed under the Credit Facility until September&nbsp;1, 2015 and, thereafter, to pay 36 consecutive, equal
monthly installments of principal and interest from October&nbsp;1, 2015 through September&nbsp;1, 2018. Term loans under the Credit Facility bear interest at an annual rate of 7.49%. Following
the occurrence and during the continuance of an event of default, borrowings under the Credit Facility will bear interest at an annual rate that is 5.00% above the rate that is otherwise applicable.
In addition, a final payment equal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=75,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=492200,FOLIO='72',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>to
3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, we raised $12.4 million in gross proceeds from the sale of 13,062,965 shares of our series B preferred stock at a price per share of $0.9503.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash Flows  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding our cash flows for the years ended December&nbsp;31, 2013 and 2014 and the three
months ended March&nbsp;31, 2014 and 2015:

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,366</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(20,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(43</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(228</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,834</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,040</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Used in Operating Activities  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities was $7.2&nbsp;million for the three months ended March&nbsp;31, 2015 and consisted primarily
of a net loss of $6.5&nbsp;million adjusted for non-cash items, including stock-based compensation expense of $0.3&nbsp;million and depreciation and amortization expense of $0.1&nbsp;million,
and a net increase in operating assets of $1.1&nbsp;million, which resulted primarily from a net decrease in accounts payable and accrued expenses of $0.9&nbsp;million and an increase in prepaid
expenses and other current assets of $0.2&nbsp;million.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities was $4.6&nbsp;million for the three months ended March&nbsp;31, 2014 and consisted primarily of a net loss of $4.5&nbsp;million adjusted for
non-cash items, including stock-based compensation expense of $0.1&nbsp;million and depreciation and amortization expense of $0.1&nbsp;million, and a net decrease in operating assets of
$0.3&nbsp;million, which resulted primarily from a net decrease in accounts payable and accrued expenses of $0.3&nbsp;million.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $20.4&nbsp;million for the year ended December&nbsp;31, 2014 and consisted primarily of a net loss of $21.9&nbsp;million adjusted for
non-cash items, including stock-based compensation expense of $0.9&nbsp;million and depreciation and amortization expense of $0.2&nbsp;million, and a net increase in operating assets of
$0.8&nbsp;million, which resulted primarily from a net increase in accounts
payable and accrued expenses of $0.5&nbsp;million partially offset by an increase in prepaid expenses and other current assets of $0.2&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $16.4&nbsp;million for the year ended December&nbsp;31, 2013, and consisted primarily of a net loss of $18.1&nbsp;million adjusted for
non-cash items, including stock-based compensation expense of $0.3&nbsp;million and depreciation and amortization expense of $0.3&nbsp;million, and a net increase in operating assets of
$1.1&nbsp;million, which resulted primarily from a net increase in accounts payable and accrued expenses of $1.0&nbsp;million and a decrease in prepaid expenses and other current assets of
$0.1&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Used in Investing Activities  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities was $25,000 during the three months ended March&nbsp;31, 2015 compared to $13,000 during the
three months ended March&nbsp;31, 2014, which resulted primarily from increased laboratory equipment expenditures in the three months ended March&nbsp;31, 2015.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=76,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=156596,FOLIO='73',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities was $0.2&nbsp;million during the year ended December&nbsp;31, 2014 compared to $43,000 during the year ended December&nbsp;31, 2013, which
resulted primarily from increased laboratory equipment expenditures in the year ended December&nbsp;31, 2014. The cash used in investing activities for the years ended December&nbsp;31, 2014 and
2013 was primarily the result of purchases of property and equipment.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Cash Provided by Financing Activities  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $16.9&nbsp;million during the three months ended March&nbsp;31, 2015 compared to
$19,000 during the three months ended March&nbsp;31, 2014. The cash provided by financing activities for the three months ended March&nbsp;31, 2015 primarily consisted of net proceeds of
$12.3&nbsp;million from the issuance 13,062,965 shares of our series&nbsp;B preferred stock in
March 2015 and gross proceeds of $5.0&nbsp;million from our borrowings under the Credit Facility offset by payments of deferred offering costs of $0.5&nbsp;million. The cash provided by financing
activities for the three months ended March&nbsp;31, 2014 primarily consisted of net proceeds of $19,000 from stock option exercises.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $4.8&nbsp;million during the year ended December&nbsp;31, 2014 compared to $41.4&nbsp;million during the year ended
December&nbsp;31, 2013. The cash provided by financing activities for the year ended December&nbsp;31, 2014 primarily consisted of gross proceeds of $5.0&nbsp;million from our borrowings under
the Credit Facility, partially offset by $0.3&nbsp;million of debt issuance costs. The cash provided by financing activities for the year ended December&nbsp;31, 2013 consisted of net proceeds of
$9.2&nbsp;million from the issuance of 13,136,951 shares of our series&nbsp;A preferred stock in January and June 2013, net proceeds of $32.2&nbsp;million from the issuance of 34,129,571 shares
of our series&nbsp;B preferred stock in October 2013 and proceeds received from stock option exercises.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development
of, and conduct clinical trials and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant
commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with
operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on
attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure
requirements at least through 2016. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of
the numerous risks and uncertainties associated with the development of CAT-1004, CAT-2054 and our other current and potential product candidates, and because the extent to which we may enter into
collaborations with third parties for the development of these product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with
completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success of any future collaborations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=77,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=233173,FOLIO='74',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_75"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or in-license other medicines and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and
defending intellectual property-related claims; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish and maintain collaborations on favorable terms, if at all. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identifying
potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we
may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success.
Our commercial
revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional
financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations,
strategic alliances and licensing arrangements. With the exception of the Credit Facility, we do not have any committed external source of funds. To the extent that we raise additional capital through
the sale of equity or convertible debt securities, our stockholders' ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders' rights. Additional debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would
otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual Obligations  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our significant contractual obligations as of payment due date by period at December&nbsp;31, 2014:

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payments due by period </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than<BR>
1 Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>1&nbsp;-&nbsp;3 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3&nbsp;-&nbsp;5 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More than<BR>
5 Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Term loan(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,044</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,787</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease obligations(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,138</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total contractual cash obligations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,925</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of repayment obligations under the Credit Facility, including interest.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
future minimum lease payments under our non-cancelable operating lease. The minimum lease payments above do not include any related common area
maintenance charges or real estate taxes.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=78,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=27395,FOLIO='75',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<A NAME="page_da15201_1_76"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March 31, 2015, we entered into an amendment to the Credit Facility. Concurrently with entering into the Credit Facility amendment, we borrowed $5.0 million under a term loan under
the Credit Facility with repayment terms that are equivalent to the initial term loan under the Credit Facility, including interest only payments until September&nbsp;1, 2015 and
36&nbsp;consecutive, equal monthly installment payments of principal and interest from October&nbsp;1, 2015 through September&nbsp;1, 2018.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
enter into agreements in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies and other
services and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon
30&nbsp;days prior written notice to the CRO, and therefore we believe that our non-cancelable obligations under these agreements are not material. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da15201_off-balance_sheet_arrangements"> </A>
<A NAME="toc_da15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Arrangements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under
applicable Securities and Exchange Commission rules. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="da15201_quantitative_and_quali__da102456"> </A>
<A NAME="toc_da15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quantitative and Qualitative Disclosures About Market Risk    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risk related to changes in interest rates. As of December&nbsp;31, 2014, we had cash and cash equivalents of
$14.7&nbsp;million and, as of March&nbsp;31, 2015, we had cash and cash equivalents of $24.3&nbsp;million, consisting primarily of money market funds. Our primary exposure to market risk is
interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term marketable securities. Our marketable
securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our
investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our marketable securities
until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014 and March&nbsp;31, 2015, we had no liabilities denominated in foreign currencies.


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=79,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=709582,FOLIO='76',FILE='DISK122:[14ZDH1.14ZDH15201]DA15201A.;76',USER='HYUNG',CD=';2-JUN-2015;11:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc15201_1_77"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc15201_business"> </A>
<A NAME="toc_dc15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc15201_overview"> </A>
<A NAME="toc_dc15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
based on our proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by
simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each
with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Our initial
focus is on treatments for rare diseases, such as Duchenne muscular dystrophy, or DMD. We are also developing other product
candidates for the treatment of serious lipid disorders. We target therapeutic areas and specific diseases with significant unmet medical need where we believe we will have a competitive advantage. We
seek to develop therapies that modulate multiple targets in the disease pathway. We have applied our SMART linker technology platform to build a development pipeline that includes three clinical-stage
product candidates and multiple programs in preclinical development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004 is an oral small molecule that we believe has the potential to be a disease-modifying therapy for the treatment of DMD that may be able to regenerate muscle in boys regardless
of the underlying dystrophin mutation. DMD is an ultimately fatal genetic disorder involving progressive muscle degeneration. CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal
anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid, or DHA, a naturally occurring unsaturated fatty acid with anti-inflammatory properties. We designed CAT-1004 to enhance the
activity of salicylate and DHA in modulating the NF-<FONT FACE="SYMBOL">k</FONT>B pathway at multiple points. NF-<FONT FACE="SYMBOL">k</FONT>B, or nuclear factor
kappa-light-chain-enhancer of activated B cells, is a protein that coordinates cellular response to damage, stress and inflammation and plays an important role in muscle health. We believe that
CAT-1004 modulates the disease pathway by inhibiting activated NF-<FONT FACE="SYMBOL">k</FONT>B and reducing the movement of activated NF-<FONT FACE="SYMBOL">k</FONT>B to the
nucleus of the cell. Activated NF-<FONT FACE="SYMBOL">k</FONT>B drives muscle degeneration and suppresses muscle regeneration. Chronic activation of
NF-<FONT FACE="SYMBOL">k</FONT>B has been reported in multiple skeletal muscle disorders, including muscular dystrophies, atrophy and inflammatory myopathies. In animal models of DMD,
CAT-1004 inhibited activated NF-<FONT FACE="SYMBOL">k</FONT>B, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase&nbsp;1 clinical trials in adults,
CAT-1004 inhibited activated NF-<FONT FACE="SYMBOL">k</FONT>B and was well tolerated with no observed safety concerns. We plan to initiate patient enrollment in a Phase&nbsp;1/2 clinical
trial of CAT-1004 in boys with DMD in June 2015. Subject to patient enrollment, we expect to report top-line Phase&nbsp;2 data in late 2016. If the results from our Phase&nbsp;1/2 clinical trial
and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase&nbsp;3 pivotal clinical trial of CAT-1004 in 2017 and seek marketing
approval based on this Phase 3 trial. The U.S. Food and Drug Administration, or FDA, has granted CAT-1004 orphan drug designation for the treatment of DMD. We hold worldwide rights to CAT-1004.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
two other clinical-stage product candidates, CAT-2054 and CAT-2003, are members of our CAT-2000 series. We applied our SMART linker technology to engineer these molecules as SMART
linker conjugates of the omega-3 fatty acid eicosapentaenoic acid, or EPA, and nicotinic acid to modulate the Sterol Regulatory Element Binding Protein, or SREBP, pathway. EPA is a naturally occurring
unsaturated fatty acid that has anti-inflammatory properties and beneficial effects on triglycerides. Nicotinic acid, which is also known as vitamin B3, is a naturally occurring essential vitamin that
has beneficial lipid effects at high doses. Because we used different SMART linkers for CAT-2054 and CAT-2003, they possess different pharmacokinetic and biodistribution characteristics. CAT-2003, our
first generation product candidate in the CAT-2000 series, is an orally administered molecule that modulates the SREBP pathway predominately in the intestine. CAT-2054, our second generation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=80,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=669430,FOLIO='77',FILE='DISK122:[14ZDH1.14ZDH15201]DC15201A.;58',USER='LPALLES',CD=';2-JUN-2015;13:20' -->
<A NAME="page_dc15201_1_78"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>product
candidate in the CAT-2000 series, is an orally administered molecule that modulates the SREBP pathway predominately in the liver. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP
is a master regulator of lipid metabolism, the processing of fats, triglycerides and cholesterol by the body, and controls the metabolism of both low density lipoprotein
cholesterol, or LDL-C, and triglycerides. We believe that the CAT-2000 product candidates modulate the disease pathway by inhibiting the maturation of the SREBP protein, thereby reducing its activity
and reducing the production of proteins involved in lipid metabolism. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have focused our initial efforts on the CAT-2000 series on lipid disorders such as hypercholesterolemia and hypertriglyceridemia because these disorders have clear short-term efficacy
biomarkers, enabling us to rapidly and efficiently demonstrate proof of concept for our technology. In the CAT-2000 series, our development priority is CAT-2054 for the treatment of
hypercholesterolemia, or elevated LDL-C, given what we believe is an attractive potential commercial opportunity in hypercholesterolemia and other SREBP-related metabolic disorders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are initially developing CAT-2054 for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient. Hypercholesterolemia is a disease that increases
the risk of cardiovascular events. By modulating the SREBP pathway, CAT-2054 may inhibit production of important cholesterol metabolism proteins, such as proprotein convertase subtilisin kexin 9, or
PCSK9; 3-hydroxy-3-methyl-glutaryl-CoA reductase, or HMG-CoA reductase; and adenosine triphosphate citrate lyase, or ATP citrate lyase, and Niemann-Pick C1-like 1, or NPC1L1. In a clinical trial of
our first generation SREBP modulator CAT-2003, we observed statistically significant reductions in LDL-C, suggesting an impact of SREBP modulation on cholesterol metabolism. Because the liver is the
primary regulator of cholesterol metabolism, we specifically designed the SMART linker in CAT-2054 to deliver more of the intact conjugate to the liver than CAT-2003. We believe that CAT-2054, if
approved, has the potential to be the first therapy to simultaneously modulate cholesterol synthesis, clearance and absorption. In January 2015, we initiated a Phase&nbsp;1 clinical trial to assess
the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. Preliminary data are available for the full range of doses tested in the single and multiple ascending dose portions of
the trial. If the final results of this clinical trial are positive, we intend to initiate a Phase&nbsp;2a clinical trial in patients with hypercholesterolemia in the fourth quarter of 2015 and
would expect to report Phase&nbsp;2a data in mid-2016. If the results of the planned Phase&nbsp;2a clinical trial are positive, we intend to initiate a Phase&nbsp;2b clinical trial of CAT-2054
in the fourth quarter of 2016. We hold worldwide rights to CAT-2054 and we intend to seek to commercialize CAT-2054 through one or more collaborations.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003
is our first generation product candidate in the CAT-2000 series. We engineered CAT-2003 as an orally administered SMART linker conjugate of EPA and nicotinic acid to modulate
the SREBP pathway. We designed CAT-2003 to target triglyceride levels in the blood and have studied CAT-2003 for the treatment of multifactorial chylomicronemia syndrome, or MFC, and refractory severe
hypertriglyceridemia, or rSHTG, diseases with niche patient populations with elevated triglycerides or
hypertriglyceridemia. We have completed three Phase&nbsp;2a trials with CAT-2003 in patient populations with hypertriglyceridemia. While we have chosen to prioritize the development of CAT-2054 over
CAT-2003, we believe that the clinical trial data for CAT-2003 support the utility of our SMART linker technology and the potential to treat lipid and metabolic disorders by modulating the SREBP
pathway. We intend to pursue collaborations to conduct exploratory evaluation of CAT-2003 in other serious diseases that involve alterations in the SREBP pathway, such as nonalcoholic steatohepatitis,
or NASH, and hepatocellular carcinoma, either to develop CAT-2003 as a product candidate or to support our development efforts for CAT-2054. We hold worldwide rights to CAT-2003. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-4001,
our most advanced preclinical product candidate, is a SMART linker conjugate of monomethyl fumarate and DHA. CAT-4001 is a small molecule that activates the Nrf2 pathway and
inhibits activated NF-<FONT FACE="SYMBOL">k</FONT>B. Nrf2, or Nuclear factor (erythroid-derived 2)-like 2, is a gene transcription </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=81,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=281545,FOLIO='78',FILE='DISK122:[14ZDH1.14ZDH15201]DC15201A.;58',USER='LPALLES',CD=';2-JUN-2015;13:20' -->
<A NAME="page_dc15201_1_79"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>factor,
a protein that works inside of cells to control the expression of genes, that controls the body's response to cellular stress and oxidative damage. We believe that CAT-4001 modulates the
disease pathway by enhancing the movement of Nrf2 to the nucleus of the cells and inhibits NF-<FONT FACE="SYMBOL">k</FONT>B by reducing the movement of activated
NF-<FONT FACE="SYMBOL">k</FONT>B to the nucleus of the cells. We are exploring CAT-4001 as a potential treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and
amyotrophic lateral sclerosis, or ALS, two diseases of the central nervous system in which the Nrf2 and NF-<FONT FACE="SYMBOL">k</FONT>B pathways have been implicated. We plan to conduct
additional preclinical evaluation of CAT-4001 in 2015, and if the results are positive we intend to advance CAT-4001 into investigational new drug application, or IND, enabling studies in 2016. We
hold worldwide rights to CAT-4001. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April&nbsp;30, 2015, we owned two issued U.S. patents relating to composition of matter and method of use claims directed to CAT-1004 and two issued U.S. patents relating to
composition of matter and method of use claims directed to the CAT-2000 series. These patents are expected to expire between 2029 and 2031, without taking potential patent term extensions into
account. In addition, our patent portfolio includes over 10 issued foreign patents, over 25 pending U.S. patent applications and over 100 pending foreign patent applications. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc15201_our_strategy"> </A>
<A NAME="toc_dc15201_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our objective is to apply our proprietary SMART linker technology platform to discover, develop and commercialize novel bi-functional
therapeutics, with an initial focus on rare diseases and serious lipid disorders, either on our own or through collaborations. We target therapeutic areas and specific diseases with significant unmet
medical need where we believe we will have a competitive advantage. We seek to develop therapies that modulate multiple targets in the disease pathway. To achieve our goals, we are pursuing the
following strategies: </FONT></P>


<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'>

<FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Complete the development of CAT-1004 through registration for
DMD.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We are devoting a significant portion of our resources to developing CAT-1004 for the treatment of DMD. We plan to initiate patient
enrollment in a Phase&nbsp;1/2 clinical trial of CAT-1004 for the treatment of DMD in June 2015. Subject to patient enrollment, we expect to report top-line Phase&nbsp;2 data in late 2016. If the
results from our Phase&nbsp;1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase&nbsp;3 pivotal clinical
trial of CAT-1004 in 2017 and seek marketing approval based on this Phase&nbsp;3 trial. Our goal is to develop the first disease-modifying oral therapy for the treatment of DMD that promotes muscle
regeneration.

</FONT>

<FONT SIZE=2>

<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'>

<FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Advance the development of CAT-2054.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In January 2015, we
initiated a Phase&nbsp;1 clinical trial of CAT-2054 to assess its safety, tolerability and pharmacokinetics in healthy volunteers. Preliminary data are available for the full range of doses tested
in the single and multiple ascending dose portions of the trial. If the final results of this clinical trial are positive, we intend to initiate a Phase&nbsp;2a clinical trial in patients with
hypercholesterolemia in the fourth quarter of 2015 and would expect to report Phase&nbsp;2a data in mid-2016. If the results of the planned Phase&nbsp;2a clinical trial are positive, we intend to
initiate a Phase&nbsp;2b clinical trial of CAT-2054 in the fourth quarter of 2016. We also plan to evaluate CAT-2054 and other CAT-2000 series molecules in other SREBP-mediated diseases.

 </FONT>

<FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Advance the development of CAT-4001.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We plan to conduct
additional preclinical evaluation of CAT-4001 in Friedreich's ataxia and ALS in 2015. If the results are positive, we intend to advance CAT-4001 into IND-enabling studies in 2016. </FONT> <FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Continue to apply our SMART linker technology
platform.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We have used our SMART linker technology platform to rapidly and efficiently identify product candidates that we have been
able to advance into clinical development. To date we have engineered more than 20 conjugate series, of which two are now in clinical development. Examples of our pre-clinical assets include

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=82,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=942729,FOLIO='79',FILE='DISK122:[14ZDH1.14ZDH15201]DC15201A.;58',USER='LPALLES',CD=';2-JUN-2015;13:20' -->
<A NAME="page_dc15201_1_80"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>



<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>conjugates
of fumarate, statins, antivirals and chemotherapeutics. We are continually advancing our conjugation capabilities and exploring new applications of our technology platform to develop
bi-functional therapeutics to treat diseases that we believe can be effectively addressed by modulating multiple biological targets in one or more related disease pathways. We are also advancing our
technology for application to the intracellular delivery of protein therapeutics. While we intend to continue our internal drug discovery and development efforts, we also plan to leverage our SMART
linker technology platform through selective collaborations with leading biotechnology and pharmaceutical companies to further broaden our pipeline of product candidates. We have a goal of identifying
at least one novel conjugate per year, either on our own or through collaborations, that we can advance into preclinical development.

 </FONT></P>

</UL>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Maintain flexibility in commercializing and maximizing the value of our development
programs.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;We intend to enter into strategic relationships with biotechnology and pharmaceutical companies where maximizing the
commercial value of our development programs will require access to broader geographic markets or the pursuit of broader patient populations or indications, such as with the CAT-2000 series and the
commercialization of CAT-1004 outside of the United States and Canada. We also plan to build focused capabilities in the United States and Canada to commercialize development programs, such as
CAT-1004 for DMD, where we believe that the medical specialists for the indications are sufficiently concentrated to allow us to effectively promote the product with a targeted sales team. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc15201_our_scientific_approach"> </A>
<A NAME="toc_dc15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Scientific Approach    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological
targets in one or more related disease pathways. The traditional model for drug discovery has focused on identifying and evaluating drug candidates with the goal of modifying a single biological
target implicated in a specific disease process. This approach of selecting a single bioactive to modulate a single target has been successful for certain types of diseases. However, many diseases are
caused by multiple abnormalities rather than by a single defect. In these cases, the traditional single-target approach to drug discovery and development may be less effective because a single target
may not address the multiple underlying defects causing the disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multi-target
therapies have in many cases been developed to provide treatment options where single-target therapies have been ineffective. These multi-target therapies have traditionally
followed one of two approaches: either use of a single drug that binds to multiple biological targets or co-administration of two or more drugs that interact with different targets. While each of
these approaches has well-established benefits in a variety of indications, each is also characterized by significant limitations. For example, use of a single broadly targeted drug can lead to
off-target toxicities, side-effects and tolerability issues, and co-administration of two or more drugs can be confounded by differences in the pharmacokinetics and tissue distribution of the drugs,
thereby reducing the likelihood of each agent being simultaneously active in the same cell. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
aim is to leverage the growing body of knowledge associated with disease pathways, and to rationally design orally bioavailable product candidates that simultaneously interact with
multiple biological targets within one or more related disease pathways. While other technologies exist to conjugate or combine two bioactives, we believe that our SMART linker technology platform
provides substantial improvements over previous approaches to bioactive conjugation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc15201_smart_linker_technology_platform"> </A>
<A NAME="toc_dc15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


SMART Linker Technology Platform    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have leveraged our SMART linker technology platform to create molecules that simultaneously modulate multiple biological targets
within one or more related disease pathways. Our technology platform includes a broad array of linkers that we use to engineer molecular series, which are </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=83,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=186346,FOLIO='80',FILE='DISK122:[14ZDH1.14ZDH15201]DC15201A.;58',USER='LPALLES',CD=';2-JUN-2015;13:20' -->
<A NAME="page_dc15201_1_81"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>susceptible
to intracellular cleavage only. The linkers used in our technology platform are small chemicals designed to join two separate bioactives into a single conjugate molecule. In systemic
circulation, our SMART linker conjugates are stable and inactive, potentially reducing off-target toxicities and side-effects. The conjugates are designed to be cleaved by specific enzymes exclusively
within cells in order to release the two bioactives inside the cells. By releasing the bioactive components of the conjugate molecule only inside cells, the SMART linker allows the bioactives to reach
their targets more efficiently and have greater efficacy than if the bioactives were dosed independently or in combination. The stability of our SMART linker conjugates outside of cells and the
release of the bioactives exclusively within cells are important differentiating features of our SMART linker technology platform. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
create a conjugate using our SMART linker technology platform, we begin by analyzing pathways that are disrupted in a disease. We then select two bioactive molecules known for their
clinical safety and demonstrated effect along one or more of these biological pathways. We then design a SMART linker that will conjugate the two selected bioactives, allow the conjugate to be carried
to biological tissues and, following entry into cells, be cleaved by enzymes resident in the cells to release the bioactives, as shown in the figures below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g239265.jpg" ALT="GRAPHIC" WIDTH="631" HEIGHT="279">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
SMART linker conjugates are designed to be stable to oral dosing, as well as stable in both the lumen of the intestine and in systemic circulation, which we have now observed in
clinical trials for two product candidate series. We design the SMART linker to chemically link the two bioactive molecules through their pharmacophores, the regions of the bioactive molecules that
are responsible for carrying out their biological activity, resulting in inactivation of the bioactives. Once the conjugate enters a cell, the SMART linker is cleaved by specific enzymes which reside
only within cells, releasing the two bioactives to interact with their biological targets. Delivery of the bioactives through the SMART linker conjugate into the cell results in the two bioactives
having the same pharmacokinetics and tissue distribution. As a result, our SMART linker conjugates can simultaneously modulate two biological targets in disease pathways of interest within the same
cell. In addition, release of the bioactives exclusively inside cells can potentially reduce or eliminate off-target, extracellular activity of the bioactives, which may improve safety and
tolerability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have observed in multiple preclinical studies that our SMART linker conjugates achieved greater efficacy than administration of the two bioactives either independently or in
combination. In clinical trials, SMART linker conjugates have demonstrated significant improvements in activity on disease pathways and tolerability relative to equivalent doses of the two bioactives
delivered in combination. We also have observed statistically significant efficacy with SMART linker conjugates at dose levels significantly lower than the prescribed doses of the two component
bioactives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=84,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=114172,FOLIO='81',FILE='DISK122:[14ZDH1.14ZDH15201]DC15201A.;58',USER='LPALLES',CD=';2-JUN-2015;13:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de15201_1_82"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe our SMART linker technology platform has the potential to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> enhance activity on disease pathways through modulation of multiple biological targets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improve efficacy by matching the pharmacokinetics and tissue distribution of the component bioactives; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improve safety and tolerability by releasing the component bioactives only within cells. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we are advancing our technology for application to the intracellular delivery of protein therapeutics. We have early evidence of the intracellular delivery of proteins into
cells with test proteins and are now exploring potential protein therapeutics. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de15201_our_product_candidates"> </A>
<A NAME="toc_de15201_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Candidates    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following chart summarizes key information regarding our product candidates. We hold worldwide rights to all of our product
candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g589761.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="330">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de15201_cat-1004"> </A>
<A NAME="toc_de15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing CAT-1004 for the treatment of DMD, with the potential to regenerate muscle and be disease modifying in boys with DMD
regardless of the underlying dystrophin mutation. CAT-1004 is an orally administered SMART linker conjugate of salicylate and DHA that we designed to enhance the activity of salicylate and DHA in
modulating the NF-<FONT FACE="SYMBOL">k</FONT>B pathway at multiple points. Emerging data suggest that activation of NF-<FONT FACE="SYMBOL">k</FONT>B drives the loss of skeletal
muscle mass in multiple diseases, including muscular dystrophies, atrophy and inflammatory myopathies. In December 2014, we submitted an IND to the FDA for CAT-1004 for DMD. We plan to initiate
patient enrollment in a Phase&nbsp;1/2 clinical trial of CAT-1004 for the treatment of DMD in June 2015. Subject to patient enrollment, we expect to report top-line Phase&nbsp;2 data in late 2016.
If the results from our Phase&nbsp;1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase&nbsp;3 pivotal
clinical trial of CAT-1004 in 2017 and seek marketing approval based on this Phase&nbsp;3 trial. We believe that CAT-1004 has the potential to be the first disease-modifying oral therapy for the
treatment of DMD that promotes muscle regeneration. The FDA has granted CAT-1004 orphan drug designation for the treatment of DMD and we plan to submit an

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=85,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=25146,FOLIO='82',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


orphan drug designation request to the European Medicines Agency, or EMA, in the second half of 2015.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview of DMD  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMD is a rare pediatric disorder involving progressive muscle degeneration that eventually leads to death. DMD is caused by various
mutations in the dystrophin gene that result in a lack of functional dystrophin in muscle fibers, which renders muscle fibers more susceptible to mechanical stress. Dystrophin is a protein that
resides in the membrane of muscle cells and is critical to the structural and membrane stability of muscle fibers in skeletal, diaphragm and heart muscle. When muscles contract or stretch during
normal use, the absence of normally functioning dystrophin results in activation of the NF-<FONT FACE="SYMBOL">k</FONT>B pathway, triggering inflammation in the muscles, resulting in muscle
damage and reducing the ability of muscles to regenerate. As muscle damage progresses, connective and adipose tissues replace muscle fibers, resulting in inexorable muscle weakness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMD
occurs almost exclusively in males, occurring in approximately 1 in 3,500 live male births. Based on this incidence rate, we estimate that DMD affects a total of approximately 15,000
patients in the United States and approximately 19,000 patients in the European Union. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Children
with DMD typically begin to show symptoms of disease between ages two and five, when they develop a waddling gait, frequently fall and have difficulty rising from the floor.
Progressive weakness then develops in the voluntary muscles in the arms, legs and trunk. This muscle weakness results in fixations, or contractures, of joints, such as knees, hips and elbows. By age
eight, most patients have difficulty ascending stairs. By their early teens, patients typically lose walking ability and are confined to wheelchairs. Patients' cardiac and respiratory muscles are also
adversely affected, typically requiring use of ventilators in their late teens. Progressive weakening of cardiac and respiratory muscles eventually results in death, generally by patients'
mid-twenties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Role of NF-<FONT FACE="SYMBOL">k</FONT>B in Duchenne Muscular Dystrophy  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NF-<FONT FACE="SYMBOL">k</FONT>B plays an important role in regulating skeletal muscle health and appears to be especially
important in regulating skeletal muscle mass in chronic diseases such as DMD. Activated NF-<FONT FACE="SYMBOL">k</FONT>B promotes the degradation of specific muscle proteins and leads to
the induction of pro-inflammatory mediators such as cytokines, including tumor necrosis factor alpha, or TNF-<FONT FACE="SYMBOL">a</FONT>, interleukin 6, or IL-6, and interleukin-1 beta, or
IL-1<FONT FACE="SYMBOL">b</FONT>; chemokines; cell adhesion molecules; and tissue degrading enzymes, such as matrix metallopeptidase&nbsp;9, or MMP-9. In addition, activated
NF-<FONT FACE="SYMBOL">k</FONT>B suppresses muscle stem cell differentiation that is required for muscle regeneration by preventing satellite stem cells from differentiating into myoblasts,
progenitor cells that differentiate, to give rise to muscle cells. Activation of NF-<FONT FACE="SYMBOL">k</FONT>B is observed in muscle tissues of patients with DMD prior to the onset of
other clinical manifestations, and activated NF-<FONT FACE="SYMBOL">k</FONT>B is persistently elevated in the immune cells and degenerating muscle fibers of patients with DMD. Moreover,
evidence exists that mechanical stress activates NF-<FONT FACE="SYMBOL">k</FONT>B in muscles by a factor of three to four times and drives NF-<FONT FACE="SYMBOL">k</FONT>B
mediated inflammation. Muscles with increased mechanical stress and inflammation, such as quadriceps and hamstrings, show the greatest progression of disease. This more rapid deterioration of muscles
bearing greater mechanical stress, and thus more activated NF-<FONT FACE="SYMBOL">k</FONT>B mediated inflammation, in boys with DMD can be observed through magnetic resonance imaging, or
MRI, such as in the following image from a study conducted by

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=86,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=423971,FOLIO='83',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>ImagingDMD,
a group of investigators at clinical sites in the United States with clinical leadership and expertise in the use of MRI as an assessment tool for DMD. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g683889.jpg" ALT="GRAPHIC" WIDTH="504" HEIGHT="441">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaddressed Market Opportunity  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no therapies approved for the treatment of DMD in the United States. Corticosteroid therapy is often prescribed to treat the
inflammation underlying DMD and to delay loss of ambulation. Corticosteroids have demonstrated efficacy in DMD patients, which is believed to be driven by reductions in activated
NF-<FONT FACE="SYMBOL">k</FONT>B. However, corticosteroids primarily act through another pathway called the glucocorticoid receptor-mediated pathway, and also can cause significant
complications including growth suppression, reduction in bone strength and compromise of the immune system. Over time, corticosteroids induce chronic myopathy in many diseases through induction of
muscle protein breakdown, which ultimately leads to muscle damage. DMD patients treated with corticosteroids typically show an initial improvement in measures of muscle function but then resume a
progressive decline. Approximately half of DMD patients treated with steroids lose the ability to walk by age eleven and almost all are in wheelchairs by age sixteen. DMD patients typically live until
their mid-twenties, despite the availability of corticosteroids.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
companies are exploring new therapies for the treatment of DMD. The three most advanced product candidates, PTC Therapeutics' ataluren, BioMarin's drisapersen and Sarepta's
eteplirsen, target mechanisms to increase levels of dystrophin in muscles. Each of these product candidates compensates for a specific genetic mutation in order to produce a partially functional
dystrophin protein. The therapeutic goal of these product candidates is to reduce disease severity and extend survival in those DMD patients with the specific mutation. Based on the prevalence of the
specific mutations that these product candidates are designed to address, they would be expected to be effective in an aggregate of approximately 26% of DMD patients. We believe that DMD patients, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=87,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=996154,FOLIO='84',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_85"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>including
those treated with these dystrophin therapies, will continue to require treatments to reduce muscle inflammation and enhance muscle regeneration. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004 for the Treatment of Duchenne Muscular Dystrophy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004 is a SMART linker conjugate of salicylate and DHA that we designed to enhance the activity of salicylate and DHA in modulating
the NF-<FONT FACE="SYMBOL">k</FONT>B pathway at multiple points. The CAT-1004 conjugate is inactive outside the cell, and, once inside the cell CAT-1004 is cleaved, releasing DHA and
salicylate simultaneously inside the cell. Based on its mechanism of action in suppressing activated NF-<FONT FACE="SYMBOL">k</FONT>B, we believe that CAT-1004 has the potential to combine
reduction of inflammation and muscle degeneration with positive effects on muscle regeneration, all of which may allow patients to retain muscle function longer. In addition, we believe that CAT-1004
has the potential to be effective in all DMD patients, regardless of the underlying mutation, and to provide significant benefit to patients, both as monotherapy and when used in combination with
other therapies, including dystrophin-targeted therapies and agents targeting myostatin. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In Phase&nbsp;1 clinical trials in adults, CAT-1004 was observed to be well tolerated and to inhibit activated NF-<FONT FACE="SYMBOL">k</FONT>B. Based on the positive
effects observed in the Phase&nbsp;1 trials and in animal studies, we plan to initiate enrollment in a Phase&nbsp;1/2 clinical trial in boys with DMD in June 2015.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004 Clinical Development  </I></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Planned Phase&nbsp;1/2 Trial of CAT-1004 in Patients with DMD  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our planned CAT-1004 Phase&nbsp;1/2 trial will enroll ambulatory boys between ages four and seven with a genetically confirmed
diagnosis of DMD. We refer to the trial as the MoveDMD trial. The enrolled boys will be steroid naive or have not used steroids for at least six months prior to the trial. The enrolled boys will not
be limited to any specific dystrophin mutations. We will conduct the trial at three sites in the United States. We plan to conduct the MoveDMD trial in two sequential parts, Part&nbsp;A and
Part&nbsp;B, as illustrated in the following diagram. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de15201_planned_movedmd_trial_design"> </A>
<A NAME="toc_de15201_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>Planned MoveDMD Trial Design    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g693927.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="246">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
Part&nbsp;A of the MoveDMD trial, we will assess the safety, tolerability and pharmacokinetics of CAT-1004 in patients at three dosing levels following seven days of dosing. We also
will compare CAT-1004 exposure levels to exposure levels achieved in previous CAT-1004 clinical trials where NF-<FONT FACE="SYMBOL">k</FONT>B biomarker activity was achieved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=88,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=912466,FOLIO='85',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_86"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Part&nbsp;B
of the MoveDMD trial will be a randomized, double-blind, placebo-controlled trial. In Part&nbsp;B, we plan to treat patients with one of two dosing levels of CAT-1004 or
placebo for 12&nbsp;weeks. After 12&nbsp;weeks of dosing, patients receiving placebo may be crossed over to one of two doses of CAT-1004 for an additional 12&nbsp;weeks. We have designed the
MoveDMD trial with the assistance of ImagingDMD. We expect that the MoveDMD trial will be conducted at ImagingDMD's three clinical sites. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that the primary efficacy endpoint in Part&nbsp;B of the MoveDMD trial will be change in muscle inflammation as measured by MRI of leg muscles. MRI studies in DMD have
recently shown that inflammatory changes occur before development of fibrosis and infiltration of fat into muscle. Inflammatory changes are most evident in muscles that ultimately show the greatest
replacement by non-contractile tissues. Both inflammation and fatty infiltration are correlated with functional ability in boys with DMD. Additionally, third party studies have shown that in young DMD
patients that are still ambulatory, decreases in muscle inflammation over 12&nbsp;weeks of glucocorticoid therapy can be clearly identified through MRI imaging. Similarly, glucocorticoids have been
observed to improve muscle strength and performance in timed functional tests after short periods of treatment. In early ambulatory DMD boys, functional abilities such as the 10 meter walk/run are
relatively stable and more homogeneous than in older boys in whom functional ability is declining. We plan to include as
exploratory endpoints timed function tests best suited for the age group of the trial subjects, specifically the 10 meter walk/run, time to stand and 4-stair climb tests. In addition, assessments of
muscle strength and a parent-proxy measure of functional ability will be included. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to patient enrollment, we expect to report top-line data from Part&nbsp;A of the MoveDMD trial in late 2015 and top-line data from Part&nbsp;B of the trial in late 2016. If
the results of this Phase 1/2 clinical trial and discussions with regulatory authorities regarding a pivotal trial are positive, we intend to initiate a six-month Phase&nbsp;3 pivotal clinical trial
of CAT-1004 in 2017 and seek marketing approval based on this Phase&nbsp;3 trial. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Completed Clinical Trials  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have studied CAT-1004 in three completed Phase&nbsp;1 clinical trials. The design and results for these clinical trials
are discussed below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-1004&#151;Completed Phase&nbsp;1 Clinical Trials  </I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR style="font-size:1.5pt;" VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="LEFT" style="font-family:times;">&nbsp;<BR></TH>
<TH style="font-family:times;">&nbsp;</TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=9 ALIGN="CENTER" style="font-family:times;border-left:solid #000000 1.0pt; border-right:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; border-right:solid #000000 1.0pt;" -->


 Subjects </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="border-top:solid #000000 1.0pt;font-family:times;border-left:solid #000000 1.0pt; "><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; " -->


&nbsp;


<!-- COMMAND=ADD_GUTTERGRID,"border-top:solid #000000 1.0pt;" -->


 </B></FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-top:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-top:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1><B>Treated with<BR>
CAT-1004</B></FONT><BR></TH>
<TH style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-top:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-left:solid #000000 1.0pt; "><FONT SIZE=1><B>


<!-- COMMAND=ADD_GUTTERGRID,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; " -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1><B>Trial</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1><B>Description</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1><B>Duration</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1><B>Total</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-left:solid #000000 1.0pt; "><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; " -->


&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GUTTERGRID,"border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;" -->


 CAT-1004-101</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>Randomized, double-blind, placebo-controlled, single ascending dose clinical trial to evaluate safety, tolerability and pharmacokinetics of CAT-1004 in healthy subjects</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>1&nbsp;day</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-top:solid #000000 1.0pt;border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;border-left:solid #000000 1.0pt; "><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; " -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GUTTERGRID,"border-bottom:solid #000000 1.0pt;" -->


 CAT-1004-102</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>Randomized, double-blind, placebo-controlled multiple ascending dose clinical trial to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CAT-1004 in adults with Type&nbsp;2 diabetes</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>14&nbsp;days</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>32</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;border-left:solid #000000 1.0pt; "><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-left:solid #000000 1.0pt; " -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GUTTERGRID,"border-bottom:solid #000000 1.0pt;" -->


 CAT-1004-103</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>Single-blind biomarker trial in healthy adults to compare activity of CAT-1004, a combination of salicylate and DHA, or placebo on activated NF-<FONT FACE="SYMBOL">k</FONT>B</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>1&nbsp;day</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="border-bottom:solid #000000 1.0pt;font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="border-bottom:solid #000000 1.0pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=89,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=940643,FOLIO='86',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;1 Single Ascending Dose Trial (CAT-1004-101):</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We conducted a randomized, double-blind, placebo-controlled, single ascending
dose
Phase&nbsp;1 clinical trial in 52 healthy volunteers at a single site in the United States to assess the safety, tolerability and pharmacokinetics of CAT-1004 in both fasted and fed states. The
participants were randomized to receive CAT-1004 or placebo. CAT-1004 was administered orally in soft gelatin capsules at doses ranging from 300 mg to 6000 mg. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Single
doses of CAT-1004, administered to subjects in both fed and fasted conditions appeared to be well tolerated. Subjects in the fasted state reported few adverse events, or AEs, with
the most commonly reported AEs being headache, diarrhea and dizziness. Of the 44 subjects in the fasted state, five&nbsp;reported headache, three&nbsp;reported diarrhea and two&nbsp;reported
dizziness. The majority of the AEs in the fasted state were mild in severity. The most common AEs in the fed state were diarrhea, headache and abdominal pain and all of the AEs in the fed state were
mild in severity. Of the 35 subjects in the fed state, six reported diarrhea, six reported headache and four reported abdominal pains. Subjects in the fed state receiving single doses of CAT-1004 of
4000 mg or more reported gastrointestinal AEs more frequently than subjects receiving lower doses. No treatment-related severe AEs were reported. There were no observed trends in laboratory, vital
signs or electrocardiogram results following CAT-1004 administration in either the fasted or fed state. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004
was rapidly absorbed in plasma, with mean maximum and overall plasma exposure generally increasing with CAT-1004 dose levels. Neither component bioactive, salicylate or DHA, was
detected in plasma at levels above background, consistent with intracellular cleavage of CAT-1004 and intracellular delivery of the component bioactives. Administration of a high-fat meal increased
CAT-1004 mean maximum and overall exposure by approximately 3- to 8-fold. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;1 Multiple Ascending Dose Trial (CAT-1004-102):</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We conducted a randomized, double-blind, placebo-controlled, multiple
ascending dose
Phase&nbsp;1 clinical trial in 44 subjects at a single center in the United States to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CAT-1004. These subjects had
Type&nbsp;2 diabetes and mild background inflammation, which enabled us to assess the
activity of CAT-1004 on activated NF-<FONT FACE="SYMBOL">k</FONT>B. Subjects were randomized to receive CAT-1004 or placebo. CAT-1004 was administered orally in soft gelatin capsules at
total daily doses ranging from 300 mg to 4000 mg. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004
administered for two weeks appeared to be well tolerated. The AEs reported in more than one subject were each reported by two subjects. These AEs were diarrhea (both instances
reported by subjects receiving 4000 mg daily doses of CAT-1004), gastroenteritis (one instance reported by a subject in the placebo group and the other by a subject receiving 1000 mg daily doses of
CAT-1004) and upper respiratory tract infection (both instances reported by subjects receiving 4000 mg daily doses of CAT-1004). The majority of the AEs were mild in severity. No treatment-related
severe AEs were reported. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-1004
was rapidly absorbed in plasma, with mean maximum and overall plasma exposure generally increasing with escalating single or multiple doses of CAT-1004. Neither component
bioactive, salicylate or DHA, was detected in plasma at levels above background, again consistent with intracellular cleavage of CAT-1004 and intracellular delivery of the component bioactives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the Phase&nbsp;1 multiple ascending dose trial, we observed by two methods that CAT-1004 inhibited activated NF-<FONT FACE="SYMBOL">k</FONT>B. For the first method, we
stimulated NF-<FONT FACE="SYMBOL">k</FONT>B activity </FONT><FONT SIZE=2><I>ex vivo</I></FONT><FONT SIZE=2> in whole blood from subjects treated with CAT-1004 or placebo, and then observed
NF-<FONT FACE="SYMBOL">k</FONT>B activity in monocytes, or immune cells, that we isolated from the whole blood. NF-<FONT FACE="SYMBOL">k</FONT>B activity was reduced in a
majority of subjects following two weeks of CAT-1004 treatment but not following treatment with placebo. For the second method, we performed gene expression analyses on whole blood taken from subjects
prior to treatment and after two weeks of treatment with CAT-1004 or placebo. CAT-1004 significantly reduced the expression of a set of genes that are controlled by
NF-<FONT FACE="SYMBOL">k</FONT>B. In contrast, treatment with placebo for two weeks did not significantly reduce expression of NF-<FONT FACE="SYMBOL">k</FONT>B regulated genes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=90,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1013572,FOLIO='87',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_88"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase&nbsp;1 NF-<FONT FACE="SYMBOL">k</FONT>B Biomarker Trial (CAT-1004-103):</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We conducted a single-blind, crossover Phase&nbsp;1
clinical trial with CAT-1004 in nine healthy adult volunteers at a single center in the United States to compare activity of a single dose of 2000 mg of CAT-1004 on activated
NF-<FONT FACE="SYMBOL">k</FONT>B to a combination of salicylate and DHA or placebo. No AEs were reported in this clinical trial. The salicylate and DHA were dosed at approximately
equivalent amounts to those contained in the CAT-1004 conjugate. We
assessed NF-<FONT FACE="SYMBOL">k</FONT>B activity in peripheral blood mononuclear cells, or PBMCs, isolated from subjects before dosing and two hours after dosing. PBMCs are circulating
immune cells that can mount an NF-<FONT FACE="SYMBOL">k</FONT>B response and migrate into tissue such as muscle and drive inflammation. Prior to the determination of
NF-<FONT FACE="SYMBOL">k</FONT>B activity, we stimulated whole blood with lipopolysaccharide, or&nbsp;LPS, to activate the NF-<FONT FACE="SYMBOL">k</FONT>B pathway. As shown in
the graph below, treatment of subjects with CAT-1004 significantly reduced the level of activated NF-<FONT FACE="SYMBOL">k</FONT>B, as measured by nuclear p65, a surrogate marker for
activated NF-<FONT FACE="SYMBOL">k</FONT>B. In contrast, no change in the level of activated NF-<FONT FACE="SYMBOL">k</FONT>B was observed upon treatment with the combination of
salicylate and DHA, or upon treatment with placebo. In this trial, CAT-1004, which is a SMART linker conjugate of salicylate and DHA, exhibited greater activity on the
NF-<FONT FACE="SYMBOL">k</FONT>B pathway than the combination of its component bioactives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>Effect of CAT-1004 on Activated NF-<FONT FACE="SYMBOL">k</FONT>B  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g884541.jpg" ALT="GRAPHIC" WIDTH="315" HEIGHT="231">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These results were statistically significant, with a p-value of less than 0.005. P-value is a conventional statistical method for measuring the statistical
significance of clinical results. A p-value of 0.05 or less represents statistical significance, meaning that there is a 1-in-20 or less statistical probability that the observed results occurred by
chance. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004 Preclinical Development  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In preclinical studies, we have observed that CAT-1004 inhibited NF-<FONT FACE="SYMBOL">k</FONT>B activity </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT
SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>, and produced disease-modifying effects in two established animal models of DMD,
the </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mouse model and the Golden Retriever muscular dystrophy, or GRMD, dog model. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


In Vivo Studies in Animal Models of DMD  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have created several SMART linker conjugates that inhibit activated NF-<FONT FACE="SYMBOL">k</FONT>B. Two of these
conjugates, CAT-1004 and CAT-1041, exhibit very similar effects on NF-<FONT FACE="SYMBOL">k</FONT>B activity in cell based assays, in animal studies and on functional activity in animal
models. CAT-1041 is a closely related analog of CAT-1004 in which the DHA component of the salicylate-DHA conjugate has been replaced with EPA. In some preclinical studies, we used CAT-1041 as a
surrogate for CAT-1004. Both CAT-1004 and CAT-1041 produced disease-modifying efficacy in established animal models of DMD. We decided to advance CAT-1004 into clinical trials rather than CAT-1041
based on scientific literature suggesting that DHA has superior anti-inflammatory activity compared to EPA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=91,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=252211,FOLIO='88',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_89"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mdx Mouse Model.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We examined the potential therapeutic effects of CAT-1004 using the </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2>
mouse model
of DMD. We observed that four weeks of treatment with CAT-1004 or prednisolone, a steroid, reduced muscle inflammation and the number of degenerating muscle fibers in </FONT> <FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice. However, only
CAT-1004-treated animals showed preservation of muscle mass and an increase in the number of regenerating fibers, suggesting
that chronic treatment with CAT-1004 can protect muscle from the damage expected to occur over time in </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
a long-term </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mouse study, we observed that, compared to the control group of </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2>
mice, six months of treatment with CAT-1041 significantly improved muscle endurance as measured by mean weekly and total running distance determined based upon cumulative revolutions on a running
wheel. As shown in the graphs below, improvements in muscle endurance following CAT-1041 treatment versus control were also observed in post-mortem assessments of twitch force, tetanic force and
specific force generation, each of which is an established measurement of muscle endurance, in excised diaphragm muscle. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-1041 Activity on Diaphragm Function in the mdx Mouse Model</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g349605.jpg" ALT="GRAPHIC" WIDTH="648" HEIGHT="187">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
shown in the graph below, we also observed in this same study that </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice treated with CAT-1041 showed significantly increased mass
of two major leg muscles, the gastrocnemius and quadriceps. These increases were independent of changes in total body weight. CAT-1041-treated mice also had a statistically significant reduction in
heart mass, suggesting that chronic treatment with CAT-1041 may have reduced the dilated cardiomyopathy typically observed in </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-1041 Activity on Muscle Mass in the mdx Mouse Model</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g16194.jpg" ALT="GRAPHIC" WIDTH="261" HEIGHT="265">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=92,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=317159,FOLIO='89',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<A NAME="page_de15201_1_90"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this study, we also observed that CAT-1004 and CAT-1041 exhibited similar activity on muscle contractions of the extensor digitorum longus muscle in </FONT> <FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice with significant preservation of muscle
function compared to control. Finally, in this study we observed a reduction in diaphragm and quadricep
muscle fibrosis in </FONT><FONT SIZE=2><I>mdx</I></FONT><FONT SIZE=2> mice treated with CAT-1041 in comparison to control. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Golden Retriever Dog Model.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We also evaluated the effects of CAT-1004 in the GRMD dog model. As shown in the graph below, a single oral
dose of
CAT-1004 inhibited basal, or unstimulated, NF-<FONT FACE="SYMBOL">k</FONT>B activity by 48% in GRMD dogs. CAT-1004 also inhibited&nbsp;LPS-stimulated
NF-<FONT FACE="SYMBOL">k</FONT>B activity by 75% and&nbsp;LPS-stimulated plasma levels of
TNF<FONT FACE="SYMBOL">a</FONT> protein, a key marker of inflammatory response, by 77%. Together, these data suggest that a single oral dose of CAT-1004 achieves sufficient exposure levels
to inhibit activated NF-<FONT FACE="SYMBOL">k</FONT>B in a dog model of DMD. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>Effect of CAT-1004 on NF-<FONT FACE="SYMBOL">k</FONT>B in the GRMD Dog Model</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g561315.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="243">
  </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


In Vitro Studies  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> study in a mouse macrophage cell line, we observed that CAT-1004
inhibited LPS-stimulated NF-<FONT FACE="SYMBOL">k</FONT>B activity to a greater extent than either of its components, salicylate and DHA, alone or in combination. We also observed that
CAT-1004 inhibited LPS-stimulated NF-<FONT FACE="SYMBOL">k</FONT>B activity in human PBMCs, which are a potential target tissue for CAT-1004. In studies performed with a mouse macrophage
cell line, CAT-1004 reduced the&nbsp;LPS-stimulated expression of a set of genes that encode pro-inflammatory mediators and whose expression is controlled by
NF-<FONT FACE="SYMBOL">k</FONT>B. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004 Orphan Drug Designation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA has granted CAT-1004 orphan drug designation for the treatment of DMD and we plan to submit an orphan drug designation request
to the European Medicines Agency, or EMA, in the second half of 2015. A product may be designated by the FDA as an "orphan drug" if it is intended to treat a rare disease or condition affecting fewer
than
200,000&nbsp;individuals in the United States. Similarly, the EMA may designate a product as an orphan drug if it is intended for the treatment of a life-threatening or chronically debilitating
condition affecting not more than five in ten thousand persons. If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the FDA
will not approve another sponsor's marketing application for the same product for the same use or indication before the expiration of seven years, except in certain limited circumstances. In Europe,
marketing authorization for an orphan drug generally leads to a ten-year period of market exclusivity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=93,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=587858,FOLIO='90',FILE='DISK122:[14ZDH1.14ZDH15201]DE15201A.;163',USER='LPALLES',CD=';2-JUN-2015;13:21' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg15201_1_91"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg15201_cat-2000_series"> </A>
<A NAME="toc_dg15201_1"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2000 Series    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our two other clinical-stage product candidates, CAT-2054 and CAT-2003, are members of our CAT-2000 series. We applied our SMART linker
technology to engineer these molecules as SMART linker conjugates of EPA and nicotinic acid in order to modulate the SREBP pathway in different organs. Because we used different SMART linkers for
CAT-2054 and CAT-2003, they possess different characteristics such as rates of cleavage, pharmacokinetics and biodistribution. CAT-2003, our first generation product candidate in the CAT-2000 series,
is an orally administered molecule that modulates the SREBP pathway predominately in the intestine. CAT-2054, our second generation product candidate in the CAT-2000 series, is an orally administered
molecule designed to modulate the SREBP pathway predominately in the liver. We have focused our initial efforts on the CAT-2000 series on lipid disorders such as hypercholesterolemia and
hypertriglyceridemia because these disorders have clear short-term efficacy biomarkers, which we believe will enable us to rapidly and efficiently determine clinical proof of concept of our
technology. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview of the SREBP Pathway  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP is a master regulator of lipid and energy metabolism and regulates the levels of LDL-C, triglycerides and fatty acids in the
body. SREBP controls lipid levels by controlling the expression of genes such as PCSK9, HMG-CoA reductase and ATP citrate lyase. Dysregulation of SREBP activity has been implicated in a number of
human metabolic diseases, including hyperlipidemias, such as hypercholesterolemia and hypertriglyceridemia, and chronic liver diseases, including NASH and hepatocellular carcinoma. Modulators of SREBP
activity could have therapeutic benefit in treating these SREBP-mediated diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
shown in the figure below, we designed the CAT-2000 molecules to inhibit the maturation of SREBP and reduce the expression of key proteins involved in LDL-C and triglyceride
metabolism. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15201_the_cat-2000_molecules_inhibit_srebp"> </A>
<A NAME="toc_dg15201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  The CAT-2000 Molecules Inhibit SREBP    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g339906.jpg" ALT="GRAPHIC" WIDTH="670" HEIGHT="421">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=94,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=50519,FOLIO='91',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_92"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP
regulates cholesterol levels by controlling expression of PCSK9, a protein that controls the clearance of LDL-C from circulation through the reduction of the amount of the LDL
receptor on the surface of the liver; HMG-CoA reductase, an enzyme that plays a central role in the synthesis of LDL-C in the liver; ATP citrate lyase, an enzyme in the LDL-C synthetic pathway; and
Niemann-Pick C1-like 1, or NPC1L1, which is the critical mediator of cholesterol absorption in the gastrointestinal
tract epithelial cells as well as in liver cells. These four proteins are important in regulating cholesterol levels because they control cholesterol clearance, synthesis and absorption. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP
regulates triglyceride levels by controlling the expression of apolipoprotein C3, or ApoC3, angiopoietin-like protein 3, or Angptl3, and angiopoietin-like protein 4, or Angptl4,
which inhibit the activity of lipoprotein lipase, or&nbsp;LPL, an enzyme responsible for the breakdown of triglycerides in the blood. SREBP regulates fatty acid levels by controlling the expression
of fatty acid synthase and acetyl-CoA carboxylase, enzymes that play a central role in the synthesis of fatty acids and regulate fatty acid oxidation. We believe that inhibiting SREBP activity will
lead to an inhibition of fatty acid synthesis and an increase in fatty acid oxidation, and will increase&nbsp;LPL enzyme activity to accelerate clearance of triglycerides. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SREBP
activity has also been implicated in a number of other metabolic processes that may provide further therapeutic applications for our CAT-2000 series of compounds. We believe that
inhibition of SREBP in the liver has the potential to enhance insulin signaling and increase glucose metabolism without increasing liver fat content, which may be useful in the treatment of
type&nbsp;2 diabetes. We also believe that inhibition of SREBP has the potential to inhibit fatty acid synthesis and activate fatty acid oxidation to reduce liver triglyceride content, which may be
useful in the treatment of fatty liver diseases. In addition, SREBP is believed to regulate Palatin-like phospholipase domain-containing protein 3, or PNPLA3, which is an enzyme found in cells that
may play a role in cellular energy storage and metabolism, as well as a specific mutation of PNPLA3 that is associated with liver fat accumulation and increased risk of chronic liver diseases. As a
result, we believe that the CAT-2000&nbsp;series of compounds has the potential to be effective in the treatment of liver diseases in which patients may be identified by the occurrence of this
specific mutation of PNPLA3, such as NASH and hepatocellular carcinoma. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2054  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are initially developing CAT-2054 for the treatment of patients with hypercholesterolemia, or elevated LDL-C, for whom existing
treatments are insufficient. By modulating the SREBP pathway, CAT-2054 may inhibit production of important cholesterol metabolism proteins, such as PCSK9, HMG-CoA reductase, ATP citrate lyase and
NPC1L1. In a clinical trial of our first generation SREBP modulator, CAT-2003, we observed statistically significant reductions in LDL-C, which we believe demonstrate the impact of SREBP modulation on
cholesterol metabolism. Because the liver is the primary regulator of cholesterol metabolism, we specifically designed the SMART linker in CAT-2054 to deliver more of the intact conjugate to the liver
than CAT-2003. We believe that CAT-2054, if approved, has the potential to be the first therapy to simultaneously modulate cholesterol synthesis, clearance and absorption. We submitted an IND to the
FDA for CAT-2054 in November 2014. In January 2015, we initiated a Phase&nbsp;1 clinical trial to assess the safety, tolerability and pharmacokinetics of CAT-2054 in healthy volunteers. Preliminary
data are available for the full range of doses tested in the single and multiple ascending dose portions of the trial. If the final results of this clinical trial show safety, tolerability and plasma
exposure, we intend to initiate a Phase&nbsp;2a clinical trial for the treatment of hypercholesterolemia in the fourth quarter of 2015 and would expect to report
Phase&nbsp;2a data in mid-2016. If the results of the planned Phase&nbsp;2a clinical trial are positive, we intend to initiate a Phase&nbsp;2b clinical trial of CAT-2054 in the fourth quarter of
2016.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=95,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=922555,FOLIO='92',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hypercholesterolemia Market Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hypercholesterolemia is a major risk factor for cardiovascular disease, or CVD, a leading cause of mortality and morbidity in the
United States. Hypercholesterolemia is a complex disease involving redundant biological pathways that are tightly regulated and have built-in feedback mechanisms. Current treatment guidelines
recognize lowering of LDL-C as a primary target for reducing the risk of CVD. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
of the lipid-lowering therapies currently available or in development target proteins in the SREBP pathway:  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Statins.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Statins are typically prescribed as first-line
therapy for reducing LDL-C based on their efficacy, established safety and proven benefit in reducing cardiovascular event risk. Statins inhibit HMG-CoA reductase. Crestor&reg; (rosuvastatin),
the largest remaining branded prescription statin, generated worldwide sales of $5.5&nbsp;billion for the 12-month period ended December 2014.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Cholesterol Absorption Inhibitors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Ezetimibe is a
cholesterol absorption inhibitor that targets NPC1L1, reducing LDL-C by inhibiting cholesterol absorption in the small intestine. It may be used alone (marketed as Zetia&reg; or
Ezetrol&reg;), for example in statin-intolerant patients, or together with statins, such as in ezetimibe/simvastatin (marketed as Vytorin&reg; and Inegy&reg;), when statins
alone do not adequately control cholesterol. Zetia and the combination product Vytorin together generated worldwide sales of $4.2&nbsp;billion for the 12-month period ended December 2014. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Monoclonal antibodies against PCSK9 and inhibitors of ATP citrate
lyase.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;In addition to the marketed therapies, several companies are developing other agents that target the synthesis and clearance of
LDL-C. Monoclonal antibodies against PCSK9 are injectable product candidates that are being evaluated as potential therapies to lower LDL-C. ATP citrate lyase inhibitors target cholesterol synthesis
in the liver but at an earlier step of the pathway than statins. To date, none of these agents has received U.S. or European marketing approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite
the availability of these classes of drugs that lower LDL-C, many patients are unable to achieve their LDL-C goals using the marketed therapies. A 2011 report of the Centers for
Disease Control and Prevention estimated that, of the 34&nbsp;million adults in the United States receiving treatment for high LDL-C, 11&nbsp;million had uncontrolled LDL-C. The limitations of the
efficacy of some existing therapies, including statins, may be partly the result of feedback mechanisms in the SREBP pathway, which ensure that cellular cholesterol levels are maintained at levels
required for normal cellular function. For example, doubling the dose of a statin is accompanied by only an incremental 6% lowering of lipids. This non-linear decrease in LDL-C as the statin dose
increases is due to feedback mechanisms that are triggered when HMG-CoA reductase is inhibited to a greater extent. As the statin dose is increased, intracellular levels of cholesterol decrease,
ultimately resulting in activation of the SREBP pathway. Activated SREBP induces the expression of PCSK9 which promotes the degradation of the LDL receptor, resulting in reduced clearance of LDL-C
from circulation. The feedback mechanism ensures that the cell is never completely depleted of cholesterol because cholesterol is required for cellular viability. Thus, high-dose statins trigger a
feedback mechanism that counteracts their beneficial effects on lipids. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
biotechnology and pharmaceutical companies have pursued compounds to inhibit SREBP but we believe that none have reached clinical development. The goal of these programs has been
to identify small molecule drugs that can block the activity of SREBP and produce beneficial effects on lipids. Directly reducing active SREBP may have a significant benefit on LDL-C levels in
circulation. SREBP modulators may work synergistically with inhibitors of proteins that are downstream of SREBP such as PCSK9, HMG-CoA reductase and ATP citrate lyase. In addition, SREBP modulators
may substantially reduce feedback mechanisms that are activated by other classes of LDL-C lowering drugs such as statins and ezetimibe. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=96,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=178641,FOLIO='93',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2054 for the Treatment of Hypercholesterolemia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2054 is a SMART linker conjugate designed to modulate SREBP in the liver and to reduce LDL-C levels in patients with
hypercholesterolemia. We designed the SMART linker in CAT-2054 to be more stable to intracellular enzymatic cleavage than the SMART linker in CAT-2003. We have observed in preclinical studies that
CAT-2054 was cleaved at a significantly slower rate than CAT-2003, and that significantly greater levels of CAT-2054 reached the liver following oral dosing than with CAT-2003. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
slower rate of cleavage enables more intact CAT-2054 to pass through the portal vein and to the liver, where SREBP controls cholesterol levels. We have observed in </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies that, once cleaved in
human liver cells, CAT-2054 inhibited the activity of SREBP by blocking its maturation, a conversion from an
inactive to an active form. As a result, the amount of mature SREBP protein in the nucleus of the cells is reduced. This inhibition reduces the expression of downstream target genes in the SREBP
pathway, including HMG-CoA reductase, PCSK9 and ATP citrate lyase. Based on this mechanism, we believe CAT-2054 may be effective in reducing elevated LDL-C and positively affect other metabolic
parameters. If approved, CAT-2054 has the potential to be prescribed in patients whose hypercholesterolemia is inadequately controlled by statins alone or are intolerant to statins, and the potential
to be used before injectable PCSK9 monoclonal antibodies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the completion of Phase&nbsp;2 clinical development, we intend to pursue development and commercialization collaborations with biotechnology and pharmaceutical companies to
maximize the value of CAT-2054 as a treatment for hypercholesterolemia. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2054 Clinical Development  </I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ongoing Phase&nbsp;1 Clinical Trial (CAT-2054-101)  </I></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are conducting a randomized, double-blind, placebo-controlled Phase&nbsp;1 trial in healthy volunteers at a single center in the
United States to assess the safety, tolerability and
pharmacokinetics of single and multiple doses of CAT-2054 in both fasting and fed states. The trial includes both coated and uncoated capsule formulations, as well as multiple doses of CAT-2054 with
atorvastatin to assess safety and pharmacokinetics of both compounds in combination in preparation for Phase&nbsp;2 studies. Preliminary data are available for the full range of doses tested in the
single and multiple ascending dose portions of the Phase&nbsp;1 trial and are described below. We expect that full results will be available in the third quarter of 2015.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the single ascending dose portion of the Phase&nbsp;1 clinical trial, approximately 60 healthy volunteers are being randomized to receive CAT-2054 in capsules at doses ranging from
50 mg to 1000 mg or placebo. When single doses of CAT-2054 were administered under fed and fasted conditions, CAT-2054 was well tolerated and no serious AEs were reported. No safety signals were
observed in laboratory, vital sign or electrocardiogram results following CAT-2054 administration. The observed AEs occurring under fed and fasted conditions at doses up to 500 mg were similar for
CAT-2054 and placebo. The most common AEs observed in fed and fasting conditions were nausea and diarrhea and all reported AEs were mild. Of the 38 subjects, eight subjects received placebo, two of
whom reported diarrhea and two of whom reported nausea. Thirty subjects received CAT-2054, of whom six reported nausea, five reported diarrhea and four reported abdominal pain. Nicotinic acid is known
to interact with a specific extracellular receptor,&nbsp;GPR109A, and causes flushing and immediate decreases in free fatty acids, followed by a rebound. We assessed flushing using a subjective
questionnaire, and administration of CAT-2054 was not associated with flushing. We also measured free fatty acid levels after administration of CAT-2054 and no differences in free fatty acid levels
relative to placebo were observed. Additionally, we did not observe decreases generally associated with nicotinic acid

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As shown in the graph below, in preliminary data from the single ascending dose portion of the Phase&nbsp;1 clinical trial, we observed that the plasma exposure of CAT-2054 increased
with dose, which

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=97,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=74569,FOLIO='94',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_95"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


was measured using a common statistical method known as area under the curve, or AUC. The plasma exposure of CAT-2054 was greater than the plasma exposure observed for the first generation CAT-2000
product candidate, CAT-2003, in the CAT-2003-101 Phase&nbsp;1 clinical trial, and consistent with our expectations for the design of the linker and the conjugate.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15201_plasma_exposure_of_cat-2054_and_cat-2003"> </A>
<A NAME="toc_dg15201_3"> </A>
<BR>

</FONT>

<FONT SIZE=2><B>  Plasma Exposure of CAT-2054 and CAT-2003

    <BR>    </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g608237.jpg" ALT="GRAPHIC" WIDTH="396" HEIGHT="250">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ongoing multiple ascending dose portion of the Phase&nbsp;1 trial, 40 healthy volunteers were randomized to receive CAT-2054 in soft gelatin capsules at daily doses ranging from
100 mg to 750 mg or placebo for 14&nbsp;days. Similar to the single ascending dose portion of the trial, the multiple ascending dose portion of the trial was designed to assess safety, tolerability
and pharmacokinetics.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When multiple doses of CAT-2054 were administered under fed and fasted conditions, CAT-2054 was well tolerated and no serious AEs were reported. We observed no safety signals in
laboratory, vital signs or electrocardiogram results following CAT-2054 administration, and all subjects completed dosing. The most common AE observed was diarrhea. Of the 40 subjects for whom results
are available, 32 received CAT-2054 among the four dosing cohorts. Eight of the subjects who received CAT-2054 reported diarrhea, four reported headache and three reported abdominal cramping. All
reported AEs were mild. Based on a subjective questionnaire, administration of CAT-2054 was not associated with flushing.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also measured lipid biomarkers in the healthy volunteers enrolled in the Phase&nbsp;1 trial. As shown in the graph below, in preliminary data from the multiple ascending dose
portion of the Phase&nbsp;1 trial, decreases in LDL-C were observed at the end of the 14-day dosing period at doses of 500 and 750 mg. Decreases in LDL-C of up to 20% were observed at day 21, which
were statistically significant compared to baseline for all dose levels. We did not observe statistically significant changes in PCSK9 in this Phase&nbsp;1 trial. Based on the results of this trial,
we believe that the magnitude of LDL-C reduction with CAT-2054 may increase with continued dosing beyond 14&nbsp;days. Based on our preclinical studies, we believe that patients with elevated PCSK9
levels reflective of activated SREBP, such as those on statins, may experience greater LDL-C reductions with CAT-2054.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=98,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=873383,FOLIO='95',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_96"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg15201_median_ldl-c_changes"> </A>
<A NAME="toc_dg15201_4"> </A>
<BR>

</FONT>

<FONT SIZE=2><B>  Median LDL-C Changes*

    <BR>    </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g342690.jpg" ALT="GRAPHIC" WIDTH="393" HEIGHT="204">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


* p&lt;0.05 (all dose levels, day 21)

 </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Planned Phase&nbsp;2a Clinical Trial  </I></FONT></P>


</UL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to initiate a randomized, double-blind, placebo-controlled Phase&nbsp;2a trial in the fourth quarter of 2015 at multiple
sites in the United States in patients with hypercholesterolemia. In this clinical trial, patients will be treated for four weeks, with 25 to 30 patients in each arm. Depending on the full results of
the Phase&nbsp;1 trial, we intend to compare multiple dose levels of CAT-2054 in a variety of populations, such as patients on statins or those with elevated lipids, triglycerides and glucose. We
expect the primary endpoint to be reduction in levels of LDL-C. We also plan to assess the safety and tolerability of CAT-2054, as well as the activity of CAT-2054 on other metabolic parameters,
including triglycerides, glucose and glycosylated hemoglobin, or HbA1c, which is a measure of glucose levels over time. We anticipate that we will report data from this trial in mid-2016. If the
results of the planned Phase&nbsp;2a clinical trial are positive, we intend to initiate a Phase&nbsp;2b clinical trial of CAT-2054 in the fourth quarter of 2016.

 </FONT></P>


<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Data for CAT-2054  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on a comprehensive program of preclinical testing of CAT-2054, including several </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> analyses and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> studies in animal models, we believe that CAT-2054 may be effective in reducing elevated LDL-C and
have positive effects on other metabolic parameters. Key findings from our preclinical program included the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CAT-2054 reduced LDL-C by week&nbsp;six in rhesus monkeys that were maintained on a high fat, high cholesterol diet. We observed no
effect on food consumption or body weight. We dosed the animals with CAT-2054 at 500 mg by capsule once daily for six weeks. As shown in the graph below, at the end of the treatment period, we
observed a statistically significant reduction of 31% in LDL-C levels relative to baseline. The effect of CAT-2054 on plasma LDL-C levels was most pronounced in the monkeys with the highest baseline
LDL-C levels. Additionally, we observed that LDL-C levels returned to near baseline after a washout period following the end of dosing with CAT-2054. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=99,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=498615,FOLIO='96',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_97"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on LDL-C in<BR>
Rhesus Monkeys on a High Cholesterol Diet  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g26767.jpg" ALT="GRAPHIC" WIDTH="411" HEIGHT="345">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CAT-2054 significantly reduced fasting plasma LDL-C in cynomolgus macaque monkeys that had developed age-related spontaneous
dyslipidemia, which were maintained on a normal diet. In this study, we dosed the animals with CAT-2054 at 100 mg/kg by oral gavage, once daily for four weeks. We observed no effect on body weight.
The mean reduction in fasting LDL-C after 14&nbsp;days of treatment with CAT-2054 was 21%. The effect of CAT-2054 on plasma LDL-C levels was most pronounced in the monkeys with the highest baseline
LDL-C levels. CAT-2054 treatment essentially returned LDL-C to normal levels in these monkeys without significantly decreasing LDL-C below the normal
threshold.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, we observed that treatment of a human liver cell line with
CAT-2054 reduced the amount of mature SREBP protein and that this reduction was greater than what we observed with approximately equivalent amounts of EPA and nicotinic acid administered either </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=100,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1004853,FOLIO='97',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_98"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>alone
or in combination. The graph below shows the reduction in the level of SREBP protein compared to control. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on Levels of the Mature SREBP Protein  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g477145.jpg" ALT="GRAPHIC" WIDTH="399" HEIGHT="244">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> study, we observed that treatment of a human liver cell line with
CAT-2054 reduced the secretion of PCSK9 protein. As shown in the graph below, the reduction in PCSK9 protein secretion was dependent on dose of CAT-2054 with higher doses resulting in greater
reductions. We also observed the bioactive components of CAT-2054, EPA and nicotinic acid, did not have a significant effect on PCSK9 secretion when administered to cells either individually or in
combination at similar concentrations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on Levels of PCSK9 Protein Secretion  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g764620.jpg" ALT="GRAPHIC" WIDTH="337" HEIGHT="312">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> study, we observed that CAT-2054 induced an increase in LDL receptor
protein levels on the surface of a human liver cell line. As shown in the graph below, the increase in </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=101,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=227740,FOLIO='98',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_99"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>LDL
receptor protein was dependent on the dose of CAT-2054, with higher doses resulting in greater increases. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on Levels of the Cell Surface LDL Receptor  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g900575.jpg" ALT="GRAPHIC" WIDTH="400" HEIGHT="315">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, we have observed that treatment of a human liver cell line with
the statin atorvastatin caused an approximately two-fold increase in the amount of mature SREBP. As shown in the graph below, CAT-2054 inhibited the activation of SREBP2, a form of SREBP that controls
the expression of genes involved in LDL-C synthesis and clearance in the liver, in the presence of atorvastatin. As expected, due to feedback mechanisms in the SREBP pathway, treatment with
atorvastatin alone increased the activation of SREBP2. These data suggest that CAT-2054 may inhibit SREBP2 maturation and subsequent SREBP2-mediated gene transcription in the presence of a statin. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on SREBP2 Activation<BR>
in the Presence of a Statin  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g765920.jpg" ALT="GRAPHIC" WIDTH="394" HEIGHT="271">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=102,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=767458,FOLIO='99',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, we have observed that treatment of a human liver cell line with
the statin atorvastatin caused an increase in the amount of secreted PCSK9. As shown in the graph below, CAT-2054 abrogated the statin-induced increase in PCSK9 secretion. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on PCSK9 Levels in the Presence of a Statin  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g927875.jpg" ALT="GRAPHIC" WIDTH="396" HEIGHT="291">
  </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> study, we observed that after a 24-hour incubation, treatment of a
human liver cell line with CAT-2054 inhibited the expression of multiple SREBP2 target genes, including PCSK9 and four genes involved in cholesterol synthesis: HMG-CoA reductase, ATP citrate lyase,
Mevalonate decarboxylase and Squalene expoxidase. These results are illustrated in the graph below. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2054 Effect on Expression of Genes Involved in<BR>
Cholesterol Metabolism  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g634352.jpg" ALT="GRAPHIC" WIDTH="673" HEIGHT="309">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=103,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=427359,FOLIO='100',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_101"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2003  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003 is our first generation product candidate in the CAT-2000 series. We engineered CAT-2003 as an orally administered SMART
linker conjugate of EPA and nicotinic acid to modulate the SREBP pathway. We designed CAT-2003 to target triglyceride levels in the blood and studied it for the treatment of MFC and rSHTG, diseases
with niche patient populations with hypertriglyceridemia. We submitted an IND to the FDA for CAT-2003 in September 2012. We have completed three Phase&nbsp;2a trials in patient populations with
elevated triglyceride or hypertriglyceridemia in which we observed positive effects of CAT-2003 on triglycerides, LDL-C and glucose. We also observed gastrointestinal side effects. These side effects
were reduced, but not
eliminated, through the use of a coated soft gelatin capsule formulation with modified release characteristics. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we have chosen to prioritize the development of CAT-2054 over CAT-2003, we believe that the clinical trial data for CAT-2003 support the utility of our SMART linker technology and
the potential to treat lipid and metabolic disorders by modulating the SREBP pathway. We intend to pursue collaborations to conduct exploratory evaluation of CAT-2003 in other serious diseases that
involve alterations in the SREBP pathway, such as NASH and hepatocellular carcinoma, either to develop CAT-2003 as a product candidate or to support our development efforts for CAT-2054. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Effect of CAT-2003 in Hypertriglyceridemias  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have completed three Phase&nbsp;2a clinical trials of CAT-2003 in patients with elevated triglycerides and two Phase&nbsp;1
clinical trials in healthy volunteers. In the Phase&nbsp;2a clinical trials, CAT-2003 reduced elevated triglycerides, including in patients treated with other triglyceride and lipid lowering
therapies. CAT-2003 also demonstrated in Phase&nbsp;2a clinical trials beneficial effects on other lipid and cardio-metabolic parameters, such as LDL-C and blood glucose levels. In our clinical
trials, CAT-2003 showed no observed trends in laboratory values, vital signs, electrocardiogram or physical examination at up to 12&nbsp;weeks of patient dosing. Mild to moderate gastrointestinal
tolerability issues were observed with CAT-2003 at higher doses with an uncoated soft gelatin capsule and were improved but not eliminated with a coated soft gelatin capsule formulation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>CAT-2003&#151;Completed Clinical Trials</I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1 Clinical Trial in Healthy Volunteers (CAT-2003-101)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted a Phase&nbsp;1 trial in healthy volunteers at a single center in the United States to assess the safety, tolerability
and pharmacokinetics of single and multiple doses of CAT-2003 in both fasting and fed states. We also measured CAT-2003 effects on post-prandial triglycerides and other lipid parameters. All subjects
were administered 500 mg immediate release niacin in the screening period so effects on flushing could be compared to CAT-2003. In this Phase&nbsp;1 trial, there were a total of 99&nbsp;subjects,
79 of whom received CAT-2003. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Single Ascending Dose:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;41 healthy volunteers were randomized to receive CAT-2003 in soft gelatin capsules at doses ranging from 300 mg
to 2000 mg or
placebo. With single doses of CAT-2003 administered under fed and fasted conditions, the most commonly reported AEs were diarrhea, which was reported in 11&nbsp;subjects, nausea, which was reported
in five&nbsp;subjects, and abdominal distention, which was reported in three&nbsp;subjects. The majority of AEs were mild in severity and there were no serious AEs reported. In subjects
administered CAT-2003, reports of gastrointestinal AEs were higher in the fed state than in the fasted state. We observed no safety signals in laboratory, vital signs or electrocardiogram results
following CAT-2003 administration in either the fasted or fed state. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003
was rapidly absorbed in plasma, with mean maximum and overall plasma exposure generally increasing with CAT-2003 dose. Nicotinic acid was not detected in plasma at levels above
background, consistent with intracellular cleavage of CAT-2003 and intracellular delivery of the component bioactives. Exposure of CAT-2003 was similar in the fasted and fed states. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=104,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=656692,FOLIO='101',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<A NAME="page_dg15201_1_102"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
measured postprandial triglycerides in healthy volunteers after single doses of 300 mg, 1000 mg and 2000 mg CAT-2003 and placebo were administered after a standardized high-fat meal.
In subjects receiving the 300 mg dose of CAT-2003, the peak postprandial increase in plasma triglycerides was reduced by approximately 50% on average compared to subjects receiving placebo, while in
subjects receiving the 1000 and 2000 mg doses of CAT-2003, the peak postprandial increase in plasma triglycerides was reduced by approximately 80% on average compared to subjects receiving placebo. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
measured flushing in subjects screened for susceptibility to niacin-induced flushing. Flushing was measured using a validated patient-reported questionnaire and also by laser Doppler
after single doses of 300 mg, 1000 mg, and 2000 mg of CAT-2003 pre-dose and four hours post-dose, the general timeframe during which niacin-related flushing would be expected to be observed. No
subject dosed with CAT-2003 experienced flushing at any dose. Results for the highest CAT-2003 dose, 2000 mg, are shown in the graphs below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2003 Effect on Flushing in Subjects Screened for Niacin-Induced Flushing</I></B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="279pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><I>Measured by Questionnaire</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><I>Measured by Laser Doppler&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>
<IMG SRC="g130958.jpg" ALT="GRAPHIC" WIDTH="637" HEIGHT="199">
 </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Multiple Ascending Dose:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;58 healthy volunteers were administered CAT-2003 in soft gelatin capsules at doses ranging from 500 mg to 1500
mg or placebo
daily for 14&nbsp;days. In addition to the safety, tolerability and pharmacokinetics of CAT-2003, we assessed the activity of CAT-2003 on lipid parameters including fasting and postprandial
triglycerides following 14&nbsp;days of dosing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003
administered for 14&nbsp;days demonstrated no safety signals in laboratory values, vital signs, electrocardiogram or physical examination that were considered to be
drug-related AEs. No serious AEs were reported. The most common AEs were gastrointestinal, including diarrhea, which was reported in 32&nbsp;subjects, nausea, which was reported in
26&nbsp;subjects, vomiting, which was reported in 12&nbsp;subjects, and headache, which was reported in 11&nbsp;subjects. The majority of subjects at a total daily dose of 1000 mg had
gastrointestinal AEs. Overall, most AEs were mild in intensity but moderate intensity gastrointestinal AEs were reported, particularly at daily doses of at least 1000 mg. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-2003
was rapidly absorbed in plasma, with mean maximum and overall plasma exposure generally increasing with CAT-2003 dose. Nicotinic acid was not detected in plasma at levels above
background, consistent with intracellular cleavage of CAT-2003 and intracellular delivery of the component bioactives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
observed that postprandial triglyceride levels were reduced after two weeks of treatment with CAT-2003. Both 500 mg and 1000 mg total daily doses of CAT-2003 substantially suppressed
the expected increase in postprandial lipids after the first meal of the day as compared to the typical increase in postprandial triglycerides observed in the placebo group. We did not assess the
statistical significance of these data and did not measure postprandial lipids after a high-fat meal in subjects receiving 1500 mg total daily doses of CAT-2003. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=105,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=284119,FOLIO='102',FILE='DISK122:[14ZDH1.14ZDH15201]DG15201A.;217',USER='DPERRY',CD=';2-JUN-2015;15:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di15201_1_103"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2a Clinical Trial in Patients with Hyperlipidemia (CAT-2003-201)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted a Phase&nbsp;2a randomized, double-blind, placebo-controlled clinical trial in 72 patients with moderate
hypertriglyceridemia with baseline triglyceride levels between 200 and 500 mg/dL and in 27 patients with hypercholesterolemia, defined as LDL-C levels between 100 mg/dL and 190 mg/dL and triglycerides
less than 200 mg/dL, while on a statin. We enrolled patients at 15 sites in the United States and Canada. Patients were treated for 28&nbsp;days with CAT-2003 at doses of 300 mg once daily, 500 mg
once daily or 300 mg twice daily, or placebo. Of the total 99&nbsp;patients, 71 were treated with CAT-2003. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
observed a median 16% reduction in fasting triglycerides in patients receiving 500 mg CAT-2003. Median triglyceride reductions in the placebo, 300 mg once daily and 300 mg twice daily
dosing cohorts were less than 5%. However, in a pre-specified subgroup of patients with a baseline fasting triglyceride value greater than 350 mg/dL, we observed a median 27% decrease in fasting
triglycerides from baseline in all CAT-2003-treated patients, and a median 44% decrease in fasting triglycerides in patients receiving 500 mg CAT-2003. The greater effect of CAT-2003 in patients with
higher baseline triglycerides is consistent with preclinical data supporting the mechanism of action of CAT-2003 in enhancing&nbsp;LPL activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
shown in the graph below in the cohort of 27 patients with hypercholesterolemia, we observed that CAT-2003 reduced LDL-C levels by a median 11% in patients who received a 500 mg once
daily dose on concomitant moderate-dose statin therapy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2003 Effect on LDL<BR>
Cholesterol in Patients with Hypercholesterolemia  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g828095.jpg" ALT="GRAPHIC" WIDTH="294" HEIGHT="247">
  </B></FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>p&lt;0.01 change from baseline<BR>
p=0.03 relative to placebo group</B></FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
shown in the graph below, in the 21 patients with Type&nbsp;2 diabetes enrolled in the trial and randomized to CAT-2003, we observed reductions in fasting glucose. In addition, we
observed a statistically significant reduction of 0.2% in HbA1c following four weeks of treatment, with a p-value of less than 0.01. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=106,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=715044,FOLIO='103',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2003 Effect on Fasting<BR>
Glucose Levels in Patients with Type 2 Diabetes  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g894296.jpg" ALT="GRAPHIC" WIDTH="247" HEIGHT="280">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
serious AEs were reported. The most common AEs reported were gastrointestinal, with nausea, diarrhea, vomiting and abdominal distention the most frequently reported. Twenty-three
patients reported nausea, 17 reported diarrhea, nine reported vomiting and five reported abdominal distention and most of the AEs were mild or moderate in severity. Four patients discontinued
treatment because of gastrointestinal AEs and several received dose reductions because of AEs. We observed no safety signals in laboratory, vital signs or electrocardiogram results. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2a Clinical Trial in Patients with SHTG and rSHTG (CAT-2003-202)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted a randomized, single-blind Phase&nbsp;2a trial in 14 patients with severe hypertriglyceridemia and rSHTG, defined as
fasting triglycerides greater than 500 mg/dL and either treatment naive or currently taking other triglyceride-lowering therapies, to evaluate the effect of CAT-2003 on triglyceride levels. Thirteen
of the 14 patients enrolled completed dosing. This clinical trial enrolled patients at four sites in the United States. A placebo run-in for two weeks was followed by treatment with 500 mg of CAT-2003
dosed once-daily for four weeks. As illustrated in the graph below, we observed a reduction in fasting triglycerides from a median of 658 mg/dL after the placebo run-in to a median of 467 mg/dL
following four weeks of CAT-2003 treatment. We observed a comparable reduction in fasting triglycerides from a median of 760 mg/dL after the placebo run-in to a median of 452 mg/dL following four
weeks of CAT-2003 treatment in the four patients on concomitant fibrate or statin therapy. In the four patients with Type&nbsp;2 diabetes, three of whom were also receiving metformin, we observed
decreases in HbA1c. No serious AEs were reported. The most common AEs reported were gastrointestinal, with nausea and diarrhea the most frequently reported. Five patients reported nausea and four
patients reported diarrhea and all of the AEs were mild in severity. We observed no safety signals in laboratory, vital signs or electrocardiogram results. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=107,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=218284,FOLIO='104',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_105"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><I>CAT-2003 Effect on Fasting<BR>
Triglycerides in Patients with Hypertriglyceridemia  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g769326.jpg" ALT="GRAPHIC" WIDTH="343" HEIGHT="268">
  </B></FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>Median-interquartile ranges<BR>
*p&lt;0.02</B></FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1 Clinical Trial of the CAT-2003 Coated Capsule Formulation (CAT-2003-102)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To improve gastrointestinal tolerability observed with the uncoated soft gelatin capsule, we reformulated CAT-2003 in a gelatin capsule
with a pH-sensitive polymer coating and modified release characteristics. We then conducted a Phase&nbsp;1 trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of
seven days of treatment with the CAT-2003 coated capsule formulation. This trial enrolled 48 subjects at one site in the United States. In this trial, the coated capsule formulation of CAT-2003
substantially reduced gastrointestinal side effects, particularly nausea and vomiting, over the seven-day treatment period while retaining the desired pharmacokinetic and pharmacodynamic profile. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2a Clinical Trial in Patients with Chylomicronemia (CAT-2003-203)  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted a two-part&nbsp;12-week single-blind Phase&nbsp;2a clinical trial of CAT-2003 in patients with chylomicronemia
syndromes and rSHTG at two sites in Canada. Patients with familial chylomicronemia, or FCS, were enrolled based on previous diagnosis, and patients with
multi-factorial chylomicronemia, or MFC, and rSHTG, were enrolled based on history of fasting triglycerides greater than 880 mg/dL, or, if on stable dose of fibrate therapy, documented fasting
triglycerides greater than 440 mg/dL. All patients enrolled in the trial participated in a run-in period, during which patients followed a low fat diet and received placebo, followed by a 12-week
CAT-2003 treatment phase. In the first part, 12 patients were dosed with the uncoated CAT-2003 capsules and in the second part seven patients were dosed with the coated capsules. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary
data from the first part of the clinical trial of patients with MFC and rSHTG indicate that CAT-2003 reduced fasting triglycerides by a median of 40% at a dose of 500 mg once
daily. Meaningful reductions in triglycerides were not observed in patients with FCS. We observed no safety signals in laboratory, vital signs or electrocardiogram results. The patients enrolled in
the trial experienced mild to moderate gastrointestinal AEs at some point. These included nausea in nine patients, diarrhea in nine patients and vomiting in six&nbsp;patients. In some cases these
AEs led to dose reduction or discontinuation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=108,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=790843,FOLIO='105',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_106"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the second part of the trial, we evaluated the effect of the coated capsule formulation of CAT-2003 on gastrointestinal tolerability compared to the uncoated capsule formulation.
Preliminary data demonstrated improvement in nausea events, with three&nbsp;patients reporting nausea, but no vomiting events. Diarrhea was observed in seven&nbsp;patients. As a result of these
AEs, four&nbsp;patients received dose reductions and two&nbsp;discontinued. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2003 Preclinical Development  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have observed that CAT-2003 reduced fasting or post-prandial triglycerides in several </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> models of hypertriglyceridemia. In some of these studies, we tested and observed that EPA and niacin, the individual bioactives, administered at doses that correspond to
the top dose of CAT-2003 did not reduce triglycerides significantly. In a study using a mouse model, we also observed that CAT-2003 reduced liver inflammation and liver fat content. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have investigated the mechanism of action of CAT-2003 based on the abilities of EPA and niacin to modulate triglyceride and cholesterol synthesis through SREBP modulation. In human
cell lines, we have observed that CAT-2003 reduced the amount of mature SREBP protein and levels of ApoC3, Angptl3 and Angptl4 to a greater extent than either EPA or niacin alone or in combination,
and also increased&nbsp;LPL activity in cells. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di15201_cat-4001"> </A>
<A NAME="toc_di15201_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-4001    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA designed to modulate the Nrf2 and
NF-<FONT FACE="SYMBOL">k</FONT>B pathways. We are developing CAT-4001 initially for the treatment of severe, rare neurodegenerative diseases, such as Friedreich's ataxia and ALS, two
diseases of the central nervous system in which the Nrf2 and NF-<FONT FACE="SYMBOL">k</FONT>B pathways have been implicated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
designed CAT-4001 to combine the potentially beneficial activities of monomethyl fumarate and DHA on the Nrf2 and NF-<FONT FACE="SYMBOL">k</FONT>B pathways. Nrf2 is a
transcription factor that regulates cellular response to oxidative stress. NF-<FONT FACE="SYMBOL">k</FONT>B is a transcription factor that controls cellular responses to stress and
inflammation. Oxidative stress and neuroinflammation are believed to play a central role in a number of neurodegenerative diseases, including Friedreich's ataxia and ALS. In addition, monomethyl
fumarate is the circulating form of the active ingredient of Tecfidera, an FDA-approved treatment for multiple sclerosis, another neurodegenerative disease. We believe that this known therapeutic
effectiveness of monomethyl fumarate offers further support for the potential for CAT-4001 to be developed for the treatment of neurodegenerative diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
observed in preclinical studies that CAT-4001 modulated the NF-<FONT FACE="SYMBOL">k</FONT>B pathway and the Nrf2&nbsp;pathway. In cellular assays and in animal models,
we observed that the activity produced by CAT-4001 was greater than that produced by the individual components, monomethyl fumarate and DHA, either alone or in combination at approximately equivalent
amounts to those contained in the CAT-4001 conjugate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on its mechanism of action, we believe that CAT-4001 has the potential to be a disease modifying agent in certain neurodegenerative diseases, such as Friedreich's ataxia or ALS. We
plan to conduct additional preclinical evaluation of CAT-4001 in 2015, and if the results are positive we intend to advance CAT-4001 into IND-enabling studies in 2016. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Friedreich's Ataxia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Friedreich's ataxia is a rare genetic disease that causes nervous system damage and compromises motor coordination. Friedreich's ataxia
is caused by a defect in the frataxin
gene, which regulates iron levels in the mitochondria. In the majority of cases, the genetic defect in Friedreich's ataxia causes a reduction in the production of the frataxin protein and iron levels
in mitochondria become poorly regulated. In Friedreich's ataxia, iron overload in mitochondria affects metabolism, causing oxidative </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=109,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=290536,FOLIO='106',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_107"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stress
and ultimately damaging mitochondrial DNA. Progressive degeneration of central and peripheral nervous systems in Friedreich's ataxia patients causes impaired gait and coordination, muscle loss
and fatigue. Disease progression varies, but generally, the patient is confined to a wheelchair within 10 to 20&nbsp;years after the appearance of the first symptoms. Patients may become completely
incapacitated in later stages of the disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nrf2
regulates mitochondrial function to control cellular energy metabolism. Activation of Nrf2 increases the mitochondrial use of fatty acids and glucose, two molecules that work as
cellular fuel, and increases the formation of new mitochondria. Preclinical studies indicate that genetic or pharmacologic Nrf2 activation positively regulates mitochondrial function and energy
production. This activity may translate into improved physical functioning and reduced fatigue in patients with Friedreich's ataxia. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Friedreich's
ataxia affects both males and females and there are approximately 6,000 patients with Friedreich's ataxia in the United States and 20,000 in the European Union. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amyotrophic Lateral Sclerosis  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ALS, sometimes called Lou Gehrig's disease or classical motor neuron disease, is a rapidly progressive, fatal neurological disease that
attacks the nerve cells responsible for controlling voluntary muscles. Eventually, muscle weakness and atrophy occurs. People with ALS lose the ability to stand and walk, and use their hands and arms.
In later stages of the disease, individuals have difficulty breathing as the muscles of the respiratory system weaken. Although ventilation support can enable breathing and prolong survival, it does
not affect the progression of ALS. Most people with ALS die from respiratory failure, usually within three to five&nbsp;years of diagnosis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According
to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year. The incidence of ALS is two per 100,000 people, and it is estimated
that as many as
30,000 Americans may have the disease at any given time. ALS occurs throughout the world and affects all racial, ethnic and socioeconomic groups. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di15201_sales_and_marketing"> </A>
<A NAME="toc_di15201_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sales and Marketing    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given our stage of development, we have not yet established a commercial organization or distribution capabilities, nor have we entered
into any collaboration or co-promotion arrangements. We plan to build focused capabilities in the United States and Canada to commercialize development programs, such as CAT-1004 for DMD, where we
believe that the medical specialists for the indications are sufficiently concentrated to allow us to effectively promote the product with a targeted sales team. We also intend to enter into strategic
relationships with biotechnology and pharmaceutical companies where realizing the full value of our development programs will require access to broader geographic markets or the pursuit of broader
patient populations or indications. In addition, we intend to expand the drug development applications of our SMART linker technology platform through selective collaborations with leading
biotechnology and pharmaceutical companies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di15201_manufacturing_and_supply"> </A>
<A NAME="toc_di15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing and Supply    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of our SMART linker conjugate product candidates is a small molecule compound manufactured from component raw materials, for each
of the bioactives and for the linker. The omega-3 fatty acid materials that we use as bioactives are purified from natural sources by established pharmaceutical intermediate manufacturers. The other
bioactive and linker raw materials that we use are readily available from established pharmaceutical intermediate manufacturers who synthesize them using well understood, conventional chemistries. The
components are conjugated to form the SMART linker product candidate using well understood, conventional chemistries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently have no manufacturing facilities and limited personnel with manufacturing experience. We rely on contract manufacturers to produce both drug substance and drug product </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=110,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=74165,FOLIO='107',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_108"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>required
for our clinical trials. We plan to continue to rely upon contract manufacturers and, potentially, collaborators to manufacture commercial quantities of our products, if approved. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di15201_competition"> </A>
<A NAME="toc_di15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new drugs is highly competitive. If we successfully develop and commercialize any of our
product candidates, we and any future collaborators will face competition from pharmaceutical and biotechnology companies worldwide. Many of the entities developing and marketing potentially competing
products have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory
approvals and marketing. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer side effects, are more
convenient or are less expensive than any products that we may develop. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price and the availability of coverage and
reimbursement from government and other third-party payors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-1004 for Duchenne Muscular Dystrophy  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are currently no therapies approved for the treatment of DMD in the United States. Although not approved for the treatment of
DMD, corticosteroid therapy is often prescribed to treat the inflammation underlying DMD and to delay loss of ambulation. Marathon Pharmaceuticals has announced that it is conducting clinical trials
and preclinical studies to support approval of deflazacort, a corticosteroid, in DMD and that it anticipates filing an NDA for deflazacort with the FDA in 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A number of companies are developing therapies to treat DMD in patients with specific mutations in the dystrophin gene. PTC Therapeutics has received conditional approval for
Translarna&#153; in the European Union for DMD patients with nonsense mutations and has begun a rolling NDA
submission for marketing approval in the United States. BioMarin Pharmaceuticals and Sarepta Therapeutics have product candidates in clinical development based on a different scientific approach,
which is referred to as exon-skipping. BioMarin has submitted an NDA for marketing approval for drisapersen for DMD in the United States. Sarepta Therapeutics is conducting Phase&nbsp;3 clinical
trials of its lead product candidate eteplirsen and plans to submit the final component of the NDA by mid-2015. Based on the prevalence of the specific mutations that these product candidates are
designed to address, they would be expected to be effective in an aggregate of approximately 26% of DMD patients.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
companies have alternative therapeutic approaches to the treatment of DMD in late stage clinical development. Santhera Pharmaceuticals has announced positive effects on respiratory
function in a Phase&nbsp;3 clinical trial of idebenone (Raxone&reg; in the European Union and Catena&reg; in the United States). Santhera has announced that it plans to seek
regulatory approval for the treatment of DMD in Europe and the United States. Eli Lilly is conducting a Phase&nbsp;3 trial of the product tadalafil (Cialis&reg;), which is currently approved
for marketing for the treatment of erectile dysfunction, to assess whether Cialis will increase blood flow to muscles and delay the loss of ambulatory function in patients with DMD. A number of
companies have products in earlier stages of clinical development for DMD, including Akashi Therapeutics, Bristol Myers Squibb, Pfizer, Phrixus Pharmaceuticals, Summit&nbsp;Plc and Taiho
Pharmaceuticals. If successfully developed, some of these alternative therapeutic approaches may be applicable to all DMD patients. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CAT-2054 for Hypercholesterolemia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are many widely available products, including statins and cholesterol absorption inhibitors, approved for the treatment of
patients with hypercholesterolemia. The market and development </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=111,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=301547,FOLIO='108',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_109"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>pipeline
for cholesterol regulating therapies is especially large and competitive. If CAT-2054 is approved for the treatment of hypercholesterolemia, either as monotherapy or in combination therapies,
it will face intense competition from current approved therapies as well as a number of therapeutic approaches in development, including: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> PCSK9 inhibitors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The most advanced of these product
candidates are the monoclonal antibodies alirocumab, being developed by Sanofi and Regeneron Pharmaceuticals, and evolocumab, being developed by Amgen. Both agents have completed Phase&nbsp;3
clinical trials and are in the process of registration with United States and European regulatory authorities. Other PCSK9 inhibitors in clinical development include Pfizer's bococizumab, which is
currently in Phase&nbsp;3 clinical trials, and Eli Lilly's LY3015014, which has completed a Phase&nbsp;2 clinical trial. In addition, Alnylam Pharmaceuticals has announced the filing of a Clinical
Trial Application with the U.K. Medicines and Healthcare Products Regulatory Agency and initiation of a Phase&nbsp;1 clinical trial of ALN-PCSsc, which targets PCSK9.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Cholesterol ester transfer protein (CETP)
inhibitors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;CETP inhibitors are intended to reduce the risk of atherosclerosis. There are two CETP inhibitors in Phase&nbsp;3 clinical
trials, Merck's&nbsp;MK-0859 and Eli Lilly's LY2484595.&nbsp;Dezima Pharma's TA-8995 has completed a Phase&nbsp;2b clinical trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Esperion
is developing ETC-1002, an inhibitor of ATP citrate lyase that is currently in Phase&nbsp;2b clinical trials, and Madrigal Pharmaceuticals' is developing MGL-3196, an
inhibitor of thyroid hormone receptors that has completed Phase&nbsp;1 clinical trials in healthy volunteers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di15201_intellectual_property"> </A>
<A NAME="toc_di15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining
patent protection intended to cover the composition of matter of our product candidates, their methods of use, related technologies and other inventions that are important to our business. In addition
to patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, including certain
aspects of our SMART linker technology platform. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and know-how
related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid
and enforceable intellectual property rights of others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the
coverage claimed in a
patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our
product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by
third parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April&nbsp;30, 2015, our patent estate included 9 issued U.S. patents and over 25 pending U.S. patent applications, 10 issued foreign patents and 100 pending foreign patent
applications. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
regard to CAT-1004, we have two issued U.S. patents and one allowed U.S. patent application with composition of matter and method of use claims directed to CAT-1004 and its use. The
issued U.S. patents and the allowed U.S. patent application, when issued, are expected to expire in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=112,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=948323,FOLIO='109',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_di15201_1_110"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2029,
without taking a potential patent term extension into account. In addition, we have patents that have been granted in Australia, China, Mexico and New Zealand, which are expected to expire in
2029, without taking potential patent term extensions into account, and at least 20 pending patent applications in various other countries and regions in North America, South America, Europe, and
Asia, which, if issued, are expected to expire in 2029, without taking potential patent term extensions into account. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
regard to CAT-2003 and CAT-2054, we have two issued U.S. patents with composition of matter and method of use claims directed to CAT-2003 and CAT-2054 and their use. These U.S.
patents are scheduled to expire in 2030 and 2031, without taking potential patent term extensions into account. In addition, we have patents that have been granted in Australia, Mexico and New
Zealand, which are expected to expire in 2030, without taking potential patent term extensions into account and at least 20 pending applications in various other countries and regions including North
and South America, Europe, and Asia, which, if issued, are expected to expire in 2030, without taking patent term extensions into account. In addition, we have a pending U.S. patent application
directed to CAT-2054, which, if issued, is expected to expire in 2033, without taking a potential patent term extension into account. We have at least 10 counterpart patent applications pending in
various countries and regions in North America, South America, Europe and Asia, which, if issued, are expected to expire in 2033, without taking potential patent term extensions into account. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
regard to CAT-4001, we have one granted U.S. patent with composition of matter and method of use claims directed to CAT-4001 and its use. This U.S. patent is scheduled to expire in
2031, without taking a potential patent term extension into account. We have at least 20 counterpart patent
applications pending in various other countries and regions in North America, South America, Europe and Asia, which, if issued, are expected to expire in 2031, without taking potential patent term
extensions into account. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is
20&nbsp;years from the earliest date of filing a non-provisional patent application. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent
term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of
14&nbsp;years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions
to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering CAT-1004, CAT-2003, CAT-2054 and CAT-4001 may be entitled to patent term extensions. If
our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to
seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether
such extensions should be granted, and even if granted, the length of such extensions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to patent protection, we also rely on trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent
protection, including, for example, certain aspects of our manufacturing processes and conjugate selection methodologies. However, trade secrets can be difficult to protect. Although we take steps to
protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and
potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable
to meaningfully protect our trade secrets and proprietary information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=113,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=798531,FOLIO='110',FILE='DISK122:[14ZDH1.14ZDH15201]DI15201A.;74',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk15201_1_111"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_government_regulation_and_product_approvals"> </A>
<A NAME="toc_dk15201_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation and Product Approvals    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including
the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising,
promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and
in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and
financial resources. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_review_and_approval_of_drugs_in_the_united_states"> </A>
<A NAME="toc_dk15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review and Approval of Drugs in the United States    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations.
The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of
administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other
types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of
profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory
practice, or GLP, regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND, which must take effect before human clinical trials may begin; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be
initiated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the
safety and efficacy of the proposed drug product for each indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparation and submission to the FDA of an NDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review of the product by an FDA advisory committee, where appropriate or if applicable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components
thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the
product's identity, strength, quality and purity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment of user fees and securing FDA approval of the NDA; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval
studies required by the FDA. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=114,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=310748,FOLIO='111',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_112"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Studies  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active
pharmaceutical ingredient and the formulated drug or drug product, as well as </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and animal studies to assess the safety and activity of the drug
for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The
results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted
to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Human Clinical Trials in Support of an NDA  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in
any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be
used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An
IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on
clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA can place an IND on clinical hold at any point in
development, and depending upon the scope of the hold, clinical trial(s) may not restart until resolution of the outstanding concerns to the FDA's satisfaction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and
the IRB must conduct a continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be
provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of
Health for public dissemination on their ClinicalTrials.gov website. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Phase&nbsp;1.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The drug is initially introduced into healthy human subjects or, in
certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an
early indication of its effectiveness and to determine optimal dosage.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Phase&nbsp;2.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The drug is administered to a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Phase&nbsp;3.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The drug is administered to an expanded patient population,
generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to
establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=115,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=254570,FOLIO='112',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_113"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety
reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that
listed in the protocol or investigator brochure. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, or at all.
Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the
IRB's requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the
integrity of the clinical data submitted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Submission of an NDA to the FDA  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical
trials, together with detailed information relating to the product's chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting
approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently exceeding
$2.1&nbsp;million, and the sponsor of an approved NDA is also subject to annual product and establishment user fees, currently exceeding $104,000 per product and $554,000 per establishment. These
fees are typically increased annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA conducts a preliminary review of an NDA within 60&nbsp;days of its receipt and informs the sponsor by the 74th&nbsp;day after the FDA's receipt of the submission to determine
whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be
resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an
in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing,
and most applications for "priority review" products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new
information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities
associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA
will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the
benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease,
expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication
guides, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=116,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=785525,FOLIO='113',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_114"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>physician
communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or
dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a
serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of
independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fast Track, Breakthrough Therapy and Priority Review Designations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the
treatment of a serious or life-threatening disease or condition. These programs are fast track designation, breakthrough therapy designation and priority review designation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or
life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have greater interactions
with the FDA and the FDA may initiate review of sections of a fast track product's NDA before the application is complete. This rolling review may be available if the FDA determines, after preliminary
evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the
remaining information and the sponsor must pay applicable user fees. However, the FDA's time period goal for reviewing a fast track application does not begin until the last section of the NDA is
submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second,
in 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory scheme allowing for expedited review of
products designated as "breakthrough therapies." A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings
with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a
cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third,
the FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or
effectiveness. The FDA determines, on a case- by-case basis, whether the proposed drug represents a significant improvement when compared with other available therapies. Significant improvement may be
illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient
compliance that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=117,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=353749,FOLIO='114',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_115"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>may
lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the
evaluation of such applications, and to shorten the FDA's goal for taking action on a marketing application from ten months to six months. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accelerated Approval Pathway  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic
advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also
grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality,
or IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and
the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to
predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical
endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with
accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint
is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a
drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical
benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs
for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes
large trials to demonstrate a clinical or survival benefit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accelerated approval pathway is usually contingent on a sponsor's agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the
drug's clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&nbsp;4 or post-approval
clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to
withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The FDA's Decision on an NDA  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the FDA's evaluation of the NDA and accompanying information, including the results of the inspection of the
manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=118,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=549772,FOLIO='115',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_116"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>for
the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has
committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that
the application does not satisfy the regulatory criteria for approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug's safety after approval, require testing and surveillance programs to monitor the
product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market
and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product.
After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee
requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state
agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition
of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=119,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=746422,FOLIO='116',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_117"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of products; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in
accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to
have improperly promoted off-label uses may be subject to significant liability. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug
samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription
pharmaceutical product samples and impose requirements to ensure accountability in distribution. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Abbreviated New Drug Applications for Generic Drugs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the
same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to
the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as
the reference-listed drug, or RLD. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent" to the innovator drug. Under the statute, a generic drug is
bioequivalent to a RLD if "the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug..." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
approval of an ANDA, the FDA indicates whether the generic product is "therapeutically equivalent" to the RLD in its publication "Approved Drug Products with Therapeutic Equivalence
Evaluations," also referred to as the "Orange Book." Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of
certain state laws and numerous health insurance programs, the FDA's designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either
the prescribing physician or patient. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years
of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has
previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE
exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification, in which case the
applicant may submit its application four years following the original product approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug
product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=120,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=276513,FOLIO='117',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_118"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>drug
product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of
three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes
decisions about awards of data exclusivity shortly before a product is approved. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hatch-Waxman Patent Certification and the 30-Month Stay  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant's product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the
FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant
is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the applicant must certify with respect to each patent that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the required patent information has not been filed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent has expired; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent is invalid, unenforceable or will not be infringed by the new product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph&nbsp;IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the
listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the ANDA applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent
holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV
certification. The filing of a patent infringement lawsuit within 45&nbsp;days after the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until
the earlier of 30&nbsp;months after the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric Studies and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety
and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the
product is safe and effective. With enactment of the FDASIA in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed
pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA,
and the FDA's internal review committee must then review the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=121,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=901681,FOLIO='118',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>information
submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults,
or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.
Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing
protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that
fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to
fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever
statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period
during which the FDA cannot approve another application. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may designate a drug product as an "orphan drug" if it is intended to treat a rare disease or
condition (generally meaning that it affects fewer than 200,000&nbsp;individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and
making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before
submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease
or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for
the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan
product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives marketing approval
for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Extension  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a
patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the
effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14&nbsp;years from the product's approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application
for the extension must be submitted prior to the expiration of the patent in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=122,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=155347,FOLIO='119',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>question.
A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the
application for any patent term extension or restoration in consultation with the FDA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_review_and_approval_of__dk102433"> </A>
<A NAME="toc_dk15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review and Approval of Drug Products in the European Union    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory
requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution
of products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence
clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing
and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval.
Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Procedures Governing Approval of Drug Products in the European Union  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been
implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the
clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be
accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and
further detailed in applicable guidance documents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
obtain marketing approval of a product under European Union regulatory systems, an applicant must submit a marketing authorization application, or MAA, either under a centralized or
decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The
centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy
products and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products
that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting the initial assessment of a
product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the
centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information or written or oral explanation is
to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the
point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150&nbsp;days. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=123,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=866784,FOLIO='120',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_121"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not received marketing approval in any
European Union member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member
state designated by the applicant, known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft
summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment report and
drafts of the related materials within 210&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the reference member state's assessment report and related materials,
each concerned member state must decide whether to approve the assessment report and related materials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute
resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Data and Market Exclusivity in the European Union  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional
two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator's data to assess a generic (abbreviated)
application for eight years, after which generic marketing authorization can be submitted, and the innovator's data may be referenced, but not approved for two years. The overall ten-year period will
be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications
which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a
new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company can
complete a full MAA with a complete database of pharmaceutical test, preclinical tests and clinical trials and obtain marketing approval of its product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for
a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those
countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time
required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not
ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Periods of Authorization and Renewals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the
basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or
the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=124,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=512724,FOLIO='121',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_122"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>authorization
was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European
Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the
actual placing of the drug on the European Union market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid
(the so-called sunset clause). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation&nbsp;141/2000 provides that a drug shall be designated as an orphan drug if its sponsor can establish: that the product is
intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Community when the
application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Community
and that without incentives it is unlikely that the marketing of the drug in the European Community would generate sufficient return to justify the necessary investment. For either of these
conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European
Community or, if such method exists, the drug will be of significant benefit to those affected by that condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation&nbsp;847/2000
sets out criteria and procedures governing designation of orphan drugs in the European Union. Specifically, an application for designation as an orphan product
can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. This period
may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is
sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply
sufficient quantities of the product, demonstration of "clinically relevant superiority" by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by
a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant to
Regulation&nbsp;141/2000 shall be eligible for incentives made available by the European Community and by the member states to support research into, and the development and availability of, orphan
drugs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_pharmaceutical_coverage,_pricing_and_reimbursement"> </A>
<A NAME="toc_dk15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmaceutical Coverage, Pricing and Reimbursement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government
authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for
a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly
challenging the prices charged for medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary,
which might not include all of the approved products for a particular indication. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=125,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=162049,FOLIO='122',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_123"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
other comparable regulatory approvals. A payor's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may
not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown
significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside
the United States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental
control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of
regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates or products to other available therapies. The
conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price
has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the
European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of
medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of
the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on
health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some
countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug
products may not allow favorable reimbursement and pricing arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_healthcare_law_and_regulation"> </A>
<A NAME="toc_dk15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Law and Regulation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug products
that are granted marketing approval. Arrangements with third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such restrictions
under applicable federal and state healthcare laws and regulations, include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of,
any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which
prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a
false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=126,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=420776,FOLIO='123',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_124"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal laws that prohibit,
among other things, knowingly and willingly executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which
also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care Education
Reconciliation Act, or the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services
information related to payments and other transfers of value to physicians and teaching hospitals and physician ownership and investment interests; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare
items or services that are reimbursed by non-governmental third-party payors, including private insurers. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the
federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and foreign laws
also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_healthcare_reform"> </A>
<A NAME="toc_dk15201_6"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Reform    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and
biopharmaceutical products, government control and other changes to the healthcare system in the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress
enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. The Affordable Care
Act:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expanded manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and
generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs
that are inhaled, infused, instilled, implanted or injected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expanded the types of entities eligible for the 340B drug discount program; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=127,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=431113,FOLIO='124',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dk15201_1_125"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50%
point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient drugs to be
covered under Medicare Part&nbsp;D. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other
things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the
years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions of Medicare
payments to providers up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer
treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and
containing or lowering the cost of healthcare. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_employees"> </A>
<A NAME="toc_dk15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, we had 34 employees, 23 of whom were primarily engaged in research and development activities. A total of
17 employees have Ph.D. degrees. None of our employees is represented by a labor union and we believe our relations with our employees are good.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_facilities"> </A>
<A NAME="toc_dk15201_8"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facilities    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our offices are located in Cambridge, Massachusetts and consist of approximately 15,000 square feet of leased office and laboratory
space. The lease expires in June 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dk15201_legal_proceedings"> </A>
<A NAME="toc_dk15201_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Proceedings    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material legal proceedings. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=128,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=902966,FOLIO='125',FILE='DISK122:[14ZDH1.14ZDH15201]DK15201A.;36',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm15201_1_126"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm15201_management"> </A>
<A NAME="toc_dm15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name, age as of May&nbsp;1, 2015 and position of each of our executive officers and directors. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian C. Sanderson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer and Treasurer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(1)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.(2)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ron Laufer, M.D.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the Audit Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Nominating
and Corporate Governance Committee  </FONT></DD></DL>
 </DIV>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jill C. Milne, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as a member of our board of directors and as our President and Chief
Executive Officer since June 2008. Prior to co-founding our company, Dr.&nbsp;Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when
it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr.&nbsp;Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of
the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of
biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr.&nbsp;Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley
College. We believe that Dr.&nbsp;Milne is qualified to serve on our board of directors because of her extensive leadership experience in the life sciences industry and her extensive knowledge of
our company based on her role as co-founder and Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Ian C. Sanderson</I></B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since December 2013 and our Treasurer since January 2014. Prior to joining
Catabasis, Mr.&nbsp;Sanderson worked as a senior advisor at JSB-Partners,&nbsp;L.P., a global life sciences advisory firm specializing in strategic partnering and mergers and acquisitions
transactions, from August 2012 to August 2013. From 1992 to August 2012, Mr.&nbsp;Sanderson worked at at Cowen and Company,&nbsp;LLC, a financial services firm, in positions of increasing
responsibility, ultimately as a managing director and senior research analyst. Prior to Cowen, Mr.&nbsp;Sanderson worked at Houlihan Lokey Howard and Zukin, a financial services firm, from 1989 to
1992, at Cambridge Associates, an investment consulting firm, from 1985 to 1987, and at U.S. Surgical Corporation (now Covidien), a global healthcare products company, from 1983 to 1985.
Mr.&nbsp;Sanderson holds an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in political economy from Williams College. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael Jirousek, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as our Chief Scientific Officer since June 2008. From 2006 to 2008,
Dr.&nbsp;Jirousek served as senior vice president of research at Sirtris Pharmaceuticals. From 2001 to 2006, Dr.&nbsp;Jirousek served as Senior Director and Head of the Diabetes Therapeutic Area
for Pfizer&nbsp;Inc., a pharmaceutical company. From 1998 to 2001, Dr.&nbsp;Jirousek was at Abbott Laboratories, serving as a Metabolic Department Head, and prior to that he worked at Eli Lilly as
a Scientist and Program Leader from 1993 to 1998 and at American Home Products </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=129,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=905437,FOLIO='126',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_127"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Cyanamid
as a Medicinal Chemist from 1991 to 1993. Dr.&nbsp;Jirousek was a Post-Doctoral fellow at Harvard University from 1989 to 1991 and holds a Ph.D. in Chemistry from Case Western University
and a B.S. in Chemistry from Kent State University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne M. Donovan, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>, has served as our Chief Medical Officer since July 2011. In addition, since 1989, she worked as a staff
physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr.&nbsp;Donovan has held an appointment at Harvard Medical School since 1990, most recently as
associate clinical professor of medicine. From 1998 to July 2011, Dr.&nbsp;Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme
Corporation, a publicly traded biotechnology company, which she joined through its acquisition of GelTex. Dr.&nbsp;Donovan holds a Ph.D. in medical engineering and medical physics from the
Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a
fellowship in gastroenterology at the Brigham and Women's Hospital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Rick Modi</I></B></FONT><FONT SIZE=2> has served as our Chief Business Officer since January 2015. Prior to joining Catabasis, Mr.&nbsp;Modi worked as the Senior
Vice President of Global Marketing at InterMune,&nbsp;Inc., which was acquired by Hoffman-La Roche AG in 2014, from July 2013 to January 2015. From February 2008 to July 2013, Mr.&nbsp;Modi worked
at MedImmune,&nbsp;LLC, a wholly-owned biologics research and development subsidiary of AstraZenca&nbsp;plc, in positions of increasing responsibility, ultimately as the Vice President of
Corporate Strategy and Portfolio Management. From January 2002 to February 2008, Mr.&nbsp;Modi worked at Janssen Biotech,&nbsp;Inc. (formerly Centocor Biotech,&nbsp;Inc.), a wholly-owned
biotechnology subsidiary of Johnson&nbsp;&amp; Johnson, serving in several positions, including the Associate Director of Global Market Development. Mr.&nbsp;Modi holds an M.B.A. from The Wharton
School of the University of Pennsylvania and a B.S. in pharmacy from the University of Iowa. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael Ross, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our board of directors since April 2010 and as Chairman since October 2010. Since 2002,
Dr.&nbsp;Ross has served as a Managing Partner at SV Life Sciences Advisers,&nbsp;LLC, a venture capital firm that he joined as a venture partner in 2001. Previously, Dr.&nbsp;Ross served as the
Chief Executive Officer of CyThera, Carta Proteomics, MetaXen and Arris Pharmaceutical. Earlier in his career, Dr.&nbsp;Ross was employed at Genentech, serving in several roles,
including Vice President of Development and later Vice President of Medicinal and Biomolecular Chemistry. Dr.&nbsp;Ross currently serves on the board of directors of Ophthotech Corporation as well
as the boards of directors of several private companies, including Adimab and Sutro Biopharma, and the Board of Overseers of the Thayer School of Engineering at Dartmouth College. Dr.&nbsp;Ross
received an A.B. from Dartmouth College and a Ph.D. in chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University. We
believe that Dr.&nbsp;Ross is qualified to serve on our board of directors because of his extensive executive leadership experience and knowledge of the life sciences industry and his service on the
board of directors of other life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Nicholas Galakatos, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our board of directors and chair of the compensation committee since February 2012.
Dr.&nbsp;Galakatos is a co-founder of Clarus Ventures, a health care and life science venture capital firm, where he has served as Managing Director since its inception in 2005. Dr.&nbsp;Galakatos
has also served as a General Partner of MPM Asset Management II&nbsp;LLC since 2000 and as a General Partner of BioVentures III&nbsp;GP,&nbsp;LP since 2002. From 1997 to 2000,
Dr.&nbsp;Galakatos served as Vice President, New Business and a member of the Management Team at Millennium Pharmaceuticals. He was a founder of Millennium Predictive Medicine and TransForm
Pharmaceuticals, where he was also the Chairman and founding chief executive officer. Dr.&nbsp;Galakatos is a director of Portola Pharmaceuticals, NanoString Technologies and Ophthotech Corporation,
and formerly was the Lead Director of Affymax and a director of Critical Therapeutics and Aveo Pharmaceuticals. Dr.&nbsp;Galakatos received a B.A. in chemistry from Reed College and a Ph.D. in
organic chemistry from the Massachusetts Institute of Technology, and performed postdoctoral studies in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=130,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=254513,FOLIO='127',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_128"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>molecular
biology at Harvard Medical School. We believe that Dr.&nbsp;Galakatos is qualified to serve on our board of directors because of his extensive experience as a venture capital investor and
a director of several public companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jean George</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since October 2013. Since February 2002, she has been a Managing Director at
Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms.&nbsp;George has served as Managing
Director at LSV Capital Management, a venture capital firm. Ms.&nbsp;George currently serves as a member of the board of directors of the public companies Acceleron Pharma, Calithera Biosciences and
Zeltiq Aesthetics, and previously served as a member of the board of directors of Portola Pharmaceuticals from 2005 to 2013. Ms.&nbsp;George also serves on the boards of the private companies Hydra
Biosciences and Thrasos Innovation. Ms.&nbsp;George holds a B.S. in Biology from the University of Maine and an M.B.A. from Simmons College Graduate School of Management. Because of
Ms.&nbsp;George's extensive investment and financial experience, we believe she is able to add valuable expertise in guiding the strategic direction of our board of directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Ron Laufer, M.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our board of directors since April 2011. Dr.&nbsp;Laufer has worked as the Senior Managing
Director at MedImmune Ventures,&nbsp;Inc. since 2010. He served as an adjunct professor of business administration at the Kelley School of Business at Indiana University from 2009 to 2014. From 2007
to 2008, he served as a managing director at Visium Asset Management, a healthcare-focused investment firm, and co-founded Lilly Ventures, the venture capital arm of Eli Lilly&nbsp;&amp; Company, in
2001. Dr.&nbsp;Laufer currently serves as a member of the boards of directors of the private companies Adheron Therapeutics, G1 Therapeutics, NeuProtect and VentiRx Pharmaceuticals.
Dr.&nbsp;Laufer received his B.Sci., M.D. and M.P.H. from Hebrew University, and his M.B.A. from the Harvard Business School. We believe that Dr.&nbsp;Laufer's management experience and more than
18 years of experience in life sciences make him a valuable contributor to our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kenneth Bate</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since January 2014. Mr.&nbsp;Bate is currently an independent consultant.
From May 2009 until January 2012, Mr.&nbsp;Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr.&nbsp;Bate
was President and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr.&nbsp;Bate was Chief Operating Officer and Chief Financial Officer of
NitroMed. From January 2005 to March 2006, Mr.&nbsp;Bate was employed at JSB-Partners, a firm that he co-founded. From 2002 to January 2005, Mr.&nbsp;Bate was head of commercial operations and
Chief Financial Officer at Millennium Pharmaceuticals. Mr.&nbsp;Bate has served as a member of the Board of Directors of Cubist Pharmaceuticals,&nbsp;Inc., a public biopharmaceutical company,
since June 2003 and as its non-executive Chair since March 2011. Mr.&nbsp;Bate is a director of four other public biopharmaceutical companies, AVEO Pharmaceuticals, BioMarin Pharmaceuticals, Genocea
Biosciences and Epizyme Pharmaceuticals. During the last five years, Mr.&nbsp;Bate also served as a director of NitroMed and Coley Pharmaceutical Group, a biopharmaceutical company, which was a
public company during the period of Mr.&nbsp;Bate's service. He holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe
Mr.&nbsp;Bate's qualifications to serve on our board of directors include his operating, finance, commercial, transactional and senior management experience in the industry, as well as his
experience serving on the boards of directors of other public companies in the life sciences industry. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dm15201_board_composition_and_election_of_directors"> </A>
<A NAME="toc_dm15201_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Composition and Election of Directors    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Composition  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors currently consists of six members. Our directors hold office until their successors have been elected and
qualified or until the earlier of their resignation or removal. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=131,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=317072,FOLIO='128',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_129"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws that will become effective upon the closing of this offering provide that the authorized number of directors may be changed only by resolution
of our board of directors. Our certificate of incorporation and bylaws will also provide that our directors may be removed only for cause by the affirmative vote of the holders of 75% of our shares of
capital stock present in person or by proxy and entitled to vote, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be
filled only by vote of a majority of our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with the terms of our certificate of incorporation and bylaws that will become effective upon the closing of this offering, our board of directors will be divided into
three classes, class&nbsp;I, class&nbsp;II and class&nbsp;III, with members of each class serving staggered three-year terms. Upon the closing of this offering, the members of the classes will
be divided as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the class&nbsp;I directors will be Jill C. Milne and Ron Laufer, and their term will expire at the annual meeting of stockholders to
be held in 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the class&nbsp;II directors will be Nicholas Galakatos and Jean George, and their term will expire at the annual meeting of
stockholders to be held in 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the class&nbsp;III directors will be Kenneth Bate and Michael Ross, and their term will expire at the annual meeting of stockholders
to be held in 2018. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the
year in which their term expires. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Applicable NASDAQ Stock Market, or NASDAQ, rules require a majority of a listed company's board of directors to be comprised of
independent directors within one year of listing. In addition, the NASDAQ rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
corporate governance committees be independent under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Audit committee members must also satisfy the independence criteria set forth
in Rule&nbsp;10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule&nbsp;10C-1 under the Exchange Act. Under applicable
NASDAQ rules, a director will only qualify as an "independent director" if, in the opinion of the listed company's board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of
a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting,
advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered
independent for purposes of Rule&nbsp;10C-1, the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a
director has a relationship to such company which is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, including,
but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated
with the company or any of its subsidiaries or affiliates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, our board of directors undertook a review of the composition of our board of directors and its committees and the independence of each director. Based upon information
requested from and provided by each director concerning his or her background, employment and affiliations, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=132,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=116886,FOLIO='129',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_130"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>including
family relationships, our board of directors has determined that each of our directors, with the exception of Dr.&nbsp;Milne, is an "independent director" as defined under applicable
NASDAQ rules, including, in the case of all the members of our audit committee, the independence criteria set forth in Rule&nbsp;10A-3 under the Exchange Act, and in the case of all the members of
our compensation committee, the independence criteria set forth in Rule&nbsp;10C-1 under the Exchange Act. In making such determination, our board of directors considered the relationships that each
such non-employee director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial
ownership of our capital stock by each non-employee director. Dr.&nbsp;Milne is not an independent director under these rules because she is our President and Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dm15201_board_committees"> </A>
<A NAME="toc_dm15201_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Committees    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance
committee. Each of these committees will operate under a charter that has been approved by our board of directors. The composition of each committee will be effective as of the date of this
prospectus. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Kenneth Bate, Ron Laufer and Michael Ross, and Mr.&nbsp;Bate is the chair of the audit
committee. Effective at the time of this offering, our audit committee's responsibilities will include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports
from that firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial
statements and related disclosures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our internal audit function, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our risk assessment and risk management policies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt
and retention of accounting related complaints and concerns; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and management; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving or ratifying any related person transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the audit committee report required by Securities and Exchange Commission, or SEC, rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
audit and non-audit services, other than </FONT><FONT SIZE=2><I>de minimis</I></FONT><FONT SIZE=2> non-audit services, to be provided to us by our independent registered public
accounting firm must be approved in advance by our audit committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=133,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=380985,FOLIO='130',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_131"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has determined that Kenneth Bate is an "audit committee financial expert" as defined in applicable SEC rules and that each of the members of our audit committee
possesses the financial sophistication required for audit committee members under NASDAQ rules. We believe that the composition of our audit committee will meet the requirements for independence under
current NASDAQ and SEC rules and regulations. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our compensation committee are Nicholas Galakatos and Kenneth Bate, and Dr. Galakatos is the chair of the compensation
committee. Effective at the time of this offering, our compensation committee's responsibilities will include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief executive
officer and our other executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing an evaluation of our senior executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and administering our cash and equity incentive plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our board of directors with respect to director compensation and management succession
planning; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing annually with management our "Compensation Discussion and Analysis" disclosure if and to the extent then
required by SEC rules; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the compensation committee report if and to the extent then required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our compensation committee will meet the requirements for independence under current NASDAQ and SEC rules and regulations. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Michael Ross, Nicholas Galakatos and Jean George, and Dr. Ross is
the chair of the nominating and
corporate governance committee. Effective at the time of this offering, our nominating and corporate governance committee's responsibilities will
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying individuals qualified to become members of our board of directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our board of directors the persons to be nominated for election as directors and to each of our board's committees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our board with respect to our board leadership structure and board committee structure; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to our board with respect to accepting director resignations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our board with respect to management succession planning; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending to our board of directors corporate governance principles; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing an annual evaluation of our board of directors and an annual review of succession planning for senior executives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our nominating and corporate governance committee will meet the requirements for independence under current NASDAQ and SEC rules and regulations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=134,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=804984,FOLIO='131',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dm15201_1_132"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dm15201_compensation_committee__dm102478"> </A>
<A NAME="toc_dm15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None
of the members of our compensation committee is, or has ever been, an officer or employee of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dm15201_code_of_business_conduct_and_ethics"> </A>
<A NAME="toc_dm15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our
principal executive officer, principal financial officer principal accounting officer or controller, or persons performing similar functions. Following this offering, we will post a copy of the code
on the Corporate Governance section of our website, which is located at www.catabasis.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics
for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=135,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=665239,FOLIO='132',FILE='DISK122:[14ZDH1.14ZDH15201]DM15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do15201_1_133"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do15201_executive_compensation"> </A>
<A NAME="toc_do15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers in
2014. Our named executive officers for 2014 are Jill&nbsp;C. Milne, Ian C.&nbsp;Sanderson and Michael Jirousek. This section also provides qualitative information regarding the manner and context
in which compensation is awarded to and earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_summary_compensation_table"> </A>
<A NAME="toc_do15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during
2014. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:101pt;"><FONT SIZE=1><B>Name and principal position


<!-- COMMAND=ADD_SCROPPEDRULE,101pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C.&nbsp;Milne, Ph.D.(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>375,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>302,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>798,554</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian C. Sanderson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
311,554</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
56,080</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
564,315</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
933,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Financial Officer and</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Treasurer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
329,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
97,936</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
161,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
589,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our named executive officers.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed
in accordance with the provisions of Financial Accounting Standards Board Accounting Standard Codification, or ASC, Topic 718. See Note&nbsp;12 to our financial statements appearing at the end of
this prospectus regarding assumptions underlying the valuation of equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each named executive officer, the cost to us of life insurance premiums paid for
the named executive officer.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Milne
also serves as a member of our board of directors but does not receive any additional compensation for her service as a director. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_narrative_to_summary_compensation_table"> </A>
<A NAME="toc_do15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2014, we paid annual base salaries of $375,000 to Dr.&nbsp;Milne, $311,554 to Mr.&nbsp;Sanderson and $329,197 to
Dr.&nbsp;Jirousek. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our named executive officers. None of our named
executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have a formal performance-based bonus plan. From time to time, our board of directors has approved discretionary annual cash bonuses to our named executive officers with
respect to their prior year performance. Dr.&nbsp;Milne, Mr.&nbsp;Sanderson and Dr.&nbsp;Jirousek earned cash bonuses of $120,000, $56,080 and $97,936, respectively, for services performed
during 2014. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=136,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=582432,FOLIO='133',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_134"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity ownership guidelines applicable to them, we
believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders.
In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incents our executive officers to remain in our employment during the
vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of our named executive officers and from time to time may grant equity incentive awards to
them in the form of stock options. In 2014, we granted Dr.&nbsp;Milne an option to purchase 750,000 shares of our common stock, Mr.&nbsp;Sanderson options to purchase an aggregate of 1,400,220
shares of our common stock and Dr.&nbsp;Jirousek an option to purchase 400,000 shares of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_outstanding_equity_awards_at_year_end"> </A>
<A NAME="toc_do15201_4"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Year End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding equity awards held by our named executive officers as of
December&nbsp;31, 2014, which consisted entirely of stock options: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="124pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Underlying Unexercised<BR>
Options<BR>
Exercisable<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Underlying Unexercised<BR>
Options<BR>
Unexercisable<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Exercise<BR>
Price<BR>
($/share) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,015,267</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,684</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,848</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71,616</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>252,142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>165,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>176,134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>750,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian C. Sanderson</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>291,205</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>784,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>325,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Michael Jirousek, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,015,267</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,684</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,848</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71,616</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>252,142</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>165,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>176,134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,449</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on March&nbsp;1, 2011 and vested as to 25% of the shares on March&nbsp;1, 2012 with the remaining 75% of the shares vesting in
equal monthly installments thereafter through March&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on December&nbsp;18, 2012 and vested as to 25% of the shares on December&nbsp;1, 2012 with the remaining 75% of the shares
vesting in equal monthly installments thereafter through December&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on December&nbsp;18, 2012 and vested as to 25% of the shares on July&nbsp;10, 2013 with the remaining 75% of the shares vesting
in equal monthly installments thereafter through July&nbsp;10, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on April&nbsp;17, 2013 and vested as to 25% of the shares on January&nbsp;18, 2014 with the remaining 75% of the shares vesting
in equal monthly installments thereafter through January&nbsp;18, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on March&nbsp;19, 2014 and vested as to 25% of the shares on January&nbsp;1, 2015 with the remaining 75% of the shares vesting
in equal monthly installments thereafter through January&nbsp;1, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
option was granted on March&nbsp;19, 2014 and vested as to 25% of the shares on November&nbsp;1, 2014 with the remaining 75% of the shares vesting
in equal monthly installments thereafter through November&nbsp;1, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=137,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=421190,FOLIO='134',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_135"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_agreements_with_our_named_executive_officers"> </A>
<A NAME="toc_do15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreements with Our Named Executive Officers    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into written employment agreements or offer letters with each of our named executive officers. These agreements set
forth the terms of the named executive officer's compensation, including his or her initial base salary, severance and an annual cash bonus opportunity. In addition, the agreements provide that the
named executive officers are eligible to participate in company-sponsored benefit programs that are available generally to all of our employees.
In connection with the commencement of their employment with us, our named executive officers executed our standard invention and non-disclosure agreement and non-competition and non-solicitation
agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The employment agreement with Dr.&nbsp;Milne provides that she is eligible to receive an annual cash bonus, as determined by the board of directors in its sole discretion, with a
target of 40% of her annual base salary earned in such particular calendar year, which percentage shall be subject to adjustment from time to time by the board of directors in its sole discretion. The
board of directors determines the amount of the bonus, if any, based on its assessment of Dr.&nbsp;Milne's performance and that of the company against appropriate goals established annually by the
board of directors after consultation with Dr.&nbsp;Milne. Mr.&nbsp;Sanderson's offer letter provides for an annual cash bonus of up to 30% of his annual base salary, as determined in the sole
discretion of the board of directors.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2015, we entered into a letter agreement with Dr.&nbsp;Jirousek that provides for him to continue as our Chief Scientific Officer until September&nbsp;30, 2015. Pursuant to
such letter agreement, which superseded the existing employment agreement between Dr.&nbsp;Jirousek and us, upon the termination of his employment, Dr.&nbsp;Jirousek will be appointed as a member
of our Scientific Advisory Board for a term ending on September&nbsp;30, 2016. Dr.&nbsp;Jirousek will also receive the benefits described below under "Potential Payment upon Termination or Change
of Control," and he will provide specified transition services.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination or Change in Control  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon execution and effectiveness of a separation agreement and release of all claims, each named executive officer is entitled to
severance payments if his or her employment is terminated under specified circumstances pursuant to the terms of his or her employment agreement or offer letter, subject to providing a release of
claims. Severance payments to the officers could be delayed for six months in certain circumstances for compliance with Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, or the
Code. On any termination of employment, the executive officer will receive any base salary and bonus earned but not paid through the date of termination and any vacation time accrued but not used to
that date and any business expenses incurred but not un-reimbursed on the date of termination. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we terminate Dr.&nbsp;Milne's or Dr.&nbsp;Jirousek's employment without "cause" or such named executive officer terminates his or her employment with us for "good reason," each as
defined in accordance with the terms of his or her employment agreement, we will be obligated to pay, in addition to the aforementioned payments:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an amount equal to up to 100% of his or her annual base salary, payable in equal installments in accordance with our standard payroll
practices, for a period of 12&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a bonus payment in an amount equal to 50% of the average annual bonus paid to the executive officer over the three calendar years
preceding the year of termination, prorated for the portion of the calendar year he or she worked in the year of termination; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> premiums for continuation health coverage under COBRA for up to 12&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event Dr.&nbsp;Milne or Dr.&nbsp;Jirousek commences any employment substantially similar to his or her employment with the company (based upon responsibility, reporting level,
or compensation), any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=138,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=689038,FOLIO='135',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_136"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>remaining
portion of the base salary payment will cease to be payable on the date 60&nbsp;days after the commencement of such new employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
12&nbsp;months following a change of control, under the terms of the employment agreements, if Dr.&nbsp;Milne's or Dr.&nbsp;Jirousek's employment is terminated by us or our
successor without cause or by such executive officer for good reason, then all of Dr.&nbsp;Milne's or Dr.&nbsp;Jirousek's remaining unvested stock options and restricted stock will automatically
vest 15&nbsp;days following the execution and effectiveness of a separation agreement and release of all claims, and we will be obligated to pay an amount equal to his or her annual base salary,
payable as a lump sum, a bonus payment equal to 50% of the average annual bonus paid to the executive officer over the three calendar years preceding the year of termination, and premiums for
continuation health coverage under COBRA for up to 12&nbsp;months. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we terminate Mr.&nbsp;Sanderson's employment without "cause" as defined in his offer letter, we will be obligated to pay an amount equal to his monthly base salary, payable in
installments in accordance with our standard payroll practice, for a period of nine months. In the event Mr.&nbsp;Sanderson commences any employment substantially similar to his employment with the
company (based upon responsibility,
reporting level, or compensation) within such nine-month period, any remaining payment will be reduced such that the number of months of base salary will be equal to that number of months between the
date of termination and the date of commencement of such new employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_stock_option_and_other_compensation_plans"> </A>
<A NAME="toc_do15201_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option and Other Compensation Plans    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The three equity incentive plans described in this section are our amended and restated 2008 equity incentive plan, as amended to date,
or the 2008 plan, our 2015 stock incentive plan, or the 2015 plan and our 2015 employee stock purchase plan, or the 2015 ESPP. Prior to this offering, we granted awards to eligible participants under
the 2008 plan. Following the closing of this offering, we expect to grant awards to eligible participants only under the 2015 plan and the 2015 ESPP.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amended and Restated 2008 Equity Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, stock
appreciation rights and performance units and performance share awards. Our employees, directors, and consultants are eligible to receive awards under our 2008 plan; however, incentive stock options
may only be granted to our employees. Our board of directors administers the 2008 plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2008 plan provides that a maximum of 23,684,539 shares of our common stock are authorized for issuance under the plan. The 2008 plan does not have a fixed expiration date, however,
no incentive stock options may be granted under the 2008 plan after December&nbsp;30, 2018 and our board of directors may amend, suspend or terminate the 2008 plan at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in
capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we shall equitably adjust (or make substitute awards, if applicable), in
the manner determined by our board of directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities available under the 2008 plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities and exercise price per share of each outstanding option; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares subject to and the repurchase price per share subject to each outstanding restricted stock award; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of each other outstanding award under the 2008 plan. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=139,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=244798,FOLIO='136',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_137"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a merger or consolidation of our company with or into another entity as a result of which all of our common stock is converted into or exchanged for the right to
receive cash, securities or other property or is cancelled; an exchange of all of our common stock for cash, securities or other property pursuant to a share exchange transaction; or a liquidation or
dissolution of our company, our board of directors may, on such terms as our board of directors determines, take any one or more of the following actions pursuant to the 2008 plan, as to some or all
outstanding awards, other than restricted stock awards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that awards shall be assumed, or substantially equivalent awards shall be substituted, by the acquiring or succeeding
corporation (or an affiliate thereof); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon written notice to a plan participant, provide that the participant's unexercised awards will terminate immediately prior to the
consummation of such transaction unless exercised by the participant within a specified period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that outstanding awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an award shall
lapse, in whole or in part prior to or upon such transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the event of a transaction under the terms of which holders of common stock will receive upon consummation thereof a cash payment
for each share surrendered in the transaction, make or provide for a cash payment to a plan participant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that, in connection with a liquidation of dissolution of the company, awards shall convert into the right to receive
liquidation proceeds; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any combination of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors is not obligated under the 2008 plan to treat all awards, all awards held by a participant, or all awards of the same type, identically. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of any corporate transaction described above, other than our liquidation or dissolution, our repurchase and other rights under each outstanding restricted stock award
will continue for the benefit of our successor and will, unless our board of directors determines otherwise, apply to the cash, securities or other property which our common stock was converted into
or exchanged for in the transaction in the same manner and to the same extent as they applied to the common stock subject to the restricted stock award. Upon our liquidation or dissolution, except to
the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the plan participant and us, all restrictions and conditions on all restricted
stock awards then outstanding will automatically be deemed terminated or satisfied. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors, in its sole discretion, may accelerate the exercisability of any option or time at which any restrictions shall lapse or be removed from any restricted stock
award, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April&nbsp;30, 2015, there were options to purchase 19,002,857 shares of our common stock outstanding under the 2008 plan, at a weighted-average exercise price of $0.43 per
share, and options to purchase 2,058,760 shares of our common stock had been exercised. Effective as of immediately prior to the closing of this offering, we will no longer grant stock options or
other awards under the 2008 plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Stock Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May 2015 our board of directors adopted, and we expect our stockholders to approve, the 2015 plan, to become effective in connection
with this offering. The 2015 plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, awards of restricted stock,

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=140,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=477099,FOLIO='137',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_138"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


restricted stock units, other stock-based awards. Upon the closing of this offering, the number of shares of our common stock that will be reserved for issuance under the 2015 plan will be the sum of
13,727,495 shares plus the number of shares reserved for issuance under the 2008 plan that remain available for future issuance immediately prior to the closing of this offering. Following the closing
of this offering, the number of shares reserved for issuance under the 2015 plan will increase by (1)&nbsp;the number of shares of our common stock subject to outstanding awards under our 2008 plan
upon the closing of this offering that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase
right and (2)&nbsp;an annual increase, to be added the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2016 and continuing until, and including, the fiscal
year ending December&nbsp;31, 2025, equal to the lowest of 16,670,752 shares of our common stock, 4% of the number of shares of our common stock outstanding on the first day of the fiscal year and
an amount determined by our board of directors. Our employees, officers, directors, consultants and advisors will be eligible to receive awards under the 2015 plan; however, incentive stock options
may only be granted to our employees.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the 2015 plan, our board of directors (or a committee delegated by our board of directors) administers the 2015 plan and, subject to any limitations set forth in
the 2015 plan, will select the recipients of awards and determine:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of common stock covered by options and the dates upon which those options become exercisable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the type of options to be granted; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the exercise price of options, which price must be at least equal to the fair market value of our common stock on the date of grant; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the duration of options, which may not be in excess of ten years; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the methods of payment of the exercise price of options; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of our common stock subject to and the terms of any stock appreciation rights, awards of restricted stock,
restricted stock units, other stock-based awards and the terms and conditions of such awards, including the issue price, conditions for repurchase, repurchase price and performance conditions (though
the measurement price of stock appreciation rights must be at least equal to the fair market value of our common stock on the date of grant and the duration of such awards may not be in excess of ten
years), if any. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our board of directors delegates authority to an executive officer to grant awards under the 2015 plan, the executive officer will have the power to make awards to all of our
employees, except executive officers. Our board of directors will fix the terms of the awards to be granted by such executive officer, including the exercise price of such awards (or a formula for
establishing such price), and the maximum number of shares subject to awards that such executive officer may make. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in
capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, we are required by the 2015 plan to make equitable adjustments (or make
substitute awards, if applicable), in a manner determined by our board, to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities available under the 2015 plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share counting rules under the 2015 plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities and exercise price per share of each outstanding option; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=141,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=147858,FOLIO='138',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_139"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share and per-share provisions and measurement price of each outstanding stock appreciation right; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares and the repurchase price per share subject to each outstanding restricted stock award or restricted stock unit
award; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share and per-share related provisions and purchase price, if any, of any outstanding other stock-based award. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
a merger or other reorganization event (as defined in our 2015 plan), our board of directors, may, on such terms as our board determines (except to the extent specifically provided
otherwise in an applicable award agreement or other agreement between the participant and us), take any one or more of the following actions pursuant to the 2015 plan, as to some or all outstanding
awards, other than restricted stock awards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that all outstanding awards will be assumed or substantially equivalent awards will be substituted by the successor
corporation (or an affiliate thereof); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon written notice to a participant, provide that the participant's unvested and/or unexercised options or other awards will
terminate immediately prior to the consummation of such transaction unless exercised by the participant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to an award will lapse,
in whole or in part, prior to or upon the reorganization event; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the event of a reorganization event pursuant to which holders of our common stock will receive a cash payment for each share
surrendered in the reorganization event, make or provide for a cash payment to the participants with respect to each award held by a participant equal to (1)&nbsp;the number of shares of our common
stock subject to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&nbsp;the
excess, if any, of the cash payment for each share surrendered in the reorganization event over the exercise, measurement or purchase price of such award and any applicable tax withholdings, in
exchange for the termination of such award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that, in connection with a liquidation or dissolution, awards convert into the right to receive liquidation proceeds (if
applicable, net of exercise, measurement or purchase price thereof and any applicable tax withholdings); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any combination of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors is not obligated by the 2015 plan to treat all awards, all awards held by a participant, or all awards of the same type, identically. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of certain restricted stock units, no assumption or substitution is permitted, and the restricted stock units will instead be settled in accordance with the terms of the
applicable restricted stock unit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a reorganization event other than a liquidation or dissolution, the repurchase and other rights under each outstanding restricted stock award will continue for the
benefit of the successor company and will, unless our board of directors may otherwise determine, apply to the cash, securities or other property which our common stock is converted into or exchanged
for pursuant to the reorganization event, unless our board provided for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or any
other agreement between the participant and us. Upon the occurrence of a reorganization event involving a liquidation or dissolution, all restrictions and conditions on each outstanding restricted
stock award will automatically be deemed terminated or satisfied, unless otherwise provided in the agreement evidencing the restricted stock award or in any other agreement between the participant and
us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=142,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=215968,FOLIO='139',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_140"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may at any time provide that any award under the 2015 plan shall become immediately exercisable in whole or in part, free of some or all restrictions or
conditions, or otherwise realizable in whole or in part, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
with respect to certain actions requiring stockholder approval under the Internal Revenue Code or the rules of the NASDAQ Stock Market, our board of directors may amend, modify or
terminate any outstanding award under the 2015 plan, including but not limited to, substituting therefor another award of the same or a different type, changing the date of exercise or realization,
and converting an incentive stock option into a nonstatutory stock option, subject to certain participant consent requirements. Unless our stockholders approve such action, the 2015 plan provides that
we may not (except as otherwise permitted in connection with a change in capitalization or reorganization event):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> amend any outstanding stock option or stock appreciation right granted under the 2015 plan to provide an exercise or measurement price
per share that is lower than the then-current exercise or measurement price per share of such outstanding award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cancel any outstanding option or stock appreciation right (whether or not granted under the 2015 plan) and grant in substitution
therefor new awards under the 2015 plan (other than substitute awards permitted in connection with a merger or consolidation of an entity with us or our acquisition of property or stock of another
entity) covering the same or a different number of shares of our common stock and having an exercise or measurement price per share lower than the then-current exercise or measurement price per share
of the cancelled award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cancel in exchange for a cash payment any outstanding option or stock appreciation right with an exercise or measurement price per
share above the then-current fair market value of our common stock; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> take any other action that constitutes a "repricing" within the meaning of the rules of the NASDAQ Stock Market. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
award may be granted under the 2015 plan after&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025. Our board of directors may amend, suspend or terminate the 2015 plan at any time, except that
stockholder
approval will be required to comply with applicable law or stock market requirements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Employee Stock Purchase Plan

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our board of directors to adopt and our stockholders to approve the 2015 ESPP, to become effective upon the closing of this
offering. The 2015 ESPP will be administered by our board of directors or by a committee appointed by our board of directors. The 2015 ESPP initially provides participating employees with the
opportunity to purchase up to an aggregate of 2,343,236 shares of our common stock. The number of shares of our common stock reserved for issuance under the 2015 ESPP will automatically increase on
the first day of each fiscal year, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2026, in an amount equal to the least of (i)&nbsp;4,686,472 shares of our common stock,
(ii)&nbsp;1% of the total number of shares of our common stock outstanding on the first day of the applicable year, and (iii)&nbsp;an amount determined by our board of directors.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of our employees or employees of any designated subsidiary, as defined in the 2015 ESPP, are eligible to participate in the 2015 ESPP, provided
that:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such person is customarily employed by us or a designated subsidiary for more than 20&nbsp;hours a week and for more than five
months in a calendar year; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such person has been employed by us or by a designated subsidiary for at least six months prior to enrolling in the 2015 ESPP; and


</FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=143,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=313165,FOLIO='140',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_141"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>



<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such person was our employee or an employee of a designated subsidiary on the first day of the applicable offering period under the
2015 ESPP.

 </FONT></DD></DL>
</UL>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No employee may purchase shares of our common stock under the 2015 ESPP and any of our other employee stock purchase plans in excess of $25,000 of the fair market value of our common
stock (as of the date of the option grant) in any calendar year. In addition, no employee may purchase shares of our common stock under the 2015 ESPP that would result in the employee owning 5% or
more of the total combined voting power or value of our stock or the stock of any of our subsidiaries.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to make one or more offerings to our eligible employees to purchase stock under the 2015 ESPP beginning at such time as our board of directors may determine. Each offering will
consist of a six-month offering period during which payroll deductions will be made and held for the purchase of our common stock at the end of the offering period. Our board of directors may, at its
discretion, choose a different period of not more than 12&nbsp;months for offerings.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the commencement date of each offering period, each eligible employee may authorize up to a maximum of 15% of his or her compensation to be deducted by us during the offering period.
Each employee who continues to be a participant in the 2015 ESPP on the last business day of the offering period will be deemed to have exercised an option to purchase from us the number of whole
shares of our common stock that his or her accumulated payroll deductions on such date will pay for, not in excess of the maximum numbers set forth above. Under the terms of the 2015 ESPP, the
purchase price shall be determined by our board of directors for each offering period and will be at least 85% of the applicable closing price of our common stock. If our board of directors does not
make a determination of the purchase price, the purchase price will be 85% of the lesser of the closing price of our common stock on the first business day of the offering period or on the last
business day of the offering period.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An employee who is not a participant on the last day of the offering period is not entitled to purchase shares under the 2015 ESPP, and the employee's accumulated payroll deductions will
be refunded. An employee's rights under the 2015 ESPP terminate upon voluntary withdrawal from an offering under the 2015 ESPP at any time, or when the employee ceases employment for any reason.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will be required to make equitable adjustments to the number and class of securities available under the 2015 ESPP, the share limitations under the 2015 ESPP, and the purchase price
for an offering period under the 2015 ESPP to reflect stock splits, reverse stock splits, stock dividends, recapitalizations, combinations of shares, reclassifications of shares, spin-offs and other
similar changes in capitalization or events or any dividends or distributions to holders of our common stock other than ordinary cash dividends.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with a merger or other reorganization event, as defined in the 2015 ESPP, our board of directors or a committee of our board of directors may take any one or more of the
following actions as to outstanding options to purchase shares of our common stock under the 2015 ESPP on such terms as our board or committee
determines:</FONT>

</P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that options shall be assumed, or substantially equivalent options shall be substituted, by the acquiring or succeeding
corporation (or an affiliate thereof); </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon written notice to employees, provide that all outstanding options will be terminated immediately prior to the consummation of
such reorganization event and that all such outstanding options will become exercisable to the extent of accumulated payroll deductions as of a date specified by our board or committee in such notice,
which date shall not be less than ten days preceding the effective date of the reorganization event; </FONT><FONT SIZE=2>



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon written notice to employees, provide that all outstanding options will be cancelled as of a date prior to the effective date of
the reorganization event and that all accumulated payroll deductions will be returned to participating employees on such date;

 </FONT></DD>

</DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=144,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=940410,FOLIO='141',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_142"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the event of a reorganization event under the terms of which holders of our common stock will receive upon consummation thereof a
cash payment for each share surrendered in the reorganization event, change the last day of the offering period to be the date of the consummation of the reorganization event and make or provide for a
cash payment to each employee equal to (1)&nbsp;the cash payment for each share surrendered in the reorganization event times the number of shares of our common stock that the employee's accumulated
payroll deductions as of immediately prior to the reorganization event could purchase at the applicable purchase price, where the acquisition price is treated as the fair market value of our common
stock on the last day of the applicable offering period for purposes of determining the purchase price and where the number of shares that could be purchased is subject to the applicable limitations
under the 2015 ESPP minus (2)&nbsp;the result of multiplying such number of shares by the purchase price; and/or </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that, in connection with our liquidation or dissolution, options shall convert into the right to receive liquidation proceeds
(net of the purchase price thereof).

 </FONT></DD>

</DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may at any time, and from time to time, amend or suspend the 2015 ESPP or any portion thereof. We will obtain stockholder approval for any amendment if such
approval is required by Section&nbsp;423 of the Internal Revenue Code. Further, our board of directors may not make any amendment that would cause the 2015 ESPP to fail to comply with
Section&nbsp;423 of the Internal Revenue Code. The 2015 ESPP may be terminated at any time by our board of directors. Upon termination, we will refund all amounts in the accounts of participating
employees.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_401(k)_retirement_plan"> </A>
<A NAME="toc_do15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Retirement Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of
the Code. In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement of their employment. The 401(k) plan includes a salary deferral
arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $18,000 in 2015, and have the amount of the reduction
contributed to the 401(k) plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_limitations_on_liability_and_indemnification"> </A>
<A NAME="toc_do15201_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on Liability and Indemnification    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation, which will become effective upon the closing of this offering, limits the personal liability of
directors for breach of fiduciary duty to the maximum extent permitted by the General Corporation Law of the State of Delaware and provides that no director will have personal liability to us or to
our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or limit the liability of any of our
directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any breach of the director's duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such
amendment or repeal. If the General Corporation Law of the State of Delaware is amended to provide for further limitations on the personal liability of directors of corporations, then the personal
liability of our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=145,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=284772,FOLIO='142',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_143"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>directors
will be further limited to the greatest extent permitted by the General Corporation Law of the State of Delaware. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our certificate of incorporation, which will become effective upon the closing of this offering, provides that we must indemnify our directors and officers and we must
advance expenses, including attorneys' fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a general liability insurance policy that covers specified liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. In addition, we have entered into indemnification agreements with certain of our directors, and we intend to enter into indemnification agreements with all of our directors and
executive officers prior to the completion of this offering. These indemnification agreements may require us, among other things, to indemnify each such director or officer for some expenses,
including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his or her service as one of our directors or officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of our non-employee directors may, through their relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members
of our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act of 1933, or the Securities Act, may be permitted to directors, executive officers or persons controlling us,
in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_rule_10b5-1_sales_plans"> </A>
<A NAME="toc_do15201_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;10b5-1 Sales Plans    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our directors and executive officers may adopt written plans, known as Rule&nbsp;10b5-1 plans, in which they will contract with a
broker to buy or sell shares of our common stock on a periodic basis. Under a Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when
entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in some circumstances.
Our directors and executive officers may also buy or sell additional shares outside of a Rule&nbsp;10b5-1 plan when they are not in possession of material, nonpublic information. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="do15201_director_compensation"> </A>
<A NAME="toc_do15201_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2014, we paid Mr.&nbsp;Bate an annual retainer of $30,000 for service on our board of directors. In addition, on
March&nbsp;19, 2014, we granted Mr.&nbsp;Bate an option to purchase 127,000 shares of our common stock, at an exercise price of $0.53 per share, which vests over four years, with 25% of the shares
having vested on January&nbsp;1, 2015 and the remainder vesting in equal monthly installments thereafter. This stock option had a grant date fair value of $58,848, computed in accordance with ASC
Topic&nbsp;718, which combined with Mr.&nbsp;Bate's annual retainer resulted in total compensation of $88,848 for Mr.&nbsp;Bate for 2014. See Note&nbsp;12 to our financial statements appearing
at the end of this prospectus regarding assumptions underlying the valuation of equity awards. None of our other non-employee directors has received any compensation from us, although we reimburse our
non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings. With the exception of the stock option granted
to Mr.&nbsp;Bate described above, there were no outstanding equity awards held by our non-employee directors as of December&nbsp;31, 2014. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=146,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=598289,FOLIO='143',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<A NAME="page_do15201_1_144"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not pay any compensation to our President and Chief Executive Officer in connection with her service on our board of directors. The compensation that we pay to our President and
Chief Executive Officer is discussed earlier in this "Executive Compensation" section. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, our board of directors approved a director compensation program to be effective at the time of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
this director compensation program, we will pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the
director is a member. The chairman of each committee will receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each
quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on our board of directors and no fee shall be payable in respect of
any period prior to the closing of this offering. The fees paid to non-employee directors for service on the board of directors
and for service on each committee of the board of directors on which the director is a member are as follows: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Additional<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also will continue to reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our board of director and committee
meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under our director compensation program to be effective at the time of this offering, each non-employee director serving on our board of directors upon the closing of this
offering and each non-employee director elected to our board of directors after the closing of this offering will receive an option to purchase 142,564 shares of our common stock. Each of these
options will vest as to one-third of the shares of our common stock underlying such option on each anniversary of the grant date until the third anniversary of the grant date, subject to the
non-employee director's continued service as a director. All options issued to our non-employee directors under our director compensation program will become exercisable in full upon a change in
control of our company. Further, on the date of the first board meeting held after each annual meeting of stockholders, each non-employee director that has served on our board of directors for at
least six months will receive an option to purchase 57,025 shares of our common stock. Each of these options will vest in full on the one-year anniversary of the grant date unless otherwise provided
at the time of grant, subject to the non-employee director's continued service as a director, and will become exercisable in full upon a change in control of our
company. The exercise price of these options will equal the fair market value of our common stock on the date of grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=147,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=751846,FOLIO='144',FILE='DISK122:[14ZDH1.14ZDH15201]DO15201A.;58',USER='LPALLES',CD=';2-JUN-2015;11:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq15201_1_145"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq15201_transactions_with_related_persons"> </A>
<A NAME="toc_dq15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  TRANSACTIONS WITH RELATED PERSONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2012, we have engaged in the following transactions in which the amount involved exceeded $120,000 and any of
our directors or executive officers or beneficial holders of more than 5% of any class of our voting securities, or any immediate family member of the foregoing persons, had a material interest. We
believe that all of these transactions were on terms comparable to terms that could have been obtained from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_series_a_preferred_stock_financing"> </A>
<A NAME="toc_dq15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Preferred Stock Financing    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In closings that occurred in July 2012, January 2013 and June 2013, we issued and sold an aggregate of 25,636,951 shares of our
series&nbsp;A preferred stock at a price per share of $0.70, for an aggregate purchase price of $17.9&nbsp;million. The following table sets forth the number of
shares of our series&nbsp;A preferred stock purchased by our directors, executive officers and 5% stockholders and their respective affiliates and the aggregate purchase price paid for such shares. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Series&nbsp;A<BR>
Preferred Stock<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,160,866</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,712,606</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V Strategic Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>172,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>120,727</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,600,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,333,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,733,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,333,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,333,333</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George Milne(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>302,115</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>211,481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,373,542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,761,480 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>George
Milne is the father-in-law of Jill C. Milne, our President and Chief Executive Officer.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_series_b_preferred_stock_financing"> </A>
<A NAME="toc_dq15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B Preferred Stock Financing    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2013, we issued and sold an aggregate of 34,129,571 shares of our series&nbsp;B preferred stock at a price per share of
$0.9503, for an aggregate purchase price of $32.4&nbsp;million. The following table sets forth the number of shares of our series&nbsp;B preferred stock purchased by our directors, executive
officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Series&nbsp;B<BR>
Preferred Stock<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,961,792</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,566,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V Strategic Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>168,259</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>159,897</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,899,973</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,507,344</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,156,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,156,897</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,999,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,539,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,214,584</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures (A),&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,352,643</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,285,417 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,236,064</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,733,332 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=148,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=364471,FOLIO='145',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_146"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, we issued and sold an aggregate of 13,062,965 additional shares of our series&nbsp;B preferred stock at a price per share of $0.9503, for an aggregate purchase price of
$12.4&nbsp;million. The following table sets forth the number of shares of our series&nbsp;B preferred stock purchased by our directors, executive officers and 5% stockholders and their affiliates
and the aggregate purchase price paid for such shares.

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of Series&nbsp;B<BR>
Preferred Stock<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,859,593</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,767,171</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SV Life Sciences Fund V Strategic Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,299</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,346</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,828,998</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,738,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,084,882</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,030,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>753,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>716,046</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>442,646</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>420,647</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lightstone Ventures (A),&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,312</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>105,229</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>99,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George Milne</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>333,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>316,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rick Modi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,614</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,261</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,570,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,244,133 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_investor_rights_agreement"> </A>
<A NAME="toc_dq15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investor Rights Agreement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to an amended and restated investor rights agreement, dated as of March&nbsp;17, 2015, with holders of our preferred
stock, including some of our directors and 5% stockholders and their affiliates and entities affiliated with our officers and directors. The amended and restated investor rights agreement provides
these holders the right, following the completion of this offering, to demand that we file&nbsp;a registration statement or request that their shares be covered by a registration statement that we
are otherwise filing. In addition, the holders of warrants to purchase shares of our preferred stock have rights under those warrants to become party to the amended and restated investor rights
agreement following exercise of the warrants, following which they will have, with respect to the shares acquired on exercise of the warrants, the same rights to require us to register the shares as
the other investor parties to the amended and restated investor rights agreement. See "Description of Capital Stock&#151;Registration Rights" for additional information regarding these
registration rights. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_employment_agreements"> </A>
<A NAME="toc_dq15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See the "Executive Compensation&#151;Agreements with Our Named Executive Officers" section of this prospectus for a further
discussion of these arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_indemnification_agreements"> </A>
<A NAME="toc_dq15201_6"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation that will become effective upon the closing of this offering provides that we will indemnify our
directors and officers to the fullest extent permitted by Delaware law. In addition, we have entered into indemnification agreements with each of our directors. See "Executive
Compensation&#151;Limitation of Liability and Indemnification" for additional information regarding these agreements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=149,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=507923,FOLIO='146',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_147"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq15201_policies_and_procedure__dq102311"> </A>
<A NAME="toc_dq15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Related Person Transactions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has adopted written policies and procedures, which will become effective at the time of this offering, for the
review of any transaction, arrangement or relationship in which our company is a participant, the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or 5%
stockholders, or their immediate family members, each of whom we refer to as a "related person," has a direct or indirect material interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a related person proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related person transaction," the related person must report the
proposed related person transaction to our Chief Financial Officer. The policy calls for the proposed related person transaction to be reviewed and approved by our audit committee. Whenever
practicable, the reporting, review and approval will occur prior to entry into the transaction. If advance review and approval is not practicable, the committee will review, and, in its discretion,
may ratify the related person transaction. The policy also permits the chairman of the audit committee to review and, if deemed appropriate, approve proposed related person transactions that arise
between committee meetings, subject to ratification by the committee at its next meeting. Any related person transactions that are ongoing in nature will be reviewed annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
related person transaction reviewed under the policy will be considered approved or ratified if it is authorized by the audit committee after full disclosure of the related person's
interest in the transaction. As appropriate for the circumstances, the committee will review and consider:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's interest in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount involved in the related person transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any
profit or loss; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction was undertaken in the ordinary course of our business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the terms of the transaction are no less favorable to us than terms that could have been reached with an unrelated third
party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purpose of, and the potential benefits to us of, the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other information regarding the related person transaction or the related person in the context of the proposed transaction that
would be material to investors in light of the circumstances of the particular transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee may approve or ratify the transaction only if the committee determines that, under all of the circumstances, the transaction is in our best interests. The committee
may impose any conditions on the related person transaction that it deems appropriate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that transactions involving compensation of executive officers shall be reviewed and approved by the compensation committee in the manner specified in its charter. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=150,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=61512,FOLIO='147',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_148"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq15201_principal_stockholders"> </A>
<A NAME="toc_dq15201_8"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information with respect to the beneficial ownership of our common stock as of April&nbsp;30, 2015
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our directors and executive officers as a group; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The column entitled "Percentage of Shares Beneficially Owned&#151;Before Offering" is based on a total of 122,689,999 shares of our common stock outstanding as of April&nbsp;30,
2015, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 116,030,239 shares of our common stock upon the closing of this offering. The column
entitled "Percentage of Shares Beneficially Owned&#151;After Offering" is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be outstanding
after this offering, including the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that we
are selling in this offering, but not including any additional shares issuable upon exercise of outstanding options or warrants or any exercise by the underwriters of their over-allotment option.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common
stock subject to options and warrants that are currently exercisable or exercisable within 60&nbsp;days after April&nbsp;30, 2015 are considered outstanding and beneficially owned by the person
holding the options or warrants for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as
otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community
property laws, where </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=151,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=523275,FOLIO='148',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_149"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>applicable.
Except as otherwise set forth below, the address of the beneficial owner is c/o Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Bldg. 1400E, Suite B14202, Cambridge, MA 02139. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:93pt;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,93pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares<BR>
Beneficially Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Before<BR>
Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>After Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with SV Life Sciences(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,695,610</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Clarus Lifesciences II,&nbsp;L.P.(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,528,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MedImmune Ventures,&nbsp;Inc.(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,108,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advanced Technology Ventures VIII,&nbsp;L.P.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,577,059</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Lightstone Ventures(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,395,203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Named Executive Officers and Directors</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,500,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ian C. Sanderson(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>540,712</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Jirousek, Ph.D.(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,276,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,695,610</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,528,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,972,262</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ron Laufer, M.D.(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,108,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(13)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,979</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Executive Officers and Directors as a Group (10&nbsp;persons)</I></FONT><FONT SIZE=2>(14)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113,554,355</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>88.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 31,039,638 shares of record held by SV Life Sciences Fund V, L.P. ("SVLS V LP") and 655,972 shares of record held by SV Life Sciences Fund V
Strategic Partners, L.P. ("SVLS V SPP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP and SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The
members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross, a member of our board of directors. SVLS V GP, SVLSF V, LLC and
each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP.
Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V LP and SVLS V SPP except to the
extent of any pecuniary interest therein. The address for the entities is One Boston Place, Suite 3900, 201 Washington Street, Boston, Massachusetts 02108.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 30,528,971 shares held of record by Clarus Lifesciences II,&nbsp;L.P. ("Clarus"). Clarus Ventures II&nbsp;GP,&nbsp;L.P. (the "GPLP"), as
the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The&nbsp;GPLP disclaims beneficial ownership of all shares held of record by
Clarus in which the&nbsp;GPLP does not have an actual pecuniary interest. Clarus Ventures II,&nbsp;LLC (the "GPLLC"), as the sole general partner of the&nbsp;GPLP, may be deemed to beneficially
own certain of the shares held of record by Clarus. The&nbsp;GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each
of Nicholas Galakatos, a member of our board of directors, and Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the&nbsp;GPLLC,
may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs.&nbsp;Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all
shares held of record by Clarus in </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=152,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=450741,FOLIO='149',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_150"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>which
he does not have an actual pecuniary interest. The address for the entities is 101 Main Street, Suite&nbsp;1210, Cambridge, MA 02142.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ron
Laufer, a member of our board of directors, is the Senior Managing Partner of MedImmune Ventures,&nbsp;Inc., and as a result, Dr.&nbsp;Laufer may be
deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures,&nbsp;Inc. Dr.&nbsp;Laufer disclaims beneficial ownership of such shares except to the extent of
any pecuniary interest therein. The address of MedImmune Ventures,&nbsp;Inc. is 1 MedImmune Way, Gaithersburg, Maryland 20878.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>ATV
Associates VIII,&nbsp;LLC ("ATV A VIII") is the General Partner of Advanced Technology Ventures VIII,&nbsp;L.P. ("ATV VIII") and exercises voting
and dispositive authority over the shares held by ATV VIII. Voting and dispositive decisions of ATV A VIII are made collectively by Michael A. Carusi, Jean George, a member of our board of directors,
Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the "ATV VIII Managing Directors"). ATV A VIII and the ATV VIII Managing Directors disclaim beneficial ownership of the shares
held by ATV VIII except to the extent of their pecuniary interest therein. The address for the entities is 500&nbsp;Boylston Street, Suite&nbsp;1380, Boston, MA 02116.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 7,388,491 shares of common stock held by Lightstone Ventures,&nbsp;L.P. and 1,006,712 shares of common stock held by Lightstone Ventures
(A),&nbsp;L.P. LSV Associates,&nbsp;LLC ("LSV&nbsp;GP") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures (A),&nbsp;L.P. (collectively, "LSV") and exercises
voting and dispositive authority over the shares held by LSV. Voting and dispositve decisions of LSV&nbsp;GP are made collectively by Michael A. Carusi, Jean George, a member of our board of
directors, Ralph E. Christoffersen and Henry A. Plain, Jr. (collectively, the "LSV Managing Directors"). LSV&nbsp;GP and the LSV Managing Directors disclaim beneficial ownership of the shares held
by LSV except to the extent of their pecuniary interest therein. The address for the entities is 500&nbsp;Boylston Street, Suite&nbsp;1380, Boston, Massachusetts 02116.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i) 2,125,622 shares of common stock issuable upon the exercise of options and (ii)&nbsp;112,499 shares of common stock issuable upon the
exercise of warrants, in each case exercisable within 60&nbsp;days after April&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 540,712 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i) 2,001,664 shares of common stock issuable upon the exercise of options and (ii)&nbsp;112,499 shares of common stock issuable upon the
exercise of warrants, in each case exercisable within 60&nbsp;days after April&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(1) above. Dr.&nbsp;Ross is a member of the investment committee of SVLSF V,&nbsp;LLC, which is the
general partner of SV Life Sciences Fund V (GP), which is the general partner of SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners,&nbsp;L.P., and, as a result,
Dr.&nbsp;Ross may be deemed to share voting, dispositive and investment power over the shares held of record by SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic
Partners&nbsp;L.P. Dr.&nbsp;Ross disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Ross' address is One Boston Place,
Suite&nbsp;3900, Boston, Massachusetts 02108.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(2) above. Dr.&nbsp;Galakatos is a Managing Director of Clarus Ventures II,&nbsp;LLC, which the sole
general partner of Clarus Ventures II&nbsp;GP,&nbsp;L.P., which is the sole general partner of Clarus Ventures II,&nbsp;L.P., and, as a result, Dr.&nbsp;Galakatos shares investment and voting
control over the shares held by Clarus Lifesciences II,&nbsp;L.P. Dr.&nbsp;Galakatos disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Dr.&nbsp;Galakatos' address is 101 Main Street, Suite&nbsp;1210, Cambridge, MA 02142. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=153,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=972851,FOLIO='150',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dq15201_1_151"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in notes&nbsp;(4) and (5) above. Ms.&nbsp;George is an ATV III Managing Director and, as a result, shares voting and
dispositive power over the shares held by Advanced Technology Ventures VIII,&nbsp;L.P. Ms. George is also an LSV Managing Director and, as a result, shares voting and dispositive power over the
shares held by LSV. Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV VIII and LSV except to the extent of any pecuniary interest therein. Ms.&nbsp;George's address is
500&nbsp;Boylston Street, Suite&nbsp;1380, Boston, MA 02116.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(3) above. Dr.&nbsp;Laufer is the Senior Managing Partner of MedImmune Ventures,&nbsp;Inc., and as a
result, Dr.&nbsp;Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures,&nbsp;Inc. Dr.&nbsp;Laufer disclaims beneficial ownership of
such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Laufer's address is c/o MedImmune Ventures, 1 MedImmune Way, Gaithersburg, Maryland&nbsp;20878.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 44,979 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i) 5,652,074 shares of common stock issuable upon the exercise of options and (ii)&nbsp;224,998 shares of common stock issuable upon the
exercise of warrants, in each case exercisable within 60&nbsp;days after April&nbsp;30, 2015.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=154,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=2599,FOLIO='151',FILE='DISK122:[14ZDH1.14ZDH15201]DQ15201A.;40',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds15201_1_152"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds15201_description_of_capital_stock"> </A>
<A NAME="toc_ds15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_general"> </A>
<A NAME="toc_ds15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the closing of this offering, our authorized capital stock will consist of 150,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share, all of which preferred stock will be undesignated. The following description of our capital stock and provisions
of our restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the certificate of incorporation and the bylaws that will be in effect upon
the closing of this offering. We have filed copies of these documents as exhibits to our registration statement of which this prospectus forms&nbsp;a part. The descriptions of the common stock and
preferred stock reflect changes to our capital structure that will occur upon the closing of this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_common_stock"> </A>
<A NAME="toc_ds15201_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, we had outstanding 122,689,999 shares of common stock, assuming the automatic conversion of all
outstanding shares of our preferred stock into common stock upon the closing of this offering, which were held of record by 27 stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of
directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters shall be decided by the affirmative vote of our
stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as otherwise disclosed below. Holders of common stock are
entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the
payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion
rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we
may designate and issue in the future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_preferred_stock"> </A>
<A NAME="toc_ds15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of our certificate of incorporation that will become effective upon the closing of this offering, our board of
directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences,
privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it
more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Upon the closing of this offering, there will be no
shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=155,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=32104,FOLIO='152',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_153"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_stock_options"> </A>
<A NAME="toc_ds15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, options to purchase 19,002,857 shares of our common stock at a weighted-average exercise price of $0.43
per share were outstanding, of which options to purchase 8,446,535 shares of our common stock were exercisable, at a weighted-average exercise price of $0.23 per share. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_warrants"> </A>
<A NAME="toc_ds15201_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrants    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, we had outstanding warrants to purchase shares of our series&nbsp;B preferred stock that upon the
closing of this offering will be exercisable for an aggregate of 315,688 shares of our common stock at an exercise price of $0.9503 per share.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of April&nbsp;30, 2015, we had outstanding warrants to purchase shares of our common stock that upon the closing of this offering will be exercisable for an aggregate of 447,850
shares of our common stock at an exercise price of $0.13 per share. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_registration_rights"> </A>
<A NAME="toc_ds15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated investor rights agreement, or the Investor Rights Agreement, provides certain holders of our preferred stock,
including some of our directors and 5% stockholders and their respective affiliates and entities affiliated with our officers and directors, the right, following the completion of this offering, to
require us to register these shares under the Securities Act of 1933, as amended, or the Securities Act, under specified circumstances as described below. In addition, the holders of warrants to
purchase shares of our preferred stock have rights under those warrants to become party to the Investor Rights Agreement following exercise of the warrants, following which they will have, with
respect to the shares acquired on exercise of the warrants, the same rights to require us to register the shares as the other investor parties to the Investor Rights Agreement. After registration
pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning six months after the closing of this offering, subject to specified limitations set forth in the Investor Rights Agreement,
at any time the holders of a majority of then outstanding registrable securities, as defined in the Investor Rights Agreement, acting together, may demand in writing that we register their registrable
securities under the Securities Act so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of
least $10.0&nbsp;million. We are not obligated to file&nbsp;a registration statement pursuant to this demand provision on more than two occasions, subject to specified exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, at any time after we become eligible to file&nbsp;a registration statement on Form&nbsp;S-3 under the Securities Act, subject to specified limitations, the holders of at
least 35% of the registrable securities then outstanding may demand in writing that we register on Form&nbsp;S-3 registrable shares held by them so long as the total amount of registrable shares
requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of least $1.0&nbsp;million. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incidental Registration Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at any time after the closing of this offering, we propose to file&nbsp;a registration statement to register any of our
securities under the Securities Act, either for our own account or for the account of any of our stockholders that are not holders of registrable shares, solely for cash and on a form that would also
permit the registration of registrable shares, the holders of our registrable shares are entitled to notice of registration and, subject to specified exceptions, we will be required to register the
registrable shares then held by them that they request that we register. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=156,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=476326,FOLIO='153',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_154"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Investor Rights Agreement, we are required to pay all registration expenses, including registration fees, printing
expenses, fees and disbursements of our counsel and accountants and reasonable fees and disbursements of one counsel representing the selling stockholders, other than any underwriting discounts and
commissions, related to any demand or incidental registration. The Investor Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the
selling stockholders in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or
omissions in the registration statement attributable to them. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_anti-takeover_effects_of_delaw__ant02502"> </A>
<A NAME="toc_ds15201_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Effects of Delaware Law and Our Charter and Bylaws    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware law contains, and upon the completion of this offering our certificate of incorporation and our bylaws will contain,
provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage
coercive takeover practices and inadequate takeover
bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Staggered Board; Removal of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our certificate of incorporation and bylaws will divide our board of directors into three classes
with staggered three-year terms. In addition, a director will only be able to be removed for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our
stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, will only
be able to be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could
make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Action by Written Consent; Special Meetings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our certificate of incorporation will provide that any action required or permitted to be taken
by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Upon the completion of this offering,
our certificate of incorporation and bylaws will also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our Chief
Executive Officer or our board of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advance Notice Requirements for Stockholder Proposals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our bylaws will establish an advance notice procedure for stockholder proposals to be brought
before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or
nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is
entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's intention
to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of
our outstanding voting securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=157,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=243200,FOLIO='154',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_155"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Business Combination Statute  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, we will be subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware.
Subject to certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following
the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is
approved in a prescribed manner. A "business combination" includes, among other things, a merger or consolidation involving us and the "interested stockholder" and the sale of more than 10% of our
assets. In general, an "interested stockholder" is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or
controlled by such entity or person. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment of Certificate of Incorporation and Bylaws  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The General Corporation Law of the State of Delaware provides generally that the affirmative vote of a majority of the shares entitled
to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or bylaws, as the case may be, requires a greater
percentage. Effective upon the completion of this offering, our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75%
of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our
stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of
incorporation described above under "&#151;Staggered Board; Removal of Directors" and "&#151;Stockholder Action by Written Consent; Special Meetings." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exclusive Forum Selection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective upon completion of this offering, our certificate of incorporation will provide that, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by
any of our directors, officers or employees to our company or our stockholders, (3)&nbsp;any action asserting a claim against our company arising pursuant to any provision of the General Corporation
Law of the State of Delaware or our certificate of incorporation or bylaws, or (4)&nbsp;any action asserting a claim against our company governed by the internal affairs doctrine. Although our
certificate of incorporation contains the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or
that such provision is unenforceable. </FONT></P>




<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_listing_on_the_nasdaq_global_market"> </A>
<A NAME="toc_ds15201_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing on The NASDAQ Global Market

    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to have our common stock listed on The NASDAQ Global Market under the symbol "CATB." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_authorized_but_unissued_shares"> </A>
<A NAME="toc_ds15201_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized but Unissued Shares    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the listing requirements of The NASDAQ Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and
employee benefit plans. The existence of authorized but unissued and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=158,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=123446,FOLIO='155',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_156"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>unreserved
common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_transfer_agent_and_registrar"> </A>
<A NAME="toc_ds15201_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock will be American Stock Transfer&nbsp;&amp; Trust Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=159,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=187528,FOLIO='156',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_157"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds15201_shares_eligible_for_future_sale"> </A>
<A NAME="toc_ds15201_12"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock, and a liquid trading market for our common stock may not
develop or be sustained after this offering. Future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options, or the
anticipation of these sales, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through sales of equity securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon the 6,659,760 shares of our common stock that were outstanding on April&nbsp;30, 2015, upon the closing of this offering, we will have
outstanding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
our common stock, after giving effect to the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering and the conversion of all
outstanding shares of our preferred stock into
116,030,239 shares of common stock upon the closing of this offering, and assuming no exercise by the underwriters of their over-allotment option and no exercise of options or warrants outstanding as
of April&nbsp;30, 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the shares to be outstanding immediately after the closing of this offering, we expect that the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares to be sold in this offering
will be freely tradable without
restriction under the Securities Act unless purchased by our "affiliates," as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining 122,689,999 shares of our common stock
outstanding after this offering will be "restricted securities" under Rule&nbsp;144, and we expect that substantially all of these restricted securities will be subject to the 180-day lock-up period
under the lock-up agreements as described below. These restricted securities may be sold in the public market only if registered or pursuant to an exemption from registration, such as Rule&nbsp;144
or Rule&nbsp;701 under the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_rule_144"> </A>
<A NAME="toc_ds15201_13"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;144    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;144, beginning 90&nbsp;days after the date of this prospectus, any person who is not our affiliate and
has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, subject to the availability of
current public information about us. In addition, under Rule&nbsp;144, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held
their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the
closing of this offering without regard to whether current public information about us is available. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning
90&nbsp;days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding three months may sell any unrestricted
securities, as well as restricted securities that the person has beneficially owned for at least six months, including the holding period of any prior owner other than one of our affiliates, under
Rule&nbsp;144. Affiliates selling restricted or unrestricted securities may sell a number of shares within any three-month period that does not exceed the greater
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately
after this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the average weekly trading volume of our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing
of a Notice of Proposed Sale of Securities Pursuant to Rule&nbsp;144 with respect to the sale. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales
under Rule&nbsp;144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of current public information about us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon expiration of the 180-day lock-up period described below, approximately 122,689,999 shares of our common stock will be eligible for sale under Rule&nbsp;144, including shares
eligible for resale

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=160,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=841841,FOLIO='157',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_158"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>immediately
upon the closing of this offering as described above. We cannot estimate the number of shares of our common stock that our existing stockholders will elect to sell under Rule&nbsp;144. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_rule_701"> </A>
<A NAME="toc_ds15201_14"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;701    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who
purchased shares from us in connection with a qualified compensatory stock plan or other written agreement is eligible to resell these shares 90&nbsp;days after the date of this prospectus in
reliance on Rule&nbsp;144, but without compliance with the holding period requirements of Rule&nbsp;144 and without regard to the volume of such sales or the availability of public information
about us. Subject to the 180-day lock-up period described below, approximately 4,358,760 shares of our common stock will be eligible for sale in accordance with Rule&nbsp;701.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_lock-up_agreements"> </A>
<A NAME="toc_ds15201_15"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lock-Up Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, and each of our executive officers and directors and the holders of substantially all of our outstanding stock have agreed that,
without the prior written consent of Citigroup Global Markets&nbsp;Inc. and Cowen and Company,&nbsp;LLC, on behalf of the underwriters, we and they will not, subject to limited exceptions, during
the period ending 180&nbsp;days after the date of this prospectus:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> offer, sell, contract to sell, pledge or otherwise dispose of, or enter into any transaction which is designed to, or might reasonably
be expected to, result in the disposition of (whether by actual disposition or effective economic disposition due to cash settlement or otherwise), directly or indirectly, including the filing (or
participation in the filing) of a registration statement (other than a registration statement on Form&nbsp;S-8) with the SEC with respect to, any shares of our capital stock or any securities
convertible into, or exercisable or exchangeable for, such capital stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish or increase a put equivalent position or liquidate or decrease a call equivalent position with respect to any shares of our
capital stock or any securities convertible into or exercisable or exchangeable for such capital stock, or publicly announce an intention to effect any such transaction; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> publicly announce an intention to effect any of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_registration_rights_1"> </A>
<A NAME="toc_ds15201_16"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the lock-up agreements described above, upon the closing of this offering, the holders of an aggregate of 116,030,239 shares
of our common stock, along with the holders of warrants to purchase an aggregate of 315,688 shares of common stock, will be entitled to various rights with respect to the registration of these shares
under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the
effectiveness of the registration. See "Description of Capital Stock&#151;Registration Rights" for additional information. Shares covered by a registration statement will be eligible for sale
in the public market upon the expiration or release from the terms of lock-up agreements applicable to such shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds15201_stock_options_and_warrants_1"> </A>
<A NAME="toc_ds15201_17"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options and Warrants    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, we had outstanding options to purchase 19,002,857 shares of our common stock, of which options to purchase
8,446,535 shares were vested. Following this offering, we intend to file one or more registration statements on Form&nbsp;S-8 under the Securities Act to register all of the shares of our common
stock subject to outstanding options and options and other awards issuable pursuant to the 2015 stock incentive plan, the 2015 employee stock purchase plan and our 2008 equity


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=161,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=30975,FOLIO='158',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_ds15201_1_159"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


incentive plan. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described above
and Rule&nbsp;144 limitations applicable to affiliates.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;30, 2015, we had outstanding warrants to purchase shares of our series&nbsp;B preferred stock that upon the closing of this offering will be exercisable for an
aggregate of 315,688 shares of our common stock. As of March&nbsp;31, 2015, we also had outstanding and exercisable warrants to purchase 447,850 shares of common stock. Any shares acquired through
the exercise of these warrants will be eligible for sale subject to the lock-up agreements and securities laws described above.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=162,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=318747,FOLIO='159',FILE='DISK122:[14ZDH1.14ZDH15201]DS15201A.;42',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_du15201_1_160"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du15201_material_u.s._federal_income_a__mat03574"> </A>
<A NAME="toc_du15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="aa1"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS<BR>  FOR NON-U.S. HOLDERS OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a general discussion of material U.S. federal income and estate tax considerations relating to ownership and
disposition of shares of our common stock by a non-U.S. holder. For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner of our common stock that is not for U.S. federal
income tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United
States or under the laws of the United States or of any political subdivision of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S.
persons have authority to control all substantial decisions of the trust or (2)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S.
person. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons who hold their common
stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its own tax advisor
regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations
promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation,
possibly with retroactive effect. Any change could alter the tax consequences to non-U.S. holders described in this prospectus. There can be no assurance that the Internal Revenue Service, or the IRS,
will not challenge one or more of the tax consequences described herein. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
assume in this discussion that a non-U.S. holder holds shares of our common stock as a capital asset (generally, property held for investment). This discussion does not address all
aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances nor does it address any aspects of
U.S. state, local or non-U.S. taxes, the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances that may
apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> brokers or dealers in securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated
investment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> insurance companies; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=163,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=79258,FOLIO='160',FILE='DISK122:[14ZDH1.14ZDH15201]DU15201A.;21',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_du15201_1_161"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulated investment companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> controlled foreign corporations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> passive foreign investment companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> persons that have a functional currency other than the U.S. dollar; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B>This discussion is for general information only and is not tax advice. Accordingly, all prospective non-U.S. holders should consult their own tax advisors regarding the U.S.
federal, state, local and non-U.S. income tax and estate tax consequences of acquiring, holding and disposing of our common stock.</B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du15201_distributions_on_our_common_stock"> </A>
<A NAME="toc_du15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions on Our Common Stock    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings
and profits, the excess will be treated as a tax-free return of the non-U.S. holder's investment, up to such holder's tax basis in the common stock. Any remaining excess will be treated as capital
gain, subject to the tax treatment described below under the heading "Gain on Disposition of Common Stock." Any such distribution would also be subject to the discussion below under the section titled
"Withholding and Information Reporting Requirements&#151;FATCA." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed under "Dividend Policy," we do not expect to pay cash dividends to holders of our common stock in the foreseeable future. In the event we do pay dividends, dividends paid to
a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States
and such holder's country of residence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and if an applicable income tax treaty so provides,
that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder
satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal
income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances,
be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder's country of
residence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence generally will be
required to provide a properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their
own tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a
U.S. tax return with the IRS. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=164,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=709458,FOLIO='161',FILE='DISK122:[14ZDH1.14ZDH15201]DU15201A.;21',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_du15201_1_162"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du15201_gain_on_disposition_of_common_stock"> </A>
<A NAME="toc_du15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on Disposition of Common Stock    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A non-U.S. holder generally will not be subject to any U.S. federal income tax on any gain realized upon such non-U.S. holder's sale,
exchange or other disposition of shares of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business, and, if an applicable income tax
treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder generally will be
taxed on a net income basis at the graduated U.S. federal income tax rates applicable to U.S. persons and, if the non-U.S. holder is a corporation, the branch profits tax described above in
"Distributions on Our Common Stock," may also apply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the non-U.S. holder is a nonresident alien who is present in the United States for 183&nbsp;days or more in the taxable year of the
disposition and certain other requirements are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between
the United States and such holder's country of residence) on the net gain derived from the disposition, which may be offset by U.S.-source capital losses of the non-U.S. holder, if any; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we are, or have been at any time during the five-year period preceding such disposition (or the non-U.S. holder's holding period, if
shorter), a "U.S. real property holding corporation," unless our common stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5% of our outstanding
common stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. Generally, a
corporation is a "U.S. real property holding corporation" if the fair market value of its "U.S. real property interests" (as defined in the Code and applicable regulations) equals or exceeds 50% of
the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a "U.S. real property holding corporation" for U.S. federal income tax
purposes. Further, no assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule described above. If we are determined to be
a "U.S. real property holding corporation" and the exception described above does not apply, then a purchaser may withhold 10% of the proceeds payable to a non-U.S. holder from a sale of our common
stock and the non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du15201_federal_estate_tax"> </A>
<A NAME="toc_du15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Estate Tax    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock that are owned or treated as owned by an individual who is not a citizen or resident of the United States
(as specially defined for U.S. federal estate tax purposes) at the time of death are considered U.S. situs assets and will be included in the individual's gross estate for U.S. federal estate tax
purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du15201_information_reporting_and_backup_withholding"> </A>
<A NAME="toc_du15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such
holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person
(as defined in the Code) in order to avoid backup </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=165,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=828255,FOLIO='162',FILE='DISK122:[14ZDH1.14ZDH15201]DU15201A.;21',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_du15201_1_163"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>withholding
at the applicable rate with respect to dividends on our common stock. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form&nbsp;W-8BEN or
W-8BEN-E (or other applicable Form&nbsp;W-8) or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an exemption. Dividends paid
to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under the heading "Distributions on Our Common Stock," will generally be exempt from U.S. backup withholding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any
broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting
and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker.
However, for
information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions
effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific
treaty or agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S.
holder's U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du15201_withholding_and_information_re__wit02250"> </A>
<A NAME="toc_du15201_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Withholding and Information Reporting Requirements&#151;FATCA    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Foreign Account Tax Compliance Act, or FATCA, generally imposes U.S. federal withholding tax of 30% on payments of dividends of,
and gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a "foreign financial institution," the foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a "foreign financial institution," the foreign entity identifies
certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Under applicable U.S. Treasury regulations, withholding under FATCA generally
(1)&nbsp;applies to payments of dividends on our common stock and (2)&nbsp;will apply to payments of gross proceeds from a sale or other disposition of our common stock made after
December&nbsp;31, 2016. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of the tax. Withholding under FATCA generally will not be reduced or limited by
bilateral income tax treaties. However, a non-U.S. holder may be exempt from FATCA withholding under an applicable intergovernmental agreement between the U.S. and a foreign government relating to the
implementation of FATCA, provided that the non-U.S. holder and the foreign government comply with the terms of the agreement. Non-U.S. holders should consult their own tax advisors regarding the
possible implications of FATCA on their investment in our common stock, and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting
the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=166,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=65317,FOLIO='163',FILE='DISK122:[14ZDH1.14ZDH15201]DU15201A.;21',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dw15201_1_164"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw15201_underwriting"> </A>
<A NAME="toc_dw15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Citigroup Global Markets&nbsp;Inc. and Cowen and Company,&nbsp;LLC are acting as joint book-running managers of this offering and
as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, the underwriters named below have
severally agreed to purchase, and we have agreed to sell to them, the number of shares of our common stock indicated below: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:43pt;"><FONT SIZE=1><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,43pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Citigroup Global Markets&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cowen and Company,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Oppenheimer&nbsp;&amp;&nbsp;Co.&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wedbush Securities&nbsp;Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriting agreement provides that the obligations of the underwriters to purchase the shares of our common stock included in this offering are subject to approval of legal matters
by counsel and to other conditions. The underwriters are obligated to purchase all of the shares of our common stock (other than those covered by the over-allotment option described below) if they
purchase any of the shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of our common stock sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover page of this prospectus. Any
shares of our common stock sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial
offering of the shares of our common stock, if all the shares of our common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other
selling terms. The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the underwriters sell more shares of our common stock than the total number set forth in the table above, we have granted to the underwriters an option, exercisable for 30&nbsp;days
from the date of this prospectus, to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock at the initial public offering price less the underwriting discount. The underwriters may
exercise the option solely for the purpose of covering over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of
additional shares of our common stock approximately
proportionate to that underwriter's initial purchase commitment set forth in the table above. Any shares of our common stock issued or sold under the option will be issued and sold on the same terms
and conditions as the other shares of our common stock that are the subject of this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
our officers and directors and substantially all of our stockholders have agreed that, subject to specified limited exceptions, for a period of 180&nbsp;days from the date of this
prospectus, we and they will not, without the prior written consent of Citigroup Global Markets&nbsp;Inc. and Cowen and Company,&nbsp;LLC, offer, sell, contract to sell, pledge or otherwise
dispose of, or hedge any shares of our capital stock or any securities convertible into, or exercisable or exchangeable for, our capital stock. Citigroup Global Markets&nbsp;Inc. and Cowen and
Company,&nbsp;LLC in their sole discretion may release any of the securities subject to these lock-up agreements at any time, which, in the case of officers and directors, shall be with notice. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to this offering, there has been no public market for our shares. Consequently, the initial public offering price for the shares of our common stock will be determined by
negotiations between us and the representatives. Among the factors considered in determining the initial public offering price </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=167,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=636552,FOLIO='164',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_165"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>will
be our results of operations, our current financial condition, our future prospects, our markets, the economic conditions in and future prospects for the industry in which we compete, our
management, and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies considered comparable to our company. We
cannot assure you, however, that the price at which the shares of our common stock will sell in the public market after this offering will not be lower than the initial public offering price or that
an active trading market in our shares of common stock will develop and continue after this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to have our shares of common stock listed on The NASDAQ Global Market under the symbol "CATB."

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per share and total underwriting discounts and commissions that we are to pay to the underwriters in connection with this offering. These amounts are shown
assuming both no exercise and full exercise of the underwriters' over-allotment option: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Paid by Catabasis </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Full exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate that expenses payable by us in connection with this offering, exclusive of underwriting discounts and commissions payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We
have also agreed to reimburse the underwriters for expenses in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;relating to the clearance of this offering with the Financial Industry Regulatory Authority,
&nbsp;Inc. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this offering, the underwriters may purchase and sell shares of our common stock in the open market. Purchases and sales in the open market may include short sales,
purchases to cover short positions, which may include purchases pursuant to the underwriters' over-allotment option, and other transactions that would stabilize, maintain or otherwise affect the price
of our common stock. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Short sales involve secondary market sales by the underwriters of a greater number of shares of our common stock than they are
required to purchase in this offering: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Covered" short sales are sales of shares of our common stock in an amount up to the number of shares of our common stock
represented by the underwriters' over-allotment option.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> "Naked" short sales are sales of shares of our common stock in an amount in excess of the number of shares of our common
stock represented by the underwriters' over-allotment option. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The underwriters can close out a short position by purchasing additional shares of our common stock, either pursuant to the
underwriters' over-allotment option or in the open market.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> To close a naked short position, the underwriters must purchase shares of our common stock in the open market. A naked
short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the open market after pricing that
could adversely affect investors who purchase in this offering.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> To close a covered short position, the underwriters must purchase shares of our common stock in the open market or
exercise their over-allotment option. In determining the source of shares of our common stock to close the covered short position, the underwriters will consider, among other things, the price of
shares of our common stock available for purchase in the open market as compared to the price at which they may purchase shares of our common stock through their over-allotment option. </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=168,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=225895,FOLIO='165',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_166"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of our common stock on
NASDAQ, as long as such bids do not exceed a specified maximum, to stabilize the price of the shares of our common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases
to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a
decline in the market price of the shares. They may also cause the price of the shares of our common stock to be higher than the price that would otherwise prevail in the open market in the absence of
these
transactions. The underwriters may conduct these transactions on NASDAQ, in the over-the-counter market or otherwise. The underwriters are not required to engage in any of these transactions and may
discontinue them at any time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to
make because of any of those liabilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on websites maintained by one or more of the underwriters or their respective affiliates. The representatives may agree with us to
allocate a number of shares of our common stock to underwriters for sale to their online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the
same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters' or their respective affiliates' websites and any information contained in any
other website maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be
relied upon by investors in this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_conflicts_of_interest"> </A>
<A NAME="toc_dw15201_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conflicts of Interest    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters are full-service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their respective affiliates may,
from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the
ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or
related derivative securities) and financial instruments (which may include bank loans or credit default swaps) for their own account and for the accounts of their customers and may at any time hold
long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their
affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients
that they acquire, long or short positions in such securities and instruments. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investor__not02526"> </A>
<A NAME="toc_dw15201_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the European Economic Area    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member
state), with effect from and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant implementation date), an offer of shares of our common
stock described in this prospectus may not be made to the public in that relevant member state other than:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=169,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=517787,FOLIO='166',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_167"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150
natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant
Dealer or Dealers nominated by us for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>provided
that no such offer of shares of our common stock shall require us or any underwriter to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this provision, the expression an "offer of securities to the public" in any relevant member state means the communication in any form and by any means of sufficient
information on the terms of the offer and the shares of our common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of our common stock, as the
expression may be varied in that member state by any measure implementing the Prospectus Directive in that member state, the expression "Prospectus Directive" means Directive 2003/71/EC (and
amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the relevant member state) and includes any relevant implementing measure in the relevant member state, and
the expression "2010 PD Amending Directive" means Directive 2010/73/EU. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sellers of the shares of our common stock have not authorized and do not authorize the making of any offer of shares of our common stock through any financial intermediary on their
behalf, other than offers made by the underwriters with a view to the final placement of the shares of our common stock as contemplated in this prospectus. Accordingly, no purchaser of the shares of
our common stock, other than the underwriters, is authorized to make any further offer of the shares of our common stock on behalf of the sellers or the underwriters. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective___dw102271"> </A>
<A NAME="toc_dw15201_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the United Kingdom    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors
within the meaning of Article&nbsp;2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act
2000 (Financial Promotion) Order 2005, or the Order, or (ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to
(d)&nbsp;of the Order (each such person being referred to as a relevant person). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the
United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_australia"> </A>
<A NAME="toc_dw15201_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Australia    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act) in
relation to our common stock has been or will be lodged with the Australian Securities&nbsp;&amp; Investments Commission, or ASIC. This document has not been lodged with ASIC and is only directed to
certain categories of exempt persons. Accordingly, if you receive this document in Australia:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> you confirm and warrant that you are either: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "sophisticated investor" under section&nbsp;708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant's certificate to us which complies with the requirements of </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=170,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=788796,FOLIO='167',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_168"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>section&nbsp;708(8)(c)(i)
or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made;  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a person associated with the company under section&nbsp;708(12) of the Corporations Act; or  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a "professional investor" within the meaning of section&nbsp;708(11)(a) or (b)&nbsp;of the Corporations Act, and to
the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under
this document is void and incapable of acceptance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> you warrant and agree that you will not offer any of our common stock for resale in Australia within 12&nbsp;months of that common
stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section&nbsp;708 of the Corporations Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_france"> </A>
<A NAME="toc_dw15201_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in France    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither this prospectus nor any other offering material relating to the shares of our common stock described in this prospectus has
been submitted to the clearance procedures of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2> or of the competent authority of another
member state of the European Economic Area and notified to the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2>. The shares of our common
stock have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the shares of
our common stock has been or will be:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> used in connection with any offer for subscription or sale of the shares of our common stock to the public in France. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
offers, sales and distributions will be made in France only:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to qualified investors (</FONT><FONT SIZE=2><I>investisseurs qualifi&eacute;s</I></FONT><FONT SIZE=2>) and/or to a restricted
circle of investors (</FONT><FONT SIZE=2><I>cercle restreint d'investisseurs</I></FONT><FONT SIZE=2>), in each case investing for their own account, all as defined in, and in accordance with
articles&nbsp;L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code mon&eacute;taire et financier; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in a transaction that, in accordance with article&nbsp;L.411-2-II-1&deg;-or-2&deg;-or 3&deg; of the French
Code </FONT><FONT SIZE=2><I>mon&eacute;taire et financier</I></FONT><FONT SIZE=2> and article&nbsp;211-2 of the General Regulations (</FONT><FONT SIZE=2><I>R&egrave;glement
G&eacute;n&eacute;ral</I></FONT><FONT SIZE=2>) of the </FONT><FONT SIZE=2><I>Autorit&eacute; des March&eacute;s Financiers</I></FONT><FONT SIZE=2>, does not constitute
a public offer (</FONT><FONT SIZE=2><I>appel public &agrave; l'&eacute;pargne</I></FONT><FONT SIZE=2>). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of our common stock may be resold directly or indirectly, only in compliance with articles&nbsp;L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code </FONT> <FONT SIZE=2><I>mon&eacute;taire et financier</I></FONT><FONT
SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_chile"> </A>
<A NAME="toc_dw15201_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Chile    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of our common stock are not registered in the Securities Registry (Registro de Valores) or subject to the control of the
Chilean Securities and Exchange Commission (Superintendencia de Valores y Seguros de Chile). This prospectus and other offering materials relating to the offer of the shares do not constitute a public
offer of, or an invitation to subscribe for or purchase, the shares in the Republic of Chile, other than to individually identified purchasers pursuant to a private offering within the meaning of
Article&nbsp;4 of the Chilean Securities Market Act (Ley de Mercado de Valores) (an </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=171,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=848576,FOLIO='168',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_169"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>offer
that is not "addressed to the public at large or to a certain sector or specific group of the public"). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_hong_kong"> </A>
<A NAME="toc_dw15201_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Hong Kong    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of our common stock may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances
which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning of the
Securities and Futures Ordinance (Cap.&nbsp;571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a "prospectus"
within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares of our common stock may be issued or may be in the
possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in
Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong
or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap.&nbsp;571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective___dw102305"> </A>
<A NAME="toc_dw15201_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the State of Israel    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the
Israeli Securities Law, 5728&nbsp;-&nbsp;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of
Section&nbsp;15 of the Israeli Securities Law, 5728&nbsp;-&nbsp;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to
certain conditions (the "Addressed Investors"); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law,
5728&nbsp;-&nbsp;1968, subject to certain conditions (the "Qualified Investors"). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered
to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish
a prospectus in accordance with and subject to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to
subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968. In
particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it
is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968; (ii)&nbsp;which of the categories listed in the First
Addendum to the Israeli Securities Law, 5728&nbsp;-&nbsp;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli
Securities Law, 5728&nbsp;-&nbsp;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of common stock that it will be
issued are, subject to exemptions available under the Israeli Securities Law, 5728&nbsp;-&nbsp;1968: (a)&nbsp;for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not
issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&nbsp;-&nbsp;1968; and (v)&nbsp;that it is willing to
provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration
containing, inter alia, the Addressed Investor's name, address and passport number or Israeli identification number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=172,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=725730,FOLIO='169',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_170"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_japan"> </A>
<A NAME="toc_dw15201_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Japan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of our common stock offered in this prospectus have not been and will not be registered under the Financial Instruments and
Exchange Law of Japan. The shares of our common stock have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan
(including any corporation or other entity organized under the laws of Japan), except (i)&nbsp;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange
Law and (ii)&nbsp;in compliance with any other applicable requirements of Japanese law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dw15201_notice_to_prospective_investors_in_singapore"> </A>
<A NAME="toc_dw15201_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Singapore    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the shares
of our common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an
institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or
any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares of our common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant party which is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust
is an individual who is an accredited investor, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>shares,
debentures and units of shares of our common stock and debentures of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred
within six&nbsp;months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer made under Section&nbsp;275 of the SFA
except:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in
Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares of our common stock and debentures of that corporation or
such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for
in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the SFA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> where no consideration is or will be given for the transfer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> where the transfer is by operation of law. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=173,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=410868,FOLIO='170',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<A NAME="page_dw15201_1_171"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw15201_legal_matters"> </A>
<A NAME="toc_dw15201_12"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of our common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and
Dorr&nbsp;LLP. Cooley&nbsp;LLP is acting as counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw15201_experts"> </A>
<A NAME="toc_dw15201_13"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young,&nbsp;LLP, independent registered public accounting firm, has audited our financial statements at
December&nbsp;31, 2013 and 2014, and for the years then ended, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the
registration statement in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's report, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw15201_where_you_can_find_more_information"> </A>
<A NAME="toc_dw15201_14"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our
common stock we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the
exhibits, schedules and amendments to the registration statement. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and
schedules to the registration statement. Statements contained in this prospectus about the contents of any contract, agreement or other document are not necessarily complete, and, in each instance, we
refer you to the copy of the contract, agreement or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference to such
contract, agreement or document. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may read and copy the registration statement of which this prospectus is a part at the SEC's public reference room, which is located at 100&nbsp;F Street, N.E., Room&nbsp;1580,
Washington, DC 20549. You can request copies of the registration statement by writing to the Securities and Exchange Commission and paying a fee for the copying cost. Please call the SEC at
1-800-SEC-0330 for more information about the operation of the SEC's public reference room. In addition, the SEC maintains an Internet website, which is located at </FONT> <FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>, that contains reports,
proxy and information statements and other information regarding issuers that file electronically with the SEC. You
may access the registration statement of which this prospectus is a part at the SEC's Internet website. Upon completion of this offering, we will be subject to the information reporting requirements
of the Securities Exchange Act of 1934, and we will file reports, proxy statements and other information with the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=174,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=237152,FOLIO='171',FILE='DISK122:[14ZDH1.14ZDH15201]DW15201A.;35',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fa15201_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fa15201_index_to_financial_statements"> </A>
<BR>

</FONT>

<FONT SIZE=2><B>  INDEX TO FINANCIAL STATEMENTS

    <BR>    </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="FA15201_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->

<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FC_1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FC_1"><FONT SIZE=2>F-2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FE_1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheets</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FE_1"><FONT SIZE=2><BR>
F-3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FG_1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Operations and Comprehensive Loss</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FG_1"><FONT SIZE=2><BR>
F-4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FI_1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FI_1"><FONT SIZE=2><BR>
F-5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FK_1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statements of Cash Flows</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FK_1"><FONT SIZE=2><BR>
F-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FM_1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FM_1"><FONT SIZE=2><BR>
F-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=175,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=407417,FOLIO='F-1',FILE='DISK122:[14ZDH1.14ZDH15201]FA15201A.;7',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fc15201_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B> <A NAME="FC_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

  </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


The Board of Directors and Stockholders of<BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying balance sheets of Catabasis Pharmaceuticals,&nbsp;Inc. (the "Company") as of December&nbsp;31, 2013 and 2014, and the related statements of
operations and comprehensive loss, convertible preferred stock and stockholders' (deficit) equity, and cash flows for the years then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial
reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Catabasis Pharmaceuticals,&nbsp;Inc. at
December&nbsp;31, 2013 and 2014, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&nbsp;1 to the financial statements, the
Company has incurred operating losses and negative cash flows from operations since inception and will be required to obtain additional financing, alternative means of financial support or both prior
to December&nbsp;31, 2015 in order to continue to fund its operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note&nbsp;1. The financial statements do not include any adjustments that may result from the outcome of this uncertainty.

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP<BR></FONT>
</TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


Boston, Massachusetts<BR>
March&nbsp;5, 2015

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=176,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=765586,FOLIO='F-2',FILE='DISK122:[14ZDH1.14ZDH15201]FC15201A.;8',USER='CHE108062',CD=';2-JUN-2015;02:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fe15201_1_3"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="FE_1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Balance Sheets

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


(in thousands, except share and per share data)

 </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>Pro Forma<BR>
March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,668</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>354</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>551</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>551</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,581</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,022</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>260</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>260</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>541</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,498</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,498</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,964</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, convertible preferred stock and stockholders' (deficit) equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>651</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,279</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current portion of notes payable, net of discount</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:24pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,930</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes payable, net of current portion and discount</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments (Note&nbsp;7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.001 par value; 68,837,703 shares authorized, issued and outstanding at December&nbsp;31, 2013
and 2014 and March&nbsp;31, 2015 (unaudited); 68,837,703 shares authorized and no shares issued or outstanding at March&nbsp;31, 2015 (pro forma) (unaudited); aggregate liquidation preference of $48,186 at December&nbsp;31, 2014 and March&nbsp;31,
2015(unaudited))</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, $0.001 par value; 37,830,473 shares authorized at December&nbsp;31, 2013 and 2014 and 56,026,590
shares authorized at March&nbsp;31, 2015 (unaudited); 34,129,571 shares issued and outstanding at December&nbsp;31, 2013 and 2014 and 47,192,536 shares issued and outstanding at March&nbsp;31, 2015 (unaudited); no shares issued and outstanding at
March&nbsp;31, 2015 (pro&nbsp;forma) (unaudited); (aggregate liquidation preference of $32,433 at December&nbsp;31, 2014 and $53,242 at March&nbsp;31, 2015 (unaudited))</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
44,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' (deficit) equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 132,000,000 shares authorized at December&nbsp;31, 2013 and 2014 and 155,000,000 shares authorized at
March&nbsp;31, 2015 (unaudited); 5,054,688, 6,337,920, 6,659,760 and 122,689,999 shares issued and outstanding at December&nbsp;31, 2013, December&nbsp;31, 2014, March&nbsp;31, 2015 (unaudited), and March&nbsp;31, 2015 (pro forma) (unaudited),
respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
1,307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,321</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
95,245</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(53,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(75,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(52,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(73,053</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(79,201</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,487</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' (deficit) equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,964</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=177,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=94428,FOLIO='F-3',FILE='DISK122:[14ZDH1.14ZDH15201]FE15201A.;23',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fg15201_1_4"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="FG_1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

  </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Statements of Operations and Comprehensive Loss

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


(in thousands, except share and per share data)

  </B></FONT></P>




<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,686</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,096</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,616</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,995</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,373</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:60pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,119</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,681</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(149</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:60pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense), net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(203</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.88</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares used in net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,870,362</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,446,186</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,085,910</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,355,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average number of common shares used in pro forma net loss per share&#151;basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108,413,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111,350,589</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=178,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=508310,FOLIO='F-4',FILE='DISK122:[14ZDH1.14ZDH15201]FG15201A.;12',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fi15201_1_5"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="FI_1"></A> </FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B>Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Statements of Convertible Preferred Stock and Stockholders' (Deficit) Equity

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


(in thousands, except share data)</B></FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A<BR>
Convertible<BR>
Preferred Stock </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B<BR>
Convertible<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
(Deficit)<BR>
Equity </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number<BR>
of Shares </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Par<BR>
Value </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-in<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2012</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
55,700,752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>38,724</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>

<!-- -->
4,810,878</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(35,378</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(34,436</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of series&nbsp;A convertible preferred stock, net of issuance costs of $22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,136,951</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,174</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of series&nbsp;B convertible preferred stock, net of issuance costs of $185</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,129,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>32,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from exercises of common stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>243,810</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2013</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,837,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,129,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>32,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,054,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,307</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(53,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(52,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from exercises of common stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,283,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>117</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>897</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>897</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at December&nbsp;31, 2014</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,837,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,129,571</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>32,248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,337,920</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,321</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(75,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(73,053</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of series&nbsp;B convertible preferred stock, net of issuance cost of $82 (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,062,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>12,331</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Proceeds from exercises of common stock options (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>321,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation expense (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Balance at March&nbsp;31, 2015</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,837,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,192,536</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>44,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,659,760</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(79,201</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=1></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Conversion of series&nbsp;A convertible preferred stock into common stock (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(68,837,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>68,837,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,829</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Conversion of series&nbsp;B convertible preferred stock into common stock (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(47,192,536</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(44,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47,192,536</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>47</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>44,532</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>44,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Conversion of series&nbsp;B preferred stock warrants into warrants for the purchase of common stock (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>211 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><B>Pro forma balance at March&nbsp;31, 2015 (unaudited)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>
<!-- -->
122,689,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>122</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,245</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(81,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,487 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=179,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=67030,FOLIO='F-5',FILE='DISK122:[14ZDH1.14ZDH15201]FI15201A.;12',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fk15201_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="FK_1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Statements of Cash Flows

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


(in thousands)

 </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(18,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(21,884</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,469</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>320</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>248</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>343</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>897</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-cash interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(194</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>462</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,156</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(742</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(837</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(20,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,603</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of available-for-sale securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sales of available-for-sale securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,976</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of preferred stock, net of issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,422</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,331</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from exercise of common stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from borrowings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred initial public offering costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(487</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Debt issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,449</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,888</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,040</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,806</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,635</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at beginning of period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,434</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,668</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents at end of period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,668</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,876</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Supplemental disclosures of cash flow information:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash paid during the period for interest</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>94</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-cash financing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants for the purchase of series&nbsp;B preferred stock issued in conjunction with credit facility</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred initial public offering cost in accounts payable and accrued liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>492</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>475</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=180,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=484811,FOLIO='F-6',FILE='DISK122:[14ZDH1.14ZDH15201]FK15201A.;11',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fm15201_1_7"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="FM_1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

  </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

  </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of Business

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Catabasis Pharmaceuticals,&nbsp;Inc. (the "Company") was incorporated on June&nbsp;26, 2008, as a Delaware corporation with operations based in Cambridge, Massachusetts. The Company
is dedicated to the discovery and development of medicines to treat inflammatory and metabolic diseases.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has incurred operating losses and negative cash flows from operations since inception. As of December&nbsp;31, 2014 and
March&nbsp;31, 2015, the Company had an accumulated deficit of $75.4&nbsp;million and $81.9&nbsp;million, respectively. The Company is subject to a number of risks similar to other life science
companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations,
protection of proprietary technology and market acceptance of the Company's products. The Company anticipates that it will continue to incur significant operating losses for the next several years as
it continues to develop its product candidates. To date, the Company has funded its operations primarily through private placements of its convertible preferred stock and the issuance of debt. On
August&nbsp;27, 2014, the Company entered into a loan and security agreement (the "Credit Facility"). The Credit Facility, as amended on March&nbsp;31, 2015, provides for initial borrowings of
$5.0&nbsp;million under a term loan and additional borrowings of up to $20.0&nbsp;million under certain conditions (Note&nbsp;6), of which $5.0&nbsp;million was drawn on March&nbsp;31, 2015.
An additional $5.0&nbsp;million was available to be drawn until May&nbsp;31, 2015, subject to completion of an additional equity financing with net cash proceeds of at least $8.0&nbsp;million.
The Company did not draw the $5&nbsp;million that was available through May&nbsp;31, 2015. An additional $10.0&nbsp;million is available until July&nbsp;31, 2015, subject to the completion of
an initial public offering with net cash proceeds to the Company of at least $50.0&nbsp;million. In March 2015, the Company issued and sold an aggregate of 13,062,965 shares of its series&nbsp;B
preferred stock ("Series&nbsp;B Preferred Stock") for gross proceeds of $12.4&nbsp;million.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will be required to obtain additional funding, alternative means of financial support, or both, in order to continue to fund its operations. These factors raise substantial
doubt about the Company's ability to continue as a going concern. The Company intends to pursue a private offering of equity securities and a public offering of its common stock (the "Common Stock")
to fund future operations. However, if the Company is unable to complete a sufficient private or public offering in a timely manner, it would need to pursue other financing alternatives, including
private financing of debt or equity or collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on
terms acceptable to the Company, or at all.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and
commitments in the normal course of business. The financial statements for the year ended December&nbsp;31, 2014 and the three months ended March&nbsp;31, 2015 do not include any adjustments to
reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from this uncertainty related to the Company's
ability to continue as a going concern.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=181,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=701754,FOLIO='F-7',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies

  </B></FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The accompanying financial statements have been prepared in accordance with United States (U.S.) generally accepted accounting
principles ("U.S.&nbsp;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of the Company's financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and
assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company utilizes significant estimates and assumptions in determining the fair value of its Common Stock. The board of directors determined the estimated fair value of the Common
Stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of
convertible preferred stock, the achievement of research and development milestones, the superior rights and preferences of securities senior to the Common Stock at the time and the likelihood of
achieving a liquidity event, such as an initial public offering or sale of the Company.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants ("AICPA"), Audit and Accounting Practice
Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation ("AICPA Practice Aid"), to estimate the fair value of its Common Stock. The methodologies included the Option
Pricing Method utilizing the Backsolve Method (a form of the market approach defined in the AICPA Practice Aid) and the Probability-Weighted Expected Return Method based upon the probability of
occurrence of certain future liquidity events such as an initial public offering or sale of the Company. Each valuation methodology includes estimates and assumptions that require the Company's
judgment. Significant changes to the key assumptions used in the valuations could result in different fair values of Common Stock at each valuation date.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service
of each contract, are determined by the Company based on input from internal project management, as well as from third-party service providers.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited Interim Financial Statements

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The unaudited interim financial statements as of March&nbsp;31, 2015 and for the three months ended March&nbsp;31, 2014 and 2015
and the related interim information contained within the notes to the financial statements are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual
financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position as of
March&nbsp;31, 2015 and its results of operations and cash flows for the three months ended March&nbsp;31, 2014 and 2015. The results of operations and cash flows for the three


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=182,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=545754,FOLIO='F-8',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">



<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


months ended March&nbsp;31, 2015 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2015 or for any other future annual or interim period.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Unaudited Pro Forma Financial Information

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2015, the Company's board of directors authorized the management of the Company to file a registration statement with the
Securities and Exchange Commission ("SEC") for the Company to sell shares of its Common Stock to the public. Upon the closing of a qualified public offering (as defined in the Company's certificate of
incorporation), all of the Company's outstanding convertible preferred stock will automatically convert into Common Stock. The unaudited pro forma balance sheet and statement of convertible preferred
stock and stockholders' (deficit) equity as of March&nbsp;31, 2015 assume (1)&nbsp;the conversion of all outstanding convertible preferred stock into shares of Common Stock, and (2)&nbsp;the
reclassification of the Company's warrant liability to additional paid-in capital, as a result of warrants to purchase preferred stock becoming warrants to purchase Common Stock upon the completion of
this proposed offering.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Risk and Concentrations of Credit Risk

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and restricted cash. The primary objectives for the Company's investment portfolio are the
preservation of capital and the maintenance of liquidity. The Company's investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable
investments that the Company believes minimizes the exposure to concentration of credit risk.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and Cash Equivalents

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash
equivalents, which consist primarily of money market funds, are stated at fair value. Cash and cash equivalents consist of the following (in thousands):

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,472</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,162</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,798</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money market fund</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,474</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Available-for-Sale Investments

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company classifies all short-term investments with a remaining maturity when purchased of greater than three months as
available-for-sale. Available-for-sale securities are recorded at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities
is adjusted for the amortization of premiums and accretion of discounts to maturity.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=183,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=400953,FOLIO='F-9',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


Such amortization is included in other income (expense), net. Realized gains and losses, interest, dividends and declines in value judged to be other-than-temporary are included in other income
(expense), net.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The cost of securities sold is based on the specific identification method for purposes of recording realized gains and losses. To determine whether an other-than-temporary impairment
exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the
investment outweighs evidence to the contrary. There were no available-for-sale investments outstanding at December&nbsp;31, 2014 or March&nbsp;31, 2015.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred Public Offering Costs

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred public offering costs, which primarily consist of direct, incremental legal and accounting fees relating to the Company's
initial public offering ("IPO"), are capitalized within other assets. The deferred issuance costs will be offset against IPO proceeds upon the consummation of the offering. In the event the offering
is terminated, deferred offering costs will be expensed. The Company incurred $0.5&nbsp;million and $1.5&nbsp;million in deferred IPO costs as of December&nbsp;31, 2014 and March&nbsp;31,
2015, respectively, that are classified in other assets on the balance sheet.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fair Value of Financial Instruments

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels as follows:
Level&nbsp;1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level&nbsp;2 inputs are inputs other than quoted prices included within Level&nbsp;1
that are observable for the asset or liability, either directly or indirectly; and Level&nbsp;3 inputs are unobservable inputs that reflect the Company's own assumptions about the assumptions market
participants would use in pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value
measurement.

</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables present information about the Company's financial assets and liabilities that have been measured at fair value, and indicates the fair value hierarchy of the
valuation inputs utilized to determine such fair value. The Company determines the fair value of the preferred stock warrants (Note&nbsp;11) using Level&nbsp;3 inputs.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the assets and liabilities measured at fair value on a recurring basis at December&nbsp;31, 2013 (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Balance at<BR>
December&nbsp;31,<BR>
2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,002</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=184,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=390147,FOLIO='F-10',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)


 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the assets and liabilities measured at fair value on a recurring basis at December&nbsp;31, 2014 (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Balance at<BR>
December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the assets and liabilities measured at fair value on a recurring basis at March&nbsp;31, 2015 (in thousands):

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Balance at<BR>
March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrant liability</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The carrying amounts reflected in the balance sheets for cash and cash equivalents, restricted cash, prepaid expenses and other current assets, other assets, accounts payable and accrued
expenses approximate their fair values at December&nbsp;31, 2013 and 2014 and March&nbsp;31, 2015, due to their short-term nature.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have been no changes to the valuation methods during the years ended December&nbsp;31, 2013 and 2014 or the three months ended March&nbsp;31, 2015. The Company evaluates
transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between levels during the years ended December&nbsp;31, 2013 and 2014 or the three
months ended March&nbsp;31, 2015. At March&nbsp;31, 2015, the carrying value of the Company's debt approximated fair value, which was determined using Level&nbsp;3 inputs, including a quoted
interest rate.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property and Equipment

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment consist of laboratory equipment, computer equipment, leasehold improvements and furniture and fixtures. Property
and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the respective assets. Costs of major

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=185,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1012848,FOLIO='F-11',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


additions and betterments are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the
cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.

</FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Impairment of Long-Lived Assets

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life
of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company has not recognized any impairment charges through March&nbsp;31, 2015.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Warrant Liability

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for warrant instruments that either conditionally or unconditionally obligate the Company to transfer assets
regardless of the timing of the redemption feature or price, even though the underlying shares may be classified as permanent or temporary equity. These warrants are subject to revaluation at each
balance sheet date, and any changes in fair value are recorded as a component of other income (expense), until the earlier of their exercise or expiration or the completion of a liquidation event,
including the completion of an initial public offering, at which time the warrant liability may be reclassified to stockholders' (deficit) equity if the criteria for recording the warrant as an equity
instrument are met. The warrant liability totaled $0, $0.1&nbsp;million, and $0.2&nbsp;million at December&nbsp;31, 2013 and 2014 and March&nbsp;31 2015, respectively (Note&nbsp;11).

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. Research and development costs include salaries and personnel-related costs,
stock-based compensation, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities and other external costs. Nonrefundable advance payments for goods
or services to be received in the future for use in research and development activities are deferred. The deferred amounts are expensed as the related goods are delivered or the services are
performed.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for its stock-based compensation awards in accordance with Accounting Standards Codification ("ASC")
Topic&nbsp;718, </FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation (</I></FONT><FONT SIZE=2>"ASC&nbsp;718"). ASC&nbsp;718 requires all share-based payments to employees,
including grants of employee stock options, to be recognized in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the board
of directors for their services on the board of directors, the Company estimates the grant date fair value of each option award using the Black- Scholes option-pricing model. The use of the
Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected
life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, the

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=186,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=795973,FOLIO='F-12',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<A NAME="page_fm15201_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


Company recognizes stock-based compensation expense, net of estimated forfeitures, equal to the grant date fair value of stock options on a straight-line basis over the requisite service period.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company expenses restricted stock awards based on the fair value of the award on a straight-line basis over the associated service period of the award.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based payments issued to non-employees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over the
related service period in accordance with the provisions of ASC Topic 505, </FONT><FONT SIZE=2><I>Equity</I></FONT><FONT SIZE=2>. For equity instruments granted to non-employees, the Company
recognizes stock-based compensation expense on a straight-line basis.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the years ended December&nbsp;31, 2013 and 2014 and the three months ended March&nbsp;31, 2014 and 2015, the Company recorded stock-based compensation expense for employee and
non-employee stock options and restricted stock, which was allocated as follows in the statements of operations (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Research and development expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>434</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>168</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>463</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>897</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>301</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No related tax benefits were recognized for the years ended December&nbsp;31, 2013 and 2014 or for the three months ended March&nbsp;31, 2014 and 2015.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grant Awards

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the years ended December&nbsp;31, 2013 and 2014 and the three months ended March&nbsp;31 2014 and 2015, the Company received
$35,000, $0, $0 and $50,000, respectively, in grants from the Muscular Dystrophy Association and Parent Project for Muscular Dystrophy. The awards were recorded as a reduction to research and
development expenses as the related expenses were incurred in the Company's statements of operations and comprehensive loss.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss Per Share and Unaudited Pro Forma Net Loss Per Share

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without
consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding
for the period, determined using the treasury-stock method. For purposes of the dilutive net loss per share calculation, preferred stock, stock options, warrants to purchase Common Stock and warrants
to purchase preferred stock are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive; therefore, basic
and diluted net loss per share were the same for all periods presented.

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=187,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=904641,FOLIO='F-13',FILE='DISK122:[14ZDH1.14ZDH15201]FM15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fo15201_1_14"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

  </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive
effect:

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,967,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,967,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,967,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,030,239</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,883,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,756,837</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,246,286</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,839,736</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock warrants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock warrants</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>315,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>114,298,367</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119,329,805</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119,661,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>134,633,513</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited pro forma net loss per share is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all convertible preferred stock
into shares of the Common Stock as if such conversion had occurred at the beginning of the period presented, or the date of original issuance, if later.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the
Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to
reverse. A valuation allowance is provided to reduce the deferred tax assets to the amount that will more likely than not be realized.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounts for uncertain tax positions in accordance with the provisions of ASC Topic&nbsp;740</FONT><FONT SIZE=2><I>, Expenses&#151;Income
Taxes</I></FONT><FONT SIZE=2>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The
determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and
circumstances. As
of December&nbsp;31, 2013 and 2014 and March&nbsp;31, 2015, the Company did not have any significant uncertain tax positions.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment Information

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise for which separate discrete financial information is available for
evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its
business in one operating segment. The Company operates in one geographic segment.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comprehensive Loss

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and
circumstances from non-owner sources. For the years ended

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=188,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=98350,FOLIO='F-14',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


December&nbsp;31, 2013 and 2014 and for the three months ended March&nbsp;31, 2014 and 2015, comprehensive loss was equal to net loss.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently Issued or Adopted Accounting Pronouncements

 </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard
setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the
impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2014, the FASB issued Accounting Standards Update ("ASU")&nbsp;2014-10, </FONT><FONT SIZE=2><I>Development Stage Entities (Topic&nbsp;915)</I></FONT><FONT SIZE=2>
("ASU&nbsp;2014-10"), which removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage entities and other
reporting entities. Accordingly, ASU 2014-10 eliminates the requirements for development stage entities to (1)&nbsp;present inception-to-date information in the statements of operations, cash flows
and shareholder equity, (2)&nbsp;label financial statements as those of a development stage entity, (3)&nbsp;disclose a description of the development stage activities in which the entity is
engaged and (4)&nbsp;disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. ASU&nbsp;2014-10 is effective
for public business entities for annual periods beginning after December&nbsp;15, 2014, and interim reporting periods beginning after December&nbsp;15, 2015, with early adoption permitted. The
Company early adopted the provisions of ASU&nbsp;2014-10 in these financial statements.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2015, the FASB issued ASU No.&nbsp;2015-03, </FONT><FONT SIZE=2><I>Simplifying the Presentation of Debt Issuance Costs</I></FONT><FONT SIZE=2>. This standard amends existing
guidance to require the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability rather than as a deferred charge. It is effective
for annual reporting periods beginning after December&nbsp;15, 2015, but early adoption is permitted. The Company is currently evaluating the impact that this standard will have on its consolidated
financial statements.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=189,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=778068,FOLIO='F-15',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Property and Equipment

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment and related accumulated depreciation were as follows (in thousands):

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="130pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Useful<BR>
Life (Years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Lab equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,269</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,281</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Lesser of useful life or<BR>
remaining<BR>
lease term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,466</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,490</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(955</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,230</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>288</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense was $0.3&nbsp;million, $0.2&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million for the years ended December&nbsp;31, 2013 and 2014 and
for the three months ended March&nbsp;31, 2014 and 2015, respectively.

 </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Restricted Cash

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2013 and 2014 and March&nbsp;31, 2015, the Company had an outstanding letter of credit for $0.1&nbsp;million as a security deposit for its operating lease
agreement for office space (Note&nbsp;7). The Company is required to maintain this deposit for the duration of the lease agreement.


</FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Accrued Expenses

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses consisted of the following (in thousands):

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Accrued compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>785</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued contracted research costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,266</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,109</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>727</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,279</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,793</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,467</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Notes Payable

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;27, 2014, the Company entered into the Credit Facility. The Credit Facility, as amended on March&nbsp;31, 2015, provides for initial borrowings of $5.0&nbsp;million
under a term loan ("Term Loan&nbsp;A") and additional borrowings of up to $20.0&nbsp;million under other term loans, for a maximum of $25.0&nbsp;million. On August&nbsp;27, 2014, the Company
received proceeds of $5.0&nbsp;million from the issuance of promissory notes under Term Loan A. On March&nbsp;31, 2015, the Company received proceeds of

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=190,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=491750,FOLIO='F-16',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Notes Payable (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


$5.0&nbsp;million from the issuance of promissory notes under another term loan ("Term Loan&nbsp;B"). Of the additional $15.0&nbsp;million available, $5.0&nbsp;million ("Term Loan C") was
available to be drawn, until May&nbsp;31, 2015, subject to completion of an additional equity financing with net cash proceeds of at least $8.0&nbsp;million and the issuance of warrants to
purchase shares of the Company's stock equal in value to 3% of the amount drawn. An additional $10.0&nbsp;million ("Term Loan D") is available until July&nbsp;31, 2015, subject to the completion
of an initial public offering with net cash proceeds to the Company of at least $50.0&nbsp;million and the issuance of warrants to purchase shares of the Company's common stock equal in value to 3%
of the amount drawn. All promissory notes issued under the Credit Facility are due on October&nbsp;1, 2018 and are collateralized by substantially all of the Company's personal property, other than
its intellectual property. As of March&nbsp;31, 2015, the Company had not drawn the Term Loan&nbsp;C and Term Loan D.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is obligated to make monthly, interest-only payments on any term loans funded under the Credit Facility until September&nbsp;1, 2015 and, thereafter, to pay 36 consecutive,
equal monthly
installments of principal and interest from October&nbsp;1, 2015 through September&nbsp;1, 2018. Term loans under the Credit Facility bear interest at an annual rate of 7.49%. In addition, a final
payment equal to 3.48% of any amounts drawn under the Credit Facility is due upon the earlier of the maturity date, acceleration of the term loans or prepayment of all or part of the term loans. The
final payment is being accrued as additional interest expense using the effective-interest method from the date of issuance through the maturity date, and is recorded as an other long-term liability
in the accompanying balance sheets. The effective interest rate as of December&nbsp;31, 2014 for the Term Loan A, including the final payment and non-cash interest, was 11.9%. The effective interest
rate as of March&nbsp;31, 2015 was 11.2%.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of prepayment, the Company is obligated to pay 1% to 3% of the amount of the outstanding principal depending upon the timing of the prepayment.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In conjunction with Term Loan&nbsp;A, the Company issued warrants to purchase 157,844 shares of Series&nbsp;B convertible preferred stock at an exercise price of $0.9503 per share
(the "2014 Warrants") to the lenders. In conjunction with Term Loan&nbsp;B, the Company issued warrants to purchase an additional 157,844 shares of Series&nbsp;B convertible preferred stock at an
exercise price of $0.9503 per share (the "2015 Warrants") to the lenders. The 2014 Warrants and 2015 Warrants were exercisable immediately and have seven-year lives. The 2014 Warrants and 2015
Warrants were initially valued at $0.1&nbsp;million and $0.1&nbsp;million, respectively, using the Black-Scholes option-pricing model. The Company recorded debt discounts of $0.1&nbsp;million
and $0.1&nbsp;million upon issuance of the 2014 Warrants and 2015 Warrants, respectively, which are being accreted as interest expense using the effective-interest method over the remaining term of
the loan. The Company recorded interest expense of $14,000 for the year ended December&nbsp;31, 2014 and $11,000 for the three months ended March&nbsp;31, 2015 related to accretion of such
discount. The Company recorded warrant liabilities (Note&nbsp;11) of $0.1&nbsp;million for both the 2014 Warrants and 2015 Warrants that are classified as long-term liabilities in the accompanying
balance sheets.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no financial covenants associated with the Credit Facility; however, there are negative covenants restricting the Company's activities, including limitations on asset
dispositions, mergers or acquisitions; encumbering or granting a security interest in its intellectual property; incurring

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=191,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=264443,FOLIO='F-17',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Notes Payable (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


indebtedness or liens; paying dividends; making certain investments; and entering into certain other business transactions.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Credit Facility also includes events of default, the occurrence and continuation of any of which provides the lenders the right to exercise remedies against the Company and the
collateral securing the loans under the Credit Facility, including cash. These events of default include, among other things, failure to pay amounts due under the Credit Facility, insolvency, the
occurrence of a material adverse
event, which includes a material adverse change in the business, operations or conditions (financial or otherwise) of the Company or a material impairment of the prospect of repayment of any portion
of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against the Company in an amount greater than $250,000. The occurrence of a material adverse
change could result in acceleration of the payment of the debt. At December&nbsp;31, 2014 and March&nbsp;31, 2015, the Company concluded that the likelihood of the acceleration of the debt was
remote, as a material adverse change had not occurred and was unlikely to occur and therefore the debt was classified in current and long-term liabilities based on scheduled principal payments.
Following the occurrence and during the continuance of an event of default, borrowings under the Credit Facility shall bear interest at a rate per annum which is five hundred basis points, or 5.00%,
above the rate that is otherwise applicable.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company assessed all terms and features of the Credit Facility in order to identify any potential embedded features that would require bifurcation or any beneficial conversion
features. As part of this analysis, the Company assessed the economic characteristics and risks of the Credit Facility, including put and call features. The Company determined that all features of the
Credit Facility are clearly and closely associated with a debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial to the Company's financial
statements. The Company will continue to reassess the features on a quarterly basis to determine if they require separate accounting.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company accounted for the amendment to the Credit Facility, effective March&nbsp;31, 2015, as a debt modification pursuant to ASC Topic 470-50 </FONT><FONT SIZE=2><I>Modifications
and Extinguishments.</I></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated future principal payments at December&nbsp;31, 2014 are as follows (in thousands):


</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:89pt;"><FONT SIZE=1><B>Year ending December&nbsp;31:

<!-- COMMAND=ADD_SCROPPEDRULE,89pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: discount for warrants and costs paid to lender</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: current portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(309</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Note payable, net of discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=192,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=595946,FOLIO='F-18',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Notes Payable (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Estimated future principal payments due under Term Loans A and B are as follows as of March&nbsp;31, 2015 (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:89pt;"><FONT SIZE=1><B>Year ending December&nbsp;31:

<!-- COMMAND=ADD_SCROPPEDRULE,89pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>833</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,501</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: discount for warrants and costs paid to lender</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: current portion</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,505</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Note payable, net of current portion and discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2014, the Company recognized $0.2&nbsp;million of interest expense related to the Credit Facility. During the three months ended
March&nbsp;31, 2015, the Company recognized $0.1&nbsp;million of interest expense related to the Credit Facility. The Company had no debt outstanding as of December&nbsp;31, 2013.

 </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Commitments

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2010, the Company entered into a five-year, non-cancelable operating lease for office and laboratory space. In December 2011, the Company signed a lease amendment that
expanded the leased
premises beginning in the second quarter of 2012. The lease amendment also extended the term of the existing lease through June&nbsp;30, 2017. The expansion lease includes a free rent period and
escalating rent payments. The Company is recognizing rent expense on a straight-line basis over the lease term. The lease agreement provides for a five-year extension upon the completion of the lease
term.

</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The future minimum lease payments under the non-cancelable operating lease as of December&nbsp;31, 2014 are as follows (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:89pt;"><FONT SIZE=1><B>Year ending December&nbsp;31:

<!-- COMMAND=ADD_SCROPPEDRULE,89pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>760</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>378</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent expense for the years ended December&nbsp;31, 2013 and 2014 and for the three months ended March&nbsp;31, 2014 and 2015 was $0.7&nbsp;million, $0.7&nbsp;million,
$0.2&nbsp;million and $0.2&nbsp;million, respectively.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=193,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=504612,FOLIO='F-19',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<A NAME="page_fo15201_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible Preferred Stock

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On April&nbsp;17, 2013, the Company's board of directors authorized the Company to increase the authorized number of shares under the Series&nbsp;A convertible preferred stock
("Series&nbsp;A Preferred Stock") financing to 68,837,703. The Company subsequently issued 636,952 shares of Series&nbsp;A Preferred Stock at $0.70 per share, and received net proceeds of
$0.4&nbsp;million.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;31, 2013, the Company completed a Series&nbsp;B Preferred Stock financing and issued 34,129,571 shares of Series&nbsp;B Preferred Stock at $0.9503 per share, for
net proceeds of $32.2&nbsp;million.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;13, 2015, the Company's board of directors authorized the Company to increase the authorized number of shares in connection with the Series&nbsp;B Preferred Stock
financing to 56,026,590.
The Company subsequently issued 13,062,965 shares of Series&nbsp;B Preferred Stock at $0.9503 per share, and received net proceeds of $12.3&nbsp;million.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company assessed the Series&nbsp;A and Series&nbsp;B Preferred Stock for any beneficial conversion features or embedded derivatives, including the conversion option, that would
require bifurcation from the Series&nbsp;A and Series&nbsp;B Preferred Stock and receive separate accounting treatment. Based on the Company's determination that the Preferred Stock is an "equity
host," the Company determined that all features of the Preferred Stock are clearly and closely related to the equity host, and do not require bifurcation as a derivative liability. On the date of
issuance, the fair value of Common Stock into which the Series&nbsp;A and Series&nbsp;B Preferred Stock was convertible was less than the effective conversion price of the Series&nbsp;A and
Series&nbsp;B Preferred Stock, and as such, there was no intrinsic value of the conversion option at the commitment date.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock (collectively, the "Preferred Stock") have the following rights and preferences:

 </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting

 </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of Preferred Stock are entitled to a number of votes equal to the number of shares of Common Stock into which the Preferred
Stock is convertible on the date of record. Holders of the Preferred Stock vote together with the holders of Common Stock as a single class, except for the election of the Company's board of
directors. For such election, holders of Series&nbsp;A Preferred Stock vote exclusively as a separate class to elect three directors and holders of Series&nbsp;B Preferred Stock vote exclusively
as a separate class to elect one director. The remainder of the directors of the Company are elected by the holders of Common Stock and the Preferred Stock voting as a single class. The approval of
60% of the then outstanding shares of Preferred Stock is required for certain events that may impact the rights and preferences of the Preferred Stock, including the liquidation, winding up or
dissolution of the business, an increase or decrease in the number of shares of Preferred Stock or Common Stock authorized for issuance, amendment of the certificate of incorporation in a manner that
adversely effects the rights, preferences or privileges of the Preferred Stock, the purchase or redemption of or payment or declaration of dividends on shares of Preferred Stock or Common Stock,
authorization of debt securities exceeding $1.0&nbsp;million, or the adoption or amendment of any equity-based compensation plans to increase the number of shares issuable thereunder.


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=194,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=960009,FOLIO='F-20',FILE='DISK122:[14ZDH1.14ZDH15201]FO15201A.;19',USER='LPALLES',CD=';2-JUN-2015;11:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_fq15201_1_21"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

  </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible Preferred Stock (Continued)

 </B></FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends accrue on Preferred Stock from the date of issuance at a rate of 8% per annum per share when and if declared by the Company's
board of directors. Dividends are not cumulative. The Company has not declared any dividends to date. The Company shall not pay a dividend to other classes of securities until the holders of Preferred
Stock have received a dividend of 8% per annum, per share from the date of issuance.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation Preference

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution, or winding up of the affairs of the Company, the holders of the then-outstanding
Preferred Stock shall receive on a pari passu basis, before any payment shall be made to the holders of Common Stock, the greater of (1)&nbsp;$0.70 per share for Series&nbsp;A Preferred Stock plus
all declared, but unpaid, dividends, and (2)&nbsp;$0.9503 per share for Series&nbsp;B Preferred Stock plus all declared, but unpaid, dividends, or (3)&nbsp;such amount per share of Preferred
Stock payable as if converted into Common Stock. After the payment of any preferential amount to holders of Preferred Stock, any remaining assets of the Company shall be distributed ratably among the
holders of Common Stock. If the assets or surplus funds to be distributed to the holders of the Preferred Stock are insufficient to permit the payment to such holders of their full preferential
amount, the assets and surplus funds legally available for distribution shall be distributed ratably among the holders of the Preferred Stock in proportion to the full preferential amount that each
holder is otherwise entitled to receive. As the Preferred Stock may become redeemable upon an event that is
outside of the control of the Company, the Preferred Stock has been classified outside of permanent equity. Since the Preferred Stock is not initially redeemable and it is not probable that it will
become redeemable, the carrying amount of the Preferred Stock has not been adjusted.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Preferred Stock is convertible at the option of the holder into a number of fully paid shares of Common Stock as
determined by dividing $0.70 by the conversion price in effect at the time for the Series&nbsp;A Preferred Stock and by dividing $0.9503 by the conversion price in effect at the time for the
Series&nbsp;B Preferred Stock. The initial conversion prices of Series&nbsp;A and Series&nbsp;B Preferred Stock are $0.70 per share and $0.9503 per share, respectively, and are subject to
adjustment in accordance with anti-dilution provisions contained in the Company's certificate of incorporation. Conversion is automatic immediately upon the closing of a firm commitment underwritten
public offering in which the public offering price equals or exceeds $1.90 per share and the gross proceeds are not less than $50,000,000, or upon the written consent of the holders of at least 60% of
the then-outstanding shares of Preferred Stock.


</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=195,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=850487,FOLIO='F-21',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">



<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Common Stock

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The voting, dividend and liquidation rights of holders of Common Stock are subject to and qualified by
the rights, powers and preferences of the holders of Preferred Stock. The Company's Common Stock has the following characteristics:

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting

 </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders and written
actions in lieu of meetings.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Common Stock are entitled to receive dividends, if and when declared by the board of directors. Cash dividends may not
be declared or paid to holders of Common Stock until paid on each series of outstanding Preferred Stock in accordance with their respective terms. No dividends have been declared or paid from the
Company's inception through March&nbsp;31, 2015.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After payment to the holders of Preferred Stock of their liquidation preferences, the holders of Common Stock are entitled to share
ratably in the Company's assets available for distribution to stockholders, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or upon the occurrence of
a deemed liquidation event, as defined in the Company's certificate of incorporation.

</FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Reserved for Future Issuance

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company had reserved for future issuance the following number of shares of Common Stock as of December&nbsp;31, 2013 and 2014 and March&nbsp;31, 2015:


</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Conversion of Series&nbsp;A Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,837,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,837,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,837,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Conversion of Series&nbsp;B Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,129,571</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,129,571</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,192,536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants for the purchase of Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>315,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Warrants for the purchase of Common Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>447,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase Common Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,075,611</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,801,379</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,325,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,490,735</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121,374,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,119,556 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Warrants

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;27, 2014 and March&nbsp;31, 2015, the Company issued the 2014 Warrants and 2015 Warrants to purchase an aggregate 315,688 shares of Series&nbsp;B Preferred Stock at
an exercise price of $0.9503 per share to the lenders in connection with the Credit Facility (Note&nbsp;6). The 2014 Warrants and 2015 Warrants were exercisable immediately on issuance and have a
seven-year life. The fair value

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=196,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=853188,FOLIO='F-22',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.


 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Warrants (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


of the 2014 Warrants and 2015 Warrants are re-measured at each reporting date using then-current assumptions. The 2014 Warrants and 2015 Warrants were valued using the Black-Scholes option-pricing
model. Significant changes to the key assumptions used in the valuation could result in significantly different fair values of the 2014 Warrants and 2015 Warrants. The following assumptions were used
in valuing the 2014 Warrants:

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>August&nbsp;27,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78.16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following assumptions were used in valuing the 2015 Warrants:

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides a roll-forward of the fair value of the 2014 Warrants and 2015 Warrants determined by Level&nbsp;3 inputs (in thousands):


</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Balance at January&nbsp;1, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of warrants at fair value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value, recorded as a component of other expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at December&nbsp;31, 2014</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Issuance of warrants at fair value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>107</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value, recorded as a component of other expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance at March&nbsp;31, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No portion of the 2014 Warrants or 2015 Warrants had been exercised as of March&nbsp;31, 2015.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At various dates from 2008 through 2010, the Company issued warrants to purchase 447,850 shares of Common Stock at an exercise price of $0.13 to various individuals, including its
founders and employees of the Company. The warrants have a six-year term.

</FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Stock Incentive Plan

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the 2008 Stock Incentive Plan (the "Plan") for employees, directors, consultants and advisors to the Company. The Plan provides for the grant of incentive and

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=197,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=989216,FOLIO='F-23',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Stock Incentive Plan (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


non-qualified stock options and restricted stock grants as determined by the Company's board of directors. As of December&nbsp;31, 2014 and March&nbsp;31, 2015, the Company had reserved 21,838,299
shares and 23,684,539 shares of Common Stock, respectively, under the Plan, of which 1,495,043 shares remained available for future issuance as of March&nbsp;31, 2015. Under the Plan, stock options
may not be granted with exercise prices at less than fair value on the date of the grant.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terms of stock option agreements, including vesting requirements, are determined by the Company's board of directors, subject to the provisions of the Plan. Options and restricted stock
awards granted by the Company generally vest ratably over four years, with a one-year cliff, and options are exercisable from the date of grant for a period of ten years. Restricted stock issuances
and early exercises of stock options are subject to a Company right of repurchase at the original issuance price, which right lapses over the vesting period of the stock. For options and restricted
stock awards granted through March&nbsp;31, 2015, the exercise price or purchase price, as applicable, equaled the estimated fair value of the Common Stock as determined by the Company's board of
directors on the date of grant.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A summary of the Company's stock option activity and related information follows:

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"120%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Stock Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-Average<BR>
Exercise Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-Average<BR>
Remaining<BR>
Contractual<BR>
Term (in years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Instrinsic<BR>
Value<BR>
(in thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Outstanding at December&nbsp;31, 2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
10,883,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
8.05</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,099</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,058,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,283,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.09</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(901,674</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.28</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
15,756,837</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,710,259</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(321,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Forfeited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(305,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.30</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at March&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
17,839,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
8.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,285</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
6,852,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
7.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,877</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
14,510,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
8.07</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,249</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at March&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
8,271,634</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
7.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,211</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested and expected to vest at March&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
16,413,270</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>
<!-- -->
8.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,898</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total intrinsic value of options exercised for the year ended December&nbsp;31, 2013 and 2014 and for the three months ended March&nbsp;31, 2014 and 2015 was $0.1&nbsp;million,
$0.6&nbsp;million, $21,000, and $0.2&nbsp;million, respectively. The total fair value of employee options vested for the year ended


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=198,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=824673,FOLIO='F-24',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Stock Incentive Plan (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


December&nbsp;31, 2013 and 2014 and for the three months ended March&nbsp;31, 2014 and 2015 was $0.3&nbsp;million, $0.5&nbsp;million, $0.1&nbsp;million and $0.6&nbsp;million, respectively.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At December&nbsp;31, 2014 and March&nbsp;31, 2015, the total unrecognized compensation expense related to unvested stock option awards, including estimated forfeitures, was
$2.3&nbsp;million and $3.4&nbsp;million, respectively. The Company expects to recognize that cost over a weighted-average period of approximately 3.0&nbsp;years and 3.1&nbsp;years,
respectively.

</FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-Based Compensation Expense

  </I></B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The weighted-average grant date fair value of options granted to employees and directors for the years ended December&nbsp;31, 2013
and 2014, and for the three months ended March&nbsp;31, 2014 and 2015 was $0.13, $0.38, $0.38 and $0.54, respectively. The fair value of stock options granted to employees and non-employees was
estimated using the Black-Scholes option-pricing model based on the assumptions noted in the following table:

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="21pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Risk-free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92&nbsp;-&nbsp;2.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.71&nbsp;-&nbsp;3.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.96&nbsp;-&nbsp;3.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.54&nbsp;-&nbsp;2.11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25&nbsp;-&nbsp;10.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.0&nbsp;-&nbsp;81.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.2&nbsp;-&nbsp;83.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.2&nbsp;-&nbsp;82.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76.5&nbsp;-&nbsp;84.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Volatility

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the Company is privately held as of the date of these financial statements, it does not have relevant historical data to support
its expected volatility. As such, the Company has used a weighted- average of expected volatility based on the volatilities of a representative group of publicly traded biopharmaceutical companies.
For purposes of identifying representative companies, the Company considered characteristics such as number of product
candidates in early stages of product development, area of therapeutic focus, length of trading history, similar vesting provisions and a similar percentage of stock options that were in-the-money.
The expected volatility was determined using a weighted-average of the historical volatilities of the representative group of companies for a period equal to the expected term of the option grant. The
Company intends to continue to consistently apply this process using the same representative companies until a sufficient amount of historical information regarding the volatility of the Company's own
share price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share
prices are publicly available would be utilized in the calculation.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk-Free Rate

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The risk-free rate was based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the
options being valued.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=199,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=123260,FOLIO='F-25',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Stock Incentive Plan (Continued)

 </B></FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expected Term

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company uses the "simplified method" to estimate the expected term of stock option grants. Under this approach, the
weighted-average expected life is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of the Company's stock options, taking into consideration
multiple vesting tranches. The Company utilizes this method due to lack of historical exercise data and the plain-vanilla nature of the Company's share-based awards.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends

  </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has never paid, and does not anticipate paying in the foreseeable future, any cash dividends and therefore uses an expected
dividend yield of zero in the option-pricing model.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Forfeitures

 </I></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is also required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual
forfeitures differ from its estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected
to vest. To the extent that actual forfeitures differ from the Company's estimates, the difference is recorded as a cumulative adjustment in the period the estimates are revised.

 </FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows for the years ended December&nbsp;31, 2013 and 2014:

 </FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Federal income tax (benefit) at statutory rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent differences</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal research and development credits and adjustments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State income tax, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(0.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(45.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(41.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective income tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=200,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=740166,FOLIO='F-26',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provision (benefit) for income taxes was as follows for the years ended December&nbsp;31, 2013 and 2014 (in thousands):

</FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Current:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's deferred tax assets consisted of the following (in thousands):

 </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Deferred tax assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,577</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax credit carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,955</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,748</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,521</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,780</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized legal expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>883</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,223</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other differences</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>195</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,523</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(22,486</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(31,523</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company recorded an increase to the valuation allowance of $8.2&nbsp;million during the year ended December&nbsp;31, 2013 and $9.0&nbsp;million during the year ended
December&nbsp;31, 2014, due primarily to an increase in the net operating loss carryforwards and tax credits.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible
amounts become deductible. Due to the Company's history of losses, the deferred tax assets were fully offset by a valuation allowance at December&nbsp;31, 2013 and 2014.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=201,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=285164,FOLIO='F-27',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<A NAME="page_fq15201_1_28"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B><BR>
Catabasis Pharmaceuticals,&nbsp;Inc.

 </B></FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


Notes to Financial Statements (Continued)

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><I>Information as of March&nbsp;31, 2015 and for the three months ended<BR>
March&nbsp;31, 2014 and 2015 is unaudited

 </I></FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Income Taxes (Continued)

 </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company had approximately $57.6&nbsp;million of federal and $56.5&nbsp;million of state net operating loss carryforwards to offset future taxable
income, if any. Such net operating loss carryforwards expire at varying times through the year 2034, if not utilized. The Company also had approximately $2.1&nbsp;million of federal and
$1.0&nbsp;million of state tax credit carryforwards available to reduce future tax liabilities as of December&nbsp;31, 2014.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Internal Revenue Code of 1986, as amended (the "Code"), provides for a limitation of the annual use of net operating losses and other tax attributes (such as research and development
tax credit carryforwards) following certain ownership changes (as defined by the Code) that could limit the Company's ability to utilize these carryforwards. At this time, the Company has not
completed a study to assess whether an ownership change under Section&nbsp;382 of the Code has occurred, or whether there have been multiple ownership changes since the Company's formation, due to
the costs and complexities associated with such a study. The Company may have experienced various ownership changes, as defined by the Code, as a result of past financing transactions. Accordingly,
the Company's ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes.
Therefore, the Company may not be able to take full advantage of these carryforwards for federal or state income tax purposes.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company does not have any significant unrecognized tax benefits.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2014, the Company had not accrued interest or penalties related to uncertain tax positions. The Company's tax returns for the years ended December&nbsp;31,
2008 through December&nbsp;31, 2014 are still subject to examination by major tax jurisdictions.

 </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


14. Defined Contribution Benefit Plan


 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company sponsors a 401(k) retirement plan, in which substantially all of its full-time employees are eligible to participate. Participants may contribute a percentage of their annual
compensation to this plan, subject to statutory limitations. The Company did not provide any contributions to this plan during the years ended December&nbsp;31, 2013 and 2014 or the three months
ended March&nbsp;31, 2014 and 2015.

 </FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


15. Subsequent Events

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has completed an evaluation of all subsequent events through the date this Amendment No.&nbsp;1 to the registration statement on Form&nbsp;S-1 was submitted to the SEC,
to ensure that this submission includes appropriate disclosure of events both recognized in the financial statements as of March&nbsp;31, 2015, and events which occurred subsequently but were not
recognized in the financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure.

 </FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=202,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=131918,FOLIO='F-28',FILE='DISK122:[14ZDH1.14ZDH15201]FQ15201A.;23',USER='LPALLES',CD=';2-JUN-2015;11:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=5><B> &nbsp;<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=5><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT
SIZE=5><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=6><B>Catabasis Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>
<IMG SRC="g664220.jpg" ALT="LOGO" WIDTH="243" HEIGHT="52">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>PRELIMINARY PROSPECTUS<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Citigroup  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B> Cowen and Company  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B> Oppenheimer&nbsp;&amp;&nbsp;Co.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B> Wedbush PacGrow</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (25&nbsp;days after the commencement of this offering), all dealers that buy, sell or
trade shares of our common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscriptions. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=203,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=5002,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]HO15201A.;25',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ja15201_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART&nbsp;II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_item_13._other_expense__ja101982"> </A>
<A NAME="toc_ja15201_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement,
other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission's registration fee, the Financial Industry
Regulatory Authority,&nbsp;Inc. filing fee and the NASDAQ listing fee. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Securities and Exchange Commission registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Industry Regulatory Authority,&nbsp;Inc. filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accountants' fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Blue Sky fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer Agent's fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing and engraving expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>* </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
be filed by amendment.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja15201_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of
its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged
in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal
benefit. Upon completion of this offering, our certificate of incorporation will provide that none of our directors shall be personally liable to us or our stockholders for monetary damages for any
breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the
elimination or limitation of liability of directors for breaches of fiduciary duty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145
of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the
corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements
actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person
acted in good faith and in a manner he or she
reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful,
except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been
adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the completion of this offering, our certificate of incorporation will provide that we will indemnify each person who was or is a party or threatened to be made a party or is
involved in to any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=863193,FOLIO='II-1',FILE='DISK122:[14ZDH1.14ZDH15201]JA15201A.;27',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<A NAME="page_ja15201_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that he or
she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by reason of any action alleged to have been taken
or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or
proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any
criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our certificate of incorporation that will be effective upon the closing of the offering
also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is
or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity
with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the
Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim,
issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is
entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us
against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we do not assume the defense, expenses must be
advanced to an Indemnitee under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer
to the fullest extent permitted by law for claims arising in his or her capacity as a director or officer of our company or in connection with their service at our request for another corporation or
entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain
presumptions that are favorable to the director or executive officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriting agreement we will enter into in connection with the offering of common stock being registered hereby provides that the underwriters will indemnify, under certain
conditions, our directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended,
or the Securities Act, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=205,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=178522,FOLIO='II-2',FILE='DISK122:[14ZDH1.14ZDH15201]JA15201A.;27',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<A NAME="page_ja15201_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja15201_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is information regarding shares of our common stock and shares of our preferred stock, and stock options and warrants
granted, by us within the past three years that were not registered under the Securities Act of 1933, as amended, or the Securities Act. Included is the consideration, if any, we received for such
shares and options and warrants and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B><I>(a)</I></B></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Issuance of shares of preferred stock</I></B></FONT></DD></DL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2012, we issued and sold an aggregate of 12,500,000 shares of our Series&nbsp;A preferred stock to five investors at a price per share of $0.70, for an aggregate purchase price
of $8,750,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2013, we issued and sold an aggregate of 12,499,999 shares of our Series&nbsp;A preferred stock to five investors at a price per share of $0.70, for an aggregate purchase
price of $8,749,999. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2013, we issued and sold an aggregate 636,952 shares of our Series&nbsp;A preferred stock to nine investors at a price per share of $0.70, for an aggregate purchase price of
$445,866. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2013, we issued and sold an aggregate of 34,129,571 shares of our Series&nbsp;B preferred stock to eleven investors at a price per share of $0.9503, for an aggregate
purchase price of $32,433,331. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, we issued and sold an aggregate of 13,062,965 shares of our series B preferred stock to twenty investors at a price per share of $0.9503, for an aggregate purchase price
of $12,413,736. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
underwriters were involved in the foregoing issuances of securities. The securities described in this section&nbsp;(a) of Item&nbsp;15 were issued to investors in reliance upon
the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation&nbsp;D promulgated thereunder relative to
transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above
represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any
distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments
representing such securities issued in such transactions.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B><I>(b)</I></B></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Stock option grants and option exercises</I></B></FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Between May&nbsp;13, 2012 and June&nbsp;2, 2015, we granted options to purchase an aggregate of 16,552,269 shares of common stock, with exercise prices ranging from $0.18 to $0.86
per share, to employees, directors and consultants pursuant to our 2008 equity incentive plan. Between May&nbsp;13, 2012 and June&nbsp;2, 2015, we issued an aggregate of 1,895,132 shares of common
stock upon the exercise of options for aggregate consideration of $201,645.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
underwriters were involved in the foregoing issuances of securities. The issuances of stock options and the shares of our common stock issued upon the exercise of the options
described in this paragraph&nbsp;(b) of Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with our employees, directors and consultants, in reliance on the exemption
provided by Rule&nbsp;701 promulgated under the Securities Act, or pursuant to Section&nbsp;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public
offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such
information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=206,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=522357,FOLIO='II-3',FILE='DISK122:[14ZDH1.14ZDH15201]JA15201A.;27',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<A NAME="page_ja15201_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B><I>(c)</I></B></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Warrant grants</I></B></FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;27, 2014, we issued warrants to purchase an aggregate of 157,844 shares of Series&nbsp;B preferred stock at a price of $0.9503 per share to Square 1 Bank, Flexpoint
MCLS Holdings, LLC and MidCap Financial Trust. On March&nbsp;31, 2015, we issued warrants to purchase an aggregate of 157,844 additional shares of series&nbsp;B preferred stock at a price of
$0.9503 per share to Square 1 Bank, Flexpoint MCLS Holdings, LLC and MidCap Financial Trust. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
underwriters were involved in the foregoing issuances of securities. The issuances of warrants described in this paragraph&nbsp;(c) of Item&nbsp;15 were issued to investors in
reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the Securities Act relative to transactions by an issuer not involving
any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors
and were acquiring the securities for their own account for investment purposes only and not with a view to the public resale or distribution thereof and that they could bear the risks of the
investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja15201_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B><I>(a)</I></B></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Exhibits.</I></B></FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B><I>(b)</I></B></FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Financial Statement Schedules.</I></B></FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes.  </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="ja15201_item_17._undertakings."> </A>
<A NAME="toc_ja15201_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such
denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be
deemed to be part of this registration statement as of the time it was declared effective. </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=207,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=887472,FOLIO='II-4',FILE='DISK122:[14ZDH1.14ZDH15201]JA15201A.;27',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<A NAME="page_ja15201_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=208,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=765026,FOLIO='II-5',FILE='DISK122:[14ZDH1.14ZDH15201]JA15201A.;27',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc15201_signatures"> </A>
<A NAME="toc_jc15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act, the registrant has duly caused this Amendment No.&nbsp;1 to the Registration
Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 2<SUP>nd</SUP> day of June, 2015.

</FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2>CATABASIS PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2> By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;JILL C. MILNE, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=340009,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]JC15201A.;29',USER='CHE108062',CD=';2-JUN-2015;02:10' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc15201_signatures_1"> </A>
<A NAME="toc_jc15201_2"> </A>
<BR>

  </FONT>

<FONT SIZE=2><B>  SIGNATURES


    <BR>    </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this Amendment No.&nbsp;1 to the Registration Statement has been signed
by the following persons in the capacities held on the dates indicated.

 </FONT>

</P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:34pt;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,34pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:17pt;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,17pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2> /s/&nbsp;JILL C. MILNE, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne, Ph.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;<BR>
President, Chief Executive Officer and<BR>
Director (principal executive officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> /s/&nbsp;IAN C. SANDERSON<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Ian C. Sanderson</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>
<BR>
Chief Financial Officer and Treasurer<BR>
(principal financial and principal<BR>
accounting officer)</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> *<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Michael Ross, Ph.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> *<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Nicholas Galakatos, Ph.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> *<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jean George</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> *<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Ron Laufer, M.D.</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2> *<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Kenneth Bate</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>June&nbsp;2, 2015</FONT></TD>
<TD VALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="43%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> *By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;JILL C. MILNE, PH.D.<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne, Ph.D.,<BR></FONT> <FONT SIZE=2><I> Attorney-in-fact </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=210,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=364000,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]JC15201A.;29',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je15201_exhibit_index"> </A>
<A NAME="toc_je15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Underwriting Agreement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Third Amended and Restated Certificate of Incorporation of the Registrant</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Bylaws of the Registrant</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Amended and Restated Bylaws of the Registrant (to be effective upon the closing of this offering)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Specimen stock certificate evidencing the shares of common stock</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Opinion of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Second Amended and Restated Investors' Rights Agreement, dated as of March&nbsp;17, 2015, among the Registrant and the other parties thereto</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on August&nbsp;27, 2014 by the Registrant to Square&nbsp;1 Bank</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Warrant to purchase shares of Series&nbsp;B Preferred Stock issued on August&nbsp;27, 2014 by the Registrant to Midcap Financial SBIC,&nbsp;L.P.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated 2008 Equity Incentive Plan, as amended</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Incentive Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Nonstatutory Stock Option Agreement under Amended and Restated 2008 Equity Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2015 Stock Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Incentive Stock Option Agreement under 2015 Stock Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Employment Agreement, dated as of April&nbsp;7, 2010, by and between the Registrant and Jill C. Milne, as amended</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Employment Agreement, dated as of April&nbsp;7, 2010, by and between the Registrant and Michael Jirousek</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated as of October&nbsp;21, 2013, by and between the Registrant and Ian C. Sanderson</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Director and Officer Indemnification Agreement by and between the Registrant and each of Jill C. Milne, Ian C. Sanderson, Michael Jirousek, Joanne M. Donovan, Rick&nbsp;Modi, Michael Ross, Nicholas Galakatos, Jean
George, Ron Laufer and Kenneth Bate</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Credit and Security Agreement, dated as of August&nbsp;27, 2014, by and among the Registrant, Midcap Financial SBIC,&nbsp;L.P., Square 1 Bank and the other lenders identified therein, as amended on March 31,
2015</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Indenture of Lease, dated as of December&nbsp;17, 2010, by and between the Registrant and RB Kendall Fee,&nbsp;LLC, as amended</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Summary of Non-employee Director Compensation Program</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=211,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=106343,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]JE15201A.;25',USER='CHE108062',CD=';2-JUN-2015;02:10' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg15201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Description of Exhibit </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> 10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Common Stock Warrant</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated as of January 22, 2015, by and between the Registrant and Rick Modi</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Warrant to purchase shares of Series B Preferred Stock issued on March 31, 2015 to Square 1 Bank</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Warrant to purchase shares of Series B Preferred Stock issued on March 31, 2015 to Midcap Financial Trust</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Warrant to purchase shares of Series B Preferred Stock issued on March 31, 2015 to Flexpoint MCLS Holdings, LLC</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2015 Employee Stock Purchase Plan</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Letter Agreement, dated May&nbsp;15, 2015, by and between the Registrant and Michael Jirousek</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP (included in Exhibit&nbsp;5.1)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>+</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Power of Attorney (included on signature page)</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
be filed by amendment.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Previously
Filed

</FONT></DD>

</DL>
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=212,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=55816,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]JE15201A.;25',USER='CHE108062',CD=';2-JUN-2015;02:10' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>a2224803zex-10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.7</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015 STOCK INCENTIVE PLAN</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Purpose</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The purpose of this 2015 Stock Incentive Plan (the &#147;<b><i style="font-weight:bold;">Plan</i></b>&#148;) of Catabasis Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the &#147;<b><i style="font-weight:bold;">Company</i></b>&#148;), is to advance the interests of the Company&#146;s stockholders by enhancing the Company&#146;s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company&#146;s stockholders.&#160; Except where the context otherwise requires, the term &#147;<b><i style="font-weight:bold;">Company</i></b>&#148; shall include any of the Company&#146;s present or future parent or subsidiary corporations as defined in Sections 424(e)&nbsp;or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the &#147;<b><i style="font-weight:bold;">Code</i></b>&#148;) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the &#147;<b><i style="font-weight:bold;">Board</i></b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Eligibility</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of the Company&#146;s employees, officers and directors, as well as consultants and advisors to the Company (as such terms are defined and interpreted for purposes of Form&nbsp;S-8 under the Securities Act of 1933, as amended (the &#147;<b><i style="font-weight:bold;">Securities Act</i></b>&#148;), or any successor form) are eligible to be granted Awards under the Plan.&#160; Each person who is granted an Award under the Plan is deemed a &#147;<b><i style="font-weight:bold;">Participant</i></b>.&#148;&#160; &#147;<b><i style="font-weight:bold;">Award</i></b>&#148; means Options (as defined in Section&nbsp;5), SARs (as defined in Section&nbsp;6), Restricted Stock (as defined in Section&nbsp;7), Restricted Stock Units (as defined in Section&nbsp;7) and Other Stock-Based Awards (as defined in Section&nbsp;8).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Administration and Delegation</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Administration by Board of Directors</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan will be administered by the Board.&#160; The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable.&#160; The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan.&#160; The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency.&#160; All decisions by the Board shall be made in the Board&#146;s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Appointment of Committees</font></u><font size="2" style="font-size:10.0pt;">.&#160; To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#147;<b><i style="font-weight:bold;">Committee</i></b>&#148;).&#160; All references in the Plan to the &#147;<b><i style="font-weight:bold;">Board</i></b>&#148; shall mean the Board or a Committee of the Board or the officers referred to in Section&nbsp;3(c)&nbsp;to the extent that the Board&#146;s powers or authority under the Plan have been delegated to such Committee or officers.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=702706,FOLIO='',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Delegation to Officers</font></u><font size="2" style="font-size:10.0pt;">.&#160; To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to grant Options and other Awards that constitute rights under Delaware law (subject to any limitations under the Plan) to employees or officers of the Company and to exercise such other powers under the Plan as the Board may determine, <i>provided</i> that the Board shall fix the terms of such Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject to such Awards that the officers may grant; <i>provided further</i>, however, that no officer shall be authorized to grant such Awards to any &#147;executive officer&#148; of the Company (as defined by Rule&nbsp;3b-7 under the Securities Exchange Act of 1934, as amended (the &#147;<b><i style="font-weight:bold;">Exchange Act</i></b>&#148;)) or to any &#147;officer&#148; of the Company (as defined by Rule&nbsp;16a-1 under the Exchange Act).&#160; The Board may not delegate authority under this Section&nbsp;3(c)&nbsp;to grant Restricted Stock, unless Delaware law then permits such delegation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Stock Available for Awards</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Number of Shares; Share Counting</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Authorized Number of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to adjustment under Section&nbsp;9, Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options, as defined in Section&nbsp;5(b)) for up to such number of shares of common stock, $0.001 par value per share, of the Company (the &#147;<b><i style="font-weight:bold;">Common Stock</i></b>&#148;) as is equal to the sum of:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">13,727,495 shares of Common Stock; plus</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">such additional number of shares of Common Stock (up to 331,922 shares) as is equal to the sum of (x)&nbsp;the number of shares of Common Stock reserved for issuance under the Company&#146;s 2008 Equity Incentive Plan (the &#147;<b><i style="font-weight:bold;">Existing Plan</i></b>&#148;) that remain available for grant under the Existing Plan immediately prior to the closing of the Company&#146;s initial public offering and (y)&nbsp;the number of shares of Common Stock subject to awards granted under the Existing Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the Code); plus</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2016 and continuing for each fiscal year until, and including, the fiscal year ending December&nbsp;31, 2025, equal to the least of (i)&nbsp;16,670,752 shares of Common Stock, (ii)&nbsp;4% of the outstanding shares on such date and (iii)&nbsp;an amount determined by the Board.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Share Counting</font></u><font size="2" style="font-size:10.0pt;">.&#160; For purposes of counting the number of shares available for the grant of Awards under the Plan:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="26552-2-LV_PB_2_155809_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=504748,FOLIO='2',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">all shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan;&#160; <i>provided, however</i>, that (i)&nbsp;SARs that may be settled only in cash shall not be so counted and (ii)&nbsp;if the Company grants an SAR in tandem with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a &#147;<b><i style="font-weight:bold;">Tandem SAR</i></b>&#148;), only the shares covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other&#146;s exercise will not restore shares to the Plan;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">if any Award (i)&nbsp;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii)&nbsp;results in any Common Stock not being issued (including as a result of an SAR that was settleable either in cash or in stock actually being settled in cash), the unused Common Stock covered by such Award shall again be available for the grant of Awards; <i>provided, however</i>, that (1)&nbsp;in the case of Incentive Stock Options, the foregoing shall be subject to any limitations under the Code, (2)&nbsp;in the case of the exercise of an SAR, the number of shares counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3)&nbsp;the shares covered by a Tandem SAR shall not again become available for grant upon the expiration or termination of such Tandem SAR; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">shares of Common Stock delivered (by actual delivery, attestation, or net exercise) to the Company by a Participant to (i)&nbsp;purchase shares of Common Stock upon the exercise of an Award or (ii)&nbsp;satisfy tax withholding obligations (including shares retained from the Award creating the tax obligation) shall be added back to the number of shares available for the future grant of Awards.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Substitute Awards</font></u><font size="2" style="font-size:10.0pt;">.&#160; In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof.&#160; Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan.&#160; Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4(a)(1), except as may be required by reason of Section&nbsp;422 and related provisions of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Stock Options</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may grant options to purchase Common Stock (each, an &#147;<b><i style="font-weight:bold;">Option</i></b>&#148;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Incentive Stock Options</font></u><font size="2" style="font-size:10.0pt;">.&#160; An Option that the Board intends to be an &#147;incentive stock option&#148; as defined in Section&nbsp;422 of the Code (an &#147;<b><i style="font-weight:bold;">Incentive Stock Option</i></b>&#148;) shall only be</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="26552-2-LV_PB_3_155821_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=335464,FOLIO='3',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">granted to employees of Catabasis Pharmaceuticals,&nbsp;Inc., any of Catabasis Pharmaceuticals,&nbsp;Inc.&#146;s present or future parent or subsidiary corporations as defined in Sections 424(e)&nbsp;or (f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code.&#160; An Option that is not intended to be an Incentive Stock Option shall be designated a &#147;<b><i style="font-weight:bold;">Nonstatutory Stock Option</i></b>.&#148;&#160; The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise Price</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board shall establish the exercise price of each Option and specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the fair market value per share of Common Stock as determined by (or in a manner approved by) the Board (&#147;<b><i style="font-weight:bold;">Fair Market Value</i></b>&#148;) on the date the Option is granted; <i>provided</i> that if the Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Duration of Options</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable option agreement; <i>provided, however</i>, that no Option will be granted with a term in excess of 10 years.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise of Options</font></u><font size="2" style="font-size:10.0pt;">.&#160; Options may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section&nbsp;5(f)) of the exercise price for the number of shares for which the Option is exercised.&#160; Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Payment Upon Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">in cash or by check, payable to the order of the Company;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i)&nbsp;delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&nbsp;such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="26552-2-LV_PB_4_155834_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=208138,FOLIO='4',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion, by delivery of a notice of &#147;net exercise&#148; to the Company, as a result of which the Participant would receive (i)&nbsp;the number of shares underlying the portion of the Option being exercised, less (ii)&nbsp;such number of shares as is equal to (A)&nbsp;the aggregate exercise price for the portion of the Option being exercised divided by (B)&nbsp;the Fair Market Value on the date of exercise;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">to the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by payment of such other lawful consideration as the Board may determine; or</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">by any combination of the above permitted forms of payment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitation on Repricing</font></u><font size="2" style="font-size:10.0pt;">. Unless such action is approved by the Company&#146;s stockholders, the Company may not (except as provided for under Section&nbsp;9):&#160; (1)&nbsp;amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option, (2)&nbsp;cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled option, (3)&nbsp;cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the then-current Fair Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a &#147;repricing&#148; within the meaning of the rules&nbsp;of the NASDAQ Stock Market (&#147;<b><i style="font-weight:bold;">NASDAQ</i></b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Stock Appreciation Rights</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may grant Awards consisting of stock appreciation rights (&#147;<b><i style="font-weight:bold;">SARs</i></b>&#148;) entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to Section&nbsp;6(b).&#160; The date as of which such appreciation is determined shall be the exercise date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Measurement Price</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement.&#160; The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; <i>provided</i> that if the Board approves the grant of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair Market Value on such future date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Duration of SARs</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; <i>provided, however</i>, that no SAR will be granted with a term in excess of 10 years.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise of SARs</font></u><font size="2" style="font-size:10.0pt;">.&#160; SARs may be exercised by delivery to the Company of a notice of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="26552-2-LV_PB_5_155845_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=816405,FOLIO='5',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitation on Repricing</font></u><font size="2" style="font-size:10.0pt;">. Unless such action is approved by the Company&#146;s stockholders, the Company may not (except as provided for under Section&nbsp;9):&#160; (1)&nbsp;amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower than the then-current measurement price per share of such outstanding SAR, (2)&nbsp;cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower than the then-current measurement price per share of the cancelled SAR, (3)&nbsp;cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current Fair Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a &#147;repricing&#148; within the meaning of the rules&nbsp;of NASDAQ.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Restricted Stock; Restricted Stock Units</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may grant Awards entitling recipients to acquire shares of Common Stock (&#147;<b><i style="font-weight:bold;">Restricted Stock</i></b>&#148;), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award.&#160; The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be delivered at the time such Award vests (&#147;<b><i style="font-weight:bold;">Restricted Stock Units</i></b>&#148;) (Restricted Stock and Restricted Stock Units are each referred to herein as a &#147;<b><i style="font-weight:bold;">Restricted Stock Award</i></b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Terms and Conditions for All Restricted Stock Awards</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Additional Provisions Relating to Restricted Stock</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Dividends</font></u><font size="2" style="font-size:10.0pt;">.&#160; Unless otherwise provided in the applicable Award agreement, any dividends (whether paid in cash, stock or property) declared and paid by the Company with respect to shares of Restricted Stock (&#147;<b><i style="font-weight:bold;">Accrued Dividends</i></b>&#148;) shall be paid to the Participant only if and when such shares become free from the restrictions on transferability and forfeitability that apply to such shares.&#160; Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Stock Certificates</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee).&#160; At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to his or her Designated Beneficiary.&#160; &#147;<b><i style="font-weight:bold;">Designated Beneficiary</i></b>&#148; means (i)&nbsp;the beneficiary designated, in a</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="26552-2-LV_PB_6_155856_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=958096,FOLIO='6',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant&#146;s death or (ii)&nbsp;in the absence of an effective designation by a Participant, the Participant&#146;s estate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Additional Provisions Relating to Restricted Stock Units</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Settlement</font></u><font size="2" style="font-size:10.0pt;">.&#160; Upon the vesting of and/or lapsing of any other restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company such number of shares of Common Stock or (if so provided in the applicable Award agreement) an amount of cash equal to the Fair Market Value of such number of shares of Common Stock as are set forth in the applicable Restricted Stock Unit agreement.&#160; The Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section&nbsp;409A of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Voting Rights</font></u><font size="2" style="font-size:10.0pt;">.&#160; A Participant shall have no voting rights with respect to any Restricted Stock Units.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Dividend Equivalents</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Award agreement for Restricted Stock Units may provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (&#147;<b><i style="font-weight:bold;">Dividend Equivalents</i></b>&#148;).&#160; Dividend Equivalents may be settled in cash and/or shares of Common Stock and shall be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid, in each case to the extent provided in the Award agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Other Stock-Based Awards</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General</font></u><font size="2" style="font-size:10.0pt;">.&#160; Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (&#147;<b><i style="font-weight:bold;">Other Stock-Based-Awards</i></b>&#148;).&#160; Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled.&#160; Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Terms and Conditions</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Adjustments for Changes in Common Stock and Certain Other Events</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Changes in Capitalization</font></u><font size="2" style="font-size:10.0pt;">.&#160; In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under the Plan, (ii)&nbsp;the share counting rules&nbsp;set forth in Section&nbsp;4(a), (iii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iv)&nbsp;the share and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="26552-2-LV_PB_7_155910_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=972738,FOLIO='7',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">per-share provisions and the measurement price of each outstanding SAR, (v)&nbsp;the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi)&nbsp;the share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board.&#160; Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Reorganization Events</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Definition</font></u><font size="2" style="font-size:10.0pt;">.&#160; A &#147;<b><i style="font-weight:bold;">Reorganization Event</i></b>&#148; shall mean:&#160; (a)&nbsp;any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Consequences of a Reorganization Event on Awards Other than Restricted Stock</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(A)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant):&#160; (i)&nbsp;provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii)&nbsp;upon written notice to a Participant, provide that all of the Participant&#146;s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice, (iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#147;<b><i style="font-weight:bold;">Acquisition Price</i></b>&#148;), make or provide for a cash payment to Participants with respect to each Award held by a Participant equal to (A)&nbsp;the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B)&nbsp;the excess, if any, of (I)&nbsp;the Acquisition Price over (II)&nbsp;the exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="26552-2-LV_PB_8_155919_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=46707,FOLIO='8',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi)&nbsp;any combination of the foregoing.&#160; In taking any of the actions permitted under this Section&nbsp;9(b)(2), the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(B)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding the terms of Section&nbsp;9(b)(2)(A), in the case of outstanding Restricted Stock Units that are subject to Section&nbsp;409A of the Code: (i)&nbsp;if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a &#147;change in control event&#148; within the meaning of Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a &#147;change in control event&#148;, then no assumption or substitution shall be permitted pursuant to Section&nbsp;9(b)(2)(A)(i)&nbsp;and the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii)&nbsp;the Board may only undertake the actions set forth in clauses (iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;9(b)(2)(A)&nbsp;if the Reorganization Event constitutes a &#147;change in control event&#148; as defined under Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i)&nbsp;and such action is permitted or required by Section&nbsp;409A of the Code; if the Reorganization Event is not a &#147;change in control event&#148; as so defined or such action is not permitted or required by Section&nbsp;409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i)&nbsp;of Section&nbsp;9(b)(2)(A), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in exchange therefor.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(C)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">For purposes of Section&nbsp;9(b)(2)(A)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); <i>provided, however</i>, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Consequences of a Reorganization Event on Restricted Stock</font></u><font size="2" style="font-size:10.0pt;">.&#160; Upon the occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company&#146;s successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="26552-2-LV_PB_9_155930_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=282462,FOLIO='9',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to the same extent as they applied to such Restricted Stock; <i>provided</i>, <i>however</i>, that the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment.&#160; Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General Provisions Applicable to Awards</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transferability of Awards</font></u><font size="2" style="font-size:10.0pt;">.&#160; Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; <i>provided, however</i>, that the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member, family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form&nbsp;S-8 under the Securities Act for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; <i>provided further</i>, that the Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award.&#160; References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.&#160; For the avoidance of doubt, nothing contained in this Section&nbsp;10(a)&nbsp;shall be deemed to restrict a transfer to the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Documentation</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine.&#160; Each Award may contain terms and conditions in addition to those set forth in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Board Discretion</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as otherwise provided by the Plan, each Award may be made alone or in addition or in relation to any other Award.&#160; The terms of each Award need not be identical, and the Board need not treat Participants uniformly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination of Status</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board shall determine the effect on an Award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant&#146;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withholding</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Participant must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award.&#160; The Company may decide to satisfy the withholding obligations through additional withholding on</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="26552-2-LV_PB_10_155943_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=1040517,FOLIO='10',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">salary or wages.&#160; If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations.&#160; Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise.&#160; If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; <i>provided, however</i>, except as otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company&#146;s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income).&#160; Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment of Award</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as otherwise provided in Sections 5(g)&nbsp;and 6(e)&nbsp;with respect to repricings and Section&nbsp;11(d)&nbsp;with respect to actions requiring stockholder approval, the Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option.&#160; The Participant&#146;s consent to such action shall be required unless (i)&nbsp;the Board determines that the action, taking into account any related action, does not materially and adversely affect the Participant&#146;s rights under the Plan or (ii)&nbsp;the change is permitted under Section&nbsp;9.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Conditions on Delivery of Stock</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules&nbsp;and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules&nbsp;or regulations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Acceleration</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Miscellaneous</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Right To Employment or Other Status</font></u><font size="2" style="font-size:10.0pt;">.&#160; No person shall have any claim or right to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company.&#160; The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="26552-2-LV_PB_11_155955_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=1011353,FOLIO='11',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Plan, except as expressly provided in the applicable Award.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">No Rights As Stockholder</font></u><font size="2" style="font-size:10.0pt;">.&#160; Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effective Date and Term of Plan</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall become effective immediately prior to the effectiveness of the Company&#146;s initial public offering (the &#147;<b><i style="font-weight:bold;">Effective Date</i></b>&#148;).&#160; No Awards shall be granted under the Plan after the expiration of 10 years from the Effective Date, but Awards previously granted may extend beyond that date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment of Plan</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may amend, suspend or terminate the Plan or any portion thereof at any time provided that (i)&nbsp;to the extent required by Section&nbsp;162(m)&nbsp;of the Code, no Award granted to a Participant that is intended to comply with Section&nbsp;162(m)&nbsp;of the Code after the date of such amendment shall become exercisable, realizable or vested, as applicable to such Award, unless and until the Company&#146;s stockholders approve such amendment in the manner required by Section&nbsp;162(m)&nbsp;of the Code; and (ii)&nbsp;no amendment that would require stockholder approval under the rules&nbsp;of NASDAQ may be made effective unless and until the Company&#146;s stockholders approve such amendment;.&#160; In addition, if at any time the approval of the Company&#146;s stockholders is required as to any other modification or amendment under Section&nbsp;422 of the Code or any successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval.&#160; Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section&nbsp;11(d)&nbsp;shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the Plan.&#160; No Award shall be made that is conditioned upon stockholder approval of any amendment to the Plan unless the Award provides that (i)&nbsp;it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no more than 12 months from the date of grant and (2)&nbsp;it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Authorization of Sub-Plans (including for Grants to non-U.S. Employees)</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions.&#160; The Board shall establish such sub-plans by adopting supplements to the Plan containing (i)&nbsp;such limitations on the Board&#146;s discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable.&#160; All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Compliance with Section&nbsp;409A of the Code</font></u><font size="2" style="font-size:10.0pt;">. Except as provided in individual Award agreements initially or by amendment, if and to the extent (i)&nbsp;any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="26552-2-LV_PB_12_160005_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=178445,FOLIO='12',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">his or her employment termination constitutes &#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code and (ii)&nbsp;the Participant is a specified employee as defined in Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of &#147;separation from service&#148; (as determined under Section&nbsp;409A of the Code) (the &#147;<b><i style="font-weight:bold;">New Payment Date</i></b>&#148;), except as Section&nbsp;409A of the Code may then permit.&#160; The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code but do not to satisfy the conditions of that section.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Limitations on Liability</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his or her capacity as a director, officer, employee or agent of the Company.&#160; The Company will indemnify and hold harmless each director, officer, employee or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Board&#146;s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person&#146;s own fraud or bad faith.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">.&#160; The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="26552-2-LV_PB_13_160015_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="2",CHK=385996,FOLIO='13',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LV_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:22 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>a2224803zex-10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.8</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">INCENTIVE STOCK OPTION AGREEMENT</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis Pharmceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) hereby grants the following stock option pursuant to its 2015 Stock Incentive Plan.&#160; The terms and conditions attached hereto are also a part hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notice of Grant</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name   of optionee (the &#147;<u>Participant</u>&#148;):</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant   Date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number   of shares of the Company&#146;s Common Stock subject to this option (&#147;<u>Shares</u>&#148;):</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option   exercise price per Share:(1)</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number,   if any, of Shares that vest immediately on the grant date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares   that are subject to vesting schedule:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting   Start Date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Final   Exercise Date: (2)</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS   PHARMACEUTICALS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature   of Participant</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Street   Address</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name   of Officer</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City/State/Zip   Code</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">This must be at least 100% of the fair market value of the Common Stock on the date of grant (or 110% in the case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a &#147;10% Shareholder&#148;)) for the option to qualify as an incentive stock option (an &#147;ISO&#148;) under Section&nbsp;422 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date of grant for the option to qualify as an ISO.&#160; The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10% stockholder).&#160; For example, an award granted to someone on April&nbsp;1, 2015 would expire on March&nbsp;31, 2025 (not on April&nbsp;1, 2025).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="3",CHK=974962,FOLIO='',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LW_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incentive Stock Option Agreement</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated Terms and Conditions</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Grant of Option</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This agreement evidences the grant by the Company, on the grant date (the &#147;<u>Grant Date</u>&#148;) set forth in the Notice of Grant that forms part of this agreement (the &#147;<u>Notice of Grant</u>&#148;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#146;s 2015 Stock Incentive Plan (the &#147;<u>Plan</u>&#148;), the number of Shares set forth in the Notice of Grant of common stock, $0.001 par value per share, of the Company (&#147;<u>Common Stock</u>&#148;), at the exercise price per Share set forth in the Notice of Grant.&#160; Unless earlier terminated, this option shall expire at 5:00&nbsp;p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the &#147;<u>Final Exercise Date</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is intended that the option evidenced by this agreement shall be an incentive stock option as defined in Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;<u>Code</u>&#148;) to the maximum extent permitted by law.&#160; Except as otherwise indicated by the context, the term &#147;<u>Participant</u>&#148;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Vesting Schedule</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option will become exercisable (&#147;<u>vest</u>&#148;) in accordance with the vesting schedule set forth in the Notice of Grant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section&nbsp;3 hereof or the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise of Option</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Form&nbsp;of Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as <u>Annex A</u>, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the Plan.&#160; The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Continuous Relationship with the Company Required</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as otherwise provided in this Section&nbsp;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="26552-2-LW_PB_2_160640_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="3",CHK=576078,FOLIO='2',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LW_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#147;<u>Eligible Participant</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination of Relationship with the Company</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs&nbsp;(d)&nbsp;and (e)&nbsp;below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), <u>provided</u>  <u>that</u> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.&#160; Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise Period Upon Death or Disability</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3)&nbsp;of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#147;cause&#148; as specified in paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <u>provided</u>  <u>that</u> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination for Cause</font></u><font size="2" style="font-size:10.0pt;">.&#160; If, prior to the Final Exercise Date, the Participant&#146;s employment is terminated by the Company for Cause (as defined in the Plan), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Tax Matters</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withholding</font></u><font size="2" style="font-size:10.0pt;">.&#160; No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Disqualifying Disposition</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transfer Restrictions.</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="26552-2-LW_PB_3_160656_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="3",CHK=775429,FOLIO='3',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LW_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Provisions of the Plan</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="26552-2-LW_PB_4_160706_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="3",CHK=287836,FOLIO='4',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LW_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">ANNEX A</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock Option Exercise Notice</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis Pharmaceuticals,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Kendall Square</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Bldg. 1400E, Suite&nbsp;B14202</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cambridge, MA 02139</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Sir or Madam:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;<u>Participant</u>&#148;), hereby irrevocably exercise the right to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of the Common Stock, $0.001 par value per share (the &#147;<u>Shares</u>&#148;), of Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) at $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share pursuant to the Company&#146;s 2015 Stock Incentive Plan and a stock option agreement with the Company dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<u>Option Agreement</u>&#148;).&#160; Enclosed herewith is a payment of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the aggregate purchase price for the Shares.&#160; The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print   Name:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name and address of persons in whose name the   Shares are to be jointly registered (if applicable):</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="26552-2-LW_PB_5_161127_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="3",CHK=250869,FOLIO='5',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LW_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>4
<FILENAME>a2224803zex-10_9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.9</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.<br>  <u>NONSTATUTORY STOCK OPTION AGREEMENT</u></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) hereby grants the following stock option pursuant to its 2015 Stock Incentive Plan.&#160; The terms and conditions attached hereto are also a part hereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notice of Grant</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name   of optionee (the &#147;<u>Participant</u>&#148;):</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant   Date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number   of shares of the Company&#146;s Common Stock subject to this option (&#147;<u>Shares</u>&#148;):</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option   exercise price per Share:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Number,   if any, of Shares that vest immediately on the grant date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares   that are subject to vesting schedule:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting   Start Date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Final   Exercise Date:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS   PHARMACEUTICALS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature   of Participant</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Street   Address</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name   of Officer</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">City/State/Zip   Code</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.44%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="4",CHK=656665,FOLIO='',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LX_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nonstatutory Stock Option Agreement</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated Terms and Conditions</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Grant of Option</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This agreement evidences the grant by the Company, on the grant date (the &#147;<u>Grant Date</u>&#148;) set forth in the Notice of Grant that forms part of this agreement (the &#147;<u>Notice of Grant</u>&#148;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#146;s 2015 Stock Incentive Plan (the &#147;<u>Plan</u>&#148;), the number of Shares set forth in the Notice of Grant of common stock, $0.001 par value per share, of the Company (&#147;<u>Common Stock</u>&#148;), at the exercise price per Share set forth in the Notice of Grant.&#160; Unless earlier terminated, this option shall expire at 5:00&nbsp;p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the &#147;<u>Final Exercise Date</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">It is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#147;<u>Code</u>&#148;).&#160; Except as otherwise indicated by the context, the term &#147;<u>Participant</u>&#148;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Vesting Schedule</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option will become exercisable (&#147;<u>vest</u>&#148;) in accordance with the vesting schedule set forth in the Notice of Grant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section&nbsp;3 hereof or the Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise of Option</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Form&nbsp;of Exercise</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as <u>Annex A</u>, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the Plan.&#160; The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Continuous Relationship with the Company Required</font></u><font size="2" style="font-size:10.0pt;">.&#160; Except as otherwise provided in this Section&nbsp;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#147;<u>Eligible Participant</u>&#148;).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="26552-2-LX_PB_2_161946_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="4",CHK=383179,FOLIO='2',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LX_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination of Relationship with the Company</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs&nbsp;(d)&nbsp;and (e)&nbsp;below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), <u>provided</u>  <u>that</u> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise Period Upon Death or Disability</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the Participant dies or becomes disabled (within the meaning of Section&nbsp;22(e)(3)&nbsp;of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for &#147;cause&#148; as specified in paragraph (e)&nbsp;below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), <u>provided</u>  <u>that</u> this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination for Cause</font></u><font size="2" style="font-size:10.0pt;">.&#160; If, prior to the Final Exercise Date, the Participant&#146;s employment or other relationship with the Company is terminated by the Company for Cause (as defined in the Plan), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withholding</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Transfer Restrictions.</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Provisions of the Plan</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="26552-2-LX_PB_3_162001_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="4",CHK=498139,FOLIO='3',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LX_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">ANNEX A</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock Option Exercise Notice</font></u></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Catabasis Pharmaceuticals,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">One Kendall Square<br> Bldg. 1400E, Suite&nbsp;B14202<br> Cambridge, MA 02139</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Sir or Madam:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;<u>Participant</u>&#148;), hereby irrevocably exercise the right to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of the Common Stock, $0.001 par value per share (the &#147;<u>Shares</u>&#148;), of Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;<u>Company</u>&#148;) at $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share pursuant to the Company&#146;s 2015 Stock Incentive Plan and a stock option agreement with the Company dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<u>Option Agreement</u>&#148;).&#160; Enclosed herewith is a payment of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the aggregate purchase price for the Shares.&#160; The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Print   Name:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Address:</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name and address of persons in whose name the   Shares are to be jointly registered (if applicable):</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="26552-2-LX_PB_4_162156_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="4",CHK=868745,FOLIO='4',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LX_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:46 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>5
<FILENAME>a2224803zex-10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.22</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CATABASIS PHARMACEUTICALS,&nbsp;INC.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2015 EMPLOYEE STOCK PURCHASE PLAN</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The purpose of this Plan is to provide eligible employees of Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) and certain of its subsidiaries with opportunities to purchase shares of the Company&#146;s common stock, $0.001 par value (the &#147;Common Stock&#148;), commencing at such time as the Company&#146;s Board of Directors (the &#147;Board&#148;) shall determine.&#160; Subject to adjustment under Section&nbsp;15 hereof, the number of shares of Common Stock that have been approved for this purpose is the sum of:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">2,343,236 </font><font size="2" style="font-size:10.0pt;">shares of Common Stock; plus</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">an annual increase to be added on the first day of each fiscal year, commencing on January&nbsp;1, 2016 and ending on December&nbsp;31, 2026, equal to the least of (i)&nbsp;4,686,472 shares of Common Stock, (ii)&nbsp;1% of the outstanding shares on such date and (iii)&nbsp;an amount determined by the Board.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Plan is intended to qualify as an &#147;employee stock purchase plan&#148; as defined in Section&nbsp;423 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and the regulations issued thereunder, and shall be interpreted consistent therewith.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Administration</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan will be administered by the Board or by a Committee appointed by the Board (the &#147;Committee&#148;).&#160; The Board or the Committee has authority to make rules&nbsp;and regulations for the administration of the Plan and its interpretation and decisions with regard thereto shall be final and conclusive.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Eligibility</font></u><font size="2" style="font-size:10.0pt;">.&#160; All employees of the Company and all employees of any subsidiary of the Company (as defined in Section&nbsp;424(f)&nbsp;of the Code) designated by the Board or the Committee from time to time (a &#147;Designated Subsidiary&#148;), are eligible to participate in any one or more of the offerings of Options (as defined in Section&nbsp;9) to purchase Common Stock under the Plan provided that:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they are customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and for more than five months in a calendar year;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they have been employed by the Company or a Designated Subsidiary for at least six (6)&nbsp;months prior to enrolling in the Plan; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">they are employees of the Company or a Designated Subsidiary on the first day of the applicable Plan Period (as&nbsp;defined below).</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No employee may be granted an Option hereunder if such employee, immediately after the Option is granted, owns 5% or more&nbsp;of the total combined voting power or value of the stock of&nbsp;the Company or any subsidiary.&#160; For purposes of the preceding sentence, the attribution rules&nbsp;of Section&nbsp;424(d)&nbsp;of the Code shall apply in determining the stock ownership of an employee,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="26552-2-LZ_PB_1_162435_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=706072,FOLIO='1',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and all stock that the employee has a contractual right to purchase shall be treated as stock owned by the employee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company retains the discretion to determine which eligible employees may participate in an offering pursuant to and consistent with Treasury Regulation Sections 1.423-2(e)&nbsp;and (f).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Offerings</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company will make one or more offerings (&#147;Offerings&#148;) to employees to purchase stock under this Plan.&#160; Offerings will begin at such time as the Board shall determine.&#160; Each Offering will consist of a six-month period (a &#147;Plan Period&#148;) during which payroll deductions will be made and held for the purchase of Common Stock at the end of the Plan Period.&#160; The Board or the Committee may, at its discretion, choose a different Plan Period of not more than twelve&nbsp;(12) months for subsequent Offerings.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Participation</font></u><font size="2" style="font-size:10.0pt;">.&#160; An employee eligible on the first day of any Plan Period of any Offering may participate in such Offering by completing and forwarding either a written or electronic payroll deduction authorization form to the employee&#146;s appropriate payroll office at least 15&nbsp;days prior to the commencement of the applicable Plan Period.&#160; The&nbsp;form will authorize a regular payroll deduction from the Compensation received by the employee during the Plan Period.&#160; Unless an employee files a new form or withdraws from the Plan, his or her deductions and purchases will continue at the same rate for future Offerings under the Plan as long as the Plan remains in effect.&#160; The term &#147;Compensation&#148; means the amount of money reportable on the employee&#146;s Federal Income Tax Withholding Statement, excluding overtime, shift premium, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances for travel expenses, income or gains associated with the grant or vesting of restricted stock, income or gains on the exercise of Company stock options or stock appreciation rights, and similar items, whether or not shown or separately identified on the employee&#146;s Federal Income Tax Withholding Statement but including, in the case of salespersons, sales commissions to the extent determined by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Deductions</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company will maintain payroll deduction accounts for all participating employees.&#160; With respect to any Offering made under this Plan, an employee may authorize a payroll deduction in any percentage amount up to a maximum of 15% (in whole percentages) of the Compensation he or she receives during the Plan Period or such shorter period during which deductions from payroll are made.&#160; The Board or the Committee may, at its discretion, designate a lower maximum contribution rate.&#160; The minimum payroll deduction is such percentage of Compensation as may be established from time to time by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Deduction Changes</font></u><font size="2" style="font-size:10.0pt;">.&#160; An employee may decrease or discontinue his or her payroll deduction once during any Plan Period, by&nbsp;filing either a written or electronic new payroll deduction authorization form.&#160; However, an&nbsp;employee may not increase his or her payroll deduction during a Plan Period.&#160; If an employee elects to discontinue his or her payroll deductions during a Plan Period, but does not elect to withdraw his or her funds pursuant to Section&nbsp;8 hereof, funds deducted prior to his election to discontinue will be applied to the purchase of Common Stock on the Exercise Date (as defined below).</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="26552-2-LZ_PB_2_162445_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=556616,FOLIO='2',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Interest</font></u><font size="2" style="font-size:10.0pt;">.&#160; Interest will not be paid on any employee accounts, except to the extent that the Board or the Committee, in&nbsp;its sole discretion, elects to credit employee accounts with interest at such rate as it may from time to time determine.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withdrawal of Funds</font></u><font size="2" style="font-size:10.0pt;">.&#160; An employee may at any time prior to the close of business on the fifteenth business day prior to the end of a Plan Period and for any reason permanently draw out the balance accumulated in the employee&#146;s account and thereby withdraw from participation in an Offering.&#160; Partial withdrawals are not permitted.&#160; The employee may not begin participation again during the remainder of the Plan Period during which the employee withdrew his or her balance.&#160; The employee may participate in any subsequent Offering in accordance with terms and conditions established by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Purchase of Shares</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Number of Shares</font></u><font size="2" style="font-size:10.0pt;">.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">On the first day of each Plan Period, the Company will grant to each eligible employee who is then a participant in the Plan an option (an &#147;Option&#148;) to purchase on the last business day of such Plan Period (the &#147;Exercise Date&#148;) at the applicable purchase price (the &#147;Option Price&#148;) up to that whole number of shares of Common Stock determined by multiplying $2,083 by the number of full months in the Plan Period and dividing the result by the closing price (as determined below) on the first day of such Plan Period; provided, however, that no employee may be granted an Option which permits his or her rights to purchase Common Stock under this Plan and any other employee stock purchase plan (as defined in Section&nbsp;423(b)&nbsp;of the Code) of the Company and its subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such Common Stock (determined at the date such Option is granted) for each calendar year in which the Option is outstanding at any time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Option Price</font></u><font size="2" style="font-size:10.0pt;">.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Board or the Committee shall determine the Option Price for each Plan Period, including whether such Option Price shall be determined based on the lesser of the closing price of the Common Stock on (i)&nbsp;the first business day of the Plan Period or (ii)&nbsp;the Exercise Date, or shall be based solely on the closing price of the Common Stock on the Exercise Date; provided, however, that such Option Price shall be at least 85% of the applicable closing price.&#160; In the absence of a determination by the Board or the Committee, the Option Price will be 85% of the lesser of the closing price of the Common Stock on (i)&nbsp;the first business day of the Plan Period and (ii)&nbsp;the Exercise Date.&#160; The closing price shall be (a)&nbsp;the closing price (for the primary trading session) on any national securities exchange on which the Common Stock is listed or (b)&nbsp;the average of the closing bid and asked prices in the over-the-counter-market, whichever is applicable, as published in <u>The Wall Street Journal</u> or another source selected by the Board or the Committee.&#160; If no sales of Common Stock were made on such a day, the price of the Common Stock shall be the reported price for the next preceding day on which sales were made.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Exercise of Option</font></u><font size="2" style="font-size:10.0pt;">.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each employee who continues to be a participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option at the Option Price on such date and shall be deemed to have purchased from the Company the number of whole shares of Common Stock reserved for the purpose of the Plan that his or her accumulated payroll deductions on such date will pay for, but not in excess of the maximum numbers determined in the manner set forth above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="26552-2-LZ_PB_3_162456_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=115235,FOLIO='3',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Return of Unused Payroll Deductions</font></u><font size="2" style="font-size:10.0pt;">.&#160; Any balance remaining in an employee&#146;s payroll deduction account at the end of a Plan Period will be automatically refunded to the employee, except that any balance that is less than the purchase price of one share of Common Stock will be carried forward into the employee&#146;s payroll deduction account for the following Offering, unless the employee elects not to participate in the following Offering under the Plan, in which case the balance in the employee&#146;s account shall be refunded.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Issuance of Certificates</font></u><font size="2" style="font-size:10.0pt;">.&#160; Certificates representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or (in the Company&#146;s sole discretion) in the name of a brokerage firm, bank, or other nominee holder designated by the employee.&#160; The Company may, in its sole discretion and in compliance with applicable laws, authorize the use of book entry registration of shares in lieu of issuing stock certificates.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Rights on Retirement, Death or Termination of Employment</font></u><font size="2" style="font-size:10.0pt;">.&#160; If a participating employee&#146;s employment ends before the last business day of a Plan Period, no payroll deduction shall be taken from any pay then due and owing to the employee and the balance in the employee&#146;s account shall be paid to the employee.&#160; In the event of the employee&#146;s death before the last business day of a Plan Period, the Company shall, upon notification of such death, pay the balance of the employee&#146;s account (a)&nbsp;to the executor or administrator of the employee&#146;s estate or (b)&nbsp;if no such executor or administrator has been appointed to the knowledge of the Company, to such other person(s)&nbsp;as the Company may, in its discretion, designate.&#160; If, before the last business day of the Plan Period, the Designated Subsidiary by which an employee is employed ceases to be a subsidiary of the Company, or if the employee is transferred to a&nbsp;subsidiary of the Company that is not a Designated Subsidiary, the employee shall be deemed to have terminated employment for the&nbsp;purposes of this Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Optionees Not Stockholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; Neither the granting of an&nbsp;Option to an employee nor the deductions from his or her pay shall make such employee a stockholder of the shares of Common Stock covered by an Option under this Plan until he or she has purchased and received such shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Options Not Transferable</font></u><font size="2" style="font-size:10.0pt;">.&#160; Options under this Plan are not transferable by a participating employee other than by will or the laws of descent and distribution, and are exercisable during the employee&#146;s lifetime only by the employee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Application of Funds</font></u><font size="2" style="font-size:10.0pt;">.&#160; All funds received or held by the Company under this Plan may be combined with other corporate funds and may be used for any corporate purpose.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Adjustment for Changes in Common Stock and Certain Other Events.</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Changes in Capitalization</font></u><font size="2" style="font-size:10.0pt;">.&#160; In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under this Plan, (ii)&nbsp;the share limitations set forth in Section&nbsp;9, and (iii)&nbsp;the Option</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="26552-2-LZ_PB_4_162506_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=264890,FOLIO='4',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Price shall be equitably adjusted to the extent determined by the Board or the Committee.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Reorganization Events</font></u><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Definition</font></u><font size="2" style="font-size:10.0pt;">.&#160; A &#147;Reorganization Event&#148; shall mean:&#160; (a)&nbsp;any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Consequences of a Reorganization Event on Options</font></u><font size="2" style="font-size:10.0pt;">.&#160; In connection with a Reorganization Event, the Board or the Committee may take any one or more of the following actions as to outstanding Options on such terms as the Board or the Committee determines:&#160; (i)&nbsp;provide that Options shall be assumed, or substantially equivalent Options shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii)&nbsp;upon written notice to employees, provide that all outstanding Options will be terminated immediately prior to the consummation of such Reorganization Event and that all such outstanding Options will become exercisable to the extent of accumulated payroll deductions as of a date specified by the Board or the Committee in such notice, which date shall not be less than ten (10)&nbsp;days preceding the effective date of the Reorganization Event, (iii)&nbsp;upon written notice to employees, provide that all outstanding Options will be cancelled as of a date prior to the effective date of the Reorganization Event and that all accumulated payroll deductions will be returned to participating employees on such date, (iv)&nbsp;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the &#147;Acquisition Price&#148;), change the last day of the Plan Period to be the date of the consummation of the Reorganization Event and make or provide for a cash payment to each employee equal to (A)&nbsp;(1)&nbsp;the Acquisition Price times (2)&nbsp;the number of shares of Common Stock that the employee&#146;s accumulated payroll deductions as of immediately prior to the Reorganization Event could purchase at the Option Price, where the Acquisition Price is treated as the fair market value of the Common Stock on the last day of the applicable Plan Period for purposes of determining the Option Price under Section&nbsp;9(b)&nbsp;hereof, and where the number of shares that could be purchased is subject to the limitations set forth in Section&nbsp;9(a), minus (B)&nbsp;the result of multiplying such number of shares by such Option Price, (v)&nbsp;provide that, in connection with a liquidation or dissolution of the Company, Options shall convert into the right to receive liquidation proceeds (net of the Option Price thereof) and (vi)&nbsp;any combination of the foregoing.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For purposes of clause (i)&nbsp;above, an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="26552-2-LZ_PB_5_162515_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=916983,FOLIO='5',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determines to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment of the Plan</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may at any time, and from time to time, amend or suspend this Plan or any portion thereof, except that (a)&nbsp;if the approval of any such amendment by the shareholders of the Company is required by Section&nbsp;423 of the Code, such amendment shall not be effected without such approval, and (b)&nbsp;in no event may any amendment be made that would cause the Plan to fail to comply with Section&nbsp;423 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Insufficient Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; If the total number of shares of Common Stock specified in elections to be purchased under any Offering plus the number of shares purchased under previous Offerings under this Plan exceeds the maximum number of shares issuable under this Plan, the Board or the Committee will allot the shares then available on a pro-rata basis.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Termination of the Plan</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Plan may be terminated at any time by the Board.&#160; Upon termination of this Plan all amounts in the accounts of participating employees shall be promptly refunded.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governmental Regulations</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company&#146;s obligation to&nbsp;sell and deliver Common Stock under this Plan is subject to listing on a national stock exchange (to the extent the Common Stock is then so listed or quoted) and the approval of all governmental authorities required in connection with the authorization, issuance or sale of such stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall be governed by Delaware law except to the extent that such law is preempted by federal law.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Issuance of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Notification upon Sale of Shares</font></u><font size="2" style="font-size:10.0pt;">.&#160; Each employee agrees, by entering the Plan, to promptly give the Company notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23</font><font size="2" style="font-size:10.0pt;">.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Grants to Employees in Foreign Jurisdictions</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Company may, to comply with the laws of a foreign jurisdiction, grant Options to employees of the Company or a Designated Subsidiary who are citizens or residents of such foreign jurisdiction (without regard to whether they are also citizens of the United States or resident aliens (within the meaning of Section&nbsp;7701(b)(1)(A)&nbsp;of the Code)) with terms that are less favorable (but not more favorable) than the terms of Options granted under the Plan to employees of the Company or a Designated Subsidiary who are resident in the United States.&#160; Notwithstanding the preceding provisions of this Plan, employees of the Company or a Designated Subsidiary who are citizens or residents of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="26552-2-LZ_PB_6_162528_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=828260,FOLIO='6',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a foreign jurisdiction (without regard to whether they are also citizens of the United States or resident aliens (within the meaning of Section&nbsp;7701(b)(1)(A)&nbsp;of the Code)) may be excluded from eligibility under the Plan if (a)&nbsp;the grant of an Option under the Plan to a citizen or resident of the foreign jurisdiction is prohibited under the laws of such jurisdiction or (b)&nbsp;compliance with the laws of the foreign jurisdiction would cause the Plan to violate the requirements of Section&nbsp;423 of the Code.&#160; The Company may add one or more appendices to this Plan describing the operation of the Plan in those foreign jurisdictions in which employees are excluded from participation or granted less favorable Options.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Authorization of Sub-Plans</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Board may from time to time establish one or more sub-plans under the Plan with respect to one or more Designated Subsidiaries, provided that such sub-plan complies with Section&nbsp;423 of the Code.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Withholding</font></u><font size="2" style="font-size:10.0pt;">.&#160; If applicable tax laws impose a tax withholding obligation, each affected employee shall, no later than the date of the event creating the tax liability, make provision satisfactory to the Board for payment of any taxes required by law to be withheld in connection with any transaction related to Options granted to or shares acquired by such employee pursuant to the Plan.&#160; The Company may, to the extent permitted by law, deduct any such taxes from any payment of any kind otherwise due to an employee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Effective Date and Approval of Shareholders</font></u><font size="2" style="font-size:10.0pt;">.&#160; The Plan shall become effective upon the closing of our initial public offering.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="26552-2-LZ_PB_7_162539_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="5",CHK=934678,FOLIO='7',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-LZ_ZDH15202.CHC",USER="DPERRY",CD='May 28 16:26 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>6
<FILENAME>a2224803zex-10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.23</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">One Kendall Square, Suite&nbsp;B14202, Cambridge MA 02139 USA</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;"><font size="2" face="Times New Roman"><img width="290" height="82" src="g265522me01i001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">By Electronic Mail</font></u></b></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">April&nbsp;15, 2015 <b>(as revised May&nbsp;15, 2015 and sent by electronic mail c/o James Conroy,&nbsp;Esq.)</b></font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael R. Jirousek</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">285 Third Street</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Apartment 404</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cambridge, MA 02142</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Michael:</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter confirms our agreement with respect to your transition and separation from employment with Catabasis Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;). Provided that you sign and return this letter agreement to me on or before May&nbsp;18, 2015 and do not revoke your acceptance, and provided further that you sign and return the Additional Release of Claims attached hereto as Attachment A (the &#147;Additional Release&#148;) on your last day of employment, which the Company will provide to you in final form on or before that day, and do not revoke the Additional Release, you will have the opportunity to remain an employee of the Company for a Transition Period pursuant to the terms and conditions set forth in paragraph 1 below, and you will be eligible to receive the Severance Benefits (as defined below) set forth in paragraph 2 below.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By timely signing, returning and not revoking this letter agreement and the Additional Release, you will be entering into binding agreements with the Company and will be agreeing to the terms and conditions set forth herein and therein. Therefore, you are advised to consult with an attorney before signing this letter agreement and the Additional Release, and you are being given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day period after you have signed it by notifying me in writing by the close of the seventh (7</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">) day. You may similarly revoke your acceptance of the Additional Release during the seven (7)&nbsp;day period after you have signed it by notifying me in writing by the close of the seventh (7</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">) day. If you do not so revoke, each of this letter agreement and the Additional Release will become a binding agreement between you and the Company upon the expiration of its respective seven day revocation period.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you choose not to sign and return this letter agreement by May&nbsp;18, 2015, your employment will end effective as of that date, and you will be eligible to receive only those severance benefits set forth in the Amended and Restated Employment Agreement dated as of April&nbsp;7, 2010 between you and the Company (the &#147;Employment Agreement&#148;) (the &#147;Old Benefits&#148;) in accordance with the terms of the Employment Agreement. If you timely sign this letter agreement, but revoke it during the applicable revocation period, your employment will end on the date of any such revocation, and you will be eligible to receive only the Old Benefits in accordance with the terms of the Employment Agreement. In addition, if you timely enter into this letter agreement but your employment is terminated for Cause (as defined below), or if you fail to timely sign and return the Additional Release, and/or you revoke your acceptance of the Additional Release, you will not be eligible to receive any severance benefits from the</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="26552-2-ME-01_PB_1_142531_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=694392,FOLIO='1',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company. Regardless of entering into this letter agreement or the Additional Release, you will receive, within thirty (30) days following the termination of your employment, any base salary earned but not paid through the date of termination and any vacation time accrued but not used to that date, as well as any bonus which may have been earned and specifically awarded to you but not yet paid as of the date of termination of your employment. You will also be reimbursed for any business expenses incurred by you but unreimbursed on the date of termination, provided that you have submitted such expenses and documentation required in accordance with Company policy within sixty (60) days following the date of termination.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following numbered paragraphs set forth our agreement:</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Separation Date; Transition Period, SAB Appointment</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> Except as set forth below, should you timely enter into this letter agreement, your effective date of separation from employment with the Company will be September&nbsp;30, 2015 or such later date as you and the Company may mutually agree upon in writing (as applicable, the &#147;Separation Date&#148;). The period between the date of this letter agreement and the Separation Date will be a transition period (the &#147;Transition Period&#148;), during which you will remain an employee of the Company and retain the title of Chief Scientific Officer, reporting to me, but will no longer supervise the employees who previously reported to you. During the Transition Period, your duties and responsibilities will consist of you using your best efforts to professionally, timely and cooperatively perform such transition duties as may reasonably be requested by and at the direction of the Company (which shall include, but not be limited to, those duties set forth on Attachment B) (collectively, the &#147;Transition Duties&#148;). During the Transition Period you will continue to receive your current salary and to participate in the Company&#146;s benefit plans (pursuant to the terms and conditions of such plans), but you may use reasonable amounts of time during the Company&#146;s regular business hours to search for new employment. During the Transition Period, the Company will also work with you on the timing and contents of a mutually acceptable notice of departure, in which you may convey that you have decided to leave the Company to pursue other interests or opportunities. As of October&nbsp;1, 2015, the Company will appoint you as a member of its Scientific Advisory Board (&#147;SAB&#148;) for a term ending on September&nbsp;30, 2016. Notwithstanding any of the foregoing, however, the Company retains the right to immediately terminate your employment prior to the Separation Date either (1)&nbsp;for &#147;Cause&#148;, which for purposes of this letter agreement shall be defined as (a)&nbsp;a reasonable and good faith determination by the Company that you engaged in fraud or embezzlement, or an act of deliberate gross misconduct that results or resulted in a material adverse effect on the Company, or (b)&nbsp;your conviction or entry of a pleading of guilty or <i>nolo contendere </i>to any crime involving moral turpitude or any felony; or (2)&nbsp;because the Company determines that you have failed to perform your duties during the Transition Period in a professional, timely and cooperative manner, or that it needs to implement cost controls. In the event the Company terminates your employment for Cause or you breach this Agreement by resigning before September&nbsp;30, 2015, you will not be eligible to receive the Severance Benefits, nor will you receive any further salary payments, benefits, or other compensation from the Company following your last day of employment, nor will you be appointed to the SAB. In the event the Company terminates your employment based on its determination that you failed to perform your duties in a professional, timely or cooperative manner, or that it needs to implement cost controls, the Company will treat your termination as involuntary and (x)&nbsp;you will remain eligible to receive the Severance Benefits, but you will not receive any further salary payments, benefits, or other compensation from the Company</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="26552-2-ME-01_PB_2_142538_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=928120,FOLIO='2',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">following your last day of employment, and (y)&nbsp;on or before your last day of employment you will be appointed to the SAB for a term ending on September&nbsp;30, 2016.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Severance Benefits</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> Provided you (a)&nbsp;timely sign, return and do not revoke this letter agreement, and comply with all of its provisions, and (b)&nbsp;timely sign, return, and do not revoke the Additional Release (allowing it to become irrevocable at the end of the seven (7)&nbsp;day revocation period described above), the Company will provide you with the following severance benefits (the &#147;Severance Benefits&#148;):</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)&nbsp;The Company will provide you with severance pay in the form of monthly salary continuation payments at your current base salary rate (less all applicable taxes and withholdings) during the period beginning on the first regular payroll date that occurs fifteen (15) days following the date the Additional Release becomes effective and enforceable (unless delayed as provided in the last paragraph of this Section&nbsp;2) and ending on the date that is the earlier of (x)&nbsp;twelve (12) months thereafter, or (y)&nbsp;sixty (60) days following your commencement of employment substantially similar to your employment by the Company immediately prior to entering this letter agreement (based on responsibility, reporting and compensation)(as applicable, the &#147;Severance Period). You agree that you shall promptly notify the Company of the date of commencement of any new employment should you commence such employment during the Severance Period. For the avoidance of doubt, part time consulting for parties unrelated to the Company will not affect your salary continuation payments.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)&nbsp;The Company will provide you, within fifteen (15) days following the date the Additional Release becomes effective and enforceable (unless delayed as provided in the last paragraph of this Section&nbsp;2), a payment equal to fifty percent (50%) of the average annual bonuses paid to you in the three (3)&nbsp;calendar years preceding the calendar year in which your date of termination occurs, prorated by multiplying such amount by a fraction, the numerator of which is the number of days in the calendar year in which your termination occurs that have elapsed since January&nbsp;1 through such date and the denominator of which is 365. Such payment will be made in one (1)&nbsp;lump sum, less all applicable taxes and withholdings.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;Should you be eligible for and timely elect to continue receiving group health and/or dental insurance coverage under the law known as COBRA, the Company shall, for the period beginning fifteen (15) days following the date the Additional Release becomes effective and enforceable and ending on the earlier of (x)&nbsp;twelve (12) months thereafter, or (y)&nbsp;the date that you become eligible to enroll in the health (or, if applicable, dental) plan of a new employer (as applicable, the &#147;COBRA Contribution Period&#148;), pay on your behalf the full premium cost for such coverage. You agree that you shall promptly notify the Company of the date on which you become eligible to receive coverage from a new employer hereunder.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other than the Severance Benefits, you will not be eligible for, nor shall you have a right to receive, any payments or benefits from the Company following your last day of employment, other than continued vesting of stock options as a member of the SAB. The payment of the Severance Benefits shall be subject to the terms and conditions set forth in Section&nbsp;12 of the Employment Agreement (Compliance with Section&nbsp;409A). The parties agree that your ceasing to be employed at the Separation Date (other than for Cause), your termination by the Company without Cause at that or an earlier date, or your termination as described in the last sentence of</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="26552-2-ME-01_PB_3_142548_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=892342,FOLIO='3',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Section&nbsp;1 would be, under the facts and circumstances, an &#147;involuntary termination&#148; as defined in Section&nbsp;409A.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Employee Release</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> In exchange for the consideration set forth herein, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of its and their respective past and present officers, directors, stockholders, investors, partners, members, managers, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#147;Released Parties&#148;) from any and all claims, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#146; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e <u>et seq.,</u> the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 <u>et seq.,</u> the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 <u>et seq.,</u> the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff <u>et seq.,</u> the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 <u>et seq.,</u> the Worker Adjustment and Retraining Notification Act (&#147;WARN&#148;), 29 U.S.C. &#167; 2101 <u>et seq.,</u> the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 <u>et seq.,</u> Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 <u>et seq.,</u> and the Employee Retirement Income Security Act of 1974 (&#147;ERISA&#148;), 29 U.S.C. &#167; 1001 <u>et seq.,</u> all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, &#167; 1 <u>et seq., </u>the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, &#167; 148 <u>et seq.</u> (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, &#167;&#167; 11H and 11l, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &#167; 102 and Mass. Gen. Laws ch. 214, &#167; 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &#167; 1 <u>et seq.,</u> Mass. Gen. Laws ch. 214, &#167; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &#167; 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &#167; 52D, all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, any claims arising out of or related to the Employment Agreement); all claims to any non-vested ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement prevents you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&#146; fees or other remedial relief in connection with any such claim, charge or proceeding and agree that if any such complaint, charge, or proceeding is filed on your behalf, you shall take all reasonable steps necessary to refuse any damages or individualized relief in connection therewith); and provided further, however, that</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="26552-2-ME-01_PB_4_142559_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=354867,FOLIO='4',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">notwithstanding anything above, nothing in this release affects or releases your rights under or claims related to this letter agreement, nor any future rights you have or may have as a stockholder of the Company or to vested pension or 401(K)&nbsp;benefits, or vested equity rights, or continued vesting of equity rights while you remain an employee of the Company or a member of the SAB. Further, nothing herein shall be construed as a release of any rights or claims you may have under the Company&#146;s certificate of incorporation, by-laws, insurance and/or any indemnification agreement between you and the Company (and/or otherwise under law) for indemnification as an officer of the Company for your service to the Company (recognizing that such indemnification is not guaranteed by this letter agreement and shall be governed by the instrument or law, if any, providing for such indemnification).</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Company Release</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> In consideration of you entering into this letter agreement, the Company hereby fully, forever, irrevocably and unconditionally releases, remises and discharges you from any and all claims, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#146; fees and costs), of every kind and nature that it ever had or now has against you, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company; provided, however, that notwithstanding anything above, nothing in this release (a)&nbsp;releases you from your continuing obligations as set forth in paragraph 5 below, (b)&nbsp;affects or releases the Company&#146;s rights under or claims related to this letter agreement, or (c)&nbsp;releases you from any claims for fraud or embezzlement, or from any civil claims based on any acts and/or omissions that satisfy the elements of a criminal offense, or from any claims arising out of any deliberate misconduct by you that resulted in material injury to the Company (provided, however, that the Company hereby represents that it knows of no such claims).</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Continuing Obligations</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You acknowledge and reaffirm your obligation to keep confidential and not to use or disclose any and all non-public information concerning the Company that you acquired during the course of your employment with the Company, including, but not limited to, any non-public information concerning the Company&#146;s business affairs, business prospects, and financial condition. You further acknowledge and reaffirm your obligations set forth in the Non-Competition and Non-Solicitation Agreement and the Invention and Non-Disclosure Agreement that you previously executed in connection with your employment, which remain in full force and effect. The Company acknowledges that it is solely responsible for determining any need for any regulatory filings or amendments to existing regulatory filings concerning or arising out of the termination of your employment or any other provisions of this letter agreement. Notwithstanding the foregoing, you acknowledge that you have responsibility for compliance with your obligations, if any, as a &#147;reporting person&#148; under Section&nbsp;16 of the Securities Exchange Act of 1934. In the event that Company undertakes and successfully completes an initial public offering of its Common Stock, the Company expects that it will file a registration statement on Form&nbsp;S-8 to register the shares of Common Stock issued to employees upon exercise of stock options and other compensatory awards granted under the Company&#146;s equity compensation plans. You acknowledge that you have entered into a lock-up agreement with certain underwriters and you will remain subject to the terms of that lock-up agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Non-Disparagement</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You understand and agree that, to the extent permitted by law, you will not, in public or private, make any false, disparaging, derogatory or defamatory statements to</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="26552-2-ME-01_PB_5_142608_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=680582,FOLIO='5',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding the Company&#146;s business affairs, business prospects, or financial condition; provided, however, that nothing herein shall be construed as preventing you from making truthful disclosures to any governmental entity or in any litigation or arbitration. The Company agrees that it will instruct Jill Milne,&nbsp;Ian Sanderson, the members of its Board of Directors, and its officers and employees with knowledge of this letter agreement to refrain from, in public or private, making any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the Company about you; provided, however, that nothing herein shall be construed as requiring the Company to instruct any person not to make truthful disclosures to any governmental entity or in any litigation or arbitration.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Return of Property</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You confirm that you will, on the Separation Date or earlier if requested by the Company, return to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones,&nbsp;etc.), Company identification and any other Company-owned property in your possession or control and will leave intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment. You further confirm that you will, on the Separation Date or earlier if requested by the Company, cancel all accounts for your benefit, if any, in the Company&#146;s name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or wireless data accounts and computer accounts.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Cooperation</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> You agree to cooperate fully with the Company, to the extent permitted by law, in the investigation, defense or prosecution of any claims or actions now in existence or that may be brought in the future against the Company by any third party or by or on behalf of the Company against any third party. You agree that your full cooperation in connection with such claims or actions will include being available to meet with the Company&#146;s counsel, at reasonable times and locations designated by the Company, to prepare for discovery, any mediation, arbitration, trial, administrative hearing or other proceeding, and to act as a witness when requested by the Company. You agree that, to the extent permitted by law, you will notify the Company promptly in the event that you are served with a subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company. You shall be entitled to receive reimbursement of all reasonable out of pocket expenses incurred by you in cooperating hereunder, including expenses related to travel and other expenses while away from home, plus an hourly fee in the amount of your currently weekly base salary, divided by forty (40), provided, however, that the Company will not pay you any fee for time spent providing testimony in any arbitration, trial, administrative hearing or other proceeding.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Confidentiality</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You understand and agree that, to the extent permitted by law, the terms and contents of this letter agreement and Additional Release, and the contents of the negotiations and discussions resulting in this letter agreement and Additional Release, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except to the extent agreed to in writing by the Company. The Company likewise agrees that, to the extent permitted by law, the terms and contents of this letter agreement and Additional Release, and</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="26552-2-ME-01_PB_6_142615_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=255153,FOLIO='6',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the contents of the negotiations and discussions resulting in this letter Agreement and Additional Release, shall be maintained as confidential by the Company and its agents and representatives and shall not be disclosed except to the extent agreed to in writing by you or as the Company believes in good faith to be reasonably necessary for a legitimate business purpose.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Amendment</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; This letter agreement and the Additional Release shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto. This letter agreement and the Additional Release are binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Waiver of Rights</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; No delay or omission by you or the Company in exercising any right under this letter agreement or the Additional Release shall operate as a waiver of that or any other right. A waiver or consent given by you or the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Validity</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151; </font></b><font size="2" style="font-size:10.0pt;">Should any provision of this letter agreement or the Additional Release be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement or the Additional Release.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Acknowledgments</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You acknowledge that you have been given at least twenty-one (21) days to consider this letter agreement and the Additional Release, and that the Company is hereby advising you to consult with an attorney of your own choosing prior to signing this letter agreement and the Additional Release. You acknowledge and agree that the changes made to the original April&nbsp;15, 2015 letter agreement and reflected herein were made at your request and that, whether material or immaterial, such changes did not re-start the twenty-one day consideration periods. You understand that you may revoke each of this letter agreement and the Additional Release, respectively, for a period of seven (7)&nbsp;days after signing it by notifying me in writing, and neither this letter agreement nor the Additional Release shall be effective or enforceable until the expiration of its applicable seven (7)&nbsp;day period. You understand and agree that by entering into this letter agreement and the Additional Release you are waiving any and all rights or claims you may have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Nature of Agreement</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; Nothing in this letter agreement or the Additional Release constitutes an admission of liability or wrongdoing on the part of the Company or you.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Voluntary Assent</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; Both parties to this letter agreement affirm that no other promises or agreements of any kind have been made to or with them by any person or entity whatsoever to cause them to sign this letter agreement or the Additional Release, and that they fully understand the meaning and intent of this letter agreement and the Additional Release. The</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="26552-2-ME-01_PB_7_142624_141"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=307891,FOLIO='7',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">parties state and represent that they have had an opportunity to fully discuss and review the terms of this letter agreement and the Additional Release with an attorney. The parties further state and represent that they have carefully read this letter agreement and the Additional Release, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign their names of their own free acts.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Applicable Law</font></u></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;"> &#151;</font></b><font size="2" style="font-size:10.0pt;"> This letter agreement and the Additional Release shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement and the Additional Release, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the Additional Release or the subject matter thereof.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Entire Agreement</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; This letter agreement and the Additional Release, upon its effective date, contain and constitute the entire understanding and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company, and cancel all previous oral and written negotiations, agreements, commitments and writings in connection therewith , including, without limitation, the Employment Agreement, which shall be null and void upon the date this letter agreement becomes effective and enforceable, except as explicitly set forth in paragraph 2 above. Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 5 above or the agreements referenced therein.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Tax Provision</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; In connection with the Severance Benefits to be provided to you pursuant to this letter agreement and the Additional Release, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such Severance Benefits under applicable law, except such taxes for which the Company is directly responsible by law. You acknowledge that you are not relying upon advice or representation of the Company with respect to the tax treatment of the Severance Benefits.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="26552-2-ME-01_PB_8_142631_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=318160,FOLIO='8',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you have any questions about the matters covered in this letter agreement or the Additional Release, please call me.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:49.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Jill C. Milne</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jill   C. Milne</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 266.85pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I hereby agree to the terms and conditions set forth above. I have been given at least twenty-one days to consider this letter agreement and I have chosen to execute this on the date below. I intend that this letter agreement will become a binding agreement if I do not revoke my acceptance within seven (7)&nbsp;days. I further understand that the Severance Benefits referenced in paragraph 2 are conditioned upon my timely execution, return and non-revocation of the Additional Release.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="47%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.08%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font><font size="2" style="font-size:10.0pt;">Michael R. Jirousek</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.92%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><i><font size="2" face="Times New Roman" style="font-size:1.0pt;font-style:italic;">&nbsp;</font></i></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date</font></p>    </td>
<td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">05/18/2015</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael   R. Jirousek</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be returned in a timely manner as set forth on the first page&nbsp;of this letter agreement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="26552-2-ME-01_PB_9_142828_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=241934,FOLIO='9',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-01_ZDH15202.CHC",USER="DPERRY",CD='May 29 14:30 2015' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT A</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADDITIONAL RELEASE OF CLAIMS</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Employee Release</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; In consideration of the Severance Benefits referenced in the letter agreement to which this Additional Release of Claims (the &#147;Additional Release) is attached, which you (Michael R. Jirousek) acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company (Catabasis Pharmaceuticals,&nbsp;Inc.), its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of its and their respective past and present officers, directors, stockholders, investors, partners, members, managers, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#147;Released Parties&#148;) from any and all claims, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#146; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e <u>et seq.,</u> the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 <u>et seq.,</u> the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 <u>et seq.,</u> the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff <u>et seq.,</u> the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 <u>et seq.,</u> the Worker Adjustment and Retraining Notification Act (&#147;WARN&#148;), 29 U.S.C. &#167; 2101 <u>et seq.,</u> the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 <u>et seq.,</u> Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 <u>et seq.,</u> and the Employee Retirement Income Security Act of 1974 (&#147;ERISA&#148;), 29 U.S.C. &#167; 1001 <u>et seq.,</u> all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, &#167; 1 <u>et seq., </u>the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, &#167; 148 <u>et seq.</u> (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, &#167;&#167; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &#167; 102 and Mass. Gen. Laws ch. 214, &#167; 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &#167; 1 <u>et seq.,</u> Mass. Gen. Laws ch. 214, &#167; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &#167; 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &#167; 52D, all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, any claims arising out of or related to the Employment Agreement); all claims to any non-vested ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Additional Release prevents you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding, and you further waive any rights or</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="26552-2-ME-03_PB_10_142623_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=390541,FOLIO='10',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-03_ZDH15202.CHC",USER="DPERRY",CD='May 29 15:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">claims to any payment, benefit, attorneys&#146; fees or other remedial relief in connection with any such claim, charge or proceeding and agree that if any such complaint, charge, or proceeding is filed on your behalf, you shall take all reasonable steps necessary to refuse any damages or individualized relief in connection therewith); and provided further, however, that notwithstanding anything above, nothing in this release affects or releases your rights under or claims related to the letter agreement or this Additional Release, nor any future rights you have or may have as a stockholder of the Company or to vested pension or 401(K)&nbsp;benefits, or vested equity rights, or continued vesting of equity rights while you remain a member of the SAB. Further, nothing herein shall be construed as a release of any rights or claims you may have under the Company&#146;s certificate of incorporation, by-laws, insurance and/or any indemnification agreement between you and the Company (and/or otherwise under law ) for indemnification as an officer of the Company for your service to the Company (recognizing that such indemnification is not guaranteed by this letter agreement and shall be governed by the instrument or law, if any, providing for such indemnification).</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Company Release</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; In consideration of your entering into this Additional Release, the Company hereby fully, forever, irrevocably and unconditionally releases, remises and discharges you from any and all claims, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#146; fees and costs), of every kind and nature that it ever had or now has against you, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company; provided, however, that notwithstanding anything above, nothing in this release (a)&nbsp;releases you from your continuing obligations as set forth in paragraph 5 of the letter agreement, (b)&nbsp;affects or releases the Company&#146;s rights under or claims related to the letter agreement and/or to this Additional Release, or (c)&nbsp;releases you from any claims for fraud or embezzlement, or from any civil claims based on any acts and/or omissions that satisfy the elements of a criminal offense, or from any claims arising out of any deliberate misconduct by you that resulted in material injury to the Company.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Business Expenses and Final Compensation</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses, and accrued, unused vacation time, and that no other compensation is owed to you except as provided in the letter agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Return of Company Property</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones,&nbsp;etc.), Company identification and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment. You further confirm that you have cancelled all accounts for your benefit, if any, in the Company&#146;s name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or wireless data accounts and computer accounts.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="26552-2-ME-03_PB_11_142630_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=773201,FOLIO='11',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-03_ZDH15202.CHC",USER="DPERRY",CD='May 29 15:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Acknowledgments</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; You acknowledge that you have been given at least twenty-one (21) days to consider this Additional Release, and that the Company has advised you in writing to consult with an attorney of your own choosing prior to signing this Additional Release. You understand that you may revoke this Additional Release for a period of seven (7)&nbsp;days after you sign it by notifying Jill C. Milne in writing, and the Additional Release shall not be effective or enforceable until the expiration of this seven (7)&nbsp;day revocation period. You understand and agree that by entering into this Additional Release, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">Voluntary Assent</font></u></b><font size="2" style="font-size:10.0pt;"> &#151; Both parties to this Additional Release affirm that no other promises or agreements of any kind have been made to or with them by any person or entity whatsoever to cause them to sign this Additional Release, and that they fully understand the meaning and intent of this Additional Release. The parties state and represent that they have had an opportunity to fully discuss and review the terms of this Additional Release with an attorney. The parties further state and represent that they have carefully read this Additional Release, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign their names of their own free acts.</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jill   C. Milne</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.34%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.66%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .25in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">I hereby provide this Additional Release as of the date below and acknowledge that the execution of this Additional Release is in further consideration of the Severance Benefits, to which I acknowledge I would not be entitled if I did not enter into this Additional Release. I intend that this Additional Release become a binding agreement between the Company and me if I do not revoke my acceptance in seven (7)&nbsp;days.</font></i></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Michael   R. Jirousek</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:48.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 240.0pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To be signed and returned on, but not before, your last day of employment.</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="26552-2-ME-03_PB_12_142637_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=209852,FOLIO='12',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-03_ZDH15202.CHC",USER="DPERRY",CD='May 29 15:26 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ATTACHMENT B</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Non-Exclusive List of Transition Duties</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in development and implementation of corporate and R&amp;D strategy</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Active member of leadership team at Catabasis (SMT, ELT member)</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">R&amp;D</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Assist in developing vision and strategy for R&amp;D</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in program meetings and functional meetings as requested</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Co-Lead and actively participate in quarterly program reviews (Hub Meetings)</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Assist in developing KOL network, SAB and advisory boards</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in SAB, advisory and KOL meetings</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">IP</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Advise on strategy and management of current and future IP portfolio</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Regulatory</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Advise on strategy and management of regulatory function</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Review and provide feedback on regulatory documents</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Help recruit head of regulatory and actively participate in the transition process</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Business Development</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in preparation for business development interactions</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in meetings with potential partners as needed </font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in diligence processes</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Scientific Publications and Conferences</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Participate in development and implementation of publication strategy</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Author and submit review article on technology platform</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Review and edit other manuscripts</font></p>
<p style="margin:0in 0in .0001pt .5in;punctuation-wrap:simple;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Represent company at scientific conferences as attendee, KOL, and/or presenter</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="26552-2-ME-03_PB_13_142750_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="6",CHK=320666,FOLIO='13',FILE="DISK126:[14ZDH2.14ZDH15202]26552-2-ME-03_ZDH15202.CHC",USER="DPERRY",CD='May 29 15:26 2015' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>a2224803zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#14ZDH15201_7">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="kg15201_exhibit_23.1"> </A>
<A NAME="toc_kg15201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="kg15201_consent_of_independent__kg102311"> </A>
<A NAME="toc_kg15201_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March&nbsp;5, 2015 in
Amendment No. 1 to the Registration Statement (Form&nbsp;S-1) and related Prospectus of Catabasis Pharmaceuticals,&nbsp;Inc. dated June&nbsp;2, 2015. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;text-align:left;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> Boston, Massachusetts<BR>
June&nbsp;2, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="7",CHK=897344,FOLIO='blank',FILE='DISK122:[14ZDH1.14ZDH15201]KG15201A.;16',USER='LPALLES',CD=';2-JUN-2015;11:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="14ZDH15201_7">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg15201_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_kg15201_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DPERRY,SEQ=,EFW="2224803",CP="CATABASIS PHARMACEUTICALS, INC",DN="7" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g265522me01i001.jpg
<DESCRIPTION>G265522ME01I001.JPG
<TEXT>
begin 644 g265522me01i001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP``+"`!2`2(!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/9J***Q]?\`$MGX>%J;I7D-Q)LV1#<RKCE\=2!P/Q%7
M=.U6PU>V%SI]W%<Q'^*-LX^H[5;HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
MI*\L\1:JFI^)+ZWU&P\R"U.+61#Y5S;X7F2,GB123G'(X'M5!6N--M_[;TFZ
MFN$.UI+V*(K(`.=LZ,>I/?IC.,9Q7>>%_&<.NR?8[J$VEZ%W*K$;9AW*=^/<
M#K73T44444444444444444444444444444445@>+M32VTTZ?!K5KI6HWJE;6
M6YQMR,9Z]..,^]>7P2W6F)#H^J6+RB+F.WNI2!M]8)P2WH0`3GVJ55>QC_M7
M2I;QK5B5\[`9K8@X,4ZCAE]"1C%1RNTR'4K"%X;FT<?:TM7)$(Q@2P$Y^0<J
MR\[2:[_P3XN.L1C3KZ17O(D!68#`N%P.<=FZ$@>M=?111111111111111111
M1111111111112$A022`!R2:^=O$D]W\3_B>+"P;_`$=',$3YRJ1*?FD_'D_E
M6S!K\NK_`!#'A&TL4U#0(V6T6UFY\I8QAI58<JP^8Y'6M36_#^H^#M3DEL)I
M$L+@$1W)`*1Y)(28?Q<\`G.=WK6>Y6U$>J:(DUDR2&+R%)8V,Q!^4=C&_8\@
M]*ED,\<46L:7(++9(!Y(P#9W)ZC':)P#CZXKU/P[KL7B#2UNUB,$JG9-`S!C
M&WID=1C!!]#6K11111113'FBC=4>1%9^%!8`GZ4^BBBN:U7XA>%]'OTL+G4T
M:Y>01^5""Y4DXYQTYKI:*******K:AJ-GI5E)>W]S';6\?WI)&P!6)H'C[0/
M$^JS:=I-Q)/+"AD9O**I@$#@GZUTE(&4D@$$CJ,]*6BBBN'^*_BO_A&_"4D4
M$FV]O\PP^JK_`!M^7'U(KRS099/!'@"?Q%&`FJZPYM;)G4YCB'WW'OTP?I7:
M?!#PK#;:4_B:8LUS=[HH@>`J`\GW)(_2O3[^PMM3L9K*\B$L$ZE70]Q7DU_I
M]QX2UAM.G0WUG/"Y9(\AY;<'CI_RT0C.?:J\:06.O/97%S(\%T(X7N4&-\#?
M-#-G))(.#N]CQ6QX0U*ZT3Q5/ITZ2R)<3_9IALV^5(!\KD9Q\PXR.O%>HU'-
M-%;PM-/*D4:#+.[!54>Y-<X_Q(\&QS>4WB"TW9QP20/QQBMZQU"RU.W%Q8W4
M-S$>-\3AA^E3LRHA=V"JHR23@`5SUW\0?"-C,T4^OV8=>H5]_P#+-7-)\5Z!
MKDGEZ9JUK<R?W$?YOR/-3:QK%CI5LQNKZ"UE>-S%YL@7<0.V>O:OG'PIKUWJ
M/Q%TK4=:U`S'[4K22W$N%4?R`'8=*^E-/U73]6B>73[R&Z2-MC-$X8!O3BJN
MJ^*-"T-PFIZK:VKGG9)(-WY=:HVOQ!\(WDJQ0Z_9EVZ!GV_SQ70HZ2QK)&ZN
MC#*LIR"/4&OEC5\+\1[D[01_:AX/?]Y7T;JOC7PUHMR;;4=9MH)QUC+98?4#
M.*NZ5K>EZW`9]+OX+N,=3$X./J.U7ZYW4O'WA7297AN];MEE3[T:-O/Z9J73
M/&WAG6)EAL-:M996QB/?M8Y[8..:W:YO4_B%X4TBXDMKS68%GB;:\:9=E/X"
MK&B^,_#OB&01:9JL$TQ_Y99VO^1YJ3Q3X<L/%.B2:;J4LL5L6$C/$P4C;SU(
M(KF/`WAGP7H6O3OX>UE[R\\DQR1&X60!<@DX4#OBNRU36-.T2T-UJ=[#:0YQ
MOE;&3Z#UKG_^%H>"A<>4-<@R?X]K;?SQ71Z=J=CJUHMWI]W%=0-TDB8,*M44
MC,J*69@JJ,DDX`%?.7B*\N?B=\34L;.0_9?-\B!NR1+]Y_YG\A3=<2X\?>/+
M?0-%7%G8I]CMMSY58H^#(3[XS[\5]#Z=8P:9IUO8VR!(;>,1H%&!@"K-<C\1
MM):]T%-1A0M/ILGG87[S1]'`_#G\*\\>2VU/13$9O-FM9%2.53N,MK*2%&>^
MR0X]@U&JS7$T%GJ)9Q.(FM;@[OG6>`@H_'&2NWZU[)HVH+JVC6FH*,?:(E<K
M_=)'(_`Y%>`?%3QC>^(?%$^E6T[II]I)Y"Q*Y"RN#RS#Z\?A746/P!B?3XVO
MM:DCO&7+K%$"BMZ9)R:Y7P_9^+?`'C%FAL+V>W@G$-SY,3&.=">W'IR#VKT;
MXL:9XOUQ+73-`@D>QD0FZV2*N]L\*<\XX_6N?\%_!6&ZTN:?Q2MS;W+.5CAB
MD"E%'\1.#G/;Z5P'B_2[?P?XQDMM#U)YDMRLD,ZN"Z'KC*\9%>P:QX4/Q&\%
MZ+J>J7SV\]O9M,WE(K!V91DY_P"`BO#O#&D1Z]XDL-*EF:%+J81F15W%<^U?
M0.E^$+KP'X+U:T\/S2W][.6D@WJJD.5"CVXQFO./#/P>US6-8E?Q.)[.V7):
M3>K22MGH#S[G-1?$WX>:%X0L+>ZTO4Y&E>41O:SR*SD$$[A@#`&.X[UV7P'U
M"XN?#%]:2ONCM;D>5D\J&7)'TR/UKQ_Q(T\?C?4F@=EG%\^QDX(;<<8KTRW^
M`YNM-%Q?:[*-1E3>X\O<H<\X))R>>IK@=/N]7^&GC@I(Q66UD"7$:D[)HSS^
M((Y%>X?$5-?U?PC':^&K=Y9+YE\R1)`A2/&[U[\#\:X7P9\%3<Q37/BSS[=E
M?$=O%(HW#&2Q;GCG]*XGX@Z#I?A?Q3]BT2^:>$1K)DN&:)CGY=P^@/XUZQXR
MU_4K7X,6E]!-(MS=00)).C<J&`W'/OT_&O,_AUH_A'6KVY3Q3J+02<>0C2>6
MKYZDMZ^U;^K_``BU&/68[WP1>1W5FH#I*;I=T4@)R`1U[<^]=?\`%*74%^$T
M9U#;#>DP"X59/X\_,!CKS7%_`7/_``EU]A<C[$<G'3YUK'^+FJ7>H?$"^M[A
MW$-H5BAC)X1=H)('N23^-=;IOP]^'.O:)&NFZ^RWK1C]XTZAMY'>,X_(?G4O
MP\\"^-O"7B>.>1(ETZ7*W*BX!#+S@[?4<5['17#?%GQ2/#GA&6"%L7FH@P1?
M[*D?.WY''U(KR[11%X(\`S>(9%/]KZTK6]AD#,,71I!]?\*[/X'^%&L=+E\1
M7*D2WH\N!2,8C!Y;\3_*O5Z*:RAT*GH1@UXW:Z9(FMW&C[CA8+FR65A\P*_O
M(V)Z_P`(_*H-.9;O1[Q%02^0;:_CC``W'F)ACJ1@Y^;KZUZ#\.;IY/#CV+JH
M.G7,EN&5L[ESN!_\>_2OGZ\=;7XASR7`PL>J,S\9X\W)KZL!!&1R*X;6/BWX
M>T77)](N(KQ[B"01N8XP1GVY]ZP_BM\2=5\.7\&DZ,4@E>$2RS.@9USG"@'@
M=*Q=&\!^-/&^CP:CK'B>>&VGR\44DC2$@]&P#@9K@_''AF/PEXC?2([MKHQQ
M([2,@7)89Z9-?0GA-=OPST\;0O\`Q+AP.GW37S_\.MW_``L'1-N,_:UZG'%?
M17C7Q)_PB?A:ZU<1":2/:L49.`S,<#\LY_"O'O#EWX]^)U[=Q)XBDL[>!0TI
M4F-!D\*`G7H>OI5;Q]\-7\)Z*NKW>N-?7$TZQ;&CQG())R23VKK/@!C^Q]7.
M>?M"<?\``:\QU:XCMOB-<W$Z9CCU,LZG!X$G-?4\4B31)+&0R.H92.X-?-7Q
M;N([OXD:B8&#[/+C..?F"`$?G7J'C_QE>^"O!FDV]AM6_O(519'^8QA57<0#
MU/('/K7)>&_"GC'XB:/_`&KJ'BFXAM)79$1W9MP'!(4$`#(Q^%<?X^\)P^#=
M;ATR._:\=K9996*;=K$D8_(`_C7N=M)H!^&^DV?B*:".RN[6*+$S[0S;<@`]
MCQG\*X5O@GIFKPM>>'/$J36[.P7?'O48[;@><?2N/U:S\3_"S7TM8=3:)W02
MH\#'RY!DCE3P>0>"*[_QKX@?Q3\$(-7FM_+EFG0.%Y`97*D^P./UKG_@*%/B
MZ])ZBR..?]M:Z[QMHO@'Q=JQ%QKT5CJZ.+9FC899\X"LIZD=.HKFM3^`NJ6T
M3RZ;JT%TR`E8Y$,;,?0=1FLCP!X_\1:3XDL=)NKR>ZLI)A;O;S?.4R<?*3R,
M'MTKZ+HKPGQ3H/BCQ[X_B\W3+RWTH3^3#),F%CB4_,WXX)_*HO%?A7Q%XM\8
MV]K9:/>6VD6RQVEL\R;4CB7@MSZX)]3Q7NEE9P:?906=L@2&",1QJ.P`P*GH
MHKS.]L;R+XF^<EA>RP/<J3.8\Q*K)M89]._M6-I^FZRJ7\+:7>JHTJYB1VBW
M!B'&Q5)Y/<XZ<UU?PS@N[==6^U:?=6QDF1M\\>W>0F#C/)Z=?>N>^)_PLO=;
MU0ZYH"(\TJC[3;EMI=A_$N>.G45RUMJ/Q:TNP_LJ*'4Q&F%4M`'=!Z!R"<?C
M6KX`^%>LR^(HM;\3V_E0PN9?*E<,\LF<@D#MGGGK6G\8/`.L:]JMOK&C6GVK
M$'ES1JP#Y!)!`/7@_I6!X=U;XJZ3I2Z1I^D3R11#]T9[;+1KZ`D@8Y[YK'U[
MX>>/[W4FO[_39;VYNQYLDD3*<'I@XP`>.@KW'P;8W4/@33M/U"%[>X6U\J5&
M`!4\CM7A=Q\-?&VB:R9-/TVX=K>7=!<P.IZ'Y6!SP:]`LO#OB[Q5\-=6TSQ&
M)AJ;7(DM/M1`X4*0,CH"=P_&N(\.VOQ%\"7L[:?HEP#.H$L;P>8C8S@\>F3T
M-7?$?A_XG>-+47VJV#>7;8\JU4*A^;@E5SD^^37:?!C0M9T"QU2VU?3I[,R2
MH\?F8PW!!Q@^P_,5Y[K/PW\4ZCXNO6AT>>.VN+QRLY`VJI;[W7IWJ[/%\6-`
MLFT.(7[V:@QHT*+)\HX^5\%@,>XI?`7PJUJ_UVWU#7K)[6QA82LLQP\Q'(&.
MN/7->@?%SP7>^*]%M9=+B$MY8R,1&7V[D8?,!VSD+^M>?>'+CXI>&;/^R--T
MFY\D2,526W#!#U.">@[^E5-?^'?Q!U6]75-1LVO;N[!:38ZYCQP`>@''0"O4
MI_!C^)OA=I^AWZO9WT%O'L,O)BE48YQU'4?0UYQHNC_%#P+-/!I>G2O%*WS*
MJK+&Q'0CT_2HKOP3\1?&^MI<ZW:R1,<(9KC:B1)GLH_'IUKT7QKX,E7X81>&
M]`LVG>!X]B*0"<'+,>G7D_C7/?"'P9XA\.>);JZU73FMH9+4H'9@<G<#C@^U
M1?$OX5ZK?:_-KOAZ%9EN2'F@5@KI)W89ZYZ^N<U3CU;XQPV/]G"PNFPFP3&W
M4R`8_O>OO4OP]^%6N0>)+;6M?B6VBMG\T1LX:21^V<9XSS7MU%%%%%%%%%%%
M%%%%%(2`,DX`K.LM?T[4+W[';S,TK1F5,H0)$!P64GJ,D"M$G`R:S-'\1:?K
MWF&P:5UC9@7:)E4X8J<$CGD&BS\1:7?7ZV-O<AIGC:2,8XD4'!*GO@U/:ZK:
MW>I7FGQ>9YUD4$NY"%^89&#T/%4/^$QT90=\TL96\%DX>%@5F.,*>.,Y&#TJ
MUJNO6&CS6\-TTIENF(BCBB:1FQU.`.`,CGWI^HZS9:9+;Q7+OYMT6$,:1EF<
MJ,D#'M3]+U2TUG3HK^R<O!+G:2I4@@X((/0@@BH]9UJUT*S2ZO!(4DF2%1&F
MX[F.!Q]:;JFNVFE2PP2)//<3Y,=O;1F20@#);`Z`>M7+2ZAOK2*ZMWWQ3*'1
MO4&L77-=ET;7+%'W26DT$SR110%Y,H`<@CV)XJW-XDTN'0(]<:XS92HK1L%.
M7W$!0!UR20,4_3=>L=4LYKJ)I(EMV9)EF0HT9'4'\.>*BTSQ-I^JZC)I\/GQ
M720B?RYXBA:,G`<9[9IFDZG=76N:Y9W#(T5C-&L.Q,':T88Y]3DT_1]>B\0Z
M3+>6$4UO@NB&ZB*\@D!L=QD50\+^+8-4MM.M+R1O[2N;3SC^Y*))C[VPG@X)
MKIJ****************0C((]:YW3?"(T_4[/4FU&6:ZMTECE<H!]H1SD!^O*
MX'3'3H*Z+M61X<T$^'],DL/MCW2--)*K,FTKO)8C@^I-,T#0)M##0?;_`+19
M1[A:Q-"`T2EB<%^K=<=JNVVFM;:K>WJW4C)>;"8&`VHRJ%R#UY`'%8=SX$M[
MB>[8:A<)%=:A'J!C`!VRKU&3_"<#CMBMF\TN2ZUBPU!;QHA9AP8@@(DW``Y/
MX4:CI37]_IUVMV\'V"8R[%4$294J0<]!@FDT#1UT'28]/2X>=4=V#N`#\S%L
M<>F<4[6])76;%;9KB2W9)HYDDCQD,C!AU^E0ZGH*W^IV>J0W4EK>6BO&LB`$
M.CCE6!Z\@$>A%7-,T^+2M,M["`LT=O&$5F.2<=S56_T=KW5+>^6\DA,$,D01
M5!!W@<_48%4CX1MW\(V_A][R=A;!##<\;T=#N5L=#@]JOV6F74.G7%K>:G+=
MR3EOWWEI&4!&`%"C''7ZU4TKPK;Z9J-OJ(O+F>ZBLELG=R,3(IR"PQ][GKFK
M>FZ.-/U/4[_[2\K:C*DC*R@"/:H4`8]A46D:#_8^ESZ=#>RR0.SF+S`"8@Q)
M(S_%RW>JMCX1ALKS1KE;V9SI%HUM&I4?O`P`)/\`WR*Z&BBBBBBBBBBBBBBB
3BBBBBBBBBBBBBBBBBBBBBBO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g664220.jpg
<DESCRIPTION>G664220.JPG
<TEXT>
begin 644 g664220.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!(35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=0T%404)!4TE37T903U\T0U],3T=/
M+D504__;`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`?_``!$(`#0`\P,!(@`"$0$#$0'_Q``?``$!``,``@,!`0``````
M````"0<("@0&`@,+`07_Q``T$``!!`(!`P,#`P(%!0$````$`@,%!@$'"``)
M$1(3%`H5(18B,1<C,D%QH?`D)35188'_Q``<`0$``@(#`0``````````````
M`0(#!P4&"`3_Q``Z$0`!`P(%`@,%!0<%`0`````!`@,1!"$`!1(Q05%A!A-Q
M!R(R@9$(%!5"<B,S8J&QP?!#@K+"T?'_V@`,`P$``A$#$0`_`._CITZ=,,?%
M2DH2I:U82A"<J4I6<82E*<>5*5G/XPG&,9SG.?QC&,YS^.ILW[=NQTWR8OFL
MK0!8:9&X;`>KX&$'MA!1:EI-)L<`^PQ,,H)*]YQ$Y%K>!P.\)Y,&3C/JVJY&
MW6U4_7ARZ57"+/.R"DC$B#A/2:(R`5A?WF6/CPGFY%P)(V,@^Z+A/M/EMK4^
MQE*5]2.BBZ_-2`TA0)`BC7,=_&8ZMERCC0))*,X0D.GVYY;+PIR_5EIF"L6&
M4$>IL-B4><4VT_Y6^T#X^K<MK\G\+Y-55U%6LZ,VJ7Z"LJ,KS!:U!35&WEE0
M4BES%:$J=6]EI45U:ULTJ"EQ8C(E26TRL@%PZ4I5`*A()TSN>(B\VV,51TQR
M=J>S\L0TO\6KVY>$)9CWC$+CII2O7C*H,MST*=?\I\N1KV/ELI4G*,D)]2\;
M.^<9_P`_S_/C_/\`]?Q_/\_C_7J#9)XUOD%Q4PVBD[2CR,#.+?'Q#1=JF6'O
M*!9AEM(::E=,D9PAB5:8$B)=Y8WRD1QKV2'MYN,_*(F5DF=2[5>>#M8;SD5#
MSDKG`Y,@8(I;;D!/^YA"69YCVU-BD*_\HEK*7LI/RC)=O97[>/Q"JI/#7C:J
M9^]U3J:/*?$GD"C:KJP:U'*\XI4G1EN;(0G2%*T,5*FW%H)E*ET44RF"`5SI
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MKJEJG;M(27%`*6K^!M.I:SPE).(#;'Y0;@[C_=^C)W3>Z;UI+CSQJ8L:BMET
M6S2E:&@>.FI)7]1[DV+*OL*;`/QM`Z/^T1J)@`\)4:[7QU#&,BN/JW@X5<JY
M'NK[`Y(0D-H8364Y0"):]Z^VE5WW@Z-9:/*V<L*AT3:L%(J0J*V7(P2$2+-F
MK67LG)'.=FHB.'8;67&F=KLAPV[>\;2FAR8G>'<-=B;99&6?W3E2X@:_/SBE
MU[.$-(.%.W1='G)0D/#C>"(*/2&L1>6R<9[`.TAPX:X9\-Z)4ID!D79^Q?&U
M=L/8:0DAFTVD(1P&M+>]&'E#TRO-1=>;:<6MM!PTD0SA&"U)QI-/A^B]H1<R
M3Q#2)K:5^G?S3-2\E+BJ%S,-/X<S05.D/T=<EDIJ@IEU*6O@6TZD*&-K^.LL
MR.BR,K2Q3NMM.LY!X;6@>4^^,LDYSG;FD'S6G*J:-HJ)\Q7[9*@"0=#CERDO
M*FZVV<R5`;)@<)AZ],S24CEF')PIH"G7`Q]:FRX\YK.&ZE;UD+7'.OA@$%$1
M17@/P'966NP)H!0Q8>UZ*PKT80TH:<MD+!Y4B1"/8;PV^3=Z1@;!HI32E'R\
M&*4VY\HF)0X]3OG3QJ8VE2R]DU9C+>P:-$%D.#,-HS^K:V+Y+,AR4YQY7(1S
M."CH)_&%.8>]Z/5ZQS,I1'(NX2=C@H?:4.2^!?:%)5R.M$D/X01),.H4U2KT
M\C'IS]P(^`Y4[6EW"&Y!YF(<?1ZY%YMWQK[1O`^9>S[Q)5Y+F;C];2/4JJV@
MS-)`=S[(F227'@@*0WXA\/.)2LN`-?>*-C4ZM"5ZJGSQ6U!HW/+=45!2=3:E
MGWW6T!/F$*B/-I[N7C4@;@6-QN'/(5K=5!3$STBP_L*GMM!SJ,NIR1+Q?A+4
M794)SA.7,&HQ\>04A/AJ3:>2O"<.M^K<7KF]UEMMC3&]-?;=A6\@T:_-*-E8
MQO/J'!BIN25"WROI4WY]S-5M`[TE%-92IU@#X;?MJSG+G71\TXV\TVZTI*VG
M4(<;6C.,I6A:<+0M.<9SC*5)SA6,^?SC.,]>R_8!X^J_&'A1S*\X=#V?>%5T
MV6UM3J4HYE0NTX7E6:ZEDJ4JL8;=#JB25K9\X_OH'(T%8FK;4-04XR4H<(_.
M%("VW8@0'4$+`OS<[X^SIU@/D;RAT#Q(UR?MCD9M*JZIH@+R!,3-E-4V[(R+
MN/+$3!10K9,O8)=_'[FHR&!-,RWA3RVD,(<=3)"L?4J=IBRVABM*W;?*VR^9
MD3]4VW1FUH"FLXPYEOY95A(KC@XP"O&'/F.M)90TK"W,H_.,;Y_GZ"8VWZ;X
MY`)4=@3Z`G%Z^G7J-$O](VA4H.^ZYME>O%+LH+4G`6FK2P4W!2X+R<*00!)1
M[SXKZ,9\H=2ESW&'DK8?0V\VMM.A_,+NS\">"\O^E.06]X>(V!D9DS^FE0B)
MS86PVQ",84R0;5J>!*FQ+;K:FW6<3"H]U]EQMUAMUM:%Y=.^W?``DP`2>>WK
MTQ1[IU#75/U&':CVQ:H^I#;YL=!.E"Q0`)';.I-CZZKCQAJ\-BM.V*>@41(*
M'',I0HJ1)$":RI.7B6T^58HEREYQ<6^'E$JU^Y![HJ^LJUL,DN)U]/R#$M-1
M]GF&X%^P#L12ZY&S*26W8Y"#6"582"0RMO*"%)=1Y?RVWMOMOUP@VMOMW_SG
MISC;;U)\X3YQA6?/C&?QG/CQY\8SXSG&//\`.,9Q_P#>OEU^8=VA.?)]8[M]
M:Y9<\N45T,J;]/Y#B3=^V98[A8(4,ZVPS0E/B0:['LR`4*`5G"&8B*@X,..`
MRE",L"^C*L?H[T+E!H#9F@HGE)3MJ520X^35;/N`&USS5U^I9K,6:9'2$R6;
M86HMR.#%.`+%=5(,C+P\SE"4*4MO"Q@<\3VXG>-I[8:5`P00;6YDB0+<WVQG
MKIU!.Y_4I]INGV$^OM;GV%<TQZUMN3^O]$[6MM8(4VY[:OA38%<0P6GU>5(=
M:1EM;>/=0I3><*S0;AUW(^&//("1>XR[MK]YFX09!=@I!PLG5-@P(KF4X27)
M4JS"1D[@'&5MH7(B"EQS3KK;+I2'EX;Z?4`[$@@';DB)N+;X%)&X(V.W7;Z_
M^XRQR(Y?<7>)4(#8>2^_=3Z/BI3+F(I_9-VA*P_+>SA67U1,><4F2DT#^G/R
M'``R&V,Y3AY:,J3C.>8*<B+-"0]C@)`66@I^+CYN&E`7</!R43+!LR$:>(]C
M&,.C&A$,$CN8QC#C+J%XQXSU^;M]6]6G9CN6ULK*?=PQPNUP@93F5.9%7F^;
MJ][`V,^<L)>_MK(2SE'O9;2IS#F4(QCK/M/>V[<O"?7.E]2[AW<5);,@M1ZH
M"M%(U=1[?M.;I[[VO8%YAJUXJ$6<#!DKPG+:P"S<20[V4M&!C+5C&9M[L&2J
M9`%P00!M,S/0;8G2J)`)]`3UN2!`'`$S(,Q;%S^G6I7$'G+Q>YV:_)V/QBVI
M#[%A(HMF-LD:@<^$M=1E'V$DLQMLJ4V.#/01+["LN"K,"P(9A#N`BB,L/X;R
M/R`Y(Z*XKZ[D=K\A=H5/4^OXQYD5^Q6R1P(R^:2KTCQL6$R@B3FI1_\`<IF,
MB`CCEMH<>P/[+3KB(Q6#M%SL/7;ZXS=TZY_2/J:>TVQ-/0Z=K;9*99-4']_$
MX\;;?K;V$YRG!K$NFO8:<CU_R@G"/"\?G"?'YZKQQEY9\=N8VNFMJ\:]JUG:
MU)R8N,,D8!]]LR&EFD)<=B+#"2+`4W`2B&U)=P%+QXCSK*DD#X>84EW+ZB=I
M!$\VG%BE0W!%X^<`_P!"/KC8KIUH+S+[G7"?@2V`/R4W5$U6T2X^3(?7T!&3
M%XV-)A8RG_KF:74PI29'`5ZL>R=(L!"$YPM(KKZFUX3IKJ3ZBCM4[=N,320]
M[6*A24V6Q'1LGMO5&PM;5AZ1+=:9$"?LUAA6H>/<(=>2A+\D4($UE*U$E,(3
ME72?GQ8$]-XVW&^(TFUC>8[QO'7Y8MV::''!E2$@4,"`",^8::8^T*(&(*TM
M\DHHE];;`XX[+:WGWWG$-,M(6XXM*$J5C7+2?,GBMR1N.P:!H+D%J;<EOU4W
M$O;#A=:W2'N#]2:G29`2(=EWX5\L)IN1*BI)@5;13R''0B$XSY;SUXG,'25"
MY6\3-Z:+N]\)HVN-SZHLE4L>Q($Z#;=KU5GHWUFV0"1FTDUW`X\?C)>"Y-+T
M2L12G2?6*I6<Q`[#?"_MO\0]M<M8C@US9F^6%N,K6J8#;L*8%4<0]"#@9_8#
MM7)B9>GU&OQ$FF8D#+&(YD&0E@F4QB,LY:RO*W()[WM:."8)WM'H?E%T6F#'
M)X'3U))^0!..F#IU,_F+W>N`G!:T9H._=X"@[(1'LRI&MJ/6[)LB\@`%82H1
MZ6@:='2;L,X8TKY(@DLZ$:2'X,9'4*XTZYA+CYW_`#M><CKS'ZZJV_3*1:9D
MUJ.@1]S:_NFHXR<D'U(0P%'6"YQ0$#DA]:\-#(,D0\%/?VAE..92A4\3P-SQ
M]=N<-*CP=IV.T@3Z20,6=Z=?'"DYQC.%8SC.,9QGSCQG&?SC.,^?&<9Q^<9Q
M^,X_.,YQTZ8C'\<6EM"G%J2A"$Y4I:\X2A*4XSE2EJSXPE"<8RI2L_A*<9SG
M\8ZXQ>1%BCNY;W,Y`V<E',\5="BR'ZDGG,NXA(71.H7";#LNP9(:3EH8K9M@
M#/BX9_.?ER(Y$,VC#P@6<-WK[N7*`[C[QB/J]/E\1>RMW$ET&NE,$>Q(0E;4
M&M^\V@9:%8='4!$+:AQ3L83@23G@GDN-NMMJQSMSP#O&7A57-90X#K.XN<"0
M;U?TMM8;GJ[QWK4ND?6=-:%RW\ELG:MA;DILIMMUA1P3GL92OSE3VH?:#GK*
MJ]C)U*)H\H9:SS-TA)6BH>\T-9/EJVTE)<-16J:<+05[R8<MY)!W=[,O#M8*
M%[.:?2WF.>U#WAO(G2H(72,EDOY_FZ5*LVBCRQ#[27YA*U+:(_:@C+/!S5<G
MW->X[9^1.RX);FF]3G1EPCZR^REF%@Z[7B\@<?\`4@@C+20F`8P0+$W-Q:$8
M;(S%2?RL.+D4E/=CN,>/]\__`+G\Y_WZG[VV.)`W$;C9`5B3%2G8][=8O^SB
M5M800/8Y:/%0)6?7_B4+4(M`\*SC/A*RVY`O"4N%N>:!==P\%Y.]E63I=K4D
M9IFKJ\RS(FZDU%22L,]@PA01'"M?$1T7QWG=/G&=J9RU2CDF3LMY3DR#\/W2
MD2&U/A(@`U3P6\2!)2I`))$G^9QC/\XQG_7_`)_S'XZYO=ZZ[C-%<MK-0Y0?
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M*P@=;\-UJT9LBF)*VWF:ZAUDPI2\M=0^RXH7DBFJDM1Q`@Q`')OSU*VQW7.[
MHYHQ^XR":&'OTSCUIT)Y+KE>UO2:R<J(V!<@(7+BV79^3>KEGL,Q(>,%R'Q0
MHY;OVL)D=%]^0_TUG!N5XNVFH\>:%+U[D;`4PLC7FT)W8EF=(M]ZCAL$A#[!
M9-+*KBX:T%LK`.^)"##UUH_!<2PRD)+*Y2;;U]8>WIW9#-LS-<FGH"N\@9K=
M5?6EC/O7;66QY66DK$[`&+1@0PL4&US\$\VVM6`9<1(1BF%D#Y5TI;Z[M?%2
MD<?[/L/4VUZ?L#9)M3*<UMKP99CTX9;SQ4M0XMFAL,L$PP,080T99&SW@G&P
MPRQQ7725L8<]YA0Y)$`=CJY[$R1UN>^-I+*QY0:F`D;7$F/BWZWXN>^-$.QA
MP*[@?`0'D!K#>C%'@M072`B[7JV*A]CAWP"M;A:=-CYDY$0#'`JB(F=B78DF
M;P$A+$D?#((='^6^IQ4Q:YV;N-O'_ED;N/NJ<YN+NTX>6D[=>]FZK*M5HBK]
M?[W:%.R407:8]X_]5EUH>0+--)"PTWDP42(BT8Q'(4/FP?`;G/SCY0ZDY:;-
MO<10L0>J]4S;.LS:C2SX8F7V\Q!3,RD9IPR;E!Y8:)!#CW38YACW&39$-I]:
M?<0RY!+MRZ&XQ<AN4TS*<Z[RLL";KDG<VY*Z7%RMC[-V.;+@/%B7.]/E`R"E
M/CF'2K$:W+`YFC&\@>6A`FX\D2!L2#W@@R1M%@"1[Q!'.]X`+)=4H@?!J\L`
MJ)L1!@D&.1-_0XP/WAZ=VGI(_2XO;4K=8C)P3-J3MYW7<+<8W74E!$BQZJLA
M;=N;:8.LPT@W)-N.1`V1U1A#@DB\M;@Z4=`7:\XE:0YX]I#CI1^8%&_K#$Z/
MM.T@-:L35@L\>37!8@J1AXAI@Z'EX\TAN-B#EQ8+)KY;`H3(S+*$MCM(1H/W
M>];\`ZDSIO5/"ZG:ICYR*F;=9]H3>K2&9X=(I,?&1M=@9NU8D)5R2/49\\_[
M2B3<S%Y:0\6T,\6REVY?9#A/LW;LI\<VTM'FW[46AK^5*R_-O8QZ?'^+*LX_
M;X\^<Y\?STU!1`]=I,@"9!$'>-AP.TEDAI"@5@@B"H^_!*@23QO`YBQD8XTN
MSCPRTIR.[A-/U#OJ@"7S5I]0W=)&U<V0F(T8D^K17NUHE9L'(QDDE<:\XE]G
M"2\(=<:Q[Z'&\8;SU7]SGM)F;HXC\?>*7&K;FK^)W$[CS(V2RVJI7^3MKM4D
MF/W/U1F2E')!]+T779*7M$TM5HD"1VY0T(AMIUP9I8T*.UA=M:<8>=U.VUMB
M:Q4:4+$;@K,G8B`3BA(DNU"D!Q+I[$<,66T&X8%\5Y]IAS(ZWV5.MI1EW+5!
MN_!O`KD!"<5!M57,JS<:MA4VX[$C28=4M&UJ^VB*LXU903*#&,1[LDBKC-J;
M`"E`\H$(G'CFAE*<9(;G5S(W`'2P!F#P#S$]^<2L*4\C23`$@D2F8),`VU1U
M,S<G&.>/_$OZ?+B[H6+I7+397&SDUO='WQ^];!KDGLB[JD3GRBU!0^N0J<Z0
MF%CHN(R&''J#]@HN49>E2#'"'/4W&GMFQL'2>[_QTL6AB)V"UU(<F9^N4QZ2
MPZU./Z;MKEDBPJ]/X4\MUW,A52A63ASG7W/>9$.(3F3'PXUT?<)^(O9EK'%?
M7>U=PF:8O%]?J418-E$[2OGNS,-<6VG"9FN!:T9FQD!8`,2]'1,*-`'%2K(X
M[S:Y1PK)!$CN'D36+'W5=-7RF5H&L4^:Y6$V"H0,8`B*BH.K%RLW]@CP8U.,
M-QR1H=(&/@MX2D=:W&<(2M./`*`B3,@W]2-QP=^8`!ZQB01#HEPR()5`$_PC
MD1OV(M&/`^IQJB)3N%5J6<94XV/Q1UMA><(RM6$#7G;;RL>,9QYQCQG*_./"
M4>I:L*1A2%61XF_3A\%2>)=*8Y"TNQ77?.QJ##66[;'!O=MAC:=9;-',S.0J
M/'AR#,.(W7$FCQKY4I&R3UD("?+E\.ME)&9T;^H*I"+)S?KY"D*7A[C71`,^
M$Y5GT+N.T$+]/GPGU)2[ZDXSG&,KQXSG&%9ZO!QG[JO$V;XRT>T;,VK6M?WN
MJT*&C[[0I5PI%A;L$%#M`F8K4>EA:[&'..!9,@78IPO#C1;(Y2QR6B&VDC8F
M+GF.;7GO8?W&,:BL--!$VN8!F8!'>)F8@;6Y/'=Q$K^S.U9W@:[KL&U2!P-4
MY!1>@-BNQB7XZ.V=JV^RH4'#&2L)[[@RL_"M=<M<6*6X8B!F6%O@/ISC'GH#
M[XG:_P!D<U-KTS<ETYE:`T!H?6]#%I],KVZI&7@H^-NLK)R)UMLC1CA+%?=E
MYQO,"&.MOW)98$2T`M:!/#;DN=?UB:[@'=A@]H0E>EHT"_\`(J"VH4U@5IXR
MJ:WUL=#28)<Y[:W!621X.G0@9SWN_%7*R&`QWG'U,I>R9WN)"[;3Y[2U*V;+
MS86M->1="C*9#MC.FQ$%6+(PW(V6YQ$$^YD,R>EW7#,E2*V%D'8A1HL<CXPG
MP\1JV/Z;Q:8O(M-HD?W&,A$K01`5HEPP";Z08!`OJF-[6Z8]UWQIGZ<W5W$.
MZZZKA6L-D\A8?3\A"5W8FN\[&L^U)_;K<`XB*MR;&RI^O"(+N"&2S&#26X,2
M$=<C,C)CDI8SKY]+MFQTOFGMNKLE+9@+KQV*-LL<AQY`!LQ4KC7'(>1P&E?Q
M%'`8FY8%LQ;2R6@'U!M/_&\M]5SVKQT[+7'CB?<[C0X72&S;X]JNRQ^NI<Z[
MHV3LJTW2?KI4;!2*(5V<-P'(C2QK!QI&($`2K>T\I3<?@=MK&B'T^=,37N:E
MM)RA?E/'VS!^\KT^E6,VJGK<5Y2A"?WN)6YA>$(PK*E>,83C&.FH=1<HB#//
MSOUN1M>TXJ-):<C4;$RLP=A.D`1$DD?VC$;>4U4'J'=JV_=.<^L+;M&L-<F[
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MN7%#L+\H>.]LWR'R2CX'0&YET"_QL81%Q[>M;"#B3K-5`6_8[4J2BH%LDUB)
M,:EE`IAWPHL$8>/`8;ZEQ]*Q52*[LKG0H(=#)3^L]$-`(]+;3.'V;%N'(J,)
MPG#33>'\H_'IPVE/\I].,XZVKX6QU_?[&7-6N6LN2+IP,3N2)U>U)K*<^!7E
M5J'(F8V%<)=<QFMCV1\_((XN<!B'NRXS&,)1E*?5/IWZ_(4VV\U9.$B<2LPC
M6.HR(N(61\1,O*`R.U"0(O):FG?BI-+PT(I_VG?9R\IWVU_X<R%"(F/=[#8P
M8'RD#MM.,:A#;R;$A8O`$71M%@;WBUL<W]"@Z%KCN'V&V=R73]WW#7@=M;4-
MY#ZYDLE-7.=LDR?-MQ4]+B$2441/1L-)/!S6(O[N-&S\$D4>,-)CTB,+KEO;
MAAV..=QFM1>&?(G5O`^WCKEA+K3-BZ^NL/!7N-,0,N)2Y%7NRP=9A;!$G9)9
M06!/O8EF"D"J#4\("2FA-;YK<-.=N]LZ[[@?"[26L2\Q\M6V=KVBT'&3D5;8
M0E(C%3L]I_2E*E:X$U@8P8"2DYUT./D6F`\LB-D>[G03NF<*>`>E'=>%<1-D
MC62PV.3D6KAK4&^B;3@("O-!/%1]D9FE_=3(!QR5]J*Q#24J?D]@GY88;"`B
M''H"^AC82#,;<&\$="0`3/7&4*U%((<0J!.DZFSUD7%[B")F+F9QUZ</M.7[
MC_QATCI.\;:%W58]84*(IQ&T288P!^X1\-AT:`D'1W[%,/>IBOIBX[)#DF:L
MSX>#,O9]_P!*74]NU_)\B\<#^/39)%MD1V("TBP1DH,!(%.U$38=O&I*4&R3
M9)Q`#-0:A&(IQ]]S.8ML/",X;PA.'5AQ<';\Q[?Y_P#3CXU"%&5)D$\1L>D1
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M%^[^W&.G3KIWM`99J/"&<,U#3;[+B:)+C3S:76EI_$:,PMM84E0D`PH$2`<?
M%F+:':*I;=0AQM31"D.)"T*$@PI*@01-X(.-:&.W!HX6V5^X(M.V%2M=KT;7
M@6W+%65!N@QE6-J8ZRVL4Q+SQ"XDYW#RTD-MK?0TM+2&TK97GSBGQ5UYQ>`M
MT?KZ8N<J/;7H9Z2_6$G#R3C*X$<H0'X2HJ`@O;PIHU[)'OX(RM?I4C+>,9PI
MTZT1[/\`+,MI_%V3/T^7T+#Z%N%#S-)3M.H+M%6MNE+B&TK27&R4.$$%:/=5
M(MCB<NI:5NL:6W3,(6E=<0M#+:5`K:82LA24@@J2E(4094$I!D`8]UY$<7=(
M<I*L-4]T4@"T"QSKY4#+H6Y'V6LF/MI0^57IX3+9\:LE"&T&#H<6$<AMM!PI
M*&T)Q-NN]D_AN)8Q33S]Q3X*"7''8"7N5?1$EH:4MQI@AZ'I<3.>TUE.$(4Q
M,L/Y1YPMY>5*5ETZ]2*`DV_*#\Y`GZ6],=I;4H"Q(N=B1P,5PU_K>@ZMI\50
M==5"OTNF0PZA8RMUZ-&CHH9I?GWL_&91A+SY*O+AA)&7B3'5+=*=><4I69:[
MA[.?#B^W.4MP@6P=>KG"BY:1KNOK#!1U55)'.9?+)%AYZJ6/$<AXA;K_`,*/
M(%CFG'G<CAM)SA*73J5`>[86(`MQT]+"W;%6R9-S<7N;W&_7'OPG:"X.XUT!
M0/Z>2WH;FP[,;<$V!QN]2YPH)H#(DA/-"-MIADMGOOJA8X"/C5&)9+4-E]K"
M^MS>.O'36W%W7G]+M4L30M11/R]B9%G9AZ;*'D)O([AZ6"GVVUM"+>8P\V,E
M/H;=<>6G\N9Z=.J#]XG])_XIP4I1205$C6=R3QC3;<':5X9[5NLS?C*A8Z=/
M6:3)F9Q%"L#<%$GRQ3JWS9#$07&RH(+YQ*U%FIC6@F""E*(6SEU;BEYIG>`7
M&2U<=:)QJL]*?G]>ZR"*9H1TA(K_`%C5BB\G.%2D39161B!CB\'E,F)2Q\`T
M=S`Y@+[*$(2Z=0/C6.`%0.D:"/H;^N+E2M+=S90BYM88TYHG94X60UH8E)EC
M9UZ$%SEQ5>M]J@UPA>6U?L;-Q6ZC6Y9]C"?V*'^[)9=;_MO-N(SG&=B(CM;<
M0H#<,5O"LT^>JUR@+I$WJ"%KMB>BJS#34*H=0;,9`#C8%$BL^QA+T:TK##B'
M'D?M2YG&'3J%<?[?^N)*E3&HP09$F]T[X]JY)]NCC1RMOC&R-NP]K-M`]6`I
MR"(.T$PHV82-,ESA&E#-#NX]]LB;D%>^E259PXG'C]GG.`]S]G[AMLFRXM3$
M/=]=2,@O"Y4?6]BBX>)DB6161E&.Q,S7;"""03AA#QGV=F,9*)4Z^\RI;SF5
M.G4G=?9<#T(N,0%*A(U&-.TF/R\8VWXL<--"<2*^=':@JJQ9:?;&_4ESGGV)
M:YV!H;*LB"2,R@0-#4:(K*G!HF,$CXMI]2B,!^^K+G7JW+?@CQYY<L1TKM.O
MR8=OKP6(V'OE//&A+<+$N%9(7#O&E1\K'R,9@A;K[`LI&')">??>`4*Z^ZM;
MIU?_`$T_I2?G:_KC'J5KF3.K>3._7?&MVF>SSPMUQ/N6@RM6O9AX^',!"[-F
M8>9B0WGV\MY+Q%0=;K89Q#7G+H^9=N1:8(])#;6'VVG$9YXY=N/C3Q:V`G9N
MI(VY1]HS79.KNN3%M+EP"(B7>!),9("=';0ZY\F/&?8=4KU,.)7EOPEQ:<NG
M6,?$/U'^C>,A4H^9*E&PW)Z8\_E%V^^,?*@S%HV52WP+P*(V*F^TLQFN6PD1
MK/H9&E3,!F@S;8S?EH14U'2#P32E-".L-JRGK4.@]E3A?`3XYLFG:=U#9<:(
M<@;3;8-$,6IGUJ]!:*M4:Q(NLNXQAMYM,BA+C/J8S_:<=0MTZLL`%4"/AV[J
M3/UDSZXA*E:#[RK3%S:PQ3^TZ*UC:],3>@':T'`ZKGJB92'ZS56F*^*#73F<
MLOAQ20F4M`*]*E+PZVTI67E+><]QQ:U*P[Q@X-:"XAR=SE],Q5BCS;Z#`1UB
M7.V$B<2\+6B9<N+2,A]EK`RFWIR04ZI'GW<+;QG&/;QG+IU8_O$_I.*@GRU7
M-U2;[FUSU.,7\FNV;Q/Y)6"4O]PJ$I5[[+8:3-V_7LD+792=<2E+:3)L0J,E
MX.3DL-8PTJ4*B')%UM*4/%.)3C&,&:M[,7"NHSR9F7BK_LA@%3;K%>V!98@N
MMK=;Q^U1D;6:Q5ER+>4Y]"QI$DH1U&/2Z.O&5>73J"!J-A^7CNG%PI7E#WC;
M4!<["('RQ7:.C(Z'CP8F)!$C(N,$&CXV-CQV@P``0V4#B!AB#I;8&%&8;;98
489;0TTTA*$)2E.,8=.G67&#'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g589761.jpg
<DESCRIPTION>G589761.JPG
<TEXT>
begin 644 g589761.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!!1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?3U527U!23T150U1?2U]/4D<N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@!20*L`0$1`/_$`!\``0$``@("
M`P$````````````(!@<!"04*`@,$"__$`&T0```%!``"`0H/#`0)!@P%!0,$
M!08'``$""`D1EQ(3&"$Q.%AAD=$4%189&C=!47%V>+:XU=<7,E-9<G>2L;.W
MUM@*-E>U(B@U.59S=8&A)S-"1U5T(R0I-$9(4F*6LK3P)F9HI\$E0X*(\?_:
M``@!`0``/P"&^SLW8\+;8KI9=OUA3L[-V/"VV*Z67;]84[.S=CPMMBNEEV_6
M%.SLW8\+;8KI9=OUA3L[-V/"VV*Z67;]84[.S=CPMMBNEEV_6%.SLW8\+;8K
MI9=OUA3L[-V/"VV*Z67;]85B:UO]O*4=##3R^WNQ@9-9..T)2`M*[KOB9P3&
MJ84B6.=\CU\K6`.88C8]1?&]\K<LKY8_X-99V=F['A;;%=++M^L*=G9NQX6V
MQ72R[?K"G9V;L>%ML5TLNWZPIV=F['A;;%=++M^L*=G9NQX6VQ72R[?K"G9V
M;L>%ML5TLNWZPKQZOOGNZ62%<R!MSL6&.52%8T`):6'9>X8Y9.-&`!+6NH7M
M>^`H>&=K7M>U[X]NU[<[7_&V-^-X%!L-E0-[=[%C&U!M-X^;&REAUVR&-GD8
MB;-#96Q/XXVR%,#""96QQMC:^5[8VM;E:WG.SLW8\+;8KI9=OUA3L[-V/"VV
M*Z67;]84[.S=CPMMBNEEV_6%.SLW8\+;8KI9=OUA3L[-V/"VV*Z67;]84[.S
M=CPMMBNEEV_6%.SLW8\+;8KI9=OUA6'O[B`;S(K255--V^V,*GBPZ#@"/A*[
MJRR#Q.N=$3S-K6S/98WZZ4-F`;\\;WMB)>]N65K7MF8N]>Z^`HN&.VVQ5L<!
M1,<;?=9=O:QQSRQM;_*'N6M:U?#L[-V/"VV*Z67;]84[.S=CPMMBNEEV_6%.
MSLW8\+;8KI9=OUA3L[-V/"VV*Z67;]84[.S=CPMMBNEEV_6%.SLW8\+;8KI9
M=OUA3L[-V/"VV*Z67;]84[.S=CPMMBNEEV_6%.SLW8\+;8KI9=OUA3L[-V/"
MVV*Z67;]84[.S=CPMMBNEEV_6%.SLW8\+;8KI9=OUA3L[-V/"VV*Z67;]84[
M.S=CPMMBNEEV_6%?8#O5NMF,#AEMML5?',8+#*WW67;V\<A,<<K?Y0]VU[VK
M"H^X@&\RVR6RKJ>WVQAI04$W(P;,9RNZ\<AA;'CH-L\K8'L<+7L&"'C_`(..
M-N6-NUSYWOF/9V;L>%ML5TLNWZPIV=F['A;;%=++M^L*=G9NQX6VQ72R[?K"
MG9V;L>%ML5TLNWZPIV=F['A;;%=++M^L*=G9NQX6VQ72R[?K"L3PW^WEN_C*
M+?;W8STM#89!9Q*_=7=?464AG6IIHAGJO1W5]7D2+A`7M?*^'4X6O;&V7/*^
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MEUU*).7U-,*'W`_%]4-EDX..XT.X$0!S1O,0,K@</G36(&-[86,&S`MK=6+G
M>_K?TI2E*4K!7'_76+_]H/SYCFZSJE*4I7BE[_(*_P#[`7?[H.UX]E_U+9GQ
M.:?S=3*R@+#KHH0?5=3UT4$+JN75=3UT7`+JNIM>U\NIZOJN5KVO?ERYVY\Z
M[59GX7JDRS4M->&9L"G>3H(F6'X.E".Q(?<\39A/&=E4)NQT$PWJZ72LLU^8
MGG&8+IBF`&HH>:66&LL#B7(A"7O.2-P]-TW`Y'JT$;7IXGW+'ET8!WI`:HR`
MATQ6<".9<",U2PQEV`$UU^'D4H84K1ZVS*P^2I8*_H]O%!,@P\_.0SP^M@96
MCYYS`L-1<CF(VI#$[R\3?KB220P"_>"D`\JJC>+MC-P);R3RBZK)IYIE'J:0
M1&R2<10PF==4%(.R?GJ$WJ7L<24WBB"Q(YA5I@?<4Q=J.GC(2JJ)0VQF26'"
M14(BEK!PPK')$&6DL!$)H@:D9`&.@AK(27E86P="H'"ZW!.JTBHCO829%YZ/
M83?4X6%?+S88*0\$=@*(*0N-AIN))=R@W3;G**N8R:N8&54%/8IT``N_C#;S
M6$'TSZ\;7M>UKV[E[6O;G:]K\KVYVYVRM;*W:OW,K6O;N7M:_:K`)2_J&N?]
MY:_ST;=;$'_Y\?\`UXW[7.OJI2E*4I2E*4I7W%O_`#DM_P!X`_:X5KF*?:W9
MG^Q\_P"\U&M@54VLNO+7G0G.KC?4L#0^QX"BDE*SL<1*-%J5U0XF'GVW&$"F
MI;30'$VU$P:LHN4F:S&"-CVP+A#=47MCCD,'LZ6^'?/3#7I`SCY,RFF,&"PX
MSE)0E1!)EV24+L*7F$?D9BG7&RGRLI[L;+D/M])5"YMH]86%()=+%D$D*H*Z
MRC$3NCYJU2V(UT06XYYNBI>CI"=2D90TI165!LG`P'&33"JT;:;A!05Y8-,U
MY%D<Z65!V>\2Z`Y@B(F1C)*L&"8N%/=KVO:U[7M>U[6O:]K\[7M?MVO:]NU>
MU[=NU[=J]NW:E8*'[:1S\UZ7\^5FKKUIUQ:4VM78*09!E\Q#C`UV9#'>SK7$
M^+%V7E=2+/R02<=)A%+:C=<C:4A!2ZNH%!S(P(YSJ2HF>=R^&``@MJD<O"5G
MO$&2@8G5TZ;%YCR?#[-1$!O)(;(-NYE39"XLTM"0!\I)<C;NT%+!.%1VH=C=
M6"-N,5V+!=.2SI\7K`!R0\]-=H@HL69I'A5WE8Y;^2U=85C@K?)+),JVW7=B
M.%5NPS:X#(9E!1'KB(TU1Q$VF90B;A!,)8BC8R7&Q#RQ=X?FYS:76&V5C7QY
M`+\E*JR@M-,*J++5ALUUMH.+I<J&Y14=U*!6/UALMF^;A<B;(9AJ&T%%+FU%
M5"*ER1O,#0\N0U)T$/(5@2VT#[+=@:2C.`%..'$=5*J3><)3T<@N%"7FXIK3
M<<2`L%;9BIRT@JZDFFKA#A!F;CEQP@YX0_;`D?\`V?&G]SN.NPK735M@R]%$
MC3')T['(6:#`E.*(C#R2X3=DU*BVYI<3G,H(8N*0T',A*2>GDK-@V$='P**>
M5[C!=;PL)<,`;>#UX36T"&CND9@I(<S.=B3K.$*O%ML(%-+X$<89;;0=03J1
M%!RN1(/.DP]4=U"&DEA(J"8>)'%"5^156]"'+DIASTIVMQCEH2QA!CT,L9^G
M&&1:9\A=`45Q5&E-5$0XQ%S8Q!<,O]*(2(L!Y)K(5%MK)B8YC>0."4;,XC@Y
MYY(I\/S<A'>Z#'BA!+@#<SD;;I=Z7<!SQP?;&#98RB61WLLK$@)[U-QZVBC.
M6#I!)=&+F=2.80U-132*@`":4"80TXR5&C]AU]..,Y/:JJR7XT3N">XFRM8%
M['TXP,4+*!7/KI,P<('21]/.$U%,4TTX=3%-.-E3R><,E1PA<M&L[_+$F_G"
MR^8K%KM'UKT::<[19'LANO8.\4*4O[*J&K$7-@&#GI*@:Y)`#5:#E3S#A7&B
MY4_-HMT]D\4\@.J&4-2#3K`F3HO70`Q,`D@\,_91GQ&@2\W6X-)*$&B3RKR?
M9I8I%@8UOK],#KB5WX%A%!Q`K<BDKV:1UYF3[/;(@J`V3!4TMIY<`4$Z/J]2
MT&W'20HW$.Z^O>V<M.)%:+%)%##54U8^Z'$UA'PAM]<1$MR'5ABJZFR@#+O+
M$I`(M46S8)G5P>P*<3,F`OU%^'YN.:?AF-B\%K@KG*,]"?XPV+JC:S.]1CH5
MS#>;3A!DW-[XQD:).%Q%#;=1`BCQ'/*B^5,HQ(F,H`"@82NZFLY&,YW$RWDA
M*C8=S26U-MN=MK900BL(*\C&Q2"JDJ9,7_#+'2)P`4`<.]\L>JPZL/,0+/`3
M+4T>_P"1US\X4E_/I=K.J4I2E.[W*YOCE:_*^-[7[O*]KVOR]_E>N*4I2E*4
MI7>;PM_:.D7\]JM^[&*:Z,J5V?Z'ZMZ_;`,1[J;WS5Y(F-/DIJ--LP`WMCHJ
MUE<QV.%5`,J#@D]J+\MM]71)0<B>N8A-Y/CHHIMP`OD'<\N*F`"D2R#RQ0X1
M$]J++E&3VSF;:S<;:E/AR.HWE]JNQ(F%U-&!%!1`<?JV462@.B&(T>1H).-D
MVZC.20R91^*2<<-M0;)&&*&K^%QX=9AK8SFQ5%YQ_+TPM[76()1:+:8+A?;:
M-QXXIIDF#T*/@'B"X&<207*INMORMD7!;8:SZ6HH`6;B5%8L/FD)YK-7'P6=
MCVZ_H]8@LB14;N]W')C-4EO%'F!*";#OBEHBO5PM]*;;BCI'>$M9+*,54<&$
MK1.B.9)>Y])5"J89!L4R%RZZ=C8*7-;9?=$.N-Q(;I6&L&C#&E=`3'BA%LK+
M2255PB1]NR`W&F\6XN)X1K$JLH2\A%#1`WA>P0IPJ(`:$T?6"N/^NL7_`.T'
MY\QS==CG#ZUZ9>S$ZN2/WRVWF\TY"@6;Y11V6P':08SH>COC=L%EIK-`BZE-
M)6T]&Q<BD+9)$.&TXP7+YF@3(V-P@!,!*Z<_"Y)2/-#9CN%W!E"BP9@:/I2E
M:'9=<2GL%(,)O5]/]68B<P5!4UX8RX:7"QDF52'RKKJP@MXI'[8603KN-EBH
MQ:P/FX9X7D6*+IUW9TLS$,=?C]VQVNUEE9C,_P!/49)13FO$<KJ[<XUWXJ,C
M`@'='<"8FJSI7#YHVD+C4<*64;">$KI+HQ+3\A\+V1WDE-I>C:<(2E%O/-D1
M\_V>X6@7DDL2=#<=.P"?K8]5$@0=#0;ZR2+1)(*F1/.T94(%`%-JF;*R`*,,
M"*3Q\N)PGID(O]&CU:E&+DQ57#NPHR=F11I/>1]59NO*XUF\JOQL-)B,YS/%
MXI+\/NPH.Q4QOHIA1,)"8N+"F(4*IN=A/K-\)R<R<A*D=9R)$HB@T]A5G7^1
MED(RZ?2.-\TV!#>R9"3W,*812Q[[GZY%J6M'"V8!+%7(+R*HH)XKUT/$UEU1
MN#K5T-PW+C8F2]T)P>AS.&`@6!D#TJ/]8-8!BVQ%#P,@]08P#%QQ%#P$QP%Q
MQ$QRM;QK+_J6S/B<T_FZF5E0.66`H0N..6761@1?\&U__P"T+@+RYVM?J>?4
M<N?N<^?*_+E79E*'%#F^6-N&=L$ZEF0U*(H_V,CV?V9K&J2>?4&.VA&`H(1X
MHVDDW9&+)@(PV*4?`)+PS7,9I'IT;%*IU[W&Q,>,AS?=JL8(Z2DR`,Y43VUN
M&O;RPO@FRTKQP>8\XK>5["`/4\G-9?M(K)SQ(MPP;3006JNB'D@YD77`B2Z=
M)!9OGQ+DAR-A859)UZP<T_*>LNRFJA>74"5%)IM4C'&Q*N]7.:/VB6S1521A
MQM=QOA1PP-"NST$J(`(!3(H46,2JN1S0+BP)**<5GZSM9RR1-3J.:4J[Z>RS
M,"PXF:O*NER@@^IDLEQ[@S$C-KH+P0D'$@J`E7,?6"*H;NJ8J9X$G@2-:52-
MU(%:3S?(["U+56O&4F0+L9"[^;AG85Q.B0G">V/7DAR+SPQ?BVQQ6TC8-(XC
M%$UMH*1'A;(\DB&1G0M+:R(&=#ZVK=5RMU5[7RY6ZK*UNIMEERMU65L>=^IM
MEESO;'G?J;7Y<[\N=8!*7]0US_O+7^>C;K8@_P#SX_\`KQOVN=?52E;WU:C9
MO3+LUKO$+N$4PFI*DXQ9'3F%13>!!8#;[S>J,WU<1*/"`&@R2E@0/CY$C>98
MQ@7,6#%R`%MC?"]>*O#;7S;;/O%O3=#R:8<+=VPDB*8<<AA]YRB[([U.D9^M
M%_Y"*:>SS3))*A!&90JN3-+"ZF`.`8;(D1`P'*J.9+<40<,UI@H3WO,<F,MS
M2HWDS1]Q7A)ANYW(+EC\CM3/L6M,N1DY7.,,5"4`%^+'[U\NI,!97C+'<1LB
M.?)GNK3;*4^S!HA9@)<BOI6FN"8E(#/W9PK!D.R*]W-B^Y-9.NLIKD<KV3=>
M1EJ%F9Z:"K"68;3*)/16;3ADI623N:<F$AQ<@0J88/!T<9:3]84>9YM::=&D
M_2G]R8XL,%KRD7<1)WCQ8:E=)16B<?<9I[>=R8OH18<%.DY'`58Y#4$Y031U
M#(S</('0BUHNBKZ##*TT)#83(8%]6W_L--4^O96D0TR\6NU=@W?#Z*\BS!#9
M0C_13KI'*-=";T;-U#7%0T<-V4E(9.-9GRP'ETGA7O\`&4C0+IV(UY8K?/RA
M!\71P]E@>2EEKR^>V38F;]A%>88K89"HI!HSU3K6)BXNA/0!VZ,$H'EG,),3
M[F377`]V>MQX]7E'[F"+@.1ANUS,EQ`$S.)PH"O-%</MU9"*G,<`\394-233
M6)<SB&'8P#8,7K>'5]1CB]*5]Q;_`,Y+?]X`_:X5KF*?:W9G^Q\_[S4:V!56
MZP[7OG55,V`&C4=Q(+YF>(T^,6Y(35<^;978V.$I#:SW,.8AF&F'Q%40VGM\
MXW1$X(RDY8`JXAVY[/`OD3,^6+[E2*;C"56J\C3@D62Y/V+U]V(-RV]G4:<*
MG@M0`1<Q=%1EM+4B9@PX2Z@;64D8N-=:3RJ(400D\HFB8#%A2%>SCQ@)B?"H
MG.J$4QW0,]C4@..37DHG9`:LL-4TXW*V[-PXFLM@.&'T9NH"(!@.I&2JH[<'
MV_"Y<V"A@.L%')A@"=1RHIGUQ55%I3'N;5%I345E3-=:!!N;4U8Z845$U<`J
M$"6!N9.F1Q[@E@`2P/7+AEP00<<`\?P5@H?MI'/S7I?SY6:O'6;;U_:KLW8Q
M)B\TXFR^YR9$?,Y`DUING-M+\:YLN22+Y4%,A@&F'1%:[E2BYYIF2N!Q*]"E
M%,<WD8-86N3$S1B;R.Q":A=+D%)7I:>(N\L#[JN&0G8^#)I?<RE":`?0K,U3
M%4DE5.9F7!@;`%+NG,^(&WP2(!,J@&@0P.L5$Y.*NWUV+I2CXKK>(ABRLSY=
M:J^.ER:BE&^9/29.QR<`GFK%2$3I\@K#OP%&(LUPG+RF33O21.#4&,ELY5,"
M#!YTY^,WBK/^-GVD:U`@*3:^ZNF/9>=4KD'7)Z^QY;8F#)5([:4JA1$AKZ:@
M-L;`!U-M:E(I,#P$7$Y.`7EM33\3>!CK9VUV2,;/20B/$-'=#=;S1CYL1NT4
M)XOW"1EX@AMS)0-BC''`4:C&1`+J:LK*!_%":[/;C81<1<2R0F`XW'$&B1#]
ML"1_]GQI_<[CKL"@C=:6-;8*ER*(9<+SC=XRI)\6/S.56,\16XKI")':"\4=
M19N:>`F##*)1TC.<D>%.XJQ+$ADB!A9$3US.`Q78T([]*D4F-6%-PL94D=PZ
MY[433M`LN)9?@N"O)BS,;-0FL=2SQ]10%DZE*Z>92C:P;=APROF%D13%*B)Q
M3J!AS.^"W%30TV'&_%*1K@,E`)!7548;!)ENS6;'I]K`^B3UQ5D(-C1LTY)1
MSDG&PCIUS.-2E!S.YON$R4/-95))!,PCJ.:K_&)(JTA7<Q37`4FB.*')"A^3
M5H62V=>='P1>SU;;Y1E<63TF"$AFC"QXI-D$@W`'A$SR-+J8MN'!X*JJ:.!&
M@^L#9V=C^R4V.^7SR:L(H:^$@I:.B+[P./Y81FZUT(@WT1.47>>3$05;-!E"
M-QQAP49(3P!3(A)*2R"66)E0I)9W^6)-_.%E\Q6+78O'&^$V0MJ^GZZPH\)`
MB)1^[H])><TB1^_#C</.I&=D>-9C%V&?3$X@";!+(QMMYN$!9"7+B"&#_6`2
M),4M8X+E+#WKLS4;75+-1AFO"P)K9N%K[D>,//(`5VC[8J+W4C#R$RS;YLPD
M9-$5X88G4GT0I&'9Z6==S6D<4R'D5J]9XO:$9"8)5#UG4VPF,6;(YFE+0D&<
M+-%,0!V3"KHA8RTH_.1[%3,7FPC^@W)ZJT%5<RE(:X:6@#21(1A[-0_DB@<9
M\8%.$>K_`#F.N(R2PI(CV(FJZ\6E(S%:$Q.)WPV[G(ZT"1G,_$:`@XX5U94"
M=*DV%@@!#*9G=$+I1XFKEW`GESP?4W-DI*TW2])$NK@)HJJ2*[U9TF"1U<4'
M,;3PCPF`9!,,.-6Q#5%X5,3"Y)/R6%$,,XH>A;&1P@LQ.M83K'O^1US\X4E_
M/I=K.J4I2E4]I>U&"]]J(/:TI1\]I5CQ7>EL'='L=I:LNNYSI!-$65+,HGH:
M`:).!;(DS)(LK.-';YPLO*;73UHDCBXJ`X%K]RK7U6U.E^6(!<J_'<&NB$'N
MF;>M/)\:<%YBA1)=;\B&$524T1MR5`$YFK.>.G7'Z&G**N3<+0>JT1>#ES0$
M9]$2B,3.`*,K(?#LA(IK"A;$.N3I;#7$IJZV3,]XI%(0R2<1J']AIE3HY;I,
M@AEW<>>C<7#"&I$5Y*?3S14-DOF_IKZC4K$F`&8);#ESAMPRXMF$UKQ"H2>S
M(^??$W?6D0K8]+$YRVCAL-*-VD^U-TMY7&NLJ)\F5-KJJ61+O0Z<,6;26&?7
MAQE#`Z+;2#FX>#`1],%W8I&E%^N63FXR!Y*<<?$4&/"24T6I:3#S%*9N=JKS
MJ0IENW3287*K1:9FPVW)'"D<.7*)Q41.+C*.'5%>W*][>]>]NW;E?M7][W/@
MKBE*4I7>;PM_:.D7\]JM^[&*:Z,J534+;829![07X[2&]#<C1RX7:C2$8C^=
MH=9TQM%,D-OI]TE(?K=3727Z\@NHLD7]*13Q$[B5/)V.!8^1,VPPRML9S<0_
M9M]M)YM615:-Y*,/(S)QG!\2%$#"=<D,?&91LC$E$HP=B@EWQ8*:XAL\A0""
M4EB`-P:]AVM9$,!%Q0<04MUY_4GC*C^]4"(FNV8(ZBB+W6L(S?Q3C!-MPH:C
ML['AIKWP/B>D+A2#D6,XR.M6N=R.C$S>8A4.YV_6=@KG$:V#<+X3I`4&WKCB
MN8"/4TZRQ/6R,"B-*2M(P)(%ZK\I$<4W,TZ5Y<]+RP]U$FI(628>N:4$<(@<
M/GA3$[3]/\E[,22=E25U%)/.<RAMMKE`&^ADVVWT1KM!,P2&TW4-&)9"XE$Q
M((8Y!@7-&CZ@.(*,8.GS0PE\[:6K!7'_`%UB_P#V@_/F.;JBHIE]ZPRJ/!88
MPZ67.OF+)(AMP^FZ4&K@#L:5V_DV7B4+`"C`8E5(RDYY!IZE:XN2>/?K^(`W
MWE;"U^VKE;6E%?+;C8"/C;?D)2CQ?7T1^1\BOA)#=$3KAQQQTZDT@I9`%RZX
MU5D^;/$?1N*DC&!A`Q%-&/"%2F8&X$WB/;)I3@Q=);[E8KA+;`2ILPD+)V,R
M1Q3;\H38UU)HRD(@J(RM<\1:KQ2U0893:XA@T7NHE$PT$:#"3BQ7'#(QWHV*
MA]/C1,8;C0$LI$T-2U`S1Q';01S.T>32[17T\RJP)D>"R55H)UY@K+;6<K%A
M4$R3)6#+F@P<\1LHSXBNS)Q1(G5]2CYXDBFMR%JD9;3SCQ-<#46XA;BP1<2<
M5<*,,>`R5',*X$Q.6%=Q^C"^2^:)`%UH@>3+9I^6W4CB0NP2-MYE1VGG<>V'
MW406%'ZZ::R.T&M#*,U6P@DVFL/O)/!.F'24DY29.;A8Q9-;Y(DT/2A?&/Y9
MDA`L4W'JF7N7I"O\K6QMZ0+O+&W:MC;TH.\K6M[EK6[5K>Y:U?@95K79C+M>
M_*UV>T[7O[UO4\F=NN]&,XMC>-]<-&%!!T'1]V73N2/*QF27$L')"Q=2,J-9
M^#,E&A^''(RCX"#$;G244L*YU!TNA-5A!Q\QU%0`LF$A14G7KBX=+$1]17O/
M1^0'\T)<:T7)T[90VY[14<+E(\<<YWB-#1C!5,=6<H&A,2^?HU/EH^UT%AOA
M33U$NUT@<`(;,ONU5X3,*."9G#"$5["2J(YHOVU8NM4M*TA1@T`$.Y)^Q2])
M;*+\8AM9RC+#@6T9+8JFW!$YPIZ06<3@/$1$PL0(VQL<_:KZRZU%]-K2-$;0
M/J&"II!O%)P#SGN+$9#ETZKQ]MC!##9RH=+(CC4$%O.9H)*^NH#8?K>$-@9M
M@\HE<D0(Z:.@%,J+<,B#R:1/FNB"K2D^)Q9>R6E</.Z5%>'T(@3:64@ISS>D
MD*6OE\7B4NZ&4JM+T-Z<W?`R"*FDFVGNDZK#MM2"R"PS/A_ZCL`E,YPZ[9+F
M!$<'#X<6S$,KI!?B@;!C.=)GE(ATPIC.J.7,K,!]7#43":;1%$@,ILG)K*CO
MNHEE-<3FV?QGG>CA^11J8Q5$^TM@Q)$DJ/971(AE-EJA=BE@S"JLLT1R".=E
M$F@Y'"X6TE)2F5-)1EK2C@GNTXCBD'43MFG#=2-TU2E_4-<_[RU_GHVZV(/_
M`,^/_KQOVN=?52E9Q&4AN:(I(C^5V6,2+/&,GJV'^U#"D2Q4DX!R-!9)KR*,
M?3LA0,3Y,-1(E\S)/(8+$R#;,&XF%L^JMOT/=B>`SK./^F33S'8C!V0C1OXB
M-0+(#!J[6+KN<<P@'@K*./HTZ?5'POB-X[ED%=O`"E2^`)W`KS%V,5XE>T!5
MJ)[6L/$HHY9,@Q'5GOG#K2`DYZD-;7BUWM"X,@2`GXD5UW^HI19Z*FE?3$2P
M9Q"Q.%#P8Y\UZ;!>#'XANS)AI.=ICJL<&,G&K2\HD'@>B=F*LC,%.GMW&GU+
M[1C![JY-05&2S'PZ3IM34D0IB;%+9&1P4U1)!BYVOF2[Q0]JE]U-1ZC#1&E.
M9H3N1V6(JC>B=*11E>9R[+4(^4G@ZKEU3.[C%<;3414I;(G<L280)<ABVPVV
M$3P"RUVG[X3HE+;=42*?$6+=;T7/2$LHM-1.@*<.N*)7Y(:S*2TP'9'"J8/)
M"RWR;S6A5!N`ABD#+=!()!5.,X8DA!#7+GWZV2>"A917W`TS.8$YPYL"E$2;
M'2$=&;CR@)M"M")T!L(B0(22T&-VHW!LDTNQR)7$J8QYF1S^1P4R8'EE\/!;
MD-[/*07,(6&<C\=KF>SB&)%<21(9?=RX?<2T*3)8YB8DR@BFI&LRQ3$03$L!
MD&!83.P=LKXO2E?<6_\`.2W_`'@#]KA6N8I]K=F?['S_`+S4:OO5;7]@2^E3
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M[UF4LQ)DRA:<X<D1+C>R>3<[IT\E&>$W$=)83S<+D8BBU59MD`QF/)(P+P%#
MLEN`<JG$QBX9SUR2V6694KGG>^6>94MGGE?NY9Y@X9997\>65[WOX[UA8?MI
M'/S7I?SY6:SJE7I(,>PC?AW09,C'CU9;DJJ&U$D1!)+Q7WF*Z3+O`:\*LQXA
M70$TLD("4SFC@J.+KZ:VKDUQ;+&PC1I2>"O@<!*D8+I6"H?M@2/_`+/C3^YW
M'6=5QE?'''++/+J,,<<LLQ+7QM</#&U[YB6OG;(.U\,+99VN)CD':]K7SQRP
MMEC?M7W!86O;1UQ:*D#KVVM8IO<;Q8BO#T:D)!>K]FM7UP.L$?-QR)M=954S
M[-0'.]7?BFK<7E4Q*9#B-HYT[<1I@(A:Y@3JII6"L[_+$F_G"R^8K%K.JR9E
M)5UUYL]#Q;JT\+K3K;219HMLW8@XW7Z9K9`CZF&^?N34;$%UQ6'])4<]=//^
M@U$\6,V)&[A6+B=D^\L60Z1U_@::(N@ILP.Y%F9I]AJ6&(UC4M`Y1XOQ^5::
MLVHGD(G,RH:7'5+[/2U!6L^Y.9::E1ZXC=\2I`L$9Q!+%^K*E8+'O^1US\X4
ME_/I=K.J4I2E>605]=:JVD.5L+2NVW&@*)180G`@*9U&7$56(#8CD5-)5DX<
ML?3E`F/CB*6.%!PAP<[<\,[=NU]]KNXVV3H?S-E1Q[)36NR1'0:@$P7LJ2`N
M&U]F!JY<4FL8ML<0?T.E662@PI19N6*XY+!7*Q93N;`#"##_`!+6VFT+D90T
M;N#8.75N/C":`CCLM4>JH=;8R6372[G($A4P;/((0-,<)0JL(V>=[CH9P`.Z
M*,G@VN#EDY7>G=$BKN%P$MK)])+;M4F\L.A5*24OECKA5FF0(I;;4ED4$QA8
M^=2$Q,3DT`P-A<0RGD"9)1N=+%P@L<&/[.;&JL7"0BISM+2C#PN7,2,3KZ7C
M+*S#]-,ERQ2Z(*;R+^EEEG*ZMBC6O9&P4>1O!/Q&QQRQT;2E*4I7>;PM_:.D
M7\]JM^[&*:Z,J4I2E*5@KC_KK%_^T'Y\QS=9U2E*4KQ2]_D%?_V`N_W0=KQ[
M+_J6S/B<T_FZF52D?;,[&1,SW!'L6SO+L=,5UYG!'&T&4_G$W6\KBJ)6Q%1'
M,)J:>`!`-*!*UBB@;(>@S1\OC@$<&'Q#PMC]O9/[&WC0&&<ISE'.)"[:R9H,
M:BNY1'96#3N?!5`VW=!'S$*"(Q11+@G4PD+B(&C&,+Y(WI?B(+CG^`SL5/AM
M:7W*8F:2LW$ZI!:\LN1?#=BD66EN3V25,$F?(!]4*"`'LW<V29LT515H(<(T
M2+F!@@\NHSO:O//?;/9^2\%8.1-@9;?`:\U7*Q5H-TO-26<%-E/)60EYUM$U
M@;RSQR;;A6FNW5141@[!D!SB(FBX`AV+8XW\QV:NX%TUJH^6T$[B);&&;!AF
MD!I+<@Y9L#LJYJ[2'1\1S@F94=O8GC8":-?/,3$F/FGCY&$_$,KAX\]M]M0I
MK_JI4MAY=/N3U&.6.+KAQXGS"EE'SQ/XJCI8V1@2V75M!;4<,#IIN9XY)(!C
M##-/*DNHPMCC$B;%3]+K7:C)E2:Y2D9G,7$+%G-=ZO==<2$W+ER&*66%34]1
M-C`V-%4O'TL*GC5C)XJG7S(ES(1444(27)2_J&N?]Y:_ST;=;$'_`.?'_P!>
M-^USKZJ4I2E*4I2E*5]Q;_SDM_W@#]KA6N8I]K=F?['S_O-1JB(LF*6(.<]W
MK#4DO:+'=DG&T?-R,-PGVXK#))[(',XEF3)$3"QQ.,BERXPA,V&.7]$%RQK`
M/`R7`%#\SAL+.X?7KVF*2!,S*E)2R:&-.M2/&C:O,J($VY95#AT\*9.G%&2&
M^`"C/(Z;,#&%M/"P`,"<L;7KDKL+.Q%0/JQ.7I!*JBJCQDWE-0+N$R$;/H4+
M*2.L1$D&A<<;7%(1JJMY"4F8!EVD4ZD)Y@"]\R^-[_O*[-[&$6E(3"(SM+1%
MD2RN+KEDYI$GVODF^_7`Z![F'.L.=-*G`0%`\YAKW$<8EK!8+]^6*N&=#QQP
MMEY_=K<)5NBY*FSLW*63</$%1`R4'ZJG<D953&^L-,BK)N1G(7(JK@M9P+C=
M%5P[V4SR,J&R"B;.`9X8!R]CCCACCAC:V..&....-NYCCC:V..-K>Y;'&UK6
MM[EK6M6#!^VD<_->E_/E9K.J5E`KV>`[*(1N,YUL5@);J4GRG,P0\)DW"+S6
M$@DWU5TEDR__`($)<44--3T@V?M_X09/)%B^7^"%:L7I6"H?M@2/_L^-/[G<
M=9U7-KWQO;+&][98Y8Y8WMW;98WMEC>WN<[96M>W/M<[51$H[<[1S<U06-,6
MP4L2<S0%5/7`6P]78:6T4-920#!9,5,28V&./HU/+&C(!0>^5\@01LP\?\"]
MK6G:E8*SO\L2;^<++YBL6LZK[BY@P4,%S90<<J;*#@&BIHJ,*6-%3187`<L:
M+&`,PQRYDL.&&.7,`B!C`#!ABA9X"88Y6VU+>P<[SZ90CDX3'),N&FP4-$6X
M-(3M57/DAE3V8(A\-,P4!Q`BHA\0L6S4#6`=SJA<L7]&F1[%P;8:?I6"Q[_D
M=<_.%)?SZ7:SJE*4I2E*4I2E*4I7>;PM_:.D7\]JM^[&*:SB&_Z.UL+-431M
M+R+M;"+>29.8[:?::@JL(2,JJ:,1="465RJ8?4R,OIQ-0.$P3.`)@X63B`!@
M7#(0$H"'ECC6RO8QFS'ABP%T`2C]M5/8QFS'ABP%T`2C]M5/8QFS'ABP%T`2
MC]M5/8QFS'ABP%T`2C]M5/8QFS'ABP%T`2C]M5/8QFS'ABP%T`2C]M5/8QFS
M'ABP%T`2C]M53_)G]'6V#:<U:SL8YMC"1P_)B_,"<FJ):#)&`)HXC8B%8=`X
MI\H/,@AA0P4"Y$1/!P*F".9(<3`YGD?#QR)7H#V,9LQX8L!=`$H_;53V,9LQ
MX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_
M;53V,9LQX8L!=`$H_;56'R'_`$:C9!L,!].(WM]!!LLA,IW+`Y4M`LF@CF0D
MQN*AW,L",--.80(AC$"X.`P@8V(.6=A;@&+8=9$Q^$?Z-UL6_P"%X??"=MQ!
MB:1>$4QLYRB<=@B2C1Q/++[(058$B9-%IF!+FAR89S$L*:!+E@S(@61C`J5Q
M$L6"VA[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,
MV8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"
M4?MJJ?=I/Z.IL+$\(.I[*^V$(K9(@LQJG9)J;!LCIYL<5RRRPVN6$Q.'9B.`
M`ADS"T$?'M<H8S,`%1"@5@!#&)PM0HG]&.V6S%&SQW&@.^.0PU\;Y0!*%KWM
MUW/E>^.,VB6QO?N\K"9VMSY6SRY=5?X>QC-F/#%@+H`E'[:J>QC-F/#%@+H`
ME'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-
MF/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E
M'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F
M/#%@+H`E'[:J>QC-F/#%@+H`E'[:J^87]&/V6#&`SSW&@.V.)@"^5\=?Y0RR
MM;KV%KY6QRFT/'*^//GU.0@=LN7*XF%K]5:>=5/Z.GL++>N\3R(D;80BAI[H
M;(B@725.#9'43I#"RXLE>L#GR4PDBQK.]R]Q>NADBF-K"6#ZS?J.O"T'[&,V
M8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4
M?MJI[&,V8\,6`N@"4?MJI[&,V8\,6`N@"4?MJJ?RW]'6V#%VG6(EMMC"6*N1
MUT;3_$6[P9(UTP0DIRT[FX$D8)]IDL=Q.`C)`I\10R.9`"`F`R>"=AF#F?%H
M#V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L
M!=`$H_;53V,9LQX8L!=`$H_;54_L/^CK;!N+8+86."VV,)%5*/4"`U$^JF(,
MD88@K!O5NOTT4")$PIDP-$,TJR&,"9S,&3N"A<T$*%BF^A\RYB@/8QFS'ABP
M%T`2C]M5/8QFS'ABP%T`2C]M5/8QFS'ABP%T`2C]M5/8QFS'ABP%T`2C]M5+
M_P!&,V8M:]^S%@+M6Y^T#*/VU5HF'/Z.7L0]7?LHCDMLH.3QHSGR[!4C!N#9
M(-!+![*$(1?.*H0"+S$!F0)^@7P23;DC0AT;T8FFSF)W(N<!*E-[>QC-F/#%
M@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J>QC-F/#%@+H`E'[:J
M7_HQFS%K7OV8L!=JW/V@91^VJM$Z]_T<O8B1FD]E=-VR@Y*!1)\V.8(P!Z#9
M(/"F3T<3>^6*H*@0I68BN`1-8/(!A2(DLPQ1B!0R"3,'3Y@$4T)O;V,9LQX8
ML!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;5
M3V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L
M!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53
MV,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!
M=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;53V,9LQX8L!=`$H_;56;
MQ7IT[^'\&]X+?K_;$I+AYXEW_@Y68UEAE)`1!P,1D)8"5FCN!QNX_F<*"M\P
M*,>LJX`&`S(&&!(MF"+USV4-#N\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_
M1Q==7/2E*4K4\\>TC,'YK9$^9JW6$:=]Z7K#\GB$?W7-2J/I2E*4J&^(WWI3
M[^.4#?2*B2KA#^]O^6)^TRKYTI2E*4I2E*4KZQ?O;?ZP']KA4/\`#:O:VC^N
MO.]K?_@87W?_`,S.&KCYV]^WEM3G;W[>6U.=O?MY;4YV]^WEM3G;W[>6U.=O
M?MY;5#*?>WKD#KOSMR["9@]O_P#V#DRKFYV]^WEM3G;W[>6U.=O?MY;4YV]^
MWEM3G;W[>6U0S"O?Q;M?$K4/YJ3#5STI2N,NY?X+_JJ--5/;/WX^64%]$74J
MK,I2E<9=R_P7_54::.>UG+/RRMZ?I>3'5F4I2E*4I2E*4I2E*]?_`'\[Y1R_
M%]G_`-P%*[3M#N\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_1Q==7/2E*4K4
M\\>TC,'YK9$^9JW6$:=]Z7K#\GB$?W7-2J/I2E*4J&^(WWI3[^.4#?2*B2KA
M#^]O^6)^TRKYTI2E*4I2E*4KX"?>V_+"_:85_/.)\6C?^"A%B'HLGC!KQU'#
MM?C19K?M&<4J]TAOI#[<H*>1S55MF*"NHY%PK]1Z+4CQLX+C;&PH^?4X\OV>
MO@<3[PEL>B*%?X`IZ^!Q/O"6QZ(H5_@"GKX'$^\);'HBA7^`*>O@<3[PEL>B
M*%?X`IZ^!Q/O"6QZ(H5_@"GKX'$^\);'HBA7^`*PD/B]\0L*1C<LASZ%C(!Y
MC)\;FE_[EL1WR%9J6Y%-W$4GTONR+I>&8"^L*)STRP)XJ8@9CT$*<S(A`EL,
MV]?`XGWA+8]$4*_P!3U\#B?>$MCT10K_``!3U\#B?>$MCT10K_`%/7P.)]X2
MV/1%"O\``%/7P.)]X2V/1%"O\`5[`O`.V(F#:?'<.89V=F+WD4R\83:0[@P0
M6\VK9M]M,!PC(I&Z4UDM'2+9%!5E2SS-XD;'#61F]S0XW6PNH]B.E*5QEW+_
M``7_`%5&FJGMG[\?+*"^B+J55F4I2N,NY?X+_JJ--'/:SEGY96]/TO)CJBF)
M+<6RB8>I2-9'8D@FXW>"G'DA%F4[4!TF&,_44(`=793O!1#YX1N.M+!-%A5%
MOJ^)15)X&`<C!7"PF//K_,;YO55V9G2!6V0U#:Y.$)FCV'Q<IMVQ5XXE5^&'
MK$D/RP(O,^+D^$G4$:*]8EG!J-HID[,LW&XV^<!R,)F!FUB^YWCQ&]*X_;KM
M=+RGILH*0P"C^.OS(TDO`128P$:2^@0*[\7H@E6V87FJ9)2TZ$-FIQ)=3"!Q
MRG#@BBUBZVA$3ZJ5_.7XC>HQIA$I!`?[K%+GGZYXPQ80<*3F+.I-^LIK`OMX
M-I7UT!C86>44\UF`;3Y#<.:K'1,HD1ZKH;Y.F0FNNHZF>^3IXCVFK356TCF)
MC*KYAX,]A/=O*#$9TB2*V#B1+:0H+D.$3;T8;0<;/175,Z>F&18<9*XNIKRE
M/.Y0!BH*\844X$WB`W$EAHMIKK9NL,SI@SCS9U?UL;3,:Q&-G4KO]'5-E'RU
M6*W;.5OHZ0>&(DD`^YK&CZF'B(FN4$F7),0VYE5RM`DN[EBC=;6V;)%4(NCB
M0!UMS@!/TRA&33/?+?:$BDHJ=A=AR@I1`_W$VTEC3$EQP]#A-L/E3C%PNHBV
M5@X4+J8X.!D`;/[%/=36I&EP[""C(V0+]3EHZU#O4,Y_&666?B>P!95-Q<)*
M)5JCQA]V`*-`1']C$.+QO)8S/Q]/P6L(GY8C7TH!Q6=$AHS<<OYS0=)1^W&_
M#[OQ6E&*)H3C3J9NP"VHM>%'G'3>.1V"YY+:,GNY'5F<SG&PT9PI2N[TTVV0
MS."QA@5$_:\N)5K0B!R<BM=QJKGD"/V=*ZL0;JBRI(9S7=<AP]$A^97M!Z7)
MZZR,&+E,K2:!(4]($8$U91D./0B#FP<S4*J3-=:8D?IU_P!^&1*<'[";`26C
MDX7CK7%1#%?:Z?7C;J($&<4UDA391R/$]F0;I`Z5)MU(ELVCFB11/4C`X#5$
M6`LK9JEDLA^MO<2S3QV,I6>[<D5S*@24\62Q`V9A#<UDY<<#ADU(/..,K,N%
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M-.6/GD6;\E-)K.!18;]121Y09[V2TH\W7"`FJX:6>,FTA1*EM(QYQ+]7G5A$
MB`X)`2DV1)(9NM#B5TUG(<J/J-&:J;:(82E`R<L3&)%[8:R0E2\I^B6_$ZP^
MB[$//I8"`2`D!*<)FR&%V%6OS[?_`-__`'XJ]?\`W\[Y1R_%]G_W`4KM.T.[
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M[7Y7]Z_+N7\5ZASB-]Z4^_CE`WTBHDK?6PL]QSJY!<K;$2X?5$N-(:9+CD%[
M'T5"5'*JEF^W2XIP]F01$<`P>/F;XVQPP#PQ#`"ZNY@\:)D`31P#[X@F]CS_
M``3'NP<4GSRI'TLQH@2BQ%%715-OJ!UM.MO`N%",*"&L%RJFF&129D#(P2.`
M!C`Y]5CSSPO@)GTYQ#N5L_$L$:#[6SU*B1.<:;EQ1BIR!'I",67'SMBY_&M2
M)2VU1UB+UIM&TTLY6KF2B!SQXX&L]"B@J`V7FV\BKK2R[=<*8NUHYN)XP2!Y
MGL]G1-)#[E>5(UU/?,.QLGGF4C'I`5]MDJ>7,UVGZH%MP%D%M9QXRM=)(?,H
MN):,8HR4VDT'%M>JEP'"*"<GAR<4^5X]FUYBO?529$Z%FK!&IKWDMN*_W+FW
M(6O3@E[9K9C7AZ++BP.O;.\K)JBJ1XPW`RRD<&%A%78X*+#Z1%X0XM(C=6?.
MKW&YUU;[IG=)&9KH5D*'6KN`M(ZBV7Q#SE=K]7='DMZJDUMK.*4=^&I$C/%9
M"CMZ8Q"YY01FVVY$]3P^0IUM9+C,"=.>WXH*O@LDXQ&U/E0#8%=GV-(&;L4B
M/6.<B%C<S:VR3M''ST=3^+J`Z4VFR0CZ+'<E266*I+A7F:[TP9/04Q^(XR6O
M*FJUOCH:XH:=%JP>8KO32+GBN.9@E$@X'S"[<=\6-:2I(?43)A)$8JM((+KG
M9T(#NC-]*3J;\+IKF,I[(1"[@31%A8<39:JO7&Z>^0.H2HBH9.$7Y,BH9@G8
MG9=QV::^S&V0:T.ZLB1D/+2B9..Q2*9J+K'3).3,F`V")6Q=T+!,=*5EYJ%1
M<5D+&8MXDK3?TDMJ)G##TC1\]G;-[`B-(3U=292R6!2Y;U2D_;R-GJJGT!<-
M`$P5"/XH<S8<[;*W4%1LO\,)/+F7`V1BSJ-:G97%[CR1Y7@2,V=$K@$%FI`9
M3GN$Z)-B1E/DL@/R7Y2AL%9CR-7`Y2R[."9&ZK%"T[YU,1T<,#Q:PU1#5,BC
MD7#)IME,R:?%!27(UD"4SFLT](<$2BX(8)0!-AFS`4&=+C9FS8F-==&DYABZ
M6[#2U&PZLIRBWY/;;5?Y%,<;JB(%574TL"Z4=99B;AK\XEIY'G)<3VHR5Q8C
MF*&#OVER$T3(S%05]SR?JE+&D+'2'&DOASN=*:K/CDLE[(.56<JV[55)*)3?
M35%PK`&.2`3(J/SB3BX-2<7?"D9Q7!3RD1_R=.4VPH[3C!DF(7;$D<`ZY$8=
M<4N2G>74YSXI+\C,DT9I:R@TC+1117@Y7%EFRCS0;BY8U<CV_P!?`3[VWY8?
M[3&OY6<H>V?*'YT9._>`Y*P:E*4I2E*4I7M]?T8OVL=O/SJ1A^[L]7M'4I2N
M,NY?X+_JJ--5/;/WX^64%]$74JK,I2E<9=R_P7_54::.VM>,Y9M?M_XY6]'_
M``V\F.]K_#:_;M?W+]NMDP9JIKOK0HS`KP/$K2C%2GR4%R9I>.-DJ9!&>\E.
M/&UE=S*ES1LU8`0SGUX<-+3,2"(3-'%(V13"QI441C4K]AM+[4V%V"F./WIJ
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MIRP'%+&B1918G.#.0^PHZC^86]&[0]-$M29[I<T6Y8.LQ'+GP7'(CK[-V`FZ
M/2LF<._7/4$.58]%E/6Y0U%46U)6;`=%F`XA=/IQC"3V>&N,7!]6<X`3M;D6
M)2`Y;I[W"$*K*FHK*5D"0#+)6&,:U<.U_0I)&OUG=-+8>,':9-.?&=K"UT6-
MS#7DPVFSLI)0(!B;WI=T*+:<YR,F"G&60D9LAF,[!\J*EF_G9@6528"1?!3O
M"H/";1OR6B4BL:\7ON=7GLR(E+C-D%?DQ'E!Y1&/'&2,CFC,MA0L20$ERY@/
MM*>Y2(0)4))N!B/R#@)AF\WEAE*?PLL"'8[86FFP@<"0SPTXDP#^YY;#!S6X
M>,X+$RX+MK6>&6"+]U3)5P0<4RV*CZB;E,53$ZY^KL1"QAT\,*47.J*T=";`
MM`EK,2G?;;:)A-O[D1PU+R5+>V,>3RU%1NN=]`/A.;C@C:/7?LE*+^0LB[63
M'NY"F3.8B\NX)[<5%US_`*Y&T/>,/<-KB.P1':\IS`_-@X5E2[+2T=K@(2N*
MZ1-*XNUN0&RED3:VL%%1065.(BJ^3&,CE2MC+F#1#!88),$45#$7EPV=I9+5
MUJ8'ALXP\9F72NM<?KJ$T6),D5Q'($"ZYD9P4DIC2(3C:?4.2L'$ZI.G90E5
MP'6J^TQKAF6&SXW,-U;:`[E,JV`1SP7WHR6Q&+('V#9QAOLEBFF6LFDN)'`F
M&E3U.\29J\0"/#K?33DG*F+?)6+)SABEU)2JLND[E8VANQ*<.8B>I)"L:O!1
M4DAA3!$1N8&"59"WK_.NO$1N8E&TA."2$1N3F^VV[#B^]S+VFM=9Q0\W4%J)
M334F]##9BY`D4_D.[G-@2#*H#11*JFOAX/1^R\[9@8LSMIL*[TVH:L_'$]U1
M8$]4Y#;I'0!_:&N5KE4X\Y@T-S*YM'?AF1T@PZ4<RSQ#Q'!G.MHN)".'S!CS
M_#]T?D34-O2@@.^56TM-MYHT?H#1BB+TZ54:%8V%9B*XDI?>+!9TN2U+:A'Y
MR3!UQ/S5XYC]7;<4M-+9[936RWAE*ZVX5;5$8\*#&.HR)QY:<K*^98+A6`9+
M5HY]`Y"X\,XY&1JV-R?JT-7M:8<H[$QZBYO*S!NM9Y\G9<EE8WW$V[7:[?=O
M?N7Y=N_/N]RN@#?SOE'+\7V?_<!2NTS1"_+2G5'EVO\`%]B*W^[)FHUK]SEV
M[VORM?W+]OW*]<?1?9%:F]4BW<"?N+U*$)[5R+Q!']KPO</H54:3[@XFGHTW
MNB+VGJD3U83T0%^M9U.%C(R`OY3^,K^F;/S6LGBZ#AH`$V;$P:*.*+*<E\8Y
M<4E2=)K*:/;*S]._#2CAB%F=+3?A=H*\>1^UDN'=CHOFDRV0XA4I.F?8YJS;
M'A$JU7<._DU.R0SJDC8I94CF#6>K:*]==]O.)^[G+//%!VW9?#RDO7QJQ!KX
MDSF_]@W3(2#-NI\=.YUD5>*UA522$MKZ8\)&5'6D"*A\@*W"20">*"YY(>&!
MFG9%V,V:4.)-PF5%+?DB1QK3MU%NV"RX=0']$1"-90;KKC37@@^$S.9UG-RN
MA8/.$@KK9?`HQ"9-#(,Y4(F1C)]T&C``A'U[%SBH[V1WK=#6Q#9W/>#]?N\F
MKVPDC;'-)P(<=KS*X?#A9FYT"060D"*6HFM`JJ18EQ8SI5>S%44F4E-QH*JZ
MF@6<SE#-+@&08=4WVGV54-SUSAI*'$;F]L:KLS8#9$JVM[O3^),)U=HL9:00
M9L.AP&KS<8CVT;+H,?/^37@Y7-B7:X3R<34;(#45U`LCA_X'L?\`"LGN5MH>
M'3IOL#.&`>4K2O`C&=[V/@I`:""O+!\D(%=U!)!<`J2(!.\F6*.@,!,+%DFV
M"Q;-(+@IF90/'S.Q'?;Z"?'78WZ.+KJYZ]=3C=[$;;L&7M2F5IB^EU"=D*,?
M9#B,SRRD%8/IV$NP%J`#&114@]P$2`N'IRF3`9D->14PB>!.$<UY%(Y^@Q#@
M908OU3%=M-U-W9"@HOKJ_=LI?C[:G8_B<;KIT:0+M"FZK2@1T5A1QQUI]JDA
M(3_?:JG)S!82E)1%QR<L,W((#)9<2DIYA`&CHUS1;LTV.XF4E<-'2V1V8T]7
M]Y7SL##S=AK%FO+<8-T3=&<O3+L#)<<%#D)-?99$>!1?G9Z,D.2G(B)!)CHY
M)(&PCE2)(9PPDI00A^&Y4XA>]>]3)X;@C.56FR">V3DVDV@,1=J1MZX-67JB
M:LP6TDB-&Y'4T[3NT@X2";*9&;Y`%&D1N-=B):``J1V=9(>&"T`;5T7N;X#<
M@RO+?#[0Y0EF4),D\Z])WV7'98DKO,O++H8L<->:74P6G'6$\%@2@6P2,W06
MD;,I,SA)Z65>`"KE9-2R"4G$2V':#/'M(S!^:V1/F:MUA&G?>EZP_)XA']US
M4KI9XB$J.>1^*/%FE$H;VRIP]-7"FBCNV?19"AN5&;`;MFN=R<O&F"HLY2F!
M\)"HF8MN)8\)V?QR/2&185;]-!UI<#/)27AZ!ZV^([Q&I]+P1HM#NG&]DPS9
M(K7UXF'>5];-P_K=+I5R;,(4-+RXP-:X^?<<12TW`.TH]V&D%$>;=?#P<Y=N
MQ6O688#N4%$DW7(2"M:VQ%Q=L-E^$=+T-;E[S1E"W%&/R*J/MDP_M8^V*T4)
MH,W1QSRZTTZ/4!"SQ3X_7B+W:9+-YCI@61E55PU\,_;`4^+<&B^(3MGL-?A_
M<0CL9`]K-0)#T8CAT&;SSL5K\6/EM@D!C-AZ)IM0UZ?RX^;A+AE?,M8BM&)G
M,(9X\D%%I+5BC5&4W"7.(\&<0O=[:AG2;M.YFAM@^(-6]&-/>'K..O$*((3%
MNUMN9!V1D]<;DK!RNVW0UE=URJE*>2.A1*WT9E+:$7:S@<F"R5L(Y<[6%Q*$
MN)3L\S9A@W9=[3;-4ZFIZE7B_M?8OA[-1MM=VAPTRM%4N5%6$4"$8Z;3/)R<
MQWX4.,"/VBYU1W+*Z8?1N7BQU?Q!'#3Q[]A'`LW+F7:!S\0EMSW*3_DM]1_L
MDSW"DD'%"\P1(SXL:4FP?'CG-Q&Q4^56"REA.0H_D,=ZMM&0G,"6?ZFVTQ&D
M=<1P4I\(ZHI=EG$;[TI]_'*!OI%1)5M#E2QXH9)'2X!LF<#-%394R$&8+&2Q
MCK@0Y<P`-CF".`,%GD&*"+AF$*'EE@)AEAE>U_C<@4]`73,``P2/H2Y'`N!A
MB"$$5ZQ<OB""&'CC@$&&#R##P#QQP#QQQQPQMCC:UNMJ,>&WK''PK)CU:?DK
MR\G17"#DBF'8OER7`W(DQ'%CO:QJ)7(HL-J(:8UC!)84F(<.1?C)*P&N.E+:
MQ]::R(XDP!QN4%8\"U.$O`S2*!G@9<V469/1P==B\=S:X)*;)^2HG!U61I':
ML,EXZ*`QZ3C5.(HC+EN2&8ZTI;CMPI,H(CP7AI0(.Y=4CBT-LLCPV=<2[(?3
M)43DIN7&4(\C".Y!=3KDQ;<#W=Y>*YFDJ?TASJKC40Q#%G8L2E+#U7UXZ1!*
M)69(Z0;B$B(#:1$A**>+4N&?!*R#+*"K/N<C\52LC;,I>4)8R052XI8IK;L5
M8-SNM,U,0FTEN(RHN-1<SM5&T3?[H?C<BY0=SC,1<@,_TPMB!M6^I&O9S8"\
MP8#*8LN(;[C&:3!`)X8Y6)+;,@J8=96(K'6UACD,`AG8\DF14W`,?$,FL+Y2
MRF"/D:0Q0+::(<+B`6_ZGBC&?4]1RWBC1:,?OIL,23040A,;'8$L/69&:W)"
M6O4V9>I(-`=<D/M/LMQBZXX=2RRG2IL)RKZRTKEDHO2LW:I1)L"J'UB1":\9
M.J.OD_ZS&<DE=,)0=XOV5Q8>,G%<`P@A;8+1JT<-KTE6K7N,C=:.6`"%L<SM
MAI)[\.2%76NX/)OO&8HLD(F]X=D!%D&.'BC%7*WW#"D)OS7=L9I(#N:+Q;7H
M14B&3'LU'(746\HW/76O3M.%2'`GI:F2UZC\)K79"0HF8:>^M@!H@B8:'%$K
M"KADPD^(Z=3A@:2%*5XV=J]B^VFY7B@NPF\U#`^[5Z+G?')V42Z>GD91S>(`
M9FQO[L>%)`P3246*6DW8XJTTI,;2+!R`'*)$9(U=2F=.#2V':Q2#4DXT327U
M;?D]@,4VCJ,NDY;6$UHM-(C,DH@1OB<:QS\BCPCM85EFF6PLN":EI=-.:5'X
M/)2U(9-:?@\CS!-.OFP3M?IRZJUCC-4E.TJ:RQ8NI+;5&:>CM.2R"FSO4489
MJE9"*[9A'A\0Y"$HBS01=LO2!)AEY3$_SKJDMZ)RZ;-NR>FC"S.E)2$*H[9;
M:<$5<!*!&`<3D(H4*MUFF"Z@FLE);K9'*-\A=U?`3[VWY8?[3&OY6<H>V?*'
MYT9._>`Y*P:E*4I2E*4I7M]?T8OVL=O/SJ1A^[L]7M'4I2N,NY?X+_JJ--5/
M;/WX^64%]$74JK,I2E<9=R_P7_54::.>UG+/RRMZ?I>3'5F5ZW4W0QLALEMI
MQ)&K"!%<3)#:\D:N-J%MD3NU$G1RGZM*QO6>%WF=6T.%FQ@?1G\E)2D?57HL
M-$4`HER:?6SK.<O6DE24U,'Z8_W.V5UV=DK.5[27$JUKTZMQ>,$VD\E)+=E)
M0<L4E-9D>;9Y;3R<,E([O=)T]'2->+%UFFHQ9D16.(;%.I!EJ'SR\CW2%/\`
M"E<2K>Q3O($,EVZDG95;$D:QEPU8."6@VYW/QG.$&SU,#V'CC4AV[8$Q9(=;
M*4(B13"8UQ'XBRD4A=Q.5]+D0K2BQ<3KI\TQN++M!([I8JLQ6C&SRC%I6T6:
MLI+:7'ZXT6I*SFVL$:1)^N=L/Z89DC5T0&"S3KH$(1C&SLAZ3W.^GLU'+'"@
MIXKBFCCI?8?Q!EN5FL]]!UYB2^[F(U5/>F$8_DA@MH%')ILJ-UYX.T/TJ=2_
MF3$<X"(EF$H`[DWT1334UP#7Q+N8)6(`AD\9*VF>9F47T:.K,L[2+*"XIEEB
M)M?=0M6Y/6(*>>QRQKU&>+;>#]5)P0)!C,Y$T;1%+ZU*RU(KL5'NA,5;R;T3
ME73FZ%%/9["=.VYS7-P84TZX=Z8K3RAWG439KAZQ3L9()9"$=Q.42SYE5CL:
M2T8FIDEID`YDG,84QP%QQXI(.;K(8'<RB$V1UG#--B@GQ#-ERT?P?LK,"W!J
M4X)<C#B&.>(RK9:4_8-"-$J.Y;UR@Z&6F[6(U)/7S,^OE\.5Q%%I2RR:B>H%
MW4NI<>QR;8:,9=#Y7-@Z[;=3_.VW^NC-E505D)1A_9S=J`7*0+H@$7')"2&U
MI-KG-K65Y4BUL2M+#41WBWU.7CR;=)`=A\`F(DE5RR(SUI24&\FY7)FVVSR3
MMIL#`<"J$3L<,26]FUY?>LD(4FRP;"3M>M"N']+37)MMH'Y916P@9.EX3F;;
M[L3&X"V6QBV"(KD340&1U%==#A[)HOVX9CPUWU,D>2UI!CI\[<PLV'NT&R&.
MIY)@[M5=?!Y[=S>1UH<OF`7+MAII;G6`3JZ=3\ATI"&SQ&%/6ZSGU,ZW<0Z7
M8[T\C!.4SS+<2VQM4>!89;[AD,ZX5AVOYV;\/<M&4J#N=6..PN<<Z_Z2IAE7
M9(I2P*CDO!GU%<R<X&(Q7#AT<4C;>)F`Z9R>"'#$A-IW1OQ-'#&$8-5G.IJG
MV:JZ.;5M>`HP4G2]3T@+>3M3GZW'E@YI:)A)35+H)A`N,U%=+("'[WOS5/8Z
M?Y-:NW#*G]1:\7NV`U(HEI$TFV8THX&3T9W1"5?P+ID.!C$XS>&P3D<'C9E2
MM9S20$CR$R,&\Z2Y!)3E`Z(-U1-@]-3?:3&7&#-NVF.GNRLJ</""E>79^G!Z
MJ\Q3H>DF8ED:5]GXY33S\6)"TZCO9)K#,J+&RWTD_%1A1"D`!Q,2+HPS16LX
M73NDO(FP84/Q7DW-C)2*,.&>-TE:OD!QSF"\NSEKUCN$V6`BL%^2BZ<%9^N)
M%C@4^XHX.KB>X<5B12C,!2Y#6'*%DNX*NQR#S?\`'V^:[+4B+3=FJ+ICW[`U
M=BH&+=R)Y/.:`5DIK0B$R+3>.K9(5*@,4FD.)@OIXR6VSIA8=Z*6D4M+8P(A
M)+P(%O";\WMELBX\K<[6R;K.O:U^[:UV^3OV_'[_`&Z[4-#NWI5JC:_<['N)
M?F4D5F*?J;JXDS6>V32M<8)3=AU0(R`I3N0B-@DYC/@G2>*<<"-R87;X;R,8
M&D_#`B9N*LY9F">&)8;/,"W6Z_47U<UK*1VR8B*P##1>*HT=R5($=QL!&K/"
M8C$?:$Y#CQ17FSVG@D60VVZTEVJ*@YTYPI!(HK$W`>.+`!O!0,CF!-AH$<1^
MU',^GHV&0TF\[Y/4D59DATHC>2DMPOY7;B`2:C?4WDL$BH*@Y5!$;":GMU).
M+`YLPG(A$HEE!`B1<('`MQQ'SD=['D!PLAI+C[C/U2_<Z>2NWDI1=+$]6:6"
MB.[U'KQLJ*IMOU4(Q<!*<'I09*>G"<"$2/\`7RX>(=M7HFI6K#:6Y><K=UM@
M5!<6P)4\1G==1X@CY-6)H)*GHJZF3E92)MX$W()11N>/9'RKK%52YW,Z;$-!
MC"&!L\\8-:*:3G8=2M>#FH>L9N`T)Q9.]$A,S`\7#Q.D.O,0P,(YDV/16OFU
M"3@$%-FQ!5HNE!J0N1HSUTUGB.+CE3R<G)Z.GD4E)(DTQ+3"95/34Y/*@$B!
M`@2`#+$R1(F5#"+%"A0L$$7+%BX08!<`,,$$/`/#'&T2[$=]OH)\==C?HXNN
MKGK!#D7QNH/G.3C[!9IV1LV,?C'-^&VTCF7AE'"HL`.%385W&,3S5KLY172I
M59/MOT5Z3G%0L6/F2@ID`$3#"XVUGUUAL^WE2)()A^,%)HQYG$C5/1_'#19Y
MMM1;FZ#+VSCA!,("20%2&,(\3AMUB-4AD71!'&9'6LR62B+F8OFC\BZ-91!:
MY:2F`S'^`R7NV)+9H+S;*,Y@FI(K*-YGV<^VX&LDSF**\&J>$$.-UR)]BZNC
M&L\C">;+BY7RJ8G5PV.'F^0219[:,:B/`JF*+I5TPHZ==(F7RB:JOA9]4;T4
M4\JJM0T7(GG:X>:ZY3)4($9<6;Y*:GD9.Y7&O7;8;#;93>16BSF^B-1JMM,)
MHK=;3;22"$WT%'3@,"R>DHJ*E%RB:E)A$L&&7)D"!4N4*@88!`!888VQM@D\
M>TC,'YK9$^9JW6$:=]Z7K#\GB$?W7-2O/3CK)KALVDHB#L=`4+SXAME1%6&Z
MCS/%[)D]+058<'$N,IHQ%ZHBT62SXP&.(`QHB&`,,#CB&+GGAAACCD*#",.-
M9T*SV;,5QVW7BO,EL1JMNI"9C>2'"K1VRL3V#/8:@KIZ<7.FF:UL%-2Q;K8%
M&R1$:R@=LGD2]C(UL_"M;6W7MC)L2([,@V(VFDP$,OF8-3&W';314^'1W6EJ
MR(YAHO)IR47+L,1PHR\N)*UFV`TS)33%A3(G+BE3QD(3/WPPV3)K.<\>R,T&
MR_&&]411;3P9;Q0TUR-5TMY7+YE%1"<*`KEC:6LI"B5$$+GDY0*F"AH#/,(<
M+/#*^-]<O7637&27C&DB2'`<,/M_0QF$)$#V>47LESNV+1`!2Y@`2/'&M(AU
M79N8!@H4,`W;QQ/ZR8*ES`74#@AB8_>V-;=>F3*SUG=FP7#[3FZ2">*?(4P-
MJ-6:A2@^2&&13/$D[W\EHQ5TN,K;-/(9W`5E4V'GF1)YB8YYE0,@\W;$<Q^R
MEE\.)GLEJ-9?DQQ%W?(JVWT!+1U9]NLH@I+5*N5X*!`J`:<B^7;*"AMX%75Q
M39\)$1TM+P'L23RH(4G<1OO2GW\<H&^D5$E7"'][?\L3]IE6JIY7I&:T'S&Y
MH>;P#MEMO17(BY%S5-`YF"KFD5(9ZRH,=O&0`S),08NM.@LE)HP.!LKD-@:R
M"Q,`WSL)CZF37V4D%C24XMRHLV.GO9A&UKX?NKTO;0K;V8:&(L6%1MK%!U;Y
M:_V-"L9K)S;>"=%:LL/G"&DX4%;A)U,9KM0H*@MQ=-(M4[;8G;MGSOJL6FJ>
M9,,O)^%=4'8NP$RG"5CQ_MQ5V<GM^K$@MMI0Z[8)&C3<V(V-'#P9432$Z&[,
M"/(&J;<B!PR)BB*;C.XK2Y/45NO>1C0VYTG7^;]BUH/6F%>(I(5VJFMMOR&H
MN_8)+XC\T1:&(_"I]BW7WVL1/"ZLK2NU(/2AD;&0'-9F*!Q&7$/%*05/:SNV
MI6L958D1-CB%[`I>@CHVA:K%-;C!+354GT=(J.BDURW*<9@3RO,!1!)LEI2F
MV89<CEE$)%+&8C<4@.N,C+J;26AXHS(Q1ONW=IRILC[BYR!/S5EF.]2-&S[3
MR0&4BH9':)K-SB$[OLQC.V968?C3T::'DW6,XVGP\HY;(++)(><I".\)%0#U
MF88;?:?I;,6TDE[ES]`,FN1W79>B*M,#->;@52;=+`SRK[(R21EW4D\8-D4`
MI8Y>%=1\$I'<@B'9&"4GP\;G%H,X.2!#Q[DZ4I2E*^`GWMORP_VF-?RLY0]L
M^4/SHR=^\!R5@U*4I2E*4I2O;Z_HQ?M8[>?G4C#]W9ZO:.I2E<9=R_P7_54:
M:J>V?OQ\LH+Z(NI5692E*XR[E_@O^JHTT<]K.6?EE;T_2\F.K,KPB<V6XD*C
M@6TE`1$Q9=ALBH.E63TH@24W(?3$HF@IIU?/EBX1M9-IZ(GD$8B94AC(Q1*)
M%$XOF&3+`@X8D?AN(E0J*14XLCA1)#J;U6QRAYCM<V5&69*3U9)D16%+F$H0
M$13?J4OKJ8]#^>&1MU)ZTK$ET4^64C@0VC0]`M&PFN=906G^LP314KM[)0;0
M4'QN&BG1&D>6E-K#&B&#=Q`',ML^Y'`:030N.1E(%7%?TO&+AJ)O`7/L]5=9
M1'='#^SU[A2[WAY!16M$[M^Y<R<7%&K:;0)PNVV^Q%?%$Q.M1&;H"@H`M].1
M!B11##4#^*2$3L=-==W`MMAM.7TH]4;>0U_U/K:>YD'T[24]5])'&D7&NE+Z
M1Z/+F/2U;3+F![IZJ2ZP?)7&%N6,!=<SZK5#OU@UKD%-;J,_M?(1?*2T!%\9
MIICRBEAND@V!G6HAJ[H%;Y1>0%`!&%<:J"$I+PB=@6S6#X09Q1N9,!X"8Y$L
M0A#3@CY%B9;B>-E6+6V8:)MNQP>9#:,L1`-1^M)CD8AA$:0B;="21F8X45(7
M&J(GD"^3?5DM/4$JY4T3`%#_`"+\`P6ZFQ9DN:&8I<#.Q078UL&JLQXT5)NA
MMI^'2:D]V^$C'$<5/!17BHIY`^Z$P(O@37SQ$F<5031DJ7%#\7'.LVND0#ES
M45P1#T<&B9BYPH:8\;,]KF2IW-`!:HQXN814<F,$?,-DL7;YL_AGB=.HI<!,
M.#CDP@PL<VSB^-1%X\Z1(]8^;F4Q%H92<6;2;^2ZH"N1";37<0IY7R3KJ!L1
M>;3,:#>6LS!D3)40VJVT@_<PGH267*8G(VN>O\OQNDP[*T(1))$2H.2#DAQB
M^HZ:+JC]&R:Q2Y!M>E+.6D@XWTVS?(99$$;$DG@8IA'+,D3L"5SS!R\<X]6]
M:G@\F;(CLU^A9S/R.T5&;C">*_%[)6'*S&^W%')7;J(UEE01#!Y!2V^JYB*2
M"12QBI=$/BBFTK`F.**)GEYB'(C-IX:2:BV.C"6$FOY&"3AV0V!2(21*IRZA
M)Z6&3$2LBV"=(Y_+(Z_".(5BKP-Y9&7$"I#7OG7AX^U\@F*(^5XGC*&HM8$7
MN#-9S7X[9[":[>9*[FXR(:6X,UML):661U?)<2P@4Q6R4BAK)0300$\U<4D"
M$!AB"1IUJ2WD)WM=O:O:\-YN2`A`MA]H:!"L;(J2\FV6,V.ED%TD$MM%"J\C
MECMK'"R<IA&2I8YCB;+A!&,,1<=DH<010V68T8Z;T9L!$8#!-H1]C,E*9S>(
MM-G'VNHX+#:/-=O%DX-)03S?5@PU5&.IA0J;3%/#%0)C`G;=?KQ)>`H.*2R;
MGDK#\8EYM/IF:*=EP!BMD*23:2(3*IPB>8>H:9BXABHJ<1(IPH8BAE<5.(DD
M\3+(D4+EP^EO?SOE'+\7V?\`W`4KM.T.[RO5'Y/<2_,I(JLJ4I2E*AC8COM]
M!/CKL;]'%UU<]*4I2M3SQ[2,P?FMD3YFK=81IWWI>L/R>(1_=<U*H^E*4I2H
M;XC?>E/OXY0-](J)*N$/[V_Y8G[3*OG6J9DA*,Y_9!F-Y<;@CO8I]50U=6:P
MR\Y4A'7Q&\I@JZ>F.4JWEE(LYFR.=+@^G;/7\E)IN8IC=-<B*K)N>93+:G4V
M\?=Y_?96M?MWOV[<^5^[V_?MRM?M6M:N>IMV^[V[<NWEE?\`7?N^]?NV]RM<
M.V)(_?#UBR0W0A74W?"J^Y7/&JM=35RMVXMN]C+\;N$[8D2/%R"IZ8,USK:1
MZ'6"I\L6]&W/E`0%(`L;"V-U-O'_`-'_`*67_1OU5O=[M[_?7[N5NUESMVJU
M;%T*1I#-GWE'3<S13,G2`MRB_P!3.K;C<RVZWTOE4U./+BRO.M77%HU<LCHJ
M*WD--N?Q1VPV$1%;#:3DAOI"<FEMJ4I2E*5\!/O;?EA_M,:_F@./3S;1_.EY
MO1C:P[`O)G.A_P`BK3:=;6B)\KS<<*.<?SER**J*LIJ*9(*:<:QQRR+G"@XH
M`UL;WPSRM:O$=@=N_P"!WL_T%R/_``_3L#MW_`[V?Z"Y'_A^G8';O^!WL_T%
MR/\`P_3L#MW_``.]G^@N1_X?IV!V[_@=[/\`07(_\/T[`[=_P.]G^@N1_P"'
MZ\+CICM_FXAFAAJQL1DZP$$NZ1VSC#C\NO@MDVJ&D,JX14FR)Z.#1#*R2.)(
M"GD#8F*I%3)+`:Y@$0/'S78';O\`@=[/]!<C_P`/T[`[=_P.]G^@N1_X?IV!
MV[_@=[/]!<C_`,/T[`[=_P`#O9_H+D?^'Z=@=N_X'>S_`$%R/_#]>T#_`$<V
M-9%B1K[?LJ56&\8U>(<A1"LB-1^-Q6:;C#1U6/5?%+5<T9;*DS^*<I9$CEB)
MRX%@#5RIFP.>=P1.I]EBE*5QEW+_``7_`%5&FJGMG[\?+*"^B+J55F4I2N,N
MY?X+_JJ--'/:SEGY96]/TO)CJS*4I2E*4I2E*4I2E>O_`+^=\HY?B^S_`.X"
ME=IVAW>5ZH_)[B7YE)%5E2E*4I4,;$=]OH)\==C?HXNNKGI2E*5J>>/:1F#\
MULB?,U;K"-.^]+UA^3Q"/[KFI5'TI2E*5#?$;[TI]_'*!OI%1)5PA_>W_+$_
M:95\Z4I2E*4I2E*5]8OWMO\`6`_M<*A_AM6YZ/ZZ]W^HPONWM_Z3.'WKU<?*
MWC\M_/3E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\].5O'Y;^>H93[?^4@==NWW
MDS!]V_/O@Y,]WNU<W*WC\M_/3E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\]0S"
MO?Q;M?$K4/YJ3#5STI2N,NY?X+_JJ--5/;/WX^64%]$74JK,I2E<9=R_P7_5
M4::.>UG+/RRMZ?I>3'5F4I2E*4I2E*4I2E*]?_?SOE'+\7V?_<!2J(TUVU7F
MWJ9K6@`ZB[@.0)&@^-$P-P-F-F&?;RU@1:B:7Q5$0X;EE--F4H]B'8P1',D"
M8XQ?/`40L!EG<+&E.S0<?@5;N=%<=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5
MQW]LU.S0<?@5;N=%<=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5QW]LU.S0<?@
M5;N=%<=_;-4<SMMFO*.T&CZKGJ+M^GB(SOV%&#2U&.6"755JYC7MREL@44J'
M+)@(R,4Q%N<,XF31/&Y0(6X&8H^%@<K&[-!Q^!5NYT5QW]LU.S0<?@5;N=%<
M=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5QW]LU.S0<?@5;N=%<=_;-3LT''X%
M6[G17'?VS5K29]Q7"?B"5B6>FNZ!'$S&<@`Y'%",8]+DBMA&>M8W'-#83"/F
M&`%:_7!;X`BB=1C>P8>>=\<;X=JKM^X$C6'7)+#T[W*5\"$"0P4P5$>,X_-I
M2AB!&;6#L<3C(TO%!AB9FV/7B^8Q4N-<+/#KH(8ELL,=^=F@X_`JW<Z*X[^V
M:G9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.
MBN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:HXWXVV7E_5U\IPNHFX*!A
MDZ82,74G#&[!(IH=R<_Q4:Q`S&+2T?'N8.9`V)DPL"V5A#@X&(N8(/7!@['O
MN:X@\Q,+:6;M96P&&QMEA%L=9X9<A<[<\<[3+:V>-_<RM:ULK=NUN5Z=F@X_
M`JW<Z*X[^V:G9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:
MG9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.B
MN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.BN._MFIV:#C\
M"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.BN._MFI;<UQ"YA!WTLW9PMF
M.7POF)%L=!AX]4.';JLQ+S+>V&-N?/+.]KVQMV[VY6J.>'[MLO-_3>`$D+4/
M<%P!E&2+ABKMZ-V">2#EO5*X+]=)F#,M)YC(/M]3_P"&*`Y]5C>_4]3?&][&
M[-!Q^!5NYT5QW]LU.S0<?@5;N=%<=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5
MQW]LU.S0<?@5;N=%<=_;-3LT''X%6[G17'?VS5')';->QW]<SA[$7;_(873A
MD)UV_C'+!NX@L`9\D0:RH*0O+-BV*8/<>Y4`3%0R,Y&`![Y%<`,<!1+&[-!Q
M^!5NYT5QW]LU.S0<?@5;N=%<=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5QW]L
MU.S0<?@5;N=%<=_;-4<Q'MFO$MQMPUK'47;\X(JM#5`$1&)1RP1UM)L2:<L]
M2,K$\Y9!`+@J'HB^1#(N<-Y7L6,8&<"^>(=A+&[-!Q^!5NYT5QW]LU.S0<?@
M5;N=%<=_;-3LT''X%6[G17'?VS4[-!Q^!5NYT5QW]LU<9;H./E?_`!*MW.Y?
M_JKCOWOSS5)VM6W2\F2-NX8#U`W%4KK.VUE,0NF1LP#)A%RQU:U<3+)2W@++
M97`JJWP3L%/$$N(<+YI:DF&+&<1AARI>LNS0<?@5;N=%<=_;-3LT''X%6[G1
M7'?VS4[-!Q^!5NYT5QW]LU.S0<?@5;N=%<=_;-7&6Z#CY7_Q*MW.Y?\`ZJX[
M][\\U2=IQMTO(T>2>7"U`W%6+&=MMTE.YA&C9@'"Y;)6VFE93S2C68TMD\\%
M5'S-Y):P#@&(7`5"ALN6,F@0<#0U9=F@X_`JW<Z*X[^V:G9H./P*MW.BN._M
MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.BN._MFIV:#C\"K=S
MHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X
M_`JW<Z*X[^V:G9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V
M:G9H./P*MW.BN._MFIV:#C\"K=SHKCO[9J=F@X_`JW<Z*X[^V:G9H./P*MW.
MBN._MFIV:#C\"K=SHKCO[9JZG=H)`-RI-;J<QZ/9$B@8,HV$NS8EE&2&\Z!<
M"S71S%E4(@A.!TDKI1K(YD`5'R4L3&1@H<"%*A6!P$&[DM#\,+Z5ZH\\,;_X
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MCYJ=;#_!X?HX^:H<XC6&%M2GWRPQMS>4#6ORQM;G;LBHC[5^UW*N#`/"]KWO
MAA>]\Q;WO?&W.]^N9=N_:KY];#_!X?HX^:G6P_P>'Z./FIUL/\'A^CCYJ=;#
M_!X?HX^:G6P_P>'Z./FIUL/\'A^CCYJ=;#_!X?HX^:G6P_P>'Z./FIUL/\'A
M^CCYJ=;#_!X?HX^:G6P_P>'Z./FIUL/\'A^CCYJ=;#_!X?HX^:G6P_P>'Z./
MFKZQ`\+8XWMAA:]A`;VO;&W.U^O8=NW:J(>&UAA?1_77GAC?_P#`PO=QM?\`
M])G#?WO?O>_PWO5Q=;#_``>'Z./FIUL/\'A^CCYJ=;#_``>'Z./FIUL/\'A^
MCCYJ=;#_``>'Z./FIUL/\'A^CCYJAE/PP]<@==NIQY=A,P;<NIMRY=D')E^7
M+ER[O;^'MU<W6P_P>'Z./FIUL/\`!X?HX^:G6P_P>'Z./FIUL/\`!X?HX^:G
M6P_P>'Z./FJ&85PPOO#NU:^.-[>HK4+M7QMR[34F&UNUR]RW:M[UNU5S=;#_
M``>'Z./FIUL/\'A^CCYJ=;#_``>'Z./FIUL/\'A^CCYJXR##Y7_\'AW+_P#1
MQ][X*C757#"\G[[\\<;_`..6'?MXVOV[ZBZE<[]NW=O[OO\`NU9?6P_P>'Z.
M/FIUL/\`!X?HX^:G6P_P>'Z./FIUL/\`!X?HX^:N,@P^5_\`P>'<O_T<?>^"
MHUT=PPO&<L\\<;_XY>]-^WC:_;OMW,=KW[=N[>UK>2WO58^%RXG7.HZUEUK.
M^`G4VPOU&>-K7RPSY<^ISQM>U[XY<LK6O:][6M>W.%WYOG'K.=,W)B+%DS28
MQ]8E-O(>QLL1JTT1QLV*W"NH2,[E%N!I-W*3D*25]@,9RME\R<EQ.RGJ893;
M<28&8Q/N6R@VR%$E=@X!.R6O0R4F6)S,N-9"]5#EC(!^M,5^(#<LGD%;)=66
MI@J9+::E!I*LDJHITV2!!!2U9+41L@R2B2''PYN;C:B.]23$9J;-:]N166W:
MF,)&3$*8([5CZN]5I.+JR,U4HH1<`XZDOK"8;*'TE,)8#F5,L:+"$,#/H@&V
M>OY(X@6I+"CN>W^B3%',P&=;&,8D&5X^A>0(Z?TD-UO@F,R80AYL$76#FEBG
M3@(Y,EFN&DHH*;+CELS08X=PZV3(&VFL,89RR3>DY1.DN"#(]6)5EAFW?34,
MOMBQ^B$05`XZ7$R2ZKFYDQ*$!-)X9(R<3``SQI51RA;(0PK)P9G[V1M7K3(0
ML1$&Q-D6&W'/,>(DK1"RS+V:Z>_9`C]?1LE]/=#88YU3!="NEW3`C0YDR12S
M`96Y!3#'SPS33UB^&D=V=<'!L0U-8F0_FS(\F.!/FDRN%X^<[,=A*-E*"1H^
M+/-M26$EN(9::KD&-2*F%$I+'2!L\CB2X2:GFF&DVP(VP"6SVLRE(;FB1/G^
M#S\ILM$7G*\(X)2FPS3Z:C>:QP1/<ZXY&F`NB+J$DMP^$(37SZH1*ET8SAD"
MI9E<K5XXGMMJBH$F&I$-D8`.I\INE;8T8GBLO1V.3D9Z-M7P0'`T6&:#<.0#
MP<B(NBA(BJBMX11/D%@8%+,@!GA@0,]>,O>"$W8I.X)2$&CQLL5S;!M%SOV2
MW'&#.::8N:YSDAP"Z@Q_3)_8N*R<Y'DX"!AGKUF_=OF".82<X%5O.U01FTIY
M'?<_5]5:[A<,>S3$<M*"+&#[EL@SXYE:*U1T.AGQV7.9.,\A8*SR140$J34B
M>2"=6G"M(390E@4,)S+B(4#,G"^;H.Q\!.%^I<2D9<BZTPJJ;FIAQ!]T%CFY
M,+8%D%/<RB6,M!+7E!4]%I2$J$E50"+!&,`TL;!7"$&2<\#^7@".X&I"DT7L
M_B.R^OAICQJJ`(DA/$*8([R:['6#0ID$HF.U>]4-DMO'3HI,W@0`5317-0N6
M']`V,]:SY;(;TO1"[2K1.M>3(Y<9-_J:TBL4RA/)LJP#R66V14U-Q)#5$(J0
M^+@5$!.15@^N)R3<V=2":2IF5$`L"0-Y@['ZV'^#P_1Q\U.MA_@\/T<?-3K8
M?X/#]''S5T`[]VM;9-RVM:UK>I]G]JUN7<0"=K?\+6M\%J[3]#N\KU1^3W$O
MS*2*K*E*4I2H8V([[?03XZ[&_1Q==7/2E*4K4\\>TC,'YK9$^9JW6$:=]Z7K
M#\GB$?W7-2J/I2E*4J&^(WWI3[^.4#?2*B2KA#^]O^6)^TRKYTI2E*4I2E*4
MKZQ?O;?ZP']KA40<-GO']=?B,+\YG#5QTI2E*AA/_P`Y"Z_D3,'Z04F5<]*4
MI4,0KW\6[7Q*U#^:DPU<]*4KC+N7^"_ZJC353VS]^/EE!?1%U*JS*4I7&7<O
M\%_U5&>CMN<92S;_`/65O1?M>+;R8[V_X^YW+]R_.U?KU6T@A;3Q8V26XC-2
M&8.[33X[MC9*L^GZLO,L5?KS!+@JI5I%E/J0T%O!]8OD5)Y>CU3+',(J?63Q
M!,1"B7*I^`]Y(4<VV;'U;$AK-E[9RVX)K9,\/AUGB#UU9>TFM1HMF4QU"(\H
MY<R%.0+?5FJ/)408B.IOE5)><%H]D-/(--N@N-:TFCZ!;.)TC-UB73(5SC%@
M;C[@[G$-E,W>LEIHDD?9B+)Y9Z1%CM81!B8DTE?(K<[6;DA/8B[QF@LQ5%K0
M*-QHDU!7#;;,_`@<*V44".6VU"YR%2JRA:E\&F``3I/-7!+EW!P\]G%*:YA,
M$QPF4&;":[@2#"9]SC,,$,VI.,EA=>2VN$7+J-X:A?AY;-;4:C1^A$6+#L")
M[3B3B0MQINL1PN5,=LVKFWDT.@LAM^867:+"JFQ$!OE4@O)$B*&#@?N3OD-%
MC]7;1+$C<^(AU9EPN]B#\R3"`IBM%2CM7E#B*3.PWVMS";.%++.[L?3&T$)!
M*PXD0NCKJ.MMX*7\6L_U9WS`^F6::L=MI6:K6'7E%#)QGC<8\,3:9,E",51Z
MI#-`:"XZ^'Q,,BX(L_F04&+'?IO!4-1@L-A`:1&"2[OD9;*.2'AEZ*7>ERC'
M#.,DY+<P3]9!<FC*J!)6X-)M`MF84G#3\]([)UV;T>:.:Q;)ZPI\I,)].=8E
M'9/"87G$+K;TEN%E&HX1$QB6.&8[7W4_D!7?+P6,I.>[B5TI:4R!\X=/S8Q=
M*]C-A#LXH"!'L1Q2U&UQ..)C/B1.QAPK[?EA\C/5G[!Z[H<>.!G_`',30^:`
M]3TDI6;DD0B^%!)4H/:*,C)[?.+HY$(AG$V<)><#R3&S&C$A'Z@PECA\Z]:-
M/YKILK"Q$Q6,/$+F=3@<SE](B$(/-R/E@.D5[C.`HF1\XX<D`)Z,)M#"+9.Z
M^"ZF%F4H\)R<I!4WUEFX(9.(;O?VR#A%2UM3<IH`TWYDXJ.LN[*,G*A01DFR
MQ@7&(H:=3=<)3.Y@K9]*2.E`C**":/.(C^Z9.%%,[[2)C+-A9A=+4Y'V,XFT
MQ%#AHZODL\D?=+2Q_P"N,>X+)@BR3`^:^FN]P-P\_;8V.`%FLDW,)9]P'R)%
M)$VL!PY)C2SXSA1%6&`77;B#IFW)=45<%Y2*F&B@\.2VH*$DKQ8-M%#:PK$W
M_;T4;;OHTLE'(S'42X3A+*2@,CWD&*>%CM^X'(W3>P!&)#[8!;/#9;;D0'!*
M2-(+>]+-%]L5V:WJU6A'C)UIAR-F3%3E;#N/$X5C9%;8Z>A%VZ43'H>2LE0N
M71:OU,US4C?$[W+E\$!7RUUB1R+9V#4I;92VW4].VIV>;S$SW76VJI.`@0S=
M"2EAPXQ!D=T-_$TV\7!.4RIB>J*)HRKW![N*4KU_]_.^4<OQ?9_]P%*[3M#N
M\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_1Q==7/2E*4K4\\>TC,'YK9$^9J
MW6$:=]Z7K#\GB$?W7-2J/I2E*4J&^(WWI3[^.4#?2*B2KA#^]O\`EB?M,J^=
M*4I2E*4I2E*^L7[VW^L!_:X5$'#9[Q_77XC"_.9PU<=*4I2H83_\Y"Z_D3,'
MZ04F5<]*4I4,0KW\6[7Q*U#^:DPU<]*4KC+N7^"_ZJC353VS]^/EE!?1%U*J
MS*4I7&7<O\%_U5&FCGM9RS\LK>GZ7DQU9E[\K7O[W;KJ:D_B5*,;;L-76;)A
M,5RLYQS;&.O)I8;4@.9P22V7C*4:*$BHSS>2(WXX6(M8+8+G"-FEBQ9!E5J2
MTMEQ0WVAMLV@*;63G)H)@\7B5%V(@Y+D37Z*(K-2-J%`VX,.$UW88T.V4QGS
MA+2%#H+8EMTC1DG&0'0@''$C/5+1XT0'BX)"*'[QNSF\:D3%)`<&!A\6B3U!
M4;<SVC@_9DQ!%G$"+;`1$AJ*^GICD'U4V6T(83CF]HG)`BYKR:`394.3;)$F
MM]D.AG-115B8*LWE(8</)!>>6RYHXO+R93>29$8\(,<2$UR2=FFZTYUDF47@
MW(=?39UO?;2C$H!:5&O$KOCN(G3.+P&E,Y%;CFET-6&\F5&0+F/2";]50B>V
M<=E#BER-!2A(&*>P"[F:21L[M@S%>3I^D=3:43-X&%%6'@&W$*7*,?0*:9$2
M*DE)\AKJS&BSL>MMY@H::S5L-QRZZ,S?-N]BFQ^RLL,Z4(.@/7.,F1)4NS6R
M)AEHL8DR0C[`CEMQI"&$<%'`.=7FPUWTM*CE=KKER/FFUB20C#I1$LI+SO6%
M$0@W2R,X9FT1VYE3<'9V6G\(*,W-<SNF&B$L0]&PJ\FFE-OKVPX<TN-_G'H1
M*L0#(\[BBHQLF9BJ)<C*K5#06LFGD1$$'=:B>38FU]F7>"0"S,E=I._:Y:!+
M;`[ODMA')*A*&<-3P-=XS>.U+-;-HI+IZ8%)(4EM5P,Z&4^.`TDKA@I**8Y,
M7_D9:AM4/VV7`_%$V&;>L31,;$1W#Q"6A],>'_L"T7ZM3J>LUGR0VI.FHN6E
MB5\"</M]41)*27BS7,_,(MA9M2:H/\FN)#%C[,9RA##W^]5XSS^"9D2/$MKZ
MT&TBKCPGABR.]I0?DH1U$'JX@38,*"SL>M&4G/!J2C1R[)&2<#\J,@;:PM!"
M.&BA)[8.C&U`PLK;>I.%^)XHS'ML-!"3""A]S`_-6P.OR/(Z8<D=4="(\]=,
MWX2<+TD5$&AY-BMN10]W#&CO:;)64*:W2ZP5Z[+`<35(9O$Z69^Z9'EB?VQQ
M&-8XC#<[,+ZYRO`VS[E--1/;)K-^J$B1.8@BZ>K.)VJ1TV1!;9$E(2D$B(3:
M2D@X*>&.''"KJX&":GITG\3C?78:(F/O*R]68Z0U->U5TD^[[)LIK#^#;#J9
M*K+X4J(449Q(SCS&=:&^%UFEHK>DG.S)VJ*`@"$D9"9R3=46G"='0<)FKBRR
M4RY)F&%F/'T5N-<*MC;-MQ.\4N1W:X\$"3M8H#<TPY*$S'$>)EJ)44%W%FLN
M7#C!MR.ORLRCQ!,1WXT"(ZHZ\8]\BU.+'(2*\]3X^D*.HR<1R6R&D;#D\RQ)
M#=*Z]FY)^W+&;"V$\A&XWHM46''\?H"^XD\H6;4POF-9!>:6?,N%F(9E*!:(
M#\[V<<NJQMERO;G:U^5[7M?M_#:U_P#A7->O_OYWRCE^+[/_`+@*5VG:'=Y7
MJC\GN)?F4D565*4I2E0QL1WV^@GQUV-^CBZZN>E*4I6IYX]I&8/S6R)\S5NL
M(T[[TO6'Y/$(_NN:E4?2E*4I4-\1OO2GW\<H&^D5$E7"'][?\L3]IE7SI2E*
M4I2E*4I7UB_>V_U@7[7"O7=U&XQ6ANO>NT8PK)\FNE(D*-$Q::#P2B$3R4N%
M$Y?17>Y"I\H`L)+;,I:B&&)A:^!M.-&B@V&6.08^5^JQPH_U^_AH_P!KSUZ$
MI9_A:GK]_#1_M>>O0E+/\+4]?OX:/]KSUZ$I9_A:GK]_#1_M>>O0E+/\+4]?
MOX:/]KSUZ$I9_A:GK]_#1_M>>O0E+/\`"U2\4XSG#_!W,7IFSE-U689_6!IQ
ML64;1'*%SF3Q29B>[J.IF239K^F&`0:`M)Y_%2R!LF"W&R*!G,CP(Q3"H?7[
M^&C_`&O/7H2EG^%J>OW\-'^UYZ]"4L_PM3U^_AH_VO/7H2EG^%JM;4G>O7#=
MT@^5+7AVK+J*1RH(28ZQ%AENMG9$CCD)J!])#+ANA+3,S^(Y9,.9B"$K#!E\
M@\<!LL,Q,+96#4,0KW\6[7Q*U#^:DPU<]*4KC+N7^"_ZJC353VS]^/EE!?1%
MU*JS*4I7&7<O\%_U5&FCGM9RS\LK>GZ7DQU9E[6O:]K]NU[<KV]^UZBUR\/_
M`%;=DM"32L,YVV>PDOM#8#$NF3#,B&QB\Y,A"1VHBRV4C!&?I&-BLA#L]"36
M<NN4%J8J+F:>!Q"7LU`BJ*N!W[%_A_:D.!GM1E"Q7DCI#!C.+8B8!UIOB1VB
MZ&$QH3?*%)D2D66\&R[DQU-M88+[;*&Y&\ZDM6`=0!PA8N863)`R<)F=?+/#
MKAAJ1K*:%KTE)#`E"1&S/*"4DB5SDH;!$TLYL_A&X$]KZZVWG*A,\[3\D"Q6
MSG$X\5%TE<5=[)%G$IC&<UETE5_QIWAH:7(L'0[&KO0%H@QM<=;2^MN#C398
MD&'O51KZF(B&5=C$FE0C5XL5)D..W1DVPE]Z-E_8JS5,*!M<.BDRP:RL>C>)
MSTJX?=CR(IRJBE8Z.3.^W5&`-T":I4B/[N"_L881U!VPHX2;'?[:#E)J21=A
M$CYB(%H!9:&)%&6C2>WTY.-.00WN+:*!M59*1(PO/F`+/LVG23CR(G>UY(>D
M'/)#79D`*QA:-V4_XN<S)=Q$A*18VF,X^QD]:P1G7F`@@&DLP>1T,P0RC7&-
M-8&ZV$63]9T9E`LQZQ-#K!;;F8"D:4&JL1%"J4X$:&T-O6P4#:/@WF>DN5?)
M(HB67`$'+GA+'C!W($MD#Y>'VOKT7CQXQ/#8;6-Q^W'O+#.>S:;BV<6"R(_'
M6YUMXRTW5DT*HG%)/6S3F?BPJK:<(="$3!UVP)7`D6L4`!U,OZ-Z>2`C$&A@
MQ@2PL6M&"X@05%@R3(#3?,7HFN9TX^X+1$!W,MYICP93@8(CU.K2.KE50BZ3
MZ*YQ@5H^K("QZ''TD[.&QP[&(EIX3K;"TSD1\NU28BF`=V*GI%3I?5)]D4JY
M%6*Y*ZJ4@_NP-V4)7.G7`+'<@".5!7'H]'P:"3+FI%>8:_3;5TMUT9LT&)[;
MK06RC\S<KX?*>4,2+)2A'+:?LFI^:7)$A,N(E-VFHJ9C]?:>.H%G:\FLSTIP
M+'IZZA31[T2[W4,LY8MCZ[N*<HL5EA:9*E.[70YM;D6`XN?$1T$T<3[FMYT3
M$Q$(J?H<WFG^AHQ]582@0,'D'KZ)U/I?Z9Y^BM9['Z!:H[9K^;BG:.5%U'E!
MCVC)UET>2)18"-)$<!+!IQI;!EI"CIZ--%EAGMYR*"BY&DWI$).1-:;@5%98
M;8":>55$8SIQ]Z7</*/'F8DV1RQ1N*!-TOYY$T=XS[*03";"YM><68;DXXUX
MJ5I&$8C33YZ<DLJ+<=I9`:B>D.Y\.<F:%#NY,2!@'X`\/701G/V(VH(F.<@\
MTXS&4CQBQE?9*?#>#@<VFR-%[18\L"LU3E(=*>\@Q>ST>+F2LR0X$U9=:@S0
MT1NNA55$HUD$+8C;*L+6N+VR@N=_F"K=)N5&:9!T2*Y3!HXHNN5)$P2&DW?3
MA:,F#(QQ=>CS2V@T$D0T.+S-H:"2R$M@7Y[NKU_]_.^4<OQ?9_\`<!2NT[0[
MO*]4?D]Q+\RDBJRI2E*4J&-B.^WT$^.NQOT<775STI2E*U//'M(S!^:V1/F:
MMUA&G?>EZP_)XA']US4JCZ4I2E*AOB-]Z4^_CE`WTBHDJX0_O;_EB?M,J^=*
M4I2E*4I2E*^`GWMORP_VF-?RLY0]L^4/SHR=^\!R5@U*4I2E*4KVY_Z,-_4S
M<GX[PQ\U'M7M0U#$*]_%NU\2M0_FI,-7/2E*XR[E_@O^JHTU4]L_?CY907T1
M=2JLRE*5QEW+_!?]51IHY[6<L_+*WI^EY,=67ESZG+J?ON5^I^'EVO\`C7KK
MO]*W&-\21SG%5P[`I:(7VECS)@%&.PMFW-&1S1P*"V8-)Z,=4TEZH&GQ-'7G
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MF,LR<`LK"*OIZA>2C\9-<^:E,(1:)KZX8;3DR"]4SH(*77`Q3.U^PP6KI=7C
MG;A01HC87`_(2:),<;RXTR0^Q42[7+[FVV=Y4A)":E'G&X&0V`$,:5Y1*IYE
M-64TN2.%',XT8I@>"WR7C:?H_P"$GH''*NS)W;K?9[BUO2]V6'%*;(!"?BFN
M*<=7[R8@M]!C,*\S&A,')DP\I&;D5@#2,LQ5B^DEOE#8AP<H/UA/%F[:-N%Y
MC2(GB;>9`47A)_%#G?65XNA`W+-2`H/!TO%EWUDL?9T3FFP[<)?';:835(F?
MFV4BMYBMV-[KZ"YF>[W>>>Y-$IYUM:1T!WS\5(1)MB*D;!;N0Q,;\>AI)WL,
ML@1O+O#1@L1%5EIJPD23Y8>1)0GLK)S2(LR/';$[6B>5FBR4N8E-LHC3BQDY
M7U&)O<-U<.'AO&G,'/&6Q!&8]$RNR%EM+=S=E'TD:4WM=(GX:3R!O+!<$0_4
MZDK8K].*YM83%UOW,JQQ:<B4H8K:CAO#0AW:&+7QK:MRR;V:4LY,T%>R_LP=
MFYZ2,\2V>S:7.L;F&&37"CU55)-:+V1XY<K];Z*DHA1&,'F*CER:L"J8-PB8
M+1>C:-/IX;+RRBC,3:YN,]`V)XO3U..M#?.Q<?F595F6--/E>"#[?EQ/<R.X
MU]KO(REK"@A`LIX#-E2?#&-)2T&*O-112`/,QD2XB"ML;KRI2NX-GD1_6,\.
MTR@!_<^V.6&T)%`FOL)&]QTZ2!V^\FAIZBW7)4`V(39DSFY*/SBVE?-G*T9I
M"PJEHE1\]K<4?6&0Y5VR=B@Q6#/BZ9D_3N`&*2=<?9RL=;J6-'O$SUS?3Y)I
M:LDF#;%C]]-V,_1<@HH_6D1TF2B(X7>V\CYYOKYPIKV8H@WX8Z7M5&D'#;CE
MF2@(W$]1M?E(@^Y?=SF(@O:*]$G!`QMIOYRKR\\%U4)2<L['"PPJJZZM*"$H
ME'FB-@P72DD1+`\%-VNTEMZ;PX=]2N][W=S(X@W#A6=;%1'6-C)8U[%T#BQ^
M:\/*2E>4I`6E1?BXZYDF44Z<'M,QJ4ELU/*P\B,?.1`+GH[0VN*C>T];_P#F
M_P"N]=`&_G?*.7XOL_\`N`I7:=H=WE>J/R>XE^921594I2E*5#&Q'?;Z"?'7
M8WZ.+KJYZ4I2E:GGCVD9@_-;(GS-6ZPC3OO2]8?D\0C^ZYJ5&^X'$.EV)-GF
M1I9J'J2-N!LNMP:M[-/AM+<W-O7B/XY@].=@T>H:VJ2(XFH]PE1WO=_EQVTU
M6>40P.KQ+&UA76$U++B#AZ$W:XU!C2Z`=3Y6=FG$RCR=L"(\G7)FNKD5TQNR
M5KU",()@2KLO+SFS04MZIKF2HG)GD0XCE2'I60?::OI*@&LMVYBY0//]J.(9
MN#"NS>O,$PYIQ!$W,_;MQ.AM:VR<L[GKL;"N@VQ('.SP[C[X:I+5N0"K*1K(
M:,NIS6/)+K>HKA%+)ALT41`E7K9.M=G]FYR@]C1:+%.IKEV.F"1EC%&5V:UI
M%165%$58)+,47B\G-+$]N=N&49E,M*LDFV\VUI1:/HMX.0RDIA=+2\CH^9/J
MM]D-,-=C=N3C'6ILMO:$&7`<);%;B/3-[L1!6M96).\H/"*FD$A-$7%0%GM4
M**<?/!XJF3.6&\C9QL33'*DJZDIJF;=3Z/U3XO[>VGVMG^!49FP.TX\U^>6Q
MK6<[_4MTHK4I>Q2=>'B.R%&2%C6$!K$WFUXQ<ZJ1/FR;P4G6.2148,@JJV&)
M96(W$H;AZ\1!!X@@>RJFV8F>47-^!YS`BMLGGN:ZA7E%F+L9L>6&'+0#;%1D
MD^S$A^LM^H3@0FVK"J*N`AGTTZICDSIT=*(9OQ&^]*??QR@;Z14255\@2(Q(
MD8KLDR3W@VX_CUC(JHYGB]'@LD6^V6RWTK`0RHJZVLJ0Q<DGD"@.-\QC!@7'
M&U[XX8]4)GAAE\FP_P!HOQA(DEQ\XT%\LEUM8D\6>Z6PK$UIN.ENJJ9BK(JR
MAK*<(9)*24K$10#)(^4%&`'+C8"A996ORKJ>:?&3U\<$/:0R:*[XB.K.QK8.
MO:<X]8LI$9'?6O#2:VGTQ[12&K&&,S"2R_7-FRC<569:DFBM=+4^N*V0URF*
MR"513E.2;Q,-18N4RC>//5YO9V*ZFPD!L-&'X;E^9'&\G-)\5NB;F,UF>GQJ
MR7)ZH'`MQ*SER0,DXD-EDD-C!-4UT1+`7D/)0^9SB8Z:E2T=J@$I**NW9%:+
M.?V#N0(XDY>9T>,J0'>L1XSG1.3I2V>:18$2%N0FXY6-B-,!QF"IKH:KO35L
M%+]2#G&2?`'>*=IZ6.OY-(.64G,I1W+C[@Q42V;KQ/;P6%^3(DS<5IJ16`B-
MN.E-9D5*A'%M';R^\6606F4P1S[<35MPA+#I;B:IX9%_%;UW?,XON'U=0/HR
M3A+4=Q[#DKIC5D-=B"0TJ4M3XGVE8BFX99!9X49QZX'F@/MT%VDU%]V!*"NG
ML[$[GZ%/+B>G#?>I<4R#G(SDUP0P5<3N6%>0=0R3?1'^SW[$-GW".V&SD>ZY
MMW86,C#S:Y`5_1CB=>9E41'"B%Q$Y2-%T`LK#(::\&XJ*6<@\4+3<RCN]<*O
MUW#I[;2DE>;@EH>EX"\T(3ADAOPXWEK73T6R2X>P2.N2P[6E'J<JQ*(ZDX5P
MNUHY9F@T9VMI75<7%XJ6MY1],QN+)"46BTEV#-FYN><COR*I%93=B4OJH_F1
M'4G,F12ZXU`32.\T]Q._,CFDX"##V.A-8B2"5!I/CG)PY<;XFNJ1`FU0SZO+
M1!Z/*:TS7A$B%1UVGI.FW&75IE_=,2&PMQ$?CPL^FN44XQQ,201=CE1TEF#L
M<@J.&SAL32E&Y74LF\6>!4Z*Y.>T,`K<DN!GMPN]F`0<+5?D?LJ=&"1FQBP:
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M`*JC353VS]^/EE!?1%U*JS*4I7&7<O\`!?\`54::.>UG+/RRMZ?I>3'5F7O:
MUKWO?E:W;O>_<M;W[U"KSXC6J+!G@MKRY7<\B[V,R:PH.]42=#TMKT3%9XDQ
M.3UUEP@I3,A,M1C!+EA5:ZLFNL5FJ3H*J*2VSQ116,B'HD``3Q;JW-TF<J+%
M$HJBO=^C)D6L;;R#KID3R$Z7B(U9D.90''COCU"*-(=<">C^/2QG&B2V@2I9
MWY@O,V34$PBEF#YL#%'=Q6=16J@,PT$I2LXWH_C<Y(K;B)L0!-[@E<NY-:LF
MZ#.B`\F.BL!168]%C`T[FQZJU)YETE%+)ZZG+R:H*J*8!/B_NBOBA:N22@0"
MH&5)[M1:G:/M?GH.EJ$826I($1J^SJ>F#0RPIID9+9HC"B]WR*JJ9=#8B>]E
MMOB/0P<;QY%#$37BSC*YMR*]ZM:)AAN6MAVD]E8G!,**4A)KXEI\,)^QPR0\
M8E"/VD]7;RH_6VWQ':VV*I)"ZW'"YFV64T(!SM]>;Y50-J24;`PF.1.*E&!-
M$C0")V2_G!(T@;2:TZZJL>2;&4P18[(]1]C#"BNMB6'>T3L=J;R)LI:C]MNM
M38JL(BED1P.Q*-L]86FTIMUY@-W.-U-V9>U3,.USMW6+"0H.AR*4"89LEMU2
MR5B@D(G.)[J31(19K\F&V([2$S3V&313S@&82TXXP0Q\EF/6LFO$\Z)`3")+
MPK,XAJLZ)O06B:@95(P=)$Z[+ZP1!*Y-UW/O%TS?JJ@/Q<D!-<L6&VJD%FNS
MG:9B&9D"-5XJ_G$L*ZU'N`;A;3<"=B5D4U0[^+,&@ZSMN>C4+$8V6WCO6[M(
M4QD;`R:"P`6FM,]\2*UE%W20X62TI1"1CMTB-%M9Q937(O`P84#::VR*\H'A
M["Y=FL!R3E,,.Q_)N:G%RWB]4$)?+JL+OXW*,8*!,V9,^@#;/?A]L,TVXDX4
MF&!D*:';*0(74/1J?<MEZ#L.+MZUK6[EK6Y6Y6Y6]SWO@IRM[UO=_P"/=\ON
M^_3J<?>M[GN6]SN>3W/>]RE[6OW;<_\`[YV\E^Y[U.5NWVK=OGS[5NWSY<^?
MP\K<_?Y6IU.-[\[VM>_.U^Y[MNY?X;>Y?NVKFO7_`-_.^4<OQ?9_]P%*[3M#
MN\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_1Q==7/2E*4K4\\>TC,'YK9$^9
MJW6$:=]Z7K#\GB$?W7-2H^W!X<C^F_91C[DZO[>OO2[9MMPNLZWNI\MV+8WF
MMK2+!JJ[<G\3:CBCZ20P4L!>:[U$'7VD[B1^QA+&-FRQM.42PF&`<[N7@.P=
M+SL;BIL]/VR^R;68NG0^IK*37M,\O-E^"#O)W.MXS;*TE2BP).;:O*JQ+QMP
M):(J1\X4D",$EHM5#:MVTL(Q!++I=$QAPU#[*2N%B"\-A5Z1W#PQ@'^02G.H
ML0DE'9J3';`#QUX0B[B#L[%7-K&VJT'*F&LU`N;<HR\=;^-C.!+TR$&*ZBV]
MX+D53>VY`1=:7@W-.S>P<VH\U;AFFW%AF1T[;T=NFG2NI+#FM(-2:QQ%:/3K
MO>2\Y'DU2:F71GOZ*])EXB*E=<`$UE(G`_6I7#$3G;N`IH;5F:$X(UYW?845
MZ\1S&C&V/BK6E_+SJB!#C=!3G$HWU>$26HX#<5+F+'-NM&4F):P2.B-M8RNI
M6V2H\&E`E&<U5];/[#.2?(32F9MJP(K@LK%D?PBI-5I;I)Q%OS.@OJ988R:C
MQD\C=JE,T!K&[)K,<!/$?T\<BZZ7)AFJC43HCPRXET$D;:]]Q>\I)<139R1&
M@\`&Z^Y%EE^81^WF;'S>9J8U<5B3)-D`\\E+TR3%A9R?ZU@4=V2*JH["'-F6
MLRVV7+;#XC?>E/OXY0-](J)*J638OCV:HZ>D32NST!_QO(;?6&F]&:YR`2FA
M.-O+`8A503%$F+RL(".%ESQ$#S",%Q\`C14<`T`",'\F3&3&C&-VU$D:-=#8
M,>,EHIS'9;2;":`F(#6;",EX(Z.CHZ:7L&"6(II$(($N!C>W^#ASSSR$SS$R
MB%(T.:T<PCHPQ"R@>?..@:06'+$$QF-8LNS\50]3I9UG.M4T467(F(;?,O%+
MDTXL=:45\RD9J90LBJ:@73#QI:)=9NO7#BVO@R,^'&7C\_FRIC9VS&P<[3$Z
M9/*)$U)48L]=U4E"!H!BB2$EO2"RLG>18L)I<$Z[G#,9/8/TN6VQBOH"X;2`
MQSI_;`/`R:R6<114Z5&*X,G8V&ND[!+TGP`0D%RNMQI\]2[L`]7E#A0_(Q2/
M8N,2`OSE(#;--A^,*;&FVT(%EJ".FC.!N*1YRU6H\/%\M%18$A0#L`D,.:H[
MD#?1=1W6_P"(+24RAV+O_.1F>)!:AQCDI%9*MDXH_>"<PC+&>0#W!!/>I`\5
M=3:4TQUG"*7]:UPPT9VH3E0GU.+S?%WOL[#VR+Y7UYM(!5S/`[&FJS`U=<B$
MKG&R9;Z.449'3F6=>RFY6^A(I5OK3B&345KV3TPH()KEM\*QYJ04=@33LP6D
M(*#(\U9A2%A&S#@#!,%8IUMV@AW913,27C:17&4=\I2R)`T8L5P.QK%6`SVN
M01E)P->.PCRX83RVH6/P22["CUQQTDR5`9U&3HK0X6CH-S:=-1[@N:.TJ5V%
M(BDD;,XO:2'$>DP5U(,:-!D+P\,*>N-P3Y4U*2%9)D,HS#[+RE;X.*J[(D;$
M2NK9(=21`H?W.AUTE1V&ZW$FI#6V@D>"9=CYL0Y9^S,[W*RX_@!\:\L<NB,U
M]NR4\'2RU%UM4)39Q=111FYNN">&26C*0V!+#F>L9XNIHSF[YC4VY"T&_<G8
M"P5<&K[KUF36H'@N21)4BC9IA!XKCV,.-XR$]3=E$[=K-9.:#4+ERF.J"_"+
M=RDQF1$3UVA#7XMU^@5:UPU>)D88)H[Q9\?+LN0A(>:G+KA"D,9'E9Z(S.U^
M8$4HRFWVQ&*-DE9.)X*Z"HNE9!R3<7`X);=Q2YD96$GQZC,A[,'9]B,%:0-?
MR_W9T(#9]_>K574)$DUQ2:X"SN%89`RJ-%O@1RUH8]5Z2=+G)+,.@REE`+V*
M].'NCO%_/%]B2@IIXKNW'3MO!$T-JDS`1%13])>PRLQ@S.2X%D.1&3KW?^2]
MD"$8Q4+^I_TKR+?_`-7J.<.#4Z2CT@%<PV2;KC1-='!HVY(ZS?D,.5SO=K!:
M:,J-628CYAK(D[`,B.(SEL5D.%_.8FUHX!?)=^2`O9J3X<S9#P1!N]K*W+#&
MWO9A6M\%A,>7^_EW??O[ENY7\K24/;/E#\Z,G?O`<E8-2E*4I2E*]N?^C#?U
M,W)^.\,?-1[5[4-0Q"O?Q;M?$K4/YJ3#5STI2N,NY?X+_JJ--5/;/WX^64%]
M$74JK,I2E<9=R_P7_54::.>UG+/RRMZ?I>3'5EY8VRQRQOW,K7QOR[O*]N5Z
MZ-MC>'S/29*3:<\(R8"XX+>7$\U9W9D>"Q8V)9OI%=*<[V,B3(OE)L49'()X
M<1)R,V"DI^H,&+S[X!=I,\13'V*US0#2MXAO\'Z84Z.R;-4]PTLT.Q=8-?M0
MXM";\(N1DH`L,0%-B'*PJ/,&;:GTH_7N/-S;10XNFD)C/V+$I1;8F0S43V\`
M;7D=>W1K%PK0(!6E-84Y8;JL`;+[Q%B#:CV(`XR:J&6WE6M;W4[B2,E&9`>^
M9-/8#A@,T&TPAC9X\L(KM"]52FH.)'/K[CTQ%_!=$C]T0ROJTM1&]LVD@Z6%
M9457!K5FJ.IRK^DK?93.:!V)SCAF%>:T7(DB-2,([*/).=;-EI;;:^FN-WQH
MYFFO+R*.SKF1]"&8'H.Z="G,^G$M-%XQ]*;`5)`24]/0'.6#E!S.YT774A/-
M#.!*!56ZHNK`5-"4O39./C)8%U0H9*FS1.^H4[AW2<\I/+3GL-LFCR#+1:5]
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M2\&F"ZFVYA4%%%?.`Z.[V,_V&[\5MM(QT<<1!..!JJ^]-5M?R6LD*H44%G*.
M\CX3FDR076ZA$<@VRJ_(,S2<\)BD941FLEBF4YIMHT^GTX,VNU2IQ2LW6]9-
M23"PMG2IE8/41?*V/=Y]OWL<LO\`Y;7Y?[Z6O:_<_5?X.7PVOW;=VWNVKFE<
M7O:W=OR]S_??N6\=[^Y;W:6O:_<OS]S_`'V[MK^]>WNV]RN:]?\`W\[Y1R_%
M]G_W`4KM.T.[RO5'Y/<2_,I(JLJ4I2E*AC8COM]!/CKL;]'%UU<]*4I2M3SQ
M[2,P?FMD3YFK=81IWWI>L/R>(1_=<U*H^E*4I2H;XC?>E/OXY0-](J)*N$/[
MV_Y8G[3*OG2G*W:[5NUW/%\'O4I2E*4I2E*^`GWMORP_VF-?RLY0]L^4/SHR
M=^\!R5@U*4I2E*4KVY_Z,-_4S<GX[PQ\U'M7M0U#$*]_%NU\2M0_FI,-7/2E
M*XR[E_@O^JHTU4]L_?CY907T1=2JLRE*5QEW+_!?]51GH[SM&4L\K<_\<K>C
MZ7DQ\[^/E;M\O=[EJ^W4Z<=DYE6-E".P>J2KK,F17/[NC>%UA2D)$>X<\12B
MA`9(4OD"J63)#MLHOVSQ%#3#%C9?"QG$J74#!U-5@R_6TVV`X95WKWJ57!%S
M7E-OQ_M[##;0G2]MV9MAU5CINEM2=3WD=1&;#329SB9JVE)BTOK;R+%S"^@!
MNUR+RNG*@),+(95,8%-'%=V,8&6\C5;AC5DJX].G"TVHAR`]09`PCB9#$Q;7
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MS(O8S<6$Q^:S`ZWNY%2DQ&>;R,.E8!DD09-5A&3,)LZT6",RINLFH2$6]*SP
MZ04TVYMP=HBFR$VP3`YV)6'@//.]BRO/61D249=/`INLFK>DDAM$HVVRKRZE
MHB%=V.N:#2*ZT9!S;K0)-LL86FTW4IZG%1:6Y46M[=BI,=#8DY!66_'S%?Q,
MV[Y8BI/49:509#$=?`:!VX(H0+LSEU,&CQ$:KP$N22`(M;[-.&5%.2W^J&CC
MR`4U)6HEN\1S8PA)6LC-9HC)5HT?K_U-U1<81J*WTMH$>2--NHB#-)TVO3@^
M9O1W4_Y5:*\K(RN9C5G-F14DY%9Q-R?LI(,@K;A7&?H6%^)]O.W8`@(:Y1MS
M2L1UI]JUL-.#X=C+2T<I,Q_8V6)A:?J759.<6P3'0("Q;#5C+%'3Y'--F6BC
MOE)0R)'FNW2";BWESL5XBJ4[7KN!H;'"-'ZQ,+>7XZW9<+CB@K/CN@%#6S32
M(:X@H3G5W"U!;76#S7NX%4FBI:@7%"`S<R@<!'*9`BYB=>*R]N(%HBK/HV?F
MAFO)=UCX<<?3?(S&DX[*<XI3D0U#>':!1:<0-I]'WRP3^#I:D(C(T-+6QKH;
MCI=KQ,Q^TW*?:YD$0^2SH.5>*/LA'D^OU$;%H<=\8*RIO]'\;*CZ:IF%8I0)
M"TPB)^.I((J.P4C2TUS;MSRDUC'8\GM<$B]M0ZRE`V*5:TLAV;6*H]_$HW$F
MW'%+,Z!\$@50V/=NQ#ACAR&%K4I81Y%AYJH&K1?87%)<^O-]DD6/I`<[M5PE
M4)ANR,-G'"RC\1E%!P#9*KZ;*NE#5I(FP!V>.&_!$RS-(;WUO5)<7(2#>[0U
M7<F#LDN9UY7?."+V.D`/J/7A=?1%#8)=(DT1+=3$?7JE9C.5%CT4^D8NF+SW
M2X8DC;S<C1C7+)*!<.2N^F-&6Y6X12')++*&VLI,772/WGCG!T6SGL>8F5AL
M(HV$).NO-:0):,3%*<G!.0VUV@Q0Y13V2X7<Y_9"9#AS=K.:CI$*XD1'(VD!
M?S)8"B#X%,UI()*>1;$84$N*+B7R-7!Q%$+@""6PMGF"%EE?#'HGW\[Y1R_%
M]G_W`4KM.T.[RO5'Y/<2_,I(JLJ4I2E*AC8COM]!/CKL;]'%UU<]*4I2M3SQ
M[2,P?FMD3YFK=81IWWI>L/R>(1_=<U*H^E*4I2H;XC?>E/OXY0-](J)*N$/[
MV_Y8G[3*OG2E*4I2E*4I2OK%^]M_K`OVN%>LIJ[P.],MEH)8,\R&K3D`]Y7*
MKSW=`+9D9.2$$-:77>XS1W%)3!FBHB$2.(F7(`MD<,7"PM;&XN=^>5]_^QR>
M'_\`]M['=+"3_`E/8Y/#_P#^V]CNEA)_@2GL<GA__P#;>QW2PD_P)3V.3P__
M`/MO8[I82?X$I[')X?\`_P!M['=+"3_`E/8Y/#__`.V]CNEA)_@2IK*\";2<
M?;M<@O-5G:S,3M<&O*Q<;&2DZR[=TK,KO%F&\!5*[0N%FE614$C<$C8CC<,Y
MD8,7'SZ[;'"E/8Y/#_\`^V]CNEA)_@2GL<GA_P#_`&WL=TL)/\"4]CD\/_\`
M[;V.Z6$G^!*[!=(>'G`N@2;(R5!IV0SA:4%-MJSDO(#J*N<4,TUB"FG)EDO,
MJAHMB861=6-7-!YXF+C"6"SQR#MA?'*ZZAB%>_BW:^)6H?S4F&KGI2E<9=R_
MP7_54::J>V?OQ\LH+Z(NI5692E*XR[E_@O\`JJ--'/:SEGY96]/TO)CJR[6M
M;GRM:W.][WY6M;G>_=O?W[W]V]ZCI8B[0Z691E5:<\1:POZ7HP<#.(R\YG9%
M<:KKV:[B-LUO.ID6=CI<+;'5,#X;),-I30S(ZF/D02,$[`N,6Q)X`%\,E#7[
M5[;B"FU'2DTB$:H3W6@U%K)2E&"%'$@V)MJ>&7-<D-4DR'ZUR:P409+><8)9
MV4TBR'UEXI)K!QJN!L8REJ]O$$(^X?3_`-;3J8CZQQ6]=>&K/K[:>48(NLB8
MX4!-F9LS8O:^2`X4V+$ME&L[#IK\"<I%Q/@@AW*V98:TXSZE=FXG3-J3^X7K
M*L2@U7]]R2%%&8X@;:6@,MW8L=CF9"C9I]85TY#2&ZK8)F;@:2#@4,KY)#*$
M!2!`$J<6RJ3B&";4@Q="*KDX?J*AHNE!AJ0?G'8LDK\19003CEO&(C:<@1[&
MP&XJFWW.U\$3%B-$1%9]D^6B9M3+E4\-:,)QPH:P<66&`5$M.#M=XYDMSR@R
MHFB)DRY+.)[)WOUMLEH-Y_R%B(:"7%7T\<2<G%%YRXCG@P%I6L8,F[&3H8"L
MI==,X!&K8@Z'!K6S)YCF+55EM3[MDX(TV/E`NEQD55%(RVVRAQZDS(\7BZT]
M"&`;B2L%,XJ9:PJN=3*7>A[%EM?"ZO=*)ET_SA>"M7'LD-0\3B""'0A(ZTF.
M5E&R;#C]72$Y?;#"/1"CK;;,$TP<@"IH$8#*49)YY-SZ^EL44XS`,P$#KJ;C
MJR58DT#B,_GL9+,2ZRLY<;-H^.82TX(VC\NY$B[`46LC1F;3W&&A"+Q<9EG2
M3-36F;31>O-T!-;Y0B*43TTB&6\%$T2</N7QT8]'4`Z_'C^M4K3"R&8$+"C+
M1E6+I#8$R+5Y1-L(D?;A8ZB%_NT@*[E%<;=!!2U=Y"9NPD;%5S&"AG89\HQ3
M3Q03BF4:AA^HJ0NW;!P^71A7<DH*Z91R;EN@F#.&2T12%<V00"J[=.S"(J!H
MDCEU"XPY8B'AXUS,2+'+BXE-XLU@K^#B:&#8=9YR-UMJUEUAI9T^KAMYPFE0
MF8LIM%/45144\$E2$'129Q1/G;%PAS9@4319S672$=86)L/0-K*877T=/.9<
ME$Q&\8#J+M/NE$4VNJ+B@[Q$D01='<Z`Z%=!5#HAXU=QIR^?3C^:@&J"A#8M
M'VN?#XDC7UD-".X&U><>MLK9I$RL5G(\5Q[>-WD=.MXIFCR$C-41!`(GUG%K
M"$BP*Y@G>G!%!ZRF"BED['T);?CCA^`Y'9R=$COBZ(GXP&/ZG<4B-'(R&4Z6
M@TK(J8*GM.R:RU-+/HJ!9)1\AR+=L53"?H%,R%+)?6BM\\*DN:HUX:\;QLRG
M+(&N^MJZR&Q)Z;$T:H+5@!@2!D0E6=7T@,(5F,EHM1IJV0#A>;Q.(H;N(D"(
M-K9IN*ZZ;``(61\I?Z`A(C60D9LMI)3D!N-U*3D%`0T@F`G)*,BHY,%.2DI+
M(%<`BQ).3B!8N3(E"X88!8J"$"#AB%ACC;H6W\[Y1R_%]G_W`4KM.T.[RO5'
MY/<2_,I(JLJ4I2E*AC8COM]!/CKL;]'%UU<]*4I2M3SQ[2,P?FMD3YFK=81I
MWWI>L/R>(1_=<U*H^E*4I2H;XC?>E/OXY0-](J)*N$/[V_Y8G[3*OG2E*4I2
ME*4I2OK%^]M_K`?VN%1!PV>\?UU^(POSF<-7'2E*4J&$_P#SD+K^1,P?I!29
M5STI2E0Q"O?Q;M?$K4/YJ3#5STI2N,NY?X+_`*JC353VS]^/EE!?1%U*JS*4
MI7&7<O\`!?\`54::.>UG+/RRMZ?I>3'5F=WNUT!OKAOGY-WK?CH=NK[*58(<
M'$-UQVZ<3I4[QD&UI(:["X>$Q1"/BNM@FMV=SH7F5M*:;3I5V\\&QDCJYIVD
M'FGB.*X+HS2H9E/AX[S91C&K*3M<\EQ^1Y$<2&6?(K(4=<5MTEGTSMX94GQ]
M-A?E>6I.+.B)K)K"4&TH,`?7IEE'#)[A>!M&D67T$HU4@LT.VY8U1F\YI)(\
M-$6T3`D!S<0U[;!)"-ZI4$`'[E:_Q8A-J22D*JA*'I86.Y0D+=;'0O1?I@&?
MMFVK@9*][%,M>ZCZ$2'`LY:[RM:-6LT5<LI<54WL2[T-:;EW&[<-D]LF_+>O
M8#H/IQW-4>I+U)IPZBDIPPBB2CD3#TIL70S`MRV>OE#AN9OS>5YK[]U1C5;U
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M75W4R4AI6U;CR4-C47AZ:`PG$22I+L6O1>3W_##^E1];$1ZP'&[%<HU6Z=7"
MZTV$()X'U)KI#X"S(IYM>`129P(C=,"\/%\QGM!%FQ@$0,UJ/`SOEQ%98EJ0
M4]1:&#[4]=M@&G*H,+-M>5TT^,JKR#9='B<?..0#9Y-:RTADEP5++&4@13M+
M>\6MSU:&T:A,LA:N)TD*+SXJ'"VE")MZ/5%&Q<W"VOR9,>K<6*>MUTPXZ"\T
M)Q\C(*4]CA9DL]EJL2/E*EXY(#J<Q%XIZDDY8HD:<;W"Q`TH_4=1L3>$#:%#
M:F*1=]R!$+M2IE=RKNCK\^GLO1XQ4>:6R5=;9(0?&C@?#`39E>,:(4CNS(K&
M4I-M(;9E7)N#,M7^%U)+HF9D*.S^MR,JPA'4_P"^<MLIFS,5UX44)'QV!B74
M1,A];^XM#AY7A]$4B#J9TW#GFPWT`ZFL1XWS=(9Q;<*D2?:II:*^&AM8FDM5
MTMRP`^6F?9T!\.*.6<;::AI\5QU<>>L+P/9['K-I25%QZR+$MI"<0!^:`%O6
MEMOA2GI)>5V5)99MN*Q[TG[9H2T4?49\/S;R'H^0VE!FU.SJMO<Y#,DHI\`J
MI&9!FR3YR,P>^G.^6C=56PQ&VPW3'Q9+&3S!]2CU')A)*&3+&T?T#44HG#ZD
M*1'"BJ2#HNUM7XA:TD<)M2R@-S+T&KZ<I/?4^;GLZ]@IW22+&=+K:67I5#[G
M08G0G4:%3I1F5%;P]E]ODR*4VR1KV3<;<L;6OW>7;^&_;O?QWO?G>]_=OVZZ
M`=_.^4<OQ?9_]P%*[3M#N\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_1Q==7
M/2E*4K4\\>TC,'YK9$^9JW6$:=]Z7K#\GB$?W7-2J/I2E*4J&^(WWI3[^.4#
M?2*B2KA#^]O^6)^TRKYTI2E*4I2E*4KZQ?O;?ZP']KA40<-GO']=?B,+\YG#
M5QTI2E*AA/\`\Y"Z_D3,'Z04F5<]*4I4,0KW\6[7Q*U#^:DPU<]*4KC+N7^"
M_P"JHTU4]L_?CY907T1=2JLRE*5QEW+_``7_`%5&FCGM9RS\LK>GZ7DQU9E^
M?*_*W._+M6[G._O<ZZA)TW*V?A#:YJM%?+Z\VBQY2\BLEC:\)H#C=6UTB0"0
MCO-RR]N3BZT&0?4K&L>Q,YP5M--LIY1,83%=%:!@$Y*R$]'TRFV-CFNV]FVS
M\":P3MB:(GRZ=A]"D3??7MF-%=6HK*M4BH.II)"W`DH/AQ*,G@+R@@($I1@L
MA2^A-1NE5D_ZN$X.-RP9!#%,Z_>'$8V4'@?AY2LDM\!D(VQ^GKDV>V2DMI:C
MSKM6SXE.I+#A9R)Z&GMV-7^TSS90#9B07PLY*+M<"DJJ#>80Q1!(J"R**'7=
MDPG*EO-CLYWHCF17HBNIJMUQI#P;8=@6ZZDM<1B2HGN1!"L?5+!HJ\4-@JJ5
MA924+8$#9?#T<;ZGT0)EE*4Y6]ZE*_,:)E#P>()PJ7-A8#E36`1D`(P'B9)&
M0CA,QC@-AGAB.5-@`F2PUK6$+F`@QP<L!0\,\?T\K>]W>[2G*WO6[7<\5*4K
MU_\`?SOE'+\7V?\`W`4KM.T.[RK5'Y/<2_,I(K6*;Q3^'PL;0#Z:)NU<7&MC
MR[I,L3./,3JO@&*_R0-A3<>$WH*CAQXH2(5RO<J98!%W&'@"HX"I>:+93!%)
MX;7&W;U8!V#DC52\QMT78>(XDQG20HH*DG"<=+>BW((D8LYKA%$4<DJ9XEE-
M+-B("(=4G.$354HX(BXE5,@,8T7`'%IT&VAEA,@Z#IK6GI*2IF9"Q:HL';#-
M,5+'+-8V];E7.JO:)FV@L\X::I(=;32;K544RKD[@72@C@ILH&/N9[[Y:<QO
ML.T-3WUL=%#7V*?@J`6:\3*[I*EG6HJ#ML9NT$<4'J<B*6O/&Q0QZCF^L'DY
M<=G46]3J>I]=!ZYB[<XE&A3L7)Y;C?VU@E15]8D)P.B=R^+^2"X,;MEIJ>:$
MZG&MGC@A9/,-]L.##U..-:1C2HFH3DS!;JH:*K1@N0%Q8[Q6^'0GP0C;,'=P
M82+0BOOI0C%*?(KIRL6,R&CD?39:9>:)8E=TE'*AHE\7"NI!U"+'$1M"`N15
M#*(0X"B)=36=+:?#:;[S9J^C.IHNQ%2W(V'.W5,FM(#B;ZV2!4D=;1%=.&,$
M%1)54\R7.IZ@2,#%#A48(<N*(%GCE>-MB.^WT$^.NQOT<775S]SNU"4F\3/1
M2')U):V23L>R&Q,1MP-%IFVT8*ND^EMEUO[`L*R&J_7PD-Y1C^.'.[P#Q`RV
M6\_G4VUA<+**<93R8Q=0)BCX*K\7SAT($UJFOBWLLAI,G(DOV@%9*J+%EDHS
M$B9;J!=)O'2I+`[`PB5/<V*J;*I>9(V^`<<%0P"G9BXG!,0;^5PXK>AIB>5#
M6=.FM279F2)?P@16;3:AN>G.D)4O9+">@#L=4?S?BY2CE.4TY65")-:,'7:`
MF(68]Q%H^0!!'%"_#&?%RX>$P3&WH%CW8](7)+=[V=L;M!/,L*6V^V7>^V,8
M6BKG:C2D9RQ^CQLZ%M.,MU;`")(3N/YJ0J<8P2?1U[86S\A`/%>X?NT$KHD)
M0=L:A/22G47>QIFH0K.DYJ$WZ%'`I@)]?<[<[V8[;:4AB->Q0X95P&4O+HY=
M.)G%3K>2:4,&@JXGCVD9@_-;(?S-6ZPC3OO2]8?D\0C^ZYJ51]*4I2E0WQ&^
M]*??QR@;Z1425<(?WM_RQ/VF5?.E*4I2E*4I2E?6+][;_6`_M<*B#AL]X_KK
M\1A?G,X:N.E*4I4,)_\`G(77\B9@_2"DRKGI2E*AB%>_BW:^)6H?S4F&KGI2
ME<9=R_P7_54::J>V?OQ\LH+Z(NI5692E*XR[E_@O^JHTT<]K.6?EE;T_2\F.
MK+O;G:]N=[<[7MSMVKVY^[:_N7M[E1$W]'T%K3I+4ZH,Z3H3/SJ_$1[RRQ#6
M,&+C+>A-N-!)8J)'2@I.&#564"T6I3:2;E$MDIDDD2*.;5W(L(XR>L.1:/G?
MR:U:!Q9K,OY.%">DHR`:0H:1-;8E"DI:;2KA".NC<6#2\CPXP3#?:3:45)$`
M414ST8Z)%//F0E@@U6:F*SM-DVV4#$\8J</UI`Q/"\.1O/.R,-M.&H$OK&'Z
M@'PUQA7]#`J*V$$PC/9+>;&=C3Q>6">UBN"'+#/;32DUHW5'$$U'.CDEPZ4O
M:+#8[5C)CLZ-V(C%VXR(_:K=9#.;Y04T,40FLTT<D@-Y&*C'1S1P4NEI">3(
M@B&C)@R(&!CF..*-EF)EE=*4I2E*4I2E>O\`[^=\HY?B^S_[@*5VF:(6O?2G
M5'E:U^6OD17Y7_\`=9B/EVO'VNUS[7/ESO;NUTB:,ZV<0O5MO1IP_G-H'K[)
MT-QMNL_YR4]\I9E..GHQG#%KGFASS$6D1KPN`+:;T[;U*37-BS&.L*J*5;+1
M6T4@L&W0?1RV.(T]0WP[.**S-R8>XH#HCZ)QY/D/B#S(]IT@%+Q1B\]L/4+8
M1'3]=Q&V[)R$FPW#\C,N$(<BZ)I1:,9M=M8.<LZLE(0HY%97N90<.VF.]3]K
M$_8KC%O%EO;+6<_M9+.K3DUHV`NV8_F6Q9/CC5F(X[?#@^Y4N+UB)NQ=QM=S
M,WTI?`2&()U_%?2P310NGFAH?FO6+==^[@Q;&<I:JO"7-76>[-1Y2GC:[7Y.
MTNAE^[W;30X8:1MO37L>27)G:<@LF$->;)J=Z31/'#377Z[CS5-)B:Z2S,"0
M$$[UP.K@X\1R4-=8&UQ-0(Q6.L\.S7>>8[0I`5I8CLZQ.("[77N!!T[-9$:A
M=OK)YX,5H/AFPVLJSM49V;#3R1Y&?@24.B*:>(M.DC4V&E?$&1]XW!Q6@-(Q
MG()(,T;!AF="3,S:^@2PSF9)6F,)ZZMR6U%X&Y%RUZ.KKC>L2+&<@MU(D,XN
M$8Z>0:B`<<:P,K-<CWZ\,/6I^:></[4G6>4%5+6)$AR$F@SWH:0S0Q]%`<@`
M`Y]62D=1'Q#$44I!-J`B$G*-P"N"@430C@),F".&6"_1L1WV^@GQUV-^CBZZ
MN7*W58WQY6O;+M7M>][<\;]K+MV[?/J>?+QUZMJ9I5ON?WR69'8L+2SK2V7_
M`+O$)=VO,";,PA-/#LV?U^::VEW,NE"UC?>#WFUN[72<Q&,P6V762S6C9%8+
MI(YN,JYRA5$;Y<GKF!.%3O(GI.@Z_-*Y,B^FRKQ"9?W>XAVIKC>FO*[KE%ZP
MI.F6YPCU4$";*>@29)CLPD^T0XBE`Y6E=C9N\IDO*3-P0$<J7`_=PX]8M^X$
M&<[^D[5CB$M;8AT+F[6Q;Q+";S:WF]'7G/4OF9B?C)2CD#M*>5E;5E%Q*"\Q
M&L7<*XU"Z>5?Y4!Z.05,1$[,WA,>G_#/XC40MO5==2(`VD:"_I5JYM`]5.--
MFMP8+EJ))2W3D/7QY->,<=/8I9<FOMM0DNEYQ>[@=8\O/M586+>::NL)8((I
MYS*8Q'N5X9W!^SU99ND+RV"G&6)FD[4+7XTRH8BIQE(@;\1:V/>8F@E%I_-L
M4M%K#;C@?BZI'1%IHI;SDYZ/U4)M<TIADCHYA6$4\>WV=;VQA27<LL;9XXQ?
M(5[X97RQQSM9G+5[XWOA?'.ULK=J]\,L<K6OSQO:_*]05JEKS/!_5[6\ZG[X
M[#HA(U`,+#ET@I&FG1LHFABQBU<\214RJ:S'%(4J6ZKK1;(^<.'>L8!V-'#8
M]A#(N_NQNV$_&"[']%>E?\KU.QNV$_&"[']%>E?\KU.QNV$_&"[']%>E?\KU
M.QNV$_&"[']%>E?\KU.QNV$_&"[']%>E?\KU.QNV$_&"[']%>E?\KU.QNV$_
M&"[']%>E?\KU1MOW`$Y)6K;Y.*N\NP#F*XNJ$0K)2G'&H9$D(.8V!BDN`9&&
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M^H`G-6TTU_/I6\VP#8)&&0+F$B)<;ZAGD\C;U2N&W6BAA?UN5E?(+E:V5_1R
MF>&ZY<3*P]@\L`0K)[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_RO4[&[83\8
M+L?T5Z5_RO4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z
M5_RO5&Q&`9OOQ`',DX[Q[`XJV&FS'.B.>T=:B74QBXD_2*"&DYD,M;+H.*:7
MZT(:#S#2\%?,Z9&R&512.)=/`LGL;MA/Q@NQ_17I7_*]3L;MA/Q@NQ_17I7_
M`"O4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_P`KU.QNV$_&"[']%>E?\KU1
MM$4`S>9W(W&3BV\>P)!2(-#4T0XO@QUJ(.?6@S33EJX8"@3-ZV#HX&"=F")9
M.S2$]-%ZR:,8*8BH+B5'*V3V-VPGXP78_HKTK_E>IV-VPGXP78_HKTK_`)7J
M=C=L)^,%V/Z*]*_Y7J=C=L)^,%V/Z*]*_P"5ZN+ZW;"<K_\`E!=C^Y?_`*J]
M*_Y7JDO6?7Z=3LC[O@DMZM@D@5.VYQ)'S12-M03(R^;OJQJV=P6%+!2UL.%R
MI_$F<*(]P44!+2LR222,73<5,93/GZU[&[83\8+L?T5Z5_RO4[&[83\8+L?T
M5Z5_RO4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_RO5Q?6[83E?_`,H+L?W+
M_P#57I7_`"O5)>FNOTZJ,=2@*G[U;!((0.W.ZA(4J0C;4$V$;-I^U$L$CJP-
MFL:V*!C`^N'"YA84@2PP"4`=.C%T=-2TL$J0`K7L;MA/Q@NQ_17I7_*]3L;M
MA/Q@NQ_17I7_`"O4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_P`KU.QNV$_&
M"[']%>E?\KU.QNV$_&"[']%>E?\`*]3L;MA/Q@NQ_17I7_*]3L;MA/Q@NQ_1
M7I7_`"O4[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_P`KU.QNV$_&"[']%>E?
M\KU.QNV$_&"[']%>E?\`*]3L;MA/Q@NQ_17I7_*]3L;MA/Q@NQ_17I7_`"O4
M[&[83\8+L?T5Z5_RO4[&[83\8+L?T5Z5_P`KU.QNV$_&"[']%>E?\KU.QNV$
M_&"[']%>E?\`*]74=M2TG.Q)N=*(]91=TU+&9)KGL'@_$>/&\M@DQVPD!!HH
M9"*&5';8NGDQRY@T6'%0157+,^.$;4C8()3`#N,T.[RO5'Y/<2_,I(JLJ<K>
M]2N.5N[RMS]_E7-.5N7+E;E[WN4J&-B.^WT$^.NQOT<775STI7'*WO6\EJ<K
M>];R5S6IYX]I&8/S6R)\S5NL(T[[TO6'Y/$(_NN:E4?2E*4I4-\1OO2GW\<H
M&^D5$E7"'][?\L3]IE7SI2E*4I2E*4I7P$[>-ORPO^`N%Z]`QO\`&=WGUX)'
M(0C-R1:28,7.9\,MI%5J+2:XK`H2*^7*7(!J*L,NE\SYO`'EB*:]#E^NWQME
M<+'.^667F_9`7$A_TNAKH83OXCI[("XD/^ET-=#"=_$=/9`7$A_TNAKH83OX
MCI[("XD/^ET-=#"=_$=/9`7$A_TNAKH83OXCI[("XD/^ET-=#"=_$=:\"XV.
M^0,K'9GP<L46?9^.TR+3)N\4E;IF322'6KO,D%BE7</6<%+%;7%"XA^PO(0G
MF"7N6Q$!]$9[#]D!<2'_`$NAKH83OXCI[("XD/\`I=#70PG?Q'3V0%Q(?]+H
M:Z&$[^(Z>R`N)#_I=#70PG?Q'3V0%Q(?]+H:Z&$[^(ZUX@<;'?)M2'(<HI+E
MB@-W2@GL),=ID>*2I@@.4C=/7TUL8IZ=FX;!)^>!9R*EU`3',:YT7(OEA8M@
M!<,38?L@+B0_Z70UT,)W\1T]D!<2'_2Z&NAA._B.OEA_2`>)!EGA:[NAKE?+
M&U_^1A.[E[VM?_TCKW%.'],SYV&TSUVFJ2S*6<?DCQLE.9T&D5*#1$H=6-FC
MX0PA%*"',AD0+X%P[8E\1Q;8WM>_57ZJ]6)EW+_!?]51IJI[9^_'RR@OHBZE
M59E*4KC+N7^"_P"JHTT<]K.6?EE;T_2\F.K,KCG;W[>6U<TI7'.W<YVY^]SK
MFE*4I2E*4I7K_P"_G?*.7XOL_P#N`I7:=H=WE>J/R>XE^921594I2E*5#&Q'
M?;Z"?'78WZ.+KJYZ4I2E:GGCVD9@_-;(GS-6ZPC3OO2]8?D\0C^ZYJ51N65L
M>[SOXL<<LK^3&U[VMX[VY4OGC:UK]N]KWY6Y6ROY;6M>]K6]V]^5K7[5[VKB
MXF.-[VO;/G;W@Q,K>_W<<;VO_NOXN[7ROE:UK7OS[?<M:U[WO_\`XVM>_P`/
M:[7NUQU>/:[?=]WE>]K?#>UN6/;YV_PKV[=KV[MKTZK'G>W/N>_:]K=KN\KW
MMROR[?/E>_+E?GRKFU[7[G/M>Y>U[7\E[6OR]Z_<O[E0YQ&^]*??QR@;Z142
M5<(?WM_RQ/VF5?.N.?<[O;[G:O[W/M]KM?[^7;[7=O:U<TISM[_=[GCIS[?+
MM]SGW+\O+W.?BY\_+:G/M\NWW.?<OR\O<Y^+GSI2G/MWMV^UXK\NW[U^Y?\`
MW=SW:6OSMS[?^^U[7\E^5Z4Y\^?=[5^7;M>WDY]VWCMSMY+TKX"?>V_+#_:8
MU_*SE#VSY0_.C)W[P')6#4I2E*4I2E*4I7S#_P"<#_+Q_P#FM7]&OA'?YMK3
MK\RZ#_\`7JU=C.7<O\%_U5&FJGMG[\?+*"^B+J55F4I2N,NY?X+_`*JC/1V_
M*,I9O_\`K*WH_P".WDQV\EN[>_N6[=^U7Z=4=TH_V]6ME$)BL*:&09UAV`=V
MNCQ,2U'AMC$G2[&<`6&4'#'IH<Z>P<#0-8FL,B1PUBEK.(.9,XH(9(DK(Y@_
M/$J(<VB<0F%XG1-O-A&G%TM03LO-RXQD!,US%3$=?AB1]46NU6VVU5PZ_+SJ
M*,\\E2Z\K+Y-3<*LN'C!@B.3<*==/"QRAJ&N+KL!'NL@$@[!P)A*"V:U[V$G
MJ,W.U94::.Y9C!A'<%F:Y*K4<K.!C=":T3*"H#-L4*$>'2C@>Q192"R]=]W9
M*Z4N"<J`7BOG6]L*DZ\/F#D1/=;7?D"0U/1)H2\?>;K9$LSNSV>\,3$6LW&)
M4C.7X5B@G(;)"EB5%5>B]82"YUPK3>CIQ)#243)G-=&^*(@;LOL%LH487;3;
M>,/JLYQDZD9[B/LT69J6ZT%MXMF=D<)D-I,AN6EI/=C;>399*0Z)01UEM"N/
M"SQ+K3054T61VQL-NG(,^2V1BQY[,/-RQ_Q.@(5!8@T0Q*6TY3]46V]8R+RT
M`[I6'BPH\TIRMB(UM^N!!5TR25)WFI2(M9!#0UQ/.F4,QY/5_BD3P3@Y+6MB
M(K;;A45;7#:C82-94/3?&<>EY%3=;MF4F&EU/E<BO-%AQS`R>8290B];;;A`
M=[YP/-LFY[KR4EOHLE-9Q_J<'&U,)49GG<GPQ&ILXU9QDV$GM(JU/+G:6IY1
M8CV$(KG)OY)NP[@@(H(AGIE2):2&K&(DN,"+6,.Z6I(EU>0@$-O(JFZ]^,SB
MRM9\[.)D$HD6>B6X9FQ.UT5UDC(`*_*C>DTW$Z3)IYT'8K;#-6FF<U_0518*
MQBKS"E3.=&N]N2JELQ3C<R1?!OQ.^LU[<1M-C=3('FYHE7*I-R-3&O&G#-B<
MO+DC[,/$>13!*:5K857/(62I`^M[.:`[62$Z7&JYV2DM);4W*X7H\%8Z4:<=
M+NPHWXER8]-V;:@J3*8^`C@<.Q39:*^PII2I,=*&HZXC)&:UE,K6;[3"9D=9
M/U(5+KS*;R1*KTD!&*X!)$FLECN/%;2F_K!P\0G9YH;.35!);7F.Y*$%WE@?
M4N`2Z7,)MCXDD&1--%?:UYR1+B\J1HNB%DUKMMGKBN82FFA.!;$%5PV@B%5P
MPA@+SCU!AQB@XHBJ"G6ZVZ1?Z,\FXBNAT'WW,T>H6PR\CN_:EVZ[E!8_A:,H
MMQ37'DR1$@FX'*X'H!",='$$T01FR]W6\4I\9(?[$KBI2=%2ZUH^D=E-E[&G
M7LIN`S`),DF2F_KZVEYO1QQ%YCU@94,PPXEEBAQ`]YK8<;-1$=*@RY*DF(%1
MRMKU*8I*Z[W:\#HR5WWVOSMW.7;O;NVOW+WMS[5[]WESY=VW<O:U^=JYI2O7
M_P!_.^4<OQ?9_P#<!2NT[0[O*]4?D]Q+\RDBJRI2E*4J&-B.^WT$^.NQOT<7
M75STI2E*U//'M(S!^:V1/F:MUA&G?>EZP_)XA']US4KH,XK3VA`UQ/(9BGB2
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M<LP`6>Z"S0WB7D80JPM?9&./=O/91&9"2NNI9;[?,F5=Q%MO1ELT\PYF:[G?
MFW.U+3V+<[MXSZ3Q7H]BV2GR_7CJ_K-"Z-(XFOLALS7!5$D=G02IQ6&1AT37
M=Y-&,P!7N*[%[(,21+8J%D[M;X$4CDW'+?$<8<?3>N3WKNS'[K6X8$=R7LA)
MFV\4$&R_H</F%A/3IOF`^<?.,]+JBA`/K9*(@L0F;$;I=#?16IC8(Z=M7:EQ
M&^]*??QR@;Z1425O/8]XS%'T!2^]M?8K)3=-C68;H6XOB91=!1FDW^\R!,<9
M$;([D/6L43;*!FUL<<AQB>!H3#`CZ8IES5E`K\XA=<I/37R/7E-<=%H=F%RQ
M4@K\F1>G.4J[RT=OM2;`1QS-$HZ2&.!-<#;ZN(9(!J93+,`QUBV08X]L>OB>
MOK%#]WL6=5N"3BGE(;;ZD[6F#:+GS>8Y-D%P/J1O6K]JUV*[3:Q%B,X_2C+>
M6'4GHJZ]RX$J.08FL%"]TXVH9AAN`ED[8XFVT.U>&MJG$,AQ'JW'.U>QQ+6%
MM/:3HF//-P-9VQGI>]YGV&NWR;C>;2;R\["FS28+K@QR"T&*C!*D6OTV.1<I
MI90R=8`G\7+=)\(Z4Z&FTHR*$(=BJ,'P_#PQ*+&_&6QIUW;7SUK4:=J*]I7V
M58CEBV&I%3813UN&EV-FM.*R$^Y*1T9?,.0@E([>?.22#MEO62DN-9T6I]92
M;&`>W/%CC)FP&T(O,MY/66)I1$&ZB;'Q.5G4=?AU0?CG<:["B6ZE@J424=$1
M5`BG'$1++'2!XT9^`>V&Y!&1=8V$M2?"B#/NXVM^DYMV;/!Q@X2D=PIAL(_]
MO)'NV6[$BU*"BSEL9)3H\284A8^[#`2^\I)>I5>>ZNN%!$6.BN"M#?O8-(<]
MMK'B]8]D7*(=>Y0RG%8CQO+I*)W3KUKYQB'YKS,TO,EE@OUPA(3F3]:F<IR:
M35[+KK+V/-Y130<#26I@6)4DV.(+M1(Q\VYE&7=;=8&BUXDBK;E$2IUCU;,!
MS'".U&RTM,*"F.*K)[X)+[3&:L-,1AD7<[6FWG6X5:?II:B9ZG4Q!0<6D]]+
M+?%;WA(L&>IC(M2,TE)/PKOT]XC8K]38R3\8S=FHLIXQVQ`1RS5V+<4WRTF'
MAL0D#8LB[8BAXRQWHLI)ING4!+N6;RUL\WLCLE'&[IO4I8FB'V&\'8X8C!EK
M;UPQVI%VVYU*.M45J8%-EH47.*31X\9*Q(JD+@600RBNGGDJ'XX?^8YIVR$9
M(/MMQWI/Q%]Q4V#=<TYKX,QRM>/8WU%=TB'G"?C;!NS:I[C[*2HV7#F!*,N[
M#L60V,UR*<0#;,`'&%&<T'EY_DA4!UYK>=RK1+TNX]Z]^+-)\2,DS!#A!.-:
MZ\5[81OM8Q`MC@#9];5V9!BN-VD$J9R(74%4C-337$W[LQY7Q%44D^F9"Q@,
MRA3@PP?ZY(WSF9EC[!)\2JB`PGCG.NR\HYHB(S4%]+3@8\':9Z:R@K.-RN38
M6>(SAE@1XW7C-:`ARF:(.%LN==0CS9)Q4U$EQFWJ]BNP($XC^Q$I;!ZYK3W<
MK';$(S2;UK802"P&<R))8-I#F[2MN[!KD;O5V($L*^Q<+3^!)"XH'6*3?D3A
M0:>@=)2#"HYCSS=>2TW_`&#\K]4'AESM?JL@K\[<^5^>>%^=N?;Y?#V_?K^5
MI*'MGRA^=&3OW@.2L&I2E*4I2E*4I2OF'_S@?Y>/_P`UJ_HU\([_`#;6G7YE
MT'_Z]6KL9R[E_@O^JHTU4]L_?CY907T1=2JLRE*5QEW+_!?]51IHY[6<L_+*
MWI^EY,=67:W+GW>W?GV[WOY.=[\K>*W*U:]4HM8:M*;0F=01<1Y)8C(?L<M9
MQ745,*Z6SI-6H_<;V2/2H([@CF_3E6BYCG/1QX@94"%D2X*::*%U!3".3>=X
M?&HI]DMB.S<4XBM!G1^_8L;J1ZM7]AZ7L>3Y9CN<'LB>C0W/BH&KK<G12PG+
M8^;,CJ9'TCLDIAPHB**HG'?+N;26!W7./W?5$"0"CI-NQBR&Y6NB2U([?BA\
M2-%Z:41(YD)^10CN0DQ7:[V:EIB&035-72!@C>#89@B\45S3):0Z-CD(ZJZN
M:L28DDV,X'&F/-S,-VM*)8Y?DYOIY)[-B5!<"`Z'LSH)CAZNU33VDPT-;5&>
M,O%VJE7LAIN#%;(IXBU45IHA"B(_BN+X>&>(;)2"K<,2U*3KE-SX#+*@=%<<
MEO$N5.N=7*X+*B;S`,'RJ``9R1T>Q=.*%B`HQ1/+@V,Y7G%Q\.?4!RQP@1>=
MC4\3:C0CU^1HS_2>0Y$2%IIMF1Y:CN=G"*@N(BZ0EDFOX2]$L=OM"<V1P9<;
MBLUB8"(=)I9A13SFD$3AJ:4OG.03S-?TV+#I-O\`?"7+[Z9^W\U''TKOA=CY
MB1?,3-D1SIK_`#)\05U,]AQJ0>3'4KER:$;:305&RDM%12D\QCOIG\/C6:/I
M.;TE,AMN]K`-150G0WXM1)/D0A!*8_&S&Y"(4*1`H3!<>,=BO=.CA+3FX$M&
M40;#,<F7=(Y,5ZAV<M9(\]*84>DRN"?1CTSM24G8W6`TG0O1ML5.T9$G"V8O
M.N-18J$K-QB2`@MLVEH1YWNHU@2S2NL'C#A5AU/`X*;SSK#8_P"'7K7&,P-:
M:VD1DPLZ6"\YD>T=H:C,\H+D<1\H;!B.%0FA/9D8+#G.L5"0Y!<3F474JII=
M#R]`KP2:(@F$=-2R28'L/'3>!ON[K.QHS=7C4F++_8TK9CF7R\<VPGR7'T+/
M?7=#>Z4RL5G!KD%X>&I`7F,N#8)F9==3P4(XI%AU9NHQ\G/;JX3.F3I2\V[B
MUY-:[3-L5L1^NL]CSU,[0;#L16!(#SE6-3+R245ZE@G8KQQ(4A.]SM!17<CN
M10TJA$5,%61TA$34W)7IPQM2GRIG#RDVI!3DYR*#J.R6TF_,\KHC%F8!YS:[
M]BEY(F%F$W;9O/\`13,PO][ND%/5B-L2A%V+[,+"AL11&;-^P.UK6MRM[][_
M`.^][WO_`,;_``6[ENU7-*5Z_P#OYWRCE^+[/_N`I7:=H=WE>J/R>XE^9215
M94I2E*5#&Q'?;Z"?'78WZ.+KJYZ4I2E:GGCVD9@_-;(GS-6ZPC3OO2]8?D\0
MC^ZYJ5OA90$-Q%@R:\CI:T4!,!&PBJLG$E,L&:`ZKK)D,N>`,`X&`>KSZT/B
M'84/JLK89XVRRY_:$C)`*@<5@4Q/"5%$N5*J"B&2*X'SQ8CUWT$7.'<0K&C0
M)3KPWH4(P*(&7ZZ+UG'#KF?5?D*-AN$`T@$B@(I,)OYFA4((JDIQ8-&$/!CA
M'1$K`$L'BFYFPS)D,UF1L!D8P,#X#7SQ%$ME\%]IMAU@@%W,W4)P@%1,QBP"
MZC)JP"7&$PZV(*`$I%36`(F8=NHSS#QQSRP_P<KWQ[5?479K2*8(895LM\L&
MV,C&;<#+HB6!@@9F[9XFLT3$(IABD9F;9YV,9)UBN0]L\K"WSME>OW@H*(74
ME!9`2$P%65@"Y945`2!0)142Q3#(,J7/GL`<31T`MAGE@7!-##!@8Y7Q!QPQ
MORKA$;Z&VR7I<WD=*0T_KPIGT"CIQ)+)^B#&5LAQ_0I``N7Z\-E:V0PO6^N"
MY6M<3+*]K<HRXC?>E/OXY0-](J)*N'"UKXWM>W.U\Q;7M?N7MUS+M7KG+''+
M&^&6..6%[7QOCE:U\;XWM>U\;XWMRO:]KWM>U[<KVO>U^U6&*C!;QUM$&VE$
MRC4P;R<8),94;B(V0S\<F\V^H-D@M,4HKH2PWT1414E3-E4JV2&;3,"HHJ8=
M3#R.9.IIF.R?#<UE#8FL\9K2`H/AB:R+TH.I);$B!-A])$JNB9FG(3=DMPS0
MG.)LG$YXJCL6).=L@JF1$D@E,WT>#4028*6#BCU4"G`D&K:K'*ZLPU%*NMP\
M"4+Q*L*<=,X^JQ<`0L3L2!CI1-HHIQD!%,4Y/Q*A-@9+#+8D2=@,0_0H'6_,
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M%A8^4U1+-GV:,"73$X`,=NF$X>P9$G:XE[E@;X?G)P#!:<XGV[T^&(H(.R4B
M_H63'.3CEFE7%(A6PF`V)=]K8")@IN\#$4,,3$%PFE$.PF&`G4WSPQRM^E_P
M="TKIJHC2C$4820CK:F@+2RDOY@-)XIBNL-3JO4LK*A!Q(ZD54%-M]7G=`/F
MPAC:-U67I:,6MEE:_P"(SK[`YQPL5VG(5B0VZHO#&"C5S&8V98[ACP(P9&.F
M`V,M"(>2DT0S!LP8-#X-\RG8BF1QC&=KC"B9Y9=]SQ@^A;D?40T/0=TMT(ER
MGJ90_0UT9[G@U-Y)-R_H#K-TQV*(01]S$+X>A%\Z'@;5P3AC#$2V+.J`X-?6
M:2(]H:BEX"(#FP>J$(Z8Y9KAS1'B$G$$<)V)&2NB',DUS!)*4F)@:\3N"JX)
MZ>1)6-V*DRP07XD#7'7MJO!OR$V(*AMN/YI-HLRVJ]T&+V,CN]LLXD1,)9-I
MM]S)R"66T9LE4XV:(%T%-/%DL`D9,%`BN!884++<@GWMORP_VF-?RLY0]L^4
M/SHR=^\!R5@U*4I2E*4I2E*5\P_^<#_+Q_\`FM7]&OA'?YMK3K\RZ#_]>K5V
M,Y=R_P`%_P!51IJI[9^_'RR@OHBZE59E*4KC+N7^"_ZJC31SVLY9^65O3]+R
M8ZLO+JNIRZGE?+J;]3:_<ZKEVN?BY]VO6VV?>.X8$C;C!,)8WB"W8)2'(B;I
MK'$,HCA4-81]72>M>)UH/%S$'Q@#K`M^F;X,/!17':KKN6P2?L4FL".FT1Q:
M`A)M+GB6N5EJ49+:L;Z\N_B&&](UC9/2]-=;FDE9V5:TDBF3T#[>*VV#:.25
M)."7.Z/%QP\C:L%Y,-!K2*TVG-*^YV^Q59N.7-6(ILTO96W>A?6F-'$^I+W^
M;^,B1+$39F]TEUF3UJ4DUV@<7/6>(&LFQ^36"!S)J2^X=2WW(K;(HC/2DUT2
MVU0[N=PIKY>!,)Q#94\2&YYD>1W[JX0V=>K&B=@\21OZ)2C*C?F-XS`FL!T1
M;P_SYK$ZO2XW3\JNE0+RNG[,$-;#$EV=<@/].9!0H@`O1-26O@J9`EI,[O):
MUXE%*6-AGHUHTX@CA!UG"5E#<]P-IMN!X\-O8U!3;.%Y;`$VW,,D1*N[1"QD
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M'#X5DE2)BR`Y>M'$Y43D`T0/E!>IRZT:)F!RXG*_4"9<KUBOW$IJ_L8F+HGD
M7^&:?<2FK^QB8NB>1?X9I]Q*:O[&)BZ)Y%_AFGW$IJ_L8F+HGD7^&:?<2FK^
MQB8NB>1?X9I]Q*:O[&)BZ)Y%_AFOR6B&7+G\DJT32K=4P(AJF:9:,WY=2P3!
M30A$)3S3K-[T;BFBG@1B(:AD!8F(=!&*8#Y&0A`L?U_<2FK^QB8NB>1?X9I]
MQ*:O[&)BZ)Y%_AFGW$IJ_L8F+HGD7^&:?<2FK^QB8NB>1?X9I]Q*:O[&)BZ)
MY%_AFOR!1#+@YLXG@1-*HY].P)"*)`&,WX,>3@U(,89-$4"0;>R-$<%($L9&
M3LS80.)\(N8%*7&#`&RP_7]Q*:O[&)BZ)Y%_AFGW$IJ_L8F+HGD7^&:^8<)3
M5US#_D8F+[_'_JGD7_VK?_EFOZ%O"B255#X=>HJ0N):FB*Q"'$,N?2EE./)"
MH1,8GE6^1<\FJ1<J>)CXVRQOD":+A"XVO:]\+6O;GV$Y=R_P7_54::J>V?OQ
M\LH+Z(NI5692E*XR[E_@O^JHTT<]K.6?EE;T_2\F.K,KXWQQO?G>W^[M\OAO
MC][>_+M<^7/EVN?*N;8VMW.?PWO>]_=]V][WY=N_*W<M[EJPY]1ZRY,12;=?
MC=3G0B)[J9+V)IJI@(*6+NN.'@B/YCK@>(8H65CS:>+<0W`FYWRO@&H)I;,0
M,4/'(++,>IMRO;EVK\[W\?/N\_\`^/>MVK<K5Q;#&W:[?=Y]N^5[WOW.W>][
MWO;EVN5[WMR[7*G48\KVY7[?COSMR[G*_/GC:WN6QO:UO<KFUK6[5OUWO^O_
M`.^=<TI2E*4I2O7_`-_.^4<OQ?9_]P%*IS3'?#2QGZDZTM9T[50"WG(WH-C)
M&7D)8E1GIZLCJR:TTPFH)BF0,JN!DD>)&01`#)4P&&,"+AEAGA:]NW3'KBFA
MWAA:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH=X86M_3`R?K>GKBFAWAA:W],#)^
MMZ>N*:'>&%K?TP,GZWIZXIH=X86M_3`R?K>GKBFAWAA:W],#)^MZC6=][=+5
M;:+1Q;3=K-?3J0WW?L.875$O++*$)HX!K7ES$R@JD/98Z@E@=.C@DB61B^%C
MIT3$H5Z\9OUJK*]<4T.\,+6_I@9/UO3UQ30[PPM;^F!D_6]/7%-#O#"UOZ8&
M3];T]<4T.\,+6_I@9/UO3UQ30[PPM;^F!D_6]/7%-#O#"UOZ8&3];UK.:>()
MHTJ0]*Z<G[=:Z'#QR,I!+E"@$NLG,<R8$9RWB$7`#LKVR%'&SOB$"#AS$&%R
MP""QS$SPPRP[5+?S2%`U?UP15K;77A,5DN`H7(J2<<EME`'"!XM&36!-$C@&
M2OU9<V5'PS`-%A;8C%C`8@`^`8P>>&._?7%-#O#"UOZ8&3];T]<4T.\,+6_I
M@9/UO3UQ30[PPM;^F!D_6]/7%-#O#"UOZ8&3];T]<4T.\,+6_I@9/UO3UQ30
M[PPM;^F!D_6]/7%-#O#"UOZ8&3];U&N_F^.E;IU:?*2W-K-?EM4R=4(FPTY,
ME=F'#PI<AL#%)T\*"5"5LAAL2A(N8.F>M89Y`DRY@T);$``83"RK\1#1`+(0
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MM-=?T-R[6P`AK1%D"AGDI3EEGD5`D+ZIG#?K1LF*L8#EA;XWMG8,<,,2X688
MEL>M"!Y961ZXAH9X8>N73(S?KFGKB&AGAAZY=,C-^N:>N(:&>&'KETR,WZYI
MZXAH9X8>N73(S?KFGKB&AGAAZY=,C-^N:>N(:&>&'KETR,WZYJ-R.]>EF&_[
MF=66UFO^+:'TU8Z2"N7EMFV31%4O/TBF1TO`[Z<];NI`E3)<X(1MEZ+P)#@F
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MGEG#MQBL(1@W*[-`!6$G#5?5M&R4TT3-6MB<(>FR0JIMC8%\P+G4XZ6Q$R%+
M#8X5KZXIH=X86M_3`R?K>GKBFAWAA:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH=
MX86M_3`R?K>N+\1/0[E?_'"UO[E_^M]D_6]27IKOMI.WHZE`JN;7Z^I)DWMQ
MNHL%0#\KLTJ,825W:F6%I%4P0Q5:V0A!623Y-23C>%K@'21D$R7$$"$ME5:^
MN*:'>&%K?TP,GZWIZXIH=X86M_3`R?K>GKBFAWAA:W],#)^MZ>N*:'>&%K?T
MP,GZWIZXIH=X86M_3`R?K>GKBFAWAA:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH
M=X86M_3`R?K>GKBFAWAA:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH=X86M_3`R?
MK>GKBFAWAA:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH=X86M_3`R?K>GKBFAWAA
M:W],#)^MZ>N*:'>&%K?TP,GZWIZXIH=X86M_3`R?K>GKBFAWAA:W],#)^MZZ
MC=J94C2;YO=+RAU^M&4&F"2;"*,Y&&X$QTH@2P4;"0;-I8BDCF393$^5+*!(
M8R4R%L.!@:!N*'A?.UJ[B]#K?XE>J/=[WN)?=O\`Z%)'CJLN5O'Y;^>G*WC\
MM_/3E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\].5O'Y;^>H9V(M_C;:"=W^NNQ
MONW\'%U^[W:N;E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\].5O'Y;^>G*WC\M_
M/6IYXM_R)3!W?:MD3W;_`.AJWXZPC3NW^*9K#W>]XA'W;_V7-3QU1_*WC\M_
M/3E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\].5O'Y;^>G*WC\M_/4-\1JW+4I]
M]W^N4#=V][_^L5$GOWJX<+6Y7[OWXGNW_"9>.OGRMX_+?STY6\?EOYZ<K>/R
MW\].5O'Y;^>G*WC\M_/3E;Q^6_GIRMX_+?STY6\?EOYZ<K>/RW\].5O'Y;^>
MG*WC\M_/3E;Q^6_GIRMX_+?STY6\?EOYZ^L6UNIMW?\`G`?=O^%P\=1!PVK<
M]']=>[_487W;V_\`29P^]>KCY6\?EOYZ<K>/RW\].5O'Y;^>G*WC\M_/3E;Q
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M>/RW\].5O'Y;^>G*WC\M_/3E;Q^6_GIRMX_+?STY6\?EOYZZ`-^^^3<OQ?9_
M]P%*[3M#N\KU1^3W$OS*2*K*E*4I2H8V([[?03XZ[&_1Q==7/2E*4K4\\>TC
M,'YK9$^9JW6$:=]Z7K#\GB$?W7-2J/I2E*4J&^(WWI3[^.4#?2*B2KAPORQO
M?M]K,6_:M>]^T)EW+6YWO?Q6M>]_<KZS!@(J7&-#7OB"`"*.+>V-[WL&$'D+
MG?J>U>][88W[7=Y]JHSUUW::>R2(UGLVH@GID18]V"G24T)=E-F-AFQXX&NN
M@I!MM#E%.S]5E8N;<I%9*'D8FI(9$04O8;$U<H8QP`%WFB3K&RR2<JSFX"B&
MUV^ZFZTR+T<AM,0V4]C#M:;1=S;5H^=1Q0Q17BWUHL\DY(3%9)-B!'G&35T4
MH&,93\KB^+F'8^(H,LB%W\ZR)1;<+JBIII343S)%0>)HQ,4M-*$V>LX-;`X$
MM9-?U?O5"2UAQ8%,TU)#%,##BY9ELP+YP+*<:`EC!P6060&4*.5/9AHR([6]
M@7+NY6*DCJ4UQQLU+$(%QJA)23CB<A"9X*QXJ?)&"I,4$T!F)XP.76:`:>P#
M@-CLDLR7VD1V.KOK`LTT-QKZ\V&JYTF[-5E@V7)N8B>Q=I-!+#D1.NCNE.6T
M`$L(<3!.KPIE[0PR^G/+3+1G4"$[89>[N8;M;*CB$4<1M48K-8+Z="BUF_8P
M,MNEOI*));2#,K*0GCE@U10]*Q,<#?6<!\L9,Z1'(6#&P:S^;AM5DB.T*6&:
MU3RB`AOI7CQQIY132G5=@+F:>]2*8(5.E\38BB@E<TTWD(GJ.!4\",7#R]4?
M#,1'(WF<L.QLI3M=H:B*U6PI+Z20<3E"2,`A585`1#9P%46@TL,<$11$3"AK
M`B&,%F:N#B)C>^LF;L[KY(#;(.]IS#'ZFVE:2WA#B0KBN9,2BJS*+"="VS74
MQT6ZR83LUEPIKB;BR2"()>!P15`)75$:Z@D#E3X^9/B3FPQ68['H9R.N(NTD
MUS'1T!G%PG([%H^TTD\LJS9;3?)F<32V[;$TXWZ';A?+%1%&"R"R##ZG++'S
M!-^,H^ZCC%*.QMCO=.123B4F8&NI.;M34%2SR"(+*BV<3F2V12S@V.8!90-$
M`B8X^&8(0V8F&6-LLI7UB_>V_P!8%^UPKH@TOXI>@D(ZR1-$TI[)-%GR&P$1
M6:[Q;!]$?)DZA+Z4['$74$TR.EM0^0%&+#8WPSS*FQP<K]L,3/&]LKU%Z\_P
MQO"V8W_P[)'\$4]>?X8WA;,;_P"'9(_@BGKS_#&\+9C?_#LD?P16T(9XG&BF
MP<D-V(H<V):CZD9V>FMV\UDU&>Q0ZI^DB.>7U3K(ZNUDY/#]!I":>/">B#@/
M5!E\\0NN"WP#RO'NTJ&$_P#SD+K^1,P?I!295STI2E0Q"O?Q;M?$K4/YJ3#5
MSTI2N,NY?X+_`*JC353VS]^/EE!?1%U*JS*4I7&7<O\`!?\`54::.>UG+/RR
MMZ?I>3'5F5H1T;5ZOLAZF8U>FQ\"M&129Y(3#;!<\PQX@/4LI+X!$RA)YAJJ
MSC*+H!Y:+JB:.DE!2&!A2!4"(I,,8,V7R$WSU>'+GU6/+MVY]5;ESQRZG*W/
MG_T<O\&_O9=J_;I?/"UNJOEC;'GRYWRMRY^]SY\N?:OY*7SPQ^^SQMVN?;RM
M;M6M>][]N_<Y6O?GW.5K^]7U^B`.MX#=>"ZT)?"P8O7,.MYW$O;$.V&?5=1E
M?.][6PMC>_57O:V/.][5]MLL;WO:U[7O;GSM:]KWMROROSMXK]J_CIU6//J>
MJQZKESZGG;GR]_EW>5<=7ARY]5CRYVMSZJW+G>W.UN[W;V[=O?MVZ\$X76UV
MDGY*SJ<:"VDK`TD$<U-P+"<BI^)UP+)%NH1/(ZI&2I;$TM+ZHF(:27N)8526
M%$BF$L!SQLN`)YWJ\+\^66-^5[VO_A6[5[7ZF]K]OM7MEVK^]?M7[=+Y8X\[
MY98VM:_*][WM;E?ESY7YW[O+M\O>[=?*E*4I7K_[^=\HY?B^S_[@*5VG:'=Y
M7JC\GN)?F4D565*4I2E0QL1WV^@GQUV-^CBZZN>IHV4W!USU"*1*>V)DM/C8
MI.4R-"`HQ,*"4X%4)QRH^@SXK:;HF3?2E7TD*FPDPX(;<:]Z6ME(##PS5U<C
MB.!<32<L\432F%;OD)]2BXO1D>;%-W4QPI+/AJ:Y)7S.PSGC`&9$V,6FW8ZC
MUTKS\6@HY,EW$KF62G+Z2@8BV35M0(*^.9#'`LN,AP^+QFBRJ7EYZJ"*OSDN
MZUD6HDZY[**LR!3BVF@._EV.U2`T^)#$VHRTFLL"[F'S56"4(^DXQ0[@;S#.
M%[Y^07^,#P\F6C1LM2//V<38RR8/XLY$F&*9KB=XX)*<[R[`$>;S8S^CE!>$
M8QL;>IC!L),GR:B,^/5M9Q&)H[E/9@#=;MEKS?&3TE:4H5:[DLLR+"J='ZE)
MZ,43%CT&TK2@FJZVR4TZX!2`;>,.!6044PX!VXG*AQ<1T`\WUI;()R<Z&Z84
M^)X]I&8/S6R)\S5NL(T[[TO6'Y/$(_NN:E4?2E*4I4-\1OO2GW\<H&^D5$E;
MSV/A(ELC`4O0*HOF0HT(RXPW0PC3]BEQ9M60VH`XB8Y'-::B[B"8Q(JI2V?/
M"PY<P4-@9#D3H`Q,T.'E^B&8>"A&`XW@Q+>+XD,&,8P;L;D'Q)[@R=$@.[!L
M-P!`+.%ZN(0$#TW<2MZ&P-JQ^Q8$,4R)G<,`,+'#"W3_`.M1#X<+2.]5QT%6
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M@"Y'($*IG#^.7G%K4"?`>)65G-H0TD%F&?V#8DE.9]/%;@A\1B*PFQJX/"@C
ML88H;?:&X4-;$I8!8O'B5&Z,MR)JTKM505G>>Q2%MSN0B%KWB%:?;:SCL:X7
M?'4-(R^WBBKHFYV$]6<J:Y("@L)>NNP&,OR>V93=\RIZU-B,Z4H`-7)PDVH&
M.1BPW`7>2[G)\F)Y@<\0.2U.O#:VT<<42_"$=ZOL=`;CC$XL#>CQQLX]J455
M<U3;'9U:D^&UIS*LJH3Z!C."%B*U5E%E42(H^%V21Y$BM,;^1EFL@BUG`%MZ
M5.'+M?)"UM8_RT<,`D6V.U"FW7IIQ<M2+CDJ1M.+LU/:[!,;>*YO!:<D>BR5
ML$LHF>N<L%FO@,NMZ+&='3U`>[C%<\J(8^R4G3_;+#B+QA/JE#:<DLIA;KS7
M)CB=C*6-;T-H.2%I'UC>T',IX!F!DXUM.^Y5,F5!E#3DAO9\M&-D.[:(`Q1'
M3V()3<&;GL#8]RW.W*_*W.WO=KN=KG;R7KFO@)][;\L/]IC7\K64,LK2?*'+
M++VT9-]V_P#I^Y/'6#=7G_[67Z5_/3J\_P#VLOTK^>G5Y_\`M9?I7\]=K_`_
MRROQ/=:;7RRO;J9=[5[WO;VE7_7]";'N6^"WZJYJ&$__`#D+K^1,P?I!295S
MTI2E0Q"O?Q;M?$K4/YJ3#5STI2N,NY?X+_JJ--5/;/WX^64%]$74JK,I2E<9
M=R_P7_54::.\_N9RQRY=^7O1W?>[+R8^?^_ESY>/WZ_1JDV-V&XM;+";?R7#
M$B("[L"[EO5XO$S256PH,O7<V`6LT&E(>:@5*!J#P3Q,1;',PA7&/@+8V9'>
M*T`H$4Y!ZQD=Y*L5[V[U6=$UF8=0'AMS#+M0V4M:8R!+V,F-L/4G5!KG5QMR
MZCDKI:2EJZVW5UDW'*6/8-9;0%0Z.)U_`<L%+6SNQ>YK!:F\2P+)VW3`AYM+
M:82TGDE$C8(9ZN-CN7>N#(^V<552YU)<:@Y'Y%AYR'8YTO1'<VB*G)VNZP8>
M20B2:>.''`0\,]YWV6;@YAK,N:I_7N'@0V/DUO,79N29+G6.Y2<Y9/U@C-UI
M[,5]AFSKK+LS&V*V-D%:74Z/5Y48QLI)CM:84(*;Y649&2&>Z]J1]).S,AO)
MG,O:R>-SF)/[@;VG+3A6/8(BQQL9G3/&$D0LU#^Q4LR`T5AI)*.WEL1^J\HI
MDVN5U*K->VJI1C-$\QFZR7,KI*&^_,%6>14>!)PX\3[GFU-3HG>'"]6I'4$Y
M1D=+?J$48.TT'($R$W85*H^+UNBQA8-VF<R(R/D&UK,U(62ELBC=)F<L_P!#
MY@V*<6Q\((#G?>P[NEYPLW;93XC<82>FNX**H(>;=D!"`@8E'J:M%@V#'06)
MLV>:$2I\3*9@A-D-^CY2<@+O.)@+W!UQ.$W;=DW_`+@91[(VVP>\#>?NSS>U
M]U@8D:V=\`#:SMB"W$HP9*!EO.9$!C\]BO*02*^TN5B[S//MQ[)&$W78-)5F
MT,L1X0_,UWG,<G28T(LUHGS=A\:=+&S6D*&Y9==)F5;2&.,NP-MDYMM(X^Z\
M\4-/DY`9QW-EZSFY"&3U)!!A>5I$<3+CQ88"^7";#5G!+!VA`E^-WF[36PCF
MF)3UT;\2)V3X;KH<.3D8,-<<J/F*IK2P@J;8&;B@\BFK@C9=+A=Y\@$XUQLG
MCLN9"&C@JH[`MK*;NW[C:!,97"D;;E:>SYU0W'E.32Z\2=J^69SKAO?G70I$
MH319>;;,`,%71]7WC,"641&FF)ZO*K'1#+G<"<\5]O`+I7RLZ;>["R`[7H[6
MN_I>:NECBW,F1NI<HC*TWZ[%3#(:&D.K*E#I=CRBR->Y@D1+BQVSRH[`.9I+
M".P<V?,K_;19D".]02ELBSGEW[Z@+$KN'5G7E=G0\.IS`KPW'JC(ZF<:"E'Z
MBJ.TXVD\=74U=C+!%*5&>M*(^?HU:;1]&0C2*K#G2`S?0<P+HY*C:4I2O7_W
M\[Y1R_%]G_W`4KM-T/O:VE6J-[]SL?(CM[M^WDRT?&W<\=[>*W=OVJAF(N+]
M><Y11LXLTCVO?FG3HGI=UM:^\+,1V6[(W4I#;3@4&<LNH_%2`XSTVH$$DGDD
MJ3=-SDJM`)FI1@MD<7KHY,$_F0S1(XM,5.7B*2UPY6S&[V5I&CN.72M-J0,S
MZ.FQW)TQL9C,62WGKXUU<_B$"7?K78LD--P+1PX<S34TN9/XG@RN*?D*/XO4
MKB0[#[)[.2AK>ZN'O(4*"Z^N%MM+8I\KNQ4`/A)BIR/N'R<R,!.!166K&5E^
MAN9OK3<*9G6792*H9U9Y*XA>R:H8`[UV4XC4*ZS[/ZF:EN-&>;LE7;)\DFBB
MA-$@1,H\:)ZR2=(K7=<FGSYTGZ2I#S4F2\$=G$RH9M7<1EGO`PGDQ"C84Q0X
M:!_I!FJA%J+$DO.(MBF/%+HC"1);U4D%7;T>J)+<]K1E+3<@]:)0@WT"1%-U
M(KJ6Y%>3/+,UM2\D1X><+8=".\[9$4$;,?#+3/&V8P:GE#I+4;:%7W63)/D:
M-7;I(F&(&&EUI@Q3$3>GAXR`<?&<QAP>JQ]E%KN:JJTU=!D=247JX'&E,]NH
MYM;&S#P[3M;=@XTVN@6)=CX=5#:O&<T,5`D!G'%$B(EJN*0OE,3&)%831,Q;
MIZRE&;&4I8(V',!E%,D;`",F`L,!Q-#;$=]OH)\==C?HXNNKGKI)XI7#G>W$
M>FN`&(X4LF0UQCC7G=M15'F97"&)E&V@EI@,V)M<U]);8*@&X<EB+RJG($E)
M#D+IHZ<EK":G%Q#81PP"5-=;6N_".WUD4WI2I;8O%[08^\=@>('OGN7+.N4I
MQLF.Q(VEEPJSX0U\08Z,CE'\6R3<X/35HXHGR*`LIJ.D&!&R<44E5$"",?HU
MNX..V#O7M)R>SBW,,5YQ.X.)%L]/,_1CL:@I&Q;WVAV$E9#BR!S;CDR/5`PL
MK[J#U*;I8LX'@AIY%ME6Z:#C84HD8II9'OMG:_5?>&2YVRA8_I<^IWT+CIBQ
M"QA7(3V=UP0Y_P!\C,398OI"+[J3;**Z+,ZE!B"^S9\HGQ$V"26JO-P'7$\G
MLZ?2!8LSL^Z_1771QZZP:$5D]337-L1,#M<T][0/=+"R#).R>I1,A*[N"2<L
MQAL[LV/D\)#B2,2M[AXID8Q^STW``&Q:^%MYSQ[2,P?FMD3YFK=81IWWI>L/
MR>(1_=<U*EG;SB,G8`GIC:G01K!+VY>T#LBA>V`6HGB9P1JQPV!!#><'J0%D
M-WO:67*UVL7$7W=8=MLQKD#)Q;<JJ0/%@L"@N26$JZ+VRXVD,:CZ[ZES\_X'
MV-(&MIUQ4Z[#+L8!Z/)JA5@1^G9J<Z2-++'<A?,\D(<)E\TZ[GQ)^B"JN"LH
MZJ@*QI!4BBL-E.U?$JG[7G9.*->V3P_WU.P.QBVOMO6N0VQLAKVT&_+RVS(;
M-36]RV*:[ED%49!5`;"2OA%U)WY$"2^92L;HPIC%33L!K/V=VY9.H>L+IV5F
ME`<1'!K-9+/6BYL737-(+KD%<+``H41,,L5-@)CL>RXXA[-Y+R)',$?.X)M?
M.'B3<(GE(MUX.SCJ0`V&O&[_`"L(;`NV-S^M6J^U^Q+]:9&-#Z)J1#^XYLHG
M0FJRP1/R&EN1UJA\<8VJN1'A]"?IQLM!*47<?PNE!8VOLB+N,;!4GSFCQ:5B
M6>D:.Y)<.SS*UVV(S;#:=D9['OG3<)7'G]I1BV8]=3MF+%412S;=1EB6<T;H
MEI8#:;A`86"JH%2Q`W5VC^ZT?;W18\9:C9GR4R$%GS=+\'&D666L,QGO=?AQ
MTYM-=/*C*4!/5"T?1IX/,0-M.\DC/%%OB(GN=!1E<N93P/"\1OO2GW\<H&^D
M5$E7#A>UL;WO?E:V8M[WOW+6ZYEV[U\N=N7/G;ERY\^?:Y=WGS[G+E[M:W9L
MQQ5(;MDQAL:0V<[GI#2ZDMB5VLWG`G*R]';A7D,NY49&>"63'%-H*BJ()H!5
M(ECX80ADGG<4.V5PQ<0]CVSQOVN?;][E>U_%W;>[_P!'_P!K_H\ZYOE:WO\`
M<Y]JU[WOS]ZUK7O>_:OVK=OE:]_<KQGIXB^G'J>]-DST^]+/3GTD]'E/3?TH
M]%^@/37TLZ]Z.]+;'O\`Q.Y[T/Z%L;YEKC=>MU%>2ZO&][6YWYW]^U[=OWKW
MO;E;+_W;\LO%6+/!],Z/THLNO9RHS51SKC:+0**:\>!321ESOUT)#)9:""8,
MY8!B*CH=J\C-Q$)XWN*H+*F2(`6R''PQO\S+U:1)X(L?FW&CEGLXFZY'<A-4
M<\`$NJ[89ZDV4ATKJ<G9Y6,&TMOJ;R:I%7-A89!$3+A2`Q[XW.@]5]3Z?K,C
M%GN*0)"<Z(S&2TDLPM.9TN-0`2D-!22EL;FE%54#66`!(H!;/&XHPV6.&%LK
M<[VYUD)U0(II0VH*!PL1($"Q@X>/'!PBI,F4*!9CFC)HT/F&7+ERH`0@QD84
M3`(`(/,07/###+*W)(^14B9103CA4^0/EBYPB>)#A&B9PH;!P,%314T7S$+F
M"YD`0,8N,")F$.$)@(%GGAECE?\`3?/&UKWO?E:W/G>]K]JUK<[WOVNUC;W<
MOO;7[5[\^U6*-=^,UZFW>0:3G1'$<8#L,L1[%D=0`/#-9Y$T9#<)ILK@8.66
M2<M%T-S-]6%3S%L1\""PG&;X];-!WOEM?`3[VWY8?[3&OY6<H>V?*'YT9._>
M`Y*P:E*[8.!__G/M:?R9=_<J_P"OZ$^/<M\%OU5S4,)_^<A=?R)F#](*3*N>
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MWZJ`VZT(;4K'T<JIACC-O)>>H1\()IF4%1V0W=_]=Y)-L`K#T@,]]!.R5V1&
MZS@L+BW'"NDIDCQ.^Y?8;T;*&]&H159!0GTU62.N1^J(899I/UHXN!VM1Y*A
M!J*!4Q^=`XE6D+I;ZBY6G/*&[BQ%R-9J%4=GMR0G:\70JODDYU1DC1U'K?:*
MB^I-07DCLA[KK3=D;MIT-1R-]D/1?1EHZBM)PGD[.88VXCF>Y>=,?QB,FNYF
M)6O<`[#-B6&^X2ZLV'PW)[><],U.())$$IAF6%;QR"5+)0.#G!!13:QFD&$]
M,/H9[`?14B<6/2>/F$['^5D1=?B:SW%%R,:3V2PWT=47`E2W,N,$MJ0F",N(
M"(DR7$P,@@JZ.H2C'RJYF'Z8(9]`35U0=1M"05BEU?;O6=OI.*^O30QT1#Z]
M/H(BPKJ^:8E%KZN#KP&P@IY0.`@DR!:)!&NO^K,V?&+E4O!).YV&%""OEE*$
M><4V")8FIPQFR3:$&S&BHQ(2<TD/YUJ44F4P*4]?]D=AQ<1X]D1FMYU)JPU&
M+K^5=2FD.7)NB&(U>V,GES@+>;_6%[<9#B*:;*[),/I&F0)>2@'HVH^+HC=9
M,HN"1EIV/-L*+W9J:UHG1F4=E=X`/%BHRV_6DK-9FK"&Z&$A+CX0U)0:R*JJ
MQ.JH[D)CRRQ&A)L:NA&>K`?K<2':SG8WS>!]&<+<7202@DJR<:PY6%+'"@X8
MF/58X"AY7S!'#"'#$#PS.E*4KU_]_.^4<OQ?9_\`<!2NTW0^W/2K5&W.]O\`
M%\B._:_]UF(^7+W>U?EROXN?<[M=<.M7"RVPU:=#0B**]_S+7T"CS9!V;$-6
M"T"#DQ.G8\CNY\K4G*.N#JV`-/-22C\(GGVX%51<(Z;&J<^G$A&3#:R6TPN9
ML9*Z3C3@-N^.'U!VS9;<F0E7;]C[W/C=.5'$H8N,?7M]B3,O.1&FYF-*#AW&
M-DPE9[0>HMN)?5SBYU92#3VDGY#D[I5BB2G]AZ9PXF<O29Q)ER87,H/6,.(0
M_(%=BHQVDLOV*'*S$V%80CB*[)-I*C]Y(+NR,+2W'I=RV46PI-D4$@;S;YS$
M\5S.9&I$FO@.0\\)EUMEN&9[V6AP*%YWUVDET,W*>98>;?<K'UMB-VQ.Q&VV
MC#@<YMRMU\%49?Q(6DA9<3E5;H"W)"6,"(9D%54`YJ/?T>!V/*+6Q!4B;@E#
MD9:MQ)*46:!GFE"8B$_HF&D6>XXGY&>,[J:C)2PV)J4H^48D8D?I2*VFU&2.
MO,TBH*"OB$Z#V"B!MW/@Y;/%)J,;W(&WT2)7$,<TH2FZGR\1=<G<>UA/1U*.
MOL=ZX8QRWX9%G;"04HXQ&W%;,?#8>1N7%`VIO0H?)N5*4&P=Q3P>X32_5YJ:
M5ZJP)JJREM6<S<@J-&Y'Q-RK@8("JY#"07RS57"=*%\Q2Q`9<63*BJV3"PHQ
M9,#-X)Y<88$K@+GK78COM]!/CKL;]'%UU<]=*/%SXFLI\/=UZ@IT71PWI*1I
M">DA27LT`IIJVJ+;%TQ@,DRS,_R8TK(RZCAISD9X,BMQ5)G5DLO)@I(DIE,D
M(R(+Z,(=><U<<S8I%>[8;C,5M;XT8DI[R[_1%'TTO"!=A=C&^EZLZ.-E@,G[
MHZE'L!R"GO9X..3MDW$NM-'=R$,D,DDVBA3')+$-$SJH9[)%GBX:^:P:@/Z8
M=H=G($G>;(3BQ`FJ68JU;1@XXE(-@28YV81BLP4U?F:7UN6X]-*J3*D9%CN$
MI.%%RS4G``?-8(1=2(I04:;"<=QP.I"U*4M06`\(Q:FSTTS$WV]-VR.I$V3T
MD/6!H2BSU4N6<H9URU?D`'85[,%9D!R1XQ$-ZJR.VDS.ZZ:6K)AIO%CJVF=E
MG"7VXF;=K4W.=)I*Q6*HF9LG=@L=V1$B.YDMN2(WBV2%=@MJ0C\52$Y7;(4-
MN1P&4)7Q68N?BX8=S;S)%Q5LJE&E"Z43MV>/:1F#\ULB?,U;K"-.^]+UA^3Q
M"/[KFI44;<Z!3^_-N6;O1IELXTM=-@".O"SJG(A25(4RG:,W]#IQ[&9);)@-
MN$WU'RF@/AAODX=6T96P5%!.5@QPTI6(V3<#Q97F"3^!LL;*O-K*6UN\6QTL
MM]B:4N#51*46XX1XP?KY<LPN=PN+9&0I/5FV*,BK#3E`F=:[((Q*FIA9#2X_
M9;?;RVK.,<CZ:&*5C;ATRLC%>$8?D^?4-_O/AI`R.1=[F*L-22,YS)N?6QZZ
MX-<R`"8<Q\1IJZ2BKR$N+YT^,X/3P\E*&(>)3-1P'`\7L3P5=5YJ`DI>:;LV
M0AN49#>T@2P;>[(V?GD<GC*CY84DL(1;LTG,^G(W$)METF5GLGBM!@I[,2LT
M)Q*B$7P+IF94L6A9._H_<@M>(D:!&?N4):+YBU/U'U2W<L_8U7I!?3_;&I3J
M4',WE37-W&I,12\+`+J*X''%9%L.]`DY!8T<FD@%N%\EA`(&<*HUIX0[N@C8
MV#W6L;"HKNUBT_ES<*<-3X>3XN4F_)B`]MT1'59[)LO2R;D)<1Y`:L;D9!D4
ME'9=`C]G+)\5UAG7BJ*ET)/*7N[1_4Q0U%:L_-Q1>Q-\9S1N-M/M(5-$D,PA
M8H"?L5*:G(I)G&`C*DIY*)QJ@*&*4:6@A"H"L*%<V"GD<,^L6_%Q&^]*??QR
M@;Z1425O/9!FS#(4!2\R-?I5+0A-;H8;H18OEHXV"+Q*L!Z'2@P:&Y3#<4@Q
MB2D$0-=3U>`Q8W<O83T8$2.#%@RHWCH\"E2&-8FIA-+I5-B)BC"&$\:2W8QF
M0&D+DQOMGL^QES*34C]'Z\&76'PKIYC%%;::';KR@H%BA4N#D-B7#]:=NZH\
M1/6MBR_+)-L+I^8]^]"=S[RTH:W-U^ILK1UNNO$9!VNU_<3[5"ZJH!E72TE*
M2)-UCC]S-8NB%$I62HP0"O4A9HB>4K"^KNQ3!G]<LQ#>WPL>HV]>KK;:@AV8
M)N<+?+ZW2QJ:F$-MEPKDL.D^6-H"M+BZO+CK<QOT4(S).3$Y7:IIKJZ&0R+S
MK$1S;R6V<P7QM`J[)O"`(1V61-!=F$2#W+*CG<<GL/2U@3TPG+LZ>;T2'S$C
M.1`G/<Q98(\RG(W`4WP99L;)*4[`3,?$WLFAZX7H)W#=>2&Y4Y&WR:LI2KIO
ME$C'D8-:FE.EYH00G<7EF'F:@/%UD3)A)CV>$K1!>:[A<V3Q#3I55@R#V7EZ
MZX[$=_&@Z?=3/GN*IK=**@IVWI&9V1M>AHL3.T=P3TZ-9$KA<M*`"I15*.-_
M*RLNP\HW*H:.]+N05\+(^TB[M4:;+MQ.*MQVFO5'\+1A/VP>NFO23&(6^CLC
MZ4(&X9$C[CN:='1L.I/!1VL+;J:>OH>3X&>\EJ!HP3&38%39O><EO77L^7BQ
M)81*+5T0R3=Y!.S*U2]HXX@,:([Z8T1`[:WC-BN3?AL(P@#HDIYO\'6M4VUX
M=2TCXQF[G<O*CM=DL%];S>WH.KJTHKRR_2MBCB2(U4O3=.1B8=3R7'*C(W"W
MWTCJ`63N0X$1V@2BAP.T]ELI%<4HN)',MEC%[@Q6B2OB+L$2BPV[2[GNS$6;
M;C2`*JX.=21<`(T4&`6"@N<VWM?*&S\U-E#8FV*6T)47N(_"\H-[+#;T^FN1
MB":\2X1U?.J,DF;LC6I`CQ\O9JM-9@M!A!O*RZT$MR$6S(DP9.=V/1&>GZX%
M;>X92:M5R9,WM<QVV@`\-]-A-NGHSVW'3$G6-)@&$B^T#6DX!:>#/UO;`AM\
M)NP"!+(>S*.H;%M4U@PE5@)"TIE8A2!-52G&>Z4?:;0>U4YN;Y+^R;PU/V-G
M55D=T/7=*67.!N@O`H::P6.F-*'EA&NQ93:"2A()2+AYHD-FZ_LUC`.4OBP'
MPZ'*^U7/OTX>;;?:5?<-VOEKNAM7ES;(.5&P.ZVVIM4XYF^X=4=4TTRY"J0K
M)R0=+%AG:A.I(-`"I:<(06T9721T\B:3AR8'8M7P$^]M^6'^TQK^5G*'MGRA
M^=&3OW@.2L&I2NV#@?\`^<^UI_)EW]RK_K^A/CW+?!;]5<U#"?\`YR%U_(F8
M/T@I,JYZ4I2H8A7OXMVOB5J'\U)AJYZ4I7&7<O\`!?\`54::J>V?OQ\LH+Z(
MNI5692E*XR[E_@O^JHTT<]K.6?EE;T_2\F.K*$M>^&=K=N]\,K6M[][VO70\
MU=*MDI=GW9\@[U)L1WK2;XJ,?[?IUU)GNU-F9V&8(AS6109X;`=)95+-A0CE
M]2,PR91;=ATGBKH26U'LRDLDOV<)159O@'SP=9`O'T"LIBRLPSF33X?S&X?4
MLC.LSL`Q6JJ-%I&S!H>2$MDP;+;"*2.66,7&]"J]"$OJQUDK]CC<&&<R8"FN
M$@ZK4FO1=8"?D(SYK.["R5-$(/US.M+;$[/B8W[##K2'U$"["SE0DUO6=ZO]
MQ<XGM]8)J[74HD;Z:DE!D@5N*#7-HRV(92Y=>O"0D>0T1WV=VP[/-O%]HJ3B
MZ5Q%AL!HH`[EQX=VW6E"\HH[+;KC*I#?033HV@"D1'0268F:>WF=DV5%25W"
MMF';AF<K<)S[K;V'6%&80$=I*C;UP9RTCM]L&":X$@0MK!N;K>O>D*QZ<B$D
MM3<)?:XNY$`<9,-%4`1E"$#A54LKACD?!*&B^_*RU(E2U782!R`4+%8ICQ/8
M\7-Z:()3)1CJ+V!(;4+.-[35%3P1-@V>L''6[&I()2'6"\`8E)!L8ZR50\X2
M[]6G,G;OX='#]>&E2<5+NZ2VT^CB;K5$6N!41K-Q?0RPQ:')XVXE5,>E_50X
M'*I!&'&C;(I*<:;YY27C",J-8^(8=CK#4PS]H\1>$]L^CQ?+<?ILW1$V$X\B
M1+:.(\;84[G(&6)&B7:UF[)DI.'BQ]/MY%]8D]P)[*P8ZE#&L:@2C`$RZEUU
M7*G14AHI*-Y64^$;.$W&GXP'I.T8MV$0W#Q%'5&.38CUS*\EF')OI(BG+J>J
M2!FON,!G72X5>"CFBW:R*2.E)3;%QA5-69YP7T#;EZ\)6>=F77.$D[03A#S?
M=^P1EO$G2AP%&;N*MQL-UM:1;H:>%<$I8?#KNNNE;/&-K"LCF#[@*D0RA%J"
M1X!B*4$3W,!]5N%3/)Q`&<[@<,"+<H@/2"S(!,:0-XKJ8C1A!B2PUTT^T-K3
MT]*>SD&O,1Q3&ZG$TRT6FP6@S&<:<$4*B>_"+Z7W>7[AM88Q?D,Z_1'%DGR8
M<F)_L5C(K==<EGT_!,-.U8(@Y6,J69?K@YH3`.V>!$`\K&CZ^J%R82HXU)27
MSJD?,;WI2E*]?_?SOE'+\7V?_<!2NT[0[O*]4?D]Q+\RDBJRI2E*4J&-B.^W
MT$^.NQOT<775SU(\J:40C-4V&)RDLHXG2N&=79<U%$:)]7+Y1]:*)S<#<79/
M%Q;]DWT7BZW0&U41OFUOTWN#BW"MTW!-MF,(9RT#I]PG-6])%Z#'!#QF4#@^
MN^M#]U9C0@]7>FKB2G,64)M&GR07(<3TYL(01B0W6^,BP"HYB]R1;-O)Y%)!
M2`LPQC@^Q-P>''K+NLT;LV5&D51T]8E.(I,D9093=8:<OS"5AYVI+S1XVE-;
M6&@N'W5&SB5$!%+.Q%'%"43R:FE2R:KI(H(1D.-6]P*X-8X,0`QEM?O3$UM>
MDF<V;!!F-I?CQ#4HLBJ?G\G2(ZXC;RLJ0VOJ0['0E=)3$IFY*IHZYDAL)J8@
MFW"IEDPAD7[0=9=:XGU'A9H0-"R,HI#&:%UPZ$,O+ZN[74XG&['`INYYO)Y.
MYP&CJZZ7@\G:MK#E<JZJ&A#!]54C&0>!8I@6*%\CGCVD9@_-;(GS-6ZPC3OO
M2]8?D\0C^ZYJ51]*4I2E0WQ&^]*??QR@;Z1425<(?WM_RQ/VF5>$=3G0&2V7
M"\74IET9LM1#5W*XE@W82Y5*0D%.,JRPI&;`ABC7+D$XF9-C6""$$N&#E8,/
M//J<;P$A<3S7M<CX)\V:.PB<=75V.$&,XZ4(%?64F33>86<L2%&*I$#63"JF
M$]$ESL1M.MW*(P*H2,QXWVFYC\KDV$&C&K6UJD<4Z'7&^'\A&&R[74Q%5F:W
M"P>WVA&,A.":YA>DZ)&RZF\XY'ATXB$EY!6H\0]=78<=1!R$D"S7()#JS>)A
M-P3RN(_#8XEO#NA!I-"/HP"5&C%3;UQQV+!*1I`;T1(SB:'SKRD!B))-RE4E
MK)B>R)`<\S,1Y1,A0ODG6EM<E\N<:H3,%5K*0Y78JEQ/H#2T<,N88^P&<M!O
MUPQTJ:W%H=5S&P"&MM2*RDYKQQ28H:CZ7"-\M$"BF/Q.7TIRJB<Y2JB5;C5$
M6WSZ(:I?$G9Q,(*3%N1&BNICGEHD?&3,F?'<0Q%*+KD]0BTYK!&NP<ANA_,I
MT(#8"#*-UER@BJ!M+;PZHNF4]TMEE`-T])QA1:0'8M&9!C)<<L%,C-)3T..$
MUE-0@P$5)21D)*1V2204\!II:8B&2Q(PC)R>@!IQ4DE#DR@R<7!"*"E2XH.8
M6&;\K>];W?<M[O=\O*W/X*<K=SE;M]N_CO[]_?OX[TZFW/GRMS[?_'N^7W??
MOV[]NG4X\^?*W/M=OEV^=NY?QWM[E^[:N.IQOVKXVY<N7+E;N>]\'/M\NYS[
M?=KY6M:W<_\`^^._OW\=*^`GWMORP_VF-?RLY0]L^4/SHR=^\!R5@U*5VP<#
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MW`CYHKAR-S;IDYP/#8[:0..&YM5BRD<PRI.<Q"!((BZ'Y-1V$=%8XDE28_'4
M@GC;MLRW`A7Q*<N;/-39W?MK!3"W+MY$X9[0FS75H'B#>BMLQ')2VZMDFK@H
MO=_/1W'D585SB\S&P(KOUQF60U$%$3B949NIX1)45U/8'#D<DCMY>EG7:?`I
M:PV$C6-=;9&?!Q];('-F6>O($KMY](R0X6:Z3;896;/73KVC"22;]8P+6*HY
M0VGH:LUUQRMM23S97M/I2E*4I2E*5Z_^_G?*.7XOL_\`N`I7:=H=WE>J/R>X
ME^921594I2E*5#&Q'?;Z"?'78WZ.+KJYZ4I2E:GGCVD9@_-;(GS-6ZPC3OO2
M]8?D\0C^ZYJ51]*4I2E0WQ&^]*??QR@;Z1425<(?WM_RQ/VF58Z]&Z,[F>ZF
MH67E=JF',VUUO@.=`"1AUUN#+24;3`EY$!<24NM\571\S6*BFAKB(L(XAPL#
M@II2B1R')C=.D5\(53A\RB/IASZT&-+S`D=@R7%EHTUO28[UJ;SA;L329"DC
MK3AU70Y4S:9UV;!L26'"7F=S1N[(B],U-MQL>:*4T@F:,37?-/SA$)LA*K;D
M)Z3I]U^9FX;A5;&=6QD*LB8(^>3BC%F;(,1S#/Z)22PPTQ707D@[+N0-"1V^
MX6HHQD894>B-EQ&L$M;#7\P3>$W')*(Y`B[*5'82,OS7K7N'<76S65&D>B--
M[:Z3M,VRK-EQHLUH-U.8*2;QF"7Q%JS#Q;>34LCM9*1E/)<%4W`JJ&#R9PH7
M3,8$@.:5)^C2393EN2RC[D?.1]2F@\H.-$FO"H$+Q:58D4J,FXR#%KTB0G98
M>;+E!FSX2=`SO>CV#=&#A:2@@MAM>&D?@UIKR;Q]$`GZ[P%7"3"*N$]LI"3.
MV(/'EV/=5HTU@0)E2G09<<?R>T=D4DI&P3^1ID:4C(N5G$ZW60=+4=Z6:2[)
M/<+';/O'S`8[#NY74\[LEGMAHW=[Y5\W`]75=M(9!$NY'@O"!A"+;I7;D?31
MP*X@0>:DKFSAW,/#(>^-LRI2E*4KZQ.UC;_6!?\`$7"U>J?KKP&M>-H8;9NP
M3JF:<6XY9=Q<;[74-MY1Q=`3%)?>3D-F":/969)]3P(`=5B&!B?/GC-[6OD(
M9SOE;'#=GL9_5GP@=C/_`-J/L_I[&?U9\('8S_\`:C[/Z>QG]6?"!V,__:C[
M/ZI'4;@;0%I_L&P=B&5,,TNERQ_9S634)V?<^](#WJH:BTTC?H_TC9Z6J?\`
MBY);',EO0QX#_P`:!!Z]UP#K@6?=O;M6M;WJ5#"?_G(77\B9@_2"DRKGI2E*
MAB%>_BW:^)6H?S4F&KGI2E<9=R_P7_54::J>V?OQ\LH+Z(NI5692E*XR[E_@
MO^JHTT<]K.6?EE;T_2\F.K,K3PNOL(CO)8D(:*V*(^'`.[#*VZ\VZGY+RH8?
M3.8,?/(8\HW"]$&!',R(MCIJK68F5[J"$RFTG#]4722N.&+O[4K6V3V%&T7O
MJ&6(X6!#MTJ\5-4TCV`2H[NAM,XPTB[-"(#$Q&_=/92@H-0K=.%`ZVWCQU)[
M9(T.")AJEH7I^L@Q875M?X]4P(6&'$C@(^G&S>""7,.\M(.24/B.?$LX6\&_
MB*<^2K9=/IXW23R2DETDTHNN)2>>+;T78?BMTJ[M7G-';,<:L_HYM$+X.+S<
M2UG-WQ;8VXCUX\<P:B6,@+C-$-NYT##MU2",I9C)P*]ARXF!\QCGBL':VPAK
M<CK:'"D=H;#(N11**B^(GYJ2@J+)I-32Z*C8*:ZO*"NNG2+?0RA5";*484LT
MILH14NBM\DFI@.!6V\:4I2E*4I2E>O\`[^=\HY?B^S_[@*5VFZ'7_P`2O5'N
M][W$ON7_`-"DCQ567.WC\E_-3G;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\U.=O
M'Y+^:G.WC\E_-4,[$7_QMM!.[_778WW+^#BZ_<[M7-SMX_)?S4YV\?DOYJ<[
M>/R7\U.=O'Y+^:G.WC\E_-3G;Q^2_FK4\\7_`.1*8.[[5LB>Y?\`T-6_%6$:
M=W_Q3-8>[WO$(^Y?^RYJ>*J/YV\?DOYJ<[>/R7\U.=O'Y+^:G.WC\E_-3G;Q
M^2_FISMX_)?S4YV\?DOYJAOB-7YZE/ON_P!<H&[MKV_]8J)/?M5PX7MROW?O
MQ/<O^$R\5?/G;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\U.=O'Y+^:G.WC\E_-3
MG;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\U.=O'Y+^:G.WC\E_-3G;Q^2_FISMX
M_)?S5]8M[=3;N_\`.`^Y?\+AXJB#AM7Y:/ZZ]W^HPON7O_Z3.'WK5<?.WC\E
M_-3G;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\U.=O'Y+^:H93[_`/E('7?M]Y,P
M?<OS[X.3/<[M7-SMX_)?S4YV\?DOYJ<[>/R7\U.=O'Y+^:G.WC\E_-4,PK?_
M`!XMVN[_`%*U#]R_^BDPU<W.WC\E_-3G;Q^2_FISMX_)?S4YV\?DOYJXRO;E
M?N]R_N7][X*C352__*?OOW>_*"]R_@BZE>*K,YV\?DOYJ<[>/R7\U.=O'Y+^
M:G.WC\E_-7&5[<K]WN7]R_O?!4::.W_Y,Y9[O?E;T^Y>_P#ZW<Q^]:K,YV\?
MDOYJ<[>/R7\U.=O'Y+^:G.WC\E_-3G;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\
MU.=O'Y+^:G.WC\E_-3G;Q^2_FISMX_)?S4YV\?DOYJ<[>/R7\U.=O'Y+^:G.
MWC\E_-3G;Q^2_FISMX_)?S5T`;]]\FY?B^S_`.X"E5EICWHFL/YAXR^;!&J6
MI2E*4J6)E[Y31[XU[4?1A7JJ>E*4I6!2M[5$K_FHE']WSEK$M:N]MUQ^3O`G
M[GV56ZJ4I2E*DO>?O6)-_P!L0C])&&*L%3_RFJ?[34?_`*T>OQ4I2E*4I2E*
M4K]Z3_E='_VNE?W@6J.M#.\TUQ_-Z9^>SPJMJ4I2E2P3[^AP_(@97TH9&JIZ
M4I2I8C#OM-Q_BII=^[J8ZJ>E*5QEW+_!?]52UKI[8N[7RO!_HN:M54U*4KC+
MN7^"_P"JI:U#]KV3_E>;K_2DE"JFI2E*4I2E*4I2E*5U$;>^WNYO]C,KYFH5
#?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g239265.jpg
<DESCRIPTION>G239265.JPG
<TEXT>
begin 644 g239265.jpg
M_]C_X``02D9)1@`!`0$!F@&:``#__@!#1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4TU!4E1?3$E.2U]&4$]?2U]02"Y%4%/_
MVP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0'_P``1"`$5`G<#`2(``A$!`Q$!_\0`'P`!``$$`P$!`0````````````@!
M!@<)`@4*`P0+_\0`41````8!!`$#`@0$`@4(!0H'`0(#!`4&!P`($2$Q"1)!
M$U$4%2)A%G&!D2,R%R1"H;$*&!DE,U+!\#1B<M'Q)R@U-D-45UB2X28X1'2B
MML+_Q``5`0$!`````````````````````?_$`"41`0`!`@,)`0$`````````
M``#P`1$A,4%187&!H;'!T>&1\?_:``P#`0`"$0,1`#\`]_&FFF@::::!IK\,
MC),(EBYDI)XU8,&:0K.GCQPFV:MTB^5%5U3%3(7G@H"(_J,(%+R80`<:&L%P
MNW!*8W"M5Y0W'\8SS`YWLBCSP8];KKGZ*HIF)PHWEYHJ#-4IBJMF;Q/O07[.
M66!K+,[^>E6<4T*(%!1VJ!!5.8>"IH)![EG"IA$/:D@FHH/(<%[U99;Y.SA0
M-2Z5*R+53@$IJPJ)UJ),41$/K)(/`--.DN.RBE'$`P?[0="/;06/:["._P`T
M40<3D\8!%2Q6%P,O+B;GPW<.`^G'I<=E;QR#5`H#[2D`"]WUH,9?DN39(PGD
M+?!UX@]`VK<"62.`#T)3O["903%.'9OIL4Q*8`*3](:XK8Q1D""2<N-WF$Q-
M[S(*S9&#8Q^!#W`C&-&@$#]0\%*8/;\?/.3]-!AT<$XZ.(F5CY)8XCR)E9R5
M4,(_(B)G/D?G@.]?=OA>H,#`>*<62(6((&26C[')$.F8O'!BE5462^`Z,0P?
M'C66]-!C0:5:F?</DNPD[]WTIV/A9](PAS[2&459M'9$QY$IA3<`H("(@8.N
M.'X[*4-[?QD-6[<V*'ZCP;U:!EC%#D14!C+BK&G.(=`F202`1\F+UK)VJ"`#
MY#L..!^>A`?/\PT&/8[)E;<ODH>5_'U:=5$"$B;*T/'*K'^?P;WE2+?$$>?8
M=H]5]X<"!0]Q0'(0&`>..P'P/`\#T!N0'P(<#YYX$>0\ZZZ1B8N9:+,)5BTE
M&*P>Q9H^02=MS\!Q^I)8IR^XOP/`&*/8"`]ZQXM3)^K&*[Q],J$9I'^HM3)]
M==_#.DBA[A;0S]90SVON#@`E1'ZCJ.`YB@JU33]QRAE735G5NZQ5A67C3$<P
MUC8IE/)UB93*TF613#[?Q!40.=*0CC'`00EHU5U&N0$!3<`(^P+QT#3330--
M--`TTTT#3330----`TTTT#3330--!$`\CQX#O[B/`!_4>@_?76R\Q%0,>XE)
MJ19Q4<U*!EWKY=-LW2]Q@(F45%3%**BJ@E312+[E%E#%32(<YBE$.RU;]@M=
M=JS8'5@EFD8D80!(JYQ,X<&'H"-6B0*.G)Q'](%014'W<!QSJQC2=ZN_M"NI
M*4JM&-^N?F&(_P`3RS80'A2%@77M"&25X#Z;N=(#H2&*LE&@'M$;EKM"KM>5
M%^BS4?3:A3`XGYERI+SJ_O$1,!I)W[E4DQYX!!H"#<@``%3`.M!T1KG9YLI3
MU2COS-%.D9FV.$J^P.F(EX72C>'$^LF;])B>Y@V]Y>P$!#C7U+!9,D1$\C=H
MJ!*;D!:5BOH.P*`]"`R%@,Y5,(!SP<C-$P&'GXXUDL"@'@`\B/\`4?/]_G[Z
MKH,7.<6,9,GTYZU76<3Y$WT7<Z+5O[C``"((QC9D4`$`X]O^7CX$0`==9_H&
MQP8.5(R0.<0`3'&;E#&$W`=^\7`&YY#D!ZX^.-9DTT&*6N'ZY&F^I"RELA%P
M`0*M'V1^(@`@("44W0N$A+P(AQ[/D0YXZU^LU2N[$/\`J?)#]9,@<D:V2#B)
M<BAOD%GC9&-?^WSQ[5A$.@#GSK)>F@QB,UDN%#F7JL59FI0Y.[J$E^%>D(7H
M3'B)X6Y5#\![A3:OU![X(!C?IUV\%D.K3SP8M%XM'3A`'ZL!-M5HB83$!$!`
MK1X5,''@1`[-1PF(=@<0U>_G71SM;@;(T%G/1+&50`PJ)E>MR+&04Z$%6RH\
M+-E2\![5&ZB2A>/TF#0=V4P&#D/'P/7QY\"/@>0$![`0$!#5=8F&"NM-.56I
M/U;7`I%,*E2LCP1E4B>_Q`6EQR8/83@$V$Z"Z(@`$(_0#@=7=6;C$6C\4BT,
MX9RL?[2RD!*-SQ\Y%',)@*+R/7X5!NJ(&!J_1^M'O0(8S1RJ!3<!=>FFF@::
M::!IIIH&FFF@::::!IIIH&FFF@:::"(!Y'CP'?W$>`#^H]!^^@:H(@'8ZMVQ
M6>'J[3\9,O0:IJJE;LT$R&<OY)V8@F)'Q,>W(J\DGZWM'Z;-JBJN8/<<"@F4
M3!98H7RZJ`=XJXQ]5U!-[&+0Z*MWDD3!RFH[?D%9E6DU0$AA;-`>2J8B*2R[
M10#``738KU5JL9)&8E")OG`?ZI%-4EG\N[-_LD;QK)-=T<3CP!#"F5,1'LX`
M`B'0!9KY,?\`U?I1(=J8.4Y*\2*;$3D$/TF"'B?S"2*)@]OZ71VAP,;VG*'`
MCJYJ[3Z[6$S_`)1%-VSE<?<[D%/<ZE7Q_`K/Y-R*KYVL?@#',LL8/<(^T`#@
M-7-P'7[==]_;[^?`=CWH,9_PO?Y#VFE<@_EY#&Y49UBO1K5,O7A)]+!)/@,`
M\@!R@0#%X$2`(CKX.<30\EP:<L%QG#@'!1?6%PF0H<B82E18IM$@*(B/(>P0
M`/\`*`:RIIH,-C@;&X]FBY`3^?>,W*>_GD!Y]_XGW<]<<^0#QK][;$4#&F%2
M$F;?!JB''OC[&\.`AQT!DGI729@#@.O;P/SK*NF@QDI5+VQ_7$9%7=E3`PIM
M;/`Q4BD8#>04>QZ<8^Z``X'W&#[E'5!GLAPH%+-TYG.M2\"9_2I/WKD3X[.,
M)-`S<JG*4!,*35VX$PF*1,IQ[UD[5/:'7[<<=_;QH+.KU]JUE758QTC]*5;A
MPZA9-!>+F&Q@Y]Q58]\F@N;V"`E,HB55+D!X4$.!&\`-R8Q?:8/:!1]P@'M-
M[N?\H\\CQQP/(!P/'G5OS]3KMG0(WG(EI(`D;WMEE2"5VS4XX^JR>I"1VS5#
MH04;K)F`0`?@-6.5&\483"T^O>ZDF4A4F)CA_&\.@7_.*#QP<&]I;HE`03;N
M3-)DY`(1%1Z<@%$,M::MZ`LT/:6@2$&^3=MDU#H.TA*H@]8.B!_B,Y-BX(D\
MC7R/)159/4$'!"B!C$]IBB-P^?&@::::!IIIH&FFF@:Z*Q6.*JT8K+3#CZ#5
M,2I)D(4573QVK^EM'Q[4G*KV0>*<)-&B)3*K*#P4``#&#ZS\]&UJ)>3,JO\`
M19LB%,8"%%1==90Y4FS1J@7E1P\=KG3;M&R8&4774(F0HF,&K&KE?EIN3)>+
MFV!"5*F<M9KIA^NVJ4>MQ_CG*<HI*V=^CP,D\+[@9DXC6ABI_7,L'RB:V^M[
MQG:+PQ_#$9JE<5RF*.!<-(4>S)R4ZB4/PK^RB50P>T?KL8DOL2:>YR55R.5"
ME]H<<B;OR(`'VZZ`.?YCR/W'5>`YYX[XX_I]N/&JZ!JGN+R(<@`AQR`]<>[G
MC^_`\?RU77GD]?/?3D+`6.L<[8<)SCNJY,W))S0SETC'1VTO4L:0BS9I.*Q*
MR)RK-7\\=TI'@[3$%4&:3K\.8JJA3E#:EDWU"]D.&[(M3\F[I,+5"SMC@D[@
MY"[1BTDR5\"D^;,#.S,E"CT<CH4C$-R4Y2B&L\XKS9B+.$"6T8?R32<EU\P^
MTTM2K)%V%HD?G@$W)H]PL=JJ/D$W)$CF#L`'C7\TV+QO3HQ`Q%(9I+/%S&4?
MRLRD$E)2+DXB95R[<NOJ'.HH<QCB`"`!SWR/)AOK%67\H;),B1.X_;=)OX&=
MI[MO(6NA,Y!9I4LBU5)P0\U7)R-%3\&9!XT%4/JF()FQ^'+;Z:Z9#:#^F*<X
M$#DWC^8!]_//'`?'/R(\<:XF5`H\>TP\@(AP`#SQQR`!SSR4>?<`\<<>?&M'
MV(,9;\]^N+Z3GJ];\5-OV-LH50EDJN-]G5.8Q<E&1$LN#J,1G,G9#2FIIU/Q
MJ9%(^7&-C63<RZ2J:"@$$1');WTRLZL?Q#VE^JCOWAIPRC]PQ7L=KHMV@$EW
M*":2!9"O2E50;OVS90GU03!5%0PF'VG3,4#:#;P<X$`1\]=#R``(\^/<(\!Q
MY$1Z`.^=:`M[W_*%=K&US($OA;#]-N>[?,E=<+LK3"8F=1J--I\BW5%%Q&6*
M[.S.&QI-J<BA7+**9/BMU`!)9R18#IDCEZI6=_5=V"[*LR.;9D##&>\=6N$9
MXN@=PE:C9/%.=L:RET%*O1DM,5%!R\K5G?R"BCL#2$`JV58K*)K@BF`<%\=$
M/C])M$LZP>+NL<W6>/JHNO6[`V5C+98'$<VL9+WDR1C1-)UQ=&9(2/%%ZX!=
M%,_TCIF$3_4#V$XF_P"5+;>Y21C8C<%MASM@LQ[&TA+%9VYH*\TJJ-'P@1*9
MFY%FK&2:"""IB@\:IQRKI)#W."$4`/8;TY4N[5/(U3KM[HE@B;93K;%,YNMV
M2#>HOXF9B7R0+-7S!VB8R:Z"B8^0$#$,!DSE*H4Q0_D]<K3DG`*Q5/K,NI83
M2OYBE7YBPMZI+7M,"P^0T[LX=)"R.PCVA##".7OM%V](!B'-[_U>T+_DON6K
M%-[1\W[?I^4=2K?;3GN4K%25>*JKF:4^Y1C:RL8MNLH)@*V8R:DB*2)1*5,7
M)_80"FZ#T?V>G1=I0:@[%=G(QJGXF%G8Y06LQ#/@#@KIB[*`C[3<%*Y9K@JR
M>I@*3INJF/M"WH>T2L-+-JC>U$"/W(^RO6A!,K6*M8%`1!JHF/Z(RQIE**CB
M-*;\.[`#+1YS$$4"9.UU$W!Q5AC'<3,-$W;%V3A5,X<'(<O`IN$%2\*(.4#`
M51NX2,55%0I3IF`P<Z#M@'GGH0X$0[^?L(?L/_[#JNL85J:EX"82H]O<G>NE
MT3GJ5E5#VELK!F41692)^R)VF.0X6?$+[$Y-L/X]J0#D>%)DX._(<>>AX^_0
M]<AV'?\`Q[T%=---`TTTT#3330----`TTTT#01X`1^W>FK4MEI1J[!-<4#OY
M-^Y+'04*V[?34LL4QF[-N!N`32*4IEWKLP"BR:)+N5A]B?8?.V6QC64&W*#F
M3F))06T+`QP%/)S#G@1%)!,3%!!NB(E.\D'`D;,41%54X&`A3=#"4I_(232U
M7YRWEIUL!CQ,(@!C5NJ`J'`A'(*@'YA+%(/L6GGR9W7ZE4F)6K80*;]]/JCJ
M.7=V2RK)2-RF4R?CW:8&,SB68C]1*OP?U/UHQC,W'U#\%5?N`%TY$QA3*G?V
M@XE+[0X_J/8CV/GL>Q[^_>N6FF@::::!IIIH&FFF@::::!JS;/38^Q"V?BX=
M14]%F.I"V*+,5"4C3F`>$A,(?2?QZ@B`.XM^5=D]3Y(HD!A`X7EIH,;U^WOF
MLHE3[LD@RLQTSGBI)L44H.WMT@#WN8DRIA,UDDB>TTE"+F^NV4$RK0SID)%@
MR1JWK)6HRT12L3(H\)G437;.D!^D\C7R`"+62CG!0][5^S/P=NN3L.!(8#)'
M.0UK5.P2K&2/2;DY24GVR`N(69`A4&UOB$N"&>HD_P`B4NQ$/IS,<0XF3,9-
MZD7\(X()0R5IIY\::!IIIH&FFF@::::!IIIH&FFF@:LJVVH\,+*(B6[>4M<T
M8Y86'4=`@4R2)@*[EI$Q`.LC#Q@&(H]533,JH)B-6I3N52E#G;K8->;M&T:Q
M--6296%G7X-%4B:C]R4OO6775$?:TBX]'EU)/U.$FZ!?;R*RJ)#_`!I]1&"!
MW*R[HLS;IHQ%YV:43]ON.7D4(R*(<!,Q@HT#'1CF1#<^WW.7!E'*RA]!\*U1
MR1KTUBL+XUDN#E($5YAPB1%NP;=B$;`1Y?\`!B8\@B'N%$/QCPY?K/G"RAAX
MO_330----`TTTT#3330----`UQ,7W!P(\!SW^_[?W[_IKEIH,?V2C%D)!.RU
MQ\:NV]LB")9-(@JLI=NGR*<;8X\#%2DV(]D36.`/F(',HR73,7V&^]4N`S"S
MJ#FF7Y%;8H@#)0JI_<DN@!O826@US%+^90SD>TW!`!5L<P-7J2*P%$]\ZM"W
M5-"RM6ZB#I6)GXI475?L#5,BCR)>&`"F$"GZ<L')0!*2CU!^@\;^XIP!0J:A
M`NX!Y#G@0_F'`_VU75C4^TN)?\9"3C4D5;H(4TIJ+*812<)*`8&L]$&,!3.8
M*5]AC-EP`PMG)7,:Y$KIHH`WSR'(AR'(<<A\ASXY#]^!X_EH&FFF@:X**%3(
M8YQ`I2@)CF,8"E(0O^<YS#T4I`Y,81Z``$1Z`1USUC#(2B\ZYB,>,%545;.5
M=S/N4#"15A48Y1#\U,0X?Y%Y5PLTAT>?*3EX<H<HB(!^*"0/D.40MDB!PK4,
M_<'I4:<1%&462_U<;A)(&Z6$5BK%KC<W"+1N7\Q`IG2R)T<ME#CGL1[$0Y^`
M^P?L'QKXMFR#-N@U:I$0;-D4F[=!(H%3111(":21"AT4A"`!2@'@`#7WY#[_
M`/G_`,B']]`TUQ$Q0*8PF*!2@(F,(@!2@7LPF'G@``.QY\?.K(E\E8_@V:[^
M5NE;9,FK^&BWC@TPQ43:/[#*I0D&U="@LJ9NI*RZJ<:S!4$RJNCBD!@.40`+
MYUY1?^4@X`N3:Q;==X\)&2$U1<=Q\YBW)YFJ)G*=48622;O8"Q+I(IBLDS7<
MK/&+EP8PH)."M"J"G]<!'U=`(#X^XA_4/.K>ME2K%[K4W3KG`1-HJMEC741/
MUZ<9(2,3+QCU(R+ID_9.2*(.&ZR1A*<AR#\"40,`"`?S4&CIK(-D7K%PB\:.
M"`H@Y;G*JBJ0P<@8IR"(#]A#GDH\@8`$!#5F9"=.CP9:S$E0<62[/F%/@8Y0
M5#+NGMB=)19#(MD$UG*_T1=`<2I)'$?]D#&`"CZU,L?\FUVF6^U2%AQ)E?-.
M`(N3=G=.Z;49"(FZNB94_N.G#MYML=[&H<B/M0%VX22`0*D0A"@`2EV<^B)L
MWVA7B.RJV:6O,V584Y%X"Z9:?LIH:Z]('4C`0C5FUBH^1(;W"@_.DX=-P-_@
MJD.`*`$[]FN#D]MFUW!F#B22TLICK'<'"O9%<@$.\E%4?S*75*G[$Q3;DDWS
MI)J0Q"J`W*F"H>\!U)O3_P`_^?[CIH(+^I%LWC=^>SG,6VIW+'K\Q<85"1I4
M^7V"E#7VM.2S-1>/"'(<#QXRS=)K(^T`4*R<KJ)B"A"Z_F9Y*QI;<-9.L6&-
MRM";8>RM!6-K%W.BVJ;M>/*W:4%72*4]DN-LS=X:)NAY!..8O*\5H5%J!/<H
M@JNDI]$G];,2@;H0YX'G^OC_`("(?R'C6!,Z;6=N.YJ(;P>X'"6,\OQC,#@R
M1OE2B9]9@!^C_ESYVW,^CQ-\BT<HB(\CYT'\KE%ZPMDXC5(%A*99R)9WMNH%
M:QA47KVPVV[,Y:<3=5-2/#'BC"&AV1EP(HY=O&3B<5;!PHY4,8RQ?Z$OH?>G
MM;]@NTI>/RTJ!<[9RM9\L9:B$5T'C&IR2[!.)KM+9OD>5'P0$`W;#(.%UE3?
MF[EXD0QB(`<\[\";%MG>UUTK(;?-MN(<3RBX*%5F:C38IE.G*K_VB?YXHBM*
ME2.'0I$=E3XZ]O'6I7>/&@::::"W+36V%IB3QK\5T!370?1\@S4^A(Q,HS/]
M5A*QK@.T'C-;@Q#"!DU4S*MG!%&RZR9^HIMC?2)I2O6`$$K56W(-Y`$`^DA*
MQZ_N4B;"Q2,/(-9-I[1<)I^Y-E)IO6)1]J!!&^A`!#@>P'6+,@M%(1>+R'&(
MJ&>U4#I32")#>Z3I[M0OYLSX*'"BT>J!)AD4XC[%$'`%`?K#P&4]-?%NNBZ0
M2=-U2KMW*23ANJ3@2*(JIE.F<@@`"8JA3`<!'O@WP&OMH&FFF@::::!IIIH&
MFF@^![X_?[?OH.KFI1A"1;Z6DW)&;".:KO7;D_9$F[<@G5-[0_4<_L`033)R
M=0XE(F!CB4-6/4HA],2"-]M"*B$TZ8J-X&$5'EO585RJ94B8)CT:PRC86ZD\
M]X]Q/:6,;`DU;G^O^6?2&Z7./J@B)X&I?@;-9P#_`+-]+&.)ZU"."\>Q5N!D
MUIIXEP)1_",DSE`%.!RMP'(#P'(>!^0Y\\?ST#3330----`TTTT#33D/OY\?
MOIH&FFF@::::!IIIH&K6M55:6AF@0ZRC"3C'2<C!3+4A!?0\FCQ['+8QP,4R
M2R?O:OFAP%%ZS55;K%$!*8ETZ:"R:9:5IYH^92B*#.SUUV,78XY`QOHH.?U'
M9OVOU.3FC)AD"<@P4$3^TBBC8YS+-EA"]M8KO'%5F(O(:`_39M02A+JF4`*F
MO6GK@I&TNL4H"9=S6Y(Z:R8\&$D:^DPX`!#64RF*<I3E,4Q3%`Q3%$#%,4P<
M@8I@Z,40$!`0Z$.PT%=---`TTTT#3330----`UT5DG&%;A7TU)*'(U8(BJ)$
M@$SARJ8Q2-V+5,!`RKM\N9-JU1)R95=4A`#L==[K%#@A[I?4F)S_`%*YCU1L
M]?)\<HR=R=H_78(F'LBB==9G*\,4.R2#QMSP9#@`[2H5V0,Y4N5J_5;)=DDA
M^#*8IV=8BQ-]8L#%?I*<.3@FO*.SB99Z]+Y*V101)D/330----`TTTT#3330
M----`TTTT#3330----!8UNK3I^JSLE?.DTM\`BY&*7/^EO*ME2B=Q7)D2^TZ
ML/(JE2/T8%6#U)N_;'*=-4BW:U.QM+5"-9=J04#G][608JC_`*U&2S,PH246
M\+P'M<,71#H'^#@4JI.4U""-QB'("'W`0^_G]M8G=A_!5Y;R)3`A`9!41BI$
M.`!%C<6Z1RQ<B)"`"9?SYH4S%T<1#ZCMHR$X\GYT&6=-4#G@.>QX#D0Z`1^>
MM-!Q.')?GR7L/CL/U?T\\_''/7'(8FI3MFY/:LFRS]%JQGWWX.'=/UDVC:.J
M<`NK&1XF6<'(@W3E9$'LL8XJ%*N#YH`B82$YN')<HO%TF<,S.*<C((MX*-,7
M_.61L+M&%9J$#D!$R"ST'`@4?<!43&#_`"\ZT];XMM>0+7>Y:/L4R=OA^UU#
M&=+H^1I'+XT6GX*K$(=Q&YVK-RQBO)-8_*1,K0:S27@'Z<-8)5K9V4214T6A
M7H]<X3/S#ZA&%\8V"UT:#ALAY7O=3A;E)RL'CJH2LG$L75#&,3M,/*VU5NG#
M-)"O+3<,:S,X\TO(UR.DD)628),A`YH$W/U6KE9K7-PN)G.%H9K7Z]+2,/'2
M$R]O\_F:Q$EJ*PBZ!BJ4B7,-&HY`?QMV!W#1+N&GE7,S`2+.0CFL>V?O&G?8
MPQS&,;+_`!HW:Y'W&9#"US,]&9-KJ3[;QC)BVE\3L<-S`KR4G(.+1-2%JJL3
M&35SEJXS*F_M\>QFH88_\&U`F1JFSB\4Q<Y3(?(>$MO[+&E;D<@7&&Q376=J
MOU>K/$A+2ETR%D++)+99%G*J;^3?*V1U#$F)$SIVY14=@N)C!A>D,-VV:,98
MCLF<,?Y/NJ%+4RU5\LT&XW=Q@>10R++BP0IV422<Y&XYK%[I];:H3D<T@X96
M0@X521;/(U:RN6ZZQ8^4+;G)46CO,46/<UM_JB]@Q@XQ)>4:;^:YON4D$3>4
MKW2\B5V*H,55(J"O%>DBK-T(ZQM[$Z<&<KN74\NY4!4L@)',>$'V1::UOV-,
MJ7A2Q.\9%1OFX:==+KQ4'E*PJUVO6E/'-E.YBH>JIRIF`?BACX(%%I9!!M&I
MG2=?3E7M]S!7\F5N:9QZ-2J]KH]QN])MU"J,E'JC6G-1MTG7&CI5K&`BH@QG
MV;)K*QZBJ0(KD=&*V4622`V@S-1MRLI#4^`A)2IYSS1;F3$49F_I880Q1#65
M\*JZA9`D78)>+80R!TC)(%1;*NR`1$%S****'$>V<;B,QNRG&%V^-&A.?\-6
MVY@J,8?@>>U&$*PGW1!#H!`#F'D>`Y'Q\S`!NS?J$P\CS^H?@>A^0`0#GCOY
MYZU7CCKOOK@!^/V_F`=\_OP//D/P*9@W)/B!^&J6%JZ8W//XVV7"SF`/_985
MV)3-QX'A7]7/QP.NM-?-TB@\_P`48)9E$O`%3I%^>F*;L./<I8V8&_80*`&X
MZ#SS</\`(.!^>1\``B/`CWR`\=?_``TY$?L`=]@/7[\>._WX^_\`4+7&W;I#
M#[O])6&4P'OVABRV&`H<=<&-<@,(#\\\#KZA=]T:8%XNF#7(@(_J6Q[>6PB`
M]!P*-K7#@0Y_V1'CR'/`:N$`X'GO[CQP/NY\]@'D!\CSR/D.`U41'GKG@/(]
M#Y'QV/'7CGOCYZT'7-\J;F&(\NH[!U@*0IOT-WEZK1E!#GP9S'S0)]^`,!@X
MY`1ZYU^U#/N=6ON&2P14I,@`')ZUFB*25-R(>XQ6UDK45[A$!,()_6]PAQR?
MQKGQR(B/7@!#SS]@Y_F/@.`#D!\ZJ'(=\#S^W8_OQ\]<<ASR'V^!T'<([IUV
M?M)9L$9KC#<?XSBO04+?8]$`#]1OKU2=>/%2AY'Z<<)O;P(%[XUWS'=W@%95
M!I-WDE&D7*A4DX[(T+.T)U]0P@!2G&S1T>U+R80`#?B1#OGQYL@0Y$!]O(\<
M\@!>>.>0[X\A]@_F&N1SF43,@L(K(F`Q3-UQ*X0.0X"!B'06^HD8IRF$IBF3
M,!@'CY'02UBIV&G6I'T)*1TRQ4`ADWL2]:R310IR^XAB.&2RZ(E,7LH^_P#4
M'9>0[UVNM;3_``9BEW)_GS&I-ZG/@8RH6#'LC,8XFOK#V*IGE*?PI7)^>S"\
M0<@(\^\I@$>;H8#FZIF(>G9K?SK-+CZ-<R_7(JX1Y2@'!$AL]>3K%UX$``/K
M/7\HJ'1CBH("`A/W7S62271517(51%9,Z2I#@`D.FH42'(8!Z$IBF$H@/0@(
MAJ'$?N8O5:43;93P[,BR`G#B[8F>?QW7TA*(@=R]K+A.,NT6@!?UB"4=,_3#
M_.H(%$PR`H.7<<9/;G7HMR@K']$3)NV35W]&59*$_P"T2D(1ZFVEV"I>>#)N
MV20A[1Y\\@'#&@J1*,[17!SG5IDG^&CCJC[E%JU*$%_!*B8>S?12,YC1'P`L
M!`.N-9.UC"7(:%R75Y,ABE;6J(DJQ(&$`*'XN+`\U!\#X]YBC*H)AT)O>("(
M\%`,G`/(`(?(`/\`?05TTTT#37$W/'`=<\!S]N1`.N.^1`1X'P`@'.N@K-KK
M=QC32]6G(NP1B<A)Q*KV)>(O4$I.%?+QDK'K'2,/TGL>^;+M7C90"*H+)F(<
MH="(7#IIIH&NNF)1M"1,G,/#>UI%L'<@X$!`!%%H@=<Y2\^3F*02D#L3'$I0
M`1$`UV.L99+$9%K7:F4#&_BRT1C!T4._^J8SWSLN(AR`?3.VC0:J`81Y!R(`
M'/8!^K&<4Z95T).4$#SEH>.++,G$`^HFXE1*LT8B8`Y`D;'?A&2:?(`3Z9^"
M$]PAK(>L=7O*>.<7LB/KU<J_5FZHD(V2DGJ97[L>`]B3"+0*O)/U!*`E*BT9
MK*"/M`H>X>X]R6Y^U6-95KB?$-BDF2B8@TO&2G!,?5!01X]KII%+)/;Q*M^.
M3%*G"1_U@X%-<"C[@"9`B`>1`/YCQK\$A+1L2W.\E7[*,9D#D[R0=MV34@<"
M/)G#E5)(H>T!,/)@X#SJ"S]WGBV&`]IS,%3:*!PK`X=JT9"-S!P)134M5V0M
M=E.<2B)1<1Z<0;W#]5(B)B%$MHIX+Q>I)?GM@K:U[G>?J#-Y,G9[(\A]3_-]
M5-.X2,K'-#_!09,&Q$Q``2(0`+P$G97=GMWC':L:EE*NV"62]Q?RBFB\NLD9
M0O0HE:U5K+&!?GKZ1Q(8!Z'C5M*[K6#LPIUG"^=K`)@_PG3JB%I\:H(CP`B\
MNDI!J%3'L?J`U.'_`*HAWKH6A$V#<C6/20CFJ)/IIM8]!&/:ID+T!$V[)-%(
MJ90Y`"E(`!]NQU40`P^X0]PCR;D>S_J'X[Y#]Q^?[Z#FXW"YI=`(P^W^)8D,
M82IJVK,E8:*^WC_,JP@(F><)#^P*'Y$.`'GO77+9<W*O4P%M6<)UPP\@)7=E
MN=G.`\AQ_P"A0$.F/M#H2@<.1[`0\:C_`+K-U&)MG>()G,F7I-=O#LETXJ`K
MT6**EGO%I=IF/'U6KLUA^FO(NBD,JY=*\,XID11\\-],A4U?/'8?7?W?3\LO
M)XXVR81JM-%<QXB+R'.W*:MSR/$XF04EGD3.PT<W=JI>P3E8QS=-,QC`7W%X
M'0>HL]YW2*CP-NP6S#@1**5$OCTY3#T)2"M9&I1#_9$PE#W>0`/&OS_Q9NE`
M?=_I+PSQSS[!Q9:P``$?`F"X\\?'(<C\\".M/>QSUCJIN/NJF&\]XY8[>,KJ
M0,W8X69-94W6([1'UR/5E9X$)Z>71=UAZPBVCR3^G,R#IBY:MSHI/$G8$35G
M=EO>?CK&37'ZM7HN<]Q3K*=86N>/D=L.)9O,<;8:R@X2:?G![5#N&M3B6#E5
M=(S%>0F4S/&ZA73=-1J!UBA)\MYW1I^T/XPP4[XY]PJT*^LQ,(=]BE9W)2^[
MP(@7KSP&OWHY:W*LR&_$UW"-D'@?:1K8+I65%/WY>0<RDGR7H2G/Y'SP/&HF
MY;W@M,,IT20LVV[=Q8*Y<:6SN,Q8\980D,F-,9+.E0*I4\DQM:E59J%M+(AA
M6?M6+*1;-TBG$KE4Y03&T=X/J$8(VA8%M^8;-.1L]:XFD5.VU#"OYLUA<FVU
M;(IU&>/VJ]3?&)8H6.EI-)PE,2+F-$88D?(H.2IOB)IF">K+/^<DQ]LAMYC)
M4I#`"BE/S!7GZP$'_:(QFX2%7/ST``*B?8\"/SKNB[J6C!3Z%JPIG>NG(`?6
M<MZ*6VQR0^1'\34).97,0`[`_P""*`@//M`-?SK]P>^K>SNON!E,[9YS+1X]
M63BG$?A3;RY<8VQQC2+GTUE(MU.SC=5LI/K-R%(C)2,E(2<DDL<I5G(`3Z!.
MPP?ZD'J+;3)*MS41G/+^4JKC>,?S-KP3FJ<CLA8^FZ*G,%!_5VUK$QYQE<SQ
MJ0R\9(,W3>8B6RG+%0C<BS=</Z,$;NTV]2#E*/6R=`5^65$I?R:Y_C:1*$5,
M8"@@9I:FD4(K\B(?3(<PB("!1'OC/,;,1LRU3?1+YE*-%>R.8YXV?MC%'@0,
M5PT461-[B"!@`#]@/0CYUKBP-FJE[H<$8NSC4`)(TC+M&A+A&1\J1O*_@BRC
M8`DH)^1PDHU5>04JD_A7HE2*0[EBHH0H%.4-?H4P7B\DF,[`UM:ASXF,H$YC
M2<G<;R7U##R)U?X/D8I@Z$QA$3?C6+DB@"8%"F*)BB&R<#`;G@0'@1`>/N'D
M/Z:KJ`S!YGJIC[JKF1.VM4RB5&`S'5(R803(`@4I"VND(U>R^X"%X*YDDIA0
MPB*BX.#"(C>4=NALU=4*VRUB"Q1#),I0<WC'+DN0J@3@?\5R]CFZ+"YPZ!0$
M!$JT&_\`87]1EA`!X"7C]BUDV;J/?(D<LGS9=F[;*A[DG#9RF9%=)0OR4Z1C
M%^!#W#P(:L3&;QP6$=UF07,XE*3*.:RZ5/[@479-BIN8)X('_68KJ#<QYOJ"
M)O>J1;]9A`=?JHN4,>Y+8#)4.X0-I;$#_'+%/TEG;0>?;['\<<4Y&/5`P"4R
M+YJW5*8!*8@"&NM.I^2Y2;']P$9WBMG;>P!#VGFJHLHL58?'*B\1)?2$QO<<
MQ6:9`X!,>`R=IIIH&FFF@::M^=L]?K:L&A/3<9"J62;;UV!"1=I-!EIURU=O
MFT.Q%82E7?NVL>]40;%,"JI4#@D!S@!#7!_Y_MYT#3330=!:)U&M5^8G5R`J
M6,8+N4D/=P9VY`@E9LR<`/\`BO7AT&:(>3*K$`.QXUU&/X1Q`UIFVDA*I//C
M*S5D<%`0_$3\N<7DDH(CQTFNH+9(."@5%!,I2@4`#747SVRLW0ZF8H';R=A_
M/90!Y_\`HZHH#,MRF`H\_36G20R1O<'M,`'(/9@Y9`S#C+%R*:EYND%7G#@2
M_A8UPY%S-2!CB`%*P@6!'4R_.<1X(#5DK^H2@(\#H,FZ<A]_/C]]0R?[E[_9
M5%F^+\-RK=B8I?PMTRZ_+28)8!`!*X95=@G*W.004`?<0%VD.80$!,8A1U9S
M\N9[B(FO.9I**8K?]O5\/P[:B10\AP!`MDD:<OYBAX,9G,10G'_93*/!0G#-
MV>O5ELH]L<W$5]@DF911]-R;&*:E(3@3F%9\N@3V$`?U&YX`>A[XYP,]W>;?
MDE5FL)?6]XD$#>T8['43.7YVH;D0]J7\+QLBV/QQV(.0X'K]]1VB,(8HAI$\
MRG2(J8G#G%4U@N:TC?9_ZG("*A9>ZO)UZB<1_4)FQT``1X``[#65B*&33!%(
MWT4"@4I44/:W0`@!P4@((_32*``'M``('`!X#CG0=NMNH4>>\E9P5FR5,'_9
MN9VO1%$CU0Y$`-]>V3;%VF4>AY4CP,!1$1*`AQKHU]P&='1BA&8'JL80X#_B
M67-,.=0H`(\"=K6ZW+F3$0_S%^L(\\!SQV%>"^>`Y[Y,(`(ASR/MY'@1'G[C
MWY\>.7/(#_0?/SQS\CR`=<`/]M!UJ^5=S#P2_A8G!U=3$@<D<2-XLQDAXX$!
M.WC81-0.AX]OM+QUS\Z_`>\;HU!,4+G@QIR(`4R./KVZ$.^1_P"WM2`#T(>2
M!_?5P#R("(]<]\^>1Y^X<_RYX#GH1'OC7+CY['CP(?N//7[?'/(B/8>-!:G\
M6;I0$!_TDX9/P;D4S8LM90`>>>1$MR$0_F'8_?CO7ZRWO=(D)1"UX)=D``$2
MJ4:_,O>;GCD3)V1U[!$..3>T0`1X`!`-=_R`<]AV`^0'L>_Z>WQQQSSV`=Z<
M%#@/[>/M\>1]OD>^O//6@_"GE[<FS(/XFJ86L8_I$OX.U7&L'-QR(CP]KTNF
M!3=='4``'H>0UV#;<+F5H4#3.WV.=D*/M.I4\Q5.05]@!SRDQG8R`=*#YX**
MA/(`/8ZX\>X!X_4//SUV``'C]_MQP/@?&GP(_MYX`?'D`\^?VY`.^>^>0[Y'
M=?$-NK-A[.];`O'U'88]5M,801Y]P@^IDA/_`.&7OA4Z"8&*'(@7D`U>-=W1
M8`L[Y.)C\J5-G.*"4@5^Q2`52?*N8/\`T8T/9213[\041`#)%1,8!$/("41Q
M>'1@$H`4>Q`0`2B'7P(<=#\<?SZ'7Y)./CYUH=C.1D;.L50]JS.:CV,NU4+P
M)?:="20<IF`"F$`_3X$0'GSH)GM7;=ZB1PU62<(*%`R:[=4BZ"@>!%-9(3)G
M`#`)1$AA#D!U]P'D.>!#G[AP/D?C_?\`R$-:V6F$*#!/59.C)6+%THJ/;O%]
MML-,:BIR/M.M7&+Y2I.R!R/*+N`60-P)3)F#C5YQ]BW%U(/^I<EUK);,H%_Z
MLRM5DH66!$H\BFTMN.THQ#ZQ@_3]>4J[T#=";@WN-H)Z:M>Y5Y.TUN5A1,";
MARV,I'N.@,SE&Q@<Q;TH^2F:ODD%@,'!@`I@`0Y$0C5%[L&T,J=OF+&UQQBB
ME^@]L;$1O>/%!```%?XCK*:LC&IJ#R80G(*/!$H`"BO/ZADO5KC5+M%(SE0L
M<)9HI=,ADY"#DFLDUX,43`4RC553Z2G'^9)8"*%$/:8H&`0T'PI5@/8ZO#2J
MQ#$>KMSMY)$P%*="3CE58^43$@>`+(-7`$\<IB4P="&FK=JAB0]VO58'D$WB
M[&\QA!`.V\ZB,=*D2#S[$I:+47.(CR!WP\``"'+08[W'A9W\?2*_4[26H2+Z
MT?FKF:+"LYUVV85]DL\.:.:2!@8)2`N56Q6CQVFX1:+&*X_#JG3(76JG<5FN
MH;;,@5*OJXEOV:\KWR#>2=:O]G?A?I8KL[*R)-'$1#OSJOGC5C:()A7[/!4M
MO#/HI&RP3Z+;R93BUUM9RZ<RERK#<YA.1E6YMT7W"'(J/)".:B81*4H<BFB(
M=<``]<??#$Y0Z79YVLV>P5>$F[%2C/5*A,R;%-V^K:LFM'N'RT2JJ/#19=U#
MQ;GZQ2&61<L&SEL=%=/Z@AI<>WS=]NWA*X%383ULJTG)1>29YO"3*U&QS+4*
MQ2$=)5S#TX$G!UJ5B9^MN*N[@[7]>>LJ3^)LTG)R!VZ2:4=J3>WS8W:Z'>LI
M72[6*%1H&=8.T5:[;?W<E9LA%K]#EDIF%KU`C<AN9QK%R"<35)%E$2=@-"/)
M5%M&MH2NOVD2D9139IR;V$((C]),3&32X`J1!4,)U#)I%#Z21E%#"<XD(4QS
M"8YQ,81-H)0'CX`.N>1[#L1^?'7G_P`!#D(Q1FT7#I2%_CE*XYH62B(^LMSY
MIM\K>6C>LPJ@JP,`$$L9E7GK>#4$QV$A)13V:!8RCA6147,*FL^U^I52I-!9
MU6KUJKLA(B0S6MP47!H'(W(":!521K5M]8$B`":7UA4%,G1!`-7`/@!`..N!
MZY,(#\B'COY'K5`$..^@$W7`]\CU^W''/_#^H..!$1Z``X`//0]?'?SWWSWY
M[T^0$.QX$0``$`\>0_8?'[_;D>0!USQYYX\>?V^P#UQSP`<#R(<Z#R(<`''0
MAP;P`@'7`AV/8?O]^-!4`[#D0X_R]]"/`<#P/GR(ZIQR`\B'(#QWP']!$0Y$
M!#OQWWSS\5-X'KGD`X'H>^0Z^Y@\?U'3]/SP/[_VYY'L>0^.1#GGC[:`/(\`
M7KD1[[^`Z[^P]<?']M4'SYY#]/?P'`_?[_U#R/[:J`=]"'(>//\`E'_B'V^P
MAY[U4I#F_00HG,')O:4IC#[0Z,/M*`]=\&,;H`#GD`'04$1'C@!X#GL?`_'/
M[_SY^_6J`/P(@'`="'[AY\?U'L-<Q(8H`(E$"FYX$`X*<`_S>TP`)3"'C])A
MXX\\\ZX_/`@(``CWS^W7?D/CP(?(:"G/W[_3T(\"'(!R//'8A_?O]_%1'@>?
M@?Y<#Y`/GG]^0YY#CKK5`^`$>^1Z'D?L`\]_;Q\<<\\Z<AP(?`=B'(^!^WSW
MT/\`7@1#05#P(<>>>./M\B'7[]=?;X[U01XY#[<<<="'Z>`'C[<_'7`_?GC3
MCG@?W`!X#^OS\<"'W#H/C00Y'SR`\"//7Q\]!QSQUU]N?C05#D/U<@`]#R'0
MEY'H0X$!#QR(\_`<\]:LBSXWI5P=)2<Y!(#.M!*+"TQ2R\%;XTY?\BD=:8A1
MI-M#%$>2D_&*(B/`&2,7K5\#]O@1YZ#SS_N$.PYYY`>1^W&J!V(<#T'[!\"/
MCKQXX$.NA^=!BU=WFNI*UY-*YH9-I<1;JO)_0NYBL,@UIFA+(MG[IE;V:`L[
M8W*Q=KD7CYQ@WD5TN2)R1S"`#L<#QQ]N0[_8?_'4(Y@O_4\N'R6+?*EZXX,B
MW46(/0^2G3`P!P/`AR`@(ZF7#.3/(F+=G'DSF.8N##\B9=JBJ81_<1..@L3,
MF7:1@;&=MR[DA^YBJ12&"$E89!HQ<23AJT</V<8DHFQ:@9RX$7;YN02(E,8"
MF$XA[2CK7<;UI]@9>><E67KGQC^S#X\^&W?'?C[?RUE#U8!$/3QW0"'G^"H?
M_P#W:K<_[M>#\PB!S@'/1AXX'OGW#[>!`0[ZX[\A\CQH/;?_`---L#,(!_I*
MLP?J((B./K/P!1.'8\-1'KCP`"/V`=>?C:YZF-EVL[H<M66,<2=SV[92RY>;
M-/TP?J(."1EAMTI(1USK;1R!ORZQMXMVFLY8@"19A$H,'H@LF@JEJ4Y$H"`"
M8!X-P/(\=@7GD!Z`1Y_5T`@'`CQJ@#\_Y1#]/0B;GD>0X$.0[YY\AQSV`Z#^
MDCBS*5#S30JWDS&EB86FF6N/3D8>8CU2J)J)FY*LV<)@(J-'[)<JC208N`(X
M9NTE4%B`8G>0=>&OTS-]&6]J^7X*CPD=8<BXOR788V%L.+8E->5E3R<BN1JW
ML5#8&,!6]F;?4`SMH0Z+":9$7_,`!=%L[1]QK587#9NX%)9`5T$EA0<D!-PB
M*A"G%)PF!C@FNGS[%2`<X$4*8H',`>X0^^H@Y_;6ZP7NIPU<O<C1XV%KTM(S
MSFOL6BED?_GKI&/;LXJ:?`LG6S@W9.15DFK160,DJ*;91`>3ZE]J*M]$JN1K
M"KS[C-XFM,A'D>"&*D_>&3'X`?\`6"F$0Y_S`'D!T&(JSC2DU-\M+QD&5S8G
M`\N[;/.75EN+XPC^H7=HG%7LN?DP^[Z:+E%`IO\`LTB``!J_#\B)CF$1$>S"
M81,8PB("/(B(C_,1$1\\<Z<^//8^/O\`(\#XX[#[<\#WWKCQUU]A$?CD`Z`>
M//[_``'/WT'/R''CGD.P'GQQ]^Q#KD?M]N-<>0\<A]A$0ZY'D0['GP/0?^/6
MJ\>.0'XX[$0`?[\A\_<``.=4XZX`/V-SV)?Y?S#H!`/`=!SH*CP`B'?8=="/
M`#U_/S\#X_KH(<`'SQ]@$1Z^W`\\\^/'`=:X@'8=CXYY$OC]_GGG[B/`?`^0
MU41'C@//R;C@!\]"(_'@.0^!ZXT'D_\`7-N4[9][.",42KA0:1CW!Y\B0D0<
M1_`N[A;IN9;2,R*0_P"&L]9LX>.8)J&`YD$FIDR&*4QBZUAZ]+/K`["[UN9J
MM!SO@*%1G,^X,0E8\]2*LFW=91QE**G?R-6C#*^U):RP4B=S)0;-59'\Q;/7
M\>W4!V5J17RQR&2H:M/W<%?XRRXZM<6LHTF*M<*Y,Q,M'OD#?3<-A079@=7Z
M:H&(4Y2A[^`$"\#H/TY#7;1T$UG%X.'LBD)8JL]1@YZ,:S,1,D/8XMN[A).*
M>IK-9&-F6JBC!_'N$E$':"OTU4S@`!K^@I2VK*.IU5CX>#8U.(1K=?*TJL.Q
M;14/7T1B&BJ4*PB6*3=DP:10*"R;M6[9)%LFD"29"%#VZ\56P3!MJW?;H,,L
MHO&%LFL#4#($+D/,5ZL,!+PU%_)::*L_$5G\8X*V_-WMFG&<8P:1[<5OK**D
M.\23CR.ER^W@QC&$YC<`)A,80*`%+R;L?:4OM*!0$1_2`<%*`%```-!4!]G`
MD$2F+Q[3$$2B7@?]D0'W%`!\^T>>^?WUYH?^4BT6)2H&S;+YJA`.AA-Q2]2O
M-S5@XT9]O!R];0>U*$6M)V@R;&%?3[*1.=HH\_`J.DDE!1^HF(CZ7RD,8#"0
MIC`0/<(E*)BD+Q_F,;@0(41Y#DP@`_&H^;J=L>,]WN"+[MZS''O%J=?8Y`IG
MS`$DIRLSL<J+JMW.MK."BBG.5Q^(/&)U`,V<IG<,G(';N5``/YTZ:JJD2O6E
M:?>5X.*B92.M]<>S"%NHL+(24D\F23\_8BKC(23B!.BW<.XAL8BS1JJ5$H<A
MP;JX\D,K*.;G)UUU8XUA#U2QRP0"+:)K;Z6FH5ZTDLK-$W;LDD$+%1B8QSR/
M?MB)"90OL*!Q`-;*LK^CCZC&V.V'C:7@UWNNH<>^GG-:R+@:V,X>P2Z<ZV%C
M^,R5C^;<LU1L+1J1,2"LSDVQ%DRBG(.TA#62MIOH:[R=P]JKH;J*0KM4P2UC
MXF,R.]G;!#RNY++E9AG`NV=.;QL&9W%U]F\5+]%U,R`1:,<S.FJ#&7<)(MRA
MOL]`^,GXSTL-NA)U%RW1>R.5Y:LHNB'*J6HR.2[$K!J)@I^H&JY"KN&HA^DR
M*I3D_2/([C0$.0X\]\_S'O@!$?OWP'0^?OJTJ%1ZEB^DU+'-$@V5:I-&KD14
MZI`1Q#`SB8&"9(Q\:R2$W*BIDVZ)1<.5O<X=N3K.W)U%UU5#787VCS\\]\=^
M/M\!USU_NT%?(_/8?`!X'[C^_'7V^_VK[A(;W%$0,'`E$HB4Q>!#OW`("'?R
M'?W'@-<>/D!ZZ^?'[@/`B'(!QV(>./VTX[`>0_D(=`'8!]N?'`#\]?MH+$LF
M,:5:'Y)M[$#'69$?<UN58>NJM<V9@X`#-[1!JLI,2AP`BBZ6<MC>WVJ(G*/&
MN$._S)7;5023-LC,ETJ*N<<!)2RI)P>0:O&RB+F&<?B9&.0&(NC93\8W34,X
M:Q<L40*N=9R)1XOX1X$?'78\]\A_E^PC^Q?N'(CYUU<X8213I8O`*-E&+L.1
M$.#-)%FY`0X'GD03X`0'D>>/Y!-\!YYXYZ$0[`?CKKGR'[_.JZ^2*@*I)J!X
M.0A_//\`G(4_']`-U^VOKH()[A?4=VJ[7LA#B_,%RF8.X!!15C%BPJDU,H!%
M3)WJ;!<7C!%1#WJ&CW7O2]WO3`@"8``P:P:/K3[!`XYR39N_C_1_9N?O_P#=
MOMK0]ZZ7_P#/8J/(A[<*XVXXZ#_TNV\\CSXZ\!]_.M-X<@`<")@'KR)A`0Z`
M2A\<<\CX\!UP`\AZ1?5.]2/;9N3V[5VEX$OUC=9!@\O4R[-#C7)VM.(]K7V4
M^4\FSE71$"I/F3M\R.U!%0K@IQ%1/_((ZEMZ5_JE,=P+&*P'GR9;1^<&#<K:
MIVAZ*+-EE%@U2`"-3F]J::-U:()B=P@)A&>3(L];?ZP15,_D!_[WN\EY\C[B
M\^.?:(CSY`.?@>.?=QP'[(R3DH5^QEXB0?1<K&ND7L;(QKI9B^8NVJA5&SMH
M\;'(NV<H*`4Z*R)RG(<H&`P:#^F*4WN#G@0^X"'`@/V$!U76H/TC=\62-VV*
M9BN95JM@<V[%A640ZRXE%`C4+TV.1)-DV?/@.FDED%HB`K3K!DV,T<LOH2HG
M;+N%4#[>Q$0XX#GD?OQQT/?_`(?UT$,<WQELLV3D&T+D.9I=;AZ<E%V!K5&S
M9G9Y9Q-ROYA^':6Q<%G-<:"UCD"NE(ENG)K^\@)O6Y2\C9]7QW2Z8NN\KU>:
MMY9UR9]9'QEYFUR2G`@*LG:9=1Y.OU#<C[C+/1*(B/M(4H\:R!8US.[[?EC_
M`/V4Q&1R8AWP1C"-1#@.NN7!N>.?U<_'(:_$(`;@>^.`[Y\`'0AYZ#C]^0X'
M^6@=F$1'R(=CWR/?GL>^0\B(^=!YX`.QX_[H\!WX'@`'[`/\_N&G`?L(<<<"
M//''GV\^>.!X^.?GR`5`1X$0Y\^!^W/@!'SSSY\^`^.PJ''8_`#Q\\_?_B/@
M0$1'SWKCW^W/S_LB/`@(AUU\^?(@.G/0\^T`X$QA$2D`.O<)CG,(%*4H`)C&
M.)2$*!A$>`'7G_W5^N?`4B\3N,=HF)V6?YBI23F(M63;9,O*_B9M*LS&1<L:
MNI$*I2]L*U<E406EOQ,=&+G3/^`3<H@5R</0";H`Y\]>#>WOY'CCC^8^>^]!
M``#@1\B`"(AS_;P'`?[OY@&O,OBGU^;_``L\S0W6;8(J#HKE9)%_?,%6"6GW
ME<354*4[^2JEF>N!DV:!#&.LBRE&+H2E'Z0G/_AF]&6.<BT7+M&J^2\:V>+N
M5&N<4WF:U8X=<5F,DP<AR!OU%*LU<MU/<@]8NDD7;)TDJW<HD.3L+TX'P'?`
M!WU\CT`@///W#P``'/\`.O/M^.>0`?'''[CY'GG[_.N0==#QP'@1X#@?MY'X
MX'7#OXY`.!^.>1[Y#YY[Y_S>`Y\:#ER/'(@```]AUQQQQS_3Y\?[AU0?//V`
M!XYX#CL`#D/GGOCY\!SIX`>>3!P'/0=AV'ZN>.P^W/(]=:Y@0Y@,/M$2E$.1
M*`^THCX`QQ`"E$0XX]QBB/Q^X<1$>!_?@./GL1ZX^_`AJ@"/'CY_8.!X[XZ^
MXC_;OYUR4(8AN%"B01X$2G*8AN!#](\"`<AP/(&X_D8=4#D!$!'SP`\\@`AW
MX\ASX'@./[\Z`'(>1Z'GL1#QX`>P\]^0'[`/6@AQP(!V'0?//7''7'QR(B(!
MXX\>`@/_`(?`!Q_W?N`C]^/G[>*\AS]@\#R/VZ^1'GGK[#QV/D-!3H?`#ST'
M(]B`]CP///'\^_/[:K]@]O8\?N''(]C]^!'D?Y^=4'H![Z_X_P"[QX`1'D.`
M`.1Y'BH?/`"`C]P`.QY$>QY``'@`[Z#@/G04*)DS<E,8HB`ARGR41`?(#QQT
M)>A*/(<?TYQM*8IJ3J5/8X).3H-M4-[QMV.Y%6I3*Z@#[B&E2QGTXV?2^H('
M.WG&+U-3LIOTB/.2N?(B'7CR'`_U$`'GO@>N`[YUP'L0[`>O`"'(!]_@.?OP
M'`!Q^PZ#\6+)?+;/*U9:Y`F*W=8=S7[-`,KPQ:?PQ9U#%*TG6,99:VB1>)D#
MD3BGJB<U#.&2?U1$BL:053G%KZ*K&:2=??$.8AV4NNH!O=[?:"]>G6IN!`0#
M@P+%#C[]^=-!D3+`A_'45SQW47/M$![#VS:7/CCP)RCQWQ_/5C]B'0\B/V$`
M_P!_`?MST'_OO[,:1DK=3W/7L>PMBC^!'RHV5C7Y`\!V)05$._!1'KSJP>1#
MSX'GD0#H!\#_`''Y$?Z!YT#L>/@H@`\<A\^`\?RYY\\Z=!UX\\#]N>@X$1['
MCL>.`#C[ZXCY\\\<^>?/?CH.@Z$>/'QJH`/@>/;R/SR(^!#@?D/(\^0X^>]`
M[Y\B/``'7(#Y^?C[_P!/Y\Z=!\`/^;@O`=_RXZY#CY_K]M`^.Q`!$>?CX$>>
M>1'[?/?'VU$W<1O:V\[8GC"`R/:I!_>99%-Q&8WHL,XM]]>MG`#]!T:#8G($
M>U<B'#=20<M3N.0,@DHG^O02RYX#O[]!QP/G[==\]]<AQ^_.@!UX'P`A\=A^
MP^!^_D!UK/K/JL;:)"?CX*_P&:<&A,K)MXFP9@QM(5VK.%E3`5$J\V@L]*Q!
M3D!^JX;_`$4@'E91,@"H79-'R+"78,I2)?,Y.,DFK=]'R,>Z1>L'S%TF"K9X
MR>-E%$'39=,Q5$ET5#)J$$!*;GP'Z?=UQQSQUP(>`YYX\CQT'?7GOXU7CCGO
MR''`]<_'/P/GR/D>1X#P(O//M#GQY\"(_'_K"//`\CY'KSJ+&X;>;M\VPF81
MV3K<NK;I9,BT-CJG1:]KR!*(JB((N4:\Q."C-HN8OM0=2*[4BX@(H$6*`CH)
M3<@`"(_`<AT//7_='ODO77R("//W'45F,<A[VMX&1=J,+DZX8@P'MSJU>D\N
MN:%(GA[ADNY6L$E&L(223'A&$C2K$0(DX3<M2$:/'YD%W;M`$,@07JP;:7$Q
M'1&0*SG/"C6863;L++E;&$C!U50ZP@1,SJ7:+/#,4S`("911JH5,H"<X@4#&
M"'\OEG)%EWYY5SCZ<^/5\[PK:@5ZJ;DBNW+:+QID"T1;P48LE#L2[MBL\G$8
M]%@X2=,U0,\?M7[M%LK$J\K!>^3\3W'TQYG'&;<09>R7><"S.0:U0,NX>R=8
MU;(0&]M<_@VMBK+SZ;9NV?H&(J=)4&A';5V0@F6<M5E$0W@G`"G$`$#%`>2F
M'KW)F*`D/QQY,02\E^!'@.O.GB4QIO-WT7G'<9N2Q'&;9MMV.[;%7N=HBEA3
MF[QDNPP9_P`3$-%?I+.C-XPB_*!ES`Q;-&ZJRX$=NSIB3<*8PJ&,80#DQA-T
M'Z"CQ_E*'P4.@*`^"@`<?.@H(\]>!\!R`]_'/?W[X\B`\]]ZJ'!OZ!Q]P^>P
M^?CSR'/CGYTXZ`.`^PB(>._CGSU_3G]@U3C@1X'KQUY\<^?OS\_'?(@'6@!U
MUSV'@!Y`>.NN>O(\<>>`Z[[U7@!Z`0'KKKQX\<<!]N@^>].>!$>.A`/[A\>>
MQ$/''^_@=<>1$P@/8`7GD.>.!$.@$._^/7]]!R$>@'OH.!Y$>QY[Z\?L(]\<
M#QJGD!$>@#XXX\<AP`]<@(_'D/'6N7QXXX_<.//'GOCC^7/P&J"/'/QV/?8\
M&_J`>0_X_;0=?+"'Y3+#QV$5)=>1``9+B(`/\@'K[CQUWJ7U7_\`JW7^N/\`
MJ2)ZXXX_ZN;=<?''V^-0^G#@$/)?!E6:[8G(\?XKP"LTP^?)UR]?///`CJ:4
M<V_!L&33K_56C9MUX_U=$B/70=?HZZ#01#]03%%YSELXSMBC&L4E-WFZ5B.C
MJ[%+O6T<D\>-[1`R2B9WKPY&S<"M&+E7WJG`HBF!0_48`UY.O^AP]0(1#_Y'
MXH/U&'D+Y5N0]PB/(?ZW^P<=_/?C7N-$`'H0Y#[#KB!2@'``''?[^1Y^?_(>
M`ZT'AS+Z-_J!B/L'#\2`&`I`,.0*N`>X1`H"81>`!2]]\]`'^;Y'6NU?'MQ1
MR`]Q<A`OI&_,K8]HYJY$D&3?N;,QEEH1S%,2,RG_`!:@22"B!5$>4C%#Z_N!
M(!,'])TP!T`%#_,`\\>/:(&_\.`_?6L39KZ<5*V\Y-RMGV[HQEPS-D;(N0+%
M"20%_$Q>/JI9;7+2K"-KY7"*9@G7K!TW--RXD^LG_P#1T>HBV!R=T&+?3!],
M2!VG0;7+65$(^Q;@[#%D()120>16+8]Z3WN(&NN1)RXGETC$1GY](2`*@*QL
M>!&A%E'6Y``X``^P<:H!0#P'`<`'`=``!X``\!_0-5T#43KB'LR!<@,'8JP)
MR_`^TT.CP'S_`+0"(?R^-2QU%?(9#HY(F2F*)0=U^NO4A^%015DV2I@^1]AR
M$*(^0Z`?]G06V(\#R'C@//'?(^!$>>N/WX#C50^?VZ$1Y#CC]^?`C\`(<?UU
M7O@.0YYXYY^/OY\\?`>>NQU0"AQ\!SX#Y^1Y\\#WP/D1[X\=Z!X\@`"'/'/V
M#OG@`'_</WXXT[Y'P`C^X]]?'CK]PY$!_;5/(B//QY\<<`/(?(<^!'CXY[TX
MXXY'@"\^>`#K@0[[XY#OOOH?YZ"H]>`Y$!XY$>!^1^X<AX']PY\>=4Y'@!\_
MMR'D/(#P`@/(?'CCGD.>]0VW`[]-N>W&P)T>X6*;M6254DU28RQE`.;M<T"+
ME`R'YHQ9'3;Q)ER""B:+QR5X*?\`B&:E((".**5ZIFV.QV2.J=X995P-*3*A
M$HAWFR@OJA7WZR@^U-()XBKMJU,J(@4IGB:3<!$`573`1,`;(/:`_P";L>``
M?G@?CQ]A^_7@?//-N3M,IUH=MWMHI]2LSUKQ^%>6.LP<Z[;`7_("#N6CWCA'
M@?\`*4BA2AQT`#QJX4E4EB)KHJ(K(+I$61615(NBN@J0JJ2Z"R1CI+HK)F*H
MDJD<Z2A#%42,8A@$>0"`#QT'[\\!P'/9N^!'^G]>]!P;HI-6Z+1NBDU:-B\-
MVC9))LS;E``#VMVK<B;=`.`]OM22*'L``#]/0_4A/JF*3G@3J%(`\"/'N-Y$
M.?CD1\@/'7.H@[A-\6`-MLLSJ5PFIVV9)DTR+1V*\9PJUTOZS93DQ';N)9J)
MHQ+;Z93K`,BX2<G2(91-J9/@XX@HOJG;6['8T*O=E<C8$G'!3K1Y<YT=]3HE
M\5(HJ@",X51XS(<Q2<$(Y(B513_"!7W"`&"-M:I%P]3;*>:K->,K9&QSMEP]
M?G>**#C7&E@4KCVVV"&1!:7LUJ?`5=%<QO<"I#+,UE2_719,S-D6QSJW338#
M(WI_[I,%X@1RM=<L[9-T3Z=I-7@LC2JTY:<79"A6S=\@I%21Q!(T0]&0:`Y!
MH@V0=M'!TEVY7C%-RK'#;OE'<C6\K[C\K;&=O<_G#:7D3)AI-O!6=XUJ;]W=
M@9$)/V+'9EGC=VXBA="NDN4Z3M$&*K-)T1)\F()S%Q-AS=+N(W'4+<ONYI\%
MAVI82;2ZN$,%1,NG-2[6V3"8-GMNM[E)5S['"2:22Z8KNQ5<JH,V:#)FR:G%
M8-IOM`X`(E*/@>1`!'G@>N!#@>!_E_?O5`*4/!0+P'@"\!S]Q``X#^H#U\AK
MF'QP(\!]^>_=SQSS_P`?D=4^.>OU!P)A'K]^OOU_(/Y:`(B''8CU\_/?Z>1$
M>@_W\=#^U0Y\AR/8^!Z^_`@/0=?OT/[ZIQV`=<<\@//DH#XX\<]\_P`OZZ<"
M`CQQSX#D?MV/0!QP/V'C@?MUH'/'''/`#WW]Q$/'CC[>`#R.JCY'YYY`0$?M
M]@`.?//''/']>0=<<!P/V`1YY\#_`"Z'P`]\!YU0>0[$..P'G@!_?@.^?/(^
M?Z``Z"O(F^__`(>/G@.^!^!X`?`]\ZZF=X"%DQ$>@:<>!Y_[5(..!^XCT'0^
M..O/;<\`/7D1'Y#CO^?SR'8<A_+CG76S"9EF(MB@(G>O(ID4I1'D1<RS)(0*
M'`CR*8G\=CP/7'.@FFQ[9,__`.U0\?LD0/\`X_8>M?JUP3*4A"D(``0A0(4`
M\`4H>T`^/@-<]!YF/5:]/'=;N8W6'R7AW'C"S4XV,J17?S)S:8*(4_-8=S85
M)!M^#D%TW'M1(^:B"H!]-7Z@@4?TCK6M_P!#?Z@??_R/18<\\_\`\?U;V]_^
MK^*\^`#L..O@.!]Q_`?8/[:<!]@_L&@\`&X'T^]T^V"CM\CYGH+&K5%U8(^M
M(2#>T0LT<9F3;O'#-L+2.75<`59&/=F%82E23^D`&,`F*`WIL`V!W_?!D0[-
MN=[5,1U=PW4R'D,6YE`;)J")DZ]6BK%!M(6>0(4023$QT(Q`#/WI1*FFBMZY
M]^^TEWO.Q=1<0A/I5F`;9@J5QN<L`>Z12J<#&6%&2;020HJHK3+Y60:M6GXG
MV-V_U5'BAC`W!)62N'L.X[P-08'&&+*PQJM/KC4J#-@S('U'#@Q2@YDY)R(?
M6DI>04**\A(N3G776-QR5(J9"!SP]B''N"<=5G%V+J\SK--JK!-C&L&9"`HX
M4``%W)R3@"E/(2\FO[W<G(K^YP\<J&4.8"@0I<F#X'^0Z````````!X``X`/
MY`&@CP`CP(\?`=C_`$#00[EAXN=^#Y"UG$0#H>!B(T0Z'SR`@(CT(\]?`Z^0
M`(CU\^>?`_'`]\<_<0#K]^==G:FWX/(%W3'])7+J#DR==F_%0Q45!'@!Z^JT
M$GNY^!\#UKJNB\#R/GD!Y#DW///`<\?;]Q#S]]!4/COL0\"/(B'_`+0!R`?(
M??\`;O01#@0`.>N0^W']?/'/CCH0XT+QQR'QR`<AV'_AWS\<?;^0.>^>>0Z`
M>`^_G_W\?`>?'`0%]4+)5CQ-L#W.7&I.'3*P%QZI7H^29J*I.8H+9(M*^\DD
M%4A*=%5O'O7()J%,42&4`P&#7C5ID,S@*K`Q;$A2HH1K54QR@`"NX<()K.'*
M@EZ,JLH<1.<>1$`*`B(`&O>9G;#U:W!89R;A&X`H%;R?3I>H2+A`@'<,#2+?
M_495J41X%U%2*;5^B4>`,=#V"(@8=>!FV.'&W;(ETP%E.;@Y*;Q;//:I_&]3
MD$K'4IUJP5,FR<$E8[ZI$7`H`FFX15*51NX*=HX*FX04*(7^<A%"'34(51-0
MADU$SE`Q%$SA[3D.40$#$.41*8H@(&`1`0$-;S/^3Y72=3@-VN%E7#AS2<?7
M^JVRHD5.HHC$.K>S=L9J'9`<QDT$%1C&C\[=,"@*R:BI@$QQ$//*IEVH.7#6
M+K*[JX6"4<(1\+!5]DY>/9.3>'*BR9(A]-,!4<N%$T4RE$QS'.!2$,(@&O7]
MZ1.TBW[4=KBB&5:RA6,R9=MS[(]^8*.A=S4:@X:HLZQ7IXXE%)E)1$<"YWL8
MW453:N'9@5.9S]0I`VG^WQX'OR(\#X'L/OXY`>^/'7G0>`$.A_\``/D1#K[?
M`>>.^]4*'(@`![A$>``/U<CT`````CR8?`?/0<";C4#\T>HWMKPU<7&.2O[C
MEC(C`XIRU-PO5W%\?P:Q/\[>:>M%TXQD[+T*C5-PZ61,(D7^BH!B%">B8$%0
MOUE/II`(F45`.?IHI@8ZZ@E^132*<X!X$0X^1'6D#%V(K;ZG,GD;.N8\O9/I
M6#XS(EGH&%L08OLBE:9IP]0>#'N;/9')BNTG,I(+>U1<PM#.EGHKF!PBP3;-
M2RIH'JE[4++,.8:XS%TP3/Q[)U*?E6<Z7)4TC]LP1.X=IQSU,7[=^Y,W2-]-
MCP@N],;\.U!5<Y2#K]VDY+W<XZ+E^V[2ML%CS=M`R%EZXV?%<1;))I4[E&B^
M=B:2F*VC^-167JCUT!FH$6;.D$U&Y"@J5\1V<0E+A(F3=F6[VD[4)_*5KS%@
MO/-.L=@Q1(7Y\I*W''EHJ2;A5S7CR1U#?6BGB#8$%BI)H,E`6:NT6K5=)<%M
MN("!@`?^\'(!YXZ^!X\_</YZUC;>\([D<H[BT-W^[J!KN.YJEU.3I>$L*UR1
M)+_P:TG/KA,6"R/"*N2_FYD'*I&X'>.'2[I0RJZ;5LU;(&V;!^GH..`#^0<=
M!P'[_'/WYZYT'+C@.!'CGX^?Y=!W]A'@>?MJ@<"(<AR`_/@.0Y`.`ZX\#Q]^
MA#CQJO8_8!$/=_8>N>?Z?R$!^^J!R(^0[#R'/7`AY`.!#W=CS_O#QH'/R`&Z
M$>@\!QQQU]A^0XY\]]=UX['CCKR'`CQX$0_\0Z[[X`.].A#OK]7D.N^1[Y\#
MT''/?'G0P>1\CY'L```^.0'H0Z_KQYT`!]W(>1$.^>>@#X\_'QQQP'[AJ@``
M`("`\B`]<<C_`$$`_E\\=]ZY<A_+G[\@/(\\!T'7?(\\C\_`AH(``<@/7?CO
MSY\]^>NA#OY^=!U$P05$6B28<G4?$`@#QP/M8OU!#D>>?TD$0`?L/?0!IKLT
M&)Y*?JL:F7WB\EWHF#W!T1M6K`N81[#H#@F'?(")@'SWIH,RYL9%_**[.B!O
M^H[(S*K[2\@#6:35AE3'-_LIIJ.T#F$?T_I`1$.-8>$!`WM\<>>?("`CUWWT
M(?OQ\]=#*BW0I;'6)R#-P!I.-<M4#CW])THF/X-?]A0=`BL`^0$G/QJ)$8Z,
M\8-G"H"1<4@3=E,40,1\U.9H^3$I@#VF(];N"\??OCO0?N'XXYYYZ'CC^_0=
M<<_&G/CCSR/'D/'`CSUT//?777SQP+QWSUY$.`$>_D1$1YY\#QJ@"(#R/?R/
M''CO@1X#CH..@$>N^!['08PS9D0N(L/90RB=`CLU"HECM+9JJ`&3</XV-64C
M$%2C_F05DC-"."AQ[T!.`"`CU!STU<'Q['&$?NQR`FC;MQFY`KO(]DR#+I)O
M):$@IQXJI"5NM*JE,6#:D:(D7>*L`2<*F%LR*LDR:E;C/G*%$C<I8WON.)<P
M)1E\IU@J;I<Q1/\`A2S<:X9HO1*40,;\$Y.@\`H"`F%'V@(<B.M7^R+<K![?
M(9#9!NEFF&+LLX:7=5ZC3EK<A&53)F/U7JJU7D*_/+D(R^NBBM])!-THFF]:
M'3,1<JS=9``VFY%HM0RW3IJ@9,@&-VIL^U6:2T%/D%ZW5(L7C\2T55$R\;*-
MAX592C!5L]9N2)JIK<%,0^HS:=G/'NRG).XG9IF[+D37:%B:TQL_@6<O#]4C
MDU&N*9Y%2K&<HMES*'C2K,WB*/L*F@87OTBD(L"8;#,S;O=NN!ZF]MM^RI4?
MHI,U5XV`@9V,G;/9'0)F,VC8&(C'3E5=T\4]B*:RPH-$/J?776`B8@,2MB>)
MYS)D]G+>+G7'T6RGMRMCCI#'M,N$''33VIXL@TU$Z^*J$PR7*U6EDA:&0,""
M*ZC)F*R@%(Y*709SM'J(;.H"LV6>CL_XVL<A!UZ;F(RNL)9XH]L,G&1CI['0
M30HQY.5Y=ZBA'I<F*`"OR8Q0#W!@STU\'Q\G1&^]/*""-QW&[C74I?GUUE4R
M.G-5J\I(.$H*O55,Y10@RE9M_<[<LDTW)4/PT>W609H"D>?-FPKB>V5NR561
MQU0T8^SU^:KKYPRI%6;/6K:=C'<6L[9+MXE)=!XT*Z_%M%T5"*HN$4SI'(<"
MF#63LKW&16UUN&Q7=5*ML;W_`!2^D8S%]TLBH1])R7CE[(KNJRO#3RQ2MD7*
M2*IRM/Q9R(NT#@B9PF\;*H:#;+=:I6<D5F7I>0(*-NE2GFJK.9KME0_,XU\W
M72,FH4Z3@QCME_88WT'[%5L^:GX5;.4E"E-K5QL'B'NW'<;NMV-(N5)#'5,<
M0>=,/.7@I*RC&KW\6+5W"2+I-)$7ZS=)>-$[IP4ZIEV:YDSD0<?2).'+6Z_;
MKA:KNK;D#+E*8QR#15RUCXJ>C9V?FCD3%0C."AHETY<OWSD`]C<AOHM_>8!5
M<)D]Q@B'L'J.0<DY,W`[ZLG5Q]2U]Q2D%`8@ITN!?S6%PO6A16@)!V'M3%$)
M;\.R2:^Y-,[Q)HXD2A]!TA[PV@@4I/!2E``YX*``(\??CCL`[X\#]^-5[Y`1
M``^P!UV(AYY$.>0Z\CI\&`1'Y$1`/_/GOSY#CQIT'/("'(!Q]^NN/CQ\?/SY
MX'05`.>@$0``#GOD?GK]AZ[#^7VX$'?8<@`!U]A'D0[\\B//`]\C\>=5]H!T
M`\#USV//[]<^?/QJ@=@'Q\@`\CXYZ\@(\"'(A_(-`ZYXX`1Y'R`<\??_`']>
M1$`Y^=!]W7COY`0#@>^PY`>1$.`_OIT/GY[`!XY_8`^WG@/GSQJ@F#Y`>AY[
M#]QZY^._^`AH*^!^`Y[#KY#R//'7'QUP/.J>1[#SQP''SWV("/'P(=]C\<:H
M`F'QUUV/'/?(#]OZ<<#YZXXYU40[#CKGOOQUWUQV''(\^/VT'R*Q/,RM;A"!
MS^:V.)!<O!A#\!&KA+/S"!>1%,J+$$SFY*4OU"\B'N#F:!>!`!`..?U<?^UV
M/]1$>1_?4;<51?YE<Y"7.F)F]9B@8MU!$?:$K.F*LZ*'/E1",:M@.'8`#T.?
M:)NY)``%#@/`<\?L'/0?T\:"NFFF@::::!IIIH&H\9@9E;V2KS`%,4'["4KR
MQ^_:*B`IS#,HAP`#[BI/0*//)N1*4.0'4A]8TRS$JR=)E%6J8J/H-1M86?7Z
MO?%*@X=$3'K]2L<#Q#C@>06]H`(B'`1_$>.NN0'X`>@'G@0_?L.N^?'D>@<?
M<!^_(=?8>?'`C^_GO^6ODDJ5=--9$PF163372,`_YDEB`HF//SR4P<<_OXU]
M0`>^!Y^!\!_7D`$1$._/SS]NPXCV(``=?;CR//?`_P`OGGQUUJ/VZW,[C;QM
MOS'FEBT1?2E#IKI_!-7)?>U4L4F]95^O*.DN?\5LSEI5J_<(CR19)J=`WZ%#
M#J0(>`^P#V'?/?\`;H0'X_GWWQAW<)A^-S_@_*.&95R5BVR'49&!1DE""<D;
M+%,C(P,DJF4P&,DQFV+!=P!1]PMRK>T!,(!H(S>GIMKK^',-5G*4VW+8<^YM
MAF>3,I9-F`*^M;Z4N:(3A(1E++`9>/BXYL](FJ1B9NI(NU%W#Y18@-TD9=9=
MQ1CS.]&E<<Y=K3*ZTZ80.FNPE>57,>L)!^E*0<B)OQL/,,C\+,WS!9$X*$*1
MP#AL=9!37GLGW@UBN5&$VJ;EYACB'<;A)DUQW(P]W>IQ$?>8>`2_`UZRUN;=
M&2CGYGD4DV*LD9=(')2(O&:SA-P<$I19\WK;=-NU4=6.Z9%KDQ*`W$\#1ZG,
M1UAMMJ?FZ:1T9'QKAP"!7*@D(L_>JH-VR)CK?XIRD24""NR[=10-M*>:]G^Y
M#,T#".]LV4I6CXOM5T>KM7-GQDY][N%C2F1;.A.:M$%--NF;V"W92)&H"9)N
MB5.2^7_4=VKT[%>0[51<YXUN-W@:?-R-1JT?(NW+R=LB30Y8=@D@9BB18#OC
MI*JD%1,#()*%$P<ZL_8/M]F35?*6X;<-1(`<N[I<B/\`*3^M6:OQ4PYI-07^
MH%3@OH3#)T:.>.&C@7SIJ1-NN@V"/2=%%3E-.6^7=NN,,IXLR%C8](HL'_'%
M1G:VC-L*76F3V'>2+-1-C)MG3*+0=H*,WH(+B=NLFH*93@40`?:(1D].;;I#
M8VQ'`9^LY@M>XC</"H9-R'DV7*5Y8D4KF`R;.L0\@<!4BHU%FJBK(BQ%NO(N
MUU4'"QH]!NS2EWG/"&.MR./9G&668)K98*8:JH,7KM,JTQ690Y3$93];E3^Y
MY%24<X.5RD+=4K9T!3(OD'**AR:U^['-UL72(&)V:;F7K7%&?L(,B4:));7!
M8N"R73X4%@KL]6IYV"$:X<%C"_2!!19(C]BW;/F;A94RS5*3.XG?)@';I5W\
MI)WBO7&\J-SDIV,Z?*M+!:K5.+`*44Q3;Q2CPK!BJ],D#Q^Z.'TD>?HH.%CE
M3$,&^E[;K23$V3=O5X<(2,]M3RO,XG92:+=%`DA55Q<3$(HH1(I$A7;*&?)>
M\2`H=$Z(+G56(90^S,`_[H``>`$H`'''SQUY^P#QP/'>M?\`Z=.$+_BG$%LN
MN8&IX_+^X+(<KER[1BP<.X$DDG^'@8-Z3GVIO6[$3/'"``46AGB;50/JHJ<;
M`N0X\\?<.^0Z\!QXX^>O[:#AQSS\\AQW]P`/T\#^X<B/CR'[ZKP//SUQST`C
MWR'V`!``Y`..?V#O5>1Y_;GGOR'Z>>^>>`\_\`T$1Z$`_F'V]H\\=>/VZ_\`
M=H'`B/@..0'[\A\]_P#@(=_R#0>OD.@'@.^@^.?U>!\?SX#O5.?(@'QSUR`=
M?VY\]]!QQ_751\>1'D!'W>.0['CY_GQT'[]:`'R/9>_U?T#GD0X#OD?Y?(AV
M(:!V'VY'K[`'?0!XYZ'^@_TU0.1`.PY['L.QX_OR/]`'KYT$.1'P`=<B/0_?
MGGCKGQ_NX#X`'?(\^.^@`/@>^^?/SSV(=_;7Z81L:2N-+BRD.<BDX:5<^T1'
MV-H)HJ[`YQ[`"&=G:$Y'D!'DH"!A+Q^?KL/<''/V#@`'L0`>?G_PUD3#T8=Y
M8;)8%`]R$6W:UEF)@Y_UP1"4EE$A[```KA@V/\^Y$P=]\!(8O/`>[CG@.0#P
M`\!R`?MSSJNFF@::::!IIIH&FFF@C9E=F=K>(Q]^DK>:K*[/D>O>^AGY7)2@
M/(`)A8OUS@`@)O:B80Z+U8X_TX$//`\@'''8_?Y#GSV'VUF_,L:9S5DYE%'Z
MCFIR32;[`>1CA]S";]@AS_V42^<N#<_IY;_]XH"&$.0^#>X``1Y`>C%$.2F+
MUP("7]0?S#D=`$H]>`XY#OQ\<#P//G^_(ZISR/(]?UY\?(!X_P#9'QSSY$0T
M$>!`>Q#G@?'7W\=<]\\^?C[ZH//@0'GL>/@`_IT/`\#^_0<\]:#7WZF68;SB
M7;#(1V,W*L;D',EN@<*56;;'.1U`+70JZ4G,-5@$!;O48TBK9HX#MNHY%=/V
MJID,765??2N0Q#5F-%AZN:1(S;(A.S3F,,Z7L\V"0&DIAVX6;J@O^*=BJ+=`
MIA2;(^PJ0`;WG-MZWRX&G=P>`)NLT\Y29!J,Q%9&QZ4P@3\3:ZL*J[:.(H(E
M(DO)-SK-6YSC[`<BB4W!3"8,Q[4/4%P'N+I,57<CV*O8[SC7&241DC%V0UVM
M?E(RRQ)2,I1U$A+_`(=%_'/729UT`05!VA[S(.6R8I@90/,\U],=Q<HY]!(5
M96'D3IKK0<M&1BL>^AYI),QX]^V6:((J%,DY*0%"B;@4Q,(<*%(8NTK8UZB&
M*'VW.H0FYG---J&9L?N9/'=I+:I%RWF+$G5%2L(RTKD39KE55D6A2MG:XG`[
MEXS67,4!4,(SSW<[]=OV`JK*5+$;^M9-W#7-DYKN.*#CLS*QRA;%+H*,XZ3E
MUHS\0A'L63A8C@4Q4.[=K%*@1#V&44+BG9SM0KV#\"U6I9`J%.L.1)5>0N%^
MD)>M5^=<IVFRK%>/HM*1D6#M91&*("3,PIK`@=P1R<B8`;W&"/.\SU#\/1^W
MBZ1NW#-](MF9KH[@<?4]K6Y)RO,0G\:2'Y1+6EI]1J@FBM!1IU?P[CWB+=V\
M;KD()TP,68VT_:[C_:7B^)I%'C4269TR;NL@W@Z8?Q/=;,Y3*O*.Y.5[=?@$
M')U&T;%I*$9-FJ*:ATE7:B[I7'6]3:A#YUVX7RBXWJ5,KN2&ZD+<\?2415Z]
M!NU+=2WPRD9#_FC!@S7;-YP@N(TXG6_#BX5:G73,0@"7H-J>_+%^:JRQJF1I
MV,Q1N`J:*<!D?&=[=(5F52GXI,C-])0YI8S5N_82!DOQATBJ$=LUUE&RB)B)
MD64"0&Y?;3CC=KC.9Q?DR);/UI%DZ0J%J51!6Q42RK(G2B)^!D1_UM,&[PR'
MYA%G5/&RK(56SMJH(I*I1R],_)UGOVV5M4;T9!U<L`7BU8!G'J""2+=^CCYT
M5G!.4D4B$2)]*$.U8*&(0AEQ9@X5Y755.:Y=SN_/#VW^L/F=7LT-DW-\RD:(
MQEBJCOF]GGINXR!!;01I)&).Z3CXEL_5;N')U#F=.@3!HT:JJK>Y/]VP+`EJ
MV^[=(B#R'Q_I1OUDL>6,G)^XJAVENO#K\<K%KG((@+N)CP9LY`"#]-.0*[23
M$P)@8P35```./:4H!X#D`#H>@X^.0#S\\?;50[YZX^!Y$1'@0_W<@`=\CXZ_
M<(]?JX#@`$1$?''SQ\=C\B']>PUQ]Y1$/U`40#D`$>.>>!^X<@(<#R`#Y'0<
MC>`Y`1#X_;R/`!Q]N>0'@.`^^@_)O]_/770"`>!_D(\@.J=]^/`@(A]P^_/`
M=B/V'KQQYU0`\`/0!SR'(<\]CXX^>Q#SUH*]<=#UQSST/?R`%^/N/P'(\_LX
M\``<=_(@(^/(=^0Y_?CH0#O50``XX#GH?D.>_/R''''']?VT$OVXZ#X'L!_D
M`<?''0`/GY#0"\\<CWV'SUUP'///`CSV/\@#CP.JAS\^`YY$?M]_MW_N`.!U
MQ['VAR''(#Q\A\#WUV(_[Q'CP.N0!V'`B'(@'ZO]H?`=^0_?KQQUQH+GQPV_
M'9$:&%$5$8.O24D<_P"H2HNY5PVC6?/'^&)U&B4GP4X^[V"8Q2]";35]X5C1
M"$E[$H3_`.LDPL=D?G]0Q$04L8Q`>>#>U1PE(.B!P`>UP!O]H!TT&:!`!Z'_
M`,_^X0^!\@.HI7:$/6[K()%$`B[452?C``@E(WD$OHMK"Q((?I_4J=G+)%XY
M_P!=>F*!@(80E;JP,D51:UUTZ4?](D[$N"2\`JKTF$BV(H0S58P?J!M(M%7#
M!<.?:`+D6$!%$`T$<Q\"''S]@[\!SQ\_'CC[\@(\:`/@``?G^8#R/0>0`>Q#
MO[ASSXU^-D[(^;IN"D.C[A437;JA[5FCE$PHN6BX#^HJS9<ADC@/R4#!T)=?
MLY\]@`!S_P#X\>1X'GW<_'CK]]!7D0#GQP''(\]?S\<\CP'0#]^1\:PYE_;Y
MA+/L4WA\R8QJF0F;/WC'K3C)1.4C#*`(#^5SD<X833$H\^[Z*+\&PG`#BB8X
M`.LQ"'?```@/QR/VZ#CP'CD!^P<!Q\\>!^`[$W'VZ'OD1$?:4`\B8>`(`>XP
M@'(Z#1K#[2=N^!O5"PS1ZQC&$/0[[MXMUL@8.TJO;@TB\A564?\`U9M@:PKO
MN70(1H?AT5@7;M`4,=-,#\'+O,```/T@`%```I2A[0`A0X*4@%X`I0```I2@
M!0*``4```#6A7=+O#Q.^WT;8<CX?0N.<O^;BPRC6,M-L45A[8$4&%K370090
M\L0"L9ART=NGGXPY3),$`3$J+E<1$0D[.>K7MO\`]'\Q)TR.ODUF-%\TKE<P
M#8*F_K]^F;;*#]"-:J))B_:DA0="3\PD$'!G92?X+=F*RQ#%"4^[#=C0=J&/
MT;+8TE[->+,O^38OQ9"*'4M61+,LJ1NFSCFK=%TZ;Q#%4Y3RLN+4Y$P*$:Q!
MQ+.FS;40L,["W><'T[N$]0B':Y'RYD:*!I%8C=.7S2F83J2AA6BJW&(1$BBL
M%C9MS@5;Z<BJC$J'4(LH_E3N71;^VH;3[^?(+S=YN\>MK9N9L[7Z-3K'Z7%5
MP)5E@#\'`U9F85VK6R@U,"#EXS$H0P*NTD5'4LY=26MDG7/[`'/'/'/DP`''
MV'OGR(B(Z#7BZ]*W8XI7;7"1N&642_LT#)P:%H<6"USLQ5%7[<R2,S7BRLRL
MS:OHY84W*/O;.!.5,R(\E4-KH/3OS%<TXV_;.,X+$2SEM4=H51%PN"A%;[B5
M(R;:G7)D=<1_,$VK91JP.[1,?Z\2M#/%>#BX/K9<`"'`\]#^WCGOL1'H.?/?
M?\QUJ\]0*AVK&=FQGOZQ%'JOKYM\,6&RK`LP$I[]@B4<"WFV3HB)`.Y7KI';
MO_'7%;\)$N4EDP`L2D4`VB``]]\B/0<_RZY^X\<<]"/]-<>0Y#OH.?WXXX[\
M_;]N`X'@!\ZU@R/JT;:7*C-IC>K9LS4^5BHZ5E6^,:`O*MJ[^/9HNSQ<K(O7
M38IY..%4S602;-CH%<HJ@DY4*(&&1.W/>U@'=`^E:[CR?EXB^P3<[J<QI?(5
M6K7J/;-P`'3M.*67<I2+-F<Q2.UV+E0[7GZCANDB/U`"6W'(`(^>0[_;KO[%
M'@.1'D?MJH#]Q`!#@?=X#P/8#P//(==@`<_/C5`'GH.O'0]!R'?`!Q_<>^/C
M[Z>.>.@Y[$?'[@`?(_'/''7'G0..`Z#D>0[,'?\`O^.>.1X#@/'?.J<<=#SP
M(_/`B(CU\>/GGOGCQH(^?MV/?/\`F^WGX^>>N?V$-5Z#@1$>!Z`/MWY[$1'G
MGCG[?`:"O'VXX`?L/8#V/`!QSUP'SSWU]_RNW*+)JY=K\_2;)F5'@1$3^/80
M@!V*BJAB)$*'(B<Y0#D1[_1P`!W_`%`?GCH.!X#P'R`<CX[\:[VDUT]MM2":
MR0F@:NNWD954?\CR9*4J\3#\"'!TFY%"2CXH\@(_@DA`IO=P&;,85U>NU5J2
M0(!)F544FIP/]HDB_`H_AQ['@&35-LR*`#QPA[@\ZR'J@``"(@``(^1``Y'C
MQR/SQ^^JZ!IIIH&FFF@::::!KYJD(JDHFH4#)J$,10@@!@.0P"!R"`\@(&*(
ME$!^!U]-/.@ADZB%*Q-S%67,8Q(M<',4=00]RT#(G.XCP*/'!Q9&!:.5,'0&
M03`?:)B@(``!YY'VB'V'Y$?//VZ#@0['C]]9IR[5W#V/:6J(;_7E:TFX%VV3
M)[EI*O+`5239H``"8[MN9%*0CRCR`KMS(]?7$=84162612<(*%5173(NDLF/
MN3535(4Z:A3<]E,0P#V///0\"'&@^@CP(AWR/8<]]CS^W`!]Q'C^7>G?(]#\
M#P`]!X'YZ]P#WQT`AV.@@(=<>```'G]P^1[`?L'(_''>@\`(>0$?(!WW]OM\
M_P`N//`"&@P5FC;-@/<*V:H9EQ55+TLP2,WC921;.&,]'HF\)M+##.8^7(DF
M8`,DV5=KMDAY^FB4!,`ZM<$[8L#80]46_8U@,;0)ZO\`\W*O9"QJSLX+6Y6M
MV1&1B23DE$.K"=\H+Q5()`H*+E7%H0YBM@2,0JA=W+AP@S;.';IPDU9M6ZSI
MTZ<J)MVS5J@F99PY<KJB5-!N@B0ZJRJHE323*8YS%*41#0)E7>?BG_I$,>YV
MP]#9$SG2L>8=N.+LHO<54^0F$S24DM(#$C#/5RHMI1HR.NBH[<JBW2_P3E:&
M6`2G$/0$/(C[AY$PB(F$P\F$1$>3&$>>1,//(^1\\]<:AON]W?U?;!78B+CH
MI7(.<LA*A$XCQ##"L\G+/,.3_A6LC)-&8*.V=::NS$*NX]J2\DJ`LXX1'ZSE
MO'2V^J]@Z2Q\F;`\7:\CY_LTX2DTG!$S6)&"MJ-O=D*5!Y;68&<(-ZU'J*`H
MLHS?*+22B9F(?EY#+.T<E[0]HEAH=CG=RNY&70R'NNR00',Q+.`3>Q&+(IP'
MO1I5$(K]9.,/'H&)'N9".,BFU;I&C(P2M`67<AB[$?IR0.1&5HROOR:)YKSW
ME=%FZFHU>3DH^OXBC4CE=,:;2SP,BU*D_B1_U5Z^:KK1B*)1C&*"Q?Q;YWV.
M7/2KVT.\.W*"P3CAGC_+I$$;'CO("<[8I2QL;=75!DH../)3$JY31BI1RF5@
M[(F@D<AE6[@%BBWY-M'X``$```XX#D1X[`/CR`<A\\_I\CP`:IXX#OCGD!#S
MX^.!^////GP`AX"%NQ/<P\W*X53?7%'\IS+C>47QYF6M."?AI".ML0)T4I=5
MDIPLBA8V:`/!-[12"33D&Q3_`.&0-32Y,`A]A^/'']_`C]N>^_GO6HG<T1SL
M@W5UK>G`L'9\)9J-'8NW20L6F((Q4JL<B-5R45ND3Z0*IKIMUU3F)]1S(LWB
M!E0&6YU>LMZLFW<).30H-#S[E^N0KIPTDK[CS&JSRGE!JH8B[ID[?O6SI^S`
M"F4(H=NR.<@`()E\@&T'Y\\]AUR'?0>1ZY#X\?TYU7^H?/`>!Y$>!$>>PX'G
MCCO]_.H^[?-T6$]T5<?63#=M_/2PZR;>P0$DQ5A;967*O)44Y^`<F669E6$I
MBH.D5W+-8Y13(X^L`D"00`40YX']^.?D?[CX_?COSH*"/8]<\!P`\<<"'''(
MCP`=B/(?L'6J\\@/V'@/MV(=A_?CL>N_D.A?'!A\_<>/`\_MY#X'Q\=Z&X\=
M<<\!X_KXX$/;QQ_QT%.PX#YX#XY$/@?'`?8.Q[#S^]1\E*'QXY\?/G^7`<?U
MUQ`.!_[O]?ZAS^W'`=#]N^>>.78\F'[#QP/?(^1Y_P!WSR/(A^X?D?O!8,W#
MPC<[M5,A0;-$N15>O%5"H,F210[.J[=J(H$``$>#F-P!2B.I24*N&JM7BXA8
MP*/BHF>RJW0BM+/U#NY!3WAR!R`X6,@D//Z444B^.-81QQ`FLMH)++)":$J#
MDQDCG+RE(VHR!DT@3.'1T:^U6545,(&#\R=H%#];,0U)_@.AX[`.`'[!H*Z:
M::!IIIH&FFF@::::#\SUHW?M'+)VD5=J[;KMG*!@Y*NW<)'161,'(<E424,0
M0Y\#J&X1RL`[DJNY,8Z];<_@$U%!_P`9W$J$^K!R!A[`PN8\2IJ&`1X<MG)1
M'DHZFCK!67ZTH1-I=V*9A/#-S,K$@D3DSN`44!3\;[0$3G6@EQ.[#GWF%DH]
M(3L0#08J[#O@`#OD.?(C\]!]^O[^>M4#KGX$>?TCV''D```[X^_WX\==4#@P
M`<AP,4P`<HAP)3E.`&(<O8`)3%$#E'Y`0']M#"/(@/0>0X^!XZXY\]_^0#G0
M/^Z`]\_8.N^_/CH.?'C^FHX9<VB;:\ZR/YWE/$E9L5@*"93V1K^85^QJ)IB'
M(+R\`[C5W8^P!(*CTKI8"\<*`(`(2/\```8>QYZXXZ``Y`!#XZ[Z#KSKH+9:
M:U2*U-7"Y3D;6*M7(]>5GY^9<E9Q43'-R\JN7C@X#["\B5-)-,IUW"YDT&Z2
MJRA$S!J3].'$.-\9[B-^E(CJ9#(S.+LX,6-&EY)L$I8X"A3$<^581;"7D1<O
M46WN2;',Z2.F\<&$3G<&*(E'<8`!QWUX``#D`+USUT/?0"(CX_IKSU8VWS8Q
MHF]+==GNIT7-.3<&9?A*`R;W"B8]?.VS:S5!JQ;3TNX0>*M4U(DYD'PM7`+)
MNW"9TU54$/>8H2PR5ZDT5E2(J6--AC1?+N?,I(NDHXLG#/(N+Q!&(B9&5LM\
M;R!2MV\E%)BHNU9F<K,&WTBR#APZ*5%BN&6MWN\&?H-CA=M&VB'2R3NXR(F1
M*'@&X)NXG%,,[(!CWB^JF$&3%1JV,,A&QDBLDB@@0LK-%3:&:-7]G8S]+#;N
MWH[E+<+#'S_F2URJEHO^5YV9L<=,.K$\`3.FM<7CI-DLSA&W/TDP>%<N'ZI3
M.U`03,BU1SQM"VAUO:Y5Y=[(S"V1<WY#=&G\OYBFP,\G[5//!!9Y'QKYV"L@
MRJC1R8XMV9EP4EER!*29?KF0;M)A\<]B'?(<_``'`#\]\]]^1Z\\=:#5#GST
MQL,Q&%YF2VGT!'&VX/'DC'9-Q;;XN6G92SS%KIJJDHUJCB1G)9TF*4ZDF=JR
M$J:)$95-@)@4345*:7NSK<>PW2X+JN1P2+'7)`RM3R=6/;]%W6,CP(E9V&/=
MLSE(HQ)(JD":CVZQ0!%D_(V,;ZC58"RA`Q@$#`<2F*`&(8H\"!@$!*8HAV4Y
M#``@8!Y`>PX$.=:--VDS.>G=G#)N>ZHF+#`>[6CW.&O1&_O1C,;9\;567/`W
M-%N@'TVY9UZHE)*K^PAW*K^6:D.!FZ/(0J]1WUS;_"91MFWO8]+4JJ15!GPI
M.3MU%UC1L<4SOAG*[-:F8L@3I*L)209.FZK12=>-Y1%\Z(H#%LU:HE>.-3\#
MZJOJ<4912TQ6]2Z7.KRU8<3*\WE+!T)*T]L^"PC")1<:P:PB4Q&2ZTDD9-,I
MD/PR,8LHX,0Y/8H&O+&LTG&8ZK\PC,V*,?2D&Z5/+OZRA;Z"MDJ;M:G$B]CB
M`>1>6Y`Z8`BOP!6K=1%7ZI0$"FNAP]/+K*JP+^P1\D_ND).PBTG,3[^63LMI
M9N82RDM>/VZOUJO5#(1SQW5B+.W+5%RLS<D`P*>T@>X#TH?4B>;]L<WF`R?5
MXO'VY'!TC&0V5:I#'6""FXV62$L)D&KM7:BSEI#S;IN\:.8P[AY^6O4B"FX,
MV=(D3VR]=>0\^W[=AYY\^?WY\<!KQ4^@*_%+U&['&TU6X+UAQM%L32\*W$C@
MLVN]@K,@G7'DZ+@QE%5UGH$_+W"HF.=!0/9QR(:]JX`'(_L'8=!\\_V$/O\`
M'7/G@`?/N^P]AWXX#Y_?SSU\\?.G'7(?R#CO]OCVB(B/WY#^^J=CUSYZYZZY
M[X#YX'@./C@>.Q#3P'/`\=]<<CV(``?/D?V'K]^]!7CH1$1Y\<AY#P'8=]>1
M'@0'P.OQNDWCH6L/'%,>4G7B42R!,!,9$SO]+E\(!W]*.9@N]5.(E`OTB`)N
M3!K]O(#SP(!^XB'`<!V81'P4/D?`!V/R.LCXAKRDB\=7=VF<C3\.O$5@#A[3
M':F4*,G-$`0Y]DDJFFW9*!P/X)L*@=.0``SA#Q;2&BX^)9`!64<S;LVY``"A
M]-!(B8&'V\`)CB05#CY%0YS"(B.FNR`.``/L`!T'`?V^/Y::"NFFF@C;DZKG
M@I!Q<HI'WPDBH4+6W2*)ORU^'M22L!$R@`_07*9-":``$$P30?>W@C@PV.`E
M$`'DO`\"42F]P&YX]H@8O)3%$!`2&`1*8H@(="7F8CA%-=!9NHDFJDNF=)5%
M4@'2524*)%$U"#^DY#D$Q3E'HQ1$!Z'45KE35<?*BZ;?6=4EPJ4J"QO<LO4E
MUCB)63\X<B-:.;DK*0.(?DX@1D[$[51)T@'1!T`\^>1`0#^?0_'?R'`A^W8:
MUT^J5E*WXQVESC:C2*T+8,HW"J8B+.(G,DM#1=T.]2F7*+D@D.U6<1[11B#@
M@@=)-VL*1B*>TP;%PX#CGOG@>0'GW"/`E,!@_28H@(&`0Z$.!`1`0'4;-V^W
M>*W38%NN'G\@$-)2R3>7J-@.0YB5Z[09U'=<E%P3`518E=&,TDBH<KECW3E1
M`IEB$*(7A@?!..=N>-JUC7&M>CH>-@XEBVDY1LV0+-6>8*U2&4GY^4*F5Y*/
MI%\*R_O75%)N@9)NW1122`NH!>J;BZOUO%T1O!IS%A6\W[>[M1;##6R/:M6K
MN<B75E8LG,).>Q(A9CZ9U$UF"KL#N42BY0!84%1*%O4GU,RX'CF&(]^&,,HX
MSS#5&J4`:X5:H*7"BY72A$$F)+77'+5RP.11^U(V5=DCOSB/6<',Y,XCU7!V
M*%JWJ]9"]46P5;%&-,=7S&^SJ!MD);LN94R3"*5F=R42!>$?QU3IT$H9?VH*
MJ)*$`R;V0_QUTI&359)LTFC@,ML_57IKEHT<J;3=Y"BCEFU<J'98G(LR467;
MI++'9+?C0^LS454.HS5$`][8Z1NO<.OTAZJ-+'L=I>](O`__`(1EYX^1_P#3
MA#G[>?Z:VILUI$B2+6.<216[-L@V;M6CM\=-JQ9H)M6J)"I''VHMVZ*2)3"4
MI>"``AWKZ'>3"(!]9[,(^\`,0%G<BF)BC_M%^HJ03E`/DO0?<1T&JC_I4J9_
M^4O>F/0]AB,G[\>'P?\`#Y`?CJ+&\7U$#YBPL[PKC[#>XG#TWF2UT_&[Z\91
MI!:K7V5:L<VW:6&.;27XE;W2$LQ-^#^A[!`6(O.!`#"([^OS*3`0'\SDO:/P
M$@\ZX_?Z_@0Y'QUP`_'&HO;R,`J[J<`VW%(V!>'LAG$5;,?V)ZX<KMX&^55U
M^8UYTX,8ZIT&#Q8%(V2<H)G6;LW9G2::PMOI*!>^#<(8]V\8XK>-,;03"%B(
M&,9M7+UJU03D[!*%03+(SDU(D3!U(R$FZ!5RH==4Z20*`@@FBB0B8:]/5)H,
M9CO']2WI8[(VIV;L$Y*H!DK3"((Q[^V52VSZ<!*UFP?A2))S*/+D%4_QA55U
M&Z[YHLJHV4!,ELX\]4^MXD2>85WH47(M!SQC!)C7+7(TVLEOE8MIFK1(C&SH
M*1K]J\B5+`T*@_(D9N\8/CKB[:ND$U@;I8WM.:5O56S+6MME"BK%C/;IC=_`
MYKR_*W]!.OY&R=$0\DFC5HFO4PQUC,H1>3<)@5<[UZ*'XL9Q\H1NT:LEPWDQ
M4@E,1D7+HI"W3E8V/E4VX]';IR3)!\1`P"'NY1*X!(0'L/:(&'W`.OVB//P/
M`AWR/''8\#_00X$>!'@/'G50*F0`(DDFBD0"II()!PD@BF4"HHI%'PFBF!$R
M!Y]I0ZY`=.>AY```?V$.1^>OD/\`C_7H*!UT)NQ['CSSUX_^'(AT`:<#\A]@
M#CGG@.^^>.!'X^?^&JCSR'\QX'KH/V#Y#Y_;QSR`Z_,NLJ+AI'L&JLC+R:GT
M8V+;F`%W:O(`9113@Q6C!O\`YGK]8/H-TP'_`#K"FD<.0IR+YXSAH1`KN=E3
M'38(&'VH-TD_:+R5?F$>$XZ-(H"R_/!W*WT&3<IUE_:65E3J["IP;*'8&45^
MB!EG;Q7IQ(OW!OK/7[KC@!6=+F,H)>/:D02()@5-,I0Z"@4)"IMG#Q^H21LT
MJFB66DP)[44TD3&.A$Q29B@=M$,5%%#(%.)EW2YU'KHXJJE31R+QQX_<?[CR
M/^_0----`TTTT#3330----`TTTT'$Q?<''(@'SQY^X>>0Z'O@0$!\&`0$0&*
M5TJIJ/->YND!:C..Q&+4`3>V#F7)E%G$,J`%`B,;(*^]S#'$1(FY.XCC&+[F
M1#2OUULO$Q\[&/8B5:IO8^00.@Y;*\^U0AA`P"!@_4FHFH!545DQ*H@L0BJ1
MBJ$*8`B,'D>>>A['D0Y'GCP/`!UT(?VT_3R/W`!'H`'@>0^XA\\_OYXXU^RQ
MU^0H\DC%22JSN'>*BG7K`Y'W"Y`>13B)E<`*DG-HEX317'V)3*93*I)I.B*(
M&_']^^.!$!Y#Q\B`AR'M['@0'OH/WT&LWU2;=96V&<9X=K4LYKRFY#-E-Q'/
MS[-4S=PPJL@Z07F&J;@H@*0295D$'`<F!5L19$P"FH<!GABS$M`P?3(C'6,J
MU&56M5]JFQ1;QC9)!P_60*!'$E+/`*#F3D7RQ3NG+IVLH<3J"4@)I@1,N#-Z
MNW![N>P@^IE;F&]<R/5I^'R%BNRNA^FWB;U653.(]!XN!3&;L)=,3QSET!#@
MR.=!X=)8B!DQB!5?57J>-FJ&/]YV+,MX9S?!(@RFF<-175JJUR_``#=6SU9T
M@]9.0;R9D_Q)FZ23^.(LJ84)<4C%2('YO4RIU=P@ZPOOFQ]",X/+&+LPTV"M
M#N"9MFSS(E)M(N(UU`2C-%,K>2DRI).6K9^)"/U6D@L@NX4!-`Z=Z%]5.E&*
M4Y-I6\\2G*4Q?IXE*8GM-^H/8?\`'`!R=_I-S^HO`_.L9NIG(_J;93Q<#'&-
MRQ1LKPQ>(_)<M8\DQJL!<,ZV^%$30,3%5\XG29U]F<!!4$G,@FR;N7C]S)+O
MEFL>ANF3>2ZPG_#NI4Y4P`1(V=/S)HD$."%%-)4P)IE#@I`'V@!2@`=`&@U3
M#ZJ5+'G_`.:3O3XY`0YQ&GW\<#P_^_?SU\\\%U7_`*5*ECT.TG>F`?'.(T__
M`/E^/`_R#^VMJZCZ71$"JOI9$YB@<"+/)!(PDX_S%*HJ41*/P<H>T>0\Z^?Y
MG)B'/YE)"''?$@\``[^!%;[>?M]PT'G\W$;FFN_7(FV;:/&X[S?A>C9-RRV?
MY.4RK5B4]Q;X"M-_S-I"P2H++BY(@NW<.'`%`IB.U61NS$`NMZM3J55H=<C*
MG1Z[$56JQ#-)A$P$(R081S)@B0J:"'TDB%,Y."9"@LY=F7=.S^]9RLJH<QAA
MYOPV]9(SI4\=7[#$V1AN!V_71'(F*U9=X<K&;.`(DFZD\=N5%`;A+MVR1F!E
M!(V5>E_".5$D78KI1OIOK';?%HE:/S!0\QXURK`O7D#=:+!T-6\1K.V12YV4
MI%0$TPE&9E0!\FJ1./EFS)['E$K59P]%/\4H'Y-VE9B=L^\?:1N*Q>T;U=YF
M;)"F&,QUN"13CHN]Q#]!NJVDWT.S(BT5D6Y'905=(IIF%9FT=F+^)^JJIN".
M7V'.F(^X4U%$P'CCD4CB3W?/'^41\<=\#^^E'"EKF_4JW20.;).(-C[`>SJP
M\4_&]A<IJ9"M&499M^*1G;C$)%2"!:(MB(+`F'U$D",$8A%5T[,\<DW6\C^X
MFXYY$0_4(B/)A`..?<(\B(CY\!SH.(CS[@'CKOL/[>0'_<`<CX\CH(@(@(??
M@!$/D.?/7@?YAQYXT```#`/@.0$1X`/VY'OQ\>>.PX\<NP\"`\`)?ZCSUQ]^
M..?//@?G@*F'P''(_`!R(#_/H.?;^WS_`'UQ1:2,W)M:]!E$TO(E]PN?8)T(
M>.*<2NIAX/8$32+[DV*8\B[?_31*4Q"K&+\@%XZ?M(6'9_F,])`)F+`J@$(F
M@41*K(R2Q0,+*';"'"[HY1%50"M6I5'!Q`DEZ-2&U.8JE.N,C,R!TW$U,&2*
M@9\X(02IHH(@)Q;1K$HBE'L?>8J!3'5,)UU553!<%=@8^M0T?"QB0IM&*`)E
M,<?<LNH<PJ.'3DX]J.7:YU'#E0?\ZRAQ``#@`[O5```#@`X#[!_?5=`TTTT#
M3330----`TTTT#7!5--9-1%8A%4E2'3534*!B*)J%$IR'*8!`Q#E$2F*("`@
M(@(<#KGIH(CV:L+T:9"+'WGKDHLH>KNC`)BLS\&67KKE8W(@N@`*+1)U!_UA
MF4S<#&70*4W6!QY#@>@'D>Q_N(]<AX_OX\RPL->BK1%.X69:@Y8/"$`X`<4U
MD54C_50=-E2\';NFJQ2+-ETQ`Z2I2F#P(#%:7AI6IRY:_-"H\,HFJK#3I$3%
M;3;)$.3@Y]A119S;0@E%^SY!-T4/Q[+E(ZJ+</@(ASP/7'`AX_W!WR/GX'QS
M\:U4[[&!\Y;F-F&SV<=NV>+\AS5MRQE*/;NEF:=RB,;-%WL=4G2R1B'4;.#Q
M[L_T2F`Q%WH."F*L@B8FU3L>_P!^0'[>1X#GKKY'KOH=0(WQX#R7?TL2Y\V^
M"P/N$VRVIS<Z9!29OHL<AUM\FF6U4!RN*B92K2C=$QXYN<Z1)%1P[C!<-%7:
M#A,)P5^O0-4A(^MUB#B*Y78IFDPC8*#CVL?%,F:28)(MD63=,B)DRI`"?O6*
MJLMP)G*BIS',.FG=>>J;%]YF`MR^.J5*+1.;DKMCS,F-,;Q"#B4NZJ#5%^VF
M:]7D010"=,JZ9N!3:`W0</H\JPI`*JH'R9#^K_M^8-#0N6\;9ZQ9ER*2(WLN
M*1QJ]L4BQE0(`"UAY`K^*6=LW*W<>O*1L8J=N=(QP6$?JGK@V"S'O#W-TO=[
MEC'<UAG"^$(V7:;=<;6L5T+M9;'.$4(MD>RM#(M#QP-45B.6W""9%'+9E',O
MKMV[A^L'<!ZJ%,``_P#FE;TO=Y$0Q(4`Y^0X%[X^P=!X_5UWS'U4J9_^4K>B
M/7_X2%_K_P#UH=C\=`''R&MK"3N:4+[D7DTL0#`F)TG,BH0#_!!.14Q0./\`
MW1'WB/0%YZUP,_EDU#IJ2$JDH7HR:KY^0Y1$.0`4SK%,7H.?U%`1`>>.^`#5
M1_TJ-*__`"E;TNN^/]$2?/'V`/QW'GR'0<CR`CJ'&9\HQWJ>;K=H.U"3QWES
M%>%#S]GR5DVJY7@_X*E<B.JS'N58J.:)IKKF>PB:+469^#$,#EV_^GPI[3D]
M#8R,GSW)R0<^.)!V'7\Q7`1['Q_7XU`'>Q@W*ESG,.;FL!KMW6X/;+,/IRMP
MDTY54;7VH.Q.YG:4*JJ@E(Z6$SM5HDJ<B;PCQRW`Z2Y4!.'D.W\^F_ES:=GB
MYV+#M`L]HPU*S-IFX:J4]=0+1B";L8+(/G=7AW(@PF8ALG],8A!<CY1L1%-,
MY"J)D7/`^-C<C9*R14L55/#>7;5DO+QZ32:!7+35D\<S=JR!4SG7+(R=R%Q'
MJ2S4"D,N_8E638(-RG!91(I2&-[<)CUA]A>5JHU?YGPCG".R6S3-'R-/JV/A
MN*SB?;"*+F*@;-&OFS&2(F\]R"9Y%M&O$^0*JW`X`!HT[,*3(;\]X3#?K.5.
M.Q1@O:N:U8FVX847DU):])WV1;D<V&_Y),*2",;*ILY951)G^'1$R@QT4S34
M:P#B1?!GWTF/3<EMCM&N^0,R347;]T.=5(U[DN7AU?Q<%38*.#\5$8YK3P4D
M?KM(QXNNM+/V_+1Z[*BDU,HU:E55V^![@^W(<="/@.>N?@0\]"(_']7'M`H`
M'V+QR`\``!P'CCXY^.!'Y#51#_*''W']@_8>`XXYZ'_]^P?[^>0X$>!X^>_V
M$?'?``/'?.@<`/VX\@`]<"'D>>QXZ_8`X^PZH(E`!YX'C[\@`!X`"CQWQ^P^
M>1Y#7*-82EDE0KM?%,K\"$4DY-=(5V-=9G$/]9>$*)"N)!8!`8V(,HDH[,`K
MKG2:)&.H'WA(!U=9L*\T%5&,;?26M,DD/TP:1ZI?>2';K![@_-I8@%`R90,+
M6+,LX4%(Z[43RZ9LVK!NBT9H)-FK=)-%!!$@$2111(5-)(A0Z*0A"@4H!T`!
MKI:O6(RHQ"$/%)'!(IU'#ITN8%7C]\N)3.Y!^XX*9=X[.`&4/P!"%*FBB1-N
MBDF6X]`TTTT#3330-?%9NBX341<))K(K)G2615(51%9,X>TY%4S@)%"&*(E$
MI@$HE,("`@.OMIH(PV['SVI*+R%=8KR-5-[UUXQJHJ[D:Z(@(J#'MC!]1["_
M_:"U24.\8&,<&R*K8"IIV4V=-WJ)'+1<BZ"@&*"J8\@!@X*9,X"!5$U2]@=)
M4I52#R4Q`'D-32X``X`.`_;K_AK%=JQ3#SCI>5AUU*S.+C]1P^8(I*LI%4!#
M@9>)4%-!Z8?_`+PDHU><";ER/0:#2-N022MWJ8[!:>HD1\TJ&.,VY'DF3E)-
MVU(90DG'LEC-ERJ(B'NC4.CIB7W@4P![@Y':&FGR5!N3VII%]B:292%(@@41
M`/TII@5-),O(B)4RE*`!T&M6N;Z3N8PGOR@]UV1\%2-_P=7\5.<-,;1@MZ[N
MTG48R1D3NW5[LU'59)6TGM(Y<FFF$4P>M&Z(F.SE'@IE35V<5^>A['&1U@@'
M[:8AG[5K(,W34QC)+M')".$#*I&*1=JHHB8`5;.TD'3<PF37134*8H!IIKD#
MDGU.,C96LLMEV^XAVEXGO+[&E)I.-Y,\)8,E6>#3XGK+/S+<R)DV93?3,!%3
MO`;BY:,6;5,4W3L?SY`H63O3(L%%R_1,QY%RGMAG[O`T;+6+<FRZL^_J:%G<
M`RC[56IAPHL<3MG)C'3%(C!0KE(C9X1TT<B=.T\:9]@/3$SMF+;/F)M,R^&[
M_8WF>,7WVGL5+)*5:,MJID9*+MM8CCKR;=@+Y`&HOP*19-XS3=)-W,?)%61X
M[F<UWKU+8B.V_P"SK']DD,?LIIA>;]FC),)(TFA.EZH"CZOU5@O*MTU%!=RX
M)`X,!S.W2AT4P9MV23AZ`;W`,10B9TCE41533<)J>/JHKID714``YX^HBH0_
M7CW<?S^A$Q4.5(._J&(F4.0_VQ`@#QXXY$.!#OG6LK"GJ",F%I8X)WD4@^US
M.+<C.+ASV-51+%V0$4$D63=_4[@L"L0P*L5-/@CN4<1(F,!$IDJI@;!F+-_J
M$[2]O<Z[J=ZR]$C>X]DN]-6*O'2EQ?1SE-L=9FA-KUUL^C85517Z`*-WSPCI
MNDH5=PV33,41"/VQMDPR)N<]1+,3UFSE6[K.49C"!<O6C5\E^74QH\26(B#I
M!5,I2?A6P%,F4/:'`"/QKH_4)<EVSYAVU[\*\5FD-/L!L*9?@DW#5BXMN+;@
MDX!(6K/WIJ2KN!^K(`":""JD>D2+<B*22!#DN/TAE(^6VMV&[HR3&0FLC9OR
M=<+&1J\;NG+-V\EOHQJ4FDBHHLQ<N(X@O$$7A$55FJQ%TB&2-[QMG*%/J^>O
M50IF+<V1S:QT#&VW%UD+$F/9LIEZY<[P]D5!GYE>,,8J,T\@D".G!V90-[TH
M-%-P11JW72.$R<-;U]K.X"?/5<39AK]DM``N=O77C>4KT[(((E$RB\<QG6;$
M9``3X.=)BHLX``,((^TONU*CD`]O/(]_(\AR(=>/(]<AU\\CV.M8V^S:C#9`
MH$)<-M>,HXFZ;&]XI$EC&1Q;#QT/-E*G-IDE(^>=116<0UA&[(!>*.IU=I^!
M!$P%7%)91$VV2FXMN,]$P[S(!T:NNO'1RDU7(1T@^?GD#LTAE&[F;1]S-FU,
M[%=,$HDCE11N)0"03$>2A:D8VE;(_4B:PR)(NTCE(]?K"=.$A_<(@921>D`P
M*KD`!$L<Q^L[.<OM6!L0?J:D;1Z%'4]NHN9092P/B@$K.."`5=Q[3<E:M4NR
M,8Y`0`J#1#VD_2"JHJK&,J-UQ,1'0;)&,B&3:.CFI`3;,VB1444BAV80*4`Y
M.<PB910XF45.)E#G,81'79Z!IIIH&FFF@::::!IIIH&FFF@::::!IIIH.NEH
MF.G&#B+E6B#Z/=IF2<M7!`.10ABB`"`]&34((@=-5,2J)G`#$,4P`8(R6>CS
M=),NY1!W8*J01.1XDD=Q-P:(]@E)-TRF5E8]$H>PLDW!1\B7V@Z;JIE%P65F
M@A_^W_#S\?S#00O071=)$7;+)N$%2@9-9(Y3IG+\\'+R`\=@/@Q3#P8`$.M7
M%P11NWJY8JC'2*,BSQ'M3MLZLW=MT7C9NXM;IXW;&^@Y(JE[Q&10.D8Y!$BG
MM,0`,!3!NWLF(XV27<2E==?PQ+N#G6<%01!S"22Y@]QE9*)]R)?KJ&]Q3NV*
MS1QP;ZBGUC%`HZ.)ZN;B=M>_#(VYG.V"YB<Q#D;'==Q/'9#P>O(9+B,=QT(]
MC7"<]:ZXWCD[LV8/`CRA+"6&*C&_74<-W#Y%'VJ!M5=.V[-JN\>K?AV$<S<N
MG*PAR1HP8-U'+DY$^0(4B#5%4Y42@0G!>`XYZTIXVQUDOU-Y.X9NR1F+)&+]
MMT?<[!3L,XGQE-*UUS.1M:>FCG]GM$J@=-0[AXN0`4,J5ZL=V=9)I^$9($!3
M=#Q$V2(73(X;RL),QKEFX7CW"3ENZCI1DHV7%%RB*B0"NS='%,PC[@$Q!,4!
M`P!HMP#NGK'IQW7*&S#<&C.+TZFVF2O6,\E4Z)7MB3>G7]S^>1S&Y0L0*\A$
M*JD<IN$EQ*91LZ.LR<-0*=!P(9VJ.-<H[#MP>#Z]'YNO64-K&X*Z/,4/JSDE
MT:P3^.<DR,%(/J(ZBI99594(N9D62$8JY14;`=,SM%W'JG!LX-MN^1Y]P"'9
MBB("`?</MUV'P/[=:T79DW!9VWR7/&3K91A:9L>/-N%Y89R<W?+,>M1:SDF]
M5A)1&LTR!3F5HTSL`(X=N&R*;\CU>0536=_ES5!(Z\V]NF_O&N8)T^*LH1,A
MMYW&QBQF<[AS)1EH=P\>I@(G<U"=ED(UE-LW@B*C)HH="243,7\*E()`#DX3
MJD)!&)82$LX.4C>(CY&76.80]I$8IBXD53"8>@#V-S<<]>.?MK65Z3L"VE-J
M;O*$M'L7<OFC.F9<DKO'S!HY=F36LXP[(Y'#A%55,!!@N=,R9B=B8Q>^!UUV
M[WU*=J=.QMF[&U:R['V3*QJ#;*W$QE6BYF=AD+'*Q2\6W9.;:Q9GKJ*R9G2H
M'4)(+()JD%$ZH*`)2R1]/VO0]8V3[9(F&?1\BQ#%,)(N7L8[;/6AIJ;7=S-A
M;F<M3G1_&QLM(.6$BV,<7#-ZW5:.BIK)"0`A-G>^UC8AO^KN;IN6:0^&=V%0
M5@LO-&H"Y<5ZX5'@&5W&`9?4D'*2XI,5EG;=K_K"[J30(91<IB&V-8/W1X`W
M'(/U,-9/KMU=1297$I#-Q>1EAC&YE!3!P[@I9JRD0:&4_2+MNDNV3$2@JJF)
MB@.O[`E$I>=_4#WJV[.,'$W"YX5FJM4L65&V((R<73J`#<`0LL5#//<S7!X?
MZ'_6"B"K5)>16>&`%G29PR1G;:_));E-K6=]H.,$1R3#93/#YI6Q^VCJ]4YG
M#SM@B2?&[OP495=!0$@<,6R95?S"0,L1(K1PNU2.0-FX\``CX$>O`\?<1^>N
M//R''@-?2&CIFV.S1]5;I.2IG^F_G70'"#BC`(`<HJD`#23XH#[DV#/WE$P`
M#MPV(81'),'A]Z_^FXN;XI&AA]PUF&64(@*?("",M,\$<R`&*'"K9FDR;>[]
M(JN$P]QLZ,8]C&,V\?'-&[)BU3(BW:M4B(H(ID``*1--,"E*```<]<B/9A$>
M1T%K4RD15.8G2:_4=R;PQ59>:=@49"57`.`,N)0]B#=,/T-F+;V-&J8%!,@G
M]YSWKH``'/'R//\`730----`TTTT#3330----`TTTT#3330-=!9*W%6F)<0\
MLB8[9<Y%DU4E3H.6CM$WO;/6BZ9@.BZ:J!]1$X")>0$BA3I&.0W?ZH(`/0@`
MAY[[T$0+#79ZD*`G/%-(PQC@5I:FJ`E;\"(^Q*>:I`88QT`?I_&$*:-<<?4,
MHV.84M?A$P&*!DQ(8IB>\ABB4Q#%$.2F*<HB42GY#@Q1'GH>1Z#4RE4DETU$
M5DTUDE2&3525(51-1,X<'(H0P"4Y#@(@8I@$I@$0$!`=8(L^'5D&[U]CMRQB
MY$J2RS.LS)G)JB\>`0QT4!4:)JR=>1<N`*5RZCB/R(I&,=*+4,0I#!IGVSI(
MW;U&/4(O;A%L_2J:.*<5QSEVW1>&;N(2+:BY*U.Y25%!0GY48HF3$B@%_3[N
M.0UL'RUDJ&P_C&^Y4LH*K0U`JDQ:7Z!#"+AZ6,:'408IG,(^Q5\[%!F101'Z
M?UO=T)0#6MS;7'9JVI;@]P['='A:Q5!#=)F<U[K68Z>LK>\.LGKA-TSC*A,V
M&+:&>UA%87AC,)>U(1")>$T)!!F8WUM;%,SXSB\VX@R+BJ3=BVC,C4^:JQI-
MN)5R-%Y)L8&3U,R8G(N5F^*V7.5,X_433.0HB)BCH-5&(-H>3][-,AMR6ZS/
M>7(-WE!B:UX]Q+BZRKU*JX\H\DJHM5DO<U.4KN068?0>`46HKBBHDI(/7+U9
M4$\@8-E<P[/-U-.VD9*R?8<U8;S?6IN;P7=+DJ"UQJ5BKH+JR=2F79CN%G39
MV#=1(@'>.$"_59/6I6WU'#8N'-KWJ2X^V^T(VVC=4TL=9R%MO>N\.+6VGP#V
M]5"U-Z:JK'1"2;NND7&.G&T<BBS6;+F52?IIIO04;K&<-DK5N5SW=;MLY4C=
M]MOP&L3&NV)LY1QA6\O>^IS^9'D\HO\`Q5+0<6\68*"NDP4`L:"3H6J)&Z":
M#F0E#J,`#?GS[N^1[\!P`]>0Z'[_`"/'[<AYU8>5+2A1\7Y(NC@X)(U:@W">
M.J;@H)GCX"051-[AY`!%Q](`Y#@!$O`<\:B[MLWYX<S^[<4>8.ZPQG.!15);
ML*90/_#=DBW+0I_Q@P[V92BVEA8)D34<\I%;R:#,OXEU')H@988A;]?4=VKO
MMONX+#6/,ML[?DZP51[1V"%<AII_6Q?R,DQ0DT"W`&1(!44F*;OVJM7:[9<P
M"5NX4`Q1,&??2JH258V4XKF9*.9_G-\D;5DE=XX8M%GH*6&;.1HNF[504<IB
M*,>11,Q%"&+[@,`!SR,=+=E6E^GIZ@5Y>W"PMJ]MZW=TC_27+LH])61&CY:@
M7!HQY,.8&/*XD4DK(Z0D51<(M0*\2G">P#ECS@CLZVN0L-`;<MOT!#/V,A#1
M>)\?,$I",>MGK!QS",C/UV[UHHJU7(5ZJ[*H9)4_M6(JFH)5"'*&NG9+C^AY
MOW#;X,W9LA82Z9II.X68QG"1=R:M9-''F,8-F+:L+Q,')$49,6\D1K^`1EEF
MQTOILCIMU$UW:YU0V-X5W'81W$1#V9PQD>OWEK&'3)*M6!W+27B!6_['\SA9
M)!G*-$U1`Q4G!VQFRAP$A5Q.`AK-)C`F4ZBARD3(03'.8Q2)ID`.3',<PE*0
MI>.1.8>``>Q`..-9-WVPV:N[U-O&;MG^+$DDIC^*ZUN1+3TF%;Q[(4LY6OX6
M2FG:RC2O'GEEW3@$4(H7#UP>.;N4F154S'4W(UW#Z!S(/[JN686`06+7&X\5
MUHH4P&3!V!R$6G%TN"F*J[!%H*GN`&(%`JF@QI7*W.7A0I803QD%]3AU:'*)
MO:H7D`41KK98@?CW/M`Q/QZQ2,$#")T3.SD$`D[7:Q#56,3BH5H#9N0QE553
M&%5V\<GY%5X]<GY5=.EC")E%51,/?M*!4RE('>)))HID33(1,A"%(0B92D(0
MA0X*0A"_I(4H=%*4."AT'0:^F@H`<``?8`#OSUJNFF@::::!IIIH&FFF@::C
MCN8W6X3VC56BW/.=J)5(+(V8\78*JC@4B+G?Y`R[:&E4JS0R9ED13CFSERK+
M6"1Y,E"UZ.E)AR46S)74BS*$(0RAS%(0@&$YS"!2E*3D3F,81`"E*!1$PB(`
M``(CH`D`>>!$!$..0X`0[Y^`#^H:L2?QE2K&85WL*BU?<F,$G#G5AI'WF-[C
M*&=QIFZBIA-R(BO]8.Q#C@1U"_&/J-XZR[+8&"DX>SU(T/=.%\<[<LOJ5RE(
M8WRE%T/'UHR.I*)O!OIK)1D+=!5.2&AM<DUJH2-F(9&219MX<CQ^UR?M(WQX
M"WHX:LN<L0S<LQIU'O60L;7YM?(U&J3M$N.+GAFMQBK4R4?/&D:6/;BA+I/0
MD%F+J%=M9))Q]!4?:%FL=A],K^?<@[CH"XV&1ON1Z/7\>3+6]-HRV0<?6J^X
M9.46D"@9"/<1@.S1K,KW_$=?7`B@CR*RG.55<6WYD@1K'EIKIF@'^KMV[B3A
M$B\A^HR;!./=LFXFY$#^PW(@/?NU;&T#?#A+>W@'_G/X;/:&>$7,O>HR%N5Z
MB6E6).M<;S\U6+;8&D8>4>R+&`83%?ED47DVWBUW3=J+Q-H#<P'U\L=;Y<*9
M=V7-=]V+RVJ\83=XPG\MIMH6+CQNXU>HHR;FVM`KSN7:HGLM?0A)@'==+)#(
M.7;`T?'D=OW#1NN&,]P.U1]G_%MIQ[?<5X_N*3^#ETJX%AG`.6"L:S!P2*EH
MR61B4Y>"4;OS-U5W$2JDHLD50BZ*Y3"4<![%?3HF]K.%XZIV"E8IG<IV!T^E
M\G7IZ[+8334@NX.DPC(YS*5=Q((U^+BDVJ!(_E))T\.[>.4U55O<&8:MZJFW
M:R?P^T=4_.U6L=_VQS>[K#E-G\:`M9\XX9KC:)=3CK%C>M3MACIBZQ:4_7SO
M<=2\E!7-!M-L)0T1^3@ZD6W<TOU)<=W?+>0,+,,"[H6%TQ%D##.-\OE?8\J;
MJ-QA/9[91LICA[:'4#D2:76KKV)EF,M-S]<:3S"LQJBCR=.Q1;KF3#%^/_3<
MM&*<ZY4R]A_+]?P_7LOQ<<G:<60&.6UHJ;*RL_8=>V036:E8Z*82CE7ZRJ2`
M0IF++\6Y020.W%-)/.+'T[\(2>1JUF++DOD+.N4*BC]*L6/(MI42CJL4ZQG*
MJ-5J]2;UN$A61G2BJY&@(.@*=0Y5%5B&.4V7[UN@J%`W,X(VNR]7NSBV[@:;
MEVYT^W,&4(I1(]MAAI7GMHAIU\O.H3Z$ZZ;66.7B6["O/V*R/UC.Y%H<I$E,
MQX_MDA=:76[7+4FVXZD9Z*0DGE'O",*2VUE983@:*GR5F:LD"220`@&6)&3D
MDV`IR>UR8WN*4+@CX:*B6P,XJ.9QC4`X!O'MD6:7_M"1N1,!./?)QY.(B(B;
ML==F`<!P'@.@U'FK;CZK:]R66ML36MW"/N&(<>8QR5+V*39Q"=0L,!E1Y:8^
M$+5G32:>3+IU&/:C+-)PLK"PZ;=P1,K%1^D8RQ9"B8`^_P#0IA^.?@!_^/7G
MK05TU0#`//'/7'DIB^?_`&@#G]^/'SJN@::::!IIIH&FFF@::::!IIIH&FFF
M@:::Q-G3..+]MN)KMF[,MI;T[&^/XM.4L<ZNU?2*I`=OFD3$QD7$139[+SU@
ML$Y(1M?K5=AF3V:L,_)QL+$,G<B^;H*!EG34)ZCOAIS_`"?C;$>5\5YCVWV_
M.*,^O@=/-L+48Z-RVK6HA"PR]=AI.E72[-*KD1M75'%@)BS(RE/R(]AHN=>Q
MU=>EKTX2/FL!@'_O>.>RF`./YB`!_3SH4K?)RUP%,HB8>.!-YXY[Z`.^^_`<
MAX'Y`=<@,`_?X\E,'G^8!S^_V[YXX'7!19)%)1=90B**1#J*JJF!)---,HF4
M44.I[2D3(4HF.<P@4I0$PB!0$=!CZ>Q52)\XN%8D(Q^/8R<`NM!OA-W^I16.
M.BFN/(\B#E)<#<`!@$-1+J&PJG8[RUF7,]5N$U,6[-ZL*-N#(;&-M;5NR@R`
M#2)AE"(QRS&+`Z:!_P`(H5P4@MT`*;A,.<C5/>1BF^9VQQ@^EM[%9@RUMLD-
MTN/\I1*,*ZQ=9\;,+35:L"<7*DFQL*TVZ6N$+*M45*VC%K0S@CI*4.L<C<TL
MN0_?X_V3?/CX_O\`;YXT$8EL8Y`9HD0:H4]\V0`2M4&TA)PY"$'P5%D:,=,V
MX&Z]Q$S@7G@#?I#G4(]\FQ&T[K\-3U:;8ZQJKEAHBR-CC(%@GU6LC47J3U`S
MDR<Y&0_YVI'F8@X(6(5%>/.N9(Y4$A+[PGCG?<G4L%2>+ZBZKUMR#E#-MGF:
MEB3%E#;P1[7=I2L5B1N]N<-G]NGJI3H2'J=/B)&P3DO9K/#LTVZ*+!B=],OX
M^.=1DN/JC;?<95#%=[RS5,RXIJN4MS#[:.24O=+C8L*%F=G9W]32:9%0;61Z
MM`TR2DHJ0=1^0F99:HJPJ*$ZK*(13^/=.0ZW;SL6CL)85JV'V6,L0JLF,$BV
MM[R<;-+`O<9]XC[K#)S+AS5UW<FD^=J+D:(NW`$9L"H-VQ6XDU:>WKTX[_MT
M3R;5\=;BCU#%M]OLA=X"B16.8JP+XR)*"?\`'0%)G[A*2*#%HL!D@,]/`J+B
MHS:N01!P+A165.YW>IAO:C9]N]%R(2VS-]W49=9X3PK3:5"(3,Q9+HZ9_CEU
MGRKZ1B(N!K40@=L:<LDM(MHZ+%ZS!P?_`!P$+JR_NOPC@G*FV_#.3;6%=OFZ
MZ[V?'F&8]5LHHUGK14Z>]N<HR=OBB"$>15DU;Q<<JJ)@D+!+1,2W*99Z4Q`Q
MAC?T^]O./\EOLU2;&W91S)*-TVLEDS*5LD+)8';9)$C=-F+)J6*KJ3!)NFFW
M28DAA;$033)],13*8)JM6;5DBFV9MD&K9(OM2;MD4D$$B]?I311(1,@!QT!2
M@`:B%F_>C3,&YMQ5M^D\8YBO61LV4_)MWQFQQW`U2686*(PY&1,OD9O^.G;K
M6R,)>"83\&HVC'I$5YU:5:M8+\P<_622P#(^KAM@_P";L7=;3JYG')F"(_$=
MLS1=;O3,9*-RXSJU$M\_0KC#WV%NLU3YV+OE;MU3M<++42/CI:RLU:W*NE6!
M8\K5XZ#:)IK`>"L_1V=F,T]98URSC<8="J/T&^4JU$P9K#"W2NH6:!GJT\@;
M%9XF6C%62QV;\"2*3^)F&KN+DV+1TC[39\T#3330----`TTTT#3330----`T
MTTT#3330---8-W+YOCMN&!LJ9LD(20M:V/Z?*3$#2883?G^0KDHF#"C8XK29
M$7"B]HR'<7D'3*VV2;KJN9J;9))HJF-[!#.6FHN8'W=8:SGM1QAO!:6V`J&(
M\C8[KM]<3MMFV,'%U$\L1%E+UZR2TP>.9Q\O6;2+VH2J#HR"I)]@LP!+\28B
M(YNALDX\L5'_`-)L!>Z=-8X_*Y.;&_1=EAGU,+#P@NRS,J>SMWIX5..AS,'Q
M)5ZH]*WCCLGA'JB!FRX)A=ZJ":Q#IJE*HFH42J)*%*HDH40$HD43.!BG((#P
M8I@'G^FL;2^(:7)K_C6;1W6Y#S^-J[Q6&,)O('49H>Z,6,!@]P?69''W?J$1
M'7VQEF3$>:8A[8,/Y/Q]E."C7Y(N1F,=W*O7.,82*C%K*(L7CZO2$@W:NEXM
M\QE&Z"YTU'$8^92"!5&3MNNK8,-NZVIV-Y9XZO;E\`STE28Y>7N4="9BQW+O
MZG%-K"G45Y&QLX^Q.'$,R1M:J594=/TT$2V%5*%]XR2A&Q@P+A;855=O$%<8
M#'5F6GVMWR)8\GV)YDN&C[+/R=GL2J9U57,ZW(S4529I)_09F,R!5,IU#>X3
M*'$<Q.<;Y()[1_"521]O!0^E-RC4WTR"/L(5-W%+$3*`=E3*I[""'``&KC?[
MJ=LL54:U?I/<+A..H]R/-IU2WOLHTIK6;&>LJ&1LQ86;6FB1TB-:7*9"Q@V<
M*#`+E,C+_@E0$FKH2SIA19R5FEE[&*CPU^0Q2#0M\JXN0R@Z:-G[7&YT/S3Z
MI+ZZ8O&;UK3CD+8G+1TV<H1JB"Z2APU6>H%Z>-RW=8O)'5N@XRC,T1LY7U:U
MDZ;GU64M!P!'?LL[)65AX?\`,I9-Y%`5LP82@.VK501.A^&X[D9C?9)6Z+A^
M$PHRQ)AY.DQ]6:UJ6CY=LWF#V$YF!&\W*S#H*R9Z_E99X+J0/(+._P`2V57)
M^$6;E;H$3LC!?JA8XM0R<)GL*?AV\RV_K<UL<Q=665N&;0NTIMXL,I'.[?\`
MFLZQK)6K-S#1@2<V46I4(I_)Q,*S-(.Y!G^(V=3]@A*K!3%GLDHR@Z]7HI_.
M3LS)N$VD?$Q$4U5?24B_=*F*DV:,6B"SARLH8")))G,8>`T&KO;9Z=62=NE(
MF\75O=!+1N.7MVF[3`1<-CR">6>GQ,T9+W52NW"W/I\&#)J5%-1)ZE`BN9Y]
M9V5-$RYTQD9B+8/MTQ!?+%EAC`V"\9:MX"%KR;DNSR5MM5@`Q4"B61*H9I`F
M2`&K8$VZ,*F@B#9'Z)$Q*(C&,WJU8(=Y8VI+L;OAN'VF[G-M.?<\MMP][RE$
MTHE2DL,3>#6C*KV%A.`SK<"2RPN:XR63&9LZ%A;*LSL7,`S/RHIL,L.X/!%2
MD*;$VC,^*Z[)9$0AG5!8S>0:G%N;HVL:P-JZYJJ3V60-/-[`Z,#6"<1OXA&9
M="#:,4=./\/0991;(MDB(-DDD$4B@1)%%)-)%(A?!4TDRD3('V`I0`/CH.-?
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M&0JOCEC`R%G6F2-K+<ZG0HD86LVBVK'LEUF&\%`I/6U7B9ES$Q1Y!RD63L<J
MDRKL"U][^<E(]DF=P`>:?9=!1^!-SFTY_L+O^7'NT;<2ZR/>]RFP;.5*NDTG
ML&!;$ETNZN3\;62XP$9:MN\>%[5C\8GQ9-%-"Y`3NQG%*_$LE4@8VCM[P9G6
MG9(PY5<78^L*>U_U.\#TEOO#GI"MV:O-,%WO:+85`RH^LL>^B8^2@)C=IMVE
M%<.H$E64<]>VF';V<B[Q-B<KCU>`).>`,'N[#CW?J'CGD![Y'COCG_+\<:%]
M@]%-S[>>?UB80Y^_ZA'X'CGQ\<:#RI[*6-S=>EQB#8]%0MSQ#D#<_O2W=4&;
M=V?#V4$H;'.%'NZ7,^;I]Y<(QLA3W\#6<O8K;0^,J9)NK!76LFME6+6B)?Z[
M%8J.2,3FR'M2?^L;L9O->D)^F6[&V8=Y6!+?BW"N38;%_P#$6Y3&]F<9DV[4
MAF7^,V1[)6\EHM[=6Z97[1,RD@PR&JE'QC1RBM%,?2RA(1SAP\:MW[1=U&KI
M-Y!LD\2578N'#9-X@@]1(J91LJLT61=(I."D.HW5273**2A#C^KW)B/(*`(F
M'V]*CQSUT``;@#?R`!^?G0>6[T_*3:=O6X;8YEW<C`YBS!2<N^GOB;!6U[+$
MW0;*D&R')==J5//GG;CDBBU*D0;"E,\RR,1'3M5S5?8%A8T'50?XELTZ=N,8
M^DM@VQEE)M/4[]9.7>P-EC(:[7[9R^IL[*U6RP\!;FE)VX,:;;G56GI6)90U
MC0KUI25@Y96$?/R-)$AT53``E.;<8`$-_E-SQ\@<1'O[B!N1#YX$1#YU4!*!
MA#W?J'R43"/QST41ZZ[Z`/OH-1F\2!1G_4D]/8LQ!V1_1T<([^Z_>9J*A[@,
M-",KQC[&\=&,YBWUMF5&K/;&G#SC6`.>:BIAZ\8K$@SF?D1YTIXVP2QR;A[8
M/'9WK&=7/\/^D3NRB<@Q5FD-PE:CVU[J=BCG.-F&0V8KQK,<BL7QK;*U5"S_
M`$KS+/6C.3;!+#'P*B/JXSKN`Q/MOIC'(68;(ZK%3D+G3,?-)1I7K19BC;,A
M6!G5JC'.VM4B)EQ'-Y:>D&4<,S*I,H./6<HFDI)FFH0YLR@).0`#?J#D/:)S
M"/D>>0$W(\=\"(#P`=#P`:)6E\[9R=]?%W#9%R>I=,`7ZXUC*.9<&L]A'I4,
M]]E&KM5S`IN%MBU:4M2,[8*_,1$7^?VUWA/+DW7+=N6Q`P2/?[E2GSQ!1=NB
MVE8J9ES&L(W*7J$V>J9FM6Z6CY;QYO,6R)A."Q?@N_,,?Y2V:3^'8.O017>X
M)BS&C1FV6-QXM+0V3:8[>UR9B\LQ#M:LLU[Y*Q;I[Z@G[^/C63N0DGS2/CV*
M"CE\^>.TF;1FV0*)U7#ITNHDBV12*43*K+*$(0H")S``#K]7)`$`$P<CX#W]
MCT(=!SW\^/D.?(<Z+:=&G/T0=OU.Q5LDQ;D9.)RJSS)E:EPS7-C_`"_:<ORE
MP>3=%G[>PKT9(UG+$B=S5OX:AI4L+&IQT'$JO()")"0<S(M6T@?<?K"%RW$X
MAQ[F;#6WZV6A>+ROG]#(#G$];-7K.\;VI+%]<-;+R!;*TB'%7BG$%`E*_.QF
M9IA(/$E$_P`N:.N3>W-^@::::!IIIH&FFF@::::!IIIH&FFF@:U:^L)A3)F:
M]FXEQ/6)6_6?#NX#;!N2>XT@40=S^2Z?M\SO1\H7FEUZ-./TYJROZE`2[ZL5
M\Q3J6&PQL;"-BB\?MA#:5K#.?<_XHVQXQE\PYLLCBHX[@I*M1$M8$*Y9K.#%
M_;['%U*NIN8^IP\W*(-G]BFHN,/)+,TXR/4>I+R;UFT`ZY`TY[Y583U&<K>F
M?CW;R6=LT%B'>/2MY^?+XI7;G48;$.&\1T>Y,I:E7>7D(R!F:?EW)DI>8ZFP
M&-Q48WMJFE9YR6C8R)K;UV&J_!^+]Q^*L5;/K9MC@,YQ>Z_).R/U7Z+89*\+
MYNE'#B\0,G:;#M4K%X'((R$)4GD?:8F.-B`MC:12[I11([3\W:3+T\C["H3(
M%7G[E=J'&J3'\1X]2JRMG3>UJRQ<2F6Y1[V3@OR>R2<4TKEH54:,'`R1:S*R
MZL&X!)G-_E[QRW04LW*6X#$V&+/ABGY&LSF!L&X#(Q<38G:$@+1,M;/?U*]-
M6HM?<2T-$R,-7UCU^NS<D@ZM#^(9.21KANS<.'8%;F#S6V"_XH0VD)YZV?8W
MWDU2E2&3=@:V_."L.+<[6IS4JKCU_:(7*,<.%+^U1DL@W>FNUX.7W?KX]),I
M7NJQ482V2-E?"\;K[3=DN(*,;T^\M8WH5@S9F/$M_E-Q;O'RF<J-8*`]EZID
M()63+6,;T.TM8ZZ06%FU@DY6+Q;&V9JVD1@@*$7]2LJ02Z^VL#I"7W`H42C_
M`+7OY#]/?'//P'8A_/GR.N0&+S[0,'/V]W)NPY^1Y\=A^WCH-!XL,88/HN4]
MM&S&GV'&6<X=KB_T&L\U&>@4:-G['#UCNJJ$=B55Y!R!6]?AWLW<XZ[U6S6"
M@QB;ETTF;+`)S5,:3"\<P!.YZ^^R=DZTX<Q]NDM^\VD9-F=N_I?Y&V<6?'^!
MK[9[Y9\D4+$M4'-]-@LN2+'^'<1Y`2SLG<!W&Q.8$(&$DJ-+)2%O>+Q+,Y(W
MV3B!`$`$P@(\@`"H8!'GKH!-V/?0^0'QQI^CD2^X.0`.0$XB/`=\B`CS]N1'
MR'0\AHEL][4IZJ>/=N.8F&W?%>X-7,V,W4M?;K<<.;M\(/;'7K9M1RQ1*4J^
MAKPYNT!$RK2HQ%HBY*3JSAU;P2I4NLHV@)KE628JMX`5.AY*WG[4L9[9-[5A
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ML.8V[+VI<K6#_P!'\32EVDI*-'+<1D#OVQ-G3>52M[6YK#UUAJ])[4Y.B?\`
M-8KMRP=E4V28;*FR:SAG3^,,<ODYN&]S;/>4%E:2VF(K'UX8VZ@P5=!LM*,W
M`,$?2\(D#@!-QQV`>\2^>?@#!R'0\`/(<!P'6GZ.R^[L?(>\1,'CQ^KDOD.@
MXXY#0D]>'FCW567*6^?<+Z7>0MN5CS+M=R%D+9UOW!ID23PU-C);<\LY:Q?A
MYC2ZEE>.OE!E82MOQN4#8Z^O'/SPMB?J5QV\J$VV6!B_==9,-:\A_P`GHW5;
M:J!MTR7A/+F+=M^<\%Y!V]NZQDNY6]]N)D'=A972<ID])1,I8\W069LC/)K(
M5,R5$K3G\90UF;RKU5@[3?LF/IBCY"-E&+.4BY!I(QK]NFZ82#%ZD]8O6JY0
M41<-7;=95LZ05(8#I+)**)G*(&(82B`Z_:(%`!$1$`$>1$3F#COX'W![0Y'P
M'`?'&@Q-@%<CG!V'ER$73*?%V/P%)TU=,72*B=2ATED'3%\BV>LG3=9-1!RT
M>-V[ILNFHBX125(<A<N:X^X@`'ZR\<<@(F`>0YXYY$>^QXYY\]:_,+]D#TL<
M+QJ$@=J=\1B+A$'AV2:R;=1V5K[_`*YFJ:ZJ2)W`)BB155-,QP.<I1#]>FN/
MO)QS[B\<\<^X..>.>//GCO\`EWH!BB/`&*(B'(``AR(>>>.?''?.@Y::::!I
MIIH&FFF@::::!IIIH&FFF@:UX;LJ'F7.N?-L>'82J9-JN!*Y8Y+/&2]PE*?X
M84;P.2L8MP?X)H9:_D%_8YUVFM<3N+G+RS;%-EBV4E7*>P!VU-(O9.#V'Z^:
MBB:?M%0Y">XQ4RB80+[CG-[2$*(\<G.8?:0@?J.8?:4!$>-!YA(/9AN)Q3@S
M>EL=5V\[G[?MFC-[..L\;/<VX_R9M_K&:Z_!7;)U/RQE*^T2*BKHE%?GV!\^
MA:\MT6FW.A5:O9%HZJL"\@F\LJG`O-@U=I&\8?2<S?1<AXCQ?FK<[)XLW-Q5
M0QI9Z;7L<UK/"$[+WG_1HMF+&]4G0I5.N^7ZV]BYS*](K%H;5EM<)Z6BV\U$
MIN'"S+;H*B13E3,8@**`8Q2"(`<Q2>WWF`H_J,4GO)[Q`!`GN+[A#D.0JI`/
ML$Q>1]P>SKG](`8P>WR/!3%,(``\%,4P\`8HB2V^_P">*4R\U:7O2MQ#N!H.
M6]X61LQ83R/B>OY_9[3+Q4U,F2V'26$TQ2=N57Q=;ZHYI.&YB2J]%"K2%:2C
MXVN1!/R2%KJ$%'-GSIZ1Z@R@P?8=N2JVWC<];J'M$<QF767J]7+>="XZA;EB
M7&V1]Q.UU7*J-LB*?2<H4>WRS2I6EE#BA:ZG7KK,0#-A<*M$M%FR2[A!T3U#
M?B&Y4R*_52!(Y/>13WD!,Y`(*GN*?GV&*"93']Q3"4"`)^?8`F"JBR"0$^HH
MFF"IR)$]YBD!110>$TR^X0]ZB@]$3+R<_P#LE'17E3S?L>S0XH>/K_M1V?;@
M<#9IE*KN^OE48W;(&*<]UNS6[<;>L<25TV^;]\87Z_357-3-U#F%/=K=:\4V
MF4-A16!!XYERS[AQ%.,D9SVY;Q";E\CQU5VF7.]UVR^K?Z?V_)3)]4M>)HK'
MKC%^-\-X4HF46<,-KNM?M+N[5>X8UM`R,9*5Z*15JJD5+MYU_(2+2&=^F8RB
M1?:!C$+R)2E`PE+R)^?8!0'CD3B`@4"\B80$``1*(!Q%5'ZWT1.G]<2?5^G[
MB_5%,#`05`)S[Q(!Q`@G`/8!Q`G/N$`T2VS#YINY6>;C'VU7=E1;!4<@O-K]
MJG7%8];/=YN>+4SW'#2,P\P%N09Y+B*3DY%\>_2,*SB(-Q9H24N4&XD$;M%M
M$SJQE8F'C4K?6ZO#^8'^Y7'&9$W.-K#C.5J>2\T8(7A+?*5>=0GEJ0^>5QG;
MXJ7J$I/0;VM6IJX9R2+879I.%<*/Z]/LFDW$OVB<@[)9ZY4*]/VRTS,9`UFJ
MPDG9[).RKM!G%P<!"LG,E+34H[6,5%E'1S!DZ>.W:YB)(H-EE#'`$S<1?S_N
MLQAMAV@6G=M#529R)B*HT6(R<UB\6-ZRP?2]+M*\;((V.&:V65JL2#(S.?1L
M3XAER2:S-1RLUCW\D<&BQ6C3"FT/<\:I^F[`Y4V.VQ-CM(]-[>MM@R+&35BV
MX6=G)Y;NU4VWU.C/*ZR-E-1-TPR*KB;(#>&FG:#(6D-+1#BV*P",\[1:XAQC
ML/W3P-:P]A+<ILJS%N#Q_F791Z>>))5K![D:?0J5MVS7L_QW"T.YT[<&E6L@
MK/YK&"EUKA,^4C(^+E+W/KS#Y>O-H%G+NRF2]6=VL\M6:L^GZ[2IO(<JS<Q#
M=.IUE_68^7>$D)>/CI!PB]MLU7H%%*!8O',W)$>RK5=1A&ND6*3J14:,U[O^
MLB"I4!.0%A(94J0F+]04R&`AU2DY]PIE,8I3J`'M*8Y2F$#&`!#FF`E(4#"`
MF`H`8P`)0,8`[,!3&.8H&']7!CF,'/ZC&'D1YZ^15DCJ*I%4(91'V?53*8HG
M3^H'N)]0@")B>\H>XGN`/>7]1/<'>K4M>0:31F43(VZSPU?9S]NK-"@UI)ZD
M@$O=+E.M:U6*Q&D$14>S4Q./$(]JP;D47!0555B)-VSE9$+PTU9=:L\Y-SM[
MBI6BV&J,*I8V4+7K!,/JR[C<B1;JLP<XM:*RW@IR5EHZ(8RLK(51PVML?7YE
M28K\DZ:QJ\&O&2CZ\#K)I^T5#E(!CE3+[Q`ON4./!"%]W'N,<WZ2%+R8YNB@
M(]:#Z::^8K)`H"(J$!42>\$Q,4%/9S[??[!'W^SW?I]WM]ON'V\\]:^F@:::
M:!IIIH&FFF@\Y&\?=KG_``7G/U#V43ER[,,7UR<](N"?3+AU"FC=L.(MSN9K
MUC;<OE.E`>'(U@3QE(C495:T3@R?\+29TK4[>IMX=N#?'^6=Q.X;#^1LL8LJ
M>Y3(TS@S%7J:^EW1<4Y2GK9$V.P6RK;EGT6_W"[:[5E"49.G&0*W42/(R9;$
M,_\`XTAX.WL8">G9!@Q3*KN%VT[?Z'6L@;FK3<,W5[<YG#)"6.L<9ZD5X6A1
M)(2IX[A;07&^/K5CBJKR,/!R`0=YL$A-C)-V1K6$HF]-"L6"39J22,%1L"3<
M*[HU:J6(I:O8^M"K!]4(.O4I_#4FY)L&DDNQ=5]@Q585NS$C)AB_6;JLV4L5
MC*-')R@W>)'4#SJ4/<+G>M;FZ-=9S>%EBS5U7UO-WVR24QU:;)47F+T=O\3M
M>S+E.+@I6IPU?C'<G8:1?Z)6S5:7"2:RT*S3<5EFW$TLX4<2P](;.F9+U=<N
MT7<#D"\9*R"?$V)\M5S)$9EJ%S+MFSKCBY6[**4%G_!"T9&0<MA)6[J$"NV[
M;_981@-+3I\&,`M(-OS1P&Y,F&L1I&(9/%V.4S)R9II,Q*-5B"G,'*8AY4@E
MB0$LD8AA*9^`@[,41**P@(@/<U+'M#H*;]*C4JI4U.562<2:=4K4)7"2*Z`*
M@BL_)"L&)7BJ(+K`DHY!4Z8+*@0Q?J']PUOQZV]/*W;'%VPQ"^J!G'$^Z3<C
M/9'V?^HS6L[9=P>QSZYG9FX;3JY%X5?98A)VJ/&DA-PU<6Q3(W%Y5'S9!D!8
MZ@Q,)7E#L8]5HO9YMUV\V#Q9O6:4O(FYN9ROL_99Q]1[%S2Y3LU/2.0=HF;,
M3O)/8YCJ^1CJMH(S#2MR1;;/Y"Q(Y9I6!O(8AE(.:EY![(/C./6++-L7U-X_
MD)U&B5M_E.9AZI)/95"NP[O(=@<L%HJ`KCUR[3;KVZ7<1B#B.B(ATI)/%&**
MS-DW%NFHD%V-X6':NG+YK%QK=X\9,XYV[08M$G3J/C@<`P9.'":)5EV;('3D
M&C94YT&P.%P033!93WAJ$V@Y#N['>Y-XFH.X&[;FMK-VV+8IW()76]6=MDUW
M1LRV/(+NIQ[6%R`R3+^7U[,=!;N;VWH+Y5=G$/J[(2M0;Q,`^/&IZZ-Q6]3=
M9@S<7O,LT;?KOE9C&5_?$KM(EL/9#@KIB6/R%@/;4WMLCM>SUM8?0T5/TC)N
M$AKT[EB"R8T>V6$S"YDFL)+2,4WF(1#7IVI^/Z)CUF[CZ'2ZG2F$@[/(/F-2
MK<+6F;U^H7VJ/7;6$8L4'+LY0`IW*Z:BQBAP)^.M?&/QOCV)L<I<(NBTV-MD
MV+H9FSQ]6@6=BEA>@D#S\RFVT>E*/Q=`@C^)_%NEA7^DD"OO!,@%#R^7S*43
M<-F.X:WU_P!0VE[P\.7>Z^G7=JO%L+:OD!SA&V3FX;&*%O9SN5Y6=65AWN41
M23M26W^?CHB8Q<XBY,D-&L*\N:/1RK3MV>8,A[JL[2\-O0KE9SYMUW8;P<2'
M]/B17E)RQ9LP[0*C<7&WZO0^#49:-4AV]IB6E+S,.YVO1DH=%N_F8*QR"L,T
M>Q,;Z%6.%,.QL`]JL=BG&S"L2<XI9Y&NLZ'4VD$_LBW_`&U@>PZ$.G'.IM7R
MI+.&JD@?_:<CKL75)QE!V-[E=[5*-$6N/KJL;(Y%<P-=C["RJD>E^(68/+@J
MS1E6U>9(-_KJM%Y,D:W21^H=,A$^0%?7?R\DN5LY5//GI8Y7SE$^I7E[*=GO
M^U;:YEO<GAVO9#@G+#;SE\V7L:IYD</INKQ3:>P##N5K);L?S>W6?,R@'$93
MEI9G"I#`SCU>543N3LEYW?VRA5SU&(C%4YMKW%[=ZUA##UHOCO(]CWE[5[/A
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M0,9%R^5>G=+I"*:RQR"(#DG133330----`TTTT#3330----`TTTT#6K[UFG[
M.-]-?<L\?OFL:U39XM24>/7:#%LF=SG+&+5!,[IPHBBF9PNLFV2*=0!665(B
M0#'4*4=H.NCL59KENBU82U0$+989=1%9:)L$3'S48LJV4*LW5582;9TT4405
M*55$YT3&24*4Z8E,`"`>:K>=N?W!TK)OJ<0M(W17VC-,6[C?18BL5*,9:F+L
MJ'7=S.5Z94,P0$,PE8%PR/6[379^1EY-L\^L[?F;)+.I56+25;'C;FG/NXZD
M2V1<9TZS3>[_`"7M-]=?'50VOTG-63H&*N]V86+8?9\Q'QA(7_\`+XY&0+%6
MNWW!O3FCN.2<`DQ84T9%BD0K]AZMW.%\0/%'*KO%>.'2KT6AGBCFB51=1T9@
M4A6(N3JQ!S+BS*FF5J*HG%L4A`0^F!2@%3X8Q"J_-*J8LQP>3,^)*&D3T6J'
M?FDB<>R0%X:(%P+TG`>UV*@N"\!PH&@\OMCW=P%HJ.U/%51]4*YXFQ#N%VF9
MYR]5=Y6X7)RE!M#[>#5K;28"4QO;[`1Q78*JSV`V<O.S;S:G/.(R#FEVCNNS
MJ,PI$&7>S[V7S><\P>H9N)8Y!WBY;NU0VYX/V%W:'QE6VE0H6++S<L\[>LFH
MY(L%FQ^XJSZWP]:FI2,B+[7Z.K8VCVL65Q&O'\M*$:-VH[6+52=LL4>J4&ZU
M3!D<I=;@>2I%,L]>QZU/;+[&,UY55_5ZY*L2#.6V/CV[F24>1+)U,,V:"[LZ
MR:*9U`NG'CO#%P7F<D8J<XSL[B4DYBNS][H!ZK,+2,Q7I(\9/0DM:*Z#A5[(
MPDNQ482T>\?K+QTBS.U=)).6XD(&E[*>YQC:/4,SY@3)^^&V[0[?M_M^S:Q[
M8<5U^3J4:AN1Q]DF,CYC(S,,=V9F\=[AE\E70ECPNYC(1NZF,7&BV$W64(^:
M5=2+Z.-(W9[E;C:MLF6XC.%Y1S7EKU6=Q^QS<UM4"5:2U/QIM_I5JSW%1\C7
M\:+Q3W_1U<L-XNQKB[+:N5%4&YK(WLTH_N+N=B+=#L$O1I887#[_`")2'EJC
M,;N\KM6,^_QPXL#"JN,@H1L45DG:'M*<22"EE191Q9B.3GG$"H1!H639ED#I
M@]1!7];VA8MBI6S9!D*?0HV;E85TVN%U>5RMLY60KK=F`/6]DLBS%-Z\AD(]
ML`.D95ZJQ39H<+$!!+@I+9XYUO.6%^;RS;-=QNYR<Q+LFOEMWC9KNEOW>>FU
MOIMEZ966RTJ0:P%YP%+1[_&>1\:02=7;IP5ZAT)N6BYR?=(3B-C9Q[8DLR%2
M+0%MCW(^^O,U`VYVNQWK>%>:#:\C_P#)Q,6;I,7/K#E"-K<M8]Y5<7MXKVO&
M24H5%24OMB.RI:%UK]=0>)SB$JW&1B$AF177]+&7-N-6S1B:,CL"VR@8<"QQ
M@A%Y0HF*,87PDEC&[0<DTL,34UWC9NPCV5PA)\7T;::_($,BX_"2!22L>N\8
MOK^H6UC!E!Q=AS$J&/*K:*W@K%\#B+'KR[UJN6J=BJ;!5:/IXLPE96)<*IJ3
M4-'(I6`&@-F\N<ZP.FYT3_2`LF,WO.YG/>)G.Z;AY_&%"WJ5&@WF8+Z:TKMO
M+';A<+T+'TAA[*C*-?;JU<C0EWF!-=<EV=F:X2=$D*]6+C)+,G6-(^C%;S7Y
MPU7Z=3>A9;COJE\54_>?D"R4;+M\]47`5K@IC+U3J=PK]FPOC=`F,:AB_!E:
M9!*X:<8IM=?DX?'N5GLTRR?G23&>M[^H#7Y2'.VV09*]/#'.9MSN?&7_`#G\
M>S#'(3/&MFR)MRL>"]N>4,H8CHK>FQF,8V)Q=>+(Q=WC#>.KK$TM^6#36K$C
M^4V5S;IZERC&9=*.6FUNOXAQ95'ZDM7<=TF'F%GZ,JXFF%6@F\X\EF\::&1E
MY"<(P"7D9@L4<\>:7?O7,FJT4505=G354*</'OMYW#*%VM[$]N47ZE#':W`3
M_I5X:S?C7/=]SB8C4=W02#.N9;QBC+'FHRN9'6P!',JJU/M2L+]P8&]P>I24
M*L\8"Z9[W/4.W&6S"VV;:E.6++:&)ZIF/.N!L5[@L]/4;%AZ-I=/OM.LC^0F
MI:8*Y2LF`8RYWZ,K-3=VUY+,'V-B60(]U+L7YROT=DKK"N'WL77(-YBO&[N&
MI\RM8ZG$N:)4UXRL6!P[4?+SE>CU8<[2$F%GJRKM64BT6CY1TJHX.N98YCC>
M5CK5=N$%)UBV0,-9ZW,MC,I>`L,4PG(259G$ICM9*)E&[N/?MCF*43H.VRR1
MA`!$@B`"`>7X]ZS?8+WMOP:Q]4*_Y/H%PVF^I;<%\SX-L-4KP7=+"V0Z$[Q&
M[A\A/FED=7>?Q%&V&0I4UFJ#D5&U^2ILH+E%B]7MJSF+BFZ_,=5L[W>8AFR[
MVO<+._\`)_-FF?:Y3#W#\QJ5IN%FM^0X7<!D:KX6C3HL[27&M;CI#,L]#5MH
MY:1%FCG<S*($:JH,T/6.O`[:$+G6L3.H?!Z60&-"D'50QNO%T`EO9XQBG2$5
M)N*[4#-0F&E%CGLXWC7JD;'I5]LZEDV:WM5>@FI<T56L,,K0E5X6"QDUN=/I
MQ?HU^+B:FWLU8H-TE95(HI131J24A:C:YJ#FTP*F@VA9V3B90HE=.F+KZ0>;
M>SY3R(]I.,V&!?5@ELN8LSEZCNSG'$!=L+WF`R18<5X^S;1+?'Y(Q6[SM=4+
MFG<I6VN8!IDBOU"1:MI_#SVP,VKF,=P"U;C29]QWEG,>)_4WI.&,CYQS=F'#
M4]D]]A+#>1ZUF>I6Z!+<:#M093EEVZ[P=O;:K5B;K&2DCL);/\7N,J@2<5<7
ME@@HNQ-H:,=1;9KO.884PY$PC"M1F*<:QM=BYAS8(R!84*ILX9A/OE"JO)IC
M%-H=)@TEW:I"*.9-LW2?+G*4ZRYS%`0[QKCG'[&V.[XRH]/:7=^15-[<&M8@
MF]I>)K((-EDW5B1CR3+@BK=LV04*L]."B+=%(X"FDF4I/?:MY*+R`>0`?N`#
MXX\A]OC^6JZ::*::::!IIIH&FFF@::::!IIIH&M"WJ7)4Q]NVQW4MVV#]Q&9
MMFF3=I>3*-276$,9YCRRUH.[0^2:X\C9%S%X1@YVT8ZR=8J&=BQPWF%XE&)4
MV7C)LK*PP"3R9D4M].N)O;R`";@0X'CW"4?/`<@`AR`CUWR`CH5I=Y6-Q6,\
MYW!_OCKKO'F8XW?1&Y5VBV7TN\EN4;]8GM<H;/'F&8]"$JN8$6#^J04;4;RQ
MS&WW8QTY8D("SN9":M-^0DX6P5QR>S4MM56F;M_'+[&69U;8_P#7?R9"-YXS
M#.9'2FS+*,(,1D-%1<P"BTVW7]JY,TLDDK^&H=B154!:06*GREZV!]@CSSX#
MGHP\<!\B`#P/'78@/Q^VGZ``1]P\!P(C[S=<^!$?=X$.^^N.]$M391XZ:EB;
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MY*O(_F/`V='N&MUUKS#1\^6[>SCW89Z4=DJ5K81^8K'.+;R<?,':>6[9BV0@
M2O:W8LQ547,<WN\O1SOI%@=]*@_]K21E!6G12ZK!Y"W_`-_E<^U/=]%;C,=[
MK<G7_%=]H^)[1"86R1L=N-`3:5-.P;F&&/75?=88K6*Y=U!6;`,ED>*M;S-,
M*J]J55_BJ33D0]++QXQCVCJ0?NV[%@R;JNWCQVY3:M&C5N0RBSEPX6431;MT
M4R&.JLH<B:9"F,<P%`1#[E%,P`<AP,4Y2B4Q3B)3%.')3!P;@?<'93!V/D!T
M5XI:%M7DC;<,!U.L8+S$_N^<O1F]2[&.XN%M-)R[(S%TRY!!BB5VFT#+2%V8
MJD2O4*\0R/\`Z&:_8_P<RR!.4;5X@IJ-RJ[7\E8Q-</^3Q67%>"\,9#B)=[L
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MX.8"4V9/);%#F(3@[^VB7-29[>(W!(Y9J>;J`XEDX!;):4LXND&-FLT$N[VW
M//5+VBM[$]I[">R=8K*M$3%BHL56,)99L*F9*_6IBX0=JF,*/8VKKQV4655?
MT*VFGPK#]RX81D6G._AU8.6A9&2G#C;(52RUCZC93HSYU(TS(M1KUXJC^0BI
MBOOGM<M,4TF8=T^@+`SC)R%>*L7K<SJ*FHUA+1S@3M)!FV=I*HD)NF%?&FS!
MX\()3<M*9MRID+:3@/<MB'(&3]I_JQ5&SUZ6P[GR#LRFX]EFBH7O#+?+>Y._
MHI0V4LE6:DENKW",Y&K,*!BA&9KM!QU/3"I_JK9?RYB3:5F#;]C#,>"-E6Z2
M)QM#[X?35REN=QQD7;GN&19,2T&9GJKF9U4\!76I$LEEM5<K$NWB=P^0<9TF
M6A\GO7<7(OIVXR#67DT?7+^CL>0'L1'DPB'P(]"(AP'GCP7GH`YT#V<<>[Y_
M[XB/0AU[A-[O/QS\\?.A;G*>::6X8/+?E;:]+Y&KGJ39(QUA>Z6+*6TOU`L(
M[T=I-+L5<ND:-]AL6;>-LKS(F.*(G94$T;57<B(TG*V-25R#7D:ZUR?&PPD8
MA*UV*2+T.YS`-:K$IAP=RV']Q$?MQW@8VW49@S"^V[[?[9G&T8UWKYXO-"O%
M-2M](H]%R9::3DFL8C<.<78DR[!0$>6G6^ESBJ$O$.;9,R"_JA92<9(JR2$?
M(LGRT0_&+ED6;Q%RK&20,V<@,>_314.9B]!A(L'OX5<$EP:/6;CV?1<(G-^\
M0`>AYZ^QC!_O`0$?ZZ*\RU'QMD&F>HS@ZX1U+R+G6*5O^`<=7F.W`4"Z1&Z+
M;@K6=D`QD;FVF;D:V1/'&7MNDG'2TA"Y\QG86$>VC]S]JN$Y&N7-H.P;AZ:"
M_P"4O("`^T.0$>1#KP(_(AX$=5X#D1[Y'_UC<?\`Z>>`_H&JZ!IIIH&FFF@:
MH;P/\A_X:KIH/,+GG+&Y_:KG;U6MT>WRY8GBJ-AG<;LKG,EX2M.+%IN:SZWO
M>.L*T>U5^-R.VN4$3'T\:!M!W%0<QM2M,S8+Q^7LY58(]P1DYD2\WQYTKV5)
M[![:8QE59[,GK"6;9C5LJH8V8Q[>FXRA-K,-N)*YEHA6</'7?+]@0C#8LKEE
MGW)F+V2D64BM6G!(EI`K;0[-L>VKW#-[C<78\/P<IER05I3J<L*TG9"1-GD<
M:K%<XZF[=249I.BVVQ4)T1)S3;'8JW)3E;<-F:T5(-CL68H=;,["=I-@B\H1
M,QAN'D&^8\M0>>[XY<3=L/+/,W5E1NI7,LP,W^?_`)Q2<@P7X)BE%6FE/:_*
MLFS%FT17*U;IH@&E'(OJ8;O(G'N<:#'9(QE$Y[VIY(]0*H2[B#PZ%KL6Y:K[
M5L.P.2L?Y0A*5(VEA2L28XAW%WKT+N+GI6U.$&-K:Q]%QX\3LURCX]C*;$^\
M[<YNIO%Z:X^R?A/`26VJA[`,DY/KM_I"]HK63J]N:Q5"9KRLJYGE;%$V;'T2
MTKDC)4;%DI%)O!0NT&]=60TVU5/&QTX+SZ:.Q;)D=BJ+R!MNH=N;86=Y#?X_
M4FQG73YB[RTFH&4%I^3_`#@DE>?](3A09*Y)7AW8D+#-)MYR33<2S5L\2^*/
MID;#FM[P;DIIMIH+.Z[;ZE6:)AV:8GL+(:S4:2Z!_2H.2CVLVE%W9G3)$!E*
M@-[965:L2IU)2$59/SF<")GX:KL'YXW1P=3A9ZVYFA\N_P`6^N=E3;/*&R#B
M6OO):*QA%Y,R/0X<M-=1TNA'U"6KS>MP"L)(HQ$C^3L6BT*V(55^XE#?0OJ'
M;OL?5+=!6;S<:';LZ^GO=MY&5MRE89XNCZH-YVL8LQDO>-J3Z,A$[-)R%)0W
M#EGJ6X+>&AIHZ"4)EA&+CW3>I`]2VUR/IY;-)2PSUK5P57&-CLV=X_<Y.RT'
M*VNNNI'/L2B[1CLI+#!S\<F6S-C/Y!Z"B*:;%:5DI*9<LUY5^Z>*Y]:X1Q(S
MO&3LDHX^K!KQF>M56FY4L+F,1>/+W5*2SGX^L5VQIO`7:R$/%,K1/M4V"J'X
M=PWE'*3M-P3V`0GS68-%;C=_ZH=9Q_;[4YI5)R'7K=6]K>4,5(4&9P#<]SLI
MCBQ3J2&YM]AC"=0ORE*S*@WJHH63!99*S,YR465D*\NPNDRA'D<20RMN(R1D
MGT3\\[C,:Y]%UDQ':CGNY0V:ZSC!WCB>;3-&97;\0DOBVW?2DL:7Z.:P@U6Q
MPL@"DC2+BWDW#`[M>/9+JR3Q[Z6&P?$U"?8TQCMVKU"J;O(]:RXW;U:S7Z)E
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M^L64Z@URA2BV=`M@-7,DI6J-/,*.Y`Z`N'SXSG.^>]N^&-T&.'V'\[TEGD/&
MLG)04S)T^0DIN,BY)_6I1M-U]=\$!)Q+ETG$33%C+,FZK@S5*18LG7TA6:HF
M(&C;+>\//6`H'U+\C854Q+$Q_IR9APPZRQBT<05VL2.\"<R)B_%.6LX9'LU@
MA9!M(46ZY$89(3K^.)^(CIH"3%$(]GT;L2:_`Q/URQNX]0ZH80]53<3#YPP8
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M1Y3^!T<?)I3*U7R#%HSEGEE'D>6Q(F)&N!DO22`\A_4P?V,(!_PU"NT^G?L[
MNZF65[=AY*P.,[ML9L\QN9*ZY%6<Y&;8:^F.+$;0N%M(J])1A22-`\'2%N8@
M&4%4W(C,QFU28M&K)`RYD6;9!JB9TY</7)DFZ1$4S.'CM59TZ7$A`%5RY65<
M+J"959514YCB'Z=---`TTTT#3330----`TTTT#3330-0WWV9>N&%L!FLM`O]
M.QQ<Y_*6$<=0$[;:C,Y"=O5<C99J-0DJWC['\%PZNN6;+!RDI$8P@'JC>OJW
M%S&/+4[9UIE*ND9D:P=N(VW82W7XOE,,[@J#'9(QO,2M<GG==D'TS$F3G*C.
M,K)6IF-FJ[(Q$_#2L+-1S1^QD8B48O$5$S)@M]%59,X0@VD[RLLV799N9SGG
M&K+V2^;6\K[X**_@ZW"1L%9[Y!;6;[?HRKHO("O2MFKL=D*T5FLQC&<8U>2D
MH`MH6<A$<MC$0+$.[;W]VF(=JE,W4NL^;;LOUG=+0MHZV(ZZRJ4#CZ4Q'?=Q
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M(DDDDF0AO8DBF4A2E'@H``B$C:?Z=.S.@UC"E/IV$XN`@-N]_D<K8?;,;1>S
M.ZIDR72,VDKZM,.+0O,V:V/6"BT2O-VU_.O#0KAQ"@H$4LHT-;T?Z<VW.I7#
M;]8,8U)MCJ,P%G?*6X^(8Q4A:Y63DLGY<I-EIEX>DE9RTOD8V-N06N3G+NU&
M.D#6"42;J(&BE',HY?!AC>_F7--`W)8WH&/[75:Q"Y!V9;Y[?%6%3&L//WR@
MY&Q!5L?2=:M->M<S)+-#Q:RUG15DJ>X@TH^2<PL>M)/W:`%:(_3:+;LS*^CG
MB#)DWDIO=LQ2NQR#R<C>KS36T^DXL$EAU"WM"VRM)33`MP,DNH+>96=2\>YL
MHJKNWAFZC@Z6IT7/;3A'(>5J7FZ[45I9,G8[JMOI%+LDE*3RA(*IY`8!&7F!
M0@R2J==<1]M8$0:V!)]$NADDF;$JYC?@6HH]5C_:9MXQ5@1YM@QOC&&I6"'\
M/9(!UCRNOIV/C3PUO,Y_B*.+()RHSJ+>22>+M#%1E4S-8\4XUD9LP;MVZ0:<
M(W?SN.@+5Z=Y[G(LL4X%W!8(V%/'.0ZW@YC=L/2&;<U2\83)>%\HSU<EE[)M
MD?6^KR]8AMM4D_K"&.9BQR:\=(VLRJ!6#&:VZO<'G&0W;8HV.X$R-1<$W;)>
MV?.VX./RU>Z,GDM.4FL7V6CTRO4""I;V5@(Q]'IOKBO;<BN@ERSR58C&C&`+
M'+2#J;C\^0VP':17Y;'DO#XB9M%,6P&+:O38XUJO#JNLX+!LD]F<+,92KO;*
MYKME'$TN_<2F/'=DC)5]4Y`&KN(<MUF+$[>XMS6RG:WO&:45KN4PW6<ICC2?
M7LM#D)1>:B)VJRCYN5G+%B+%6)6$GF\5/LB)L+-`?F1H*S,"$93T=(-2$2`D
MSDXM$NXW=K:=K&Z/=%NAKY,56_(UE]-?TBZTYM59?LV6')"ZYXWN[G</O<D,
M[)8)"-:+T6#/932]9D+;-M&KY@QKL1.3+!DX5=M\WW'=AZA-,B7.*\@W[#>-
M,OO\Z9C_`-'$-$P6/\R;C[UA.M8"7RQ38>R8VI-D)A?'5CK,^J5QE"]6JT0-
M=>XG3@IBMM8^TV5L@;;):=CVU&[SF3;!<,(T^S/,R8B@L"9+8S:<A(UNUX:J
MQW:U7QT[J+A^>K-*U67;^0D*ZTBX=B>$DY!])QJS9^Z7<'Q$CZ4_I](T#$.,
M/^;+2W-+P5>9K).,8V1E;E*/8.Y66,3A;+*R5AD;*YL=N1L<(BU@[!#W&6GH
M2;@V$;"R4<YBXUBT0*UA4?U$MY-M1P0>7N.,ZU->H?Z<.W#-NR:'_P!%R"<+
M&;OKJI2F.<<<K2\I:BNK_!4.#N==S`SA'`14@UQR[N;B3>%0IJ4F][V)]17>
ML67NN>VU2H]JVM;>LZ[N\%9VBY>S8GJ5AL;/;;$V^M5F4QM%,IV0RDRSO>+O
M0!M+K%$]7CP<A4+RQ9UA0B,6PGI;<K1=GVV?&L)@*N4?#=-K\+M<4L*N`&+5
MHY6)BU:U0$I5K`O6%7CIRX1<2E?FI.*<+NE7*OX5VH5(Z9BI&3M>&V$[/J_N
M2MF[N%P)2([<->6+IC;LA-DI,AYX[^&3KDE+OZP,B-,4M$M7DBP,O<"UTMJE
MH8ZT9(S#EFNNDJ3YK6>]6G3:Y;,I9?\`4\]/K<9DR[4.Z.MPGH\YMRTS0H]-
M90;6DEO^8MLUX+2(ZRM'[]U<*A6F%HC8&'E9L4I9U)Q$I-N"H&L(QD7??J+;
MV-S6UJZ>H_-XJDL1IO\`!6QC:OG_`!,_GL1DE)=M(VW/F6<>VRI7>=1M#*1N
M4&NUKBDE62%/$-JF]F9)="+DUU7"KK8_A#TS=BNW#),)EO"FW:HT+(568W"*
MJ=@CI6WOC5""OT@:5M=<I\7,V.2A:G5I*1,=TE6*_'1]?BU%%@B8YB594#77
MEG8-M+SI8<HVG+.)&MTF<UTFLXURLM(VN]-VEZQ]3)HUCJE+G8R.L[*,6K<!
M85'$W&1:+1!LWE7;UZ!17>.3JEDF#1GN+W9[X&]JR!MGE\^U]&R8X]5CTOL/
MHY6H^(8JI+3N(-VM:IV2YK'\Q47MAG6ZC*G6=P#4DRC.-I:TUML6(L!R%<R"
MKF1M@]0C<TC$W/<M4YBH3F(L+^IU7]@N0-NBV/N+S9*/+Y&QS@%UD5I=$Y1"
M9@\IIWW(<?EQA`MHF1I[G%YVD(+`SE8UH#999/3MV:7-KE-E<,(0UL;9M<XR
M?Y5)9+%=9H]TE,,,XZ-Q3-2:S^RK+HSM"C(EA%UV;CE&4JRBTE([\6=HX<HJ
MW:TV3;7(_+ZV=([#]=CLC.K)7[L\>Q[J:8UQ]?:G4CT*L9#?4%K*(T-YD.OT
MH_\`"T1>W%;4M3&#1:,$)4J3%F"`2G*/(<C]S!_^DPEY_D/'(?L/G5=/&F@:
M:::!IIIH&FFF@::::!IIIH&M#OJ)SERF-_NWG!T=NJSA@NA9&V-[W[_<ZUB?
M+K?&BBL_AISB:3H%U;NDVAI6'DHL)ZUKN9IJ\0(]C(APR6$L4UFD7>^+5N2=
M0JDT_))S%9K\K)$9+QQ'\E"1C]Z5@X(JFX9%=NVBS@K1=-=8BK4%005(JH51
M,Q5#@8/(LPWH;ML=89CLQ8ZW'9.SGF'./H5VW=T]IT_88>\Q$;G/'F1<'U%7
M(N(L6QK`T57I"NT.XY$E)>O5R*=,;9)U@DE8V$O-,Y-R[R]G[=[E'!.0<PPN
M#MTV0,G;%+!1/3+L&1]QLM?#Y+DMK\+N'W%.,7YOO%<S9(C)'ADKG@EI&9!?
M)O)5RTQ0O*K9(@6M:82#3V>H*/H=)B73-]%U"KQKV/;*LF#N/KT,R=,FBXJ"
MLU:.&K))9LV6%9454$#II*"JI[R&]YN:Q]$I45`R%6C*C5XZM2P/"RE?8UZ'
M9P<B$@04GX/XALR2CG@/DQ%-X#ELK^*((D7^H7K0DGMX_%=RM6PINLS!>\(;
MO'+O#KWU[]FE8SIE%3/4?:ZC(;;<B>FK6X^;;95R$ZF742[QDPRM5(+'\#9K
M/+&;L)FOLZP,^YFT7!E<Y[<MT,7E/+GIZVBS9Y/E$*/ZH?K+T.N6*P7%*Y6U
MOCFDXKW91^'(97\2L:<DSM\9$J)JHS?-S24Q"NH11$')9)LJOZ@BXRQP2"=5
M<E!I1:V^_+P>U\M3KY81V$45`D6#J)"."/<!'$:MB,/K-C_@RMT"MOI`BF!?
MWA1:4#EH]"HU@'C!^YE&+H*]#@Y9R3Q<7+N0:K_@OJMGSIP(N'#M`Z;E=815
M55.<?=HF5MTV^WA[NV\*PYVVR;W:A";MLC9<Q5D'TEH#<Q".Y[<(VM^2W>1J
MYN8N,-?[):H>E)Q\#@*QO<<'A`R[MBH;Z6IF-:HM"QEJ(DZ,L)=EUCW-+W_=
M5?,44GU)1P,KBG(VSZP;0HUP^NF;)W=MM]M=9K<C;E*-2@R5`5C=<RR_DB7R
M9C2R6EG$W&R8T3J\-+14E%,*VV%WZ*YE'"^,644C/-\;42.N%@;X^AD9%G6*
MXSLEFR/+>UM3V"2K=HC*S%WFQX)!I%6<6*3'DS9VZ'D;P&FU$TG!S8U>NFF*
MPR5C:W*C!Q0R4!'+H_AUV,(_%I^+B6:S?_`5:QRS9NHC_AG3$G6BM6^_O<*C
MC/==L+P[D[-+K;OMIS6TW3R61<HI9!0Q"VDLIXNI^/Y'"V,7^45W<6%;0L#.
MRY'N3:'_`#E@-UDL?Q\4JG)LDGD2]U#^CIEIH-(].S$;'<9/I8YOVSWU)OXG
MJ[#+#"/9R4]2-Y<XX@LF'-&JLI!KDAG6K-/22UN17052CS&D$6;1%%54?5I?
M&-!=5I^]R6TJ*]0KI!M$H[O#:%7KD&G`IJ/C6!^M8$E(R-)#I)JO!EES(?EY
M"*+@X1*4QM6O2&&$<B52I7_'C#&5SI<_749"D6^J1U6FZ[,52=26=(/*S-1C
M9=B\@9=!\NX26C'!H^01=JK%%8C@YSAY/MHE5QXZC?\`DY#^-S->I(UM-O-1
M0;(;@;!^!_.8K;U?Q85^N"VL!6T(+^9390#^-BBH*O$I1:">)K@]_#G_`&J[
MMLEY#VQ;E]PL1ZFDQ4<_4S9GOB-F[:-57<\WR#B'.6-[A)2%:NL_'VNZSC7;
M4YP[98MMCJI'BJ%6J]F:K3T-%-@>R3UI+K^MIKCF@,CQIV=(J#0\,X.\B3MJ
MQ!-S1CLZJ:QW4>9&/(9BX.LDDJ9=H**IE$R*"83D*(6?/O,"5VZQU)LJ^*(;
M(><COPC*K,%J+*WY7-4(\TK)G;0SM,DQ=@K,8D9^]4,A)$AVA`75,W3]HB'F
MKRIDJVXQE<78$R+ZG&2\!U/-^Q1'<OAK=5G/)%A?NK3N;M=G0/D>`HEAJMKQ
MG3[N7%E=C:)/X^VT32UBB)F*R%/1D3$RA)%(T79=HW#9L@MP6[JZ2F^C-AR[
M;]\?I4U"IU:2O;+'V,Y"&W*8YQ4&<JO<<-/R`2,@+E(6&VR26,+"]=.\;2C1
MPR9N$9R`DGIO4[`-,.Y3J%-L%9:XYR#1$!;3E!F(9I6;15419JJ(M)>I/6J+
MV*0,V7152;OX8Z9D5$CD25(8@@'=NL<X_?*OEWM'I[M>3>DDI)9U6()PK(2"
M1UE$WSY1:/.=V\3.X<'(Z<&5<%.NL8J@&5.)B89[<>ENS5%Z2J=,A+1ZCU)B
M\F6:XW:J^H9GU"T5>WY.F[[8ZI!.'$&>DR4K&STF_D8$]ICRO%&,@\(BK8XN
M)9`W5=1\.T!ON0U^!I%1C!S(O&,<Q9NY=P1W*.6K-LV<23I)!-JFY?KH))JO
M7";9%)N19T=54B"::13@F0I0_?HIIIIH&FFF@::::!H/0"/V#^7_`!TU00`P
M"`^!`0'^0]#H-3V3O4'R5B_>KCG;Y,8NH3O&N1-Q%.VXLI"%OSRRY6BUKO@R
MW9=ALS7")KL9(4G'%(>6&K+8U@,>WJ=BLI6Q8DA>XF-3JK>/&4S-N1W495K&
M:8;:]MFQ]1LA[@Y+;OD[<X2)RC;I6DTIU3,<V^FX^C*>WG(2+EWS>T9`NUT:
M1$?-N69Z_4&$:^F9Y!\59@Q6LR9]*[;_`#>=[5GE:^;B(^4M&XNF[L#4&!S-
M/0&,X;/=1H37%Z]^AZW$MFSHCZUX_9-JM8V;^5?QX1Z8JP3:%?G!XGE7<]L1
MQCN?R!BK+DA?LY88RWB&+N54KN3MO>3Y/%UQD\<Y$/#KWK&5G?,VL@UG*987
MU>@9<B"[(LO7IZ'CYZKRL-*HBY,.?/#U;HA7E3U5K[28O=!D:$P-%2./-@DO
M@^M;R*N\NQW&2H^PY3I]"O60VF'W40P5I]G:X"JV08N7G7\VLS99(5B[!%U-
MS$J,VCV0ZQOZI6;PRXY9R>W['37!-?\`5"8^FK8+0QRI.2.1)*;OM=I+S&>4
M*S6U:9'0989E-W.+2R!"SDJT?H,7ABU8TFI%K/)&5$WZ7NV*4M60YB*;WBI4
M_-<3B"(S]B2L6Q9IC;.`8)7B#8WD[W'.VCZ<1G6L?!15:M\S5Y^OO,F5-H%;
MR(>QQYU2'Z3(WI[8LA:QDBVTZ(RYD>U.MWT-ZB<9C=CE"K5HMLW041O"GKK.
M'F[+7T8.OU^3-6()I_#LT_0JJKEBT-+/&C91Z[T$?-L6^>7<7G%6+(C`-"QP
MIN!WT^HU@>U%@K]9;0T@<D;>6F1,B.\CD>R<'%JV5MD^4ILNI/1I&E9"`6E6
M@Q"2S=!5L6RIKUC+>C@K%&3&N'*97+5;=KF[_=9.Q=VNLW'TBPQ.SBUO:Y;L
M-8LMR4&W<3N5+BS9*V5C^8QGT*A6BEEY2"FT51(CEK"7IIJ6;%5=F<W3N2,+
M9DB]Z6Z7>927F&<CQT3=<6_\Y:R9!;2F,9>XQ+*<K\V+O%]X<UFZ.(#\4T;3
M*IWE0L8K14;.*Q+W`^F7D/&]GVNXOP1CO=#DW;5@B@9*;T2RXHW;XQJV9:/E
MG*>2V5ML4A>6&XYDK39:@1\8P;*U2>J+6:O\=)NIQO,$>1JC-NZ'"3IO2*R!
MZHN;,<WC;DVM>!L;PE.R_:-CE/L<*WRE-6;*L:\WLW2/H[>P$J\;4F2F.:WB
M&;FH>*DULVQ=+=90G3S$/0"_7AA.\QQB+U'MS,7'W:FY'@Z5>\R9(]0#>OMO
MPBA3:QE*T5RK5C:_(VV0EU;%5J57Y"]3,/&5>K1T?#C`-UY:3EYUQ-3KB*C6
M+@I<UUWTA:?D!Q'Y3W.YJS_<,\6I+;5;<N.Z-EQ[2*'9\Q;4IU"9PAE-:OU.
MOUMB^O=+8L(>%?2J4=%UBR/HP;7_``7%SPL'4=D:Z^D/MMMQ[?)1^0=S%"MT
MUN1L.Z^B7J@YRL%?M6#,SW8DRED6:PTZ!FY9UZ*R:A8K`TR)!3K*RLK:PF7L
M;)>Z/*U;-P^.<-VVY9CZ16XC=^VPZMMOW-8]VN9]R1_HPRJ#R33I-NQ-!7)1
M65*FU19OY6,F&=8-<*$WEVD0[>,):O(VIG%+#*-4=5>9]U.X#:/O`W,[J(:@
MX^R?*X[]&K97N`SY!3F2K96HJ3B8+/FXI&[/,?H(5>9&0R!8*A&"6*-)LZQ7
MR/8%JA-/5B/$`UZ%'FT[$TOM;NFT.Q!<+3BK)&-<AXPR$_LMRFIC(5VB\LQ\
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MRE7&#!X^/(2QG1%.S9>E!@!MF=QFQ;).YIW,J;C:ONO:U(V<[`SQY'YR@:.3
M'LU;T*E%-(]FO_'M9(+2WQSPZ[$HK.PJZ-;1?.TE9&;3=FV*MEN(G^#L*S&2
M$L=*6*VS];AKC>7]P"@)7&7E)]]7*&,JW%&"K+&;FI64C8XS=ZM^.?N'4D\D
MEC^X!/34C6?5&D\7;=MASFI85Q!@>L[D\63L_4%<GW2\1."29)1OB<'"[9JO
MF<(0M5JV2+&R?3%JK<GF"5IT#:@CR5ZKH/)1XY2@_0^`\_;R(=?L(A_?[_8>
MM:PE/2@V]*X8@]O*]US>_P`*,L6-,*63'$U>HJ<@+WC:.R5(96B(NR'?U0T@
MTL$'9I1\V@;W5W=>ND/`N5(AG-D(5NNWV=IID2(1-,H$33*4A"!T!2$*!2E`
M/@"E`"@'V#0<]---`TTTT#3330----`TTTT#3330-05]2C*B&%-F>7,E/L6U
MO,L375L>EFL?VJT2=1B)6+F,GTN!6?&E8B-DGJSJOKRC:?:1)/R\DNM&`P/*
M,@7`QYU:P3N5V^4?=-ABWX*R0]L[&E7@]>_/%:=-DKL^H2MV>&MT>@TF18R!
MVB2LO`Q_XTJ3<3.V15V)S`@Y6*8-2F0O4"W-X'OWJ5VRX5"MY!Q3MRSQMSQC
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M(II#.K!)W&?>(I5^/BHZ$_%I-85@Q9-&S=,-6.4/5)S_`+9*`NPR5BS&%PN[
M?T[H/>3B)PA?+3&K[D;'47=0@LLX@@6PU)9PPR6P5N%1E(&/BF<^YL[BYQ[=
MG#M6S)\X3S<CZD=_R#ES$^&<+U#$4ZZW(-VI,$9.F[K85:+*&J.W*%W!YIGI
MB,B8U*7E8>G!;:1CZ&BJU)C/O++97SJPIP+*GS*;B5+?T^MO*_\`S07=P9W+
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MN&US^%#V+%&28S*;#*3*T/UY6=R<_P`W2%AE\O66\V`H-7\Q:<A35JGY>P39
M3-G(OI`3QX,46S-%O%"M^DCMSAL.(X>G[[N,R22L3>+YS#F2<F9DEK;EC;TK
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M^-K]6KL8('C&*3XRCU2T3>G;B?'=?I,S0W>8K'9<'9*W/[@,:U]6_P`#[I_*
MFYUA?%,D,)I::C(6)D(>P/L@VA&(C):4BXJN!-*F0>MTFS8S<-=U=]<;(F.\
M785S]NWVSU?&V&-R^R+).Z["DEC++*M]M:ELPO`5JQ7/%-\AY:M0<=7CW*&N
M5<F\>V:-DYB.9M7AXNXC'S+9ZW99?S]ZI&Y#:ZIGS'N3MMN-K#F3&F",,;GL
M?IT_*=@98XOV+LGYLC<%6ZKJSDS4G4E%9'Q5=9:*;F*[*QKF0(:40LC%S5$T
ME8<_9[$O2QJ+;9!MVQ1O6HMPM5VH^T.X;5Y[$V2[_4\B5C&]=R@1FRS.UH$]
M11514+D`(2("(LCFQ2]HJE.9PE/AGT$QBS1Y9)S'I:8(M]*N%4R+>\YY(F[G
MBG#>"9#)EKR`R6R8UPU@>Z?Z0L?T1A9659:HHD/<"IV*[6A6,7NF1)A,DA;[
M#)+$3!,28>N".$EZJ>2:A=\@[=;]B"IH[DHG>9&;4Z23&[[).3\=RL;8]L+;
M=HPR$_BHNFQF3I-2L8Z5<P-EJ=<@3OY"S-B/HEVV@57+AC:=S]3S>W#05)CT
M]DU'Q[DF8VF;L]Q]HK&:<MVZK*0SK:7<*]7Y1BA$1V.'4X6L9:AYV,LF-))Z
M`3;=A/,RW6*K;B(?MWTN,O\`I4[=,RRV6K;.6K.%:R3E+.6.=R;#*M"R8I4,
MA8GS7BS'"&(:M=\0SD1"MPJ2I\9H?P788-TWF:[9X1PZ0FXQTJN9?5UJ^F[A
M)R:$</KGG&6DXC`&<=N[R=G,G+3\]:*QN.E(V;S';+;+SD+(OIS(MMEX>,?E
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MXEO"SZJ<F[9'4E8"`8RY*J+-_//UE-Z.L`9BVJ;;MP=BI-LSA@_&>5[%CAE;
MXRD2U\J459'5=C+]'-XFY1C'\R063&-L;%FS3E(]PFNT<*LF3OZ)7;-LND'G
M<D_4(WXML`[Q)>KYYJ<K=L,X>]/3.&++]?=OU)B"7&*W.RLS7+V9+&]?L363
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M,D>]7EH:.CF)"8X=?F6MN6;J:9NWWPYJSC,L<:9`Q%5L78CWUY#V79Q9Y!DL
M61$D2LU6NGI4%=,?UP[-UD'_`)P=ROR;++%"IL\JKCJT4":2@V<.\;-$)V0A
MABK>GNXP=Z?FQK)5@R]D*?QS:]N%OR1GO/M5Q=0<\Y&P_;+!=63.B9#SEBE<
MX9`EMM!/PE\4O62L>Q4M9H.R.F[N?>QE7BOH']`]2V%;3*EF>'W*IX3I$YN4
MC*O7:P\S]88=O*90L1JU6$J>RM-BG%0!"2O:U?35BGEW49!9UHQTZB@E"Q:Y
MV@]3&^G)L<A(DD!`;9L75R!!E9HIU!UN&<5V%EX&Y33*PVBKV&)A7K!A9:A-
MR\;'.G]0GV\E65BQT>U"**S9-FZ99G_9BL??=F3(N,F>RZP8QL%:2@LD;YML
M&*[TSE:A%7!*RX]RO8W$0[_AZ5D5R!591F<6LK&6B/9NWY`+]!H#(ZX/$=?&
M#-V6^?\`YP.%O])V;*#>\6W'U)]Y&QJ=Q[#X0AJ2]>TG$](R]9L>Y$+:&\Q,
MRK*WPM@QRSC7T<S<#792K.W:D@1>?,5TTWC9+PMBO,<?5(K)U$KMUCJ-<ZYD
M2GLIYD+IM6KU3W`NZI;89(BB16-@K;H?Q,')H^US%K_XS,Z*GZ@QE&;,=K4/
M)UZ9C,&X^8RM3RY:,]UJ0;PQDW<%FB[,G,=<<H1:WXD3,[Q:8]Z^96"PH^V0
MEVCY\W?*KI/715A,Y.-6M;>S-9(4]3[:W1T,F33+%$QZ??J*7*<Q@C%0AJ]-
M3M9-M_K_`.-DG2S8\@_=/6%L,DBHZ46"#:Q[E"%(T_B"<6<:D=G^_?=)L@V*
M8(82-OI.2L=QGH>X:W38PJ\EC^.J33$-BA\NXCP,S_.+4WE/S*VU=M4<EM+I
M=G=F=-4$)*J2#R-7AX"04:,_6%E7;1@/.%FH5TRWB6D9`MN+DK6ACRQ6:%1D
M9>GHWE@RC;:E!/C"1=BG/-(V-*^(F?VG6CF#M,$W;)LNE8\3L=VB0D;%PL;M
MTQ*A"0N%Y?;E%PAZA'NH5G@2=?C*R^&TXAX#B-'&;^3]D@XIBC4\$9XBW<E9
M%5;-SI!BO9A<-T\E:MQ%=W(62@VFN1=BHENP$[AINAR>4VV+KG5#`Y993C\6
MQL?11!6UP$Y)8ZL$.V;N;)5I%)"2:B[AS/GVIC&F=<L[RLM>E%NJELB0<&VR
MQN`]1ROT_&B-"KRY<0!1Z)FO&M$CU9G\0RM$[8H*.HAWF2XB>?\`X:>M4JJC
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MUHF%ZDQBAB8![([54M@FSIM#U6NL\`4.-K=+J8T&OUJ);R<36F]"&V#>_P"!
M7]>CI-M#3E*_C(1L_P#"<ZRDH`9H1?\`Y?\`6$QAXF]/W94?,62=P"FV3#ZF
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M0\_96LI+&,[$GS?W[I54B8?V&FU.?E/R49*;K,!+R`UR0-+5\7TG$LWKO\CE
M#D3-)0_XA=7\K?F3(9XP_#N1(451`+HU\T446Z2:""2:""*9$D44B%32223*
M!$TTTR`!")ID*4A"%`"D(4I2@!0``^FBFFFF@::::!J@B``(CX`!$?Y!WJNJ
M"'("`#P(@(`(>0Y^?Z:#6+:O4KA6N?<^;?L;X9LF4K1MUB+&KD+\MR1BFK3$
M3.0^#7^;X963Q]9[(TR/%8QMR18+'E>S4M65:`_R+._D+1ZZ"(DUTHFP?K4S
M-*V8;>]V.XC:?DFI0&2=O+#<=DJUUNS8W2QA4*,\D:>Q9(U"Q6"XM_X\R+:6
M=G>VBH8+@W#K*;JIUB8<RD<RE%XB/DI47OTSH+*.Z2)W.7[),?(V.J7O(<]2
MYF$Q=$5S,41C'(N`YW"LEMQF\S-+,X<W#`C&9LTSEB/I4[3U1;WE1F*+U%@T
M,1Q"6V^A);[EA6A8$E]^%W=X_I>RNZ['$V,AM\Q3)JM<:3LO%.*S9:5^,E3M
MZ)?X^NPD;3[];8]"1GLEP:/M4E*PLTAC1!*WTQRV<]FCKZEZA]QVH;N_4<B,
MT5S<KF+;34=ZNVZC+YE//TZ?QSM+KFX/"F'6U:BG,).6J"N9J,YRO>&QY1IC
M^I6$E*BK"SG[,]*#A(KC(&!]^[O;]2\WTO(%@O\`N$RY/^H;OUQ=@.G72_P<
M9/2N/,#6)&P2<4OD&ZGC:O7*SC^L.V<5"(R!T0=/I6`K\>DL[D1<%SM/^E6K
M<[=N&_CC<1+6O$.[')NV/+^X''#S%=686"V7/;1$XY81[&`O\1.,F]5HV0'6
M**2ZM]="DRLNU;,Y..K=HB"3#EP6W+#Z3]U3D6F2\4[NIK$FXNI;M]R>Z7&F
M68S#%:M5=K[+=D@S:9HPS;\6V:XN(N_T*9:QL5^42*U@K]HA'\1%RC>2.[:`
M<Q4D,B;RZ%9_31RAO:)5=P=2QZGMGR5E6>J\1&-\7;DJ3!UNKSREQ3AFEO=Q
MK*LY$IA(J7>1$DJ[<1RCV,:S$&M,,G$>9Y&V\^KS2<1R=XJA=NFXN]5[`>'=
MIN9\OY(1D,9.8^M8<W*J.HF+R`Z7D;FRF[;*U!2*>O;C78B)&V2B;.6E(2'<
M,FHK+37ROM2E\O;(\L;/K9F>V3TMFC">1L/7K-UJAHV<M;\^68&:@KK;&M:8
M/*_7HYT"-ADSU6N1QVE:JR*<5%M63F*C2M5X5WCTE).[1FYN+6W(&C$]SFUK
M;-M=GU6F&XY<U8A=M#F?4A+?"`\R$M^*F[2VLLDWF6$D92*8F*T<1B1%$%"K
MDI>U+YZSTFEO.WI8^V74[&%FO$>>4=9BS'5L'T5LZL]1H%:&Y6J)L$\R4MN1
M,@RT%2Z9#C%5F43:NYJ2(XF)Y6(K<.S>2TNV2"-;GU1`@++DFG7_`&JYMQU:
M*-L@8;WH"#M5AQ,A(Y*KCAS&0<KBJG-6MR<+$RG6KM($HM@BYXD3&,I]U7E`
M?J15PJ\A)RCW3[8G^YZC4?'L[:J(M3(ZPB^RUCK).&(/+^)LYU5>H3D`YI5Q
MHD]98A>-CVU@DHJ\0$Q#V,D]`6"MQ(MGJR8N3J:UE-D58=9B]-7::THFY*UP
M?IQ5]G<[#NJMC1W6<=WZBMJ.G%U_"KFV.%W*&5QMF3(/'EAM>+VBSMC4X?&\
M8O873A#\`22*D*7U/%IBU9_Q_4-N-OF;_MNQY)SV5*<]RU@Z-L]-R"RP,CG!
MI2;354[J\M,55Y;\6WH,1F1*)>8UF[BC()PDN_BDF$C(X4C?6.=5;;UA3(>2
MMM.0);+-KVUXXW1Y1Q3C2R4&=L5>P_D1Z$-7+I0XH+`Y4R++6YXQL<U6,2UU
MXYR.G6Z_(+3#!G)$;L7<@+WZ9-;REN63W(Y`R!#R-GBI/,S6N6.O8JB*EF1'
M%V8L42>,G.![=F&,M!U\A8?J3N9D;K5JY9Z@X=QT^$<V;R3:*CP;+X5H_I29
M[Q,.`)[$?J'Y`I.1<7[:J7L\RG<E<`8JL#/,^WS%EAEIK$T:WJTA*)L,=Y-Q
MRVL5FCX3)[-W:'3T;%)NIR!D@,W:H":?D_5S73U@ZK3LC7NI_P#-8W%3E/QG
MN@P+M6N618HV+DVK2[[H*/C>X8(E(JG2=]8727B;NXRQ18-RT2BV\W4G,XW=
M6QA$D(X;MZO/41K&24,1,;EBS<UA&_UGU+*3LPR-0ZU=<9"-1R^]HC7(54C,
MI6.M6>:@,@X0O%"O-5L;]E17$NZ6D'<?%RGY8\B'A3=_=/2W7MDYFV92S\_9
M&S'O2V?[RA*_QT2P/(";V;0V%(*BTEQ*OK\D^LS"T,L#TQ6Y6:2.WG7L@\LC
MQF1L:2:DCOTROICRLG>+-=ASZ1!:T>H_CSU&GD>7$[=1%&X8YQ+2</1>,4'!
MLA`H%2?5VBQ;V0FA(%@-*KO%&YT6BA&I`SMA+>VMG3)=:A:CMZS0I@G(D9DM
MWB[=(1O59/%5I=XHL1JS/-YZ.C)U>Z8_8VMVB\?XGGK7"-HG),.R</HI9H=1
MHV<3NUK4V=;"\D;1+,\K<9NUNUYVL5BQY-LF#=M\ECJH02N,?])]HG[0[K5A
MRW'OW=IR;3*4XM,XSQQ7)*)KR%>:N&)I->?6@H`\9LKT#3330----`TTTT#3
M330----`TTTT#6L?U;\A7K$FT1ME#'-LR;5K-3-R&T-;Z.*))1E9[C`67<YB
MNDVS'QF9#)?GT?=*Q996#5@#.X].2=.FB2S]LW^L8VSC47-Y.VH-VF!)_#"5
M[D,9RKRVXKOU:O,=7XNUFK]NP]E*GY:J3I[6)E=FPL$.K8Z7&M9J(4?QRKZ*
M7=H-I%BY,DZ3#7?9_4TIMZ?US&F1L0[M=NN9Z#Z@NU/;E?\`&$5:L8QMAKLO
MG63&T8/L=VM]4M]HI-\V^9:@6JK:VQ5$G+#,'13DZS))1C]J9V7/<#ZGF-9O
M(F,67^C>_-MON;\^6_:WA[=$5]4I#'5SSS3E[;'+UA2NQ\RO>(&L6:RT"ZTJ
MCWN2B/R:Q7*"3AA1CTYRO/)2T+YZ7JN1K2ME:R9T$V;K!O"VP[M+W=X_&#=M
M6IPVT5B>.PUB6OT5>^.QJM(C$'$@M,2J]FL5NF'TO*/%I<AE6J;3[4'TMHFC
M$K&.T\V3DAMIQMNUO6\3$6&QI<<UL6/\@V\+M/Q542RF-B=.YG'M`RKD"P99
MI3)>I-+<ULZ,+'3%PEZY&&C'8Z.MIGJ\8LDPS4CDO#F6<+S6**#B#(\;3+FY
MH3_(%HC<^90?8:Q#3)JF5ZT/Y;%&7;CD4*[!(XTR>2OR\<2YUU_(N4&X2_Y9
MU^2_4=W$T^Y;<<>)["LLUN[Y:W:2FW2V0-YO>*(]B:%C\$W#.4==,279K;34
MO),3-P-:<I/))K*,TZC)UZT5&P,D+?\`DT<]CU5/0JD&6-K'CR][U;_;5)S`
M-1PTC;Z_AC&E"MR%NQ!FUKN%P1GJ5L#-[-3MIR[1\KLV]QND]899X.6YY$CR
MRG8MSN&3B6\UL`S_`'J"P+/Y2WSVJX[@L$;CVF>X7+K'!>.Z[5%(]/%%^PQ(
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M.$G6RVIQTY#U:M1-GL1K?9(N`AHZP6P\2Q@3V><91S9M+6(\'%B,9#&FWZ3B
M3-%1PBQCA="S:"+=%/0E\/R4YK@TTTT#3330----`TTTT#3330----`TTTT#
M3330----`TTTT#6JK=_NQWBT/=-CW:OM0Q'@&]6;)>V7-.<X.P9IO]XJS!E8
M,-VR@0BM8D&-4@7BBK*U)WAG&1#UJ]%1G*+&E)<[*)C%$)/:KK4_N3VE9/S9
MZC.V_,;)MD&J8@QQM8W,XELF4<<9.KE)L\1;,TS^,W4<Q:1"CEW892+5K]-G
M&SJ8;PX/*O/O*].5M9&68$F(H271$3]9G*EKJFU/,],P]CB,Q-FB(V>.;S29
MNPW:V9MB9+<OF93#5Y431H\,K4,4U+$<TBJ-7NV8Q8PN=Y/B%H_X(R3AX2%F
M;\N;L<YA2+AEQ?"EJGL)?\H^Q-@+;R6&0NM;-6DJ9<G52=0MADG!Y@4Z.]A2
M0[QT>,C7LZ_DU;(LN4Q7<6DRW+6/T:ME,Y.JR<3%YBQ["+4/`=#5H.+,\9-Q
MUCQ0FU]XV=X'MBU4K$VQ:.;QC<&WTH&RNE5URJ+N)5P@O/J%ER7X[]+G;,XN
M<S=$'N8V2LQNQJ^]H*RGE^U/:+$;C*HY0D6=Y@J9,FE8**-)S*)IFRQR#86E
MF?K*!-%>,BH,T!.$KB@Y&>J'NA8-]O*F1J1MNH4)<]V>[O8=FO)2\EE&0Q_2
MMPF!S90+B&S0*@.64BUQ;F1QCLT.^_BX[69J<V[(T3D)07C`#6WC#U9MT>6-
MM%1SG6\<;7X>P0.)9=[N5J.3[UD7$D3@S.<KN*4P54L?25EM;=03.J^UBK7;
M+-1):/CLD74T!%5_'3)60O%>ULS<^G%M?F\-9$P)>*S/9&QGD_<.]W26F$O5
MD<32Q\QR>2X_+<I/QTBDU8O(UB_O,>$DK!-U/RI%J\D(EDW:1;Q5KJWLC^EU
MM(R11MR-%<U:VU!'=/N`J&Z'*-GQY?;#3+N&<:(M27E5O53M,6M^/JKV*DZ#
M"3"+..`8XTLO,R!VIG$R^,H,=.WVB!6*O5CS[,7/"LSE['V%\=[;9;=MNJV1
MYRS+))99JLK4,T8+E+B7%4JRHER*TDZ75\]QD"R81D;?SJS--N!',!+KN?S>
M!54V[[2;WFG*&WG&61]P%5IU&R;>X(UMDZA1UK$O#UZ#GWCB2ID<[/:@"92L
MA*>XA%K:R7*",;9%I*-9G7:-$G*^MK+7INMBPK'9SC'!T9D/:;N1SLTW)[O,
MNY\W"W.\W"K7:LWZI9#G#8[HMA0F)R3R#F.:K97BMUC[)"1=9F9"<F)9B^`\
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M8V)#O*VT&18M+)?&L`]M+6+4:%?N6_ZL>[:-Z^$-V>XR0QG>L)2&TO=!GBJ;
MFY^3LC:P%SOBJXLZ90:7E'&]6@@AG](N59RC%XQKK>%MLU-0LCC@LY97J$//
MO6L,0F$<)["=S^.<J[<[K,M</.(;%N_'U"]U=M;,+_9EWYZ9O7F<K2-<KM>*
MM0FZ+ZT4`N4C!.GD58^,ETX%5&,=)&EBG9B2EZ)EV'U--IM9M\K3I&R9!46C
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M:L:DY_`_FL21WC3'/J98XS;'TY^1UDS`1Y;?W>]G]=;6["%SG4,I6#%UZO%$
M?T]Q,.X-M"X\7M[VH23AU,R$D1W4'L6-?=$&<<*L2Q4O7I[;]+WEZAV60MNW
M]_CW$]P]/?)^)8BS7+*"KK'<MM@;03+--`C:U7JVPJTJ7)$RRD[E%9=E"N+@
M>+6:8T<1,=#%:R4-?$7Z?>[*K-(&H,YK!-DI-0]6N[^H)7G@S-UK]G=8\R!F
M3*.8;#5)E!6ORL4E;FCC*3BNP;)F=Q$@$!^<R-@$)1*+8"<,L$[6/J.[3)"_
M1V/V^0)95S8IK+=4HEL3H=V6QYD^\X(;O7.7,?XNO;:"7KV0;W34XF=*K5ZP
M[?R<^O6[,UJB,\YKTPDSZK:[ZF.TC>);J[3L&VVZR\E=,1+9QHC^V8ARACFO
M7['4?96].L4O1['?*M`0]K=5*S.V,/;(J%=.Y"!=NT2/D"@FX%#7UB?TLL\4
M2F[2\!6JTX_MV(]@>\;+F\3">0&4Q,0V0\M#9&F>G^*<0W.O'K[F-H:53G\Y
MO&=YNK.?M:=GA:E"KQD(T?RK\&%R[4-@V[K;7$[(TD?]!4S/[2-C.>-N*[QW
M=KF>#LN4KK+5RP4"=19MZ4VD2T$7]&AV=M$SEI8F32=>'B&CX\0F#\-[NFNG
MKIK`:OP9K8G#HVDT/&&LB-?6>N(%*?%D@,RG".))%O(+Q!)'\26-6?MT'BK(
M$#ND4ES*$+W&@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!
MIIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH
M&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF
M@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@:::
M:!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!II
KIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@::::#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g683889.jpg
<DESCRIPTION>G683889.JPG
<TEXT>
begin 644 g683889.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!#1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?0U)/4U-?4T5#7T903U]+7U!(5"Y%4%/_
MVP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0'_P``1"`&Y`?@#`2(``A$!`Q$!_\0`'P```00"`P$!``````````````<(
M"0H%!@,$"P(!_\0`6A````8!`P,"`@0'"PH#!`@'`0(#!`4&!P`($0D2(1,Q
M%"(*%4%1%AHC,F&7UQ<Y4EAQ>(&1DK?1)#,X0E-5:'>ALQBQMADG0V(E*#1'
M2'*"HO`F@[+!PI/_Q``8`0$!`0$!`````````````````0(#!/_$`#$1``(!
M`P(%!0`"`@$$`P`````!$2$Q00)187&!D?`2H;'!T2+A`_$R0E)B<H*2LO_:
M``P#`0`"$0,1`#\`O\:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
M:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0";YB,8F)LFF(
M/:<N/;N8AN.>#!5I<2CQ]O`\#QJHCT_\HY!VY='9;8W49KT,R9PQELC1V6.)
M?XEVJ:L]7#&U>=*3J(.UT2R#3!^8B;MI^443=I,HNO8X10<D:I%:BYN/S\(Q
MLL',5Z3*J>.G8J2AGY45116,RE62[!V5)8H"9)06[A0$U``1(<2G`!$.-,*J
MG2^VC4_(FS#*<;3)MW<]AN$F6`<!2$Q:'\HW8T2'J2E+K:ULCET@96NSU.%?
M6`*O97B*$A"/+79GK3M6E!]$"+[HXW*3VX8PV$;)\>!%KX9E)[K2Q3A[,M'+
MVU&:[3M^:-&Q@LQF!>HI-4WL->9QQ9$W3!XM(N?J\Z2[+X-4KKFR/OSWNWJE
M75[69F<P]BVC]1[?)MFRMN4P'M0?[KK[AC%FWZZH5G!JTA@I-_:9&28WIP:5
M99/RS'46[H548=B7\#H)"S#8X&1*W=+/#DA6L1Q6*LO[D=MULPED/<GD"AY2
MPAD&LM+\V#=QD:3REGVFRPY$H60:?.4NZV^0;23>-DJBM)5A>!KCBLR\8\BB
MNEL!$])'"%#Q[5*A@W->ZS`5OI66\RYE@\V8_P`PM+%EE>T;A7D=(YJ9VQ[E
MZH9+IF08+(4I$1<Q*M+[2K)(1T['M)R`E(F42,Z.`V"G;L-U>[I'9_MXV\[L
M=O\`$67)^W7.>XS,.]O$N&U[Y`3M7PSFJJ8,JE8Q)AS+4@VA:7D"X6.TBOF>
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MU!P0I:\D5*FURVXAS`,_-1]'&;L,ADZ(FZ29C9[XZC;:A-03H>F!NBRAEO(&
M3,999W9M,W6^&QW3L@S6'<O;0;/LCW681L<Q.RL-9(>4Q;)L6=?O&$TE4F$=
M6;W!.[0[C;&@ZBI.^7%I*Q,D5<Z5TN<-Q4?DB/ROF+=%N>_#[!MFVSQS[<!F
M=><D\:8*N"D:XL=$QV_H4!CU=A*3#J#KKN4RO8QLV:I1>MP)I+(CHD>5-10=
MM^PJI8!R@\S=9\Y;B-SN8$\<+X9J&1MR=MI5EL..L0/+'%6R4Q[3TL>X\QI#
M"QL%AK]:E+39K+%V*]V=U6H'ZYM+I&.31,!'KOIZA.[_``!E/=UMNQ!6\86+
M/=HCME,QT[H>QU*?>0]H0SI-7^E9G9Y-4CIUNI9`QU,X1R%9UG<*6(-7ZW9J
M>$FB]*F=PZ;U=>I=<-U--890B<8X9N&VR,S#T,:_46%VJKJY$<Y\W;9AQ7EK
M*\^SF4++%_5\[@*AY*Q$C0&IHHZM?R8LYL4HO(&CAKY9VLD;.L$96W+[>MVM
MRJ[M]FK;%$Y+AL53S>9?,XYDRRI#H0EB"<@T3?`6!9DT3='K:\@45*^[E99V
MQ$%GR@E1"E=+O:1CS!*&W*G52P0F,VNZ:N;PB1[.SKDDPS#4<PU_-=85/)E:
M`J-6@[+4ZW#1M:%(&S:FPK"M)K@V0*MH"!R&@=Q9,6W!J\S)CVP7)Y])B;PV
M/9N3P],,*_3)]CF*<:V.?G*\PRNL^N$2]*X0DH*I,[!4!C'3#ZO>65\TDU7C
M";38EE/<:3.N\W:EN)RU`9^DMM:NWRTTO,K/%T#B"RV"M;@*+:;0K5[A4*?)
MOJ:J\I4M4G;*(GX%M$GE(.09MYABXE(]>6D=]K?3APM7K/?YU:XY=L4)=MYU
M>WX1-"G+1`?@CC?/L,JO(2KZBFB:C%V?\%+C/.#V&S5BW62U-AD@*C!.(.*`
MT>=S%*P#CR@9BS5G.OMY9*^9]C,50^07#N66=1;AIAV$L%?I98F+.F5&*51C
M[+)DD5$3J&DE3H*J@04"`($'>Z/=5U"(FJ]2G<YB_.V(,=8IZ;><+!`5?";C
M`+&ZO=Q-7I6#<`Y@N-<RUD&;N*,Q3TG7[I4S!TZ;Q<SK\NQ<BC+6`\RT8H0[
MK)9IW=;^+<TZC6[+`>6,.XYP?TR,D95Q^WVRW+$*%O>[H$]N6)*5EO.4ID+,
M:EC8V;&*\^TM$G7<-)X[B$4H5W$,)V\HVMI*FC$)8;?LAP5=\6[ML/3L?9E:
M9O5M-IN&<$&UE=-I!_,W#'-!Q=,GK<@1`RM:;*57&]91;MVI%RMWR3Q\4QE'
MAR%;GFOI*;>LW9(R9<93(NXJD8_W`2U9G]TFW+&V4T:O@#=#.U6&@ZXRF,O5
M8]:D;.@_FJW6:_7K\IC2YX^+E"%AV4?D4ED2*L*P&];T]XMDPQL6/N4P[`QC
MV\Y'_P##S4L1,,@LI`*]!W#=)DC&^+J).Y!CHURSDE8&EO\`)K&R6F':/HUU
M)-X5S"I2<8=Z#YM"CE<>H5MBZ@&8[6YS3C+=OGC%'16SSEO"]E?X*98D7N`4
MO>-AFVY#Q1;J%2KM)U]PK-Q=?7K>-+/7EXB1C1L;7\)(ZRS$`K*3ME//FWW%
MVY3"=ZV^Y4@EI+&N0(!*`EHZ&D7M;DHTK!VQE*_,5B:A56LA6K'49V*A[%4I
MR*50>U^>AHJ28F*JS3`65T'8C%[4[/>]VE>LNZ#?3NP:8)G\,P3[/6:,?%M-
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MLX;F<PY$W,PF(*Y?-S%_N6/3YVAH3`%[_=/PK#T-6K8MK&*JG#X\R$J^N#"(
M:8O786"=E91W<4;"+H"I`-DRSO3WD8NRUU*;S*W3%;S;YTN\,4Z_O,?0&*G#
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M6;(;*K#U&N3N1LE.[MD1Y6(:.A):[*0C9PBL`UFE[H-]4!4MB>8MQ69<2Y4Q
M'U2<;2%7E,/TO#;''H[7LBWS9M>MR6-%L77)K9YRW9-J;U"D3E,R0;):CQPG
M(R<7:ZRZKD:@-:=:7TR+GO`P/MNZ'DI:,\4'(&W[==B'#>W@FWUEA!A5EL6Q
M3#9CDG-E`R#`9>+;):Y6.[@GA]M`Y"CK$S4I4Z%A<.*C`4Q2)36DWC[%^D52
ML)XYVFSN;,B;A\B9`P'MLKV/J)AS)&8V5XP]MAO5TPG&XTS:OA-I#PC.1<O)
M!D]M5/@I>XW#(;.GU*3?0&-1K=;=ILBOSINRC!U%QOLVQ7`L+*G4]B;NKO<!
MHNK(Y<OH]>H87NV!88;0^%N0]G(3']_L+=PFY3;%<2JC24-VJ-")&`A2VI9Z
MW?[D:QLQVW;;K_@S933[UT\7FY>SVG'NWJ,O\A2K/&;BVN-(*G8GHE[N+BC1
M-2F(Z1D'%D&T-+,]8D:F^H10D)8C^)E&V>YYR'N9Z;U7S%EP:X;)-CQ5EN&O
M+ZGQ+F$KDM8J#.Y$QO)V&&@7<A*+0K6Q*U`9\L(,D]3BE9%2/1=K(-TCBJV`
M]B>`]MLWC:P8RC[0UD,4[?S;::D:9M#N911Q@;(:>3Q:OT5T$BOYK\*4RJA,
MJ"1<&/+$$O3'NTJ&'-N6-<&X.8;?:`A--L=QK.[,6B,C,K2<P1&_6.S6FP",
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M\TICN$J@*LTV/9P'TD,'X)ONWR]CFO=1EU+:,O8FVT^DY>RO#3-`V]U*RX]L
M.+7M&IE=JE'IXV2$;4:Q'KL7-9.?7J\QD5$0L>SMB+%N];2`&F]$.)RO&;+)
MX<K9+@,E2"^[K>^C%/H+'JN/PC$X;>'FF!L23ELI=;I]8)3MQC)^UPZ15V):
MM`S<92@&:+7@L<M$AAC>1DO#&%,!;6\8WJ\X8=Y_W2]9W+MUSMC+:Q>=XV0Z
M-3\&=0O(,&PK%+PM3:9?6BDE?;1DMFE,WVXUJ4J]+@()=D=@:<ML')15E3:W
MM6JVTZNY)IU'OF2[73K]FK*&;(BL9!E*S+1^,)++UOE,@W*FX^=0E4KTP6DN
M+U/V.T,VURD[?8FK^>?MOPC4BTH]@R;I.]+7`PU7'L7B^^9SP#D+$N2-QF3<
M99RQ%>H5OEFH/]V&19?*&>JPFM>J?>*)8\?WZV2B#Q[3KC1;#&1ZD!5WT0+*
M:KT?*$`C8M&^OJ`7';AM[LTK'YBVSU(<P;G,8;C-W%0Z?V1LJ79G!8;M$+"[
M<LNM]H-_:FR+BW%NYFJNYBW7FQ.L<9&+C66A`J[5.`BY]K;(C,9BWL[N9;!>
MS3)5<W+5.K8!R%BK(=HRSU`=H>S:Y;N\:264J;:$86GUJTX:DC3]ZP+BRQUU
MA8)3(ED>5BSO:_?HJ8QJ>TXY-#-YR8D3E>F)BYK0L-U?$^<]TV`KQA20RK*0
MV=,7Y7CG^7+L^SQ8F%PS>YRVXRE3\D4'*"^3[A&,+9+K6JA.U*U/,F;G'QJ>
MV;)LPQCSI9XRB*MB*&PQN%W:;=+;B>%R+7E<K8ERI7'=_P`HQ.7LD/<P90#+
MJ>5,?Y*HUOF+AE26G,@&M*-*B+16;'/3!Z9+5Z+?KQ@AYYY%Y'A[7,F.<R[=
M,)93?WG%&3)*]XRJ%DEK_@MW*.\/VZ8D(=L>8GL<FG%5YUM4G\F5VM$QTXNO
M-1*`_5<LLK(,G!S&LGM[P'C+:]AC'^!</0BU?QUC:%-#5]B[D7LQ)KF=/WLS
M,S4W,R*JS^:L5EL$G+6.QS+Q0SF6G961D5^U1R8I30"S:-&C0!HT:-`&C1HT
M`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
M:-`&C1HT`:-&C0!HT:-`,ZWA[MO_``IQF$VT5B"^YPOVX?-#?`.*J%09"J0S
MA_D*3QIDG)44K99^XRT1#5FG$CL:2R-@LZIWPP""Y)(T8_204;GCE0ZRN4X>
MK2^1LE]/C)V/\782W&PVU7>/>!SSA:SEP5EJR7W'M#AU\=UJ'7+9]P%`1=9:
MQI+3ULBXV@OH^,LZQ(NN3\A`3C5E)7N6VZS><\@[-KE$V**@FVV7="GGN=9R
M3-ZZ7LT.7`V<<1#`1"C0Q4V4F,CE>/E@=ONYF#**>("47"[?AD^5NF?>,A;:
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M[B,#1F3=UF`EKFO4G.4<<T&HV/'MJQ?F2`G'=<E7>-9B^VNEEQ:O<9<TE7+\
ME&1J2KH'FT?J&XIOVXVB[5\P[=J;M_W2[A9[<+)9=N,;<W6Y+;M*9+4J"N9*
MQCC'Y*M8,0Y=&?>5^8EL>V:]6.GA1']H<H3M<NL?"QK=8!%(3J<[@<'O]Z=V
MR?M[R7FO;7@#?UE+%=YSE&WG#]7'#N)3?N-1-288_P`8NWK.[YACZ+*7E5Y=
MU54ZV_CV;YTG7)6^R[%S#,'0[I^I1D[;!8<CVN5V0Y6F]J6$;'`UK+.XZ:R9
MBW&C]RK+DJAW]AP;AR\/F5IS=3*VK<8V)D[`SFJDI-V2.L-?H4;<'T.<%^CD
MKIQ7:\[5.H)M\:9'JK":WC[D,AYOK-A<0\VI&4V+N<WB:5:0L\T24![(R+%/
M'3Q)PYC#)M53R#440*5%;3!MVG1HW&9YN6^1ZRB=CV39S<O:)N_8FW5[D(O)
MEQW'X2CD8>JIT?;I1ZNE4Y>G8UHE1>5=2%KN8J!<FTS!0D^_L,CB2WW)-V[E
MP'X[@>J+><<Y>W68@P9LLREN*D=D<%CJ][C[0AD_%.*:E$X[R%BM[EINXQN\
MN,B\D<AY%85N*EC#CM2-K""_P!7#FW1R,C$%?Z8KU2L556_;C[5`+;C,RNGE
M1Z<*&#L`(0.,(R,ME[WN0.0GF&ZKAMZNXA)F'L-]3COKC,\OF:SMZ?1(ZLHS
M,(\:1K&=2=+55]D.3EK;U),BW*V4..L6_P#Q;ARMI5^M?A',0V,[72-K#W!M
MH*M.2<="N[17U;3(KRT$^0A8:2<P#=+ZQC6,DL9JBS?_`-C_`)KK2TYD"@9J
MQDAF"GPG2ML&$#66J6EY0S9-Z=6.LE8^LL;DINR<HS84#,\)DJ=@V[^KG4L]
M,;/`G2-I*1CF[!R`\N$WZ[@CT+);*W=/+/D+N<H%PQE48[!-7M=+OE%N[;,"
M,DXIN0J_N28)1>.66+8!*#GT\N6>Q1L5*XO?PRC&0K4JI/4L]G:GD#J6Y:R!
M0757;X]G-K&XS"'43Z=VWC/E):7_`!GFVMJT[<AF/%#Z0C:ODBK-W,5,Q-RQ
M=;7D1-H25:I]SK+Q9R@:.8*_5TJOG=P.RSJ*[ML-3*.?K_MCDIH,^X1R9&[+
M(6>R>.TJX8HQ'`6QM8<,96S>GCJ&S-:R97NMGB,C627=XSD*;&/\94&I*8ZG
MH!:VKSB28?Z1&<:E/YA!XQV<85H.4-S/3@W6P&/MM%8N-9IN.+#L]O5>>Y(Q
M0RK#BJ03:SLK75J7"S$+FA=W7YJS7:P3J5CQK7(:,C73@"5W>SN[':)1<;RL
M/C=?+.1LV9CKV!\0T57(%*Q+79O(MDK5RN#%"W92R$Z0K%)@BP%#L`I.S-)Z
M>FIL8>L5:LS\_-,6)V19BZAN[&M273Z9Q^RK*.-Y_/6]B=VV[@J%=K!B!XO6
MV%>QID>PF#'MOD+M7XJ]5RUIP!<G4G*-4;*Q4G2Z#:JO+1T%?)N#K+IZ&_3"
M&5\^8784K%=5VTY0]*Z1LM?L';N*HI8<&YPH"<//L9"AV":85"^3N.YMI.2%
M?NE5OT)3[.XBYJJHQ;V">1DR\4;QQ8PZ8VYC$>)-MS6IS>#26S#/4H-O18X#
M_=!S.XP-A[#MHQ)<<+VG`&$,E6RM6_(*[2NM+Q/Y5KAI:A5FI25ZF9JN1=9H
M-4<,SM@%DC.KY%R-"RUF@^UG,4;@VCY5DML>,+S+6G%[6P[C=W*&Y*2VRQ&%
ML3T)*R.'S6NSEU;QZJ>7[[+5*HQI7,LV?M2DJ\T^3^YGJXM\6XYS^?<5MRG\
M2;C-O[K;HA+X,89@Q?<*G:V.[K(4ABO;Y:Z]N&D'%)QK%4>=OL-/5S(%EO*%
M2+C%W`2*\NRDF+ZKNK%BLA]*:1R!T]EMH,S;L<62XU?=I>MVM#?7>DN[/A^Q
M3SO>%>]SM4QQEJCO5OCYVA6&OVU3&61DHYP#DK60DYJ"2>"V9LG6CXKZ;6=J
M#B+<Z[I^).F/M^R=F_\`<=@H?;[B_;Q&W/;),8VQA/RLM>L>YSR-)XPQYE'*
M+//;"PS4(_D%:(A'81;!%2%%KEAEALSJQ@+?=^IOD'#6!)&^Y_V79)Q)FIQG
M3%VW;'V*G^4L92N+,I7_`#4Q;2..IZI;HQ7BL;,<6*)JNXVWW6UQ,!(U:S1;
MJI)56:L4E6(^PO@VPYFR9FJ@R\QF';M>]LN2:I<):E6C'EPG:[<XE\ZC8^(E
M6MMQGD6JG)"9%QO.L9MLG#6I..K[[ZV83L)+U^)DH9RB,0.+.F)N=QK@3<?6
M*C7]DV/6V<LI8FN7_@%5;Y$SAL+6H%(K4A7LG8Q>3&3Z*VFZ,IGA60CIR:L.
M,,'0L!09BATQ>*HMB5=6MW+O:Z9VS/(FSVCYEC[PO0*5'9:RNGD>G[:<)6W(
M-YV_;:8@M,K5:DZ9B:RY2BX*W/&-QGX:3O\`9FS2KTFDQD_/+1],HT$P;N%Y
M,#2LT=2W)6"LF%6O6R7*4)M5)N!I&VH^XNQ9/Q94K7+WR_Y)KV(J];Z1MUL;
MUC>[MAMY?+,Q;,KM%SJ5AG:XVD+G6:+,UE)K(//JT=5JM5+)>\9A-8`R;%;=
M>G^:Z-MU>Z*8L-":T^N3$%AFC9EJM:QE0&,U)Y&RE8K;&75M#N6+>'KK:KOR
MQBD@_=A8(U`(Y,T]&G=#=I_.4U"5[89>LF3FZ=CNNQOO"S4WRE.;I+8G6MPU
M5S=1MN%A=$H4S$8`HE4KE4BL,-<AXHL5Q;%Q_%M`B\-QDG,33D)$;7TR7&4L
M,]5O#&0<A,(V(ZD64)3(<1*5F*6E'F*32&W#!F(V"4BUFR,6-N6@[KB)6RF0
M(6-93D$[;1JYHYTJY^'`5C;;OJN^4LR1V"=P&V&V[6<@9`QG9,UX08SN3<=9
M68Y$QI3)BGPMV:3LECQRJTQ_EFBN,AT1S;\</%)Z.2CK.U>U>\6I.-GBQ>1R
M5OLDZSO;KFQG'&W;(F5KX?%^*\_9,R*A9Z'2L38DP)?<G7S&<_=K%/626^NY
M>T5=]1'DC$X\@:^[E;NV<+!%R,>WA)U\Q;CL(Z>UXP!G%YF;(>`>G+@->`Q3
M)XNA&.R3#!8NQ9+F;#.5N3L63KMD.XX_J5OQW$+LZLT8P^":B^M,"V<RLA*V
MO(%Q=159+&NZ:[4)(V_#,&Z^5L$*_I.4MFN'=KBM$^#DB32+S'66LZY`G)QW
M)$438FB9N(RZTAV;5L))!L[C'KA4X(K-PT`VG#G52)E2Z80EY7;?>:%M5W77
M];&6U7<[)7['TZ3)=L4B[I/5->Z8?A72EVQ/3\N0^/+6[Q#999Y/.9T4(MI<
MH2@2$Y&-54XVU[W]UC_9/MIM]6V]9`WI9XRP]W#/Y^;4MU%PAC*I5;%^<;G5
M6K_)67K!$#5:Y+/HE2N5Z@U&&K,S9+>:)FI)1JSB:_8;`U179GT<K5MERAMW
MB7.(^G/%XRVL6-[+U[<G1<`M7V\S/,+$PMF@L<0=Y&TT9.MX8M<&C-Q4GD++
M=%R%>;5D:0KA4(9E0(ZR3;<G)<NDEFIIC/9C2F\7M1W7U_;>QW*Q-HP3NG=Y
M2KF`Y*QYYR\6_P!9SK$P=2K-]:V[(6*JPM.T=C4<@4YQ#R<5<+(XKMJI,FJ6
M1<`;[6>K%E'-V:>FI%X7V\6UOC;<WF/=MAG<*RF[-A>3D<?7G;.QO=6N5?B+
M*QR,+&Q1U#M-)D<C+7*BIV"#O^.6J,=5?C;A)HUI)>MDO4,QGD>O[>,<SDWF
M:6D,K[2+]NHJF9<[,L;0KZYU'%V7C8ZR=%V4^.SL:NPNE"3L-,L$BTB8AI$K
MTR?C'[9=>083I&[5=L?2^W6;:GFSUS'RVUJ=0VP[]MY69'T15!OV+*E,;<=Y
MD-<4IHU&IS2FVQK0<@8KE,@S3"G8@"3F*+(UN`@FZF4X99TY(SSF1NC?=[OL
M*V@;6(?.<)1LL;<$[]CVP9B@X">41L6`]P<!>\:;E:#`,/CVLC$REUQC=D3U
MN8=+&^I+O5*[,`9$K8CA`!1H+K!RF7J]5)_:[LZREG`0P93=T.68J4R9BG%<
MEC?`^57]X=86=Q0V23DF%_RYF#'U!E\L5#$[-Y7R1]#=PKBY7.LS$W%Q3M+<
MD]5V)Q]N9>YYB[1<LC[&U.D]@3>2TJ5+A()P^08Y9W=)T"7S2JA(),YM/\!L
M3S:,]=*Z>9,JS@*O-H,(5S9$"I+_`)NCZ/RD[N&O.:-O^`.GUEN*S#AW#6(I
M2M[U<;3%G4V[RF"*W.4.B9)PLZA:7>!N4(K09&"A+-@^>/C^,F9.BUN80R,Q
M!W)M`52\[&L+[=I*Z9MSW?,=0FT:K])J)Z>^4X*.QZC06)Z\E?YV3MEPCZ=C
MJ,)4JI6[+%6U:)BZ#2H9,D1)ODXZ#;I1R;4I0)'Z9N5J60-R.7=N52B)F8?X
M0QUB>[9`OS92,-2HV<S*M;'M0QTU7^+^LY"WA3*LED"6!JR/$QU7M506._.\
MFDVR3C]0[]#C;=D+`>Q"C6C-[^QS>?=Q+IAFK*4W<X@L%<31H4RIXQP=7;)"
MBNX5@)>G;<\<XFK\Q7U5"K1-B;SJ3U/ZS4?K+3$:`-&C1H`T:-&@#1HT:`-&
MC1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@
M#1HT:`-&C1H`T:-&@#1HU^&]A_D'_P`M`,;M/4LV(4O-$5M\LVZ#%D9EJ6MA
MZ$-9-+/736"O@S:M;9T6Z6IC'.:;0+K-3R1XBLU.\V*NV"U2'#6MQ\JH<@'W
M>2WS;0X?+%MP=([AL7MLJ8]JU\N^1ZB-C04=XQJ.,X6M6.[6+*#](AX;&T3"
MP-OK\Q\7>9*`3DHUZJ[B!D$8^3,SK56&PW_*VWSK`;"\7[3=P5]RONFZC.\&
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MYW"U;I72`WX[3/J[/6'9#"5ZS=F[<0SJ,KC7#=,I-F=DG+3`XI<8_L)CW6/1
M/C]:T7F/CJ3/SK-]).VS>D*'N%I&1*-N:^!ZDU-H6>.FQM!P33H+;?M+QED+
M(\+D7!+7),3D+;=G/%VXG`&3KMA:,N,Y:6%KK-YGHRAXCDE7]C-D&T_#QU77
M`"Q;N&WX;1=JM;H5LSMG:ETN&RDD=YC<6II:YREZB4&3*3?V2J5Z@Q=JL,[4
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M63B5M5E1J*UBCZ\XDEP)V<!;_MG.Z"7O4'@K/U&OTECB)5LEG3:*RT*W_`U%
MVLQ/D.MO[1%0<?><7B]049IY0H[JQX^6=@#=*RG5.0IFTT7JX[6L\;E]O&W_
M`&OY*QWG=++LIG!E<IVN6.592-*C,3XU&\PUK@8.2@6@WNCW22*K7XJ_0;A:
MCO54%S05BF'2"S0D0C/:SG_>#0[[189'J(J7Z@=-;=YMMJKG>?BO;GMDQ1BC
M)V?L3T3&C+`E06Q;MTQO9,\1LJO3VBSO(E+NT_A2CQ=;C+&SG+?8;`FT2>-B
M^TW/=#O4Z9=\J>Q3<?M]JVTK%>Y:B9GM.9\/NL30>*)N^X-IU4KV#J(XG5T'
M.3JE]?U-90+]CMM.8L(:"JZ,797KZ=%%H`^W<]U!JS@7>ML>V1QW[G3K(>[:
M2R!.2[J\WUW5EJ?CN@1K;X8:Y!QU=G'-LOV2;&[<P&/85^\KL`[4JUM4D)M-
MRS8M'675ZKO3I3JV1[NCN[PY)U#$P49"]6:`G'MC@6$UDE[8HZD4V'E(*,D6
MEOR+8'M3GV[3&E-4G\@)&8@9[6FJ;QB=S@-Q6)<D6KJ7=-/+E>J$Q+8VQ)C;
M?S$Y(N#1)$\-4)+)=2P$QH3.85.N19):T.JU/(18(H+E4/%.P5,B!2">'_"6
MV'/6UC:-T7LO6_;+DZXMMD&7-TEPW+[?\>4U&X9FA5=P,'G:J5O-M>QA'.5'
M>1+%C^?N$989>+K)Y3('U#<)&;JT9)2#%PT`">>$Z@.RRP8(A]S<?N9Q`C@>
M<MK?'[/)DS;6=<KS:_N7IHU.@3?X0EBY&M7TLB7ZN<4JQL(JSM)`R;)U%HN5
M4DSH`UZT'3#=15:F0W>XZ:L;/<G="($I%7Z&>U:RLY"+BS(Y/BY:G,I7#T0Z
M?340C%6C+#*EU::"28JP\R_0<IJC&#/[><\[CI&R;BX#;;E;'N.<\=:WIT[C
M(#".2Z>VJE_C<*[=X7$5(RKN.R5C61>'>T,][DZ<^L+ZN6)%K;T*O5:W-6*!
M83<FX9D5G<UM/SO<:_\`2+F]>P_9)UUNMQ]@Z)V_$;1T<NKEU]5=EE-HD@UJ
MXKN2B_5A;TSD(,P/S-OAY9!<4!$!!8P$]>3LGX\POC^VY5RQ=*UCO'%#A'EB
MN%UM\LT@JY785@4#.9"4E'RB3=LB4QB(I%$QE7+E9!HU36=.$$5([\&]5S;?
MN+W!Y!Q_B>^4"PX/QGM1C=R-WS:^L<C41I#TV4+I29^JY#J5W@ZU(X_9P58J
MS:]*S-N&'67A)1*1(P&$,VE7/+U4\,Y1RUM)IXXQI4MDZ<PKN1V?;D+-A^#^
M$4LF6*#MVSU0,HY"Q_6X^2=,HN;M,G6:[(O*W77[UJE89V*80R*Y7SQH!H>M
MWN%L^]1RW]0'*FWS:MN%Q15LL=/_`&VXIIU@S%CAI@;(.X*ZX+WBR.9LCX[;
M8]S0Q:R5?D)?%_J8RJ[[,-295>VC*J'42D:.@5=R!8(PIO\`MG.X6H9+ON*L
M^T>9J6'(T9[*$Q/'F,?IT:K&CGTNUN]A:Y&B:D_8X]E(F,DI2"R&9J:D6"-C
MG[Z$GW[9FY43T_#_`%/^G]GJ)NDUBC=EANUL\=4>X9.O*060\'*57&5#&/\`
MPHR5-P=E9PTXQQVP3E8]RWO*D=^"TNQ>(2$)*R3)3X@(!,W[<<T[L:!O(R[$
MJ;^\AR<=M`K6$XQ_OVH>W;:+&Y(9EW2XTSQ>]MM:Q;$8!P([LKIY7<<3-(:9
MCN5B3Q2C(Y/=4VEO)B&F)B6C=VW4VV=WQ;AMQ4;B#:ON&H-JMG0-ZB&':M!9
MLQ&\PSDF_P!HN&2L/1-3QS#4&TNVEL^KJ]//GT+"S<@S84^>E;-(&H,M/1"$
ME*I@3FS/4QV+0>)7N<U]QM*E,6M\HS6%XZTU5G:[L6X9-KK=-Y.53&T-3J[.
MV+*CJ+8G5D'KW&T1:XA"/8RK\TC\'#RJ[/.Y*ZANRS$F$,>[C+UN+QQ&X>RV
MLW:8KMT?(O;..1WZZ+E=2,HU=J<?.VVTRD6BRD%;%%PL`\D*LE&2RED;1)8J
M0%O%COCP%F#'66.FOGJ@GW0XWPWMMVS9OP!<7.RW#N/LXY?PU8,CUW`1*4]8
M8,MF*<TN9Z@/XS%UAH=EE<>4*3M=-=_@P)7$?5Y&?>IM]PKA?*6S"_[-=Z%P
MVX;Q,FXM%;J9%R+59*GU7-VZ7"E\WIYQQIEFFY]E,&;<L?TY.!)EJ(QW-Q5Y
MQWC"B2DGA(]^:P5F>2)#3KN)`E*QCU;-K4]B',6?LG9-QO1,.4S=5D/;?BJ[
M5ZT/\CHYP)3X&M6")FL>PM/A96Q6^>G&$O,.UJI1XBT.HUA7I%ZJJ*#1^9GE
M;WU?-B]2KNU:ZP^<:)<:1NPSY(8`I]HC+*SBFU:LD%6+!,VEU<(R?1CYN#<5
M&=8U:E6>KRD=&6F#LF0*FA)1K5%X<VH;8BN[NL55]ADF#VRYYVN8]RGU,]]N
M>K)>,6[2\=;HMX>",79BHU64Q2\QUB]Q!9<2QZ&XJ6>SR&8[17*%>9:AG^(I
M%B8Q+=]+SL;RX-J>=<61<19,C8)WQV!:B]>LFYRSR^1\)NKQF2RX*SCLYNV.
MJ?F"398*J2=&L+-G;+/"QF0HS%\0=GA4BQ*]=(FO.8"211`G4G^H'@?#&.LB
MY/W.9<P?C:K5?<9DO`M77I5^ELHR=DF*9,N&4;4SU>`J@7!?-I8YF^>W?$M2
MK]KD:>=B^$9"08,W+Y+<Y/J"[*8?"5$W&26YG$37"N3RS2>.;Z:UM5(N\R==
MC)F6FJU5&B)%)B=N<:VKTXBZHT?&+W$DI%/H0((TT@>/"$"-P_GC:[N>I&\J
M^;9\U9*Q-C/>SUAS3T%B>A/<HY9JE>WA73$DKA+<?2\45A1[<[M5G<)C>V4:
M9=4IA(W*#@LA%?H0BT&XGC([O@':]G&X9JVS[@[1M]O5'Q]D/J^;OM[[7&U_
MA8N-MN!\47S9)><3XZLN3:JE(O"4FVW_`"S%#DMW7C.'\W6[;E%NA,)LYY-^
MFR`E>+U-MBA]NZ&ZHFXNGJ80<W9SC)O9$XRX*6)?)K(ZI7N,D<8DK)LJJY+9
MIH+NWF/B4@UP:QR"\HXADXU%1V5S6%<X8EW&8UK>8,'W^N9,QM;4GBD%;:L]
M^-CG2L8_<Q4O'N"*)H/8R9A)=D]AY^"E6C&:@IAD\B9=@RD&CALG`5FO!U[H
MDUNBRG;\4;R*XG_[5V:SUA_/6S6"9W?..&JY-;$,,8D+FNO85"GY*5SSBZZ3
MT5;\(9*HWX`VMPWCIAY95JTNRAE):.DNZ8+O</([=+%*;C:@%>LTMG/+TM2K
M-,85K^W/)F7<82EB0?5?,>:\(UQRNQQYEV\N%YIU:(MPTA9B5;,H>R3U;K<S
M-O(1D!NQ^I;L52W"DVL*[E,?)9P5NO[F:555-.IQ"V4`6!J.*T,@GA2XV7RJ
M1Z(,#XR2N![VG(<QYX`KXIFX<-FZFFPNHYCA,`V#=#C!GE6=OSC%2=;0DI.0
M:PN3D)]2K)8[N=JBHMY3\?7B4L:9H2OU6]V&MSEEDQ39UYE)JJI%/7JS.EO-
MMH1S:\XRWV)RF$NI?BK<+>=K.`]G>.*EL[I&$J-O?B+T.0ZCDRM8M-E#>+;+
M12DR95ED\;Y*L-SGL@6">M-XQU6V=>>HMWTY`VG9J<;!-_6/83#5@<9&RYU1
MKQG>OUAE'1Y)J^TA;?\`8@OT-?DBF=$1D&JF*:>6682#U<CM"N0:"*9$B-4&
MX`.LWR]8;:7M`A\Q4Z+RKC&^;FL61%=<)8'=6N0A7$C9+'/5MA'T*0N#*#EZ
M[#Y#>0D_^$T=CI5^KD"1A44I1M6%(E?X\LM@#S_6(?U#QJI3G;'F<Z]M.ZA/
M3I_\%FX_*.=<Z;XLZ[CL8Y'IF)W%AP-?\<9=W:5_<)3LQS&>'#II0*[=L8TP
MB%6E,=SLNAE9&T4B.B:C6YF#<QLP-M4/_P#(_P#41T!^Z-&C0!HT:-`&C1HT
M`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
M:-`&C1HT`:-&C0!HT:-`&CWT:-`)IC;#V-L0I79''-59U=+(N2;GEZZ$:.9)
MT$]D?(+]*4N-H<?63U\*#R<?HI.5VS(6L<@<@%9,FQ!$@J1R7@1X$.1\AV&`
M3"(!]G;R8>/?P/`!YXX'C0\JN7#/&60W;5=9LY:T:X.&[ANLHW7070K<HJBL
MBNB8BJ*R2A"J)*I'(HDH4IR&*8H"%0^%H-BIW3>Z/4HQ>R&3DNHK,X!F=]EY
MW,[Q<TXPC,\S!-GM_M>&\+Y'SJ@RR;-T3'4];FD/68:GUNKLH7("U0K6-K-]
M8.+W-OY0"Y9\@`(@`\#X$.TPCXYX`2\<\<>P<<<#X\"'*0Y>SGC;!R&.G&1Y
M9W$I94RYC[!M,%M#2DL:1R)E"46AZ?$."QS9P:/9R+]!1-Q+O@2C&!"^J]<)
M)B!M5,G4PG4\?8PQ!F3/E$Q?LN>]:/'V`3TO`>\7.EXHN'<;3FRS)+[*FTZS
M;G+/3L&2,IBJ4S@%:<?@Q7'TE6\=-+U*XR6LT6XKZ,7%;"4]1HNXVZ;;MO5H
M<SVRW!75MZ-JF$82.NLKDC'V+,L9%C;O,[BL18YN<S.6=5K"P;Z,QQ;Y;';.
MQ.XZAV2^2K=E'PXS"C'0%PKN((AX$?L`>PW'V>`-V\<#X^W@?;SK][B@/`<A
MQX\%'M#C[.0#M#CCCW\#X\"/&J5[3)E%G,V;3=YF+H&'QO(Y@ZI%)QNEN+S3
MU`<A63>QFW&$SN3M5`R%0)W:Q7*I`XJQ]AIK$(/*XUQ-:;.<F+L91$"5]3F=
M],#Q%X^%(S:ODIU?MVVZW<??,==06L]3>[X2AY"KY:O3S)^(#P&\!''.!-H=
M`P1&2DA"36'\I8<9TK\+*Q^Y=.QE[J.1;1EFQO73QH%OB@+1`"0!X`./LY[1
M[>/N`W';QS[``\<^`\Z_/D`0^4>2^`'L-X#R'!1[>`#[``!X\\![AS3`VUS6
M;+3?=INYB8GMOF-MV^5^H0XQYFC+\GO;S]<-P>285CGK)$/E_959MF,=MX?T
MBHUFK8DB3P-1I+BT,J)AEM4*YEL]SC7#YW9EE+S1ABOVVM3>YN=N&9EL\J=?
M\VU"#R1'9[S%`S=(VT9/WT1&"[[@^@I0-WC8RFT"SXYL$]&R,/!,&CCXV65E
MFSIO(,(9:,`MZ\E'YA`>2^PB0P&#GW`H"'=YX\@`>>./<-`=G``!?`#X#L$.
M!Y\"!>`$//D!X#[^=4]]QT!*;1)_=AM-VT(EI^U67ZB/3DI>2L=W#<3E+$^,
MJGB3/VWZPV7+,&^SR1KDZ_X-I.<LMUG'%/O,Y6&:OJGNTFT2(S&U23A7]1BL
MFU3%NXG`U2R72<(X5)U#>DUBBKX<V@;L,XYE#;3-98S-2XG<K0*[G&SXRPX>
MK0F3JA+TNTDQ+296RLZ#*6NVGDR0BEE8QRX%LO)N3\>X:H=DR=E*U0U'H%/9
MIR=FM=A6,SAX5DJ\;,4WC]QZ2ADDC/'C5`%/3-PJL0!X\B&I;B=P&+=K6&KQ
MGK,TP[K^-,?,XU_:YAA"2EB=LVTK/1-89'2AH1J\E'QE):;CFQB-6RIDDU3+
MJ`5!%0Y:K6_/;/AS">(>M?MBQNRN--V]T+;3L(W%U/&;3,.6OP<J^6;ID7/-
M>O=Q8+/[VO)MF]PC*/5W%P@UY(]4L<M"-K#-P[R;(I(FE;ZXL)6*MT2]W%?J
M\I(-Z97<)4:*A)TUEF[9+,:U%9(QLW93A+=.2<W8K#*,(M`DDC8)27EIF3>(
M$D';]\\5.LH!-GW%-R'`B`")1`2&\\&[1XY#Y@Y#R(<@`>1'CSK]X+R(<`(B
M'`B(<\A]PF$//O\`FB/M]G&JFN<,,TBF9IM>&^E7F:\3<OE+IT[@=V616]'W
M*9%S2G*;@<"99V^9'V:YJL,K+Y%M;E.YY^MS+(V*KB^;23`,Q8\F+6QG(Z<9
M0)",9..E?GU]O[M>X+J)Q<]=$L(Y1;XJP3MNQ]-R$XR@:_5,-U,D[FBXHU-<
MZ,.A:+1N%R!?*#+SHMG<F\A<.0#4DA]7D31,`^:RY$VY[C[_`)YV.6RMFRFI
M7\7P9\^U&>Q[.R^+&U9RLR7""H5GMKZ+"G/+=9:X)K*C26<DXL32M':V-5NQ
M059N#:'1=NFR;IYUO)><8F%C\6Q@UJ!C<CY?R?D/)F3;&RH\!)G3KE:=9!R]
M;;_;XJC0\O.'4BZG%RK2LL9!^+I*+*Y-ZX0=9L@<18,SSUPKPZ8YP?R63LT=
M.7$PP%"W0W/$"ERGMP\!C$XTJ<RG<[)-57!F.+I=9Y&O7W(</&14YCW$$K9*
MOC9[`-G,7$C'#FZH5J'QEUF=L1(K%^*,38\V@;-\[1&W?;3O1S5GG%^-LLJ9
MYR[7[;87]PL2.-GT-<9F`2JRN2*'!5YCCUPQ2H<K96$U8Q)(I@7RQ[1#G[N>
M./<!#P/''GGW#Q[^VOP!((>"B';Y#Y#%$.??M#M`>?/GM\^>!]]1S]0&ZXWV
MX]-C.4^:=S1&XVI6&HZI0TQA+*S>$S(I&S<C7J!54JUG3)+RQA6)"5=S<5'3
M69+7*2+ZK0KV8O3V:"0C0DTZMN3+):=L4OU/<789:XWVJ1;CHEYES\KAK:YO
MBR[N:0K>;(#+\?"0^6K-<K5!T52E9J+59IVW!]1&2SV9@#-I^PV6556B#,P+
MU0=GD`+QQR;\P2^?81`>`Y'CP(A[A^@=)/9\V8[IV6<5X1G91VTR%F:#R98Z
M!$)Q$FX:2D5B%M47=Y7<RJ#<\;%&C4+S73-T)!=NK)F=JD8$7,T<@G6TWC8D
M=]/Q[D"W[+IW+U7ROFCI([[\HY6M1LD9&R;<<E99PO:=G/X/9[DHNXV"RM9/
M-%&K&5LN3L/9(2+9OU/CBQ!6ZD-'Q,4S4+!N(-CN&NJ/T](K97EEU=HF];0-
MZ&2;;7D\_P!XSE%S:$XTVTDKF?Y(]ONUQ+$7O*1!DF5@L#<\:\OJ4.#Q^V<*
M5X%T@)YLB;D\58RS'@_`5A>S[K*NX,U[>8]K%:I]ELYPKN,HZ*?WR\6R3A(U
MW$T>D5I:Q5:%?VFTOHR.4L-LK<$T4<R$LBB&H8BWEX0S5?J_BZHNKO'9"L&W
MJI;H&M/O6,;WCRPQV);O>++CJ"DYZ)N4'#OZ[8%;55)M@^I\PW9V:-102>OH
MY%H[;JJ1W[F,4TV6ZX/3UR,\3LH6N(V2;]I1BX9WZ^QL0F[HERVOL:V*M4C;
M,TJ;MLDWR7;@EF+R#78V=9Q"N;.VF7-/IZT!!QL>IFWC=GFG8PGU`,F2MHCK
M)T","W5P&2MPN0<>$R5;HG=GEU_.W"WW&*R)3YR\V#'T2!Y^)&P6&5"O+2#Z
MYMVB<I",Y>+`O`\D]P#\X>>0*/D?S>1$`_.X#@>?(`'G@`T`8H>`Y#R/GM,`
M"//GYN.!$1'WY\C]XZJ%=/N'F=[&?=@--W%9:SKEW$-7V%[I<TTN*L65<C5Y
MAG:)P;U.*W2MFV9<Q14'-P)LC2I<.LZ-=6,C94W_`.%$@>+G;"M,-'CIH]Q&
MWQ]AA+%.PC>#"[A;Y,=5'-^_W%&,-P;9UG"\/,B7QY:-RD[5=U^V#(>`'%J?
M56LXAPCA\;@\K]:3QE7HC&D3CRFWJ%7C74D>3F0+A?).?8??@!`AN`$P\"(&
M`.`Y$?F$!X'R(B/`ZT'&.2*]EFD15]K3"U1\+,NYYJV9W.F6:B6--:NV*5K+
M\[^JVR,BI^/17D89TXBW+U@BC,1*C&:C3N8N09.EJNVW:0H.$-Z6$LQ6:4;[
MB9?<3O3R[AVK;V]O6Z_(X9?O<I;G^5&$9@;>KL=R*T29M*/A]S&OZV^'%BR]
M6Q.YQS5,@(T_',(C+%50"&@Y3<CB;:/*Y1R%2-VDI6<)[P[=,;+]Q&[G+VUF
MROT(O>MF.NPFZC#>?HTTG3K%E''[.%B\8?462UQ3QO5V\!,5>S8Z1DG3J;`N
MD"4H\\E`0'R("'@1^\0'QSX#R(<^-?6FH;%,IUO->S;;#E&H!D\:U<<'XXDX
M97-,DG.Y7=,DJTQCR/;_`&9`/@[?:'QV)WDG=8TZ\3=55PMD2Y=1LRU<*NOT
M`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
M:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`&C1HT!Q+(HN456[A)-=!=-1
M%9%9,BJ2J2I#)J)*IJ`8BB:A#&(<ARF*<AC%,`E$0%/[-B#$]UQRXP]<<98^
MM>)G<,UKCO&%DI=;F\>.J^Q(DFR@G%*DHQS6E8=HF@@1K&FC/@VQ44@;HI^D
MGVJ+HT`QS,6PC"64(3:I0X:JT+'F']KF;/W6HK"]=QA40QA:H=3$67,4.L<+
MTQ!*,K,'6WB.67DZZ^'AI!%=Q%E9K1BI9%=V@XNAX'PCBVE5O&V-</XMQ]CR
MG2[>P5.B4C'U2JM-K$\U='?(3=>K$'$,86%F$GRBKU.4CF3>03=J'<$<@L83
MZ5C1H!LTGLMV?34QD&Q3&U7;A*V#+3V'D\ISLEA#&;V9R5(UZ98V.`?WV4<5
ME1];GL)88R-G8EW/+OEV$S'LI1NH1\U07)MCW;5MVD<PLMPTA@?#3[/D;'DB
M8[-SS&%)=9<811$A;DC&61UX-2X-6)&YCMTVR$P1--N<[<@%1,9,5MT:`1J,
MVZ;?X7+DOG^'P=B"*SK8(P86>S1&XUIC'*\W#B0J8Q,MD1K"I6Z1CA3332,S
M=RZR)TDDDCE,FF0A=Z5HE)6:BQ6J%659#:D[R+12O0RC4;HE*DG4K:+<[(41
MLZ<VFG,)V`2?7!)0A)$KT'A2K!M>C0&DV'&N.[=&7*%M5$IMEALB,$8J_P`3
M/U:"F8R\1:#(8U&-N#"2CW+6SQZ4>(L$V<XD_;ILA%JFF5#Y-:]1,#X1Q=1(
M+%V-,/8MQ[C6L2C2<K>/:1C^I56D5^9822<RREX6JPD0R@XN5:S"*4JWDF3%
M%\C)ID?I.".R$5*J^C0&C6G&.-[S&7.%NE`I5NA\C5LM.R!%6:JP4['7BI$1
MD6Y:Q;V<FP<H66O%0F)5$L+,D>QQ$I.0(FV*5ZY!7GCL=4"'I$+C2)I%1C,=
M5R%A*Y7Z&PK<,UIL'7ZTFS2KL)$5A)D6$CHB!2CH].&CFK%)I&$8M"LD40;(
M]FY:-`-4=[5*3CK'&8*_LXKF&]GN3<M&=2S[*F.,`X^<=MV>.?45OEHIL66F
MQN0K$BDL_%JM:)14A'SL'CD':1%V3O:=J>VW'^T';KB#;3B\)$])P]2HRHQ3
M^9517G)YT@99]/6JP+MD6[1:Q6^QOI>T6!9FU:,U)B7>F:-&S84D$W!:-`:'
M9\68RNT/=J]<L=T:VP&2F*$9D6#LU1K\[$7V-:LB1S>.ND;*1SII:6*$>0C%
M%K.I/T469"-DB$1*4@)5$;.-I%?@AJT%M?V\PM9'&$YA(:]%88QS'08X;L\H
MG-V3%`Q3.N(L38WL$TBE+S=*.@:NRLHF60?1Z[LH+:<CHT!I3/&V/(_'S/$S
M"B4YEBV/JC:B,<;MJS"HT-G26<8G"M*>VJ)67X/I5=M#I)Q2$`6/"*3C2$8E
M:@V*"6D<JNR_9_16L`QI.U;;E3V54AKO7*NSJ^$<:0+2N5_)B;)'(T'!MHRL
MMD8R(OR4='I7.-:D39V=-BT3F47B;=$I',:-`89Q78!V_92KJ%B7$G&QDE"Q
MTBO&L57["'F31YY>*9/%$#.6D;*'B8L\BP;JIM'QHY@9TBL+-L*22XIVP[;L
M$K2KG".W_">'EYV<E+--K8NQ71:"K,6.;12;3,])JU6!BE'LQ*MT$4)&17.=
MT\0221<**)D*4%ST:`PSFNP#R:C[([A(AU8(F/DXJ*G'$8Q7F(V+FU&"TQ',
M)15N=^R82RL7&*R3-LX2;/U(]B=VDL=HW%-#,E[9=J61ZU"4C+NWS`N0*=#D
MA4Z_4K_B'']MK44G57;Q[7B1<)-UM_&1J5?>2TBYATVK9NC&+R3]5F1(SUT*
MKC-)?=%_4DT40$>&[0O(?8!UCF.(A_*0J?\`5H#8HNNT9K(1LO#0E6;2D/7`
MI\3)1T7#MY",JA5VCHM8CWC9L1TQKQ7+!BN6#:JHQ95F;14K0#MD#)Z)$[;M
MO,#ER8S]!X)PY#9VL3`\58,T16,:3'98G8Q0GIJ1TQD1I!HV^39*)@1)1L\F
M%DU4B$35*=,A2AAQ\?-]H>0'[?'W#]FETC41;Q[)$PB)DVJ!3"(B(B?TRB<1
M$1$1Y,(^1$1T`C$%M?VV5?,$]N#K6W["=>SS:4%FMFS7!XKHT5EFQ-G)`2<(
M3F16$$A;I5)RD!4G)7LNM\2DFFDX%4A"E#IY,VG[7<T5^KU/,.W'`^5JM2)A
MU8:96\CXAQ_=H"I3[YT=\^FJU#V.O2,?!2KYVJHY?/XMNU<O5U#JNU%E#F,*
M^J&[$U#?P2'-_9*(_P#^-(\E99M,.0?J&Y#V4315X^WW.F(^/Y?Y=`*TQ8LH
MQDTC8UHV81\>U;LF+%DW1:,V;-HB1NU:-&K<B:#9LV0331;MT$TT442$22(1
M,A2AVM:+69N3DWRB#M5)1)-L=81*B1,_<"B1"^2<!Q\YA$.WSQ[^-;UH`T:-
M&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-
M&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&
M@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#2,6%85YJ0,(\@1?T2C_\J)"I
M\?R`8IO^NEE.8"%,<P\%*43"/W`4!$1_J#2"K*BLLJL/NLJHJ/\`*H<Q^/Z.
M[C0'(T1%PZ;(``B*SA%+@/<0.H4IN/\`](B.EX`````/``'`!]P!I':RB"\V
MR`>>$A57\?>DD<2\_P#ZQ+I8M`=*24]&/?*_P&C@P?R@D<0_ZZ0P`X``^X.-
M+/85!3A)(P?:V,3_`/ZF*G__`+Z1C0&\4=/EV_5_@-T4P_\`ZBAC#_V@TI&M
M#HR?"4BK_"5;I!_^@ASC_P!S6^:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT
M:`9%U!=^N%>G+MOLNXK-*S]\S9/&M9HU&@3-OPJR9D*7;NUX&EUWXPZ;-JJY
M18OI29FGYRQ]<KD9+3CPJR;(C5S6^0Z\'67=XM4W6M>D7%*[22QBER"UEF,F
M?7!L=IIFD%+@G+B!9-:LIQ!3/#W%'%1JW\*4TL10T047(<WTMY1TI!].1A93
M&)AAUGC(1\C*`9;T"N"1N/FZ0N@2`2@)*`\R,H@/A8$P="B`CWB%N([2@(4!
M1DNA5T\;(U`[15!T6/+4DZ*G`BB=!P5?B.+7"UH!(L57_(0B>\%.&W=H!J_3
MYWZ89ZC.VRK[CL-&D8QC(/'M:NU'GS-C6;&]_A4VJD]3IY5B91@],@B]8RD-
M-1RAH^P5Z3BIEJ5#XM5FU>6G-1"TBM$)2<>I*MD2N'$8F\;'D4$#B`$678%5
M%VBB81``551(F(_ZWMJK9U.=WVU'8[TH<U7OI$2VW.H*9.S50\*V"^[0GM&;
M-J)9K75)*<F;*1[014CVF0BXTJ(P=;D%Q^LX5.:B9EGQ]7LATP_.70JHNWSI
M@.>H3C[<UN/B]\V.L%5;=#9<J(Y;DDH*P30P\->K778<R#1&SL4FS"0=I4^<
M6M#Z5<SS5JYG#R;.1<,4P+RHB```_8/V@`B'\O@!\?I]M8].7BU9%>(3D&*D
MHV;ING$:1VW/((-5C=J3E9D5472+=0WA-=5$B1Q_-..O/_ZG^\K->ZSI(]&W
M<+-6V8K.:;-G^\U.UV^!?/8@D[><:-YO'J%[=Q\4Y:M7)9B5K3*X/891(\:6
M2<.VJ;4B':36Q]9SIVQ72/8;5-\NV_<GN6G=S]BW"-X+*.3<D9'7L,GD"W*5
MJ:R*\N"HMFD:XCF,M,P$W%S5)=O)NLR5:L(12C8AF*KE^!:YWT=4/$>PW,NT
MO"V1L?Y*N$[N\O84"DRU(2K*D/6I,;A0J9\7:C3LY%/"L@?9`C'0_5#:1<?!
MLWH^AZWPZ:TF8'`?O]S!["/YIA+[@`AY$/`>X^/'(AJBA](DVB8I==1'IXY`
M,_R$2<WRY5IU7S,B6]2YHJ*BX*Q[>\8,38QCS@9/'[\:W.O5G;^).=9W-E:S
M"H?%-P$W>ZG>WF[P?69Z8>QK;;GG*F#H=39KCS`5<R6E;IVQ72LT,)C<76[3
M855W,@U2L60'6.VTW&,+'(@C(_7;MC(C(-%6J3E`"\JRDH^2257CWS1\D@Y<
M,EE&3E!V1)XT4,BZ:*&;**E(Y;*E,FNW,(+(J%$BI"'`2AQ,IJ(DEGC>/DX]
M\O'+?#OT63UL[58K\"/HO$VZJIVBO`"/IN2I'_\`EU2TZK>.+1TP]K>QGI-;
M*<RY7J5=WG;B;U^'V9;?:6B>0UH^U7''E?DZRYM-.BZFX:5N;M>3VTU8_@$F
M\L]@J^,"[F'+>6?JK)IU1>E?6^BA@'%^_C85N+W$U/-6-\NT&KY#=7+(H2L3
ME!O:222!GLC!QD5"M'"#Z?C&[6S5.3-+5Z6I<E)LSMDW[)&24`GZWR]4?(VU
M'J/=/[9-6L4TBVU'>'+QT=:;S.V.Q1EDIB;W(*-..I7HB-9+Q,J<C147I2RC
MEN47``D(^D(FU-<4>0`?O`!_K#5++J'Y./FSJ]_1T,S*180BN7*/A;*"L*54
MRY(A6_WVM6M2+36/P=9.//+&:)JF\J$1*<1$3<ZNF$_,+_\`E+_Y!H#ZT:-&
M@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`K2
M]3#K0;NMIN_ZF;%]K6T&E;F+=?,1U#(-7C7-OML3=YR9G'&15IB%C(B*:!$*
MM8B$H2\L#A9^BL=$'PJ%`$42G;V'TAW>=M>O^/$NIUTP[IMAPMD29/!-LHUZ
M:LLFXB%D")KR$@A$SL6M"V@L(R,>5F:\PLT7:`A4W$E$1TJ9J9HMJFZ[C\;(
MV)\\?Z/T![_?^YYNQX_IYXX_3QQYT^SZ3R>AI])K(I;8#/ZV/E[!`8[]8I14
M+>`O"!U#LA#_`#;@*02Y`X4#CB,^-*J/H&/H#L=9/K/9`Z=+7:%*8"Q/C3<!
M![IH6^ST7+6"WV:(:'BX!OCA[5']65JS!^28:6=C>Q=D6<"D`HHLSMN[XA4"
MNMQ%U/H:_P#2*/U.9^M0,(XB=NV0,JV6A1LX[DX:-OV/@L,+(4<LNH@E*E:N
MKE"(Q:2[EH2239R"*QFYUNP%*HN["*F7&#OHI\/D)LX<.7Y:"QEV<PBL*B]<
ME,I[7D&3-Z@^**AT5JFZ9-SIK%$BK8X%`!1.`#P62\3>,NE5OGZ24:]51R2C
MUC([9A3&WJF1>2./<U99+DB*D#1R0BX1KCYI19_U%$`5;.T)-$A>]-<!,!/=
MT5.M5FSJ<YDSKBO+>`<=X:/B#&M(NR*U/M=PGY%_(VJS.H5>.D6EFC6";1JW
M9I(/FJJ(F<*BN4%2%)P(L&P[](/ZK&YF6R@WVP=+6G9WA\5W61IMIE*+?+X]
M+"/"R,PC")3!'B$=Z#N6C8A:033;@ND4I%0%0H`0#[#T-JY&T[K8]:&GPR)&
M\/4)9I48I!-,J2:4;5LQRU?8D(D3Y4R`VCDQ`A>0#GW$>1UV/HF0$&,ZF'>!
M1#_Q-5#\[CCGZOR1Q[_;[_\`70#]^F_URY+<_N8F]C&\3;)9MF>[Q@QD)&OT
MV=DI%_`6X8R)3L3RO$3L45!6.NVPU74_"B#9N6TO!VVO-WTA`SZJC4&KBPI[
M^VJ7/592:.OI+72O1Q.>(2R(2.P,KD)6*33,]!@AE/*3IY^$?P@"N=R;#R-@
M32%WRH2!49B/^0BB&KHA>.T...WCY>/;M_U>/T<<:`^M&C1H#%3B_P`/$2*H
M>X-5"!]GS*AZ1?\`J<-(I[:56XK^E$"F!N#.7**?'VB4@BL;^KTPY_ETE6@-
MTI*'>_=N!`!!%J5,!^T#+J`/_P#:B8/Z=*9K2J2AV,';@0#E9UV`/V]J*90X
M_D`ZA^./MYUNN@-:MJGIPC@/]JJW3_K6*<?^A!TDFE0NJG;%H)_[5ZG_`%)I
M*G_\P#27Z`4ZDD[8URI_M'I@#]($11#_`*"(A_+K<M:Q4"=D*D/''J+N3_R_
ME!(`_P!1`UL^@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@&!=27IZ8CZEFV
MB<V]94>/ZT[1EFURQKD2%:H/9S'&1(IA(QT58VL>Y41:SD4XCY62A+-67B[=
MK8*_)OF974>_!A*,:ZZ/2/\`I!BN(3;&7?4<PRGL]&O%I:EB3-87%\_<W]$C
M`U"2.;&J&4?P=+"!]3$JA\M$BAA@_!HTV$`84M7)=&@(4$^AGM99]+R5Z9<;
M)SR,!++%O;G-+E@P=78^?TG3630S(:&*JA$%%!ZR;0J5,;KH11*`F--^-,55
M>56B@ENC]UT<G8/A>GQE7?UMW2V-0$74J@I/P-.E7V4YO&=1DV:T#3W;-:EQ
M5@DF\(TCHXS:(G\B&CW?P#"*F9Z8BFADG%P[1H"N!U"^A?,YWVF;!]I6T:[8
M]QG2=E]_)8UG6636I\_MD6>&!"6DC.ZI#R`N;C9;&XE++..G:#&.5?2;@6Q4
M4@30(XWK@=,K+O4_P3AG%>'\@8VQ[-8VS>EE"6D<EI6I6+?PZ=$ME5&.C@JD
M7*NPDQ>V!JY`72*33X5!P'J^MZ9#39:-`0+]83I/YQW^2VS/)NW?-6/<1YAV
MAVF4L<*XR57IV>JDN\7?8_L<#)H_4C217;OJ[:<>Q[H6,E#R<7-Q[Y=J[(V%
MN!76HW/I3[N<K=2'IQ[^\JYNPC8IG:U@.AT+<,E&0=M@9?)64(9'+REOM..H
M9E!)UR%K4O)9&8+Q4;*N(UPU09ODU&J/^3%4L+:-`1+]73I:5GJ?8)JM1:W8
M^*,XX<LJUZP9E4C-U(M*]8'+5NVEX&P,&3EI(KU>RD812[MS$N4)J#FX2!L,
M89RM&*1SZ(>X]'KK`[^Y3%^(>J-O9PK9-I^(KQ&6E[`X3K:B&0<KK1$8M$%>
M2KUO1*&WCYF6A'DI"'L,\]E%8`)B3G(RO.IQ5%TE;@T:`@CWF])W(^?>H7TU
M-U6)[ABB@X;V+DK,;-8ZF6UK)9)&O5>ZL9V,AZ*6(BWD$@@Q@&"$4S)-/V92
MK))@8WH@*FIVRAP4`'[``/Z@U^Z-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
M:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0%9[J2=(+?=N+ZCV/^H!LUW*X/P1;,
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M4LS-6V-XF9377DB/6<<O,IMR`Y<@FM92T:`@\V$]+W,.U#J/=1/>9=<AXSLE
M!WB65_-4.JU5*UDN%6;N\ER]V(E;CS$4S@SK%CY!)H?ZE>O2?&D4$#"AVJ&B
M7VX]#SK6[,9+,/\`X2NH)M@Q!!YEOKN[VQ@C1[-95Y5VW?3HUY1RO;L3V-1F
MO'14VLS62BUF[1PJ8RJI'!DT%"W*]&@*]732Z)ETVU[FK9OVWO[D7F[?>98V
M<M%PUH19RC&HTI&8CB5^1FFKB;,E,6&QK55!&JP@#%UNM4FM'>Q%>@#&=@^;
MV%=&C0!HT:-`)]>5OFCFX#X`'"Y@_3^33)_5R?\`KUH&MIN"_JS)D_L;-D$O
MT=QP,L;C^A4H#]O(>?LUJW`CX#W'P'W\CX``_2(CXT`L-80]"$9>!`52J+FY
M^]50Y@__`&=NL_K@:H@W;-T`]D4$DON_S:92?9X^S7/H#1+R;AO'$_A+K&_L
MI`'_`/OI.M;U>3\N(]/G\U%P<0__`#'2*`__`+!UHHCP`C]P<Z`66ME[(..#
M[T1./Z>]10_/_P"[6;UT(H@)QD>0`X[63;^L42"/]/(CS^G7?T`:-&C0'G`]
M2#Z47U/-K6_'=MMUQF;;F;'^&,]Y%QU30L6'7TO.EK=9FE&$5];2A+PR)(/Q
M;DX<NBM6X+*%,H"293E3(R;\<(ZNO_"U^HQ_^T+44?6Q_?;.HA_.SS%_ZG<Z
MBZT(K+DBU#^.$=77_A:_48__`&A:_2_3!^KJ8>!-M8+X'R;!DCQX#GCY<@F'
MD?8/''(^1`/.JKNC0I:F'Z8'U>``3#_X6>`3*IS^X:__`#3F`H``?NA<\\CP
M(?9P(^WG7%^.$=77_A:_48__`&A:JTB=`2&*=,`."*)$C)%["@;DIE#J@/!C
MG$!,7NY[1X^4.!`0XB)IJ+`F"@$3,?M!54.T"EY\&.`"/'CR(`(\>W(ZL2TE
MF.]J[5]AYXK_`&6H!^F!=7D$BK<;613,82=P8-?CVF#_`%3!^Z%R41#R7G\X
M`'CG@>.+\<(ZNO\`PM?J,?\`[0M58S"0A5$^T#F`_P`JP',!>TH\>">P@8.1
M`1\@!M<6C\^_%0%J0OTP3J\*"4J9=KBAQ`1["8*D3&#@?N#((B/CSX]N=?'X
MX1U=@'@0VM`(#P(?N&/^0^_Q^Z%[_HU5?*8Q1`2&,4WV"41`?/CP(>?/MKL"
ML)CJG!!+A0G9V^F)@3Y#\\@\^#CVB/>/(B/(^=*>_MY?I`+3:GTP;JY$.)4U
M-K:I`XX4'!,@GW>//!1R&(@`#X#G@1XYX#7Q^.$=77_A:_48_P#VA:K`UVHV
M:VN3,ZU!R<V[)VB9".:J.#$*;N#N/V`/;Y#W'P``(B.G>8OZ?NY#*"C08NB2
MK=!R9,``4%73LP&#D?2;-$E>3F'@`24,4R8"/J>0XTB:T2]NDU<=61M+=\E+
MZQ:>B)Q/QP;J[\"/;M<X``$1_<+D.``1X`1']T+@`$?`"/@1\!K\_'!NKOR4
M.W:WR;\T/W"Y#DW/@.W_`-X7GD?'C35L:]!7=+>'+QF]J=U8IQ:#--5:0CF$
M*T,K($,Y0206?/SG63X`!.=-`@)F`.2B8>!=E0_HV&5I`B;NW3K.%0(/;\/(
MV>/4$"E`>\#)-8[U43=_'!$SF[0``$Q@YY0O^Y=GPI;GV$\'[?OS!U_QP;J\
M<"/;M<X+^</[A<AP7D>T.1_=!\<B`AY^WQ[Z/QP;J[]O?V[7.WGCN_<+D.WG
MSX[OW0N.?`^.>?`_=I;8WZ,LH^34,\R966;@G`H)(R3YT@=#R(&-V)$`#AW<
MB!@_.\B&B3^C(/0;G)&Y(KS@YFI@05-)NT`*MW&$1$%4#%)R)A$HB'/L`F$`
M`-*;\J<HGWY1DDZO^WW7#C7.V!$!^F#]78/`AM:`?N'!D@'OY#_[POM#SK]_
M'!NKOX^7:W\W/;_[BY#YN!X'C_WA>>!`0'C[0XUQW/Z-)F^'06<P=AAY=!!N
M!^UI8(]R[74-P`)$([CD"IB`>"_EA`OV:9[>>A!NHIR#EX:GVUPBB("V+'M(
MR9]<."@8#'92")D^TQN>X$OF#QX'2%NN=8^)]BSP?M^CQ?QPCJ[#[!M:_48_
M_:%H_'".KK_PM?J,?_M"U#M=.GQG_&T8Z2L^,7A7C$CI50':$M#R"*'J$]%P
M*RJ(Q[DW`%,8AA%)(>4P.`<F%EDQBC($*JJF]JTL44C")Q30!P0I!'@HF5;F
M43Y$>0'@W`\AV\^>*]-$TT^"NK8O=Q;!E:IF4],.^J$FMY\^8LN?CA'5U_X6
MOU&/_P!H6C\<(ZNO_"U^HQ_^T+56APS<-1,59,Q#$4%(X&*)1*H43`8@E,!3
M]Q1*(&`2AVCQS[E$>L("'N`AR'(<AQR`^P_R#]^LPU=0;+4'XX1U=?\`A:_4
M8_\`VA:/QPCJZ_\`"U^HQ_\`M"U5>T``B/``(C]P>1T!:A_'".KK_P`+7ZC'
M_P"T+7,M],"ZNZ(E`1VL'*<A3D.3!L@)3%'WXYR"`@)1Y*8!`!`0]N!`1JM`
M`=Q0/R4HB'<(!R(%$?(@`B'(@'D`Y#GVY#WUSF,FHX*51=4[<ABI@J)1$X(E
M\`)2"8>W@/8O(\?<(^-5+\5?GA&8'GGGP6F/QPCJZ_\`"U^HQ_\`M"T?CA'5
MU_X6OU&/_P!H6JKYNT#&`HB)0,/:(^XEY\"/@/(A^@/Y`U^:@+4/XX1U=?\`
MA:_48_\`VA:/QPCJZ_\`"U^HQ_\`M"U5>T:`]%_Z/U](*W^=2;?^WVX;C1PA
M^YR?"N3[X<*!C)U5)X9ZIJU<D3Q*K6N9*#("RSSXEN#3E8?2_*$[>=7F=>5%
M]#[_`'WII_-BSI_WZ+KU7=`44.N]](LW_P#3DZAU]VP[?HO;Z[QK7,>XFLT<
MKD+&<_9K*,E<ZDG-S(.)6/O]>;JM@>*<,TBQQ#((`"9CJF`5#0W?CC?5K_W#
MM%_4G;?VN:2KZ6O^_,9;_P"3FWK^[MOJLYH"UQ^.-]6O_<.T7]2=M_:YH_'&
M^K7_`+AVB_J3MO[7-51]&@+7'XXWU:_]P[1?U)VW]KFC\<;ZM?\`N':+^I.V
M_M<U5'T:`M<?CC?5K_W#M%_4G;?VN:/QQOJU_P"X=HOZD[;^US54?1H"UQ^.
M-]6O_<.T7]2=M_:YH_'&^K7_`+AVB_J3MO[7-51]&@+7'XXWU:_]P[1?U)VW
M]KFC\<;ZM?\`N':+^I.V_M<U5'T<"/L'_P#'O_Y`(_T:`M<?CC?5K_W#M%_4
MG;?VN:/QQOJU_P"X=HOZD[;^US54?6YU;']QNAS)UFNRLT<I@3XCVBCC\J/L
M00(`CSQ]@!Q]YB^^B4V$I7<%H7\<;ZM?^X=HOZD[;^US1^.-]6O_`'#M%_4G
M;?VN:@OHG3KW5WZ2BXV(Q'=.9984V[P\.(-"@"1E0]0YEB`43`!0Y$W!1Y]P
MXY>+4^A3O,G14&6@$((@F`&YW)T0%0H$$QQ43%813$!`2EX,8!'Q_+8B[6]T
M_B>UR+4G53C#5^:5"0O\<;ZM?^X=HOZD[;^US1^.-]6O_<.T7]2=M_:YIFK?
MZ/YNK40!9:3@VQNSN,151/Y3=P`!1,"O`=P#R41\#P(>^L'8N@1O$C4#JPOX
M.S8I@4YB_&E;@)>!$Q0Y[OF#Q[_I``$1TA;KW_!-J.L=)W^Q\Y?IC/5L,(`6
M`VC&$?8`PE;1$>/(^`RYS[?=KG7^F-]6403%*O;1TQ`@%5*?"=OY,KR/<).<
MNF#M``#D![1`1`.!Y\0V6[I*;[Z2J*JF#[!/()&*8KBN+,'11^8?("N\;"3@
M`$Q1^?G@.2B`\"U2\X"S34TG36U8HND"XKP'+*.'<`Y31;@<5/2!RJW*JW,N
MIZ)O66*LH!A*40X$VM+3*=5,2E1S56K*=YG^R-U5'?BHE95$]JYLIM8V_'&^
MK7_N':+^I.V_M<U]%^F,]6LP\!`[11X*8W`X4MH<]A1-QS^ZX/'(!QSP/'OP
M/MJJ0=,Y#"4Q1`P<<@("`AS[<@/D!^P0$.0'P/`^-*K@?&K[,N;L/X@C$'#J
M2RGE&@8Y8-F@&%RN[N]LB*TDDCVAR"IQDQ`AA$`*(=PB'&L&CVJ=K=UR?DK;
M/MYR/FM2`4R[D/"&++]DG\%8EQ!5M*WW:E0UIE6L'#.Y"5=1D<Q-+IL46CB2
M?*D,V4.9R?O`"Z1OLW$N=I&S#=)N:CRQJDW@_!U^R!5V\RV4>1#RZ1D0=K16
M$HR1<-%GD?(71_7V+UJDZ;*.&SA5$CA`QP5(Z",A(ZLQL=68@GIQ%9CH^M1"
M?//IQ-=9-X2+)S]O;'L&P<_ZP@(_;QJO#]*;S.3%'2#RK64908V6SUE7#F'&
M!"``J2,=^$;C)MG8E[O!2'AL<B*Q^!'TQ$@<"?D`*M@_3&NK8`\&@=HH&#@#
M`.%+:/S`'!O/[K8<_-S]@?R:_/QQOJU_[AVB_J3MO[7-52!$1$1'W$1$?Y1\
MZ`#D0#[Q`/Z]`>NIT'^H3N1ZF>R6:W)[GF6/F-U1SUD#&U>3QK5)*H5]2H5&
MLX_D$%U6$G8;*L[DCSMDFDG#]-^F@9)!%J5L51JJJK-$*B*("LY$0;(@*SD0
M,!1!LB457`@8>0*(($4$#"`@4>!$!XXU7\^B^U@M<Z+^VAX+8S=S<+MN%M[D
M3%$IG`N,RV:NM''!@`3%/'UAH0A_('(F42B)1+J;#.MQ:XZP=FS(+Y0J3.B8
M;RQ<W2IS=I$D*OCRR3BBAC?84A6(F$?L`!\A[Z`\[J[?3#NJ1&W&UQ]0A-J!
MZFQLM@9U@[[#=I=O35UK,/4((7;I/*K4CAR,4FS^(7(V0*LMWJ%2(!@*&L?C
MC?5K_P!P[1?U)VW]KFJI2@B)A$PB(F`IA$?(B)P`XB(_:(B81'7QH"Y%ML^E
MM]4_+.XG`F+;-";4TZWDG-6*J#8%(O#EI9R1(.Y7R`KDN:/=JY4=)MGQ8^2<
MBT<';+D1<`FH9%0I1()JL#L=_P!-/:'_`#H-O_\`>U4-&AC5J:B./T.AZV/[
M[9U$/YV>8O\`U.YU%UJ47K8_OMG40_G9YB_]3N=1=:&M-ER7P&C1HT*=U,C0
MR#DRBJHN")HBW*``!!$1*"H&$P]P^GR)2@7P(`)N!#VZ6C1JMS%$H6,U=:]N
M@.0ADRE5`Z7>8Q0!,_>8HI&`0$3<!X.`AR`E,'W"`AK[%0RQT@,1,>PJ:0%`
M/3`Q2>`$XE$!$PA^<;D!_P#+7&0@G,!0YY,/`<%,8>1_-`"E`1$3#P```>XZ
ML&=,'H=9BW<D991R8V-C_#R*C-V,O,I`DHY9KMCN2KI,%T_4=G4)Z)$D/!!%
M7YA-SX)VVS:M9KO>DSV3(_=V]IY*T_;(7,38+RAF67BXS'=-DI]PX7.W15:I
M"4CMT0!5.@F*AA]=9,O)>U!,X>``_;XU8IVG?1X\J716'ELO,Y:`*Y3:O%(:
M611;.6Y/3%4"%CVCPRZQ.!*4?C5P1*`B'HD`1(-K?;/L#VZ[<J<V843'588M
MX8Z??<IF$CE;3)KD2(@HZ9J+(&-&-7@%[R@EVJE`XASR(Z=!*V21!HX8U8#,
M6Y!32^)$.'9DSFX!4%`_RA<0*'``!@3`!Y[0#G2=J19PDZ16EK8KNW<1O/*7
M%YZ[;<"-O"'21VD[=&C926K"EJF2MVH_"N&J!6PK(DX/RWC%BH`8QSCW%<BH
M?@`$QA#G3WF#"O8]9LXFD42K5=B01*TBVS2/0>KID#@ISE!$ZI1$@B)C`H)N
M1Y$?<=;6DT=+IG![(.'+A4$O44,<XG[Q_.%(@&Y`P\"/N`![\_=KDU)5RFJE
M?V.5A8]!QP@@ZG'C=%<G'RF,W!RL(@(\@`CP'OX\ZA3]+9;Q*$.G%Q4<J8AE
M!>(2;]1`4#<CZ7P2HEY<@4G=P0Y@+R`<!X#62]0K6/\`1+/)MYY8$E`(^:ID
M<MW!@`%$6?J@9NZ2$XB4AS\',4`'WXX;],[S=J]2?.HV;RW4?C$1`IFR3M%0
MZ1B&$H@)D@`O=W`(`F)A`!#D-)[(=0[:%*.UXU#(5=DI&-124*9003<LA5,(
M$5!8/SOS1[##[\<%#GW`>@>/MZ2)W1+8I\+Z:*1VYHI@W*BJ8H"94BI0`Z@F
M'D`+QVAQ]PZ[!`NYHWO(_CGZB'J+*F<IIM%`0`H=J8`0HE,(!Y#@>!$?LYXT
MS2)ZB6V-ZV0:CE"+6*"WHBFZ'T@,9,_9VE55`2JAR'@XB//N&EHC]W&"[$]B
MZ\C?HADO91[(LA%VRZSI(A`6.)2(&$_8)1*!@.!?E\<<AH!5F3ZWF=)-Y-&$
M:I.>[TT3K%%14@#X6,)D_P#.F]P3$>`'VUVG:RY;)'1)8QJ\>F:.%A3.8R"1
MT4P*(*`9,"E,(>_(<^0]_.MCBK)6K,LW;HO8:6*LW,HS](A4S)IH@`%,'=VG
M*)@X'CD!Y'].L/8:XN=]%ST&Z]"0AG)SN6IA,8%V';V.4"&$W//`@)$P$0$2
M\@'VZ`URP14(]?)FFH%F1<Z9?61<1+>5;K-S<=P"#Q)4AB>1Y(`=IO`F#QI)
MLB[)]GN9XY9:]X%HC\JR(E^OHQDI599)4X<"Y07A3M$N_OY.8#"4.>0X$!'3
MDH$O<H!W@_6R"S=V<CA4@`JD7D1.0Z9P$1`AN")!QSX`.`#D-:]''4E5IAE"
MA(L3($344;R)`!JB9-0WA%(1%/TED_<I0Y$X\_9X`@DS3]'6VR9+.\>XXR!:
MZ&X5`0*TF(J/MD2LFNX%8$W$N^>%FF#80$$P59NDSIIE()3^/$&>YSZ/3N[Q
M<_F96@4<N3::Q;**L'^+)9C8I)7L<BF4%ZY*/6T@410`JIQ2E5P2`P`1`QA$
M=7OVGJJ-E?A3&^(4$"'*W7,4B*A?E,F9$#<`3P*A"\=I1$?8`XUB'BT^Q<0Q
MG+@"QZJQF;TK<ZC=XW4/ZBB2_J@((J(F(``?DI^!$"B'<`\67:96SMYR,O2K
MJCF95)Y[]3RD\BX#R5BVR/JE=:U*UZQL1<&5@)QDO"SQ4$53H>J$1*$:.W!2
M+$.DX/'%?HIF*/8LJ42F%'Q*9HY,14HB=!0Q%"%.9,0.01*8O<``8HE,'`AP
M`@("`@`\Z]8/*NV';GGU@O%YIPSCS)":A1%&2L-2AAGD"J=W(,[,R:$DB%[C
M"J'<Y^90W>;D1YU7=WG_`$;:IV63D<@;1K`VB14;*I.L471PO\"JHNHJJ=W`
M6%`0<-SH@HD0A797"8D3$@D$?.K2E]+GFOWY_)_-3;4HQ_'4WG_QMM%BDP<Y
ME#"8XB8P@`<C]Q0`H?U``!KYT_'=KT^-R>T&=^J<N8PL59C5%5PC+(=+ZTK<
MFW%0I45&T\P*=KVB;U1(FY09K"!B?*83!IB[I%5$R95$CI#Z8<=R8)]X`8P"
M8.!'O^X3B/</L(!P&CTM5NG6558F=FFX<PRK4G:F(:A]GP.MHT:-9-!HT:-`
M6F_H??[[TT_FQ9T_[]%UZKNO*B^A]_OO33^;%G3_`+]%UZKN@/)J^EK_`+\Q
MEO\`Y.;>O[NV^JSFK,?TM?\`?F,M_P#)S;U_=VWU6<T`:-&C0!HT:-`&C1K]
M`!$>`#D?(_U!R/\`4`<Z`_-?1"]YRE^8>XP`/87O-P(^>TH<=P\>Q>0Y'QR&
MEJPCMZRUN&MK*E8FIDQ;IQVHFFHDQ:G^%8E4/V@L_?'$C=JF4H@J'J'`QB@/
M!1`/-DC:;T#(B*286S=191"415*<U&B$D3-$C>B0WINW`<_%F`XG_,[$BB`?
M+W`(C8B\8I=QT^VB3M5^W?Z4O@5M\=X&R!DA8@UN%=O$2*%*J1)N#MZ<>>>&
M\8W44<K>>T!*J5`H@(CW]@=PR[[9.BOES*?P$K>&3VE5]X)'!G=G00BG)$Q*
M`F.@P(_3,HF8!'L36.8H<#R3M'S:^Q)MTP5AZ&3C<:X?ID"9@B5(TP_@8U:2
M=]I"I_$'<J-C'**B92B(B;C[@]M;DK'II**FG)@ANU8RB+5)4&T>#("AV(IE
M;@4$P*(`'`%`!``#@`X#5;V22[ON_J"0Z-MS2BHI^7U;7`B9Q+T4MF^/)AC.
MW61?Y-FVX"F9@@!H^$`H%*4`7;QDG\*?M,!A45.B*AN0Y$W'&I4\=X"P9BUL
M9&@X?H-91(<`17&(:/%%@`@!ZQ7+]%4YS&X#GQSSSQK8XY[5BE5:Q[=-TNFF
M;UT6B8`/`B!A.94P`4@$#R!S&\>!$/?A)I*QR!%W"<9-L"'!SWL6+B5^,;D0
M((@9%0J`&.53N$0,4@<AP''/@=9EN[DJ25EP%WD',JD?TH\C=)),AE$SL6;)
M@*7<'`$2!!,O''@.XO;[_:`>,<4ME=$4*\*[3742(!$C.ES]Z9!$2GX`2E$0
M'R(<^>??VTE<-E>:A_51LX5HK01**#TS&5$I0$>T2CWD*H4H#P)3!W<CR.E0
M;9$82"B*S&0H\@X!,#$:FF'+%02@`B``#@I>T??D@\?=[\:%.$P2J2H(G([3
M5X)RDL=<"N"@(]ZA1,80X)]W'`\\%\:S)EW+5R1NXC)!OZR)CE<I.EU$51,4
M>X`)SV!X\@'V<\!S]G>6FY&0;?%JU];@"`3XF%?M)%%$PCX[3!R<1'[`XXX]
MQ\:UMW9","-U'CQX3O$2D&38*)BF)@X`HG1Y(/`<\F\!R7GSXT!F6CLC!("I
M/GQS"8YNU8AU4^XPB';V*"<H@4?;\WCC[N-8-*%J\L#Y&7K=:D#O550=HRT$
MP7([2`O<!53*MS@80$1[2F\@(FXUVI%XFJS17AW*#T2`4P@CV'*)C"8ZA50$
M2F``[2\@)1,`#[^^L<Q%:44<2*@BW:^D0/03,)3&7*!@5],1$."^?/("(@(!
MQ[:`;!EWIQ;0,Z>J>XX)KS%T]:>D:>JH+P[]$0%0Q3)J19V9BB!CB<`]0`$P
M%$1#@HZ1'8KT&<4X_P"HQM3SIC6_S*]%Q'DZ,RA-T6<8H.':CG'L?+6")42E
M5919^4A;,WKHN2J)N$U$"'**13J"J612-C7J<DH*3Z5;-56ICE(=RJ<@<@')
M4R";LX$0]O<0\!QP(:D6Z>\"^4RA9Y)8R3AG7Z,N;XE0G:[!Y8Y5DS1)QR(=
MOP[%\)Q'@PAP`<AW`%E^=+;61(7>_'F2]EY``Y'D>`Y'[Q^T?Z1\ZI'_`$T?
M,",?B#8Q@!,HJ+VK(N7\TOC%4`00;TFM5O'\*"J(<CRX<W>P&05,''^2N"$'
MGN'5W'53[Z0%TR8CJ,9;J$Q$9$>TS)F'<6QM/J[1^0'51D&T[/RURD$WJ'>0
MS9ZL>332.Z2[%3@BV(<QB(D`(4\TC7VF(`H01]@.41_D[@Y_Z:?5NPZ=FYK9
M]-J,LL4"395]0ZAF-UCDQDZJ\1,X%%N<9!H506(K`*8E3>%+R)^TIS"4PZ8Z
MLT,W.=-0WY0H&$"]AN#D`AC>H4P\!QW%$H>//'<'CC6O2X]5U:4\TIOG8B:=
M,Q,;<SV&NAY5F]/Z1/3VBVZ((E?;;JU:UB@4"B=S=IZRVY=80#W%<9DJG=[F
M`0,/(CR*H]5^ZI8\Z8W4!MRIRIC'[0\ZQ[<QC]G+ZU4>2ID:0!Y#YE)*QM$B
M``\F,<"!^=K?.G=1%\8;`MD..W)>UU3=I.WB#=!V"G_E2.*:LY<B*8\]@F7=
M*&$HCR!C"`^=,8^D479O1>C/O>>+JE2/9J?CN@-!$P%]1W<LRX\8E1#GCN,J
MT;O0`A1$QN!'@0*.LE/(V-R!A`0X$."B'W"4`*(?T"&OG7T<>XYS?PC&'^L1
M'7SH!TFQW_33VA_SH-O_`/>U4-&C8[_II[0_YT&W_P#O:J&C0Y_Y,=?H='UL
M2A_[6?J''\\FW;YF*/W<$LRHA_3\X\_T:BXU*3UL?WV7J&_SN<T_^ICZBVU7
M]+W2-JRY(-&C7Z`"//`"/`<C^@.0#D?T<B`?TZA3\US-T17721`#B*AP(!4R
M"HH8QAX*1,@>3J'-P0A0\F.8`^W6_P!!Q-D;)\D2+H5.G;4[]1NFJG$1[AV1
M`S@_:F#@Z1.$Q$.1$H"*G;[%Y$-7"NBO]'WFUK1`[F=Y\!+5QC67)Y>E8OD8
M]C\-8E3I`:/D)=&11.X.B('!0C8Z/I$[>X0$_`A>+[9?W;-B3A5=/?R8,)T,
M>@G`94@X7==N]1=Q592(SE\>T1:,;K_7"+B/,Y8R$DS<E(HN=4[I%;TE`41(
M!"AVB8HB%M5*)>XQ8M:_)/XIY56)T4*7!0L0TB1+&M0*BT;/6#))),XMDB(B
M=4Q1+P0P_P"J&E"MEE1AF4=5ZJA'L6,.T2C&;&,039QT$S9)E0;$43:D303.
MDD0$DDRE#O$.!*''&F^6W(=<J42_L%NF6+%K$-'#B1G9Q^1JV8ICSW'%PY/Z
M;9$>0*4H&`#<@4"\B`#)GSI]%-FFK!]>D>/7(BW*V3])--L<3I&$1%,"`0!*
M100$?'!>"CQ[<<Z9!G;=_B/;9'&6R':F:%B?)&&O4R.6-(W.<(CP0P,XAN)U
M13Y4(*RG9VI)=QC'*!3"#.,H;\)#,%$R^PV@VVJ2$W68QXFSLYBJ2+AU*M%!
M,Y8UB+6.V:R2HD+VF<)G%(>X!3,(@.J_4++J3*I+).NK!/WV;2,]M,U<7+Q_
M8F4RN4%9-DB60.NK$H)/3KIECVBA&S4@`DF':`"($G^7^JCN"R`22C:2TB\)
MT\Q%BL9]J*LO>WS)8PE05>MWJ)HV%6],/(%.Y,0QS>>XH<1YV2[VBYR+F2LU
MONV2I=82JNIFUS\@<A$U#^L"+1@@X2A6J8&Y$BB#--8Y."]W<`#K75HMVX>I
M/')G`I&0(FH0X"=),`$>U0Q1$0[N1YY,`^?OXUFS0(#\&X=G5(B3M^&4(()D
M.F'L4Q"?G"("'S&#QSR''&@,6F[4^(1=.6#!10Z*P',HF@!RG$0^%-V=@^H<
M2_ZRG)A$.1$>1U\R+MM&.6#U*,205?JLF;Y>+:(?'N#K&$J!E@(0I!3*81'R
M(]O(^/(AK8EHU@DV5?G;E*F0Y4BCZ_?PJF(@7O$0Y`/X'/V>"CKXE4"JU\%A
M9(HBO(Q969TS"53D'(=ZAC^#)&*7R`B)1^P!]]`=5)]()@HF=LJ3A13L2,DQ
M624%,1$3E!1(PIKF'@PIE\`8?/G@==UO)':OHJ3116<S3-7XEHZ=-#H+L0.7
M_-IR,69)9L4P`(G`H@!@#D0$-9IDP:-#B3\HNX;J#Z!#\+`HBM\RIW:A@,9,
MJ1A$J:@"/(!\P^=86<H3&POVKY"7F:O),%T7Z#N&>*)MGIDR&`6TE&F,5!XW
M$1$I@,`@/@0`!*&@'4XSWN9&Q(]9.W+A2Q0C8O<NUDI%Z]C4"<@4Z+>79F"2
M;K```*"#HPE,``"P^XC/EMCW,8XW)5-K/4F^.DYQ@DW)9Z2X<(G>,7*A#G,D
M4QE#.3)`)#*(*"(&,F)0,//(:JM(L)M8Q&LXR:$40#X9"5AT_00<=_E)=]'"
M`M@65(`"=3R8!'R(:*ODNR[:,G0N8JYR@A`/V3:YL6[IRTCIJJNCBE(NG39L
MHF@+UF54B[9<"*"02BD'!1\`77'DTZKB#6:9BA8H(BB:+U`JA6\LP^($/4.+
M9/@5``YC"</F``*/Z-992QQZCE)5NW78IR3,_P`.LZ(9%JN//)2@X'DJ@EY\
M`/D1^WQINU3R4O/4NDV:+KOX=U=S$0\['V2M)"O)MH^1:(O%DIMHA\KLR*BP
M)E55`Q_23-R'`#K98XM-G)R2M+6X3[N(7CE63VBCY;Q[Q0P*E=D9JB#F.<(^
M2@**0`(`;G@-`+#5VR;%R^.58RJCXPK"*@@8?5'P)$0#D`*4!XY^T/(C]NLV
MFW1*Z66D'!'#1)(YTD'`?FN!4^1,H<_,`@(B''_0`'G3&C5<4VJU,=@_21:"
M)%'7'*"I2>6BQ>>/44(`E]3D3@/S>-9.`FRRQ42S+48F9;O@3-%K%$512*F<
M1<(@KY52,;CL.'(=I@_I`[CD[MB_;N0;D81#GRN`&.H9,_\`J>BF/("0X`!E
M!_U1'@/`:S:$HS*X*H5R9L8Q^TR:)168JHF3\*J&/\Q3\_G"4."F^WQY^Y)5
M9RS$6P('%)8!.10@&,8A2CW)B4?E)Y#P`>P_HXUU(]9-R@!EFZ#<QP,5JF4`
M`5"$X[R"3CMY$0,/'CD?OY\@<]BKU-R#".*YD:G5VY5IV@+%:$L\4VEH>1;J
MB(G4$7:"Z[0#D$@E.@8A1$"\<"&JNW4]^CMU>VHV'-NQ:/4CK,JE(S$O@"16
M(W@Y`5#I'%6@/"BJZ272*=RLE'+F!F842)`DD50QQM-1<BR]5PP<CZ*I>PZ*
M:@=Q!./'<DH!@^5,@\@)2\%`X"(<>==M207:J&(U`PBEZAB&[C&$#<!PHS4`
MW<B8!$`$"#P/`E^WS4VK?J[.C(TGY7N>1SD#&$U1)J=K\U#6"#G*@Y"'M\'/
MQPL9BOSJ0F!ZC)-2E,*#4%``K18OJ%7*8@E,!1Y!+W`G$X`=(B)BIIAV$(!`
M$.P!`X@'N8X"!A']/'@```]*3J0])O"^^R!-:&"`TG.T3'JJ0UVK;.-C@E'9
MU2+`VMS4C=%*535],4SK2)US"0X\"4P`.J#VY7:5E';3DZS8LS%3)RF7Z+5?
MJPR+UF="-O35)X8B<[7%%@%!RR=%,)TT6I@10(4"E()1+K<+6HTT=)58<)*5
M$Y;I3J8EZ/\`E_+3*C4E+4M+^7!/-:1-FQFNC6:,DU2362<`"#TAR()I&2$$
M/D*8JBZR@CZ@*IG`Z2I"@)/5`1X,8I2AA1\"/V_I#VUAJ(M7;X>4^#-IS:>J
MB<TG!:;^A]_OO33^;%G3_OT77JNZ\J+Z'W^^]-/YL6=/^_1=>J[J%/)J^EK_
M`+\QEO\`Y.;>O[NV^JSFK,?TM?\`?F,M_P#)S;U_=VWU6<T`:-&C0!HT:-`&
MI']A73NR;O3M*3AJF^JV)8QTLUL^1Q8I+LT3MTTUE(N*3=`FFZE5RJ"4GD2$
M`JA3`8W`#B.GOL<MN]?,D34D&LQ&8[AP-(WVXL(T%$HU@V(FN$>DNN'P_P!9
M/04`B7*A#>@;U`(J/!0OSXCQ;1<&X[A*'0ZW$UFM0+4C9A$M&C5FW<*%#L/)
MO"H(HD=2#Q0OKN%CD,H4QSE[C!P.K;BX[3#3^:$O^\4[?O;>$QVX[<\1;6\:
MP%$Q95&$`U:-&3=Y8/JYL-GMSU!HDBM*/W`IF<H>NH3O.D5?L`!$P>/.EODF
MZCPB9U%4T#D4Y.FZ5*EW!P(C\YA'N]^X0`?/`@/W#B'<U&1;P[V4DTC/)$?A
MVC<5@`B9Q$0(BR`.3$$P_*;M[0`H"/V#K4YV8*]<MV8$&3GE%"F;PK0QA(V;
M%Y'UGIB"(MB%#\H*O/<IV@`^^H4QMFMR<6D[(I(HQ$>D4`<SC@YW*A_3,'*3
M%CX*X`!`"]P%^0O)N..=,7W+;],$8+680ZLR[R'DV<:(JU['==;E5E)#U2G%
M)W.JD$P0<<`)***N'`$*FD0PD$3^-/E4J1)=Y]8V!3ZR^#/V-V:;5!NR1("0
M_*D@4#`X,10WI^HH4#*C\QA'58??W@#+3G=1/9%Q_1[#.'GHYK6;(V80ARM:
MK`&%8&TM'/4!(J==0#@"Z?!BE3$PD`H]W-7EE[OS!',4_8XQDVW*V_O</F!B
MQB&-QBMOQG7J2ZT%C!F2T'EXV.<'3$9"RS#5,WJ+=Q4UV;)(H]Z0<',4W.DO
MO?4LW$RU26I<,M%XA:.G*4(VN_U*W);E/AT@$9E=.6*5!LT=*)"558A#%*50
M3D.4#`(:WCS;KFFX90&A7O%!*[B)&O+24KD&&6>-VGH(-022=1[L>TB*@JAR
M\COE2!4HJ@8QC"4,,P@*7A6-;V@C>7S5+?!S%'12O!`DXYJB^66+%RY_53<)
M%#M*D@FL`")_D`#B8.`4S7ET]\;*M&9?J<>EPE>4Y<1UWM#GE51^G_U*\_5R
MT,JSG>RQ5IQ$_GY-I)9-M[@YW,4L("@V:P12MSM9)11YZ'PZ1BEX35-P<_``
M-@G.692.<'/Y[!]WPN%N<-V[B*EK3]6)@_0`4U5SM&:)T7"KP&P'*1!,0[ER
M_,/'(#4#J@VE],S$?"5^ML(=*Q,9"QQTJ@L@\KMC9)(-G8040)"I"@1,"JJF
M%,@@LJ*X&$W(`M=^K$U('K4=$RT^*3<[AQ*-"KJBCVJ=Q@;*+$4]1#\J)52I
M`!2+%-Z)Q[!'5:4[)P\VCFZOG?90-+?IE)N**84UBDPXBM5/6@_3;9U=KJ"[
MB"S@V90DG\=,L*Q>J=ZQ&<Z[@G2K5Y'2L(JH$8@[`$@5*0QR++(*"H4"=G`R
M@[5^K5MUS[.O<;72Q0].R,SDE(F(C9LJ*,/<2)%*!7D8_5$[;XE8X*"9J@X,
M(&``(7M`W%<NC93POB&N&R:OMU8W7+M+LSZ&1C)"1=,:Y*HF3*#N7?P:35VV
M55*110RKXR(KF+P4QC<"`JWDK&.,MZF*66XBH5B!VV9@BD'#`E,J2C<U>N0H
M)I3+1VQ4!-@XBYL7*BA47S,"O%"IIH&$R?)!K2O#TJBF92;K6[AJNZ<PG8)N
MTK528K,45W2CY4C>2WU.TJ`?/6\JV-]5/T44U3+QSD[9-1-S\J2*K,B@-E2&
M`0$K@2B8?`\^=:@^KMJ9K%")?_638ZRBPLU"E*H<I>04+ZR8@4O@I3<<<B//
M'DOF'+I2[D[5E/%!F.1):3>6RBS;RK6>OR#M^^>MD8<&A&DJH9^LH\]=<I_\
MH;#RDF(=Y#<>TPD;CQ.0R'*Y78Y#F)II.5QC7V%(;NBIURND;KJNEY))FDIZ
MBDN[]8$72ZZ1#%(D1,#=O.L&DYJ9:-M?8\0;OD58]0B0-NY<%#I'$>0,!3FX
M+R!@$"B`\>!'@!YU,GT[(`J5'R#;SE(=6=M,?"(.0$#'.UK\8+I5(/?A,KF:
M(8`#P)RB/N4=10O&*169D7*35=(4P%!)T1-%SW%$>[L4,')P'YA`0\@("4/.
MIM]C5:3KFVVE*$!0#69_9;88%""0P$E)IPT:`7D`$4O@(MJ=(PA\Y%`,')1*
M(BCN>!-\H>1-\H!]XCX`/Z1'C4&.<[.:=SQDQ\FX!Q'A;7S!`.>XAVT*1"(3
M`AO/:4IV*@%3#@.[N'CSJ;^5DT(2+DYET<J;:'CG\LNH?\PB,8S7?*&-X'Y0
M(W'GQ[:K4(VHTFI+S`&*M+2;YY*/&IQ$JWQ,F[6?+F](WS?YQP<W(<@4!`.?
M(:`5R0CZA?8YW5+O5(6YUYR4?BX>QQR,BU43`.0`OQ"2IB`4P?*)!+Y`!U7X
MWO?1Z:+EU:7R7M"GD*;87:`D<XP>LV@UIZ_<.1[U&KOUBO(XQ"*%*D1N4H#V
M>2B(CS.PPLZ"#5-R("1P<"D`B9144[_82``")A-R':)?L]Q`>-*KBF2</K'5
M61T3,GLM:X5D"29SB;N=2K1$@*@(^!4`PAV<#Y\!]^JFTY7G[R$23>4:!"J4
M>D54`*4*M2:;6.TO@I1K=7B8,0+_`/*`QX@7_P"7C5>'Z5Q8`ANCW?8T5`(-
MMW#;>*^!1'@5`:R]JM1B%#_6$/P:*IQY\)B/'CG5D@_'J*<>`]13C^03FX_Z
M:JB_2]HW(%BZ>.$ZU1Z]+6%FXW3QUCN)(EFN]4CH2J8JOAF3]PD@/*;8LI-E
M3.L<IP3$WRE$3")8+'F?Z-?1R&(/:8.#![E'W*("("4P>Y3`("!BCP(#X$-?
M.@'2;'?]-/:'_.@V_P#][50T:-CO^FGM#_G0;?\`^]JH:-#G_DQU^ATO6Q_?
M9>H;_.YS3_ZF/J+;4I/6Q\]67J&<?QN<T_\`J8^HNS(+D$"G14((@(@!R&)R
M`"`"(=P!X`1`.?O$`]Q#5?UI^$;5ER1\%*8W(E*8P%#DP@`B!0YXY'CV#D0#
MD?M$`]QU(1L(V'Y'WCYCKE$@(5ZHUDED#I*+LSE8O_`JK(G7.)?R""9.]<Z?
M^<3$`(H4!$=+;T]>E3F_>#D:HD-6)B'H$B8',A/*Q#Q5FT120%8HNSN"(H`1
M7Y%2AZHB`F)VB`>->@GL^V28=V24*&A(*,AG]MB(TA'=]48)H/6KDC<B#@K1
M3N5`IUP[B&X'SR`>/?2W/X_OXYVDMNE%2N7FG#=YMQ-&V.])G;;LSJL+)3M?
MK%HR$P8QCMRJ2+:)1\!)%:@1?X4ATN5UC.#G*8RQE3`(`83"/D7G6[+CF9>N
M*[4BF0B(LJ))"6;F!$K04?R01#-,G:4Z@B`!RF`]A1X`0#6C9`RJ08";3;2#
M2)B&318TK8W;LB:3!L'(J**JJ=A$SJ)]X]PF[DQ$1#CC4`FX3JG'6/*8EVJL
MF;EJU,XC9S/*[HKF"A)%LJHB]2KK4[=4EAE#G()553*"U3.83"MWE``AHDUW
M5[V\3[9H%RE9YLDA<7#59U6L:PSM!Q>;8N10GKJ,8WN.<$VXF%20?.C$2:HD
M444$.`XK@;C]V&4=RKHZ^39->O4&0(9:*PM%OEAB7*7<*R(W%0JAC3#\3$;&
M2105^!(NCW`4P"`Z:I-W&RS5AGYV96F+S=923$9B\6IXHK(RI'*QQ=#$-Q%9
M"-:@`F.5FR!!NF0?3`!#P/VC"/GIA<NY92/2`IB@<4`]8Y5.12$.[D"\#\H`
M4`+VAXXYX$#J46\W^A7:#90A9$8!ZLN)(]H0C,8A`$C'`JJ:8E!1L5),$2D^
M<?Y0$1UB['>+1`93?O+:BC(42^/W2M;MK=J**%7?$(=9U6[+V`!6Y'RQB)1;
MX`X,H`IJ&[C%UWW,*)I)A8"R*C=W'(B@V=.%SM6I2G$S<ZAT2F]-54Z0CP8P
M"(#\P"''(:G!V>P6EE.L[=7XB*AVLJY9*,G+H7@R+-!4X,Y!<AD2@S+)@4JB
M"B8@9(1`PG$!TWY?E5Q_N41\WOPI==9S7*L+R,F@JV202,@1)VW$P+<B<B*?
M'Y(G<4!]0W`@)5!`0,!@$//G7"V=@8")NWAU"H%5033(`F.F0Y!,B<@&#[3\
ME*(![#XX\Z;A"35MI:BL9;7\?-UL[KXNO6!F<R85QBY6,+2JV!(I>3()E])!
MI+`)U%2=QU/3``$536L#=T4CAJH'IN4@[5FYRG,4&J8**'3.7DAVQ3>2FY$>
MSR(<".A5VYF:7>'C#BB].92/EE4R-#*F,HD9V!QY35+R8`7Y$.TO`<&'SQK)
M319)[$/(Z,5(U65<,'"2CH3F1.[9F*X(@8"?-PJ/Y-0@!V\\`)A#QK1W3]9=
M)94AFRQ6[0'#!-(`6.NJ<O<FJAR'RG./YQB^PB(A[:UJD6N[NDW:$K#KQ$DR
M?F30<+_E$Y-L8QC)=G)``@BD4.WCD2<^1Y]P%@E;8UK31&5E%EB/4VR*)")*
M%,9VX<@4JR*9..X2(J<@("(=@>3AQSSL3%TY54;O64JS43=$2.;UTECN2N%4
MBJ?!)]OY/M`3>?!0,("8.`'@4@DI@SI%15\@R<2B95CLXY0"JNBJ@)@,D1/M
M,3A40$PG$!-YYX``\_D)/3RB;9E(`6-4<+$.WCVX`95F@DF`$6<+B0@&$Q?S
M"=P]A0X^[0"WJN4H],AY!T/JH^HHX:D.(KR!CB()&``,/I_#AP''/@``/N#2
M?V>`:Y+?0U-3E21QYYZG%IE5=%09(H/#@90T^HN?CT"F+R1(`$#''R`#YT-"
M"[4(FV50.[`Y4B?&J&$SHH@8ZBI0[^\QP$?S`^7G@.>-;0W%[)(E5],6IVWI
M$3=-F)$R-%DS`F53DW!SB<0\B/)@]A$-`3*7'+^0MJ>T>V1F+[K'.K]3XNGQ
ME3?E?'/&2TB]49,BL6X-2"HHBD1<2JE0*8?33-QS[Z:U)[W=S#:-:C*Y0QM'
MWI\V1=NG0-I*,20??(!(]5R5105RNN1!03I]W`"80+SVZC*RA=,B2.6]M":T
MU*.J1!SZZ5SJ*"QDX>1<MDW8Q,M(F`0%50AP2$J2G<B0XD,4.2\AH,$_=9=O
MF5Y^^5Z;5B\6Y&4)7`:`Y2:G@EV)O6:+JI'0([*"XE,4!*LF41`2B`!JQ\3[
MQYP)/#/M2OUXXLK;,NI&^L;@V-=P4=$4F\.)1NTBK3!2_P!95B?452Y(L#HZ
M0*-S.A$``ITR`)C`7GGSJ7Y\2.L\:95BL1271%,T8Y:J`5^R.``<"I+%\&26
M((JCQR40,`#[ZHE,RQ$F]L3YDM8J,FS;&*U2<JN%2B<1`Z;J/4,J!DQ;I^F=
M($Q*8A^1`0'4\G1[WLVK)T#9]O66W!97(=(54+5;$Y>@64ME"!JW!O)@S!,B
MHKLW!RLU#"=4PF;F,)_F#B?0FJ6_GG(G&3F)U@W!J_`[Q(0*0S],H_$J>F7@
MX/$R^YPX'DX`'M[@&MFC;'%J-"D4:B4Y#`=%TEP9)0H\<I&#W3-V_,/D/^OC
M4CM;+$E`3L%)E'L2,F8A13<>FIR/DO``H4Q?E,81$W@0$>?&OM15OZ99)BD,
M*Y2#O.Q<?/'++',/KM7(F#M1.`>$S@0>T`Y`="BC+*0[A-"40*'Q!N4#\<&+
M\,)O)3![B<I_81\\#S]_&1:,SE].4=.12;^G\[4A0](B7L"JA@#[1$.>WGC@
M`]PUH$4[9.VCEZAW(F,KV/X?O]0&ZW`")6RPB!CMS!VF(N``!PX#W$0#8FLJ
MNL"#-4Y52JI]K0!$``2)B(F:K"(@4AB%#U``W/(\%]QT!LIU^"-3M!*B+PRZ
M(.#E'T%13Y,!%N0Y$IB`':`\>1`0\^!C&ZH73QJ/4#PC(5[ZLA8S--<9`[QC
MD+X`JLG"O$'3=TM"N7)`!R:*E6K==!`I3@!5U"FYX#4E)EG!R@"@^J5#YB(E
M`"^H!@X`""'@IBE#N\>?Y`]^A(.GQBB+1J06Z/I@JHBJ8%BH@/@I^`$1.4_'
M(CSP`<@''.E@U-&>3AEG'-EQE<K30KW!J5^_TB9>PUF@WB*B2KIXP67*\D`(
M<I#%*J)2]IR'4%0#`<0`YE.42'R(B`<`(CX^[]&KI7TA;I\J6^KLMZ&*ZR49
MBEE48Y7C(2,[E)>#>.BJ)6)X#4P&55CU%U`=N!1,=1N8X>H40`Y:<%@ATTFS
M6>C$?_H61.9,AB"90C1ZF4!78&.(CR9,!*H0QP`3E.'D1`0#IJ?KTIJ$]-UO
M:J4SS[\^:C0UI?JAMK2W5636F;K,8HTL(LW_`$/O]]Z:?S8LZ?\`?HNO5=UY
M47T/O]]Z:?S8LZ?]^BZ]5W7,Z'DU?2U_WYC+?_)S;U_=VWU6<U9C^EK_`+\Q
MEO\`Y.;>O[NV^JSF@#1HT:`-=^+9+R3YO'-4#N7;Y0K1HBF!C*'<KF!-$I"$
M`QU#F.($*0H"81,`@!N.T>AJ17I4841SSODPG3'K)!]%LYXMGD479!.U,VKY
MD78@J3N*4X=YD_D/W$-R`&*("&JK^=NI';\^>F>!=)Z<>SNO;/MN%*H[>,8A
M;[7'-;M?;"FD`2+N0FFC=VTC')C$35%)BW4*CVG`O`)%+P`!P#U+(];(I*KK
M(IJ)MA*#=%3D17$!^94>WR7L$/S@\<E`/N#6Z.@21,_<HF*V*1Q\*@U4^41;
MMB_"IIHE\AZ1$R?D@*':`>```+SI&+G.QK%&4=3#I%G%1#/ZRG7)E0[6K%N/
M=Z!3CV@!G!C)B8./SAY\B&H42>^S$5%'8.',<P>66=>'"M-G1_21B42%'XB2
M.)CAVD;^1,HIR0"CR(`(\:TRL9;P8,@]K=9RQ0IVTIJ>A/IM+"W>3;E]^<J@
MX]%4?2114#T$D2%`>XH#QX$=0&=0;>(\L#R;AH.WRE5B(./?R]F=P4@49A=C
M\4NA`8^9K$,DK&/+$!1D7+UNLFJDT2!(P_E"B$-^VW)5GP)G&FY.6AK-;89-
MPM.(Q,6[D5VLJN_0,FF60<NP.FX%@"@BX5,=7M5("AP,0>1UITO4FY5,9;X8
MYUH8>M)Q[SQ2>':;9="^7%VMK*)248602!QZQ3D.!Q[C@F0H"4#F`#'`I`_-
MX_I\#I)MP='<JUATK"S32/LTI&B1E/$$I3,5#$,5N5T00,"J)%/"@<"<"B/8
M`&TUO$FY^M9)BXG)[EHS@:Y)&(SEG)9%)9O7I,J91(83MRD14(<_""GL`',/
M("("&G09YDV5AQ(2>9/V[1TV2([;20'[&+EH7M.@J=4H`"::@>3E$!'YA$0U
MDV-#P33<E3]4:1.74P0FDXVP5^8;QI%R04I'F,)FLPD5<`7.1V!^PWG@AP^P
M`#2=9_VLT.Y8=B&]48$J+VM"W<R2<"<%%_2AW'Q#<)%<O>+8CA4I![0^<Q>"
M<``B.GHXHL<?:ZO7;@RD64I&@9>!EHR.D4GKILY!+\JX1],Q%U&93"F(%$I2
M`;D>==YO2Z/76(U\A+.WAKI93,YI[/IJM&L7)JH*NDG:JRBRIE(UUZ144@`Q
M4P4.4H$#08B_//,J(9"@'=%SLZE'<I)/)65NS=V[FVH*QT-,,+.U!9)E+'*4
MO8^@%$A$J1031<$`I`^8_`N$DI4]>DGCMV:!9-'2*`F</WZ;7XQND<3!,IG7
M,*(M5U@%$Z7)3F.3P//(`]WJ&;5D5E;#D&$^'49P\-"L5BUTA7#AG(0TND_:
M3#-L<2(2$D8I2-'#,X%,9J<P$,)AX&+-_"9)RHBW@[MB*=+!*.6#2.)$I.&L
MM+(`J"Y7*3%0C=VQ*`@`N"-3BW1^8#=_D=:NE+M1MM3%(A.)BM%ML<TO0VIG
MU.=*ATW3A.U'[[L19HR>9=SL[JL0I8*[7K(N1,\[`).N3`T.JJ]EFJ"Q%&J[
M9T0P$%9,INY(I3E$0]GZT#!MIP`E.5RG7-IE&B3<O$R\-%O`51D495H[)\6F
ML*12(HNG+4H)CZ12=ZH`40[0XT\S;%LZM4'9(BWL:T:HUR-B%632*E8H'3AH
MJ9GV$]9TY]0X'7[RDX[C?.41#D1U*=5]H=0;T^*D'S%LM/2LB@Y.DJD<B0/"
MG06,0``X"5--;A4"D*``/@0`!YT>INBLDM/-)RF^-E3"BQ=.F);AMN>3:2:7
M"9>+S$C4=K.,J]B#<(_5K$8]AH_,M;4MDC&N&AB)1LZNW25D&RY0`/RX&;]I
M3F$1.`C]@AJ9YS`MXE-K(58Q$Y$S%N#ANQ3$S=ZFJ`"H+A,!Y(N"A1`P<<#P
M'W`.D[F<5Q\-<(V\2HH_$M*TT@CJI,^U%*10(8!5(0O:"?K)B!/4*GR<`'GG
MCG6P9$RIAS$E9CK->9YK#+RJ"35$ZDB+=%)8?"2RP'5*4YQ6Y[4^T`\B`ZR;
M'I;3\Q!5[@GCO,-<BY?%F07"$>@-IB8Z1)3[:H<J#61%)\U6%*NSHG1BYGL.
M0K-S]6RG;Z:;T3SA1<3&P4:QA8:.9Q$3$M4H^.BX]NFT8Q[-L7TT6C1LD!4D
M&Z!0[$TDP`A`#@H<:H/L.K%5HG<#?,(7-B2SU.OPC:RL;RP>)J,VC5;U3NF[
MLR#<!22;M"%,8YES";N,`%_)F'5L38AOGQ;G3"C:7?Y#@'2%8@TI!E;G4JA]
M7SU-0(V;M71GQE#&=S,&==M%2B)"J/GA%8QXFBNNY7'5::OLGT=B)I_'8D$N
MM</<*A9ZFG)*PYK+!24$,F@U3>KL4Y1L=FLX2:JJHIN%"HJJ%*F=5,!$_/<`
M@',"^X+!=0Q//I1+#*D/;K2V,H@^A8&+>,I.'1,3N;EGG)7KR*2>J?*08Q-8
M[TJ8^JLBV3`GJ.&S=OWF+K-36/<2-I2H0+<#M7-ID2@PMUM:JE$JR]<03,=6
MM1!2@(`Y,<9YZF;N[HQ(_H'CZ>1P#(]R*Z"SIPMVG$RJHK)&,<ZBBAU#B)C+
M**',*AS&%150PF.<QA$1A3J0R$G&K@94PD7!4QDRF$_H=@\=HD]Q%4?8X^>#
M#X\`.G0;:Y=";S5C>*52%NY_#Z`5%J<1,8P-'!G9UP$P\F+W-P$.`Y*8`\?9
MILLK=<=4]^U@)ZUL4;&\$#-8Z2<HH.C&$`-_DXG4#N[1$1[0#Y@^\?&G3;/F
M$99=R>,72:Q%%H9[8)CU&_/"WU;69=9$%RE'M+V*J)&YX'D2AQYXX`GM`>0`
M?O\`/]>F%;ZJU3,@0--Q]>XEA,0$V2T.UD)%(JR":R;>.CB*=AO8QDGC@@F#
MSV\EYX'C3]0#@`#[@XU&-OCLY6>1*-"G7(0$*<X?$3Y_*"K)SSM`1*3CR`IQ
MI//CD0^X`'0%#;JX=')?#ZTWF#`M6].M(MS2$C7H&/6%JJ+AZNHLNV(BF8I7
M?IB4P)E,4B@"/("(@.JQRR"S=51!=)1%9%11)5)0HD.FJD<4U$SE,`"4Z9RF
M(<HAR4P"`@`AKU>YQ"$R)79&E7%JTD(N3;F0(5\B14BA..2@`G*``!1`?`"'
M`^P\:\_KJV[%)':;F^6GH=HH>@WN0?2L2+5JJDSB7;M\946@CW*$[7@JJJ)<
M&*`*%,'9R8-6^;*G&,?G8EN7W1*.'FXRC8[_`*:>T/\`G0;?_P"]JH:-?NQX
M!+O4VB%,`E,&Z'``"`@("`AENH<@(#Y`0^T!T:AC_)CK]#K.M.HHCU:NH8JD
MDFL9/=SF@>%4P53+S9S``F(/RB`_F_,`AP(_;P(/PZ/71UE]R=AA\Z;B6<E"
M8?BCMI&#@';(.^XF52!T@8X.2')\"'<FNW3(``J<OS^/DTL5JV.H;[/I#._;
M']B25_<\J>Z+.=OO+@2&,T)'H6)P@P2<"#AL/*KXZ(D(!A$_!O'`"`W-,98:
MJ6-:*SA:LQ:0=?J3%C'0S=LEZ:1THM,B23Q<O(B83E#M.`B<2``=IC>-:U/"
M;LOA?UO'6FDK;))/C3X7O7KNV/Z9C_"U'1AZ'68>FQ3)%%O%P#!F@U?R9$D2
M$*Y=_#ID,!#D)\X$,`")..!TD&3<K5>GU>:R#D6Q-:_6JXS=2DF[D7(M(6+8
MDY67.H*IC"8Q"E^8RP&(4W:!0Y'2C6Z1CV3+Z]4>+)I#'`X5DP.=-,A4SF]4
MB93\E(10H'`#B`").[^0:J74(W62VZ&[SN)JG*K0>WNCRKN,L+8IE3?NV2\<
MN)':*ZOI)G;5J$?(("3X5=0LJ\*=NH'HD,`Y-&J[M.I8;-=0S_.I0$A`80I\
M(\C\9E-8%(4V8%I=P=DC9'#9LX#OKP)*-7<<L*C=PY,!@%L4G;WQQU6[8]GH
M>CQ%0GJ^T81T%&M)")CECLVR4@FR*I*%:`JFDHX=^N<YW+E8#&5$PG,<P@(Z
M[66<6&OT'$5!K+.*RPDP;*OU6;(BPI1:"B*Z+$K5<Q4$TNYN!04[04[#B;P(
M`&LVSQ)3$@3E)N#CYQ^S8(P[26.V^&5<-R\$51,1N9-)-94`[UQ3*'JCV]P\
M\#JTCC/M"^Y?]1&?Y3B(VW=<S1?6TO:SM8U`Z+U)TS*0H)]A1>)"!VYO!3D$
M0'YA)Y,8!\^_GC6"F[3'()'3:&///>2%9M(G_*E2*@;YBNA$2D*BD'!A$I^0
M*`B`#P`:QL_6(&42!!LD2,3:]C('92+*"DB0.T0:D.H!173(`)\G#M*4.?(^
M^K.IFO4YL@@WF64"R:@#15R8B:GQZIE"HM4#&`#'*\54'@PF,)C&.!>1#VAH
MSDZ\E9:'$J3"."9,40+'NGBZ,2S1#@RKYX=`/7*=/@2E`O)CG^0>2\""4FC+
M%(6!E,2-U>-RMHQ1@M!1<>@E794K@@)?$.70_P"4F50*7AN4X\AR'(@)C:V1
M2SH"B<0[WZ_Q"@-2JI^F*A%O\Z*Y2%`HD[/D`OL`^?<1$,=\,U<"U:^K\*"R
MAB&1,Z(0$S^F*ZBICCV@"`>"I$,/(AP``'V!YV-R0;%D6ZS15%-84&)FCMH=
M$JIG"8IB7L$"CW"B<H!P?R)0$1+P(<BAQH.^5<9QUCN5(Z7*H0Y,:V9%TZKC
MY-<1!=.KR;90LHP>`01]5BHJ#0J@E#Y4P$!R%ZL;VMJPU074?,[C='29:F@4
M5F2_P;8Q1*^3=F2*T>L5T@,=85%C@B0O:01.<-;<JJXD:PU2K%S;04_+B9G-
M7.%9%D'[-9F;T5V\6N]<&8H)"<JS5\\1;BJBIW&1#O\`:KV='*I$]\8K2A'#
MYK9PUY*HZ54T-NPQ2MP.2F4M,V+&E=Q75:DD@WEIZU7!5DW5`Q3*B:';)-'Z
MJX\%],"**%[1,4O>8?&M(=AE>WO;-#-IF+H->;/5V,#.08+RT],-VZRJ99E,
M9-)-L@T=IIE,@)"$.1-4?E*(`.LI48IA&.9%=-Q+R*[0[4#'DY5ZY4>.DR""
MC]=RJH`.0<*%,L5(Z8$`QQ*!"EXXV%$%)%Z*0'>-VKDJA"M4TO335,;DIB)K
MD\'X4\CWF^40$"``:GGG]R(M/L[^R^JB9TZO95J:<DI8;.UL[:,<G!FQ5A__
M`*2E&ACB<D@YED5>Y.06,80*@7E$I0[2>.>5Y3D8":8,I`KQ`H(B*IS,C=Q6
M[ULA^4CW:P@505RG,8BZ/E(3D]^`UAG3,7""11;NVCIGZ*?IHNP.!DVORIG-
M[E.H3@3%[@$>>0$3?;V:K'LRKR*#D$CIF<HN6:33@RRG>W`BJ;@Q0*7UUQ_*
M*F'PGY(/'&@2A0OEOY-<<4EJF'X6NW;\9`C1=LVD_C%D$6*#M/@#),R'*F*Z
M1S=I%C%[@'R`^.-(5CIMN4@4;#"FEGRS5-ZI)5.7F%EGQI5FD[.J9!\8RIP*
MDX04["*%#N2'@0+R4`TZ*8CEG+9TQ6.<6AED0,F!S%(Y1,;DK<H`;A(Y?)53
M>.\>1\=VNXXE7%.@[58S&].,B:ZX(R8M&Y'*K9)%N550XD.`]_)4C&*4`'M$
M?SOOLQ[>P:3K,1/QGE":XI&$O<-E6P4;&&5TJ_-TYA^ZC7Z=/1"2;214:LY!
M-R!YV87!3ED9W(HMPBP3.K_D*_Y8@&[@#69*[O9[;WEZ2KZRE6N$$_>-I1>%
M7*>6>R\1)`@X(9D`"*BCML`F5(KR9-%7O)QXT^O;;B/<%N^V/2-?K%+1A&4O
M86%EJ.5K3/IM[!]:P$L=VV4B(F-213=``(+-4A?."&2!3@Y3#SW-W4QS8:+F
M.UG/7ZPP@%T`>9(3E7"A9MQ?6"?U>+R-8<J)/PE61#)KH%*5$!!-4"F/W#I9
MXH[=<\.K=#*EJ4VTTJQNH32FC3JZ)0^!D8JNFFJ34UPBA08+QD8XE'(F%6R/
M#N&:3@ZC-)17T!(8X\*=QN>T1`/(<:E@Z;>UR%J601W&.K'7ZI,(,5JXS@91
M\@6:?0KD$W(G43(8P)F47^<42'$I/)?<-021N`;_`'5[)O;CD"QTNN*699[0
M::S?_P"61$$8HB?XIZ*A%G+(YR^H1FL)B-RG](@`'/"]R-]J.($H*6BF$HM-
M1:[)J"L?,RI9!^\[@;D<-6A%54WCIPH45?3,F8I"=P<@!=3K/?[73IM#>D[R
MH7'[V+L8SAP8L/KA<R!P.4(N29.C*12K,W)P(HJ/!A<=H@82*$X*(B!1^W6[
MKA'F9*$:(H61F8"`Y303(8![B`8YE`#@1.F!@,8`Y[A\^VHOL99#O$3B?'5U
MMCLAG<TWA@9TB<5;-GTHW=,T3IBIZGS)G*4?)@*43>//OP[>`O%64?HM6;J7
MQ[.OA!R:+,!G`G6,0!.*0J"JW<)^_P"5`P"*8``!SXT**%=6->B(M&S1D\X@
M5F@IIIM@,4J3I557L!HNB)>3H`HH"92AR)!#NYY#C7/6YJ/E_CX>:$(N08H)
MN'K4H'!P8Y""Y!RW4_UT5>STQ.02B8O@0\#K6[B5:P(0[*R12T\P:B9PSL;5
M(6R2*O(]JSEJF*:)C\&]0`4(;@Q@X]@UC'F/GLPDWEFUMDF[]@F=*&D@(D0/
M2,F!A8.Q(<"N&RI!],!6*/88P"7@?8!C5?ZN&'9G<;:-O2-.GHR0IDVC`N;B
M8!4J@S?H**FBWKHRPN$W)VWIJG(F@(%]9/M./.I08"R*SKA59!F)D5T4G"O'
M<E'))+%`4S`XY`S@3E,'I@`&$P=HFX'D-1IUSIF[=)C<FEN#?IR=0NTL<!ND
M"4SAQ`V:9314*A8EDA>@V*\,002*LDW(=0A$R',(%#MDK8V.$,];UN&13%K$
MJ'ASNN!(!R-2""0J<`':;A,`Y$PAY\CR/.GGZ*YX]II[7XFIY&IT1>ZW:J!;
MBE>5BV0[^!?,%&Y%$EXZ2:J-50,BH4Z9A0`_<F)R_(H!3AY*`AYL&]#;1-;5
MMQ&7]L[MJ[5@&\B\N%"<O6HIN587N7=QZJ)2D*BH@=DW<LUS-BD.'H$./J&$
MPZ].R:.DR;)G$0,JHF<@BJ(%3*(AQP8W')@*`@8OGWX'50/Z1K@<[8N+-U,(
M5-G8H0S:BV-VFEPLYBW:KTK#U5_4$@"=1^=(#F2,8$SFX'GCC6EUC>D7OP,Z
MU*XJSXRO*TW$6^A^?OO;7V_T8\Z>W/'^?HOMSYX^[GS]^O5<UY5OT0KT_P#V
MPY12-WIGVS9V5*;SP(*.*,80`1\F`IA,4#?ZP%Y]^0#U4M1J&ULVNQI66#R:
MOI:_[\QEO_DYMZ_N[;ZK.:LQ_2U_WYC+?_)S;U_=VWU6<U`&C1HT`:GE^CP5
M=[8.H%'J(M!73A\57.95$B0G!`C<\60RIA$/R1Q`O)E/N`>!\CQ`X4H&`WG@
M0`!`/'D.0`?<0'D.>0``$1^[P(ZNJ_1WMG<[A_&]YW77ABM&6+)D,I4Z.T<M
M?\K:UDXF![*]QU3&+\>"1%`)Z8=Z8I?,`_*6JS]NZGS^B/"XST3G\IQ+`MB(
MH@X9R#@R"#!$CTJJ!AY(HX5]0Q#F5-P(')^<0H>![N`'4*?4GW4EQ-37&-(0
M6\C=;@R;O31J"@_%.E'#WX>*BU`(8#^FJF!5W`&Y+V$$P^`\3$Y*?M&4$U6>
MK"JD@HM*+B<XD`&S9,3\J"'L50P=B9..!,/`@.J<.[N[3=ZW86:<<.EY1:+C
M$VK9$2%.RK;QZ14&#Q=+L_RDD;%)J./3XY`RI0`"B/.H'.+MQBF[JU,*OT,W
M&B5[+]GF6%LN2K&'4EU$IF4!8.QW./!*Y5D%%U.[U$6905;(E6$Q44FY$!*!
M>`%,,L)4R#A&%`H>3YVP.PDQ80J:;4"G<LT5!2.@LNW]%44#N"B7U4S%,4GD
MI3E)VZ4&=KJ<!0XAA&-`&9LTV`@4#+H`HT?NU#*2,B8QCBBD<I5GBQ>X/3;=
MJ91`/&G$OL.XX12KMZFB'44C(<T?7TF3(Z[950_:+N8["B`"4A_4;)B<A@Y#
MN(;D?.TTHF6DW"I=6G@Y?%8F#GZ6VZ).$]3AQ+=H;2_BDFY3G92:)AC+N5<?
M)UW#MC@5XV/DBH-8IO&).3TJ-(Y(4[-Y)G45!PK)+JE,905R*\G.0P'#GD9C
MZ3NLD\-)L\/[E62;>L6:/)&UFQS`J?5TB^=)?DFT:=QZA!.1,2BFB/'RAP7G
MVU#I"8\OLOD>!O%NC31]29NP_!2FE=J."QQ4DS$C9.053*51Y*O0[UTFRB8D
M9IKE()S&3[M3K0]3:Y^P+%5G+.-UV4J23%_`2,D4%GL0K&(I?"RK-P4B1TTC
M"F4Y""<G`B8#`.LN_._/R_6*'13TFD[4X*(JJRZ2Y$OKX6+`%S<OTVA'&/;$
MR<RZEF7D58SZF7?#V-VR:"'^3F:B1),X&X[^XPB`#J2?;MER@;E**_I=OL$`
MO*PZWR'AI=&2DE6S0Q%&S\J"A0_RA,>TX`!^XP<\ZB*A)_*=;M\O3\K0+:U4
M<J`LXJS-2>NL#(>$TFBS5),Z8>D!3"*AE!,(&Y]_.MB88,O^$PALF;9H5VYB
M$IPSY[CI!H6,9RSI<ZBCV1+-+&66;G[51.*9TA2.?D.`Y`0A29V5Q)2KA-#1
MY2M3*T#,02J`S$PP:'BI*33,*S>0,4IS"*XJIH]_)>XW`%YY]FDH49A2=P*%
M=R%4XF-1;55VQJ\B5@1O$K/FY7*K-=JJJF*@KR!2@U%(P]H''DH_,/&R8DWH
MXPN39PVR&N^QY:VQU6DA6)>9#X=%9H3O.DDZ$I2I*'.`G]1$P`8`YY\CK0\[
M9]DLLSM.:X?QK$Y08.%"L'*\O831C2/&..HLI)-Y=NU775'TB`"90,00,'/(
M![@2#N['7QQQ'("S:Q$PM\$HZBG2!4SI>F)1.JHJF`G]/O+RF8.>1`/E`/&E
M"K0-YQ6/%\JU<!#HMW21FI0!-,'!.WN.```E`@)\BJ'S'$`*;[!!H&/K0FLN
MZ6SDQK%18-`9LJO&LK)ZS.95[`2*FD\5*DX.N@8>%3=I@,8.>!]]/,9N(B-I
M;N=C4HQ)I'$!Q]4Q$ND[+(IH)E/P^EC@'PQ42B50[7@0\"`<]X\`=6ZD3LDX
MQCD#NE&/PPN&Q"KE1</G"*@B+L$C>[4`[@```1,D4WRAJKCUC<B.++GW&6,7
M2DY!Q],<Q<[::<T$4AF(`'CX&-LCT2G`CB-%Z@=&0\@*!$P[DQ[RZD6SKOMF
ML?;Q<*MIQ]!ML>O:5<IYJ>'>-U&X.&\0[3:,)!$&XG5`KDHE16]0I"+E$>T1
M/P$(FXK.9-[VY;'$FW:+QUOD:K;X%U^3*#EO`L9224A"IJ]B/JJ_&"#DS=3D
MOHF,<WCMYJORE]E)G4Z1>J37!M3%(I*_:#0IR+R8A=[?D>@Q*]E@4'$H1Y88
M[\H5>M.F8I+UA_'&%,KA2,(?U4#F.'`&.7R8>W3^>E'NXL^"UJYBG)#ADCA3
M)DO-+5&YKOG?PU/N;CT#!!K%7`&K<S\R22"**9"]CD5DTCG\`5B!T)^H0>5<
M.VF>>P]S:JR;R8AHQ03ISS9J@"D=-LG)!`K518$TTWK5/M!?M.!0,`Z;S*.;
ME=J&SE(>24;-ZHP:NY2'0*1DW*^CA5]&?8*MQ233>G)V+&1#M6;'2Y$W<(=W
M2&TIAPHF,0HAMJ:N%9;S*2Y)^EI^J/55IM0FW+4NU$Y=722_7DJSS<!CM[=Z
MM6W-VL-::?%,(Z(<@UF)-N9,@F(Q7$Q2JG43_*@)S@4Y!`.>.=*%CR2<V"FU
MFT2R"T(]LD4VD',0]^>0C'"B95%4'ZG<<HJH*&,0RJ1Q#O`1#V\-*V0WQSF7
M:CB.URQC/7*U)B8B46,N*RCB0C89BT4<KJ`(&!18P'%0AA$Q3!P(B8!'3V*D
MS,6";-R$3!JS$44^`[^`*8>2E4'R!@``X+X#R(!KD=R%O>EL0S_N!W24*\4*
MVV..J,2W2/*MD'+X"HKI")R.&P(J>FJ98H__`!A$"%#N*!1\ZLB],;'#NIY;
M:,951RYD:[0+&NL[>G,JZ=+J)1,,"YQ.(]@'*\7#@/(B/`>!'EORE@>PW82/
M])!14I@Y.4#&XX'@2")1XX+P'O\`:(AQSSI^'3D!>7R-DJ:>%.=>,I,:S374
M+P/_`-+6%,RJ9?T"6,`W(<"/;[>!T^B1?BY]DOHEXU"COUF72V?A;(`7B!IU
M0;)'_..8[M.0EUDN`X$``7HF$H#\W>`B'GS-</@!'[M0);S)=1WN8R.#;A4&
M05B)'O$!(56/JD055,`'QWD5.<`*'GO`/`^VA1,6,B]<J$0]!19(B93`N`*J
M+`)B]Y3`4A>$P-R(#[<^/T@+'>I#MIC=T.WFSPC^OI.9^)9F6BW"D>HK(HJ-
MRF.BY;J=@J)'1.)52&*8/M`1X'R_C&N9KSBQZ[E:'),8R0?-"M'(NH6*FR`W
M$J0G*"<NV<H$/W))CW)D!0OS`4>#"`OJVW;C<I99R`M4KW.0,[6WM0L[IW&&
MIM6C_55:1YS)B+IA&I.`2*<?F`INTP?*/<'C2P/*(VD0#ZK[\]K4!)MU&DA$
M;L<&QKQ!4#`8CAAF2J-53?,(F$JADA.4QOS@-W`(E,`B:D5W!86-A[K&;>B(
M-@:QELW780G&:92=@$%3-]<*8`)R/@4Q3.0>`$2#P(<AR)JN_9]U7L<VFTJJ
M5*=]TN/#N6'M@R)''7HZS)ED4E&YLS9,36-W&*Y3*;(@]HIFX`>P1`H*!R'<
M`CSR&K'K]TS?/AB&Z@K1,40#RJ1"]B2C\QA*BQ6X$H^BB`E6.8O<"@>!\AJN
M5L(=(LNNEUL':IDQ21R[DGL;J<`9PH?)`$(4AN?E.`_-R7R/`\B`>T^+F43K
MW89#UY>4D%Q<+I"4"(M5?1-V`JH'(J))@8`[3AY-S\O&FJ_1?"-Z;+D1?]7/
M<K,XMP2.)<=NFR.8,NO/P-H;`JYFJHLSJ`[L,FB"8E5^%C()&07!5(Q3F4`"
ME#SSJNE'5$T?!0S4IGZ!H9@U8%*FF"B"4HB00=.I$QSF6.X?.!.NOW"H91=0
M3"8PB.G9;[T+OG'>3=KK.V"09-\/L28\QU"QO8LSC)V09.)*<M9D512(:0.R
M??5Z2:A52D1*)BG`1``9\>"L<.W4;Q60+.=R4WQ,N=\R9+((/0'\NX<G4[SG
M%R//I)I""+?D1`H!J%W]O/,&"J-)>Q$--FE%[%+2RMD>RA)&0(HJ#DKU0.U)
MEV"<&T0U(':@0HD[1`1[`$1'6.N<['UI)!6RS4/7X]KZ#EP:1D$6+%$J@B4H
MNC&`YP=<<=XE`.XP@`CR.L1/MW*S"0C8&YV%2P/63Q-9VP?D"/C'K@#@9V\0
M.(IN7)1$1(R3**13%*8I2B8=(97,:Q==@W;"3>*W=^N)CR$I:"*OW)WIE`.Z
M65065.GP(F,9JB0I4P,'R%``\.9."5(O\+<W.5L,/8I%FG$S2,Q%KJJ&(K%+
M+%CUT5R]X]SDA2D<`(#\JG/S!P/OXUJKYFT0;/T`BD3HB\;BK'K(?$F,1NN0
M4W*:H@<3'2-VJ@8.##VA]X:[2,>I&1AXZ/631:)*K*B1%`C1-,."F*"2?')2
MD+X$I3=@"`\<<\:PBL^T@DE'SE<3`<IC$%L)3/E5S`!"I-FIQ[57/=P!"CR5
M;N#U.T`#0IR/W3?X1$6K=5P!E%%/B&K10JGOV@41,!3E`@AP(??R/W@"?7<6
M#%6,?VA29?)G1*9E7(20282LRL7TB)=R7JI&])$!!510%D_D*<![N.-=UI+6
MRS212@W:UJK)I.021^+6/8902@`G=R*?:5"/46$."-43G!(Y#=@_-R&RM:97
MG+YJLG%E(^5X/]9K*NUG9D!3$QB"HNJ8@%/Q\_:4`^SD0U>?^_PRYU*FZNFJ
M9:45X3"?*^)F:E$7EU$3=I7DYU:*9MVU:B7<DN\2K;(A2G48ME!,505?!2.@
M,;Y^T"]PAR`[LHT;L8Z*AD$&4=%,(X[EDQ8MQ`@>FMP=$P`!1*X6'D.1\B;D
M0,;GNUU:NV>MW[N.<QJ_U2)E4VBJ90!%ZD0QP])18O*A3@/!OE'M.`_,80'Q
MM??#(/FS54",GKI<X1S,.X'+P4""/`$,(IH%;B'(")@$1+W<"(AS)=IHK+:;
MEA)RDI><[W,;%)N@:N$W:*A#O%3$CEDC@591`J8F.!Q[C"D9OP(',/`FX^S6
MV1AGR*C04TE$F*0E06:N#`!W9NT!1<LNT!`!'R(\B7O$3"("/D?L8QF<QU4F
MPJ.^P#`7O.8JBJX=@+#W"!0`Q^17`.!$P:Q%I&=:5F10AB(IR9&BB[4CE7U#
MC(H)`1ER/SBD@=8.5!3\I$\@'.A3=D)$PI.GJC8B:(I',8_8=-=0!$R1NWUO
MR8`D<.3F+\IA`>!'VUQ1_:V65(SY0(JD13XI3CXER*@@8QVQ$_E[%!$!.;Y/
M)Q'6@TNRC;F]=C%$TDIMY%"WDXP'Y@^!=-S`5Z9L!A*NY2]<J@E%4H`8!`3&
M`1'2BM6KB/,9LN8%GC(BA#R*8`DL1`#B1%)-`"BGWII\`8WL(AX$3#H#[D4W
M:+==PH(N1%RV6<-T"$.)4!*"8)J$,(`')1`ZIB<F$>1#[@TR^3;*.JERB9=R
MTCH^3J$SZ,LHJJ+=-D5F9)X\6Y`3(&:`<K4A``QE%.1+SQK<#G!)1%1TT[DD
ME0.JL*Y_674,'Y-9T`B!!+Y`?2#D"\@'D-(EG6UP,!&E9V%@:?)8GL?`LX9N
M<A5I!&05*H=!!N0!5%NW_/6(GP*_8)5!^;C556N9'9\LCZ^GMOER+4\$TR@S
M48>+C:NP?L*TBW(JT1G88'+A1K-*)G`G"BB?IF!7@>_U`.7CNX!"FZ%IM>>,
MM9_OZB+OU7Y(W%T.\>KG:P[1PEWR#E=F40;KJJJE%1)P<JJP%.)0.4."ZZ<6
MDB"[0O@A8V+;LHX2%*T19M`0(H9H5-(2$[%#``'*("H(E^_G72AYT7AUVS@2
M)A\>*;=%0QP0,Z*!C@=,XE`PD](HE#O^4#^`\"&DWX^<.7(11*\1[6_>=10)
MAP^4(SD74TJ_?N@.;ZM;E,=8_KCPFDW[A`J20!R(!R4H\<CK0Y&RS4CZE:QA
M$PSJT).A-(Y!E_0D&=!=%[C';Q;(2G-)6@$S`9),2?5[<!7!PY(=,"FZ4G<R
M-6SQP8R48Q.U=(D=%5,FLD9D<`+\,X<!RFY=&`R`'*4"`)A*0WL.OBGNXJ)3
M;A",3I-)AFZE?2(<IW8^NL(ND3<B(%<'75,H94#=ZP`90!^;S"^>><CAS#.9
M)@<<L;F\M>0,B6FBOV*DD%CLJWU1(E>+@F\?I(HN/0:$C2"*B0HI%:HIAZ*)
M!.`:=_C7>1EF'A*_,H1$G9XY(C=,1K4^XE',2B*13$?OF4@H50[5,>T#J-%Q
M$H'*)TP$!TU]*=CF"#E@HNA(L%EE$7K!VL*Y3(KDX6(<5!,"RI"\E!(_)2\<
M!X`.=+L,I8ZLC#(8U@&[N'?+)-)R0!R:+DH:-`3"5?X(>]NNW2*1-/D1()@X
M$.>.`?WP_HEN22A)2Z=YFG(?WNPWJ9UC*U2\X#D>VM,8P\/^#%KH53G`C9)_
M9920;)Q5A_+@"*R;1!06JS51T@'J*%4$1!(-;7M3Z@N6\?3`FD;S;+G"R2K1
MX?&N0%RGD4XX2JF7"$D&A5D'JR8']<W+@2<I%3*<PAX9!**UR6JKNEVDC)[7
M[J11M98^0D!10D4U"`="3;!W<-Y!FY31<^JV,GW$2`HF\"&F_P`8V&'D"463
MG5WC+'D(,)$6]NJ1O)JP9FRJJ<SZ*9B=[(K=,B9U4Q6$RB1C@<H\@+'&?:G]
M]^S/!SWI];4O,9O1X0S#4L^TUC<*E+>JLR$I7;,P@5XS6$A3J,7J8`4P*)"<
M2)%\A\OOI;*JI%I-YE8&O#Q)^H9T<Q"@<HJ%$I0/]HK"81$?T!S^@*2VQ+?/
ME#:3GW'TQ-S06W:WD$S./M$V*R::;!P[!W'QMC>+J)&(W5.\49)KCZG!TP(*
M@$5$1&Z?0G3>><3CZ.60<PTX2*LL.]:JIK(O(]^AZC:2(=/Y%2.`.4#%(80Y
MX'C@-`G/GE!2ZO<6M/FH69L<1%V.-<N'#19A/IF-%HKN6XIMA<%#\IRH)R@D
M!0$H'[1]]?.5K1A#,;VL8SR?M(P3D>JS]\J,+(1ULKIIADW0DI$B17R;585$
M3.FABE50'YDNX"B<`\AK7YU1K*Q:\?*)B!B@5-N<0$`3<HCWHK\E`O:)3$'Y
MN1'SX#C7/`Q*CG)N*G0I&.#NRT\[PZQ3@?XAN^'L'M(44S_F%4*H/:;V]^="
ME:?H6TFJXY^DW[IZ11ZZPJ=/JU5W:0-9KT4B+>+BX.,L%';L6L<W$`]!JF`*
M$21(4J292@1(H%#7HXZ\YSHC.#.?I1^\=0>1*:.WB"'D1`HC::9W``CX\"`<
M@'MR`>W&O1CU6Y?1=X4^Y$H4?OV>35]+7_?F,M_\G-O7]W;?59S5F/Z6O^_,
M9;_Y.;>O[NV^JSFH4-&C7.@W4<G!-(HG.)BE*0H"910QQX*1,A0$QSF'P4I0
M$1$0T2FB`['9)@%YN1W%4#&;9DL^82,LFZENUL*Q`8,4CKJ)*$#N#L75]-(P
M"8OY/DP<C\H>EGCS'<3BS&]5H$(V18MZQ#Q\5\$Q(4&_KBU*"BH$^4A")B!A
M4[0$>0X'R.H&OH_73K<XXH$SN;RA"M`GGYBC3T'C)PD^1;NHLZ;8A%#'(F'!
MG`'$/2.8%3>_@!U8$NLP6OI+G6,0KX_"A$Q5$HB80$QT@`>[D1Y`H"(<<\`'
M`:KQP7O?VMT(M]^$4BU:_P"QHN:91.:?)5DK@K5J\3.XDW`*"!$H**(==\DF
M4!Y`[I0A4S`/N`\\:K3VZA2"5WN;S':4;:KE:I)\Y%Q.$4"/C'*ZAFK)JNH"
M:AU$6D8B11-(H#W"!2%$.X=2"[T]YL9B1Q+"T(:3M-C,XB(6';.B$>C"M%#F
ML4MV`4QBHBMV,FYB@!15.0HF^8>8ZASN>":N7KA>K0,E(M6\A(KH2J"R<&"Y
M$_A8PH$3,Z=S#Y`0%8I2_DE#FX$.T-0NZ[^8(Z@A,W0BUEJ=IK#Z3@'%P=NT
M)@`(=W;';5P8X13-<3'^JX%,A3E]'A)93@J9B"01T[&/N-BMV.'MNN2(8,KU
M4<-F4C)V4K4\DZ:1R*9BQD-&(?$)?#/%!*FDO\JC@X"(D#N`1>C@2[X^M,\V
M:IQ,,X!#N2%[/K)OG4@^6$'`_5D4GZJ:33U%.\ZJG:N8XB!Q+QY97O'HCF3D
MYV9DJM<I&GU*=;/+!$L".&J3Y0YC&17;,&ZB23A!%,Y#%(N/YA`$G!@*`V[5
M(KA?"\J8AZ51MPK-T[Q,+/MQ_=ON6;>:^KWM]7YJ8C#J.6U0KJC9B8YF1"@1
MO89%!PIV(.7J9A.V3`#'33,0#D(/(!*ECC=+#NVYVN7Z78<7U*MD<JN)NPOF
M/K6%,2^L9:-;1SMQPT.<_H?E025`2B7TRAQS74Q9DJM*9(F;@R86I.!C14:1
M$6XDQ90$0\*1(IY68%1Q\0LX21$4RH>FHU3`Q!,`'+K;\X[G96ZV%)6DED)R
M,H<<47CY)9-:N+20_D_7=`;_`.VI-%3%.DR:I*BNJ0`$G;R.M/0YBED[T4Q=
MO-5/.A%K2TRY<-JU76&XNEE<$JEC9MN3VE2L4HV,@+'XE,SE1&-,V+,MVAC]
MB+@RSY0&S<%2_,`JJ<@41$0[N=*M2Y;'>02%QQ"79!./G6:J8M'MG;.%EX8R
M7>55!TT/W)&[@*51=,P=AN4RB(>=4])>(L;B`92)[#896Q3=E^N75DE6,DA6
M2.`:@0T:>.)R4%FY"%7`J[7X<R92I@0/`F47:^.5<ZY$3QCCEO87=W=Q[ALC
M;#V-ZVB&#=JHHLO-3[=#TTA9)"0R;4B8)`1(R*0@`#W#/2XE/>;J(Z<]G2B8
M7^27;:SEU2:I&947S+4$F6<=O.&<&[CH#;]8[LX6Q7DPYY]"/K=H<6>\O[.X
M75$8,I2J_$1+-<&X!]8N)%-,G'I"!`'YG`;@6=)VL[9EX#;_`)+&L1BTRFO:
M+!,O5GD]3T5W"*2D5'+F%RH^?JCZ:!3MU`:>JJ8@'$2#RVVT8*Q5M?P3E&R6
M6$-O`R'+G>0=OR1#3DHSDL:/W**1A2BWR#U9=!&'5`KQ1RW.'"7>7D2@8`9K
M3;#(3=>Q_,Y5RXD^J$>E\!&,@!HZ4LS=JLH[C8UXL]0^)?.(XQN3N")`*YTB
M^N<X!Y1F97JCFZ8JZ[M;3F*W6&H?INJ>E-I1-.='-**S:^;8,J2E\S;56E9&
MZ9&O%4HK^3=6++,FL:"@Q."ZA9=S%M7*Y/6,F!CHD!H543"4ICICK';H\P7=
MGGB#8,]T[A]06]/86C*;"!FG,74F,J]FGS8U5:QL:<3.WCPB/81!8I71DBD,
M//8)00#(UCBDKO/NL&O[.;*.2PB2(0T&V0;MW-%9=RLHR(_(H!B+220N&ZR9
M4R`83E*!R\"(*+MVV6.<O[BWSO.E*D,5X?J4#%7&9CUEWB;5^D15P$7!.)%9
MRD!73AT0$GA".#CP9(J)1!0XFL)0VX445VW&4ZJLPX]+:ZD3U?\`'_E6K4JB
M:3PUQ<ZI:JIAI:[!XOM6=,R/\T5?&UYJN'QB'E>QZ6R+NG#:0G1CQ;)"U%X[
M4.DP</C!("1)/T#%/\PB<!+I.<%UR+1N2C$CMZGN!I+Z]-+#&.'H(+N_2==O
MIQ2Y0^'4;E$QRHB3L.1!0I#\";C5B>X59&[3S&B4Q..A6D145)B&K%>1YC*O
M$%8KMX,7[A`A#%DG!A(L`'$ZAE%"<F/R&J]F,\+9KPMF6VY.O.(KU-A45;0[
MLB9XV0,[=)OIPYVL^CP(BLV%FCW%,`!ZB9Q$Q0[0`)+:=4H2S%%2%6MY:#4-
M3+JVW%%:KA45'UNXDP]?N$&H3,F0[<TG$K?$S;%M-QDL@DXDV4>F!FR;`JA.
M]4C1PIZI6_/:03"8QS]H"8,9MSH"N8K];,7!5WS?'%P9/[)$'.0$W\4[?D!:
M/+'KM5%$3MU5DE3'1,N)2$*`F)\YRBYS;?DN,W,[K[T^BL:0\50[5CU2MVNK
M+%2<.Y:39(NBQU@,V!(!+((BX6%PF4Y>SL`IC&4\ZDWZ=73Y:87F+':K=,)R
M+=Q*R*3!VZ;N&!&,84Q?@TNP[@?33!-0Q#@3[?)0#P&M-I3=.-,7I"TQR:P^
MF8"TMQE++S+]4Q2]G=;*@X7II4?(6!MK$]3;\I(JL:Q?YU5A(%`?\GB'#M0R
M!#D4,7Y$T`3*5,@B0PD-P!0\#*;3)91M#)IJ&071D`2DHIPB=04W;)T3N`XA
MVAVJG`0[R"`]@AX'6'7C\9!53U0JR!8MX]*L[$C@?AECIG#TA$4EA,JDJ8`$
M>XQ1[?<!`1UN3<D(D@R8LW,>BW:I$00%`P\`4B8%*1(%```1*F'`%Y$"\CP/
M/'/.YT5$EL:[.LWMB.=O'2A6ZJ?E-)4#I>D?MX$R:I>>3%^SG@!]QXU(GTEK
M;>[-:-U$/;JHZ@(S';C#-:KLN[%(YK2,]#W.?EGB!TO!D(\S*.1'O'U!4>#R
M4`*`F8@U:I>N!0<M4W**@JE>)+IF1!-0!$J:HB(`F(E*;@OGO'GQP`\3(=/-
M@T2QQ?Y5L@D4\G>VC==RGZ9C.QB*XS2*)U$Q-W`@+XY"`<>XH'$/8=`2`B'/
M@/<?`?RCX#_KJN-N=4._S[F.70<>JFK?YLY2"8Q2=D>JDQ*7O#GL#AIQX\<\
M?=JQXEP"J0F'@H*IB81]@*!RB(C^@`Y$=5@,C3$I,VO(<JU,8Z4C;+:\335`
MJGQ)%IZ250.0PE$2]Q1*"?GR00\@(`&@.L1=),K=TXX2.HD8P-$Q`RO!R@)3
M"<1`!3$0Y$YAYX^P?M?'LPHUYBLJNK-,UF>C8`V.+0HP>NHMTV8."O(LIVZA
M':I014!<AO41[##W=_(!QSJ/6O6J.73!F[1%E9$2@(LGR@>NHW3*`&,@57@J
MA!+QV<!_3XU*)M,SWDV[6J1I5AN#V3J</B^?*T@5D&*2*"<3'I-F(E5;M4W(
M^@@0"@`K"4`$.!'@1T!35ZD]7;)=1;8-;.U!1^XW/8-CU5BD[53@;-$`J4#!
MQR(<)`0PCYY*`!XT:[W4FGFSOJ`;!8DQP(\3W28+=?##P!R(?NRP10,!2\B)
M1$X"!S#W#W``>!XT:NW*G=F<NDUVG&GMX\#WMG+@$>N#UJ$R*`B5;-60@36,
M41%(Y<F%-W`)@\<AR3MY\@/MP&I[['*MXUE(*B8IE6Z'S.._GM<B0HE<*<<C
MV@`^2@'`<<^??5=G;:^6;]<KK&LDS]A'^?;ZF;@X)B0$\E"<3%-XX^4O:(>>
M0'CC@1U.#?7P)QD@HU<@'K^JFZ5_.,`=Q2E`"F`>>`'P8H>XB/OH[]-/PBZ;
M+BD_;._B*Z>=W?U)N9S-3KC<6L?8[+:V60XQ)P)$`=5&8B$8EJLP$P?E/1D&
M2S0YRB(%64*00[N0TSNWV!2.>V2(]9RI#I+*LESB('72*50P$,H8I1,L#\0[
M`*'/I]P"8``-.[ZK>("/24;<,DNNNMBP$8>V2<>10\LXH+U\HL5FJ4`$BPP<
MP[2ERJG)R5(IB@8Q2"&H\SV5"SMTIZ-DT'S.=*1=NN@NFJ#T%2%.+M(Z?()N
M.P0.<``.!YX#VU///835KM6ZWX5E=#63RCV.`7["/(0B953_``!#`+KO`>P!
M,L(CP<A.!]A\%X'R/C$OU4E#.UEA]`[Q)GZ(^J8#F.`E4$X@0/)RJ&$@BH("
M/'D!#6R*L0;MW9$"*INSI";XD!$QCJ&-R8YP,8?RAP\FX#@>?(![ZU90ZGH*
MI(%`7ITT_CBBF)5A*`]I7#=N0O:')0`3*!\P&`>>/M%,0":KEXB#M98P_*F1
MJJ8P-S@?GN5$Z?YH&``#M$PCXX#W#6K6."!%=C,-HT)E:#3?.3Q":O#MPAV\
M@XC"B()J&)VB43*&*8.`#P(`&E8;Q)DF+<6XE4[@!5TT[3&,Z$?!52*'Y,DH
M3W.3QP/<'D`XUD6=:$')W::OH"FFX%H?P;T5%@Y=&4$>[U"^2E*GSP40$>//
M``)W#C&3:)56;?T6KE-L^<*FX,HR4%/N49K^P^L43=JJ7("00$>-;.T9)@^.
M0J7HKH()$34.X4*U(D<QBBY3/R`&5\@!D2<@GR`>PZZ\+6$8BQRL9'E)&L)8
M`L2(I`)@/)B!B3+ER53O[57P@D)4R<%`Q0X*'G6W/(EP[9-`0,V14:.3A\8L
M4QA;IJ#W&1!'@!%4."E,H)1[1YX'0"$V)>WLLI4F-A9F6(F]3E6SR/;L14KS
MA0X$%NM)N0'ABY`#&]!80,*HCVE`!Y$5D?0R;I)JX=M"*/8HYW"R;D#&(NX3
M$`=)>JD/>B9,Q>2\?*/)>0'DW`4RBTFQ;I>FW?'5;HK*"3E)!-N;PY4+Q\H+
M<`)5!]_'(B(<:V]-)=L[?)@F"9SJ@07)_P`HBZ(KR"Y`*/</Y4>![A`!'O#C
MQ[)M2U.=6Y?>,T711*];N>5$H7:>;.KZADB"=%,738&?"AVY^PR)%!*8H*`8
M0`Y`Y'YN!$>`X'CQKA+&IJGY.@=RBT6263,F(E526=D$X?$%Y[%F8D$`.`B/
M``/GD!XRRB0(H.#'8&6[>QJF3D>U5,#^`,'<`>B'()%Y\`7CCP`B&4!(Q(YP
M5JB`',5-($.0(8I@+P#<PAR/;_Y_:(AH4:F2M-87<I'VJ.!W$-$:5*H/6Z!5
ME&;J?<&Y9$:F#N2*FLGVJ+$^4P*%[O8VG`H?7GI!(/WQ5DCE%1R5DB'KJ)+&
M[RMS"(=R1&W<)3G*')@`1Y'VUE6<.X;0SLZS=%=\B]!ZP2,*AQ3.=03*I`KQ
MRD0P"/)?(`/@./;7(L(%7;R#0&R3`3?#3)5"F4.W.=$!3;(`'YPE./!C!W=O
M/D0'G26[N<=-B)1/%R<$@1RZ,B1,R?U6F"3M=0Y@^'^&23,*9.XWDQS&[1'G
M@.0$1\:25A%Q-NNK2]2C9NN-#,]CZDBJGZA?K9]W'/+*FY!,Q6Z:78F(E,!>
M\0`-*+;/7^HG<9'H^M(3!3,$S%,*@=HE`RW*8>QD@Y],0`.W@.-8E.)9P$?7
M*JU;"F#\C1B8P>J98ZA_RCEPH8IA!50YQ,3M'D"@/;R/L(OG8YV<1*N(UJ^D
MG#H%WJCJ5;-P'CE3US"0YBEX*H"_)5$2G``23$?8`UK,]/H%,C7&9CRMA=K*
M'EW#7@$(=)$!55.Y4*'"1$B\)`8H]QC`;CR/&M4R/E&89RR>)L<OTG-E=H*)
MS-J(0KAC04SF]1!JX3$?36FUVQ5&[=EW&*0WE0@"40UF8"O,ZE7@=#*HMW;Q
MJB6767$JZKIPW./J`4P@8P+**B)^SPF!S"`!P&K$>8QWQWM!)GIGCL<J$`FJ
MNR4GWGX0IIL5D'*P-E6\6<CI85FC-@@`@;O0`2D%P/)UQ`QA#YQ`,1/20LE0
M>12AXQ%J1%%**1'Y5O3Y(4Y#AR).2<@!1Y$!]_;G62FI(5U8EY'FD/B`#U71
M53`)4`+S\,L!0X(0I^2F%$`X*!@`0#W'4'Y@[$UW!0<.';C\HFF7A(QC&.8P
MI]H!RK]Q/S2B(_8'.H4ZZTQ\5VI*'%HN?_+"MA'\LY=#]PEY+R`&[_FX$!#@
M0`!$!V.*N0L8\"V$7":'QY(Q:0<G].*=>J4/0CSN1`PE/W&)R(_(!N2E'D0#
M6(;P#:3(:-1B%DW<BX`B)1,+=4J1R'!=U\07E1L[`>?13`2@<P`;R(B&L[4:
M9%Q<`6L//K1_!LI)0M@>SO"K2117*9))%X(``G>E5,4?4(!!3(4!`1``'0CG
M"PZ\:0HXUY1Q-AGG+5:/34=E;K(Q9C*-!,0KU&(2'L.#0BJ(_P"5(JF-P14.
M1*4P&$"^>.'(-06L#:AY1QY774W8JH@X+=*]&JD3+9Z(HW].7AE16.!$UHM)
M1R_;G%-0_!#(DX%3N#::#BB/?.[)6:_9TL4LZS$R;UI-N'3-W6IA-%DHNE&`
ME-I.C+.S"4`(BSX.0`+Y#@>.IM/N+YU5:VZO3V/.[LY!&MRD84T>9T07\@PD
MVTPW-V-TRNFJ7K`5`A3'*<P@'@-54KLTN<S[4<B]&KUHY2B-XL^%>Z64>0^*
M+=B)G#T:$<.\?RL6Y9*5]L!Q712<&*H1S&J'[?R:*YDU!!,W>BJFH!>#%$`M
M']$#,$SFS:VM#V95U]>80E4<6+2;\?B'+F(AD`2C"F.D4@\HH)HD_*]RGN(C
MSR(UQL1KQ\FE?L8-X5M$2.'[>XBXY1,H`VGX*93)+1CYN<!$PF0.LX24%/GD
M$P[Q'SQ.9T`H>RPM5W71TW,-Y1@IEA.8:*-"?#"W*Y0,0[-?O+VJ*I@!0[P`
M?8!#P(:/^Z\?+Y"Q:T.+2O>E:$XMB039'6221!=NHN`*)E*(B('$R?=WB`\]
MQC`8I!$!`?;GVTL5#R:2#>XPKJ=6J,HNXO5>@UWTI'+N)AN+QPKPLFZ3<%!)
MTU33[FYA2,4H"/</L.DQM\>X+$KO6BJ@D^MF9$DU#D.42>L4PJ=Q2B(%3'@3
M@'@1`?OUC6KE1IF+!4<"0@6;S%4RB<I!.@9=)E(N%USG[A$04*EPF/@G\+@>
M`U"E9#H:%./TG_=VJ?N'UHC>&JF<0#A1(;93P3.`@'`\AR`B'CN#C\X!#7HX
MZ\W[H./!>?29]U*A5%%$2P.\9(@G-R4JA;C4C+`0/L+W"7GG@1-SX``#GT@=
M5_2^%/GQ8BF*^>9/)J^EK_OS&6_^3FWK^[MOJLYJS']+7_?F,M_\G-O7]W;?
M59S4*&IL>C%TYK!O0SU%3<XP73QE3GI'T@X7;.R,Y=ZT$BQ$$W)03)Z;,W)E
M>3<'5X)P)2F'48.W7!5MW%Y4KF+Z<P</9.=<]IS()G4!JT1[5'+A0$RF$`!+
MDB8CP'J&+R`ASQZ=^P[:U3=D6VNLTVOQ+**N4U%,3R1TP,(D.JS2%TH=14QS
M^L<W>)QX*`GY'W$=6R3R[<JI_P!=27E8SSH_]_=8<PE5J3C*B)5RN]L=4Z<S
M;-BMF@B0JCI%(B1EN.3"<0%(?M'@1U&SG6[EAP?6ATNKZ;U`[6#CG!P*NZ>N
M_P`FT*@WX$3''Y3``@(B'G@/L==EBXK@U;U>/6432D%B).I!4"`W!4RIC+`(
M\#SVI]P`''(>1X\:C]RXV+;,H41K)*E.VB%G$Y\,`?D$F<&V`?C.?`B(E^9(
M#B!0,?GCVU"D4>[S:5C>P/&^7+??VT5,56I.&YV?Q?8W01=G+(2**X**>GZQ
MW0$[4_SQ.00X]]5O(:`@IY"U7&2LLM^"#:U2#6O&>/C-/BBF.*)Y$5$`]4P*
MJ`HBRY`0(F<H=I>3!I^^Y++4OGG<%D:K627>(8AI#Q0Q:FD]*TCY2PK*.'B,
MG-2:(E56:,RB`#&$<@53\P$_<!0RCO,/7N38040J9>)K4J+^5>NFYVD2N[30
M5^&CX\1.!!:HB<#>LN'<8Q!#@PB&MJ=.^&X5M+AJ&U1N;V4T;;ISU:5JQINZ
M:O\`J<)2Z52X.7$40GNW[+L_7<C)NHVQ(XSHR3U-J]D2IMG$C+QC97@2KS,B
M95%BD90@G5,W2245[RD`W=R(SB3MQ)DFN/:159@SAS?F;5>-G&Q47)'RK=$A
M`9IJ*E,9PJJ1/N,<H%_.Y*/''$*V4:)68-"SJ5.ML)XUN@53_79U'KI)B]<.
M3I)QS%FFI\*``7AP8P%X,(<J"!0``5RM;G*MM6QW!H4^B6">R&@9(8ZU6%\L
MJP/)>@0%P;MESF,"*)2&`B+-#TR^>.>!*!I:FO2G+I#BZ2FN:N[J^!-$Z$UJ
M:A)52:2FB46==DN0GZ52GZ#8;=3)3$J-0E!G7B5IN&29)-2*65.L8K5RC%M5
M#NW:+A`A#LVR)"%$YRD5\E'6C1Q,1PMUG6532CZVY@D2.I"S7=46,:_=+$%4
M6=0KGJ^LO\8N(N2/':7"#;\F`<D#G<LFY<RGN(R&>T0J#(7BM0;3+\KX&1HQ
M6RJ^F0!?*KE!%HE$D4,X*W[B]_9V*E`XE'6HSN,8E+)#F:>C')Q\76HR'DYL
M\@#XT[9Y!IZTE/NU3`+9-!(IQ*V38B!$4"=AB%*'.F\N*52;EVHY;FCI6%'.
M9>RE)J'%%%E2R3EM[Q:B7/)9!M"N"33E.I$\FZFK#*P#F5<%6E2()K$*J[F8
M9OZ0&,=WP1HS'L]-`AA`#<%#3^MD%(;[3,17+*N=8-O5"34(5V]9OU7"4D]K
MSLS?TD5SHB95L=T)R@+5IW'`#&[>T1-PR:HYRO5.Q",9$GK4J%=R(6.B3R*2
M#1M:&J`$4%*$^4O"((")%E1$Q"&35'OY,';\W7<]<\]`K/97FFL]5X04P=4H
MXLJ[2V9F!^QFQAFC<$)>QKD(4OJ.I%8[4A@.9%/D"\5)PU%/5&IJ'JI'[2R;
MA7N]>E9KZ4ZJ$K*K6T-TEQZFG"<2H+9=QSGRJ.\=L)^(PA2K;5Y`\S.MVRH-
MHFL(?EU'@<HG*8ZC,@LQ57`RYS*^H<>`YTTO.FW/;G$UR(5VSY4_#N6Q76F%
MRBY*=9N`I,@TD718]6$8R#@J9'KQQW"X`@'5,"BB9!$I`$--JQ5F[*3*[/\`
M*4!38Z[5.'AI"M$Q+7EVDK#MX86IDRA)1RQ2R;U!=-0157:',L!AX+PF3D7-
M[=*R[W,3+YWERT5=OCMF!WT;BBNJI1Z4*^:`9U#U%-%FFW>(1<4X21DGAW:O
MQRK@BB2IOA@*F,>EZ;Q>&I3K6C6\3PC-4:6I:U:97%2E#]2=TIRI;:6R.MD7
M"^XJCY;V@Y,R+2Z_5)FTL"5[MCH<C.&9M9,BKZ->.#QRYFYU#MCF*@4P>L*G
M!CF.`>)4IXV-KRY"L7"7D;6!&K6*5K5954CHF9M+!V5PP:S"A!(YD/3=IE<F
M*@8"I$2Y5^4>1B<W];I7^6;G2*_5K1.%PKA&'C$+!')MSH0\OE")<G;DAX27
M32*\=.V[<K5N"`.O11,(BH@H)P,"K]+.+R9><XVW)V4#V8(>&9.G%:J4@@N9
MNV4F&ZY$7"!123%---$Z:*0B`'$@F.?GP89#B:>T\.=^<5M:II-J6YCX2:]I
M?5<"9F#E,?8)Q?9<C3[T7,P]E&K&RRS;N6>JR2#ANVBJI%H*&!($&KL&T>@0
MA![S&,901$>=:WN3R%N]JV$)K.L]B"CLF4_$1\0C54W:9+0M799'MC#2Z2K7
MX0KT[9<RBQ4CF`#`)4SF$.0A%W'9IRFON+R'@N\V2?J5+8S,+8JS58J)*,I-
M.4W:<FT7:NCM%3F8).VJ!W8E,(^F0?G'YPT_2%ON[[/SMA'YGL<*EBB*C(E$
M(]NBH#^90C"I_5R3A7T$B)G22`I52)CWF/R/=P&I$>S[FIF558FE[\5:+[BD
M[.=MFW:AU>,S4,##T7(3GU91TNW>NEQ$[X`7>-Q544$GI)G.HGZ()`5,Q^"`
M`"(:=@[M\W=(B1+`3BL"R<2+LZ)$6B:B2S4GIBF]=@4O'"@=R@%*("8"AQI"
MIJ)9R$<E`Q#=6$C@.B1RJ7DXE9")"G3:(#W@8R@``=P@`E$>?MUPVR\Q]`B6
ME:HL:^E'Q&R(IM')3"P16$1`SN5=B(B'=V`)4A,)"CP';XXU"Q'E^(JU/L[F
MF.O@+!(+R2DD946$:)@,=\FF!O4EVYS")D6H#VG,B(AV=Y2AX\:=[C:?0G&2
MI'JR2A&AA5(_54!$J:)P`1;=P<&[B_FCP`\CX#GVU&U61?'!!S:)4D[99`Q#
MR,DU`PMX9BN`'&,C1;E*B5,A3>D)S%$_8GSW>=2.8YK\?#5AFJ9`BZ[]0%R'
M(=02(MP*!42*$.(@90P?-R("(B)N?(AP`Y[$67W>(\B1%MI\%^%J:H!'6FJK
MM6SF#LM<,J0SJ/D`D45FK=ZB'#R$D2I^LPD4TE1$[<[I)6QYC.=I%IIT59\?
MLXUA7[`G]9?"1\8PAUFT@H1,CYI,,(]%%)O.,E"%9R)%"F5[T2"511L9NH:G
MSNDW;8ZVBXC?W.SQCF3<"HW;LF38ASF.]?*D;M^QLD/J&$%5"\FX[2B(&-P7
M2-[;^O'8]EN1\*L]P4#.3.']P4U&M[5#1+`[Z<J$%(.FT>UR-6VR8`=_(55-
MZT5FJ\0P*V6"3<L&QR2J$8J424L[>]$7IA`#`)1`1[P$G`<\F[@$HE#CSR(#
MP''G[O.H2-R[7:U7S3%!PY6`?6R.<';SUB8VV=>56MN.\7#N-:I+R#Q&<F04
M$$G1@64C(DRBB1E'3TAD&[+MQ?TA3;9=\SR6V?"ES>1T"F5:/F<ENFSJ#=70
M5?32,G5D'Q&TE`U);U>PLC(HL;#/(F,<K&*CCD^+XV+J,?L#NX]9)4KM$[Q1
MPV$IFSDATN4?1$@B02]@E$>WP''VCYT*:CD^CEDJY&3[`?AK!!II*MWA3*=Y
MFZ"G<H03$'YD3I',0>\/(<"'G@-2';)\1W2KVN8O<]4[9&1DIAVQKH2<I%2#
M2)*228-5VH-72Z16JH/$S>L@8#',=,0,`<<Z:=_D[JME04(910S?L$`$3*=I
MB@'REX'D`'C^@!^WP#Y]HN9<H6N(M%8M-^LDW68'$MJ0CH.4=(FC6B4(U29Q
MQ2IE;I'`C)J1-N@!E#=A"@`]P^1`HD;X,D?A7U@MJ%:0`QVU;W'8#3]8Y@$W
MKJYJK(@0."\<)@4X>!_U^?<`X-,^O-T/>.L=A^1,Z*[*QWA8,BB+$,0Y!*VS
M+6#=I3D_.`@J"0>?)1+P(B(:-5XY+WK]F?4M-6KMNBVA5F,03V8/%0>M]UD"
MM_G<$SCDETW$Q^T1.WR.!Q`!\#W"41X$/(`&I>;)=U5F2A#MW"AG2'JAV\>F
MAR``<ACB7DPB(#P(!X`...0'4/V#6BKSKH=7TA"'3;ESKDXSER7N$&Z0Y"$O
M!N!]CB/'(A[\!S[ZE8FD'ISK1R+<ZR#=19$%3`?M%`HF.4X`("`EY-XX'WT=
M^FGX1=-ER7P,+S4F:WM[12GCP#Q=EA7+):->%!9J[%8BB2@"13D3=@&`1*(]
MWR_9[C!)&8O<X\A[_!1\<^92^!GO?=*R@@=PM9*)).A)!Y/JS0QSF2;M"`JA
M.-D05,=LP,(IAR01LF6O';::D6CU^R6*1D93N733,3M,(#^<?@/D4[@(//@?
MTZ:WG?;#-HS]/W$8H@7]ML5`16C;QC./*4'&5,:RI3-9^H.$U/R+HZ#1PXDX
MPJW85-RB(`H0J@B,^.?F)Y!JS5U3H[\=G1U@B;A6K6R18R3%5"2CUDFR[5XS
M/ZA'9!(4Y5FY@$!%%8@`<`XY`#>?80UT@81[>4#M33674(J4W8D("!P#DJ1U
M>/```^"\\<\@'C63ISN&A\I9+Q15VA(:(BY5[8\71;MHI$N$ZW).W!!QY)D<
M>4)FL&(J0AT!.1?U$D3'X)Y6`:05-%L82>@NN`G7+\.`'*Y$.Y8CSD!,1V!N
M2'2`/2#M[@\B.@3GX<;Y$A3@W*I5%46YB"N(<L`./I"H/DRI5B?E43F*/(@'
M`"(\<>?':6K[=BBBHV540!/O468=YE"&65$2J\J")CI]I>3BF'RFX`1UO[9D
M(2CA!`5R(,$!.Z%`O^=.43$,4O`AWG$0\\#X#P'''&N$T<"X.ET6JO8B"8F$
M#F*4?B1%,IECB/>1<`$0.0HB''@.?.A1(SM$5G[-JY:+J+D=**L)!102<@4`
M/VE%(W/H?<13D!$/)1$0'6V<$65.)FZ1#D5*W<&/X,''/*I2E'A4%A]^X!X$
M.0\ZV0T,1N<O`-$E"(=WSG$J1S_-W"4Q1[BJ"`AP4I>!-^D=8/TS%4,!FJI.
M2&6$3%'NY3\&-QQSP`"(\AX[1#GV\`8%U")?%K2`)B"RI3H+G2)PY3;IE_(&
M$!X*HD41-V%$#"GR/L;W^E6J35=JF<%5#J(&4`_(J'3("/)5EBC^><W'CQR3
MCQ[:RRS@HJ"14_R&(`E`1^81$0'N$!$."CXYX'^C7`N84G*3M-4I3()"(+*?
MYDW>3CT1+]J9"!PJ'L'@1Y'0&%L4S!5:&<V"R2S.+K\8V27=N7KDJ`@4H>JD
MB@F(B9PJJI^80I#B500`P`//$?%JWV22+]ZRH]1"/02<G5&0GG7Q!W2:2ATR
M.3(MTQ*W*J4"&1.!CAR8`-QV\"A>Y3+<ODRS24>1=5*I5!Y(1$6@@X.+(TF@
MX,#N3<%+^37!V=(4F0E$XE2*4G:4W<&EBV4[44]PHV"Z6(5!J53!&%4CDFYD
M5Y-ZNU!X"@.4B)E,"(F*)5`/ZG><.``2\CT6E)+5JS6.%N#RLQC#C$O5,6F-
MGAS,4I--JY2-2I^[C*'X0J!-S#\[!^X()T&IFX)$./"AE#-'"'<HU`AO)VYO
M8G).0YXD;H5Z86B$8.VQ6A@E$S/FJD<L5;XPY0(60=$2-R*1V9Q$%VJ@E.!^
M1*`\!K&YJZ<^/OW#K;EZBO+)&V:C0"LJ6/?E-(1A6\,H919N("95T/*"9R"<
MQO3$/)BB`::;LHGDY."LT*J`(+Q#Y&>CCJ*"<2`X;IF?-3&[4^QLY6$Z@H]H
ME$I@`3#QX:O2T]6E--748HE:BYYO%XFEZDTFJ-;O5#6VIU:X-4WB)?"X'FSM
M"M0%1%I'BNJN4I@25=NS<=@'$/"_9[D\%#C@1XXTD]HL!;!(/8.!GABI1'U8
MY:>.)0<4I,X@91T!U`]'XAYV"1`Y#=Z?=P`AY'62N.3$,?5<9MT@O8+!.OW+
M&`KD:`&D)B15.=%B@U)R4WPS(@=ZJ@%$H%*)@`1\:2C%5%?Q$;)/K\W-)OYU
M^M9+#%'!0S<CITHLJVBG"_!?G9@LD0J1.""9(WOR(ZQ%)XTI??MUN:;EPO\`
MY.8A87-](4N9@S\?0XN-:`O68]P=\W%5P9PY$QU)^5<J#\3*R3OR9VJ<3JJD
M54,<P"8.TP<:WU.&449-&BHB=VU!(LBH"('9F$X@(I<"/<0Z1A^90`$!'D>1
M``TH,:+Y-K'$>MD6L:^*<L<1`@D,@42\I)KDX[2]I2D#L`W:4?'D-=1_&JH`
M<1>K&66,`K`APDW],#<D0#L[0,80^43#R(B/'WZAI)*B4+9&LH5Y)=\LF1-L
MDT(@*0.#F'TC/`*'SJ(B)053*7Y`X\"?\W@P#KH,XYNW2.HZ,V)\(N+AL`D'
MXXWH$'N321-R0I%N#"40`3CQ^:(CYW-S'IJ-TU2%2:B0J0K@N<07(F40,()I
M%^4P&X\=P\&,/(B/.NBJV8?&.IMR<CQBQ],C)DDFN!DW0I@LJX5`!*"[H%.X
MI"AW%2YXY#M$-`:?!V@'+MS/2%:GHAD9PD59_*-2($;-DUC)%,F5$"J&47$Q
M5$#D`1%$R?J=IN0TIJ,&N20>.4)-1>.*!C*LB`0[9XJ(]Z"OHJ`8HN#$[2'6
M'DP'Y\\ASI/W4B?("\"5G$ST$P:@O(JO)$2H"\30741<-7+0%#`+98G"Q#"`
MF$`(8>!TLS6+?)DC31BQ?AT&YSKHH%(X3%'R5!$JB@")E#!VG`IQX3$1#QP(
MZ!60B,C;9EIG*J0;=H2?CHFBM'3Z/B1261BK1+2IVZE?D7BR?P;:8;PX"]=H
MG.*BC(WY,2\@`N><5NKN)AVWCHAC+-#F*XBVC!,$FK5T3N[C,S)&*5$P#SR8
MG88_)N?)A#3?,@S:E)JZ2$I'.8^&MMO%"6M(.$V[:D"LW$RTP^.4/65?.A3(
MQ(W:B<0,L4W/:7@=-R/DL<+2&#K94)*8EL734/)M+@=)BY;G1F5!33B)N3?+
MD,4$TU'!%$E%5"E<>F)?3[C@(V&XA<%.6KUWK[I41F4IE\7O#=*;*U-GD=!%
MI,(VR2I'[,U9<PTFP5!\F[Y4<_6;11(J+]!/N<+(HB'8F*HF*3N,!!`>=6).
MC-7C0^)\CW`I"?5=PO1FRA$0-V.'#)(W:X`XB8.TYA+SW=H]ORCR(#J!2][;
M=R$'/164Z1C.Y90QAG/&E9?,;%3X?ZW/5YQLLX*Y<6A!R*`-$7R"Z)T7S$QS
M%(3DZ0%)R%H'ID4;]QK:'4JQ-(&+//9-S)RRC@IA,1T*)15%<IN.0(H)D3&#
MQW@/:(^.8:'\6!X5K)QT7VD1*\<@841^9-/TP%01$.!`Q!$.>?L#WX^SL5S.
MM^J.9]M6-8TL06NWC,C*NR1E8J/7?&9N8&=DE3-WCAL=RF?U6"0`JT5(HD3G
MM,!3'`=5G7WUC8(-5-0G>DV?F6`Y0*D*":!OD*IQWB)_S2^!X#@/M\)+&1-H
MF=V.QQ\W@9T\1&[@W3MZ_1CG:T4T:-,?7(I%EWH(G121]15)`#J'23*H<A0'
MU#E#0%;[H!<C])8W/*B=-0KFL;PG"9TR@4HIGN]<*7N`/<X"F8#F'R8>!UZ3
M&O-+^CO.Q>_20=R[@Q3$,:O;RR@4RGJ=J:=]KR9"!_``!(8X$'R'?]W`Z]+3
M5?TOA2152G8\FKZ6O^_,9;_Y.;>O[NV^JSI0Y,`#R("(!XXY\C]G/CG[N?&K
M,7TM?]^8RW_R<V]?W=M]5G2@(B`!SS]G'OS]@!QYY$?;C4*6[?HYVU]DT;R6
MY:R1)'+$SR19,'3IJ8`9E:E4:I%37,<"G!95(ZH*$)VF`X<<@4!&UA=LJJ(0
M[R933.Z54$C:,004(?T!.IV(J?.4`(0."B?P``0/L'QJ+?II5)EAO8UBNOQB
M!&KFQ0T3)NRE[BG.Y>M4U%53D/Y%4XJF[C>/(_R:<;E&T`\>MX%%4I19H-?B
M!(3@I`,4!,8!(`"940$2^_("(B(^^A%;9NKYNYA;I>G[R^0$2J)E19PSZ7=(
M"H/8#DQ4DRKJ\`)`.853`D4!$>.>`XTU_*=X3B[5<)AXH1F+/%U@;MG(J@FF
MB#TK9JJ`";@"B"93<F#R''/OSKN5"]OY^8L;Z:A5(A_#2`PK!)P<`=NXLACD
M3DEN?=`XD`2\\@!?8??3%>H+8EHVG6=JW5<N%+)CJVQR;=JY!JNN^(T!PBFB
MJ0P&2.(E$Q.P0'D`$`^T12NS3YMBC%9A/).8Y`\QDBV$CK1*NQ.0_INW)&HH
M(J\D=BD1+M1,'>0QA`O(\CK8=JV+Z4TD1FKG:XJ.6?23TT`:3="FF4!%1JD8
MD=Z@)/)!RIRJ@)DU/1(IV$$H@/&+BL7XZR+4<=4ME:63=K#)FE;7.M3=H+R:
MR1ECP").[TSN$C.CE?N.0/W>H//J"(AO\YM5>EEJ[*U2THG<RJK2N4\S!BI\
M/6DBE4,LZ;B8@HD<'!%8ZC@Q3F3%904S?.//1M)-)M3$T<PH5[U_Y1;$*AQ2
M;].I:4TE:BJX:A^J/X_R7-IRX8OV=&.,ZAA>9EF\ZE+QL+:H&.?LF/)':;ER
MJF8STOHB"HHCW$%VF`F,*/>`$$`$-,4RQ=$[IF2A,'YCM8MG#)`V,FS!,2-'
M":ADVC!`J8`8SDP$!%R)06]4W/?X'AV^3ZC2HVA8UJZ+)W::]&6Q-W<$(TJK
M\EHGTT5&XH3LCWG-\0V7*9T=)94#'*0A!#L`":T#(5'H)8]ID^"<A/VVMS+`
MJB<4)'AXLZSDC-M'>DF81*UB4W`+KI')P02&.)`'WFEI.E75+K"S;,M;FM2]
M2K"5&\RE7%TF[2^DU3:UX2EX>K&EZY,@DJ=$L@3#$<DY%[88E1R`/I"<4!0H
M?$*J&*)N1[.Y,B(\=P\J!,U=HWI$=(V5Y'H(U2".[-4##VJRL]/MBM6;),Y?
MF5%F14B;8#&.!5$S#X`!T]ZHT.=>1UO"%>.;!D($XAM'6$K!-TC#0[\K9VM'
M&5!/E0JPB=4XBF;DPEY$./#1=Q6);S"W@EE.T1/&5G'<C9YN$=D4:%;*-'XH
M,Y!NAVE3.Y46[P`QA#TDQ`/F`?!-N$VJ2]I<)13+A*76M6QJTI:=323HJ1-G
M,Q&+^E0J=F!VV584AX>"+))6%6J5X(>)04'TT&$])=[V3>`F`F(=6-:*D8$4
M*(J&.<2@)3=VD0@JC=+@L=G6Z]/6-9L05#MX>/>29VZ?@>\Q&J:PID^;Y1,(
M`(B(`(CSKCDQ-.S[@Y!'UG\B02%5$3)@+]4@@!SE`%#G!581./`B8GL8`+J_
M7L:VPX+VN[<:A7(*!B'-QL4`UL5PM;IHW6GG\M*M$5C(*/7BBR:4>D0P%;I(
M]@E*`!VE-Y&ZW5IS1M2FEZFHEM5B77F^(T*%2:I.N%"A7YUK6:T2*$K1]>\9
MV1N^(M8*?98\R3ANH<'4;((&*("0_IJD+Z@=HB`IJD,F8AA*<H@(E&>';E=Z
M'F78]N3LQY1'&V::\>)FINSQHM$9-9XQ<1:S.T1B:1$CHC-IE-%2:)"_#*<J
M_*)S"&GQ]6_;)A>X;=;AF!2!A('(M!CVLG"6AH'PSV29`^20<0;M%NJDBY8K
ME<&,@=9!0Q7?8H42B'(5P]I%\)6,@S%9F$?K''UWJ<M$WV+=.#)L1CF<:N^;
MNA.4_80[%\DDLEW*$`ZI2D!03=I1BJFW+K1-RZ1,**TZ;K*TY7/?%82RZIQ>
ML)Q<D#QUC]W.X>89*R$]8S%?CIIC9:O@^#*R?3U]R%.IM_6LME><%**;=91-
MZDS(<4$@3,=8.2E*$N6WCXO;E0'%LRL];O;[?WRDA%UN)2`CUXDLU;F1;HI`
M01(V9%,*(%["$*8AQ``\\,EV74?"E3Q?#FJ4%(9?N<K,RTS"F4]1R2NL9)1-
M./C4#-E1(+M)`H*.BK$$Z"8<F/W&YU(8ZJ)H<Z=YR*[2>2D`T[&K=NF`MJXU
M6*/$>DHN8@_%D,8R2@$((]Q0X'[LZG6,)N,>WCW&E0EQ2S,\9_*;"69&CXW)
MEZ;Y4L],A4;RQC$F$3(.FR?Q$1&JE.0P++E`IC+`F82&]^[GM`1'CC-M)V,@
M62CAS*JNUB(@5,C1$Q6J2HE``,1)8"@<"&*(E-P)0$?M\AK3%V.6<N/3J5:(
M;T.BB<H&L]R*J560]$XG%=HV%,X'35*?EL*JA2B)!X+YUMDM1*37H]!2QV:Q
M9.?E(1$A4E&L>P$0+VBBBV:.$0!ND<I@%0"\F*8OOX#4-'&CE%`#)E;14]*.
M#'+\Y"HG5=&.!N"I)E#Y$@$`[C#X+X$>.0UDDJQ,W8Q'\VY84-LJH;L^M7J9
MI#T@'N_*($\""G=X$>1`2C]ND]ALD0K*:7KT;CZ-JB+<4P;RCB275^90P`/(
M.#G[>[D`!0#]H#]@<^5/E)"-30<N9"-1E7I")F1$IP7,DF?N$YA*(^FL0XB'
M;R`@7GQ]G("Z5Y*CU^,3KS.7B9UZZ%!$JB+E$CI;D`!4Z:9``P%``[CB/`@'
MR\Z<9#V`J96;1(_8V33!)(Z@@0AP01$!`P"/S&#@2E'@`$0XY^^-B'<5-1VC
M8(EDFQFHL1%TD0PI*&14,`F,*?</83@!YX#V+]@:=Q7K8TG4(]9NY(HF=,Y`
M],P'*I\I1#TQ`1$I@'N*/L`B/GG[`([NL-89^1I-%B(MTRAHE24;NIZSO3D(
M2/("Q#-$D2*>%%7)_P`B(<&-Y)Q]^H*;[<9K+YZ&G.7)\G><9N$XV,A)TQ2M
M"0:+E%V,HS41*4I4S(-".0*)QY3,)3``\:>QU`5L]Y7S'?&<E!V9W1\>1$:M
M181%LW7A74JJ<Y5'KI`B0J/'Z8]BC)!8JJ)3$,;MYYTWA&#K2\WZU6K;]TV"
M&1&\RTT05I)62!FA\5"%2*=4R`>5?3:E,DBF!1(5,NNB<:<.K:AI-.--'EJU
M.T.6N.KU/4XE3"3>7.%>D3-DFWNA#K,(34GDR4I2UBL#Z4>5I>-G(]LB0GUD
MU`_QJ;605[#$:-C!PJL4_!OR9>3%$H#9JZ4N\Q]EC"+VEWMYZUZQD[/`/DW+
MQ-1X\C4DR`WD.P``Y2`0?2,<PB!U"',01)P(UU<F7VRJ45:N5K&JE?K\V9NQ
MA9Y,OP3^.00<$*Z"30:I"***Q2F*D)UOS.!/VAR&G2],QC)8VW82&.HF4^N6
M]SQ"ZE'[H2E$Q)%J1N=$$CD[^44P5,0IC""ACF+\H\".HX]/6E9I&E72AXVK
MM9W3351W2FD5=KN8NU=O&2ZU6W7Q;!B<IDU#*I@LB(G-P5`"`8G=V&*83#Y[
M0*(]W//'VZ>YMVQ7E.D5;+%MME+E8&NO<+WU]%R[E1B,>X;R31%W&_#@U=+N
M"?%-Q^(2!9(I^SGO[3?*,>&/EBNZ1$+HJG2=@P;<F-^<19NF1(Y2^!^4P]QC
M%X\B/M]NGI;3+'<)!EGR"FK!(RL6WPO?%$$7<@[5:H=C=JFW2(R5,9$A&R9A
M33,4`!,O)2@`"(#@ZGFG81>+/^IOA1RN<5%5-[^+^XXCR(\9\@NWD!\@(%$`
MX'R``'/OHUF\9-6[+JF8=;-FI6A$M[V)RF2*?U"BH.=*^*JI3>_"QQ%7M'R3
MN[?LT:NJ[\ICV.6JVF-MHPMX+6FT"NJ6/KA]:9%`J!ET\S9(.05?(``9&Y-P
M4.1'D`^P!X'^74P#R):H*.$7+=)%PD10B@%*/>)>1[A`H\"?GW[>/`<!]FHM
MNGZLS;]>WK+JN73=(Z.9\F'(Q7/PH[3-D,R:H(E$0[SI`;U/;Y>WD-3X9$I,
M.5R252;D%)83KH+B4XJ$]<#<&X*`@/'D1-[@(B/.COTT_".BLN2&;MH:!D#@
MP=IHJ"H;@4'!#IB<"@!@#GP)B\>0X'@!^WVULT95JV@I\*!$6JBH')R@Y,F*
M/I`'`)G[@$I@\<@`@*A1[1YXTI[./C'912<L"IR#`H$17!(J8ND0$1]=$YP]
M3D0,)3?;R`_8.LTUK,(Z$3+@CV]Q3_,7N-Z@<#P8!#D!#W`2^`']/G4*1:[I
M>F70=Q+%W;:"LVH>8(LKAY#6ABX5;&=/ESE<(K.P;B9-ZW.Y)WK)+(G+R81,
M7GVB1"-O.-[@ZPIGVNNZMDYBFF5&Q.VR[2L7MN7E%.2KTN=--F^5=^F9P[8$
M,#]OW")D^W@=6PST5BL!CQZR\6J<QC(.DECB"2PF`>_TP\E(8W(B`^X#QS]R
M(;@]M]9W&4%?&N5XYE*."E36J]N*55K+0$FD;N82,;(I%!PU<(JD*?\`)&#O
M#N(?DAQ`0*TSJE'BU5C`@81<KK"LY2.(^1$>#E#R()B'M]G;P(\#YTF;AQ&M
MAE&0@9=W']AG/@06-W`<$$T4A'\J4IP$P*E*(E'SR/;Y=9D6AY'VT79'$V;8
MY8[-Z=RUH&2&:#D:Y;8ED<XLRRDBNF1&.GQ0(F5ZW="1)ZJ?_)#F,H(:2J=J
M;1243DDFR1EU"JJIN4B!RN!R&,9`2B7M`$"^4A*/`<@'/OH!#`%JNS)).T$F
MRC5`@',!C']%$1'TSJ=X@!ESF$0/X[RC[_HZ,@FH)T7;(P&(HFF5R4QN14;J
MAR!T5#<@4%.>3%`2B(?>'ON=E9$70<D*S551:D15^!5X*X54,<`$4Q(':<I1
M+S\P\CSQ["'&`(3N:-P613;>D)5$D#D`$3%(3M%)TF'!1$@>"C[%$!\Z`3MY
M'HN717!#@FJW.IP('.)5DQ_^$HF`CW]H#XY`0#D1Y'G6(D4EC,52H_(N9*00
M;D`GR`"R"@%#V'S["7P(@/'D1UM;XCAJH#EHS`Z!%^7;A)4#@U;F-P=<H%$1
M.GW=W!`_-`..>`$-8E4`,/K>OW)E.H?N`1`HE4Y[%2G'R!N!\``@)3"/@/(:
M`KQ6/UO4D&:RAT5F4I,)N$1$QQ75^M%E2]Z8!R0Q!4``.?@0#@!#@=6`NEI8
MX9IMDG(-$S<))U=WJ\H8QD!42%-,OPO)!$5@,*';V@)0*8...0]H==PN-'&-
M[Y8VZZ9UBW&2<VBJR3+UOAE&"[I95U%%1,4"#)H++)D4.'<0J:9C$,03`!N'
M;/N"?X#NCQZNM+.*Q(-EDYB&CC($<O'J20I,W2)WITD4E$0$Q#'$Y%#$$`$#
M&`!UUUSZ=+2OI2J[1&[=85DE6L5DQIA-T<IN85/Y0V^*F8_%):*W#79M1=FF
MX$]?].0MDE4`:QC911%)%!I)F]&:,HFH8`563:*G7;HE(81$OCM$VJ_FR)+X
M>#R#."F@#8A$FKD[I1,A3KE9IG`0$>"IIE;=JIP[@`%#]H&'M*.N_G7?.CE6
M@S-.K<38F,S.I(,U9.3=,_@HV'3$3.F[%NP<+G=/9!$H-CKG1*<I>X/SNP0Z
M&$*_:JOB1=)]'QD=#VR>^)G'$@5VFY:UIJP313*!#F,1-V]5(DFD3Y2"W,!5
M"`IR&LQ&C5*NXQ6&G3BOM[42GJ43O3JJK9RGT3V%.QV[;V^QAD^3DEGL8Q/(
M,*!'S[9)D^@W9"BU7=L&P%$5H9<2E%&1'O4((%`P@(B&G"FG53J))@P<,(N/
M1^-<KN.#)/%EB@4QDA*!O5,*@B)3=PCR("'V!KKP5>BF"30"LV)G"$:Q*V%-
M`A6S5F=(JIF:(&+PF=4ARF4(4``ZG`F\\:W`I&ZC8L:H1,K<R(D1$Q"G,5,B
MPB("(A\I@X],I@]QXYUEN?KE[==W6YI*.;<OG^87!(^F%D8ST5ZK%%5P1)(R
M3,@)^F1)4/(C\WRD$H@`"8W`F$/LY$=88WQKVN2*CLR8.$$G!D"H*=H++MB&
M5(9,@#R"P=G:)0Y*8W(!W`.LOCT"/'4XW<1232.36+\"@=0"$6!-,P*E5*/R
M\^H7D0`?SA_D#6)DP;1ZYS"H9LFFNH0A%`'T#)"H/"0E*7@RH%$2IG'SQSQX
M\ZA31,66A]>J(G.S[5Q%2?J.DE4G910>$29.%4D3D2$I``ZA$@,"(E`Q>0#C
M@0`=C0L(/`]-(CDJB*1G"!WZ162`*D$R*@K.!#M1*8@G7$#%'M#R/'OK49RQ
M1L!8J_26S47+FZG67B8UL)!68`D!EG4S+J=Q3,HE,P<&7*4RYES%*4.#B(9$
MRZ\(9S,NB*RTDCW$"46,JI$M&(F^',D=JU,"JGJEX_*&*/(#\X\"("?;8BVO
M%'V-W@1C'CF/7B%F4ZB#15`9>,?MY-HHLH85'"#EVW44;)BF("0I1`JIP#V]
MPUO=:C))6#FTU7"B#IS,JIQJ/!D!!LFF0X$9^"\-N_N.?P/<83"'(CX;O&8[
MC&UDAI_%<W'X\L<@_2D):#4>2!<;751<_:Z3DXL>%F4GZ9A,T72(5%-41,8#
M@)@!=:+?'LYES)]$E&TBQ6I+R+60;2BL<+6.:JM6P.W+11F<3N&:RZI@:K+%
M*J"9P[N!``U8VK2M+6OPEPG/9N!.]-JWI-+/?!J=XFJJYRU3L?WQK+V)A1Z*
MZR2:N5^,=3325L9W"D>U*[8L`.HJ_1;"LL@1^7M.()G(43\</*PXPQMFZPXM
MH-TK2<E2<FOHCBD3R?H2/H,S`Z(WDHPAR.XQP@=LDHLR#@Q!3`AB\%'2&XM;
M?6"]UN:(A#V.8NSY>.EFQ"G=R%>C/\E08-'1@]83^H4ZA2D/Z?8;GD!$=2$]
M/C#[;+>[NJ9`>129F&($74W+.@;*IF5>OVL@V0(LOV&2*[`Y0%43F`3_`'CS
MJ<BQ?B3X/8F;J]!DH>",G6ZFDV85JM0D:GZ/JL$DDFZ*(`8@BF")!$"@'MX$
M>1$>5\2BXFFT*IPT,DDR1;0D<BJV`Q5%3/ECIJ.CK\B)P4-P8RG=Y`3#P``(
M:T!P];V>SIK@Z*G4Z@LJFX-P!FSB26'U#$-^<4XMR^D4HCP8%..?8.<L[47F
MUC2ABF(T4>&(S2`>TQFQ`^94W(>%%`X`AA\B7MY'D-`9U:2))2AG:9@,#1$4
M"]I>P$SF$1,8@%^7DPAQR/`B`%#CC6@UW=?ERG;W=C&WZK756/Q]DS+%GCKO
M6#M8A8)2+:XWN<^D@DX<M57Y432L.Q<&68N$C%^'[!."?J$-O$2U3:I/VP$,
M8BBYW9DA``6,W.F'803<<F%/^%YX'N$!$0Y!CS"@9)G.KATS[A%XYO4K0Z];
MLG/I^]1M4G75-K+0,29#9,OKZQ(M30T6HZD'C9FD#IR`JN'**"8E55*70CG&
MZ[2I]B#KZ-PH=;Z1+N)64%,ZBE=WK&.=,PCWC^Z;$@!C_8!^W@!+X```.``.
M->FCKS)OHV`=OTB'<2')>?P>WJB/8<3E^;)$*?[0Y`W)A$X"/`&Y*`!V>?39
MU7=\_,+X05ERY'DU?2U_WYC+?_)S;U_=VWU6]K)40F8I1=(5R!*,`]$I14,H
M7XE+U"&3*`]Q3D,)0`0^8W!0\^!LA?2U_P!^8RW_`,G-O7]W;?5;2!=`PEHU
M_P!Q2F9R+)<HF'@I036!0QS#]@%`GGQ[#R`@(!RTW7/Y&JSO9VORZGI";?Y)
MB;;UA92)1.U9'J4*84C-S)*I&;,FP*%$BGD.3\]@#^:'D/;6A7BY2HR$@\2[
ME%OC1:'``*9)!(I#&(LL;MX*(%+V^_(!Y^\=;_@MF>3P)A:19*<LY"D0"GJD
M.*R(F-'-14,A]AP\B`ASS_)YTBV5FSJN_'QW:KW2S]3TW/!N!`XG(`*?P1*!
MN?(``%#^0=0HA[RQ'<2ZRK"02[5DU$G;D#`;U5A.`'``/R'"8B(%X'@HAX]M
M,LWP$2<X];S[I59\G'RC-J\465$#E92*9F+C@P&`2I&!0.X>2E`"@/(``Z7^
MSE=E[18-?AOAOR((%^4ZZQ##ZCKN#SZ9S!SV]W/OSXX'2.YFK<A><76J#,ER
MJ>&7,"9QY,*C=$5P,'@1,(&)R`>YOS>>1#@"O-BP%#W*M5UV\:-:2V-:49%,
M[E)%5@\KCI8TBJN]Y*H=-=#TE628J"5<YQ)QR4.)/J#O'QC>J_)PL)7E/@*B
MJU9U6,8LB$>N%(\A2/I9ZY$P*M8Y<QCB9VZ.0!$>`$.[@T5]PI39Q<+NVC5V
M2U<=0C"6;I-RJD>"_?,_@W92$3*7M`DLW4]?R)1.0O("8QBCT:O8XJCX1R72
MHOXTF29E=I%3:BJ8(N0KRHH'+'0IB&,Y$G9Z8&'M[3*'.8W:40$.NK2M4-7<
M)KBW,NK=9:HG:7>#SZ-3T>K3JLFX;;<I:=*?\G9^JE=Y4U'NN=S<+A-O9J:O
M5HZP1-I?R-_90D0Q&22B9J0<?"M&*CT#&$7BIO476`JHIE$3#QSQR\39A7\(
MV]&TQ<G"D82+UDX?2!'!%2$;2,@U*Z2,`JJ%[.3G`.X0#@0'WX#AF--V[V*1
MI5?GF-<4:W)""BHUTO81$`03<-4G9'1B$`W>8%1*)E3!W#V_G"'&G:X_QXKC
M>SRB$XZ0/)6"N1*;M>.6-\&JNF0J7()"!0(/<`]ZG`"''(ZPXLII=S=[I;;'
M93=QP6RA>\^8'PUIK&U.AN758008R+EHVBE'"2R9S_$LW!P,[.4IS`)C()E+
MZG'=P;C@=,MW5GC<QM9BRU!VD(IT&2J%EA7ZPI+.ETR*K@9NEW"4Z:[D`,4`
M,`F-Y#W$`65U>Z!A1W&0E^EBF@GQ0366%V444G#TJBS585CJ)B*W<`)%$QA`
M`-V\"'NW6W2.-LH2<M7L1RSZ!N,,R"SOVJ**:Z#J,*X.DX2722,LH)%2%$4N
M\O:`#W`/(CJ<2TS'^_TK[V5L9$T3.1;9P1)^!2.4Q04[&,_%&*B\9%*`=G<F
M"2#@"B)@4`QA*'84P!;DV)=2'!^8,7U^N9$LT+1KW58Z/KTY%6=ZS8,IA%@V
M(1O+Q"RSE-)85"E`5$R`!R*]X'(`@(ZB`R-L6GEY%6S59ZC:\9W>+3FVD3!@
MX.YB+$<?2?/8]UVE:)O6PI"9TW\*'354*/=X(#*+]LUS30XDLX2LA:8<QCG4
M>5YNX=231(GY0#RS!5)%5L<@`9-0[4%1$YNXXF(!0#=-3O5UZN**MVZO???&
ME:M*2BU$Y;E2DIVA4]XNE-]U=]S.&7.&Y+'M$OD9:;1>%HY$K&"D$)5O'PC5
MT1RX4?G;K+(M16*@8J1#"0QSF+V\!R;5?&GTE\WQ;?;K)JA%1!OJJ"0<J).4
MEW:RCYLJJ@R``33=>JFH)#F$#`!R?,8$P$P[#@';M=,XV@C"-:/$8!LX[9^:
M407]!GZ*(K+)\BB<GJCW`B8@A^1[U`*4JI2AI]5FV?9MSI=HO%E#:2$1ANBL
MF;9];YIHLUJJ,P5!0)!Z"H)"\DGZZ/H-VHD1]%-0Q.3<`8=14<442Z]-MXLG
M*4WE%?\`+":;2<=&J_\`C>UX5)<2=]-TS<^W]LPP?3I%S<5040<VVSKM6<'7
M&:[=(4V1%>3)K2+TP'6<'1(=8"&`JA@,'&M9RAMYWF-,@1]MO6>:FXH;=\NN
M?'S%T5B@HH)U%$TSIJMRA)>F<2BGR83B8@`01Y$-.6Q''5';1C.NX=I+A4$V
M!2G=RKL@"1:2.FDD]<+`D!%#G6,GZR2IDPX[N.?EX#?9-E&695I(S,H#I]'B
M)FJ[@ICD+WE$QG""8]W<8Y>2]Y@*``("(:S-6]YND[_?%6P:BB3Q'L(I8I^[
MY,KL;4&TZ:OD_))2CLG:V.JU9`8?"10]1`>P2@0R92^J`!R`Z;TUAJO2[8-2
ME;)/V/ZQ*J[8SC]PJDBS4('!F";@3)I@F04S&*0WS#W!Y'R.G(KK4=.U*L%H
M!=!-\@NZ4DTY(5'ZZ@%-PJ*:"GIE15$!`J8\"4!\@'C2590I%$C(1PY@Z\LL
MH[4*L@[]99PHW>JE-W*J-Q$R:*9?`J]OS!SX#SP,*:38&+!Q(EBDIA8Z,O'N
M56YU7@'.=4A1$$RN`,8Y?3,4#D`IQ]@XYUJM)R_+P:QJ7;)4%'3!-P";I8$R
MMY&*.(?!(E='%+EPB"8^N`"!O!1X\^4BL%U>OIJEXYK,:^5L#$HKSDTDT[H9
MJD!0,":*X&]9-0Q2G(H0$A`.[YA`!TD^?*:[E2J`[^+4^HC-II-\P650:@Z(
M<#&;G55X*<O<F`';@`%-W``_G#HKUHLN\$;HXJUBJK$[/?$[#S;A>5%F*TE4
MI),)-NT%-4[<04$0$ORI*$X,*A03Y#\T0/[@(_;LN!LU6M*'F`F5E'D@R;JN
M(PR2!4B%,W245](Z?:00,;D"E*(<B("'OXU&K7,K6QZ>'N,$F*$.FF$9-PTT
MDD94Z#`"HJNT"MQ.<O"15S()G,!5!,"O`B4-.<ALAQ]8:K7N08/5(5)T1K*,
M6)#'4=%<%(#==LB/!2E$BO)Q\>0\^VD5C-@M2:E6A-/#34RN`W:.W#V*WR%V
MF+7D"R-;S,6B5;,*RO$($;M(EB]43CC)MO@TUA110`%#K&[B^H(`8P^`TEZJ
M4]B2KVO)1[(M932L\Q5F(\GH-G"R\@N#4A4&9TR@`J"H7UC)E`3II#Q]NNE8
M<HQ-LR!D'-<.@6'_``648U6+JDHT]9:5;/'"R7K(I-"G5*^<KE`4@$W:!2G%
M;@!\;6.76\O0W]OO>.G8-XR5C6;J)3(V1?")5T2,9!LQ4.4S@R"JA1$Q@*<`
M*<`Y$`YZ--42</TK4G271I++54_EMILYK4G,O^2GTNM5EM2ZRJS90X4P8M:S
M3<^6GU;\'WL9!7R)DG-I>JM'(D:`N0%&C1K)"0$FJQR&,54@'34`/)0Y#3C.
ME]0%:]U"T*VJ^5=MFV+[(\9',Z4<*),"A&D;(+F$!`02,F/')A[2^F(]WD==
M&*E'EFKI1>PZS*(6:F=Q:3@B)'I$A0]1#\FF(]AR%/R</</(<^VG,]'W&DI+
M[ELNYLX-)5:H51]28^>4*H4HR3EHU%\U2`$P24%%1L0%%0.)BG*(%_.-SE.F
MI52A=_52;5AM=.VE=-N6[.(I"G>]\+EFSMBUX5:G,!6*!DT7[])1003$0(DN
M)2@*?(=W(AQY`0YU)E@W!>1,9XZSGD*S1T8SKLY@>XOH<[2P1,F^42EHUG),
MP79,G2SEH8S8!%4BZ8>B?\B;@WC48V*VRK2NQ1U5!,U<KO%S'*7D1%=4>T`$
M0Y`!`Y0$??QY'@-.WP(1Q"0>ZE1)15!`=KN3Y),AE%#%%=/X$A7!"B82=P%'
MM$2E``_-#@-9-GG&XB6*XZH>&ERF*<5=[^*SG,4.`$YL[5X1YX``[@`2@?R/
MS<^>>>#6O;=S'/U(L#G.J=8RF]G%BHJ&]CF/GFO]YBA]G!RF*(CY,)>>`T:K
M<MLY:U"TK91\;D\"&X5MMW^D?;Z9Z8D#-:U9MT&<JY/I'<)H-EVIK(NLEZ@J
M'*3N*MV'\@/($XY#@.;PS$\/;8-JYC7K:0A7T<REH95!=-8'+-VV*JD!3$$P
M*%3$>!$HB'(B`^X#KS%.LI./Z[U=^H'+Q3QTPDF6[W-*K1XT.0BJ)QL:I##R
M8H]Q3%,("01[!Y^8IO;5OOH`[^"[J,$FQK<9)%?+.*T(N+**A2D.O`-F2::A
MR%*<QU$3#\_>0"E*KWDX^3Q=24N/**NT.?R]-Z<3E*.R\Z/")BK1%E),QR*G
M:V56(9-$IP%/N,`&,4HF````-P(`0WN/V#SK7_JP0>&43(LFY0Y+VE`3)J"0
M>#!X*(&$H\^>>>!\CQ[."O5:/-Q1U6A4"OFQ050>&\]BR1P.00`"F$?`B!A]
MQ`0`1'WTG48D*S1$YQ#X]`HI/@(4>3.2``',3CG@#B(@(<!R(``\^-9-'7;/
M!]$AC$,F9,I2*J<<B?[P*````8!$0'[0#[1UV3J(.4U4''"B7(`4Y0`WPQA#
MD3<\>1.'RF#SV?<`Z^"E%MZB*A2G345,8R9^`%,..0$`,/(F`P![#[\#_)@/
MK'T%#`F4Y4C&$IR*EY]0_(_,8?<PAXX$>...!^W0&DY:Q9CW,5'E<;Y7KK:V
M5&92*0!4*7U8\R1RJ(.&[@`!1NY062253,4P"`@``/G5=_<+@?(VTB<13E&T
MID;!<JZ<)U^Z1K%RZD\=QG>*#>,M((I+.)!DH19!LA(E)W-`*HJ[$2%[PLBK
MN%D.?!3D7.`J(`8?15`?S1,`"(@)0'@`_1]O.M=EHV,D6Z\?(L&\C$/$EFS^
M%<D!9N\;N2&37252$.T2"0YN`,(^WVZ`JPR4,R>(_6D4_92$2Z;D.D=JX3<B
M<I@[^4G*)C?.0IB\D,)3@(\"4HAQI)K#`O7+"0;MWID%SID*#H$.'`(GY$Z9
MDC@`*F[?SEB^?M]QX&3_`'7;&W^($GV3=J42K+5-1V,C<,`N#?Y2X%TLK\=(
M8YD5"(-()RF<R:KABZ5,U<HI"F!2J&`X1W5ZY5/*\8^<5\KQC,P2Y&\[5YTA
M(^T5Z3;'%-U$ODA(FFI\*HDH@L)1525,F)TU5"B4=!YYW$!AZ^]JC&712E'<
MH[73<_"_%E.9$A#IG[4.TY?\T)C#Z@@!B@;^H,>W7:S+!1(C<Z3I-J)7C!0W
MPX)R+<.#I)J&[0]-<2]Z2Q.2$(8/(^0TO$NU343.8R(J)E3,FH!``@H=X@"A
M3GX_-'CD2@/D0'[PUH3VNH`=-TDFFJ19,R?`@'H%0(F(G4=D``,5(I?(J`;L
MY*)NWP.@&WY4Q3!Y5JZL+.)D:NXP@K5^;2(8'<(_<E*8KM`WRF601,0A'R11
M`BPE`P<#J'[)>!LFU6Q.XUS4I*17*LH*4K"MG,C'S*`J'*D^;'134]-5P4I5
M56ISBJD8_:!```#4YEVO%;@8]%A&HA=)MRV5+!PM=42?+NS&X`0?O4Q*DE%I
M*\E,=90#@F`\`(@`:3%]#9DFXY-F><I$0P522>-HN/9OR.XI\`=X(A**F-VJ
M)`()J@FF4JIRB'(@(:TM4)IU3K''=.*.G7)EI>I-+^41,4CC:8YR18X,V^2<
M]/NIG(S5[3Z;6`3?2LA,(N(LJYRAZB35NX6!#YE`*)3<'$.1[.T3<]KRI@QL
MKR<+76KL\!BQ@=(ZD8P2.Y>6)&*<`5B]F91,`*VC7*::2K=HD4RBP&(HLH!B
M@`YZVXUMF3;)$4JR65_*T6!:`]O?P,J4$IF<$05AXYNB=D)Q!`Q1!P)A`2?P
M^_@2N-:4VFXY;)RMEE&E)CF[%!I%5P#JRUTLC<R292A%Q<8BLX41,!4RE$B"
M)RF[C+JB'<;2:*.,+9TK.6^5(45M(;;FV79:J)VPE6<-S-*&+:O&_P"1033%
M)D1+\B*X'4<O%4B%2`Y6Q"F6'L(0``X%#MX#QR'.B43.!6KMLN9LB)UFRYQ;
MG[W!>0,0A05'UA*!P`QNT@ASY]@$-*?*W7$5,QD,W0L<Y(LN5IQ^C"0K.UJ,
M(&LU]H['O?6.7407/((QC5L`K'.945@.)2BD4QA$&71RMUN^1K7/0#QTZ2%C
M$(4=N-G=)4Y63.S,VL;AF8QWRS%JA)(JHD<O2&*LH4`2`"*&U-ZV7>J4>\]#
M3=4HO[*M?KFT.$=R9H5TR141<.'+F.4421:E*DV554$#'465'\U0O(B)0`3%
M#P`!P(!A'BCB<KMXO0-9-*LT>'/*V%T4I!8)N&)063:-G1P`GKJ"0W/881[>
M2B7SK8MM6,<G9-@;8WSA9Z_0[-5)-T#!U86S)..+7$P`[B?D035(@M'HF*5J
MW=HE144$Y3*)&4.(CI.3+J\R/"R6%\//6--V]5]96.R==$6!6+C,4H14Q)!_
M7553'52A6Y.YN546XG='$"H&4*!S:G;OY^\!*IN[++CA]V$=Q/7RO',CF#(=
MN9$F+XB16+@VSE,SV,K!RE!G'IKF$2MR@4"+N2@!"'/Y#N-W"+@XMS6S>J%;
ME8U=@9(R:I'+HBKL_:/(IJ"J;@Z!QX$#)E'MX`P#P/&D:;8XA:<A%QL(P6?M
MA035<.Y+M55>QC<@IM@)W!ZA6I4^TY2'_*%#W#GG6RMZG6QE(91R"\=*KQ[D
M81-JF`LP;G.(*KK]I#>YQ$J!SB!@()>/?Q6Y;?;@L+HAI4)3>%/%Y?<W=S57
MTT8KH)AI$Q!TQ`O^2`Z%FX*<#(N&Q@X$42J%,(G`.#!R(^/.NX:F#2;!?LCE
M<-I*1NE)38RCILOP#IPD5NDV49%Y$4Q4%)-02%$0*(@`<<:VS&+@1ACQ4U'@
M:5KJJC1R#M(P%>Q3@YQ8KB'(BJF!C&%0?'N7D`XXTX3%NVRUYJ?6FK5A9JBU
M95=S(QTLZ;+B@P<I%!5*-.1$O*B`JB7TA^4_R@3D``NI]W+"=U:JX/<1JI(2
MCRB8Y;LV;XBE78M1(V8N@%V\GW2`E,W6,D!S*FY4`54N1,(E'O#P(ZL;[.Z(
MXVZX$?R4FHLKD+*J+"9G4B,S@^(X>G*E&0+=OVE7,Z;`N*ZQT$Q*)/F4#[=1
M'](?9?GEU;KU9]R;1RTI..;S+!5&;LH-3V.<_*%4DR%+ZW,&0ARK1Z2Y_71#
MN*<>0*.K(U-@DYZZ15F?(BXBJ:)E(%P8!]!_)K)J(*+ID,43&;M2]GIF$0'N
M`>T1Y#@Z<>1%9<C:*G1Y=I`-(=P\%@57AZ^15*)U7SE<@+&7>@(`)3$$`^3W
MX+VB(<"`;6^;OF"";`3M71Q(W<H?"F%)0Z1%``PF(;D.>`'[.W]'L&E)32*+
M8[Y54%W"R@B0Q^XPG`1Y.4_=SP?R()`'/(<>/.NM#U@\@]6E%D#@L4"MVS<1
M-WE:F$1$#E`/D5]Q'SX#CG[`T*8QN#QP"KXJ9D3&1,D!!*(+"F(<`)."]O@I
MN.>/'GCWXU%7CS>GGH?I`&S[:33\T7=E@!+'5\E,BXGB)XQ:/-SWX"7R68JV
M&'1(9)1VU=1L>Z)ZRA#>LBW,`!V?-,=+PMH90DZXK56D[=+1L%)R+2M0Z;=6
M6D3-T#'09LR+KH('745`@`(K$('CU!]]5NNF7LDZBD?UD*1O"W';8\BX[I$E
M:,PS4U;;"XJJ<?5JLKC*T0U-BG:4;.R"PE.Y=)@F8B2JB;EV(*@FD`\59Y<.
M&_U4C<11NJWIQ<??/`SCZ,\<5/I">?E!'D3U;>@<1]^1-D>',(\_IYUZ<^O,
M.^C(J`K]('SFH`]P*4W>2<!Y`0$#Y"@S`("7P("`\\_;SR'CC7IXZA3R:OI:
M_P"_,9;_`.3FWK^[MOJLZ4!$0`/'(\<C[>?'GW^_[M68OI:_[\QEO_DYMZ_N
M[;ZK.E'@Q1X$>!`>`\"/`^P#]@_=H#T=NFA9V67-@FWJVL3-ECP4,A6I!%NN
M1R+)U%G!FH5R*)C^FJH='Y2J=JG:'`E`>=;WN)JRR:!Y$$%>&ZS=P=0I#&#T
M@.7O*!0+^9QSYX``#GG],(OT9C=S!'DLA;([M*_"_AIZUQQL9Z9-)(DFR155
ME&953F\B=8R"R!"%,J<RJP^0+R-H[*6.`LL1*1781N]2(M'JK\*F*BY3!1(#
M>F!1'TC!^4-P404+Q[\Z/S\Z!64WR0G3%,70]0%>52J*"X0.!#&`Z*XE43(4
M`#S\IQ'QSY+]O(\8=&F-UDUR.TUE"K)F)V@53D.2"4.>"\?;P`#X'V$?/EW+
M&O.#@ZB9U),)BOJGCQ`G!47C9N8Q$7*9>.0,``4/(%-Y[>WCD=8F0J+X_P`0
M5#TV:ITRBF/!C`8Q1`Q15#CY2B/\'SQP/`"&@*M^XG;E/XVL5S?T^`D']HJ+
M9[(O()N50_X:8RF7RLF^=P34J9CJR]0>*'56(@"JHD.;DO`@73=\'XRKLWEF
M"R=<;,P<U:PG%@BP=&2;G"7^$2(B@OZABH%,U*V.DHS[BK>NFKW$`0$-6N<E
M8!/DR&CW<6X+6\CT]8\C3[6U,HN@R=G$3/&D@`$,LYA94G+:39$$A5$#B`B4
M0`=0/;F=HTC1UK%9Z[!,*V6*43N5ZV^J&=JO;'-LE!^(R!AYX1/X(Y%R*?%O
M8154ZZYA<)>D4Y0,.DVZ9M.8<?Q\C*;:B,-156NTYB5"3A)V2Z.IE[3GIM^&
MZ\9!2C0]>EFK2.*/Q:"10=Q:@M3$(83`0Z0-T^3@F8>`*(F$-)-<<JOJ);&L
MS(O4IU&35&,;(IND@0;-'`\MS!VG,10`.42`?N`"@(\#[Z8QF%=G.06*8BF-
M%6%@DG<G)DE(D5P8I0+P%&2ZKQ%!-91HLT=B5)\*J0>FH"Q.2@;C2GO*#*S]
MUQ[@QM#3KMJI!-5'=O9_Y8W6=N0,5)^U>MT5%SLTEA$4&RGIG3<]HJ]Z8"72
M+3*WI9;WE_T]B/5JK"3<4O#;],32U76;8J==^3-V[F^OZ#C>I2EL9!:V[5=X
M[9KJP<(9DB"Z!74BU,HB1NB=(QC%4$#F]0J8$,!M3][6=EU$V8DG\T;F,MTI
MM;[-56R9J.I(QII)BDU0)Z@M&QUBR"R0F$Y"IJH'`PCP4O(:R&!-KN7-L>WH
ML%A.8C,1+3DD@_R/D.RUV1NE\LRKD$R_%TN)C`1:-9!8/AT$57R*B+<I%3JH
MF$0$%Z8]+?!DHU_=1S%9LPY'R_.()@`Y&N;9=U(_$*)N@1<PT7&IMXIHJ)C&
M3;>H4[9(01Y[RCH]6%1+A?\`XRWS]*?T%I:<NNK+;IT6Z3:5%$OK%[(9\Q[C
MK)4DYVUM<Q9%J]SD2JML2PU)=3<(TL#M41D)R%E5&9B1#=1),AU6ZZZ#,AP.
M?M$5#<O[>[1G6?D(:R,;/8\1V)]#D4ES2$HQ:I1[CM$5&"E<_P#LCI<Y![3*
M'[A`W(E`>.=205G#T)B:N)0>)*M&X]ATX\II!!FD!'*0=@E=$(NB(&%(YR$_
M/`5#E'CR(^*U.6-W6Y>XW?)$MC*3@ZY5,8VAW74Z/+19G%EL,I'J$%Q)S[SU
MNZ-9.4%A%@DF3O,`)JB<I1'B)3_?-+[-S'&:I5;I>[]J$I&+=FN.<7(NQ?Y&
M=R;5E*F6DHQA'IQR;UT8@F476113**Q7"O*ARE#MX$?/''*GSV0\:NUF-3J$
M=,N&[,IR*)I13L47#D@F*!%1(B")A#@.TRIN""`<_8.F]8(W.XOR168:9M>0
M&-%6<(MX^Q(68!8&@;`()H&BEYL`6;R"SE=0J+06:BA045(4YRASPYM?*.$J
M,\;P#*Y,W4C+S"$0U)%J%F73^7>%`0:*BP[CDX*)5#%`@&12$3G,7SJ%5E%L
M"/26#G\U*J6]\0D>V%`&J<,"BJSLY2G$Y'#@W)46X%`>`+Y$P?+R/'`:>YBO
M@';Z(JJ4+,6$K$`7B$;,U4EQ0+W@`G:G.H9EW#W%`PD`#=HE[@$NI*Q@J_'L
M2F?"61<\D;JHJ.`42.J!>\_I))!V*$3[NTI5!%1,P"!Q[A$-(F[K^%J?8GTN
ME"8[IUEFDQ5?2DH_AHN9D&P&4,F'J'<F7.W(H*@@0R?@QC!R'L`$=!J/?HN7
M3GGN,9U1DE'K`L1"2;G5*KZ9^U!N7M`AS^H(#Z@"(^#"'/.MOJ=5L+VK+/9]
M]%0`',Z?*0Q5"N7C9J<H"D:155`#)K%+^36(!2\F#\F!N!#3_"D/*?#.V+J#
ME()/O#U(]8TCZI!#RH@LB84A$O(#X]P$1\@.D"R]C8D<_:6"$8+.$I-=!"?3
M3<(-T%FJASB15=$Y.#*M.[O*GR(B(B(<"`Z`AGS,E(PLZ$K3K!%5F31<.1Y0
M9FDW4@Q$QOB2J)I`/H&5)R9(ZH`4AB=W:;P&D1.UO.0X:$FX6T.9BF3C20BG
MU:=1B+B4<65N82D=)/&I2J%;$4,!CM5P(!"@`]W`\%?C>*"\D;[/LJ$R*K+$
M[1<E<%3%LY(B*A0$Q52%6.;TA-R9/\F8!X$>.!UPNJ,EB*H-191;&#L;]XYD
MW\V)E%SE<N>PZOPJ!``C?DB8D$3%#P```\>-)\A$\[/R=Q@;_'R]6F(]K$1R
MK%Y,,&0K**)'*BG/0I`!TT60.`HIDE$S+(%%/D1'Y1`3"`Z<+BZTH7!U;*>G
M7P9R$`E'O#L7292MI!N1,5GB;<52%$QFX$43$I0,)#"4OV\ZS+2&GK!7Y.9<
MN&DM)0SP]@CT3N5EG#LB#GXDGY(G`(E-P(@D<P%$1#WXUGY=1K!VF(M+F"E(
MJ0=M6'I!64$WJ2HRZ1!<+R"(B)^$Q$2K'`P^D43B/RCSH(B(A*:J+W[5K_LC
MXW.4<N,<KP\]6'";2(R]&(M6CA)H1V$!:H\Y2L3IAP+<ASG<_#KH'`JB@=R@
MB`EXUL6)<BQ.2/C*Q;JFBRL$(Z/$2,BJ!!C%9*.*(%=(B($,`J&2.HHB<!%,
MYD^>0$HBYO=/@.SWS'<A,T14Z4E$OXZWPU80$7K9Z\BUR.W;ECZ1#^D]5*"@
M+)"<"E6.4I@`.=,OQW+5]>(D+`DU?@X</PD+0NZ`ID`D%TNURW%)`Q?A7S`Z
M1T'152B;O$O(G,/.M2GIJJV3[1/28O;FS,1KHX35L>4G&3:\KY#EZ25.C0S-
MQ9+%:%"QU0^JDA/RN_,#80$B('54%JJHB/80!`0X*82`/(6<=H&WJ/VB[2(:
MED$B]DG&2<_:7)^[UWUCLB!%_2`5ORQCI+*"0J9N3%X*4W@HAJ)?IO;3)3<#
MFQON&ML>JUQ-06#EM3@?HN(_U)DABF<RBAU$/36`5DOR1BB50Q"`8OZ;#C\I
M;2](L4AAKT:Z038]X")I.1;B`"[2#CDR*!@_)F,`&'N$Q>0`=1T275\_ZMSD
MNFLO_P"O_K"KU<OE`[S;UMZLV4J2N,/::'`%@2QC-RC;[*U@G#A1ZV^-[V(+
M&`RR*92"FZ53X!-82IZ<M*84EL%87W-W"V7[%L@U6VO9/K4:U@+Q$O91U)/6
MZ+YNBB@HLGZWJ%;&23[!.J=8R9"D$3\#'VIPS+\.HD14QTTQ$"@`J%[B%\=Q
MA`0+VC\X![_I'38M[MT94#;CDV?<G;MSM*JHQ;%3%,!%PLD(@=(3B'Y0/MX]
MQ#]`#J&BDEMC7*[ZB6WAX0#E*]WEXA>%`_;W!\1G*N*F`>WY>0.8P"!?E`0$
M`\:-:[LT<&=[Y-ISHZAU#N=U."')A/SW`+C,=56'D1$0$3>IZ@B4>!$_C1JN
M[BTTY'+7;3R_!SG6F!`W5LZA)7`&%,V[S,Q>0-V@'-F.`B;QSQ^:'@Q>/(B(
M@'&MMZ,F[Y_L\WJU6P.')D:W;2*UJ=377239G;G%11)=8'/8DH(E%1),P"!@
M[B@`CQSK2NMB(AU9.H8`"(!_XNLT#P`CQR%E.`#Q[<@'CGWU'&$@!T6,G&BN
MQEHD_>9TBX[5S&2`JJ+E(1Y.D=)8`'Y!`IB`8H?./`[A:DTKJ&MWIA2J7B$T
MN?,U+7IA-RHFD*E)S&IT<3BT2>PSCW(%9OL&RF("3;RT'86A'[%ZV<(.$40>
M%*<S,YT#G*15(!\D$>[@0Y`.0UHL\BYJ,X[<H=XQ:ZPBY'M$Q"`*A@!4IQ#P
M)1$!$"<#Q[\ZJ,_1UNI#.V"?E]HN6K0\D9&QKN)BA2TBY1%P@JV8%$&39550
M@^J!F)C*II)<BB<%3>XCJX-9%E5JNX:/C%&00`Z'<?@2E.0.%5#=O</"PASP
M/N'@.0#QS??D;7^^!K$DH@].15LHFJ(E37*J(#VBD<0-VB8O'S#[\^_`ZZ*Z
M3%TMW*`4#"0/F*?D@CSQP!0$0[_'`\ASP/MK@BSI((M4"B+AL=LGV"EP"9%Q
M*`"4#"`<$*8`[0']/`>==8R(,UP(`F5+WF6'N`0[BF'GM3'[3E$?(CSQP``'
M''`'678`@JDJAV*G.<Z:?:?CTPY\D.3V+X]A$O'=X'6.79)',HH<#IF+SZIC
M"("8P<B`IB'D`Y$`'C[`\`/@-9IPJ5,P*>B8G/<)^>WD4Q)R43I\\BIYY$X<
M&Y'W\`&NJW$[M0ZBY#)@4"@8QQ[B'('GN`G/'=QP'`^>/Y-`:'*,A%L95T4R
MB2(@=,4@'XA01-\J29>.#$+R)C"(#R'/(Z8+GO8IB;-"CBW0$>./\NM_46C,
MA5M(S1550Q_6*VL,,D46<TS/R<CDKA`YP%50Q3`8>X)-)U)HLEV$[0.4"&$Q
M!^4`\!P4H>`-Q^=X#D!X'[=::H1`ATA27*FIV`4"<]HF,/D3=P"`=P^1[?</
ML#GW`K%YFQ7?</NW5<R-#R%;751/VY#C(=Y/8WF7'(E3DI06J)W%<;KF[%%D
M':J2;83F`51(GX:*P-*7&PAC:PRD#46RL5)OG%H4?G)4KLQ13.9L-<F$3%.@
M5='@B[,%2G!104_)^!U<3EJ;#6^,E8R<:LW<(^:N&LE%2**;MK)D<%,58JB!
MRG`2*`(@8IPX\\\".H7-Z6W?'V#H=I?J_0(JR0"9AB&E(^K2!'Q:LG))@48H
MIB%1;N5S*^H4`$O`E*!>!$-`1*TC%)Z*HRKU=PM.NV\FU4(2\T!I*S,*14IQ
M*@V=+/2'7:+.`-ZI"**'((=QCJ>0Y>KCC9?<)B'D;9DZ01QO631;I5)U87#6
M,>L$#HB8DHJHH4K5%1(.TW#A3@3`(%XXU*K@"8CWF#Y:PQ44UBXAA$HF5BSH
MIE7BI!O'$.)5T!#O*8@E],0[>0$!$?.H%+SE_*V[MG?9J[6&2:8?J-NLM.@\
M=QCQ5LPN1(.7<QRTA/\`*@@[:K*-@%I''%-NLD(^J4_<``'#R@U2310QU8[;
M'U2_&SVZ,[EV-2ERPI(BJ0LL5TX(W7G))NFE^$";8X$."S4RA%D2?,/:?D>2
MF8]6CGB5JL4BE<KS()D6FY]XN84FZ9B`=Q'0P*CQ&QR#DZGP[=`"]J92<B8=
M;Y;F#9K&(KPU=+%,8R(,5M%MSMX]!JFDB5!14A4P*0@@F0"`01$PE#M`.!X#
M'8V5:R-?;ODGI'2#D@K-RN4EP2250."9VIRF`AE_/L;M%(XAR7D/:S[]"0OR
M:]:^+!Q6-#XKXB,%JU<D?,#QP-"BJ8\B+TXD/'BH(B"A%T_STB\&X#QP'.OB
MQXKJ6#Z''U:G6<(;(UX9.6]<JJGP4FE1E5$QDWDB][1.\*U0344=$9+J>J*K
ME)-,2%`H:^;^K&QM9<3"TQ,0)HQP58[^$(FA(JKF.)"E:&=)+`F)>1`52%`0
M(`<&*.FHSMPQ]5+EC_(4$M:<C,F=<M\%DA^W.[L-FA9J<6;.8Z:ERE(*CQ$6
MH`U7%!,R;8I`(D!"ID+HO[X4M/QUXDU.(MM,PTFU,9XOER-CO&#99Y-U1]"6
M>4>P1XE=+*(/GSH\A;'R)TU2+B_5.=NBW(H0H-&"0)D(012$##QPMS2JQ+Z*
M9MGC-1LS2,@NQ9)D]$K9)-/L*@Z2(4"*F-_G!`2<`<1,(<\:WBI,HJ>I,<>N
M28RD,NW1<C()KF4:*JJ]KLK8$A#UB*H#P!TEB@8IR&*8H"7@,B8QFC9U,*'*
MZ:MV3A=8RW:DF@9`A@.=4JHAZ1"=@<>W(<#X'G4*DE;/E]OUC>)U]&U>:AT5
MEWDH]$RT3`P38@JOWI7!S*G$J1"""35N7N346<`!"@7Y3``@&MS8RT.8Q4Y6
MN.(6R+I_`MV3I8QFS9,3=R2Q7/`(E14,'JF2*8.3&X`!``UV\:Q\'*DE<D2;
MJ(>R5C.`0BB#E-=T$&V*KYCD!.9PT`RI3E<&1`@*<@8W@>-;M&VB'M5?:34O
M4%$8TRIFJ1)1L"$J"R"AT4ERIF_*"B8I/43,8OD!*81`1#0+IPC;[W]N+U.1
MIV1Y2T5&<H2[>8F$C_4MWB4NXR+N-=I=S-RDFEWAPT==@JG$H<H`)>X!#D9N
MMB%*RS'8WFX:\H,(Z_2L\YCGK^'0.5B6$0(B9!VBL*0&1!5(I2F+SP"O<`"/
MCE@6VHH5_(K:=A8HL@#>/<D^K$R^JI*K*@`-Q7+V]O"8G(`BKQR8!X\\!JP!
MA2`E(JJLX)!/TIB5*F]FGWYX-B."D.E'MS&#@@MQ-PH4HB4!*(B'VZ"*Y\C\
M]V+!`1K9.'88TIX=Z3<GJ6&72'Y&':0HN!=+`/>J^>G)Y#N[@(8>1^]R4!7U
M`C48R-.DDHW0203[2B)2)`'Y4"EXX%4Y>1`>.[GSX^W`T2CM6!B1L4B4BCHZ
M:TH]*7E5RX$H`?U3@`&.HJ(<`)N[M]N>`\O,H5'0X2`68`JB!5#*]@"L*P<\
ME`"AY'[`,/DP`(B/'&A31Z]4E53-2KMCD$I"E:-5B'`3J%+P+I3P`B!1^8`'
M[A\^W&Z66/KN,JA.W"Y3456(:/:?6TI8)M\WBXM@D0>T[EV^>*(MT"G,8J22
M2B@"HHH0H`81XTXNP(4_&%1>Y.R=+1%.J=:BE9&9FIMVW9-8Z/:I"HJZ<N'*
MB:39,Q0*0"&`3**&*FB03'`!H6]:GJ[H;HG;NCPTG,5S:*BL\95_'1C$:3.X
M!]'R**T=?;<1J8[V*QTBLU2=5V#?$8R$F^;(O7*8L.`4)2TEYYXT1N%/GGOL
MFQ)NJ7UG,D96OS(FW6^7C$&&,=R4M&MYV!=C"6'-4VW.9-)S$OFO+M&E&;@1
M4KLI2DDE2E(FIZ7<)H%[1U.-]-C=RHGW4YT1C)`':!8PE_ETVR3%RDHB+0Y2
MJ=ZA#IJ&(J/J%$Q1,`?9PU;(.1K/DV5-+S,D<K*+2,SAV(B"#2,8>J<S5@R;
MH\D2`$RE#M(`E()1`G:F`%!+]:F$H5;S&VT\9EY::3A01)O_`)5X85G7C]<V
MW:C^B#.EWW6%!ZZ557<N]M6>G3A==0RJRR[AW1U5EEE3?,JJHH<QU%#?,<YA
M,81$1'7JJZ\J+Z'W^^]-/YL6=/\`OT77JNZR:L>35]+7_?F,M_\`)S;U_=VW
MU6<]O;5F/Z6O^_,9;_Y.;>O[NV^JSF@%=P9F:Y[?\I4W+M`E7$5;*5--I>,<
MHB`E."`\KM%B&'M.@\2Y05#D!`OMYXX]079]NQI6]3;I2<W5%VV),R,+#1]^
MAR+LE'C6=39-RO70MVZRHHI_%`J"@#VF]Q'P'.O*@(H8@\E[1^8IN#%*8!$@
M\AR!@'Q]X>Q@\"`AJ;KHJ=1=?9AN`85.]3+L,)9)71B+$S$"BRB9=\<C=M(&
M*HHFDDV'GTW"@^"CPH(@4IA&XX_7.>>"6VC.\T2_"[YDO';2"O*$TBP168RS
M90T@*:AP,(F,!/4)P/:!@[@4$0\_+SSYTE,I#*,G(\%'X8!,"0]O>(`("(%4
M$>1'GD!3Y'[Q\AI\-D;M;95B+PBK1^C)QC>:KLDBJFN@O&O4DW;<4E4C'*<Q
MT%2)B0H\@/'(:;B=JL<K-PX1%(3D,5XD8.[L<->$@*`#X`!*!^`\<@/MJ%$1
M1B3DX%L<J1#G.81(40$IA$.\3%`0$>.0$>X.T>?/.DQS7@JJYN@QAY],$IR'
M(+NIW".7(C*U>:33/\,]8.B$.4Y">JH5PU<E5;G(HH51(0[0TN\\@O%+*NT1
M!-L(B*B"H"7N%<?'ICX*41+X#CS]G/WXYFLDD=`4RB=$>5U"$X`1`X<"D`^.
M1`3<]WL;D/T<@5\1V*5ZLWYV\L]!EGMT1(_24-2'XLJQ;3G<J&*Y-&.RJ?53
MMZ'Y5<C<A&YEU5%0#MXXD"V\[/V%6E8:QC18;%D#'LU#-:@@NI.3\FJH?U5G
MCF2=&6(T364.8IVJ($`#%.<H%Y\.SRO;XFI6*L69"$=S<U$^JV9PD>D19[,&
M<@9-,KPQ3=A4T1$#"=4Y`*!>.>>0TH]2;W"P(QKV8619R*@?6,^L!B@+!LH)
MC)1#<0$2^HFD<A5#E[B%'NX-H1)*R2Y4%38/5W,4A&PB+6/18=I2KG1(=NT(
M0H?(F"Y#&4<B80^?R0IA$1XUWX%FS;MGJT@H+R34.H)53&3.<W`").3B3YP,
M8.?32_,#D`'[`2><RK3:_)(0SJ5;,W*Y`$&:'!EB)E$Y3*'$G<F*RO8`J&$W
M<`#W"'OK9)JTKJLA5J<Q&114&!7)W3]+XIT[44+X09&2$4TU!*/("K\I3"!O
MO#0IE6\E&N98L78SN(@BC?XL@O%D6J#E4AN")(@J;UES]OLF/@>/;Y1'3*LW
M]/G`<_+W#,=6H:3*TS,2NE8'K6QO&"]C[0`4TS1*2H(.%U%.T`4!(%A*`%!3
MMY`,G(Y"K\#/H)6N;<S%N7-\225G51>*,H\W=Z16R"(%32.F<AP`Z2)A*7\X
M>WD1:YO+S4XDZ]58''63EZ=+S%FB")W20:RS5BS`'*8J(N4TB%<N6[@$SMD_
M1)Z0**D,H/;XT#Y3DB=7VO;G<D[3,TTV/VR.:=+DNR981.8(XCG9H!E*-G(2
MR3R:7#X<"MT!4,NB)3"7D45`,(""[=,7!\I@&FVJYYIE*Y&1$?8'\G+V&7D2
M+MH<X,4&P,(V6DU3I++E5[2K.FJAQ,)Q(10>.32S96S_`$G(6?*=M8G+V]7>
M,Z"WL=YKT8X<$=V")BXT[EV@44Q$Y%Y,Z(%^&,8IC(J!WE*`CJO-ONW'QN=<
MK&HF-7,^RP3B]VVJ4UM^@H`T6Y=,6[@R_P!:S'<X)]822#\&RHI@!T11:D4.
M`'*`ZU,THEGVR^*64INS+<5F<5XO@O$.TW/]0^5K$#:HO`T4U<0-2(U>OGCY
M3XF4DXVR.C$^M8AP"YA:HB<Z9TA=B55QSRF0"`!M12.ZQD++$W4;(ICN7OQ;
M'.O(:SR-AL\M*6&-=M"!*N.\L2^%K#0H(.#@W*"0JG4`R2@E`Q#:T6\6>I-W
M=ZQI<VD[6F%K7AIJJNH\QEY08EN<A"DGB$,J51R@9$4DB*IF33;@`@8.`XDU
MZ9E3RO26=Z(PKQ7\99+C]<PEDD2F<-BPCUDW(X45=&$O+UVU(F0A""(%`1*/
MN`Z1"G?.&FE*O$Z7=73BQF?4XF.&:.DTI2EX=4YL;I;,@9>VQX32=XNG6%?&
M9=Q+.L14N=212@S+KIH@)T71C+N"RIB?!MB*G[DCJ`8?`#I:Z7U#8JR1Z$#E
MVC7.BV:.;Q:4BRGH4SB&F)(&Z17CYC*QQ%&9&RZ_JF3*H=,WDI0*'/G+[SL<
M.XIC4)B0BUQ82]OBDW+,K-=1%JW:*'=1Y2HI$*5+ETF4$S";P!A$1XTE$=7<
ML6#),Y>'[N#=8W?P\5'.<9R,<49%LO%K&*XF6#I?DI`70,B/I`<1`R/>`@8>
M!DTB.N<&X<J'2BC&?*>^'A5ZZX9SBVD;CB.R5U6SQB2\>O&.5FS2?AY%FGP[
M;F8KG35<$X,4$RBF/>4?M]]-'L$I/3!+`QM,9-J..'C)SZ;4H%*BB`B5?DX>
MB@53DI0.F("4`#@1YTGVYC`-2Q.RKVYG'C22C"59X$O8U*N(HO+'&22A6LJT
M>)(%`KL\6DL+L#K&+Z(HB<I_(@+=<];PZK54S.*E+V#(M2?PD1)J,S3C!N#1
M22,)3HNW"G"RRI3@3M:E`QC]QQ`>TAC`BT>\*N:B8HXG''C'G,5_#ITV4V>N
M,E$3QCQ!4)!V</K%<Z0`H"C)59`!]'T2<E,3P8!]A-V^'-5*M+N:E86SY1J]
MEJM+$2:+$;*F-^#[Y83,"=XAZA111$R2AN!],0`.0\:2C:#=\`;AZW)N<4,E
M\;Y#B00)-04RZ2*Z<./0!9P]9@A^35;K@"OSG'DQ1$O`#W!I4J-D12JYU:TZ
M713.6Q-Y",>-SKHE:S`H`KZ*Y"`(JIF1'DZ2G;QW<>1X`-0J<U0HVWVLNHVZ
M?@_.(L"0J17SF&$?5'TCOB&45!4ZPB"P'/\`ZIC<!QQP`!KMATYMJ=IMLK9)
MB-G:ZZ5FEG\S"0LJ\;PLZ^56!V1ZLP1$4#"HJ`F5X`._V.';XTYBE5%L[=A(
MMJFX=J,%E4`6=NB)K$'DW!N1],#(`!A$#<\G`?80X#3E*94'TN_7E!B2BW*H
M"7KN./1$03^8B0E$!*8.>WR(%X_.'[A&D[I.+2I.C0(1&)@8['U.8IP./H@@
M)?"II>@9Z9$@`F/)0`Q^\O(*"/@W(^/MTM#1`J:X`D4J:#$B(I)E``!,0(`<
M@'''<(!\PB'(B/D1Y\9!M$JI.2$;)(MT62*BJH@!2HI"0```+[]QS#P4H>>X
M?`>>=9YA771XTIBE`74@MZZA3@(<)#W>EV!P(E$0$1,`"`>2\@`AQH4Q/HJ2
M#P[TY^1Y3212(41\CX$>T.0$0+SW<C[<<^W.H)NNOF`]+PPRQHU>)DDKDY3]
M9L"Y"K"S(IP942]Y3@F5,!*!0^TP?R#/%/R\!1"/I*9=)LXV"C32TN[67201
M:)%(`"8QUQ*0#\#PF41$>3=P<`'.J%/4LW:/MTVXVS3;)VLO3*H]?5VJ(KG(
MH4S9BZ40<.@*0QDS%<*I`)##W`8A"'((`;S5>=J_GO!'+4+-.F9YJG-H0[8Z
M(CO3VA\B(_\`UH-OX>?N#+50X#^0/LT:-CO^FGM#_G0;?_[VJAHU#'^3'7Z'
M2];']]EZAO\`.YS3_P"ICZC`;+BB5P4#@0%D#$\IB?N'P(%`0,'8)O(`<0,`
M#QR`?G!)_P!;']]EZAO\[G-/_J8^HMM:;AIK9?\`Y6QM5TJ=D+3MYS)8<`9E
MH&6ZP?LEZ7.H2:(=@G]1`X"W>I`!1*83*-5%"D`3=O?QSX$>?44VC[A:MN7V
M_8MS-7I5O)MKS4X=S92)*D,:.GCL43N&;Q'N,9D<3F%,Q!_U@^T=>4S&("Y2
M=IH`(O"I"HF'<7@Z)>!5)V&-VG`>`$P"41``\<`)M61_H_&_U/$&6?\`PLY+
MFU4<;9-?(*P:JX`<(BPHH*_Y.5T;@6[919-OZ28=A2`*I`%3D!T>G^*=*R_I
MKFHEXAS))J^F9O:D4F<NL<"\=-MU:[R=+E2,<F%1<I2]WP@@8#$,42CSV_,`
M<!SR`<#Y\#D&TDW<1Q71U$5TTQ%1)0``3$*;M\=GN4P\C\OV>X>>=9.'=(3:
M+B'="4ZJ:8=I^2E(NVX!1%=,P\^H54@`8I@,///N/L"?1<2,3)RD>LL<B;I<
M5FA03Y050.H)A3`1`>PY``3=P<<@'OK)HS;YK\>*;AN_^',NGVH@<O:`]HCW
M=Q_LY]@$0_\`/74CW*+7ANY!;U3@H4O:41344`H@(`/D"\<=P&$>.!X#[-=Y
MXB\[DTP](&RG!DQ(!0X*4>``QN."%$/<?]8>?L'Q^.&P()E!1JNH81(?U2'`
M2)B(\]R9@+P`#_K%Y^8/<=`8H4T0,`\G`XE$03,`F\F$0'N((?G>/<!X\`//
M'G6)&O$>)N/5!(A@,!TB"L!3@(<F*IW<"!3`/'(`/`=P!K/*2BP*IH.$2*I>
M4P?)I@0#I@'/H@(!R)DP\"?P////`:R!FD<[.0"B=$G:)>P%!`RIN/\`.]QN
M0\^.2CX$?(!H#2(UF01[%^?60.<G>4X\]Q/M`W^MS]_`\_9I/,NXM9Y,JS^!
M>@51N[*0Y4SGX$K]JH5=DY#DHB42+D+WF`H_)P`^-+0O&N&8B"12'3#V,(!R
M7OY'R8/('\#R/G[.!XUVDBD7216*5,5DS"CVAP;CM'L'UA4\AWAR7P')N..>
M=`,OK%!J$ACBTQ449VVG'C%[#6IDB0R!&$BV;"BJX4Y)^:N0AUTU@`04'P41
M]M5@\$5Q"+CMSU.65<((U'.-WCHN".OWKIQSB7=ND%_5$!,HE)B(NTRG[!:]
MPIAV@`<6W[:T6I%C5N#)@L[AI!,S:WQS0G>Z6CA$PBL@F4H@+AF0YE&X@4QC
MI\D#R&J_.['``;5\\RF:F#=>1P!N1?-).PSC90[Q*KV1TH="/5?IFY&,:/RN
M2H29#'3^%<(@H)`[C:$BJ?/W_P!+885+DE9U,E;.BV8)KF4!-5=3XH#(I#V@
MBIR8!1-QX$#CP8.?Y`[,744:P4KH?C%W7H()H)";EJD7D2]R92APD@81$Q?\
M0TIEGJJ,5?6H,Y!N>/GX\7,?VF*X:O&ZH`JD)EB")4S$3,4P&,8#&+R/Z-<%
MV@2HI$;QML9U^)*V,]F5W9P=/'!&9!%V6/.<XJI(>H'!.THE`.>T``0T*)LZ
M4<MF@QTG'LGK=\JLJF=RS,X32.<1Y*!A#M$0$1#G@0]_/W:\TK,-7UBV=HS0
MBW*@),'Z[%H5)FZC%'!CG(=J0`%;TE@`HJG$0[A'GP(:4#'<O&WRJ@>(D%7;
M(ZRR;&3505;"#1NJ*:ADBK$*J;U1+WH+<?.F8!`1`>=9>3A7D&_;M)-XR<1<
MBX2C8<5B_$%<'7)ZJ[==+Y@*7U`$P"/:!#``^`]@$')6XRLOQ/4+*_H<E;)%
M0!8M&1'T&_E#@=9&1&/43`D:H=(%"JG1."3@RG>H('X+I.<NQV:QA&S&3;4:
MPT]29;.[F]@5QB+6-?0.7UTTV`N%$E3+"85'J@<?D@,0J(]P"#EYQ*'KK-^]
ML4NDE#1JI6[AVLL@"D>#Y4B2;9!PIR)&X*G3*`\]I`X'D!UDI").=FT9HI1(
M%,1)1VZ4%-TZ.P.7TTRK-R@8[I1=,""!"B*8EX.("(!H2*1;E00S'^*Z6TE8
M*\U&&1C';:!/&1AA76<1*D>Z'USG(0O"22A3"'@!*)A`??SI7SQ\HT5:O)@&
M+L#'$SDY.!.9/YB)(L6@"8!4,`E^4`$WN`AR`Z35>F(XTE$)AC.6A"'D/B`6
MI[1R>02>NG'*B?U/&&]16.Y.;_,D*4I.[@P!VZE9V;[,Y>\R,;F'+$?(1=70
M317K]4?/5%55""BFJ@Z=,RAV?&BH?DX*$$4P[B^2Z!*,)<A0=D^`%86-=Y!E
M(UTF\G!:K0K5V)R+D:J\&]-9J)>6Z8!P;GY1,(=WGG4UE$K")V[9F9,PJ+D*
M)A;E!,Z9N"E,*9@+R8.2B`F`![@\\AR.D_K=50:/(YDR;$1;$5(W*4H]PIMD
MTB@F7QX\<`'D``GL'W`[*C1Q6\JR8D[EGZZ`=@D(8R39,>!#DX@("8H>!`#>
MX^?MX%%3Q]57,:+-,A3'^(,4B9NP5%"?*/:=8P!R(```/`_;R'MI=LK9QPOL
MWP]8,V9[M+*"K\!%B[19-3`[LE@<(&2(6,KT"D(OI>4=+.$4D&K)%93E4!XX
M`1TC&?-U.$-A.%'V8,W.WLF9N=HRJ5%JJ1).[Y`L,@JFU9058A$A5>NGIUE2
MJN%2H^@T9HN7C@Z2")SEH0]6CJMY/S=FA&Z9'-$$R!40GTL'XVAO@'5.P)7I
MI%-MV6=9BY58W?)CAF)TWM@+R2+-PW8)I&**IZE+CYHES>"-QYY7RTL7_K#]
M:._;IGCR"LBQ:CAI-)I*XTV_MDVYI*=0;/RN6MBS2*:IU59)N9)NZ85!4B24
M>JV35?=Z@F3)5&O>1)K(M@D[-9Y5T^D7*K@R`>B5,#$65,<"*&*H(`B4HE("
M(@)2I@5%,"IE`-:]:;5-VN;D)Z<D5).4DUU7;UXJ/>*KAQR*QDP.7E(G!O3*
MF4>TI0'@>1$=:QK7J6FREY;^H=IEK?.Q(;J\0TMK7E7Q.S:W;_>1X[>1[>>>
M.1XY`!`!X]N0`1#GWX$=?FC1K!HM-_0^_P!]Z:?S8LZ?]^BZ]5W7E1?0^_WW
MII_-BSI_WZ+KU7=`>35]+7_?F,M_\G-O7]W;?59S5F/Z6O\`OS&6_P#DYMZ_
MN[;ZK.:`-?13G(!@*80`P"4P!]H"`@/]8")1$//:(ASP(@/SHT!?#^CU;\)?
M/F%9/;9D23;O\BX=4*ZI#@#)B^DZ.E%`N)#E$X_&#'>FFW,1,#'13(!C=IC<
M:G`MU?>'>/G+42>G(%!VBWX^5-V0!(X$A@#Y4U^.03$>2G$1`1\CKSH>D_N7
M?[7=].$LG`X*A%'E7%0L0^GW`O"V5HLQ5(J4IB%'\K\.'JG`W80OS`/OKTDY
M*31531=,B%<(.4&DTT`I>XOU=(I%>ICW#SW"":I0^7D.!\<>=5Q-+>;4[$7Q
M3V3SS&RR*1)6+7(LW.KZ'!1(H`%/W)%,`#V@'Y4I1Y*4W(>WD.=:BVACOTSB
MDL+<IDP3*J!>P12#P8P>!`O:(=IA#W#GC2POHPL-**H<"=&24-(-#D'Y"%5*
M(J$-X]BG,/)1]_/C6K/$",$3MS=Q$E2F42[1`/5$Y^XY`+SX()@'D/'/V<\\
M!"B(S5491L;*NVO>HN<Q$#2(F!15(QBB*AB*"')!#GY3%YX'S^;XUE45SM:M
M&Q,>^!NNZC#(JR3TQ>]1=4QN_P#**&(8_P"3#W`!Y'QS[:W"?:).:VZ0*F<3
M"GZAA`0*F0I0Y`!#[>?(``<<#]WN*.2\1^%*5=D%2*'90@`@U!(YDB&<@!@$
M714Q`RW8!Q,4#@`"/`#R'C0"#25%/&6P'1W3Z=/^34.W;(D61X,4_<JDL;GP
M*@\"'=[>/;C6GY?N]EB%X>LU8LDFN]]11PV5C#BH8.T?R1G/A-(@`4.#<"`_
M9R/G2YV>XDCWGPD.S$ZD:0HO2`D5$Z9"C\XF,?@5$O/($`0YY]^?.D"3L#I_
MDE23>2Z[Y%=$&OPY"`FLQ0(43^J0RPC\I>[LY('(%`>/L$`%%PCBAHT6<WZ]
MBD\N3IF8L1$.7!'IT$C@!"#Z9B]J0B/J"8XC\OV>_&D>WDQ+6MU>.MKF/8V>
MRMY>+481*W8I&1J":X'Y7$`$HBGW#\I?(FX`?`>'F&&4^HC3S%*!8,H]$2O)
M22(7XY0Y2"()L2=Q3&1*4Y3B4"B!C=WN(!IDNZR0=O*#%*Q;P';=1PT,VD2$
M%)HH[56#U2F.?@Q?33$XB0_(!X#GGW`B*RUFYI2\QSFX-G"&)EQWC^S?5<HD
MW4:H%0(FK'E0,D8P.)!ZD=3ALU0$H)(=APY+ICQ:Q%(5^2N%8MLE,9%M(KVO
M(%EB$S/;8B@\;>M(QC*4.4[*#42-WD79"!W8H_DQ*4YP'6V"QL>?]R:-WB&R
MSS'54DYNIRY'CPK!202@SKF%5@B;C@5GA?RJY!346!/P)B#Y4F!=L,=-G\14
M65>5KDE:)<QSJQ;Y0L;,OT1(8)YVJ(&DRO%C$035()DO6,4HFX#Q73G2?I=,
MI]J)O"_DV_\`IQ=3$5XSAU4)-.HT*L2.):1"C,9C;NK<WR'5Y"7K)8\[A:W0
M4*<BK&,93LT*8$%P=V8'!FPID.`^H4.\I!$;173%4:WG9[1H6:30C7[1JR2.
M452>LTBBQ[`63YP0GD'9DRF$`/V"!T^X2\&``JQ;D:[89-(1L#YI'15$CD'[
MI^:)+$IS,C(/.Q"JUM%N0XN@9D_+@[<%%LU`R2ACF'VGKV"7F&?X@<3.*JQ>
M*]6I="#KTJ>=D`F1=R2$:W^L)EN=(I%4$%RJ`1-%$`]$?G["]PZUJJDUE[RM
M,85**&NVZ<30H;4646J[5;LY<M5R2]9)95^,ASK3DJUF(&,;*KQ,M)*).59!
MVV1.#5=P0PAZ((J)<\&X`2\A[!SJ)I/<[AC-=T85^(<?#34)!3,K(OV:9H^.
M=)1+I=DN1$PE`JK47":P%5[O24$``AQ[1TXC<!9JE/UB/P?'K2;=&?28M+,W
M#XQ&=1CG)5BHEAIT2^FB:4.447(%$5D4E3"8`$.=,$KFU'*KS,3*LQ]2K4!C
MV,A6=379P*)5)1O4F7K&C&,G,%,!5WA1.9=^?M$5C+"8PB;N$<'07_.MZKD%
ML?R%;7ZJS:`7=/HJ%4,=/@Y9%`&I$DTU0X5`RBQ1,F'(J`(%Y\ZB#PKAQKE>
M_P!4Q<%<@9['4CC>$<RUHAH@J"L5-*I.`-Z[8IC@B];F[#`KV\)G,`^YN-/U
MZM2:>-L'8(VE5QMZ\W>YY"72!`AUTFL<U6;IE<*"F!3@8I@(=502B`)I',8`
MXY!=MDF`7.$$VTJ]%&0-+HEAI>415%5<KHC1N*#Q`AO)$2G/^8'("7W'QSK5
MM,Y;:OM%:6:>]YHJ&&EJU?\`K'[$.5#[TY&EX:Z=&'L(SSJ?K<Y<Y6W%069I
M.G$H9:/.0Y5>"J@BD0R('$W!P.("!0$H#XUO&/\`8_,VG*D-FNT65Y#3M$<2
ML?&M2NOCVBZ;[P8!2`I3BD9,I`((F*!![O<>=2`)XI""L<C/2\PK&D<L7#UH
M^:.E`C'B8)&^59#YDR."]Y1/Z@@(FYXXX'G?L.0[DM8733?#)2UJE7`QA%C`
MJK\-ZO9ZA0`!$A2$#N(/D`*'@=26W+;G?)I)*B1D,45.9DY9Y"*"HDBB4AG#
MHZO)5B=HB`HA]@'#SV<B)?'(#XT\1W1D$*P8G>^*Q2,0I6S5<K=5=UX`@@IV
M@(%$0'O`.`XY\<\CK>:OCZ/JD*S9(-R'FU44E7:ZG!Q'Y"F64!3M[DTTP`PF
M+R`G'@O`^^E%CJ^K8';1HFDJ+0I139LT2B+IVL)?RCD0X$/3,/\`FP'@2@(`
M`ASJ%$?AJHU=M46Z@*IQ[0&Z[M7DQU57(`!DFWJ@7\L4I@Y5X+[@(B(<\#MT
MBQ_!Z.<V65.VCH]!!RL1:0<)M6[5N@F)U'3LZPD*DV2(3O,8YB\EY*'`^SC;
M?#8PVT8TG,VY^M<-2J97&9UO5E'2:+5N;TCJ@FDT4,"LA*.O3]-!ND4QQ5'T
MR`(B`#0VZMO6JO>[>4F\58;35Q[M]4,5-(J1@:7J[I-E7;474VY:*E".KTB@
MHIV0ZB2;\Z`_Y3Z/(%&I-\%N[(C:4++LE=_TLMT.?JY]3^)R/)6_;S@*<3DJ
M6]0%ED&["B<R\[*(.5R.8:%6(<I4HM'@$OB"@H4Y2@)#B(\A7+.<RAA.<1,8
M?M'[@\``![``!X``\!K[76,NH90P%*)OL('!0`/8`#D1\?I$1UQ:/;SM+78)
M9=_*+@.DV._Z:>T/^=!M_P#[VJAHT;'?]-/:'_.@V_\`][50T:AC_)CK]#I>
MMC^^R]0W^=SFG_U,?46VI2>MC^^R]0W^=SFG_P!3'U%MJN_33\(WILN2^#N,
MG"[58'+=<$%$>%"F[NTQA(("!">!$3&'QP'V<B.MVCEIFO2$=>*Z_!G(QCUA
M((+-S"55!Z18BZ+A$3]I52E63*)^T!`A@$50[1$13W648.EA#X`5#F;N!!,J
M0J'*D4ZIR`8XE`P%\E`>?'/<!1`0$.=;T-0]+FMFKK5;I-G[TMG4G1J%_P!T
MI.=.U6K8K3Y]#/I#]0^(WD8AA:U/3R;?-&-(2"@W23]VT25LI6+!-!PBW2*H
M514O<BNJU.)?RH"!0\@.ILO4+96I)"..0CJ/3[%FJ_(*&.`=JB"9>!$%0\@8
M#>>`]^WR/E$X)SWD/;1DR'R#C.8/%SL.Y;J!\4BFHT=%:K'$R)Q,8!,0$S*@
MW4*/)55"\")``NKY_3@ZKV*]S%*JD?.RL97<M"LHC.E?/6C&,D'";<HF^*24
M%$&KT3`IW/![D5#`7L.81$`SJTPWMPK%L]:;E3LFZQ3BM]Y\WB:=@0KU!5N9
M<4ERCV*MU!#DHB'SD!(PA^:`<<EY#@/.N2.65:JEBGW+4J@CZ9E![D3I>0)P
M8P_()@#QY$1Y\??H:NH&[()2#%RDF_;I`4'K)RBLW4-SW',1=NH9%=(_N4Q^
M1.40^_7R8KQT\&)>';.ES-P4:E,F!>\4Q,/J*"`B`&*4H"8H>/L#CGQDT=M>
M-*U3!9LD94J1S'!HH(=G(\@<"'`!$PF`0,(AXX'R&M2<G[!4*HW`J_'J)(J@
M*8I"(@(`F;P!P`!#@?8>/Z`SBL9,,0*HY?\`/8J4JOHF,8$$E/E3%$!-P(`'
M@Y3>./T<B'2=LWTJ<0&9:NR)`HH54C-,AB"ESZ:8`0PF-R'/)0]Q`>0$?(@=
MZ%;3$FW])9XDQ8G3Y+WI"=UV@(]ID^2\\AP(`//(_:/'&NW^"3DB:JT?.D,8
MH`4S5TS,B+I0#`(&(8H>12$1,)^1$>?Y=8MI(/&@-SJNB*)&34(H4R0H*IF3
MX`IRF-SW%4_@CXX\>P^,S^%#-,S<#N0]9`AS-N3`8XD,4?6(F'YHJ<\B`&Y`
MH<<:`',-9F:2RP-(R6(!"BJB"Y"J'4[!\D$W'`%`1`Y#CP80XX^S31LCXYA<
MA56UTQ_4V$M5;4UD6]PH=C1,,))F5$Y5'*;?M%))T!A.8CAL4OJ&$IC#X#3N
MI"V^BT7],A%')&X$(0"E*"P*\G3`P``)J&*7\\QAY*/MY#QH%?A7TGZ\I(N%
M5'2[A15!,C@%#-T3")0203$P`9(@\`?QP(!XT!6.R+M[F-K[MY"-,:6*\XS5
M7?/8$K4R@V6H,#'44"#*_<$.TD(U`#%:Q?Y1)=%HDFDH<P>-,SHT5BW(D[9[
M)49%5I<7*OU&ZC,G^ND]@VJ!SB:*B(]44T!;GY,45$$SIKG**GS@'.KJCEBJ
MJ"Y99D@^25,"')4"J(F*D/S%59@42&,(#Y.(>!Y'GSIM&6=H6W7*I5!LV*JX
M[7/RY;R3..)$RJ#OO,<ZS:39$2<MU04,(]Q3E,')B_FCY#Z*LSJ9M"MP:THE
M20B:Z@V,UC[167+9\_>/FR?IK+OF[0HH,(LBA3$;MU"_$&()>XH".L=`!DJ-
M6EVUI@TG,'%/S*Q=B<%,22!-03]JPMS$`I#D[@3]0GGC[N=6!_\`V5VT,[X)
MB,@\H5V8(=4SP*WD.R1C=PHH(B95=JV<$;N#\B/<NH4YQ#@1$?M^%NE]MB,Y
M2=/$<LS)T3&[VDIE2U*L5BB("*;AF+L45BB/^H<@E#C@/;R!`B_K&/+_`!!*
M#;XA9]&VQV#=]V=B*+E,5`<&4=+I=RA"I&2`R/YH^J4H\\^SA8?:C=+`VBZO
M@6\S<I$QS=G'IO[W3DE5X=FF!2E:-;&DV2=R;=NF7M;N'1UU^\@`H<Q0U.#3
M]H^`JF^CVT#C]%LI'(G*W,^?*NNT_(AW.%5R<KAV@(%]41Y#^D0=%&Q3..;)
M1J'P[-FV)Z*:$<@FU213*'R%$0X*<_``7OXY#C^70$4FW/IS4G&%I3R3D1ZX
MR7D1%(KCXZ7,<[**4%,`628MU@!-(HFY,"1$_'''L&I.&,8FBS2<HI%%!,H%
M0;'X3^4"]@>F7CA,J8<`'CSX#].LT<(\JIFC0HG)Z@&7<**F4X.'D"I&\BJI
MX^8`^4HCQSK86$.HLZ(<Z1Q8*$_*(*&$JZI^0[#%,/E`@`'DH!P(_>.@,C2J
M\1L8SU4P&7(0AD`(8>[@P<F`"B'GWX$>?O`??7:W);G\5[,,)63-&27B"!HB
M/*>&B2*HA(/G1R&,FW:-C"#AZ[44(($203,)A'M[1UA,MY0QYMTH;[)N4K-#
MU&KP[(7QG<@[;MG"@)@?L0CV[A4JSPZPE](B*)#JK'`!(`B(!JCSU&>HE9]P
ME_6RO?0(T@X-5=';=BYTT03>,(Q5=P@2[WYN!#$)(KHK+&814@@"C5!9!<P`
MX[1*1&X\Y?MLB>[[.H?DG.&097.5_G7[+(,U%R".$H%%R*#C$6/)YV<2)M&?
M*B3"[3B!O3F90A`<-8Q069!#U#EU!3-R$E+R+J6E%#K.I)PN\46-[*J+'$ZJ
MA0`1`!.<>X_`\B8>1Y$>=9VZVZ>NT])66=='?/9!VHX<+&*`D(HLJ=7T!`H`
MD(<\#P`<?8(B(CSJ!SJ'`O?SVAW>F''!``3")@('L!0,(^`\`/CQK3:B/?>W
MM=QO>I-*KZFY<1TZ4ET;:582LD<>C1HUDT&C1HT!:;^A]_OO33^;%G3_`+]%
MUZKNO*B^A]_OO33^;%G3_OT77JNZ`\FKZ6O^_,9;_P"3FWK^[MOJLYJS']+7
M_?F,M_\`)S;U_=VWU6<T`:-&C0',BX6;F[D5#)GY(8#D$2G*9,P'(8I@\E,4
MP`8!#R`AR`@/G7HB=';?5%;P-L==BYB544RYB2,9U2\1[M9NH]EX:/1^$CI=
MDDD853M?@D4`7,<G@XB`_8(^=KIT>T;=IEC9MF>`S3B25183T2F=E),'J0.8
MN>A'*B0R$7(M%%")*D<))@"9N!,DH`'('DW-\6U\[$\?'VO_`*XKTU;*Q3$@
ML3=QC)][J*>B;@OH'Y469J'#G\T1$4BB//`"0.1TD\NNF\.BU5;@JZ;"1-4X
MG`JB"'D1,4`$.T/80``$1Y#D?.DAVG;X\,;V\+Q]^Q_,M&;QP=)M=J:\=),I
MRN6!L"9GIX]!02+ECU%S&4;*)$,B8!`"F$OG2W72+<,'`R21`78@DW%=XW()
M5TD@(``"R)0`ZG*8`)U0Y(8WS`'<.H4XQ",.R39N7!"'5;F`@$4*"KA+M$H=
MQ3#R)@'WY#[!]_?3>D!>0IY2*3=`D)7QU6ZI"F4*HW4'@H&*/`F,`^!,7V#Y
M@\AI3'YX><;L#@B"9BJE*G)$5]'DI3"/:8A0[RG[O<IQ*'W\AYUJ]DJLJLH5
MQ'IG]1LD#E!P4!,<#I<F$IQ\<@8/*9`Y`YAXYX$0T`WR[2\<FB]?.86;`I""
M@LZ(<L>W64[P[C$6-PJ<G/)@$Q1X`."^0TA=3;0KE_)V",;(/&[/EPX(JL8$
MQ62.82@[>.Q(=0J8@("1/DH\=O`@.E0M]H^-M3"2M3=\E'MUBLY!9>70C8DH
M$[R]ZL:Y*!>_NX$QR?+S]H\<:TO)<339&RP8U5S]8L3D2=KQ$3((/&K\3#R`
M.R-3`D5'V,IZG)0#R`".@%"B)1K8CQWX66<9>8F%1-%03,@)L(V"1#@JJR1`
M*4$@.11,0.`B<..`$`Y#,;D,5U:YT&P1!91&)AS0)2D32,!&D>\$2=RR":/L
MJH4HE+V\&`3>>`\Z9T[N$XRR'8I=@V1CV5710:S#XJ15$VQCD%1NP:DX`5CI
M(F+W@41`IO\`5YX'3HZ2BYRA56+]VP61K7H*O?0=G$CV4?%$?RS@1Y,DAR)3
M$2,''`?8'@0*U6-&Z,/:,_UNGKF*ZAK#^!-68S0BFA&'5B&ZCNTG.`)@BS55
M64.*B@B=4P"3NY$`UV$Y9Y&PM2PQ#H2F04SIIP]HOJ,DS9"R5/ZSQ;TRN1(J
MOV+"`-5RE'M*8HD/R0!!S>]C#S'$E[5S,_8N6N/<O%6Q!E<8TAP)%'='.I79
MMJF5,0:>LY.A&+O4@`Q_7*8R@"0.&'WM>BP.4%8.GH3].-"4R%7D;XYE#/:U
M&-(5-R:(8O(5V'P\FH_(E\.=^@I\2HNN!#_F`;6KXVQFBK%>/%Q2IFBG$<:1
M?-*UQAJ48>P6V`LJEEPN^BGMO''SA5LA`6-\S<K3`)'^'0=-K,991P58#F`S
MDJ2@'*1,"F+W#VZFMZ7V-[!AZ(:5NV2$BY52@7EGCJZT?F?Q45]>-B)H@S4.
M'HI`V(@"/+D?5]),!$H";4!X62NN(&OY<RK'$$';ZQ,X[\!8X*\JW=I*'/$3
M,A'J]BRS23%3UE&HB8@"8AA*82]P3:],^Q7ZL;4[YDEPLZR.=Y9!?QS5<H-9
M+ZED&[(OU&4[PYA*HV;&,*9$^"`J/Y,.=&H7!.MX]2HX=K5PZQ6$9TN7-Z4>
M6GZ6I6[Q5T6&V/%Q?+H6"?S@^OD@TE7YYU%O"*NS)+)MT(Y1$6Y&0IAV(+E-
MR"HI#R8`.41\^%?VI8XRHID"<N]HFD%Z6L[F5640CR3XPSI`A&ZSM0Q?+=(A
M2@D4W($'N'@H#K-XLVIL+5`Q4J=L_K<;92#;&D>;O1>Q:$FJ1Z9D]=`4#.'(
M'!0@F,`B0!X#P/.G?3\`.)\0SXQ[HJKI5)XUB4N167!)5MZ2`^F!A$R@&+WG
M$`Y`>#<ZR="%C(S:M9EWMW?)4[Q)T7"E198JK(&$%2-;D^6>+V!1,P`9)0HH
MK,FY3#^43,F8!`O?QI\&'<=*I/T(V0;.&->FV))-BHH@<ZC9TSY,4Y3E#@"J
M$*3D@"(\!P(<>-1T59D[P3"S<//HN9PN2K'8K99'Z*`F+%6"24%>.<'(!3G3
M1,9%-$_`CW<"`F$0U+1M/R\YR!C6@2QY"'2E&BDI#N(B43(V3=@U(DD<[=TL
M(`142@(@F?@3`8`]@T(OFKS4X,J.99M3K/2X%O&+O)Q%!BU"03.NQ6.N<"G7
M1*4HJM7B:0&4+P!0,/<`CX#3K-KF'8>HU6!GY84UGL2R2;HN5`.1-,Q$2@X^
M18H`"8G$W:<!\``#[@'*/T*GV>8O4K.6=:/E(@LNY%-)FV31^"8>JJ/H]A3"
MFJN0H%(9U_K$#GV$-/LHB2F0IL(&/C%BT^.`K-!DF0"+RD@@7D#&=)@5(L:0
MY"B<I^!6$3%$W'.A3(T%22R#=GT5"Q3E\*JPHM4!;J$9.0;@<WQ*RXEX!LF)
M0,/!@,L```!SYUM&[O>_MBZ75%"3R'VY&SY861G%0QC67#)29D5U2'1^(?*.
M%02@X-DH4#.'#XZ`F1+\@F.)2ZC8ZCO69K^QAQ_X<]J`U&8W2R4427LUEM$<
MG*X]QC5DS@$D\E"(+($6ETV9')8^-(\*L+M-(IBIIG[PH0[G]VF1<\7*TST[
M:9.Q/K+)F>3]ME5E/KVPN"+KJG32$JG$96#&5`\?`)_DVZ7I@H90>1-4G$XW
M_KVVG-R-UA7]L9Y/RB;H^IIU/<^;\<G/+#E&[?6C*&E79*I1H$3H8[H\>"BG
MPJ#"+5$4Y.R-B=J;J>43,F"I#F:^%`-J)A=TJX,8RG:)CF,<YNT.\YS]HG.<
MX\G,<XE`QC&,)A-R(CR(\\`B(B(B(B(^1$1Y$1^\1'WU^:-N(LMNU>=%+(M,
M2[MN6_A+9+"ZW;#1HT:AH=)L=_TT]H?\Z#;_`/WM5#1HV._Z:>T/^=!M_P#[
MVJAHT.?^3'7Z'2];']]EZAO\[G-/_J8^HMM2D];']]EZAO\`.YS3_P"ICZBV
MU7?II^$;TV7)?`:^BF,0Q3E'@Q1`Q1#[!`>0'^O7SHU"G?%T=ZJD1XL!$BF,
M(G`@`)0$//`$*/(CP`!R'`#]P<ZW.B7&>HTRTL-5EUH>78E4!NY1622<'34*
M)EFZR9RG16:J'*'*2A@'GCD!+R.M&(N3D@JI`<$R"0A2=B8>2B'<I^3,90W(
M@;DP^X<>W@.-=85U3*B4I!-VAVE````*4I`]@`.1`H"8>`Y,(CP'/&MK5#E_
MR;HTYEJEVY44A9WP2,12^(33QF>.*03W[+.MUFO`LJQBLCOEIJJ"DT2$L+'I
MF0$I6ATP&28*K)@HN``4_J,NTA``.$S#R.K7FS_JFX"W-1B3V.DUX:Q"=C'I
M%D2HBS44%(5#D0635,9J1<PF(<BGD#"`'`/(:\UHCDY6QD.P3=JI54U.1_)"
M`"4X<`'`@<HB`\CQP(^/.E)QWE*^XMGF\]0;`_@7T6H1=4&CH_PK[T!'M!RP
M46!%<IQ$X'`@=Q0.)RB)BEU(3B'5XK3A:KRW;9844IWE6K'"LYNU9R\H]:E"
M3;S[,R\.H`-EB)D?).#@9142B!Q.W.`F(LB4#`*:A/'`B`>0'GB-&1:A7)&I
M#MA*<"E.01(*:Y/S@Y]Q*IY'G_6Y`??VHQ;4NO%D'&[>-:91)(,TRI&0/*L!
M-98A9%!F10H*P*AADV)U#E`H"B=4@&.''W:L(8$ZS^$LJ-#J6R(9B1:.1D6S
M^H33+ZT6;"D!R"YK;\K1PDN)>#"G\1ZR?S%[!,40U&FKIK^ZE33BM^Y+ZZ00
M;LB)N!45/R8P&4/W$.<#!P`<^3&-SSW<>^N%BW9+'<J.V1FY.Q'M,8H&4%8`
MX`R9P\D*<!#D@!SQY\!IN%<WL[9[PFS1C[X:.4<I)JE8VF%<1"B8G^80,^<*
M?")BGX!10%#)]P>#"`Z6V+R!39CX4(RWUA\T4.!D_AK%#.1<=P=R)R`#HJAP
M`!#N`G/!0$!X'P$*;8[CHQ02D!R15,J0KJ)$,(G-V>`.N80Y2`>>TH%X`>?(
M>?/7;"RAC)K=SMBF!/E5<I`9J4@CSVD[`[A#R'GQS\H"`AKK,#D;RW:H+%5*
M02/Z;ANY;J-P`P\E*J)5%!`#>Y1$PA[C[ZVUTN94#,TT.Y91,I$P5,19`Q@#
MD2E,)!`/'@H=OW>?(:`Z24_"$5`Z4Q'IK"453*G/V!VFY[RE(8O)##SQ]W(!
MSSQQKIN9RO@"YD9,BQ2D.')E!-W&-_G`3'P'`B/("`#YX\:[;:(;O51$T6V(
M=`@I&3%DDJ4RAAY$>\"%'CD!X*`<_9SQSK*DA(\X=I(^/!)LB85D19=@G4-_
MK)\!R7M^T/<?(?<`@)VC/1GH*F(452'.8$%4E/3,03CP`&\!R!>/`_8/MQKH
M`_7>NDTFY&_I<=IO6Y,H("'YY3@(`40^X0'@1]ATJ(0[83I-P:HF`R0``),1
M31$>>X!#E(.#A]PB(>_D1'G7=4@&*O8)F*B9B@!4R%1]/D0_.%14Q2$``'W$
M#"'W#Y'0"-)%;@\,DZ23(90X"8X`943E`3"'`>0#D0#P`?T!P.LLM36LB[,J
M/QK=J?A?TR*B0G!O``F4`'M`WL8/'CVUA\FVR@X[,>3M-PKU=23;@8Z3R8BC
M.#I%$A3%;MDG8N%%2"(%["HF,''D.`'AB.3.K1MXQL=RPHM>N&7I)JS6,\5(
MW&DU%@Z1-Z0?6-RL29(PS<QBB<1CTW2G8`F*@("`B!(Y%5-BR=IF09@*S8#*
M%.)?4*4``P<^J80*GR!>XX>_/(CI@6[_`*D^"]MCEY2(/XW*F8B,#O2TFHI)
M.&465(QTU1ME@562BZ^1(0]8?CG"1U41(*15#&`IJY&]7K@WS(Z[RO1=Z5J<
M<V,X:N\6X-5>I+2)55#^@SE\QNV[<#)@EV_$*5N%*NJ<AB)."$-R%>;)NYR]
MY&=RC<B[BHUR6>?%24-`OGAWDP<JORK6&;>J*2DV]]`1*LJ]7.BLH4IA0('.
MK%IHG_7Z2=J]?/::]8DFWV]26];C[@WF+E/(9/NM2D7IZ77&;00Q5B]F=9PF
M@WCXP%1_"FSQ:9@1//NA5034[S->PAP#4,MBLDW99F2FYUXX>RTHNHO).W1A
M4<N5U3=RAE3F`##YX*0O``FD1,A0X(`CPNW`)F[F8>B)RJ>DN@<WJJMU>043
M<\=@^KP(&.;CYA'@/`B(8Y5)84B.E.1*L<2%.(EY,)`X'D`'NY#M]Q#@0\\\
MCK324I-MJ[5GI^<P\.F3*EN7$.V\TGABF5%>`L[46110,!"IHA\H$+V]P^W<
M8`'@3<<^0`.1,81#D1'7.IZQS-6RX%*4J102'Y0[2*@`^KR7CO$`#\P1Y$P"
M0?G\CTTE!24*H4I#"4>0*H4#D'P(<&*/@0\^PZY/B5/241$J8E4/ZG<*9>\@
MB("()F_^&41`.2E``U)F9;K=;I1"?.RVB34><\_/]'Z[3116,F@H94A0*`G.
M':(G$.3<%X`2@'(!VF^8H@(#Y#76URHJ>DJ57L(IVB(]B@=Q#<@(?,'V\<\_
MRAKY.?O$![2EX#CY2]O/S";D0^_SQSX\``?9J.'6TMTV6/.!599/C1HT:@+3
M?T/O]]Z:?S8LZ?\`?HNO5=UY47T/O]]Z:?S8LZ?]^BZ]5W0'DU?2U_WYC+?_
M`"<V]?W=M]5G-68_I:_[\QEO_DYMZ_N[;ZK.:`-&C1H`T:-&@%NP7N%RCMTN
MS.^XLL*U?G6J)FJPE#U&4@R4[059R+,>U-R@;L(<@")3I*E]5,X&,81MY[&^
MO#C;+$3#4?<2P=5[(1_3;'EF+--.(>MRHE`CD1,Z.8Z1A+P)>`4((@(D$/F&
MD]KF0<+-E2+H++(+)\^FJBH9)4@\"`"10@@8H^>.2B`@'MJS-^4Y5N\)0D[$
MY?[M]+^F>G1`/,99.BS3&/)YL_2='%X863HO!O7*"Q#*MA$1Y$IRB(!X`?'M
MQK*HO+I!)`5^T;R<0GR4SF/`2O4R`'84%D#"'RD#@Q^`$>/)?/@?.XPIOBW'
MX)?M7=*R)/F0:$2*2/D)!TY;`DB0"BEQW]XI@F0"D*<3E*'(F`WN%AC:/U[0
MFP95//<`S4='5*F,BT$K9P9,$"%%85TD?0<B*@^$3B10YC`'`\#I&U?GM^2)
MW_KO[5B2<2]X^I67FSNKV!O'JK2B"R::3MNJEW%$15("B?@R@B/(#V#W%\"`
M^!`8[X7:5D[#ERGVM4EX]K#NT"GCH";54*TD&:"QSII,)(2%,DJB'<9-LJ?N
M$"@'D.0U(+C[='M/S4G%`VMJ<3*R@#\*VED%8=TFJ0@J?D'9C@)2\<""A>"G
M$1`0`-+J-<+(13E+ZTCKC$<F%FF\.WD%2$*/)02D6ZAE2CV"`%-R"G'V:A2N
M7D7<&K#V1/#J!%*Y/.%GUXL[9\4BKV1C(XYFIWK==(QRJ(J+)`FFV4$#*%+R
M4H>^I$=GVX:HY'HDC'0[MUZH)E501>%(5TY3*<H'<(I<]_IIJ%$H$`/!0$/(
M>=+%9MGV*Y"X&R`E3H*!LRC/X)12QMEYB(E&Y^\3ME'O:9['ICW"(@("7NY'
MMY`!UJ-/VRXQP5<Z[D&7J%BJ31E\0+8,?R2%TK)T'?JE4(HDR$CUBDH=43"@
M[0-Z/)>T`'V`<WE7;YC;/N('&-KY&`^KMSKYH>8DD3?#'(H)_B8V2:K%*)VK
MZ/?IH*)+"43<$`H@(#JO?G7I%;J(2LN,5UV%K&6*JNZ`8*W1LV2(N+>,8N2O
M(9D\</T`;*JIBD)5P52%%3U/53*4X@&K,\%<J6^CS)U^:5?0ZZ0)`P<MC,U@
M$/M*R?$2,0Y0$/G[R%`2]WGC@?MI>(ROO4J^$VWE"G`[Q*-?.41F"('*82E;
M&(HJ*Z)!*80/QR7@2^`#5EKO/4C2=^73SM@IVYUV9[A+MCJ!H5;V[Y%<93J,
MDT^M7L\C%1ZC-",*4AW`+MW01,VU=$3!-!=(Q#\#ZID>!\3B=./9QDQA@U)G
MN91=-YOZ^93S.M1+QO%D8(-&;(S9@Y2:E]%WZ*B:A51(IVF`O@.T`U+$QO-9
M2/("#&0,D[*!W)C-'2CCL*(_*"GIG_/[A*':(%,4H\<:QCFW8]9B9V@[G"&*
M4#?`I1LJ<$.?``0A"`4QC`80,/`!P'/'WI<)83;XUC.%P5\V06E)RIM$33'Y
M\BN+2*2J+9DW1,5DR330(V,4J9D?31`H)`<!'N3[>PO("(?=I#YIXC+6IJA)
MHD6CHT/4.F9,3L4CJB=(0/V<B=4A#!X#R(@''D/.45GW,^T[(E!XQ8&,0"/W
MB:C0_8`#R!DU.Q0Q>T0`![^?`\\_9W`N],J$&JQ</V#=4GJ'>OWH)+N5U#$`
M!,W2[5%%2]Q3"4>?`@''WZA1EV=\0)14M+7.H5Q>T5MRR2:3$2H!A5340.L<
M#-FZOI'403,KZ@`!O`>`Y$>--ZQQ1+#+.&T=/1:%,J4E,A(-$6*QVXNEB=JB
M3DI0[U63L?E*X'@$U2E[1`0`.7['O9[.V6:5+UG#!<RHNIR4#T4Q4-X$"LU`
M`3E,':4@%XX`?M^W:Z)BU.RJ-26"33CX1FHX5>KBAZ?KIE3`>4G:IR>BCR;\
MPGCCV]N=`*3BNMOK,HUK%(,9&&%1-O8IQYP87!VZ9"BV9@("<Q3`4Q3'$G(B
M8#"/.D3ZJ/4;J73LP`ZHF&Q24SQ;F;>+@"%*BJX:/':I6BS@B"BZ1RHM`4,X
M<*$*(E(`G+P;SIM>\7K(X/VH1CW!^VN"0R/FMRV,V8'352BZK6UD5/A7;^S6
ME9-5LU!`A%G!$0$R[DZ8ID`#'`VJ9NZ3=9;\O7Z9O=SN;S)64)%9RS>V==`[
M2NU)HHLHJI!4Z.7,N"Q4P4,@K-*>FHY],JA2B42@725F[37VIEV<V=):3B#.
MINVF'J^./G"6I4H%E3)%QL4O:)6VRXS5WOLNXG[]-KJ*J/5I15ZNY&)`X&["
MM4`6(<2$$2B(>GW"`#R@QC"8PF'CD1$1X#CR/OXU]JJJ+JJ++',HJJ<RBBAS
M"8QU#B)CF,(\B)C"/(B/D=<>IJ<NE%A>>8F@TZ?2DIEW;W;Y_%M@T:-&H:#1
MHT:`=)L=_P!-/:'_`#H-O_\`>U4-&C8[_II[0_YT&W_^]JH:-#G_`),=?H=+
MUL?WV7J&_P`[G-/_`*F/J+;4I/6Q_?9>H;_.YS3_`.ICZB\0(!E">PCZB8%(
M)!4[^XP`(=@"'<`!Y$O(=WMR'/.M-2TMUI^$;TV7)?!P\"//`"/'O^C^71K8
MW0@T+(H-BHG352;E7.!"(J))]Q!`B?<8X@=0Y1$X<=_8/V@;Q@E!2`I`1,8>
MXB9E0.4`$%@[P,!#!R(D#GP/("//S!R`::M/I<3+4ST<0M]WM573"<_6<)UV
MO;]/P%"@D=/TR"8QRF!4>>\H%`>2E^P`-SR;[^`U\@<`3%/L((B<#>H(#W@`
M`(=@#SQVCSR/("/(>^OC1K)3MM7BS7O`G:8A^.Y-0O>01#V'MY#@>/'/GQ]@
M\!QET^%5&@$310<"0AA75[54#$,F8!%42>4S`)>2%,7N.<0`1Y$!UKY#=I@-
MP!N/L$"B`^/'(&*8HAS]@@//_77:4>'4,8P$3(8Z'H'[2`4HAW`;O*!0#M/P
M`!R(F\<\<`(`'33JA5;:34+JFX>'3A%ZF6IY[]K[K@^7+M$<)D37!543JB[(
MKPF`"93M$W?V*B!N"B(%\]W`AQP!M<Q99ZP4*LU.X8/Q.@N*[58[8Q")E[D`
M0%`Q3I\E/R<>\>[GR4!#74,^]4$B&331`G:)EDDP%;U`+VF4+P)"AW^.2`'`
M<<@//G6/$1,/)A$1^\1$1\>WD?NT>MQ"U2HBT6K-6W-;J%$Y;@ENDO-,6C;.
MVPXNB;K,XX^$Q8F]3,BV.F"(L+&]=ST<1+Y@%-)B\<`F1,Q3"!TP.`&$"FY#
M@`TM[;J'9=]6-=256QU(/8H`^%>IP\I%N2'X*4RA3QLPD4AS`7GN*0``WD"^
M_+!-&N<_EEYUN6.:Y/ZM%"5:O]4;*,'((2J4ADYHJ"P*K,(O*ME:PX@(!W(M
MV:CI1--)(?"")BG!,G:`B/&G5UWK:9#8@S%:RYB:'[$5UN;@K()(.41[2E2%
MTLF19(Q@$@F$4Q/P'R\AYK_]QN`+R/:`B(%Y'@!'W$`]@$?M'7YR/''/CWX^
MSG[]5<I[^>6$<7YSGEUWAEFMAU][RF[C':]VRN!HM3N^"(VCS-9)<>"@F_.,
MARMQQR3O,!>>X1X#QK/MOI!U];_'.26C(Z[YXN)T&BT3%%:((G$YS"!@D0*`
M%[3`7W$P$YXX\ZJZZ`$0\@(@/GR'CW\#_6'@=)6R[O\`?-AU?M^>2^$69)_K
M_P"4)1$RC*Q946<"BH46C5VV@R*.#@(I'"13>'!ND8@"J`=H\%X`H#P/+8+O
MUK,U6>,4BCS6679%45TU?C\JSR94C+G$PE3%DX2'N((`7N)P0H?F=P"&H.P$
M0Y`!$`'WX$0Y\"'G[_`B'\@C]^OS25%J[R_9?-[T@5F]-O/ZZDE;_J39WFVX
MFCH2D1ZC(W#6=DXV3LEA*L<AN"&EI>46%1RN'('5,D0#"8QC!SV\,OON:\H9
M%D'SFZ7.S2@+/UG01*LN])"M#J&X42:Q`KG:MTB@`%*BF'I@'(>0$>4W:*O@
M:N$6X@*!E4E%4N0Y,H4B@$,4@B`B)"]PB)0Y+P`\\:Q@B(CR(B(C[B/D1_IU
MIPEI:33K5V;G$S,6O3G4B57+FT5>(J\77]UA?7<(&$2"8OGDH@/:(``^/S?M
M#]'VZ_4R@H<"F.4G/</><1[>0`1X$0`1Y,(<`/MR(<CKXT:P:.VF\6*LBJ90
MWY$A4@X`HCZ)>0$G`AVCR41#DW(^P\^`UW4E_B5U!*!C#\ZK5J)"G0(?D1$3
M%'M(!2I@)Q,':`#]OC@V*(4X`*I2@)4C$$PCP(`(B/:`@(^0$2B'_G[Z^RG*
M=4YU#F2[O4-RB0!X,;D0*!>\@`01'@>#>"_8/MK2U.B;<2GCE,OEFE%,P2%P
MHHY6:I[\,7.ZZ/Z2KHA`1#UB)BH1,I52E$>3&%-4`#L$`$!,!0[?G$OGM`==
M198ITTDB%$I$P$?F`HF$QBE[^3AY$O<!A(40^0#<<CKA[C?>/@O:/'CY?;@>
M/L]@\^_VZ^=1ZFV\3==9CO6E)P$HCA^1\!HT:-0H:-&OH2@`<]Q1^82^.>1X
M_P!;R`?*/L'V\@/C0%IGZ'W^^]-/YL6=/^_1=>J[KRHOH??[[TT_FQ9T_P"_
M1=>J[H#R:OI:_P"_,9;_`.3FWK^[MOJLYJS']+7_`'YC+?\`R<V]?W=M]5G-
M`&C1HT`:-&C0!HT:-`&OM,XIG*</<H\AQQR`A["'("'(#Y#P/G7QHT`LU1SO
MD.FE20C9M5VV1*F#=.5^(>BU$J8)F!F<79%&H?G"!DC@81`!$`Y$`>3@;J'9
MFPW(.)&,R)>4TG"B2JL<YL<M/UUNJ8"E*5K&/I)L9L4PE^9$BA@+SSW%\EU&
MAHUI:EE)^SHJ5Z+WWE1JT-J-K1E-6^U@M7X-ZZN0BNBL,B,<7WQLN03^L=M)
M5M\W;B5/@QR23UVV76+R8W>40*H)^"=O:;4E5$ZENV^\L&X6JE7&F*/W`K?%
MU9RSDF3DW:!P772CE5S=AO'`F3^8@AW"`<:H3<C]X^W']`>P?R:V"*M-AA3^
MK%S<NP6*4"HJ,Y)TW]/@0#\PBG8)>WDH!P42^.!#R`RG%>_TO-KBJ6'[;7O.
M6W['HEP>?-MUM(DO!96AF;MP<K9!M9JRY9FY4X,FFL=1,AA.8H]HG_-$QO/`
M".LVT@:):Y1P]3?TAQ(MB@U:R$/-,F4L5$>1.#5R<X+-TE"J#^3#QV&$!'[_
M`#^J]NASG6TTDF.1)Q9-`Q5$4I!0C]),Q>0[!!P4YSE$H%`.3?+R(>P<:6Z%
MZBVY&!,0[.:K:QR&*<3.JI'&44-V`4P'634*K\HAW$/W"(B/DI0YY=>\_4^9
M$O9^WZO>"]6;'4JU75)$S5F;D2#L`T7;F[@J;<.3``D_-5-SY$HAR'N'D0#7
MTA%3A45DEY>[>F`AWN%IAL)SF#DH!VE*(E+XY``$0'[?`:I#)=4K<Z0I@&3@
M?G-W']!H_9"8>/(\-I`"`'/@``/8.1]_'&'4_P!QWIJD-(MB^J;N.9)_/E,(
M^X^?K4O'W``!X#G4\\F("<X:YQ]-HN]O*RX!HF52<N,F4_`K)GE.2ID-SX2,
M(=H&``#DOD1Y\!QYUQ$K,<FW^)?C48IL!#)`[LL@P.X23'D`4_++>IZH\>``
M@`)^\?LU1\)U--R*0&!O-))EXY*561L#@.[GW[5),2@80^WG@./MU@)'J*;A
MI%$6ZLG`B4QC'%RY@R/W9#&#DWIJ.WAP\G$WSC\P!P(<&$=5*<I<Q-;/G2/F
M?8NE7'<UMGP!&N7DW<G^0+6P177;U*I-#/8\W`&*ASZ*8-Q-WA^<*@%#@!]@
MYU"_O>ZL]\N\9^#E5>Q.':8Z0;)G3:'=O[V\3<)+E439M(V2(V8+G,4G*[@1
M!(I1^0PCXKN6_<EE^]+'6G[I*)E%($/AH@B<6W52#NX*N1JHD8W'/MWF#]/@
M.4.<.W#M0%G*ZRZ_GN765.JH8.1,7DYQ$WRB8W'S<<#P`!P/)0H;K6W:_?9S
M##E\.,N>RCY_!3+/D+XXDHPA`D2,)>26?S$K)/5'$_8'8K'5!S)/C")Q(H)Q
M4%N('`IAX$YM)6(B81,81$1'D1$>1$?TCK\T:-M[=/.`26E0IZ^1V0:-&C4*
M&C1HT`:-&C0#I-CO^FGM#_G0;?\`^]JH:-&QW_33VA_SH-O_`/>U4-&AS_R8
MZ_0Z;K8`<W5EZAP%(<>-W&:!Y`HB'FS*>/`>X<<_R"`AX'49+5%98P&33!%1
MJD44Q*B8?64`XB`J#P/!A`P@)N.."E`>!\Z]F;+G03Z1^=LGW[,V6=F-,N>3
M,H6J7NU[M3Z\Y>9NK!:)UP+N7EEV<5D%C%M%7KDQEU&\<R:,RJ&.9)NGW&Y3
MO\6[Z)O\0N@_K!S9^TO6DX<\J)Q:T.ZB%7@;BD+$<;'CL/5UWBOJ*-RI&`I"
MB5)(2%Y(`@)N`_UCB/)Q\\F`!\>VN$[-R1)-8R1P35$0(/`B(B'/N4/)>>!$
M.0#D/(<Z]BW\6[Z)O\0N@_K!S9^TO1^+=]$W^(70?U@YL_:7J-RVW+;SQX^+
MZ+:(P>.9Z:G^S/\`V3?X:/34_P!F?^R;_#7L9_BW?1-_B%T']8.;/VEZ/Q;O
MHF_Q"Z#^L'-G[2]0'CF>FI_LS_V3?X:/34_V9_[)O\->QG^+=]$W^(70?U@Y
ML_:7H_%N^B;_`!"Z#^L'-G[2]`>.9Z:G^S/_`&3?X:/34_V9_P"R;_#7L9_B
MW?1-_B%T']8.;/VEZ/Q;OHF_Q"Z#^L'-G[2]`>.9Z:G^S/\`V3?X:/34_P!F
M?^R;_#7L9_BW?1-_B%T']8.;/VEZ/Q;OHF_Q"Z#^L'-G[2]`>.9Z:G^S/_9-
M_AH]-3_9G_LF_P`->QG^+=]$W^(70?U@YL_:7H_%N^B;_$+H/ZP<V?M+T!XY
MGIJ?[,_]DW^&CTU/]F?^R;_#7L9_BW?1-_B%T']8.;/VEZ/Q;OHF_P`0N@_K
M!S9^TO0'CF>FI_LS_P!DW^&CTU/]F?\`LF_PU[&?XMWT3?XA=!_6#FS]I>C\
M6[Z)O\0N@_K!S9^TO0'CFE*L00,4JA1`>0$"F`0'^K](A_((AK\]-3_9G_LF
M_P`->QG^+=]$W^(70?U@YL_:7H_%N^B;_$+H/ZP<V?M+T!XYGIJ?[,_]DW^&
MCTU/X!_[!O\`#7L9_BW?1-_B%T']8.;/VEZ/Q;OHF_Q"Z#^L'-G[2]`>.F=N
MHD8.2B)3%(<`$H>H*:H<EX+P<"G[.##P(B3D!YUQ'3$3F]-)4"<CV`<!,8"\
M^.X0*4!'CWX``U[&/XMWT3?XA=!_6#FS]I>C\6[Z)O\`$+H/ZP<V?M+T!XYY
M?7(4Y"@H4J@`!P`I@`X`/(`;QY`!\\>W(`/N`:^/34_V9_[)O\->QG^+=]$W
M^(70?U@YL_:7H_%N^B;_`!"Z#^L'-G[2]`>.@0C@PE3(10>X1*4O:80Y4[0$
M`#@?)N"@/'D>`#7P9%8AA*9)0IBB(&*8A@$!#W`0$.0$->QE^+==$W^(70?U
M@YL_:7H_%NNB;_$+H/ZP<V?M+T\_`>.LTCGKY0Z35LHJ<B9UC%`O'":91,<?
MFXYX`!X`.1$?``(^-<*C9=(>#I&`?80#@P@/'/`@41X$/M`>!`?`\#XU[%_X
MMUT31_\`P%T']8.;0_\`+)>OT?HW?1.'_P#`70/U@9L#_P`LE:M(S.\T[1]B
MO3%.]9KV74HR_0_"F+U>FG<4P?\`U8LZ>X"'_P`>B?>'Z0_K#[]>JWJ,_:KT
M=^FULDRJGF[:WM;JV(\HI5N;J)+;#VW)4PZ"NV,S$TS&"QM-SG(DR;XT:R$R
MYF`NDO0X;KI`HJ!Y,-0'DU_2UBF'K,9;X`1_]SFWKV`1_P#N[0_P'59WL/\`
MP3?V1_PU[4VZGHI=,O>QF*7S[N;VQ1&4,LSL-7J_*6Q[?\JP*KJ)JK`8N!:_
M5=6N\)"H_`L>&_KH1R;AP4I#.E5SD*8K<OQ9_HE?Q'JY^M;.O[3-`>/-V'_@
MF_LC_AH[#_P3?V1_PU[#/XL_T2OXCU<_6MG7]IFC\6?Z)7\1ZN?K6SK^TS0'
MCS=A_P"";^R/^&CL/_!-_9'_``U[#/XL_P!$K^(]7/UK9U_:9H_%G^B5_$>K
MGZULZ_M,T!X\W8?^";^R/^&CL/\`P3?V1_PU[#/XL_T2OXCU<_6MG7]IFC\6
M?Z)7\1ZN?K6SK^TS0'CS=A_X)O[(_P"&CL/_``3?V1_PU[#/XL_T2OXCU<_6
MMG7]IFC\6?Z)7\1ZN?K6SK^TS0'CS=A_X)O[(_X:.P_\$W]D?\->PS^+/]$K
M^(]7/UK9U_:9H_%G^B5_$>KGZULZ_M,T!X\W8?\`@F_LC_AH[#_P3?V1_P`-
M>PS^+/\`1*_B/5S]:V=?VF:/Q9_HE?Q'JY^M;.O[3-`>/-V'_@F_LC_AH[#_
M`,$W]D?\->PS^+/]$K^(]7/UK9U_:9H_%G^B5_$>KGZULZ_M,T!X\W8?^";^
MR/\`AH[#_P`$W]D?\->PS^+/]$K^(]7/UK9U_:9H_%G^B5_$>KGZULZ_M,T!
MX\W8?^";^R/^&CL/_!-_9'_#7L,_BS_1*_B/5S]:V=?VF:/Q9_HE?Q'JY^M;
M.O[3-`>/41`YP$>2EX^PX]HCXY\`(>?\=<?8?^";^R/^&O89_%G^B5_$>KGZ
MULZ_M,T?BS_1*_B/5S]:V=?VF:`\>;L/_!-_9'_#7V1$YQ$/!>`YY/R4!_0`
MB'O^C7L+?BS_`$2OXCU<_6MG7]IFC\6?Z)7\1ZN?K6SK^TS0'CSB0X"(=HCP
M(AR`"(#Q]H#QY#[AU^=A_P"";^R/^&O89_%G^B5_$>KGZULZ_M,T?BS_`$2O
MXCU<_6MG7]IF@/'F[#_P3?V1_P`-'8?^";^R/^&O89_%G^B5_$>KGZULZ_M,
MT?BS_1*_B/5S]:V=?VF:`\>;L/\`P3?V1_PT=A_X)O[(_P"&O89_%G^B5_$>
MKGZULZ_M,T?BS_1*_B/5S]:V=?VF:`\HS8ZDI_XS]HBG;P4-T>WY/SX$3#EF
MH#P`?=QQR/V<AHUZR]-^CF]&N@6^J7NH[,("%M=(LU?N%8F$<HYM75B[%5Y=
MG.P<B1!WD==HX%E*,&CGX=V@NT<@GZ#I!9N=1(YH1I._WPXKSWFYT:-&A0T:
M-&@#4<^[?JH;/MFMXB,19%M]LO>>;#'(2\%MZP/CZU9KS8_B70&,UE75)I#%
M\K7HQX4O>QD+4]@FCY,?59JK)`*@2).%"HHJ*G[NQ(AE3@4O<82)E%0X%+_K
M"8A3%``\B(@&J]/T?:NPF8\5;G.HE<VB-@W`;QMV&>'<]=Y9JBI8Z_BO'5V7
MI..,51;U1$',16*]'0H.1A6`M&2BQV*+ENH6(CP;@2.;/.IKM+WNSUJH6([?
M9:[F.AM"R%YP)F2BV;#^;JK&F401&6?X]NK*/DI"#2<N6[1Q/5Y69A6SI=!N
MX?)*+H`K(!IDN9]AF$LR[I=M^\I^[N](SWME5LC2L6S'4O&0!K[3K3'+1TMC
M;+`N8&5>VZ@=CI^X90J;^)68.Y*06;/B`Y$A8K['NUZH^XOJ';Y]C>TZ8VX8
MIH.V>5V]SBF?LDT&PVV=IU3O6/8RRRE*8U1M-NHR]WR_3CF6/$S<HRA("D52
MMR`.6LO,2\8NW`L5:-0$7G<WU'=[F[#<UM_Z>=\P3MLPELTM,'BG*.XK,.,)
M7,EFR7GM>%:6.T8_H%+3F8F`B:Q2F;QM%667D/B949,3'9K)%=,D"=;&/51W
M%8CPMU+JIO/Q+39[=OTRJ&WR+,L\''EVE`W&XXMM.EK/C#(U2B9=63G*A'2P
MQ1D;NW76>_@^@=1V@S;ND'<0T`L`:-5R<496ZUEGQMBG>/0\Y;']Y-)R`.,;
M=;]F6%L<MZBZ@L=7A_$GM+/%^X2:RL<TG>:%`2KAVN-^01BI.3A7T>1F5846
MKA;]Z^\'=;/[[*3TZ=J>6,![3K'*[<%]Q]FW";BJ@>_O[(V<7=W2HG&V"<=N
M[-5Z[:;+'G8.IVZ2$O(OPC(ODK.-`S119R!./HU'GL9G.H(QF,SXIWV1&+[J
M7'\A3'F%]TF&HAM2Z9GNIV>%<NYYO+XS<V^R3E)NU#F6Q&$N8J+6M3C62;.(
M(ZQ6BRSC`=5C>G=MC&UUEDS&L+0W^0L@YFQ'@.F6#+$H]B,18YG<OV0U?0R5
ME5['*-GY:-3T$7#Z1;M7\:=Z[.P9J2#1!9530$E>C4+N!''5YQ?F_#7[K^7=
ML^_+;+EJ9GX/)UQPSC&*P9;=N?%:?359NT<NIDN<A\D8]7FV:%8D(Q%D_NH!
M+,I5'ELV=*:PN1=S^\S=UO)W`;1]CN2L4[:<;;/6U"B-P>YC)&,1S/:+%F/(
M<":WQ.(L34"3LE4J;5I6*S\.\O5JLB\HX%R^28PL>W`$7ZX$WFC4'F#NICD?
M#QNH)AWJ!I4%;*W3LQA7,\3N6<.1,G6:%GW`MVJ$Q9:C<:_2IN8LKVF7,TG!
M/:?/P`V"4A#3JS1S&N4&IEVZ2`Q.6.O3=MNS7J!U%YM5"%F\>DS73.FPVPO>
M+'?K'C%ZQ+9Z_3%<\,;2A8U<\6"GJ-19,HJJC6OPC>-HWZH!0QVR8%A*2R!0
MX:X5K'LO=:G%WVYL)R4J%)D+%$,[=:HRLIMUK'(5RN.':<Q-L8!)VU4FG<:S
M<H19'+<STZ!5DQ,EN/-SN'LI9RS_`+=*;8'LCE;;(3&*F7X)>`FH]G7RY?KT
ME:**+*<>M$8B?^LX>*>N'`0SIV,8HF5N_P#0643(:N?NQ6WUY*ZQW3,O.-+/
M@W$DKD+:_GVX81IF9,/7^7M.(*X]QWAZ4W%T'-S:/NT`XLE\>RSM>,I+J`0J
M32GG8K-K)%3R_)U)`G'4=?8<W!=9M[F&'I:>&NG[BW;CDJKJUBOFA+];0O.'
MKC<IF`M=H5?R+>=?2=AB8JO4]<T3'H019,4W)7B1SJD`FOT:K1DRO](!<[=R
M]0%*=V9-Z\ICD<X(=/57%UN_",V+#10V].O.,^'LZ<PEEXU($'QFGP!(4DR`
M1IXTC\31(+1NZZJ6:4-KG3&W&[&Z+1[M*;^LXXCH43CS*8O$TUV>4*'8I0E3
M<6B(D6):G*0-OCT&-BLY6$VDSC(B:^&AU'"J!D0)]-&J[EFW!=5/8QN?V51V
M[C-^V3<YA+>MN-A-LTO4<58-FL+S^$[Q=8&3EJW-4BQO[E9WERJ<:ZBW!'X7
M`B\L_C45$R`S?.V[EK8?55(BD=54Y$R)D,=10Y@*FF0A1,HH<QA*!2)E`QS"
M(AP4H^=`<FD_RME/'^$,;7G+^5K5%4C&^-JM,W.[6R;6%",@*W`,E7\I).C$
M*HLH"+=(P)-FR2SMVX,DT:(+N5DDCU_L3[B^K[U)HZ];F]E63-K&US:O#Y*R
M!2MO%4S'B&SY8N>X^"QQ//JLYO\`>K2TFXQ*@5&X6".>HP252CS2C!FBH=16
M13;E?R#;M\^[_<MOEZ%.[J[+0N+\%Y)P0YSE@'J"XEG(6?MZZDKBATPBK3!8
M.GV%I8_@L[L#UY7K+7[!;VEL8-X=>1B/@I-1%M.F`LD[7-S^,]WN)8O-6(VV
M0&]&FY*3CXE3)&,[QBB>D"1ID.V6:UC($-!3JT#*-W3=]!SA&0QLPQ6*Y8KJ
MD*IV.)TT+8M%;A(?;-C1IN6N&*[OD(8&*793&'Z;8Z+4TJ4O!PYZ;&+0EHLE
MIDCV".B>U"?DDY))A(O^Y=C'1R'#8C$=[VZO?'![_P#;GL=V?FP?"CGW;1FS
M)D[D7,%3L%H;XI?8YNE2B@OY8F!L\$O<&C"*E5H2/Q\3X#Z]M-AA9)_8XV$A
MI1N[`FKUK%VN$%CVFVR^VATHQK5)K,_;K"\1:N'JK2#K42\FY=TDS:$5=.U&
M\>Q<JD;-DU'"YB`DB0ZARE&MOC/<-UF;%NQW!],1WG3:3)Y<QACS'NX-+>X^
MP3/-4(?$>0CNXB/IK+;K$VMI7IW(CRT%30CYF3M+.`KD!"SB\JTMK^4AQ9N.
MVB[Q]Y+>)ZI&W#=U*XGR;N`Z?=6B[5`9AHU)/4J1EJH9,PQ;LCT1S9,=%E7"
M,7)QSNKKM9^.CWK5H]8/2LBB19L:1?`3$X)S9CW<AAK&&>\32SF>QGF&C5O(
MU#F7D5(P3N4JELC49:$?.(:7;M92,6<L7"2JC&0;(.VQC"FND10HE#6,][FL
M0[:@Q`.6YV0@PSGFZA;>L<_5]=F[#];91R4N\;U*&>_4K-Y]3,7RK!R5Q.RO
MPT/'@0IGKI$#D$80;'U4=Q@;*^E#4\#47$LYOTZG..:&K36TG$2<'@O$#4*+
M"6G)V4YNFPTB_L!Z=4$)9,L)66<BJF`E6.\?NDH[ZODF=[YQZFV+LM]*[$V^
M?(^WO<;0;SU/-K5KI&;,-8YG\/VBH7NFVE91]C^]4UX]D:W,P-BK<\]D:C9(
M48J3;NZU),YMJY,Z:GT!<!__`(_JUIS/(=!D;K-XWC[M4G^0ZU#1%BL5#96.
M(=7*!K\^LNW@YR:K*#P\U%P\PNU<HQ<D]9(,Y!1NN1JLJ9%0"Y%6U5I!Z,:K
M88-*1*Y*U,Q5EXU-X#E0Y2D;BU.Z*X!=03D*1(4P4,8Y`*41,`#68VZUK>V3
MZ05O%6?9.VXJ1K/!NV^6RDBTQ3>F\C/[:GMTR9^Y)2:<Z5OK@D'ERN$`A;W=
MI<)6K6-03*0M1@B@5-`"P)MLW08=W9T:=R+A*>D;%5:YDG(N)Y5[)UV<K"Z%
MVQ79752N<<FPGV3%XNVCYQFNV;R:*)V$BF0'+%=9`Q3C^;G]T.'-GV))+-^=
M["^J^.XJQ4JJO9>.K\U9G2<UD"UQ5+K#8L3`,WTDH1[8)J/:+."-Q09)*F=.
MCI-TE%"UE^E=3NI[DK;?G"'VC9MVU[9,:5;?;O178V[)6)K!GB_Y8MCW.TZ_
MG8IU"!8*I5\98_A'2J5?+((A;KA8G02,HV"N,V;(DDX26ZM.X6U]'*S;OY.@
M8<C]P^+]V,'M:R'%/*Y)VW#\_8*MN9K&(+9;ZQ6I*=:S+!G+0\H:3@F<E..W
M$%.$%P"KUHB@B8"S.`\_UB']0B`_]0T"(!Y'[P#^D1``_P"HZA#WM;O-ZE]W
MF5_IN=.97$-'RVPPF.X+<%N/S1"R%TJN%*)+V!Q7:'7Z[1(\Q4[!>KA),U5`
M),)/F#6->,%2,024>R<<GVTO>%U(H7J:PW3MWNL=OLTTAMI=KS>WS#ARKV>$
M;YL%"^P$%5[C&QT[,?\`\AJ1*;N?J=WIA8N0:N;%$(ST-)LHI^@P$"7O;9N@
MP[NSHT[D7"4](V*JUS).1<3RKV3KLY6%T+MBNRNJE<XY-A/LF+Q=M'SC-=LW
MDT43L)%,@.6*ZR!BG%P>JBO2OI_4[R5MPSC"[1<U[:ML>,JSONWHKL+EDO$]
MBSSD3*=K>YWG'\Y%+01;#4JGC:@0SA9.OC($_"VWV%T1_)M"UMFU9ED)NNDY
MO0R)OEVFDRAF"K5>K9:HF7LQX$R6G1CORTB=N&%[H[J,E::DREG+Z6BH2P)I
M-WJ45(OWSA@Z%TD1TLU^'$`),-&H@^K1O0W+[04-D\=M<J6.[S?-R>\:E;>'
M54R,A()1DVPM]1M;]BR9S\?*,#U)<9Z,BUG]C493@,H1"2(A$.':K<Z;'<@;
M@.M7M<W;;>]KEQRSLWW,3>_"MY;C<36)'"UMPY5MM5VQ-%0%CMEJFXB*NE@L
M63\?P=:EW#QC6WU@9V6VR16#$T_5TDW*[P"R]HU`UMGW([_\%=2BK;`=[F6L
M-;FH+/6W"][A,39:Q?B$^$9RD/\`'%MCX*QTFRU9.Q3T=)PSEH_%2,?E7=2I
M5@8K+2*I#OVJ+M.E?NTRKO&V]9"R=EU&I(66L;JMSN&XTE-A7D%%C4,19:EJ
M55%'3-],3:JTRI#LD32[XCM)!Z]$ZZ+)F0P(@!)CHU62ANLCN/8]+B=W83E?
MPDOFZS[_`&[;*:#-V1O-4?!&.F:^<9?&=2R=EPQ)Z4EAK53@HM20M"K.:BBR
M\HJS2*M%-EE0!XV!7/5[QCG#"RF6LP;8]^FV3+L].0V4[9AK&47@VT[;T/P6
MD9JLW2#=_ND3T7DR@.IYJSK;Z-,RD;D*4FTE$#%;HN50`FGTWK=+NBPYLVPI
M:=P6>I^1K.,*:\K#">F8JMSML?-7-PL\33X(B4%6V4A+NRN9V;CVRIVS50C1
M)4[MR*;9%50L4U]W0;^]ZF[;<IMGZ?5ZPUMJQ9LOF*O0LT[C<OXND<UV&_9P
ML<(C:7.-,:4(L_68&-KE0A%T$;;99AT^DU9-PFE'(,DE&AW##.J%EW>'>.CC
MOWQGO<Q7%5/,&!,_;>:"QRW0*O:*OA/<A1W^:,06*M97Q8SM;A\_;IB1ZZKU
MQAT)23:0EGC7#=%RF58&C<"V:BJ1=)-9,1%-5,BI!$!`1(H0#E$0'@0$2F`>
M!\A[#YUR:AXW@[N]QSG=+@WIT[*G.,:?FW)>%I[<%EG<!EJ'<WFI;?L)5N69
MU%E(1.-(R;@5KMD:Z6E?ZKJ\=.3$?78])(9&41D&:JIV6'V_;I-VF"-\],Z?
MV]R]XIST&=L-WC+FV/<KB_'ZF(YBSO\`%,FU0R3C'+&-T[/9:VSLK"#D&EFK
M]DI;IE$2+)!ZR7ATW1#JM@):<F9#JV(\<9`RO>7RT92<8TBUY#N$DW9.Y)Q'
MU:EP+^R6!\A',$EWT@LTB8UVNDR9(K.W1TRH-DE%E"$'I8CRE3<X8KQMF;'4
MBO+T#+-#J62:1*NH][$N9*I7>"8V2NOW$7)(MY&-6=Q,BT758/T$'C0ZAD'*
M2:Q#D#0-V>0)K$VU;<QE2M-H=[8\:;?<S9`K[.PQXRU?=S5-QS9+'%-IR+*X
M:&DX==]&H)2<>5VU%XR.NV!PB*GJEABS[U&]X^/]LG1BM>WRA83MV9-_RV)*
MO;J7:8B:K>/QF[_M[;WHH5]W$3AWM"JU=LC@9R1$J=F>)4V%>PC!,9%RWD$@
M+#^OP1`/(_>`?TF$`#_J(:KR*[BNI_LAWB[)\<;Q,V[<=T^&-]&6I_!Q&6*L
M&RN#K1A._(TQY;X20KCYU<+3^%U+`62K9V2S*.IQ9F17M6:O?AU%;#`CW)D-
MQQW&2'CWXY.0>/\`KH!!MMFYC$>[/&*>7\)3LA8J*K;\@T4DE)UZ;K#H;'C"
MZ35`N#08JP,V,B"+"SP$FS;O1;_"R*")'S%59HNBJ=?=4W>E`WZL^9MK5RJ>
MR[)^VC:]AK#>ZW=A$-;OF3&-AS!<\\WB=SW=;[9&*$<@_CX:@XUJ@62.J*TN
MR92EDEYQ.==,WJ"<:#1-^E9ZV60ZIL,W(Y%S3@V'-OPVK;AHO93;L"4N6<A2
ML@[E[M/159Q-*55^X<O9:-QQ>UYI&<51<O'4FU9PTZR8/UP,Q=E`L7:-5K,U
M9ZZV?3YQ4;>[NGO.TC<A@>H/*M,[DMMF'\3V;'UTQ#CZ=DV$59)[%&47=BE@
MNKK'ZLDFYF/PM8N&3]HU<N$%$V`*/6S^5M\%]JW5'Q)M5MBM/=[>-VFT22S-
MMIL3""DF%Q_=7QM+(OLB5"P3*THXC)=C,X[DV%LK[5O&,'489FZ;+.GQG2)$
MP)6M&H,+5U/LK1V?^JU.U"E0-XVJ],+;:T7E6<1&.R7S)VZU"J3>3;94&=H4
MDCMH^KU&JL65<F&#>L.7;2;56EC2JR!F\<=$<69:ZV-GQ=C#>7CS-^QS>=4K
MZGC6WV?95A?'S:F*Q=`NSR*4LL=C;<9.9264=7>C0DHLY=*WME]4O9.'?L2L
M!5!)HY`L>Z-?)!$Q2B)1*(@`B4W'<7D.>#=HF+W![&X$0Y`>!$.!'ZT`:-&C
M0!HT:-`&C1HT!^"'(>/?P(>>/(#R`#Q]@\<#]X<AJL7AG)U_Z&67-SF%,WX*
MSID'IYY9S3=-QFVG<5@['$YF1##S_*;Q.:R!A?+M4IC9Y9ZVPCI_UWM9L!(S
MZO<`#EP0CM.8.$+9UU^"4!'G[?;D!$!X^[D!`1#R/C0%=2,R[N"ZM^\+:Q;L
M%T_<3MZZ=&U2X*YKR5D[)L%=\!V'=ED]O&+H4/&--H3Y]"VVT8F@SJIREIEI
M]FWJ\HH[>MG+%^Z;0R!UZV(42\5[JR]:NX3M+MT%4KU.;'E*/:YJLSD56;F2
M!P9/,)U2I6"08-XBS)PD@HFQF#P;Q^6+>*$:/A;KG*F,V(``>WO]XB(C_)R(
MB/'Z/;1QP(CY\\<^1$/'W`(\!^G@`Y^W0%:6L;F9+H[[N-^E5W1XBSK,;6=V
MFXR3W?X`W#X>P[;\P5AO;\IUVOQ63<1WYO0X^3F*S9HJQ5YJ-:)(-00D8PI7
M"9P3?I*DZF!'&[W+EKZJ?58H.T&;)8,N8?Q5A;93MCW&QSFCV7->(<),YV2L
M\ED&FJ`25KY\J/)V4/48.:(9:0,N2'4.YB#(NWUF42@/GSS]X"(<_P`O`ASQ
M]G/M]FC@.../`^_/GG[///OX\>?LT!1>S9&=-[+%$7E>FAL_W@[5>KC)#6"X
M[QO@S#>YG`1\7YA<3T(O(*YG2%G#8`8XLAGPR/X56"<(:$D(%NFH=,1_()2S
M=1N]X.89AH.-.K=L2A\V[37&"ZO)T/>+0<-Y$RS(4'<&9<(_+-(MR^-8QS<<
M2P,L5)I/TB<@`:(/U3)@N"JC59:+L==H?I']`F,(?T@(B`_TZ_1`!^_^@1`?
MZP$.?<=`5Q.C!2$:]N5W2S&T2&W.U#I9OL98HC\.UO<P3+#!O);AVTM.KW^P
MX$A,Z=^2(S%"5+/!,))VL5I`RUC6(6-37&/[FTB_5*O=YQ[ML:S$5M'AM[&'
M'V1J?![I\'N*LYOML<;=9-PX)=;CCS'Z1%D+Q;J8]2AYAM7UVS@XM".))L5)
M:.%TWDD``#VY_E$1$?ZQ$1X_1[>1^_0(`/@?\/ZA#R']&@*:6**=LMLV[?:5
M8>AIBS=7A[):>X:GRVZU5A1]QV*-I-?VPL6TB;,E6S!4\UM&>.R6V28%9QM`
MJM-8&L"=D<@X8@W!!!VV^MS>S+9)@/J%[T<E=4#:9FS*>"-S]YK&;MN^Z+$S
M'<C;*E37[ZI1U>R/A#*$'M\FROJO/(VF+)/U.8L$&[2FXV0(S8R+9NBDT+<J
M[0Y`?(\>W)C"'\O`B(<_I]]?HE`?(\\_H$0_KX$.??QSSQ]F@*EFW3IRXJW'
M;9>J7![3=CDSLSQ#N7P&?`6V7)&8K;GMMF[/HL8:4LCBU7;%>:[C)DQAC5+(
MAHR.I$@M'0\_.Q;F1E)-(T>V31,LE/ZS61*EM.K.V6F[+]UA.JA5,15[$T+M
MPG=NN0UZ`VR]`PC&D,;_`#&4B(LL>GP8209$MCJQ_A>S37@P,S!ZW`_UF2S>
M``'V>_OSY$?Y1'D1_I^SQK\[0_3Q]W<;CC[NWGCC]''&@*W.]_*EDVQ]0WH[
M;F-T5=N+N'@=ONYO$V8;IAS%5[R'5(K/F6JKB*+8U]C%TN.LTI&Q<[:D9H8#
MXL5N(5BN\4=+-F$@[;ZWE'9GE#=3G;Z1MAF/KEFJX;DL&[.ZMAVY3\!*0M.N
M5QK>$+HY:,H*TRS1K`S#%E;F4-!VAY%OGJ=>"0$9($%0(D>S6(`/OS_0(A_Y
M"&C@.1'SY]^1$0\?<`CP'Z>`#G[>=`5BB=:FVI;5`VU.ME&\O_VFY,/CB8^W
M)+;O=AKCG+A*S^`XWMOE`L6KCL,0J2H#<"SOUH=N2&`8_P!11`/K4W#>-EN4
M=LVVOZ/-MS3K%BN]DVZ[XL!R>9I2EP<U:H2JR+JEY*L.0K%+24.Q>-X:F1EQ
MLS]@C8I0S"&22,R(+E$%D"&L]=A?T\?=W&X_DXYXX_1QQQXXXU^B`#Q[^/;@
M1#^O@0Y#]`\AH"$OJZT2\7/+W1^>T^EVZVLZ7U3<(6VY.ZO6)RPM:C5&%/NR
M+ZT6EQ#L'J-=K;)9=!%Y/3)V42U57137>)G53*::F09I2#%VQ7[O0>MG#1;L
M'M."+I%1NJ)!X-P<$U#"4>T?F`/&NV(<\>_@>?`B']?`AR'Z!Y#7[H"J[LHW
M[#TB<'&Z>>]#;WNF_#[`%ZR95]NMIP]M\O&6Z=N=Q%-W:P7'&LK1;52V;R"1
MMSIG.JQ$["3CN,5C'B*9Y%5JX(]9M-:G=M6Y<_0[ZMV3LJX9N%:W)=0>U[A=
MSX[?H>(E++D"FQ%Y5J-?QCCMY5X*.<2*UV9TRL,74S%L&:\@59T0D@U:RJ4B
MU0MB]H?I#^0Q@#^7@!`.?O'7[P'''L'Z!$/^H<#S^GGG0"<8=:N6.)L8LWK9
MPS>-,>TALZ:.T56SILY;U:)17;N&ZQ"+(+H*D.DLBJ0BB2A#)J%*<H@$6V6:
M1='G7*V?7]G3[4[H<)T_]V5<F;NVKDRXI\189G+.(7D/`REG19'@X^;E6;%Z
M[C8EX_1D'S9HY7:MU4D%3EF1U^<>>?/CQ[CQ_5SP/\HAR'V:`@]PG0;VPZ^6
M]O(KZDV]ECZ>V";6ZW!7QW6)QM2YJPQ%]LCF6@8BUKL$X"2FHQNNBO(13*07
M?LD5"*N6Z1!`VDZJF.<AH[R?I#$XM0;NE"Y(V^;:XW'4PK4;$G%9`D8O:QEB
M)DX^C21XTK*X/HV5>-(N0:5Q>2<,I)VV8.DTG;A%$]@?CSSYYXX]QX_JYXY_
M3QSHX#R/GS[^1_D\!SP7^CCD?(^=`5`SX-W"[?MJ_P!']ZA5.PCE&_RNPS`E
M=H&Z'!T!3I9UF:'PUE_$L!4[Q.UW&,@SC[!)6NA+MWII>O\`IHS3--RBNHP(
MV92+EINN\C?0IU)LL]-J#VA8!W07#"^%NHSMFRAN`S%<-N62,>52IN6-N_!R
MM5B.-;X9C.RCN/5D[%8<@2T9&'K=)A(=FK8YENC)HF"V/V@(<#SP'MY'D/T]
MW/=S^GGG].OSM#P/GD!Y`1,81_ZC[#]H>P_:`Z`C^M/2LZ>5WS@[W)VS:3AV
M=SH^OL1D]WD^0@7BMJ<7^OO8N0A;4H]+)D2&6CGD)$N6RX-P(15BW,*9@*(&
MCMC<GQ6W[Z05FIGE"M9(BFF\/:=M;QO@2SQ6-;E9:9;;?CVR9(D[I'O[?7HB
M1@*LE7VJI#R+VRO(MDV,HB19=,SN/!Y85U^<!SSYY_E$`_I`!X'^D-`0M=#"
MCW:A;1\LP][IMMI$N^WU;UK"SB;C6INK2CN`G\^3LE!3C:.GF,>\7AYJ.53?
MQ,HDB=C),SD=,EUT#`H,*!<%9O+T)MTF/QPSEK\/9?JRVZY15'#&MV&Y2=0<
M;XJ18$+7'58(,9Y]658%%:;3GFL>M$FB$%Y('8LD55R75`#C[_O\B(^_\HC_
M`%>P?9H[0XX^;WY_.-S_`%\\\?HYX_1H"NKN/GYGIK=6#)_4$R)B?+>0-H^[
M?;%C?$.1<FX@H\_E*5P+EK"T^N$`I=Z14V4C9V]"N]868MVE@C63IJVGTW";
MP$S%(FOH&W_<9-;L^OGC[+,7AW*.+\3M>F-D6/Q/(9>J,ECR\Y'J0Y]K0S62
MWF.;`1O;J159&WOE*Y3$+A'1,U86$.M9$HU"+E&!U9)]V>U+>7*[B:GNUV-;
MG*MCC(4=C+]R#(>!-P\'=[_MBRG56UC=6:%L1X2H62)GL=9'@WS]TW/<JFU6
M?V"((PA9(R+)JJ#HV>;'<V8]W&Y5WM[PL]5[.&Y_*.,JWA.(BL849[CG".%<
M-UZQ+7(U`QY!STY9K9.*R]O6^NIRVV:72?R1T&Y`C&QA744`1WH94:[T#:1E
MJ&OE-MM(F'F^O>O8&<3<:U-U>3=P$]GR=DH.<;1\ZQCWCB&FHY1-_$RB*)V,
MDR.1TR<+H&!0<+T#Z#>L=[1\VPN0:5;Z),/]^V].QL(FZ5F<JDF]KT]EYV_@
MYYG'S["/=NH699'*[BI5!%1A(MA]=FX63^;4WP!Q]_W^1$??^41_J]@^S0`<
M>W/OSY$1_P#,1\?H]@^S0$)O5XHEXN>8.D`]I]+MUM94OJGX2MMR=U>L3EB:
MU&J,*A=T7UHM+B'8/4:[6V2RZ"+R>F3LHEJJNBFN\3.JF4VQ;T*3=)SJR]'2
MX0E/M<S4:4TWZ%N=KB:W-2=9J!K#AJDLH`+58&+%>(K@SKU!=G"A-/&(RSM!
M9M'_`!"Z2B99D!#GCW\#SX$0_KX$.0_0/(:..1`?/CGCR(!Y^\`'@?T<@/'V
M:`A`S10KT]Z^VR'([*DV]YCVO[!]T-=GKXTK$XZI<)8):_UIU%0,M:D&"D#&
MS4FV06<1\2]D$)!ZBF=1LW5('.F![$=]T+TV:UN1V29MV\;K[%NI9[QMU.0,
M78WQCM\R)>X3-U?S#DU_=\9R]%R-!PZ]*0K\TWF&",M/3TI&1]>;G7>R*J96
MCM%O:[X\\^>>./<>/ZN>.?T\<Z_!*`_?_:,`?U`/'\OCS]N@*A>R!?<%@;HM
MR;C+&P*;W"QMBWYYN>[M]K5SQK.35T1V]7S+LU+Y%NF.<:3,>V7R++T^35BY
M.II),G<?-13=Q8(Q<R+1-^CH>+*?LILV[?:-8^AOBK=5A[*)-Q=-EMUQXVB[
MD<4;3ZUME9,Y0V8JMFBIYE:L\=)6B1CO0BJ!5:>R4F4K,Y%=D"`)-7C>YCVA
MQQYX_2(B(?R"(\A^C@?'V:_.T.0'R/'MR8PA_+P(B'/Z??0%9RH[B7'1^WI=
M0MGNHQ%FUSMNWE;@V>ZS`.X/#^(KSF>JKVFXTR`JM[Q)=VU"C9>8JENCI>`9
MJP#628(-))J*ZS9T=L[8J@E6_P#R7O5WU])/?I?K5MMOU*HEWW`X';;,,-*8
MJMS7<E-8*JF7\5*RF0LHX^8'GYYC)6N:;3EBBHGZHC7<%3V174FU,V[)-S:Y
M$H#Y\\_>`B'/\O`ASQ]G/M]FCM#@0\@`^_`B`_R]P"!N?'OS[>/;0%4[JN;+
M\*-NH1B?>9O"VNY>W,;*+EM>98/RI*X;3RO-VO;KE:C6B0LE&R-8*9A68B,A
MRV/+!79V9K<V]9H3,="R/:_>,DG";,KS.]-3;+L6M>_"L9OV#]/R]8]V^X3Q
MI;)$F\O.DWNQH\S9\MW5J_IK2BX%QGF2W&97:K)TJ4GW%YNMAJ81\>NZ9-()
M9.2!LX5M*"`#[_9["`B`A_2'`^?M^_0``'MS_2(B/]8B.@&K;ZXB6G]D.\>!
M@(N2G)R;VJ[A8B%A(9@[E9B8EI+$=O91T7%1;!%P^DI*0>+(M&+!DW7=O'2R
M3=LBJLH0AH/;#BO*"N,_HP+5/&N0E'6*+EA-?*;8E(M!G.,T&&RZ3@GRV1$"
MQ0JT=)E.')#/%+22)*UEC!&KBF]'T-6;/_X^[_RU^<!X]_'MY'[N//GYOZ>?
M/GWT!![U4:#>[=NYZ*LU4Z3;[1#T3?R[L=XEJY6)R=C*97C8<LC`)ZV2$4P=
MM*W"B^719A*S2S%@+E0B'Q'JF`NIO@`?23#@>0]'D/M\&)S_`%?;KD$.>/?P
M//@1#^O@0Y#]`\AK]T!49Z8_4//TY-MUOPKO8VR[N<?LIG<KN=NNW6VU+;1D
MV^Q>6ZE=\U7&8>5M-.LP[M]6;['W$\\6/C+JVKR-AJLK6;%".'<(M\<?266P
M;>3G#9;O2WNLL(2])W3[ANH?ASJ.8:VN7)0T5<5,=;8;&P=8[QS:F+L6XPF1
M;O3SVMRG!O2).A>N8)FY3:2#Q-NA<:["_P#S?VC<C_*//G]'//`>`X#QK]X#
MCCCQ_7^GSS[CSY$1\B/G0%5S>MU+W?4NVH9%V!;/]JN[0-U>YV`CL.Y!K&8=
MO][QG2MM=;N#MBEE"SY6R-:(YA5&[:LP`2[6&<1;MX,L\.U=MFQE/2CW#A>M
MUBNP8`V=;5=Z&,&+6?R7TJ,MX?RU&$D'3]HPL6+&T?$8KRG79,61RO"PDU&+
MP,K.'*J"S:%BI)1,!<B40L.]H?I'^4QA#^H1$/'V?</G45W4$V(YVWY6W'6+
M9C<77:!L2%[0K)N#P=%XR&4RAF6<QY?_`,-6-9;Y0<3R$?6L?64C&`C['%J5
MZ4<F^JECI_$HR)T$0&V[#<1;BMM/1_M.3Z5B^`S9O7W#U[)6]/(&-<E.7K1A
ME3+^=G?X=NL=6%4%#NT7)<>K0]!CF*ZA&QI5BV0?))HNWH&@[SK&]-W+&.G\
MMTTMG>\7:KU=)%K7BXVQI@?#6YK`+[&.8%Y>'<2"F7$B-(/`3'&<2[^L@L]B
MF^(B1@D$E#$YX11O1-FK=FW1:-4$6S5LDFW;MFZ2:+=!NB0$T4$$4RE32012
M*5)%(A2D32(4A0`I0#7+VA^D?T"8PA_2`B(#_3H#3L=(7-M0*.VR,]82606]
M0K"%YD8I-)&,?W%&#8)VA[&I(H-44V#J=+(+LR)-FZ9&RB14T4B`5,NYZ-&@
M#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C
M1H`T:-&@#1HT:`-)/D//.$,1O(V.RMF+%>,G\R7OAV60LAT^E.Y8OJ"CW1C:
MS3,6N_+ZH"EW-4U2>H`D[N\!*"KFX$!`1$`$..0]_/CQ^GSX_3JL2M7^GKDW
M>3OJL49L6W#]67--AR\WI>3;W8\$86OF$,$3%$JD-7#;=,899S]:<<T:`BZ>
MHDHZL<?5G<Q,(3S]\>6D'146I$P+,,)/0EEB&$_79>,GH.4;D=1DQ"R#25BI
M%JH(@1PPD8]9RR>H'$!`BS5=5,P@)2F$0$`2UIN/V^2$A:HB/SIAQ]+45F[D
M+M%L\H45S(T]BP6(W?/;2R1GSN:\T9KJIHNW,NFS0;*J$3743.8I1II5?,&2
M]KG0]ZF=.P_79W;I-.NJ=EK:G1J=$6S\)#[7*AE:_8HJ<]4("V1;YTR*QI47
M,6&`3G*Z_*R)*2;B=A7@.ETGZCM>K%T4NGWMGZ16?KWAS"5;H6:MOV"SS\=F
MR!?336]7Y^W4A(^],LCS*TFL-YA<F-7<LE*0,ZDXBD'+]D>&:1I&+5(@%KR8
MN-2KU97ND]9Z]"T]K'I2[JU2TW%QM;;12Y$U$9-Q//7:$2A'JIJI*)/57A&R
MA%$S)JF`Y!-KV.<OXGS#&.9K$N3L>Y0AF:P-G<OCJZUF[Q;5P;OX;N9"L2DJ
MT;KCZ9^$EE2*&[#]I1[3<5.][.4F5JSYT=-J64]O&=]UFV6I;((3=G?MM.`J
M;&9!E,RY!@ZC7Z!C$;W0YJQ5:$M>-\9/6CR>G(64DUHM5W8(TSR(D2`1(%-Q
M^ZFS]4[95GC9CTL-Z>RVH6C]T?"F]U>X[=:I@O"UYQ9/U07V,K=:(?&-OF:\
M_LV.[O'&=(6*:C63Q%JM%,"/':(BW2`M>"/'O^@/ZQX#_KJ"'<)UT-O%:WD[
M6]D&V6U4;..8<G;M8'`VX))(MK&'PE52/I6!M92S+9I&0\KDM*SMVL0PA&LE
M+,H<K.8<6%J0?J]-Q.X41$I1$.!$H"(#[@(AY`?Y!U`!U@Z[`Q.Y_HHR$9"1
M$<_D>JA03/WS&+8,WCTR^/+BNL+MTV;I+N157(1905E#BHJ4JB@F.4H@!)!U
M!-ZL9L2V]&S$?'5BS#=K/?\`'N&\/XCJKYI$S.3<P95G4Z[1J@A,/DG+:';/
M'@N'<E*':/E&4<Q<J(LG2XII#')?>H;U*=ECS%>4NH9M9VMP^U3(V0:+C*[W
MS;-FF_6Z];<9W)4TR@*M,Y-A+[5HB'M]7;3;U*&GY2C.0;LG`F<HO%$!8)R<
MK>[>X;6,58=<YTW?$QPUQ7@.;@\N,K/DB"C[`VI5XK*YDZA9ZBR=LI!\7(3>
M3?`PIIJZU4LZ\L_390A3.G0%-#C>ZQNTZV+O&M<N.#)':'TN&60Z+ERR!FD2
M-MV.[F/Q_-,[G1(B,Q@Q,\981Q/8)IM$R,FZN$@I=9B*;E59LTV[I-`0+%I#
M`<H&`0$!#D!`>0$/L$H_:40\E-_K%$!#P.HU^HAU4]I/3@IK];-V28EIER;H
ML_:<287:-I:3NN3'S`7,9%-X]G&LUF\5".K(1"+D;)./HJ'C""NHL\!0A$SY
MC,N\'<CB_+\QC6B=-K<YF^D13RLM(_-%`O&VR&HDTVFHV(=R;R.B+OEJN71!
MK57$@\BY1)[7FRZ[B%>'BDWK51FLX6#?!6:[,;2MT4E+0$+)OX_;7G3X%Y)1
M,<_=,^S&5J6(+5R[;++M^U8I5R`BH0`4`#\=P<Z`^MBF?+1NFV;[9-QEUA8"
MN6[-F$L>9,LL%5321ZW$3=NK[65D8^"/,.'4J:*:N5E$F1I!RN\%`I!75.IW
M#IDW6'ZJ*'35PHTD<>TN+R[N)N#9[-T['$@M)G@ZSCJLR,2UON9,G!7U4IJ(
MQQ65IB'K39ZFXCQF[M9(&#:/2`$BHW.G=F>K;=.AUM1SW>$I-S4,-]/G'>3;
M,VA6Z;N9=PM+Q,A8)%I%-UUFZ"TF\09';,BN7#=M\2JF9RX10!10M7#/N_\`
MV+9WZ>_4`S-DK=!1;SU--]],I4.VQ%"0>1GC#`V':?E6I67&VU3'5CD:>VK7
MP5-KT>^MN2YY"9;L;QDI>7E`4<),8@#`>@)"/E).'BY%9,B2KZ.8/%4T^X4T
MU';-!P<A.X1-V$.J)2]PB;M`.1$>=9337MG^ZG`&\/"4#EW;9DB-RGCDKQY3
M36B*C+#$M0LU108L+'$BTLT1"27K1;M4B"JP,A:JF-RV76(`F!T.@#1HT:`-
M&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&
M@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&C1H`T:-&@#1HT:`-&
MC1H`T:-&@/P0Y#C]("'\H"`A_P!0#4(]6Z=&^#;U=<\5G9YOAQOBS;CN)S;D
MK/\`)PF1MLR.5<QX/O>6I(DY?"8>N!LAUZH3D?+SQG$G%$R?5)Y"M*&;$2CY
M8J#H9";G1H"LO<NG7CW8+L1ZFU`WBYRO.?\`IYY>F%\Y2+F'QQ+3N\*AWR[S
M=2;W;)]DO<3,GAKTYK-DB*K>&TC&TF+&.^IYN>G&YX@SN'!A/4=J^>ENE9=J
MCD[JY8MW1X:M]+H]*VBXUQ%C*C4W-N[NW3<M587$%7RM:HJY6Q[=$*Q(+L9F
MQ5K'E7BW]H<P2;Z\6!,[5VR<V]]Q_P#H]9V_Y.9-_P#1<UKRW>A=^_#;7_\`
MF_*__P!TAH#T%<V]-JW97I.R/(N*LWR&VG>5LHQY$5''V7&%4C,C5:9@)/'M
M?JV2,3Y-HKV2A4+CCRW/8%FJN#698R<0Y;&?Q"PK+G*.6P5L8W-RFZ&C;P=\
M6ZR(S'?<14ZX4["N%<%8[G,+[=\=K7IL2+MUZDX&<O5WLV2+U.PI`CV[^UR`
M,*T0QC0K7U$VBK:5TOL'\@?^6OW0!IA6\K9)_P"+7)6R'(7[I(T/_P`'.ZBN
M[EAB0J863]T+ZAK4U7OP-%Z-@A1K`.OKCXOZ^!K."C\/Z/U2IZGJD?KHT!&K
MU+MA]^WZ8_PG3*)N!C\".\-Y[I^?"O9O#L+FVO6R?Q]&S`4N+GZ18;-6X.2C
MH.RR36U$:S'UO&.GT6T2=1:I2E4(C,5L\ZOS23C',GUDJQ*1C:3CW4G&%Z<N
M#&)I2.;O4%I&-*^1OAUF1Y%DFNR*]2(=5F9<'*1#G2*49D-&@/D2$$>1*41^
M\2AS^CR/GP&DVS1CO]UW#V5\4?6_U!^Z=C6]X\^O09!)C"_AK5I6M?6P1PNF
M02'U;]9_&?!"]:`[]'T!=-_4]4BEZ-`-@V@[;6NUO:3@':P^LB&2&>$L,T?$
M+JTNZ\C!M[BA3Z^V@599Q6%9&>0C4I8C<RRD2I)RB;<J@H&=.2@)S)7OOV(T
MK>=M)S5MBB7M8Q`_RY7XB";Y&CL=0EA>5<8NW5VT"[1A6SRL*OQ<E@1CC)%G
M&'81X9<5%/1]%5^>C0&OU>M152@X^"AV,>P:,6S='THR/:QC959%LBW5=?"-
M"$1(HX%$%%!`#&$1`#'-V@.M@T:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT
>:-`&C1HT`:-&C0!HT:-`&C1HT`:-&C0!HT:-`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g693927.jpg
<DESCRIPTION>G693927.JPG
<TEXT>
begin 644 g693927.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!"1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?5%))04Q?1$5324=.7TM?3U)'+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_```L(`/4":`$!$0#_Q``>``$``00#
M`0$`````````````"0$&!P@$!0H"`__$`'$0```%!`$!`04-"Q<'"`@'``,$
M!08'``$""`D1$A,4(3%9%187&!DY46&1F+C1U@HX05AQ>'F2E]+8(B,H,C,U
M4U17<G-T=H&3E9FRL[2UM]4D8I2AL=/7)2<I0D52EO`T-TA69(C!\29$1TEW
M@K;_V@`(`0$``#\`]_%*4I2E*4I2E*4I2E*4I2E?`G:L'G?"]L<[89=F^6/:
MM;+LW[-[XVRP[5K7Z7OCVL>MNMNUCUZV@!/<HFS<>MI=EQ\-:"Y`CYK\KC@X
MVC<7L%N/YFS4[TTU+J=#;+D",#BS)+\1'M(P"LI8.EP1'9JI)=7:I!=-([Q1
MQ4>]S4I[<WEU5=BZXFZ@3"A*!YM-"5'^.<LEN@LW5YEP<Z\F+,3F8;M-H(#5
MDM(BYXXX-B0#,=K+ILTEP<JF+>)0T;+8#:YD>7G2MVO#7QH10_%Z7LMB9-)Q
MJUU]BQQ*1]L)@RC!;BV`3EM07A&+@G&R"DR44IW@72C!PWF;/J%S>)(LSGJ,
M@;Z3!*+>A>,'Q*CI[KFB,=N*2\9)ELP<#ZJ8*A7P34!)Q,9AA#K3B5A"*`AE
M;YVN<5U,B6PZY#8]=:.._;%<W(U>:LJ/YGDHQFQON5_P_L7$)0[8_G$6P,.O
M)784I1\.8Q-J%A0DQ<2+*2,9[_.8*3;5T55`-&"YX(;/>&E*4I2E*5B2>IOC
MS6N%Y1GZ6E4VAQG#K&<<BOM7(I*@NG$UK-5.%5%DX51TD$RI*8X!,`3,,D1`
M&-&,K6#!#RSO:U7NS78B/UI-=[MHR(<;KQ;J&ZD$V,6')BFD5Q)1192C`I0U
M@&9*B#D#Q<7,N8##'`RSN$+A@)AEC:Y*4I2E*4I2E*5P5/!0%3S@:2;*$5,0
ML*&GG3Y$53)%#F>-\2Y@VG`'TH8\6!%OB(,4"4B`A@/'(+`X7RRL+C`5KORM
M3XM-[C'D*>6Y`ZJR^18U,;7.(T5DWDR7S!BS%;=D!]F9'-DGH_W\G2#"B.T(
M_.6E9R"YL$S%XJFE+HPZ^F',D\"2L#D6TR&CJ398'G%#2X_AZ.F',$@.)>;[
MX;P"3$<H!GA8XE9-)KC63U-UQB_<4M4LS9`:!%>:3E$3%$))5S(I$U@%9K#Y
M-=8)7V+C;7&+5QU/IP20S9J=Y)U)D=2229B=C"#Z8<>.1)'7E=F$"!LT9<+Z
M+Y`*10UDWBB24**QQ8P)NMFB+O7[/[+37&6XFFFND>K,.H#1V::FSBTXG+([
M%=;K66T?U_:+&=*>$@8(DM1TF'0G/B\A2QXLI87&30$?,X6',]\"!%KCT,VQ
M>6T"3L0COQNLT-R:W;(/+7D[)<3J"NK0O,]FPW&DY[/J.#*YD;44FY#-V",E
M^,L5>>.+'D-KN-NX/-PXEN^`M]Z4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4KX
M$OE8/.^.-\\NQEV<+7QM?++LWZ8VOE>V-KY7Z6M?*]K6O?K>]K=;U%IH/ID>
MB!=V7?TY0O$Q23Y"W@V8V-C%^$`FF]W@E,&;G/@JMQ/%=V;?)KS;=*0AV'15
M]-331A-`"%P*I2\J$Q3%@=(HQTPWT+S)K]*DFQC$>"O'$*\F$+24*QI?)H+&
M-J.Q#JC-U0PYH5B=.9A%KL1@JA*.RJ0IH.0:.^@EY86W-)JJZ%DG9T._.L9Z
M1;),:!^$5!#0HU&?W'0<:;?FUM&9`.D4):12^FDIZIK[G8#I3V6K^;.9-9>J
M:^"2&J(*";5T7`ZFBFTQ6PQ[KOAM)%#]G)T0!&X2.:R@DM)0<DSBX4.2#C&=
MQ8S&1(5RPLB(!))"!55LAG+X#6>KF&*KB$*G`,=*+`8+H2H?)`Z]:S:JRSJO
MO/M&NL%)LK:@;2M^,I2<*D[)747'(C:VW:2`HL>0W@4;RR1.'55I2['*3%Q-
M>5#SIS6R3X8@AT!$R0U>YDI*72E*4I2E*U=W9UPSV_U&V0U=#>&,?B3]#3^B
M?![YH&3IQ:F;V032+BO9-S!8;^:YBF9&+&<DO%;2LCEL+@V4"M\NZXYAB9B^
MAA%T<1OYI^;7G`83-9/FQWGYG^:OG3;26WO-+O"YDYWEW_YF]]]Z=]F>]N[=
MP[X'[GW7/(-*4I2E*4I2E*Z]5,'"B:>-)Z?FK'BQ48<HF!F2Q,10,@X7$!)X
M&SF894MD8SQL%8<QGB"%VNV)E;&UZB)T+T4>NM''FWHJ48CUR;VYS7@^6XW!
M?AQ`07RT'$Z'2H/)<;6;O=I%M([P=,=*JLLM_-[()XJ2-J)<FIE!"9K'`D;,
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MPPEM!$JB\#6PFZ;FVN(KA)$+M9,7X&A*',&2;3S*F*KGRQN)49+-+^:\`;3R
MHI=<R&+IV*4&*GXABG#=\K!Y4X]D>6>-[>&,X@;RZ[90?>L$PM5@MAL6RNX5
M]U+304"2,DHV.`H&62D>-BX`%,<1@\LA<[8VRMUK9K79%7FW`4(MYU$SB>YD
M*(8R1W"04;WR4"2ZEL9`(*Y0]E<06^1PLHES(!J]Q!+W'#$OV\^O:OA?9N"]
MJI8<+74]?MX71JHAI"*H$'$VT'7^"YA!=JL94`3)%=,*LL(JHIHHJ:2#%3<$
M]($"(&L![FC.&1D/#.VL_I-.2GRQ,C>\?TT^2-/2:<E/EB9&]X_II\D:>DTY
M*?+$R-[Q_33Y(T])IR4^6)D;WC^FGR1IZ33DI\L3(WO']-/DC3TFG)3Y8F1O
M>/Z:?)&GI-.2GRQ,C>\?TT^2-/2:<E/EB9&]X_II\D:>DTY*?+$R-[Q_33Y(
MT])IR4^6)D;WC^FGR1IZ33DI\L3(WO']-/DC3TFG)3Y8F1O>/Z:?)&GI-.2G
MRQ,C>\?TT^2-/2:<E/EB9&]X_II\D:>DTY*?+$R-[Q_33Y(T])IR4^6)D;WC
M^FGR1IZ33DI\L3(WO']-/DC3TFG)3Y8F1O>/Z:?)&GI-.2GRQ,C>\?TT^2-/
M2:<E/EB9&]X_II\D:>DTY*?+$R-[Q_33Y(T])IR4^6)D;WC^FGR1IZ33DI\L
M3(WO']-/DC3TFG)3Y8F1O>/Z:?)&GI-.2GRQ,C>\?TT^2-/2:<E/EB9&]X_I
MI\D:>DTY*?+$R-[Q_33Y(T])IR4^6)D;WC^FGR1IZ33DI\L3(WO']-/DC3TF
MG)3Y8F1O>/Z:?)&GI-.2GRQ,C>\?TT^2-/2:<E/EB9&]X_II\D:N!IZC<AZ,
MZVNL.7EFD!X-Q(<B`JN%H&=,]1D,N[$%-5B9U9:YA;1FJ"L(P#B3`#2,,KI`
MP2JF!G<CR<*&=+@9XRB4I2E*4I2E*4I2E*4K5;:G=W5'2-NM9U[63DQH.;SU
M6S;<:JH]SAXJ77%H@G9*QU/(8IZ>HC""E4['OH?+,+`$/#(/'(6P@H6&>D/J
M_P!PX>4$@#^-G+\F*>K_`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!P
MX>4$@#^-G+\F*>K_`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!PX>4$
M@#^-G+\F*>K_`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!PX>4$@#^-
MG+\F*>K_`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!PX>4$@#^-G+\F
M*>K_`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!PX>4$@#^-G+\F*>K_
M`'#AY02`/XV<OR8IZO\`<.'E!(`_C9R_)BGJ_P!PX>4$@#^-G+\F*W&U0W\T
MYWD#?(FIFP<>SIC&N;>#?5F,?/FA&SD[,5C-N74PE!.310\%>S?6;$Q0L!@Q
M,DTUAEGAF'V;\7D/V">FJ.C&V>RD=)S:5GW!L`R;*#13'D145-J'G"SVT<5T
MHJX4](5D%3.HXQH`/$^5(+26;&`OF&`?+9WL+CGJ$'JJ23#432$N%R)19?49
ML%Y*Q5+"'!32ZFZ6BC+R@`0!,F#9@(D";4!@R@8YHR,&7Q#P%'&$MD+GE&E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I4-6_>&`G)AP<X"8XYX
M9;&;G7RPSQMECE?'069LL>N.5KVOV<K6O;K;P7M:]NE[6O4P^*<0Z6_R(IXK
M?_E2_L?L5?%R:7:][7+$+7MX+VN`5ZVO[%_QNG>:7^ER'\`5^\IWFE_I<A_`
M%?O*=YI?Z7(?P!7[RG>:7^ER'\`5^\IWFE_I<A_`%?O*=YI?Z7(?P!7[RG>:
M7^ER'\`5^\IWFE_I<A_`%?O*^\2"=E;KB4)96Z].N)8M>W7V.M@[^'PVJOF<
M0_213_12_P#NJ>9Q#])%/]%+_P"ZIYG$/TD4_P!%+_[JGF<0_213_12_^ZIY
MG$/TD4_T4O\`[JGF<0_213_12_\`NJ>9Q#])%/\`12_^ZIYG$/TD4_T4O_NJ
MAVU-PQPYG.7###''##'73BWMCCC:V.-K8H&V>-K6QQM:UK6QQQQM:UK6MCC:
MUO!:UJW\W.>4$QYJAL0^=GFR7>6O+2A]]N":&H:;@;O+.&-DQ#,F78CC-<84
M`)?#/I6`X&24(,%@<MEW'(3"V5\K9=BQ49ZW&<>+,>D`TMAJS&:"FRDT$A9*
M"3VD?;J8;;1$-,QO?%.#*(@Q`O@1M>]B>(=BUKWL%5^TI2E*4I2E*4I2E*4I
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M&';R[.';RMK'V<.Z9?B<.U>W;R_$X]<O!5/2"SKY8#E=^ZKKA^#)3T@LZ^6`
MY7?NJZX?@R5\YZ#3MCAEE;F`Y7>N.-[VZRKKATZVM>_A_(R5L/Q".J9@W-R)
MP=+.PLP;)INMVY*=&D;/V=5!IK,CA,]8UPA.1#*4KK+/:3,23H(3F=RT8)X@
MHA7`J`/B$'A:]Q<Q9I*4I2E*5#7JAZ\_RX_6Z\7']A;:5OENSKAGM_J-LAJZ
M&\,8_$GZ&G]$^#WS0,G3BU,WL@FD7%>R;F"PW\US%,R,6,Y)>*VE9'+87!LH
M%;Y=UQS#$S%]#"+HXC?S3\VO.`PF:R?-CO/S/\U?.FVDMO>:7>%S)SO+O_S-
M[[[T[[,][=V[AWP/W/NN>0:4I2E?-\[6OTO;+P>QAG>WNVQO:_[UZIW3'V,_
MX,3[VG=,?8S_`(,3[VG=,?8S_@Q/O:=TQ]C/^#$^]IW3'V,_X,3[VG=,?8S_
M`(,3[VG=,?8S_@Q/O:=TQ]C/^#$^]IW3'V,_X,3[VG=,?8S_`(,3[VONE*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I5+7M>W6U[7M[-K];?ZJAMWX]<RX./KB]T/@
M"3/4Q^7Y3']<%_285YU^*?YW"6OL@')!\,:4:DLI6EN\,?@R2PHG;1&1%N'G
MN<V-B3".Y=:@W<W7'+I#&7CQ)PII?++$JNHMCQ!+*O=GJ]LF^^&>.JM%;[F4
M6;#@X&@=S;>O("=ELO$S)B&?DN:6FQ)M2'&'8:/G,J,R`X[+#R%"2VI99"."
M))$5CV3T9)X3`LK)Q-;/M9T%0W4VUS,3"CO?&SQ#<5K!RZFQX^EMGN+3EJ13
M`YMLKIE!=;4F]ZOTELALM#ZZC+9=M`2K`I5'0QW$ONIM.@DPF(Q3:3@88N<H
M8+J]-M]2]LK=;],K6O:V5NO@RM:_AM:]O#TOX;=>E_#2O@3\S$_69?S;UJMQ
M2_/*\R'V09L?`WUMJ:RE*5@M];,P+&<R0SKX_)2:C7F?87!["0Q':H=%"<,@
M81TD@+CRR100P!"^-D9,,!F+V4#)*ZAG84JE6/G`!RX6=/'XJ4J&O5#UY_EQ
M^MUXN/["VTK9;E3CV1Y9XWMX8SB!O+KME!]ZP3"U6"V&Q;*[A7W4M-!0)(R2
MC8X"@99*1XV+@`4QQ&#RR%SMC;*W6MFM=D5>;<!0BWG43.)[F0HAC)'<)!1O
M?)0)+J6QD`@KE#V5Q!;Y'"RB7,@&KW$$O<<,2_;SZ]J^9*4I2][6M>][]+6\
M-[W\5K>S>O@2_P"-YWM?_J97M>WZV_2]KUYDFUK*P=J]M^3=R30]MF5(['.[
MI.,6,G,7<3:R'FLV&,4U*U>>(*"DLN))@9;2+!7<SP<BN,;P1K'C)I5'[X,B
M88`X!Y16^-[3YLI1U><KYVL;:$FA8C**XXN2[>A!14X'(3`'$906%C9@DFD`
M<A1`PK#&S0(5Q!`P[9]O/'&_";7'CI8\R`ZJS9+V;>*65.")QI3:')]NXZDT
MJHA!!CBIQL^WMGU(H54`P!@1Q")@8(W@`,$/D#8(4//*X+<8>K%^G1P;B7[5
MNN/3D8WY\-O9M^2.\-O;M5,N,;57`/,7-Q[@AA!XY9B#"<C>^X8(>`=KY"""
M"Y['XAAAAXXY9"""98X!X8Y99Y8XXWO;@(O&WJ"Y$I.7FX]ML'"A+!4,\D+B
M!R5;V+:*K$ALLL03J4KI>RIM.4B8V6&=@39$R8+#7QR[D+G:W6NFMQ^Z0711
MW):5MD;MPJK#()IQ6Y1MUKM\LO%SH::803*Y;:*Z267"ZD*$G&$4<X&J`*`P
M)`4I@<%#`RNO'C`U;SRQPP7=Q\\\LL<<,,.1;?O///+*]L<<,,,=C;Y99997
MMCCCC:^665[8VM>][6KH6_QUZ9.T%0,-21-I'2625@\WE0RVN3/>5?*IR^EY
M88*:(=-I.S)PL65DW,0,-03AA<#9$3*P9H($2U\;<9I<>^D[_2+N!AR=LV^$
M'$^=2\EQF\G6\#I1\5--SPP44W)40=FU`CB?(YBA6-D[CV,%["@Y"AXX#!99
MZP\A>CD,P)HIMS-L4OO<-L29%$!OQ]L-Q"<@.\2\&B.E`*`&$I2S17!L`IH2
MK@6&O?+(@KIQY/,6O?`R5%P_$UZP4S++).(Y999997)E;Y997OEEE>Y<*][Y
M997O?*][WO>][WO>][WO>_6]<ZE*4I2E*4I2E*4I2E*4I2E*4I2OG/+L899=
M.O9QRRZ>+KV;7OTZ^'IUZ>Q4"0G(_P`DDP;#[?Q7IYH)`DJQ[J7/IC7Q:?,F
M[AG8J7G"YR+':CV,*(+5M#ZZ`4(#$'63L%B$K'.YYX9A9#CB8B987?Z9KG:\
ME_I__*'&?^!%?6.S7.SVP[7XO]0.EQ`[7Z<AQKK>U\\;7M;_`)AA/';P=>YB
M=.O7L9_E;PI\`O(=SV;"R!9J3%KR%L'IV&^%I(5-EIF5\XH7V`E@.@X142\?
M2GFAF,]E`FS?$^6!1`V.XEDX:*$TU6DMF$+XY%IU]^/7,N#CZXO=#X`DS]/_
M`#]#VZF/R_*8_K@OZ3"O.OQ3^#6^6OH_](!R0>"WCO\`DQI1\5;.'-AS9&:W
M)"8L)2R95$^*7/+#-<J7=BJB-)"<SW4UV4L(24F@.S%=9:FI.-WI15BJ,D%&
MP@O\D0=BHB'PBK24^Z<R+=CF>_8:4)J>2>8@MO-QU2(S'F%+#D9B>EMA:C&0
M%B-'"=PD!+73<?N5FJ+E1AL6D^4%=&0G04,E>\L@5"YA.+]ZW]E->G*HF4AK
MS]#2XJEV\\G.>3425&6=/%FK'RP,WY`73Q8JN9"ED-DK98=+>!XWB&3;IL`3
M%8S*!X]TK'$Y[D1+#$(NV<D\[:96ZR@7:,J(<4.5H*RV$$PV8Z9$?`8V2HMD
M$U&.-9I-%;651)6C*<J];$BP)$0TJ$\1LMGYXAE%*#F%N7XV0`"BR<;:MBKR
M`V4T)'<Z>633*XVEO,PJA%TE;0@E!+LY"2GD4S0KFTWS<[QL:(]UQE->VT40
M.P9MD=Z'@,6]"C5LNCYV<C12<Y"7_0P6)ASCZ/#+@6DQ.5G@&PDY.6<@C)PL
MGY!.))SP-9`X&Q0KM)[,Z_#6.%U":8I0%I%;;3=#L;2](S.3%YDI[TP;N"&&
M[B1M8!R13(RHZVZ@9AG.Y98+RTC)0F`1Y:2"YW+Q192%7-;+):JFJ1EOJ8Z"
MO%R!XL;'0UT`D34!T58!+BB")BN"04DX\*FG<0#H9-0(FLP,0#9<02+352?I
MD@6<N6I8A[5A^;0JBURH0&S%5OL9R)C<-MUK/O4R$2+OD,X.HI"QB82(R)HR
M6I+1`,$(51#<9`,,XGA@&3-I"'MOCM^V2NS`Z#Q?SD\A85V%C^(HJ+)TC-LI
MGL=&KL65A.<<],W(5IF+(#68Q%.)*ZDB*%E0P<+K1(+S7(9!&Q`.QDK>3;9E
M^F4\ZW&?-DB^@Q.L3Q=%OF-(3>(>F)CY^]\>?&:F?WPU#/F"W(O[B'YM)![S
M5%4N^R_85DWLF^]?VDW>#;)DHNWBDU.-6:Y)/:^2I&+%A=&1)!;B>:VN:#V-
M@EW7)C!%-M<<)LHT;@B"'%A.4K+(B@#ACB$H$A+CXEKW7=QIT;;^V(0ES2N1
M4B-(3EK6AEM>:%-^-TDSY5BZ8%$L%-T[I()A%P%;[-U50LE!SR(0/FSYI=2T
MPQBEG4X>]\0_/`LZ^/CE;1=E.4%O*IYM3NX7<V5;AR5UD$=*-PQ%>HKS5EZ'
M'A@45"H9U(PW.DDHZE>14T^`:PLQG.@VP$%+8%,0?3+H1MVV-YM48CV2;R29
M:J@]40TGR#'RGB,"N1=+;04C;4E:,5XF;Q"4"BFQWVD+:+:RB5)FCB<`GJG>
MH0!\'KN)2H:]4/7G^7'ZW7BX_L+;2MP.1N>WSJWH=MWL9&82"/($)Z^2A)C-
M!="<,KMT1QM%LG%9*P6DPN=3ASZ;D:`PL;*!'R@@X7:PQ,!7OVK9_@MY*\BP
MK$3_`%_`F&NO>+X^=ZS@G`9E2&"JYV>BKBE@2+"#&!"Y3$Z?'Q+`9CCYA`6#
M#R&%RQOGEE6OP-#][%QS%\>W8`$4;LVO:U\NY!Y"=FU[^"W:[/3K?P6Z]:\[
MFN_)QRM[FPZT-FM6N-77E=U]E;)R*D5J\F[R69#^/MA#=J\T,#+K:I"'%H@B
MJXI]NG\AR9%642F&%PL@#8N.?6V:O3-<[7DO]/\`^4.,_P#`BM/.0;<?G*8>
MC^UST5-'->X"(-:")"73,U1AOB><\A1<$FHPAC-[LYN@PRCB+CA0,<;G4Q*Q
M5TOOXSAB7N=#MG?`2Z>`[<7FEV=8!4;D1U90V_$7G>%,LS9QX98PC,;X%P*6
M%3L3^OP2&-@["2O<0$0)_E4B'4+S.N&=($WD:%&RQSAJ?\\QRV?9&L/@2:<U
M?&^;1<L@Z1[<1^RVPL/1Y/S727&6T&FWTD1;67"Z7.S51&;Z2G)H6&=QC!M5
M.%0\11.YERF-\C9D<```0;#0*6F?L")M&E;(Z]PU+D5PVG15!\#;3Y(++'C2
M;)X;9Z?VJZ'2]HFC0@6S=JRM:XQ43=:):3C2$3D-0;LFO)KPZ76C[9***=U&
M:QR8)(I4BU;RX_U+!K[`EHJ\^:,KLE3ND8'=E#.LKZF=44DH>%7ZYU!`QAE(
MEB/)-&B^66VX0(A=:0HN,HY)E9Q"0[3O)^CQ:N*4M.&:'P36'@86D=/G^'52
M.I"06J<:C5\\;`-LQQN9\/-SHZ6[`':&1/NHR-FK&E-4;[.`58Z36<?/8GT2
M7#$+ZUZ+ZNR,PY*9$K*>NK@PNCJ<?*A)OM0]$1H+)RM9X+@71/9SA$3G"0/-
M-(/@AE'$F%3ETH]88N5*&\"/?7Z:VS)<JRQ!;,651J3UN&VDS9Z&'(G'FX47
MF8ARM#I^.]QXC++);$B.ZXZ;[74&O)J8G``E)9B`,LJAC!O:-$<=8RILW!^[
M1Z!=BRK$V%<+U=#AC%^I+39[/P$;SQ.B+PP)<\39*^<Q)E4U[8LT9Q$66>S.
MD[XND='R!.%!L@C0/8PNV]DBT<R]'!5CLUVZP$E:8&+!36E9%<6O^P3BUX$A
MY%2F%'P#39;+:C(;0)M]''G'2*[GVG,!V^<4)(=JPGY*.!9:5/WXVV)+$?L*
M24B5@7(O&1%2&P6S*K]8"W$\DOI`;D#LMH><=_Q^KE4\IDL:\&D&\1D9/;J:
M11YE2"95WG,E9U`N5<4NRY;?6O\`?[ZU25?[-+U/\E_G:0_:13^K!5SZ4I2E
M*4I2E*4I492AS/<3R6?.IA[D4T[!.IYH<D;"M/+#&L&8+"9!#86&+JHQ<:V`
MF.6-A`!10L^G4,3/'I>_#]6MXE/*,:>?=U9/^(T]6MXE/*,:>?=U9/\`B-/5
MK>)3RC&GGW=63_B-/5K>)3RC&GGW=63_`(C3U:WB4\HQIY]W5D_XC3U:WB4\
MHQIY]W5D_P"(T]6MXE/*,:>?=U9/^(T]6MXE/*,:>?=U9/\`B-/5K>)3RC&G
MGW=63_B-/5K>)3RC&GGW=63_`(C3U:WB4\HQIY]W5D_XC3U:WB4\HQIY]W5D
M_P"(U<#3Y@^+=].EM,AG;_:G.5VO%?1FJUFZC36S3RNO.-PJ)9(0T5+)!*%Q
M3:BJJ9PJ0(E@[7S,&C`0.%KY9VM4D/6U_%?KX[?OVOTO;]Z_@O[=?F-^9"_L
M>?\`-O4(_$K\\QS8?90G!\'*#:F\I7X%RQ<H"$7*@!%P``\00`00\`@@0L,;
M8X!`A!XXAA!88XVM@$'CB'C:UK8XVM4.>_'KF7!Q]<7NA\`29ZF/R_*8_K@O
MZ3"O.IQ4B88ZX2U:XF&.7J@')!X,LK6Z?DQ91Z=;7O:_2LX.&#9'69O4-@"3
MA@I'D-FQY*T:PJK%6$^\3:FUY&.L=51T78Q0*O@FIO9#C]5:2BJ-]'8AUOE+
M+[G/N5-P;IP$XFKN/W1I.3<&G&R.K"0XV&QQ=D5F6G&?';K(.#15&2C+[D27
M`MHT?1T*O)IS%J)0B6*<*)XRPDW4W4MN)SCE4K%7S2"^NNQO'XZG04G^0DI7
M:#_4G\[-U9-"B1!8YU)45TYM?K3$6NQ)GI"^9D]IA7-QQZ%1.1")LPKH@KQ.
MBX-,D(V#(1)4-=ZVM/Y.EV$=FFC)!YM1ZZ9Y9\[-L!\*;3>HCF<D@[$M%A,R
M19XD9@N)ZB*2:N)S08"#'[7:B2XF^0/(1(\H=P1@U,4RL8SFO3F:TINQ+%"6
M$%.C)0F1M5%AE?\`.J[K'EB"IU-QN:QUPFQ;;LPM]S+>2N<;@YA1V!-)>*BX
MDYMH=WDM(3W#570[=@YMT@?LPM(`RG2;'S*DAW0YNK$<J%EAHK#TCH1-W=9K
M>0'`=99=.6VXN%%R&/.)';39"D=%NFO&.6^LM]?()=UHB,G8N4M#G4UEMWR+
M)"X4V(;:I$6Q\+*42P_&EVG(+K;FR8NNY1-,H0CGE=+CAK+D7+4-`.!2?5@,
MW4XR.!9_NI8<3]0B_8D;@*/UR*H:93.>SP&D"1@$;S:E:1#]B02C(<L.2]UJ
M17L?Q(`%25AUQS&SMR^),J6)@)99-)DBQ<F6+@!X\XIK89[*<Q]^F.>/J@[8
MO:_@RMUMIOK;TO:_AMUM?KTO;Q7J:RX>%^O7#"_6]KWZXV\-[>*]_!X;V^A>
M_AM2X>%^O7#"_:O:^77&U^M[>*]_!X;V^A>_AM2^&%^UUPQOVKVOEUQM^*O;
MQ7R\'AO;Z%[UK-N3K,E;CZOS9J\N2`_(M0)R9)Q@.5[1D812CT(-M7,E//"G
M)HS@25M(N5<R*">:RZ$;31\C#>654L5%)FA@3@$:;:X@)T9K:;S.:?+MOHVV
MHTD%&:S8;R*SM,D](06XWDPJC(:*E$B^M>`)-/2TLD5(DRX...`(``>-O#:]
M[[6<?''B2T%QV(%*[%S=L`H;)RYZ.#V-RZ!&R85(22H(^"0[G0WT&+V2QF^G
MJS^Q*I)QYG,4SM+)]$3#N>&!RQXR=D;I4->J'KS_`"X_6Z\7']A;:5OUN<\H
M)CS5#8A\[/-DN\M>6E#[[<$T-0TW`W>6<,;)B&9,NQ'&:XPH`2^&?2L!P,DH
M08+`Y;+N.0F%LKY6R[%BHSUN,X\68](!I;#5F,T%-E)H)"R4$GM(^W4PVVB(
M:9C>^*<&41!B!?`C:][$\0[%K7O8*K]K@J?YW'OVF;_JXM0F_,WOK)^AW[@Y
M%_OVE:IP*_$P6+FP1"YH`$R`+:V(@!@(,8$3&V5LK6S"%QSPSM;+''*ULL;V
MM>UK^.UKU]Y86[&>.-O#ECE;V[WO;I;K>_AO?V[WO7GLP9&_6N^SF^BNP>/Y
MQ[%1SL1M23G9@R(V=J];XN+B-\77*`XJ,))]HR(IW<Y-1).&,%L3,<T"5",%
M1RN8`'8Z##7Q>7>2&]KVOQ#2->U_':^]VFM[7^K:Y^J6ESD@M;I;B%D6UKWM
M>]K;VZ:VMUMTZ7\!_P`=NENE_H=+57T7>2'R0LC>_MTU]O\`^/\`;O[M_9O2
MTN\D-K=+<0TC6M[%M[M-;6]RQ^OSM+'(Y86P]N(&0;#V!N6L/;>G3&P]BV0N
M`^1:PUCO=;%LAPPQ\B]L^XY#AAC7#N+AAG;]/1=Y(?)#2-X;];_D[M-?'[/_
M`*?X_;JMY>Y(KVO:_$-(][7\%[7WNTUZ7M[%_P#E"GHO<D/DAI'\/C_)W::^
M'KX_^T/HU2TO<D-O%Q#2-;Q>+>[37Z%NEO\`M#Z%K6M;V+6Z5K=N,B<FNTFJ
M.Q.MR+Q6O)EJTYQ([(Q3G<N[O:BJR,VC3H+@E0UI42TM5`4E`D0[%QARA$8,
MT/A;L`YVSO:O3(0"$`)%`1<;8B!%2X8F-KVRMCF&`'AG:V5O!>ULL;VZV\%^
MG6W@KETI2E*4I2E*4I2O)'\SML]GJG#MJ&H*S09ZH>&]'3OA056BVE,\-8+8
M:40@[F#R@E&3@]@@<,`@^ZC"=S!#P"#MB'AAA;>`AMUI<<G;+7(TU\4&2[S:
M?UN*^>/7'!-92A.I./"4LEHO)/\``;1]M7<Z_&ZB3=[4".FB)%S)XW>24>&7
M<,T?';;%`A[-/S5\4"'LDD+OZPJM9"C2Z2%=+$R!5,152Q'S/#R2A\,P%7',
MSCDF#X9@G[%A<<L+=F$QHW&&`+A,F,\QS(I8`N#9GL.P@XIRV-R886-TFU\\
MC6.>&9;IX!PLK#!7R"OVZPK!<E:R;&QLV)7BU#89YGO)RO\`9S;S<L9-1G+R
MLZ(O>3A8+Y1"+:7D8NK'3Z&YVJN%102`)S(<F3Q5@+9II@`QG^Y&0=:UEZ-)
MB-AOLA[*SO=,ML@NJ,2*F^\F@W'=""<64)$;S]>2"W3C?8ZBG"&;(J4&OG"X
M;A<Y8^VT@4RK)QTN!E"R!#V2:$LXH$/9(PX.1@!9Q0HTR1AR^)GO+(P`L6(^
M9@Y?$[_D.1@(WF#B>_R+(2QK\:KL\6-'&1@<IBQHXR-E<0<S13%DLC(V4Q,]
MU[WR-E,4:YDKB8[@-WMD8""Q,6!&[A<3N(O8_7T/H_\`U/X__P#`3._P.GH?
M1_\`J?Q__P"`F=_@=/0^C_\`4_C_`/\``3._P.GH?1_^I_'_`/X"9W^!T]#Z
M/_U/X_\`_`3._P`#J.#E):#12=>8B/)+1:*2>#W^XX\`SR2TVVE'@L!=Q(NP
M%P".IR65-AX"X7O@+@&-CB+A>^`ELL;WM7I*#_*W_7B?TF54&_,A?V//^;>H
M1^)7YYCFP^RA.#X.4&U-Y2E0V;\>N9<''UQ>Z'P!)GJ9'I;+'&U_\V_[^-[9
M6_UVM4'Y+A'3FJJOP6)^2SDZA%I/R5I4F$6,XMER!4EA-QUS$^EJ1'I@VD]:
MUN7U8LGFG(O'AP0U!94C=@KAV,'#`MLQL^S]1R?/E@^7G[MNN/X*]/4<GSY8
M/EY^[;KC^"O3U')\W\?,'R\_=MUQ_!7JEN'%\6MTMS!<O%K6\5K39KC:UOWK
M:KTOPXOB_3KS!<O%^E^MNLV:XWZ7]FW75;P7JOJ.3Y\L'R\_=MUQ_!7I?AR?
M-_!?F"Y>;V]B\VZXW\5^MO\`V5_H7\/U:7X<GS>U[7Y@^7F]KVZ7MZ-NN/AM
M?_Y5ZW(T>T09VCJ1,P*),L]SZ\)\E7&89/E#8MT-!UR`X7:"R&K'I/NAYDL2
M/D8,@2;#-0R8`7F)F:RS`S$%-B8Y!AA[STI2E*4J&O5#UY_EQ^MUXN/["VTK
M?G=#74EMQJ=L5K$HN\6/R,]0Z_(I-/<!(`7Q6H`]$(TC"+P:(95$0!5R3+&.
M^K$!5A,P-=BX61XMVNZXY>BMC@1G&4=QT64LUDNPF*T&6`KBE\"@BH"U&XF(
M`2B(5"&,AELSP:=B:S+AF!\`<AKA8#"XX6$ROVN"I_G<>_:9O^KBU";\S>^L
MGZ'?N#D7^_:5JG`I2E*4I2E*4I2E*4I2E*4I2E*4KRB_,YN/:X:M/\>O3M>C
MQCU\?3KL3*ENO3Z/3KUZ?1\76U991^-L!>EO?"7I($:I=^;!28^G]J](C>=<
M@.!<UN4WUJ^WM<C+Y*LLZ7:3*(2NDY(&+E2WHA!J[A(I9NS?2'2DB@B&18V\
MN/*;=>5W2=$<$?1Y,>*WN0R5!0BMM)[O7H"CMK15Q?&=4E)ZR`[PXJ/E640V
M`D]N)+S>:HI,3`@4<"VUR"RK.AQ%E%:*Y2:'#_L>PUC5<$E)T,OA*A9F\6(+
MV=3G5GVC.HXY./B=)$DMRMYHIA5B.($V@O!H2"$S&(XEQ<1S*0F-,FE+:"5*
M*(8B?;8W$!ML00=;6^C/'6S+&#Y`5))5EJSNE0@NN!2'Y,Q=U$QL%1SD7+:8
M4;Y*.%=60L#R(C,YSY2,"(&MN9UL8PB)B/>SIX=)Q54$DSVC)4(1J63W;RYG
MPI%98#U2GN;;_(<V5Q*BC)12TUF)`8IZ)S"O@DN-&P=69(JV`C5F>LG30X">
M!:4C\,4[28RC:2:<6OJ%BMJG(RLD(Q&/NI4CN&L]PM1XXUNBQ&CDP3C/`HH%
M(_>S`,S>ZC95ILX,JX'2;S:*><<Q,5<.S*:]08[HP?;F=+N:4%@G%77S5&*1
M9-8XT@'IG?Z["C$4VT[24I*3E!)M4XQT!8'#-1&.W$U/<)H@LK0KX`[_``2.
M(6W5[VMX;WZ6]F].MK>._2E*5&GRL?.X1+]D`XW_`(8T75Z*0_RM_P!>)_29
M50;\R%_8\_YMZA'XE?GF.;#[*$X/@Y0;4WE*5#9OQZYEP<?7%[H?`$F>IDL?
M%;ZEO]E5I2E*4I2E*4I2E*5#7JAZ\_RX_6Z\7']A;:5L?RN1F_IEXUMYXIBQ
MK*[WD:0]7)C:#):""#B96G*Y5UGJ!%)1$LOEF%B,>430N!8N%<3'N@F=L>OA
MK9W7%`6FKK]!K9<A`RE.%O0]%Z$NIAVUL3B<LI#$;Z<J$35L<\\;&29\L8+#
MVMGG:PH6=K996\-\T5P5/\[CW[3-_P!7%J$WYF]]9/T._<'(O]^TK5.!2E*4
MI2E*4I2E*4I2E*4I2E*4I7E'^9RK6OPW:>8WRMA;+.=<;YY=;XX6RV+E.U\\
MK8VOE?'"U^UEV;7OTM?I:]^EJD;UQG63YI5Y\3I'U@E#7`K$4RJ\:,13DE03
MSY>=6@G`"#%);9-D]-(!%FLJ=@#O<((TOE.AXL&"OFS8"D4(9"G];7VU`<[N
M1JK:BW',V(2EYUMU=2K%!#Z.X&G'#G<B&I@`*)!53C-R2HE%1Q2I],4"9HMB
M.6,%!0AL\:B7A/>R86/(K2C.9\)#5EZ>("T`<T"(4^YQ:AG'7+&R[F/Q]([\
M3'[!:"JI2%KPEN$ZU0<&R\2*C,`;Q&$1F2VLT)Q)G<-HV3OVK.-QMMBN2%RS
M,?3V<$C16Q$4W)=SY!ZS[!FQ%X+GB.$15Q817'%`8+9%(SZ0>HP(QI<B<9;%
M.M1#5F,[L25T,S=^SFA7966E*/4YL*VN^(-C\;.EZ'V`Y[GU)OA+:$COX:2&
M4U2S'\W+G4O%JO-$#?L<2@CG@')$;J>I0X2(98L2N1=ZJY(DFIFL#F7)#"=L
MS,A19J0ONH#%TNJ%]JVCJ^MMB+QU:+@'"8=0X;S3)A4&[(S29*FU6`7.E%@N
M(H%E510^;AR).8VPG=+*?K8\18F+Y9G(_D3$\NN--<3?0)-?L<2`M+[3CQG/
M22[DF2$RR;U7U&-F1(B>V&NZ/_QADBJ#(=X(=J<AV\2Y"^K+:=T<.TNP'Y($
M>QM+X#Z0FVXY8:B,RCKVBP%>;[,>+:9J^QUQ?>Q=V'T)LN-6$3B6#')N!^):
M>85#+/3S>T$\RPCO",Y>=D82S-<6DX,R<RXMFFE%!YCN!]J&2.KDX\9#96]B
M8:6$%9;[B=)A'+CJ;%;ZZ;.*)A`3LW`C@F1RJOLU'R.[6\P6.@/]PC.Y^HC-
M:Z2^G48+)I,9R/5/0B!5W+F91'))J25LIN()2-!ETQ/(D0@1`\"Q0`*V(=KO
MI4:?*Q\[A$OV0#C?^&-%U>BD/\K?]>)_2950;\R%_8\_YMZA'XE?GF.;#[*$
MX/@Y0;4WE*5#9OQZYEP<?7%[H?`$F>IDL?%;ZEO]E?-Q0K7O:X@=KVOTO:^>
M-KVO;QVO;KX+VJG=@OT4/[?'XZ=V"_10_M\?CIW8+]%#^WQ^.G=@OT4/[?'X
MZ=V"_10_M\?CIW8+]%#^WQ^.G=@OT4/[?'XZ=V"_10_M\?CK[QRQRMUQRQRM
MUZ=<;VO;K['6W7P^&U5I2E*4I4->J'KS_+C];KQ<?V%MI6X'(W/;YU;T.V[V
M,C,)!'D"$]?)0DQF@NA.&5VZ(XVBV3BLE8+287.IPY]-R-`86-E`CY00<+M8
M8F`KW[5L_P`%O)7D6%8B?Z_@3P7'O%\?.]9P3@,RQ#!5<[/15Q2Q)%A!C`A<
MGB=/CV+`YF!\P@+!AY#"Y8WSRRK7!4_SN/?M,W_5Q:A-^9O?63]#OW!R+_?M
M*U3@4I2E*4I2E*4I2E*4I2E*4I2E*5Y1OF<OUFS3[ZL[_"*E2IN\@<PNS?,$
M0*PENWA?,+,.PF/C[>%\L<;"8WZVOVL>MKVRM?KTO;KCB7ER,FS%<C.*:3+=
M)Q"BLMPJ,FF':!<VU\&.`GC6<(:^2L"8R4$LV1S$)&4O`L:$5^^<4H,H;$.X
M%1M=&#'.FB\CO"/4S79F1MB[EYH1T[8XD:#L(F=+O66<T4^6&$@EDE>3R2TY
MRS(:Q<J\V:8:JF?36,:13QM!-(;A;:EBG9>0X/::.\V.Z490`*L>+D131HEB
MI(;K+(L>/7>O8+2`]7VB+Q%)N\E)Y.9%651K*!-5<1H@FY*#E.`D<W&YED[E
MQ+P;KXWF(KQ40A)HF8SE91!9#Q9Z"QLG$S50$,@I=P)OD(O8Z51&D@XI0R43
MS/#DD)G+)I,2D<NBJ:H5QSU'<&H>I4PSF\&(S2H+'<L,-]&4)*833C)'34T,
MWL:X5U\82"T'\(33UY'E!\'HZ5";R=;<7'#EB=:R#FM(9-X()!4K;475K6:V
M3Q.Y0=%I89^O-/>KV4R[?*IAQQ2"5,&LD]SJ2N0,$CH3N$4%H^;S421PBIK"
MVNJ"JH74%M=/'3V1\T!EN=L.&+5-C`9,%!R0&H=9;B9EDU@*28CI[;<#<#;Z
M*>)A-Y?:B'EBB%DHXF%,T=)<*`,CD^XJ+=$#`N5P)B.[014ASE"3B!N=1UXP
MF+'94?\`+DE?*N!"6#!0<3,3NA-SHQ153CHV%PKK*6&-AF(8*9XX]G83$448
M/$3$4<'N69D/'/$0<"QK#,8N(9"QRR%`Q-AX"#%LQ\<+&@L!!0+B889968Y8
MY8VRQRQRQRM:^.6.6.6.5KVZVOCEC>^.6-[>&V6-[VO;PVO>U5J-/E8^=PB7
M[(!QO_#&BZO12'^5O^O$_I,JH-^9"_L>?\V]0C\2OSS'-A]E"<'P<H-J;RE*
MALWX]<RX./KB]T/@"3/4R%[WMAC>WLAV_>OGC:_NVO>U>4K66+-H=R6[,\WO
M#E$Y#HQ41MQ=SXV2V'#;[@QO1RV&A#^QK\CQEI3<1W%`KJ520)1M(B>7,8#K
M9H,0<+(4'`#'.^%;'^D%G7RP'*[]U77#\&2GI!9U\L!RN_=5UP_!DK[QT!GG
M.V>6'+YRPYXA87$%RPE'7//$(.U[6N(+ECK%>P8=KWM:^>=\<+7O:U[];VJF
M6@,\XXX99<OG+#C@):]P\\I2USQP$M:_9RN'EEK';$2V.5KXY7POE;'*U\;]
M+VZ52V@<[WMEE;E^Y7[XX=GMY6E/7&^&';R[.';RMK'V<.Z9?B<.U>W;R_$X
M]<O!5/2"SKY8#E=^ZKKA^#)3T@LZ^6`Y7?NJZX?@R5\YZ#3MCAEE;F`Y7>N.
M-[VZRKKATZVM>_A_(R5L/Q".J9@W-R)P=+.PLP;)INMVY*=&D;/V=5!IK,CA
M,]8UPA.1#*4KK+/:3,23H(3F=RT8)X@HA7`J`/B$'A:]Q<Q9I*4I2E*5#7JA
MZ\_RX_6Z\7']A;:5('N$_8-BW5K8&1=F&N0>NOS*B1\.696DJM$@_DUR1PDH
MADTZT4\RU3'--=)512L!RXR$>QN44<,[EQ_QO.]99C)9:3BCA@K[!(@I;'7&
M4TUAG)I=,"1@$]JJ;?3CS<)`I`&.(*6"413!$N$G!8XA$<`\2H>-L`<;6OBN
M"I_G<>_:9O\`JXM0F_,WOK)^AW[@Y%_OVE:IP*4JG7ZON7^*G6WM^Y?XJ=;>
MW[E_BIUM[?N7^*G6WM^Y?XJ=;>W[E_BIUM[?N7^*G6WM^Y?XJ=;>W[E_BIUM
M[?N7^*G6WM^Y?XJK2E*4I2E*4I2E*5Y1_F<J]\>&[3S*W3KCG.N5K98VRQO?
M'8N4[VMEAE:^.>-[VZ98Y6OCE;KCE:]KWM4A^L^HD>ZKK6Q2ZQ7;*SJ-[+SF
MN3X]`Y/?`KT`;CG72G>@S?8O=B!,PCM(F'D)WH443"PK9!6)$S2N8))*6`5S
M!,C7-/>)9,9I%H,*03CK8KF;I=ARGCEE&CTS6$P<CDU7_;!,6A,&BOA#")BZ
M.$CJHY4D9$-@)QT<`,N)$61XX9RN&U$M`<R4R&#$\ES&;UG9DGRVXM@'QJVQ
M99TP?$#9&&#,)QK7=2ZEL>;W(ARA&$<J2]YIL=KMHH02'ZBJ%T]";_XM7C:D
ML\H1PJ*S1CB+%)%C39I)5U4I-#CFPPPI\DB%(5C"(M@XU25..V.A!&V.[(FQ
MD5.($2K;=J.I8HCM5UE;E(XNJB?VB)H#/UUN,7BB$HL@-907AK>K.9MQT_E)
M;;S;>$/:M[&P/(6R+$[FT$P!3?L@N&8(T4B+85BR.MK;9A1(5I$=.#W/E2Q3
M*FJ6H$O14F;'`/N.H:;`\OZD:UPI<DQ)".N$B]Y<AF+9KCJ09"=1DRQT@^3(
MRFKOU#>HSA6AUY[FAC:QY[2QU?+CFS>F2OQ:[)6AIQQ$E-37P9)=D.1<US]\
MY/7<14J:6/QV.C5A<EU/#6(V4F^.?=,P&T%R+CJ4F^JR8.T2B<Y&FJ,:047!
M2*;97T:G(\2DUXEU*-V9-BALS&<UQBZ+.%5?285:R_J;$.J.T;;=_?;913(I
MQZHB))CU0``<3Z>I/,O&J^H#D#957+AY=@C4)QQ)M6\Y*4$9*5F*F*CQQB!\
M`2XY0U@A$3O8L;LY(@-Q0S@U2Y`3"/LXW2;);J47ZN,VR423E]J,Y!D%7<QP
M/428..38B36Y(*'W:+1'F:/;.D3LOC/M80UC9QD3ML=&LQQD@S$23FH?6VN>
M@5K-,\A)Y@X==9<HKH;82HQR1F@XG-DCS?(*`W&LC)S<:#:1V8U48M8BWFBW
MR1-.0VRDX"""%$))()P)=/*$$W$6Y<N"1+@%+8X=H`$,/*V%NVJ-/E8^=PB7
M[(!QO_#&BZO12'^5O^O$_I,JH-^9"_L>?\V]0C\2OSS'-A]E"<'P<H-J;RE4
MM>U_%?Q>.WT;>U>WCM?VKU#;OQZYEP<?7%[H?`$F>IC\ORF/ZX+^DPKSK\4_
MSN$M?9`.2#X8THU)92M+=X8_!DEA1.VB,B+<//<YL;$F$=RZU!NYNN.72&,O
M'B3A32^66)5=1;'B"65>[/5[9-]\,\=5:*WW,HLV'!P-`[FV]>0$[+9>)F3$
M,_)<TM-B3:D.,.PT?.949D!QV6'D*$EM2RR$<$22(K'LGHR3PF!963B:V?:S
MH*ANIMKF8F%'>^-GB&XK6#EU-CQ]+;/<6G+4BF!S;973*"ZVI-[U?I+9#9:'
MUU&6R[:`E6!2J.ACN)?=3:=!)A,1BFTG`PQ<Y0P75Z;;ZE[96ZWZ96M>ULK=
M?!E:U_#:U[>'I?PVZ]+^&E?`GYF)^LR_FWK5;BE^>5YD/L@S8^!OK;4UE*4J
M%/<'F(:>JN^\$:G#QX.YHI/X,</<+8((^8";6J!_8A;4F-J>4=UP@<DLOC)S
MZ1%'%QF%T\G!M=HFD5Q_CI8_?/&:O&_6UK^+V;>"_2]O!>U^G6W6U^MK]+WM
MUMX*K2H:]4/7G^7'ZW7BX_L+;2M^=T-=26W&IVQ6L2B[Q8_(SU#K\BDT]P$@
M!?%:@#T0C2,(O!HAE41`%7),L8[ZL0%6$S`UV+A9'BW:[KCEZ*V.!&<91W'1
M92S62["8K098"N*7P*"*@+4;B8@!*(A4(8R&6S/!IV)K,N&8'P!R&N%@,+CA
M83*_:X*G^=Q[]IF_ZN+4)OS-[ZR?H=^X.1?[]I6J<"E[]/#_`++7O_JMX:^,
M[_C>>6-_^IE>U[7]BU_#:]O_`*5YI6Y!@VT>V7)<LR7L;O(B`Q=NL3BI@->'
MMX=DX28358Q74_6-[!HZ0PXX?:*V"=Q'0]'*KFC9=/"'-&5,7(>^=[6RODU;
MT*AELI1U><NVW(RVT)-"Q&45QQ<JFWJ"BIP.0F`.(R@L+$M$DT@#D*(&%88V
M:!"N((&';/MYXXWX3:T<@=YD!U5F[D<A#Q2RIP1.-*;0Y9-L74FE5$((,<5.
M-GV],*D4*J`8`P(XA$P,$;P`&"'R!L$*'GE<%N.^,[].FSG)C?M6ZX].3[<[
MPV]FW_.CX;>W:N&H<?\`$:0G'UA6VLY(TI(2R9I15%94Y2]Q$U*3$XB"(9/*
M"DIGI7+D4\@2+!"F#ATX8`*E0`Q!AQ0P\,LK=<U=&(+?;=2'>QMPN0][-)P%
M;'D!U,_E<VX=+97"60H@%CB,OH,NJ"0J%;CA"@7'(G!P\1PA@,LL1@A`\>';
M2G7NZ*.Y+;I[_7;A56&033BMRV;5W;Y9>+G0TTP@F5RTR722RX74A0DXPBCG
M`U0!0&!("E,#@H8&5UX\=D;9Y8X8;-<FF>>66..&&')YNAGGGEE>V..&&&,H
M7RRRRRO;'''&U\LLKVQM:][VM70M_1>#7:"H&&IN!R(NDLDK!YO*AEM<K.W2
M^53E]+RPP4T0Z;29<.%BRLFYB!AJ"<,+@;(B96#-!`B6OC;C-+2*`G^D7<##
MW*Y"'P@XGSJ7DN,WE@VU=*/BIIN>&"BFY*B#+R@1Q/D<Q0K&R=Q[&"]A0<A0
M\<!@LL]:.0+4TCKYH[ME.D7;6<DB1(\1P0^9`8RHJ<DFWSB34]SMXJ`92S1]
M`5Y,'2UDH&+>_=TU1!%)FL+W#'#RPO>U>JM-RRS3R.6>66>>1,KEEGGE?+/+
M+(N%?++++*][Y997O>^65[WO>][WO?K>N=2E*4I2E*4I2E*\HWS.7ZS9I]]6
M=_A%2I4W-8TF26&C!<6/J7WV*>":<?H62XKX)97`ZJG+C'R*,DI"24%'*`#J
MJ\OJJ0@IF!LX2(8GU,L*HGR">&:.E]!9,W)EYSRE&NN43QPYXMEU8V&DJ"9=
M%</H-OQ0CM39>L)W9=DGFB$XGBBL!_MB2FX<;BIYXK'T[,L@$G>U@,FX_04P
MX&A7==WHVD#.W9V7S+%D67?.6O)C3*)[#8S6B!-=0ZJDY>;LH%G"L(I6,S"@
MFEQB3WED9(5VNI'BB&]5K$FMD%=)Y>7)8FD,Y,*JNNLQ*"^SY2?K$:3'8/F)
M(CU?*%%,)0E,4C.$NGLX==*E5M)QG!J-9NM;`;,N\W$LH",CN(,<RIGT_(1'
M?-,<+T<<>LV`9=<CM)RU+L+,1+-KD6M064GI`K-PD*7`V_@M._,PVD]K-(^V
MQ2H[T*I!E?<SK2&>4)E3Y-PG47%";R4LJ02+QPAQ%DEW.QW1LR'Q"#35VHPF
MS;%+<&JSFV07W:;4%1TY8CIS'14<,)\MQ^#(BQB_`@(^9Y=01U.[H!REJ'NH
M0GP&+XZ7T[(.7SFKD(SC(YZYMN-X#(U(\1Q8^33B1(X%.!.X2/'`O/\`441K
M/1ODEIF6<#3=S./J*,M(I`FK88;&]<H`R?L,&YHZ=KG+QZ_-M&DR=?6.3B"[
MC/1UIT#%JG(4Q%9).O<`\JND0.1DELXQ:H@W)/1RO1JA,D\VBC7=ZD8VWUXV
MP;FT`LF'XQ9#M*,!@*!!!2I6=YUII[3?*^L1U'4J)`:&WTQPJ+[)(N;&E1H+
MQY87D-("+=M61+X8+B;F5RMR#MR$65&)-CQ<;)/H!37I+65-\O=@+9>5X`D`
MNVFNO.MQG->9O(IK>3)3#1"#</%7(CBH"&MLE9-I2&X0A3!S`WGT>E&R[LG\
MFY,)23UYB2MFPH6FP>&C[00$MML&)-@D)?<L0G&9(*,KN$]+82DFH2N@O=TN
M(^@*A.0&LO$BL<,5#&22AW"?,KD]\-.&QG&0+6,2/ANKH%E'Y=\#JI5ECO;'
M:Z.KM0%WF4$$PN%VN*OV3\'`.C%QU4%)R.")P(IS$'#+8JZQ\TE8Y9VP8?"=
MGC846ULK27O):V707.W:QME'H>5L;W\./:PPR[/3M88WZXV^!%GYI*[F)VF#
MPH=GL9]>DE[Q=>G9OUZ=6!TZ]/%U\'6HK^.I2YR0IVY4\H5:7%4==>>_RQE/
M04F/K;0BWRLM7A*+,30$0C-AD&%$_'&+6P;@@)MYA)CGR7AE8+-/\SPBHEI4
M_-GYI+_]P>$_[I>\7R`JMEGYI+OEA:[#X3\;7SPM?*\E[R7M:U\\;7O>V,?9
MY=FUORW3#._9Z],<K_B;PL?,_DD_-&CC>Y4G,;;2';HG9Z*H2B\MQ3SK0WJ2
M;N+F->:MM97(*2-S.^"`16PV#.QD5$6HJR32I5)3G,V+6OD#/#OQZYEP<?7%
M[H?`$F?I4Q^7Y3']<%_285YU^*?P:WRUU\H!R0?#&E&MBC^U+2,2=*<2Q\V%
MV6'A":%=0DQ*9J^Q2:RF.<X@IS@0XV;#;<SC2%M[/0Z17FJ.YC9`!-C^,RCN
M;@[]?:4>-FT@CWL?;$H+G9LF/:1FPIZ])42/]9CI[#3"\8J!1TY704QK'U-0
MP>C,?;J8V2.6..U/;@I@9Q`&`W054D3,K8T6QL+WS?V4UZ<JB92&O/T-+BJ7
M;SR<YY-1)499T\6:L?+`S?D!=/%BJYD*60V2MEATMX'C>(9-NFP!,5C,H'CW
M2L<3GN1$L,0B[9R3SMIE;K*!=HRHAQ0Y6@K+803#9CID1\!C9*BV0348XUFD
MT5M95$E:,IRKUL2+`D1#2H3Q&RV?GB&44H.86Y?C9``*+)QMJV*O(#930D=S
MIY9-,KC:6\S"J$725M""4$NSD)*>13-"N;3?-SO&QHCW7&4U[;11`[!FV1WH
M>`Q;T*-6RZ/G9R-%)SD)?]#!8F'./H\,N!:3$Y6>`;"3DY9R",G"R?D$XDG/
M`UD#@;%"NTGLSK\-8X74)IBE`6D5MM-T.QM+TC,Y,7F2GO3!NX(8;N)&U@')
M%,C*CK;J!F&<[EE@O+2,E"8!'EI(+G<O%%E(5<ULLEJJ:I&6^ICH*\7('BQL
M=#70"1-0'15@$N*((F*X)!23CPJ:=Q`.ADU`B:S`Q`-EQ!(LM53VZQ&<N6K/
M3!'U]5W3GRH0($[`Y],O$NCA10-J5"5IC,HEV@=(F<GH52<&G=B8FA,TS(Z,
MN9*I<T&$3!O(,]EOF;#*[-W8#2T''-D]A6"5U)LYE&7L`%36,186L9)4)NN1
M6@L@)=!0\&^(U,&M<DW;*(ZK8^0-`@%<1NSDM9YA0?3+>A,U-%#7>DYQ06U/
M\^RA+`?FGKN-WWZ,QV:O,M:![C*!7LD?.%BU^\D*_=#?FL1-]Q![O^DH+/+^
M"B;>Y1"U=%S3@(RI&`.D(;Z4)8"2UF'!3H5I<,[#9)"P$8+/LLG]UR8]F;<@
MDW-96Q529D(*UQ["VVVKW>TW8>[^S4N)NII'56"G=KJ\81,AJ,@!R:YX$#54
M\MM.@/P,92L@6FY>S-`M764JB8$F^HO!;1BKO+FB_=,A8-=994XUI1TSG]&W
MBWLTH6)UY,#;JF?<H`SL]#(JBRG!)24`6C:+6T(*\S`R8#JJR2K.;K'+`F,@
MT-[-I6/D.XX#XAXS4\&N\=MO=2C\?/&3F1+<\Z;O4YK',<BL!W(CW:TN!LHK
M@!&$_MQQMY15DM60YLCXNFN,8\7/BVQ>1%Z)@H98RF#%0)HZ5YBG"<Y'RG,S
MR5WX]D'2M<'$UVXY?1;MN(Y9O;H1;#%"V/\`.+Z'=X8;Z[D;S&OD[?/7YY.]
M,0,0F]YD7&N,HV#X^]<=_-&4^::;00LX8GXG7(B2C!TAL95;L+21MB++:X0<
MB$833:5&X<AM-#8F;R-@#B!H6#O6TAO9G.QBIJ``%[]K-<0D_FD%F11&+1)1
MQPW$RC7CIBMXL3=<E[G^>@F"B-1'2PR;D\Q&,91O/`4P*6+K?F0:-I7FH$;\
MS3ALCWN9%R)YL_-)?_N#PG_=+WB^0%<4\L_-(_>9ONS"X4K!=ZFNZ7#DO>&^
M?8[W%[?8ME'_`&>WV>O8[73'M]GM98VZY6BQX0E/G)+\6&H(6K#0XK5.`\6<
M]O0[.3T^MLDF7!4^\O2+YJ>?5/8#+4&<7/8N'S7Q(8H1\V7S1+)8A@7`_F;`
M!E8\V?FDO_W!X3_NE[Q?("M->0UT?-%*7HWM<I.QN\8#:;Q""G^;5%W6>2MV
MK["I98%)SRN>A2QQEIQ3T32N?8'9_?*BGA76,"]N^PQ+X8YWWP(/7GJ=3$)W
MY.68Q2<'6;H^3(=DQ]]M/=(^8L3QQ0\5]F-5-S1#K>QN'F"IGY=)LB5.ZWQ/
MC7<V)GMAYSU/^>8Y;/LC6'P)-.:OC?-HN60=(]N(_9;86'H\GYKI+C+:#3;Z
M2(MK+A=+G9JHC-])3DT+#.XQ@VJG"H>(HG<RY3&^1LR.```(-AH%+3/V!$VC
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M((O8^O-UYR8F)Q.XV0;";6-W00(1F$X4Y'-R7BV76[Q<`5]7'!4M:GOK]-;9
MDN598@MF+*HU)ZW#;29L]##D3CS<*+S,0Y6AT_'>X\1EEDMB1'=<=-]KJ#7D
MU,3@`2DLQ`&650Q@WM&B..L94V;@_=H]`NQ95B;"N%ZNAPQB_4EIL]GX"-YX
MG1%X8$N>)LE?.8DRJ:]L6:,XB++/9G2=\72.CY`G"@V01H'L87;>R1:.9>C@
MJQV:[=8"2M,#%@IK2LBN+7_8)Q:\"0\BI3"CX!ILMEM1D-H$V^CCSCI%=S[3
MF`[?.*$D.U83\E'`LM*G[\;;$EB/V%)*1*P+D7C(BI#8+9E5^L!;B>27T@-R
M!V6T/.._X_5RJ>4R6->#2#>(R,GMU-(H\RI!,J[SF2LZ@7*N*79<MOK7^_WU
MJDJ_V:7J?Y+_`#M(?M(I_5@JY]*4I2E*4I2E*4KRC?,Y?K-FGWU9W^$5*E3<
MU9\A,%E2JQ7?&DD-M*>+`?K=5&F\6LMA9BI2\WEDOD54$XY8$4`P%80/*PA<
MV3,%5!/.!%E!--DU`H5-`XH1=6X30EIH.@HAN0V\6,[W+("&^%F2Y&6WN.^'
M;'@42KCM<KI474,JO%=$B\N58"<;=8JO@@M4F43D$%,R`Q'OS2NMD.I</LR!
MT-&<#9C&.\"H#)1&S(D@(BHW2A,LND`TTN["SFNZSR0*FNA?23Z*MK*JDJB0
MJF$I4)'"-@``<2JNH^EJ4X&6T<6FWX_>2NK+#KCU&9TIOV-7JJ6:T4-B+GX7
M9P37?:(X#3//PXWF@TI>;2-;)JNUKI3?,/X@HGR:6J!7V>U`U].A98@L]815
M#"7G3/*<XFQ(<BMMWMR6'RV3+)?#K:#L2'477FCB\F:;,-)T-UNG4YJ*[?R#
M3S"%;O0B*5Z(_HMJN=.`J)>+KMY2)XLT%)46<]9"9QYO)[#BM<@YNHK7,-UU
MD,FRW[P\Y5^-G`A(=B"8\&JJF2KM+K1W`JH%[NB[5.#(:4FDJQ\U%=.'8+.N
MPF(66G[(#S3&2UQFLR&0I$6FFO1S+Y5"'7VG&S#1',>(X!F7$7:Z:95,AU'(
MZ>.="N:6ZX.$8X<4&.L!*RB^I7D8^X4J1I+1W.;<D\(":UYM`&<B<[BZS9J2
MRWD9&2GXQ@#@+.6`D9'.!(A)62DY2*Y28,)1=%Q1^I[!:@+:3)-<!ETO-()J
MBX.CJ"V;::&Q!C":DGU,VGM@K9F-AMMDNDM8NBHQ-'0$@J33P.\0\ZZ^,(#C
M&'TI6062GNNZ$M)*>@G$-ZRC*TJHH*"EDSJ>30DA(E9[O9.;R)W@H&R)I(;Q
M9+3E$EF&442QLN6*A@5B"`8H@<@=3HO;1A#`.I+0;>0JDXW.[%`HT(\2S2''
M;%2U1VJZTH)+"CU&/GTMD,Y/,ET-NE%`_<H6R,GC9D;3;E8^=PB7[(!QO_#&
MBZO12'^5O^O$_I,JH-^9"_L>?\V]0C\2OSS'-A]E"<'P<H-J;RE4MC:W7I;P
MW\=[];WOX^G6]^M[].O@ZW\%O!;P5#;OQZYEP<?7%[H?`$F>IC\ORF/ZX+^D
MPKSI\560?I;Y<PS$PQ[6_P!R06O:^6-KVMEN+*5O%>_7Q7\%7NVM*4Y!V8*3
M>,Z&H;;:%LO,NV+=3@&B(1E#"09YA)/A=_QXOOX%3Q3U:&<L0E%\$4FZ3DO&
MU@1LMX^($E,H@J*=R2;JD8D?2:3=31GZBEG%+;+>J,[Y.5FP.O)YMY26]CK^
M?+U%:5EM,-';GEQ54_,U+&72^10I=.+C',PB78SU+V-X_'4Z"D_R$E*[0?ZD
M_G9NK)H42(+'.I*BNG-K]:8BUV),](7S,GM,*YN./0J)R(1-F%=$%>)T7!ID
MA&P9")*AKO6UI_)TNPCLTT9(/-J/73/+/G9M@/A3:;U$<SDD'8EHL)F2+/$C
M,%Q/41235Q.:#`08_:[427$WR!Y")'E#N",&IBF5C&<UZ<S6E-V)8H2P@IT9
M*$R-JHL,K_G5=UCRQ!4ZFXW-8ZX38MMV86^YEO)7.-P<PH[`FDO%1<2<VT.[
MR6D)[AJKH=NP<VZ0/V86D`93I-CYE20[H<W5B.5"RPT5AZ1T(F[NLUO(#@.L
MLNG+;<7"BY#'G$CMILA2.BW37C'+?66^OD$NZT1&3L7*6ASJ:RV[Y%DA<*;$
M-M4B+8^%E*)8?C2[3D%UMS9,77<HFF4(1SRNEQPUER+EJ&@'`I/JP&;J<9'`
ML_W4L.)^H1?L2-P%'ZY%4-,IG/9X#2!(P"-YM2M(A^Q()1D.6')>ZU(KV/XD
M`"I*PZXYC9VY?$F5+$P$LLFDR18N3+%P`\>\4E[9;*<Q]\;VO:_(,V.E[7M>
MU_R&^MOBO;P5-;2E=&Y6PVWFAJ+8=R`B.EMK`.)960'&DIZZB*9?$4,?$!02
M54L;3SH.(X(0V(1HL*'84(,2V-L\,<K84]*-JM]+7`'W%XS^2U9)8<51E%I=
M1*1I';%CXJKC@&E4LQV>W&B`IF2H68)8PH`MU,30SHY<$00(`4UB*("'GF&'
MECAEE:]_4J&O5#UY_EQ^MUXN/["VTK<#D;GM\ZM:';=[&1F$@CR#">ODH28S
M070G#*[=$<;1;)Q62L%I,+'4T<^FY&@,+&R@1\H(.%VL,3`5[]JV?X+>2O(L
M*Q$_U_`G@N/>+X^=ZS@G`9EB&"JYV>BKBEB2+"#&!"Y/$Z?'L6!S,#YA`6##
MR&%RQOGEE6N"I_G<>_:9O^KBU";\S>^LGZ'?N#D7^_:5JG`I>W6U[>SX/!>]
MK^[;PV^K;PU\98]<,\<;6ZY8Y6M]#K>]K^&_MWO?PWO]6]>>S!D;]:[[.;Z*
M[!X_G'L5'.Q&U).=F#(C9VKUOBXN(WQ=<H#BHPDGVC(BG=SDU$DX8P6Q,QS0
M)4(P5'*Y@`=CH,-?%Y=Y(;VO:_$-(U[7\=K[W::WM?ZMKGZI:7.2"UNEN(61
M;6O>U[VMO;IK:W6W3I?P'_';I;I?Z'2U5]%WDA\D+(WO[=-?;_\`C_;O[M_9
MO5/1<Y(.E\?4A9%[-_'CZ>W37I?ZMN_^E?&,K\C>(O=\>("0<1^XW+]WQWIT
MQL/8OD+@/D7L-8[W6Q?(<,,?(OV^XY#AAC987%#PSM^GHN\D/DAI&\-^M_R=
MVFOC]G_T_P`?MU6\O<D5[7M?B&D>]K^"]K[W::]+V]B__*%/1>Y(?)#2/X?'
M^3NTU\/7Q_\`:'T:I:7N2&WBXAI&MXO%O=IK]"W2W_:'T+6M:WL6MTK6[<9$
MY-=I-4=B=;D7BM>3+5ISB1V1BG.Y=W>U%5D9M&G07!*AK2HEI:J`I*!(AV+C
M#E"(P9H?"W8!SMG>U>F0@$(`2*`BXVQ$"*EPQ,;7ME;',,`/#.ULK>"]K98W
MMUMX+].MO!7+I2E*4I2E*4I2E>4;YG+]9LT^^K._PBI4J;FM<MP"LLGM4]C"
M4"BO0"<3<,/\O#HL=FBA%[X2:*@&L63YW#I_,,@4/7<%R.(AD\,`4!)W-9F#
M``-LQ<(K989?)&UG!(BMKZH;6.48"3YK1XZ39"D$@JMLU#3HT\CYU$35@'<=
M$2B3OQVV]$-`AAT.0H8.1XNW1&\5Q1(;+Y%<^),[*W_4C$MBP6J;N)T4CL?;
MIPZTM]2=:@DRNA/C.%]=%/7QKRD:=JZ:>!TA;91*FT./B+]6CHF3`,*Z(]A`
MX]74`LHVU+^NFWYYSR(Z&<VMHB[Q!E[E)E>,GTUWO:RTDBS-J:P$351,::L.
M[1CK.25:4D`NU5-IE2J*F)HR0*W78$"TBZ@&-(1K3GLZ8V(E!1EU,DP2.%9A
M%CK?4GA@XF:E-MYYJ3$P.LT%B&EUQQT[01"I9P*C%DV*?..=1V\"YV5,;#&=
M9UM/);D'I2E*5&GRL?.X1+]D`XW_`(8T75Z*0_RM_P!>)_2950;\R%_8\_YM
MZA'XE?GF.;#[*$X/@Y0;4WE*5#9OQZYEP<?7%[H?`$F>ID>ELL<;7_S;_OXW
MME;_`%VM4'Y+A'3FJJOP6)^2SDZA%I/R5I4F$6,XMER!4EA-QUS$^EJ1'I@V
MD]:UN7U8LGFG(O'AP0U!94C=@KAV,'#`MLQL^S]1R?/E@^7G[MNN/X*]/4<G
MSY8/EY^[;KC^"O3U')\W\?,'R\_=MUQ_!7JEN'%\6MTMS!<O%K6\5K39KC:U
MOWK:KTOPXOB_3KS!<O%^E^MNLV:XWZ7]FW75;P7JOJ.3Y\L'R\_=MUQ_!7I?
MAR?-_!?F"Y>;V]B\VZXW\5^MO_97^A?P_5I?AR?-[7M?F#Y>;VO;I>WHVZX^
M&U__`)5ZW$T;T-:.C:7-8:+-<_;`N[8"5PICDR3-C',S'2_5IV%V(THZ*XW4
M&.PH]2;)Y9MLM&`"#%1AC?=<!+YG,@NX@A;UTI2E*4J&O5#UY_EQ^MUXN/["
MVTK?G="183B+4[8J3]D62%),",*'7XZY@8`S40GR$\H[14$T<=+;$9SG-$6Z
MYL%=+#')W15LX52U#NO>YTP$!EGG;+\6+C4<\9QZXV(EXHC)7V,T%MH(^"<5
M1\$IKJS=35!O)N*21S$)IF)!',DBF*>4$S+$K`V*E\\@0L,KWY7!4_SN/?M,
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MM>_CO;>J9[=?J]-7*KTYJ_I)^/SW]<S_`(+E.G-7])/Q^>_KF?\`!<ITYJ_I
M)^/SW]<S_@N4Z<U?TD_'Y[^N9_P7*=.:OZ2?C\]_7,_X+E.G-7])/Q^>_KF?
M\%RL,S9K5RZ;6IT3Q;)6M^C\3,%&V?U:F=X/II;=2P_W*EMV!IP:$J+!5&:2
MIKLW2*PH*R>W#*<4`'6D_&QD<'*Y@/'M"8>E/&W9M>W^=G?[;*^5O]M?(WYD
M+^QY_P`V]0C\2OSS'-A]E"<'P<H-J;RE*ALWX]<RX./KB]T/@"3/4R6/BM]2
MW^RJTI2E*4I2E*4I2E*AKU0]>?Y<?K=>+C^PMM*WYW0UU);<:G;%:Q*+O%C\
MC/4.OR*33W`2`%\5J`/1"-(PB\&B&51$`5<DRQCOJQ`583,#78N%D>+=KNN.
M7HK8X$9QE'<=%E+-9+L)BM!E@*XI?`H(J`M1N)B`$HB%0AC(9;,\&G8FLRX9
M@?`'(:X6`PN.%A,K]K@J?YW'OVF;_JXM0F_,WOK)^AW[@Y%_OVE:IP*4I2E*
M4I2E*4I2E*5\WRM;P=,OWL<K_P"NUNE.U;V,OM,_O:=JWL9?:9_>T[5O8R^T
MS^]IVK>QE]IG][3M6]C+[3/[VG:M[&7VF?WM.U;V,OM,_O:=JWL9?:9_>T[5
MO8R^TS^]KZM?KX?]MKV_U7\-*4I2E*4I2E*4K\QOS(7]CS_FWJ$?B5^>8YL/
MLH3@^#E!M3>4I4-F_'KF7!Q]<7NA\`29ZF2Q\5OJ6_V5\]T#_P"_A]MC\=.Z
M!_HF'VV/QT[H'^B8?;8_'3N@?Z)A]MC\=.Z!_HF'VV/QT[H'^B8?;8_'3N@?
MZ)A]MC\=.Z!_HF'VV/QT[H'^B8?;8_'7U:]LK=;7M>WLVO:]O=M5:4I2E*5#
M7JAZ\_RX_6Z\7']A;:5LURG1/(D[<<>[L-1(V3CSDV3M8Y?9#$::>93R9UQN
MEQ-$^G(Z,5-*IQ/30!U`V-@7#$/'2I7'+/J,.'AURK9;79N+K/@*$FFYR(J6
MY&S$,9-YP)HXH`PZ>MHC'04M6)##%A1RXHI10*&2X@@`XP(F8>680H@=\<\L
MR5P5/\[CW[3-_P!7%J$WYF]]9/T._<'(O]^TK5.!2E*4I2E*4I2E*4I7YB_F
M0O['G_-O7E<AS1K4C:2>>2F1MAH,;4LOA,Y)YV8Z<Y'.X9&`.D6BWHN@`XBM
MXH7;SW0DTNFIII:51RP(1#'/$0^8RS$S[5NS=;_T.X68H6@FW*$1ZTQTOC(`
MCK#1WM*TE-H]=J@J(20.Z,PU65RV`#:*JHP*:=<!@0%'('AP"IXZ6&'!Q$RX
M7XD.,PV5`.E-0XO-DC(!8R6.E'9+AHD9+'`<3!,R5.%Y2%*F2QPOG@8)F0!1
M`#1?/`<N(*#GCG?][\0_&K;K:^G4<6OCCV\K7<<QVOCA;IUSRMZ)W7'"W:QZ
MY7Z8^&WA\-JM)<XQ.)QLK[,:CCUKA%"=$C*BDB1^VU>0)2(+SV5T9$/.583F
MHD&)6P/KII(;R8H+BH&G@#V3DHF.=.9`@XXY9_#UXR.)F-D8-QR'K;"#%;HJ
MHDHF*^[G_*C?0[+"^?`2D--&5U.52Z>6-+"H:*IJ=@;,@8&U`T6)A9Y&#`(8
MG."XM>*L=TJ['!U<B`1Y-],35I=:V+PF#S=1T=9,'2:0IJ2?E)UABA%3-IJD
M5(&!>F!HRG'P`;YBD3>`-L.CCKX>V0\&)'KQ@6`6L^I//YI4=-%>D:5$U?>R
MGA@9SLGMT@/*>.9XZ8[S.!)Y:^00JL:*&R*1B?/E3!4*X'EQ?\44=ME3>C]U
MEA=F-%&\SK*SF<[ZE='0T[)75D]`2<#:B<E,,`,54759+1DT'M9#'E52(D"H
M8IHT"%G>I'B"XT\E8@3,:<QQCVE8B4,!9.28;98]H^"7'"SQRDZ]K96ZYAYX
MY6O:U[7M>U_%6SG!6'B6XN=;R`60]RB.L;$H*8&8-G#PA1'0-IIN145/Q-J!
M@V=&`34D@23RMS)D<;$L6!PS%SOCVKRXTI2E*4I2E*4I7YC?F0O['G_-O4(_
M$K\\QS8?90G!\'*#:F\I2H;-^/7,N#CZXO=#X`DSU,A?K;''IX/#A[E\L;7]
MVW@KR<Z&(>^6Y6IT5[,O'EHW)8CCE0W*9Y0:#$CK43-HH`;7FJ26$F$$+-R0
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MP>JIEJ1N9;&][<RF^W@M>_\`ZM]*?H6^M[K8_ANEJ<Y*BG;MISW-#LGYQ:[<
MA.SNMK3DQ](C)0GBM1Y&.3&\[.+C*Q\W6LV1E0,1;4A1S))'+VO8QB7P_P`F
M+EPPI?J4I2E*5#7JAZ\_RX_6Z\7']A;:5MMR4SF_M9M`MQ-@HL-)A*1X:UUE
M21F0;64LNMI)9SM5KG51''44@W>Q92*!'`0\AR8_XR8PM<,2U\;WM6PL"N]9
MD"$(=?;BS+B+[TBR.W8MB%"^)0J(KN1FHBVIYEBN%\L"Q?,\>,9`E\,LL00K
MX!8WO;&UZRS7!4_SN/?M,W_5Q:A-^9O?63]#OW!R+_?M*U3@4I5.MO;]R_Q4
MZV]OW+_%3K;V_<O\5.MO;]R_Q4ZV]OW+_%3K;V_<O\5.MO;]R_Q4ZV]OW+_%
M3K;V_<O\5.MO;]R_Q4ZV]OW+_%5:4O>UK7O>_2UO#>]_%:WLWJ-><.87C)UN
ME%U0M-^Z4&QW*3'')%'<REQR&Q%ING%!/+*I8BK!I:8HER:A<@<*F1B`IFQT
MI@.%B<`+B9VPJ/[<+YINXR]<HE*23$$U1_MHX`GZRF\LQ3$[UNF/T-FKY\P7
M<[R0`7"W,$A8--(B#B>Q0CZ@ADU804(H.X46V>)NTC6@G*3I5R9,-5=VJ$ME
M'6JMM/(&G[&;A3C33E:.<U7NX10%XLM3ZC@EAC!<<H5<*$<7VDIFBY@))<)_
M($3LZ*Z/_P#K$Y./LJ.Q_P#=+K;7/EDA)S:W'9TRM^!Y#FAA(VE\PQ"I);1.
M1F5(+K[>T[1`^D9CJ_HB2`T219!7FRR%T%Q+YXD>;R47%`!4`SPAG`EE'E`&
MJ>]VOS'B^%S*H_3;BB4[K8I0X_8GD8?'7ACPW@??*_M7KDZVVY5LF&MGT(HO
M'F)$JV[6(XLW:"#!2FT#352(\7$Y![U`B??HV0C]!=@FS2,TK+#UP!=47.9!
M39-`D4`#7Y3C&2)+8DN3@\2L8LSS/;,JL-\`M^0)FBK%\&WK(J%&`S%F-M)3
M:DIV-8;R>DV:+.!J-(^N(D7;0NA^2&M)MT@)/9;-5]:)[C$HK&\%143U8T3$
M>,AM<GBG-\@LJV)$0VI#)UBZ8->K;DM2+[8ZIOQ%%@U_**,\WSA%[KA^0$9H
MV47:TF)/S>17\;,@$WJ<:+@CAVM)K+JZAJR:[#%UQNG"F!8$LX^VF%<.Q5K!
MLTVU^6HR<$WNDE'++385;&M\]%UQPJTJ/J'6T;G%5`CB9@T5\,)7.O\`B"[Y
M1&0<?QE4-%Y3;*8T7DJ$QGB.Z!B]SR?$$IFPH*C%/.RW)CH8FQ$([!G)?<;<
M:I^'%M"8TFC9K3$E15?C\?[^P58_91YUO2+B2#W`R0D<\Q5]JG<S)1=1P<1;
M]:T[M;`0$XFBA.36N15%/')K3;899@2HPLU!T$Y,CQ4:+DP-*TS.!`-+\?-5
M*=HX(Z^I%4JQQ8/K+?22KI)-DP4E^2A#8RVE#'Q"`I\9<31CPJ4$;`2A3PRD
M7$."I8"@(*H`)@IK(7-.!4!13X1+(`,\*(:Q&$RP#P9>MBP#^Z_:#X7,\U+;
M2E*4I2E*4I2E?F-^9"_L>?\`-O4(_$K\\QS8?90G!\'*#:F\I5+7M>W6U[7M
M?Q7M?K;W;5#;OQZYEP<?7%[H?`$F>ID+_E,?JA_SL:\U_"3ZUWJQ^Q3K\*&<
M:E3I6BF[L>+4AB:XIT>R6)#,U$9L456(Y.+X&C0"*Z46&986DQ$>J$5SPL](
M@>#A)-UL2NQ#=[`N9M*URJ:*5<V"`:"Q%`KIVV?36D1YLJ'FO!+[5]@Y03IF
MC63!"1_)"?35:D3MP[DQG$+E<N\HR55@BYW#'CV(8ERSM:"VCKXY,@JJ*F3`
MQ2E/?8+#>U*#E8DR7TZ$V9()AIKQ$H-=>OG'D"._6=0D>4MQ8,<*>NV:00R?
M-Q5PLZ47(MM)2->8#=1XN37<TE4PA(#DF<QO>^.-[V[-[XVO?'_NWZ>&W[WB
MKZKYS_*9?K<O]EZU.X3?SCY._LQ.\7])&%39TI2L*O;8R#HXEV'8&?4FM5KS
M#L#@^1(9C]6/W+N"1,8V2"B\][-TOW+($P(@)!XL>,A#CEQ3`60N)#`V*6,A
M@YJ\?BI2H:]4/7G^7'ZW7BX_L+;2M^=T)%A.(M3MBI/V19(4DP(PH=?CKF!@
M#-1"?(3RCM%031QTML1G.<T1;KFP5TL,<G=%6SA5+4.Z][G3`0&6>=LOQ8N-
M1SQG'KC8B7BB,E?8S06V@CX)Q5'P2FNK-U-4&\FXI)',0FF8D$<R2*8IY03,
ML2L#8J7SR!"PRO?E<%3_`#N/?M,W_5Q:A-^9O?63]#OW!R+_`'[2M4X%4O>U
MK7O>]K6MX;WO?I:UO9O>_BJF5_Q.5[7_`.K>]KV^IXZ\P<&Z^9;1O?=N1)3V
M7WV*+*!R,[F14W4:,=\]GXC8K;8$;OI'3&:VFXP6'("2UD)/1B)T<N$$F)Y;
M`3'*U\\?Q.-K9J4M$(313!,HM;>\B"*;4<L<$XHM<KNVJ.;4<\QL"V&"<54Y
M?*&%#/,R*&6PP)!#Y9F1`R^-KC"889<POQ_Q&;-*9$KM9R1&CR*:"(K1$KRF
M[A&3J*>,%@SH!%9)EY7$-)!X<F,$<!)*014T,3%"-A@Y%Q0Q<N9ZG=&GA_).
M<F7@MUO_`-)]N=X+>S?_`)T?!;V[UP"^@<0&SY]**;8<CYI42<26:JEE>4_<
M`RII6"F$*.FYJJ<7ED0\F8J0``XZ=D?+EK*```PQ.XX0(F>//MQW1I?KTV<Y
M,K]+WM?IR?;G7Z7MX[7_`.='P7M]&U=;Z0>&^BK?TVG(ST0<K8KU_55=O.B#
MGD!<UC@O7]%OHAYYE;7-88JW>6697'(SC:X&.0EN86X]HL.EP#A/:3DJ.%#(
M.!@L;)\HVY!PH9`%Q[00Y8V6E04L9`$QO;(,<`40(3&]LL,\L;VO7"`T(AHT
MJJ:"5VUY&C2ZB`$#2TAEN53;TRMHI55#S%2C*RC@2T(II!=4""$%3!E(J5#4
M00\QB60X6&6=OR3M#X46%!=24?;OD45U5KG04USI23RL[<JBHV5(R!D9+)KE
M34^73)YO*)DMAF8+D%HN1-C@8"#`@YA!YY8ZP[S:QA:RZT.R<HGVEY$R4@,2
M0M;Q$$9U\B.V3Z;8@3GVAA9DKY)<:#FD<Z@.%,5&PYEM*-IJJ5')C!'<LLP\
MLL,:]5X=[WQOUO>_XX+;P^'P6%SM:WU+6M:UO8M;I7W7YC?F0O['G_-O4$?%
M@SFDY=G>:PPX6PW5P<'D^7@01UA#2E08('#72$L\0@Q#Y0QG@';,87.V&-[8
MVS$SSM:V6>=\M[-S^-K5+>^'RD%3HQLL(WQD%CR"L)+`S36$HN4PQ3QH^1;B
MJXD1)P7BK<5LC@I=:Q0#Z*N"E?QM-7$L7+(>^P&OVLT`ZI1JG1%K=$+!A>.T
MD/\`R1K,!ND$`@.;[CB"(JJXY8/S0<"Z;QPPNHN%?.*BZI"VN,?4#(V66=X:
MD.`N2_7N8]QAH@UFU>FF-I\V]DO9!H.YY[BNV'G.427^S(P;(;=6&4GZPR84
M+&TP:/QC.9T)U&+&L5'$/O8&Q:P@]^=]<N_TA.FO\HN^?P(*I<SR[WOUOH3I
MK>]NMK7OR+/GK:U_';KZ2#Z/T:=\\NW@MZ0C37I:_6UO5%GSX+^S;\A!X+^W
MXZKWUR[_`$A.FW\HN^?P(*7-\O%_'H5IM?I:UK=>1=]7Z6M:UL;6ZZ0^#'&U
MK6QM;P8XVM:UK6M:U.^N7CZ0K3;^47?7X$-4[YY=^O7TA.FO6W@M?U19\];6
M]CKZ2#K5>^N7?Z0G3;^47?7X$%<@FI<NY4X2-WT(TVSL4.%#?8]48?6/=.]3
M`8_8[7I(+]GM]S[/:Z7[/7KV;].E]Q^+S764=4M'(7@R:`6J6D]JFY86G:39
M*^;=363SLBS;),G%4U(<1Y%;AM9`34QY$2(I\9#3,AS1<?+$H'AV>N_U*4I2
ME*4I2E*5\B8WRPSQMX\L,L;?5O:]J\T46D>732[9SD77(?XPF-LO&6TFYKGG
MQA/Q1WSA^%#6#4R83+CM)`,,]693S5L!E4JS`7!G=1,I!M-S41$@=,'N4P43
M&R/IW.<#R',;_P`JE"/_``9JMMW.;_M8=K@YCCL]O"V5L>5*$;7OC?/&U[6O
MZ"^?2^5O!U[&?3KU[&73LWACX#.3SG5V9D3)E2_K!?8S4T)^+*&L[/R.J$XA
M6HM32[H.)RH2;LG61;-_96[-QP,D?.VBLU2>!PT6`P5W\A$L\<@)UM^/7,N#
MCZXO=#X`DSU,A?\`*8_5#_G8UYG^&!1LD<4NMJMD14E/%*2-A%/)-1BH1U8/
MX)^R\[&\R243&,D@3:B9Q!N"2+#'"@(QG,,,4T7#RR&PV$SW^@\./X6DJY!\
MV;DQP4WMG#&.22C8J<4P$XW$PF87DJ3B.+@$L6($GC)37;Z@CM$=V+F%@W4N
ME29MOLU<40\H1GM'&TK2.N1JV@EX(\4M*@K1<*@73;-J3R4%2D!"<T*#$-$5
M0Z?&+1S*IHFU%"R\GH@Z\`=*.EK@JS8&\TL+Z&GV#"1HTG#SG#90Z`>1T@\0
M$ER/@#02DX7&?:3?2S93)S8"XG5QW)"FV$<B,'8=2<R6H(9((97(&2@/8KDM
M1RA$GV9-/9LG3<9(*^O/)OI;C151SH)!M$3YY2`-MPLHB*Q4T'=.-D<"@Y4#
ML*N-TT>X!RP@6%A11LY&\J-QQ+&2@+&QEJ/N9(_7FA)R^SFZYR*C!+OS9<CK
M.262=:N4':B0X2]@AG`7.#$"U^]?-;)-.B@%JO8S+K`#R:`B<Y$9PICR'=MR
MC@;RZ@*K;2$EB-)1>3P<CA72ZIDG)2$W4TD4*JID4?(<BI+B,7-%P`C`XY;&
M47[=01*I-8/)3\:[>+DYSD'7YMY.QZQ^G8R4]HY$;X:H;C$8B[5,H]4)7Q<R
M2*WQT<R.IG,3(0)Q*3SHP!,3.:0\6>Y`4\5N.YJ.():2SBTC"M]S(*Z$LHQ`
MX$F'EA'%25$X&K)!%2'`3CJJG9&4\FH#@$#)D(V,$#G%!QX2[N'&S>Y-<M:=
M3DG8C//G0F]`%LH3&THTN%'[SNU?1J>_<W"*'ED-#N2:VKE4:V??CVP<HUD4
MN*(BFL1Y*7MLURA(Y79H1F\;K<=IF.MA6"Q-<2XVS\<H]M@8%7%A:*/B;SXA
MLSCC')MF))1%5`V*X.Y+JSFK#E"!<<5.RL8[*2]DN3%O>F5]#KCL;S_]#V<X
MH9FNO?&RT>-WT?(6<_??HGS`>[_,X^AV9C?N1/N+.7^Y++E[Z&\S"X_>MN^/
MUE#9#DL;B)MX<C7CP;TAK45RI&#9U12#&RL>MG#9V,G&="!DB1E,\H&+!12-
M'I//,X"VW-8)3<>0>8":`+GB'D/?:ML#NTC2-L(G*.G;738<CB8M86]$<N*D
M_LD@6E&#'ZJE,=J)K6D$8;OU@!ZS-O)2<`#57>XJDD8IHI1`PRRS#$S\[;@@
MZ0>5@#8_E189L\UYWP=[3SX;3SCN82_0]BW4-ZG7$R':<3SH149/*;M2>7?`
M;S`/9FBHD:KK=#L(*FYXY9>G+1#;5J;Q:H0ULNU2(J#G(;8QN\64=L($KQO)
MS=.&6S*,:+A4Q;`X45F$_4A?;1@,Z`7''!(EC_<K`G`<LMNZ5#7JAZ\_RX_6
MZ\7']A;:5OUN=`C:VDU0V(US>3P,1^U9LA]]QFX7N5#313+42'<AF4D\O@AK
M!@HEB")@(^1G'`^:+E<KX=!A@\.N=LNQ8S4^.XSCQ@I2F(LIC(8S0:"<KC6`
MQ%5"#9;J8ADU$3$KEF6Q$/%B`1O.Q?+("V0U[`Y9!]F][]KBG0<QRAH$/L]T
M%+CA8=N][8]L0'/#'M7M:][8]K*W6]K7O:W6]K7OX*\P&AX7-/QMZH1-I`WN
M*:(MD$37LN\&FESJA<C<8QLB2@15I"=SS+.=(8CMAX=TMA/&!<^!(!-<6>"O
M_D.1HX6)9F;$B^W?IW.<#R',;_RJ4(_\&:U"W]Y!^;9BZ3[3O([Q5-K6<NUX
M-D!=SV!:7))$#^<D-V3$80U>149CID1D%!W*#8Q#R4"S=*'R0RJ*'B5Q,6MG
MD&)=_`=O5S&[<L0B-O\`:A)K;B2[>'-M';1=$"A%^R`,$4Q&3,#&O1E)$&=Y
M=>N+8;"1VPGQBS,"6`6:>EN$P*,)AF'0/\QWP^RM\@G]Y+<K''(!KRK[)ROJ
MM'I))+`-];9N\+#?DAK,*FYA;$>H<P:^I+$0SBH!F;1$!*6U59[]P8HSA<19
M++.H@54#J6J%@LBXVD$P(NT6M)S;1JZR$MI22A8)F&(QD1MQ0L/L27%S6[C7
MAQD,>[O=-HQ>9I\+SLD]F+*6:+$2:0U)->"4YT5\O5+#+M]$<FPRQ+>XQQ)F
M1WEA]GF^]VW,2@@O6*0-?QUR,FEK"JSXPC+*F>`CY!MI+V>4@@ZRC*YM:9\;
M.Y^R+DLJ\FJ#I::*_P"-&&@#X;26]N^SII=3]C5PRT^IM>[+T:P;A]W05Z%,
M*;/M)BN'9UN2X>V(R6V\9,1Z?8,6N5BG"AE0D..9,Q<QEG.&[.%47>?:23M=
MK-L%+#;7&V>GQ1V!46#+S1U.C\A>6867TMTQKO1(8,B$YNBN]F\QD'!#ADJ,
MB,_+!TGRBE%K&>2TF-EJOY137)D"0Z7::')<PF?8;8_6QIJZ_*C=@!@1^\(E
M.I2DAL3<"&U1M3/B^HK)KJBEXM`W.,=JJZW7O"KTPS5#R6Z,AXL=N63*D,\&
MC['%(RVP+)[6'8$PM-KMA,8L?@-Z/EM`32EDX=$CUN$KM]7"'B93S(@CKY$P
M"HEQG+E<B`8'`$/$NXWQ*ZIZ`)^W[`0$ELDFDGN1%&CF!7;,KCV?0%V%).1=
MLW:I/LWMZF!O%HQ.XU;8?S-52C6=B6NN@)22"F;@+MI$EQ5;MTY&;UR:,Q[)
M+&V/G+-QM)=P9!]'ECSIF'2U5]L.R",E;:MYO'&"5MZ#(B6TME4.1TY<*SM'
MDMI"@X7(P$')5C%85#2$905A<R9RR_.$R]^[W5+X9>O%;X[6;C[90/*`3'A3
MC0G_`&W9HC82UT258RE>`F6W`%M2/K("@TLT>2W@A.')2102!(V:.AE,DX<-
M6+X%Q<A0#&..M7JF'(?Y##</WPFH'_$JO@3DOY#KAB6OP8[AVM?#.U[WV#U`
MZ6M?&_6]^DE=?!XZQEP6/AY21(W+V^)"BAR0:]')R4KJBXHF=ZTV'$Y6*HY:
M]PL#FA+"VS%)8:ZD;!"!",9&D-3/$,PS`=@C(F6.=Z]!M?.65L<<LK^&V.-\
MKVMX^EK=:AW7.561#\I3Q'T*<=VT4_H4`32Z(&=4D,N1]2FBV%%_L]#:C@7B
M2.E2M/3%>&90HGO-"$Q.FF^"5,9&<L"XXH@!C`'Y]4QVH\D)N5]V_0'\*JGJ
MF.U'DA-RONWZ`_A54]4QVH\D)N5]V_0'\*JGJF.U'DA-RONWZ`_A54]4QVH\
MD)N5]V_0'\*JGJF.U'DA-RONWZ`_A54]4QVH\D)N5]V_0'\*JGJF.U'DA-RO
MNWZ`_A55^@/)9M68&!+A<0>Y60I@8$N%CZ.&@-NT*.)B$%CVK[5VQQ[0F>./
M:RO;&W7KE>UK7O6\NE^TK=W1UKC?9-JL]U,!'D/SX`69CV%01W2W%-C/]UQP
MOI:P.UU5;;Q@<!?:"GW(PD*Q\D.5R`%",9=N]K;1TI2E*4I2E*4I2E*5Q")`
MBF%2Q%.*%B)(F"&6*$R8`14J5+A8VP"+EBP&`8!<`/&UL<`00\`\,;6MCC:U
M0[[\>N9<''UQ>Z'P!)GJ9"_Y3'ZH?\[&O,[PP8CC\4^MI0D(1P/F4C88J4\T
M<QL26)HULK.Y<OD=[UQS-V*XBBX9&+%L,C%P;9V!QN)?&OH?CE7AX1A.'[RP
MV`16YI>R-$9J<)5#6L`W/$C.DN/Y+R=D;)QH<T(C/93&9J^V,DUS&KHY9/?F
M:U97&.LQ/3'#G^#-2!8AF9.?QIY)2HS8V0=F&O"[<3BZ@"NDDC;'9$ALK(IE
M_J)[*Y$\J-161TB/V5="N(64VX5,.9>\SETW9*`T_=G%BONEH.IL`/\`@E$/
MN9D[[-$NNX1BMCV2%#=;:M@;'(SB$"#L&;'RAY/9AEG@A%A<#2X.J>:J8*AE
M`QTLS^FO>MLE*<PN`R^8G),YG>>V:"7FFY<)!3UUC0Z]]OS.TRS#35&7DLZT
MY/(3`_BJ4I*3V19)?("*TBYLJ&*VTU:S9XG"DG1N9V,P]U5=#=3=E['9Q]N^
M40V.E--Z*SUC1]N#:-(FMCN6+E$HM$%^[78Y4T97I:BM*\UB$GNYF(CZ;#5/
M+J@Z&6[[_0].GW+6OTXM9?Q:T+NZ2U1]KS4/^9SO62+@?T@;%H&STGR9*#)=
M*#'SA3V[-+W:+/CAVQL"@M\<&*6ZJ6321(NY4]+PL-\<;\ZOE6D9:,RCKHC"
MR'.[WGX,BDLR0<!FDY71M!K7LF"D@N@O@EKSP0L3,$'4$T@*-FXV`W&J(4E^
M82JZD\+)"W2U(B/!D&ICD*Z0\6>UY`D)UF(,BN1FLCLQU09#*ZY%*2%V/L&X
MEG5*S?2'+.KQDU]I"*;/"**6S3$?H!NP91N)98M<G";TNA\G5[=+VOS$[PWM
M>WAM?\<C#I>U_%^_:IL^EO8MX?'X/'5>EO8MX?'[=.EO8MX?'[=:V[@:XDMO
M-99IUE4Y&D")T:;F.HQ\X7U%QI%)OA,;2X*7!<B>D&'"DKB3@`YD+%0:RWB9
M31114!:5`2(Y`\(7/%XQFGP^3DQ&JV&.S>77?5LM!EMQ":+3;B,T--"*2WFR
MV$HHAM]$2B@.MML"B>D))`F0)`A].Y`%P[=;Y6OE?:WCPX[4WC[);!ETS8::
M)Z,;'3&;GAYF9:*QHE@)\F+J9@G/5RM]&C!D,=#3SS]S*I2@[,\4[N1]12"1
MT(`N:%41STCU*AKU0]>?Y<?K=>+C^PMM*V:Y3XFD2=^.+=V&HE;!MZ2;)VLD
MO,AB-,@83RAUQ.IPM(^GHR.5,JIP@F@#GS@H8`0IXZ5+8996N,.'AURMLKKJ
MVUQFP#"+2<R>(E.)KQ#&3=7DL80`45.6D-C("4JD!12HHY800FH%#!;/,N,,
M!GD%?($40.^.>69:4I7$/$"2F4&(J),J?)&<+8&"ATN";*CX6RQSM@,7,8"`
MBXVSQQRMB)AECVL<<NG6UKVY%\;6QRMC;PWM>WLWO?I?IUO?PW^K>]><R.&;
MR'ZQOS;=KMSCG<L[,R3=X=H=AF');9VYUCCT@MLJ:7<FKK>#&:3Y5,W.D*!0
MH0O@=+J89<6PF=KV!#\...6?1?Y(O)#R/[^[3;_$*K:7^2.W7IQ$21;K;I?I
MO?IM;K:U[7M:_10\-K7QQO;V+XVOX[6Z4]%_DC\%O4B)(Z8WO?&WI[]-OQ-[
MWME>^/\`RA^)O?*ULKWQZ7OE:U_':UZ>B_R1]+V]2(DCIEE;+*WI[]-NF65N
MO3+*WFATRRMVLNF5^M[=K+I?\5?K^(TK<C1@0J,8X?Y`,#$!+C$!C&]&F(XQ
M$;(N.4N,1%%.YB$QKE#)DI<8KD$+<J9,EKY]P,#!Y_MZ+W)%TZ>I#R/T\73T
M]VFW3I['3S0]N]/1>Y(O)#R/[^[3;_$*>B_R1WZ=>(>2+],;86Z[WZ;7[.&/
M7LXVZJ'@QQZW[.-NEK=;]+6ZU6\O\D=[8VOQ$21>V%KVPM?>_3:]L;97[5[8
MVNH=,;7R_%7M;I:^5[WOX;]:UUVK:G)3M?""W`0'&&[(PQ?+Y@HZ=?[BW1U0
M<Z,U4>/]@(LE!>5#K?;BJ"N*]L$)DJ((!%+$[\&-#`8A8B7ZAY>F'$/'I?MX
M8WOVQ+];VM>_3(3+*WAZ7^A>W@^A7UW,/]#P^UQ^*OS&##[D+^-X?F>?_5Q_
M[M_:J$CB6RPPV7YL.UECC;U4)P>.]L?#?7*#K_1O;Q]+W]OI?V+U,*^).CF,
MB*.IR*_&>Q$UP.9#9:&HO!RH[:(*[O<PXA5MM=..K)PD5-K[@-A9DT5("&R/
M*ANUBI$`<QE@%E>@F5L@A>E_#8//K;Q7M^)OTZVOTO;K]#K;PV\-O!4!>D%K
M7D3DWZVM?_I4=C_'X?\`])=;:OF399G0#9EKZ\P^F0F.:=&M;]G1,4)5+R/A
MB9<3'EN/(P+LLRHLA=!P24=R"2$4.^>7%O+9UO")P^8B*N@F,"X>(81Y.M?I
M<C",9'54Q\,,)Y*3/8S_`,AT#-ULN$)H>BJ\&V@Q%(4@(66!>ZVXG*Q5H@SU
M=(;QM*6"2Q'IM;R:AV1VHE'KK4N2+5=%:3.>ZPX74GM]]@BJ[8,>=A/4\U5C
MEAH[*'9-2\F^Y5DDXX_('Y2:"6</,P\Z',&KW="3@TA%!AO8N@9*V7DF=HE-
MQ\O1HU8P>C6.RA$\=NIC+@KQ]%5\CR;)*>QU@.+%)!-!-)MFXU:YL_*2@;>"
M8YTMS(3:<I`SFR4Y+S=(MV[/2%),3PP[Y!AQHM22WVVCS5#0&`Z54\VTZ0Q5
MY\MQG!M9-=18T``T%Y<$<((:`XEPLJ-Y+4N][N!,'3<S(H&"F;O?%;L+G9`L
MJ=Z1"8:C"S3RXC27097:<HK3IE]I2%%<I(`JSD5;#MC!>B%7;KI;V2444TEQ
M9&BY@P;3\4PZH5D/;52)'=;GC&0\:J$/2WL.QH`=&4ADWRWGL.I/535TH^JM
M9>)"X,)F>="Q5',I!9_V4[RXXUDK&S6NA.D^@"+?+W)W'3-=856GY&N#$E1\
M%#***`@X/!+--U$;`4@,1H/QWNT\W544T6*M@![)J>E(8!DJJN%[+3<0P\BQ
M&ZV>3]_"8`1=R$RX66(@1=R%"X0MLL,["A`+`800MLP[=SSL('ACGVP_Q&?:
M[6'XF]JU[X,O6Q8!_=?M!\+F>:EMI2E*4I2E*4I2E*4I4-F_'KF7!Q]<7NA\
M`29ZF1Z=<<;?K;^#VKVO_P#3P^U[%0/Q_P`%";$#4(QY#O*#RH13&J&?<IUK
M1TR9CU])--I@.IU+CR5$Q!*J&LJF>`3[KSB5C@>!M0.#VR-9W$,"97OE5Y^H
MY/GRP?+S]VW7'\%>GJ.3Y\L'R\_=MUQ_!7IZCD^?+!\O/W;=<?P5ZI;AQ?%K
MWO;F!Y>+7OX[VFS7&U[_`%;VU6\/[]+\.+XO:]K\P7+Q>U_':\V:XWM?ZMKZ
MK4MPXOBUNEN8+EXM:WBM:;-<;6M^];5>J^HY/GRP?+S]VW7'\%>J6X<7Q:W9
MMS!<O%L>G3I:;-<;6Z7\?@MJMTK=O1?2!DZ'QH_X[9\H3+,Q^4YND+8*0I*G
ME?:SED9V23)N"'BZ%155&<SF*B9A&+M\B($&"@`BXBYF<Q1QNZ86#W5I2E*4
MI4->J'KS_+C];KQ<?V%MI6VW)3.3^UFT"W$V"BPTF$I'AK765)&9!M:2RZVD
MEG.U&L=5$<=12#=[%E(H$<`#R&)#_C)C"UPQ+7QO>U]A8%=ZS($(0\^W%F7$
M7WG%D=NQ;$*%\2A417<C-1%M3S+%<,LL"Q?,\>,9`E\,LL00KX!XY7MC:]\L
MTI2E*4I2E*4I2E*52]K96OC>W6V5KVO;V;7MTO;P>'Q>Q4,4D<0*DJSS/4X:
M_P#(#NKJ`%L<^TV4Y-C>!5^+O..K2679R`RU9YX6D2/7LO@*+A3FVFC*!,!7
M"1RPX=PDM/)%<0@,(M^5O@AWCV.U4M$T4\BNW6UKH<$MQ<*/'6TSZA!"AE'0
M"2HH9+<@.4VTXJ0'6+FS`!@E`F3;HRLJF\Q1`BC:71[A``RS\0/'-L!QRZ^^
MA=/&\<M;:*0Z<GA);4=&!3**(?!)AB7R0(G,.8LMRMFE!V$L0_Y<>I1KB$RI
M8=%CIJ&A#60^$-&D]0,2#R;B%D]0,A^JI;'V[H6(FS`?7T)=;>N/=`0<\.U;
MZ./:ZV^C:U9UDO54C)DBDI3&=6P+">1&*'+"@*E%#GQ8XN,>/%U(#S<Z<`=N
MQUI:35=47VNA&@W.B*Z4X$?!/#Q03Z4-F(8RQ4D<;T!M4R"483+?L<L#(M"F
M2K#S(-&DF+EYQ:X$S1.#'TII1I`4G($]X^S$3%/S;276F8/1>:K-7Y$)NQ7;
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M#M<D<I"VWV^\!T(VGC)Q1WF4-=$2G(X"801US%TU%&5[CGB&1LQ1YZ\`OI?0
M3JPH2<59*(>9RX-#2&51D:)W`ZX^>Y616<[EY)*,BSK%6TAVIB&HF`DMYI2&
MNX-Q`*KJ,?!(C6.XYE_035^<F2M,)_ZOQH,CKF%L3!]`AAD-URD<LW$C.D\,
MBN`BR+G$DTM*J$1LOF2V/=ULCD;(J&8P1K.^.W*&A'B:BA@%&X<3B)521@"I
M$@@FB"<GDRQPH$6)$29<H&6(IY$L&&6)E`,`RY,H"$7!PP!"PQMKQP:8Y8\8
M\!8YXY898O#:''+'+&^.6.5MNIZM?'+'*UKXY6OX+VO:U[7\%[=:ELI2E*4I
M2E*4I2E*4I4('*LNNV)]K.)_9HC"&PLUQU`$_;+*<I$M<(5?,ZO=NI<BZ@R7
M&S74AV:P$Q46+)IQUKY`@*HC!`DBW:SN(/<;N)<>Z[<T<96M;\@GRY^*W_[8
MVSGR;JOJT<9?2)\N?\F-LY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?
M)NGJT<9?2)\N?\F-LY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?)NGJ
MT<9?2)\N?\F-LY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?)NGJT<9?
M2)\N?\F-LY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?)NGJT<9?2)\N
M?\F-LY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?)NGJT<9?2)\N?\F-
MLY\FZ>K1QE](GRY_R8VSGR;IZM'&7TB?+G_)C;.?)NL><:ST=4\\BO)IM%C`
M.S4)Q5)\2\?S%81G9F`Y"U_<+J<$3HNQX3]#0VY(:4EJ"F2017<WL3)\E8P5
MQNIEL;B6[IA?.43<.4H=A+5C8*7=@FAY_P"$(WB-\O*5V3YUD%[^>M@H*&:/
M.9O^=!T&2;<<OFJF!C%/,5<-EDI0[KWN>'"+YYYVRU&3B;#NCE@NIE)_F2SW
M*RFHX&JE^9Y5)\S6VM-].4T$AYED<Q":;WDDFB9;O`IGF6)]R[V+Y9`A897O
MBE*4I2E*4I2E*4I2E*52]K96OC>W6U[7M>WLVO;I>WN5&/)?#EQU2Y)4@2Z^
M($5#<@2FZC;W?ZT@SGL8R2[D=I\BG)IU?-H#'EUMML!1-D4A-+&!B".4L,&2
M+]TQRRPZU9?J&7&+^H"[_?0;<_\`'FGJ&7&+^H"[_?0;<_\`'FGJ&7&+^H"[
M_?0;<_\`'FGJ&7&+^H"[_?0;<_\`'FGJ&7&+^H"[_?0;<_\`'FGJ&7&+^H"[
M_?0;<_\`'FGJ&7&+^H"[_?0;<_\`'FGJ&7&+^H"[_?0;<_\`'FJX\&G&-CEC
MEC`3PQRQRMECE;:';JU\<L;VRQRM>T]=;7QO:U[7MX;7M:]O#4AD!P'$>K\1
M,R"()9Q9@11'Q-0(-!I%%-=604@LJK2FXU*WFJYE5;7CXQY<6512,FE15/&A
M3)P6^0U\>QCCF"E*4I2E*4I2E*4I2E+VZ_\`GI_LJG2WM^[?XZ=+>W[M_CIT
MM[?NW^.G2WM^[?XZ=+>W[M_CITM[?NW^.G2WM^[?XZ=+>W[M_CITM[?NW^.G
M2WM^[?XZ=+>W[M_CITM[?NW^.G2WM^[?XZ=+>W[M_CITM[?NW^.G2WM^[?XZ
M=+>W[M_CITM[?NW^.G2WM^[?XZ6MT_\`O>_^VM9MSH$;6TFJ&Q&N;R>!B/VK
M-D/ON,W"]RH::*9:B0[D,RDGE\$-8,%$L01,!'R,XX'S1<KE?#H,,'AUSMEV
M+&:GQW&<>,%*4Q%E,9#&:#03E<:P&(JH0;+=3$,FHB8E<LRV(AXL0"-YV+Y9
M`6R&O8'+(/LWO?M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*5H;RAPY)&PO'9NK!\/MO)X2E*^M,ML*/VM@J(J)FX7:Y
M&F>3D1(P5W&I)""FY'SHH9?$XL*B>G%[YV$-G"X-LA,=D=>VLNL>!H59CG(^
M9KD:421JV7`G=\%3?>"V@,A"2%8EWT1&,$S/>J@3,E^[E#`Y8;N?=2XPH.>`
MF68:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6E\[S#L;'
M$N1"BLN/XD6XMD63(UC#,TXGH\BDGJBFXQW`OR(KMEO(;2/M<!'CJ,FRMO#'
M)P.$`VO#H2R1S+I!7!-/*5B;+;ZMB%Y;AJ&F>G@O9VNW8>$HBE>_>3B%1HN;
M\R-Y^.5*,*C@1B1E'(OTPB,VSA1F>LFBXYUN'"BD-@'DN-<%:N6,^136"4CJ
M,F(KB>:.I+;R-L0`H\XMD-F>9R_AK^4VG20G(9<+>)$FB7=6OIST36H,ZC*,
M(M)A%91`P`7<@+;=3\K1)M3$TW.M4:,?&'4I'D9'#55$\>93D1T=/'R1F`X1
MFXL*"F1+V;SQ+(LG,M4S:#C!1W`:3E45132)\@EJIHEJ#.W+#K[&<4RX]F($
MYY&=#$8)*1&0W@&@[R*3+;*/3&BP&:D2-W"$BFBCVCUIR4OII%V++?R%%*II
MYO*Q4/-"?#*75N0Z+#<@'V$W3DHAM/!\&"YH18R9!9TD&V8"NHG?,<Z327L6
M+.I!-'T&R6=6&VM]]G6TMF%%!R5%D-.#5CN0*4I6MNXLV+VMFJFQ&PK90$AU
MK<'0Z_Y:*-A=4#R2EN+"/FX>=)Q#,JJ:5/'4S)5(IADD64`21VQ(T,`8%)F0
M0Q`<]6#6_JW#$[7U[V>CH,HY'A#Z1-,'NF!BSUDLC*":9DUFQ`XX].LLRW"K
MF9\@M9[R/'F>!D8^ML9::;MQ<IYSM/%NN(@2SI&F^6M$NI2,L,%X+RT1<C6U
MW>C<SSCY^)8CB;.TQ]<2H<56^"K-XD*M%U94:KO3G-9,Q-"1Z<:+G"?N+=LB
M'<@^V>FQ"NS-N8O@%20VL4CU^ZT[`SJ?D10<APHJH2I!;[@AL'48XC#I0*&5
M;)I&F>RT.Y1G",:"&1ABHB03*8=_F>@U"VH6=GE?9T-2CXQ'J3"L^)T7LH%4
M,&\G&[&,MP+"DT-I].5*-E2F;74G.2EBQTHU<P\CR,@^8P:WD`OBJI`EN=2M
M(>2F<W_K+H%N)L%%9I,(R/#6NLJ2.QSBREEUI*+.=J-8ZJ(XZ@D&[V+*10(X
M`'D,2'OW(QA:X8EKXWO:^PL#.]9D"$(>?;BS+BK[TBR.W8MB%"^)0J(KN1FH
MBVIYEBN&66!8OF>/&,@0,,LL00KX!XY7MC:]\LTI2E*4K579&?W+"#UU+;J,
MU$-PH^P^RJ;`[G5%-<44U3:))5B66I'(KR"E%$@X47S0AZ,\4@V64E9%`(E%
M+(\#YI#AXE,;.C*=9_/;9ON`Y1C-A%6/E$6$SL1[QZY'*LJ323A)'-Q^CL&7
M2RVB$D>[L?2>5-OAH*K3/!)G>K<?3;-I8^+93W:Y>0T.0'61]+19MMMTNTTX
M#B&.X"J,=BR2D92&)DMBC6IZN4Q*++8("XK:#/Q(RP%]O"XAKB,-8NOGR`#7
M/IRT<Q*?Y<=%2*$ZE[&8`3Q=K%2R[<HFHQ\\HN-CFF>]G_A(C/)@6RS<S+#9
MT;/Y<&4$_+)2P#;(J=9'R6EEL)B[]1GR/1NL'-H\I(&34-!@&5WVD)[G9I1R
M.IN#PPVXAA.5&W)3\<8:?=OL4=[!2_@E-,FMJ*83=XZ.IB-015+H#G-I.T2U
ML]&;>C)MR<LAO!.*/-YXQLSF<=9BX3D9UR(,XEEL%68WV4;``5%)5.'V\M*!
M4X#?S`%:B8<?7FU@R0!7!CJ:T.0HE/\`L9"\.:QIJ6YFB\X:'V#>#_?C9D]!
M)8,M%F90A)[QTEXEVZ#DRI@8KC0'79<1I#*!E`'4W<8U4RZ$MJ8BTDR=VZ]+
M=>G7IX>GBZ_1Z>U2E*4I2E*TB)[$R\[9\V_U_9+"C^S@@MAZTNF,%YP.YPAI
M;F$GW"40%(Z_BI)N6,H95E&XW.FP49L"+1QR$.Y%\%I*/*5K)'3Q#N;</5O&
M?MGT%-C+)ORXZH6<ZRP078_8]7SZ#/2C`+7E5EC@HF3I+1/)*Z`C.--6'&FX
M%6@AKMSCA7S;;21GB;N$?D"UC":8SO\`/BL8)X3M=D>8%%!GN5`519(9LW'=
M<U2/,R+D3T;S.=QJ9$E<:"&G+(R8`NX-YPN1,.&&DAJ:\6UQDSEXU;+Q`\W=
M!KZ19-?WI=Y3F6+&Z:(N(@@NITQ]K^Y]C"L9.,\5)9K+7=9V.FLIN%12#B:"
M;3D\@HE!!L%\MBD";%H>]L,'D.-CAP1V&5:2`[!H)1N,-WK)-Q9I*0QS;W7V
M(8P3<!)!8++59`;J.NOADX.-OD1QU`<0]FGMQU'T2\Y<W&@F$7L28L@.-63U
M#OJ,BSJ64]K.%;:<9VFM\&8SAXY*3G2B!E)82=)3_)G&LUU!<'!*B'"9H\J"
M):&!FK6L/339M^[58RZ_C+*(LF)FS+,KP\R4Q<17\W91P<L'3'(L1O$XZB;E
M2"C:4DE>\YR6OI8K:,%CS25SR]'[F(G%=N"K!K>"E*4I2E*4I2E*4I2E*4I2
ME8W<<7-YTR+'$DJPZF*JQ<4?`;82\!P+(>*H^TU)0S[B-E<RN9D1<2T`@JH2
M*:+G"P)5-=CG!,%S>9XN(3TYF+CCBB8)C69>SDZ;(_5'+(,+3`ZVQ'CJ;2:A
MK4IP2U')'S$?X)A=9SC<S67!6&N%VFMC,Y=;X"B7:#.5B@:<Y4(59/:_&^*-
MG-MH"Q"W5EPOZ/)3D779\S,_9(?Z2TW\PL]5V8PV<T5F(DB*8@;155=<M-5B
M!,F65%==[8*"IS@=*Z,$Y`W(O-A2WA8^H4>L;99[[2E%AP*,AO9IG&,9P,DV
M:F%"C1-'FHIDFP>4VPTT!TOE`9QYIXC1@0DI?>646ANI_$&,.C)3Q44\/6/+
MB8@$:/%2*3+\F<5AE&2X8LBM,NXVF*=A&)G;-S,G]RQNP%4ZR#IA10%%\1Q'
MJ87.R#B]7`CL9D-UJ)"N3#`/'U"4C#'L8VQZWROX;WO?I;M97OURRZ6\%NUE
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M+%%DZ%XRAU^/:48\!;C9>`KU8S?031]QM@-K/,XGM-P9+*<&,2LD.,\41CW=
M>X*!@(OEGG;+T6.5MO*,X\=S.2LD)I.AC-!Q-A%S(D4S-(;JXW4U50TO-.3!
M1DXADGI9LH3R)$!A212X-RY000N&'GE?M*4I2E*P9,D!M>;5Z#'`Y5QTI)B`
M)E2IQ:)5N&40L35G>D-!YL8J3<]E9!63)QOY-Y_.8`<BDF40]F9-%C>"H$(2
M`M5O11KD8BR0Y`D`2=IPD/"1%5R+BBS'^=BX5HI2NXCZ2,&<2<F=%3-=P^+8
M0T--9;.(.1VN%+;;2`R($"5CHXZD)BE&X\=:T78#'9),2G/C(Y:8I%F6V`CJ
M.&6R&XI2C=!8CP;=VV,&(0P8QY60P)@":5K8$2\W*"E*.%[KYS$0/&Z+QDL1
MJ-R+T)L["['H`\$JYTM`Z_@O16IJ<5QFM-T^RE:&"99?B9507ZSU)J'4YOX.
M65T9^2T3Q:3`4DZ1"RXSDQ0S[,KQEQ(BR3.$M-&5)S9[XV)+O0A+BBDKD=J)
M-ZI+K;4=-E)2'0DNB,7`G.TI'($;ECD>FG<`O+"6*]I52UA37VM);I;IR\\.
M/Z($_7^'X#:RX\F,2@"6DZ<(6=[,&;B(K1G(28ZW2YBH31:X;=%CA(CH!/>[
MMCPC$A9FX1ZBQ8MC,9`1$DB22C)#OH0T<BF!9*295:*^_3SG(16\XO4`5Y50
MSJ2X1)(G%P[&R)("P`5;9`_Y^WE+CL<CC4QDY33VJ5`5A4I':B<3+D\2^YU*
M4I2E*4K49V:?MARNW9A\)THR\QG3M''D61D\5IDJS)(GFBVXE\^8:`)'8RRP
M5[)&6%(G(3O(KRFM^>408NJXB)(:,;($#)>XL]9&NJ:Z/O6R17Q($ILF0&@]
M6.X%UZ&&0EN<NU'@D&4/S(0?0Z8[!:+7*M-)&!*LZZ`TDX1#S($5#(0VIA"'
MA=>2W&%KXB-![(#%<$K,9?>$FPQ-2=(B,\2:R[&;+$'M5":[:?#?+/%"<K/4
MS;KNEK;BE9*>C7=:!*KID.25]YIBDH/$^/CRU+CH8:GE-B>).>P@"#L3&ZVS
MIF;0#F8&91WNIRQ*+!RW,&!TY&QM<;CU4X^P32`[;;:BE0WYLMEK.(&,`U=!
M`&$M/'BG@LNQF'%91^RWA%48RAE*\<QV8,QJ90HS<N1MGJX`D1*'H:`NJ'<T
M5RM0^XV@I1FXFTL,D>09+0&J?2F2ZL6JF9CF'1"*IHE5RR:X7$_$PI)38A]G
MS;'2,HH>+"F=`@.1%>4(F+N\FI-]27$LTVW(OKA$\H,Q=;1MTM)5,M9R"*)`
M%.$(YP@6#6]KZS5QE-IP.ER$G#*<QR^I*3P&03"KD[)TE!U3`^L`LVZWVT0#
M2LWJ]'`91R=T_,=.3S(";D<-!%`<[9KI2E*4I2E*4I2E*4I2E*4I75+II3(H
MRL<14NRVKE$P^92T:YT%-LK*1<F.,03+J)C',N0LH&\`2=SH^&016P_=Q,;X
M!Y6KR[PYM!.V6P&<S.!=D)M"[&PMQM-7;*52\'%&]?3Q1,+_`"#CRLRBR,YF
M$9;!0*+9K]"F"5QS2:GR"KQHU'H3>3_45]+NFN5.NF0-S=^%.#GVE/AO!+;P
M'T;G)QEVFWX,3'FF.U_MB+9,4(\59@U^>K"P=R6W=CD]+8CK:@K)>3^:*2\7
MB'K%)T4,MWCIB\XLAR?NYO4RI'V)-M%>**[&;:MOJVHL3G3!!\@Q4Q%B#4:!
M9P@%\*+G;[:,.M7[]E%=D^-DPV&8/H$CC`F6HE-X\[6]D*4E%T-FQTSDSI;<
MCDE!KR0F$)H74Z-P2!=ND)":,6"M9I*;60IK3FJ7*-X"3!U,ZYE(09`+A)!A
MH#M2_9\VL%VV.]E*4KYSZ]C+I:][]+]+6OTO>_\`W>OCMVO%UMTO;KUM>U[5
MY=B#MFV(Y=V8?Q=QO5G.:2=@>2-L-C:=?@%OOM?3#45MB$'-J5KID>-L`8RO
M0_,!W%]*K7)%`#=W>J1&1C>&G$T'@]3(JYU3D=6PZ`\5J<$'7-<.;)I7(`MS
MNGPVG-QR'$063E+YGM`1EMG$7&`2`)*#..;3@7A\5?+K("8X'^2+M2R]9UF`
M1,=E@]FM]UY*67#"SP=DT1)F^8/8[0DP2!6FE/8\N;1:_K;8&)+;5NU6^FD$
MO5':\S#3HDA3LA`AM>*Y&DF/I,-*+PAI:6`=X-:)EW,DB(HX>;VB$R26)#-G
M&J_";B6&_&[C@TY'C:0H[>#O3&<HL@Z/))=]S$B24]V60%-)1(5@9L8R7RP(
M+MRA>*-#Y'-O'P3U[1W)+1^"2;^,<>K6F&1C^O24E#,5]RSK3N>I;:-A%#DQ
MF#M<!<9,UP4R;XE3R<X<6"IXJ24I%%-M'<T^\[^D;YFV2M38"?6QB&`@36Y8
MV05*02A="--3`ZLYX#!!.'-H'[]_LT=V)8*<ZC3-/X!'FD96AFX<`+F4P4`+
M:>M9=SH$;6TFJ&Q&N;R>!B/VK-D/ON,W"]RH::*9:B0[D,RDGE\$-8,%$L01
M,!'R,XX'S1<KE?#H,,'AUSMEV+&:GQW&<>,%*4Q%E,9#&:#03E<:P&(JH0;+
M=3$,FHB8E<LRV(AXL0"-YV+Y9`6R&O8'+(/LWO?M*4I2E*5K!NC)LJPUJQ.<
MH0DS##^E!D1\L+[4;)1(/.,V8-%+E['U,HUDL0%5=QIMHPBFZ"S.21@59W#(
MN#;3!0SRH!E;S^L?8.?(F5MS$J(9`?A)L2%-VZDQ1-L,?@Q+=!";M@VOKQI0
MI:[PVKHQ*-R#8,(<U%5.2U`4S&[;:BQ*;@:2HVX^<35=R8J$E799<VPVO<;@
M?"*_F\$&"VMA]&;#-PE&;<ER.F0@N3=6.&A,;=4LS4?H#Y84MPDRLG*Y15=>
M]$EEK3<8A;:6&Y7*-LR.W&;B:/M_=Y$1HE7#,CJ.!HBXU=5G4[5E1@@)B+C(
M+NW=R?H'F5"C8,5I#((CW$A=KQ))%T>5,50DW$L\N/S(\BMEP-XH'-SI(_W_
M`"?J_$[WE-^1S),BK22JW>#KBG#$%EF%HBY5I.%2B9;#'`,JL-XN5*H#L+@V
ML6"=R<N8D<<2'>F-MJZ4I2E*4I2E0Q<R<DR@E0J\87;^#@;L;33I_OF"KO=N
MQ]>0#;AF9HP:`8A37T;`=$<))OARZ66Y$<10X73BKJ<BI%Q%ELAPH3@6L,SN
MMJ7N'N2G@&R+)/B-HXSAII82_$4B1.M8MR,8&:&M3?=VN&W`3U;\=N:0E4L^
MWSBTT5?L.DOM),J,H.!J),5&'-!+R33?6DMM-O5!P%7"0++;3<;B:NDB"<>#
MBU]8CY=!=)>W*)*L*3HEEI/CANE&3*+#9^N!HE)[*?#>`0VH:8MRFP'G)9H,
M@*:<F<EC[Y[9BGH894C2^S8]<"H(U"AEVR;&J8PTAV([1W[G"#Y<7Y23U5NI
M)-`<$@ZNLV.'I!)6-32$F&I+5%AS.9"2HM7&SVO1OC?K;KUM?PW\73P=+WMT
MOTO>W7'Q7\/CM>JTI2E*4I2E*4I2E*4I2E*4I2OGL8^'\MX?\_/P>&]_!^*_
M$^/IX.G@\'BM:U.Q;_.MX.G@SSM_JMEX+^WX[^SX;U:3\8+.DYGN%@O]O)SK
M9[J3#"0OH"N'F8(J!$QV,KX9VQ$#&`'`&"!-D3I08N>3CY<LH)YDJ>+`&`_P
M8L>-6.4PREM8D>"P/&^_U-165YQ.QPK!ZQ<$F&<7'4[E9><ZX9`)%BI`J.L+
M!X0H0*EB)7($F7!`PO:E*4KY[%KVZ?BO'U_+9=?#]#KUZ]/\W\K[5.S;KU_%
M>/KT[673ZG3KTZ>UTZ>U2V&-K=.E[^&U^M[WO?P>+PWO>_3VNO3QV^C>JVM:
MUNEO%_Y]FL=OF)V!)*C'BL]F\"O*$4OHK)<?F#!Y6+W;3Z)(:ZV2KD)AD%`F
M",?`0'.X4C"Q\,X6L065(O<O?`V+;+(EK6QM:UK=+6MTM:WT+6JM1@<U7K2O
M(S]9U.__`/AE*MOM3_G7M<O_`.!H<_NV;%;`TI2E*4I2]K7MTOXKU\=SQ_SO
M'U\.>=[^+ITO>^5[WM_FWO?'KX>G7PU7L6\/Y;PWZ_E\_H>Q^*\%O#XK=+>+
MP>"U8\DB*&'+:,FH;\0[K!5#<20[F^<+*RX@+S:=2%D8\RG(V'.VE1&<S:72
M8)P^3P54%73SN::HJ26,,*G*)TJ8N5K-9!9:$0;3:3PTQ'3<!<2Q7`4P8$R%
M,F!3ATX<.'!C)]14E$Z8,'U15431M35%`R94%$V:.F!S`EP4I2E*4I2E*I?&
MV73KU\'T;998W]W&]K]/:\76UK].MK53L8];W_%>&W3\METM[=K=>ELK^'KE
M;IE?K?K?PWIV+>SE]OG]#_\`M_\`?Z-8<<.O\2NE_6DQ::09AX"I:$BJI\NM
M.1-(.=*:RF?66N0>K=2UHDV'T6;"HJ*1YMAO-%7K()D^;$2;D[CB6RS+:W3Q
+?^?_`#]&E*5__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g884541.jpg
<DESCRIPTION>G884541.JPG
<TEXT>
begin 644 g884541.jpg
M_]C_X``02D9)1@`!`0$!10%%``#__@!!1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4$520T5.5%]2141?2U]"05(N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@`YP$[`0$1`/_$`!\``0`!`P4!
M`0`````````````)!P@*`0(#!08+!/_$`%X0```&`@$"``0*%`P$`0T```(#
M!`4&!P`!"`D1$A,AN`H4%1HQ.5%YF-<6,C,V.$%35F%Q<G-X@9&3LK.VTA<8
M&2(W5%=8=IFAUB.6L=62)"@I-49(662"B+?1\?_:``@!`0``/P#/XQC&1-]2
M[FM;?&N7\<J<I%%#TL^O>-<O[%+EL\9ULDCC2R\1.-DBN_<9-8VYT9E6S[#E
MH8=&5ST!:8:PQ(4J5MB0<@,952*MC!S]KPK@IQ\YS3B&VD5$;UJ.B[.+A]45
M98=YS5B.NV$LDM0M6HC6$=D<H<$3(8[#1.3T0T[0I2R"U*LPD)X.]JK+UX^#
MLD<I4S1V*\VWYW@KV3&ILU,O3WYD.CE#I&H:D3ZG8)2A0U`>JCSV>R.3<\$M
M3N4C7FM2]$X@3B1JDYQGHP];+B4,00`JSGZ(8Q!```>FYS;$(8QBT$``AU2V
M]B$(6]!"'6M[$+>M:UO>\M)<?15_1?9W!<TNU_V4UNC8L5-[DVN/&J]T2]O7
MHCS$JQ"N1J844I2+$BDHU.J3*"BSTYY9A)H`&`$'7XO78'1/_O'3[X.EX?[.
MQZ[`Z)_]XZ??!TO#_9V:Z]%?]%#?L<C9_O[7'.\-_P#2&YIZ[`Z)_P#>.GWP
M=+P_V=CUV!T3_P"\=/O@Z7A_L['KL#HG_P!XZ??!TO#_`&=E4*L]$H]+:\W=
MR8*4F7(RX'UF;/5MW9:MX;<G+!=FMF].)F_U6<6V(UN\+$+9Z?6)$/I]424D
M].*DR;QOCSR@"KE_+:<2?[+N?G^6[S:^);'\MIQ)_LNY^?Y;O-KXELW!ZV7$
ML8@@!5G/X8QB"```]-OFV(0QC%H(`!#JEM[$(0MZ"$.M;V(6]:UK>]ZR@Z3T
M2OTL%Y9IJ&;\B%A1"UP;CC$O#GDTH+)<&E<H:W5":,FN!A+6-KDD5M[@E'O1
MZ)<E4)%)92@@TL/Z?7)?2\^NSDC\#+D_\6N/7)?2\^NSDC\#+D_\6N/7)?2\
M^NSDC\#+D_\`%KCUR7TO/KLY(_`RY/\`Q:X]<E]+SZ[.2/P,N3_Q:X]<E]+S
MZ[.2/P,N3_Q:YWL0]$1].&P9&KA\"5\KIM+$#%J4+HQ$>#?*Z2R)'&MN1;-J
M0JV1EJU:YIV/;N:4U:=SDH&_;D86ATH]-#"5NJ'\MIQ)_LNY^?Y;O-KXEL?R
MVG$G^R[GY_EN\VOB6S<'K9<2QB"`%6<_AC&((``#TV^;8A#&,6@@`$.J6WL0
MA"WH(0ZUO8A;UK6M[WK*--GHCSIE/242YFD')MV1`6N3:-6V<*N4B]*!Q9G!
M4T.Z`2A+69I05K4ZHEC8Y)=CT>A<$BE$J+*4D&E`[#UQ/TWOZ]RK^`[RM^*[
M'KB?IO?U[E7\!WE;\5V/7$_3>_KW*OX#O*WXKL>N)^F]_7N5?P'>5OQ78]<3
M]-[^O<J_@.\K?BNQZXGZ;W]>Y5_`=Y6_%=G[8WZ(4Z=\QDRB%Q$/+B4S%)']
M2Q5%(YP3Y:/DE31;;H!DU)%#"UU4J=26#;R86T:>3$@6W;F,"#TSZ;$$G=1O
MY;3B3_9=S\_RW>;7Q+8_EM.)/]EW/S_+=YM?$MDP&,8RT_E'PUJ#EJ1!CK&%
M*V.2UL.QBH5.8$^)X_+V)GN"LI+3MK1U,O6M;V@&RSVNI6[,+L4>UFK6Y66R
MRJ,KF*81N/OS;7Z"P*(5=7\.K*`,2.+0.NH?'8)"HRU^.+;H[$8@R(X]&V%O
M":::<!"T,S>B;T@##3!Z(3@\8,8_"'N*_IO!UOEYUH>^Q>V!0??D$+7_`+D7
M&#W-Z]W?D]CV/<UVE_\`%A]T?YPS][/`FU/6!YIIQU=P4XXXPPXXXV'1HPTT
MXX8C#333!M8AF&FF"$888,0AF#$(8Q;$+>][/X(JL_LW@/\`R7&/^TX_@BJS
M^S>`_P#)<8_[3F)=Z,8@L*C73?X_K(]$8PQ+#N=%8)35;-'F=J4FIC:AO,PQ
M,8>@1)S1D#,)*,&2(6RQC++$((M@!X.6"TU)5HFMM%NMX#O>V]#WWN&1G>][
M]*$Z[[V)JWO>]_;^UVUY,[#^"*K/[-X#_P`EQC_M./X(JL_LW@/_`"7&/^TY
MW3'!H9&5!RR.12-L"M01I,>J8V)I9U!Z?1@3=$''MJ-*::1HT(3-$F#$7HP(
M1^#X0=;UZ?Q8?='^<,_>QXL/NC_.&?O9QF`UH(=]Q^0PG?E,'O7S8'LZV+MO
M[6_)GS(J0--!%IF$!IH0ZY!\I]:T$TS6M=^2EJ[WVUH6M>7?EW[N_+ORY6'Q
MY_U<_P#/&_OX\>?]7/\`SQO[^/'G_5S_`,\;^_CQY_U<_P#/&_OX\>?]7/\`
MSQO[^/'G_5S_`,\;^_DD/08$,SJ[V]XP9@__`$:Q6M;$8/8M:_C6LN^VA;%X
M6M=_I:WKZ?N[S-?\6'W1_G#/WL>+#[H_SAG[V;1E:WK7;8N^AEB\I@]Z[!,"
M+?DV+>M^36_)OV?8S"-KOII=8"DFF30"+\3:*GD;+MN\Y@PRQ9S19X6K=V:S
M+EG-CM8U,8#5L@TTGID,I3I#21.RHPPP@1QNDYA@DQ7O?XE?6=_N/4#\/EI^
M)3'\2OK._P!QZ@?A\M/Q*993SVE742Z;=&IN0_)_AI5[/6RN=QZN254*YDI9
ML\"DTG;W]S:BA,Z*GD1@$0TD:<]GK-G^"28$@'BQ^.V(%X;)Q#ZR$@9FA^;>
M$-"F-[VU-KPA&=ST;"#1(W5"G<$FS21TGX11NTZDOQA>]BT`?A!T(6M:%OL_
MXE?6=_N/4#\/EI^)3'\2OK._W'J!^'RT_$IE[G2CX+\\:IY]V'RDY84W6U/1
M)=PX#Q[CC=";]072O=9'J]&FS=+E0TD2B*AI2>I>EZ;81)5!.CDI.]*!#6;*
M(R6_%A]T?YPS]['BP^Z/\X9^]F_&,8S89\S,^X%^CO(@NF[]%YUH??`H/YD7
M%_)@,8S3OKW=?EUF(KZ,RWK?36X]]M]__/OJW_\`#U[YEL,^]>I+;Y=?^KT/
MT_\`Y0G.R[Z]W7Y<UQC&<9ORNOOA/ZT&?,<I+YUYI^$'RG\Y2U<J_C&,8R27
MH*>V\6_[VL5YUK+F;'C&,8S%!]&1>U(Q[\+RF/V+N#,GJHOZ+*W_`,`PO]F&
MG*B8QC&:;WK7;OO6N_L>[O[&M?3W]C6-;UOOVWK?;?;?V-^YOW-_8WY<UQC-
MAGS,S[@7Z.\B"Z;OT7G6A]\"@_F1<7\F`QG32,AZ4L#VGCBM.@D![0Z$LBU4
M$(TR-X-0*"VM4H").K"(A.O$G.."),HT(LL>MD':WLH>(T#AUZ,$T67H?5&X
M0['HL&A[W!XD+>QZ!K0]^%KA`7H7<7???19>M]^^BP:_FZM&YG=$[T2[U!*T
MCM0<M>?'""U:]BL]:[-8F'TFKAFT,U969]8&UX]5(%Q%C+NITF:9*])?4]4N
M.;3/3NSS48U!"<TJ[<KAMZ+^(**)*ZH?"`!1)99)8=0:*;\$LH`2P![[X1[W
MOL`(=;%O>Q"WKPA;V+>][ONZ=/'?T0M6_)EHD_49YP\9[WXS$PN:H7>OZNC4
M?:94IFBY*@!"G8I0W\8JP5[0M*HM>:N""8I2]EG!":V.GA`TDR$L8QG&;\KK
M[X3^M!GS'*2^=>:?A!\I_.4M7*OXQC&,DEZ"GMO%O^]K%>=:RYFQXQC&,Q0?
M1D7M2,>_"\IC]B[@S)ZJ+^BRM_\``,+_`&8:<J)C&,9$+U5VMZ+B<!=WF;=1
M5TB#_,V:O(EQ^Z9CS'ZWN6Q)^ZL4TE"^03JV%[W#I`VPN/Q:+K36]D:+*KQE
M&YIQA=P3IX>(^U,OK>ERQ3IOK&3+US[SN:X,*5OK"AIWJ0O\2L7DA6[XR:9#
MP+6VS8T]2-Z<J_E36[#6H6&>36R79*:0A<621L"!4OCFY3<\A/YY$ZOA<FL&
M=/!+!$8@T*WQ^=3B%JS:5`B!X0])F]L3+75T7J1[+2-K.T(5[N\.)Z5L:4"U
MQ5IDIMD3-U4^",BI"/<A6*]$KG6TFF5BP!!LJ#V2FG2*6T]&I%-K>9I'5"^'
MI+0B2FJ(/$Y%-;'^2>(-((=$VW;Z]"3(EC<-9?FS/K+)V!KDD==4#Y'Y`T(7
MMC>FE42O;'=G=D)+@UNC<M3",3K$#@A4IUB-40,9*A,<4<4,0!AWN)CIN_1>
M=:'WP*#^9%Q@R8#&,8QC&,8SC-^5U]\)_6@SYCE)?.O-/P@^4_G*6KE7\8QC
M&22]!3VWBW_>UBO.M9<S8\8QC&8H/HR+VI&/?A>4Q^Q=P9D]5%_196_^`87^
MS#3E1,8QC(=NMQ&(C+^(K"SV'5L"L&!%7'%':4R>TZ%Y!\H*YIE$W1F;;)M&
M54)QB6MMKV(20<?\AC02F<VZ+1>03%IE\O5":F7255WG1:BT;B'#0+1"JM@U
M:P?=LV`XPQQK.C[[XTP*UH^Z$QU:3;$8H3DLZ/-M5@AD*TU:RJ&AY<U;.]N<
M973&(C!%I(U$ERVY8_=<4YD1JQ)?=M6V4QVY64;K!V,B/!G^"BOHL]V/;"!@
M<`Q<\SE-++`;]PQL5R\;*[K=K8@H3,[>VJ@IAKE!A))D%8N`W,R30:D+N<^(
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M_LPTY43&,8R"SJV5S=9#]7<UIR`\SK%;K-<X36]C:XP]1QIX5K(@7"PV4YUZ
MF8R[`F<%B#8\6/,)VE9'Y_8I(6\3;3+&8.O:%S@9&C1W;=+B(3^&<93VZS(;
M?,#ERBU;*4N$;Y,<KH_S,NA$!,YHF5-J9W3&9!*VM2J"6T;)31,,E=U412$E
M-2PU&HT-K02.XQFPSYF9]P+]'>1!=-WZ+SK0^^!0?S(N+^3`8QC&,8QC&<9O
MRNOOA/ZT&?,<I+YUYI^$'RG\Y2U<J_C&,8R27H*>V\6_[VL5YUK+F;'C&,8S
M%!]&1>U(Q[\+RF/V+N#,GJHOZ+*W_P``PO\`9AIRHF,8QD4O5]BZ%]XYU\]D
M1'D7*)[`;]@TXJ%PXS5/QHO&=P&SF>.3<+)8BZL^7*Q%23RR1Q`>[`+=712C
ME<9DB^./D&<VF1)$R\G\/1Q(9@<;+)6Z5<GG.QGKDO;+W>KYS!.JA-?#[<2]
M!"QO[I)(A23_`":L:Z8S&`,630:$Q1W/0(X4D8GCRC>]F#EHQC-AGS,S[@7Z
M.\B"Z;OT7G6A]\"@_F1<7\F`QC&,8QC&,XS?E=??"?UH,^8Y27SKS3\(/E/Y
MREJY5_&,8QDDO04]MXM_WM8KSK67,V/&,9QG'%IRC3S1>`426,TP7;>_!++!
ML8Q=@ZWO?@A#O?;6M[WV[:UO?DR`DWT4#T0"#323>:6@&DF&$F!W07)7>PF%
M#$6,/?50[UOL,(M:%K>PBUKP@[V'>M[Q[O1+/6FZ:W/[IU-%&\3N1H+3M))R
M/K"='Q?^"VY(<(,58(O93>\.NG:=U_&F(042Q]:21(].?I\[:T(TJ4\HE2,B
M=RO/1-_1*8(%"&1TYGED.31#XJVN"<-#<DSM)UZ"/MJ1:FV:540BC1)E1)Q`
MC"1F$&"+V,@TTD0#1WG<1>M_TR.=ERH./_%KDCNSK8<X[(I6CB^JFNJ)`-8H
MH0F4OJP3Y-J\CL?)$C(5D&`2'.@%BS6QZ1)U&R3M%RPXQC,>GKCKKF;V&!KK
M#;>G"MX()Y/!"9,KYR\<^3'(-JB-SGMEKA#/YB11\YCT>B->(64R/Q"*NTO9
M%+>">2L\QXD3"5MD,-N(Z',GCTKX8NRZ%1+C''*_1WQ:S5`GOAS0%A\=>.=C
M1M#\C>@S^MXE:)RN8R-`Y/!KPR.4\5N#HW2%YCS@F8W1P9FA"J-F.QFG?7L]
M]=M=^^^^OI=][_)K6][]SMO-IGS,?W`OT=Y$%TW?HO.M#[X%!_,BXOY,!C&,
M8QC&,9QF_*Z^^$_K09\QRDOG7FGX0?*?SE+5RK^,8QC))>@I[;Q;_O:Q7G6L
MN9L>,8S:,`#`"+,"$8!A$`8!ZT((@BUL(@B#O6];"(.]ZWK>MZWK>];\F\L$
M%TI.F&,0ACZ=_",8QB$,8Q<7*6V(8QBV,8Q"W#=[$(8Q;$(6][V(6][WO>][
MWFW^2AZ8._9Z=O"+?_VMTK_LS'\E%TP?_AW<(O@MTK_LS*FU%P,X14!-$UCT
M9Q`XRTY8*-M<V9+.*OHVM8)+4S0]`)+=VLB0QF.-CJ4WNA:9.!P1@5!3K`$$
MA4%F:+!X-V6,8R*WJXLEJ3#C_75=4Q89D#L:T;UB]?15*XR&_H!!9B^/$,L!
M:SQ^R;:XW$'6!5<2;G1J23(#\Z@5UY+)%%V&K9\SOK)/!-2BXGA!&.3L;JN3
MG<N9_3TPN64VI-)<XQ>@C)8MJ2FF-[*91,=30Y[GINIQ(4S40G.EKF[25N83
M?5N:.;>Q1UCB3?'F\F\G(_N474-K3B\X6)'I/6/)![>(+6X[`U*&'C3?K[1Z
MP:H!1#,Q+;YB-<2B`MSB>YJT25W0)53I(&@@P\9;$N<"R&Y3C+U5U(^3]^02
M,QLKDU8;LUROF3UN$4LN"(M,YI\],7Q6XP2JWN*$0AQ4E;F-]BT`9"W%JLDB
MLEIIAZPJ$)XO:R1S+)L"-N.1[7')[E?*>FQQ1Y-U_P`9R^2?(^WN/W&FPIM3
MA5HPWCZ2%XL^MXQ([$>291/6M4Q-!,;7NBM<3&S4(5JLHP#<CV683WRU/HUR
M^T9[<_5QEMTT_P#P"6>]<]HH?+*C_A`CMI_(6L(X<\<$:1#\GT33(X](_3K4
MF0/'IEM3%%)O5+U.-T)2C/&*=C&,8QC&,8SC-^5U]\)_6@SYCE)?.O-/P@^4
M_G*6KE7\8QC&22]!3VWBW_>UBO.M9<S8\8QC&,8QC&,M$YMT1Q&ONB7QMYN0
MV&36@:U4F7!)4-@G.A<1:3H4POQ>I([DM*Q$H7!96MX=C4R,6U6AK#4QJ=$>
MX%(-!I_TVF[@<@XT-YG3G011GXXN,TESDC9(BV36/(F::*3D`):B71&Q$K=,
MH@ZFFD('!4Q/;4U&Z)6I71*BTA=$RA1?WFFPZ%K>M]_+[@A!_)O6];U^++?)
M'Q-XR2V*.4&D-!5$YP]YL.2VT[QP^`QL+0Z6=-1NNYO/G!(2@*+5RZ<%OT@2
M39^/\-PF#=(']KDISHVOCJD65[+3)T:,"5(02F2IDP4Z=,G*`200025HHDDD
MDH(2RB2BP!+**+"$!980@`$(0ZUJ(CIN_1>=:'WP*#^9%Q?R8#&,8QC&,8SC
M-^5U]\)_6@SYCE)?.O-/P@^4_G*6KE7\8QC&22]!3VWBW_>UBO.M9<S8\8QC
M&,8QC&,Q[.HU>4,6\\Z2X5-4&?6*Q>45;H8/(Y\HL%M%#;"A,D631"UPR8<5
ME2]A?^0-?1%8E>'6>6E64ZJBWN/;4O62&!62@]+OC2NE)X*TDV<>J+*JU!2R
MBDE3',),<^-1ET3#D(CFKRM&A./L9EMVS'Y\M>6,4B2^DT;4"TRF*:1U.S:B
MI[&0RLC*N<+RL8S89\S,^X%^CO(@NF[]%YUH??`H/YD7%_)@,8QC&,8QC.,W
MY77WPG]:#/F.4E\Z\T_"#Y3^<I:N5?QC&,9)+T%/;>+?][6*\ZUES-CQC&,8
MQC&,8RQ?EA17(6<JDL[XO\UE?$F:LC>F(F)<PJ:"\@Z7DT:2:<C4ZR2UW,GB
M(/43?T(5*P">902QX9ZI-Y84,P;Y4E:F?;-Z/B?2MZ5^UKYAR.Y<NG+:PY&E
M+):)"QUM#:/J"+150-.O`@KZKH,XR'2@QV/*2K'*8SJ=6#)591"9"R.;"QB4
MMBN\7&,V&?,S/N!?H[R(+IN_1>=:'WP*#^9%Q?R8#&,8QC&,8SC-^5U]\)_6
M@SYCE)?.O-/P@^4_G*6KE7\8QC&22]!3VWBW_>UBO.M9<S8\8QC&,8QC&,QC
M^KIQ\I^?<FG&WYK;5F.\>CT'X1Q+E'P-@E+/MLS_`)ET+$.1=N3^JX'4L<B#
M\DD$C(L*ZY*.(V&C<&95$P)(02ED+_&&S:Y4LE1Z8K\CD=*V4YLL445/$Q<@
M;"(@W'%PH"0<9GSB_!B&6%%Q.E9-5+X,U*WR<AFTFL1_?8D:9`92Y6&H?H*/
M<96H.TC^4^M>TX#1]96!<5IR5##JVJZ&R.?SN5.>C]H8_$XFTJGM^=3RTQ1Z
MM1I&W(SS0)$2=2M6':+2(DZA6>22.,>5]6V&1NI*1LPFF9:[/7)$F[)A3M6(
MIO`U4^6U)QYI=[O:T9;.O45:_16#S-NAS(6U-]3ADDCDI<VE$1B<M7P]:=+#
M8;(/&>1U+2RBJYY&DV%%V"G;9@T%L"$S29/C1$&AQCEEQ]ODD---6OZ]$B2K
M'=L=$@B4!BKTP)0(:<L)A@-Y&KTN9/&YGRAZR4EB$@8Y5''7G_##6M_C;LWO
MK(Y%$<*N,J0XU`ZM:A6@6%E*DYZ<P:=09HL\DTD>PFEC`&9S&,8QC&,8SC-^
M5U]\)_6@SYCE)?.O-/P@^4_G*6KE7\8QC&22]!3VWBW_`'M8KSK67,V/&,8Q
MC&,8QC(!/1!\:X_ZXU4W/+@@/'T<F17W'*_@-_7IKDXB!Q\'+XW*Y(ZR&.N'
M"Y4Q\F'53)CX$UQSY$8=+XI%E;FK:93/'<ADBFQ:Z/H3<RN(TDK$?":H76BR
M;9K979D\5H..E?<JHO`+)@A3U"AN-WKW3E>P"LTV7/TEGR*,2I/-K&LF3N3P
MR&/+=)G.)'-6T&0OD9_.7IEU[S9AO(%H>[@Y"PN07A04II$E"VWG;+A1<;->
M&4U$RS%3QG^31!3\B>FAU"A=5BM4Q)7AS,2^-*>F]T"C=4=B*WHPV2L6.]T(
M[1J6+<A)/>G*.V'.-1J%R9+0#`V\M.$T0X96&W1YE(5H9"-[2GP:.WN:["0-
M1<GDP'2`+26=M<")LWRO13@]QU;N(5)\+;.K."<@J5HVJZEK%CCEX0:*V&SO
M9%,P]IB,5DKU'),VNK"9(0$-(7$*LM%K:):J4;0B*!O66#=)2L*UIGD+U@JS
MJ"OH155<17GW$$L7K^N(HQ0B$QM(LX9<:W56E8(K&D+8Q,R90YKUS@<G;D*8
MDQ:L4J1`V<>8,4W.,8QC&,8QG&;\KK[X3^M!GS'*2^=>:?A!\I_.4M7*OXQC
M&,DEZ"GMO%O^]K%>=:RYFQXQC&,8QC&,9%GS1ZC;YQ<M9OK.(<*^2'*`]%"8
MI(GB:5`@AVHI#+"N:32BL>/%;NB^3/+>X`=K6GS&JC3[(VA(I:*M8'MIE<R'
MJ/N)^T]R/#'D!-N2]/D3>X^/S_QDO&'RV7UM;-(R>3L%AJJ[F\;5(Q+4;!9$
M:))C\ZBLA8%\;DS!*F(E,A=VIV2@,(+4)#0!N[QC-AGS,S[@7Z.\B"Z;OT7G
M6A]\"@_F1<7\F`QC&,8QC&,XS?E=??"?UH,^9!2!1HHM,Q!*-$'?(/E/V$$H
M8@[[<E+5UOMO0=ZWVWY-]M^3?DWY<K!X@_Z@?^9-_<QX@_Z@?^9-_<QX@_Z@
M?^9-_<QX@_Z@?^9-_<QX@_Z@?^9-_<QX@_Z@?^9-_<R2+H+@&#J\6]H8!@WO
MIK%;UH8!`WO7\:UF\NM"UK>]?9S-AQC&,8QC&,8R%7J@\,.G)*Y#'.8'.VKH
MS+(K'VYHK:Q['FUW6I6R"JZEB3!:TZ:7B+0^NI3'`SM\'/G)*G=FTE.X2DIB
M<ULA;?3:6(^I9E;^DS&./L;XP.IG%FF7JC*%DEPV+*ZYA\CLI/9+ZY,SUI@$
M.;.@A3.?OL%43=8G42(%9323'3F$IEA#?+6>*O!I\599.\8S89\S,^X%^CO(
M@NF[]%YUH??`H/YD7%_)@,8QC&,8QC--ZT+7;?L=P[_&$6A:_P!=:R")V]#A
M]+QW>Y`^C@E\-JJ32222QS2Q_EGR+CK/ZMRQ]<)(^J43*RV`B:VXM:\NBY8)
M.B2DDA,/'O0>^][W^#UMITO/K3Y(_#-Y/_&5CUMITO/K3Y(_#-Y/_&5D!/HD
M#I3<3^G7T]FF_>*P[[A%GK.1%9U^<]O/)V^9NEW%I%&;'<G="%FEDZ<VD)JE
M7'VDP*W2/:PC2<19!Q0#SPFSCU]Z'-Z9,A@D*?7*+<CC7%XB,7='`TOF3R<)
M`:N<6%N6+3@DEV5XLK1RH\XW196@%`\/P"BRR]!+#Z_UMITO/K3Y(_#-Y/\`
MQE8];:=+SZT^2/PS>3_QE9=OPMZ1?"G@-:<JN;CM$;%;+$F-?:J][?Y]=EJ6
MN8.$ZDK?+_49&18DF?R6XO3^V)5VC40230B\>`.]!5*-&2;8QC&,8QC&,9%G
MU';'X[RBJKMHVWDE:,4AC56MLMJZW.2%=1V6<=*UY$6LT6E`.-SFX+I2P3AO
M'.T,R:W)R0IB8#(#$*0Q$06!6\21B8W:\/BG4$3HZA*TK^+1&L(>>@B4<7S)
M+4,&8*ZA3W8;K'6A7.9<BB\=C$-1(U$MD&U3ZI./C+,X*=+"3%S>D._\F)N)
MS:,8"@#,,$$``!$,8Q;T$(0AUL0A"WOMK00AUO>][WK6M:WO>]:UGG]RZ+::
M$L@^21A]0EJI.B1O7JPV^I*M8K6!;DJ5,Y>FO2*A0I<!!0IR"3QFGK1!2%`&
MHWHK._,^9C^X%_TWD073=^B\ZT/O@4'\R+B_DP&,8QC&,8QC&,9B@^C(O:D8
M]^%Y3'[%W!F3U47]%E;_`.`87^S#3E1,8QC&,8QC&,8QF.'UAZAX\M\NL3E#
MRIO/J0\=:3@E3TRQO<CXH<JH!0=/SE^C\PLZ7Q-E45^_2]DE=KWHQOXD:N-D
MQ^.R)>2!5$P1[9"]K<S4<B72BBC#'^([&_QA3S@71ZS)C*[+9G#J(O*5]Y3N
M;=)0M!"1QFR[3X^/7J.L(:BSX8GEFVJ2IXP-N+6-)*32!6LDJR$KK"6+R2,X
MN\T*I3\4+#E/&]]XKS-$LY`43?K2DNE+)I*U::!,[/126OG.3J(TQN*U*JGT
M@)DBT@=;D2]6".N>B?4E9`7\@_(DJ*:2\GFMMFE8,?,'JKLEW6E6C*I3\8+Q
MLV1]+2-0OB[:M1PIF9TR&$-SNK022N(\V,9CNVG\HUDH31*0'V1+T,;:<H&I
MH=SG<.FOQ*B\:L>$5-S)0<=.-*>W)5?]:O\`;[>FF[;5\8)MULDL489U7KFJ
MEJR0`7IU#F&2@)1NQ:TTU.L\9KP;5>CHTW`QW=U=FJ_)G!["MQ'SXBH)I,:W
MA#K7$)?%IG#GC@<A4,$)>Y;.W5@3D,QC:B4)EDM>S#UR54M"J`4J`G)G2QC&
M,8QC&,8QFSQ@?<'^;,_=S%#]&0BT+I(Q_MX7DY>4O[(1!_\`8NX?8\+6N_XL
MR>*C'K565OY!_.#"M_,Q[]F+M._I!_+KV=;\F_+E1=#UO?;6A?C`,.OR[#K7
M^N;L8QC&,8QC&,8R,OD?TRJ^Y/\`+FKN7-CV7.5C]0T&0QFC:P<FF"S>FZ[F
M!KZ]ODANE%75B1B4Q]3<CB%7'V=IF@TP#H\U1AL,1)#'E,UNS5?+5L,FT);)
M`BG%JOMM+726.CXU/,ACL1C:UC8ER1K(114I)"FED9E21J4HURHAQ$VD."O;
MF9ZH#4J"MJCJGYIO7?7;?^F]ZW^77;>OMZS;HL&M>#K7@ZU[&@[V'M]C7;>N
MVO+WUK7DUORZUWUWP9KL4/6O8T`6M?\`AWD073=^B\ZT/O@4'\R+B_DP&,8Q
MC&,8QC&=+(VDY]C[VRIW!2TGN[.Z-9+HC\+TTVFN"!0C+7IO`-('Z81#/"I(
M\$XD7C2@>":7OL,.(SKT+]RE\$.M]>[G_P!]!"'?@J+!"'>PAUK>PAWR6%L.
MM[UWT'8A;UK?;PM]N^_`65Z$GM"Y8X&'7#UH^8%L1$#FD>016RXH^SR-A>$!
M2I.A=@L4IY!.S6%R0D+UQ*5PTETJ2DK%8"CBRU!VA^[(]"[\GDQ!"9+UZ.?B
M=*F((3)4Z<V?$ITZ5,4`A,G3DE\DPEDITY!99)!)80EE$@`66$(`A#J_+IS]
M$6\N"O)=JOV>=53E=RUCS=#9E%C:?M\R6F1%:LE*1&E1R`T3Q=$V1!7,`DQB
MA$$3`::(X_PBEB/8!;-R$L8QC&,8QC&,8QC&,9L,^9F?<"_1WD073=^B\ZT/
MO@4'\R+B_DP&,8QC&,8QC&,98)U"./?)7D36$0C7&.ZRZ;ES%.D$K=E3JYF-
MT<>D\62G3"&A7^I,&E,F5+FZU8Q`=DDH7A@CY4><)8KF+-9S.G#64GO:B+4Y
ML45C3*]/CG)G=H8&9K=9(]&-ASQ(')O;4J1>]NQK*QQEF,<W962<X+S&F.,#
M8-6H-&@9&I+LI`G]#C&,8QC&,8QC&,8QC&;#/F9GW`OT=Y$%TW?HO.M#[X%!
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MVGJ&TNS\#N/W.^Y`2V!5U>M1479`6N*5S9EQOS`X7E"&65L\?W&JFA\SER\M
M`H=AMJAW(81-Y&B`*%RA*`\O8K/^D!9<:O&WNJS>]?I9F*K[=YSQ>25R_36M
MK%JMPE#`U\1>/,26.R6)VE%H;,4B,N0QYX;0F.3`B$::B,,+`(D91@YO\8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC/"3VKJUM-O0-5FU]![$:VMP"[-K;.HC'I>@
M;W0*<Y(%Q0HY$VN29(OTE4'IM+$Y12G2<\XG1NBS1A%:1(NG/QRFDCYLODY1
MRZ9-_4!@$1K7D=$7N0I@15[C,"A3E7L-U%TK.S-+K#'6/1-U5MZ!Y97HMQ$K
MTE?%1ZA^0(7)/X*0]*?C/*6(XMZ=+6560XV5:MK2"]PS%L3W%)I3=U&AXSVD
M%X>2(N"+::970J5GK83:UPYL*8D4<C,HC`V6>L#=*R9`(#`HA5T#A58P!B1Q
M:!UU$HW!(5&6O9Q;='8C$&9%'XVPM^C#3#@(6AF;D3>E`8:8/1"<'C!C'X0M
M^M"'0==M;%OZ?\X0A;_*+>]Z^UKR9NQFFQ:#[/?R^X$0OT=;[?CQH6M[[:[^
MQW]C?;[6][UVT+7TP[_G:^GK-<TWOMKOOO\`BUO>_P`FM;WO\6LUQC&,8WO6
MM=][UK6O9WOR:U^/-NA:%[&A?_4$0?TM:S7OKMO?EWV\F^VM[W^36M[W^+6:
M:%K>^VM"_&`8=?E$'6O]<U[Z[[UW]CR[^Q]O?L:^UOR]O+FGAA[;W_.[=^W;
MP1=]_:#V\(6O<WK6];UK>]>36\U\+7D^S['DW_\`KR?9[]NWT\UQC-NQZUOM
MOPOM^"+P?_%V\'M[N^_;7T^W;&QZUOM_.]WR`'O7XMZ#O6_Q;WFOA:[:WY=:
MW[NMZW^3>M;U^/7L>7V,;WK7L_\`3>_^FM_:UKZ>]ZUKOO>M8T+0M=]=_P`8
M1!W^06M;_P!,>%KR^SY-ZU\J+V=^Q]+RZ]W>O)KZ>]9KFG?R]O+W[=_8WV_+
MV[=_L=^^:]]>[[/L?9QC&,8QC&,9!YUP'EU9XSTZ$T>=5"-YFG5$XNUHN8B;
M-D=4H;!@TV;[%2S2NI3)8P8:X_(3)R434"2EC:)`G3`2(G$+.I6(T>M1D++!
MY3=+VU8>RWORCC4YL>E.C!S$LQ:]V]9-SRBAP3$SGO2".DV*4'JDR^R;/555
M#)]JHHA8+O&B[)FJ<`4[DJC[4Z+1-E4([UF^3LXC=&P5HE/%:K)]8G*#J9<?
MD][7R6-MHYQDW!]TCZND:_L-;"+#>8O7DDY!QB3&'OS]$)I-D01P]S5U:V/A
M<D:](*9<Y^H;REOOB7UDT#:?%:NA?&0GE36L>'#9>I@O(:M9EQRN2A6RFIXV
MB99L&PW!GN>(2R6SI\D:J-0I@C[>97K9$'&4M\@D!IMQ-K]6'E3!)-/JC:U%
M,)FZ%\J.;-7,O*9\B3L.LI%">+G`AKYDQ*)J6P4T3L8)P_3-V<:IE[^@E!Z<
M,;K:<KF5E2R_1RMCGWXMVX]7_P`9^/-[22&K*YD5T4=4]L/U?.!AYJZ#/-BP
M-AE[G#U9JI,C5FJ(VM>#F@PU6B1*S-I/#4HTIXC"05WQC&1>]:.UN2-(=+WF
M-:7$H#V"]HA5Q:V+ND90;<Y)%F%5*HZVV1-X\D"68/;[!JT6RZ6-*LL/C&M:
MSE.Q81F(`ASJ*G6\&>.-20*^ZRM@#@R1'BT[3H(DET.LK471")$5`%)=CS=.
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MA3=DXY%QR6S%4[B5HDUG7)$^,\LMID7.`"WV:3I(=+`&&66X)W?M*ZYZ\P7B
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M:`R-J)/T2&N]K\E>3Y'1>X,"XB3::2/D;3W!SB#U!+M=6TQ;.G^7L%<M,#GZ
MZ#VB]*GP3VA3\A'J/6L\/\@<%#P<_)ZQE497('`N2&$F7(<M.1S9SWJ/5G\?
M.3;7QXK-JX(5]9;#<KQ(5Q$1B%T<_P"TX56]01NW"HZO2.;"@C\*@-I5Y8K@
M#:9ZKUJN-;*T1:=\9FX95H>^HW?7$GC[?)1U:TYQIY613D'*ZULJ`AL-VNGC
M),W>K^!\TY)1=TX.IG63L3#&8O+V]CK5WMJMYO/HJ.N&:4/I3.6\7E,XS%7*
MGK3S9L"U;^LBRGIV4'Q6[^9/H9MY%79%JVRVPBMT_*FK6J1S_<`W#K"AQS:G
M)DQZ=Y<$#CZ=B,W5QW0;$BDE+&K`"\>)]6+FC-^&G(/FU#UO%=_;Z+FA4IM7
MBVVQN7/?)2B:LJ3E/;M5<JH5.(N58K"4"31;CQ&Z^NBLYV^B:12*5IK*:5%>
M*(NIAWI;IK^YR7#1G,ZVK^<[$B$,0-_1%?\`D)#HO;ZJR8Q33<ND'/50Q4B^
MV/6L5/DSR79">M93#87)5C4T%/SM*E1D<&=&F95Z5:?+5YU9>5EKVIP@)]7X
MJG8DW*SJ^4[:\8B#`S&K+_+X0URZ.5(1M3N.SB6Q]@F$^97I,+;)"9)+XXX6
M"!EFD8%(&!*UL!DJ_2+YD7OS=H))=EPE4^:SSJ#TO9$'65<^LIZ]I5V-`O52
MS*WET39Y=.#HX.KK';GR+QE?)'INF4B80`W+XHP2!G7;7RS8QC&,8QC//OT3
MB\HVBW)(XPR#;<88:W[>V9L=]H33?%^-,1^J*53Z5,,\45XP9'BQ#\67X6]^
M`'M^*20&#3$"LJ6PV*2<IP9U4>7ER*.,KX6M85VQ;6LJL#HA5A4M"OPA>FFP
M[0T*CPA>.('O>\ZE94=5N+=MG<*V@"YI%*TTZ$V+(9&5+?N;(MI]HY?M">UF
M)=RA)M*EVFD.RMO!&TY'BEH/%%^#V(:[@('N2R4,)B(9%,D[0CES]J-,FGJ4
MI&#6PL261NOI#T^^IV4(A::2'50L*;-"%I"`C6^V=:=455*(BWU^?6L`.@C2
MM*<FN%FPR,FQ)M<"5ASB2N01HQK$R(EA3@H/7%*DR$H\M8><J`9H\TPP51-:
MUK6M:\FM:[:U[FM8QC&:;UH6MZWKOK?DWK*;,M-5''&U[9X_5]=,33)%A+C(
M6QF@\6:VY]<$RDQ8G7/*%"TITCJL(5G'*252\E0>4H--/+,":8,8O3ZA\4T]
M:DFHS']2#1&TNGS3(UZ>-)A)M(A)].GI3T_H@2/6DNR=*/%[3:T1L/BM:!F]
MAB<7BY2DB-QQACY"PP!RLED9FQH*4FEAV$LU06W)4P#S`!%L(!FA&((=[T'>
MM;WK&XG%]OP91N.,/R2A+V2&0>H[;ZN!*V1Z6V6%W]*^J(2]IO\`@;!I5H.R
M?^%V\7_-SI]5E7.HV]PW4"A>HE)5CBX2*+ZBK!J.OR]W4A6NRUZ8]-WJ4ZJW
M-8$*MQ4N"12>M4A"H5&&G!"/7I#&1F.+:R36IM-*9#TZIG+,0)#`-2E(G,2)
M5#:`9(@H#TZ4TU,0<DT282G,,(*$`H8@;[3&,\DI@,'6/I,G5P^+*9(G4E+4
M[^HCK,<]D+""@D$*R7<Q")Q*4DDA"44H+4A.*+"$LL80:T'7&XUY`W=<L='6
M%Q)R<G$GTNO7N$:8UJU:1L)(-DK%:I`:I5%;"G3AV6>:8#82"0^#V*+T$EKR
M!(BUA2.%1)*6XMH&=>6FC+&0!:TE&;.+;%8"4``J6\LT0C0(3]&)0&;V,).A
M;WO-J*N8`VHG1M;X1$$+>]FHCWA"CC#$E1NI[=L&V\YR2IV\M.O-0[*+VC,5
MEG#2[++V0(O8`]NI24W4B%G9X\BK"NT;#'GE9(F!D2P>+)VAD?W!.M2+WMG;
M"6D"%L=UJ5R<4RMS0D$+E*=>M)//,*5'A,_:FJRM$:4A"DKZ#I4:5.SI4R1/
M$8X0F3I8^0%,Q)B$Y38`DDAE3@`0TDE@"6VD@"4A"06'0=4HM;BQ6UI$D%%J
MY166U]C-MAV(=3[DW5^?=H$D8D4-<H+=YS<S'CLNOY+'),N0OC&_;,6[.2,S
MFT.[0ZLS<M(K&^U[`Y04O(DL+B<A(=&,Z,N1#Y&F1W*<(XIWK:A@7%N*!2!6
MR';UKQK2HT8WF=M>&F%O6LWM\!@[2+0FN'15M$%^42D(D$=9D0M296D`WJI#
MK:9"5O3ZI0EEHCWC6].)R0L"8U2,D(0:YHK"H=!4:]NA44C<10.CRY2)R0QA
MB:H^C<)`\G:4.[XN2M"-$0K>'50'1[DZ*"S%R\[6C5:@X>M"UZ?&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC+1YKS@XY5_R,A?%F3SDE!;<Y3AVV->TPQ(
MD;LXJHJFB<:=%7AA4$O\[!*!+8@0D0KD"Y#&Y6<Y.+2)G\6IN&>;$@,==&]C
M?YM$6-Y=G!H:6MH>)*R-;HXNC^<:G8VU`W+EZ=:L<'D\@XEJ1)B#5+B:2:4B
M*/,+&$/E+&OVE*A=HRP6=:D"@L@FBHQ'$8])I0T-4@DYQ`##E@F%A4J@O#JE
M;4I"A<[+D2$Y`TMZ94O<U*1&G./!1+B?SIHWF0!\#5!DN0+FB!T_;B5HF\>!
M'760TOR"8WJ1T=;[$D)<73QL)L]FCC\K8@N1C9*&LUH7-LNC4<=2M(14$CO5
MZX?2QC=GM@=INX;4%U&MJ=G#&VY.]\B&2^^0\GXK4U(J31J9$24\LU@WI$G:
M(-ITQ4P=4RMXVF<2U''H"^M$G6:2GJX\861DX^N$7BW(BX9'R.76<W1"MJ.H
MF76O9<:54Q/3*KM;=C1**B4J86@@EE)72$OKTM/4,87AE>CD;DK:&Q2YAE%U
MOOKO_P!?R?\`\W[&]>76]Z\N:XQC&,8QC&,8QC&,8QC&,8QC&,8QE$Y#QSI:
M5W%%+_D,!:G2XH*A0-D/GRE4[Z>XVVMR.>("V]H\4Y%(D2)6DLN9$O"0I'I.
M_P"G)*-]+<C&*/#:<:KJI<4IMS1ZJMC<<JI:H&FL:R.CG"$+39$S7'M)M,B;
MNH]%)`3;;`H0,+N[.<BA:./.+@Q-+4K9G)6\$M:$#H@0K5ZU),>[]-B+,L[N
M&;TS:$DK[7)74W1\C&&:,33=A<[0V*P.;%)UT2GLX4%W36#LF]4=.,3C;%:+
MC1\75)"4Z&E1(1F$BL]X1<"N:G$J25K+"R>/C\XLW'WIY]/VP4*^;3?TFHXQ
M</(9<K58U^0<]#"RCMVM8,DG,3%7]92$I.Q,S&V/QLIDPEZ]"G06>UGT*^04
M';:#=5TTKI?*>"<,X=UW0+>E?G4EIOEFXK]0B0\QG)^G*HZ,#/K5=.*Z/C-=
M,[6E+D);58^Y&[.:WY#TC0I<ZL/W1NFDVIZ.TY8%+T`Z3]Y>N2%ZQGF[%K(?
M8WR1X8<BKOY6SKD7'VJI5:6LT+[**SKY%+6\D"M#8+(*8SIF>BWN"H8K*1N#
M?DMEAV``0[$(>]:UK8Q^!X0]ZUK6QB\`(`:$/>O"%H``@\+>_!#K7;6;\8QC
3&,8QC&,8QC&,8QC&,8QC&,__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g349605.jpg
<DESCRIPTION>G349605.JPG
<TEXT>
begin 644 g349605.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!#1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?0T%47T1)05!(4D%'35]+7T)!4BY%4%/_
MVP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`"[`H@!`1$`_\0`'P`!``$$
M`@,!``````````````D&!P@*`0(#!0L$_\0`9!```00"`@$!`0@'$0P&"`0'
M!0,$!@<!`@`("1$A"A(3%!46,5$7&#E!87BW,C,W.%AQ<WF!D9.7LK.VN-(:
M(B8G<G5WEK'6U_`9*%-7=J$C*39#4EG4U20ZB)A(8H*'P<;1_]H`"`$!```_
M`-_CCCEG>PLMD\!HFXYU"W0EG+855\\F$;<'12QP)J9BL6*R`?H7$-B81R1&
M.'`W1L^:M3`MTHV64^+$&BV-%M8".M'E_P"S2HGQ`V-V7C5,2*K/+`++0312
MI(A,8+**'[!)ZY=PYIHG([#GXZ?5A.D=TPJB3C$=D\/)H.3*YL^-4T%HY!4_
MYL.OD7ZAT_=W9.U`\_E$SKZ][DF$EZ[41<<?@D?IND>R;CK[-+$<0VR5EYR)
M#U]+#41ADG'9=FYG)SVIJ40B'$XEIE=GDQ:7EXZ:4]:D^J>:R&PVI"HY5UUC
M%PS-A5LL)U?4Z';%NGOU]E4[L-HVWCXR'V,_<-0K,TS6([A"CC&LF8AF;=Z]
M:XX]//+NVL7LK?'5CL4'V`3=AY&NT?3+K3*8+6LM95_-1%!5C$[28@IU,2)\
M^%;6X_CI&2D'6@_84"79#A&'`Z/NS(E$K>>.^:/I1*XP7G`)U>;V"A7ZT4=3
MO;KK;32#J6O]GN.=;!](-9>]CR$<<6X6M&61YHUB^"6K5G&"2<W.&`\41<E4
M:E;>7KIJ^B5<2`<?GI*06=)>TD2"UDQKTPO9`XYTJ`FY%VB;'`F%L"6B-2,`
MN$B+QG("+24$348%P):5OY(*07M5)_.[T$B4/3GY4W=&8<G1U.=G#$@9T+8C
ML=&NN=[3;6OJ]N61+IC\:CXL1DRB#5P+U^,39!NM\<1B;I!L]V:YY=9NWM2]
MK?LU-:UTF@P[U]N,[1EJ1:?PXK")+&YV$!`91HCN**XVW<"S$9DX(X(()*9R
MHU?9:OVPXJT?#FT-W7/R5]K+^[%]K.M8^T.K`FY:)[ZV1UYJ6IWU-SC!6XZ$
MI%E$IC:4T/GT[SUUA\O3AALD$"2AH*=1)"<[QE![$7(\D_PRD"AGEMZ93W$1
M^;4LG#M2>07M38,206K"8LEBX7IC)7D4[!M-$W;%'+8W##+/+9L+>_%59-A9
MNM'-R*:^N<4;$O-7T+E4$M*S%IS/HC!JLZ_U-V?='9W4D\BFTSI6[S[Z&UC+
M:["OQ>TAE>TMG;',&"!DQ+(R6DKT4@(8D!Q5B36]28\OU3.+CZATI!ZDN\[,
M>S?8CLCUYD`D]`G$1-5#+>JL$>RZTQ4C$%B">317"[R(;@2$6>&X,3B90Y+4
MI@IH!^2GU%4YY?ZD$==XC85[SP;:4_D"O<^;D6G6>CK:8,0%)=/K0.QNU9\9
MA5A/5):.%5(&S'@$Q*J.EW4]FN":-4QZ5):_`)WAGGF/Z00&9YA[Z73P\BV;
M=73A6;Q"KY=):T"P;N218A^O5BD;`8M<1WYG3XN38#F;ABZ?&VZJZBZP'XDQ
M).F=S_(I;O9/K]UUN+L-1!BI!X'K[UN[*7=,15E02238A,I55\$;2BLX<%V!
M6'`DHY'RSH=*U)P<<:G27Q-J'8`6;)R\<DV^._7[R$2B*=9NFG97NM+H,RC'
M?*,]/!538JBGYP'802^>RL1=FG->3TPYG,^'CX04+/HT.@$_D"T7'LG62XF7
M/,NE@SUWZ2Y_+]2$@Z;7]?O6"R@8PQ5D4MY\I.;?I^T)-7%>&Z/LR`UE8FMG
M0J!N&5C+)C#D\'MQ`@)IH4D[7+N31Y,O&@)IVE5#7S`4B!MGO!!+0C4VA<*Z
M-B>L+"86CF,/GXZQ;`[-1IC(H1&8%%1C@K(U'$RWEU=A*W#NTMCTF,GB^'J`
MH2%T*O<<[O\`-J%JGL+1CA"'RU7JX=HSR!3'L&)(T?.ENPU6V)T..1P;/V"0
MYI)&X)I&XVW?R1U+2+H>:CA%D%9/XK-E?CZ+9Y.O7L\BUI0*$V9!R>IJ%V)$
M8U.H@9U;N6FA:+R\*QD,?)Z-7J+=XWU?B2+-UA!T@BY1PK\$NDFKKOIK6'''
M''''(;.SG;;MI'/)YU_Z*T?(*-C45OKJE>5UM)59=4RZ=&HU8-2%&HH(-64C
MMMP-J0@\@6(-E#S'4<A(6B:*^1)]/99/1'&_J)YIB/9G3HP0G+FJZ`-638/?
M*F^S=5E8?:UA$S5E]+:I2GTEVH.QX]\!&H?&A8C.;',[6N,($3,77WA$64*2
MP:J0>97-O-UT-VJRUKE)2RR0<#IR*=9K(EI`C44T5)+5+W"(M0_72U`4?$-2
MIPO%+$+/6HW5@FQ2G$5>.&Z$UAT=V<M_A;)=I?,:/BL+IZ4]<`!!_*!_E,Z\
M^/[L]3EO5--FEM0IE;3ERY,_-:$B3@LLYF1B+J`I%5!H:I+HW)TRV&61;T@W
M?L1N0&?,_P!*\U[1E@I/+G?Y['$>R$9J."1^C+"F%G26P^JBIEO<-6ZP:'C3
MQ=O8`EV$>,P0G?7+"7+_``6T=+/6^RJZ-P!GE5ZED+JAM$N2]@QZ93":Q:J<
MNI76LDC0&+71,J'']E@5.S-\73;/H_.E*<)-Y*2RH*<Q0$1T=1`Y*A\R:.`*
M=K1OFVZ+%01*5-)!:>\59=5YOW;9R+-/R_Y..=5:_L4G5A^Y`^FJ.2.X7$O%
MJMF(`B/&S9X->!C>L83%'!#IYP.\V/2E_+]X6OM>04HUM/K)5AAQ(J)G8,9'
M%^Y0?4QUCF4C>OVR6`T*MW791B"=O$M)$+?-GOSGC`-DQ>/4?!Y<>\-P=&@W
M2*0U>6J@.#[%=[:5ZFVD9MB(FY,-AD#MMI*79:R`BX2=0KX@8A",57=_`%]B
MP8@U=+?&D&V6NBBOZZS\DT0A;"LE.P=H1:?B.V6MT6=TEF].4S.(ZVM"AZ-H
MD;<]@J3`*O,;$9!IR!&BIT9$/L'PHB?Q).+*``C*1.WX9+]5A>:;I#7D%KVP
MW1FVI-';0ZGD.[</5AM+3H\X==;`#P>VEEB%],,VC>+MX@@48OSXJ3NA!9)L
MY;I#FA(B[9L'%VBGD_ZG,KRB]!"Y%-);*Y(6I&,NSL.KB62*#PR8=EH-*+'Z
M_1&>R9HRUTBQRUH;$2AP'AZRV%!6CJ/;S8M$]93'MB.%M"^8-MV?TZ'63%VP
M:@JG[2]A>W%9.(_>-?S4S,Y[$NOP>U?D92`S2$FU*_KN2,OL>;R^QB-AJ.HD
M+&MCT3`E"ID3N[>WL7\W'0P;6DYMR13*P(Q!(52,%[.H%3M5RUJ^G/6>Q[1W
MIJ*WU7<;;HNY-*(`YL3XH$(I:B64Q`H%X^:.1)@#D(8B]S$ZU]PJM[8L;LTJ
M=M,Q\GH*USU)V1#[*AIFOI+';"$1L#+6C-\(,:;.,##$>E,?+L'VF<K:-WRC
M,BS'%V+\:VC!A7;'R,F_(;->@9>9]3_G1`>A]3]M7TL9T98S0.8L:6VVG`I;
M6B.BE^D'3"!HL$'Z,=DOO'4D:D=VI@DU)M$U`*M_+2\S?4R"0;L_+8MB>68\
MZWU1V"M9J.CD7W8B[A%]7YLQJ^\D:JDI=VV''FU5V29"1F;F'28]@@U?*R>+
MYE<<9KD,>S<>7_J]"A51-[B^?<`F,ZKCK38,_%:020%0=.C^UDJ<US3CZ:GM
M4T=<AIO9(PO'!"\>;R0L)8MFLCFHF+`G[8@I6;/RN]2WW85MUI2(6:E/E>RA
M_J(\*O:IEK&OQ?8<+7[NT&=:NIXZ02`NBTFA+%R8CKP,J6$J)_%M3+X+A^/V
M=8X5%YBZ;C_7"$V7V`GK2SIQ*2?;:3D&_6.@;HT:QNFNKES/H!8D]/0&9*$)
MP,"U,W*1*-3DWMNZ5F$PW+*UF!D@YJXRVFO8/FI-DS(LE?AF;]JW>-5O>*)_
M"MG2.CANK\&MHFKI\(BIIO[Q5/137WWO=]-=\;:X_7QQQR-7R]=K[:Z,^/+L
M5VTI%O!"%B4B%BTE$A;*CIF30T\W+3R+0\@++,(_*H891]\TDJCUJ^8'D%&[
MMDCJJ@Y;JJI9CRO#RO\`8GK#:UY=;[B7HQO(G_CC,]_.MO8M"L[.VKZ,L(C\
M8&6-"+\J&+3:9S60I1!ZQ)2D?(ZT,#UB\5;IC7$7V-8PLZS]W\K?5*,6+5%*
MS&;F2%@3T]U8K8K)XU6<S8UN%MON)"C<NZ\Q0@\->_+BU+A:18\XC>C1"3,(
MCC(P78Q^-$7[39U^>MO+1U.NNU8O1D!-V0'G-E2WL-4=<2.:4],8_`C]Y=9D
MG.]O5.PD15-FP(3>',D-S^HWX5N%DXIH^0C4B(E&3Y@UPM\=GG<K'L!U'C=F
M=HV!.!7K'NF5G=X;;%P"I9XSK=]1E3W-,JIG$SJ;!<O)S$J:PU8`+UD(MJ4)
MO'3YVY5C*QQ!)P@QS%V\P74A2!A+$'L;W(1V=$]F-/+*4//8[M>8]GUZ=]HC
MLKJ)S,V<8%2J%QRG!I@\4E2Y,4(6*"EHP$<&9`^#,"GX9EYH>B,/A>MD:SF;
M2B`-*,ZZ=BY++(C6,O*CH35W;27MX)UX)2]LZ9C2XDU94H<:#V463&O)#'D?
M0I,!\=$JMGR_ZI)YB>H$6LYU4Q!.[G$I']ETNG)-891LY(Q]CV=+0AU8$-IK
M$@;-MAQ25SV/,G*T84`J%@NJNB>9&5CK1PV>*Y&T]VY@/;?IPGVMZSGW&T7F
M$)L@I"2<UB3YH\#RBO"<KBAL3+88Y(C7OQB.S>(%PAL6B9:://B2VXLWEJX:
M$MH=O'_Y>[:[$=5X#W*N&S.OFT-K.@)MV)[]5/6%*S_654G6VN+Y'5Y(Z[.X
MN28OR!)0E2;@Y)(*=BALP3AQ!X4!%&3IFP9E9`)%YD^BD6@UWV.8GLV3B'7:
M+]1IQ:Q)G4T_)K`H;WC&L"G7"1,1@T.Z*2)K-42HY!ZQ`,R!J+/W:;"2"ASK
M55-.HA/E=ZI'*]-34<I:2D@$=N3W15"GU:R-M[E.=I(^,3D;VK@D)763T7>_
M,Y3Y[;FGQ<='1\83<NS144]:.1R6*-@>:2$RG6^@U!1H^&$UYXTU>_`#L%;5
M9SIW6X,;*$Y3I#G4UJV/J#+8<16*XALB=6"P9,V$K=/Q:\=BC`DNGE\OD/$_
M+/U;;[59$9I82I^4&HUT\:VE94'K>8"J6KZP>ZT2T-]?1LO>R1=4]7C6XW".
MSV,#3:9E6#B3\.TM`S&MI&'>DJAJWRT]0;?[%1OK#$BUEIV3*;?[)]?13B15
M1+HS#UKSZF"&\BO"K$Y88;-QKN2Q2..,'-'(SX_'"#-/=NV.Y*[(#E\8/(KY
M02?3'MQ6U)6+.8?UAIZR:#)2NI.R%PU1*9S15B]F5I9(@3>CK*GP"1`D*=C\
M7C8D#*BYU79)P4;S1(@[D<5$Q?+:67[EWE]ZE5--I#5MIR*7H2NJB?6&.7S-
M(G6\ID=+500[:B&:E(2J26B/16C*=>6*?<X!@I,,=EDF#E=!8\@,&:.2:%4R
M'RX=&XA/KA@TLM1Q'&M(MNPJ<RGA2-%]*_<RGJ=&(3,NR%>Q8VU3=$)5/ZCC
MEAQ-\?C@@(NH5=/"02(N9(>C<E%B+8'O)Y&YA/.K(2L2V:P;3[N.OU@MR"]A
M:'ML?8Y0\\Z^N;NBT&KE>/ODHM&97*XV<A\S#366$"L"S&]BX9^Z82YFX`9P
MGZA>6#LAV"LKK-85B2WK_2O7_LCV>[AT0*J.7T?;[NV'&G6+[,#QMO%;I#3Q
M6N@N4X=%XM()Z9LZ)"!:!L!8XZ/.$D=!@5O+UU/[_4#W,=R-I3.]A;8"P2O+
M9#D)M6LJ@HF?5#;*\J;5K:,"(GFB2!R)3!>$R71BFOD=)F";!)P<C8ML2%K/
M8IZL\D_;&WNV?<[J5'[/ZL`+?I#MPI2'6^O)%3DT<$+J@,9K%2[+!?S8NTO5
MBI'3`F%#3`!G-@0C6/,)(YCK@A#GZ3]4?S.;7S$])LMIF8WETTQ$8W7/9^V8
MO.M:\/JQ&XH'TOE*L0[2&*8)(Y5<3]:FS"#C8X+:L6)21!VCV3P%G+HRS<ED
MO#OYANHZT(CT[$,+[.#+"+:CZ5',J!L1E(.P(MIU_<=G9+-*/#2$>#<6!`(7
M3K`G(95-&6S8$P(,DHTS=$I";C(XW6@/RM=,9/:M85/'Y^;(E+43H!J)D*D,
MD`>*1V5]JZRE5P]<*]G#^0-Q!2)V#;]=PP^>C46(!,O!^^@</+-XX=E,6&&)
M'^..6UN2`NK4J:RJS9'=8PXL*"2R$:R+83H=R$3E@)_'W)1(0H0%(D'+)J17
M7:-W#Y!MLZT1V<X60U4;JQ0]=_#-!*BWZ*MK)NN67=&_&W$).(ZFPPE#P,*B
MX6<ROWZ#JWK-;A2Q0I8T[!#-&8J'H(EHI$X\DDX*XCKV1N$S37$R8>YUFDHZ
MRP/J>GW6L%&HH+2O:"K&<:.4U!Y2%^=G9*^'M];W4-`OI.@+"6=#21(E7K21
MM4W!U>L'KB/QHW!RA$\=,TTX\4EM=BNZ7DFKRZGDLA?4R]P'B5T5L1I"P67'
M8M'H\(P?G,<B)-O-/E&I%UI\)C;$D4(QPSJ_`$32$51<JL$CS?->'^'"/0WL
M.&[`L;\D;@@&\CU^^1M"-N*_"88J37L+4`FEI=7"A%.28<_-(=%0K-T$*8;9
M.)F=EW3S+IONFU2]D'\2Q>)]!I'T;@W:R<1%L?[#G;W<66.@0E-X7%S"\MKR
MG%/S.*LI:P2E%:3$F],1.0#$)*!6,0]]H!.;%A.2PXU'A='B*NR@HW0-7]?Y
M*'L6'L^PGD*O&4V$=ZMC98WKQCVW@8^*9I?$#IJ]J.L5G#Y.%D]DA7).NI$*
M@*R+0`RF<%;:B(/AK=QUX4)=VNH*?)=BYI$.M4^[$]'^OG3*?U%USK,5I5=0
M0+K?=2]H5^I5(PU,26`#HH*:"QAB).GLB!0Y%Z[`@RYG(9H=>2V]3.FR75VP
M^X-AZV,\G+SM[?\`]L+(1B\69QME#I0O!8W`B(@&HW-&7)`(Y&1(,Z0P14T>
MM'>'NVSASHZTPWH?IIX_1?4RQ.U=BNK(4M`AVB[1R[MH[;%(,-C?V.+)G$?4
MB$A9PYXSD!E=2/KQ7X$,@B2U4*Z:9?*N"CO#_=%'"VL/!X'K*8QXXT[-RDO&
MX``\A,/K:*O*NC""@&*^0B0.I?-T9`?0DWQN52"$29SA<"8T9@AA(0V;BG4=
M8+[/"CJD7'N?>K)!3DQI.9]B+$+1:5^/WKOT.1?A(A'HP?",>JUJYN*E[>9D
M$S!9-27AYBB/5/!=FZ00ZR8Z()+"EE=W&N:1GQXSNPY[T*O&Z.UDJL'L%T:L
M2R)F/GPRJ(!#8K90>VZQ1JB=Q0E7S=P8Q&4"4=:IO61QI*31@<<('7R6ZB#L
M.SC^)P3P61R*5\)B\2[)2,1+6];=_J..3AY6`,I\L4QY"YEO8ED@FD;WES=D
M(FU;SA=X;J::_'R`QHB]<B9Y"YPPPWU;_KG_`((ZQD+2P(W![UF<"@<JJ?QV
MT[&HVM#0<L?0R+^-N2"Y'3VZ4A>G!:Q]])%!V["9K$!S?#AFXQD?JV<(ZK*2
MR]JJ'QV>ZS7KUN=2M6%L+XJB=5$>E;((@<?!@%BQXA%I(^$"GA)@TW*Z""K[
MY)W>NEFC)[LW<NFQ!)'=JOB+.O&'7]J>,.+^,BQY^=-PJ'U%453`K4%`F$>F
MK!.C'\3>UM,F3)L2>,QTN%;0L)N\?#'[1%T[^/.&J(]%WAHE;"P?#)0DBJ;R
M451`I.5JX=Y*#$/(SQX#C@@@E6;*+P6$PYX-@PA9XP9.-I`0C!J8$7Y13XRH
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M38E.T)9E#0@-I5(.<!F@VUW.SV22Y_N8EHI0A)1KQ,>ZC**C;0`Q4'I)F!!]
MNY>H.,<XGX/:;J1ITJ941<MG5FYZ9K=N9,+FCAD`EMEV?;'<BJ"M6V1<<TE;
M[Y,&LYT)U*_.R*_(<7;@19P:'8ZB,QT8V$:QA]NO!==--='^V8:BK+F7;.].
MQ-5^/>F"\;'U9`H#(9.8ZI]H8A9T@O(S)R$W=X.2Z1Q-"3R2<O)P6,GI1,M7
M1)Y)C*I@9'Q\H\@\.X"P#AFTY#>L@UM:;>2OK[Y+Y%(F=:LA`3>2]:H\*CE/
MTXR@S^7/G(6'BP(MLC*C#N0D9@<+.2KG+H8CNR8#N])^&J/TK.^ELW%W](C6
M_2SL)W3ON(#']=@D$I:X[MZG$9[%I`Y1DJBC)C%FTF.:Q(J,3P]PNLR5+(/$
MV66SG\UG^(,U8/=43W7,=I9?)3,$[5U]V?KJO9%643-NXJ$@=0&*O=]>HU8;
MV3L2L>J\\H6>R<4/"L`0@1*2IF0RH/-Y$^TDC&-/J+XO>X$JJJ6=:;LB-,5[
M7-X=&+1ZMVK:#;K:5K6_^O`F3S8C.0M0U1(/MA[2J*P8$ZFLZL<R1CU50ZKJ
MI8*M8S(AB2;,7&(IMGS)O!L!DDML:8[]DY(R)V-,_&G-GJ2-7@%6@LGXR@3T
M+5J##127_"J-)]L0=/I[J[55535RDWCR@YLGG3?.?OIT3^W?4ZI**VT1JW/5
M'MA5_<",9%0P9*U)+8U0;E-X<(-;DS@GXI%?4V4R9;#=="S[;=ILT*C?BN^'
M-(=R_&W'^U$OZLSJ*V<\HZ0=7''9%G'TH_!04K`FXKVJI23TG:@OY$*%!*(<
MWH'DRYR)GOABP\0924^5(T>:N-4V^()KP4Q(Q5E6U5GL?+6XFM/&9:GC'P1Q
M7,>5?&ZUM)\&<O;"5US)=$1\V$(1F/HLFJ6'(5==N0<KI:Z$=6K+).B/&6>Z
MX=J379"J^S\O#A[<J7K57O9VJWM<Q(L*N"2]5*]95=6<\C,B?DEWE3*D82Q2
M!SD&*%R7)YJHIN*-QYVFT=L[-U=X2X#5T2Z?ULVO:9RFM>G%^]J;>A,;DT+C
M6K^31/M<(L`%,JODTACI("YRT&#;4G>S&7LFB9M=^0&.,-630.D/<V<E/N>R
MM9Q1,GI.5]D)T^]YT;KKQVU7,6$`C0XO`^MM?=A1G87"DA&9..1$]MB2FHO!
MXR=FR24/CB8")-7`:`C#)<X^?2E]3.FZ/5RQ.WUAZ6*]G+WMW?:78.1#G$79
M1UE$98K`(Q`"HT(HV,EW#\*^8Q$2^;ID-M';%WE[KEP[2<)_`TQ'^BN@+R/3
MKR'8M-X[-3KK9'>L+VK-H:R1`L85%9EBP`QII)]9$H7VE&)/NXR_<+#MA+L0
MO@>F*:N44B>,0*^\)L!@M8=X>OV;M+D*$[>B>Q@B,`FM15@+MND6/9\A\OV$
M'9WKNT)2NQ8V&E&5C4$`R(:*2%:/'+&3NYCA`0X$V][%^#<_V0Q!F\P[KSAR
M-KVF.J-:Q(0>I>#287#I7U?LP182M@P!@I)1C.`K6\D%&@[(81MNWD1A`6#0
M?SLG%Q6D07O$MX>@FU^N+V0OR0(.]_)*V\D;:-;UZ$69HSE*FEJ/<URH2Q)D
MW*\1>1+=%UN3PV0-HFTMGB/O6ZN6FEOJR\)Y"BS?6JP*/[?S6O[:Z[2SMAC,
MT5J2%R<38-0=PK)<VU9%8R&&%S^1S(G&9TZ4-5O.61%7`91-LE)8E+DFR.NL
M[C9+=!N@CNNLZW1122V<N/@OAW&R>FNFRRWP"2"/PRN=<J*Y2112^$VV^#23
MT][IKYN...85>0WIPP[_`/4.W.H9N?DJSC5S,H^'D\N!Q]C)#[(*#E8.7;MP
MC,H2'#6SY\_CP]MN0>ZD$V[+=YJDQV=*H.FN%5G>&F(7BIV0FUQWM+IA>%[=
M,=N@\5L!M"P`.+41UV?:[*R<?6E;(EWJ;B<3DDY>EY9-97+S3I5UNV&@&$>C
M.C\"4MO9WA")6?>52W*<[BS9VWH^P_'Q8]60LW4<1DC"O7_11CNT(1J!F24G
MR4AL'OL@NO,;!C\?U:N%)UHP+FRDT#A04='6B\=/C,MM>7@;G[$+2VI7G73R
M&>2;LO2%0E(B"V5DKOM80+QRNK)DDR&2LA\HQ0/`9`8,BX"U'A#NLM*+Z3`Q
MD:-'@-:MJWW/S"*KK)M6(KLS-"(U'QI=C_&.H2?UI&-7Z]4]CK@D=PFYUMHW
MDNC72=QDO(W`D+IHG\@.1K5JH1'JO,N%5LK[X\6I.[.O/2_KCIV;EL2@?5*)
M:P:5@TZXBTGA_8&/LJ*>4=&7<_@<@,+1U*305)PA8$)>/-9-&`4_;ZR#$/=/
M68!P!B)L7QA=S*1DD%JRDH[4E^0RC.EG3BAX,I?_`%B?2ZM.SDOZW678UBQA
M"R"=<=GX*A7+*!RA_!'C;[-46M((#W9JR."ZK)J2`27DO(>'-K(+(WM0I?1$
M<9?^3JNO*8]CH^OQA(.TMVOZH5JEE6;8NYD8PB^KE00Y77<D]V(R3O7VNKS7
M=CHIEFEEETSZ')=+^D"72^&6L0E;`5F[]HW8<DAHUN3&[W7.IM83_)"."SB(
MXM\WSD\,)C]="0[5XP0'H/,841<+N;84'XJZXI7QK2+QN/;!-2Z)'^O5P=9M
M[?UBX6-V/I6=M*V$\42=)-WI8(^*Q@E9<D>AU\HMAZNVZ&'0SX;=ZY>88;>`
M025I'LU4,L[8RPR[[1U5XZJMF4K&5!%`?S>9^-]0!K5I*)@=Y:412VF3..,4
MYFT.DS6^KI=\Z#O6:"C5@SNU*_"L/*C+(+P[LY+X%;YKR;//*C4UDLJXCQ@=
M5=\&XH*@\FAQ*$/I*FUL:J#\7&9'.@)0X".:[.-E<R%9/"K=Q=*Y_%(C=<U[
M!V'(^R$W3EG:;QY$.@-V.-:^@.XTX(=.IJNSM*/CFF@S,8/C4K"DJ*,9:NG8
M1SEO'%'SMQD84UD%HVG@TK)%UD6XNN5.Z[G&WCG+7]$-H<*1*VI*?&E'&44I
MU^#E6A_?-;@K`!1F`L+?`L@DD>$DXAA6!R&!.SYARI4M4>&B.5;V8K3LLUO^
M3&#U;=Y^\G>-K'G5?`&@TI)^^4*8PBS(&Y>(2%1RWCD98--WD-)H([&$GSC?
MY9R2;)HHZ9;]K>F$F[/,KFAQ.VX[BG+VI@74,TI^R:5`V[%`KL>O,??VI7_R
MC+8PK'[0W8RY%!D^-(RB*,'\3B1O$5<$QBZCV%6(^&V4SCM!WUZY2%*PZRZ%
M2ZN?#M`8'+B@D-*Y->D&\=T6:J/X4+G6).-+PD\VDL;APF23(S#'>\H&/9`X
MC(W"S=(LRSB=>$2K"A3R!1@S;))[0O?P_=MA22`IU56^EJU=:G84>RTL^0PC
ML20;%9EM#'<A'LIE'ZT4!L1`D^S0;DB9Z.K%096Z6OC2LV517HB/NKM\;MF:
M=%+XCMV16:K4M$HCI.OF;5Y"IHU%I$#"RQ;=HBK'BY8Q*C^AHF5/2M[DB.3C
M@E!$%BU=<>%*'P0%U4B[^]3\HCW6#L3VROU!@[K\2,4L#[<`//0-BPDXZ8RO
M=0.*%B[-ER$<+"-<DF^ZHA5XFZV&*8?YB>/+I7-NB-'A^NA/LE*K[JNMF&L.
MHL?*X!#X@>K^L610L_!QF32"-K.5[#D(AD2;Q_25*-HL/W!AA:+>(,GN'SYY
MZGJEX_1?6F^.W=ZOK&VLDIVPOEGV(=AB4&'Q]"LYVQAY:NTM(82:R(L[7&*P
M8LX!NL%4522VRSUS@BFD0<LLX1+>!:J%('FI]+KE"%:0"E_(K2/6X(E#!^QJ
MGH]Y,3Y`G>A61R%>3J8M4W$PI@Q$JE4?"XHQ!!W^7<M9S0XW;DM,B;8\73B:
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M?KXQG_;SGCCCCCCCCCCCCCCCCCCCE&RBQ8!"7X`7,IO$8F3E;K+&,#Y+)0H)
M](WN'HP=EF":%'K1<LYP0-!V.4&";A3#TL,:9U^,D622_8?84"+3`]7@J;1$
ME/HLR8DI/"&$E"O)?'!Y-)!88_/1IL^5-"&1%%TV68.B#%N@[2<(*(**:+I9
MWK#G&<8VQZ;8QG'U9QC./WL\Y^CZ...<8UUQZ^FN,>OT^F,8]?U_3Z?ISSGC
MCCCCCCCCCCCCCCCCCCE'$[$@`4)*Y*9F\0$QV".7;2;'B4F",0L/=,&K-\^;
MRDHY?),8\NS9$6#QVB879JMVKUFX6TT2=(;J>\!F@DD#C9!&RHLZ!-,FQ,0:
M"/FA006'/$M5FA`:28*KLG[)TCOHLV=M5U4%TMM5$E-]-L9S[7CG&==<YQG.
MN,YQ]&<XQG./UL_3CG/''''''''.,:ZXSG.,8QG/TYQC'KG]?/TYYSQQQQQQ
MQQQS&SN0!;2CJ;V4C;N/9EJ9^BK7#(QC0"M*%C[\G!#S(2(:QUNR(N#+U^66
M8MV`]NQ=.'#W=OJ@CNK[STUFKDZFM+\\:_B-KR4*7)"NTO7_`*&!'=/47;G2
M)E?W6B<=@Z[I*L(W*:2[.P2X*.EC"'6"<+QEW!(C\JG8%)F@4I.3,3V-*^F%
MMD2Y'?<I#K$.=]8XEUM'=I\`Z[4^9][&Y^/H@*[WR%S8P;<Q5P\K+=D0P_)I
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MC%!=R:W.&/LY01C)?1ELS&PJ(RZ91^MNI5`=F07D[B)(O#IJ"2KKNCYJ+BN^
M4D!1UE&3_7KM4XHAUU4:LYLZ&-P,W:RA4)!M8T`'$73X.G2LA9N&HW-?.&:>
M>_E4[*>33J)"+)[*=78-T:FG5VB*'+VQ;`^^I/?8J]RAJ&NSQ:7!J\&5X&6@
M*XYS#VX/$><R0X.<?.%4O@C[U@@QU<RH51.L6A5]<V3@7D)BP('#IO@-E[\H
MY$XEL;&2'`S)##5CA]EA@E\4R\PR:?&O@?A_BK?X3X'2X'''''''''''''''
M''''''''.N_YG;T]?S.?H]?7Z,_1Z>WU^KT]O-3B*4E;0[KYVL8QBI;#BT*A
M_NDFO>VDKAVM73.-HR[ID"[2=?9V<L.%Q)2,--K#KIF,BY&=N-8FP+LW`N&F
M'R23AR/PV6EX\75?W36G1$F*?`M(]+3ER=U;$I&(60V/@FP"O+,[,7//Z!%R
MP5EBC(XT!>1:0QHON!3;;%XY%R[<;HT9OVF!3.R_4+NCY#=/(.]Z">0&M^FP
MZ2GNFQ3MU!)OU`E=V&`S,7&;F`TZ8B\O:7*&%NUR!8A(-2PQ0(FFW%,AGO7;
MLLX+Y;A9N>......................<9UQGT]?7V?AS[?P9]O]]C\&?7'*
M3G[B8-()-'5>C@1>?-HE)'$($R@B\$1DG+T0SU2,CY$5'M7K\8">F]6+8N08
MLW;QD/5<.6S9PLEHEO`]X*W]Q$[$\O3_`+`1Z!12Y77DG-JV'':OD)J5P`3(
MOM>J6U<-(K(9")!&RPG5#5MNB[)!QSK93=73=JGC37UV#N..........0Q]O
M?*/.^M7<VK.LP;KS(YB-D?Q?XXDB;JE"47%]DH./`TO]ALN:NF*QRN/?W*G)
MZ_D/VQ[.`_9$(1YZ!H3[(<J15%XF<QGU_P"?^?UN.........:ZW>WLS(:?[
MBR.G^JM-]>.Y/D%N1K#%H+4#B@B,ID=+TFUC47%JS/M?V55M0,'IBFFDDQ*I
M%&(PWC")0PI(6*@\62?2-4\M,7U:IK>KX&W,RN(T/%+KG+(>1O;;K/$S$#IP
M]8K!4@D0(@HR9(ORCQ^/T<_-UY,I)\%,90U$,=SJ(ULS%1X'ZGL+WMZ:=4)'
M&8CV5[-4K1THF0Q4Q%(_9D_"1(O(Q2!'Y(5?"1Y)RDX(--"F?B'PB*>^F7?O
MD-??*:[8Q<6+]CZ+F=LRJCHM9T3-VQ"T22TDA#$ALH8'[`THJO)&VN-DM&3X
MC$TIY!=YF,%NWI.'8FT/UE301M)P>KZ*[W0@CVE5\8?:C;KX^H-I!$Z"N[?L
MDE<0RPG\M=U#B`/=G:%(K0LDP#C['V=ZJ:MW4[0(1G5JIC91IE?3&W)/^IWK
M]J[UQ]?3U^P+3?KZ?1Z_8VC'KZ?@YD#QQQQQQQQQST<G/M(I&Y!*'[4L]91P
M(6//&8$.2D)QVU#CW!)PV#``S9Z8-E7"+;=(<(%,W9(F\W19,6R[I=)+>//I
MCY+ZO[FV7;E91.$6+'"M>2F1MPA$E!;)U#D8*"C]7OVY6R29JOHR-HBV"4@L
M`N!QURLAZSMUBRA1:3.@V`[A'=.2CCCCCCCCCE%V)/0-8PN0SN2IFUPT<8Y>
MN6<9CAZ824DKNJDU8B(Y$XL/+2232`P_<-180`"&/RQ<F[:L6+55=;77D=$.
M\DT[(S`8UM'QP=_*'J4V\U:-;SL.$4T=B4;;[Z;;IG;-AU57385IUM&-M=,[
M/I":A;H?&4-]7LRWC8Y%^]8RDZ;ZJ:Z[Z;8VUVQC;7;7.,Z[:YQZXSC.,YQG
M&<9QG&V,YQMC.,XSG&<9YSZ8SC./;[?PY_\`+/KZXSC[V<>F<9]O&,8QCT_Y
M]O\`MSG/W_ISGD!Z$PB<L]TG1Q.+2>/212->&FUHW(TP!L89WC\A8]XX#AZ!
M-Z#73G849:>GJY%O\-W[?UQ\,WTSZXQ/CQQQQQQQQQQR+[R>=^99T2KZ#'8O
M6>\D>V!)68EE.SNX4G7\8S')#&)-/(\<APJ=QZX#\A*T./N*:18G`XO)8M#5
M*\?RJVB$6KX89,M\YJ'M%W=E/U];+R"R"M=K!CC.4M89*3D"DAT0**[*N`F[
MT]5\MGE?E<%@V6!MH\BLPD`I9@3:[)$%%/A-=+M\<<<<<<P([*]PK?JZ4+5]
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M`@"D`OXZR6^(&@SYX+*-?@GK!TNU625VQNE7G<\0A2=`L32*7,1LF5(A'$<Q
M)_'IV)=S:1-Z:.+3R.+!<%Z<4D!A&K)*8<3((H/PYT@QPFM(F&PD@^W>JW9S
M[H)\>VN-MLI=N\8UUVVSG/0[MUKC&-<9VSG.=JFQC'LQGVYSC'UYY,G!9B&L
M2$P^?QW!+$?G$6CTP!8,B"0`O@-)A#,V,^5`1ALS+A2.&+Y#X\)*M&I$:Z^%
M9/FR#I!5+6JN.......:]OEYE%?=4)S6=HP6!=+8Q:G:.52)A;5N]B.KW97M
M--Y()IRNXRVA`(/6_4M!.V"P`&WV31<R<R04@E<.%V>GR5DU8&S_`$D:\8DD
M;S#I%34I;?8URG('5IEMU*?JRUJ2K1PZ>W-8B[YW$:HO+.;:@HYV]V<.5@4[
M]Z:1(*O5LZZLUVFN/P=YNOJ=[?8=@0BL!![%JWG2X6];$WCPYP_C_76DI$:[
M`G8V8DBB.2K4!.9)#1]6L!3)QC&7]IDG:*:'OW[O6+GJ_P!&.SL-\B\&F<JB
MI@)!J8[D>8?LI([&<J-]8A8E:=\W57/:'B44(-2+ET6-).MBSB6QQTUU3A;R
MH%=C2;/4K7CH[<#W0%&>^A#I5W&.4M:G6J-]4&'2^S];D@5@U;/I)=<B=-QT
MG7E^\!G82:!XG'4B,44"L`>AJ-F,CS#8D^>:.6SIOHUF+ZG>OVKO7'U]N?L"
MTWZYQ[,>OV-HQZ_^?,@N........6=O^]()UJI^;WA9F)3F"U\/9DY#\RH7*
M+$D_Q5\8'`T/DF&PL89DYQ;X\5:Y60$C72K=IAP^7UT:-7"J<4NWN@?Q[>W&
M4>W>?3/Z@WMWZ>NN?7&?7[$OWLX]?JYB7UO\MOA`HPO*B?6N"=AHP8&AA5*3
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MTUD%FV([`S7K%6&-+,C3QF:;NHR\`/$MUJQ#Z-F<P?OR+-R[=;$>,8QC&,8Q
MC&,>F,8]F,8Q]&,8^]C'/R/GS(8S<D"+MLP8LT5'#MZ\72:M&K=+7.RJ[ERO
MNF@@BGKC.RBJJFB>FN,[;[8QCUYW:NFKYJW>LG"#MF[12<M7395-PV<MUM-5
M$5VZZ6VZ2R*J>VJB2R6^Z:FFVN^FVVN<9SKQPBBZ<I3W2FNZJ.LH16[FW?$C
M<ELV@O#(Z.`*S^S)#WC@&#D\EJ@]%'8Y*BNN-='YI_E9\YUUUU45SIKKKKL2
M<<<<<<<<<<C.[:=K^_U+VHA#^M/BSF'<2N5(D%-*VV"[<]=:29MY*_>&$"T/
MVAEI.49*HL#:L1;W<VGC(PA@UJ@T]%6#GUC([9^5ON_052O;\[:^`PZ)JRM2
MP<>K,)1W8Z=6)O%BUO/V]'L-10@*(E4B04F.]C?,`NY#B\IJQ^4%&)Y9.-NB
MWKD2&[V^6B,"!<;CON?.:@0$>',@00&#\A72`:%#"!#9(<-%"!PUTB/8"QS)
ML@S'LF"*3)JT110:IZ()IZXD_P"I-N=A;IJQQ,.S'5$QTXL5*6F@J%2G+AKB
M[WKF-,&PM81,<3*K5%(TDB<7>$6N@3?;Y3';B5%7?JD\:[;90<<<<<<UF>_=
M4=@.SO<ZRJ$JZN[NZL]>?A*VE/9COI5D:MFP[TMN0Y@D&U84EU.&PO0C%*FV
M%PL:""V'<!U@HZ'O]WS8,Q6?MWK22SN]40T#CE!0&-5F!MB.0J+IR*+!A]YJ
M6`XME?$9EAX"_-S9[:C\I890G)28YY(FYB5O529D64'E/>-VKMLV1_#W.:,B
M'4CLRQ(>_P#BSRA;;;8U1<NFCA1VM`SV@U%JX8+(/M'JY3+)%CHR5T=KO%$&
M[?WZRNB>^L1V.:]0Y5X8O%%5?9WYY`;?F'5GJU%H/:P"G[]M^R.JQ:J(O49V
M[K0A<<J"#3210&\&!6)8J^-$G;&-$"\V+MH_)36(*'FS779V['V3?<!H8G.^
ML'7E#LM;6OS5VCU,RFV0E!9+C#1(>B?>$Y_+0DB&@W\9!.G9E<<[%KN2KQBH
M)1W1=.-5-8AO!-*;3FU@^7B5795#*CK5.>2<X^F]3#[!%6LR@AO?KW2VBH%O
M8802!%2U-!NFW6^5V(<<@MLXV3U:I[([>NPCQQQQQQQQQSIE/7.<Y]5/;GU]
MBJN,>WZL8WQC&/P8QC&/O<@R[MZ8QYO_``<X]=O3-;>5+'MWWSGT^PC37W\[
M9SC/MS[<9]?H]O\`>Z^DYGP6OUJ?PRO]OGDQCTQZ?5[/;G.<_NYS[<_KY]O'
M'''''''(/?*@U,FI;6>L^H+RBR>!0AX;.U[;OBAL741838G*XZU`2:(7$#C$
M\KVYQ#-#9CJ[!*1!&50"0M7J3F2D@Q81@3MF3XZ?GLUZ^`@AJK^S=9PD&J33
M@>>[EA"K![>S5`]))#+#,MN-T&E<[U$8W=GD!$79RJ8$;&<BQVZTR#1A9%@S
M>Y(VWV`JBDG<&$3^2;-I59YYY&:R@@$,<F%AV$=&BUS9AE"X)$QQF5'TX^#;
MKFY239"]@T3!)J&I.2$"\?&\T?#>W_72?7;)>O<3L<:4M>,+39B^":#C3<>1
M+5?B!_93C\;E3H:A%I9(ZLWM"O$+(`1LR4*PAU+A+.0-63OXZBSC7]T(0&_)
MCXP^U!:G>P8VF(G!Z"NZ27;$'U/QZS%KTKE.`/47-:,9&:/"'E5.7"V%7>LW
M`M#11'?*;?4=LEKMOR3_`*G>OVKO7'USZY^P+3?KGZ/7/V-HQ[?3\/,@>...
M.....<9QC.,XSZ^F?JSG7/[F=<XSC]S//%NEK[S;VJ?F=O\`WROU9_\`Y^0;
M^%/3&TQ\SGKG;[MEVX^C??7Z*YH/_P"';'UY]?K]GKZ^]U])R\)ZXSC.,[^N
M/K44VQ^[C;?.,_NXYWXXXXXXXYTWQZXQ[?3^_3S^\IKGT_=^C]WFI%XTJBJ6
MK^TW4^RAW9>JG;.Y+0[;16B:1?>-OJAU[O.8`8]$KB+8E["X(9)C?9=>K-8V
M.+$([/)TT;J62)&"D+.T`R.5!6#[;@^GD07FN&RX_P!3:[B\!>3"/363]Q^G
M@^)V$,8:&*MJB3CKQC<ECEE=F@"[9VTD/6^.G`0_2Q`;]'4>3?/HR@_?!6?P
MQH?Y?#T^ML1XPJ[<RBL'K*X@Y?M`]<P]_(]1T8GTUSV`N$VD:K8P1#,-(G2%
MEGG?RE2[58*H-B%5F(PV8.I(%'LCYF/'JG;/;*W_`'08#/=O^HP7IU/1WAXL
M<7'8"#[$1#LBVDT6W[D5F^4E:TLAL6B@\"X1-+O`.T=<-7[G?4?@MH_^+O4V
MR&T-QQQQQQQRU]W6]#>OU-VO>UB+D&T!IFN)K:<V<B1ZA4FWB<!CI"42!8<,
M2W25(/4A0QUNU9)J)[NEM=$==],[XVQ`XT]U">-=^T:OF4=[D/&3YLW>,W;7
MJ/93EJZ:.T='#9RV<(;J(N&[A!1-9%=%3=)9+?11/??3;7;/G_NGGQOY^F*=
MSL__`*0+.Y&'YC/.CTW[I>/BXNNE(0GMD^LJ:3'KP:!MI)U>L>-A]V-<=CZH
MLR3;.2[I%=%LJE%X@859I[:9R\>Z-V2?HHYUWTD\_NG?QO8SMC$4[G9Q[_?.
M,_:@V?GUQG?;.,^N==<Y]<9QGVZZY^O7&?9CG^Z>?'!CZ(IW/Q_^D&S^76H;
MW0WT`[#WE4?7N%C^S`6?W9,V\!@F]@]<YI!(V]DCH<0*)-'<@.KHM&N,LQCI
M7;.FCA7777&^4?@L;J:3J:[8VUUVQ]&V,;8_6SCUQ_Y<YXXXYKX^=R;"HIMU
M"82F?QZ#PV02ZZ4C.EC^0:S_`!W5&:*"8"!(1Y&36C3`4Y84CF`]79\[@4<V
M:ZPOX-25:R)34P0BF<2&>+4@(*]$Z,?@"\7/!G.ME;C2\+[`2_M/%7S/%P6"
MFDL!["3YD.F5KC?[S*:$KD3%J2<9TW9J):Z,T_60+./7'I[?;]6<XS^_CTSC
M]S/.F=-<XQCUW]GLQZ**8S^[G&V,[?KYSG/*3L`Q(X[`YJ?AT17L"6@XC)#$
M6@C4T,CCF:R(8%>O0<2;R$WG4,"7DA-!J&2,EMM1@M1[J^?YPT06SR!SP2S&
MRK`G_EVF5PT^[H*S9#Y)#)":4X_G$6LEW7IO?KS2J;B.KSJ$J*Q24;MDTD5L
M%@2FX]?5QKJEMG9/?FPEQQQQQQQS`;R,>0ZI?&A1<>ONXH-;-B@)1;,)ID'%
M:6!1J1S<A,)\W/.`.C45*99#1R[3?,>=MU<(E]W^[IPS1:,7.5=\IP__`-U+
M]8L?3T(\H/\`$!57_'KC^ZF.L/Z@CR@_Q`U5_P`>N1Q]A_.M4]N^1?QR]NX]
MTE\AK"N.H,0[J`;'"F*0@2$T./NQM=0*(P?>%#FEOO`Y%J,)Q1ZM*53!T$HP
M8N&JPQN87V5;)R.?W4QUA_4$>4'^(&JO^/7']U,=8?U!'E!_B!JK_CUS.+QX
M>;/K]Y'+UG?7FNZ([54O8,!J5&YB2/8B!06%,R4/<3(=!TMPVD:LN:%'#K<T
M1U]YET-9L%$&CWWC[9PA\7VF7XXXXXXY&;Y)^P/:3KF!HN;=>ZFL6V(CBVPG
MV;0=-TT#O:V2\-8EHZ[4@\3AA:V:T=@49O'L39%Y9($19Q>)%`T?'_,=H-DC
M^;Q/)_J+9=H7#U]@=F6_6IJHIC,-Y660K^4.(XK,PD*VFDB0K-:>M(>4.Q<'
M8!JN48L<G,8!&RH^+RHB6`).\;C]T$8>_*KTB[L7)VJC'8/J>8F`Z4-NG$AH
M&E9U!;53KE]UN[!ONTU,VRXM&<L'\E`MI93MBU3&9##+*"#1$^>&64281,A"
M'[63L7[#\G6GQR]C*^[^PBR)<Q;#ZQI+MUY8>T[:PT3`)T)M$)Y!]JZ5K."!
M03(KF4BCT+6<3M2?:GP#`&+7@P#Y"?GDI8P7%_M]T#4+VSFG2_N%;%9=[)!3
M/7Z'=,+/1LOJLRZ]TW.@]PKAQTG+R%R\M^6-E;(@V\L!/!467TB:R.H=`-H3
M&[8?$7VJDRG4[U^U=ZX^N?7/V!:;]<_1ZY^QM&/;Z?AYD#QQQQQQQS4;\G_E
MP\C%">1&V>K/5XSU?CU=UM3E'V!\:N&IYO-9$_*V8UD&Q-),G&9['V^K9LN'
MTV025':932WQIA57?&^W,)_^FB\U7_>)T#__`&Z6]_Q9YQGS1>:K.,XS8G0/
MVXSC]+I;WW__`.[',9>MW?'RL]6278\I6=E]+5G':/LO8':RR=9/1MJET6]F
MV0(BP20-HQJWL4;N+BR;*("<C1+W<J]:K;.U%2SG"^-$\F_^FB\U7_>)T#__
M`&Z6]_Q9YVT\T'FKW43T^R+T#Q[_`'TT]?M=+>]GO]L:^OZ+/WO7UYLY>&'N
M!;O?'QP]?^TMZH0YO:=CN[?9RA*`!'T=B?OH%=UBUT+4$AR)<Z\9ZK!HH/6=
M86*.<K/=W"^N$=%=4$I2......6#[.%WP.F),0%RRWH.4R3A0T7*:)A`"R;.
M#DCDXC@)@Z!P630^>A9,/U=DT?G6.=1,MOB(_+KIIJT>-D'S:#?HN?ZS1;R5
M3*J8#`^FMB]J\Q<^>[#VC7O1*X.K?:>M1$D%+']C=QR@+";'H!X:LV1(BDY,
M/=630,CD3PJ@2^9<@*M\#'>R)SC;7&V/3;'KC/TXS]&?P9^O&<>S.,^S./7&
M<9QGC&,:XQC&/3&/H_YS]7T8^K'L^CD&1G_\R7`?VD^S/Z\<`_Y_#][DYW''
M'''''(^_++]RY\C7XC/:S\A\VYH04>NOBDZ:QA=;&,5+6>,8PLIC&,?,@%[,
M8QMZ8QC[V,?1RZ'PZ_\`VZ_\,K_;X^'7_P"W7_AE?[?'PZ__`&Z_\,K_`&^/
MAU_^W7_AE?[?*HZ\J*;^1SQ68W44WQCNT(SC&ZF^^,9^Q=/O;C&VV<8S^'GT
M9T?SI+]CT_DXYY....1N]NJ![I2J8CI_U5N3JUIIJWRV>5=W1ZYF;HA@,D[:
M-!9`]5\YKJ?UM/X&I(&+$?I)HL2S,`!TDR9OA>T;56*-BU]>IE1795D&=8OV
MV('9,^/.MGRPNEJH2H^B8,T7=ORJH6N:\4DLU/**/2Q<D3D<TF$Q.2&6D%DG
M66X!@@W#I96\XSMC7T]?7V_5C.?W<^F,^F/KSGTQC[^>4G/CAF,P6:22.Q0E
M.Y!'XG(S8*$!G@T>7F)@2&>D!D5%$#"[80Q(R)\W0#L7A1RW'-G3Q)=\NDUT
M54U@>\%<XF=DV)Y>IS8542.C9I)O).;)R.I9<:C4BDD#)*=>J525`ESD.(%8
MP3=H:))K;.@I%XQ4T<)X37WVUW]-@[CCCCCCCFM1[J3_`$C76/\`;)>HW\NQ
M>:W^^,>_V]F/S6WWL?7GG7TQ]6/WL<>F/JQ^]CCTQ]6/WL<>F/JQ^]CDCW@"
MQC'F)O[TQZ?^K8CO]9T=S=[XXXXXXY!%YGI'6D0FO1B3S7L_%>DLJ%V/<GV+
M^VEC1;KQ:%=U%+MZW'+*:D:FOILKL5F$J&MEA4&L6$N@Y&M'293$@+;1^6N`
M9O/WQQ1RJ(OTVJ(?2O80GVM@3Q6Q9&CV**$1A):W99+;6G$HLB7L]P39G'F0
M5Y8Y>6(@0\<;:1X(&;,A(51R/9H.U_<]G.]%&]4)95T#L9M;,EG%OXD"\-B%
M+TC:5Z23(Z,NP(\L<D`>JXS)WL3CJ3^2"V*4@D:0T.X<[NTDGFWR>_RWZU_W
MPZYV7V!/=;8O*2*M@"#5M18:[?!'3")3*8]?]X`C?4.A4D64^+GY)3SJT84R
MFS'1NV12>D2K8&Z.*1&9XC^!ON@RK;*L+QA=KCL$["32F`M;=?KNF%A0^+1J
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MQC]WG&,XVQZ^WT_#C.N?9GZLXQG_`,N:VM2=8:5ZV^Z5Y._IV+$HT[O_`,5U
MWWQ:ZI&;3N98D5HRWO%7^IT^Q2F\ED2$28NM,::(Q6&I1^(L,:^^8`FRFZBB
MFR7QQQQQQQR/ORR?<N?(U^(SVL_(?-N:#='_`*"E-_Z):S_H0"Y=#CCCE5==
MONCOBM_':$?DNGW/HU(_G27['I_)QSR<<<<A,\OL05L26]'X5$[/'5Q<6;GD
ML^JTI8%(/+NHZ'OZG&Q>P2%U6<W3N2EF5<.ZN>!0`J)68J8EA`7FQ)!&AL&?
M:RM])8MEGXOSXF4=*ZO.";Y6[,[/))=*1ZY](Y'XA'Y5-!]Y6.,GC2OXM$BI
MZ)@*JBLR9G(C5`N+GCT?;5T#C6!)LJSV3>JR`<UW?/4&["#HU!;$JT\?,AM:
M-[,TW5]35W9[NO[E?=Z[BS53;IK:U2QEB]'O+4E-<RF-R9JZ$BW*LAAL3/RN
M1#6"X9W)WPR6RV+BM_K[U<$V,4HRS>S]P!(W70Z85=U_9Q)S,9-+#"00/-"T
M::28W%8U@,&*N2AU[C<DST3"ME=F**FVJ2&8J/!989NU[&\O=B2.KI[2IN6^
M2DZ6(U9:"`)M/X2X4Z]TLCD+*D(R9D(%(JEHAHX5U%&R;3"3A+.CQ7.=LXV#
M>.......:U'NI/\`2-=8_P!LEZC?R[%YK@;_`)O;_*V_VYYUXXXY([X`_NQ-
M_?M;$=_K.CN;O?''''''(:_*,I:=F:0F%==E+IGS^M31);L)%>C<XZ>"^Y]>
ML9K'Q#ZK%VVW:P<?CT3K27*,"R\T:A&X.P)*BVASL*Z>PUE+&ZV;710!<D8Z
MN5D&OH,7CUE(:RMT4#2C>IUYVQ$DYM(R<4TLU[1(D#31.UEHL\$.K.*UF(90
M\G-US;X5ASA=5ZYPD\DW1(AW'LV'*`>O\:$V+%:P<N*%\A,4NIW`+VZJ78(F
M>"T?10AHX0P*R>M=F+EU(G.@N425"0&<OHC((`Q&D$I>TL]UU\8-R5GWMB%O
M2@O'L512G:?R>=K(?)V!E!X9L-[Y%/F%D+`G\43'LEXTXJW;%E_.LLJI\F$]
MF%?JQ?8GI(9*VB/J?=`75>Q;(Z4]QKY!=R>RU40VN^F%GH&^M]?$*\0I.TU(
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M*2]U5AVV.PO5[KY++P9Y717HBL[YO2&5E85L)$6^OP@%P`CY]<:RDZ2K5W%W
MQQK(!KQJ6'#W"?O_`!O7@O8O1,58S"C?F.2A,C[%03:O(#*#$_8SXU0UMV+6
M;F5P*<3IUH?FB-ODX,I(Q$AEQ9^3)E3ZNYF3GE-5Y&0BKZN=D9WV;]T'@IC8
M'5/L!U'*@_#O9$>:07L2QA#"5R-COW*K0KF5!$H++9@/VC^B[K<+ML0>,"6"
MC)WID=\5U1=+[/W'''''''(^_+)]RY\C7XC/:S\A\VYH-T?^@I3?^B6L_P"A
M`+ET....55UV^Z.^*W\=H1^2Z?<^C4C^=)?L>G\G'/)QQQR"GS@D6,;B/6>9
M63U^ZW=F^N,?LV:H7+57;*XNI'7JFUR!N!J#ZUD_V9.TL=+J`)]'Y!DCB(QR
MM"L;,R]F_DC23/W$=8[MLR-="I(WEW4.C)`/HNM>M(5_$5<1BD*=FU>635T#
MAS0Z88PUE!)[4S=K6TLC):+-A$C&&86W2`N43/HSUSG13;;+SGH7<6C3\\*E
M+Z/A'DF!-2#$)(G0D>X.B&1;">I1F+,+-MR0YJ2U11P0;LW*"+W"2>KG17&F
MN,>OL"0/8G!)I*1L6.3@C&8G(Y"/A<738JR67/@@9Z39QB.I$W3$:H=/N&J8
MD/H_>LV6Q!VVPZ=-T,J+:0/^"NPS=L6)Y>K%D=73VE3<N\DYLP2JRT$`;6?P
MAPMUZI9+(.5-XV8/@DBR.B.BZV@PR2:X3<)>]=*;>^]-@[CCCCCCCFM1[J3_
M`$C76/\`;)>HW\NQ>:X&_P";V_RMO]N>=>...2.^`/[L3?W[6Q'?ZSH[F[WQ
MQQQQQR"SMMTH\DMG=AIW-.N%Q],*]IXK=51WH#`VU5%V2.Q#<UKFGH37!%E.
M)%5]F007):X-;1O#=>OCS,J/?,F33<COG39!LC*KU>!]@(W1\-#]I9?")[?#
M5Q+5)[+*V"/XU`RRKR:R-]'OFI'RJ[HF&#L(DY`"VXTBZ=OVNS)1-X^?.,*/
M%Z6[8]Q*7Z:0^"RVX2177:S;AJNC:_C<<8)%9+*9];<W!P@$V8,G#M@T0%"'
M!S0W)S!!\S9"PC-;"2CPT]"!BMKJT\C/7ZT^R9/K1'\RIM(OGEV$K2'3,H-&
M-H/8MF=3U:^;=C8%$W*)ES(=3M8.[)$-76Q^/!1TD4`SM6)O3+2&DW.V&_NA
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M\E9QE6NHRVK_`%C\.=.TD]@CGJS8,-)1!*/R(2-.@C+)P-+A3+!H4$E1SQ+9
M%VP)#7Z+AD_9.D=]DG+1V@LW72VV353WTVSKGN(#B0`L>#!C!X8,*9H#Q8D4
MR:CA@Y@U3U1;,F#!FD@T9LVR.NJ2#9LBD@BGKJFFGKIC&,0@F-==?=)<!QKK
MC7&/"?9GIC&,8QC_`*\<`^C&,8^_G/[^<_?Y.?Q_S_\`]Y#59XGW0&I9,_4I
MN;>(5K4:DSDV]7-;*KWN,]L1O7VQ=WM#T)V\C$W:1MU,$@.6*<C<@&K8,L6U
M=*#4$FFR6FN!]K]J_=!U1=LNI74`Z7\/Q.=]P@/8>00.3B*U[CXB,8;=;XG%
MY?+$)?J]L]`UEP>8RMBUCGR*R?:8=MW62>6R/P&ZF6^0WNDSTSZ3[PG>OIGT
M]:T[Q^GKZ>SU_P`/_7T]?3U]/;Z?1R92L-+*3K>`IW*XA+NW-(9&=+/=5JV.
MLJ[<6!J'9XF"\%9R=P[D;6(*G\/]XXV/NG)E$1LT3)KK/-5E-JZXY'WY9/N7
M/D:_$9[6?D/FW-!NC_T%*;_T2UG_`$(!<NAQQQRJNNWW1WQ6_CM"/R73[GT:
MD?SI+]CT_DXYY....0B>0R.#>RLW#QG,ZD'6.84'=\;IFH[FD75JIN[$`M&Q
MK[JN%S<_"FU)2F&3Q]$7(N//8JR&VR1*U61'E]Y)'QYPQ$BDB'$I(NG]$`>M
M/7R#4Q'YKFQ$H@XEVQJ8ZQF`P9J:F1^:R&23I<?`*K`Q:MZ^'(S`N;:LH-#8
MZ*$Q=!OJ)W2<D6[]^\R9YQG.,>W.<8Q[,>N<^GMSGTQC]W.<8Q]>?9RD;!DZ
MD)@<VF2,9E$U5B41DLF2AT('(&)G+%`(5Z5TC42$N7;!L4DY[9I@4`'.'S)!
MZ6=M&JKMLFKLMI`YX);16NJ?^7:U'%96I32TX\DIH\I5]W1EC#;7A67'7FE4
ML!)W%QIJ1,0A]'".%G+!L;)I))KHYP[4SOGTV$N.......:U'NI/](UUC_;)
M>HW\NQ>:X&_YO;_*V_VYYUXXXY([X`_NQ-_?M;$=_K.CN;O?''''''->WRX=
M]8S24]JYS6':JOJMMKK+;>&,UIJ]<=UX#2-ER6TZ75F->_/*7=7*CL$E90V$
M174A*L0!P,D59$WYK5M,WP"9`XUKI(=XM)O([+Z*498<LN\)V)D$W3L64$K4
MBL5GD*A9-8S;,\>:QF`QVTV0ZRVM?5QHIK7$%>3YFWEAF*1009,((N'_`,%I
MC1Y0O&3=/>$W")C3G;65TH5B\FZW*NH(^B54GJ]W$4UV+#7@9F`@M(JEG=A!
M[#V5%B2`L2(/"H#,Y%`Z^'62,*1P6IJA35"^+"<U=W;CM[R&<QLE6-3=DO(Q
MVHK=8:X(XG$HFGD3^863\/F4?6!-P00+5.S&ROBIL/(R:\P^680HF)CN!)]L
M[M5[H&Z4"[<Z7]PNSCCLQW,KU_5'3"SFB%)5-V'D4$ZVV#K%1TGE"2EK4\/'
MKAYRL;6+9$250@\1^68^-#BEM=$AJ2O)E.IV/3J[UQQ[<^E"TWCUS].?\6T8
M^G\/U\R!YAWW![06'UACL-.5[U!['=NWDI.D`Y&.]<V$#?F8@U9"_E!$Y(]9
MY,(>S2%/UO4:SW9.G2^7N,ZJHZ:9TVVCPD'F(O\`BH$W)Y%X8/)R(`1L.5D!
MPJ]!=<TV@T.$8."A1^YWQ>&VV$&;!HX<J^\UW4SHEMA/3??.NF::J[S<6U=-
M<PBVZL\/'DMF]<6/&!$RA$N!A.NRPB21@\UU>B#(Y1:[$%]F;]IOHX;Y6015
MV2WUVV3UQMCUS\Z?]S;6[.R:8@+"Z%]MNHC*+@1Q@?).Q8RLF(67NGQ)1@J#
MCBD#GTQ<J%1Z*>"+S1\@T0U9;Z[:*[*YUTVS\XXYH0>6G[M/VM_%>ZA?S$[Y
MB-QQQSRH?GZ'[.C_`#NG-J?W,G]Q5ZB_YZ[,_P!:Z[>3V<<<<<<Z[^GICUQZ
MX]]I[/3;/M]_KZ9]-<9S[,^F<Y_,XQCUVSC7&<XT\?&H+H%'RI-',&ZO=/X?
M:[*1WTM+XS5E!^0B(=N^LFAB/S/4F?['7A=X0=UVL;YRN7BD0E&&`6",)%)9
MF&-4V5GX8:S7*;B''./9G'KC/L^O'-;2I*`:43[I7D[QI;5\6IFY?%?>%PN&
MMWV@4LIE6CF2]XJ_^$KJG&Y-LVUKVHP^WJI'X"-RL/$J[J;I+;[*;YVD9\K_
M`)+X1XI>L`_L[/JSE=K`R%JP^K-(Q#C(4$63?2\7*2J!79Z>258Y9LDHLX36
M0QIA911TCG3?1/17;&MK_=N/5W]1+?\`_&16'_TW']VX]7?U$M__`,9%8?\`
MTW(_;[]U54!;_?SQ_P#<(?U6N(/&^G44[@1^2P][-X&Y.3%QV2@,(B`)P#?M
MTM1H]*-NHFL[*ZD<9V=H.D=&6N54E??R!?W;CU=_42W_`/QD5A_]-Q_=N/5W
M]1+?_P#&16'_`--R6OQ!^Z"Z@\N]VV92E==?;+J(E6M5?93>FYM*XB?8$V.)
MC'X?D4U;1Y!-PB\PXD#=YA=;?9'X!!9/;3539+.VPER/ORR?<N?(U^(SVL_(
M?-N:#='_`*"E-_Z):S_H0"Y=#CCCE5==ONCOBM_':$?DNGW/HU(_G27['I_)
MQSR<<<<@:\CG0CPE;V<1[4>2`[%Z^G%Q%X^!82ZQ>WUST,)//('"PL>%!8O&
M85;D$C[QR#CXAJ\?O681V63W?;N2I/X%PQ23DEZ$Q+JM!NIM21?I)(A,KZMC
M6LNS41T#-S%D!789]/Y62,)"YU("1DY*&+&6/)`P;EBQ@L^7T:^]7)OMD_C*
MF8'('_+[W7M_KO8]'UQ!FQM"JAU`]P.[7932&S]*J;4LRF>F<>@!0[2]1V*K
M'I$YC1TSFP=IW+7$<Q&ID2BD(S%H].X/K)2,C:247%VIC=(]7!O8\?3_`&1N
MN,.H_71$36U%U<=N.]R(JP-0B`ISK`VQ7Y;)J@VAAN1F3I<JY<BV30F0>+O-
MT%-U8IO!-:R%X6#Y>+7:P&TZM0G/DG.&TZ_NR#OZVM6*84Z]TLWR)G,%)JKD
M(R=2V;947%NU=UDD54%-LX^%QC&PCQQQQQQQS6H]U)_I&NL?[9+U&_EV+S7`
MW_-[?Y6W^W/.O''')'?`']V)O[]K8CO]9T=S=[XXXXXXY"KYD8?VTED>Z\XZ
MT9[(N`8^:3O>U!?6[NA3W10^Y;NHJ.3A+T[<EKPV8;F1K(TD1;-JWCV@OY?7
M)+R$NY<Z1-@T5R]\:#2>#^D]+,;.<6"YGC/6PFDF4M:_(9VCL;0@VM:=(_%9
MA?\`7HL+#K/,L6VC=DN>"B1Z2";=(,[:ID1;SU\O<SN>6Z?JU*7<]>;1MV`3
MRUJMJF7RZNBD)P0@Y>YYX,K.O\AX,>-L);:1%U+2S/<['H*R<DH_&LJR%SLN
MGIAGM;FI?)W3]L]IE^M(Z-R,1H:LGM13%8V&0=BU0MB6QTH5KYOV-B38*UVW
M+`<1US/5](@2(J+Z3-O7]AO_`(H"9C(ZK*,<O=!G7N+73XPNUTND$PMN,OZ+
MZ_7=9<<'5Q9<H@<>E99M`GB&@.SPH!P@PL.&[X1U57B<BT<"E5??*[H_W^VV
M)..I^?>=7.N'W_2AZ9U]N?;[:XBVOKG/M]?3U]?P\TY.P?NSO:B;[N^D=O'C
MB2YIRX+-JK$CU[29$XD&M=S<[#]#GR5F@W^1>2^@;4CL-^/O\,-G.6F'SS".
M'*MG]O=QVNWYKQJ:[>GT>^[98SZ?O]=\\H"U?=J:%FUA8]<;>./`;$_@$VA&
M"^G:C1YL*WET7+1W0GEGGKZVP]U'[D]7BC+#IKEYHALUU=M-EL.4K/\`2WW7
M\CU"ZD]<.KOV@&)_M0%-02IMYMOV7TCF)5M"@R(?Y>UC_P!@HWD)J2U0U<9&
M;&2V6N^V^OQ]?&<9QD_K[N-TU]?>^-/77U^GWO;+&/7]?TZ[XYSGW<AM[W;W
MGC5QG?&F^=<;=M<ZZYVUUSG7&VV.NVV=<9SC&,[8UVSC&?7&NV<>F=]N(G_G
M5%8W)?BOQ'YP``ISXG\-\8^*?*XMH2^+?#_!(_#?%_C7P/POP*7POO/A/@T_
M?>\UJ+FA!Y:?NT_:W\5[J%_,3OF(W'''/*A^?H?LZ/\`.Z<VI_<R?W%7J+_G
MKLS_`%KKMY/9QQQQQS"WR$Q>QICU,L8%4].[=@IYN>J(J&I+:Q=:D:6BWC=U
M5U)#T++60KZMH@!-QT06;2`J]3<,,!,OVCYF^:.EF:^"/2&X/+TO>3:&=L^B
MZ%84?.;#L62+6L][BT;=J]/PA.%FR%<4Y'*\J:J:W(/1C64,F`G-CR)T9+*-
M'FK(RC[]1@[;S@<PU[V=J0G4.AG=CEGK@.]D4H`5M&9+O!)_8H&'R*7ZO_@)
MG+HS6<<E,N(1J)C!A4\Y'#Q:7SC(L1<0^50JLB1*M,3/#/VCEE^>)#K)V2LB
M43^Z;">5++3-C'E094C/9I-8=)IDC)68D0Y9B]C91RZ%_)$=:A$\@R"F&`^/
M.E1V&RF(]NJ?;D?W']T&`[`'=>^U_7)&.^'BQXKO$^W=&&J$G1M13N169K)Z
M-1HX0(KFHJEA[\DK'FJ^6FIUF0&:^^5:*;<HKW8]]R5C?XW]*_T-N#GRPN..
M..;G_N)S]/MVK_%`5_+;6//I<\C[\LGW+GR-?B,]K/R'S;F@W1_Z"E-_Z):S
M_H0"Y=#CCCE5==ONCOBM_':$?DNGW/HU(_G27['I_)QSR<<<<U[?)U`!,2[5
M4)9=K>0Z_NN`.SRLZB-8*BFGC^B-%==HZ%K*)9MF12J?]M88\-E=9RN,&E'4
M2C924R@R]VT?Q^'-A$&(F6DC?C(FT-L/I75,KK^TY5>$2?G;E:B[>F,>A<9,
M6-N'O.R@Q&6I,:Y`1:`OP)@HP>N8K)8A'`8*71C81)V8D?DLJU2SWY9JXNN]
M&=@V<='W?4L`M5E$R;LO'&T[BXN2(B'I$<N&+99Z$6ZV-&AL,Z<ASXW?WXP^
M(75&&F;]COEORMY]*V,!@DSG!(>=*C87$I'*WXN+!7LBDI)C&PSTPZ'QV/#-
M-R!TX\;LE&P@,P3W>%'ZC=BUTV773US`_P""NV0MZ6)Y>K;CD>GL3"3SR3FS
MPV.6A"S==3\.V6Z]4JAAE*H3)$&IR-ED]V^^5AA-NBZ23V2WW3UU4UQS8.Y2
MLZ.F8Q"9A)8Y$R4\D,>BTA.`H.&>#1QB9&1(AX0%Q040,KM1#`E(GS=`.Q>%
M7+<:U=/4EWRZ+5-536&O'DP\A_IKG/@P[A>N==<YQCL)U!SC&<ZXSG7&=K(U
MSGWN<YQZYUUSGT^C'T<LY$/-CVMGMQW)0$1\-';(W;_7X=69:X(2WOCJPD_A
M`^X@Q605NX?OG<X;AGV)0'"%7K5,,3)K,]&2J15-@OE-+?)RL_(5WMFEC0*'
MR[PU=JZPBLIF,;CTELB17GU8+@(`!,%V@\M,S0J/6`]/$A4:8KK&"#`,T<E7
M;5HJ@/06=;I)[3"\<<UJ/=2?Z1KK'^V2]1OY=B\UP-_S>W^5M_MSSKQQQR1W
MP!_=B;^_:V([_6='<W>^......:]/FT&=9[3G'6.H>R<#[!GH^-3L^=_'X#T
M5F_=*OB0)81'Q)<<W&1F'S(=![7#$T(^9C]@.!A%U%(OI*XT4CY2,6<_W3SW
M\25=,JJ\?E`PL;L4V8,T[-+L<ENM6.GSCXG*;CL*3M?BW6W91=U50C*!;38`
M$*.'!MZ!V&&S2VQ(FXQKZCO[TCG/>SY&J.6D:<8]?6CRJK"!2[:,RY#L[2=Z
M5=:K&:9L:G9NR+[QE#,EA+#6"-=,LXJ8BJ[XT5(%I['3#J#\M/2?BLS5G<P9
MV')6,P-0.N;][Z=G*HCC,4192Y.S?(7O!M[/$S)^LY6!NXI7N0<ZUANPM+#\
M^E.PVI=L#6@.R\RL#[H"Z'4'<_2GN-VNFVUL8MFG>F%GM(7B,WC;4.@'P<0&
MR>6"/G)5T7E@NOY?MDJ9?8([R<`4^5F'Q4:1PX9L&:;>8?JCCTZM]<,?51%+
MX]OMS[*ZBOTY^_SXIGD)_3[]W?QO.RWY:IOS#_CCCG;7Z<_Y._\`(VY][*HO
MT+*W_P#`,+_HP)Y<3FA!Y:?NT_:W\5[J%_,3OF(W'''/*A^?H?LZ/\[IS:G]
MS)_<5>HO^>NS/]:Z[>3V<<<<<<]2<.!HV-7,R`N+!"6JC31T4,D&8L<VV>/&
M[%KJN^?K-VJ.SEXY;M&^JBNNR[I=%NCC==5-/:$3JMV/\E9WL34-%7E5S!",
MB['[#E[][#2.?]4@\#FL94"SIW4-2]7ZHJ.PYM;,CVC15"*/TIK8S.)2UG!(
MU-MK3`:RD@U1&3H_K\Z*)Z*Z;:*8]]IMC.NVOKG&-M=L9USKGTSCUUSC.<9Q
MGV9QGTSCE(5]7<!J>&1ZNJOA44KJ`1(?J)BT)@X`7%HI'!::JJZ8T%'PC5D+
M$L4UEUE=&C%J@AHHJIOJGC.^V<PQ&?3^Z2X#Z9]?_4GV9]_U_P#XXX!C/[V<
M9Q^OCT^]S!/W8]]R5C?XW]*_T-N#GRPN....;G_N)S]/MVK_`!0%?RVUCSZ7
M/(^_+)]RY\C7XC/:S\A\VYH-T?\`H*4W_HEK/^A`+ET....55UV^Z.^*W\=H
M1^2Z?<^C4C^=)?L>G\G'/)QQQS6X\OEP1LY9K*"&>X0ZF*^K%P.BMFTW<OB2
MMKR%U9-9_+HD)LV"S"*,HQ&FH(TZCL63<HE9!H5DPJ"EWF`Z3D'(2A,6[EQ\
M=<H;S+IC19]E:*MSLEP!T>QLO>@B75MM)68*:R<$UR'Z^F=="]4QP.W&IQ^,
M10KIH1;1X2,<O-<+N]^9K<<I*?S`/7L$FD]D6"60$(B4DEQS`822/%_D>-!G
MIHG\E@PS=V7,D?B3%?XB)%-7)(BZ^"9L6ZSI9)/:![P5W!#+^L3R]7'7OSC^
M9=@^2<W(8YF71&2P.29&K]>J602R7B$Q&!I/'WF=VRF=AYH6Q?)Z?![J-D]5
M-/7!CW0_Y\^W_B9[.4G377>O>O,PBUC4-BSCCRWXI8!XZVD&UBRZ):MA;N(V
M9"6*`G4;'FRN6[D:\=[/5EU</M$?>-\:_/\`=I?D^S]-&](/XNKK_P"/O.G]
MVC^3K_N*Z._Q<75_Q\YBK5_NHSOG4W:CM5VYCE1]3W=B]O`/7Z/6.$+PFU7$
M-"M.N,5D<1A:T-8-;B9F&#DJ/DY!Q)\F#AQ!T]3:;BD!""6S=3*K'NTCR=XS
MZXHKH[C./;C.*XNKUQGZ_P!'SG?^[2_)]_W&](/XNKK_`./O-QSW/?Y/+X\K
MG3BQ^PG86*U7$)E$.QLLJ,:-J(+*`4<6C8.O*QEK-X]:2R834BH94(30FBX<
M(E$&>[1!EHFP15366<3O\UJ/=2?Z1KK'^V2]1OY=B\UP-_S>W^5M_MSSKQQQ
MR1WP!_=B;^_:V([_`%G1W-WOCCCCCCD/O?:"=C.UTF$QCJ%*X_`;&Z>7'`):
M8V["/[IA/76QYD[$5_:T:;HF*&M",2V<FJY#[B_E*-3B#3FHGH^Q#@]^&TFP
M^/22,9V=0X;:L!H"%QB\+3B5Q6TU(3DA/9A7XM\%KUG(#T_E!]S`J^%%R\@/
M,H+5>I).LHBC)#9*1X`Q-AL<50)9<,VV/7?3N->73]6I9A"^MPVYZ<.VY2%7
M6J;0M'6,V:/?7[:X>GH@SI:L4(?(,VG(PAX\,.2P69D4&02!O6&H!R;WQ)7T
M0M#2GE3#VQW$:]<G-<8"0J>77WBZZ5%.DI`N^D!BU_'ZM7S:XT99&-A2#`/&
MIAO*9HYKTD,-$ETV-:;K'DM'$V%-0]M/="/62C+^\8W:B:VQ&'LAEG7&@+LM
MZGGC.=3F)ZQB>MH&\8-CCT3$9.!&2]K\%IHUR"FK"11Q7*FWOQ6ZZGO^2@=4
M<8QU<ZX8Q]&*(I?&/UL5U%>?%+\A/Z??N[^-YV6_+5-^8?\`'''.VOTY_P`G
M?^1MS[V51?H65O\`^`87_1@3RXG-"#RT_=I^UOXKW4+^8G?,1N...>5#\_0_
M9T?YW3FU/[F3^XJ]1?\`/79G^M==O)[......1R>6>.0J4]![M%V#,*PA$82
M)TT8W,74+FA>I'D@CU[5F>A$7L5G7*#B>:Q69S@='(F2>Q-/<P-T,:D$4UD&
M[A!37Q\6DUJ=SY(:TCJ@WP28OW):^VMC..E$&[%L^W2,P90:PEITHG)YQ'VL
M`W';&T2*-@N52RWR@/463![NEU4<\W*>./UOP?\`/[O-;FJ:MLJLO=*TB7L2
M_P":WLA87BKNZ?P1G,8U"HZG3$&,=XX!\E4]%5(<)%*GXM&\^N[`[+-BDJ=>
M^]Z^)*Z:ZIIV*]V/?<E8W^-_2O\`0VX.?+"XXXXYN?\`N)S]/MVK_%`5_+;6
M//I<\C[\LGW+GR-?B,]K/R'S;F@W1_Z"E-_Z):S_`*$`N70XXXY577;[H[XK
M?QVA'Y+I]SZ-2/YTE^QZ?R<<\G'''()?.':=VUS"*)']=II/X=;,XD=A1T%M
M1?7RVNPO9@\Q2"Q4B;"4"#@1(1!(K*U!J"CTG+KR?)U:/$,UM2*:S_9#3,I7
M4-S/WG6NH'5I+WBYL!>)I*2EQV4C]-Q6\EB.7KO_`-)8T=Z_K.:A$'-D,(Y3
M9PURY;ICOB62KA8]L44VR0Y$/YHKF[(=:.GTC[(]=[:F59DZ<.0R0R#2+4I$
MKGC3V-+3F-(34]>0L^)-RIC0T.KW66EYPYJ-(+9C)78>6#FUDAVX9_F_V-[;
M4/U3H0EV/O29$(U4`[6*)/)2#@L_G;O.\Z(CP\8W;1*OHW*YBX2)D"S!/WS8
M*XP.1<?&":C9!%=?2(?P3776W8NP?+Q=M0''LEK2Q_).<D<..D(U*H<]*!E^
MO=+-47;B,3<+'98%WW6:KX^(G08P@GKKKLHT3UWT]=5?W;'^GVZJ?B@)?EML
M[FF!QQQQSZ??N+3[F#>7X[]B_D4H+FW[S6H]U)_I&NL?[9+U&_EV+S7`W_-[
M?Y6W^W/.O''')'?`']V)O[]K8CO]9T=S=[XXXXXXY#C=GA+Z)]L>SEZ=BNX'
M7FLKO/V.ZK;:$GG!ZY(M+HV"AE:QJ"OHM(DXY9`J)&F*92/*'P)48%%$DDC[
MP2:U(_$&#[:1?K/UTI_J92<,Z^4%'<Q"H:YS(V<)BORN4.IQL><EIZ5.PC8H
M<>DC+EF.+GB+=E@J1?OV[31%JY=K[H94SC?W`Z=W=V6LRDIM7?<V<];H]3;P
M@:UAL/IBD[)TDLI,?"B"$MW.6Y'I2M&)*QA#PS$(F>BXQ@:B2$EDI0:2W?%,
M8:T+4GBZJZI^U"'9!E,#)@=%K;[>WU5M?.PS1GB#6WWDQ`<W\==2MH2^%DP-
M?>&F<P&/+1\5O%M+$F"1<M*]&T/^;.!GNB'I%T'L[IQVD[8WW6T`(]HJZZBV
M;&:#L.43R1QN0M"<0$R>8Q8)%8\WF0:/24F,/R`L6;L58^9?.-GVZ;G1PUU1
M;Z37]4<8QU;ZX8Q]&*(I?&/UOL=17TY\4SR$_I]^[OXWG9;\M4WYA_QQQSMK
M].?\G?\`D;<^]E47Z%E;_P#@&%_T8$\N)S0@\M/W:?M;^*]U"_F)WS$;CCCG
ME0_/T/V='^=TYM3^YD_N*O47_/79G^M==O)[......=%-==]?>[8QG'OM,^F
MV,9QZZ[Z[8]F<9]OKC'I^'T^CZ>:VO02?]Q)CV$JR*G>PM-3#K%4?8;LS&Y#
M<SZ=WO,;=[=V3(JZE<PB57P:,6!1-/U56=412,RAG9<-'UN9LN+(@ZN?QZEK
M!E\1934MOLFX^C'W_P`/U\QU[5M9RYHV<;0.^/M9GS$6Z+FKO:0$!99^`1D,
MR>%"Y>*Q"6LR\3)R';XJV:MM)#').T^*+/DF0%Z;6%;M[1](K(["H]"Z8M'O
M<BSC]^C*>6EU[8$QE86[9+!TBY;)`S!P3=TN"FSB%M!)6;P@*PS\A35P<C8D
M:EAHV8Z0P=5.\_63OO[H,!V?U9GAFP(7$_#Q8\+/E#=9VG5KAE(UNY%9R))D
MB'MF%P@T3;J!B+)WJ5$L'X?WRV6>7^'Z#EJA1/NQ[[DK&_QOZ5_H;<'/EA<<
M<<<W/_<3GZ?;M7^*`K^6VL>?2YY'WY9/N7/D:_$9[6?D/FW-!NC_`-!2F_\`
M1+6?]"`7+H<<<<JKKM]T=\5OX[0C\ET^Y]&I'\Z2_8]/Y..>3CCCD"E@QORH
MK=X>Y!CHP]\=T>C"QJD&AHGV]KGMV6M0DSS0==?%T8G(8'(0E</*N1--CVH]
MC$-5W+2:)2_$OVP7V;8Y+5U;3[)I4;#4^WBU6..Q";B6Z6*O23<ZSJ99;6:R
M/$:5@+24K.90VCRD-Q'=VR$E<+GTELKZ%E5'N%=\Y`\QJN#J11M[S`9-K-CT
MB.%&,'/UD2$M+'L>/PF9UU*"C`T<A-D5W'96*@=DQQ\3&-'&6,WCIS*"67X]
MLJD*,&6+^\T]F<6K2!S.PIJ51C\+@,2D<SEAQ9%VNW"QB*AGIT\56;CF[I\L
M@-$CW;M1!DU<NE$T,I-FZRN4TMH'?!-=U6=D+`\NMY4G+FD\JJS/)(9E$&E[
M%B7&M)`!==>*50;D$&!X>*,-4U%6R^F$2`YHXURGGWR.NN=<YU5_=L?Z?;JI
M^*`E^6VSN:8'''''/I]^XM/N8-Y?COV+^12@N;?O-:CW4G^D:ZQ_MDO4;^78
MO-<#?\WM_E;?[<\Z\<<<D=\`?W8F_OVMB._UG1W-WOCCCCCCD'OF:F<7@2?5
M\[*N[4XZ/B59=90@U.Z.INRKO[)26*EX]%V9V/5-'J^A-B-(:S4<;"&TMM2:
M0V0@(>X)Q1B+';3.11ETTRX\5NL`TZ)TJG5TKF\\@6CRV<1J<64!MJ-6!,V.
MUUV-NI+9F)O/UM-.3R5YNZ-'7<JWV5(E7KQ^+PD$<#6Z-2=I^UDPH"^>B-3!
M(-&Y%'>W/821TI)I44DA5B9@^@&D;-MYJ]!QAF$48GMRV*]4%KOB$F&Z!_C&
MFR88SESLL/P]HCRKFK8[H`J#*P(`,K.T^P?D(ZRU04';F5)N/GOCQS7"4SD$
MU=.WV03^.VML9LI[&QXD&'>0EK#XLV)%)8ZF3[,8MK[H7<=))/X]NT\.[!F^
MMQ&^89UFN"Q^NT/M.2UXG:H::/XF7"`IA5,8D91&58./GXQP(%%HV/4<.WC%
MPP:K*KMUD,2V]4?3'5OKAZ>GI]@BE_3T^CT^QU%?3T_!Z<^*9Y"?T^_=W\;S
MLM^6J;\P_P"...=M?IS_`)._\C;GWLJB_0LK?_P#"_Z,">7$YH0>6G[M/VM_
M%>ZA?S$[YB-QQQSRH?GZ'[.C_.Z<VI_<R?W%7J+_`)Z[,_UKKMY/9QQQQQSK
MMG&,8SG_`.+3'T^GMVWUUQ_YYQ[/O_1]_FB9U.[P^/RAN_['LG=TMZ)UG'-I
M9=8&/P09W"[XV]='3<UF/RN..B*]76F!*]8!KEX+CCFI3(VEF$7:Q(=+6`*F
MR$@@V%13_>B"EV)\0+."U<KC3`Y@58+;)J([*LB+1%ZT5RDKKHJEE1NNEOE-
M33533.V=-]==L9QBSO8[K73';6ISE'=@(DYG=629Z"(2"))2R:P]L9<1HPT/
MA-")&!R.+FW+-B;8,"NHY0GE@L^8LEW+9?=JA[SV'7_K[4'5NI(E1=#PQM`*
ML@Z99.,Q9L5/G,,<G3I.2F5US4I+'9&5>DCI@D2>/S!@@]7<.]_?N,IZIZ:1
M+&<>GNDN`X]OW$^R_ISG.?T\<`^_GUSS!+W8]]R5C?XW]*_T-N#GRPN....;
MG_N)S]/MVK_%`5_+;6//I<\C[\LGW+GR-?B,]K/R'S;F@W1_Z"E-_P"B6L_Z
M$`N70XXXY577;[H[XK?QVA'Y+I]SZ-2/YTE^QZ?R<<\G'''./3VYS[?;Z??S
MZ>SZL>OIC\/IC'K]_G/''*6G$LC,"A4OG,U+L8_#H9%Y!*Y8=)[;:#@L:C@E
MX8/%B&^J:NVK(:*9.WKO;5)3;5!!3.$]\XQKF"3P;V[6=\V=Y@+@IR8A;`K&
MP/)6<D4,F<=547"R,*YZ\TJBD2'+*HH**-U5FZ^N-]TM-L[I[^N,_3G5*]VQ
M_I]NJGXH"7Y;;.YI@<<<<<^GW[BT^Y@WE^._8OY%*"YM^\UJ/=2?Z1KK'^V2
M]1OY=B\UP-_S>W^5M_MSSKQQQR1WP!_=B;^_:V([_6='<W>^......:[/D@[
M`7J\[.-*1,>)&:]J:^@3X/(Z2O1CW9AW4>%SE.?5^*&SZNBKJ8&XB"FR;4^H
M_'2"M)-*"021N`\+DF(2H8CX`TC)WXU8&=K3IC4L/D]$2_K/(F#^TGQRDI_<
MI;L--(24/W#/S[W$ENTT9D#NS3$C6)YESV6(EG8PBL?VR(VT&)M4]:Y[#]2X
MWV)LSJW:)N>3>(F>IEOO;L@(Z*)1%03(I82@4KK)\QFVDEC1Y\\CJT-F\D9:
MLX\]C9))^[:DTS&JK%%/-GZN\:=$53V9<]E`CV4/WX^?]D;<KZ!$]PF\1K6V
M.WV8/GL9.HXX:B6TC=/9WF!H;,!QDN^&Q?:8V'H-25;2(<WC^!WNABNN@R'0
M?M1:_8V$=2$>R1/JY;5?];K%NB.U$G=;^7!HV:D<;AE(RN;-,39S)19<N].!
MH_!7VY5F\)/B+-JGL\=*J2_]4?3[5SKAZ>GI]@BE_3T^CT^QU%?3T_!SXI?D
M)_3[]W?QO.RWY:IOS#_CCCG;7Z<_Y._\C;GWLJB_0LK?_P``PO\`HP)Y<3FA
M!Y:?NT_:W\5[J%_,3OF(W'''/*A^?H?LZ/\`.Z<VI_<R?W%7J+_GKLS_`%KK
MMY/9QQQQQS&CMX:LR-T%,3]3L+*)R<*_A9,@SI@7$S]P*09C.(XYLG-7QV<-
M'T6D<ZU@"<CS'@!-JX5*N_\`\(':/SZ@E@YASZ2%>_,][#1:YNQ3'LA4$#[%
MV5:HJMNB1>F0BG7GKKTHA<`E[2"F;YE#.OWFD*[4V=.1X$\B&<6.R)9'G"<;
M/1A843:C@FPZV;H-&Z#5J@BV;-T4D&[=NEH@@@@BGJDBBBBGKHFDDDGIJFFG
MIKKHGIKKIKKC77&,>;CFMQ5$5[`QCW2M(E+XMF%VDSD/BKN^04NVA]:[5TI6
M]./.\<!Q&J[E2^\CD'S\E`?;UW?SG5,#J5QO[W`-O[WX52Q?NQ[[DK&_QOZ5
M_H;<'/EA<<<<<W/_`'$Y^GV[5_B@*_EMK'GTN>1]^63[ESY&OQ&>UGY#YMS0
M;H_]!2F_]$M9_P!"`7+H<<<<JKKM]T=\5OX[0C\ET^Y]&I'\Z2_8]/Y..>3C
MCCCCCD-/D_[^W)U1D[6'4F*A"A:)=).\??*7/)X'(F1\FCG3$%6Y!E4(W06:
M$N`BMDO9X^U+3'7XV\CC0$Q2%L'"Q9TY'Y^3+M104%ZV!>RMX3^&4W2LKAT'
M//I/:YP1'8X):6@.%;QX.>)$E<BM'9%<\S#8;[J*(O'RWQ=/X3577&==WQA^
M3OQKT]>WEJ(S#NEU8K^+V=Y$3<\JMR4MF$`@TU@;BBJC"(RJ&[8?I-#$;4-A
MRPW0H,PJQV?LG:'PV54]L;:P?NMOM5UL[;=SNMLTZR7I5E[Q..]7-(P>D-63
M0),0X>1:V]817(0D^$.G"+,G\F$&)#XFOE-?+-VW<8TRDKIOMJA_!;?6G_#)
M?V^/@MOK3_ADO[?./@]LYSCUT]<>GKZJ)XQ[?JSG?TS^'TSGT^_Z<Y^"V^M/
M^&2_M\?!;?6G_#)?V^?0R]R<^0GH[U.\>5PU[V7[84'1<Y+]O9U+A43M"S(S
M#SQ"+OJDI<0S/M!I9Z@Y7$N2@0LP0>II[(*NASM+7?WZ.V.;0?\`TU7B5_\`
MF,].OX]X-_\`<N0$^Z*O)5X_^QG3WKY$**[D=<K9E$>[]=8)V=`0&UHK)2PB
M%1O>>?.&5/V`U\LY;@0GQUGDH2REELRPZ0ROOI\*GC:"#;M;UCSMMG'8&H_3
M.V<_^VHOZ_\`+YU^VLZQ_J@*C_UU%_V^<9[7=8\9QC[8"I/7/KZ>DS&9Q[/I
M]=L;9QK^#WV<>OWO7G/VUG6/]4!4?^NHO^WQ]M9UC_5`5'_KJ+_M\SL\*O>S
MIE2?E,NRTK9[1497E<&>@@&!B9O+K%CP&,$IJCV'8'EHHR+$73=LY/)`]-RZ
M@U#91SH.TV=[:81UVWUW.Z:\H'CO[#V/'J@HSNEUKMFT)9\J?-F`P"V8K)I6
M=^1`[^0%_DL*-?+/'GR<$%D2KSX%/;X!@R<N=_1-'?.,[^.....07]U_%Q?W
M>?L3-35Y=FY!,>C^XR("(5T1%S:Q*9K"0K#XZ$5EQZ]9'36`\TMAN8FR#\D"
MB1&0L64>;M&+AL4S\9R/8RI]7ZQ)TQ1,`JHG&Z\B&("S+Q@)&*JWDZL$"0X7
M)#*,$'A59DY>R=55"%_(.#:A=VX74D&2VZ2RC39OMF_F?7&,^GT_>]?H]<^S
M'K^#U^GD$/7GRDVA:'>B-4O(XU%4JBN;LMY+.K%>#!PUXVF,)D_CI4KQ/2:'
M9(H7<LI(-MY)U:;PF(T##=HKLWKID*6=?!RAV1I3W0M?/0T-T3[64;V#L/K4
MAV3>=5+6FG7FN+5?01S:VDED4>D$5C,HJ8-)4ES[$\6+B20029BV&Y-PZ'NV
MB"^?BRGO+O\`6WS%>*V-=>:$C)_R$=1`YT'3=1AC(DA><%;/114;`XTR)#GZ
M*A7'Q5V/>(+M7B"VR:C5P@JBOA)1-377Y*_=Z2Q^<]T.W4UAYL3)(G+^S]_R
M>,2(,0;/A!Z/'[:EY8*:%/45,HO1I4:[:OV#M'.4G+1PBNEMLFIKG.+WP6WU
MI_PR7]OCX/;ZT_X5+/\`LWYQA/;.,9QG3V^WVJIXS^[C.^,X_6SC&><_!;?6
MG_#)?V^<X3VQZYSE/TQKO_[U+.?S&WT8QOG.<Y^C&,8SG.?9C'KS[/E9^9KQ
M0BJZ@(TCY$.G[-^PA,1:/6CB]8,FNU=MHX,1<MET_E/.4UVZ^BB*R6_HHDJG
MNFIKHIKMKBN/^FJ\2O\`\QGIU_'O!O\`[ES3!\E_=7J)9GEF[)VO`>RM*2^M
M))UUZN`(_.X]8($O%3)R-MICF0B!QI@Y<,G)$'EZTU*L]%?AV.SA+1SHGOO[
MS&,WVUG6/]4!4?\`KJ+_`+?'VUG6/]4!4?\`KJ+_`+?.,=KNL>?7T[`5)[,Y
MQGUF8S7VX^KUVQZX^K;'KKG[V?9GG/VUG6/]4!4?^NHO^WSR(]KNL6JR.V>P
M-1XQJLEMG.9J+],8PIKG.<_W_P!&,8SG/-C;W/KY0O'9U[\3'6.I;O[K=:*J
MLR,%^P2LA@LZMR)1R4!DC_9.VY*#5(AR#]-XTT+`#`PPPV63UPY'/VCI+.R:
MVN<;+77?M=UK[;1DW,^LMY5?>\3C9[YKGY%5<P$3,.(D6!K(QD*0?AUW"#8E
M@618O\M%-\*X:NT%LZ^]4USG(+CCCCC.,9QZ9QC.,_3C/MQG]SG&-=<>GIC&
M/3U]/3&,>GK]/I]7K]_Z^<\P4\@79N5]9*JJMU`6@O:=7UVOZJ=3XJ<.,-S`
M6$O>REUQ:LR4^(`DR`I0_O#HX4.&Q(/)%HU*R!L(:$EM12C[&WY.A_;<EV)Z
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MUYQOZ8_!ZYQZ_>]><_!;?6G_``R7]OCX+;ZT_P"&2_M\VO/<DG:KK9U)[G=D
MIIV;O2K*(B<BZN;Q@#(;3F@2'!S$BVMZO2N`@U\7=-T7A/Y,'OB&6:&5%\,V
MCAQG3"26^^N_S_TU7B5_^8STZ_CW@W_W+F$ODL\N?C#LSQV=[Z[K_OKU3F,Z
MG?3SLC#X9$H[=,,*'Y/*9)44M#@(^$&MR.S@@6,%'C9@.9-]-UG3M=)%/7.V
M^/32^J#LYUR$5)50DI>M5CR@JLZ_&$A[N8#$7;`@/B`9F^9.D=M_?).6CI%5
MNNEM_?)JI[Z9]NN>7$^VLZQ_J@*C_P!=1?\`;YQMVNZQZX]<]@*D],>GT3,9
MMGVY]/HUVSG/X?3'LQ[<^S&><_;6=8_U0%1_ZZB_[?'VUG6/]4!4?^NHO^WR
MHJ-[;=7@7?+QO3DMV#J$?#:[[=BI7/).\G(5H"A\8TKN:#E)!(R;EPBS$B$W
M[UHTW?O%DF^CARBGOOKE3'-[P9YG/%"2<CQK#R']07A!\NT8LV;:\X2LY<O'
M:J39LV02T(YW467<*IHIZ:XSG93?77'T\DX]?7Z/PX_>SZ9_\^......8<=J
M>C-&]P%@;RU$96Q)":]MZFWY2%2#6.OY32-_BP`:[*<DRJ@\EH\A%DL(K'$S
M.[%(;*12PAN\B<FCKQ9ZNZR4-US`)+$T8%(H1$#T(;H"VJ$/-1D(6BR#8)EO
MD*V1CQ%BZ#IH"/BC7Y,2U9XT8?%F^6N$MD4\ZVPQU.ZNX]?3KC0N/7VY]*;K
M;VY^O/\`@Q[><9ZF=7-OS76^A-OUZ:K7/^V+\ZYZF=6,>OKUPH''IC&<^M-5
MICTQG/IC.?\`!?V8SGV8]?ISSG[4KJU^INH/^)FM/]U^84TSXJ:2K+NEW5[/
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M3<GBNI.S^Z72KM`!B%(Q2$]78WV@!S>I6])Q%5E;CB^H7$8Q%W[YTQ08AFNU
M=O(Z]+-=#(([LYV*;ZC=Q2V'"[C-?[4[JW[?^KC0GLSZ9_Q.5K[,^SV9_P`&
M/9GVX]GX<<?:G=7/3U^UQH3TSZ>F?L-UKZ9]<^F/;\V/OY]F/P\8ZG=7/7/I
MUQH3WV,8QGTINM?7&,^W&,_X,>OIGZ<>O*BBW7JAH.=8RB&4K4D2D@SXS\G2
M",UI"(^;8?'&JS)W\2+"`3,@T^,LW"[5Q\7<I_#MEE4%??HJ;Z;7AXXXXXXX
MXSCUQZ9^_P#N9_<SCVXS]6<>W'WN82U]X_NNM:=A"78^-!3F)@O++PL*/1\B
M6;OX5!+'[+X@7VP-@0L4H,T+#9-;.]<QY61*/SY46+5=2O>("XW\^9A@UD3-
MJ0IFRBB!NPZFK.=F6K!,6V+3.`1&5$VXQ%=PZ2'H/SX8@[28IN73EPFT36U;
MZ+N%U=4L*+*;;4?]J=U>_4XT-_$Y6W^['.GVI?5K/T];J#_B9K7_`'7YQCJ9
MU8SZ>G7"@L^N/7'I35:9]<?7C_!?VX_#RAK0Z/\`6N>5K8<'$430\:*3."S&
M)#I"C3%>[*@GLFC90$U,)Z,P#)UON,7()OM4V[MLLIE#&B:Z6VV%-;2=-_&W
M0?6KJGUXZ_3>KZ,M:74U4$'KB1V2\I6$(.IP8BH9`:0DZZ!H6:*(JF'*2CS=
M-^5?NM=E,Y7=KJYW4VR5^U*ZM?J;J#_B9K3_`'7YQCJ7U9SCUQUOH+./;CUQ
M35:9QZX]F<>R+_>S]//)]J=U>_4XT-_$Y6W^[''VIW5[]3C0W\3E;?[L<ZYZ
MG]6\9SZ]<J$QGT]<^M.5KZ^]Q]_/K&/7TQG/T_1CU_#SG[4[JY[/^KC0GM^C
M_$W6OM]GK[/\&/;[/;^MSQ[]4.K.,;:YZZ4%KGTSCVT[6F,XSG'K[<?-CU^C
MV_K>WF%O3CQ6TGUI+]PRDUAU(VNCV4[F6MV=AS=[2<1;ZU7"["CT&#B:H9[F
MFYW1TRC3B*OWZ3L5H%$*;&=\-`C-35RJYS5^U.ZM^S_JXT)[?H_Q.5K[?UO\
M&.<_:G=7/U.-"?1Z_H-UK]'U_P#LQ]'&O4[JYC&/>]<:%QK]./>TW6OIZ9]O
MKCTC'I[?IY<V#UM7E9L'@JNH)#8$,(/?E)^.A<6`Q1B](?%T6GQYVS`#QS9R
M\^*MT&WQI=)1?X!!%'X3X-+376M>.......61[`=?Z^[)0)I`;#0)IM0L[K:
MTXA(8^\0'2B#V=3\Z!636<]BQ%TS(M&QZ(S.-B2S1(B.*!2:*3H+(!)<"3)#
M'?6BNO-8]>:C'4M7XA;>'-GLT,F-I$LD<*R^3V5*S\ZL>5RUVLV1;ESL[F,J
MD4AD:F&39@N\+.&S,>R%IM6#?UN.IG5S7&N->N%"8QKKC37&*:K7&-=-<8QC
M77TB_LUQC&,8UQ[,8QC&,>SC/4WJYMCTVZX4+G'U9INMLX_>S%^=,]2^K./3
MUZWT%CU^CUIJM,>OIC.<^G^"_M],8SG];&<\8ZE]6<X]<=;Z"SC/T9Q35:9Q
MG]W$7YA5<WBII*S>Z72KL^#A=(1*$]7HWV@!S>I$*0B"C*W7%]0N(Q>+OWSI
MDW8!FNU=O8Z]+-=#($[LXW*[Z#=Q2V'"[C-;[4KJU^INH/\`B9K3_=?G&>I?
M5G'IZ];Z"QZY],>M-5ICUSGZ,8]8O[<Y^K'MYVQU,ZN:_F>M]":_K4U6N/\`
M9%^=OM3NKWZG&AOXG*V_W8XSU.ZNYQG&>N-#9QGV9QFFZV],X^K/^#'.F.I_
M5K/IC'7*@_;CUQC%.5K[<8]GKC&(Q]&/H]GLYSGJ?U;QC.<]<J$QC'TYS3E:
MXQC]?/S8]G[O,)_(9XKJ1[F]3+#Z[5Q$*0HR7S*15&:'6:-I.'O7@)M7%PP2
MR3#%-M'6\9*[ZR<-$W\56V;F&VB2)K=1TF\9ZN&+G-G/4_J[G;;UZY4+G;;;
M??./L.5MG/\`?;9SZ_WT8SMGT]?3USG.?7Z<YSSC'4[JWGZ.N-"9]/I]*<K7
M/_\`K''VIW5OUU_ZN-">N?;K_B;K7US[/IU_P8^KZOO<\J75/K$@JDNCUUHE
M)9!5)=%5.GJX352614U51524TC.NZ:J2NFBB:FFVNZ>^NN^FV-M<9Q?[CCCC
MCCCCCG&V?3&<^N,>SZ<_1C\.?H]F/IS[<>S'TXY`3U'GEO\`>&VO+69N*^[?
MH<GUK[7V/U%HF'P*;$:_C%$U?7<"`'(U?9&.)89QFQ)5:CN1/9^\D5NM9S'F
MT?&,0\7:@H_JKAQ2D@\UDTBLRN(,I2H,E%8P]\I%?U4ZWD!K24$9_P"*JNXQ
M,)N9M)/*/Q(-"KW7=RAM$%XV@^*09!C$'1?>7K399K&;(O/-7VDL&%Z"8M5U
M/UE8C_M%X9X8Q*ZR&43>/MZB\G45A=ED!#[!,(&<;S2&(+F8.3/M1Z8EZ%*_
M.$,(''6#=+F2+[RP]EVD3[765F@*73KGKWWB)>.:.$5K/G6\FF%^'^P]`4U7
MUEF02$&V%1BE6(6X#QR=M,R9Y-?G#%Q(&,ZN1DC4/B_#U([VW'V6\H<2KTV1
M*1"&Q3JIY"JXM&K0Y)T\K"1WWTX\@E9==TKBAR9)+Y3P.D$:(&5A'QY;)`2V
M//HJ4='%X\V.O=@7CD.'EO[`7+61CQ\T96<TD-/Q#N9WHK3KE<UV1/75K+XG
M7QD,;D"L(@LD6:.T8/.;??B4H8#G"">YJ.M,%W$:RR/*,C`N]%^.I%ULJZ\4
M:INN?'K#MUM!JIH.%SXQ,;F4I2U);'9.'8S+&VJ<NMX]$AK%,C=$S'F71XKH
M$K>2+AGZ(G*3$7'U2':NS.Y?A>.=DS=IVS5/:3J'17:6&]@04,D3R"'-.W'6
MZG)O$"^UD-6;-F32TQ)&`2YV4*4RR'_*)T(VD#!\P8.1"]\NB/8\E5?4KH7:
M5TRGN=V%F_>GK9U6F3]P%J"Y.QT2K^SC%3P3-@RJ3S"`1*0C*6B4]D$Z'R-\
MG,GT?AP[</(BL?RS$CC"([#XKVW[28B?<2)/+@L$^AGW0UUDZ'-IKHH.CTIK
M+JI:L@Z=#I?%(@9A`6--8=NZ86!*(D.F3!HSDXY::*&VI[$SV'GM,3;M\OMP
M5GU(HNOI!=<[AME".]#F*3"V5JSM*026V^KE7^4&6=>Q,?!3N*0PE&<20S4%
M>'E+-DRY[YT2EA&&L<`")))+6(.`DZO4&XK9F/DH\LE03.R9+,JUI1UT>7IZ
M+'&X!H/KL?;%&2V<S`0"1!@0:JK8B?RDY4>G\EY$LDV9M2)EXFR;:I2L<<<<
M<<<<<<<<<C[\JW9&U^H7CM[=]DZ/!MSUJU%39^40Q!X-R88B"7QD>+6F)$5[
MQ1$D,@0XB]G!)B\UR/=,HZNB2S@?NZSC#VT+3=]!>@\9[QI7I=G9,_`.M#.:
MR"'S^UR)D%V;G%LI5B,!V*51+)$F]:1V*S":-#J^*CC@6'Q&!GB;+6$NU&,:
MPPM)-?,3>X,OBIHY2=3E+>`=GN_/4Z72$[+IH%K1:7=,^H2G<418D6&BQTAD
M[N,3V%J,(D7B),HB7BTQW(MT)068#]73FTDI\U/8<%#[R[0,JTKE]3U7^(;H
MGY`Q%)O39IG(B4U[8%Y60/1Q[8K0*[W1;Q\6%V`CG:8!5I[QFT).!RKDL\P*
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MS^"A'<#(/P?82;BEBX%8DI*JN4`*_(Q)PV<U[WV<V5$.\?C<BL.['7Z'@?=#
MM%;D4L^-Q.TS4?C25?17J*:.1:,P9K'U6S>.,&DNBC>?_+8W;Y=,'S)7<F6>
MA%F0IE[?NYV_F%?^/;OW"Z>E7;2$]A.EG4^8/]>R=@=<YO`@L]F=<1G85O,(
M-:-G5JK4]G.Y42%KEBY.N7)-1-H27.QXB*Q\2)M\4>YG<+M'`;TEKR#SJ;LO
MM=Z$\.4ZK.O1S\FA'K?D?<?OXI1'8+Y_`VJ2BMD:RFNA[>#"-7:)+>#D-2$@
MB*8J7OERF*<A'E#G/8GOQY`817MY3N(0J!>,:<V-1D!'UG-(TXK*R:QM^V@!
MV;R)O;U9:QD_81P*"@LCV(D`I.'CP<A:UY&',B,Q69%%IP?&K8<TMSQW=$K6
ML>1$9=85F=/>MU@3J5%E-52<DF,RJ"(R*2G7^^FB:>SLJ9(O'R_P2::6%%\X
M23T3QKKC-GCCCCCCCCCCCCD*-FW#:EO>:F$]'9'.9_5_7"ONA!;MHSCU>222
M5T9[$VT4N5K5.[0]8T1<@Y=M!:>CSC8DI`8K)12)F4GF1>::F1;$2,2HRX/(
MU+NE]F':/;MG_8>ONOPGJ[-KBL^<2;+RXI@"[W=ZIGUC@,5K9O'AK.+FBG7S
M+?723$)'LFO,T8^VB&B$;/\`RG)=++&/-5?`V479''=%U0.:Q&/^9Z.UV7:3
M28&G3ZR_$V^C"*1Z8"W0<*V:P>VV\J;Z[``[]T>CSD:LK\X'C=[JV;7#H3R9
M]N)9(:.JPS5M.3)TQ\9?5'R-]@K65EDPCI9_7UGN)D'LN)5U7`6(E612VEDH
M8M(X2S>&8Y`W9!P_CY9Z";:"GR^+)_RT]A+T)^/T.V&-J1/VGV9\/]XFE:KE
MI<Q'9-UC\BD8OTGM0L^R?&-UG\HBKFL%&<J(MFS$3*DL,#D>&1K9@Z9K;5>N
M?777.?ISKC/_`)<[<C[\JW9&U^H7CM[=]DZ/!MSUJU%39^40Q!X-R88B"7QD
M>+6F)$5[Q1$D,@0XB]G!)B\UR/=,HZNB2S@?NZSCT/7N'"ZLJ2@KND_;JX)R
M.8]>2]B6J5LJR'TO"WAJ;@4:G)VVL@3:V[&':Q#U(&@86JA<6@P4#(M@SB+?
M!-H^N-P4Z&=M[N[47QY`^C_96:V+5-A."]>=L.MA6+L)!5MB!>F]V-(JCM7\
M:VE<='FVYVD)O'B]5V#,T!VZ>\LEII6-/-4&(]9M2/CYOZP@\6[O]F+MMSN#
M<@#K-Y-N]G5&/53`8U:?98J8J,#8<`BU1BT:H@H652\J]JG?1TX2F@P.Y.Z!
MS<A7FI4DQT0=C+Z'^V]U[>2":C(5([(>U$Z\*QSN!7_7Z?0A6&KAK@TN[`40
MX.PA[%X_9PN7/P0Y@".Q.;O'IR/$')80S8`UW#QCR*RK?*E>U%4'*U;`NJ>R
M$Y=7C&\=W92&6[.(+8=UB:C[3=H*"[$SRZBZK2$1F2;#8Z5<58%D%>54\T`5
MY'I4LS%-,1:`NCBP_,KJSW"O&R"GN;I\A>E@R&*]K^IM]/\`L@$.-F>B5I6E
M4'4R*%7,JE1(U%F,V*&!EFO)2YRZ1-Z0Z0K(LI(+&OT-QAE?90XXXXXXXXYC
MLQ[7]?B-SOJ!964#7LMA&PTE4'Z?&?D!PF=F\UKME'1TV^!^9A.?I2VO)<-)
MUN/.N)X'U$*O"D>:,U$5]\B?I^CCF/<KZI];9U8KRV992E<G;'*,`PH_+WT8
M89,RH7&EOAXT,F2Z2:24U'1I?.RT=92U(VV!;[[["4F>-\^O@>=2>L+^5V1-
MG]"U0]E5OQ^1Q:T#3R#`W3N>1V8L`@J;!Y/E=GNB693D7&8R+G"*Z6<S4=&8
MZPE.3#4`*29_@8],^H@P<8%,>LE"MA4A>56_.CDJGA6&1E]1C=JSI5V2:9"[
M)/7-0L6+)A6*RVFZD$'M&S&+[#&:":&M1XZO]<\0RS:\3H^JTH+<\F)S>V(F
MA!X^B`L>;&G+%Z5FTS&I,M&TAF)!\+%$',K(Z+2!0@*%D/E'#T:Q7;]X1UBZ
M[UL<A\H@=)UA$I1`(E(H'#90"A8(?)HY#9A(U9C,8T,D"#/4PB'F$R65F,M9
M[/5-)/+5-Y.>^4#NV2'+Z<<M[:-35E=L*+5Q;\!B%EP,YEIN5B4XCXR2@'BX
MYVD0&/%!I5NY;Z$!)%NV)B"*.J1`23:MB(UTU>MT7"=&1SK+0$3<Q(@"J.#,
MR\%D968Q(_N#;O9("EIP'F+&).RDA#+L_B0$XKG,5?&%R2Q!Q%]MHXHXR$VV
M89_$-ZG=9`P2WHV)H&H!@#L"1=F+V#,*^C30;<Y<AHLD3+6JT0'Z(V`3*H.%
MVI8A*M2KLJS5W9D5G+7/P/+JP6!0JL(?':]KF*1^"P2("VX.*0V)B60",1H(
MSU]XR#``8U)N-$"&*7H@Q&,&Z#)DWUT;M4$D--$];6(]4^M;8/:8%K155M!-
MX'6\JN%DTA()LE9TN9K-'+&8SG9!HFK)9B/=#A;H=+2BCB2#W0D0Y8E&ZXH<
MHUJ-2@:/7KV+U,YJ.N7E8PHE$S42K][#@3V'QPW!)`SED+.!X\Z9+#&!N+2L
M>RDX$P@WU)C)&T0.M7295/5WS]D8I*H(584ZMJ(UG!XU:%GI#4+(L()&Q8V9
MSY$)KLF#1F<D:MTRLF2`H[J-@29AT\U"M%56@O#1LJHEM='CCCCCCCCCGJS9
ML-&@Y20R(L,`@08]V6,FC+]H*$"18]#=T^(DR;]9NQ'L&;9-1P[>O%T6S9!/
M=9=5-/3;;%GJ<[*4M?:\O9U?-6IXE!II/H)(A#M@4CQM`Q6LP?0.4D6`:0LQ
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M%RN.@)0/0;'PPTBVK&N:IK.H`Y./57`8A70$S)Y%-2P:%1X9&A9*82\BH8ED
MI?,1+=JV=2&3F%ER\A,+)[D#19PY)$G#EZX674K_`(Y82R.KG7FWI@,L*R:=
M@,OG0D`O$FLP+1]IO)58<Z>8(NX42--\-R!J%.G^,OG,.-.",87=[JN51.RR
MRVZG<YU=ZXR:,V5"I)1=42"&W*]$D+<B)J"1TG%K/>`1@H(&7G\=>,%@\NR+
M"`0(5CH=9/4FP<""%)::CPPQLU\Q+K-UY,$JA,EJ4K`F7Z_(MT*)*$(6">$:
M:2:L41:&*M>N&:CB!;:"6Z`?X2,*#%-PZ*8I3?<=IJVQ75C5G7MP0L_7%JPF
M+6/7TK9[C93!YN$'R:)248IGU6%R".ET'0DT,<?0Y'$FCEDYU_O%T%-?9RA7
MG6?KZ1.5E)7]-5P\/4TQ'BZM+.8D(7?006'<(O`8V-KJ-]MA[``_;-2<>9Z^
M^;1\LT:E@B0\DV0=IU!(:/IV6'I1*I+5\".RB;U\VJ:8R8K%@[V0RFK690J;
M:UQ(#:S78F6@K<N=.$DHF^=+`M'IDLYPQ^$)/=E_?5Y7,!J2%QVN*NAL9KRO
MH@/3$1.$0P*PCD3C`A';;9N(CT?%(-A842U]]G5H,&MFS%HGZ)-D$D]==,5I
MQQQQQQQQQRQ5Q]E*7H1>(,[0FK4"2G,T@,$CHAHP*2$TN7LJ8L8'%R+\-'F9
M,H%B&\H(LQIJ=F6C&&1G*V'$A.#&^-E<7A"&PTE#BY#'2PP\!.#VA8,:#/VA
M406%D$-'3$B,)L%G#$@P>-E$W#1ZS76;.4%-%D%5$]]=L^TY9BV.O5(W@\B1
M*V*RB$W-0)X0?P61&1">\GA;HRTP/-*124,\M9%'-3C#75B<1$%&3<RR33;%
M4G:"*>FGH7_4_K*1D5;2Q[0]3K2.GVHQC69?YB@-'D+9`C>LGC[,'LBQT3;-
M8Y*M-99'&ZB:R4>E>GSI"Z,#^-B7/6BNFW4D(:VD`GK318\[OM:6ZA=O5<.3
M(*J7CA+%UJ*/,A\JK*6_E%OM:.^^^^T_4;-U)9DMNW1V3JR!=;NOU62-E,*T
MI6K8!*AM<A*@'2*&P:.1LRQJB-.]B$=K1H1$#VCE"!`2"BI`-$4U-0(P@NX?
M,V*+MRX65H6.](>H$38,Q<=ZSTB)'#9_%+3$LV=<1C1N$L.`H/6E?R\$GL/W
MP#-U^S)DF<!=",LL0AF2(-(JF(;OG:2V4O\`S^_QS\A`>Q+,7HLFS:D1I%HX
M8D![YNB\9/F3Q'=N[9O&CC15NZ:NFZBB#ELNFHBNBINDJGNGOMKG&6.=(^H\
M3BD@@8#KK40^#2>/JQ`Q"M84)<1%6&."J)QQ"6<:>(N0PB$+F&S0DO#0S(=&
M%GC-DNJ)WW9M<HW%4Z_4>O:H2]'%2UZYNJ-1-:!1ZW7,4#N;,!P=RFJFZAPF
M<KM5)*PB[O*ZJ[L`V))BW3M39\X:JO,_&.?JJFBZ9HIA(Q5,59`:J&2^3$9K
M*Q]?14/$F4EF9C.NQF7GFP1JS1+RDUMHGN9D+_1<P64334(O'*B>FVOEVI*H
M-[92OC>LX/O=;>,*PE"V-HV+VL1&%K+X=K0Y*7Y;Y.)Q15]C!%2.:/<!MR>,
M$MF67^,.<>F@?7"A*O`3&*UY3U<PV-6"JZWFP".Q$,+#2A)V.5#*,#0ULUT:
M/A*89=<.T"JI?(X\2LJ-'L&K%51#;\R?63KLB1IPLA1]5-R77<*A'*#>MH+'
M6SBE(^V%(`4PE4*(,$\U\)R`;-@"PZ*_);1P";-@SA)48W1:Z7SXXXXXXXYQ
MG'KCT_>^_P"F?O9]OU9]O(JHUXE.OD7[GJ=T!Z8#64J6K,K/TK[2FJ6;P%B2
MD\%#"&)8*S0AFKX!:@:RDIC;SOL`%<,;LF!NPY/$YE,C4(P-#M+%^77NWV!Z
MI69U=KZF;1JNHPEX5'WYE4FF=GP9A+T0TFZM]=4;NK=,/N2DT=&M6\A/-%XY
M*&3](JJ0C[M?Y"U%G$6A#3W]7]A_*7<D3HJVQ%'Q.(0JVJQZ]64=BQ2%P18I
M$%;"KF`2JQXTX6EG:^!31-2.'C,H&-TC4`$'F*#-NU7&DG;;#HC&1T?[,D>O
MU^"KP[+V8[@@4-4_E:D'D@D,L(DW+2(3&,>4T97W4@E9HAC\>=B9`PKTN_@M
M,-VXW=?>H<;,8RRVA0ANNPPO[467W9$&N[AFF#%CZ]AU3_GY&79K&B!+:>`N
ML,%$]<L]1#N[5!]J3$B8C`'<.===#`O75X-0ETD(5]CY2E,K<NKOW[==OP1Y
M8U3T[+(]&^@Y+R)]JSL!/G#4F0Z^3&*=?/&?7W8>&=3MYG"Y=$W`>@KG[/B+
M$9&A`&5,1,BD,;EL!2:RM@ZD<#,[:W5.>NK4ZP=<K.?5K]AE]8U$5%/'M0Y;
M)L\U8[F$`C\A<UUEHFQ%Z-?F6L1WCV&^!8O9#4?A/<:PWUV:I7]XXXXXXXXX
MXXXXXXXXXXY2,_@\9LR#R^O)F"C\HB4XC)R)R6.2R.A9=&#H.0#7`LF*D$6D
M;,C'Y&&?-7*B!$&;8/1)5KLJR(M7#195+?`3H1XRZAZ"DIR;@IGYZR*?1"M(
MX4E4CKJKPDO8NHB'6TFN!$MB,8$R)A!+$F"FD^0IM(EBJJN._&F=51B+AGSA
MCF-B]O)EVYKOR3VAUUA9VKI)`JW[C^.6B`%+;5_JM9]@5QW?I^<';/E6LI1E
M*;_5Q19>,)V&**CX^."-HF'D[&?.70W")8;^WO39OEV9=$^ZQ`E#4(LY']3;
MI?B))644@06=B##6-I[K$HF3A/:RTI0.,-(]F1O&#H-#R#]JL@FX8/Q;]%F0
M3LV4[*.ZGZM^9"D>O]EJAC<VDG<QWXLHY`B+XB^/QVGNC-%3V]&_6M^&V=M?
MDJL+'EDH-A&P-TCEG/")]A$,$#;!VP8XXWC/ST+Z/>2%Q5U@EXGUG@_>?Q0(
M]8Y%"+&+`HGLA-HAX_L]IXG&S`62-4Y#`US4BF9.>Q5YL0BJ4O.S\T39[R),
M\\9;ES55-P@FNBKHLBMC*R*R6^JB2J*NV5$54E-,[:*)*)[:;I[Z9SIOIMKM
MKG.N<9YY^....................1K=]_&74/?HE!CDY,_,J0P&(67'!<JC
ME=U>;E[YS+A".D*U,2V71@M(B$$KN8)[SY>FUB6:JM$[\69VI&)0&9-V./>=
MZ;`/=$O&EV&LCKF(@$1,]5^LLAD]5QO6""6%:C$ZIC*+D+&4J_BRD8#"(FJQ
M%Y$(`HWN%9A&"^B071HFS;)8P`HGN%Y&;G<=CHC4F:RO=&C>P$/B@JZ8Y6\)
M8Q&8PRS^KU-WLM%V[<UV%K>,J2*GYW8!ZORY".2.2D'8O0`VE`H:>8D#1Z/7
MR#V!WN^S,6<V"W)QOL(!ZB]53G3..1Q,6#:/.S)GRMPR+6$E6@6/V;9<=(S@
M_4?V(XG8S<?,B+UY5<B>AY"W#Q&2R8<X]_Y8NRLJN&UY?8G66QB$RBT:Z$6@
MATL-Q!Z1;-7OD5JGR44A5$U`5XDI@<X*6\&1&12!+-&J&S\E74JD;$0Y>P"<
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M./K]G/1"P0,6V%MA@82-;"T7:0QN/',V2`U)WMC9TD.1;(I)L4W.V,;N$VNJ
M6BV^/?JXVV]O.K2/@&@QL,:`PS4:V6=+-AS86Q08-E7:SE5VJW9I(:-D%'2K
MERJYW22TV75<.%%<[[K*[;>[23322322TT2233T3333UUT333TUQKIIIIKC&
MNFFFN,:ZZZXQKKKC&,8QC&,<\G''''''''''''''''''''',"O*%&@LSZ`=I
MH=)&FY".2^L'D2D0]-X^'[$8])BPD*=&Y>C'+,@UT("WKIFHNR=MG:::VVR"
MZ2GO=\9+4`/'CJ3JI,<P9#TG-?0Y^NBP:-V2*KU]'1KEZ[W1;)I)9<O'*BCA
MTM[SX1PX4466VW5WVVS<M\+&/G@IZ]','CP2Z5="G;IFW<.1CI9HNS6<CEUD
M]U6+A9FNNT57:[I*J-5E6^^^R*F^FWYE00-;(O*P82KD63<%A>5!S/?Y-*N/
MCOQ@F/\`?(Y^)$5\/GV%GS;X)TKAZ[PHKMARO[_V+=FT;J;;-VK9#;U4SG9%
L!)+;.5-_?J9SLGIKG/O]\YWW]<Y]]OGWVWKM[>?LXXXXXXXXXXXXXXXY_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g16194.jpg
<DESCRIPTION>G16194.JPG
<TEXT>
begin 644 g16194.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!`1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?0T%47TU54T-,15]+7T)!4BY%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$)`04!`1$`_\0`'P`!``(!!0$!
M`0````````````@)"@$$!@<+`P4"_\0`91````4$`0$`"@D.!PH*"P```P0%
M!@<``0(("1$*$A,A,3@Y>+2W%!4S-5%Q=+&X%A<8-$%8<W9Y@9BRMM<9&B)6
M89&7)"924Y.AP='2UB,G*#)9<G62E>$V-T-(:(*4EK78\/_:``@!`0``/P#/
MXI7Y:XI"HR*KJX"4IKHR6F'U`%$1`R@JRKBDB@QD)+20CYQ/("*2@(%B3(X'
M3Y$G<T,%8T<*@=T'#I.9_+=*3`D??YE;MZC_`%@D31[6I$VS//N*IA*3ZU''
M'+E).`V@1\L*_P!1,>E&U-JU]32F$@M+*YD@O#$%L8@=L@)J6XW+P$'G>8<<
M1K/3OV0BS!D.B*-!H'Y%6LT&*\<G7B]XFV(R`06G'%UA:06]BER2V)+5FI';
MA4O81AK*EW8CNE+L3+8*"(4G%IKOOGL3.6Q^K4C,Q&8,]:V-K7V0G"2:SD.N
MEE.J/=DHT)2&TE9LJ:LCH"UBHM%2$5V(\"1Y,Q`$.IR,Y4TP&2=6"*AV0=?C
M_JO_`*JUK$M[+(W@VPTBU]U-=6J,Y/>#G`]9H?:`ZU1DF$XN9749-CT)2(IQ
MZZBG*(>9<LH"9&PL<0\+V&_E7O>]L;XX,G\8#YDO^D#GO_Q%J_[JU,[CEYPN
M6"6>0+2&+Y%WCFMV,"1=M->F.]VLJGFWFF.1INJ56NB.%"4,2[;+C9$E5*/&
MB1JP0P8EP!L[89X9]KGCZP+G<B.SFTX':X3H:<@MA%5W"MJ`ULKA$$=#(&51
M3.BVQM?*X90@4,&,L<;=;XAWM;I>_6JL-6YFW$W5U)(;IL!U,F)%2;60Z9"U
M@@)SL),=#23&.>LMXPT).SP#5R;S7'>^4TJC.ATF(]7V6V66$X@6^GH[MNWS
MBXXY0N[>&$XJ&Q3966E-N9MA>C2/YA>1!N+SABN%9/E%/;P[39DIR4C)@K99
M9M7-NEM!74584NBH1=W,I0=Y]L)SS;)A3X8<Y-M1R,MG(8,NQ^@NA(V02]27
M(L#0G,0$?M*?W(AM9;93!=LCCLD)F-P>0<7FW4V/EA36`4)Z*RD7)M]2.ACE
M3)CJYG<MFNRBTY(?$BH$M16W6AN\OZ)->ZS$<G.%6?,MI;@Q9R*6(IC3:*SF
M0,.UV$UE-14DP+DH!?WND5,(DYG,GMZNZ%KD5UD;C93WJX5M^-UF!)<8JDB.
M=Q1-(R`G0,',10@=CTGL.76&Z25X25%,JK(YY;3'ZF)1QBHJVA.:00FHUEQ)
M7#O'=8)UE9_[H<D,*OE>25=CZ\R'K>FQ.3(-I/0SJ&@2KKL@26OIJPI%11SC
ME.8.-1,W"53XN&6!3$$L7*%@@\K"6%4I2E*4I2E*4I2E==RXYGTS(OD%VQC&
MP\Q2(VF>X%QDQ26=B$Q#,BNA,3AS:*RR[S<^&;=:X[B/!`I@*ZN8W2DP0QB:
M/7L7#$RMC.2'Q//;<N3M]=@X\B:2-(2>\G'*^X)EZ&YK<R"<O(.Z"^\DMT,:
M451OQ\^9(;Q)OQN3:)!N+KT)**?DXPW#<RRF[8D,\\U6+\H\*.U.Y$:;&K#D
M9!F%WP#PUZ=:$1<SGXOM7/-Y[$P$]&7-4@C8J;7<*VF$(\!=T6-J-V\]E$R"
MFN(5S*;I3R@S<1@CI^X'CRT[EYN;[;J[XRHREV*46;86T\@*+H^=9MOC/,4O
M"$1-TE*KK<9)MK"^G)*=E(17%IL_"ZJ*:6RC=6W.&!9NJ[9/J<3.R!-5W;$^
MJ6Y/(S$V\O(G%,L,MMQBN->*HUV\?C)UO13@#OC",3(:=$3?`(EB1561C9Y7
M602JV#[8N@\=6QLNZ&10;Y-B;EEDGDLL\\L\[E"M\L\\KY9YY7+AWRRSROW\
MLLKWOEEE?OWO>][]^]8FW99FDFUV[.ONIC6U4@Q]SDX&7-+[7G4E,4B4/&D)
M&4H\"32*B?Q.'B.`18RH!Y%`L[9Y=1OY%^E[X6RP7_X`?F-_Z/G83_P)!_WC
MJ9_''PC<K<4<@>C\GR)HU.;28,>;:Z\O9[.E71D4)+;;3:TJM9;<"ZHB`KPX
M@9%*2R1HZ;SP"SRP`!$RQPSRMCAEZQCC;J,[F\NM5QIX"LWW*D*J`N)9FXEB
MZDC+1$RF*A`>X688M@3I`V8+"W#SPSM@+E?#*V5K7JN#377':/32!&WITAJ$
M6R3%</IBDR(%G5Q.AR)#_2XIP4S8S$;4I1048YM%<#NC1OG06L"XFG(B0AR$
M40DQ2/(K",F3Q3'I.2..:87:VN0C6H-S,1?UKY"I"`D]<?SC5%<O+D,JKV9$
M5Q[.S>36<2:8K8?("X1B\!X1,OAN]HW9+F<9A*5T,VB-=)'5/RGUQW;$N6^Q
MV:>KPWAG,/+3JKR`MVQQX/8#%/C+7?'5S!49BUW",C/<7ZX\=;;XIV!'$^VR
MGU8AY'%S.Z`)98_-5^-W8PLG+C=0''"JNC8<R2#R7-PZJN!]MY4,QZ))>$J.
MF/5LJ48+D*%'L64LA&PWC">;/-\^2`P<2HHI@QG)O%>QI:T'FMUC<DL.M]PQ
MVK:\<F0!97=#A=2DO`R)`#K<\',?7"7K(#3+MI21Y,1EN/H];CNC?(P]64.T
M7Z&>2U<F?;XY97*R.UAU6>T&[1;NR\K'FJ8C_8Q8UP,1NG)BVNJKM14N#(%0
MH8.@O0-3;B6G!G5<5##6B0J2L+>-RYC(`\($:PRS$GS2E*4I2E*6OUMU[_?^
M&U[7_JOTO;\]J4I2E*5I:UL;=+6M:WP6M:UOZK4M:UO!:UN_U[UNG?OX;][[
MM+6M:W2UK6M\%K=+?YJI`[)"\B?OC^(<=>O:*:NR3/>XC\C*>CA5N\[87M;M
M\;96^YUP[?I^;I?I7\=H#_BL?\C?_8K6V`-KVO8+&U[7MTOW+ITO]R_7M;=.
MGP_<KZUIVV-NO7*W>O:U^_;O7OX+7^"]_N?#6O\`_?U^"OYRRQQZ=MECCU\'
M;7M;KT\/3K?OTQSPR_YN6.7>Z_R<K7[WP]Z_@K6][6Z=;VMU[UNM_#?X+?#2
M][6\-[6^._PWM:W]=[VM\=[6K6][6\-[6ZWZ6Z_=O\'QUIUMUZ=;=>G7IU[_
M`$\'7IX>G7[M:TI2E*5&/<<*>[ZW2@?UB7%M%G)OHQ5UL$LW6>P'RL.]1:JJ
M0<!J-B2%)[D9[*#SDY,3SC"%7E9T(.;6`<`KD35,LJI9+*\5^*F)=OH7A%S1
M[MN[EM74F*[0H\C1N*8"6N)B:QF4CE2^#T;$KG'[($IRHAR>H*0KANK30>1'
MTW58DJ-D)MD6\12#:A:)2E*4I2E*H_[)"\B?OC^(<=>O:*:NR3/>XC\C*>CA
M50?S1,5G2A-7'BP9$;B>\64JNK:]44FNLB'[HQ]10-?L#B(=-E2)TE<P.E&Q
M!#)'(43/$`;/(3''M^_:O+[!G3O[W",O_I%__>"N#N[5[7>)W1KB^XTAUFL9
MY).[>BI5,<S=Q7":L2++FW$/H:P7`&$6QP^X*:.H'DP\"("(&8)&S``F-\!+
MVK,1D%YI\<L)ZR`K`F#*4QVFYG@I%RF-LC0Z>V$5073H);&_>R,"E4\4,"U[
M7M<7+#K:]NMJJ>T62IOW:T(9.U\BS[)["V&VVC%4EQDJ,:/1728TUT2)$`53
ML2LIB13G?./G62CULF&YBXEV4&R]W8]7-@X%-36P2QA&3D/Y<IVRFQ$'PPV&
MSKF]&<6V'CIF7V[D)/4E(HG8R)#6K*PS'%),1MTNJF_9H"WL:M&PXV;MQ,3Q
MO-!R>F(`0I\IB:*RQ>AQN;20;'6T$633*"/&"KKZ\)681.-'HKL,@^@9,83>
M=<>.QU&VZ;+*YT5FI9(WFD-_,\&FXJC@4!5DL>S(%RV$?..YQX)&E.F>X,^[
M//;(Y,^E6NJS*(LX2\%G'RS*DC,QG/@P^$^[U42B0TW.J*2DNH]DMNCIJ0HI
MYXJ4+HX8J47SS_:WWF%WHB_QF.^%IE64YDRWR"0I'#M+,%:;9]ERS&#ZC69%
MX<@K+1-/4CRJABGVJB*)"S><9!*4.Y9>V02L7S"P"A;M5L[/BLXN:Z0&7)[K
MCW+BB@B)W%`;<;BL=(-)RR@G:[&-PY*<,KM@#/%/DQ"?R.HLV',&^Z\SR0WV
MH0<RFV4MOO!8P=N/[FX._#L>:IHXNPQ*I:)8XRWAT,:<UAI[Q;8;BD$W-JL2
M5GQ!JSW%1N>2&+&;26TDW*ASN`=W&[E1)9.9DF1:;[(GIK.1^R6F<N4'1D#)
M;P&B-[\?.SLA*44"#HP;'`?T=3]JBV&^]2Q<DC%5HVO^T$BN9-%'6EQ7*%BQ
MS+!')I=AC=S5F%*4I2MDI*))(3SRJI&0R:>FDS1\\;&O>P)8F2`$-&C`M[6R
MO8,`N$(+G>UKWMCA?I:]^]517\/OPY7M:]^077OI>UK],EU>M?I>UKVZXW;E
MKVOTO;O7M:]O!>W6M<>?;ASRO:V/(+KUUROTM;V]7;7O>]^G@NW+7ZW_`*:L
MWAZ88SGZ,V9,D./%'D&,9"107$RWF@"#BHSA13`HP`*BGB&0"IC(#,8N.';N
MI<'.V86=LL+=*[*I2E*_&<3A0VBWUQU.94)(;;;*.IN!P+:D/@534=$12(ZD
MK*J@:$O8,L13R!8P;-F!+VP!`!$$ROTQJN?4WEPTFW*DR9X<BI\O-NR=!3:"
M?[X9,TQ3(4&N2T6F0B`Y24TM'D]";JB98Q@LK))S,^=+)JH03UA$455&3T];
M2C)SAD"\V''UL6CSJZ6%)CX3&1K;%JA,LQ/R1(4EJ-&:U8_(#"!8*H2Z\VFE
M`KYQ5P`-&$!";H2HNKX)8:Z2GFQ>YA"3%UUVZA_9I2DAM,(VX4A_1`,P;2;&
MKY;YAJOUF$)79)"1XN6UA#'&-X61'^R5(%:;Z@4.F@\3)1<;2O@E.]L.9OI%
M;W9(7D3]\?Q#CKU[135V29[W$?D93T<*JG>376/9.;'UJ5)VN3+CN0E&#7%.
M0CL:<@2J:B+`VDRK%6+'35!'<1>.Y)#,F4M3#L.<3AT8OW8IGVP1W#/'M,H.
M?8T\G/WI&NWZ<QS_`/4ROR36E'(S)#JA=*=VO<`1^T6OLKK)+#L=A#;D^^E)
M,:\+3RP)7<`:6T@];6I=<55%):)M-3">;B20;GC0`@YO$+#/'+)A,E2QTL8)
MG"X!LH:!&+F2ID$,P6,ES&&80Y<P`+CD$,`,%GF$,$)CE@('GF'G:^.5[7@+
MKKI0ZM4X]-Z]PE.Y]"UB3%%=$BQAKS"*..3X3;+F7U!R'HZCR8!763)G6$WC
MRLI$H]`D*-GN[V:A#ET:[P6RJ2BW3NTFIJRCDI@F*5I!5$"5,I`(QJVV&C.]
MAIRD9BEBQFB*9%,9B<Y5Q9<2LY2"FXE]ROA845+`@JG'0YED80SF2R32:;U?
MJSI*MZMZK//5)O3%9Q,TPI2S:(3:A'11/PAIFRJNN-Q81ND)11XCXN)EQZ>=
M*FGQR24E(D>0VT"EMPX>4TU*)8!<TAC2>*F-IW!>F<QM]@[+1S!4;QI&B-A+
M$6M);2%]-B-!3VVQUU<9;@LZVW]5">GI94814)A!!V4^['4XJF]U[AA^=/VE
MC;EE+U&;<?+*!![-U#V#CF?&2S&;'")FV#@D8MMVM1N1^41$Y5;"4TV7BD/5
M9#%+-\C@;+B!)7M8(0`*&2Y[K38/C?:4XN;9$RGR.NQ^QMUX]C"+=P&8E(H"
MH;E!I19FH(Z>89KF,+!+.,W4\8S652')#<'M,[PUF/,42Z"EM=X-Y.=--EN*
M32_9-1CM>6(%@UKNAF;!1-.[C=21`\3G'))EHQ7;+!M@/I;/-O%36FH^`,0D
MET8*!L^(;3P0@Q03-L>UKN]>U=-K.ZD7[?@R%D1M&>O<HZ\EXVQ:!0<BK-^5
MWM&S]7EP=TW703Q)6(K<3,X%(`+(^:>"EXK!4R":,*!<XG2YI2E*@[R/;#21
MJOIS*LW1"`S!Y';2G$R"U;R$BK+C9I8]),U1S%XZBNH+?<;06%8JEI[T.*01
M`BY484P;*%P\CP85Q+955*>VW)T8Q44H]+NBI\D+[-3C98WIS-@Y8X5S[J4,
M`&"XNY^80H!D&^88P(F.6`@0F8>=LL<KVO7DY]63+F:[C:UM8^%!O8.)MKK;
MQ7&SQ1C)3A0<5M'.(^*RW5''9P6R:NHUCEE%#/6!%Q(JA0F9[B+B#W/+I_5W
MC\-:P0:R(0PB_BHGNS)]O^UEG8_C1'DF9W3=><BLY.KP>OV2"5=9NC75?:-"
MO[``]@-].3$__A/8O=<[/F#L)R#1.S&]'46N[COC>/F@FA([38K$T=EIIM!L
M(X&8@@"4WVXB;CDDE'3@<Q1<PB1`J`7#S$$RQ#M?/+K9MQG[.SULBV-E2&PQ
MN*E5Z05L?G$*<OQ"QG5';;7FV9@R$Y9)G3C8=TB2>I%EDLH2>II1DP"Y\B9H
MHG$A@R)47(;NEF%*4KBC[<;19[+=CL?R@E)+';#=67"[E5<QPR1DQMHJ>84E
MI05,1`Q<+D"2>6,&3-KA"7R"#RQP#$SRQPRQ(X/VQXY-\9OY,=H'NZMB&HXY
M0TKD"*'PXF7!TJLQ<UKX^(M4`6Z?6`7.J1>H*+RG2>'&ZKO=13X_1I$46NUB
MK6:J6G6S8#H<*O&#9C6G9AT:"<@<-:.[Q31R8<?TJ:+,N<XG69'>WU[);B*3
MXPV!BQS'X-:S^(%R"NYB3^@9MR(J91@*G$G(U1&HF()]CD5Q:3C;LMHXO6HY
MGORO<CVSS/-W6==W'K/QX1&@O=,&R,L]\R<UX&;CE<1!!4@<KD5A0CA&5`$]
MSW+W%R;ZF[@T(T(75L%4@5Z5[)+:G(C?17>MRE)>U8#T7LT8IS-Q<8B.1,]C
M1$S"0HB*J8)>3L'P&Q0SHT@XBJQ0<1GC@@M;+%($`R4L?;+#*92^OM:0Z]+W
M]A%.M[6Z6Z^Q@NO2U^_:W7[EZW]*4I2E*4I2E*4I55_--Y.6:/Q\U9^EU`U5
M]*'O@H?+SOI0M;2E:9>"_P`5_FJ8O#Q[MR'>?(0^ACJ+5SE*A'M]O&S]3PV\
MW$Z(Y[V:FQZ%#2DSM?-7XX-R=*!]`)'`DPZ]G/U-I+2C2.4]5,EDPT^I%<K<
M1C:EF*E-_P!OE@L:30(G0IRSN1>>"`TMLN/;=W1U-=JT2;[=EV7F&@O.`P%M
M74B2*WD1]RI&*PNEXK/N594"J6BJ<A(:&RC"@,6(#O$J=.DBYBXSO96^Y>W^
MFU_\U[7M\=KV^&M.TQO:]K];VO:]KVOEE>U[7\-N_>_A_P#*OF"6`+A]R`!#
M!#ZY9=H#AB%A;+/*^>>5L0[8XXY9YWOGEEC:V66=^VO>^7?K^2Q4L3"L`4`!
M+`VR$SL"`%@"%;,83,87.P8>..&.0HP@@HN5L;7$%SS$SOEGGEE>D?LD+R)^
M^/XAQUZ]HIJ[),][B/R,IZ.%6^I2E*4I2E*4K2^6./\`SLK8_'>UOGJOCD0W
M>?FCD9L=_P`>Z<[&;I*;O?UF6=8NM3:-NEU-4A]32VOW=Z\4)(RWD6;UC*2"
MAW-"@EPO;-4(@V,7$%#!%H[D/LH!\Q(HQ^D2GPT<C,<*DKNXLP(Q3GTU0&H>
MD-\G,BN)1G,DJMM0D,Z'0:R/$L2Z$C8'%,;(X5Q#+97,!6SEAKWSB[`3=.D2
MP\X>&/DEA=$DN0&ZR5:5Y*C%73&#'1%<.V*&7>\5$1F%`2#>0\+W-*AD<X3"
M"`PRZF,,[X8YS*YI,\<^.69^URM>]WWJS?I:]KWM_P`KJ!O#:W?^[T^.J_%#
MWP4/EYWTH6MI2M,O!?XK_-4Q>'CW;D.\^0A]#'46KG*57=RB.-]1GI7.4G1$
M]'-#C\0@XJ5%F;X^C`Q+KSC-@-67&BK/5_"1<E#IZI*Z$PF,,\5E:CZZB$76
M6R8<I(3H2.*(1C%_<G)?-LJ(&B#'>&]LX.V%521MN)+D+<1H:E.73\YL)#4>
MZYI1C7)9?T>GVV]&`<C)?W$<I_7%:;^((3.FTX10$=4:Y(PN)IY2S;F>>6%-
MJ-E1<"9@BKI]OHIU:1P\,PPTI6-)90PIIN`8@@V>&!`\(8*8X9BBY88@VQR$
MSO:^5^1TI5'_`&2%Y$_?'\0XZ]>T4U=DF>]Q'Y&4]'"K?4I2E*4I2E*5BZ]E
M3;U[8Z%:@:\R-J/,JW"ST>&RV#)<JZA(S26C"JULHI?J]=(&+N]O.(B$#[;I
M*<>[L6*@FNZ%<,+#V"R$#SP4/XR#S8W_`/?VD/\`^PX0M\T75'6=>8_DKV7<
M$).J<=J7;(#@URDY,F6%E-1:D8IX[$DM'%3QTQU$,4)C)(*@:)BI9',(DNA*
MJ5VP-^W(9=U'L)(G^,@\V/7K]GM(G?O>_P#Z!PATZWOUOWOK7=+6Z_<Z=/N=
M.E<B9/-]RG;5R3#^ONP.WKSDJ'I+G."$I\,A59\4)Q%?3TV96(XB1<<\WX_1
MUHK8!91DT[B(GJ907/(M8$03,L*."+G@G+WN=.WOW[W.F[WO_3<P+>];:E:9
M>"_Q7^:IB\/'NW(=Y\A#Z&.HM7.4JM3E_F5VZ_\`'7L;+#(FX_KJXFRG1\"!
M+R&S"LANYL)KAEEAMAPEH_99_+$@X)+<C=655L1R24!"B?=YK"**?54,H&,M
MIU('!SM"+-VZKF:7\)SO3NT7(:\R.N#1IM!JX)`+%;=RC^B4B`]T9;L\%;!Q
M.@G=0S0R:*,DB9%TM<5E$,V1R+W".Y=5==,*8(GE09T%XQDZ/9%,,A:$;;S`
M8CU;+P&:+B!N)B,@.<)N*BEF@+85P1;")2KB4/XW#$M<OU#SMCO6A)L<R"GJ
MRLPW\RWLEH"@:25Q2:+J07*01E8B%@.=2U4XBJ!TLG*),$0,8T2."@F``L\!
M1`\0\L<[[AD2$PI,1;N..7LT7\WL3IA.NO,IR(SJ1;*!.P=S9'VT03I\C[,*
M=V"]DE>[]W`L*'<0/'$0.^5-_9(7D3]\?Q#CKU[135V29[W$?D93T<*M]2E*
M4I2E*4I6&!V;'XA.JGG?A>I*3J\T:E*D/J+XUNLOG!PMZRVQ7J,G/MPY\L-^
MD"5MZ5IEX+_%?YJF+P\>[<AWGR$/H8ZBU<Y2JQN2IU1+(43.C31Z[5HNDDDS
MNB-!5AR<WQ[0H9`1=9<FMITJ(<1K;Q7FNV'/+K1^IHBH@M$DY4UYH0*XA/=)
M`S(DA5,A`#5=,QTHG=+D#9+G-4M^OJ[:BU%$4ZT.#ZUHS[<TH/AUL?-OJ$3,
MJ-'^ZW.]'3;%%/-TP2"0O:Q%1E]0<"PJH:(EJI\+(6=3;2WJU'$TES`[[3.I
M!56ZKA$%`XDJ-TQ;(&$Q1!)JR68+**8;$*&AP@%),.%CQ,3+$T1.`#AA#X84
MTN05`\.!<VFZW'6IQ)!316^.*2M;H6A&`W&VD*TC91`$0$V;VY08W9!TD793
M=990ABR(U=8`()]RK2*^I5`#L7=S;6W9!K<5_P`[1=%6U38@2RHB,)S=C)\9
MYB1PFT$(03\0`I8CF+O9YJQ`8J#D=QA!ZR\V@Q!,!Q\6ADL%L,;)R?GB%D0<
M::R\DGF4Y/X]0RXA6(`]4>,=VJ:43+V`0461\->DAI(0Q(H#D&235%:8B2;3
M#=RQ7$4^CLQ`*C"6*M].!#Z9[)+V>V-!T4WKUY!T-F4U`XK1BDJ+N;A(T-AQ
M24+&Y"B-R&E$1B"NC"51`$YPB9L4<$!NC&15@/-2!!NB?W=AE+I=[W32%[VO
M:]R12][7Z=;7]C!=;7Z=[K;^CO5OZ4I2E;)144]'3SRJJG2B:F)A,TH**@?,
M`E"1$B2`$-'#ALT8S#`+%2I8(4P8,#"8!`@AYBB9XX8996B3!F^FJVQC^=4;
M13+S-<3F0U#/!K`@.=KBE9F:I=B1^_E*4(',$5T]>78E14^2FVB+<C-`(ZVD
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M8>"`KMAQ)N)U03KJ*&O$#"6K$+GDHV04BN)P@:,%LQR)TJ:P#%RN"8"SZ9VA
M7KEQ<\?6I+B=CLUTU-AV*7`^F0HQL\%)N-T805QL)7.D5!6:2L$L'U4J<0E0
MVFD!%(@(7N">Q*``FK"@!V"KL^/-(]4XL9\A,%EPBS";.E9@MZ)Y#0%@!1=Y
M!U1,T&JHL=GQ*I8O%07Q;Q0S6<L*[79T9EQ0&.U$)64TQOH2>64#>`W.H5UQ
MA;7@JYBT0L4BU!GH>0%%WK`BBNN-SN@PTVDBL)I8N%W.Q57G2LE&BQVX@LYI
M)R@L&$]KM9(3T%!*IZ:6P+U5;V2%CC_`H[Y9=K;K=AQUUOTMUO\`\>T4^&_A
M^Y;^JU79IGO<1^1E/1PJWU*4I2OD.`$9!%+CAAC`#89!#`BX8"!#!"6O@*"*
M&)CE@($+A?(,3#/&^.>&66-[=+U7WJAQKP-I[*#YER,5=\*;LDE$4DYZY.L*
M.!"2TL*,D/%^V>(8;7CMK&D1P$D1T),2$RK>.)+6O$\<QJWSC;-JS5"<!FPF
ME*4K#`[-C\0G53SOPO4E)U>:-2E2'U%\:W67S@X6]9;8KU&3GVX<^6&_2!*V
M]*TR\%_BO\U3%X>/=N0[SY"'T,=1:N<I5>_*2J-U%TKDA1<2D[T"X+O@T!M.
MYBR0S(?<C!?IZ=HW3X^D<I*$D(KACID%8\>1I%>:JMOI&/M<))1#Q=2+#7,`
MAY47<%:KJ@:F-EMC6&,MG"$"LMN[@I<![)RR[(6<B)O)(I20H;(;6;2.I"36
M4D3X4<F2@)&[!CV0%99^M*99P*@QKH3;DC!32<\MFE*51_V2%Y$_?'\0XZ]>
MT4U=DF>]Q'Y&4]'"K?4I2OD.,&7!%'&R[0($,047/I>_:AA89"9Y=,;7ROVN
M&-[]+6O>_3I:U[]ZJG4CFST!<2.G.!MNG89?0EH@75$-<1M']U%1&64PZ%8<
M@II2F1@08FHIIX#+`P3/%!A2QHOG@.`+F%GCG>AO9CG5Y9$R>Y6(:G0EK6ZM
M<"KM,A0XX)9U2Y!TB2%9F8DB-RIMX)Y1OH9<NL"'[J-A,`T1(MB7Q+X^PL;V
MN./&)`[(&Y^5I4="><U`U4;)=O*F"<05W%JWOJ`E/`#+V3U5VH(EJ*N<,I6'
M<,+YBK!%#.6]E%K6(Y7N/8"X/CQYN97<#/D@?DZ9Q6.GP7=:.%%A#5_3/?1Q
MH:DS1$*^:V;=!E5C1ZY`JX#AMW`F'@93+9D,[?W$/?"YO.X/7+D5U8VJDI4B
M&(7+)`DB)#$-R68;<BZ_SW"XYID$'&DM,^O)!N8(W8Z>N`$7"NI*:<+HYL\<
M*BG@!!RX8-[B6G%2E88'9L?B$ZJ>=^%ZDI.KS1J4J0^HOC6ZR^<'"WK+;%>H
MR<^W#GRPWZ0)6WI6F7@O\5_FJ8O#Q[MR'>?(0^ACJ+5SE*KJY8Y'5XHX^]D7
MHDH,+KP)5K(:,YLMBV,M2?!3983K>K9:\AOZ6(V;:,Y'`_6/'S)5UUY+322&
MZNF5L)%P)YI1PMD.#E0KPN["SH[.0E"@F=I-TD45"/M(WR>8D7ZVZ.*\(.IG
MQ<9?T-N**32?(RO&C/*(T'OZ/GXERK%[>8:X::[A)NI0(/)JMF16L824C+_K
M2U[7Z]+VOTOTOTOUZ7MX;7^"]O@IVV-^O3+'O6ZW[]N];X;_``6I:]K^"_7I
MX?Z/N]^WW.]W_B[]4@=DA>1/WQ_$..O7M%-79)GO<1^1E/1PJWU*4K\I=]Y5
M;_LQ0]#'K$3T=$$MIAJ;:PHMK?8YP]TM83.UK?WD)'>M:V72UOZ+5*3N@O\`
MC1?\J)_M4[H)_C1?\IG_`+5.Z"_XT7_*B?[5<VT=SSRY2$&V6>>73CTF;IVV
M6673_E10+X.VO?I61/2E88'9L?B$ZJ>=^%ZDI.KS1J4J0^HOC6ZR^<'"WK+;
M%>HR<^W#GRPWZ0)6WI6F7@O\5_FJ8O#Q[MR'>?(0^ACJ+5SE*Q^>4V1N;"-M
M@T&^A3;U?4M3'/#2&#(#RV,:;V?:<RI4).5\%'(0.(<4XJ[\3&HOLH\TS1U<
M466LLP`9-.8*"ZAYY#ESW[O&HJ<R+PGT!\;WJ&@KFUR.PX^45I.S28PJ*QLW
M(J4[(_P;26\%M=R'%$;*<A6?^"0FHAGN)%?L<#6"P`^)#&U\1G`00L8P!&R+
MBY@"XA#X8!B9`"9!Y8X#8AC8YA9Y!97MGC@+CD'E?&V.>.6-[VOC4<>.R&XJ
MHN<_&`K[E3;J4]9=JY$CS5]CO`^T03!LRU(]<(4;L!!0TPO'\:-9.4W`$B8K
MPB2EMA..]S-K:MW51$,FA:CT_?V<M,=1N3E;>TX<J;7Y&(CU98*FA0+R$O)A
MOYHM%'EJ:V3$9_9?6T=H("4SG>GM%V/4F&"JJ*,:*H6)=.2D\-?2A'#<O>GQ
MM;'R46Y(=\=&7`\7H^(HB^`M()]BD5_.=9?#C9Z[*<--TO,26(\'0>4W.II3
MT=8Z8^2J4?4#1)$<)IV#).)$BM!II:*'9)G)?HZ2T6WHX_C4_H`.X!QIQ2E%
M83NVG]DMC*"L_P")I(3BUE[!I9,NV1EDB8+^.>3FL'@6OW`7,,[;(K;*;2[V
MNG$+V[]KDBE[?%<L%>U;^E[VMW[WZ6^&]?SV^'^%C_WK?ZZ=OA_A8_\`>M_K
MK\Q<]Y5;_LQ0]#'K$0T=\3#4WS<X>_8A(J4E*5S?1SRI"#^3TF7Z44#5D4TI
M6&!V;'XA.JGG?A>I*3J\T:E*D/J+XUNLOG!PMZRVQ7J,G/MPY\L-^D"5MZ5I
MEX+_`!7^:IB\/'NW(=Y\A#Z&.HM7.4J@SDVAWERV7V/;40ZH3HY=8-'R43M=
M3F&2(4(QV3V9>DE+#L>02XS8Y=K_`'@SA6HF)C-36L;NYD!?01TI65L\!L7-
M83-/3>>\9''Q%''J^%9`BO7;8Q+7YB07@X9HV:V"V!1)B=,@.E'56F=2P7,D
M,Y^J[13'.[C:TO+(BXEL5OYFL&^>+*2VI&S)8,2[$?`00$;`$3$(7,(3`(7(
M/NN(8F6&5L!,@NW#[I;#*]LKAWSP[>UKX]OCU[:U5T%\7Y:`!>0%586STU(;
MQY!'^X9<>3\0$F.$1U1#)Z^`JE+N2'3-VRI$4\JGE5(($DENY/=0H>1``Q94
MP-"FAQOU7+QA,2>H=?T=[JR0O[2/R1=<7%JPLS2;9[)BEX$(M<KD17NI&D)'
M8Q#-L)[U./UIL9^'E\<@=3!W4Q&P9*-Q.3@%)-4^U]3]%F=K+),YSJ?>"Q*,
M[[#IL+-F1)$6D1$;87U%:^1T1C2,&JW6TAV%)(A0%.+J3I=9K`X9'<KW<2NH
MX8)#=)M=JMR$?9()<"W"KOF/8$*PV;"CG'(6P>%A<K6G>)^ELA+8]OE:W:8]
M+7RO:W:X][^3;I=PF>]Q'Y&4]'"KJK8*?8HU;AB1-@9Q<^3,B:*6X9=C[=&"
M(ON/-%02@Y<L.=P0VLEK3A5,L1C9</$HDI9XZ)<2W<R^=L<NF/3M'V15PYSM
M`,KP_'/)Z\-='T_FH<;K:FV/]?-G##RC95',E10W*W@B\<(`PB@6P+BE\,05
MI-$[F9%O@;"O:U[XP^T6]+(CJ!I*>^M'92.^.PDY("40-QY"ZG#FQD9D7VJ&
M'"CD3R8,^5XY[3M_$@@G%9;Q,G\@PC&258B'G[(-`X9=B1WN-`SBCAC+<A=E
MG;\L*05]B-=5>[(+:][.N(LR7FKMP@<<[5`<*<?`+K@;77C)Y'#64\0,NIV(
M6/$ANXCA"WR=FWV3#PI-^.4-HJ>^J@\UQ$9*:WE!U*\`;,!JKJ54MN@)9M?4
ML<HF-=HHKQTN(I'+9&1[8&C@MLS`EK7&O"_1D3`;2S4@8._;!C:W0T,'ETO;
MM@QF(C"AY=+VM>W;!YXY=+VME;KTRM:]KVM*>E*YOHYY4A!_)Z3+]**!JR*:
M4K#`[-C\0G53SOPO4E)U>:-2E2'U%\:W67S@X6]9;8KU&3GVX<^6&_2!*V]*
MTR\%_BO\U3%X>/=N0[SY"'T,=1:N<I48MQ9Z4]:=>7W+Z*4CT=60!&LE)ZC,
M#^%BN'&L:>+P068"]YADDN@N@RQ8J9(B_BYW\YRK>5C*8W$L]F"6PSSL9+UZ
MZ+\N;%VWFN%M;4AV0?,$KK^HCHG.?UO5UT*S_C"%))8L@,YC&&P:=!@11)"M
M>4+NQ15([`4E0H^$DHS;CNI&R+O=!$3[IZ4I5'_9(7D3]\?Q#CKU[135V29[
MW$?D93T<*JBN?GR.7(-YOBY_^?;=>,>->_=1>_?W3/[M_P#"O7SZW^&_]=.M
M_AO_`%WK6U[_``W\&7W;_!>O3ET+\1[3KS8(,]7+?J6-*5S?1SRI"#^3TF7Z
M44#5D4TI6&!V;'XA.JGG?A>I*3J\T:E*D/J+XUNLOG!PMZRVQ7J,G/MPY\L-
M^D"5MZ5IEX+_`!7^:IB\/'NW(=Y\A#Z&.HM7.4JC?E<,\FK-$=LM:_;6:$:T
M:5LB%B5IB.[B,!==_LER'EQS$'0<,F4ULKQ"[354%49K9(-TWB9.+JV9.IY1
M+."J!<`SU!Q.ZX;BZQ[`B(DQO?B^(P_+L`K<IMU@:$ZVIFO#B?BK@YH^+MR4
MEH0E&[-*OQJ(*,OJJ:H9$5$V<;BF^6H96"(!=Q(XPN1/2E*H_P"R0O(G[X_B
M''7KVBFKLDSWN(_(RGHX55%<_/D<N0;S?%S]H&W7C'#>ZB_A,_UKU\Z5K;P_
MFR^:]>G-H7XCVG7FP09ZN6_4L:4KF^CGE2$'\GI,OTHH&K(II2L,#LV/Q"=5
M/._"]24G5YHU*5(?47QK=9?.#A;UEMBO49.?;ASY8;]($K;TK3+P7^*_S5,7
MAX]VY#O/D(?0QU%JYRE0:Y&RC44-27XGNGZYEC*DZX;26`)#;=C1XR<4F-7F
M=@I<+J319\R#EXL=1I)E$XU51407^+BU%!OE%C!9Z%,1,PZ'>'1\MJ>>0B69
M>ES>+:_?R4XV8TP:YZ^SJ\M9F#KAI6HHB`YXO6-BDC7,G&3W=**\7FD*!&-`
M'0Z#"$RD9=;]BBDW;.\G[7J"/E@F,AL`!LRX88H^`0F0(0PN0`0@N.&5PPQ!
M\`3&8(>>=L<,Q<0!L@\;WSL$+?&P>6/5"O,+,(4:<U\O[*1Q%J8E<7DJ/EAL
MQEQ,J.HSB]0F*RE50)IRR^7:"7,*2N]W@73$TNLEF6UR*$35,`?:$X(1$.GH
M]./GKD;6R,]A#VP+7CY]R,T>+O6'D>B@!H)BNQV^?<&QZVAQL?A)>+&UYQ'S
M3<9DL/=AW1':3-@N118JFL!+1<=<205<[9?HEO=($N[8[9:1S9DU%F1]<XZU
M<F9N2$SD$VTDY\LG8V*TIVKR4>:9E9<."4H1P_!CB*04"JL(&MM%;;%CY?V_
M2EI56>JNR03`%^%7?,"PP5QL&%'.605A,+BXVO.\3]+Y!VR[?&U^WQZ7OC:U
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MQS!3IU(X^-;FQ%.FTQ(D%G=1MRFSLBK$VV4EZ(U=Z,`-LLR57@FM[!PJ[G+R
M&_74XD01U/A93D51/N14,I9WV/E;&+BX@#9`AV%&Q!$N$%<2P5A!+897P#N)
MECEB';//IC?.^.5L+7[:]KVMTOCO0[Q'32M,SF[BG894C-N,GE-E21Y&C9<C
MAVKKZ7HT+O-!6DA##>J*O,-CD<UUK*PR$Y+A(*LN):E[$-I>*@3RQ`/#Q[<_
M`A)VRT;;!EM@'5'S`DAU<6VL''%$N;-6UA[MDHYM<UM`DM4FAQF#K80#Y1KO
M&5V&P@$!M$R1ET)S!)KYI8R)N)4*)1&S31/0Z0XDVVVRW?FZS51)%V(C;5Z%
M6U';,<9UW)C*9&NT5HC5<*PIN<TA-T)45)#?Y0ZK)1$HEXX(C,1FWF?,8.%:
M7$=%K,[),XT-'3NBV]'(":@!`&W`)M.*54K-EW*_L5L%027_`!-&Z<9L@X.W
M%EWR+,D/!`QPR;-P\RUN[BX"';Y&KY3:7:UDXA:W>M8D4M;XK%@K6JHOGY\C
MER#>;XN?M`VZ\8X;W47\)G^M>OG2M;>'\V7S7KTYM"_$>TZ\V"#/5RWZEC2E
M<WT<\J0@_D])E^E%`U9%-*5A@=FQ^(3JIYWX7J2DZO-&I2I#ZB^-;K+YP<+>
MLML5ZC)S[<.?+#?I`E;>E:9>"_Q7^:IB\/'NW(=Y\A#Z&.HM7.4K'+YB=^W;
M&LJ!Z#.KBJE7D+A38"'62_,PV0YE!HM]R+23)"]FM1:=$%9ZT4=*VD'F6R'3
MF@-];!7,TM;"#4445.'",F.H>&E28"3MRX&XRN!!V\4PCA@E\*RA.$A)BN84
MG[BW7E&@):*FVKJ+*;V*9B>R<`[M7"(:EEDJA-5.$R3C%DRQHCE)4I2J/^R0
MO(G[X_B''7KVBFKLDSWN(_(RGHX55%<_/D<N0;S?%S]H&W7C'#>ZB_A,_P!:
M]?.E:V\/YLOFO7IS:%^(]IUYL$&>KEOU+&E*YOHYY4A!_)Z3+]**!JR*:4K#
M`[-C\0G53SOPO4E)U>:-2E2'U%\:W67S@X6]9;8KU&3GVX<^6&_2!*V]*TR\
M%_BO\U3%X>/=N0[SY"'T,=1:N<I6/ARR[?[VEYG2=%]--.HKDA+>L0MR1)-V
MLV9:[\DC6^)\'4['BVTYHJD;LMA.;ZIWX7*L\=U)I`<9QFQ21HL+:/U,B$.9
M$Y_Q+L&8=>#`D6;#[]3?MW(TEH;R?:4P%_7):AV!H@*MQ8:PKE3(J67W'B2^
MLDQ+'>:*A-UJ8O--:Q5OBY"(,5-X)-'-%;T*4I5'_9(7D3]\?Q#CKU[135V2
M9[W$?D93T<*JBN?GR.7(-YOBY^T#;KQCAO=1?PF?ZUZ^=*UMX?S9?->O3FT+
M\1[3KS8(,]7+?J6-*5S?1SRI"#^3TF7Z44#5D4TI6&!V;'XA.JGG?A>I*3J\
MT:E*D/J+XUNLOG!PMZRVQ7J,G/MPY\L-^D"5MZ5IEX+_`!7^:IB\/'NW(=Y\
MA#Z&.HM7.4KXXEP,!11\`0\!Q\0L1AL,,<11<0;9V!L*)C:V8E@K"9V#MG>]
ML+9Y6QZ6ROU9%P,Q0A\P0\QP<1,01L\,<A0L1K86&L$)E:^8=A;!X6$MA>UL
M[88VSZVQMT^U<;>3N;L?M%T/MWJ8"(TV6W%QV.=9-=M[%2&\VTLVM+2F9[3'
M+.Q<@F$31H:^..67<PLNUQOETM>GV.>9=%5HBV&V(GK2'=34:`=>87$FD_*.
MP3`:B"DR6G&CA<JVFE%!-)=JB.Z7@Z?9);%-)"CIR83-'THHLJB;FIEQ*F!J
MAO*S]F9%G.#SS15XQG37=/A9QR/':RLH[C"#9NPL=E9+BUT-]S(G<B"V5-I8
MBHVW05#*%AVT]6VLIN.2LWS+8=+CA)V2%EC_``*.^6/;6ZV8<==;=;=;?\>T
M4^&WA^[;^NU79IGO<1^1E/1PJJ*Y^?(Y<@WF^+G[0-NO&.&]U%_"9_K7KYTK
M6WA_-E\UZ].;0OQ'M.O-@@SU<M^I8TI7-]'/*D(/Y/29?I10-6132E88'9L?
MB$ZJ>=^%ZDI.KS1J4J0^HOC6ZR^<'"WK+;%>HR<^W#GRPWZ0)6WI6F7@O\5_
MFJ8O#Q[MR'>?(0^ACJ+5SE*4I4<-P$UD+.KD_),E0Y(NPL>J<3O4@]X-B0L9
M.R3+34-HQ@!>C]F$";I9)I17G0FYF$LFFEW4AC*/=\R09[#(Q;`3$FE[AY//
MW4;?!J\7C6V7B353:#2YM.H+2O8E'ER/U!'W+B^?HXE=LH<9M'8`$N[6TL+L
M<,9[,9[Y"G#C0.NEP,Q,27XIH6.8#2MJXVM=90-<DN^6\*XT'HQ8AD_7_2"!
M(P`D!JKS%<CQ<D60RVC4LJWU(.D@E.$BD,AS!E&($JGT\`JL.4!UEDC,X11;
MGS45^R2]8=C1M%-Z]A@=\IE*P.$T8I-"Z981S#8D4FRQ20HC;9I.$?8K7SE4
M,!1<(>;Z'&`<0)D)8$S301K(G]PYY2Z7:]DTA:][WO8D4M>]^G6]_8P76]^G
M>ZW_`*.]51?/SY'+D&\WQ<_:!MUXQPWNHOX3/]:]?.E:V\/YLOFO7IS:%^(]
MIUYL$&>KEOU+&E*YOHYY4A!_)Z3+]**!JR*:4K#`[-C\0G53SOPO4E)U>:-2
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MY\L-^D"5MZ5IEX+_`!7^:IB\/'NW(=Y\A#Z&.HM7.4I2E*4JC_LD+R)^^/XA
MQUZ]HIJ[),][B/R,IZ.%517/SY'+D&\WQ<_:!MUXQPWNHOX3/]:]?.E:V\/Y
MLOFO7IS:%^(]IUYL$&>KEOU+&E*YOHYY4A!_)Z3+]**!JR*:4K#`[-C\0G53
MSOPO4E)U>:-2E2'U%\:W67S@X6]9;8KU&3GVX<^6&_2!*V]*TR\%_BO\U3%X
M>/=N0[SY"'T,=1:N<I2E*5QQX.]K1^TW,^WRXD1H,MF("PZW<ZW*IDT5NMEL
MM]/,*RZOKRPH"@$$I'1TPH94%)1.C@E21,N,8'%P"#RRMUK"VQD+["E'(:B)
M]$'6*SCR$GNU'$3UQN.AKF'4U49]-/)Q-!UI:$ZD4H[F2X4)XM%04D8LGNIJ
MJZ<X4`THI1L(U>JSLD+R)^^/XAQUZ]HIJ[),][B/R,IZ.%517/SY'+D&\WQ<
M_:!MUXQPWNHOX3/]:]?.E:V\/YLOFO7IS:%^(]IUYL$&>KEOU+&E*YOHYY4A
M!_)Z3+]**!JR*:4K#`[-C\0G53SOPO4E)U>:-2E2'U%\:W67S@X6]9;8KU&3
MGVX<^6&_2!*V]*TR\%_BO\U3%X>/=N0[SY"'T,=1:N<I2E*52MV1,VY(=7##
MOFEQ8"I&7(#%:&NJH"0$,,>%CQKR4QW+*UK8@`C">P@HV27095N]CA[3EU"X
MHF`-A+U&?C2(/54YE>4![H0PQR'#&J/&,W%97)C8F&ZKR7AKTD.AO%B9X'$0
MF?5$I@KIY5-AE360Q-%=Z`=-!7*KR2,)R[F*U]Y9=WXEV:TR@>)M+0]:9A0V
M(B-J5Y!G63VW,)<-&5&&^EL=39*;&3@:1;,-WMU21$_`%9'L90,BJD-F$=&$
M*X=G%Y.[(*``!`MJ5Q@Y6!!!!ME?;'8"U\K`A8!6RO;&%K6ZY=IVU_Z;]^][
M];WBYNY%G/9NUJA.NJ;IUQXVF4@SDQ#C%4G6W]I9Q4EA!+'%!-/Y'R!!5A:Q
M`V/A=.L%B"8S"#O87+*^?\GM,\2S+L./EJRRRRNY-0+7RROET^O4\^]UO>_3
M_P!4%?S_`!.'EJ_G)J!_;4\OW04_B</+5_.34#^VIY?N@K7'L.'EI[;#&[FT
M_P`+9YX!]OE-#URQP[IE8.V65@X>RSOCC?+KE;##+/I:_:XY7Z6O<UQP1KR\
M3!I[$XT(P+H>J,")PG%K:259#V"FIMNM75=:W`?A=Q+!])18[5TH`!47&>>.
M)^90[T,$Q`A\R9"XEBV$YOL5N=/[W?C9_2@GW]U-/L5N=/[W?C9_2@GW]U-/
ML5N=/[W?C9_2@GW]U-?I1#K3SMQ#L>2V.2M>N-U06B4$NV"\&X8VAG0%*%2W
M9)+'D<PO"&[P^:/6429QDETP`J#W(J(5/F!ALKBA!XY3J^NGV07]Z3Q@_I9;
M!?N6I]=/L@O[TGC!_2RV"_<M3ZZ?9!?WI/&#^EEL%^Y:JE.7SCLYR>7>$HSA
M21(AX]8B3(UE7ZZ9-;9.RDP+Y]3/69S@9^*2:+.&&0BX!2Q=PCG;C@YYC=V`
M""QPQPS%RRQ[?XG#RU?SDU`_MJ>7[H*?Q.'EJ_G)J!_;4\OW04_B</+5_.34
M#^VIY?N@KI^<>QS^2/C-9*7O%*YO6)PLB!)3@Q=/(;6E9WJZPJJR_-##9[5(
MXDA(U0[9)YEU.!&"6C`:H7,D4;(^>*8&3)8,L+ERC:L\Z8@XXGV._&Q>^9@?
M._:[03_VO7(7/*_:]O%&.?:];W[7M\<<^G3ML;9=;6^?V*W.G][OQL_I03[^
MZFGV*W.G][OQL_I03[^ZFE]5N=.]KV^QWXV>_P#_`!03[^ZFNS-6(DYZ=61)
MX$;NN'&NY+3M,I>8U0-4VDG4G@@*1>(XNB7VF3<BT-CC&B.9"+R"QD8."^R+
M'E0X7MC[&`*WM+#ZZ?9!?WI/&#^EEL%^Y:NQ6!(W-V<R5_KE:S<>2-B'BG>T
MOU);*S<L7,9YY*'MG[89*44D>X6!QP3?8E@<,^Z7%-=TRMW,.U6]TI2OB8+@
M&P!BID$(P6,A"`&`!P\!01P1L,@Q01@A,<@Q0A0\LL!`\\<L,\,LL,\;XWO:
M_%&/'C!C)&S;L<,AH,!OB'1U+-"9+:16HC9*)K`(,T?R2T$BGD<CIG``#$<U
M<"XXN`(6&8F6`0>.',+WM:U[WOTM:U[WO\%K=^]ZIU4^1*5)ZY#I;X\]+FY%
MX*GJNQFH]]K-AIL*N]ULQF+;ZP+",^'8ZC%@KS+5'L]U,D?"55MRKDE-)O-8
M%*7DW%-7U<A8#.5#0V1D>*F]-KAWN(0S!#0BIWLIM,^7D%[J^4=3$D/%`0LT
MYP))%XD2"^U74I/U:%C@I$F`[S7;N4@5*H+D>5G"D9W_`&TOD$TV6XK!F9&V
M`8BJPC$IGX-"-IPRP<<.4U)6!D=6B&[#+I`D@XR@D$"1U85V#FU<74E(!$\X
M5!*+(9,RHA=(!\MFF:QM;KQJ6QY-1W\]-C(359]:3B;`YLZU`H_,#()6-C("
MF&F"`KJA+9A45AF:12!A<L4MKJJFK9DL#K?!6.UF#R6:!2BKW0H^W!UZ=JH$
MQ9$DP\719.;9K!(8$3#AEY)=R^:N;P)MU"9>>>8B\>7C":&2+%%$Y>V9-,41
MRO,FAO-J&^V))$EM_86+LV-#S:;[WE)PK+D`:Q1@,=V-L-YLQ]NP%UX(AY%8
MSU:@@;F8SS.%`VP]$._MFU557*XY"6Z1BW;GC-@B%S"O&DPZ]PO"A*?W5$ZU
M@$=*1LW6WLB\U8^]W6P':DKA1%--"4G.I*A]V'&\Z"*.LJX9\1<!+CDC&)K+
MNEI[VZ@ON+5F:&;L'&KFC=`E`2$51Q(JWD>R`F7%=(-HK$P2*"6R<9Z2U==5
MDA,;S%3T<VYW*96$CZGTQ3#5"`AC\Q?Y!]*&JVHG>#FV;A]OMJ=,'7:'U98=
MQ1.+R,>8AD4@]4-IXFL0AU9T-)4`&1G(TP0;.=$70LT)11RZQC<C7&(LY.=`
MIN=<3,:)=LX4?SOG),<BI%#>;CN!/*CULS\#(SI2$HMW##(-V()4F;.*+)4;
MD7B7)%1SN2#[##R'KK'7'D>C-V1A@_-BIFU'9.;SVTD/6B'ST1SCE(+,>*V2
M7P0(S8)QQJZ2B>PIX7$$X6%<$;8@8*18Y;$4$B0'&.(:-WH-R#:7X,X^_"VQ
MT8JS:3);7H%.F&\M#.91"F=IHHCE=\8XMYO$E-R#O5G-@N<=+P0"R.,=:;73
MU-R.(--0TQ0/EI-L%^,Z46.T)*CQQI3P8;_;*&\F6[$(SB=1',U7*G%U=`7T
M<[A:V!Q+5TLV6/IYL.W<S)0<(8/KAGC>_++WM:U[WOTM:U[WO\%K=^]ZIU-<
MB,G[!\@LZ<?^F"5%Q!0U'CQO/#9N?9K1WB]&@AO=^!`Y,6&F!'3!=C`4W"N#
M%C&:J[GJL/\`24UM62%I"(-E?5"MQK?AZG<R,2/A"W$;&YYN.M3IDX^YD3H7
MV>,*CX$,PKE=U+2HA1A*K%>[B((RH784I&TD<ND)[N3B*P@+0Y)`/FU(121U
M!3GZ/O%J"4!FXP=V/A\@'K<(T`9W]L'ND$!(H'D*]\6`6>P)T8N,BFWV)W,%
ME$Q@\C3L,&"A=O@J(YPH&/QXCR$Z6J,*2+L.#L?%Y2(HB=QR/90=BTN"-VT>
MR*2.)R=G'3S05\HF.IN2`94%A'(IK(5$$NZE8VLI`"4D'A%,EB/5O%_)YJ[N
M:+R@1EO"DZWI6FVG4^P?'Q&0)&'/_6\?9-TJ!QYL96DM,?5ADQL.1NOYHMLD
M0)F;$<B;U*`E1BB>L`EB.-F/\)1H>(TEQ\)NU$..%MM^3%V'39MHNG!Y&CTH
M-AJEWTYF.W$=IEUI<=[A;S+,V=JX2:2:N626X`>6CXA=/3CY@MR-U;]Z9LN'
MH_GUP;(12!$$JH2\Z(W?)!R@KB2]VTTD)0=#S<+:!0`E135D-B-M*5%Y_JQ5
M/S(,-'3%%0>!A$+$C(@?(G3NAJHS#[!3W%/<9$A9.;C$>;+,@N4HI):HRI2<
M2>SXP?!E;2;'D9#9$DO!53FC'SR<2@D-AZNHZ6;C:55-9%Q)5U2I\H''TBR:
M##2KMU!R?*&<KV@PVR33S+!+B'+XAL9.*QTZB^0-@V@[%%2+&4M(274,C#+"
MJ6,I:7<X?+C%\.W4W<3659G#/7!)F5F*4T8+2ZV/J')'#9HZ([&JTP7V[&<`
MJ`DLV\8>;19AI/=+M9X"R(YFN@JJ,IKZ4G%5E*S.26I2E*4I6F6-LL<L;^#*
MU\;_`!7MTO\`YJH7;FC,\:2<HNUF\>OT;7V.@O?YGL@M.$6H#]9<?3'$,MQ]
MCD"1>+*SDY7:S'?<?NPH96!UM-$D)HNIMK2X*.E$EE/2R00L5W+I%RFN'2W>
MU'>;;:FPLIS7O"ER+JU"VSTSH\WGH"U/3WJCJ#?3&R:DXX]X+:D[1RFF5M59
MQ\RHOA!3E$L7/*2D[C"<DH)R,S1X<-M`H2W&CJ58=DC)TR/RP/#=C7N8H#W$
M:1;8R'R:_#3J*-2<&/)3W4&($])&07M@WV4^F_)!V/3C\3W2Y74DF&HIMYO+
M^$[M;N/O?.+^0?0G<R:\XJE4ZRN+(OIMLVKM%UD6FII,U@26M2BL/5(;?U+I
M:(ZD5<+J1=%L,VPT3%6>UE1=4T]LHAZRA?I367ACV`3N$[<71-_)$>1%L_.;
MDV54VB^DM:0UXB=)R4[F6^VDC.=\M0D>6RC9=-V*W6/(1?`J?'+(I+$8)*6R
MZ8E%\^FIUX7=W=HV3N^\0,T&!G[).E''IKQ"\8NU_-]RIKVD33YS1S++Y5Y$
M-L05R-=(9BNZ&+]1$:&!E,^IG\5(^ZG6AM%/L&F&Y4;O:5;A;R:;1"3):20E
MK)L2J[]:Y;0;!LAN2M%ZO=Y7B-*/HT@2.\'VW$I+1'6YW(4!14AED!S[H<%V
MHG)9=S+*4.5LCDHG//B,Y!"S>VADEC,EG*DB)?/@J\KD*Q09F\)E@3C#:B`Y
M&_C'YR06HID1XJE$HEK5U))5CZL1)((@YG`DM#G<[6PEI(O&M-J[,/$3*<2Z
MPMF%6=K-MSL+M-L/%@FP5I37FL;G#-NG5`R"]GTNF,I"D5?<Y18>3OP;QLNT
MDQ5/"E$%75\^V53T*M2^'+?"'1>*:SOCEF`7U#Y"MN-E)G&3)291_&\<3E]0
MX+/,-VX9X(9QN$L`E*.*TF"8%,R81`,,L:.>RB^&.X1^'K?-N:-QS'X<<,]5
MEJ'^=A&Y(@V`4E1E@V>T$XJ^)@=*0W:=/EVRFOHD$;S'-HSC-IQ+($D9R(*9
MXUF3)&MVC\/>X!C6F=VG(T/.UOSF\>5?;#>V"I8U1VG9#1E;7`Q+43D@HS>[
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MA/5K71ROS>HOH(I01%$O/F+)?:Q'['M%+-!^F7(1=!`*/R<MM-+'L\(V,.`J
MN1R1>Z;?V2I.E+3"(3IZF.<,G(:8C[<A3#9:`,^_X6/5WDBA5JN/8A)>YW8Q
MJ16B.0-X1@[I/4D](S2'ID,XPC-W"^V^V6XM/5)O<B72VWBGK%N233Q.\A<\
MZ\<\"$-";)83\Y)]A=8),@9HJ4VL-9#2FW%[V(.9U9/UPHPF:2C'BZ24P`#+
M$LU6YY=S-DR>0Z67++RC:IO7IEL&^&AH`U=9-<8.S)L)[Y&9W<>"XPHHF2&D
MHS""0PP5*&I3^IIS_4:$KGD9-9TK.J-$96E,XPD1%0([-IH8V2XBU0ZJ\5_)
M)J5#'$\\!=>8RGASZ@L/>O6/9W4AP31'9-*?L.;8RL[7<4?;&>;@#4(U'%&2
MEPD"\&JO9W/*B"AHZ&.6,>V2H519=S#Q?3EGN^_G3]B3%L\Z5[>:FZMP,_H1
M0MG71`,?:F.G6(<D"ST8NU6F$T!).@)!`"Q6&R@,]I9KA1?+WS26ZT<`[BK%
M5B9J3L#OH[^=K4:$640`^N;S01>N.>=%!\-MOI\+-J,G:<?#G<IQ$."!O)>6
M?:I)`(,H@R2:V;/+2V>P6AVR03LE!6O"A+039:+>7!U[2Q@WW'"&NLF21/;O
MVC8:U+#,DN#9]4U&/R+<A2?8BCG$P,_84V:<#A5%4"813*.2;@C'25`-`>@9
M9[JL;WR$*4I2E*4I2E*4I2E*4I2M+VM>W2_@_/;_`#V[]?A(36;38L>Q;C>0
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MD2(SFI=I30.SVTP7VX55M,=.>#R:#5-J*Y%([K36D]PB:\`-AG(E<VDUH;+H
M`9+DV&@UOO(TZP&(4:2W+D>I3F-O@SB+F79I9`/N,NK#.L?``?,%NAD[K`N`
M(N09/*P>73F4IR]%4&LM6D>9I(8L41^A!XB++VD9UH;*:J9;/M^Y8G5YQ'DY
M,!%&RPN&`7N9N8,"WQ"`"$$RQQO5E)O,5%PKHUUC?6!A+TV2)L^:V-4HNO(I
M*0==V`L1YJY$(LKR+(Z8Y'K&*FYG&TG(:R3H[BYQMYD'6J^'6965,BX\6LU%
M55&E)!/(7`\Y\?3?Y'R)A7;,$'X*<\[.8-6"*FG`SD:/TQ=-2,WCX)$QD345
M]H*K6<3?%#3Q\BZHHIV%R&=P38-[03U^YQ(]?X+B$G.*<(.N+QNI?*O&^2=(
MH#_+.C5<^<<Q%03G&;-M!CAMB7VP.AIMUIJIN+H;QC%P`V270;R335ANW^,?
MD-VFWU,NARRCHFBZT0J0::<K,F6T/;V(]ETR0G2H*H9<9HIQ**$C`HC#(J/8
M=67#:LLAFR0PB<FV2,Q#@I@K;W2E*4I2E*4I2E*4I2E*4I7&'LS6W(K-=D?O
M%-LL-%\ME>9[H2;FSY"RHW7.DFT-<3KGDLT14R5CR6?-%;FTXZ3/%K"]V*&B
MYC`,;#K&%=:X.UO3W:G0?'2)'":]3[75W*FMX13P35%394:LR(6T=LG'%`X2
M(F"$=QZS6V)FF@$_;$)#+J*K8\L#G5$U@[[1P`^MH]ONR8M=86UE79QGN9)%
MXXFG#SP1D)C^UD2.$LGHKN6'&ZG\XUA+5(Q1;(3?4UW-R$`LT]0,-_VI.&L%
M4VCE3^5-.7%HRYX7X(GA7E5],W<J`HQ;C%:,[DP6]++1$44E(#"4E17@*=D9
M_0^>%6%X935S3K;[99,M6P-!!$)*2LRI3,K7=M=J!OF5W+T>WJE!NM'9E6UY
M8N[NO<@E=4F<MM97767,\%N-+@22/K32(]%\^BK2O)2TJLN3T=NR"]4)I@*+
M5>A4^"U<W59J<%UPT<W"B/B]BSA-<.O!X1*F[CVVD,2UM\7DQ!'CZ`MC)9<+
MY<[>A%9:99*53CIP(*KT2$A4<C:7<B!D$NH*+;*K:<64E$C&+7/CZV9+KK&G
M&;]"7C*[3TYX.(DXZ7%J<_7!'#=/[4SVCR8H+TFMUE*!ISKK368R:C8+!*J8
M]%+,1%>JNH(0#(P5EA/.A)MCO$OQ_M_7K;6<=I=<-=YNT3U2GC7>.VVYM.YN
M44X)5RV:1GVKJBW(;:::0_I%Q:S4:['"+MHEFIKH.*ZMNYQC-=*(-0D4Q$R(
MJ4I2E*4I2E*4I2E*4I2E*5_`GN8G_4R_5O6,AQ2^7*[(6_'S3KU>N>LG*MN9
M]R_^:W^FG_MP_P`#E^MC7Q#]R-?A!/\`17T)^XV_ZV7SUNJ4I2E*4I2E*4I2
%E*4K_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g561315.jpg
<DESCRIPTION>G561315.JPG
<TEXT>
begin 644 g561315.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!`1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?149&14-47T-!5%]+7T)!4BY%4%/_VP!#
M``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`#S`JP!`1$`_\0`'P`!``$#!0$!
M``````````````D'"`H!`@4&"P0#_\0`;Q````4$`0$!!@P/"0H("PD``P0%
M!@<``0(("1$A"A(3%!4Q%ADY05%A<G5WLK:W%Q@U-SA8<7:!D9BTN-'6(C(S
M.E59='AY(T)2<Y*4EZ&STR0E)U.QU=CP)B@I-$=45V:3M=(V1$AB@X:DIL'_
MV@`(`0$``#\`S^*4I2E*52^;'TJ1?#\H22B)">OJL?L!WO<DAJJD91T]9$:3
M?4'#FE&E8FGJQE,P4`4T4IB?!2U'(H(-@/<B:PPR!RA4U'YM5S824./5A/76
MI':B9R,0+(\W1^JQ=,YF77!"UXRP.#K*5.[-,1<R#S<92L`5Q)MR6")\5$.N
M00=OG$(AX@;4,),&]R&:2.I+DM;0-G8?4D>(6@0D)^*@#M*8D$M@*ZH=0D5]
MIQL;$(!U,I><"<=;:`[&>(X&^O.0OFW4=1/+>09#/]GGR`:<QVS2;]?D_L1G
M-LZKR*AXBN4=6158HH0^>+IDO656P?2074BDHE/FRA64E981""3'0QLK@\CR
M+XR!X2E4/[^`2WR#[`Z1);#1A&Y#VNT&[#MB;$1^XKI.0$.:QQP"26&UP&V$
M132Z;@7\>(N%/>2^4<!`R5'"))]LNV@BGRR"QMR7&>/38*$,(C0)*&S;>IFT
M=WZ.OQA.4KAM)F/8Q##B2C#/0#$;2(71'\W`2"99>=(#B5C1-.2A[#KS>Q4.
MMR9RI2['4P<9$)B:^QD><G)"BR\>)KQB;72G-F%CT0-0F^5;!5SSAT=0>R4I
M-Y3(A`J`1=H#$%((_8T3S(A`FAI.X&E)]OR,!WQ+[,:,:J("LZ!"N;0?YJ0F
M,XH^(F,S[,DIO.Q4:+$4<T9Z,P9.<PJ>I-HB:;ID<\B#F%+R=93-]80]P8"D
M5/C_``AV5F)(J[,[*<;VAH-$/JRN@/)$0B;C&#7S*VWDA6"0FHH&FFXB::X5
M7$H57#"&L%6S9<4$XP3QAQU,YYUK8;'CA7G3J\B-MI\D#RFR/6:F1I.!N5)7
MAMRPR[U]I&%Z2(W,1,S<U"*5O-O&E51DA"7`R[&*9VLX4?,'#$X/-AM5L(W=
M5=;YHV+="8HKJ5$,<.=\8-E'`-&5MVJR2F#"MYF(8!(F?,"+;O7\DQMI5L"H
MN.!Y3"&&M8N$-GCT6&=V8+EO3F(]VAG@B-"'I6C:/GZ755I1ZAHZB_[I2238
MXN6)?`TI/$%]*F$=E&^FD1UM;>F(+?1TPVK'2A$6EY[E#T]RE+4>*&C)I.15
MO<T26QXF5F&5/N)N8HT(D5T&0U-P*I(H)BDFT-[HV,9FVR8"P=))\#'4Q324
M\-O.`9/XO4SDCAZ?V-#`\AN^#8WF>=CTX91U$4?STWIW!=Z!"+T=J"X5AEO=
MK(:,FNTPD-EM`.=_I*8GY&HW,'AD)QB8F261@;H;YY9X&CAV3DNN9=C(UK5#
M.E+'W*#EQHRXE.N27BWGHYE!%($D77L@A8/*S,528K1%9TJ^51FJ[%IVD$$G
M8(0$X;*7$1_R"ZHOQ')F/HNM-MNH/7-%VJ=4>+ZCD6?#&A!51R"J8D)T(@9;
M(R4:*2(>\F'G.'@(B9*!8P`6-C7#O:UY9(Z642910)"XCDSQ8N<*CXVRMB,6
M-`X#@"XVSQPSMB($)AG:V>..5K96MEC:_6UOJI2E*4I2E<$YU)51VXO*R$@C
MNE:34=2/I#9*GR*6:<*F4)C&"*&54E/(--(FE8R&&0+&U$4$@`8,!B'!@2]A
M!<(,$[GMAE1U1URW#M`<O)T53WM:8T[<(2NN1V0<6O$L7>AQEIPD])]UP4!M
M-LV833ZL;44`VY3:2D9I`QY/L,MD0;R%2ANCC&CY/M#"&GF]29;8*"]>P'`U
MW?%I`J.O2^C`.%PK^1-\N]GF/),1(JJV#[Z3R`BFX#0;J2<&PF*XP2J&G4%V
M`Y@]4X69LCO)L*"A.1:&MO8ITNEA/BY4:QHXS)7E41%*ELA\U=9(EE!':RHN
MET)U&2HN.1-Q)CF;Y/QQ7:RV3*R5,21&#*"#Z*HV>[1D!L74UA&Q<3(<J([$
M+-6;ZD81UQ-Q5T`\H)]U!'52AI-527C'C2<?+CDCH0!D$0+'\E&2X[2%TXUU
M5]LU,<J<A9N@^WE%TH)%<)-H,<$KFX3:0:4`5$LAX&3`!?)7'+!IV(XP(5S-
MA!0\<N9(NEM*:L<04YP(AY;3TI*73Z.35D\RJDD1=S.AHJN;3@#(APLEJXB:
MHX):B,!@24<R!W$F./<J8L'U]=DQFHB2>4[+J(J#E45TKA)((.-L`J*T`S_%
MPET%*R5EI,3<Q"*@>34D\9.*!-,25)43@%H^FXFL!*Z#"<]),JQ#',FNA"'A
MQ:?3>9:NH1L_'4Q3CJ9RJ_1/%VTV%L\TW&N-HTL+)G(,!%P2%8Y@M"CA`)]A
M3GA2@-6"[P:9MR'&:5<S?,NY.(^4S[6`6DP5QDDZ^13&R@<0PS62J5(Y9GR6
M-C8Y0,O?(V5M83J9`\)8NF<@C94^25>XU0HP>`<BM[74KM$<DG-9;-X]%B\\
MY2;+*`ER]C/HLR=N3K.AD!47-%#(!$L!%.RX(%X,`3K>V7(X3U>V6AK5PM`T
M@RW(4\Q'.<O1YFS70P4-,-IFN[:R=DAMQ2'>BLB^3G&92,BN+2QSS%15D^:P
M+**P@A!#F@Z70CS*Z\[4*^K+<UC;Z_(#HVGU^?.S36;#T76K$BRF1S&\C&8E
M=C:!P<Q\\0=DO`2$DNI#),ALGS2#D19CD=2R^D)I8HZTK20LB9F\XX2:LZ/(
MF=AMN+K#1W\OIDL&DEIJD<D%--`4CB6_S!E0NB(*JW?#W(N'JJCIQ$^7,!A*
M!H#`,R+3%R[PZJ-:0X!BX[.,='GCLTHO\C#I%$=B`M%'.!%Z2LJ3Y6,58@I#
M)A9%03J**U3!\0WE81Z'"#4+A"JXI@`KQ,*[J17)<.M:6Y#,).N7HK'D[(BS
M9FDR'2;@Q1HL<J\BKKEL?:K_`'&V3:'=*0_18*9)+0XJ*@'BX[A!2Q<1<+5F
M(;`P0JC'RZ7-,3*1A*8:3*2F`0DAEG!DZ,U["PB%(A\(NMB9DV*M!WMFDN\S
M8)NJ6%[9$U(;&]KWHELKO%"FN^O,X;!%W`@RR2@F%E*?7&Q8U>[)57HK1LF$
MPU+-=1">:WXMF34D[+(="4CPI5%6!K@%RZGC<R&);OT:;4PO(C)@%TF7NU&*
MN[(QNP9*C.-WN\&DC2&MIL@-0D[4U,36WFLW.+RJ3)&Q2YT-O!J9>YD@>L5&
M'"+YYVM^?_)7K^@@SRGQ@,//CXUNF>+(+E1@1PZXS3%M'>TD*#7"/%"JG(+W
M:#:/7CY*<MU!\!8JX6:4?1EYLVRR<*(M$DR\^TK1A=]FHM^B*Q+2822<G`<C
MN[O;OHZ*(&(88MUTRT?*7HA`1O!#`B^4Q4[`E8(8(2XUL!0\LN':4\0B_G"7
M:+'F&+'BZS;>-NTJV&K(;.<;A,M4@KW;YYS`(J*M'E(9ODEZUT4VM!ELDTLK
M_P#%HQG`[_<*JO2E*4I5DG(7NFE<>^K3\VQ=,5/Z7&)%YA`'?J%&9AMX.U%;
M*ZLDV[=V`DG.I)!%224585$FR\$6/6/D4LT.KAES!5/.8X4H;O)@P%G>:-]'
M3T?.)'7)CU>MMG$DR#.9HG8BDB-PRY2YY.:J@4-^B(XZTPP,<-'TTRADR6+9
M3#3I+J)@@*3",]K9_((SU)<1"\B1ZNQ"QC6L#QVK=,NO1^Q*%'C!C]L/+)%3
M@79WCS`>94PZ65D6E1+5@&>*W"3..EP5E5(+H9Q-*TJ3^874Y2ES61B!+.:=
M&^U&J[OVT8VP+F<;):,4-U@,Q0(IRFF/X^XG"0.-9PYCJB<!XH<PN&G*`PR.
MLYIJJ3,E<)5"QLJ=*ESQ,P`;)FP`314T5%#,%S)<P'@*7'+C`Y9AC@CA9X"`
MBA99X"AYXYX998Y6O?IB'*$;.?(/!MO]DN#,5;4VT%BANQO*^0CB10@AU=!#
MQ3E(SEFM)8(X(RBE86R4"(0H0ALL#@)AEERQ%YM%3;^;L3G0W3[7#S4`\W&2
M7$HT@X")*@:2E0/-9`-B)N.::IDCB<?PR-6R)'RADF:L$9+C!846FS8I.B@J
MT,6VT%285YRS+&41JC68;LC<@N,X*03J7D=>CA+O1X-K"Z(T&ZK$'2KI"7F?
M=9]'/IIE'1310YX\!6DF\FDHF0B2>YV\>.#))M>!*$UM+-&1D,BH72CBT$7+
MFQ!A$DJI6\0,J6&%R9<[_P`$'&#,=0K$!WMEX)9E69;B;KL(ES1I.N>0%U.6
M$W%4*6P\,GCJ"0,H@%S(&8H.)H&]LS!7$7#,0O\`NL<<K&^/WD$:O(`B;#+[
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M23L%`P5+98F3().XPA<"]A1L<`\L<KV92OR50"QP-FTB.A3$^2=J>Y(H:$J1
M/&[IC9)=`#EE582B0*"EJ\CO1EL\PKLY(4[K[V)&E\GY#!*CH@@N;D#,)):[
M,]/D');E+LM4F.*DQXFW2G,8JTU"1F84<QE[*Y$TII;.`01UO!5&=2BG$3I\
M@WPBF:L=)$S9LH4'+%Q!<=$J?X*74M"6T2:(G645SNI08S;5TJ1V8H);@>B2
M<S3E5HH:@46Q2BNYTM0#$(*+?3AC*N2.AB%3!,,?#(.UK<V\B<-0[*NFL:D`
M!Y5);GS<YH#9;XC!S,QQM=H/AKMT5R'O1:8"6NN9'`H6-%!\4,114R"B#8J=
M3@O"X9U<FH[*:^)2;)ZLH3=$Y8C":"?<\QB?1":0V<5H"6"?,**M(1<LK#&6
M@2)@I:EF,.N`DL;7(&PL>^&+BAXT'A_?6+)^>FOR/#Z&OO:/MB=?5G8-K2V0
M7(\+MQ!12)QO`I#5=+5./,&1B;L7R:V8.A$B#340$?-)42"^,GG22F&FW"I^
MPD"J[54WTDS9$:HR45<`;"P\$Z2F4=:R2Y3.13$!O*3A+K@B.07!LCQ+$))-
MG05`7(V5L$7S\8!\)VMCR3'DFD%95CA]LU_IB"XE9H+BBR70ANP@C.Q`$""7
M6PJG&^?42R<X4448$)61#@H*FFB"AX'"H.0F%LNZTI2E*4JD4_M!PR!!TP,-
MI@IP[F>\9/MG((:P?$2TGRLZVLK-\B*J*()%3')IY<PI!F#HY=./F,"P0OBY
M,R-?`'/'(U/X9=M865>,Y4Q-ZPPDX=$X&EV-IO?43NA_.9;W6.O-)4@F3%LH
M)X,81D54X!;KC&+NI9P?9QU.7QY06`6@@("E<)RC4F@GA`VE!6I0-[+QIJ^\
MV3,/&4S]1'E$C%FUZLQFEY-:VTI*6#MXV+LZ#6<B0>P;-C$1RQB1C]L'TN/7
MNEI02ZAO4Z=<KC7>PS-Q!<C\H:NL#7E:D>')='2(,Y$XL*R_-4@'BFSC83IY
M/%2&LC:?L^->&%URRPBD8^1D=(GQ/;PS`37R[/%,7.??C#::6BK-_/';QV;%
M:T;>K>PDK&XL#:*UQRZ2ZF@HS/>"^XW.5DK7%JI"6]E(V7/,9NI'H04CN!P-
MM*918,J9P,MB,H(B7B8PQPK]M;QSMS?>)]MH0V'14YH)<B3(W9=UOEIBN@RK
M21$SZ9T/QLPF=+"5:Z$VA6>]&ZYF&>.#(J2O+))PLQ:&05!=+W43Y8I8[+7$
MI/<OO_A(/2<#`\PL/CWB!_,#;E,D1<6E*\YJ\I0JT(J=1YGMI6CY>2G(5'6V
MXH.Y3N^E1N#J&"H$&%E92`$'REG5])VL=DB#)`0IPVG8*5`C9831;D0QU/KL
M9T&.Q&CP4SY(#DJ+$T.Z"^!E`B."DKXRIEC=82$Y+3C-K`D0KU8)QFZ$[<<>
M[:3XQ/N.+Y3BEYPL*H26FC/QSCN=B;/-U2<*6BY1"N+4?`FE2`G['8[:*KS-
M=)U+^A0_D1178W2#B`\EU$(V$Z5\'VV<"M/BW9RNN:Z0L\=$YIE22YMV6@MW
MO-:ES8:-'W)#J?>&M8)0Q$L>9FHM=91>3DB1;2(Z5<D6$1BH[<;2A:U^_P`@
M38"'9)FV3H:0;'_0O!S),+\ANER-MUHP+\4I/)IAAO1ZW\V0ZHQ>+67(_3TQ
M==;@6C9U<)*.+N!9(A-%-E4H\;P@'9'#;OC$FG#VU4C20(0`;>MG))'&_'&^
MF..0WNH%\&3'\L&9)#UWV%-)L8))-LD0U$09R(RRQ4QWIEW<J&13@*:6*EC8
M<@2KH!,JCN;QL[CLF-];(52-:D#<@O-^O3'<ZR11D];VT*E514<D>.9!B-'1
M'^Z\W3=867THKK6CG%SN!8'6[J`^69D<6SJ$^$:?V=I)I7%2Q*3"C;:[4'>J
M1I_;TOQ@MKCB2RT&S]*;MM/+`2%1P,EOJ8BH\(.?9]+,)AE`*)AI[MI#`%6+
M(N8JC7<=V.'&<MCI[WJ=$8K\-Q[$T_\`%(S="X8(*RX[1EANOUC2BF2$DG76
MA)K.,%$6-_)9(-L`JB.O.AQ%A`/'LVL.!?$'/LSJU=+RON-QY-E(?)%F[,Z@
MZ_)D,;X,MHH4A++,D72^4HT551#:!>2G(P6>@/-OJ<X0PC$B7DO`DIH8KN<?
ME4DGJ("8"<R(+6Z6M:_3KY[].O3K?MO>UKWO>UKWO>]K=;]/-6M*4I2E*4K2
M]NMKV]GS7[+]+^>U[=>SK:_2]O;M6+K+7!0Z9-4>96,#)Y$MK/MOX#8C3R.1
M;H^:8PMWG^Q3(TG2P8!QR`-MPXD/YG-5.0A0[`DA6J_W6`!WERXN5ZT;6Z![
M9O\`T.XVHC3DC&9MC8GW8TKVFVT=P[D8S>R5E^/#QQRS\],%%P+2&4730"NI
M9H[93DD0XJ*:0G$``0KAA7SSLHE7B;W.5]?^0"&B,(MEV&IVYW$O?=@F2,AQ
MC@CO;6AR22VG>L!J!=QKR&*CJ[20D-0)++2<8)4P?5E7,FVBZV0R,*8DL_%!
MJA/6IB+R3H3[C]%CTI-W);MELMKHF676LJM(6'I9Q;64;YC)3%6%'-HA@CH&
M>*VU!B:8?3"@@6``(V8F5@8XM2^/.?B,<,E<W)THD/83:*4$S9*`-CGC)DVZ
MU%(U0`]LG*IJ,X;&`%FLO.)WRFQW0SFI&$>DLE\8[)3*8+3CZ-HQAEM(R6ZE
M;*2?ABU/E#5C5U-CS9&"V:S]CXX#&@%S;`D%1F.IX;0Q)#[E<Z5!+W4G0C'%
MQX@,9-C`\WTAF,>05\)9:`@:\EEVBV$S$G93B3D?A[VY3-)MY&>QHKCY<EE[
M[([VM#3IB(3M:Q57CC4/?G9"+@I=4#*RYE-O,-$,EH,9"^K-*-0EL<%/'<YM
M;45#T:X);90KV3W%&^E#=">WLV([B=DZV.35;0D@T4-76,E(RO;2Z1NEX/"&
MS@"<D$1#"2@,`RE1JVW*_P!0"(K2HR\5IIMM`4@7.M*R!TOC4XUMHF7+.C\Y
M;,9J;,7]5-=-BCTI9+SB0'1)>Q&\&\L@#.K9=]/-P-)Q.-)68Z9Z*W&:F-%6
M55492="L&E63$1N-YD)UCU<S>M>S;.YVW]OJ0@-UOK756X[T75Q.6VF]X3*.
M8Y)9*84R0S`H33>\I,Y2#;6*.3S)XJYNY47)4RP"P("$[Y'<:93MI[M/N'O1
MQL;!3YK@N($4L"&=X&-LTV6A.;5;ZO'Q+9`(=NQFQ!%Z/I8;3H>ODQH$$E-E
M%5CQ1.(:GXVH>)XJA(T92@>Y;\\6\";`IC"@(;1=9PA:`8/2L]19LU%>L=1!
M-NN<T^BAU!JC.:B<N/%A`8LQ23"K$=>*HM&EUJ@NL-045U.LKC8N5+KF_=.I
MWF'A]96H.U3HDJ9-AS,2Z^MV57[";^;K3E+*2F*_8^=`LDL]]OL\CMYR.N,%
M5O$WJ(9="BDX2N?9ILH9/)*D[03Q2Q2`M%N09+V,XA=F-A6<R9&=.M*;R(-+
M9)?;^<5QN[SF&PCN5#L23*ZV,B+`K//2"]TBX;PELDP'`Y3I:2%X^*8$.F#B
MRX;6G:Y<2FZK'9/$>WI(U]23@>I>QW)S*$WHXS]AI=+(#=V-2W?E"!A,"N]!
MT]R*"DLJJ(9'*(@AS-L&BEC:M<C<H"+;KNF'#MO9%R-K^UGO$"`R+IG"CNMH
MQ(RYE(\9JB6CS_-LX28^6$47<6NYUA6<+9.-I8;0IMR(J:ODDH:Y5/-8`B)X
MMB_4XVXM.1=0AZ:D%R:KG6.NN'N?=D<:+32E:88`4CKAV*8CL$R'$,BMV351
M.1&>M$36:FCN%34K!622@=E7%-5S`2*%V>:>,#D%<KTA$5I:DIB2!#;HX-G*
MMOMGS3%N2E+Y'3=C+"#..3R*/F1S0Z(\X'77*?2(_1XP3V`SG6R<G"ZU=SR:
M[5)N(B)5+8WBHW><T"<NL1,^&D!U+NVO*E%6X,)KJ=)4:)R4Y8E+OZ-7>X`U
MG)R.!"4VTMM)/:*Z74TM:*`"'E93+@-BR\3-'5(&MC9XV-U4S=).7S10S@WD
MKG`F7DR$V1NZFF9('=5Y`UB1HP1=>RI'-PWDW%ZXBEQX74&J,UBS)3V0GXKQ
M9PC)&9`D)17C.XH]P]8)[XMY"?T!HK+*Z_9\HA/91S(CWB$\>S`V5>II6@,R
M=S;;N,K+Z)9(OB((X)0!4'9_@,"YDF3L%C:LO2E*4I2J7S;$+*G^'Y1@Z2$L
M):8,O,!W1J\DL8,+.QQM/5"/-Y7##\+AGB&9P)GQ!R@]L?"%S80!@++`4+#/
M'%W8W!YM>6USXP#KLD\B'N-I]L-]#5]RH1,H=U%)XYU`%]0JM0VU%<,2^"D#
MG!6:*O)J<:Q%-E7*^W@6S#R,XWSQNJW_`..O8W8+=>4GI$4=-\I#SKX/]MM"
MFJZU5U,]$0TJ;9:4EHS&S;,M_%3,N\HU"1(<@$<<A5L'$Q)$Z8!^%R#SRJQ:
M5.)C<>2HSTR;:AK6WCJC"G!+M1HXY$Q8?L*JA1K[5O2&Q([C$8D.8=F9,P$M
M.,E=>P?"$&?(MD)6+FE-4+*`9[`O)).NL6\PO!OKUJ3%#?<!+8-M0CIY"FPC
M):DC-!$D=<BYC`L)J;,LN,)',O-&8OHG=3+17`BI2F??J`G*[94E0F77$I5/
ME,0K0=GN-R=5V#'RV]4]*G"TYGCO8N)N1.-Y?D*=(1:KEE*5VYFAL58UD9J%
M$"NB(D&!$]?VR1AX!O)!YMPB@-8DV215[OAQ"KKGPEUVKU$397XHMD]2H<UP
MCJ*523M7)F0(RUX:Y5@MIELN6GTW'(XFFG89MP%(CQ+6D^454BX%MP)0N2+@
M[/*2X`MJH>7ED]'*Q.,"?D'='C<D*2(P8KZ:D?,]RS%N5)B"ZT$=NJ^T#(U,
MBO3V$B)I'=-D]]O4%$8R,^';B[DYI^"=[R6!!7*5:2.CMXJ!:HC\,6UK5T-B
MR,`F<UDE_$IN5H`?C5C9W)Y>14CBMFK?50V/GN+R;X'6V^D.%?4FV18P=HS*
M.O!%(L=*?S:17`KKTCK#?QG#XY]3)/U[.;CS1,`J>G/W<3:%QSJ3B-K&2AIN
MPS&3?;*!%\,1M@;)#XH"N]R<8LMNCOM90L";>LO&`6VDCJ:2V"K@5+!.-N!]
M]-%H6Y`VV-J6O+\I;&\A>PFQ,)FL)5UZ$8B8PIN4V2D-YS2";RF`%=(CLU/3
M%1V.)HI"(JJBJ73@$%(,Y**GX0GW+7OC,'=O(;R;3/M_KK9U0M.&P^M<WZU7
M=+_1G)'BZKP;%!IB"N%[0^W9$-IIY>2W"+@M,:TG,-7Q3"^>:D3Q157#(OE2
M?8[C/D:7-M$'<2#8*?6H>^C7VX0,!]H8EE9EE8+G;49M2XEAJ*SL7'Y-Y@*S
MA<3D@,J9;QMCEV$(YW.[P&^3="V=9HQX=K7`<Q^F^SFP3A@B6M.$AR8[!Q.U
M909J6H*:O%JUKM(,?RV\HA*2-KWM!%4EJJ>:6XQD9LH!ER9/ICEEU;9AR/\`
M(.[=4E]59!Y%CQW,XJ=VI&A/G:BB.H>;SL5]\MI]:IRUW7RLD1LCIB^VV:Z(
MM6G@G.#%S+B*HM57;1=I.$4Y@MD@"R@<,D`VZ97,CYLR4X;=#B@W'FS9?DGE
MAI:])#@1-CMJN("0H?4U!\PT26#\;ZD-=32]C3!S!6>9<XW`['_)OB",>&+G
MWEB&6%+$QL"W0+Z%[C$WE;K5<R^A0!9QG6'W3Z4Y5V/'"'(\.D5AY:@&EP(/
M/)EF%=\)30;;S)%;^4CK(=BXU!@R0.=BQ@T>L&3$:V<7^][$"XYA7=!)%".Z
M_<L&X6VLIE0Y5B=236W$4Q$%41AJ9902G69&7!3QU8"(GDQ!2CZ^D@DCQPTA
M!AV(`FZ-:Z<2^_UER:@G-K"@0"VYFX/=P]%D1E@RY&SAC.*)_D/8Z0I&8+.2
MS)"0)(DY2C!;3'>&ZT5]/5=DQXX*RLYS;F-L\&Z.S4JO*KQ7[UOAO:3M1*CH
ME#JW%'!?LAH*\W\/)4>#E8]V.?D9%&,S#`)AEN94<BBCK2LCC*B@ZVBE*F""
M2<`9K(WFKA'00*'3+Q&\@4P:7[SL!M0R"S7),NDW$;JVP(/7)#B,GBZI3TF7
M6$<F*3#:RF.\^R$1K(+>0%EE1TK*"X`XGBF&#/?(2,E`(V)RX8'C:W89NPF[
M;ECV`3+;BJ8]L'++$4)S1D:&&RE68JK%<0M4F)DV2,BI>#?-XK#/6BPJ8,1`
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MJH[O>""S"`+79*+81==1\N=7P%`=%02QY<-)I(_=)3E`\&"2'LQ9_+7K3($@
M:Z1RSVQ.:BN[`MB17@IX+<7&F`=U]0XSD]G0DO"[%-61U5I/EA'C,P/]GL%,
M24IKNE2%-+Z8YS18JQ#Q-TF)1+=O_?\`U=G6W92E*^4\+F"3-#!WZ"!%C`F%
M[VM>ULPP1,\;WM>U[7Z98VOTO;I?S7[*C'X8-FI>W'XR=4ME)Z7R+HEN4VH\
ME5YKJ:@(S7(J)U'E5_-8B(706^4(HZ=B$C(2:7R#)%`<!1`<S`F.0XPN>4H5
M*4I2E*4I2E*4I2E*LWV_W<C'2Q*8"O)++F]\`R(O+B"DIT#Q`[IN=!'-O-\9
MQJ2NK,M@E5-V`MPN3!Q+&G"62#24FGS:<55#)+-1(>,]/A+D:@'838E^Z]Q<
M3?ZY=@MB*5HQ,`K=($H?<3@F.)"4^-".FRL#KF+N-O?Z"RB1D54+J+*2T$BD
MC#)>2]FYB)U$!OXI2E1:\SNSTPZ<\=LS;!P,X"+8E!G/+7-'05I2;Z*Z"94A
M(>RL1QPZ0A45P$SR4:R.M-V+9$$4P5$$(CF0SQ3((X6`%PE)QO>]NW_"RM^"
MV5[6_P!5JUI2E*4I2E*4I2E*4I2E*4I2E*BZ86S$P+G+YL+J<I.(F/!S"T7U
M\FMKM;%`0P3J?(K[E^4&HZ%D1R@D,'$=+J*$WD8I@DG5(=*)9D_&2),L9,&Q
MC$HM*4I2E*4I2E*4I2E*C=Y9#+6*:/R:(Y61LN^CAAQ16CL0EI\[OH<[&HLI
MN.3FJW(R=,8R;F=($XX5D!YJR2://!5'%14Y&S42RPG+*<>,)!Z'SCFTN!F*
M?$U^2[`G*IJX^8*CEA$\7WN#M>V9C7]IR)B:24GOI,?8ED-RF5`-SO2-8C6Y
M+S1%5DE,BS(82`R4AK)`3EQ7\J2UNENGG]N_GO[-[].ENWVK6M[%J_,>XU@1
M?%[!W'\'GX&PM\L0KBWQO8*PF6&.6>(=Q.][_+#'+*V'?7QQOETM?&"QYG]E
MV;Q_\IFR\CM2(#TR:E\CCXT.A=`:""Z`(WN.1>$+10UW2Z`5AQBN9PAD%I_K
MS\7\1%A!S6@"`3<3PT,,4`0/MHG+-.%Y2#TH"4&_A-5N6^W'V--V;0("C9P1
M]!C.=_HL!,ZV(3("F"Y.X<;W(9$!F/XSAF_+-;O!,6D'(CQI;^%MU]"HEV1E
M')GQV_'5E*[&>B0&I@(K?-O:&W\ZHT<RNU05Q2$-8(CA&;Q5TDDS(\J#H!9?
M!1C:D=%)7.#T#[F\[>$_0V]NVUV%(E[7]FUYVE:]KV]J]NVU3=#F`"P?A3`P
M0`?6V-Q!A`PL+99?O;=^)ECCUO?LM;KUOZUJ^/RPD_RFG_Y\4_WU1F[:NGEO
M*RJ"%HTD<:2S"EVDBYF#>U#_`-BD&3K/FYQ8LX00243MU8:V35P(60;HXV9G
M%5S.9*UC@6(.).]XO]S=ZN>[1G79Y[-2U&W#TXV&QEJ.$)71XWD3<!;>!DW)
M\DM.+4`5-3EY$;*4,6)N!XI9U9S,+144NBEU`T4!/&@`B0]TN;P[HW#$$#NT
MN$#J&)F'E_RL;LX_N@\\L+W[T1BX"8]N-_W.>&&=O-ECCEUM:2W4AP[;&HL,
M"[TXZM(\U6=JW@4*:JN:1%R,KL:Q9+NW1C!V62*0Z+.K,WDM8K`(96Z3@6P3
M,R0MQ!#6`=T'EA)_E-/_`,^*?[ZN2I2E*4I2E*4J"OFWM91;^M#79L<<CKRG
M-Q/>0,8X6N-B;R>N\J)#60VPC.&46T\9,635T/-FO%.36X-DS!DH\M+IQL9+
MC=-HIYIBJ./"<3FG+/)N>0]LC<,;GZDO-0DY71CFL&R$XI$HIF>;<A2-XQCF
M1S%@$M0<&0K1BP=>CF/PU)_+HMV\JK:@[AG(LXM8XUY[ZB:YA-QYZTBUYC&4
MX')QL:4'=LY`,*.X:0DA>6QDUKR\_4YK'E-I)R2K(Z?FX2@&9FP`[@%.)96P
MV!FZ8?%!Q+YV5<@_,!*.K<X;LXLI-;IB+N-U@Z`O>6&@I-VYQ<FDQN7L(GQ^
M]DDLZA#^`K0*1Y$*TDN%C&$--&,'I%$-6=.2PV@<6_E^#1YBI*7MJR&`Y!O9
MZ]N/F'DSB#260$W!`W*4.L6`&\]4F>,GAF=LHF%U;FTTJMT^V#"67;!6+S:9
MD`2!=:8;<"K5;NC]TMOTIO8IMY+Z)BXQ)#TY$Q0+JZ=Y:RQSW&@(Y;+%*\9\
M?RQ\5#S,6RL7Z9%\,A[=0L<L\9Z<?-?W6?Q\JW4KX15-.`$R"&/D@A<+VMF&
M*;+AB8WO:V5K989BXY8WO:]KVM>UNMKVOYKVKHTDR%Z!H]?+T06RM2:N-)HN
M)RH\<,8RB#O1^J:(DFU$BSFD"KJB8DBN5RF2X20B!J:B0(9J1LOB;.%@+YC8
M1'>FR[-=G_D4.3[MM:_U$UM]>W7UYTM?[O6UJI0UN=>0'M*TKP<U.(OD@7)8
M@TA'JG++&()>N@BXQ2$K)*FN1X97`\YM#+!8.M)1E,\EV+F3.>0)(?QC$OGC
M;"]QD;\GFPCYD)BLM>XB.12,D-VN]NMI8D=\I.OP#+828MJQ5.//%VC(\S*:
MJ"VFT6,"JZV*FIQ\_@G%#&10F9,6#!SEQ\LI/\II_K__`'XKZW_ZWK^M7T%S
MI,W?.Q4T6,7#MC?.P`X(U\+9=;8WRL%GG?&V5\;]+Y=.O2_3KTO7U4I2E*4I
M2E*4I5H.VN^^H6B[?1'#M/.;1BD-T#&0&DW38:TYY`>8I*V-S]F5&+(2G+(C
MP#3?"`^53+=;"B42;#@74S!2PX5\^NZA<D&E.]]W`5U:GIM20X&H1+JKG8QQ
M(=L?R6WD<V,&6*KBQ&$EMYG/\DWS)H8$H7<&;=NB#'!0BF"A<R(&%E;`8WFF
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M"BD5L-C/TR"Y!7,$AAP;"XAC!9Y8=_WUL!`\^G>YX993J5L\)C[&?_PQ/_IJ
MU_;+;!GZ@QVCR2](YGV3$M:>!!F`(6O$(OF=7F4/*"0M+`:JIM)B$3JNGMH`
M!#'*FW`8"Q3RRD;3$\3/QA1+8Y1Z6YS8"RRQQQU$Y2LLLLK8XXVXW]D[Y999
M7M;''&UFYUOEE>]K6M;MO>]K6[:Z@Q>Z#M190;!![1IKWR.2&S50PJ%$QVL;
M02>7:V5$TAJIQ"6BQ%?;Z2HI)L=(6TY01U0$N;$$3U0B<3S>()PJ."'>?J;R
M11?M](BQ&[+@O<^,U1%9Y]YCKNP^I<N02S#9%/5T5'$2DUV/Q)(I*@Y1AEPN
M:)M\N+DH&TXHJ'@<,@$TS?&0OPF/L9__``Q/_IK=:]KVZVZ_AM?&_P"*]K7_
M`-5:TI2E*4I2E*AHY:L)*ER+I/U9,Z71IM=![_AYE.X=!>.Y27K&<?LIH6PS
M$R`BM2L4%1GFWF<DLE.5)4/R2F.8BG'CS7#CT0M<=8SSSM#X*]6$S6J4=C,"
M/&[#^@YAUQ]&`ADY%F_3AW7%DL%,=3XQ*@+A-P/5T"QT&V1#)T5.-%BA()U"
M*Y\#(T:S;]P"N2G7YC6%N$)8'(/`:^&7@LA<,A`\1>]OX/(3##,/+,.V?>WS
MPQ$#RRQM?''/"][96@Z2.%%J'=5>035N3)N'>27OAMJ^]T!GBA1H"T%6()B=
MCM9#]1<6\FG'X["[D;C/=L=MDZ3)J!U*4%E,NLHRJH>`4[#ENT6X@T*QC*6[
MR>EWVJRY"K<C=I,O'P_T/\)*M'^,27BK%@V>EG+>(KQIC=,N#G(F3JL[,\GC
M97M:V*!CSK,X2=!DC4G7W5Z;X8:.S21K6G2FI-)VRJC965A7M-#G,2#+CL+D
M451*E4OT8N_(`W@E7,*6*2DI:(C`GS.*9B;'Z'W-YZB?H9;_``6#(>-O:MC.
MLJXXV]GLM:UO/?S5:+W7.*(#P]/+,(3,/.VP.O\`>V8>>6&5KX.-7$PO;+"]
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M<`#.76<XFXOAO%26XZ1X]<!Y4',IA,R\0RV)(<N>J]'A(A=/@34UY1XG:CL#
M2D(I/KX4QH6C;:%2VZ;F)I2:,<BCNW*6E=R.D_92<&6&.!UJ#*(-F_9.`[P@
M6P/6R&F(J/?D?T8/<@,-L>'`Y7+1(FM*<HDF\XM78.;^.JZA#SI!=J"W@"MW
MLRP$LBJ*(.(2N?S%4C'B=O!$RX`N5QJM[VWXA(_VPE:9'LN/W%LL_:]GZDLK
M;1EDFA=0.R*FZ=3>#-C`-LARBN8MZ!5%V9@%XW?(BNCO0N,PR2=F@EDIQ%1U
M,[O1N(*-D79LM,)9\7^A0G[Z/;DM3H@]">'E0+:Q^P2EPDL&S#[S<&9?.-B9
MM.&EA);!5H$UXO(1ZP(KI&:Y())'L*[I$T7U(&THG_=L6!V&)M<F/C3E,(3G
MF2.W?15/PV;@R.O%0COC]B>.%V0?-MN__`>N28-F%G?+/O!,,GS'S7]UG\?*
MMU;!/X,3W&7Q;UXZO=':B?+<UV^P9<Z;!#^B(PK]X":'"PZ_0/BRW7O0Q,<>
MO2UK=>G7I:UO-:U0BW6%6]KVNI'[VO:]KVN=-7M>U^R]KVN-TO:]O/:OS\HG
M_P#UTW_G1C_>ULL>.8YYB6-&;""6QMGG8P-;/.V%KVPMEE82V65L;7O;&V5[
M][:][6Z6K]+*2A:]KV/'+7M>U[7L:,6O:]NVU[7L+UM>U_->OT\L*W\IJ'^?
M&_\`?5G8=Q`FS1J5.0W(R9',7QC[6ZV-QQA1KVM9U2_>UK7$SSO:W7*]^EK]
M.V_LWKT-J4I2E*4I2E*4JTV>Y5U7U'/$M@9K.HC&<DKNZ,]?49[>A1S/%ZNU
MR.54/%(ZC1"*M1$<SLS3;J)I;7,TE()%V\CX7<CR7;$@<%A8M3J(TM\R-M+L
M0-/AK6]TCZ^R4U3^J8,<(KS29TBJ,Y(BW,LO92\L.`8($]C(J@&M%4X-H"&F
M.X";94`U+QA9;X*8V>N":#FCG)J?Y%U.4TP_@=T]%TSRA42.,_$,F$/)EY5'
M<AM\"OH84XXS#AS$3QBF30"1LD`2Y6Y:YZUU'.R6-.`V"FJSUV*'K(BT]8C1
M-.MEM&X.;Q5ME4-QQM#FS\P+LPNI?7',;6G`"[I.9QM21F@Q7&31FNE%6^W<
ME!:0E5:73@Q.YG6_BJBZ,R^TQN>%9%V&7=O8M@2!I=*G&;FSF0IPMKE#9:&6
M4T`&U9SN54#,N9/R776_C^+FP+J2^O8D4E/2TE"3<1+&-&-5==]/><G;V)]9
M8E:,,1R9XY-8'<.T643,$D<5S+,[RL155G,$R:-B7.GRR.F@F!/"],\"8/7'
MO[99YY`DJ&3!.,Y"-E!QBIHLQW>8+&2PN8!@N8`;BH*".`,%EB($,"+A@($*
M'ECF&)CCGAE;+&U[>(-?D(WWMTM;=S;SI;#"WV2LTV_O,?6L]K6_%:UJ_0+D
M0W^+Y7S`WBW!!SO;O;Y!;-38'E?&][7OC?+!\8WO:][6OTZ].MK7]:OIMR.\
MA6.6.6.]NY6.6.5LL<K;0SC;+'+&]KXY8WL^^MLL;VM>U[=MKVM>W;74&+NY
MN;%[8(LF-=M]G(]9J685#2:TF-/DKM)LIYI<53BZM&2*"WW:G)10PKK:BH+"
MH,7*!B*"H>.*!O(8V:'&$[2+R*<@1C&V`^\VX@V%K]];$79R;A,;96M>ULK8
MYOG*UKVM>]NO3KTO>WKU\_IA.^_V[NWGY2TT_MO7J7=S!R5(LM</4`OB57\]
M9,>BF^]@`%%WR"ZEUYN@^`G3.[B*>`=<#D/J2L;!($@029(,P;$P*E0@BX%L
M`@\<+9!5*4I2E*4I2H1.8[C0U>VOC=8V5DF$M?I0FN%6FTB;=/;-3!(4*1.:
MBQK2`,\GE'ZU([-<:42C7-V%5I=+D)`4TA8"3ED9+(JMRR`9/C@65<!<%QNQ
MYMV.DF.($T4U,)+\4QPSU*#-3-SSNZCS6#*0]W<K`27)3L2WHXF*Q$$<,YFW
M6:@I1+R\O&@E\ZK'@2Z.4*BY2%*4KX5/ZG'OZ&;_`#<6H3>YO?43]#OO#D7Y
M]I6JT'NNSU'=Y_U@(!^4"S7E"TI2E<DC_59,]\"/YV#7OJ(_U)3/>\C^:`UR
M5*4I2E*4I6E[6RM>U_->U[7^Y?LO6+=S.\7>H)%S@[P6T\TWGN2GR^%H":D/
M;3;Y[:F?1-6EMIMQO,$\QY///),C@JM,A+:1XMG'JP32$]P(IX==**%G&W2]
ME"^/@BB1J1)J5(Y5D-'5J,&T]]C7H_"<,ZCSLN[*QO#HRBP(N133(7)I5W(Y
M23PD`7)!P=3HQ;)DHV4+!R)B(E$L<"68F4U]*4J#/NC_`-2!V.^$;3S]-#7^
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M/O!>GR85J\$W+SV]SA\3&MM*4I7K<=RA>HHZY_"!L;\^+RK)`I2E*4I2E*5"
MCS<OK7MUZC2[KB^)LU`84K%$*$]C2;9W!&7EF*R,=L39Z+TC)\R(P&F44W"Z
MV(>=N19A@IMTE11%IQK91*6B]TO(\,!9'W/TH1FHR?LUG'CUXB'18)AQA93*
M\7$.2/%(Y'PCI>N9469!'VCDPUL`7O1@&/BGGA1B.8+DR-E<,30)@7**I2E?
M"I_4X]_0S?YN+4)O<WOJ)^AWWAR+\^TK5:#W79ZCN\_ZP$`_*!9KRA:4I2N2
M1_JLF>^!'\[!KWU$?ZDIGO>1_-`:Y*E*4I2E*4I>]K6O>]^EK=M[W\UK>S>L
M7KGF?&M<G9PD.-/'%V3=&L<V2-'4C-SD,0GU*\<(;EDN%&\Y"[*SCZ/TM8P!
M?`R!F@/,JJ+>*>.C%4T#%(5L#8JXC&[W>"$TT#FFSM,,AQZ(NA#SV!?5L3_'
M6P';&NNH)H-G1L&.3!;;T34M9]'&%L`S#K4+!&21NQE,Q+G!+@"`@344I2H,
M^Z/_`%('8[X1M//TT-?ZG*Q\U_=9_'RK=6P3^#$]QE\6]>.3W2%ZMCOM\(;"
M^9"+:A`I2E*SNNX>OKI<AWP?ZW_*J7J]#ZE*4I2E*4I2HPN0V<-O8Y>.K$:Z
M.FH96YWEQ\OD0:+Y^0%8M%[TBYA-M)4Y#6UN5F\ZDASQF=8P:XB'$3!H-"57
M.[51:+D\&$(V4=T.%"^CCAE_9R2C.VS?VY\FMR7H[V/$2RT3MM8:+[8\51VY
MHP8+O8J2PI?;*6VUF4&JZRRJHOHD?DMF,B2FB*OCL1<;PR4WT%Q+U$^=-`@A
MYZ?M)B3W"<=3VDNZ>&808C(F?:4UII"P4C$&F_U9&7I.GHBNMY01T9)1R;@R
M1&BBG#*Z_G@*WVXGDL`QS:LDT%[GZ9$`1A'NR$>P[KK`>OKJ2WI&Z[*!;5_=
M54W@A1XG%]I+(+45DU^N%XO%R,%YIR6D*">ZHQ63]Q2:;DU7B1'.IKO*BX9#
M=*5!_%G\8,VV_LP=3?T@IIJ7R7?K621]X+T^3"M7@FY>>WN</B8UMI2E*];C
MN4+U%'7/X0-C?GQ>59(%*4I2E*4I2L;#F@VCDB&YU:*:T)1XRH[:T70"4G5]
M1GO(JQ\0D3<LN')3DS1=>(P-/+#,\V6\B#QD;=8[N2`S(A&4%F.@?%1@K'`\
MN?X2G&Z24J;$1^]-R-#M\E(XP(PE!)ES2QHPBSQ8C#<CG?",YH`>I.&4PN$I
MLQ'6$P@X8A6W4;Q<!\F*[<ATQ.+X%B^$NFTTX3]&Y1#:>K^M)G8R7'.&*:#P
M=$BH\*0LP44,Z53,5Z2936$MQJ5QSI\W8!O,B/&6]GHX,R:@.8(MY%+9KUK;
MX0V-Y)&T\4!`W=TPA]`8CH6"J'A,VI$_K4Q)S"5EA0+IC?PDV*G]'S"?1-I'
M3I@`HI/YCJ#T+MD4X44G4V$1I@+KH0I3+7Z_]_QVI7PJ?U./?T,W^;BU";W-
M[ZB?H=]X<B_/M*U6@]UV>H[O/^L!`/R@6:\H6E*4KDD?ZK)GO@1_.P:]]1'^
MI*9[WD?S0&N2I2E*4I2E*VYW[W'++IUZ8WOT]GI:]^E8?/(AM1+>6W,^LY%V
MDX=H+9`LJI.M#:8&S!B$#FR4,N1UQBQ#*]OT\B;^*&!E-3;^0634:#"<9.[9
M<$?!M0VJF`@<`C]3,<,;C4U;5AXMM:F[6;9Y7C2>GTPCNS>J2-'[<C>?0`&P
MP'2A/M7;\7$R;&1Y%2VTZT>/7Z21;G<<%ED=\95%(UF,;%K#M!/V\*<\#,8Z
M1ZD,J5UA)*@B.J8=BYHM!\*HRH93RRN7;3136ZV7W*4JK@"<<)9KY]&;C;8C
M>,*!=+]&JNXB3A0D'E=7I_W"7'/A&.ZNJ+<A1W*"8:/LN48(EH2>H$?8Z05`
M-KB"?4U!H,608H>)<N,*?245ZM4\V'*FD%&Z"_SJX3$;][^J5!GW1_ZD#L=\
M(VGGZ:&O]3E8^:_NL_CY5NK8)_!B>XR^+>O')[I"]6QWV^$-A?,A%M0@4I2E
M9W7</7UTN0[X/];_`)52]7H?4I2E*4I2E*58EN1!FGN[;,>&MLXLV(M@'E':
M45EM(B!7<(.<ALIQX):O@PWH3+--QH<D,7RV9Q-HQ)P)BDWL5],-*R+BH&B!
MH\!?AN+;6]H:Q:+:ZLM`UX96L#Q=$6L"2IQB=CHZDDD42>GHR&Z>E,%2\NK[
MM<9Q237$&,WPQ'`['(HD$I&3$7!7,$4PG;#E3[>9VTLS;6P;,K@CF8H+9J#$
M[!=.I3VC=@.U-Q6G.UB<G8R:\A%Q-4UU8;SE!6$5*8)$4J22TASQ\\5(HJ*B
ME@$3;7(:F,>#8`?4ZZK:_1W"D6L&,;Q?(I9DPNQV^P2K:,S`AN(L81WPF-P(
M$JK/<<>.!W99?4`"RV=9[K:I10"'"3B2FI7PTI4'\6?Q@S;;^S!U-_2"FFI?
M)=^M9)'W@O3Y,*U>";EY[>YP^)C6VE*4KUN.Y0O44=<_A`V-^?%Y5D@4I2E*
M4I2E*M5FO1W3;9%YDY"V*U=@*>'BFMD@S49=F6)V1)I]";2<JK2X$CM[-Y(B
MS=%*#JJ\HGSX258M=2,9%LSWA[D2?@.EZ\0?Q]P#,LCL/56+-8X:F<JR&F<E
MUC0(SH\8+G"9IY;61&*HR2VF`G)@P0)A6P<F+0-.DM@;%PLO8HW?%,3][?'R
M,KJBG:K/E%:3:@!_28Z%>-$J-8YV7<WH8B-WND:8(Z*$/1:<+'B2O9*;QP\3
M<.0R-<8Z64D]*N&".,(`6'L6U>;O(/!X@F#RV_B/=^67F]XC6%C4V-`V5&D'
MZX0>XWL494E/2.I.D)2?.PKY06"DE%%33";D<ATXL*Q$J@I[.+'5CQH6=.W7
MU[=.V_K]>SKV7_#;MZ>MYNWSTKX5/ZG'OZ&;_-Q:A-[F]]1/T.^\.1?GVE:K
M0>Z[/4=WG_6`@'Y0+->4+2E*5R2/]5DSWP(_G8->^HC_`%)3/>\C^:`UR5*4
MI2E*4I6E[6O:]K]MKVO:]O:OYZLC?7&UQ\2<]7;),JZ5:LRG(KZ6Q7$[GY)T
M$QK(#T<"D(23TL,54<[K;:LMFBQ%,2TY-3B@IS(DEIY,`H2!+EP^]OW34UGZ
M>,)I2`T-*T&"VI'C?E5?2WVUM>4]G)#!;LO$F^U"[N23*0P@0&REN\NF!MJ[
MK)%0L#X2EG_QUA@KY',,;/.3TQ+SF,:_QWK0%IQG.9Y^NL\5>&V;I=B2G0@V
M0H[5\E:4V2FQRY$!\*#["!$"1$1/(CE2B@35#]E-1(HH2D*)S.FI+;J,#T7Q
M8\]FT[D2;P!Z4T?9'8D\2B6)S$$.I':K-=D7L-N,1E64G2_/1>$Z\<+&'0X'
M&K)C=L`YEQUVR-(Z4HRITJ#/NC_U('8[X1M//TT-?ZG*Q\U_=9_'RK=6P3^#
M$]QE\6]>.3W2%ZMCOM\(;"^9"+:A`I2E*SNNX>OKI<AWP?ZW_*J7J]#ZE*4I
M2E*4I2L;7D#BKES=TY;--;1C7_7%<AZ4C,%K*S,CHV`DF`9X+OACL!NDS:,A
MNB(WRU'!BU$Y,+ET\$%2S#L,&YG45"L9)'\O!R3\=KEY&5M$DI.Y"H<@N&5A
MO&F0G1&AP"['"^&HHM&Z0LW7#ZLY72NKZV9<@*R$6)&BI@T$&7304PQ@"(*=
M'-F:/\G/%9I%N;DF;";"21(VK;^BIIBMHWM)#4TD8$="?&-U,15%9S\=B\7/
M,Q491=9-CJ)#T3IUS2$>.&_(RL0`4E`J<N?T$TFU=T.AQ3AG6`(XH)IIVF'=
M)3V<[SRD22I!D1=0T0<9U24\!\_&%!PGFQZ'<R)4,JE)1)`$2\D5)*$#>`IF
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M*YANH!5+5C2X3Q;Y<,@MG^\&/FA1DTB'CD1TKX5/ZG'OZ&;_`#<6H3>YO?43
M]#OO#D7Y]I6JT'NNSU'=Y_U@(!^4"S7E"TI2E<DC_59,]\"/YV#7OJ(_U)3/
M>\C^:`UR5*5MOGAC?O;Y8VROTZ8]]:V5^O9:UK7O;SW[+5#PX>69.35;D1/(
M$)N)W1SI!`,+S@T'@BJXYD:>$:3EB<6\X'0BI!%"43J%$[,6886!?1V5+.4\
MY6FF.9\MQN*K?!:N;GZ+)G+FOQ<RE0U]"%L28N);SGI'2))C=]'SVNTFM77_
M`$74=YW*Y(T?@R":45TPJI)`6%"A,L444@E(":ZEBS@4R+25F]A)7&6PHDP.
M]N)3*9RD$U<(I:TAR0X'")=,.,5R24AMUT1S%F28&&/90?`C54U%TOHI<P6"
M9:+FS1![G17REV+7,4I2E_-?MZ>W['MU`AR;\8FU.[#T65@MN]/JKJZ(U'`2
M4=%(M=#.UQ*.-S8H&15,Q.3BW6LI*S^;9Y7QL,N1W*F)0H9S,973)#;!,M8D
M+>SQD07`FM>OJI"FOT"NO71%8CU)IC^8+K1UU,S-RQG%<7#O1SHR@N*SAQ=B
M.L7S3`,GH@N!>;#D64]8.(JPHA8BFA(L>8K5Q<V;DAO>CWCET'V*<R5*"''6
MK;OV`VM<\(NV2(V58<4GG*1!8R:(C(<!I?:DDDPD]DQO@LOLH*@YN!^$R"$+
M@?.F;_>'76U_ZJZVO:*7]IO`>DHX<RK[E18RUWDMU2XSW*EKK09-QWXLO9ZJ
MJHY3CH.JQ10;AA./B!`I**VD0JG873_%\JEGI4&?='_J0.QWPC:>?IH:_P!3
ME8^:_NL_CY5NK8)_!B>XR^+>O')[I"]6QWV^$-A?,A%M0@4I2E9W7</7UTN0
M[X/];_E5+U>A]2E*4I2E*4I6*MRK2#(LL;@/'2/4.%V1#;\>K*8CGVTY,IF8
MRN]&]"[-5FT&CM)EP4BHI-9$<,\#L\'(RWP3/DP9!\,.HIY5,N*:DIIRX<8$
M*:L:S1,N:_ZYR)(\ON!E6:"S,DK2XM/URR&_G8Z4<]9)7UY:>X)<N7#'34,S
MBF-=H%2;8;"?B`4"+9*9E1/'NJ\Q$:,&6]9VRR7HZ$!EGS4D'%AJNY^PM'NP
ML0LL9N1'*JV^'[-<62:X&RW3$9L:*B3\<BB]2"R0=L>KI)ON5IBG%@`%#6;7
M^!9Y%9@8\^SRM3Y-^P+_`).-PV4`>$F:M*.I4;J,&1VUW4QH/<FOL?'5UV9.
MB.'+=,D"QB35!QY.ETK:.9(N9`;QA$*`&\@.E*@_BS^,&;;?V8.IOZ04TU+Y
M+OUK)(^\%Z?)A6KP3<O/;W.'Q,:VTI2E>MQW*%ZBCKG\(&QOSXO*LD"E*4I2
ME*4I6.#S([;&(?V`C77/66+AWWOKL5$R4(WG[*4WO:%-4-?83:3U>Y>\M3"H
MH,@,M'73:<XEEU^36_<(TJJ]B9<KF.I7Q162ZKPN*&%&;KHQU>.G%R$2!R![
M.N)!2)`F5].^?G+*C;;Q0VI'TI.2HOCPP[W*V(FC\%;!6"*3B""`Z7:.3.&E
MD\(GI26@-KG>5#=*+($A.48OSV;8FM<\9PV#/K=>TAPJ]9S;#'BIB3C$S&?<
MD*3!;C+=9!Y"HIY[)J2C,OI=>6%E2+*!$J72T=77D>R+@LFW2)^NB<6SKKR2
M;,;\S.>0$20IGPE%D/\`AB$V7B?6[HA93A37\_'+`B^)B2ZK!C@F45B>6SN1
M8MA98/Y!!D\Q<CRE?"I_4X]_0S?YN+4)O<WOJ)^AWWAR+\^TK5:#W79ZCN\_
MZP$`_*!9KRA:4I2N21_JLF>^!'\[!KWU$?ZDIGO>1_-`:Y*E*M"FW40M-[Q5
M'4?V)VHCU/6(Z7HX.L.*Y?P:,=YE'`W'4VS3GLU1FNK@W>A4!U"*2>NB&\\2
MJRAML_XD)=*L$8C$"XIMFHP?V[;VAW;=_N8.;-4-58(A\I*CO;2.HYC0;(,A
M.1Z-!YJ$0P8POH?MA4C]=#B>,7S'V"DXF0G2=*3E46XM*R4RO$KDM:-)'%"<
M;;-M]'B:(V_&TC221E#6;3-SJ960X/UL<X["34%Y9-\UFV@$UHLYZ20(X)(&
MC&.TO%K-;%27`FB,E&GLKI*33V6^/#8L>6(G6(=GA13FLB)T(J+F="XYUQ+<
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M23,'`#(5CHR"RR!`X64\S3FR36\/=_PQ23J7(6I!PMIQMEL;N;&C%DI99J],
M6SBO(BJ_/1V$VFHOK+72PI):#%445I)*8O(II&0&^VB;22,E(R41<Q;X&N\E
MNI4&?='_`*D#L=\(VGGZ:&O]3E8^:_NL_CY5NK8)_!B>XR^+>O')[I"]6QWV
M^$-A?,A%M0@4I2E9W7</7UTN0[X/];_E5+U>A]2E*4I2E*4I6/AL=MYR'0!O
M!L:2U9XU9=WR8XJ)"Q`1UIVYK<B*/(^4A(Y3U=49Z1#3O251$!<ID4V5<2U(
M9,O=77":PG((YD(BA``"WX<?6S^W6RH4O&]NM%%C11S,Y28Z>T6@NRBAS$??
M+?64A<43CGQ>C8145!P*D%4`5%";Q?`V=2A@C)P^8PNK`%@*!<["RPTO2#(O
M*+/UU5H[5989!%UR/M;$<LS?!D#%\2#D.)DI.Q@PD1-/PP>,+!8E'3<5!#S;
M9J:L/P#)\K^;>',-IR4\X,9R"GF/)R<)5VZQ3>0;:Y%#((;-:HP9,L`1Q(1)
MJ,`=#2(M-LB6$-)3,5R!VZGHB,7'BS*T>$&F[FR@!)*$YTEPDA)WZ4J#^+/X
MP9MM_9@ZF_I!334ODN_6LDC[P7I\F%:O!-R\]O<X?$QK;2E*5ZW'<H7J*.N?
MP@;&_/B\JR0*4I2E*4I2E0/<ITL;(FYE:NN^MF\FHO&H848E2I(EC9Z>3<9*
MLM/%%./)Z-B.XJB!C2&?2R!]$1SR.^W,^G8<-8"MTRM-E.;1@H;7%ZQKN'%)
M+<\G79+,![([FZK<ACLCYGLEZ1UM/KMFQ";O-L%U+3A05J/9N:3"-'4)KKJ*
MZ&T76&@IIIT\`]$9241E`:RRW#=Q*T<NBM,C#U05YIB3;2,M1"T,.)HO>0GK
M+\-*,T,1>:))ZM7,)"-(#33E61\5\5=!3`FPE,5,6CSV4COH(-(@N2Z264+H
M7'RB;G(TS.4UNEN'`$X+CO@1GN^'(WAC7U7@\4)A*KL&.+DDJ6#M%NO'QK&C
MC8;"JC$"Q+-`$/HF+Q)EU$TW,;RR.]VMI@M-SOIYK:<VF>RV\MNQUN-7,8E$
ME`;3<3#2RNK:H;$_N95.2DLD;/G3(G[@`L7%$R[,:LLB[D^T+FR-W#+<2;+L
M&1V"V7XQXL4%MG!.==%-R=)1HD28,;MQ$)-[-PO!_O`XHD";?9K125QQJ1HX
M6+ET[(4;#&]UC%DU@3+&2/)T6NU$?+!>*$956VZ6Z=P/):F4M8V4'L&+C;$0
M`V1/%C::J)IP(LI)"J3.I2H4)J1(T5!B([F]]1/T.^\.1?GVE:K0>Z[/4=WG
M_6`@'Y0+->4+2E*5R2/]5DSWP(_G8->^HC_4E,][R/YH#7)4K;W^'^%C_E6_
M75O>T)K:4O#J^+IF0@)5GW%0;MFP2V65I`1HC$2LEPE9UY+I^,$]5>`1\-N7
M4,V_B0)"EQ%JQ/!1O@2N-E46UESNDF][6]`G";VWM;ZYN\5_/>UO-9@7O?S^
MM:]_8M>_95J^JN['/YN`F3HJQC%G$&C`:^;/S7J8]@GN^MR4P=0DB!UA/0W@
MLMJR*WG`"=9:D<4@<VVHJ(R4MFRX8V:F@).=@@Q9&M;5;FW,3.S@=NFGQ<)>
MOF=E[T?'M=GUM2L3"#?%NJN39]"*=)#02V88L(Z[(H2YY8/`>";^:F,0\(HA
ME0LY6^_Q]?+'_*M^NM;7M?S7M?[E[7_Z*UI6F5[6QRO>W6UL;WO;V;6MUO:L
M8+=:3=P)?V;F9B:_<MVD'%%$<+/LLU<&BZ2,).W8&;I#R:K0=+TDN2T:1%I(
M]!C6&/+X399284'S4'4DH`SG<98P264'Q:6KC)F&2I?U_7[S1)&O$W3!&LIN
M2+9$GG5U91%B(IO4$!NLY<;$BIN*#AB10W*<C]SM!#?C6#$%+MEZ(*VD).6*
M$72@P[2N5A4VS8,P:H+VO>]L#ZV@2]((D!-:*9PUJ=,YC2!,;Z2QP6Z8:`D9
M):@Y2Y01.*9XNX\^`D]B,8B2*N91=R63&&3#%X7'DBS\V&7,[9VIV'B[8/8-
M%FPZ7?9B)XS&B9MQP1$CJ/!&@Q\&JHC&5H>Q]O>+2$47CP^1)4)O8/%!QLD%
M0<LJ@;2<@FF.E*FR$7:;8F.(46)(`6#+&2GFI'05)S%T`RFDE89+(IJ>I&A0
MBAQ832E\Q`@L1C)L,N6N.+B)@'W^^V&O.,SAZ^9RB@!R\(I)R!Z$!0E8+,)V
M*[$,RDDL,TMBIN#;)R0IQB2.20G1L:607X=8!0T\RS=$;A<91PB[[H_[>('8
MWI_[1M//TT-?ZG*Q\U_=9_'RK=6P3^#$]QE\6]>.3W2%ZMCOM\(;"^9"+:A`
MI2E*SNNX>OKI<AWP?ZW_`"JEZO0^I2E*^4Z>))Q>YH^;+$BUA2P%S!L<(L!8
M8X9")E0KC#YAAV$,FQP2P&%\N^&'%#!#MD()AC>E<(3Q$^QT>H<IPR[RKS8[
MC"4!TE6"(JZ,9'!3'"NM4V*80W$GI#@3@[+S97")?-22BF!VZ<.8(Y&2G>#Y
MU>I2E*58AM5.FC7':F/'=G95<:L)X/XRPHF=THAMEVK[B?B@4Q5,X_:AA`8J
M0X5YV**01+KIA*R`0#II#0BJR9$-DD<`[GCKH[R2Z>\C"7)*_I_(ZO)[<BE:
M;S<>3@-QK)4>I99?<B4<6222GY2.TVF95SI5/)W'5<$XJ8P3<32=D9$QP42>
M0L9_+VS=U(O7,]G6;R4;,:XZN#*C/9CYC;7_`$J8>TP,5-\JS7,;7Y4=B8:!
M47ZK(#J=A));*P(G(Y]%9^*VG*JL$:3,C01;N'!?*$N2RVME'&ZMF]D-NH<`
M=46IL*3//>J29J$E'<RK06\)#:\7QR1NGCK#=;JK="NMNS)K-U.-KZ@*E$<E
M<VD*AVI[KWZ6O?V.VK)FQR.Z.O/8!]ZM-C9B+UF?8PP>PLB1J35S=UIE`1N7
MP,OPRYC0J>$AHY5IAYVP731U6"+IYBV9087$V$*!A6&"]FX)V535A5A&1T5^
M%4$%JG54,D`K):B51WXVR;R8+E\CN%-1U@=H2"T3Y1TQ\\BQ`9JOINCXK336
M%=.Q$,81;Q9_&#-MO[,'4W](*::E\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I
M2O6X[E"]11US^$#8WY\7E62!2E*51@IL+#9Z9537\H^DL>6D9B($E*+5P"4.
M]`:#F>;MCU%/8KUR=FT84#3P8SJ1!&X661G,3,)`PIY'+%12XXU9Z4I2E1M;
M7Z&<:FW<Q!N+;R)X0F*6V/#A4<HE28N%A%QFPRD.ISGQG2"W<5]+-I31&="P
MM`JKN.%+I69TD&1%40<R&0-<9QX:R\6\8`OF7^,]&UR#;KT"(L&0'/K*^4%\
M,U:/L\^;6$])7U!M.5SI@;A;PJ\=RP+YFBI\N35LL3``@`A7/"JO(ZX66V=.
MI<4WLR9>D(#,-GI34:\`NX2/9L,R6NOIM(L7J47R*&NMGZ'CO;[]/H#A3WT.
MND"35"2S*PH6/$2QA,.PF\&8Q!7VBFIWO*%.0KZ,+H@8``/8[D<VMBZ>)(.,
M%G30?9RA#,5M>.D9K%F\RDF0TE<5'B:`;X5T]T(::27,P3"VC7/S5\EZ-#KB
MT9V(0=@99F*"X76FBFI,C2Q`2,X%Z5F6VE!VMTL;46R1:[$DQ:"+F!<P$YSJ
MI9E*X2$TCJZLGAD<@1-+B=C?/*%-QV06U13WO-:IMII?J5S+:)3?&VW:RG("
M<XW)K<^(I<9-VNR8G$U02;>>;8U_?SO:"&I30;P'(W).M755]>(I;3/I3+NG
MX[6YRCPCQX1OCK#"<`O+Z)>P^]4K++?VND:3(<5&A$[_`)X7'%"Z@S$IL,9S
MG3I5_IYUWOX4)<+(]RR2NMA0*8B^6C616\3N;SU$[0SV?0#(??>UE]'25>^M
M;MOUM;+K:U^M^MK6O5H/==GJ.[S_`*P$`_*!9KRA:4I2N21_JLF>^!'\[!KW
MU$?ZDIGO>1_-`:Y*M@E[VQM>U^G[L*WX+BX6O;\-KWM?VKUAQ0&!+4PQ4A28
M\]P]]+.=WN.63JK@W=RIE;*`7NFS7)+>3B:*WDM7#345+3T9&32!%-)88%BQ
M<KA@%C:W958?H7//[</D-_+FG3_KJGT+GG]N%R&_ES3I_P!<U3R.]4D"(@'>
M5BR?]W8Z+2`_W7*SY`9VY4U(@3ODU]&@3ST?[BQ*K%O*;M=1PN`:7ED>]S"@
M8!#%%OWUJJ']"YY_;A\AOY<TZ?\`75/H7//[</D-_+FG3_KJK^^(EQ2%A*^]
M49.N8INEML1ZY]:3C+SG*5W7+R^V_1Y"&;B=!)*<+O-&E(JEJ2T%BH730\[%
M@C%\\\,>N=[U.)2M,K6OCE;*_2U[7M>_7ITM>W;?KZW9Z]0P[%<>'":_73L%
ML]M3%FICE<:.\P#&Q4QS`^$4J&QW2806L224.1'">=Z2E,<<NVA6B"BH*YY+
M,733Z28+@&+JH1@W?#I'`FG\!0F73=&4*-$/7R15\Y*3=^@ZO$7-&BVH+R2B
M(9]QM):3%1;33Q!7`;!`08=.539(4Z"9%"N'F(*'C87S</IOLR$8YL09&[#D
MF`VZ74IQXY=!I908/G:/VVUFGDN2DX!9`=HAAIG&4=0@D9&5H^7VT]P7JNG&
MSDFM7-:0DY<1.(X(DYNID`SR$0A+9.*GB;V'&6Y/=^X<_,S8C96<W@Y(?BIR
M$)3D9XLNP2:2)G6.KM%)9*>5*$4E0:!%+<R*`(57!31BVGE0BUQ.7:MZRYIQ
MN[-T>\D$,ZV,1SQMIFYV$$Z=8]D8\;SW<*H181%K.6.2",_W.^7(NK"&Y%QK
M2,OK4:&5%`6EU/9B:4"7"UC;NU^V-'W1-Q.83E_*8ECNE_7'>@+`D54S0(>G
MR/IRN*SGD]/4A`,"AN+&NF@&X1.+^1BR:6>N)2/#F83D.EDD>ZCND9S;XVU$
MGYME8JUMRT7S>^G&:C)XTH/H/8TLIWV2@\Y<N4C+!H9,48G:1\$]%N(([@A+
M-,0RLV#%4@@R%LIG'S7]UG\?*MU;!/X,3W&7Q;UXY/=(7JV.^WPAL+YD(MJ$
M"E*4K.Z[AZ^NER'?!_K?\JI>KT/J4I2J#;00,W-GM>Y>@-TEVL(G2>QUEN$S
MKT8#:E-NMQS9!6/,MZG([>.`C7>!EAO`FAO1)1%W&R:;6$(A8QF'A;PF-O\`
MH;H#'&AB%+*,R5?%X'I1?".XS3W7FLC$I-&;+?9R*AM]E/N0RPIIRRJ6;#DR
M?KC:2V\C@ZDUTE^"L9)P!;K=2<<K^:4I2E14<O:FV4G7%BF%..=X)*=XLYLH
M&-4;CX"3PMA+.,LANU:<!+-56K9(1*,'7'*0]63*!!8!.@.5KN0PW"1.RLI$
M#Z?1'AD3C-Q=L70-#?(W!))SOV.+MJ,^0H^CV-,IG([47"359$!HB.7%R*1.
MQ4G,)I)ZPON!R.Q1*I2(AKJH9NTRIT_(?NML@S]9H)<[P<Z5+#E4W`GN)JLQ
MI09&[LE:5%]QBLUS+HN;9:C/"\="";B`A++I67"K*+?;J`EHPYI4<";GF3\-
MTK0=\(Q&%H[U>6I3/RQ.NKFO>KS;FIV+`BL:67@>=\/IAYO2@</K:@KK1H.2
M!D!S*5[N-1S=&*DFJN2R#E@,04E2^G/][?MO;IVVO:U\KVO;MM^YQ[<NE[6O
MWMOWW[WMZ]+X7X6MDYJ43;1LWC<V_GC>36';K4+DC9,FL#8QKX)$WZY[(EFN
MJGVJE-Y66(_BN06&<F&37"HQYE$;N:[>#,)RJ.]$](7TX`JYFU<5Q9-'9*TP
M;+3K`#21E?%(XFN,&"V.ER@;<K)C-T;3QI""HI+,<.Q?()!Q62E2(Q#^38E,
MF03#C@8"NZKMU73RB^"H)A:L6@*YMDX.;[;T]N6P82CB6[<=&L(!5OP&_7;(
MK'S9X<YRCFBJ(R^\VPTE?!?,GA%D)23\$O,D6`+$12YTUD9&RPR$I=^M9)'W
M@O3Y,*U>";EY[>YP^)C6VE*4KUN.Y0O44=<_A`V-^?%Y5D@4I2M+VZVO;\5^
MG7I?UK]/:OVU$8U^(>&FONP)N254VIF)>9'G+I.'\(58!9@(BNY&$B)R0XFX
M$%EEY!FM'EZ\@S"L["IY`*2WM>2UB/7`<R:B.AW*RZ6M:UK6MV6M;I:WL6M2
ME*4K&?YO])8^V",;,SF#N>1U6<[#X^$J&=B`GBS5E8;!G41R['E)Q<*FC*C5
M%P>@"R\EF'%Z-%`%!0G^"K$3UVP"V++2N5\;N4XL9XUOV`EQ^&]-QD6']:HD
MUQAF,FAJZI:ZN[7Z5RJA@[WR8^BV[`W8W40F^&$<0$M&;49*S0/K@":?-2#B
M\,DQ?5"89V8N5HLC>;XZ>41R\RVY(<:R"@'VR\V4[$T!60'$A*&%L#1!0)&+
M=Z)AWV(8X0P601DD:!+G2@Y8V7+F`XY=&+<1+VV$V`E+013U@<^P:<UF'$T\
M."#W`355THS&07+(#(2#A$BH"(X;>#Q:Q!)]$;7(73W(<:R8565M7/MXC8I*
MU>W6W2_7\%[VO^.U[7M^"].]M['GO:]^V_6_3V;^?VNGFO;K:_9>]J^%2MT3
MCUK?^IF_/>][_P#FXOGO?K>_W;U"=W-[ZB?H=]X<B_/M*U6@]UV>H[O/^L!`
M/R@6:\H6E*4KDD?ZK)GO@1_.P:]]1'^I*9[WD?S0&N2K\Q?WMO\`&`_[7"L0
M33+[&F.O?>9OTA9=JY^E*4JXWB8^R8Y'??O3G]'4>ITZ5MSZ=YGUOTMWN76]
MO/:W2_6_XJQ%.2'5K5*.YJ4=V9OV2`<NIBKR:,62=DM/U>%W._7M+NR\4Z]X
M1+&4/LQ%:6:GF]R0))%+R069SV9!=#5&HM+CB-NT5N'4K(:;_C`E9#GB+9OF
M=FO-IKD=R#LL_5"-H^:\2.R#U&"62E-1@(*7%,E1T^$)ON9,F#PZ8<D"150<
MC9$<2J^P5MG#G6@<1#YFYS:-BZLN6/"3\VY0HG/1EKV[$'80F[)CP106I%;M
MC$0940Y-Q6%X0`DWSS;\*9\&IYCX!B%S1E/,!FRQP4H-0;C<0^.4O"[Q>?&<
M#"0L+27+SR>;W5H//9GT%1EXZ&F!NG%8#-&1SS?52B?BBV)M+,ND)R$@F$JZ
M`B$$0\3N/(5?&U[];]>VUK=.^RZ=+?\`Y>O3[O9VV[+];5IWN/7KT[>O7SWZ
M=;>UUZ>WYO/TOY[6O4&O='_J0.QWPC:>?IH:_P!3E8^:_NL_CY5NK8)_!B>X
MR^+>O')[I"]6QWV^$-A?,A%M0@4I2E9W7</7UTN0[X/];_E5+U>A]2E*5;]&
MFV6K,T.<TR8>V4@&5GF2(GU,XT8UF2.7VYRB<E&2Y)4/F4!JN565@"2:<-%2
MA\T*4P`)F3(!<P(&*,'AE^"+MUJJY6NM/=L;*0*YV<VW`&TG"Z6S+\?.)OH3
MI%(CJF#;6%=$<)\BFKUTLJ:5+I!L8)0P3"AM2S+XD2I@P%6<5VM8$\W4P5QH
M8:D[PCH[5(9*I&QMR`)I#!54!T(OX?PJJ`23!0E`V,1Q'"+DQ0C`N>(0H>>?
M8:4I2H;.;V"WYL/JS&D=,2%!-CQ#&RL;*;C@X?:074-"D!`)-U_8`E%^5R2D
MCJPUD5SF&TOM=KI*AXVH/M.:RKDFK19$'2C5(^"77Y4@5C[*)Y[49%U+#6)+
M:181!;N[P^]":Z%MKME31UXT9D$VJJYQFKK<,"%T)889P8N9)9V+*(A,&Q['
M(2IG.C(L,1UJ?&`^QK;0W/`;KVFB-DS`5NWIN6I/3&*NHS]&5U[7]3@)RM1\
M,Z9DK!-Q%2W096+-O%G9O5#6$MQ>6RS:6/CX5G%QC*L9S4E<:#2D5+;"6^VT
M9F-Z2R@3.3D%]OM6;`N2,.MN:?1QI%<P*&VB`11-#O8!L(14WXHA%PAS*K:\
MU];;8VM[-^G6W;>^5^WS]N5[W[:UM:UO-U];SWO?S?=O?\/LWZWOVWO>H0(L
M_C!FVW]F#J;^D%--2^2[]:R2/O!>GR85J\$W+SV]SA\3&MM*4I7K<=RA>HHZ
MY_"!L;\^+RK)`I2E*4I2E*5#/S1Z]P2_]=,9E?8NV+;EN/%%ML.)G)HM?`?9
M)Z*LIR&RD]#A,JUE,,=CR6Q7E(R:QU]8:4EELFPB*;8(O1/56VMI`2F)03AE
M$>Q9^3']-*G<G0.U!MD-DT26N1$\QSK4'B#!U'B)@GKN!$(MHR;F/HOLB&I8
M33Y4!\*9X=AG!SRL@%"'D^X/DLV+C>!GVRQB4G3ZU)C5&"H!N1N,?7^=]HM<
M#$&F5)<!4%C;2/8N1E,M'3"%4BKF)(LO,]89DPI'BCB,I1IYL5N.II"]0XNM
M:8W@*4WV$NK^W@L[_0S))#49&P\RY3Y"[*@`1<;YL#'3V7F\Q68V9#B)55B;
M*+F5-[WSGE'((K+3I';32Q,$;KTW]*^%3^IQ[^AF_P`W%J$WN;WU$_0[[PY%
M^?:5JM![KL]1W>?]8"`?E`LUY0M*4I7)(_U63/?`C^=@U[ZB/]24SWO(_F@-
M<E7YB_O;?XP'_:X5B":9?8TQU[[S-^D++M7/TI2E7&\3'V3'([[]Z<_HZCU.
MG2E8V7-%`C;:\K0[.NNYGD=0-W)46%D)O-KCPS:BF5D7"+([--93E&<FQ*ML
MXJ0SL>QL^AHQ0Y4#%39`.HSV36#G@Z&\3)%6[?CQ#Y)I?6YTE%Q-W82YJ#EQ
M>PV"SY!E%,5]C5.3C+2:*B3-#+#<&$8QV-L8[%:`$7%HYP)M-*:I/$A=-).(
MLXL<[/=Z)-CQXSM*.J$8R#L0OJTRJC69TK1^M-&?TC6(*<+68[ACA(A#>1$9
M3D:>H^UA4X78J\VDS$T\X!7WP&AMB0F`VY'=Q]RB7W<843QA$43/]`:KJVM=
M\HF)%\-/"ANRHEE/8I.?)1J("<BMYQ'4!$0XZ4&FB,PJBEV*MQ'BM1DX$<01
M:;[H<1DZI'[R84J#/NC_`-2!V.^$;3S]-#7^IRL?-?W6?Q\JW5L$_@Q/<9?%
MO7CD]TA>K8[[?"&POF0BVH0*4I2L[KN'KZZ7(=\'^M_RJEZO0^I2E6X2._I/
M!E-KQ.GZPO.1H@?"-8H^YM3Y#AU$9S&`5K+R>JI2ZRG(^4>5%VY<@5(B&1F>
MU58$8%P%@R8XA@DIXE(X340Z^K\N[Q/M0<[1U.@"!]9$[C^0)98:I%\3DXJ-
MOQ&39)V&=S<<:V@BLQHGVZ1<VNS`0E5;)'4Q!<S`4R5R=S!<4"]`FCJ4YI2C
M]_1T^]CF2YXST<E5YNB$=LRT;QLAH[\CV6])I4@>3VK.;7B`./8Q<$B:Z,N8
M%DJ5E%@%VN1/#I+,P<"`66B+V33/QX;2J^BBQ!"4IP/(S]LE:M0ZVHM+O!4N
M1?#8U>3]F=7M/FJR6\E$D<T66MFI./2HWMBID0SF:5<N"A1_#9H;(9%+.M-R
M-<;]];KTO;MRMV]G[W*^/7[E^G6WM7M6M*4J&WG!4&\CZC(*R;D.?(X?*7*A
M42*UO6;7-)VHF,%T*,:R8B.=2:$5+`R>`GJ+8BI4D%U%93).!I+,4'4<J[4A
MQA'"X:2KT!X"4W5A'CZ:4'4B"MD(-C1J(VN;6N%L?K>F0"[))4`(]<3E$E18
M5@7.NK,SOY_W=0CL=TE+">A%<&\M1ZTF@6R9+?0"J?9]RH;S2K"/(*,=1]I=
MRH[+ZVHD+.*/M:M?=1W-,^OTW`.4O9V2:4V)>Z(,...KOI$-&F`W")8$J8BY
M/3D]ZHN!I76#??3J:,\A,0;]!RJK0ZQYG:2-%ZFT$%3.37%[BB5>6E!S)BRM
M!8I39=882X91TPD4!#NLC!`E3:@<-ERH70F*,-?[2E0?Q9_&#-MO[,'4W](*
M::E\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I2O6X[E"]11US^$#8WY\7E62!2
ME:7O:UNM^OX+7RO^*UKW_P!51:[U37OY!X:V_8*"U-O'F3F@J*XS8\GM27WI
M*DKRM,<AMV/<`;*K.DF.VTPVV467BE`%@A45ZJ@:8W72ZE48FG9D4X'K4[[$
M\@D,3O&20`BZM/*.I<F>441EPRUV7,ZU/AR$HBB20Y46G89D;&0T]A`O5R`,
M5#;Z4D%XL.(Z.ZY59C8&-+PY(XJ*'0]4>2&;YUB1X'7%&3/(RVL!:Z)D,9D`
MW`DQXLOB<-6(VV`E!!<HJH?.J@"%J0J.]R$YA6L#J>J9M]O)Z.81T205<HD'
MIFD<X&?2DXX$HD%C`R2+#8JJ7;"R<I6$!PO<\1L&:.X8E#67?#E\,#AK'`+/
M'"QD?O;BY\E2E*M,W2@&%]L804]89S>:XT&?,3B9I0+!GR`''#Z<*NQ78BR8
MEHC/<`0N"QBHB*#/*FS@+?#%5_))8[F!<OC;,R%%%K[P?<;OT16W.L%[$;+2
M8Y8?DYJ&!U4AN^ZY@;`#QB5Z)[W`83_2L55;1E0LFKQ?JO,=P7MD7LHG,Q"9
M0X9Q,6KQRFZPPI)3@B*=)KX_)%WE:T5$E<DIE-=GFMHD^M(L(K$UDD$=BPG+
M41H^R<2*!JQG)>C0VK.)<1%+#(XB,)XISH<8:5WZ`.0F4-IW2VV9!_'MN?"#
M8+*J<&^I:W6AU/UFCME,]/'QNJ%&FSU-YJ,G28]3Y`K='::&V&B1:)$V<+JC
MI>B,D)HA%0E:MU]?S^U_W_U^O[%J5\*G]3CW]#-_FXM0F]S>^HGZ'?>'(OS[
M2M5H/==GJ.[S_K`0#\H%FO*%I2E*Y)'^JR9[X$?SL&O?41_J2F>]Y'\T!KDJ
M_,7][;_&`_[7"L033+[&F.O?>9OTA9=JY^E*4JXWB8^R8Y'??O3G]'4>ITZ4
MJ,[D2T[U&W-3&8D[03&\(Q(Z^)SWFK`6/Y]^@4L(3;/(6+2<;\=:\FG"BX19
M*,EYGB!I7',I[>+B*!L%2.B=_8O>@>@G$[HA`[[9&XFIDVSC+B<NHSM.-USK
M&U2]L!$;Z(/=%#:RJXR7CAM7;RPI8ETHL4+.=+/W4`;IN28.:%+AB%`Z=[>1
ME`FM.Z^&]4A\7.R&S+O!]#BPR)[TS"=$VJ"(ZDEMA-W$27]2,9::9,604,`C
M?%FS4V8RD(+-&S1@%5:9SC;A#,Y?CJQMW,.V+D"6TG3;876."TE+."J3LW":
MZ'%$H/EPF`0<$="CF$TEX.AXHR&GW&$4G0]Y.!:06614H@M-LN01445]L2`4
MJ#/NC_U('8[X1M//TT-?ZG*Q\U_=9_'RK=6P3^#$]QE\6]>.3W2%ZMCOM\(;
M"^9"+:A`I2E*SNNX>OKI<AWP?ZW_`"JEZO0^I2E?D,.`!A;,<4(+"]^]MD*)
M@'C>][7OWO43+'&][VM>_3KUO:U^SI:]=0/-Z/U-$7VTI(;/4&ZZ[JMW.@G4
MQ!-HKBNN=]9:NNI1@`0@L75^^R\J742YGRAWV7CGAN^OUT2V_'R,URC*145G
MI;,($,$L@U$Q.0B+9))@5_[FG$T$H"$D%B(=[?N"8!,,OAEUOB%:_6]<D<1V
MJX%!(4#Z8@+*HWAQCR$=-DTQ1/HAH?'`(<XE&1@QS*88&#QP"&,DLP!1,+8X
M9B96MC:NQTI2E8\O*I)^VS[F1LZH-/C]A#8Z,E=48DB0^XGCR-MS3V7GI)C+
M+".%P`QLTB*@DR6KD&;8QBDN<PWS!E*7D135D=8+CIXIL(.NW$+`,P0\:VK=
MTW:58:9O.6W^Q5X%O$-MU3;!L+R`E(#A#()3".F3/DB)F"PSZLJI37BM"32*
M<W2:KD`FY6;83<2T;KVT?+^@Z*;=R+#VRNOTTAQ4XT>*%*`9%@B!Y:E-1D8\
M=9+M59:5GFLHR869??M=40VRR6ZTFR?6WN3*IZNY72`2;0Z+XO>;HSR`0;OP
M2DURPLS9E:H4<J;5;CC'FJ)7!$2^IF%M,55M,P2T=U7P75%)(%\#=O*`@`1#
M$Z<,@$LA1+',[7\4I4'\6?Q@S;;^S!U-_2"FFI?)=^M9)'W@O3Y,*U>";EY[
M>YP^)C6VE*4KUN.Y0O44=<_A`V-^?%Y5D@4I5+ICAMASRPU*-9)*N(ZTE<VD
MGCQ=JOU_QHLYF$12+JR?<N[8R=#.=Y$+`\5!S,ER*Z6+*)>PA%1!-D1ABPE%
MG!JRFG7%J.C(:EB4AC5I:77H19SD474^'.OO5(CY1CN(C9YZ/!:75Y7*LHD\
MGPY#QYT*RTNJ+K`9ZKXZ(83#!BNY#0F?5-I2>P*\M$CR,RH+-1/%S6Q*BY&F
MXM/U\A.J8W4:-C6\5[]T);&AQNI`9,*QP@4;#A\9-9`K89<.W/:#1Q5V:8VP
M*4KR)Z%WC(J8TF=%JLCE#F*+'4;LZ1V++:FTC)`$4J.?SFU[LZ^$W*I>^(CA
M:F39;6!8V59I,52KAJ!KR>UFB15CY2=%G*<<,S[#3..`0`')-5FY3].3^FBT
M;L--,99#)['CO%[V:3=#$Q+7.%DP16LFHV*C9&(724I2L6GG!UGDN>=E$599
M7'-L1NPXFAJJGIL#S!$6TB%KV5U"FQ<DZ1%<:1FFFKIU/+N233PC:CA4S5?"
M*`22@-)/2C1`,)=\,+6WA@@]8A2:Y["1>+5\\6T=N2&(:)&&6NSHW)M;\SO5
MDNM_D,7P&,VSJF`WWF@MM="370I'S@:J]P5A,/GP1Q46QT?(HO:U[=+VM>W9
M?I>UKVZV[;7[?8OYJ=[:U^O2W7ITZ^OT\_3KY^GM=:UI7PJ?U./?T,W^;BU"
M;W-[ZB?H=]X<B_/M*U6@]UV>H[O/^L!`/R@6:\H6E*4KDD?ZK)GO@1_.P:]]
M1'^I*9[WD?S0&N2K\Q?WMO\`&`_[7"L033+[&F.O?>9OTA9=JY^E*4JXWB8^
MR8Y'??O3G]'4>ITZ5MSZVPSZ=>O>Y=.GGZ]+].GM]:PLM^=/Y-E3=W863`>&
M?9;<!06=C&Y==V/;FY[;B)L3/K:UXT8K>4=7;1DOKJ3=/AG-03`PUTO9.[YT
MNI*5%H-<&)'!"($[O#3&ZU%>N<K-0]IP[-!V]ELJ_E]AZLNB3$R6"\<-ESLF
M,%Q1&:3I11!D<%HNU]FWH[B#<2QQ2+945E61P+A8%[%P9<;VM?I>]K7O;S7]
M>WW+^>WX*6M:W7I:UNM^M^ENV]_9O?U[^W?MK6E09]T?^I`['?"-IY^FAK_4
MY6/FO[K/X^5;JV"?P8GN,OBWKQR>Z0O5L=]OA#87S(1;4(%*4I6=UW#U]=+D
M.^#_`%O^54O5Z'U*ZH_'FAQPR'A(+G%'`;C&:SB>*^.5+Y&S(*(UT8ZNJPI<
MKA?',P.&GIYG,(#'+'(83'$/&]KY6O42B+S80:XD5%<2)JYR!*2(XD9)<"*I
M%M4%W,LHHRZG%5=(4"V=W3:^1<^FG"IL#*]K7R!&PRO:U[]*MHV[V^X_]\(X
M1HDVSX]=\9DCMO/)/D%';*SK1)*&5(O!*2%M!3UL,VSI+;:F(.627&M$\2XY
MX4EG@?$S$*YC!@"!1T6U4[GQ[['KPP;E][W^'??\B6R?[WOK=]_Z?Q/[WK_>
M9^XR\U[--`=+>+!G:JL!O;W<2FW,A;/$W!*XS[=B1$\XK1!005&6WNI1<7!4
M6I-*$AC9I$5&V6CF,"J:"*7,$!2I[(RH`&C9B7+45V\2>B$CK4N:F\7.\4-R
M(X6:>CY9<R-KS,ZX:/,]36$1?/(@A1XS"Y$P,`PKMU%.Y&`"(1W$0@&&&:P!
M$'"%D9OS,1!:U[WU0Y"+6M;K>_TIRYV6M_\`NJKYM3ML8YW$C=8DJ-D60VR2
M;<A/2+7*V)39IIAO9NO1@G2Q%Q)*PVS9L\*4R`%-ELRXOC.>!D`;`7#I:_2K
MGJ4K%?Y+]#=S)SW<?TYPAH=KA/:NWD>`?H%;-3=LR_HIE&%'-%I<!ZDBT+M]
M!.#(R2B(<B&SKC5C]R)>SO6U=:2'#@L)),,J#,_HN_N09]WE@??:$H<@U43U
M!F!1>WX5D`[)S<5$,TFKH[G5E)UJ()0UY;Q6L29(1'\1*%T].+IXX&(UU`4P
M)T_E9.SREZQ9*<'?32`E23P*"RVHZ/M2,'ON`F1ADV72":-0&V9:/I[<..09
MW"-(@Y32-D;?A!A&W.89!`=8QL*7HIPQ*FP:O$$C&Y4-\@BG%]EYM`0VI\G[
M)C%C;=CF@R*W>2"ZNGQ\I'E90BP!1R;1B/E61<`'D*IG7H4`L.TR;='O,Y2E
M0?Q9_&#-MO[,'4W](*::E\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I2O6X[E"
M]11US^$#8WY\7E62!2MM\[6OTO;+\&&>5OQVQO;_`%UQZJ(I63%&Z)@3S6+$
M3ETK!4L<#3<E+Q87Q#%0S*A9F<"61OP-C>9?#(?$O<7(''(2V-KPAXK'=)W>
MX]\P.$^^7>X]_>TE;QVQOGWMN_[VUV#E>V/?=>]M?+*]K=+7O>_;5K)7=7G_
M`#>ZRSH:'%7$+C,2)J^A;9F5\1\;EVCH:.'!*BK$)-%++&+=S<.3U!<J.</&
MDX9K@(F"'X(R"X!S^=TZUVJ8K]T=W4DZRPPN%W!(NH$?*V:;(^[@JCBE^-@^
M4KIX9IAAELS]B/C%R6)C/$O<UX'P_P#<N_M4WEA+>O;/SW\P8GFZ]G][Y^G3
MK[=:VRM>_2ULOPX9XV_'EC:W^NMU*59WO4:<"/KXINMG,29Y(?++?D3.MAM.
M!D]NKK\/O9(DEM7;`AAKN^18I:SJ8Q56,%QY+0EQ^-PL.P,7"<+*9)2(D3A:
MSCC,>>Y$R/\`F>9]S8ZV+B%ZKJ`VD!KQ4X2D%)^ID>M--=#I&3VY!9J-)IEF
M1I$DG'&]CLW2S+P37,.0^:0D1E-5H-QM!M\.8NE*5\*G]3CW]#-_FXM0F]S>
M^HGZ'?>'(OS[2M5H/==GJ.[S_K`0#\H%FO*%I2E*Y)'^JR9[X$?SL&O?41_J
M2F>]Y'\T!KDJ_,7][;_&`_[7"L033+[&F.O?>9OTA9=JY^E*4JXWB8^R8Y'?
M?O3G]'4>ITZ4J+KDFDB>X6`B:5]7(`EK82=D(C,"(UVHVL&=>%,$E=;#?/KU
MY]/N^6HGLU$?(=MHJDSGPW33B<26J(:LV0D?%&>"P8#[[QK%YLS@1<<.Q.6S
M&<Q/*3%USO;+9Q`A=FJ_E8PV6:G"A1$P('DV76/'L`E;IGB<9-`R^UYWD@2Z
MPH/)677`IG'&L2$4I2H,^Z/_`%('8[X1M//TT-?ZG*Q\U_=9_'RK=6P3^#$]
MQE\6]>.3W2%ZMCOM\(;"^9"+:A`I2E*SNNX>OKI<AWP?ZW_*J7J]#ZE6W;C_
M`&).T']7:</FM=E8Y^O88=]?-?NN&%_^0.$/[W'_`-E+/]JJO>##_P";P_R<
M?U4\&'_S>'^3C^JG@P_^;P_R<?U4\&'_`,WA_DX_JK8(&'X,3^YX?O,O[W'_
M``;^U5\7#/:UH@VOM:UK6MR$;8]+6[+6_P"/&KZU3"4I2E6H3CN%$D,M38X]
M=2P>$@ZTQ"I3.](A2C0*2^#+.+(`RXEKQ`%?P(E<V<H"!9)IV0R^9UEMH\46
M"R^K$CZ"K$"ULG%[R/F.0]GRRKJT91S';ABAV(*&H9PQLW'&W44+9!TI)U51
M[I<QQDF(B)B\DX),-6>#%.)02FW"9YK+'C9U,=2<('*52E0?Q9_&#-MO[,'4
MW](*::E\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I2O6X[E"]11US^$#8WY\7E
M62!2L5/9IA$)>Y"=\PWR[IH,$F$[]:FVS4=K;%[#QJW6XBK&K4>NE5)IC8C"
M4V8VP;J3B4CZP?-Y)69\V=-"B&#0EN]QQZ']*[%_\N[#?EE;F?\`:!I]*[%_
M\N[#?EE;F?\`:!KK6.E.ON#Q&D3!-ES"03+9`99E^8;3[9XO8PS2JH(N%6@.
M[<9SLX1FJ66Q15DNW!%+)&`5A1%((C@=$S'OV7Z5V+_Y=V&_+*W,_P"T#3Z5
MV+_Y=V&_+*W,_P"T#5:-(&<6B;DCUV0&8[)?]#[[U[W!,.UOO&?IZE)OK)IG
M*&LPS7.C(4K26]T@JH(>;C7?$%%/)$SX6"J=!R,Y@C7#ME`4I5HTJ[.G8GDB
M1$MSQRH9PE#L"($Z29+2&<<;P=2;Y><\CI91KMB%&.Q'.[799+18N7W6XETJ
MJE,B1#,DG)"$O*8V8(7&:%1"P]>M88OB!BN5SN%#!QD.0D(T_P!LYL5\G$>5
MY7><K"#*S+.%R2FBA)Y^0,DH`N?(%#P0`)/%4+E5,4P7PO,I2E?"I_4X]_0S
M?YN+4)O<WOJ)^AWWAR+\^TK5:#W79ZCN\_ZP$`_*!9KRA:4I2N21_JLF>^!'
M\[!KWU$?ZDIGO>1_-`:Y*OS%_>V_Q@/^UPK$$TR^QICKWWF;](67:N?I2E*N
M-XF/LF.1WW[TY_1U'J=.E:97[W'++S][:]^GW+=:BKVDEU!G2!]P]=YN9SXC
M&)IA<;YT&8LE1DB.Z=7LZ5^8&$D,,9W'H_9D=G"4;$,'9()AKM@9VN!223R@
M@#*SE4&PC'2.1B29BD4Q$:Z(UTP_X]BTT5OMTQX7P(9\OFGM]*L5P5"@.67B
M)X=-S)'LRHEL,L0C06>&-P<P\LNWTI2H,^Z/_4@=COA&T\_30U_J<K'S7]UG
M\?*MU;!/X,3W&7Q;UXY/=(7JV.^WPAL+YD(MJ$"E*4K.Z[AZ^NER'?!_K?\`
M*J7J]#ZE6W;C_8D[0?U=IP^:UV5CI:]?8^:_?`'!_P`U#/JKU*4K8)_!B>XR
M^+>KW^&?ZT.U_P#:$;8__/&K4PE*4I6-WR)SWL`YN0N$M7T^!6P=8Q-<CH>-
MGZBQCN(7VC/&7^(D$)!EO7/;*)668UV@$C%(!TX6?#3F)Q'V^^TQG+25+9`B
MP'8@@*<T>L,<RS#Z"Y(UD02)W`W$%7"-QY(\;M%/B]=?B:L8FS2V:E**&TB$
M6$W)"(*0862RZX^40VK(8BCFN%&-&@A<1M5=#2E0?Q9_&#-MO[,'4W](*::E
M\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I2O6X[E"]11US^$#8WY\7E62!2L8J
M3O5"N2+X2]6?T.XPKE:4I2OMUI]4ZU(_J[;S?GFIE9*=*5`#RI<?NG>UDX&I
M?VV8>V9IMQ'K@WBAN2X?F!I0Y#C99H;UEAP.0)[+SCD%CX#+22';)66!U"YA
M'2VX<1[8CA&U`0`:GW`A&''1A><9TXXDW<LW&+M3&O';A?VS-W4?8CU5&4XW
M.=+!P\XGFH"G%S%OC*:F7=9AM%!VZ%F=2"YE0P5P!2ELC^E*5\*G]3CW]#-_
MFXM0F]S>^HGZ'?>'(OS[2M5H/==GJ.[S_K`0#\H%FO*%I2E*Y)'^JR9[X$?S
ML&O?41_J2F>]Y'\T!KDJ_,7][;_&`_[7"L033+[&F.O?>9OTA9=JY^E*4JXW
MB8^R8Y'??O3G]'4>ITZ5MSMUPRMVWZXY6Z6\]^MK^;V_8K$CY)-!^+=*>NU6
M]&^S5WHCU!O*XYIW28VYN0H^C!?/)K<9R`UL(J8Y*14IR.0XJ%DPFFI*<C-(
MX[U]P);A/%RAM-)8*.$OW#3%&MT7:<@&M2VSLNUH*E&1'!*S+*[7)Z\G2BJE
MG"W&<D9N8H$Z30[E&8[D#;A=5:!Q;+IY@\0,"G$\L,B#I9\Y+!2E*@S[H_\`
M4@=COA&T\_30U_J<K'S7]UG\?*MU;!/X,3W&7Q;UXY/=(7JV.^WPAL+YD(MJ
M$"E*4K.Z[AZ^NER'?!_K?\JI>KT/J5;=N/\`8D[0?U=IP^:UV5CI:]?8^:_?
M`'!_S4,^JO4I2M@G\&)[C+XMZO?X9_K0[7_VA&V/_P`\:M3"4I2E6(;1P3N`
MOKV,DZ7;6($)O(=*+I;JC*<(GPG2`'YY-#-!HZSBDI[E9$C1D\"89OQ4VO,=
MY#-QP)Y,@$Y6$KJA(FME^KZTZ][R@O-)DO>#;QDRH;;1<41H0IK?"PT&0NDN
M$R1/I)EW/56<;P?LFRNK@)B@8";R*IK;58"`<,"+@[,77*0;:XWY%_-2E0?Q
M9_&#-MO[,'4W](*::E\EWZUDD?>"]/DPK5X)N7GM[G#XF-;:4I2O6X[E"]11
MUS^$#8WY\7E62!2L8J3O5"N2+X2]6?T.XPKE:4I2OMUI]4ZU(_J[;S?GFIE9
M*=*5"/R8<94R\C$]0V3?4Q)XFB$4M<DXGCJ(=5G@UV]L+-_HE<1DFIRHX(^Q
M(.0VP6<AEV@,0;>:H9LIJMU/%+]"Q@0\M*,C$$LR9([.D&.L-?7]E0>TXZ1&
M\P&G":,X6\`W59)53)3%&+HBH7*HZ4T2#4#2@4,@AE@,2YZREB9#Q"N2ZW04
MI4/O(UMS*<7;1\?&GD5.D_'!O;\YN,ZGC)J&E-A9<[>:FJNK[HE1*06Z4>:$
MY6V"8=<BGF5Y;.G$0Z8]"B*MHY'(D96[*)/E]'N3N))RX[-0]JMH)8@[7][;
M%1"<53Z8^Y&9\9HSA?+*.'F;(YEB$7LXR1DRB>B9,S5"J<6.*QA"35Q((J!T
M83((R8L2[GUW2TZC'AYTD8TD;8:TQ^]D!D/X!>9[VG>*VHZ40<S-DG'RP"NW
MU]UIZLFC&")LJ=!#.$P<Q2ADN8#MD",'GE:GW5'MSJE,G$X[F9$6S>O<IO`:
M=8,4`6I',TQJ^'(*0(+JP*?/!(38<RHJ"$R(>6(APSB5N"6#RQS&SPQOUKS#
M.E_:_';]=.E_:_';]=.E_:_';]=.E_:_';]=.E_:_';]=<@E98AJ:=GGECAA
M@>)Y9999XXXXXXF@KY997O>UK6M:U[WO>]K6M:][WM:UZ]Q-*Y#-!0TQ.PSW
M@U`QSP($L<L<MF(5QRQRQ*A6RQRQR>]KVOC>U[7M>UNE[7M7(>F'Z!_;PZ?_
M`)3,)_MQ6S/D-T$RMCCCO#J!>]Q0;6M;9B%+W_A</6L][WO^"U[UBIZB;1:R
MHVNS`35C8_7](4BZI+@AA.59KC%,4"^!Z>)44B61@B>=1<T!B;3SA0^6N*#A
MX<D:+&@N_`'"$SN1^FUU2^VAUO\`]/,3?M?3Z;75+[:'6_\`T\Q-^U]:WVTU
M3MY]H-<+=;6O;K/$3VZVOYKVZN^W6U_6O;LOZUZT^FUU2^VAUO\`]/,3?M?3
MZ;75+[:'6_\`T\Q-^U]5[XO=S=/F9L5R!JCNVNUH;*8Y5G4O-N*2]/44)*<O
MX(\!#IJODB'SSM`**N*2HV\04[D!C'B!W_@IKP0_]SJ:.W(=H'>_2V\.G][W
M[+6MLS"G6]_8_P#MQ5SK,>S-D=K(CXCUVME]LMS$`U1N.]FKZ4Z&NX$P;+/`
M)11'`AFSZ2JD1<PQ,0S9`X8+YY89XXB7OCE:W9LNO>W[W]]TOTZ^;KT[.OX:
M@`EKB4E[9#D)=>Z.T+\C39&.8V74HMI+JO+=GD-"^OJ:F(S>\LR&LM!L%B[=
MD*2'<Z2BLI89N@@?"1"@**(IGG.836P394T\28S/B2=UIJM'EE+T7B79OT./
M1#=,NR?0RV/`W6;N;JI7<7HJ]%GC5\+W)>3/(_BW[KPU59I6W*_2WMWO;&U^
MG7I?*]L;7Z=;=;6O?K>W7S5B]P?RXSX]MP8O'75`N9A&<^5O=;C>38JL@M\`
MJSF/KU%K<4HIDY(7"J>"ZA9!79%(K:@_?+;A66V::KO%0TE"3C38152]5^Z2
M-B(!)<9VQD)GYPA\C,]WMI\JWB(Y)K)+2=BF8;8P2ZQ5"["'6PW7XB$V"1QQ
M"&[I-B^*$4,K%Q+)P`QG"6JW(=H';K:^\.G_`%MGG;[)F%+?W^7K7?%K_CM:
M]:^F'Z!_;PZ?_E,PG^W%;!.0[0.X>=K;PZ?]>\R__$S"?L7_`/?BO)C[H+?3
M(DSF(W??,</%J2`RG`_F2807@R7$CNIK+9<M#<:D#`Z0X$(X?25($`\4-$QA
M21L;`(V6,%A+XC`BX8PU]+^U^.WZZ=+^U^.WZZ=/N?CM^NG2_M?CM^NG2_M?
MCM^NLU[N-"?H)@>2M]3<X33$L-E7&Q-?2[>,RI)#-CPNO#ICGE012`1AW>M(
MX2H,GA'28AX(CF/F4#-%LS%@\3`-\\]7TP_0/[>'3_\`*9A/]N*>F'Z!_;PZ
M?_E,PG^W%6^[9[]:*KFK>R*,C;HZFJRNJP%,Z<EI:9L=#B@HJ2@=C1T%B1`@
M1*/08T<.G#(H18J5+A"#F!Q0P@L,L\\<;P'0-M3JZG01!2<H;+:\$%!.@Z&D
M]0('9QBPH=('R,8M0H>(G2AAV!F"APD;!&*FRI@,,<L9"%`&#P%#SPM57Z;7
M5+[:'6__`$\Q-^U]/IM=4OMH=;_]/,3?M?6M]M-4[7Z7V@UPM?V+SQ$]K]O;
M;K:[OM?MMVV]KMK3Z;75+[:'6_\`T\Q-^U];!-M=4KAYVMM#K?U[S+_T\Q/[
M%_\`WOJ\7B0W9TT8T5;/DGIMOK$TSBOOAM"X4DLY)^B9$'5&^K++8%2EU-#4
MG<6R/HRF&&)FGJA3PQ$[@&)D6'$QPRO:5STP_0/[>'3_`/*9A/\`;BGIA^@?
MV\.G_P"4S"?[<5W:/-Q-2)==9%B13M'KI)KW5"Y\VFLZ/9OC%Z.I0*I17,\I
MF2+>;3H4U@V`G$@Q#A\8N3$#)E0\S!C(,''+.UQU*4I4:G,#N.\M!..#:/:J
M.4],49$CEG(29'^"R5L?2"+WDA]-6+VLO*B?EEB&I)[95WD6<1M+&RQ`5`TO
MR</EB":$O:F^DVZ2VJS%R;Z_;`2*GGF_Q\3+'J86GB13#-9&9Z(I5A!NRB5.
M2:J)9%IL8HI,MPAO4B:<Q5*;28*T\FW@HE,E1.4EA5L;C3='3LISL[32*;VO
MUJ+1\K<;VKS62GT8G:+`6<IN=(G675%6;B>YQ77BAG5Y+3U`B>44@L>$4"1,
MX5,F2X8!D`025:4^070L[&DA%">[6HIHV98SP`+%BVRD+CF#`XS;5`P0``0G
MMF**,,)EB&$&'CEGF)ECCC:][VM7B%Y6[;>;][AZ]O\`!M[=;>E_:_';]=.E
M_:_';]=.GW/QV_73I?VOQV_73I?VOQV_77J5]S#;A:E1%P]0"QI7VBUUC%ZI
MK[V`,*+0D*;HR93H(`*4S.P^G#G6^Y70F*Q4$^1,`'20HY0/`T4&",@7$`$#
M$RR"/3#]`_MX=/\`\IF$_P!N*>F'Z!_;PZ?_`)3,)_MQ6.9(FVNJ9W?#D&<A
M39[70=O.>1-:#3;7<)RBWR.X"R5J;&Z,J&4-2R=>)-7+IJP5-))\=.&,@DU,
ML8(&,PS0(@6/*_3:ZI?;0ZW_`.GF)OVOI]-KJE]M#K?_`*>8F_:^M?IM-4^G
M7Z:#7#IUZ=]]'B)^]Z^?IU]%_3KT[>G7KT[>E:?3:ZI?;0ZW_P"GF)OVOI]-
MKJE]M#K?_IYB;]KZ^G7K;K4](Y&]674J;0ZY$&PD0'NBFJSB-3G%@2&EJ*Z:
MU>S0R"DK9.SQ!/.+.*.KY))8X8!&4;):E<G@-8B:N#D*^F'Z!_;PZ?\`Y3,)
M_MQ5R;`D2/Y7::4_8N?+.DACKMCET1Y,)SHCQ:BQ9//&4L_=+<3=/*2.H6(J
M1(XGG/%#HWBQXJ9*#]X8`%#P[C2E*4JRO;/2QJ;0N>!9/#=BM&\T:T."3UF(
MI&24=&<OD@C-<1.J$93;JNVG!C=-6$=R,EUB'2ML3!`VE/!N-)<L8.D$Y305
MKK#:XOM#DS7W7;6E\:P0M.T<:N,`K'L16V#B^/Y@6T!/N22R[A6`3[O;)TN1
M<#W.I)1;>9Q$(I!5:5\,![D0"Y8D5+?%GQ*\68F5\Q>-_1,43+MR$%U-@L43
M*]K6M:^0@C'RSRO:UK6M?+*_2UK6MV6M:N`<W&'Q&1^WU=Y/#07CW9+7;Y(5
M07G6X=9M?&TA(::%TL.>5UU09Y(@F$`K7Q\.:.FP"P>-[7%$QQ[:Z9&FCG";
M-`BD%#VJ?&5*XB,32E!8PC6']97UDDD%T(0=$.J6+6157(B46001ADHT:L$7
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M`,#.WL[;]/6KYO2DN+#^;;T/_)*@C]A:>E)<6'\VWH?^25!'["U\"IQ3<3J(
MFGUA:XZ]`DE(2R9A04U-2U3@(DGIY`H%D.;.GCAED!ERI0J!AF,8,CB8`@!8
M9B"YXX8WRM2>-M*^"V9U01&B'5OBNE=9#2,G`,EQQ$6J;\5`T'`_FD76Q238
M158WBCXJ8(J9=3N%XC@?!$(W'Q,AY!8UI]*8XL^W_P`G#HG^YZ]]_P"*?!?9
MT\_7_P`!^SIZ_7S5LRXG.+##(*V7')HACD*);`*V6J$$V\+GCCF)</"V3'Z9
MY=X&)E?"ULK]YAGE?&^..72U75G@CX^M>4:>P)4UIU#GZTG;.SC/C15'UJ=$
M(.4/1I):L15FK!#?&7"+JS]!,4)Y`=.0,B(Z"B8%C1C-.:R$'D,"+7B/^.'A
MNEEL%'M%FC_&_)3,/FE$D2=K`UXUN>+9.'4@\.F*I0JO-UK*248-)BD6,)Z@
M7"-YC$CP`Q0U@$8"$#Q[KZ4OQ:=>GI<.B?6_FM]*?!?6_P"#T#TOQ+<6>?2V
M7&_HD);#K;''/4Z"\[8=]?KE;'')CWMAWU^F65L;6[Z_;?K?MK2W$GQ8VO:]
MN-S0^U[7ZVO;4J"+7M>WFO:_H%[+VJ]:/(YC^)&4W(WBMCM&-H]9Z:&CM-C,
M-N)#2:#920A!10DQ`;B$4(I"0GA"C#"!DR!0N7P$%$SQ#MEGE>_<Z4I2M+VZ
MVO;S=?7[.MK^M>W7K;K:_;;L\]17,7B9@=A;0)NPZ8X74*B-?9F>]S61$@A5
M#";#;V8V8CI$C*6'MFLA%?+*LWATE+5'&TF:9P`!;3X>+G71EA9(@-!$:=RD
MK\?>B,\/I1D^;=,=5I?DE7*IA%5D&38!BU]/92)(R>$DI!0^Z7*UU)<-EDQ+
M``32``Y[,,H0!#)@8X%\,0[4S]*2XL/YMO0_\DJ"/V%IZ4EQ8?S;>A_Y)4$?
ML+3TI+BP_FV]#_R2H(_86J+2!IUP5P^N^A&4=:N+"+7)@BYN+%L/V+-5F*M8
MMX/.V`BX&B.))2CMD7`7*P8BK@6\GX"WO@(8Q$ZVJM1/BMXM5`H6/D>/;1DX
M2.EP3A,X5UAA`P5-%#(>(Q<R6,`L_,$<N.%G@*".#GF$,%G@('GEAECE?Z/2
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M+5^?I27%A_-MZ'_DE01^PM/2DN+#^;;T/_)*@C]A:X!T\7_$0PV\K/!ZZ`<>
M3.:K>*9J2ZZ7-K%KRWT!"(`7QN*HJRVJ,THG)9,"]\<A3IPT7`![,LQ<+=M=
M(C31+A#FD53#A[4?B_ED5'*)2BLXQM"FKC\$2R*\&*.BGE.S70%;,D56@01A
MTLV;L$`I!A"BDQ1\<,\K58]*8XL^G?>EQ:)]+>>_TI\%]/Q^@?I6VW$[Q8X"
M@X>ER:'V%RO<0(//4^",KBV!RPRS[T+-CWL+CC;+'PF-\<\+8Y6L):^.5K7M
M$U%X-N.;3_5EOQSL!KUIML,OQX:E5U/'8F6]6X;2E51;SDD5Y2$GXN11=I9W
MFD]'CEIKB>S2IQ3=1@B60&L5,!8))#$-.)W+,WC-X@9%:R$^(^T.X[7TRW00
M"5&T[V=K;KLYVNX4PQ?+$!10W`AM(\DJQ`;+#.P1Q/.&"XE\,K8"97QOT[/Z
M4OQ:=>GI<.B?7V/I3X+Z_B]`_M7K2_$KQ9"=+Y<;^B0E\;6PM?/4V"A+XXX]
M>F%KY,;*^../6_3"U[8X]O2UJT]*2XL/YMO0_P#)*@C]A:>E)<6'\VWH?^25
M!'["U4N)./C0Z`GRF2=!FENJ<-R.C%E,FD/Z+=?8J8+S2RBT1&2U@JG.9K-5
M+629=533`Z>H@ES@89TD,*5,8B`B9X7N_I2E*MQVZU<B_=76N9-6)F+J@T;S
M6S#S/<0R$;`(KR1D(.54D5RMXV;**!$LXFJX4Y)<J`.H)RBGAJZ43N?3SQ/P
MY0:D\):&1-'*3M+:3@4O8!S;K/GT;[-GY%9;6R9\BX%8^;<6(S)O&V!4^VRT
M?)+):Q,GBW%7-P"**HJN-44U`SBJA$B/7K\2O%I?&P=^-_1.X=L\A+!WU.@N
MX5A,K6MD)B'=C]Y83*UK6RSMC;/*UK6RO>UK6K9Z4EQ86Z7]+<T/M>U[7M>V
MI4$6O:_7LO:]F+UM>U_->W;U\U4/2-2."1P/3&-T'7;BM6Y$R<)IHXL%)C;5
M50>UW41*#'SS9LU"J:*O>B$D1+&#IM#\G^52Y0`8P*4Q!"SSQKSZ5%Q?_P`W
M;I!V^;_Q6X4[?_Z96N/%'Q@6RQSPX[M'[WPSQRMUU9A//'KAE:_3+')EY896
MOTZ98Y8Y8WMUMEC>W6U[&=6>'+B^T;UZAV!MFHOT;FB25>0'Z@-N7YO@*#FH
M\Y;<LDR<[GPSV`AEGR,YEEPKK7;[C2F(W$%/<*THG$EN$LDQ-(E+A)A.^7TJ
M+B_O>]K<=VD%[V\]OI6X4ZV^[;T&=E:>E1\7W2]_2[M'^EO/?Z5R%.EONW]!
MG2U?EGQ+<6@N5Q!>.#1083*UNH@VIT&#"96M;I:UQ!&/GG>UK=F-KY7M:W9;
MI:MGI27%A_-MZ'_DE01^PM/2DN+#^;;T/_)*@C]A:H3GI[P,A/<2+\]:N*`*
M2"KC),X6.A(JU,">Y9V*N(XR>ULV?FD8+P#B4L"YD<DAY)V"F>P`'&+%1L0Q
M,K5X]*8XL^O3TN'1/KTZ]/I3X+Z]/-UZ>@?KY^S[M;!.)SBP"P$%$XY-$<`P
ML<LQ,\]48*QP#QPM>^>6>63(MCACC;&]\LLKVMC:U[WO:UKWJUHKP.Z``;L+
M.SXFLFHQB'E/5Q!@DKJQGJ7$5X\39%29557^<GTMGD0S;^+R5FT?*1\9N"R2
MZU=$3@K#.HR1S\DAUO0^.?AI<SR=\=-S2/C<7Y!CX)('?C%1=>M;51Y,D!?"
M%'01G:UR+7'7&V"M@`##)`JR1)!J8(0@I'(?`//*W>?2F.+/I:_I<.B?2_FO
M]*?!?2_7LMTOZ!^GG[*7XE^+.]KX7XX=$[XY=,KAWU/@N^.7>]>]ROA=CWQR
MOCWU^]RO:]\>^RZ7MUOUV^E)<6'\VWH?^25!'["U>/%41Q7!3#0XMA2-6%$4
M:-BRA9N1]&3106*R4"RLJ'5M5LBM9LD$Q$3+*2RHJ"L?\2)`^-J1XV>'\(9,
MC"9U#I2E*4I2K/>0L<$MH/NV,.*"`%CJ-LE;(0<3`(+&^<,O7#"V68E\<+=_
MGECAC;*]N^RRMC;K>]K5C#:FZT25''&JPN8AO3NBM&3->.`%QPEKVV(P:I'+
MR<>:D?N:4"CWF)S.]0<J)(;@;CL*ER"''@[)*-1MJ*?<V?S6#]L``:O+6Y>\
M$?:X\4,D2;N.946WRA(K)4Y4F!SAP?`C%UO>OTEJR\V#'C)D=/B5Q([;+S3-
MQQ$<+@/OI$<YX^H,199+=%;"$\#X*;(Q(6Z'([%FH$DNLQJ8WY1>$7Z&NB5P
M=O8PEZ-77!<H[`,W7GT7CJ#`@VP#<G%88SCDLLH`(17-G(]E,@7Q$)A!H)Y/
M/BX[23NC-<4SGM1NE#4I8[/;'$.YL-9YG"=ZU@S7*,GR$X93:"W)KD.-YEHR
M2B7(Q8*Y'+)I]GG$?$FA$4ST/*Q<!O%`B8-_SLWTY!4L#<E@P:_/H_LG579?
M0]4:3E<,AQ:P);V8BZ6M(5#8K9W6F(YFNR[1R<EAGNE,3Y00<0VV,XPF`?7H
MW)Y*(YEJH^7=8?Y'-I9XVFA:,F7/K8CYL%-;.+78F(PMEU]FQ$[-PXCV#R6C
MNVSB7XY;L6/<T^)34TDPDL%E-V)E=K-B-Y,1TY<31%)O.E0')96UNO3M[;VZ
MVZ^STO>UKW[+6ZWMY^ENG7KT[*UKB5T<$LBJYDR*$`7+IB@,...)@""""$3&
MS$%&%$RQ#""#PM?+,3/+'##&U\LLK6M>]837"CJ3(TB<?G'3R'H#Q0E=4XYH
MBY+SD%P+&C?4K/V;Y.D^2IFO9DS*_B[@RS`9F)I-)!MR-VTU['%<ZX0EA070
M\1KIQNHD1<BW)!*49J;7B*;VL_'[+_$AJ!NT8D&3E6,F<U(KVWF#<4W$SPUW
M:[W)-=/:,6"SE&N"NPHC;L@A*>,>R"W$ET"*1(`1S'C';F9N7+,_;C<';]4G
MS/K91'HE<L2JM0Q*3IC1L+!N?H66'7&R+"BZY"3?2H]D)1:Y@TL0.RI"R(E%
M9R-`8)QW*-9\+CO,"WX[0[X[FI4B\<##F*'')QTL#8S=9=BR9'<IR_!,H*QE
MH-B#CT@QZU"$C-:SN8C)`E>2_'&R:+'0RCQ4B[`-D4<X62W$8N8@UX^=NIOB
M'0WCQA:-9>,Q-%DN+7-M)<H3BV@V2"L6D?6LG*,L0ZPL%UR(JXTVR35U`WG*
M:TBB)89I[H3;`2RE[,PF[2*K(M$O)/O:X9?XX'C.0:ZFQCM["FE"<.@PLJ1P
M248WV@D)H2T_%MF["PFY6\KOTM%NYB*T0EN-Y0;:TE@PFBLLV3`\J#8/(@KW
M?<(VWVT6Y",2F68YSAUZH$APD(K2'!R:["AB8H!V::<XOYN/%NB1@F1VW#\1
M1I9@'&BU`6I(3O<KG'764G.=*&5LW.[G`=R#J4I2E*4I2E*Q>N2UCN:7>;'4
M>%V2Y(Z;3FESC'WNC'!1DI'..INDD^0!\&\?,F6:FK*`==8X28.H'2;=S6$P
MJL8D#8!@Z"6#,B!\&S8RVAU:W5TIX6M?]ZY+C&#FGQ5N=\'Y`M'$+N^0E>36
M'/A],)N]NXR.T7G=O@&DX[DW2S,R4EMNH<<$,T)+!P6R)5WD^]:7[[[T3;*4
MZOPD-',MNR-Y(W<AZ1N/;Z-+`8,S(#DBV;V<B:U"1\V75'J&6C]-0XH*.\[*
M<@R7*AUN2:.[DA602@*X40VT2MWY5-T-HGH>G'6Z>DA7T?C1S\&^_NPH$7'W
MS$+T.2KL8A.53C),C!9DM(*+[8>!%!B;&SO`8;`5TY6%SD<,^NY&5!!1[)MI
MZAR.;=Z\:>PTEPL^!&0D:L<)O%AL#KPR""4V5]+V;ER6)0B"'9);CF)G4A07
MWPAD$XP9A<DR&4HI2N@.9;/+V)RSQ-M$R@WI3KR0[ZP%-G(0C';JKU7VA`.Z
MFPFFEH_5HWD."5)OPFT8>35B'I?828W\9.C><-0%IS&'>[13ZZ(ASD([U)-'
M"+I.<:JPDP_%I+<HS'%[_>3PG^+=BXV<2]'CO@UWLF2TF4WJWV<\(982F[F=
M*[B:\7Q>U"[A+2J"^',W$(FFG5QM,YTI+8<`A7R&EA9RC4JSWD+'!+:#[MC#
MB@@!8ZC;)6R$'$P""QOG#+UPPMEF)?'"W?YY8X8VRO;OLLK8VZWO:U8O.J\"
MS9"?'!$/-!&[P;SMF#6_@R38*U]A>/6BHF$X^"CIIM\JCXG=?&7SYF33;#/"
MG%,G&*4WV^C(PK7'R&5#B@);Q;OZ3OSR)JR+M!'T(R<2V#*PHJ<5,H-):=SU
MC*-)"GDIL;KS>8]G=3HKFH)J`QTE2@]1$HD]XUQ%;AE9:3><BXTD+(7R]%Z(
M7YO7K<67)CY-M/9/;3]G*94)T<`ZKL-!L)20OQ3#:].TV/790%-<+45BYQ-3
MXK2I"=C;:#9R<#A;AA.2[%&6B.)*4$9B&\T0:N6^N[VV)Z3=;X.FUJ+?'_',
MWZJ\E#S>C=5G_"TBGY`D2&HD-@Q8Q1Y11"SE9%TD9`55"33;+03Q)PK>5B">
MMYW()!HB<BF@C?;9J`^/K4Y@1;)HT-1Q#'`?,>\<9O%,(LX0K,6V$7[*HT<)
MT0N,V]$->(.EM,AM'L/1!&;<S35I;-R4`:5C%C"6WLB5_;XY,^0**YHV,S?+
M;<`SF5M5=C-CM3V"PC[)?<3DWM"FE,:2,^=0-B(M*H&,QQK,T#2*[;28,X\G
M5CE,!-ZI+!")6(&&DI(DL?$3-DRSS%+JD.0=BHDV+CUZH$"R'$ZVR9!2)`D-
MFCO>%V\9EYFRL,UHWCIL-<Q:6$QQN5HLCQ=2<[+3G`J-%<LEI2$V2.,N]*4I
M2E*4I7YB]H0MK>?P>?Q;UAI1-H\?Y$]Q.7F%Q9;;\91U''+Y`.Q#Q56^C&5V
M9S!^(HN#.(*5&BR$XDA,C4ZL*7C26<D,R0<:@DA%U5/3D,P8&&R!N5CW;KD`
M<Y7FSV#1-BW`^RG&ILINTTH'U8)Q7$IEO2(A-B"%-:CAJ/Y90V63D]:2(Y>)
MM+=;5+MYPIKI<8S>7FVY5MQ@+!.R%<1I1N-O.O0/>58];C&Y.&S)F$)O1E`Q
M5M#!;=D:'DYW0"@JDI)DOKCQ:$2L@B*H34EN`^SHU1RRN]6$1<*JWW)9';Z`
MVB50X;=[52KL;L'#0>QDD^@ET0'W5!J?`;*UK/GV0G)<;ZZLQBE%%BR5<E9-
M`=*H<>1Y><KK49)/+JBWE[%;\F)/BZ`F(9,E=5'')EOFZ=C&.EB2.C-IQS5L
M9S)0-(,1OQ!03,:ZI,K3*,$A=UTDY<)I*$`\T$@P7)DAJ,JN=P**D7DU)D8\
M6#3<C!Z-22'U-F\HNWZ9%4+L*;GJ\H?=ZGO;%^H^WTH/N587S8$>YK&G6<ML
METP?LTTXS<;$3X[VS=QQI2:DN%S-=>.1F075*.$L]Z&%QH.%(RD]/5J6G#J]
M!"K/#RC219D'C%K`R7(,.GC*G&+[>1$ABGKCS91XRWFK8PA.DV4R7"V9)O):
M3B(?&P1"]T;`@*)<E6E_-?[EZPS'II@J<C_)YW0;I^1EAG14QW\\.)1TR,\@
MVYD\I:2T:(XFR>&.,-%L7"B)+;=IA82+-M0?"WBM!M`NJB^`;ZD:-7*U<*J\
MA^YC;W=NS"3A7C%VYS5POQMD-8CX+=42JUI8[-5%V1%K818*F$*\DG7D:.$B
ML[92MFXL$,HWTW-LW*9MH91+'(]]GMW]TGGQI;^Q[.\N/Y,F^+%K0?-WR'%S
MSC=P:[R]!>R6T#U2\9J@N06.W$E;9+$F%E`W9#QAEY#V,,M)CQ*+YG\17#)C
M8!GDW[WGWDU^U&W=?L.:K.#)O0?K@[GC!>XZK+T#R@A2.<(>@Q/)24'$#,'S
M<X'D]MN)VR7@*O-<%G7LP!?+";=#6"I4:`MP[?2?K7,W.%LGK3-&$S2:2U`X
M<Q$69U81COU216Q(Z8VFG)<RF`4-'*M=?$CA"?*BZK'%!"';K;,F4I2=9(TV
MD4RGF;RI@Y#=]&''VU1Q@O)9EN)-*^1"?(Z55M)?<2L78N;]4X_U=,R<YRL3
M/1TM!58TCR%J0[5$S)KT1`VN87Y+8S0(,9<N>R37P<5+E=2M[MHMA=ZU./@I
M[83<;40RQK\@CPM,SA1([D2<]0I;TH2GV0EQNPPEQ6L.E;F9Z38XTJ3+KZ2_
MD-E,!NMQ>B]5*@I@)I:6\F?&][XXWOTZWM:]^G7IUZ=O3KV]/8Z]O2M:4I2E
M*4I7P*B4F+9`PEK"<154TWCC@:3U(F6/DC.&.>(F.(Y0V$,7&QQ$PPSQQ%"S
MM;/''*UK98VO;BRK0:A%$,-LDVF^4;QOP_C2&61$LNCF?&KVR,^,)8)3`@-X
MQ>UKC^%+9^&O:UQ.^O:U<6NQI';H:EF&Y6(S'"R;7+Y>@]<:J`K-:]RAGQPK
M>[=4$XRC=2QNUC1>_B/4`S:PX5\!?W==S"!"!"#`!#P"!"#Q"#"#QQ###"PQ
MMA@&'AA;''###"UL<,,;6QQQM;'&UK6M:NAMB)XO90HXS.CEB-04T3%3S(K:
M9S;0!#!`8X=41B0XB2F$\Q2@I]343HA83+(`0V?.F<P\AS9@03YL8:B/!G_0
M^QB^.L6'8V8/V96+':V+2L>-W'R-';-JR39$L;,Y&C-S!GQ#PX]S`]Q1,_"B
M=]S!V/&$I+K6="BRFD?<K'`-%F8X3K;1#:XTBYTM8F=`;"N8(B*+?!-E+6*F
M@D<R2#,%K6`&QS"MWE=QI7S'"911*F")\J6.DC8(A8T4-@!&2IDN-C?`4`P7
M'P$!&!$PO?$0(7#,//&]\<L;VO>U<6@M=MM<N.5;:`B-\L9&L8,%T1)3D@`<
MQ;#$.PXP*<6*ABC6#QQPL*)CD);#''&V7>VM:W`%8LC0B0<Z42CUCE$Q[*8B
MT\4\LT6Z7(NM8&$#&%57*3!3<"R^I"BA!"B'U<(X;S$#PSR&OGCC>W+)S+:"
M.GMU)26NW4Q*:-L,6JFIZ&EDD]M8AEQ"@>+?)%2@15%QP*#"E<+)812V)840
M#'H$)GAE^KG:+5>J79$>+:0'6C6.IZE9)<B,FKR9Y02#@*BE'O)ZL5.%/'$T
M^7`/)YKP/C!(X`":*B!#AX"8]=-1'%9YKEV0=C9@'&:44@5@JTS3,;)ALEE8
MN/D9`4P$`9*S2`5$`QGD.">")X&@ALLA<!L1,LLK\P.Q&49<Z<]C+1;!AY)!
M84DE.P=OHXSF329@N*4'*IZ^(2R5R18<J.,6&+EC@0(I<44#/#((3/#(WF(R
M6DI.98:S0:[;5GHIXK;O5$!OHZ,HNI9P"R!P5G(>3214TO*>`.606*@K#'#F
M(>66%AK8Y7M?M=*4I2E*4I2E=9.,MH*"T7<AYK-PXX"F9<0LN&T)),K!<0I:
M]BH@"H.3$/@YE[97L!D$8PR!M>]@[X];U]@K;;PZV6<HR&CC.$F7R*%%T5+(
M"+)8KGB-AF7+JN9?)0``RP,#X9`A&<`LL1A<;X7L+G;+C4UALE'=*\]TEH-=
M,>;J+$";F=J>WD<DYG$42L;X)A5=<!4D$KK!9.QRRQ(`*1PT$3QRO8M@%:_2
MOR=L>,)_63L7RR6B\L4?,^(DXNMM(CCQ3!%5.'2%,1.Q6B!ZQ$112C1E,/YE
M;`Y'$\P.2,W%*BYA9?F;C>/CYAI&CS&9YPTP1\C+&,&FNA&!V:8S#P!S,-08
M9/S$;8^800868J+D1$R##PPOEWN&-K?0183(3'`LNQ-9[63W0XBOB*^XR+=1
MB:\MDK#9&+%%=9+$@E)3*V'RS&L7/&C`/ALLA>\[^]\J_1GL=F1ZC8MQAM)L
MLIOX&SI_!#:2`D-I'P/*1C,VHG<4M$)D"&)L^:$S,G3.)>PQHQGD,/F()E?*
M_::5\"HE)BV0,):PG$55--XXX&D]2)ECY(SACGB)CB.4-A#%QL<1,,,\<10L
M[6SQQRM:V6-KV^9&;Z$W2'DI`1DI$3?"##>3T=-))9+PQB_4<7Q0@`7+^$&O
MTN*)X+OA+VZYWRKIX4.Q,`U#3$!C&/`F0>/FE4ZSPF0UPVL;4SU\LCJ@:;N"
M3BC&#QS+//(T<&)9F3%\LKC"YWO>NW@-U`+")`Q=%20!6^0S2T(0%-(A"(J:
M("`7$().88&.2:2$`*E@,RA&X!;,$N`%D%<,$/''CW4QV8^2Z>4>C2;+N*I*
MB&L)99SH"0X"Z:K!%S!0)4(`+!,Z$240RILV6#/%L`C6!<R8`Q&L$,+AGQ9J
M*XS/)[623L>L8VEL<\55&8G&6@W3!!I*1+'O":@V"8R9F6;YXIA^Y+'$<(D9
M+XVM8(7"UK5R9-BLI/<RB]"#1;!)X+!*Z:K.HFWT@JY5-.N*`-<BH+P!,-6.
MD[C%BXWBIHX*!X4``3P??@AY8F>Q65'R6.B,-H-=E(QE2/K)A):3?1VTF#JZ
MH+8=351B"(2(E!5)1&M88\?$!R-G!;6$,#"Y6M>W:J4I2E*4I2E=91V6T&\?
M-JB"UFXBJ1[#,,Z?24))33IL,0;QC,,T;(DRY@QAF8_N^6(PN>.0W]URM<3]
MU7UI;:;R(84S2,A(Z2:6A_&E<RF)9!/,*AGOAL[&%$8F7`%/#VS,#Y6&-YC"
MVR&%R[_OA,[Y?`SV*RH^2QT1AM!KLI&,J1]9,)+2;Z.VDP=75!;#J:J,01"1
M$H*I*(UK#'CX@.1LX+:PA@87*UKVXM0BJ,E=RY/-5CQC*3NRS2A<G2H-!N'7
M'<1""/@(F=UTTF"JM\D<%44P4K*YN^2<$HG@R5P,#9C$3D`F`Q@7"O.T%FM4
M)TNI,!17,Y`VXBX+[B1RP=@2Z4NK.)&RFL)I<+'$(`@I&C10(/''#`''&UK6
MX46'(E'9RG'@T81X*P5HX,H+#($9#7$:"J?,&`CA@ZI-C-)NAGS8YL`$T,9-
MD!AQ3`00^8EQ0\,L:@E2I8B6+DB9<`H4*`!%BI4L$&`7+%@`\0@"Y<`+'`($
M`$+#`,($+#`,(/''##'''&UK?O2NLD&6T$I7,KZ8UFXG+ASQCQI8(H22353/
MC8EA37C"D6)A'1_&1,;"#^%'S\-G:V8O?96M>MF;'9N;N"?V;3;6;Y`2<T$!
MY9H"3DZP4/,6X^:,$X\B=UH))S'RR&S3<#V)+(6]Q+@7SO>]_A2(TCM`(+R4
MA,1FHR8Z3&1MS)R2UD%-(.$UD6#)Y&5TF23P"RP/D4!!*Y#*01H3(N$$!?*X
M0>&%NWYDRHA3,B(6`S)9E\BF93,$/(MF6R"N#D7R`RQN%D!D#>X60.6%P\@[
MW#OC?"]\:Z*W(EBUGD3Z8TXW8383E1)!05(@W6:VD,DH(A<MD2`2#Q1+2RA<
MVE@D\LBH2<9#%)!EKW+X`8@WOA?\18=B49JI3&&C&/!64A"W'1&@*R&N(UT<
M:XH@]Q4IO9I-T=.%N.*(/<0D2`SN,)F)?*^>>65^<$8;(&>!60AF>UQ7Z11A
MFZ2>HK>1Q'<40#`UC!A#*N;,EDN%T<<Q:PXR6"?P(BC6L((7RS_=5VRE*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E;<[WQQROCCWV5L;WMCUZ=;VM>]K7OTOTZW[.O2_3KUZ7J+/6#
MEJU_VFV'VFU";C.DZ.MI=4SB\`Y88E8!BM]8DE-;BJ=0%1UQ`NHKV<;;=S/*
MKQ4JEF5DXHHHA"ZRBGE$B43SV9DO?O#LK%):B6-)8';:W'I>4&LWW8D-)YG&
MT(YTLFZ2(:HB)BP(UEUQMS-<'3ARXXQ%$7UD$(43,L$;,"`"WMJ?FZ+DZ:6U
MKP9>"5]&5VQL[9>1V""+D87<HU9+B:;27GB?+`8B>2D3!RO1!1$TVHY%L5I0
MS42Z3XYFC*_B53AC94N("$.8!!$,7SQ`P%%P#R&R#PN*)B%CGE:XF086.0HF
M.%LKX!XY"9VMAC?*U*V5.T4R+(LO12RGBF.-]0,H,]&EI%3+C&+LE<?3<R=[
M<05@WB'XF$N&FS<JN&4G`<0\G)RDE&%`$OBI%+"?M+\X13`L1ON=I9?""RXG
MC9M*+M>#T53H=DA+14W#^Z"8"@W%R/G39C(%-24LAB94EA8-$DA,*FE(X6+"
M=*3-A!%79D_KB%"L[%B!*"TJ;L-@CT?BEM=5`55=V;5QB1/D7,_>X\R$B^.#
MK467DE!YE6J*&IY',KW\%7;I5G>)H4;K7=,E/=%;2,]I&CF)&:,8,XF!W7(\
ML.Q,93!:#=)E?#&EE97UY5+X!%B`0]RJ<`I+1VY=(2E$Z6ZO&<_#2/,FQ,1#
M0O.4?E=?E2/4P"5)%8>3;B6;;/UJ"N@PHP0[KJ!K%^I;%$!NVWX;L33K(+DS
MP3KX#];B6KQ=23\2>*C<Z4L0SP#$P/7,`V)Y!BWQL&+B:OG8O<,2^>&(8EA+
MX9Y98XX99996M>R2?]^8OUUVLTXU'>#/D-7?>\!V5DJ(G,VBC7,LE(5(?:Y9
MVN<L_#*DZ$MQ)`!M-4$T)&.(;=<@9HV;O@9Q)@EAA[?3H!OG%/(K`=]AH@:\
MALYIAR)(49C(LG)[:37*$OQLMXH"Z8\"TW0[T?-*,G<K")1C%8N9'+7MF:*$
MQ>H%KWK98Y6ZVO:]O9M?K_T>UV^W:]O9JW;9#8;#7J,\)'38>F[8(3-[L=E7
M8FN3'M)<@!7>3M(M4XYAF\"I)]PVLR;&AUQ[*F1B_D-%3SID4'*X6=L+@?'"
MMC.).XX6)O,(0?`K<3"QC,`(3$(0?`#OO"Y@8"9X89C8X7#PSSPPRRQSRMC?
M],QPL.][[.UKYY7P#MUZ7%SMCEEX,/KT\)GWN&5^\PZY=,<K].]QRO:.6;^3
M&*=;(PW>FF=XAV-BZ*M(E9J)"N^'9&."8@[`BO,@A60C6M)\RN`DY'31W6XD
MQAF58V:;Z6F.@?O%4Z13P3APIS6K^]CBV*EE<B-?TMW$@$=`C]3?F4J3!'*`
M5@5T8$7F5:I%OL"66N[%](=JZX4XZ`]4`B&13C!QHAFU(8N6N7PQ,7]8'R0@
M`IH,V7S+`7'Q&,8#!Y``Y%LL\#.(HV.5PP[ELPA,3%L\L;E\L,[#=Y?'*UOU
M",`#A!C`"AC`C8VS!%"RL*&+A>UKVS"S#OEB)A>U[7MGA?+"]KVO:][7JE<V
M3I%&NL5O":YD>B0QHT8I$,ZXW.JBY7*E;F5$LC)R>6!+X#&E%965P\10D1%3
MP3"FL+9XFDIY4<\8#`RJS:_7M^[;\-K]+_BO:M:4I2E4KF::XSU_CUSR?+#I
M*-9I-1NNIS'QL@32FLJ)%F--<>Z\2:S82@3CD>3B`;#;6U4HUFHEK#C5`$XS
M9-3#68>6-N?8$BLJ46T2=S"<2:Y$$[@%T-D!K7&)&A"A4Z*E+!`3O#Z&ND`3
MI?!50%@L164@SG<HID2IK#,+'N=L\,K],<L;WZ=>ELK7OTZ].O2U_-U[.OLT
MRSQQZ];^;MOZ_2W2^77+UL;=+7OURZ6[//5)HGGJ%IU*+9^&Y28DG$FX>+$%
MLVQW,E.,LGC'BUSJ8,,,F&!P\B"R1MD?0E4'(5*72&.1Y&.GRF&8V.@$]PL:
ME@Y!1:4F(8F)/)7/'8V!<R6*\2H6*417Q`1T3`QD;"4`FZJ)3D'2<L+*P#:5
MDMQ#$0T-2)*`_P`;/V,@9_J[_0F5,$<.A6BRQ[.0R:*[T0\(T"Z4HK",K'%S
M,(Y<$FGI"ZW7(WEA2N+DG)+B;;B;RD:*K2"KD">YA[%03)[&7),8$O1TZX];
M`PP+C>:.[D4PVD"X*607K"K2QF;#))14PWE9(<I`X?&+DU)LK*.Y$XP:0E9.
M4#7>&$_F1*;-;4B1L[6Z_&$\T<FX6B\FDKDE]L.9!40_#)RT@K::,83U9)/@
M]!R2@1''*&P,L1BXH@6>.=^W4I2E*4I2E*4I2E*4I7%K:VC-I'5'"XE9,04%
M#3S:LLK2R?*)20DI:>!F:/**FIGQBY%/($RP8A@V=.#@EBP`>8PXH8>&65J/
M0YLI"T]CN\G%[U*KRDQGH_F(XD@V05&\M@+$:O`\PW2HD$9PDTQ46FA@Z4XX
MFHK[1BAYF.:X-S#>7%(O?$6]<^_PM?I?+'KUM;IWUNO6_FMTZ]>M_6M6M\K8
M^>_LWZ>>]^ENM^EK=;WZ6[>EK7O5)`)[A4U+!R"BTIL0>84\E<\=C8%S)0CQ
M*!8I1%?$!,(F!BYL(^"W51*<@Z5GC96+MI52W$.1#0U(DH#I.GN%H7.-1.EF
M4V''1Y\'3!%I$WBYTI!,KPI,REDCXR>"?,@B")Z:>74`@J*V>(:2EGW`@$E$
M\5-K:4"<T6I\A5NR@@PJNRFQ$F67.5*'4*.S[F2RSN40%$);'2;@HHIC$W@*
MN%VPZ3#?+#X!&G`7:CI'1`%`)M+F9`WI\A5VR6YH<;$IL->E)G`FQW.PDES)
M1YT(F*;Y&\KAGDDN8S,!F4*SD;.3A)XXYG&]@Z&QFN%T_%QHES_-,>7(MDQ2
M>Z/'4B,E]JD:N3!G2$09[G1G(99#M$2R2Y9KNH-'.'/(3ALC*2<J"(JC<NI`
MD3Y,R,6##,@WSJ'2E*4I2E*4I2E*4K;EECACEGE?ICCC?+*_2]^F.-KWO?LM
M>_9:U_\`_.VL9#>#CY?>TD2MW?;1;->BKDSTMG;9Q^0.XE=GN)AJ,VL,SL!+
M#P%@)\IST2FL;<+-DEHN',U'9U;PS:IP-TGD$12),]_.!2*69;@Q-M*X5-NN
M>7(BDUU1(Y^YQGE%.LS!;4;OUZ8QOR0KZ2PAC+13&PC(BRIL'8A9!S12L?N%
M6R3U_P`GM5034-?)J#;6@<:Q:;ZA[",'F2U+FW<"`7P^G:H<+NOK#>NP`\?*
M<BM@ONVQ'(TDA\JCOE,@GJ2`V9/1V4GGR)]SN551U%P$\#6#>&5K*18$SWSF
MLAF75[=_7J7X;9KIV'5D*.8<CIV:AR!"$DN.')59;LV6-*)ETZ_;&LQ/,)&N
M.UL9J",6?;P5EA?88BC$[<05X\X'&TFNY6$N68*>LSN@AC=TIJ[DTJVH5W9*
MFRXSWAD;7%KNR*)"E6#WT^FLOW)Q)/C?8SH*FV*J+9TFXI99K%*/%8,M-(=9
M%=9P1L#/(G97,>I&VLJZ3<YD/-_6>:7'A?;;1_8O7R.F[JK*$.-A32S^9?*7
M7MKU"C@2S"@FF##;$QR<C/;HBK(8:/WV;K2`U812`"DMGS7YR+/(5N#@QXMV
MR@;4Q[\!MX9;+RU_UVD]..M21S,K-=8Q:4=LA/1&VG+<R$6)A<\H1*44$F0U
MYHW6&=A=+73^)8"S-SZ>[%R'K-I2;E+3-%D8G`/.-&)V6I$UXUGD1$;^Q6L*
M=%L=L9U[$C:P#LM*<C';KA!9Z$PY91&=&:"R%QY,U1<9A'S-FE5P*]5ME(=W
M>3WIW0RI:]P%L(*UWA,W&H](Z8C98$@L\O..O<3`',]H8\@<R"CIZ0Y<Q0?)
MR"_4"/#!TVX$6[@;P9=:#4!4X_<_LU'L**L6:F&-2]6]XU"*MB]V=AI=4&M(
M4(SJK0;$COEB%+6>I>1-*5UAXKR_'(J_X^UX599@O&,-,Z53CXE4B^5!C`'P
MW79AHI%&U)D+N6Q6E*%=E?*NL+NY'&W/JV]X>EL'.&F\LJZFV(?`D976FOB&
MU6ZH(I1-0&2?6C19),)Z<$02C-R:?C@#N@;3O8]E<*#7V$;L,R:Q-S^._D/E
M?<F*8VD5F/*.77(4>DI9;JV^8^';CK12*DHM*48_&`7DH?!!5"BLK-A*"2A+
M'<A;XY;:'#F4;:72HU%8HZVB[W\Q)ZDF3<H0S"&D!(DZ:2SS?\@7BL^7L5\H
M.UN.%SG$2-S]L2N0YE";5\`2F%L`0<*5V:W;<I7'!L1#[=@!]RHN,3:;C?(0
M[LA#>K,YPW,.Q,8LDE(*XNYS)KUFW"SA;DTZZM9<Q;,[R@6;X@KF473@@OM_
M/UT-HXXCU9=L5/416Y.ME(DV4WGAV/ED3E&U.F]1<6R*'+!.9FO#L71*.JJ^
MK['3KQ8LQ4:UW?QV26^WFJ['3,#/8PC?#=BR\&$J"):&I/'IFV.LNSPVR?(!
M+3`UTV6/.)(YL=$I2U^>C3AR8S^1>(T%NS"#,<CQ$;26V.3%814]BB%W^]&?
M@*B&@Q$4!;4S!49,PS[;O/J]L/),#]TOM=/UKGM[J<I[CZB/?51%(PE)[@$D
M0)`?^03W>,%%`&L:"=1%,217)=Q.-C8GB01$\<%/'?`*`>1BZ>=X`V[*;P[;
M@Z<Q/,#!)KG<[:;"D!N9I1^^&''H&Q!5R,Q6+QTSG=DBHS-;TU!1@454]M@9
M*:>Y6ZHV30/&$D^1Q\4W*K;B8UQLDY6A;3OD(;$J2A*/&XU]FX/QCG8B.V0R
MYFA%*+1NO.-W0J/&RHO35$J&"G`+^QB;$K050]A1L8]1EY]MY[XG%1JV,A0)
MML?XVY#A4Q`^S0R\Q>Z)P7<Q6:W]>IB81QM:N*PV*^L.:.V2@(YPVP(5#&.*
MRL=(M-5,--DCJ@1(94#.C%C!KEIOTIV,=O'_`,K</-;5:;U=LLKGE4YYUUC#
M"&)!%$QUE6)!`(''U`C+.MVRHYH\4$490$,8QFG*Y4RG#*9_(GD`,<,9YX\8
MIS428^9Z:Q6A=@LPD@)Y=JLR[8R97H:;X8-K)*19H"EB0[8Q*$_!88H)DB0-
MI6-[$S9`D9"%*@]ZI2E*5:3N9IW&.[45I,32D6(614N16(^@%B[2:3A<R2$V
M5P`5SD60NN9*45&-7"^60.YHX,R6PS"%(S4;CN7#+-<*0JBA&L?NU"U39&G>
MO[;@-D#DSZ>BG7,?5'8093&CM>>*LY5T^?%<[M*1LA-I%6'QDE#I22N/DP1S
M=#Q-HH+F=*DI.,\H'Q\5#C>WUWSF:0.,^Z9MHY)GD+9Q[\I$3;%L60$5DO5A
MQBP]=L39B`);76`PR4<+;:%9KG.M,!85#+M;RK*28Z2[,NY"HJDWADZ1V7H+
MWG.1GL`B["->?)SVP<&OFQR!K#L'"LKDQ-0&7*BY`DJ)S0S3]9FK:+5Z%G2I
M>4+MIM.>4F!L:=2%Y43T_'8K,Z?)9B6%<:FR$>:O2Y&VQ\NR,&Q]6&9P;<..
MM$GKY8@X'.G)NTSJ7%AO1W'*VDLY)<"L$^FP4./`BYDTR4P.,,@X,3;L#2$X
M]B:QZ0VF7L1;<PK&I-2.E-BR_=0&S<[ADS1FXR\GZLK.AR$:;TB'$_Q<R>`B
M@W#R@BLXJM#)MV\8%%+-`,851OB2O8+$<6[/.C4)BQO%A!W7F&+>!3E7C;9I
MKE?'3CS2W<M[HNL(Y%;Q``#/G\)*>ZTWG69;C;/YA.%T")"\?1K&@PC0^4F\
M&II9VM7G@D-1S;J_K$N\6FB;41597NE*T;+DU,OCJ7%`\60QSP9EOCNIFD5=
MCEUG`L-@HIBDILXF8"N?+I^!2>'A+-%3?$CQUYE#`!G`'46%"8V1<8,?$(X2
M9Y$L=*B9!99XX&2AD,0`T!G>PI<?#,(;#`3'+&TI%*4I2E*4I2E*4I2E*5U%
M_L=LR8QW?'CS0F^Z&D^&RN--RMQV-U%=S874-P)IA+4TIP-9QDU%ON-&/%3(
M@"BAK9`ZDJI7(4DHE3!084+.P30CC+B'092?*VQEGT:N%_-"-&XJ.IQQW%Z(
M\")IHHXV#ULCNUHMA)<2>Q)$>`F#^`AL%2M%47+OC1.*FPUT8\8(WQ^N2O?#
M<")-J>7AO1)MA(+07M1V'QPR?IU`B5Z!%%*?$FS6[V.V9"8AAHGFH<>TJ(#X
MP<5T@9C`+9DJ1/N8LH$BI<X50\R$NNP49;IK\@N)S;)(<I[(:@*X=E%+@/22
M0RL!/ACHXZ+;-6;LU,89Q-J2=G,"(PY@BHF([VD1D)V`%[E0=7CHP^``L*+'
M:DW)&YC889L\?39B1.Z@9^V%4TDT:S*N),TL,Z&M13(O8RF#88J:7%QC7XRF
ML,FI&B15%Q-"%V38S@L86)X_IR3SXT=K9)GO:Z&7T*_]2]E^YT-TH@U==0J8
MX6XGOV?T';]@H4B1^TVP[TE`<1F2E@P&R"Q-M8H]W&XBJ04,))(V2(8#6H[(
M<=[0H$_3M&LA#KV6T;ZW@[F]=$79'!QQEUP)T=0Y9-?CQ;`-P+'#3:CAXLF5
M!9'6R*?DF(1]!>:TOB^",'#YNL&G3/FG#D"T.9Q_-2&EB+.4_GD?VS(7A!!3
MB/%KR;C<N"ZWN7Q!N($RY+,.V/\`-CJJD4"2'*87FB<0QKVQ)&"\H7!!9EDI
M@YKT9C6:Y1`)<M,U&$5*:=D@NC%4,=ELD`D.ED$;O"0"4,9+'`2PQ4'`H*.`
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M_*RO?\-[WZW_`%=+>:UJLQV-UVB"6YTU%DJ0&L;77C#[SD0JPSX;L>:,G$2+
MV:!90=":NMM`<*6V'LDJQ]AM$X*DOA'<::7,H948F5+B9&,AKS^EO-_W[?/^
M'V_/UK;?#&]KVOUO;+K:_P"ZRZWM?KV=>O6UNV_2UK]+=>SI41+^UFA93V1>
MT"J344%"%-DG`:EZ<XK.O9^FF')#_7P<5%P*R\V1W/FE63W";:#?$<+7(%B3
M37<"0H"LAG`%!2".2ZX88XXXVQMWMK6M:UK7O:UK=.RUK6OTM:UNRUK6M:UK
M6M:UK6M:MW2WM_CO^NG2WW?6Z7O>]O8[;>:]:=[;V^V_7KWU^OGZ^?KUM;S]
MG7ITO>W3I>]:VQM;LMUM;[M^SV+6[>RUO6M;I:WK6IWMK^?M[;7[;WOTO;S7
MMV]E_N5K:UK=EK=+>Q:E*4I2E<.X3(Y)"63A;/P1DHE*)HN)WN&?@QRQ(<8$
M3O!,<P\^\%#PR[W/'+#+IWN>.6-[VO!SW/"U6XWN/\G@CHR>2$)3C/Y$`YB!
MB*I^)*DA&'8=)#*P_A5,T4$<2^KJ818T;&`*BG,@BH8!<(N"%.[>UK].MK7Z
M>;K;S=G3K;V+]+WMUM7`!MY`"*'R@2&C!E3ZQFL'RN"61Q+'E<0\"=$5CH&(
M%@C2H(=!!."*`^`AS,V""9R&N,$'GC]EDI+LLYK-DTA98S3<$W-6L3+^4\TW
M`T*:P3LE#P?C>1#`T((:P)7&N6Q,B9F,0K#9Y9W$DE+(G%4Z232!,XKF@C2L
M;*$RY8TJ&@"H),`RHF`0\!CQD$H``5!,&LQ1@BP(1?#/$(/##'YB:"A$DW-,
M)HJ043;G#)VZ<6320!"YTR>$/F3ER80&!:YHP?%%/&#%P_##'!!#0N>0^>0E
M^4*%BQ4/(,J7`+!Y"9BY!EP0P`[B"7[X02^`6.&-Q!,KWRSSO;OLLNW*][U]
M-*4I2E*4I2E*4I2E*4K2_9:_W+U`7JFWD,[SG\FZZ>22!Y7/Q)K&(,>.E@C@
MH(S%0DU(:IE/L9Q%#2C:2FN!8*XG$S`F:-X'<\SXQH0,#,*?2]K7MTO:U[7M
MTO:]NMKV]CIYNE<99*2[+&:S9-(66,TT--R5K$R]E3)-#-"&@T[)0L'XW<@&
M:$$-8$KC>+8&<\S&(5ALLL[_`!7;K?R*HY7)"1KE4=1#44@M=+(^+I2B%<U<
M)03`/`>"3SX5S1JX9TI@"9#N9,=X+;PXO??:.E)8ZL15ATT@,JIY4Z5(*8I,
MN(HD2I[(OD>+$SV8=S14N=R*ELC@``H81JY<"X^`EP0^]T!24H%5/JH*8GA*
MBB4)E%!2#)%L%`^4)7,W)%3IW$.QDT6)W-&;E"XXH@):YD>X&`?AA.^WDDU.
M(Y7R))Y$GEX'$#OBA0N6OX'#*^6`/4$/"_@L,LLLL0^O>8Y97O:UKWO>N2I2
*E*4I2E*4I2O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g339906.jpg
<DESCRIPTION>G339906.JPG
<TEXT>
begin 644 g339906.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@!"1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?24Y(24)?4U)%0E!?2U]&3$]7+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_``!$(`:4"G@,!(@`"$0$#$0'_Q``?``$``@("`P$!````````````"`D&
M!P4*`0,$"P+_Q`!J$```!@("``0"!`,1"0L%#0D!`@,$!08`!P@1"1(3(10Q
M%2)!419A<0H7(S(U-CE3='>!D9*ALK?1&"1"4F)UL;3P&1HE,T-8E*+!U-8F
M5W*7\2<H-#=C9'."E;/2U>)%1U1EEIBCPN'_Q``7`0$!`0$`````````````
M`````0(#_\0`*Q$!``("`0,"!@$%`0````````$1(3%!`E%A<:$2(H&1L?#1
M$R,RP?%R_]H`#`,!``(1`Q$`/P#O\8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC
M`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC
M`8QC`8QC`8QC`8QC`8QC`94=SAY1<G3\MN,_A]<-9'65!VQN_76T=];0WEM^
MFR6Q*]J32&JYBLUE16GZ[C[)54KUL"WVZR-X5@REIQA$030@2;TKI-8YFEN.
M5V\T^`9N4&P-'[_U1OF^<4^5''8]LC]:;SU[6Z==/B:7?TF"5WUQL2@WADXK
MU_HLXI%L)%.&D'#,T7,M@DV+@JJJQ#V-Y_>WNDW6.\:FL7%^U_S"`NE_%Z9:
MITCR&L7(?>W%[FE+Z?W+JO3NG[+P/GX12Z[RLN\9>5K6O*7?=-S5OD:_HJ^%
MM\-,PCZ1F=CJT9]#0,W9@>1A(I1F]V$GXW]&2C*+"/\`BUO;\_>8Y?L^%E^X
MZP-ATY<+_1]J3VEYS=])E8FR5J^2&LK_`$:\5B+01@[;#W.,AVIU)A_/NXB.
MK4JN&NK#X`U*V'6N2(;@Y2[#VGLSDC+<9-BSFR;!J3331K7-U\7YJ^/*I:XS
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M>S.*WP'Y^]/MNS=@[(A]0NIN%^E8@M#:U6W3X;24FHE.J*&,X5!MQF^_`JUA
MO64W/<93;B:&P[_S>E>:]`F;7HW6>V:90YBRZ2INC;9JNXZIV8I8*3N#7]C@
M*;'S3Q.>9P3]K86D%(L#-W$&"S[^+'X(,8]X]:GT97N0=9;-Z58-H6G8D+>.
M%G$[8/'W;M@V@\CG2LX]XPJTJOZ]H,]04(EA#:TL5%D(VP04`5:+G)2RD4(H
MBBJSN_I7G'XR?/G'$559S%[G<Q<1QSX3AW[X@E3T-X?-@\0:>U%MQ&I5[7E/
MV)(Z@MD(UH&WXMI;+/7*PI`SL).+N6,5/PB]@!R]03=R+*109&4@GLFW?1SE
MQ%K:'C(-=<!1JRGPNY*S>Z+?K38W(J5T4\F='T:^T'BS0KD^JD;N&Y.KYLR`
MJ[>P;(29*R>OM)0\W+[4?F1>P\W#04LS%!;8$QX3])7\*%3PJX#<U[CZ@>BL
M*<GN"PQ$1:+:@HEM)EM=^\0K!7<)`-8GZ70=0E=JT>Y9Q-4K!XZ(C3+(Q*(K
M8QX@/A`47F[N.A[_`(W9<#K/:M3U$]T5+N[UQPT5RBI<_KU2PN+5$/(^@[U@
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M;15Y"POH2]4[;CAX"=]U5,%;PA6")61)F2*5%1#X%O`@06H_(R*0Y9S,/?\`
M>>[.&W(BN7.K\>=15"KZFV?PV(`TUO7=255>'H\CKN2<(L02IATXM[%,F*:$
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MUBUY7GCT(Y[(S)*Q/PRL@=Z3A9SP+9E9W`T&G\X]G5#B71^;U?YT:[XMAIW6
M$M"5+8#/;#C;]BI_YY0+QE\EZ-(663G!JT2\<D1J)I,'SA"RO6#)1-'PWXJ.
M^-7KG?CSP?/4[N\9Z?'MOSXJK[`Q1$0$1_QCA_`4YBA_,&?UG@H>4.OQF'^4
M83?S=]9YS+H8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8
MQC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8
MQC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`96AXP_(#;?%GPVN4N_-$V92G;9UQ4
MZI)TRQHP4#95X]]([-HU?>`A!6>/E8*2</(F8D8]!O(L%TO6=D43%)<B2Z5E
M^17YL\4*=SBXN;=XJW^RVJGT_<,+$P<Y9*0>*2M46VB;3`VI):&5FX^5C$G*
MKN`;MCJN&"YDFZZRC<47145T[&XO5Q:=5S$Q&ZFO6L*J=M^-+MGCPQWW&;XX
M&6O7>PM)Z*H?+Z/IZF]:7;27CB));@K6H-J;`7FZ?5I)M4ML:?>6%.?L>HG#
M65B9%HV<-8K8ZB9"/U;(>-7,17DMOWF+K&LZ\)'ZOXK7;5^LH?<I;665;;;O
M=SU7`;8N<?#5M"!;HPD7KZ&N-/CEI)2QRZTU)2ZY/@8L&!BK1&F_#18:@J/+
M+;C>1WQXB&_-L<8)CBS3:7R.W'0:R9OH)\NNX+HBKW-M2*[6("-E)615L-CV
M)=HFS72P2,4Q=S,R^D2G7=[K\([A9.\"N!6C^/U[5CWVVV<9)73=,S'3#VQ)
M2VTKK(J3$\`V!^!5IPM<CPA*6SE2II-WL?6&:S5(C8R1<35?;\1?VF_6\:9C
MXKB]9F=<8B+B*N;O%:\TIAY"\^^>&IN4.^H?<_*VQ<&FU>Y1)U#B_3MS\&%K
M;X?VX]!%G*\QJ+R\<R*G4[9=86];5B#RR[ARE9:JG2+,9&%4B$6IEU(G`>9W
MB=;=U;S$\3O7=N\3N^\1(?C4GK1QQ@U94^(6N=Z0MW=3O'Z,ODXPM%B?Z:M<
MI'H*WQ1E')C8+U60.UGUU49!!@Q]9E;5??!2TU?7^P:>YY*\P(3BKMK94IMW
M9?"^&VA6AT-9;K-71EL&90:/9:BRFUJI19JX,4IZ5UW5MA1575>J."LFS!JL
M9`)+I^';K`MC\1JQ*7:^K*>)/6H&K;48G&L@THC"`T?)Z);GUYY8/U066KLF
MK+*_A2>>2+-)(^BDG'E,S-8F.W%:B>8U<;W/M:3T]4\U\U[ZM5/:8Q=:KO,*
M$MQ^(9S\)N#@KK_8&X^1&B7>VO"WHO)?;]6X-\1];<R[0]WI,;))7GDTX@7>
MO]C.*]0W];=)K2$A"/!K$+.FB89F[7^D$W;O:/++FORRUI&^%+3J;R:YP1T;
MR0I?,"R;AND%P$UO9N8UR6UL2F3FO$IGBH[U')(TL]7).OHBP(U^HPYF]5(C
M9IT%EC`\+/>7\&Y%I/<:;GJ+G#RKX_W[C5PUI_!^&NFJV&B!E;KJ&F3K>P,%
M+>VO.J;E%%G'KV.ACR*T`QB&2BD2W5;-6OJN"*9?M7PJK3M=#BA997Q`N7T3
MOCB6AOQE4N2,4RX]&VG;8[D"I`M[+'V]I(::>:_%M#0%>95F#-"4V+<!$BH>
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MH48E&NTV`@!AF*'DA7;,ZZYCW!@'7?S]Q[^?^C[OX,DS%3C<WQC6/S''\7IZ
M>JXF9G$1BYF\5G-<\Q,W&^_G&,9ET,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q
M@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q
M@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q\OG@
M,\&,4A1,8P%*4.Q,80`H!]XB/0`'XQS7E@O[2/.HTBB$?NB>8AW`F'X-$X#T
M)0$H@9R<H]]@F8J8"'0JB("7-`WW:$+6HY2;V'=(FNQ)?,8JTY*-HQF<>NO3
M9-#'(9VH;R^4J31NX7.?ZH`8P@`A*)S:J\T$P+2S03%'H2(G%R?OOKKRMRJC
MV`AT/W#\\XP;]60'KXM<?Q@R==?SI`/\WY,J5MGB%Z+@G1F-;:7&^NRG\A1A
MHE&'8K`(`(*-G,^NT>."=CY.R18#V`B`&+UWAO\`NA0K?HC/COLURV^8+`\$
M0$/GWVA6'"7RZ[_1>@[^?7O@73(76LN!\H2B:0__`#A)=N'\M9(A/X/-F0MG
MC1X0%6CE!RF/OYT%2*E_A$AC`'Y!Z'*1XWQ&];%=)-K?KC8U/(H;RF<K$B9,
M$Q]_;X-16'?*^X==))'.'S\H]=#+36/(C4^RU4QU]L&,<3'D!4859PM`65(/
MJ^8#0\D#-XX`ACE(8S,KU`3CT50WO@6&8S3,)L-XV$K>:3%XB`^0721"D=I=
M=!^BI!Y2+^4`'S=`FMWWWZAAZS;C)ZTD&Z;MDNFX;JAV11,>P_&4P>QB'*/L
M8AP*8H]@8`'`^K&,8#&:`Y);S5X]ZZ)?D:+.;".:Q0\!]`5]8Z#\`EBO!%^)
MR1TH;X=I\(`*E^&Z$52?HI.OK0)_W5!__P`U;:/_`-I./_!N!;KC*^.-_/J'
MW]M-35+_`%;9-;S9ZY)ST>>>E2OE'JD69DJNP.P)"1KAB8\<Y5D$G;LQ$%2-
M_12!119(<L'P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P
M&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P
M&,8P&,8P&,8P&,8P&,8P&,8P&,8P`B``(B/0![B(_(`^\<TM<+@H_44BHI42
ML2F%)PX3$0.]4`1`R:9@]_A0$.OJ^[@>_FCT"F1W^P&8-21+13RNGQ#&<G*/
M1T678E$H"'Z4SDP&(`]@()D5$.A$HY4GRCVU=[I<HOBCH=-9_?[B*32XRD>Y
M,@>"C7*7Q"\(=\D/<4D$4)I6X2AA*>+@C(LD!^-?JIE#[-P<LYV1MY-*<8X$
MVQ-GOG2T8XFV;5.4AH-VW.*;Q.+0.8K"57CNCC)S4DNA5H7R*?$K/E"&(3--
M6^&N[N$@&PN6]]G;]<)#I96J0\XZ2C(\##Y@:2%H3!&0>$(40($?64:]$M1*
M)$UI!,WFR:G%[BW1>,M*3A(%%.5MTLBV5N=S<()ED)Q\FF4?A&OU`/'5U@KY
MRQ$.D;TTB"+IX9S(KN7)Y/8&JJ!H[4&K6R#77^MZ=50;^;R.HN"8DDSB8"@8
M[B8727EG2A@*'G5</55#CV8QA,(CFU.@_'_&/]N><8'`6"J5>VLQCK378*R,
M!`P"RGHF/F&H@<OE-^@2+=RF`F*/0B!0'KV[R!>W_#1X^[`0</Z,Q>:@M8&^
M)8R51465KZ;Q,!%([FI.W`L44O/Y3F/`.()X10H*)N>_,4]B>,"B%387)7A9
M/Q=4Y%1SO9.I7S@(Z"V+$*+2KMN4!,"";2;=D0=.7:2*8JGJ-K]&5.@4YH65
M<D3,*ED^M-F1$Y$15SI$RTL%8G$2.$EVBO;9XD'1545DS!ZK&29G\R#ENX33
M=LG!#H.$@+V4TE+;4:S?*Y+5*XP<=8ZW.LU&,K#RK<KED\;*!^E.0W1DU4C@
M59LY0,DY:.")N6JR*Z2:A:.[;4[7X=.Y&J[5S*V;C)M"3\BBC@IG;VONTRF,
M=!P8@$3"U5YH)G#5V0$RW"LHN4UTC2K`XH!>Q&23669(OV9_.BL7OH>@.F</
M8Z2I>Q\BB9O8Q1_$8!$HE$?OR.FNK@R*>/?,'[:1KEC;LG39^U5!9FNW>I$6
MCY1JJ7LID5DEDQ,;H.T%`$X`=("ED7@.N_\`VB'^C/'0?C_C'^W/.,"HAG^R
MY3'[UA?M[_\`W<P_^W\^6[Y40S_9<IG]ZPO]7,/EN^`QC&`QC&`QC&`QC&`Q
MC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`Q
MC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`S^3G*
MF0QSF`I"%,<YA^12E`3&,/X@`!$<_K,=MCH6E=E50$2F.V%N00'H?,Z,5N'7
MY/5$?R!@0SY!;=::WHMZV@_`JJD:T.6"8J'*'Q\R\,6.K48`F`0$JKM1!5QT
M0W35!VJ)!`ALU5X:FC5X>CRW(F])GD]C;B=/7T;*R/:K]I3U7IUC.R&/T=!Q
M<)8BTPZ,`#ZL0A`I$$B1#I#'GGJM(7&6T'HN(,L+S8EY2<N6Z9_(FNFH_CZK
M%@H(#V!F[F9DG:8B'1!1]0H^8O07:04+'5R$B*]#M@9Q,%&,(:+:%$1*UCHM
MJDQ9(%$?<2I-D$B`(^X]=CV(C@<KC&,!C&,!C&,!FIMXZBKN\]7VS6EE(0C2
MPQYB,)+T4U7,%.-1^(A)YD)P\R;J+D"(K_H9TC+MOB69S@BY5`VV<?/`I0X/
M7.Q0Z>P>-U_`6]OTW,O6\<W54,93Z!^DEF,DP;>8`,=C$RXI/(T_?7T3/L@(
M0J:91RX>G2AI6":JJF\SAMYF;@PCV8QVX`!%#>XCYE$13.81$1$QA'OWRG_D
MQ%$TGX@VI=C,"':0FZ(UI#V(4DB$0<2:Y@I,OV0HE*=4Q%J?)KK'^L"P"J'9
M^Q&TS63HQ5I:/,(^Y$'12_<=,QFZP_P^9$/_`*N!MS&,8%1#/]ERF?WK"_U<
MP^6[Y40S_9<IG]ZPO]7,/EN^`QC&`QC&`QC&`QC&`QC&`QC&`S^3&\I3&$.P
M*43=??T`CUG]9_"@"9,Y0^9B&`/RB40#^?`J[IWBR\:'.R^7-#W#,QO'J%XH
M\FZ#Q7>[#VI:X*-J&P-B;&I"UXKI()XD`%@D%X]H^2$MB7;IE%HNX6>())J%
M3VQ1?$^\/39MCU%4*#S*X[6NU;X<2++4E=AMG5UU-WB0C)1>%<1<3&?$D>)R
MRLNU<QD=$R2+"2F'Z"K6':OUB&*%)MW\+CEW9>17)N[*:RJLI0=J>-OP5YDP
M?TC?:2HE-<;]*U1>)V=8Y"&=/EE"/HQR<B3>ER39*=G`$XL&"Z)`54R6P>%?
MR"4J?(5*"TOKMG:;IX_&H.=%$?LK!KYD_'B[3-BZ@GI.UDE"*-UH>38PL)?!
M0HJCA&Q'(\?MFC!52:,B[UBO/_./K/,:X<_BZKC';<3O%_[X[3Q4VQL_%U\,
MI\$EZ7.3C:BI$5.QW>1;O]EPT6Z:UNIS[RL3SP[.4.S='=,IQBY8%ATD5)MZ
M<A5H^-=M5D7"FP[OXCO!'7&F]:\@KORRT37=-;C551U7L%[L&%-`["6:'].4
M1J)VJSA[.*P*@&3LJ;)FH>L*$43L)8LZ:A2T9\,/"AY)ZLGO"ED=LZ7UX"?&
M3E;XFVX-[+N+/KVR+0D'R!&Z.M!3[0$%7A[9*N'SRKKI)Q1G,I3E6C-R]"/5
MC2?#Z8UYX8?B1ZMH>E:1!ZFKC:KPNX?$NE+.TUSN;1^L]KUN+Y+[48RVG'+3
M=,[K_9\_5=#SE)4E3;)UYI4]=V`^DQ8%G&KU!HWB22:XS]8U==OK?%Z(ZNJL
MQG&HGMTS//F8]8VO-M?BX\-:ERJUEQ:=;$BY%[M/C?:^3D#M>$F(67U4G0ZY
M%+6IBD>?CGCI=\YM-"C+1?J_(Q+5]!+5JJ3*KJ2;O18,WDBG'.GB.TKNHK:Y
MWWKY"N;ZU3L'>&GY962=$:;`U/JJF,]A;$O=>$6/J.(&HTN09V.9<+)MUF\:
MX34*@JH(IAU]-!^%MS7I%?\`#]I=GUQ5H]A4O"<Y=^'IOF?;;+J#T=,7O<<J
MTEZA?48=L[45V+35U*W'M#LZ<\6FF:<VDX?-6OT:Z;J810O#Y\3FSZ[X+:NV
M3QHUGKN(X0<!>=7$).R0G):I7F1VE<MQ\5F6J=<W1"&)`5]"HU:QV6`B6"#5
MU*3<W$JR,A(V)"%BHYNO(6(Z>^/IG>8^VJO)\75VW$3_`(SC/3<3G<1,UJYB
MN,]@A_XG/A^Q>I)S>[_E[H9MJ&N6.J4V8ORE^C!K[6XW>G1&P*Q3RN""9=W;
M92ESD;92UABV=3K2)64<R#!F#1Z5M+O7NPZ)MFDUC9.L;A6[_K^ZP[.P5*YU
M"986"LV.$D$_49RD-,QB[EB_9+E[\BS=8X`<ITC^15-0A>M)M;PK^3U+XS^$
M)+\<:$UJ^WN$.KI")WQJ?2NQ-$:AO4]M#9NA*-0;AL:E;-VOJ/<FD9VZURU5
MB79V";M]-D)&UUNRRJU:LT5("5TO;_X7/%FS</N'5$U!<FDQ"6A:R;'V+/TV
M5V/`[72HDQM&\S5YDJE%72JZSU!6)"/8/IAP]5:UK7T#7(R7DI5A``]AT&+Y
M>5%7?/[C_L<<9L3U3-3%143>=S$:QZQ6\>5AN,8R-F,8P&,8P&,8P&,8P&,8
MP&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8
MP&,8P&81L$PEK:P!_ANV91_&`+`?_20!S-\P;8?ZW#_NUI_3-@5!7QN6>\2'
MC3$O!$[2*A(R7;I#^D(Z8I7V>34*'V&%Y&LSF'W[%$OR\N7:E^0?D#_1E(&[
M77X#\\>*5Z<*IH1TPI#UQ==4WI(MRGG9BLNU%51^J`%;VY`X^80`"A[CT.7?
MA\@_%[?Q>PX'G(E<F-PV'65ETA`Q5D9U&'V':KE$62PJ4.8V)),FE>U_,VB.
M3BZ_"+`\%1U)QZ"#QV+1XDV9&5.H1$`]<DM<P>PZ^KMGME`NDHF]--ZVD+#)
MUD[=ZJW:INK-6GU4E!?-2!Z;\AHF0<%;IK"`-W(D<D^N0`P(E43;V\=EO:70
M6<C6Z=..Z[LR[SE\L&L["R<3]+KVSG-`U?(0>L9^R1$E6W5[C$RVV<+/2;D\
M3')LVS!@0]B;.(?X=B[NWY2W%*CY^*:1D<YJD^2T;'U/J>Z\@*NALR+LKV%8
MQLS6*Q+(7"DU)6%9IV-^9PQF')'SU]54[*T=UP[^;E'L73U;V,_@IUQ)VJIV
MRM-Y1A#W*B6%U6+,VAIWX09N!6?()N$)"$E%H^.=N(Z29NT4I&.CY5C\)),T
M'9,&4XM:W9-:VA37]ZUJZK5=<U-.6U_=9B#EYN`>2[VQ/&MI?.329[&^<624
MF+&:PRA5K,E.SD[*MYE%W,R2CD(PQO,>[V+81-50;FA.YJ\0O'X]0V)'PUF>
MZFJKC9U'L=AL<S*SCM6/5G59R5KDE$:@I+]:L3UFEVXQLLJP(VD%T]GH\EYN
M,W/!42;GZ`LVG]P36G2:T:1DJGMF`:Q]5F9J`V?//1G1CU*[:7<&FL@V2J$;
M$)PMH@U6-F?2K1W'.MK-.+.G6%<NU480DDR@KW6:-5Y)JVGI-->-;:W9N&].
ME:_(^L,G#V:(>N/I\EF0>'FE[,DC8%W:DF4RY\H9Z3K:%W97E_.WB?=Q<@O.
MPT%8+8_E*I"VEY`FK;^TQ,`H1-LREW<2O((%2(<8:-6F)EY"Q$6\E':Z@;A`
M>P`0^0@`_P`>><8P*?\`Q41*QGN*DXD7IVPO\^4AP[\PD3>T20`OL'?_`!K0
M!#\8C]^6*:[-W87H@'0*,71NON[=MS`'R^SOK^/*Y?$U=(V#:O$B@-S$5?N;
MA(2CAJ4?,J5K)66D1#54Z8>X)K?"R0$,8.C?#+@`])GZL9UX(#8GHE_2BR=B
M7_T1=MQ#K\7776!NW&,8%1#/]ERF?WK"_P!7,/EN^5$,_P!ERF?WK"_U<P^6
M[X#&,8#&,8#&,8#&,8#&,8#&,8#&,8'@P^4._P`90_A,8"A_!V(=C]@=CE$N
MK?&)VYNZ^2\AI[@;9-H<<Z]R:L/&ZQ7NB<A->V+D56TJGLUSJFR;DL7$=G71
MMT-J^$LC-R_DU'=T+9F=01&VJ0XQAB`-[1@$0$`'H?O#H1#\8=@(=A\P[`0[
MZ[`0[#.K5L[PDN:>Z.0M%M=QUOX>M+NU)Y.5'<+[Q+=(%V#I[E]>-95'8[*X
M&J=ITU1J-#TN9O=LJ3%'75JD;'L^=ISMF=Q/DB_CC$2RQ7/[^_7TEF;Q5[S5
M9^]U[8O,322^RO&%Y-5MYX@5LUKP'I^R]&>'9M6ZZWVY?93F'`ZUN$XVH=*K
MNP9R=K-"L&FG\8H8*S8VSAI&.KND+MXBI'-72[HZ29_,[XT>R[1OJ;T_Q^XN
MZCM$+#<<N,?)`;AR'YEUSBR]>5OD[3'=QKD$UK-FU+;_`%IRMMV2K2QMTY@3
MLSG;K+I-P<HIFC+O'P"B[UK_`(M^P[I2-8S/*+DIO/86S>$.QU=H;(BF=!C9
M"@T=O1OP^CH5-G7&#YAL&#FY)\U>U>\)%8N6_J.':/ILFS<OA?<MK+S'V+R0
MLG"GPY><$%M'C/Q-UDM"\O-@OFCG7FPM/4F2B]FR]3CTN/&RH_X:W3,L+11^
MR5ASR47$1RBK=)+^\$K\OM'W^7S'GM_MC^Y&\W,:J9B,]NG$8CB=W>TYN1'B
ME;UTMMWB_H"#XNZ1L6V=^\8K-R*LP7CFO6]5ZNH:E/L-1K<U3:_M23U%-Q&Q
MA7>6]HY@)UK'5X)Z.:N7S>+10(<R>H(SQN-GW_7_``F>:@X4L[-N+F/R`Y/<
M=&&NK7R0BJM1JU;N+R4TO9;#7MRPVJ[?"[&H=G;5V6<5FU0]=CV3TB!"-Q=F
M.)RX)RV\/3E=NK>7"G?Z?"?P[=W1FFN&UST/L/BUO/8TL?1=$O%FN%%FX-QJ
MM=YQ]NJ<W"T.#J3J`K,D\IE9=-V$HX;(,F"?U3Z/H_@/;@G:QP.U_P`A6^EI
M[46L>9O,;DCO#1FM=B[0K.NM-ZQW]1S,-=:*XWR[*.K=U>5>F7!C'3;U(LG1
M6S5U(S98I(8A7Z.</EQZ3?.<^8\5%1ZK,]=S5S%Q6*J/EO?3_P"KW,=L+L_#
M^YRS',V*Y"0=^TF\X_[HXM[\G./6XM<AL*#VQ7FEMB:S7+:VDZIL6O14$QL4
M/(P]E9B<BT+&2,6^1<L'S4JI`$;"<CQQDXH<>>'&M0U'QIU77-34$\[*VE]"
MP)Y1ZYF;1.&1-+V2QS\_(3%DLT^_!NV1<3,_+R,@9HU:,P<%:-&Z*4A\S/C]
M_?KZRW%U%YFLSY^T?B#&,84QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`Q
MC&`QC&`QC&!$CGARD_N*.('(+E7^!0;%_.+US+7[\"#6(*D6R?1CADA]&'L@
MP]@"&(K\9ZAWPPTCZ)4A_O53S=E@1JKQG*)N=UX8[>BZED%5O$`O^[-3WR*F
M[DG%67C%LS0NL7-[O-.LT&%:<J6V30E&AH=J51>H'<0;V'MR21FTHA'Y+KQ0
M.-^P^7OA_P#+#C1J=:N-]C;HT[8J+3UK=*.86M)34JLP.V/,RC.-EW3)D4K=
M05%T8UX<IO(4$A`PF+5V_P#"!W56/$A\/_EUK*ST9CJ+6C=M=N6&LW\^^9J#
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M5HJM2>P]#HZ-A?K55EL/88TRLR\JR620<(K`JW1W!9O$3X>U"'Y=3\_MY%I$
M<%4*HZY1/D:??)!'6S>[U-G=ZNNE]'5ET:Z(RU7?M)5!2AELQ$TUR(KF2<]I
M!0=OCP4.8MAE45==V:G6BN;QX*<5N*&^ZA*\N-]\?ZQ3[-HO6R^M+,Z=P&I]
M;65+D1J"P04B^>-*--2.N9-O8E9:1;R35.PN!;<SR#\(7GK&P7B7:+XRN^,-
MDT=X@^DN/574N6VMB[.KNR-:6#C_`*)KFF356.K$;1+9'6-A<DZRT<,+C.75
M-S76[Q5[+Q]D?-19OE16_?S'B9YG[7I/BZ^>G&,UG7:XO/:JC[KQ;AXE_!V@
M;JAN/MQW_7:_M&9D:!!A&/X&[!6H*S;6CF4MK&G778R584UO0+OL*,D6+^ET
MN[VR`L]D:O&BT5%."NFXJSK`0'W#W^?\P]"'Y0'V$/L'VSK'\@/"UYZ67EK:
MMP\=K#J;1QMAWKC+9)S=-%Y';OJC2:K&G:YKV`M<7R.X83E!V3H_DEL!./JL
MQ`4/8$99]5(_0[J$<2T-'2T<Z=O>S>4!`/<>_<P_P"81`/X`$`R37':/Q^Q]
M&NF9F[C4X[3[W]:B,QY><8QD:,8Q@,8Q@,8Q@,8Q@,P;8?ZW#_NUI_3-F<Y@
MVP_UN'_=K3^F;`J3\02E2,OJRN;"A"?\+:KMC6:45(F)E$8J6,V9G=F.40,5
M"-FFL([6Z`W29E%``@$,?+4-(;/B]S:HHNRXDR8(VNOLW[QNF)1^CYDA1:SL
M6H4#J"16,F4'S(Y#&\P>B`F`/-FCIZ#B[-!S%<G&I'T-/Q;Z&E6AP`2N(^2;
M*-'2?O[`<4E3&3-_@*E(?YE#(+<,-E27%7=-FXF[2?%1JELFOIO6-G=F]%DM
M+2A2-X[]'4$J:3*Z-&B+?KV387&.=,#@"DD8^!=?C`#W[_[?[?BQ@,8Q@,8Q
M@,#[!]_XOEV/V!_#C(,<[>3S?0&KUX2NO/-M;8C5Y"TIFV+Z[N*;J^FTE+8J
M@F8%"EC".0;0Q>A,^L+AB@DDNF@\!,(4KRQN1OB'6.V-5/C:/Q]C!A(IVFH1
MPS5DH07L6W%%=),$C@^N4K/OR$$QA,VAA.1003`<M-UO[3JX?_RU?_[]KD&.
M(FD%-*ZL;)3;<R5YN:J%DN(K&!1PR6.B8D3`**_IC&AF*IOC1,81/,/9,YO?
MK)SZW_5U?_-J_P#K#7`WAC&,"HAG^RY3/[UA?ZN8?+=\J(9_LN4S^]87^KF'
MRW?`8QC`8R/E:W8\G^1NS=%J5YLU94"B4>XH60DFLLZDUK<N[158*Q9F2:+1
M)B#8#)N"/ESN!.('11\H".M[AOW=7Y]&P-4:HU!3[P37=3I5KEGL_LAW3Y%^
ME<4I8[>.BF85.88K/`4AW*"(NI!H@911`RRJ1#F$H3+QD*Z#S`9[(NW'>OU^
MGJM8;>-+V;8W[J6E`3F:?-:S<C&2U=5CVK1=G)'"70>,U'OQS0OHHHO$$%".
M"D+,URZ09H+NG*@(MVR*KA=8P&\B2""9E55#B`#T4B9#&'[>@]@$1`!#WXR#
M%6Y8;)N+&$V57N.UFFM"62P)PD+:X2>2EMDKQ:LNK#)WI75S.)57"H&<HG64
M^'G5IA".*,B=D9$/*:<^`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&
M`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QG$RD[%PR?G?NTTC"'9$"_HCA3Y]>1`
MG:@@(AUYQ`"`/Z8P9K:2V6X/YB13`B)?<"N'IO54$/L,#=(03(/?^,LJ'WEP
M-OYX$0#YB`?E'K(W.[18'HB*\J[*41[]-NI\*F'Y"MP3$0_$839PRBZZP]K+
MKJC]ZJRB@_\`7,;_`/Y@2H]1/]L)_*+_`&X]1/\`;"?RB_VY%/L?O'^,<=C]
MX_QC@2L]1/\`;"?RB_VX]1/]L)_*+_;D4^Q^\?XQQV/WC_&.!*SU$_VPG\HO
M]N/43_;"?RB_VY%/L?O'^,<=C]X_QC@2L]1/]L)_*+_;CU$_VPG\HO\`;D4^
MQ^\?XQQV/WC_`!C@2L]1/]L)_*+_`&X]1/\`;"?RB_VY%/L?O'^,<=C]X_QC
M@2L]1/\`;"?RB_VX]1/_`!R?RB_VY%/L?O'^,<=C]X_QC@2OQD5TG;M#_B';
MI#K]I<K)!_$0Y0_)]WV9SS*X6)B)?)(JN"!_R;P"N2B'??7G4#U@^X.E0Z#Y
M8$BL9JV,V4BH)$Y=D+<1]A<LS&52`?O,W/\`HI"_>)%%C?Y.;'9/V4BB#ABY
M1=(CU]=(X&\HC[^4Y?8Z9_O(H4I@^T`P/KQC&`QC&`S!MA_K</\`NUI_3-F<
MY@VP_P!;A_W:T_IFP-$9$OF-JS5%WI$879.QM::=N#<CEWKBV;'O=3HGQ2WE
M!5Q$'_"*7BWTC`2*A$S+'9IJ*QSLB,JP$5DEDW&\-R;)+I;2F[=U&BB3IM-:
M>V+M)O!JB8$9E]2ZT]E8V-<&+[D;.9%-J#H_1@!N57S$.7LH_FN;;VQL??=_
ML.U-S6^7V)L*V/EI*<LED<GD7!UG"JBP,8Q)P*C>%@8\53-H6`BDVD1#L"),
MV#1%(G1@_1"XE\TH6&K"5$Y(;VXR@YKS))K7MC1O)[1TXM.1[4A$$&%H9L[R
M>0--(IE#T)Y%J9.6;E*:61:29%73^8G]V3Q#`1`>5''`!#YA^?EK#L/R_P#E
M3GYGO&.A4*UW:[3-]J:-UK.I=';?WBZU^F]=P">PW>LJ^V?1E.D)N$]&>BX!
MV^D49FU.X%=M-!5H*:0CWL>JN,BTD]KO6FM^2=;V';H+BS6=3RKG0.R(NGR]
M5?VLFB['N6%W?QYIM>LFNV-HEK+-UJ?J<'M%2$V/$C:K;6!-.1LVTBHF4<NF
M2H?H1_W97$+_`)U/&_\`]>6K_P#Q3C^[*XA?\ZGC?_Z\M7_^*<_/LV!X<L%K
MVU-HR1V?*/X"*EMTU^Z*1&M]?S-T1?Z8BHE^M8:E6H#=$W`M];7=[*_0\#>-
MQW+4*-8>L'"=[CX=P]BF;WB-@<`*=K]O)@]W&^DY:7W-H_4&JX6$TN%E>VU;
M>.FZ1O"/F[(G3[M9/H4U0J=N5834-2#;)>6.?9,F-*5EVTL+Q@'Z%7]V5Q"_
MYU/&_P#]>6K_`/Q3C^[*XA?\ZGC?_P"O+5__`(IS\]^:X&ZCKU;F]GS.[[2P
MU-!Z/V3N%9T&EZ-+;,=O=8[XH6BW]/;U*L[OGJ>V<65_?HVQ03Z6V''O(=JV
M=Q5Q@X9\CYE<2VAPKUAIXKA*[[U<-WUT=[`-H1.(T=(S;>[0E$US3=@IR^R2
M1UI7E]<+61U>8>D,(JL1&S7$/.-Y2P6!5E36R4LL'Z"NQN<?'6`J$M(Z]WMQ
MOOMP(D"4'7%.1VFZXR</%>RIN)28E;B@DTC&H]*O!:D=R"I.D6;4QU!51K>T
M!"U;:^\76Y=Z<AN/>P-O2$N4E`US4=\:IMPM5T4U!9+L(B'M;\AFL*DH9&JU
MZ/%T9LL5:<DU'$J8AS=/[DSP44XWT1>RR5UBIJQ5NWTJC76N.8NB1S9>9NE-
M?6D9+6J\%L>W6JS5JI2,8]J-L>W>EZWDDI0\7+Q46]A95,S>!Q6[8ARG(V;$
M.0Q3D.1NB0Y#E$!*<ARD`Q#E$`$IBB!BB`"40$`'`_4R707;+*(.4E$%TS"5
M5)8AB*$-\^CE,`#V("!@$?8P"!@$0$!'.];_`*NK_P";5_\`6&N4#>`[RMV5
MR-XM[$U[M::EKA8.-%TJ58K-WGY!>4GI;7.P(69DZ_7)R4>&7DIE[39.N2[*
M.E)%TN\&O/(N/756%@"Q[^=;_JZO_FU?_6&N!O#&,8%1#/\`9<IG]ZPO]7,/
MEN^5$,_V7*9_>L+_`%<P^6[X#&,8$!+=K#DS5.3.R-TZ>@-26.'OE#HE1%K?
M;=8X1TT4J@.EUUR-H6OOPZ5<N13(8[HP'1`#^1,W91]#[7W+2N[CNVUJ%7-)
MO'^S=8:HK4X6SW*TMV-9M50CI<9AQ%LH^M+.9J'0E9MP#'XIXQ<OF;5$RH-5
M55"!8%C`J^1XI;RU'+<:IW3YM<W69T[2]I1=I5O,U,U=A-VC:DN68G)!BC$0
M\J[!BD[=R`1Y554ETVZ#))P"AQ5.$HHO2CW9+BI['WK'J0FU()NZC58C6FS]
M@EUX$>VDY<\4*\*=Y#Q<\NX821CR0S4(X!54X,U1<LVJ!0D_C`KZUQI/EEKB
M"J6C8#8.MX?3M*F&_P!';-CV4FYVV[H;.96DT*<>MR;!Y4&DJLT5^A'5B%9R
MDFP'XELS%X4HFL%#\?\`M_[,8P&,8P&/E\\^=TZ;,6SAZ\<(M6C1!5RZ=.54
MT&[=N@F95====8Q$D444B'5665.1-),AE%#%(4Q@ZPW*?Q?>1_*;=,AP[\(>
MF'OM@0!ZQN?(OZ.8O(F-;D5&/?R]'=SYTJK6*G%KF4;CM.YI/6DR^Z0I$&_4
M(QDGP=E2T7ZCTA-!6Y7&JU--SYOAU+-8H:OD7\H]&]$TP]9%5Z'V'TQ-T/SS
MDX"R5^U1R4Q69R'L,2N<Y$92#DV,O'+'3Z`Y$GT<X=-%#D\P>8A5A,7L.P#O
M.L=K[\S<0NR?_+KG7RQV_N;:<V0SR>&GR*(,&$@N;U%44;CLEE<;'/%3$QBF
M=!%5QHJ8`%O%MD0(F&I-P>%)S.\+-TXY*^&%O&_;`J%8(K+;!T-96S5_+2D"
MT`RS]9Q3X8(RH[8B"-"*'D8]I#5W8,>4H/ZN]?/42`V#MS8RM_PU/$;UEXAN
MED+;""PJVX*@VCX_<VJ2NEUG5/GW(+IMY2'4>)I.96EV,6B[NO2W2JC<07A)
M<Z4U'NDC608#&,8#&,8#/F>/6D<U</G[INR9M$5'#IV[62;-6R"11.HNX<+G
M31013(`F.JJ<A"E`1,8`#([<L^5&J.&FC;COK<4JHQJ]601091;`$5I^W661
M,*$!3ZNQ651*_GYQYTBW3$Y&[)JF[EI%9M%Q[QREU@Z1I?Q"O'GL*FVMW7Z:
MXM\#S2+TE!HE9%T=*XQS5RNB7Z!@5%F".Q7R8E,TF=IWD#U7XU-PUI%;<MDG
M35J';0KVU=96U^:*JNPZ-99,@&$\=7[?7)I^0"`(G$S.,DW3D/*`")NTO8`'
MOY9GW?>=9&V?F8KC8QB&S[1_(??&L]BQ:0.(VU2QZC/LQDT$Q.W4,VK,+19R
M,2.Y!/SJQ$\FX03[%(%#E`#:6IG/;Q'O"-V14M0>)1`R6_>-%@E#PE5Y#P2B
MMHL39LF8!!S!W(Y&#NWJQS8#.WVO-C,(S81F155H*;DF[9N@Z#MKXS`M7;0H
M&Z=?5+:FK;5$7;7]YAFL_5K1!N/B(Z5C'91\BB8F*FNV<H*E4:/X]XBWD(Q^
M@YCY!LV>MET$\]P&,8P&,8P&,8P&,8P&,8P&,8P&,9X,8I2F,8P%*4!,8QA`
M"E*`=B8PCT````(B(CT`>XX`QBD*8YS`4I0$QC&$"E*4H=B8PCT````(B(B`
M``=CFJ+)L`0%1E`B'8")%)(Q0$.P'H09IF`0,'V>NH`E'_DR&#RJ9PUPMYY9
M12.CE#$BTS`"BI1,4S\Y1]Q'Y"#0H@'ID$/T40]0X>7R%+@&![%EE7"IUUU5
M%EE#"9154YCJ',(]B)CF$3"/Y1]OD'MGKQE&OB'>+:ZTM>$^+'#JM-]S<J96
M83J\H9O$.K1`:]G792%1K;&#8'3->MD^94IW$`DN6#JJ9%%[*NX=H+PZ`756
M6V52EQGTU<[36J?#>82_2]LL$/68LQP[[(20G'K!FHH'0]IIK&.'0_5S&Z9M
M[4NQW"K37FT];7UVB4QUF5+OM3M+Y),@>8ZBC&"EW[PB1"^YU3(`F0/<Q@`!
M'.M[KSP3^2O*Z4+M_P`2#DG<"V::-\8?7D*_C[S:HD@]^DS?SKU577=-(B43
M%3@*-!23:.3$&WQA?**2?-;M_,^K;7T438_![>&P*_MZH]2\#!W:4BH=U-/F
M@^LFVKFRJDSK3^I3"IB@5D>4:NX51;RI/7;)(XKD#LV?/Y8R@'PV_%2N=GV`
MKPNYVMCT/DG79<M*JEOL#(D$M?K`Q#X<]+O;8GECHO9"H)D7AIUH*$%L$BZ?
MPH(RR[0TO?\`?>`@("`B`@("`@(#T("`^X"`@("`]"`@("'>`QC&`QC&`QC&
M`QC&`QC&`Q\OGFB]\<C]2<;ZTWLFT;&9@I*+'9UBK0S)Q/W>YRA0``BZE58X
MJDG,NO.=,JZR::;%B"A5'SMN00$:XW?(WQ!N34K&P>F-/QO$W5]B<Q#?\]W;
M7PL]?$*_96TDO%6*(KQE46C55XA%/08&9Q3Y-)\9J@YE6HG]<`N';/6;P7(,
MWC1V+-VLP>`U<H.19OVWD^)8NP044%L];^HG\0T7]-RAZA/52)YR]\JQD'L8
MN#E@Y5;+!["9,?8Y?\50A@%-4G^0H4Q>_<`[`!R-_&.'UK6M6IU76-O<[#85
M>TVF$N.P'ZRC^3N^ST9`'.PK++38IE:S\K(3[I8'\G&KO8U)9(8EJ\5",.4D
MA,#>=9N[:6%-E(@1G(C]4A@'IL[,'[48PB*2QOGZ)Q$##[)'./U0SW(G_P"W
MY/N$/N$/L'-PTNX&="G#RJO;GZI&+L_S<``=`W7-\A7``_0E!Z]8/JF$5@`5
M`V?C&,!F#;#_`%N'_=K3^F;,YS!MA_K</^[6G],V!'B9A(&T0-BJ5KBT9VI7
M*N3U.ML&Y[!O,UBSQ;J%G(Q80ZZ*ZCWBQ"F^1%03.("!1`>FKO\`_,]O,JF7
MN4;<;TZ5O_5+EVZ6JDTKL&IT*]1$/ZP@PB;W7;P_@&OT\T;B1NXDZW)2T7*^
MB,D"<69U]'-^YUG@2E'Y@`_E`!_TX'2`H?@O^+OJ^X0-_P!>Z>:U&YU=X9_`
MV*'WMHM-_'.56KABX`I'-V<LW;5ZP=O(Z1CI!J\C9.-=NXZ19NF3I=NILZS>
M&)XX%N>O'LW06?\`?>O7FJ4HZ$VSQDJ-?AM>R-IB;O(5BK5>GS<!6:<TD+C!
MQ5I?O:G$0LP^GV9)1W)+.C*J'[F'D+_B%$1]@`"@(B(^P```'8B(^P`'S'-%
M[3Y'Z8TX=5G=+<S).))'5_!>$0-.6,/*7S%*YCV7:47ZH>R:DRZC4S#V('$"
MF$`ZL+WPZ?'6DK`UL[^AU]Y*(,;A'O4G%UX?'@;,EL,L66_.KY4@,6H['E[L
M:#@UK58-@05FGYMU"Q+M])JNH]JLGP5P\.3QPK7-TV1M]?9.+-7;G4;S2I!3
M=W&&#GT;QKJLM:E3[!'+1=BBGDK,5>I,F$`Q%4L@5"%81K)P@HU8LB(]A)'F
MWLG8CE9MH7C3;[NW("HDE'C>8E$S)E/Y".!;U6-6CT"@/7J)+SJ@D-]0RG?F
MZQ*SU_Q`MA6W6NPWO'",926KI65FZNU*VAF*2CF88IL'*<LSEKW](K)D;D+Z
M1$3,%"J>8QS&#L@!1+<_#1\<38%5?T>TZYKSJFR5?GZFM6(F^\2JG!(5:TVB
MJW>P5V+C::[KS:%AI:XTJMVETPAR,4!GF3B33*FYEYL\E]:7AQ>.TA!V2N)5
M7RQ-J;O&LFF;;O&15\T1E:%":MG`J\VM,J3U%/9M<UN"I=L7HLG6E[7`1J#2
MQ*29C+*J]@)UR2Y>:[3,YVKQ,E31+4Y`?2\!$6=D@DD/L82/&1;=$>?KKRG5
M7*EV'N(!WULK7'.K0][62C9E^_UQ.'5(W.RN+=(L65T<YB"@%DCQ7C4!*8`*
M89=.'$#CY1*`E'`ZP5_\*+QI=HUN(J5]U?%6*"AG,6^215VOQFC9"6DH*OIU
M2"E[A8(.<BK)?IN"JZ9:["S5[E[)*Q4,)V#%X@DLN"NL(;P%/$WDY1BPD=-4
M:JL73E)!U8;%O+5'T-$HJ&`JCZ0+7[)8)I1LW*(J*DC(:2>&(401:JGZ*/>4
M04;.447+91NY;.4BK-W+<Z2[=PB<.R+-UTA.BNB</TBJ1SIF_P`$PY[0*4/<
M"E`?O``_LP(.^'GP=K'`7CRAJ5E.LKML6VV`;WN6_P`<U6:Q$_;_`*/2B8N$
MJJ+Q)*13IE.B$S1L*I(E3>2CMU*3KINU7DS-D;)-;_JZO_FU?_6&N:_S8&M_
MU=7_`,VK_P"L-<#>&,8P*B&?[+E,_O6%_JYA\MWRHAG^RY3/[UA?ZN8?+=\!
MC&,!GH^)0#_E2?QY[\T*I93`HH'K![**!]OV','W?BP-Y_$M_P!M)_'CXEO^
MVD_CS1/X3#^W!_/_`&8_"8?VX/Y_[,#?9#E.'F(8#%]P[#Y>WSS^LQFHN_CH
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MBEBKLI6%EFQ'+-P00^LDL4IA0>-%RINF+U%RR=HHN6ZR1`SO/`@`AT/R_P!A
M`0$/<!`?<!#W`?</?/.,#J^^(]P#WAP]W\_\5+P[C'9S,`LO;>0VCHUNX-'3
M\2/I*WFQQT%'^D6=I5DCFRDALJGI$/+1<F0]^IX!((.4V-Q7A[^(1IKQ"M-H
M;&URL,!<8(&<?M#5DH^;NK)KZ?=)'4;D651!,DS69M-%5Y5;2U1(SF&15$5T
MV4PRDXQG/8Y"J%,0Y0,4P"4Q3`!@$#`("`@("`@("("`@(&`1`0$!$,ZC_B`
M\:]D>$'RDKWB5\+X]1MHBX6=G`\@]+0Z)V];BR621([FH59FBD=C'ZZOSM'U
M:\Y,1)/7.S#1JT<=**E&K%(.W%C-.\?]YZ]Y*Z:UWO35DM],T795:8V2#<J%
M*F\:E<E%-_#RJ!#J%:3<#)).X:;9@HH#248ND2G4(4BA]Q8#-(<B^16I>*NH
MK;N[==I;5.B5!F"SMT<OQ,G+23@3)1-;KD4F8',W99YYY&,/$-`%5RX.*BIV
M[-!TZ0W'(2#&)8/923>-8^-CFCE_(/WSA)HR8L6:)W+MX\=+F(BV:M6Z2B[A
MPL<J:**9U#F`I1'.GU-*WS\T#<\GU9BY>R5GPYN+,R@X<NV1'+$+TX.JO'FD
M6K@$_AQONU"(2`5MPOVI0-6)+R!6Y)N7,22#*-+:LWEX]O)B%Y1\AZ^_UWX>
MVF;$]B]::<>R;XQ=DKL%%3/8PAV)VS64?R#XC1+:UZ1]-JBR3_.VIZS@C:6?
MM>VM#0L17(B+@("+CH2#A(YE$0T-$,F\=%1,5'-TVD?&QL>T32:L6#%JDDV9
MLVR2:#9!,B21"D*`!PU$HE.UC3JUK[7U;B*A2J=#,:_6*S`LTF$1"0T:B5NR
MCV+5(`*FBBD7W,;S*K*F4<+J*N%55#Y9@,U1N[2.L.16L;9I_<-2C+I0+G&J
MQLU"R20&Z\Q1%M)1KHO3F)G(IQY'T+-,%4)&*D$47;-=-1/WVOG\**$2(=10
MQ2$(4QSF.8"E*4H"8QC&,(%*4H`(F,80*4H"8P@`".!U2/#NL&Q_"K\2*U^%
M_LB>DKCH3?[MQ>N.]I?BJF=C,R<=+2D!(D;F*9NW/:(JM3%*O;%BDBU_#ZN,
M9]D)6TH[%?M<@("`"'R$`$/R#[YU*XV\K>)OX]>N=@:9;A(:)X*PJ3:8V2U2
M%6)L(4]_;S_%M7R2AFJZ5OV/9UH:G%(L)Y2M5N6L22(LA.)>VH4.BE`1[$``
M!'[^@Z[P/.,8P&,8P&,8P&,8P&,8P&,8P&:KV!8Q3*,"R4Z,H4#22A##YBIF
M`!3:`(?(52CZB_V@GY"?)0X!L*8DDXB-=R"H`8&Z0F(3]L6,($13^_ZZIB%$
M0^0")OD`Y&=PNJZ76<N#BHNX5.LL<?F910PF,/Y.QZ`/L*``'L&!Z<8Q@5R>
M*GRVD>'7#V[WZJ/BQ^S+H^9:NU>^$2">&M%I:OU7MM(F<IP.>FUR/F)YMYTS
M)!*HQ1%1*53O(V>#=P%A./FG(7DEL=BK.<CM^U]O;G\O8"&>2>OJ99^Y>,KD
M8X?"N\0L=E:N4;!?9X52R,FZD$H8RPL&2X//N\=CCQ9=Y\)75DJ+5Q)RVAKD
MWVG)Q#5([AT^I"L+(UF[NF;9,AS.'<!&23>Q"D`>88V,E/(!C`!#29\,SEW3
M^7?%;7]@BG[-/8.NJ_7=;;=JR9D$W<!;JY"M8UO))LTSF.%<MT8Q1G:Z_`H(
M+IJO8\1*\C':*86#_+Y8QC`J!\5'PRH3FC2R[+UBW:5OE!KZ,44JDRU,C%!L
MR,8`#IG0[/+$.W.UD6KA+UJ+:55RKP$H8K%PX)$.A.QUCX3OB02.WF:G$'E0
M^D:ORUU:J^K3)2[IA$3.U8NOF,@I'.TW)4!':U2;HBTL468#.[7'-TK3&B^<
M?3()WF?/YY0WXP7ATO\`;$./,CC:S?0')G4A&-GL:544583>QZY4BD>-9N*.
MTZ6#9M"09)OH)ZCY7$]"LUH9R+AVTBBG"^3Y_+&5F^%GSP0YS\>RS5F49-MV
M:Q=L:?MZ/:^@@E+OUF0.8'8<:P3\IF<3=V22Z[AKZ9$HZQL9N/0*#,C$3V98
M#&,8#&,8#&,8#&,^"3E(N&9+R4S)1T1&M@*+F1E7S6-8-P.8"$]=X]60;)><
MX@0@**E$YQ`A`,80#`ZY'B([VOU+\1[7CC55JBZI9J5KZB:W;6^X19)RI46P
M;.E'4RI)%8E1?^ZD:Z9#+>=BLL)`6$K=4&Y%$YC0GAC;-O;]F[Y4<P-D[*AD
MA3^/UUKLKNAU!VBC(NY5.(^/3?)N4H9O(/GJC=%C"M%DDG!R,EV1#%\D,>=N
MM*[(<XWC>859O-:<S]4UR#J%V@PCYY2*VY35&T77WM:E@>DCHN2/;8R`AI5Z
M#PR#6M6>0550^H04K>^`F\K!O;CC7I2[@3\\?7DU.Z@V,JD<JB+^UZ]<)Q"T
MRBH4ZGJ$FH_X%^JIV`*O#NU2%!(Z>!*VF4RJZ[JD!1Z1`QU8J56C&T/`0,2@
M#:/C(YH7RHH()@)C&,(B95PX6.JY=.%%7+I95PJHH;)L8P&>0$2B!BB)3%$#
M%,41`Q3`/8&*(="`@(`("`@("'8#WGC&!O\`IMB^G&'HN#@,DQ*0CGOYKICV
M"3H`Z#W4\HE5`/8JH&'V*<H9F.1IK\LI"RK5\4QO1*<$W9`]_4:J"`+%Z^0F
M('2J?_RB9?L[[DH0Y5"$4(8#D.4IR&*/93%,`&*8!^T!`0$!^T!P/ZS!MA_K
M</\`NUI_3-F<Y@VP_P!;A_W:T_IFP-$9\SUZSC6;N1D7;9@P8-EWCY\\73;,
MV;-LF99RZ=.5C$20;H)$,HLJH8I"$*(B.?3_`#B/L`![B(C[```'N(B/L`!\
MQRMK=]BNG*S<S+B=IZ0!K6HQ<SO:UL2`Z\:F$4LD:2(\4;F\KF&K2IT6B<>"
MB9;!;UD6!S_"L/4`%DW9NCE7<I#3_$^/=QM7:F*VMNV7`K1::<>X.=$[TLH9
M(RM:A'!2*BP39)+W&PI$.=@U8M05ZF=H;PY]*:J!O/WIO^?%?C*$>N9JWM@7
M@&C_`,WJ'5B:NNJZ:*J@H(?\)6!::DU1("I56OJ'1S.Y9O2N%&L-5UZA0C)C
M5I':=*I]ND%X>7GI^51LR4@A,V=PC7DU966M+MRP:>FJFR?MVJ!A:H1Z<<U0
M3;:JO'-6SL9F0>T&$A9^EU_=&K*E.#,UFYP5D/KZ:U#=-G[*DH]A-&A703\$
MSJ_QT&Z<Q)8A2-;O47"3I4Y7;4+%F3!E&M464>T;,6;<GI-VC-!)JU03`1$"
M(MD")H)%[$1\J:90]Q]O<<^KH/N#^(,@#<.6-^B-P;/HM<J]3E*_&,]84K5;
M^27F&:MDVY=MB1]!GW5@E&AGC9"A5=]8H]%R2-CAEE7U8M+)-Z9VO'MTMMTW
M<4K!W:\T[;&S-)RC6IU]I/.IZ$2E-92-?<%E6D1+1MAK%NLUJ8KPR;F6A/HV
MW1]N(D+R0)!R<0W>*,7K\)1]!\OE]OMV'^CK(Z[CXHZ)WFR<)7FB17TPJ57X
M>W0**,!;F2RH>ZZ4W'I)JN^C?7%K+I24>J8`]=FJ'MF+DV;NB]S>R9G5*6L1
MI.L+:C3FD';$IH\[L]]%1<)-7)^SN<9/(0NO(M%M.DCJBZ=UFYC+/(YQ*RR<
M=#OF@IYJRY#U=YL-O1!K-W9QTC;IC7<+L9]$QJ&OYO8=?A7<],4V.?!,J3QG
MS1G&R[5.7<U]M6)&:@Y>!C)QY+,_A5`JDN6I.1O`-TO::/*.]R<>"J%5G(A^
M15%:MI*&`HK24<V%T-;43[!-*UUXBD"J;HM@B&0*)`,V-1[@I.ZJFA;*5("X
M1*9-M,1+H"I3%=E#I`L>+EVI3&!-8"=J-7:)E&4DW#XIDLH0%")95QTY/I;]
MO>V*9*(TM:`20&U:J"">A)O;'J52QV/7;QY<F:SMXDWFUK'5EYH[$&K)N6HW
M.IHKM5'?QJJL$.1FFY_@[M2-Y!:78.E],6J22C-@4-H=0(Z$.\7$XQ/D$3D0
M@Y-515U47RGZVK`F2(%0L;(-6Y@L6S8&M_U=7_S:O_K#7-.U&UP=YK$#<*T\
M+(0-DC&TM%N@#RF.V<E$?373[$47394JK5X@(B*#M!9$1'R=CN+6_P"KJ_\`
MFU?_`%AK@;PQC&!40S_9<IG]ZPO]7,/EN^5$,_V7*9_>L+_5S#Y;O@,8Q@,@
M&XL73ER'JF#RN7!>O/\`XJQP_P"S)^940]L)0>O0]0OL]>`/??S!TL4?L_%@
M;U_"/_Y8W\K'X1__`"QOY6:!_"(O[87^?^S'X1%_;"_S_P!F!9CJ!U\92FBW
M8F$SZ3#L1['ZCPY??-GYHKCHZ!YK&.7`0-YI6>+V'R^K)*!F]<!C&,#37(/0
MFM.3NG;WHS;T%^$%!V%"JP\TS36,T?M#@HFZC9J%?D`QXV>@9-!I+PLB0IQ:
M2+-`YR*HBJBIU=.,6\-T>!+R)<\0>7KF8M/"#:5BF)?2F[V[19U&5`RKQ`[V
MR,F#4SI2/BC?'M`V]04"B]K$N(7NL-I"(DGOTGV\,C3RTXHZBYF:3M6C]QP9
M)*`GVYG$/--DT2V*DVALDJ$+<ZF_5(8T=/PKA3U$3@/PT@T,ZB)1)U%OG;54
M)$1DG'34<PEXA\TDXJ49-)*-DH]RD\8R$>^03=,GS)V@=1!TT=ME4G#9PB<Z
M2Z*A%$S&(8!'[LZDW"3F-N3PA=[%\.GQ`WJ_YP[EV\=Z"WLM\<\KE=K\C*&2
MB7[624]4YM2R[E11.3CU"%DM.V51=C)MTZNX%PP[:+-XUD&K9\Q<H/&3Q!%T
MT=M5DW#9TV<)E6;N&[A$QT5VZZ)R*HK)'.DLD<BB9S$,4PA]&:NW;J:J[WU%
MLG35V9(/ZKLVEV*ES2#A!-R5-K/1CAB1ZBFJ4Y"O8QRJA)1ZX`!VSYFW<)&(
MHD0P;1R"?B2<LZ_PQX>[?W')2!&UH&NOJ=JV/*KZ;N:VC;F+R+J#1H`IJ%,2
M,='6LLJ<_D3;PD'(N#J$\A1$*F_S,Y;;$OQ>Y":KEI(9&(U+R0F(RNB($.1J
MA8:M$/YI-LN41`S9[/,'LN")>DTG$BY43#]',)NRAE$7YGHXX6#1_`YI>KBT
M>L[+R.O4IN!-!]]1P%-4BHNKT9XLW.0%DE9^'AEK1^BG$QVTXT/Y"`/UKW<"
MJ7QM-J3NI?#0Y+R];67:R]J@*[K$KQOWYVL7LNW0M0L9NP$!+\16Y*78E4[`
M4SNR'#L0ZS^/!/TI5]+^'!QT+`-FX2NT:M^?+<I)$J7J2MEV$L>3+ZRB8`)T
MX2"3A:VQ*<QQ091"*8"`^8,D=XAW'=[RKX6\A]%PZ!7%GN.O9%Q24C'32]6^
M59PUMM);^NL8J3<CVS0<:P664,4A$':HG,!/,.5I?F>CE0RVOP^'C99USQVV
M^*$S(4B6KDD`-ID=?R4S*/*<^4:+"1QYH![]-4.52](3L'M=:E="F,@U*<+_
M`#&,"/7O_M_M^+`"/7SSK$>)SXB&RN4VQ7'AB>&[Z]]V;>%Y2K[QVA6I!)M`
MUVOLS%:6^FQ-L25^'C(M@@J9#:MY25^'AHXYJE7CRD_*.TF>?>*YXHUW&[H^
M'9X?Q'NP>5FR7QZ/>;33RD?'U6E*-RD?5NO2'1V"=^"-77=VFPK&-%:J@4GC
MZ0<)60A$XBP;PR?#5UCX=VG2P$::/N&Z[HW9O=O[7^!%!S.OT?,NVJM;!QYW
M<90JTJJJE$,3G*YEW7KV*:`\F]!-J&<^'-P)U[X?/'R*U/53H3=UG56EFV[?
M03.16Z7HT<W9N%&1%B$5852!02^AZ?"^1,L?$I?$.$S2DA)+K3ZQC`8SQV'W
MA_&&.P^\/XPP/.,\=A]X?QACL/O#^,,#SC/'8?>'\88[#[P_C#`\XS^#&`"F
M$!#L"B/S#[LHNU7XJ+.H>*3R:X$;\F6$?6I"_P!61XW7A^<C,D?8)S6U!E'N
MGYY<$R-A1GY61D9>AR[I1%0)AR^J;M9<[^N$*%ZF,`(#[A_M_8(?:'S`<8#&
M,"(!\Q`/RX&J-ER)@"/BB#T4_G?+@`A[@411;E$/GUYA6/[^PB4H_,`'-39D
M]S>`[LDD;S`)6YTV9`[]@!NF4IP`/_IC*B/W]_P9%CE?<K'KOC!R&O\`3I0T
M+;:3IK8-LK$NFD@Y/&3T!7GDG%/0;.2*-G((/&R1U&SA,Z+A+SH*E%-0V!(#
M&0(\/3G92N=.ED;>R",K^UZ?\%";CUVT<G.:MV%9-3X.>ADW'3IQ2K@DW6D:
MZ\$5A9+%?UY^M])12@K3WP/4X00=(+M72"+ELY16;.6SE)-=NY;.$S(N&[A!
M4ITEV[A$YT5T%2&261.=)0IB',4>J+RCT5N'P:^3J',OBNP--<7=DS*,!?\`
M6JAG1H6N(3,B$@[UI9S)@<6-<?/1</M0W3Z[FLS94X!R(^0B<SVO\QVWU&L7
MZK6"DW6!B[34;7$O8*QUV;:)/HJ9B)%$R#QB]:K%,0Z2J9NR'+Y5FZQ$G+91
M)RBDJ0-5<;>1^J^5NH:SNK3\T>5J=C(LW<,GI4F]@JM@8B4DS4;7')J*_1EB
MA5S`FZ0`YV[MN=M*1JSF->M7"F]\ZE^P==[T\"GD@KNC4C*P;7X2[9?-8&Q5
MN2ECI$:.'2IE&-7L[E(#(1NP*LB#M36%Y=-R,K8Q(K!3J@JJ2#0.S?H??6JN
M2VL*YM_35J:6VD65(_P[M(!;R,5)MP($E7+)%*#\7!V6&6.#>5B'A2JHG\CA
M`SE@Y:.W`;ASP/L'?0#U[]&*!BCU]ABCV!BC\C%,`E,41*8!`1#/.8O=[I5]
M<TVU;`NTLW@J?2:]+VJT3+M0J:$;`P3%:1DG1S&]O.5L@<B!``3+.5$4"%,=
M4I1#K2\0:NSXQ>//R$T7KPPQNN=B4R_RJU=;=`P8M)6J5S<L-'%2`>D4ZU8'
M4@WC.B_WNQ>&:E$B9_(/:"SK)^#U`6OEOS<Y8>)3<8US$0CZ3L=&H#%4?,F2
M7NJ$2#B)1,IYCBG1=7Q=<BG0IB!"RE@`I1,4IDR=FS`8QGCL`^8@'\.!YQGC
ML/O#^,,@MXDF\[WQLX>[(WAK-ZV:7+7D]K&9C4WR8+QDJU/L:MLIFO3"(%,=
M2&L4.Y?0TH"/E=)-'AW+)1)Z@W5($ZL9&#B#ROUKS-T?6=UZU7^&1D0&*N%0
M=.4W$WKR[LD4CS=.G!)T*BC0RJ;R'DP(1O/P+J/F&O7Q"Z#:3^`]Q$``!$1$
M```^8B/L`!]XB/L`??E+'*S?Z?*39+SCGH6H7G81=-/+//;%ML(R9J41:>A6
MC./7@XYVHZ3/-O:^#QWZJZ`'3!\HJBR:K^3XTMPUNDF4/4[1*R4VA6H^-K<\
M]>6)TLF@W@6[>*=J*3*RRWZ$F2,`/C1,IV7M$`Z,(@4>KAQ3Y=[PEHJC\?.(
M^C*1*;+@`_":5LTK9&YD[3989Q,1UCOR,5-2M>:*J7^JR35A>XN0DGYWQFJ,
M@P:MC($]$.=Y%\:^1DCH-:65DX>#IVJW#/;K+7CQ$ZMV<.[;7Y<Z5I@)-BFL
ME!,5H*K+J.H@9!%=U((-)%=F1RFDJ%Z/`W4-<TYQ;U7&02SF0>W:NQFTK=.O
ME3KOY^W7^+83DI(.5%!$P$126:QS1,!Z(U9D,/F445.:N6.X9^))O"+"L[QW
MQ4=3T!]#Q]8E82HJ1DQ8#U:/6E56\6V;UB*;LC*-T9V48H*R-J.`-ERMW0.6
MZ?D-=]5:Y&4ZKUNHPJ9D8:J5^%K40D<P&43C(&-:Q3$JA@``,I\,T3%0P``"
M<3"``'6!SV,8P&,8P&;\H<B+Z`12.;S+1ZAV1^_GZ9.CMQ$?M#T#D)V/0B*9
MON['0>;,UF[\C^19"/17#5-P4/O.V4],W7W?47]_;W\H>_M@;DS!MA_K</\`
MNUI_3-F<Y@VP_P!;A_W:T_IFP((<E=K#IO3ELN#51-.<4;IP%6!3H2A8YP%&
MK)T8O?NE%H%=RZO?0"5@!!,45`',A\.;0Q=4:09W6=:&_#S;H-K=,.W9#C(M
M*ZN0RM5AUE50]3S'9KJV!_\`I3*R<TL"HK?#(G"''-Q!?8FTN,VB6RA"DN%R
M2?R'F,82E)+3495TA63*`@*:<<,VN!A`1#L_0=`.7C-6S=DV;LVB*39JU12;
M-6Z!"IHH-D"%20123(`%(FDD0B:9"@!2D*!0``#K`Q&YT*#O1ZD>:/($&F72
M#O<1\`Z*U`\W`$?)L2/0,BM\0P,617^(:E](RP@GTL3R"!L$FN/FOK#;)&X2
MQ)EX^EIV/GY%@I(IC$/%X_55STZ#)9G\(*AHUW3KY.D>-P<@=:3%H^*ND5N9
M!7QR/L-QJ^H+++4&6/!6WZ1I<9$3"<0VGC1IY^^U>`>.QB'B*[5\1&.E'AE$
M5B`0$_,H*J`D!=.(DKNOD)`;TD]>QRIK"XK5A8UN"JL\O6FCO9%,:ZF)8WFP
M'$+"TI*PGEIJX$?H$ML'.5_6D*ZCOP2?P[*06.HH$@(GAYJ.)JS6H$>7AZT9
M4=O3$))[<'?X1D.SV,IM9C<BSK-%G(IWECL`R=A:6)%5/TGC9N4&9DTS$-GL
M-H>N,KDI?+'9;IL2P*TQU01_#N2AI*$)7'DS!V!=!*L14!"5M)ZI+5]BZ7E$
MXHL@\$/3?N'236.(QKAJNZ[0A>6&R%MPO+FJAKSC$.T9A[0H^ML=:Q]TWTY0
MVM4)(B$$R9Q<=!L7*[5ZWF4U[EK^-;^O9ITYW3:03V2MR5M]A=JOE]O2&N]>
M.Y7D`_H=Z9:Y968]]FJ3M)*K4K7#:`>5Q5_,,$ZUU*LH2#+&W?9C:037J]C1
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MJ\AK6JR]*AQ@4(^-3E*U,1T#'N8VRBV8$7G"('K,-(M%7"Y%F\FU,Z`Y@772
M4S[8%&KNRZ59J%;619"NVN'>0TJV-['^'=)]%<-S]"*+QDN5)ZQ<%#SMWC=!
M=,0.F40BAQ`VML[9:MK_``QEV=EA&-:H$DG+A)0$B_C;M/-YIQ;JP8U4I]7A
M8]G'(H1*Z56D%)&Y4]RLXCK.Z5^+CCY-_`H[X<2D[JK8^X.*%Q?_`!3ZB3DE
M,5-<P>1-VT2<)%FA:`H)3@A*,'D':4&Q$Q*B9U+&\W7?=JFM_P!75_\`-J_^
ML-<K3YFQWYU/.'COMV/(*+782#"K6'RK&(+U>/D4ZD_%;V\OIF@+5#`)/?U1
MC"^;KRE'++=<E$L^Y(/S)'N"#^4KEL4?YPP-WXQC`J(9_LN4S^]87^KF'RW?
M*B&?[+E,_O6%_JYA\MWP&,8P&4,R-@(61D`]4WM(2`?,/L>N`^_+YLZV4K-]
M2DJ'G^4K*!\_ND'(?XV!MO\`"$G[:;^;^W'X0D_;3?S?VYI7Z<_R_P#K?_JQ
M].?Y?_6__5@7B<2G7QFF8E<!$P#-V8O8_,?)+K!_-UUDF,B/PC<_%Z#A%N^^
M[#;B]]]_I9QP'WC_`*<EQ@,8Q@,8Q@0UYP\&])<]=-/]2;ABC(NFAW,IK_8$
M2@U"X:UM2C?T$YZN.G!#)K-G)"D:V"O/?/#V2-`6<@D55)D]9]<G7O(CQ0?!
M-,ZTGO31U@Y>\28%YZ>NMFU8UC70J]>%8Z+*.@;FSB;*>J,5$P3'\[79$:DE
M`O@.VJMC&$.F9QW`,\=`/O\`P^PB'?Y>NN_R#V&!UJT_S39Q:+%E4><<.4:$
M^4@"Y@DH.AN02.`@*R:4A^%R`K^0GF,GVP1.J8`(*:9C#Y8Y>-%<T.1W+?PG
MM=[#-9:KP_W8%&V`\^FHIQ#/74UL.[5V%L$798UPHDHPG(6CR];@7*"Q_7KS
M>]3CDAE!$PYVT!AXD7/QHQD>+SOS?%BQ:"Y\W^-ZXH^KW[![^?OVSK]_FDG3
MKBZ\&:YMZ&37)9./FX*K9V\BV*8',;!70B](DG!'!/T1NDVGI"IRBQP$I0-&
MI*"8#IIX'8%B(J,@HJ-A(5@TBH>'8M(J*BX]NDT81L;'-TV3"/9-4"D1;,V3
M5!%LV02(1-%!)-,A2E*`!R.1HX:[J)R,XJ<?-W^J59WLK4M*LLP8@`!"6->%
M;-K.@0`,?HK>Q-91`H"83`"8`;HP"`27P/`^X#W_`&=?C[^SK[_LSJ?Q\8CH
M?\TJI5;CD14D1NFA+3/(BG1B2K2$AU;9K^5N5M>K@DJ9)0JDU`T?80D."1&U
MCL"B220`\\I^UVX5201577.1)%%,ZJRAQ\I$T4RB=4YS?X)2)E,8PC\@#O.J
M_P"!PBXY/<^/$=YYRP)NFDK;'.OJ2JLF9<$8^XVIW.$+'.%/,"01M#H](CS$
M2./D;R7D`PD5,!@DMLW\T6<7=6;'V3K2;T+R?=2NO+C8Z6#UM4*HQ;3[^L23
MB'?/&C.:MD;*Q[)P_:./@OI%DFNLS]%V9%,%BIEAQL;Q:_$)\1-K(:+\.KB/
MLK5+*U')`3^]K&N[--56*D"G(Y=$MZ<5':\U<HJU,8#S_P!.VFQM4A.:M,TI
M<&KDG;'<1,6[5(N[CF+E=/KTUG#-LNJ3KY>155(ZA>OLZ,'7V9]Q2%*``4``
MI0``*'L4`+UT`%#HH==!UT`=?9@5+>%_X5&M_#^J;VUS[]EM#DY?&0_GC[;<
MM53E8HO%@?O*;1!D0/),:T$@8SF7EWIRS]UDR_2TZ**16$3'6UXQ@:)V=.3,
M8=P$=*OF(%*42@V<'2\OM]GE^7>03O6UMF,3K`SOMK:@45.O0EW"8!U\NNO<
M.ORY-C;G_&./_1+_`*,KIV*`^=Q[#\U?L'\6!'JZ<A-ZLQ5!IM_83;KS=>C9
M'A.O;[.OE\\BG:^5W)IJ90&V_=KMP#OKTK?($^W\0^W\'6;,OI3>97V'_"^P
M?N#(;7(A_.K]4WV_X(_>'XL#AK/S2Y=-14^'Y+;I0``/T"5YDR=="/7VCF@[
M'SPYJ-_/Z'*O?"/Z;_BM@RI/E]W7R_@S@[<0_:OU3?(_^"/WC^+(V6@AQ\_1
M##^F_P`$?Q?BP,]L'B&<[6XB"'+_`)#(]>;_`(O9,P7Y![?;FFYOQ(_$"1%7
MT>:'))+H3=>39\T7K[`^0_9W_'FH;,FIYC?H9_\`#_P3?=^3-%3Z:G:WZ&?Y
MG_P3?>'XL"2Q_$Q\0_S&#^[;Y,]=F#K\].;^78AU\\BE>]D;`VC=9C9.R+K9
MKQL&PO&<A.7:R2[F0M$J_CVC-C'OGDP8Q'9WC!G'1[=DZ(<BS5-DT]`Z9D$S
M%P\Z:GG-^AG_`$QO\$WWC^+/6("`]"`@/RZ$![[^[KYX'?8\$3Q5D>8>O4>/
M6\[(U_NH-8PB?P4I)+I-W6[J#&(IMTK>T`XIE>7BO)%2:[`CVY16=D%K<6Z9
MFTC*IQ=_^=)/\S\>&K:]G[+K'._8RLO6-7:KL$D.FX]D[D(:3V;?F#9S$2$\
M=PT5:N%-;U4'KZ-=)D5,RNMA!U!N2N8&'G&DEW;`]@`/NP.#LJZS:!E5VZIT
M5TFBATU4S"51,P==&(8/<I@^P0RG'?>YMMP*KP(79-TB@((^0&$XZ;@7W']*
M!1]NNOORXFV?K;F/W$I_I+E%G)$!]9_[#\Q^P?O-@5:;AY4\EHY9TK'[ZVLR
M4.JJ<QVUPD43&.)^S&$2&#ZPC[B/WB.5F;IYC\L9^"L=2F^1^Y9:L62*D8*P
M5^0O$HYB)J%DVRK61BI)D<WINF#UL<Z#ENIV15(QBF]A')<[M*;S./JF_3J?
M8/\`C_DRK;:9#^=T/E-T'G$1\H^P>4WN/M@8GQ1Y8[/X8[W@]T:P=%6<,1")
MN%1>.%4(#8=)=.$5IBFV`$@,)&[L44GD3)D(=U`3K6/F68&.V417_01XZ\@M
M:<H]/4[=NI9CZ7I]P9"H5%<4RR]<G&?D2GJA96B9C?1]EK;\QF$JS-T4_2$@
MT%6.?,G"WYLC.$F;-9(ZN5R)D9ZP6"680D%!Q#55]*S,S*NDF49%1C)`IUG;
M]^\62;-6Z91,HJH4/8OF,'?<\+;@JZX*\>CU>US"LOMK94HSN^U4V<J\=U6O
MS:<>#"*J5:9'5^CA&M1A_H^=LK5LDXM$N"RQE#Q,?"IIA99C&,#"]B:ZHVVJ
M39-;[*JT/=*+;XU:(LE9GFI7D9*,%A`WD53'I1%PW6*FZ8/FQT7L<]10>LET
M'*":A>L+<^)'/;PC]M3FVN#A;-R`XTVER5]:]:+13RU.VK-`ZA48G8=,A%"3
M+Y[#,S`C7MLTAN243:E%O.MFP"NS>=J[`"("!@$2F*/93%$2F*/WE,`@)1_&
M`@.!UI:[^:.:A'-3,-M<0=E5NUM3G0>,*O>X4[$JZ0^10!;7:`KLTS.*@&[;
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M;V4;_F?S;J^P>#;RAOW!%'VD]KVFKLT!/YG#>JW%NQO\`FL43&.5-!_,V)BA
M[%3*FT!%,`]$0R\C`P+9#]]&U=TZCW;ADY(H4"KME#)*E#TU1$`,7H>A$`'K
M[P#*>=X;QW)!JO2PVT;S%@0Q_(#&P.VX%]O;R^0?;K[/Y^\M[VK^M!Y_](7_
M`.[5RC+D*4WK/_8?TQ_L'`@%L_F+ROC%'81W([<C$"";R@UN\HCY>A-UUY3>
MWR_'E:^_N7O*?955FZ!L'D/N"ZT>;,U"8J-ENTG*U^3^`>HOV/QT:N847'P;
MYLW=MP/[)N$4U"_6(&29V\0_J/?JF^9_\$?\8_XLK=V00X'7$2F``.;L?*/0
M?6^T>NL"2GAX\[;OP1W>UN\:1]8=7VWX&!W%KU)RH1*RUHCCM&=B4A$R"-WI
MXK.)*L/C)]NB'?UUVH6.F5S(]_S76Q*3MNBU79FM[)&V^B7:&:3]7LD2J"K*
M4BWA1%-0`[%1L[;JD5924<X`CR+DFSN->I).VJR9?S2]4ZMO>[-C4W4^LJ\[
MM-[ODZSK];A&91\SAX[.(JN7:P%,1C$Q;0CB4FI1?IM%Q+-X^<&]-`0-^A'P
M1XCPW"7C?4=&1EC?6Z59O)*U7:R.'+PT;+7NR@T4L:]7C'9A"!JJ2K-NTA8Q
M)-%19%L>8DRGF9614,&+>)DG-GX-\@#031W(KH5Z`=R4:S!V*DE76=TKCFR,
M5Q8].R1[F'2=$E%$1**4<#I0QBD*<P4O2G&_5W*+7=.Y`\0;1'T7<=3BXX9V
MB1;XE=5CPK;&O4JEQ)#00GDX';-SM"+YQ!2`J&96.-,XD)%PBFT,XSM#NFS9
MZV<LGC=!VS>-UFCMHZ13<-735RD=!RU<MU2G27;N$%%$5T%2F352.=,Y3$,(
M#UT.4?A_;=XF;,<<G^%;J=0J,:_4L\E3ZRF,G8]:*H$6</G#2`>$=-KQKQ%-
M1VH9@L@]E*ZT760,@M'D(\1#,>/7B2[MT/;$-,\Y:]83M(^2-`O-A3<49C?:
MH[3,@7U+*FT3"%V%7VA%T57T]`+'GF3)5-^X2E4A.);]HN4C)R-CYF%D&4M#
MRS)K)14K&N4GL=)1SU$CAD_8/$#'0=,W;=1-=NX1.9-5(Y3E$0'.JYL3G\KN
M3CZWU5=-;UZ>OLB=^SC[2HP9S]27D+!ZQ[1L")BWAEY<V[+&X>%@:[%"FA`U
M%BNYDHQ5PX!NW:]C#BCK67T]QKTCK.?.J:=I^NX",F4UEU'!VDFJDI(O8WUE
M#&,<L4N^-&%Z'R`#3RI@5,"%`)!8QC`8QC`9FE`.);,V#L?T1J\(/XP!(%/?
M^%,,PO,QH0"-G9B'^"@]$?R?#G+_`*3!@;_S!MA_K</^[6G],V9SF#;#_6X?
M]VM/Z9L"H6WHIR'B6<<FKL`.@UK3%V@4_N0'#:-V/((G*`]@!RO$$E`$.A`R
M91#W`,NR+\@_('^C*.N1[Q/7?,?B?M-RH=K%+RD57Y9Z)#"BW;M;.>,>E$0#
MKSC$W!54Q0^MZ9!,`"!<O%#Y>WV=A[^WR]O^S`T5L+D!4-<[1U3JJ78S3V8V
MF[?-TI.+19K0]/3(=&/@'EO45=HNV#2X65PC5*THU;.S/9P5$%"I((+K$QF.
MWS='NX%M2K:&NS)=HTC[`^M"URU@K"-J5+62;K4;:Q:-K6I,K).7,"]<FA48
M\\X@V%+UF95S>D7`=L<6;1M2=W#=%]AR=<MTPSH\=IH(.;F&M<KS;6'P]SI:
M][B$&K<DZL7;KN>L$BDV!<20+EFQ;NU5TU$R[XB]?SJ.YI':,@\B`:2FHZ?1
M%XQF9ZHY1G8.W6RRR3M)5=!)(\0HG846S$QQ*]$Z"IG""913$P:WU=R:4V'(
M4`LIJ:\T>N;90F5-;VV:EZ/+15A=0L=(3IHQVSK=FDYNOOY"O1,I,QP2L<DV
M70CG;1PY;/P;MG&V;3M_7U8<6>#/;:J]N]7JLO;7-""XUB,M2L;%1"LV<ZC2
M:EX]*,;JL4R.!DYE9C%,V:Q)!^\;1OF=!JGCWQ<I&F:[3'3V$AY+9M>K;V$?
MVYN\GI)$KB8<"XG58!M.O%D81&5$C=-V$:PCE%T$"-E`^%*5'->VOC=LR79;
MAI4:]U,K3]B3VY+Q%VFP0LR_V"QL>TM=RE1:0YB@S/'0Z<`_ECM?PZC91],.
M-?LFE)0K#0!<29PWU`<C-*V)S,LF^Q:HR>0FPI#5KAK*S\5&KO+S&I1JCF"B
M$W#XAY9R8TJT1:E8E5.Z5%0K=,_IF'/EM?)K1%/@K#8I#:%-?,:I/UVL6-*"
ML</-OH6:M%B1JL4RDF#&0479G-+'<IN17*0&R49++*>\8\*EK*$X[VUGN2-O
M\E(5%6#@-K;:V'"E2"3=30(;*UO6JDV*=HZC$F+"5@Y6*E`.NVDG*+^&>I&(
M=HY.Y9CIK^Y,W8[*NZDIS5QI)IK;7],8@V?6M**DIC7&ZZIM5K+!$-ZPQAJ3
M`VIK#R48XJ=5B5FE1<_`JMG5I3<+G9A/N,V!0YBS2U+B+G5I2WP*0KS=786"
M+>V")1(9`AU)&'0=JOV9$S.F@*F70("1G;4%O(9PB"F89"K4?&>TZ_VF-GFK
M&2=K4)/[FL5:=.K?;Y26<.=P6M>S.FSFHN64?5:\M%ED7S*5EFDI9#6E9M'2
M:4;6EP<I&FK@5`>*N/P\GQ9?I``.VNP;!Z)@]C]%<4AT!0'V'KUVZ/MV`=B'
MVY8EKP1-87AA^9F+LPA]PF=-Q$/X!'K*XO$?>!;=^\1]6LRF7D"V%6PNVQ""
M82LIFUUA@@J;H!'H&U:FU3]!]5)N<XAY>NK'==F`]A>'#Y'8NSA^0SIN8/YA
MP-VXQC`J(9_LN4S^]87^KF'RW?*B&?[+E,_O6%_JYA\MWP&,8P/`_+^$O^D,
MZJDQ,B$Q,![>TQ+!\Q#Y23H,[58_+^$O^D,Z?DW,B$W-AYP]IN9#],'V2CS\
M6!L?Z9'\7\8X^F1_%_&.:E^FA_QP_E!_9CZ:'_'#^4']F!V0N`#CXGC?`*^W
MO9KJ'L/?Z6P.0R:N0.\-]Q\3Q<KBO??FM=\#Y@/Z6R.@R>.`QC&`QC&`QC&`
MR%/B/:X:[8X&\N:,[3!4)/06R9!JF/?8RE8KKNV0XEZ`?KDE8)F<G^44/X)K
M9K/<[5@_U#M-A**HHQKW6]Z:2*S@Q"-T6#FJRZ+M5P=003(@1N=0RAU!*F!`
M,)A``'`J"_,[U^>7?PS-=QSMQ\0.N]B[8H;<HCV+5BC9_P`*HYH/N/E!%G:T
M_*7_`!1#KVZ$;R<ZTOYF!?.%.'.[XT5#&81O(]]\$4>Q(`O-8T!5R<@]B7M8
MZ::AO*/VAYO<??LM8$5><U]6UAPSY47]JZ,R?U7C[MR5BW93>4[:73H\TA$+
M$-T/1TY)=J8GM^G`N57_`)F[UVVIWATM+2#?R/MG[EV99'+@2@!UVM9<QFN8
MXHCT`F(F2HN#%'L>C*J?+L0R7WC-O73#PPN82[,QRK*:V8,CBF(@86DE=JI'
M/RB("'U#,73@JH#]44S&`W9>PS'O!"91;#PNN*!(U5NI\56KK(2!FYB&`)>0
MVA=G<DDL)1'RNDG*ADUB'Z4`Q>S%#`M=QC&`QC&!P<G6X*9$PR<8U>B8.C"N
M0QNPZZ]^C%^S,'?:1U1)>;X^BP+KS=^;U6ZP]]_/OI</GFU,8$?GG%;CS(>;
MXW4M1<>;Y^JS<#W^7IT&8LZX0<3WHB+O15"7$WS$\>['O\O3X/XLE5C`ADY\
M/+A4\[^*XXZU7[[[\\8]'Y_/_P#:(?/."<>&9P,=]_$<7-5*B/S\\2^'Y_?U
M)ADZL8%?*_A4>'@Y_P#A'$K4"OS_`$\-(#\_8>_^%OM^W.(6\(KPV''?K\.M
M,*>;Y^:$DO?\O4N&6.XP*TC^#OX9/E,/]QAI/OHP]_0<E\^A'O\`5C.M<U\(
M*!Y/>+MR7T[0:<74O#30EQHRVP5ZBBO&L&3&6UI1["AJRC.5#K?#6NZ/9"0D
M'KPBJHU:!<2$^<I7KB`:/N[]\_GG#Q-?@H)687A8>,BEK#,+V"=5CF+=FK,S
MCEHR8+S$HH@F0[^358QL>R4?.A5<&:,6;85/1;(D('Q4ZGU?7U4KM'I,#&5>
MHU*%C:[6J[#-2,HJ$@XAHDQC8R/:I@!$&K-JBFBD0.Q$"B<XF4,<QLEQC`]+
MEL@[05;.4BK-UR"FJD<.RJ$'YE,`"`]#^7-03O'O2]G$XS^NJW*BI[G%VV7/
MYA^\?*Y+WFY<8%:=VX5<5W4Y*-)/0^OGJ1')C)E<,I,P`BL4BR8?4E4PZ`BA
M0$```]AZ``ZR$',G@APUK'%;DE>(+CEK&'M=2T?LNRUZQM6$LG(0<W#U>0>Q
MTNS55FE$4G3!RD1RBHJDHF0Z8&.F8H"&70[)8BC*-'Y2CY'K7TCF]O+ZS4W0
M!^4R2I/GWV!!Z^6:JE(J,G(U]#34<REXB3;*,Y*+DFJ+Z/D&:O7JM'K-R11N
MZ;*@``JW73415*'E4(8HB`AU[/!9\-+\Z:*CN8F]*\*6U+=%BMI>H3#0`<ZV
MIDPU`IKU(M%R^=E>KI'+"2&24*1W5ZBZ,<Q4)>?7*P[$7R^6/M$1]Q$1$1^\
M1^8_[>WV![8P&,8P&,8P&`217$J#@H';KF!!P0?<#MUQ])<@A]H&1.<HA]PC
MC'E.;LJ93G.8!`A"%,<YC=#T!2%`3&-]P%`1'[L#K#^!WZNH^9_B&\:U1(V:
MP\JZF(YCYNA`^O=KV.HHF2*/0]$@+2R!3KY$33$W0`7.SQG6)X5K(QOC\\V(
MV)735CI..WNH[%L<BB`G([UU+G)YT#&3[;RIU4S^_P!5P!R"`*E,&=G;`^&0
MC6$LV.SDFB+UJ<>S(+@84S"`"`"(%,4>P`1^T/F.:GF>.^C;$)QG-7524%3L
M3B[;/3"81^??D?I_]F;FQ@1-DN"/#F8$PRG'+6;\3_IQ<,)<?-W\^_+,E^?_
M`+.LK"\5G@GQ*UEP;W-L#57'#7U6V5$N=?-*S8JQ$S:ED;O)[8=;A%FL2D,J
M]^(>2S=^I%IM4V:Z[HSL&[<@KJIY??G&RL-$3C=NUFHN/EVK23BYIJVDV:#Y
MNWEX1ZE)0TFD@X(HD5]$R*"#^.<^05&;U!%T@)%T4SE"G3PAO#6;<.M=!MW;
M$,4.36SX($)IHY,BX_.EI#Y5%ZWUY''2,JD%BD_09R.P9)(XJ?&IM:J@<&<,
MZ,_N=Q_.(^XB/N(B/N(B(^XB(^XB/S'/8B)060$XE`@+HB<3]`0"`J03B<3"
M!0(!`,)Q,(%`H"(B`=X%=/,3Q)=(\2G:M+63=[(W$=LBJCKJN.46Q(;XPGF8
MJW*P*D7;00N2F36;0Z#=]8'K<Y%D6"2)R+C5A8]F^(SSFAG+J2/$\>-`34!/
MV9-[(OG.K*%+5B'(W1D$G5I?'5N^P$BB\;IBR1%C'/@746!!1HBH)(M:[Y44
MK1>S-NV.+TT7;/+5;D/?UJSL:>DT[C49.I24^[9DAE*Z1*2E)"4]1`QX"4J9
MVDP0YFAV\R#-)6-<3#H_$+GAS8DX:P<AK!):9U.PEW=CKU<L$:2/+"'EG2D@
ML&O=.-G!0BS>990K.2O#I(K,BGZ"T<)=M\"--1XQ4M_O+CQ7]72LE*MAOVM5
M;M;+<=K5EI*;:V%N^E?P<KS`%&,)4F,<DI'L&\@\DK//29D';E1FB?X0W;;.
M(&.H8H>4IE#F*7Y>4IC"8`$/L$`$`$,K\UKX?U-U]LB"O*]]L%HCZQ(M9F&@
M7\-&,%5Y9G^B-5YN39KF3=MVSH"/"MV;!F#E8A"+&31*8BE@/\_WC]XC\Q'\
M8C[C@,8Q@,8Q@,V!KAN*LXNX_P`%JP4]_P#*752(4/Y)3C_!FO\`-U:W8"A%
MNGY@^L_<^1/O]I:`9,!`>NP\RQU@'H>A`I1^>!L;,&V'^MP_[M:?TS9G.8-L
M/];A_P!VM/Z9L"K/GEKIY==(JV*(*J::UC+I7%N*/8JEAS(_1]A53*`")SL6
MQVDN4.R@4D8L<1$2E#+`^+FY&F]]'T;8";A-68<QB41;FY3@8[&X0J:;&?;J
ME*0@)_$.B!)M0\O1V$@T6((D4*(X6Y;-WC=PS=H)N6CM!9JZ;+%`Z+EJY2.@
MY;JD'L#)+H**)*%'YD..5OZ4NSK@1R*EM97%\X)Q\VVY))U^P.P,=I7G8&!K
M&RKA40$B)X?U$JS<Q(?S_1J<)852&01`1"];/!A$"F$/F!1$/R@&>M!=%TBD
MX;+).&ZZ::R"Z*A%45D52%425253$Q%$U$S%.FH0QB'(8IRF$H@(^T0[`0'Y
M#[#@0>F>3LAK.<V*QM,2]LS8;-M-I0!1>(M7#^TU1IJM"IZE9-48HWF>W%S=
MUW$+**.7CDJK24158K)MTCCRKGE/8FEFL$.AK%K:6#>*W0>IJT:XNK#,62S:
M5;M3RM87:'IS&O-'UD=N%64,WAK79)B.=-P86"&CY8SB-9[5M^B*Y;+709=1
M**9P-/VBMNR0B?HMP\DI_9S2NNZW79D9=S*&;Q;**0?J2#EFVB5'#R2C84[=
MXP;MWR+_`-3SB_H:1E7LR_US$O'K]6UJK%<O9M5@F6]-W*%R:,H@\J,3&QEH
M5=K2D[$QK%I%R5A!"S.F:EA:M91$-!.N:R[6.@V(4RMN+Q+3][C7$4C:;V:"
MB8^@Q-1E'ZTP/YSYMCP,Y)*WB`CH^OV/6,.</4<3:L@,",8]E9GT:TI7FE5&
MZ(1LG#(VVM0=D2B)IL=G+Q1)N,;201LHU4*0S>18_$_"O$1*'IN$E"A[=#FO
M'/'73SN'2A7-24623EWTZ:5/9+:-K<R<I%-H&4</[M]/_AC)$E(!DRK\FUD)
MYRSD8!BRA'K=>+9MFB6XF#!C%,647&-&T?'1S1LPCV+-%-NT9,F:)&[1HU;I
M%*D@W;-TTT4$4RE322(0A"@4H``?7G\*'*F0RAS%(0A1,8YS`4A2E`1,8YAZ
M`I2@`F,81Z*4!$?8,_O*S/$'Y+N:G7DN.^KS+S&W=K()0KQM"+"K*5JMS!BM
MA2\C<3*(3ML2.I'12*H$,WB%)*;5,BFBS46",NMY4O);G'L_>"*@/J+JU`*[
M2G0`?X=<Z;9U7*\Y;%4.80^)(2T68%$_JF*[9J&(7UB#EKNM_:=7_P`VK_\`
MW[7(E\<]-,]&ZMA*:7X=:=6[FKA(-P`4WUE?))@[(@IUV=A%()MXB-[$0%LS
M]<ONX-DM-;_JZO\`YM7_`-8:X&\,8Q@5$,_V7*9_>L+_`%<P^6[Y40S_`&7*
M9_>L+_5S#Y;O@,CSR*:<APJ19GCI-U5.U1`.%GE2MT"WD6MJ:B4IBMXF64?Q
MY8::0$AOA2OCJ1D@"@MW"T>H";L9#8P.M_+^)1S!KTK(0<\6E0TU#O%6$K$R
MFN56,C&OVQ_*LT>M%YM-=NND8/K$.4/,42J)B9,Y#FKM<R#EVY<NUC$%9VY<
MNUA(0"D%9TNHX5$A??RD]14WE+V/E+T7L>N\[0'+#A90.3$6,L4R-0VC&M/1
MA;NT9D5^.113/\/"VQJF*:DQ#><0!!8IRRL0(BI&N/1,NQ==;K:VH]@:4M[V
MD;'KSJOS;4#K-S*`*T;,QX*F12F(&2(4K>5B7!RB5-TAT=)4#-GB+5XFJW(&
MO?B5?O#^2&/B5?O#^2&>C/8BBLX61;MTE5W#A9)NW003.LNNX74*D@@@BD4Z
MJRZZIBI(HI$.JJH8J:9#',4HA+O3_.'?&CJ0SU]0WE/1KK!_*R2!)FJA*O@<
MS#PSYZ*CP95H!D_7.84B^@44R#Y!.<``0M?X>;*YL;]<1M[OKZET_3I%RKHN
M0H0-+'>TTC`)D*P1Q+*E8PJ@_46M#ENL@MT=&&;/3^H[::.X;>&\831.S^1L
M28@E,1]7]2/DB]`)1`[20OY`,/F4*8"KHU$H^D0/(%B,J?U8A*ZY!!%LBDW;
MI)H(()IHHHHID22222(":22::92D333(4I$TR%*0A"@4A0*```>W&,8#&,8#
M&,8#.G;^:'9SDXRY$:OB]B3V[:OX?4E6*RVDY/3*/K12]H7?S"=W"TH.I.'K
M,K>4&HL`JT'?)1G7WD&<1B04>FEC!W$LH(\<?Q$MA<2ZWJ?0.IJCK^0N7)9&
MRLI.Y[AB8N8UM5*G%OX.!<E<1=B.6J24BZD["T<R#NV)O:S68-FO)R\8_!VV
M*D$H/!W;<'XSB%%Q'!>U3-JHS:TR;S8;V[@+3:9=GRC"-7F`V/#&;,B0TN,6
ME%)1+*,:%KI(%NQ"`<OVA5'BUJ^4V^"WP'<<)>/MHF[!LRH;.O'(:=A=AV*3
MUG)-IC5\1'QT6X8UZ%I<VR(BRL:**3^0<R-D8M6$<^6<(L8IDE%QC11>Y+`C
M=R]6X]$XT[D;<JYF%@>/\K2):%V9)3KYQ'MDH&73*P]-BX8E/)C/+/5FI*VC
M#(N)I>>^CDXALXD!;I&Z6_AK2-]B?$LH57\+^Z\GKMQ60O,2?<P;?C6\744]
M:K.W0W)W>(N#<K5=JFA%")J-,S,?7M@R=H-'`G$I"JNB;M[>(EPP@N>?%VY:
M!F+<^HC]X_AK?4;6V*9PQA[E4EEWT"M88TJB`R]:6457:S3`CANX!JN+YBX1
M?LFIPHA\&CF/MK1W*+_<I=H,M#[`KU<B;<%'VMQY4A)*-0FJE"_A*[3LUDJB
M+>)NB+V%0<,I.9F(QG>*_944(BTO)!;UA;!VP`^0?]OS_%W^/[_QYYQC`8QC
M`8QC`8QC`8QC`8QC`8QC`8QC`8QC`Q:X1`R\(Y32)YW340>-0`/K&.B`^HD4
M?GVLB*B8%^0G$G?R#J/&2PS0EW@!B)(72!.F$B<ZJ7E#ZJ#D?KKMQZ#HH&$1
M51#[2"<@?\4(X&%8QC`8QC`\"(`(`(@`F'H`$0`1'H1Z`!$/,/0"/E#L>@$>
MN@$0\]AWUV'?0#UV'FZ$1`!\O?F\HB`@!NNA$!`!$0$`BKRRB9V8K6K$ZL==
M.TQ6ZJ[::QZ"IT17L%.I&QK5%1ZZA#D#X28<PY81X50WI':R2Q3@;L`&/E>V
M*Y<W_<>^6MAD*W$[;UKJDU#F',='.FU5UVAN>T:_J$NY:6IRRK4"C+-&DU8Y
M*=LYR0T/^$3&7F6KQ!NFQ7"R[H>A'H>@Z`1Z'H!'OH!'Y`(]#T`_/H>OD.0O
MYP\;-O<J-61VK=6\CYSC<R=32[V]S=8@7TE.7*`"/.V9U,LK&6*N2,+#B^64
MD)A-FZ,:9!%FS<"FV04(OI%QNW8#MFSO".SC'EJI4>6<(PCFS*H.XJUN-?7;
M6RM<F):/BXI*.F9U.AR*]A^*KS5E'.8:-4L$*Q;PTI,*OM\L-N639&W)>KZX
MV/"GHC;:18%M/UR'KEG(\KT/HZ(OLM#0LT\3<Q2SR0M;D[0U@6"32CVJ[QFV
M(99NV,U#0_A_^%OJ'@6^L]TBK?9=L;>N45]`3.P[0R:0Z<=7U'J$F]A:U7V3
MJ0!BG*R;9N[F9:3E).8E!:M4#KM6J1VZMGF0NXW;GV5LRTJM;:,<1!Q39B>L
MM<!]2U9#7-K;7!&)C*NC'U=-2QQ#,(PTC'2,?L]R-L<R<.G-Q?GBG3U)O-'`
M8QC`8QC`9$?GK(VZ(X9\D9.BO'S"SL=6SJS-W&"J6009>HT3G#-%$/T9%4T$
MI))BNE]=!(ZJI1`2=A+C./EHJ-GHJ3@YEDA)P\U'/8F6C711.VD(R2:JLG[)
MP4!`11=-%UD%.A`P%4$2B!@`0#JI1GAY53<G'+6'(/A_:YN'L%7AX%A9U[G.
MN&\K?-L2,M%,W412A@RD_`=Q3IE^E%,GK\R#::*NB\:JII,7$FYV74^<?B)<
M+G_X*<C:-(;.I4),.ZNI+WMNZ<&.[@P1-*-(+<]=1>,IATR;KI>I]/?2PH^<
M@.3)&(IY.`VQQ<YD^&[LR8V3QI5L%ZX]?A0SNJ4<Q:.K3"Q812RZT9%;2H;=
M0SE8(%-<[=C:F2)FZS9%J\5?L7B(I$WKHOQ;]53T/%0>^*/-5Q[$4K8K&3F8
MMD6]5.V7NY/6CY>2E(44"R4`W=IIR#-=-XWEFS,KE)N"HH$%0@3)T]XO7%[8
M:31O?$;?I66<"8IE+5'?A)4?,'7E,6XU-)ZB@FIV/0R<3'@EUTLH4/K!9'2M
MA4/9,26=UY=*K>88Q2F^DZE/QE@:)@8.R^NI&.7`M3?>FZ*BH`@(&(`@(!4D
M;A7P8Y0IZVD]/6&`KTO/T:9;2T_HVQ,"E4M,'$UEP1[8J0Y^*9"Z244FROTG
M<3$.'OF[47\Z::V1"2\.?ECJ5K"[6T?8F=O56CVDTB^U;8GNM-G-B>ZOPRT!
M(+MX*U'3$@>=F$JNFZ-YB@P,!@((=EK&1@X?;3F-L:)JDK<)*5?[*KAGU.VD
MWL4$G5[-%7J"=*)OV=@KJ;5BG%OU6*L>]*5)JD@\;N"/4?,5839)_`8QC`^A
MJU6>N6[-N7S+NEDT$@_RU#`7L?\`)*'9S#\@*4PC[`(Y)N.9)1K%HP1#]#:H
M$1*/77F$H?7.(>_UE#B8YO<?K&'-:Z\@!#S3SI/KS%,E'%,`]^4>RK.@#Y=&
M#]"1-T/9?5,'L8HCM?`9@VP_UN'_`':T_IFS.<P;8?ZW#_NUI_3-@:,23]4X
M$%1%$@%4557<*D0;-FZ"9UW+ITNH)4T&K5NFJX<KJ&*FB@DHH<0*41SK1<T/
M'0XFRDY+:GH?&J1Y0U*KV$01VA8]E/M45F7DXT5FCN4URE6H2:MZL&Y$3MF\
MS*+13>Q1P?$)QZT<NS7/?YR(J]QO/&[DK1M=&7+L2Z\>=Q56A`U5.W=K6V9I
M,JVB&C1REVHV=OU/.P:KDZ,FNY3$#%'H0_,U%)1#]`505:J("+=5JND=!=HJ
MV$4%F;A!0I5&[AFJF=LY;J%*JW72405(51,Q0#M(ZP_-)5FHL%7-::[X0LG4
M<W<-86K0+GD5?;G+BM(.4F<7`1"TKK>2FG1#N5D&$+#HJ.!2,JBPCD0*9)`-
M][(_-%'*#3R46XVKX<BVO6TV_E8F(=VG;-CCV4C,P0MPG81L^+K)9D:=A/C&
MGTQ!*.$YF+!TW%^P;E63$W5)T/:$:1N[4-S<7-UKE&I[*I=D-L!E5D+RYI!H
M6>9/T;62F.%VR-K2@ET$I!Y7C+IGE6*+IHCYW"B29[4X^Q<?Y^XZLI4A7>+Q
M[5N+D+)TBP47AM;-J;%TK.TS>&L;'J"P;KM&L;RK)P6IMJUNY6*CV&@+Z_5C
M+.2(96A"<@(9I!PZCH+#?]].WCS`3^XXI7G$P$`@[XF@.*A@$2I@0=9>83F`
M!$"``F'H>@]AS*U_S3%NUK77]N=\"XUI5HMQ4&LC87FX;.TB6;C8,7)3E$(N
M\=:M1(4MSA8:5EZNL7S-YR,8.7L<LNW(50U:RN^>-=*G=6:6AD-"*ZO@.1NU
M=(;AF[/JRASMDM/'ZA:-U+JZ)NTO:9JIN;'`PVS=IP6R=DQ\M`O(ZR)6=\A(
M$D4CQR`'XR>YDQC75M8D1V%I*V7&;@?"WAG\/+:^UG;EH:NZKU5MBH\AHN=I
M\M1S5V(F("?F%HNQKNHQU*H56T,$8*1;Q,FU3;!8H/YJ:O8'!,>&M.!02F."
M8[UG`4$A3`4QP(.L?.)2F$"F,`"4IA`!$!'K.7B/S3WM6P(SCB$X0UB50K,,
MZL5A59;RF520T$Q>Q\<\E'X_G:%%)JV?RT8T6\H'6*L^;E](0,82UHW:X<#4
MM$WVM45QK=NDY3WS%.H=X^JX2Z^RY3D/9EM0[!JU;:Z;FMWV"LUC3AZ:-*DZ
MCN2J41C2VEEK%BB&T_(."2_+[6V/Q$EI"QR;B<XY*N%]2[4J]?IM5BZ3<:-$
M1P;QX[S.NV\)>=<:>U1;5&3ZC,-FQT'0KC5Y/>=(I["S@_O$HZLR;$`G^7\U
M-7HX").&U-.`&,03)[VFS@4Y!\IR")=8F*!R#[&*/N4?8P9HC7GCMZ9K6TU]
MG3G`9P>Q3"\BM-7)ER>N%RN:2\L`E?240WO]1+`EDE$A%KZBCA@)8\31S9RS
M:&$I:N>>MIU3<;'KV:UU8-:24J*&QF=B@]6CK:=KM;KZ%P;K:W1;W[6.J-+1
MM@C7=><O4*[5[51OSPM>PL6E'6RPRZTTU0C8!@`B/0!V(^P`'S$?NP/TN^.7
M(G4O+#356WOI*<<S-'LZCN.<,I5NBQM%,M44"/TY2+G%H+NDHRR0XN$%3D17
M692<<Y93$4X=1CYJY4E;K?\`5U?_`#:O_K#7.M1^9Q:;>H3C)R-NDZ@^;:^V
M!N>FMM<%='6(UDIFCU&6C=B3L2V4*5-5GZDG6JV[DVPJ)+R4(XCCG!6*,4G9
M7UO^KJ_^;5_]8:X&\,8Q@5$,_P!ERF?WK"_U<P^6[Y40S_9<IG]ZPO\`5S#Y
M;O@,8Q@,TOO+0>M^0=.7I^PX8CM(OJKPLXS!)O8:Q)')Y2R<!)F244:+B(%!
MTV.56/DD2_#2+1R@/D#=&,#JW[GX*[UU7LJ*HD-6938L;;9(S*C6JM1JPQ\O
MWYU?A9WS"=M5)1BU(=S)DE':<81J@XD64@X8I+"WM[X><"*IH-!C>=@%C+EM
M\Y"K(O`1!S7Z*)@'^]:JFZ2*HO+`4YDWUH722=*?60BD8]H*HN[%>O\`;^W[
M_P"'&`QC&`QC&`QC&`QC&`SK8_F@/D1J!:%U5PI-QP;\D^2>W0+8M4M%S33!
MUJX\\^?4R(LU8DJVX93DM<K%+M7<;%T]O(-H.0;1QWMR*XBB,6+[LG92]XQ_
MAV:1Y6Z3N'(2S2%LI6XN-^GMC6BI7.EK-?B9R#JT'+W-&D6:/?(K)O84\PU6
M<Q[^.6C)R"<2$BO'OS)NW#18.8\$KACOCA-Q&>Z_Y`R:#:V6_8LQ?X_7;&71
MG6.L8B2AH2,"!&29++1)I:7?1;JQSC2#.M$LI"1%!)V]=@[<GN)RE;P!MJ;)
MVUX<]#F=GW*<O,S`;`V;3(>:LLHYFYQ*JUV<;IP$0^EWRJ\@_3AT'2K".4?+
MK.$8E)BT%04VZ8!=3@1,YV:0OW)+B%O_`$9J^W$HU^V3KV3KU:L*SEVS:%>G
M7:/%(:3>,>W;.&M+1HYJTR\;D64:Q<R[7!LZ*F9LKUC_``6+36.!7,63X/\`
M*3BI'ZHY4['3?0U1WNE)K6.5GF"Z3VR15'4(D[D:Y'T>>90CI2LVW7QVK&<D
M8M%C<61WY47C/M"\V+G:M=</>4=]H\NM`7*F<?MNV>KSC82@ZAIZ%HLV_BI1
MF8X"0CV/>().F1SE,0CI)$YR'*42CU[?`#X(ZRV54JSXD>U[7L':.^G%RV;"
MUU*[30R\)69:*E'M9?707+XKN?L]OE(]R\\DI-RZS.'4D'OT;&IO`3?%#M7@
M/8`(?(0`?X\\X`.@Z#Y![!C`8QC`8QC`8QC`C=S#W!9./W%CD'N^GLX20M.J
M-0WN_P!?8V1!XY@'<O5X%W*,6\RA'OHQ\M&JKH$([3:2#)P=$3`DY1/T<.G"
M'YIQYSB/0:PXHB(^P`%5V:(B(_(``-M=B(_8`?/.\K8ZW7KA`R]6MD%#V>LV
M".=Q$]7K#&,IF#FHI^D9!]&2T3(HN&,C'O$#F1=,W:"S=PD8R:J9R"(9`3DK
MPKX=0G'3?DS#<4>-L5+Q6E-K2,7*1NCM:,I&-D6-!L#ED_8/6]:3<,WK-RDD
MY:.FZB:[9PDFNBH15,AP#JT&_--O.L@=GU7Q5('R[/4=H%#O[NS;9`._Q989
MX6GC?<I.;G,JD<>=HT?04'3K)4-BS[V1H4#=V%F3>5&NC+QR;5S-[!L$>5LL
MX#R/2J1BJAT?JHJH'^OE/7YGQUIKG;?.PE7VK0:5LNLCQRV+,#7;_5H2XP8R
M[64UNDUE/HFPL9!A](M4WSPC9]\/\2@5VY!%4GK*>;O6T3BUQFU;9&MRUIQX
MT=KRW,F[QFSM-'U11:I8FC211^'D&K::@H-C(H-WS?\`0'B*3DJ;E']"6*<G
MM@;XQC&`QC&`QC&`SX).-;2S)=@[)YD5R]>8.O.DH'NFLD(@/E43-T8H_+V$
MI@$HF`?OQ@1FFX5W!/3LW1>P]SMW``()N4>^@4(/R`P>P*)]B9,_U1[*)3&X
MC).2\.QFVAFCU/S%]S)*EZ!9NKUT"J)Q`?*8/D8H@)#E[*<IBCUFA9^LR,`L
M(+D%=F8P`B^2(;T3]]^4BH=B*"WM[IG$0-UVF<X>^!CN,8P-9V[9;.MV6,ID
M=5[/=[=(5V2N7X/51.`^/9U2)D&T0\FSGL<[`-G1ADWB3!E$Q:SV9?K"J*+,
MJ"1E38N]W6FM)_1=3U;LB_$+KNK['DUH1C4H8\76+>K8$H=I(PMXLM7F_IDQ
M:S+B[KY(Y1PS41(S7(1VH"(<7N74SO8,_7I=:C:LV5%0\2\8M8._KRM5G*O.
MNI%%R%MJ6P:U#3%@9)N6)`CIJMI`P*Z.SC)2.DFKY!<%,1@N,1'JJB.V)YUL
MKS:+H>JW%E6L5PAIZ7F8*2V(YLDM)EBI=@JZ9NV=LB&L8ZE9"5EURQSA62.#
MQ1RY?!F;'?;6S2X1^N=7[!V2F6AZ^V.:6@!H<(T;P.SH^6>50BA+G;J[(DDW
M#"$>%?-DVIRL2E2;*KF`?*7VO]\Q4)+6!N_UU?&E1J-\@M:63835K4'-6@[3
M84:F1B@YCF5F-;C1B3V[5Z)?2K*N.&C5T[.KTI'HJ.@T=$\?;_$3D?.3^O\`
M4VU'8:4TCKUPO8-B66I*QEBU?%V2/FW<>2+H4J@^BIQ268N6:ZB;%='X95-5
MB3V\WW6?CO<;#:M@2"-2UFP?V_:5=V)6]LGNUL-<]=&B(F@-TSQ508U=M'3$
MM".ZG*IPIG-C:1[].407E4R-TW#`X;FKF^XV?DHTBFO[[!UNQ;(L.JX6]R2=
M16KLO>ZY,6*N&CEFT1:)"SL$I*2J<TRAY67@V[-4S9!%==J#QMYM]@("`"'R
M$.P_(.1QU)Q\KU),I/V2/0E;HEL;:5VBGA++;96"ARW6\6J;A7<36Y22)5XF
M?8UJ>2C'4C&5UJ[;NE9,&KY7XM=TZD=@,8Q@,8Q@,8Q@>0$0]P$0'H0[`1`>
MA]A#V^P0]A#Y"'L/MD-=\\!N+G(=5U*W76S&%N#GU#C?J$H6G6TRYDQ3*N_=
M1B01TX)!Z,*<Y&OP4$H`<_63)Q@==;9O@\[AUS+)V[C3M!M;5X\R:K!E.R2F
MK]ELS@;W^C;G`JHU]Z8@`42E=C""J`>4X&^W$Z3S6YM<.G</K?=U3>34&P]-
MC%UW=,0O`RCF/;F,F+>G;9@2J1<R4!-YFYI$+"4QA`5!*0_MV5<X&S56L76$
M>5JXUR"ME=D$Q2?05DB6$W$.R"(#Y5X^10<-3B!@*8I_3!0IBE,0Y3``@&#Z
M1VK`[NU?4MIUYH:-;V^-3?/XA=TP?2,',(?WI)P4N\CC';.)&)71%LHH4P^=
M`&ZA2ID4(F7:V1RT_P`9Z7H2T6:0U/+V*KT*VD.\E=/G=)RU$C[,"A/0LM0^
MD05F*DI\)ZK)]"1[U6$D$A;*&;(*,6XA(W`9E]3JZL\Y!9<IDXMNH`.%?THK
MG#HWPJ(_,1,'7K*![)$'H!]0Q0SZJU2G<P9-T_*HSC.P,`B`D<.R_/RH%,':
M:9@^;@P="'_%%./9B;P;-F[-!)JU2(@W1(!$DDR@4I2A^(/F(CV8QA[,8PB8
MPB81$0]B:9$DR))$*FFF0J:9"`!2D(0`*4I2A[`4I0```/8`#K/[QC`9@VP_
MUN'_`':T_IFS.<P;8?ZW#_NUI_3-@:*(<Z1R*I',FHF<JB:A#"4Y#D,!B'(8
M.A*8I@`Q1`>P$`'*]N1'A6\#>4-\DMI;/TH]C-B3RYG=IL^J[S8-8&M\@<I0
M4F+/"P0J0$E/.!+YWLZ2.;2<@H(J/W#E4?/E@^,"GK_<'O#4_P#-[NO_`/N"
MMO\`W#,AK/@E>'_3)A*Q4Z#Y&U.P-F<FR0G:SR;O\#,MF$S'.8F9:HRL4BT?
M-VDI$O'D;)))N").X]TY:.0.@LH0TP=_<K*'HT/H,$U+CL5T1(&%(B%P!=L9
MT!?@U["]33<C$HN1.06C!-!S,R0&*#-D5,Y7)=+5[C5S)Y9%^GMQW1QHO7$@
M8JC*CLFCUM*.H]10!$BE3;/V2Z?::?U'MYE%WYSF(L6$*W4`N!!^V^%/X,5"
M44:61_?63QJ`>>+8<D[;.228%#R`0(^`C))8IR@7R^F8I#E\OE$I>@#-!3W"
M#P8XZ>JT;#4CD!8(.4>NT+58`W=LF+&I,D$`49OF\2[JYW5D%XX,9N+1DHU4
M:%#USG,4WE#L-:_\-+BS2VR03%5EMAR)2I&4?W.=?J(G7(/F.HG"02D-"ID4
M-^F15:.2^7ZIA-]83;_0XI\:6R(((Z&U*"8`!0`]$KRIN@]O=19D=01^\PG$
M1'W$1$1P.MO7_#@\$6R*@V:2.U8U8YB`5*R[UV/6R'.H/12E7EJ^W9F,(]=C
M\1T'8"8P9(>.\#/PQ)IDG)1%0VY,1RP#Z,A%\D;)),50[]P3>,VR[<_0_,I5
M1$!]A`!#K+@K=P,XH7!!PFYT_7X)TLD9).0IRTE47383?\JBG!O&K`ZI1#L!
M<L7)/GYB&`1#(9V[PV=A:P=N[9Q0W58(%^C_`'PE3;0]%D1^"1O5*R+8(Q(L
M2^*<0\B;6S5IPV6.;IW(H)B90H16'P'_``UC?IM?;L-^7D';1_TL<Y6#\#'P
MSX:592BVHMGV)-DN1P,+9=\WIY`R`IF`P-Y1G'_1CIVR.(=+MB/FX+IB9(YP
M*<<W9K[F!9:;:D]4\L*>YUA<T2E(G;%V)HZ"?$.IZ+9Y+,4Q<MFC%T<J@)V:
M">/JVJ8H&6+'%$ZA9_HK).$47#=5)=NX12<-UT5"+(+H+IE517163,9-9%9(
MY%$E4S&343,4Y#&*8!$.-KM>K=.K=>I=+K<%3:748AI`52H5>-;PU<K<*R)Y
M&L9$1;0I$&K=,.SG$`,JNL<Z[A118YCCM;6_ZNK_`.;5_P#6&N:_S8&M_P!7
M5_\`-J_^L-<#>&,8P*B&?[+E,_O6%_JYA\MWRHAG^RY3/[UA?ZN8?+=\!C&,
M!C&,!C&,!C&,!C&,!C&,!C&,!F(;`I<1LBAW77EA!8T!?*E9*9.E;G!-P:'M
M,,]@I,J!Q*<"+"R?K^D82F`JGE$0$`S+\8'3CX5\QI?P+=C;:X(<VJ7>WFJ7
MM[>;"TYN"E1*<Q%/HF:9H1AIB.B'*K%Q.5^UI1$;(R*4+(.IRGVM&=B96$43
M52<DN(2\?+PP%$D%3[XG$/62,H9-;4.U@4;B!0,"2X)5-4I53=^4H$.H4Q@$
M`.`!V-I^RM0ZKW+`FJ^VM<4?9==,8Z@0E[JT+:HQ-90GIF70:33)XFV<"3ZH
M.&P(K@'72@=!D+UO"3\-==4RRG"[07J',)C>2DH)$[$?,(`DDY(D4O?N!"D`
MH>X```(X%(WB'^,Q4^:.LGW"#P[J?LO;.S.0CM+7MBL:E.>UYLA3)95)&7BJ
MPPE%"RYW5D3'Z+F;-88Z%K=6K"LO).'JCDR!FM^WAW\4@X6<0--\?';UI*V2
MJ0CZ5O,M'^H+"1OEOEGMIMZL<9414/%M9B47C(I0Y4SJQK!JL=,AU!*&Y-,\
M8^/''=HX9:,TGJ_4Z3Q`K5^K0J5!5M[(MB*`L1O)24>S2DI%`BI05(B]>.$B
MJ?7`@&]\WI@,8Q@,8Q@,8Q@,9\$G*1D)'O9:8D&45%1K59[(R4D[08Q\>R;D
M,JX>/GKI1)LT:H)E,HLX<*IHI$*8YSE*`CE/N]O&AXYT:0?532;5YO>VMS+-
M2R<4Y-7];MW:?U1#\+7;5P\G2$4*<I5*Y#O(Y?TS`27(0Q5<"Y`1`/<1``^\
M1ZS0G*H0_N8N18>__P`1&X![Z'K_`.+NR#\^NOY\ZLNT?%VYH;'.^:,[A!:@
MCC"HB,1K6MM6<@'D5,)3_A-95+'.%6`@%`56+J.25('F]`OFZ"&]WY#[UN[B
M4-:=Q;7LPR`*(/&LM>;2^:OT%T?16;*QI9((Y1JND8R*S46I6ZR9S)J)G(8Q
M1#COS->8O^Z%)^X"/]S!LT>@'L>OIC5OOT'8]?P?/H/F(9W[O,`?,0#OY=^W
M?Y.^N\_/\K]ZGM:-(R4@45:Q/E8F10D(1%>!D&S-P<3*IJ2<&+!\"2HII@>/
M*X]%4R20KIB"9`#:U5\1GE;K]ZDYKN^=EIE17!R2-DIH]BASF+]4`7B+:C-,
MU4A```Z)DBD/U[@'V!WKL9U5M*>/7MN`<,6&[M;5C94*7TT74W3Q-1[L`";]
M%?'8+JOZC,+@0>RL6K6LH'.'_P`*2#+XN+_/+C3RX;G0U->TOPM:MC.Y/7-I
M;_@Y?XY`@B"KCZ!=JG"78HB``K*5UU+QJ0F3!9RD90A1"8^,8P&,8P&,8P&>
MM5))=,Z*R9%4E"B51-0I3IG*/S*8A@$I@'[A`0SV8P-936NFRXG7AE@9J#V8
M6BXF.V,/7?22@>95#L?\$P*D#OZH$*`!FLY&!EXHPE?,%TR@/0+D+ZS<_P#Z
M*Z7F3^7OT82F`/F4/<,DSCY_/`B?V`_(>\9)5Y6X)\(F<Q;0QQ#H5")`BI^7
MU$!3/WV/?8CWG!*Z]KB@]D3>(?B2=G$/_P#,"P_S_DP-#XS>/YV]?_;I/_I2
M7_=L?G;U_P#;I/\`Z4E_W;`T=C-X_G;U_P#;I/\`Z4E_W;'YV]?_`&Z3_P"E
M)?\`=L#1V,WC^=O7_P!ND_\`I27_`';'YV]?_;I/_I27_=L#1V,WC^=O7_VZ
M3_Z4E_W;'YV]?_;I/_I27_=L#1V,WC^=O7_VZ3_Z4E_W;'YV]?\`VZ3_`.E)
M?]VP-'8S>/YV]?\`VZ3_`.E)?]VQ^=O7_P!MD_\`I27_`';`T=CYB`![B/L`
M![B(_<`![B/X@S?B%`K2/0G;.'`A^WNU^A_$()&2*(#]O8?S9D+.%B8\0%E'
M-&Y@'L%"(D]4!ZZ[]4P"I\O\K`T-%U.<EA*9%F=NW,(=NG@"W1`HC^F(4X>J
ML'SZ]),P#U[F#YYM*#H<7&"1=]U)O"B!@%4GE:)&#W`4VXB8#F`?D=<5/?H2
ME((9G6,!C&,!C&,!F#;#_6X?]VM/Z9LSG,&V'^MP_P"[6G],V!HC(=\J^1K_
M`%2SB=?:Z:JS>Y;YZ#:MQ[-H$FO!M9!R+!K*_1P%/\;,2+SSLZS&'3.FN[36
MD'9#,FGD<29O5RAM>TZRW>P*^E$5>'>2[SH?T1?X<G39D@'8"9S(/#MV#8A1
M\QEW*8%`1]LBMX>.I);:-LMW,C:B(OK!8)F6B]>-5RF%I'I(E^CIF<CTC@(%
M;QJ1/P-K8D-TU:L9E<"BJZ36`-X\0.#T1J,B&U-N@C=][32QYMS)22QI5K2G
M<BF"SAM&JKG53D;/ZBB@2]J.!E?7\[.#,UCR&6>V)@`!\O\`;\?Y?QX^7RQ@
M,8Q@,8Q@:1WMQ]UKR&J"M3V##%<&0!9:!L+'R-K%6)%1,2!(0LCY#'2[[*+N
M/<%7BY,A"I2+-P0I!)4?KRV[#X8[7;<<]YOQD]:3JWFUI?E!43BXYFX<F0:N
M6ZJXJ';0*[M5%A/PBZRAZA+K(NVQQA78JKWO9%SEUQVBN2&H)FJ"@U3N,.FX
MG-?2ZY2`:/LJ#<Q2,55Q$#$BK`@`P\ND(F2%%PB\%(Z[!OY0^+_;Y@(?P"'8
M"`_8("("'N`B'OFP-;_JZO\`YM7_`-8:Y79PDV[)WO7DA0+<5RC>]0NDJM+I
MOQ.+]S#)J.F<0L^%0PG-(Q:T>^KTD(^_J1K54W0N<L3UO^KJ_P#FU?\`UAK@
M;PQC&!40S_9<IG]ZPO\`5S#Y;OE1#/\`9<IG]ZPO]7,/EN^`QC&`QC&`QC&`
MQC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`R._)GE!J?BAK=]LC:LW\(V`5
MVE<K<>";FT72=(W.X1@*Q%F4(9X]5*4IW+I4R$;$M3"_E7C1H3U#9;O/=-'X
M]ZKN&W-AR`L*S3XM1\NFCY#R$L^4,5O%0,.W.8@.YF;D%6\=&M@,!3N%P46,
MFW265)TU.1G)797*Z[R.P]E)D,E)/7)*)4$NG3"@U$7`?!5^'+TDDX<J$]%U
M/2ZJ1'4[)%.\6%)L1BT9AP7,#Q".0_,N<=LK*;\$=3I/15@-/0:SM6O(I)F`
M&CJVO2G:*W>>$"D5,YE40B&3DQA@H>/+^B*1IJ="EY!P@YE&L?#-TNE!!)D!
MWP$]P`XAZWIM@Z$/+ZACJ#\O2#K-R0U?9L!26=-V[E?S`8#E`13;E,/_`!:`
M*"?R+"41`Z@G'W[!("EZ`=C-D8UPEVT;%21$XE$@F[/YP$Q1$X@/N)?L^0``
M@'S]\#4R,-$I$'T8YJY%,QO[\?(`NY5$!$!./JF,4!,("'92E`"]`'77MS0_
MWL982MVWD^0^1$I3%Z+_`(!2G#[Q'H`^8>^<N1D@`&Z`Q1`#C^F[+V`F[^J(
M>_?0_/[^_LSZ%V2)E#^;S#]<0]AZ#H``/<`#KW_V^>!C$@BH8B+E#TW":B90
M`RZ8^8I^Q$2&$#?I@`/8!`.Q'H!S%7T>B[`2O(>-<%\HE$%H]-7OO[/,;S"'
MY0,`A]GOFZV;5F2/1,HBF9,$0,H4XCT)`,8WOV(!]4/D/S`>NOE[<(N#,RWF
M9-BHHF*7R@<P^8GF`.S',`_5*/?7V#W\A]^\"/<AK^-=D$[%BTC%NA\I?@S.
MD#&^?NDHOZA>@#YI*$Z[`?*/768."%OHLU'34>4L!+1+LCR#LD"J[BY-@^1[
M41>Q4Q'NVTA%/B_,JJ2S9V4.P()B]B,O$DR&0=()(H@JLD8@*BF'F`P%$?J"
M(B;KL``#&'OW`?;K,"=-4EDUD':":Z1^R*I*D`Q3!]QBCWT8ON8H^QBC]8HE
M$.P"Z3P]_&3?/Y"&TYS'EXY$[H4(RJ;V,5%@V!P!019Q6TT$B)M6YG(@FV;7
MMFF@V,X%,+0S;^JM/#V145DG"2:Z"A%452$4253.51-1-0H'(HF<@F(<AR&*
M<AR&$IRB!BB)1`1_.<N%:&$,+UF4R\6L;R'*?HYFAE!\H)+]@/J-U/-Y"*&`
M>^P25[,8HGOW\'SQ(WK*7@.(F^;$X?1\J=K$:'NDPY*=:*>%3]%IJJ;?+CZS
MAB_\H$H+YTJ=5D[(-2444;NX!-J'9PQC&`QC&`QC&`QC&`QC&`QC&`QC&`QC
M&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`S!MA_K</\`NUI_3-F<Y@VP_P!;A_W:
MT_IFP*??$&L<FYJFL]1P*QOI79]X;$7:H^<SAPRBUV;&,)Z9!_1&ZEBF62BB
M1@,54[$G90\GF"X?7-'AM:42HT"O)%1AZA7XROL0*0$Q53C6J;=1TH4!-^CO
M5RJO')NQ$[APH<1$3=C3UM-`UL\0OBS5W!NV4"VB;&DF8`,7XAH_M5I4\Q1[
M`044K3$@B(#UY`Z'H`R[@/<`_(&!YQ@1Z`1^X.\B#(<N(>+F>2,`]I,PVDM!
M,G$M%>M)-2,MH0\97:S+6-Y7GA6IRQCBKREJB(2?CWZ;APR"3@I;M1E-MBIA
M+[&0\L?*.=KMDMQ5M9,76OJ3N6GZ8F+*WV&V+<%YFXA04&<M$:\5J@%E&#:2
MV)#-EF3:V_3#AJUD7C)@NHBBS7RRK[WMMPF&4I7]/S<GJ*2O,I1&&PFECC%I
MU8\5*OJVO=SZ^*P!TEK92RQKN/1L/X1'FQC`1M*U62KBIGZ827QD7)SE'7XU
MEO!TQJ-L<JZ.F:-!S"$W'.ZB,^[NSM@V2=0!9QBF\<PS(K\JJ,X+$T5.`DH>
M$<NV@IO#[)W'MV)TS4D;9+P=FGD7-@K]=09UJ%D)0R3JPS;&%0?2[YLV6CZ[
M",U'I7#^;G'#&-1*0K4KA1^Z9MEPVU@?<!#[_N^>>`'O^,0_B$0_[,\X%)6R
MXO\`.`\1R-?M3`SJ?(>'26?)^H!6Q9:?%6->"?I,J8*)W*"CY)-,!%3SS9Q,
MI^CB!K1=;_JZOV'7_!J_M]WZ.U]LKM\41-.(O'$RW(_4>1]YF6QEBAT?T6TU
M09=,OF^8@0Z"PE#[/.;[QRQ77G7X1/?+^E%D[$O_`*(NVXA_-U@;MQC&!40S
M_9<IG]ZPO]7,/EN^5$,_V7*9_>L+_5S#Y;O@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@
M,8Q@,8Q@,8Q@,8Q@,8Q@,"/0=_[?P?C^[&1NY>;T;<;.-NW]T*^BH_I=.D'%
M<:K>02/[?)BG"U!@9(ZB0KD<V.1C2KHIF]4S4JYDP[+V`=;OQ<N6SO>?(=/0
M50E%E=5Z+?N&=B2;K)GCK+M,A56]AD#BF0OKIU!LM^"4858RI6\J-G71Z%<H
MA`:*;MU`;OCE],ZC;T4$C=`+=L(`4OE)[>YP`H@8.S>F!>Q^L(!JBF).9Z0<
MR4T\7?SD^]=S$[(.3&5<OGKYPK(2+QRL<PF5</WBZ[E94P]G7<'-\QZ';$CY
MBF3*0?*!/D!0Z\H%^0>P^P!T'0?8'L'M@<AZXE/T3KR@(^<INO*8"B(F\W8>
M_0!["`@(=`("'0=<Q".BD<%;]]$<B/:8^XD6Z'R&+WV)DS!]4W78E[+V`_/,
M9(NF'JF4,4$RA^B*=AY$U%P*4A%1[\J9E1$P$*<Q1-\B@8!SZ"N09&*Z]0B9
MDS=HG,<I"%,'0>H<Q^BE\HB!2@(]&/T`]]"`AS2YBMQ.02"*GUNN_;R^XB'F
M`?</;Y=_?W[Y_1UP,J8AB@!A/]40]@]P`.OD/7W!]_\``'7'+O4A."[ETB"R
MQ04$%5T4SJ"(=&$H'.01#OY"!?+_`((?+/[%=!PJH"*R*HICV<$EDE1*`@`_
M6](YO)[`/7?0CT/7R'`Y:17*@R:,Q$Q?42`RHB40,)`$0(0I3!WV8WUSC[`!
M0+WF/BN;I,H?53`OE$@?(1+V7LP_,P@``/O[>W0`'R#RZ?J/5P*X5*9R4OE3
M*8Y`,JBF(^P$]A.)`]RB4/K@`]_+O/B47)T1%,Y!5.8X`3S%`P@8._,0HB(G
M+Y@'L2^P``@/VC@<TBJDF=(_FZ^9^A'ZWG,'8=!UV(^7H0Z#KWS&Y\!!7UDR
M^5)P(B)0``_1/<1$WW`8`\Q?Q]@/MG](J?WZ':I0]03%3*80`3@4`*!2!V43
M"!0#L"@/XP^0YRCY-`S84U52%,H(^D!A*'F.`=`!0$>SF[Z``*`CT(]AT.!K
MY=LDNDHDJD15!5,R:J2A?,10APZ,0P"'N!@_&`@/N`@(`(1MM3)U4YI'X-PY
M:J)+HR4-(M5CMWC4[=<JS9=LY3$JJ#Z.=)I'173,55)=-!P0P'ZR2BJAO,<@
MD\OE$Q1$OWA]H_=^/[?;-?WR"),0BRQ0#XJ,`SU`P`'F%-,/[Z2\P^_E40`3
M@7Y>HD0>N^\#N4>&%R^'E]QCKUBL<BD[VQKY5*@[93`J:*SNPQ[-):-MA6R9
MS`1I<X4[:8\Y")(%EPFF*1"_`G*6Q;.EOX*._%-.\R([7L@\,G4^0-?<T)VB
MJJN#9*Y1)7%CHK_T4SE1,Z67;3-<266*82DL'ID$#&*`]T@![`!^\.\!C&,!
MC&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!F#;#_6X?
M]VM/Z9LSG,&V'^MP_P"[6G],V!3_`+,<&JWB)<7K&Y((,IUC$U]!3Y`9R\=6
M^L'`>Q``!->?8"8>Q'H_L'R\UW`>P!^0,I`\02$DXJ$U-N2!15"5UE>FX+.V
MYS$6;MGZ[*7B!`2B!BE&>@DF_J`(`F=\4#"`*!ERE$N$/L&F5>\5]<KB%ML#
M%V&-5*H13^]95HD\33.8@B7U4!5,W6+[>19)0@@`E$,#+!#L!#[PZR$VUN(/
MYY%7VLR:W)*N7&Y[0D]A4^X-80SE:KQ]AI%(H5LITLS.^(,_`VZO5B183C8B
M[!,X2$7(-DT9>NQSTLV<8$=ZAQOU]![$V!M*P56D6>\VK9*E[KUL>T^*5M-4
M:A3JC5V42TGWB;N1]1BI7'KQN[9K,R(IRRB"""1P76<8[5]%[(J#N,IL'ME"
M,TC#75S=8ZOQU8>,MD%9+V%[:2:S7OR=E&./0$9QX(*K)5=&TR%93"H/90[-
M1Y(O)58P(H['X[S=Q:<AQB;;%1DEN9OJ\T(I(P;Q\RKK_6R;0R9Y5!I*LEY=
MG*.69#'19+QBS=`YR%6.IY5`R.?USM;9&L+92-DV?7J4Q,2U><P\K2*M9HZ-
M9QL//P4^NA)1\_:9EV]?.5XIPW2<-'S-NBBNB8[90Z1_4D7C`\`'0?PF'^,1
M'_MSSC`CT`C]P=X%/WBD&)*7#B;5TNS.Y"^3:PIA[F])>6H,40W70C]8[DX`
M(!_@C[98KKT`"Q/0#Y`R=@7\@.VX!_,`95UN"4#?7B-5NOM"E>5?CY#H*2AR
M@L9N$M"^>?D/5*8P%(L:T3,!#@HF7RG5B_(;S>D(A:#K?OZ=7['L?HU?L?O'
MXAKV/\.!O#&,8%1#/]ERF?WK"_U<P^6[Y40S_9<IG]ZPO]7,/EN^`QC&`QC&
M`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC&`RD/QTKBHRXZZPULGY2I[$VZ
MQ?20B<P'/$4&$D9T4RI@(%434G7L""AC#]0Q4A#LP@&7>9URO'BD5@G.-$<0
M>TTXG:\@0H_(%COJ"U,<`'V$X)DZ`>N^NP`0[]PHTI[3T_C52%-]0$&X'`.@
M`HAYS@'7?OT5+L0^7R_%F6%*H\D6<>90$3/7;5D1TIT*;4SQRDU*Y5`?84VX
MJ^L<!'KR$,`B`>X<)5#_`/!JPE]C+.U#=CV`]>DB'F$/?W^?0>W78?(,^QX0
MOJF*;ZXG()!+YA*(@J`D,4YP$!#V$?J%]^O<#%$`'`LNW/O2_:$W59-2ZX19
M1NE-.S\5K@-3/J[`/JKLMC"L8MO97]]9KQ3E[:938KY21D%YY^X<2L:C)L?H
M-PT49HBIQ?$^KST%==][\@-$3MH+IY$L/3M)/*Q,W5XQN6S+*6/C:]*1:D2G
M,.$J'16]E=NI%Y#MG")RQ2[M)LZ<IE6U4GRIJ,O(P6PM@Z&@K_O.LLX!LSO[
M^^62*I]HD*FP:1M7L^R-7,6*D?:;%"-8V+`QV$[!14\O&-5YZ.=>=<BFM9_D
M/?+10V]'<R#UH[?;5NFY;Q;&LU)H6"_WFXL&,6#Z;4:F:)H,X&-:.6T7'ME%
M&PGDW;@Z:9R-R$"?M0;VO1W/*(T5#+DC=4[`WG4[.G4IBH5A<DI1=BD;34-&
MO23\`^F8SX.'>%K3V/:NXXS5Y$.2&;MW)5,BI;"<B.1LA:56L%9-EQFKI.PG
M=*5FF5MHVJ44]>OC$4E5:O"0IOAW#.OF.B>2,\,1&-<"@9,PK^KQ<?R9L;6T
M\;+O(5R-F;3QQ:L(V/FG\Q+F>WN%@K"\GZS&VA94CD[<\`21>Q#>19"X<NHY
M5(')/,V3*,?)1^X?R<J^\QT%)%^^?'(BJIY4COG*SHQ"]"05"(G7,4GJ=^8H
M!V`"8V!8'I&PM9N*J;R7U/KFG<.*S4@KVZ[EL*I5%W*WZWC!/5[9(T[8+J/3
MOTOLV6G',>775:HK]4M23;L$I9NW8A(J*<SK2.J[:U<8>.7X!TV1H&[=2TVP
M;0E9>FUZ1V#)6O<C.U/8^RQ%_79J6&OKT,B%71A6=?>LXMHI$2HNVKT)%V)H
MYV?DIK2UP]%B+GQHKMA'7E(A*+6E4]R;3@H]C'1#8R:CYE6X8486/D9J05<S
M4^Z:H_$S$J[7<2#ET82B7Y*ERM;5B#I4FXU@SE]RZFJ4A0]2;2&Y3+".K%7<
MC.A"C8*`BQ6C+A8:.C9IM"G3"\K&H(E79&FXZ7/&MQ,&V*!,1&JHSA[0B4'7
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M<T1M:,$#F$=(2IWB`2AHY^Y;F"/>\J(TUWMK9]*C%A<1]/V%<ZJS6,83G490
M5CDHY@=0XB85#BR;HD44$1$ZA#'$1$PYI[H#D,D8H&*H!B'`?<!(</*<!`0$
M!`2B/S]OOS:%BEY&UR\Y.3;@7LK89:4FY1ZH'2CF3F'SB1?N1#L0)ZKQTLH!
M0$0*4P$`?*4!S`TF2Q5#E4((`0X@;L._-T/?W^X>_L/VA\L#2VMY)]K#:E,O
MK;S%=:YV#6;>T`AQ35,-1LK&:3`IP]R"L@Q,CW\@!4QA[#V']$^.>H23!G(M
M3^HV?M6[UN<.A`Z#Q$CE$P"`B`@*2I!`?D/S#VS\^![774G8I-($O(W654(!
M"I"9545$"@;R=#Y2@7L3J*J"0A"`)A\P]`/?4T*LNYT;IERZ/ZKISJC72[E0
M3><5%U:?#'6.)P_3B=03&\WV]]X&V,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q
M@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,P;8?ZW#_NUI_3-F<Y@VP_UN'_=K3^F;`BI
ML6C1&RZ-::'.%#Z-M$.ZBU5O*!CLG"@`K'R2/8&`'$9(I-7Z)@`1!1N`!\^A
MC?X<NXI.E25KX?;2.I&W*DR\P^HP.U#>C(1@F^-G(".%3R^=)LHH>UP7D%0'
ML'+NA1\A(WTQF4W;K.UTFR!/467.!$R]@4.Q[$3&.80(1,A0,=10YBD33*8Y
MS%*41#KG<S?%>\/.L;U:KU:$WYN'9VJY(D.ZVKHFR4O7]%5EH%X<Z24)9[2G
M*2-T/69`KM@WG8^!;P+]%1RT;24Q%`D`!VV\9U=*Q^:;-=6J6AJI5N&._KE:
M)A9&,AX2`L]+G;+8)$43&!O'0<!%+.Y&1<%157%I%QYA'RJF0;)HI^4GJ/\`
MFGO5J<:694X;;P3ASRCF"++*7&EDBS3C)J@_>0I9$S(&9I=HQ=-GKJ,*L+YN
MS<(.ED"(+)*'#M(8SJP?[Z0TQ[?^])V_[_+_`,OZ![]_+K]`]^\?[Z0TS_S2
M=O\`W_K_`*#\OO\`_@^!VG\9U94?S43I]RJ1!MQ"W,Y74$P)H-KS1G"Z@E(9
M0X)HH-5%5!(F0ZI_(0WD2(=0W1"&,'O>?FG_`%3'?!A(\.MVL/I&-93,?\==
M*2T^D(>33,M&R['XAFG\9%2*)#JL)%OZC-ZD0RC9=4A1$`[2>1QY3\@(7CEJ
M*?O+Q5FO8ETE(BC0;E8"'G+6[2/\"EZ8`8YV$80%)B84#R$2C62Q!5(LN@!N
MO=_OI#3'7?\`<D[?Z^_\/Z#U_'Z'61MV-XY/"KD-M"I7'=_'GE6A#5H6Z#&&
M@[]JN=JT8W(LDX>`--40@G,L27<HMUIP3V9%Z^3;(LDURL4DV8!=#P>U7,UB
MCS>U;HHY<WO<SXMD>N'Y!!^G`G<.GS!5T*@`JF[L+Y\[L+M+ZI2H+Q:8D[1`
M<L@UO^KJ_P#FU?\`UAKD==-;@U;R!U;3]RZ5MK&ZZTNS)1:"F&C96-=,G+!3
MX24K<_!N2IO:Y9*\[*,?+P3U)-9DJ0@I@HU405/(K6_ZNK_YM7_UAK@9KL39
MU"U-7PM6QK1%U&O&D&D466F%546@R#\%A:-/.DDL;U5P06%,/)T/IF[$/;O1
MG]W'Q,_\^U#_`.G/?_R_-U;.U/KW<M:"G[,K;>U5LLDRF`BW+R29)!)1X+`S
M=>M%/6#KS(`X6`">OZ1O./J)GZ+U'W_<_P#A_P#^92'_`/ZBNW_B;`A!KB^T
M_9OBF.[G0K!'VFKR.LG;=E-Q1U%6+A>.H44R?))J*))&$S9TF=!3L@`!RB`"
M/OU=+D==;\3./&HK0C=-=:RBJU:&[%[&H3",E87[A%E(D(F^11)+3#]NE\2F
MF1-14B(*^F!DP4`AS@,BNP#YCU@,9X[`?D(#_#GG`8QC`8QC`8QC`8QC`8QC
M`8QC`8QC`8QC`8QC`8QC`9U]/'4I$O(-^/-X9HE4C84FS8*26$P?WNK)_@9(
ML1$H]B(*)QSX>R@(@*7?R['.P7E97BOU49;BVXMR<4I*&US<ZY8'Q"&``1@)
M51>K3:ZI!`0400),,W"Q3`)2E1\Y@$"^P=4JEME1BG(ID$0(Z.85CF\QE/,B
MD)CAUWY0^J(%*`@(>X=Y];M$Q%.^A`Q@[Z$!$"B(_6$.P]Q$.BE^0![YLJ$9
M0LDX7&#55C6JA/.K%.V:*::9B]F4,@^0,(F#HPD%NL'F3`"^F8I2B7.+DV*0
MNC?X```%#RB!RB`=@`%$3EZ*/V^4/<>Q`!$,#`P2.?H``??[?E\OQC^3-\\:
MM=5+9.Y*O4+R[<$@W[.SO2132>95A[;)V%K,K+UJBL[-(D.PKSJZ3C-C`HS+
MDIBLQ=CZ0?$J(&+K4L48W7I@18P]^4#'#S"(?(OUB$,`_<(&$.PZ^T<V9J^*
MH#2YIL-RPDLM2YF"GH9>0KX+.YFK2TM'J-Z]=F40F]8I6(:O*E0?.JXZ=I-I
M=D+EN83+%0*8-K;-B:6SK<Q$6?CQ;>.FW8^3@%*C%MU-B/ZS;H!T9PE96%B:
M[&<OWC2:B&PL9*%L%<>JLIU0[IBXBFQ#MUPX*Z<:[]4(>W23Z6H<C/:]B(VP
M;)UU`VY*2V1KR$E#,DTI.UUX&"+1-O'+2<6WL24+,3;NKKR3)*P(1PJ*"E(H
MFQJGJ;4%HUXTW>\Y'GGIFA3%'JRM7NT73-7R-.M;&RO+05WL9$DE&3LHQ8_@
MTG7Z<B:)7:2#U>8=N$V[8A]C;OY)0%MKF[I6!VE%O"[D@9R&@M:06@:74[Y`
MDN3UFZL<1M/:BU/`9>OQ2";ELT>5:Q2D]<'*,2_D'D2H@Z.<(;VCBO<];NKS
M'7IM2)JQPFI;;?7-:@=IMRV"@QL.XJ"D;=[)&L(IR5TV?L[&D>`J,@X8.;"U
M=+23D\:DP:@_PG^YBV$2"3?+3.O6UM<T);:;/43JXII[=>:\1CUILUF;5(8X
M68E/7&[FU(0"T\A:W%7;K3J,$=GZ8J;]N^V*C8-R\L+:R-+*1&ZM.6ZB4M1:
M*=$>+S<XVURWCR2;4Z@&C&90JTD4[I8WD1(BU)T!5DBA(*?Y3Q+YF2_L-H5^
MGR;75$=4PU.WX[T>4VLA?8S7:5"`D?NB8IDLQ-KF241^E'4XYGBVEA7W+VJQ
MT$DH1DY3"O\`>\9[M'55S8W5GU<,W&T:+V;*ZN1O;4VV8BA3+=C(,Y^0J1X]
M-J'J0\C'3YX5";<6!O!OF\FK$@DJ)2Z@3:+>AYC)><I>P$.^C`(=@/0]?B'H
M>_+^+[1L-+L?4#[4J4->]@U_;45':E_!JBZ]M^H'9-]:ZV*E!-F$*,-O",CX
MN,-KZL6!,SV-6DK#..'-/2;UH:\B[`Q\AFI%I-T&SE=T4K=8@G,W01*N=0P#
M]?L3CZ:13&`PB(^80`0```0[$,-CX-S(E]<H]-FY^E%!,`&]P`?((F-V(^_0
M]`/91]O?ZHY"K74ER@N50C<R103$3)F5.H4!'RB@EUT4Q0$>E5""(#T(``!T
M/T+3:+9+T6#$R:/Z4@"<"B`C["8X$*8!'OHXCV`F$>Q,/68H]L,@0%C"":23
M9)510Q0%01,0IC#T*@"(]]`4.@`>^A^0A@>\T,W;?23I-91)0XN.@!N*BAOT
M+R=F5%0#'\X@`@7R@7O[##[9W:=1PJU;U3K.N.1[<0&OJ7"+CT`=K15:C&*H
M]![!VH@8>@]@^09T?](5::W%OO36MB*N9'\/MHT^(>L!4,5-*&"8;R=G45*!
MR%!LUK3&8<*F^9DD3%`!.)0-WOTRE(0I2`4I"@`$*4`*4I`]B%`H```!2@``
M'0=``!@?WC&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,
M!C&,!F#;#_6X?]VM/Z9LSG,&V'^MP_[M:?TS8$*>1;.[2/&KDU':R^*_/*D.
M.FYV6O@8#Y9(UN<466)%DBS]=IRBA?B$XY0H@8CLZ0D,4X`8/S,D?3]!#T@`
MJ/PZ`(E`/*!402(")0*/N4"I@4OE]A+UY1`.NL_4Q065;+).$%#)+(J%524(
M/1B'(/93%'[P$/D/L(=@("`B&5+<B/!.X&<C-@3.SW4-M#2MKLSM:3M#31]A
MK432Y^:=K*N)&=-3+36IV/@)2264]9_^#2\9&NW/JO5HXSURY<*AU*.#]VUY
MI)YM[D1<[Y8J9;-?4QA2='CKHM3E=L,]L;8?N(DVQ*A6+;+P<:]C]9T"$N3B
M8F7,FR:Q,E9Z\V!5=Y)-FBUC+R5T%8G$X]UL3AS:--;>YK1G(6T57DC<M<Q]
MJU3Q\W=H[6S_`&VTKE=>7."<5:VTJV(7VG21J,A+[%K<E7J@TI359O)'6>V@
M_P"]U>"W??Y[/+#OY=_3NIN^ON[_``![Z^\/MZ#[L\?[W4X*_/\`/8Y7]]@;
MOZ;U)WY@^1N_P`[\P?8/S#[!P*7H&N\'7U4T9^$2&EZ]K=ELS4Z2DC*2E`E[
MIL"$E9#8#>P.+];:C<(;D13V9'J5)<[^K&UM<*U*HULSEMJ"WL_0CI&>PVTR
MNGJ9KK:-JN^N^$;KDT3CK#)*4S5J5"N.GXBYR_)NOUNNV*IUNGVJ;U\MN%KI
M5S:)"Q0].E)&%9UE"G6RUQ8V$TZB:]/_`'NKP5`1,&V>6`&$``3!.:E`P@7Y
M`8WX`]B!?L[$>OLZP'YG6X*%\HEVURN+Y1[+U.:D`"CWW]4`H/0>_N/778]]
M_,<"NR+-I#2?)>16E8#@W0I&M<@@HO&8:&YUFZ5&BSVE]QP&V2<A4)NQ/#0"
M,=97&NX]&Q;F:UJ4@=CRLS!4M=*@/)`B,5-)Q''YW4M5",3P[FKB>.XQQ/(Y
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M/O\`5S4OS^7?ZP?GU[=_/KV[ZSE87\SQ\!HV3:/I2^<J+.R:K)K*P3VZ:\@V
M4F"9RG%H\DX*AIS+9JL`"FN:,<-'OIF$6[MNJ!5"AJW\S?,+TWXT<FY"8*_)
MK>3WI24:""YA"/6N450WB6S%XY,P`)C$CG-#9R2R?F2^-;IMS"5TW<%#LOZW
M_5U?_-J_^L-<TAKW7M`U%0JIJO5%.A=>ZUHL;]$5*FU]-0D=$LS*&7<*J+N#
MJO925DG1U'TS-R:[F4EY!59Z_<K.%3''=^M_U=7_`,VK_P"L-<#>&,8P&:_V
M34YZXUXL97=A6G6K]N^2D#3]1;5QU)KMV[=T4\6HG9X6=C@9NE%4E5CD9%=`
M=LD"3A(AE0/L#/Y.0%"'(/8`<IB"(?/HP"`]=@(=]#[=@/Y,"JG4>[MQU#1^
MD]RS]GM^]K-OB\(ZP9Z^FGM*JD-#2SF7NS>.E8.2C*HQ7*Z<C5F;-[].2)X]
M!J\>O2@51LB@MMI#DM::`XY7V?8T7(/E=3-]%D8Z_BIJ*D(R/M.P*3$`XK5=
MFQ@H=T:.=V^602<S4P>0.9'U)%LT9H@$9FZH3BW08&@Z8UTTEK8I"Z-V"SV/
M5'+A]%FDG\VQ>61\DUGEDX=-NZC#*VA^51%BUCG)DTFH`Z*8BIEN,VAQPA+!
M7.1SB&8&L]DWTPJ:LK`66R+UV`3E*)$LXFOFAYN$A7DO77*9&*,BE(J(30(3
MB#5P9M\"59J(1BV3RLW0A9%M92]18ZGN52O'%]>??URUMKJSF8/:NSRU^:A6
MBTA66"81[J%3,V6=^@WD$7H/6Z'D33:R2V[5^5=B0LL_K\U`CB["8<E8#24/
M"'L3SX61IUA@_P`-FVRW#@(3XMJU;45I,2CABDR<-?I*.^C2R7E5,X3U!JCA
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MZZ,5'SC9E&*N?A9!:35$#M,,D.56V&%YT?<-AU`=8ZML&KMV[5D8B%L\3<OP
MKJT!18FTUI"8%2#BWL);H9%5-RI%Q[E:*<*339/Z5<G1<M6LOYOCW0['/4B<
MFSS$@6C:SN&IVL.LZ:!$S54O$;"Q,ZG.I$8D=.'BC&#;I(JLG;!%/XAT)T%/
M.EZ.J(#A#K2)DJX\F;GMB]Q]4J%RU]!5R\V]K-0#"C7:`"MR-7;MD81@Y28M
M(P`38O".PE_,1N5Y(NT&+%!N&LJ5S[;3["[.)2BPS^2@].2^[:Y`ZPV-$[+E
M7L'$+LF[ZFVU"-C&2E0V#'?2D<ZD8<R4FU19&D%TG"HQJA%=\<:>0J^^H^R.
M%HVCI#`&A%$9;7NRHK85>D49QBH]!FJ`,8*T0$W#'3-'R\?8:U'HG=D.>*=O
MT"*'3X^L\0Z76X6<@3[!W+-LY*HM:1"JR-]%@_H]?8O&KYBG4'U8B:^X:R35
MPQ8`6:E3R\HLU9IQ[ERLP7?-G>9:FX[U/4UHM5X;6&XW.ZW"+A8*8M%T>P:T
M@:%@%':T;&H-JU7ZS$E*1=ZNX<O5HY>3>+F`SAZ<I2D`-_8QC`8QC`8QC`8Q
MC`8QC`8QC`9A.R:%`[1H-QUU:&X.8"[5N7K,J02$4.1I,,E69W"(*`)2N69E
M"/&JGS1<H(JE$#$`0S;&!TKI[7LKJV\6;7%A;"C/U"P2E9D@]%1(%3QJZK=)
MXW24#SBUDFX(2;14>_6:NT5"G,0Y3#K]TU(X,'G`1\P!T(?8(E`>^_R]C\O8
M0^X!R\_Q7N-TNB>*Y3T-@5RG#H1\#N&-1`WJ_0Z*Q&U?O?E`H^H2*!5.!L2G
MG*9&*&(?>048]\J7KXQEZ,M)OVC]NFU30<*)`JD/F32424.F8%/./92F$H%,
M;W`BGN(%*(C@9T$>)#]@`BFB3S'Z#L>@$/GY?D8QO8!]_<0'\><RB93OXETJ
M*RP!Y2@H8#"DD8/JD((=^7R]"'MT/MW\QSXD3G.B01.)O6`J@^_0``_I"]=`
M/7VCW[#[#[^V?5Z/MUWT/8?B[``$?;V_'W_!\\#V?$I"83>43"'8>4>PZ^SO
ML?<WMUV(?,?G[CWG]JN4O4$3$$G0CUT'F[]@^P.A_*/RZ^S/2#81[]^ON'KL
M/Q]_+^;/8JV$#F^MW[_8`]!]_>`5,58"J)'!%9(>TE"CT<IS=]=&Z#H/G[?(
M/L[]@#AUFJSA0'"GF,(J&*N8PA[J=!YA$W8@(*%^L`!T'N(??UR8)=>8.Q]R
M@/M]X#^0/G\L]9@,7SI`<2"<.N_-T`&]A)V'WB/U1]NQ`>O;`XY)B1!4.N_-
MV!A$0`>@$>P`"A[!U\@Z_%]N90<@"U1(<`#]#,8H]AWYA44Z$/F`@(`'MT(C
MU[?=F%K2PHE$X%%44SBF;S?5*!B&'S>X?6$>NA$/L`?LSD'$RJ8C<GE!,/AT
MQ,"8^8`$X";\H@(#W\Q`?8/?`]+E%)L8RAC`3R]`*0]B!A-W]<I>A-[>P^P=
M_<`9JN]V!./9I-V2/J*.3"*ZB@B!2ID-V!#@7LQA44``Z,!`$A3=F]_?9CA5
MD1`5'"A0,(?H0*&\HF4$!$`#S&['S?,?M*7W'Y>^$U#5]MW1LBLZYI3$TO<+
MS-M8.(:?6%B!W!C>=X^,0AQ:P\,S(YD91^(>5G&M'3DXB)``0M.\$#0[Z\;>
MN_).PQ8!7]90J]&I3LQ%4T7-[MB"2L^Z9B)#(KF@*C_>CDWG*=!:TMP3[,"G
ME[0^:$XQZ!JW&/2-$TU5/*X:U6+_`.%I@44T7%CL\BH9_9+&[*F4H^M+RR[A
M=),XJ&:L@:,@4,FV(.;[P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8P&,8
MP&,8P&,8P&,8P&,8P&8-L/\`6X?]VM/Z9LSG,&V'^MP_[M:?TS8&B,8S&+G<
MZUKZLR]PM\JA#5^$;"Y?OE^S"'F,":#5J@3]%>/WJXD;,&*`&7=N3D23+^F,
M4,B770:H+.7*R+9LV247<N7"J:#=N@D43JKN%UC$1002*`F565.1),H"8YRE
M#O(2[-YUZSJ<J%6UW%2NX;:JX%DBTJXJ)P1W@&`@MVTNDT?NYM<#B)/2KT9(
MI"<HA\8`"`CJ>!@][^(A8'R$0Y=ZJXSPDL+-\]4*)W=B4;'`3MC))F*G:[&"
M8E568&7)4:L90A'9Y&33(DZMGT?QBTWQ\C"L]=U-JWEE401DK=*^25M\N`=]
M_&SBZ15T6YO82QT:1A%I=%])D40[$*Q6#OQ)]P)_&U36\!J"!<E*+9>PM8N%
MD`05./IK`-M5EK'ZQ"="8P5YB!@^N1``.4!RM/B;XC#I,J[CDY4F:Q@`PMDY
M>7$I!'W\AA:Z]30[`1$!\A#$[#V$0ZZN/Z`/^W[Q_*/V_P`.,"E=_JOQ/-<B
MLY96"E;<9-B@LHU*[KDBZ<D(8/.BV;S<13Y(3G#OL$'H*C[^0WF`,X.-YPVJ
M@S+6L\EM(VK6K]54Z!IN.CY0C110AR@9="#G$R*/FB9#`=1:!GID1Z*9%!0B
M@`%X@@`^PAV'W#F+V^E5&_P3RL76MPMI@'Z9DW43.QS:29'[(8A5"HN4S@BX
M3`PB@Z;BDY;GZ40634*4X!$JEWRF[%A$K%1[)%6>&5$I1>1;DJPMUC!YOAG[
M4P$>1KP`[\S.0;MG`="()B3HPY;D%=S\'-A<?9=UNCAS,S($8HJ+V/5CM96;
M<NXU(PK+H0Y'AS?A;%E3*(GK$N8\TW*GZE?E5W0I,R[6XX\DZSO^`<>D@6`O
M4`BB6UU-903&1$1]`9B&.KY5WD&NZ*=$PK)D>1+L0CY(@*"@X<A)3-@:W_5U
M?_-J_P#K#7-?YL#6_P"KJ_\`FU?_`%AK@;P[Z_\`8(_Z,\=A^/\`B'^S(_\`
M)31)^0^N2:_)>)C7YB6.'L'T]!MC.GPA$E>E^`%,DC&#Z#KXOM0WQ/1?2+^A
M'[^K`?\`W*AQ_P`Z+8__`-C+?^,<"WCOO[_XA#_2&><I!XRTJP\>O$'E-)HW
M^>N\,?6,@I(2,]\0!WI'L%"VQN1)@O)22#%5D_323!RW5%9=`ATSB1-90@W?
M8#&,8#&>!'H!'[@$?XLQ?\*6GXO^M@93C,6_"EI^+_K8_"EI^+_K8&4XSY&+
MLCYLFY3_`$B@G`/G_@',0?G^,HY]>`QC&`QC&`QC&`QC&`QC&`QC&`QC&`QC
M&!\<C',)>/?14HS:R,9)LW,?(Q[Y!)TR?,7B)V[MF\:K%.BY:N6ZBB+A!4AD
MU4CG(<HE,(9U4>=_AWR?'*[2FQ:.Q=RN@;-)&=I*)`HY=:\?O%Q6-59U40,K
M]!KKF]&M3RYA(JB=.%E%BR:3=Q)]KK.-F(:)L,5(P4[&L9B&EV;B.E(J3:HO
MH^18.TC(NF;UFX(H@Y;.$CF3615(9-0AA`P#@='%@Z,4/(KYC")AZ`"`!DP$
MP@1/R%`!!,A.BE#KLA0Z]P#VR=`#AT81`Q0[_P`H``>_M^WW'[Q^?V9<'RI\
M*)_"O)2_\92J2D2HJJ]>:C>NBA)128D$ZI:1,2#@"RK,AA4]"O3*Z4@@EY6\
M9)/O*BQ+4++0T]5I=]!6"*E:].1BHHR4+.1[J*E6"I1\IB/(U^BW=MS`(==J
MHD`?F4>A[P/H[2*43&*`%`.Q-^+WZ]@^_P"09_9S(G,<2`4P`;H1#L.A$`Z^
M8?;]F:^>6@QESMTT3J()&$!73Z$JAP^8@0>NP*("4/K#[]]`'89]99])NY/Y
ME?(7S>50ATC@/7E#H?8HE]NQ$!['[>O8,#*%P,/NG[?9V`>_V=_Q=C[A_P"W
MBCD'W*<![_G_`"@/S_ASD"N4ETR*I+$4(<`$IR=]&`?</+T`]_/WZ]_OZSY5
MQ*/R\QAZ'KKH`[[$0'L>A^8?=_VX'#O6!5OT0@=BH8OJE]@[.'13'`/EV<OE
M\P>WOV(>V>F1*@T4,*AR@)$2"F0!`#^4$RB``7H0`O0>7SFZ*`AT'U@$,]S9
MP*TLVCW)@9-G!P25<C]<R?J>8A#@)O(4`#Y?+KLQ1[Z`1&4&K.*^SN1<\>)U
M56G,HP9/082UVE$5HJEPY$P3*L,A856ZC=RZ1`X*C%1!9*6<$]T60D\ZB80P
M8PUANUAB(*OQ<G8)Z:DVT3!P4*S5?/Y%^[.";9C'LT_,JNY7,(=B!?*!2F55
M,FBF<Z?:4\/#@3&<6:RI?+XW9RF];C&IMY=PFHF]94*"6.5R%.@G10$B[Q94
MJ2UJF6YO2D7J"#!B(Q;!-9]LSB-P-U;Q::ISQ2HW?:[ILHA(;!DX])NK&MW*
M8$<Q-0CQ4<%K\8<OF2<N2+*S,L01"1?"V%)@A.G`8QC`8QC`8QC`8QC`8QC`
M8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`8QC`9@VP_P!;A_W:T_IFS.<P
M;8?ZW#_NUI_3-@:(_A`/QF$"E#\9C&$"E*'S$QA`I0[$1``$<K+=1TUS\Y%A
MKB"D)!EQYU*Y^-M<W&G%$LTY(LLS6>M5C])FE+&Y1=0U44.FM]%0;23L!$/5
M7\IY%\R=JKZIT=8'46Z,ULEP4+2Z^JB<2NFQY5NN>:DFH%$#BO'0:+T41((&
M3=N6AP[$``9+<&M&(:+X_P!4BW;0J%MN#=O=KFH8@%7)*S3-N=E#G,)04!&O
M0Y6,41(P^4'*+U<"$4<J@(2DJ]7K]*KT/5*K$LH*NU^/;Q</$1Z0(M&#%J0$
MT44B]B8P^PJ++*&.NY7.HX<**+JJ*&_BW6>*I-6L=PG%3(PU6@I>PRJI0\QT
MXZ&8.)%X9,G8>=3T&QRI)A[J*F(0O9C``Y%FE][ZPD-R49+7:4R2&KL]:*L:
M_J)*R#:5DJ)$S#>;GZ]!R$8L@YBY.Q#',H<\D"R1F<6\DE4%"N_AA`,.I_*O
M5\MK*G;$V!)M--N[6\L<&I2]AR\4RLL/;::^?1]NJBZ;-PX;R$M7U8YTN^)&
M&<E+'D^D.@:@=0FR%]VZA;S]4JZNRJ2%@O,=%2]/BBV2+4=V.,G_`%_P??Q!
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M:>[FZI)WNH.;C&PT>G;*?$347`OYIK'L)Z3G:\9-Y.0JZ43=8BM33AC*MUT&
M!U6LJWCL+JNG=M5)6%I$7LN$CM1UV\/;BT5CH&01V1(U]U:)6U-]72<@O)K5
MY&O-7<D2,>6A@S3FIBL,DX-2)8/5W<^I[-9Z.ME>VX^VY=9FD/K,I1%]?RDY
M3:NXKTSM%/Z2K[^+M^QP.\4C49F`;02K&#A(-LM&QHS]B<-I%-F^;1#$)2"'
M?SRGOG1Q[E]2V5GS%T0W0AINNR)7VT(1JGY(]^W>'3:*VD\<D!$EFD@"HQEY
M9I!_?B#IO82IIO&;]T>X3..EXJ.G8J3A)ADWDHF8CWD7*1SI,%6K^.?MU&CU
MDX2'V40=-E5452#[&(<P#@0:U-LJ$V[KZN7^!_0FLXS[=L#*%47AIAJ;X>7A
M71@'W7C7I%$@.(!Z[8S9T``5<`"0VM_U=7_S:O\`ZPURJ#C:U=\>N3>Y^+4D
MY=J0+MVO:*`H]$2BLBT:)2#%5,@F.059:H/$4G2I5!%P^K(CY1.8_EM?UO\`
MJZO_`)M7_P!8:X&\,8Q@5$,_V7*9_>L+_5S#Y;OE1#/]ERF?WK"_U<P^6[X#
M&,8'\*CTFH/W$./\11'(9#<1[']$#YC_`*?R9,IP/3=<?N15'^(ALJ7-;``Q
M@]<?F/\`AA]_Y,"3OX8C^V!_&/\`9C\,1_;`_C'^S(P_A:'[>/\`+#_\./PM
M#]O'^6'_`.'`LXUT]^D*C&.^^_4.^#OL1_2/W)/MZ_Q?X\S?-/:&>?'ZNKSK
MS>;U%9D/,(]]^2:?D^?MWUY>LW#@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@
M,8Q@,TQMSCUIG>K`&&T]?5^UF204;M)1TW.TL$<F<JH=1MBCE&DTQ`IE3*%3
M0?%0!3ZYD3#WWN?&!2=LSP9*(^,Z?:>VM8*DH8#J-X&\13:X115#&`2()3+!
M6#G&[9,OF*!W:<RZ-]43JF,!A-%2T>#]R79'57A[5J*SD,/:2:,S88-T```@
M`J)RE<4;%\P_("O%.A[`1$.ASLN8P.L#7_"IY=IJ@S>1VM63,W8E=*WT%RH'
M$0[$$FD*NN8I@[$0*3L`#H`#OK-[UGP>]K/';;\,]M4""CS]?%#6HFQ6:13#
MH1Z1)))5ED8_?0"*BPDZ[,'?7E'L#XP*V-4>%GQEH"S>3MT=,;>G401.*UW<
MIIUU-PB)#`JVJ<.5G'')YRB<J<RO-&)WY?4,7ONQB,BXR%8-8J'CV,5&,4@0
M91T:T;L6#-$HB)46K-JFDW;I`)C"":*9"]B(]=B(Y]^,!C&,!C&,!C&,!C&,
M!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!C&,!F#;#_6X?]VM
M/Z9LSG,'V&'=<4_$\:"/\L0_TB&!39RV:ALCD?Q5TJJH<T;*69C,3+<A`.8J
M$M9F3%=<Q1`?,4L'`RI1`P>4"**#WV(B%Y10````^7V?9T'V``?<`>P?B#*3
M[5Z?^Z7\=?BO+Z/X+-?0\WR];Z'V7Z77?MW\3Y?+\Q]3R]?6R[`OR#\@?Z,#
MYGSUI&LG<@_=(,F+%LN\>O'*I$6[1HU2.NZ<KK*"5-)%N@FHLJH<0(F0AC&$
M``<JFU9R[V`T8;ONDNWLEO):J,RW[J"H7.'L5%C(&'<7%2BJZ\B9Z1J2))&%
M95U_JFYR$W#A:2-I>]3*GK*,%8M(]I=BK\/;(";J]A8(RD!8XF0@IN,<"J#:
M2B)9HJQD6#GT5$E#-WC-=9LN0BA!.BJ<GF`##F'V_5VM+4VC%;=5(63:U>(E
MXR+%ZBH5&*A)1M'$F&")4%$BECW2$'%&<-C%.B)HQDJ4@*MD3E".;CD1M1.>
M=ZS0U]0%]J1UON48Z]:^3K&@*5BF:]UQL9[*-II2FJV#Z:>,MGP$"VB3P'PB
M;UI+2[B2)'-T$%\4IO+R_6N(;7@VN*:RH4>IQQ9V8"7V3=7).0Y"UO7<BU"$
MARU,(MRRJLQL:+:JJOY9HXL<:TD5XQ%N_;MF3[[)YOH;E2<D;JR\0?TO+R2V
MR)*06UB^L\':2*5.+HI;$F\LD7!M3R#>N)0S&&D(>QD8/H]+X*;A;3`.'D>?
MXM9Z[X=U.`1WY&S].NM:@)2G52G7I\BTE304CJ2LP6E(F`BUXMH"]AG6,U4W
M3B.2"+>/V5FDI-:N-V_KE7.&%ZUV9NW922D5;-ELJA8Y6BU1=0*C]!I*2CEO
MO'D%"R4/K@MK:1D6TV#;JI1H:!8O91L]:-&T6XE2MB.`._99?4.1\[7-7M[1
MLAW9?C]4M-MRFRHR4;0!+9ZD-L.3UQK"FW$]5:/:RM.2:;M)U-6.K')6!DJZ
MI.`[&&57\VP8]KPTEH.#CV1M<GBMN7!_0J^T,Z>-'$Q?8B;MVSG%4C47"S>3
MKMMA)]_<+6TBD@A)>%D7;]Q'I-55DB&WEK.!U3`(S\-J^-KT8A69!"E6%C7T
MC(DC)2$9IS!8A^3Y?')(6KZ6=*"*B[MS.+R#QPY>O7"QPTAPXV]+[<J^T'=C
MV!6M@SM:W1=X%1]4B))5V+AC!&2-?A8(`12=NH*-9NUF,1+R0K24VV:C*O52
MKNCH(3!S@(&K5^L#,C`1+2*&PSTC9YH6A#$&2GY?T/I*5<^8QO,[>?#(>L<O
ME*;TB=%#K.?P*:^?D>77W*_BKMZ.*1NXFWR%6E3$2*4'*4)9(YF91P<!`5CJ
MPMW>M/T3OR(MD0#LI0`+)M=%\E@=$_Q&#DG\ARV+_P!F5W>*UY_C>+?H]_%?
MGA6'X;R_I_-ZM*\OE_'Z_H_P]=>_66):\[_"%YYN_-\"Z\W?S\WQ3;S=_P#U
MN\#=N,8P*B&?[+E,_O6%_JYA\MWRHAG^RY3/[UA?ZN8?+=\!C&,#YW8]-7(_
M<W6'^),V4$&M'UC_`%U/TY_\+_*'+]'P],W0_P#S9Q_,BH/OG6.-83`<X>?Y
M*'#],'^./X\#?GX4?Y:G\K'X4?Y:G\K-`_A$;_'_`.L']N/PB-_C_P#6#^W`
MOVXK.P>Z.J+CL1]1>Q>YOG]6R2I??\G0!DB,BKPK<B[XYT1P(]^=>UAWWW^E
MMDR3_P#UR56`QC&`QC&`QC&`QC&`QC&`QC&`QC&!P%KM$#2*O9+G:9%*(K-1
M@9BSV*6<%5.WBX*`CG,M+R+@J)%%C(LH]FX<J`DF=0Q$Q*F0QQ*48PZ-Y-WG
M:]EAXRX<7]T:9K5^J+B^ZLNEO&HV")G*\V"'6^A]@MJ/.3SO3.PGL;.Q\Y%4
MJ\^09.,+*,V\W^%,!/5F-D-LR@P>U=<W[6%G!P-;V-2[11;`#0Z:;L86VP;Z
M`E!:JJIK)I.BLY!8[94Z1RIKE3.8A@`2C`5QQ_Y\62CRM7L_)S6T/+5/1VP-
M6ZYG=?4JUP9+_L&XUMK3H/>&[(Z7EII-H_H,.W7GX'7%"5&#=W^5>S[^QC%-
M(>OQX9!J/GD_Y%:ZW1;-"Z(M%NMFI-PO-?,J':;O3J"O?M?*>D_J>\:S8I`)
M6*2H5_K!E[)4&TBDC,OVK-PW60;J`10^W>)G(VY\C-+0V\;OIA[I"JW&KUF^
M45O+;"JU]D)VCV:LM[,WFY$M3:(I5]TT0<E;NHAR9XY\Y#J)*G(`%'4G'#@8
MVXH[<3L6J=G7>8U-+<9Z;HBST79]JL5[G"S&FI4J6E+/6IZ4<J-XB*@:99-A
M5><KB#-L@X*]K3F/423BG#=7:>I.,KW7W'GC+JZ2N<\XNW&W6E)K,5+5"\;*
MH=%M5KIU.BZ^FYNE2JEHA"WFE.Y&+2='J-S"99`S5<)>@5PNJH8-4H>)!K9)
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MVPJH/%VJ;HU]R*;P+Z`FE]PFOVN=1U[6D53@L1)$M0-1Y&P5:'V3(3!HDMB3
M>&DJBU9_1SIM-,>=W-PUV+LKD$XOU;O-8H%%M)Z,>[2U4<;"A=A3$/5JS/U6
M<J=CJ*4\_P!*;,5GXJ50;T_9-PJK.^Z?2!P%47DEVT(ZC`D`/-;B46K7"[#R
M+TZ%0H,M!0=PLQ[Y`D@H&2M,BZAZND^E#NBLRHV:78/XJNOT55HZ=DF#YA%.
MW;MFY12^4G,C0T-#)SNQMFZUUPPEMA7NB51><V-5G:-C+1I5O'R$N"S%T)88
MC9%_%.K+'3(-'-&5E&,=;58Y\X134@#J?PP+Y3HF@L+;?:A,N]72W#JO04HX
ML6^KV$[K3BSMZ(V>^(K$[6V#:X+7SJWC!1*<-0Z'')5&ER[9R]2G):.=MHN*
M]FVO#'V#=+1;K7`;0A06V&KRLIUFA'UNWM1Z\SUSR2VZVV@U>_"Z>O=*?7.:
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MMM>XU1:.N;OE&ZC(I>#D59"+_/\`=-<5-71?JNU%S-C&@W&@+"]F#-B)_2$=
M9XUFU]-1I("L&Z*IS2T;9]M[$T>>YU6%V93KF6J5FJR5M@0E=DM%=)4/>3:R
M5-JDX,(Q+RL75Q\`5T8',@VJ]@G6)',,T4<HX;K'Q`M![!M]BUC(W.BT[;$4
M^KK&`U[)[+IDA*WHMCT-KW?#&1J+R->F82<2[AKP^C89^1026-.GV.QP9'L"
MU.X1Q"A\*;'4&,<W<7&J.EV?(#3>XE7#>$D$15B=8\-M<\974.4RBPJ!(OIN
MEOK''/#&^%9P4@WBU""\274/'JM^'-O&-1-KJ2V-I174,OM+BWN>?F8^AV<F
MWD;/Q@T)I+6L778::=R*L&2(MUUTQ%S)[$J1O.5.CR<_4V+"8>S_`-*PP2^I
MWB%<7+!"V]]8=J4VER6MHW3*NQF<K8V#Z&@IO>6O(K9-)A("WQOJP&P?I&!D
MQ.TE*4M*,GY&3MVV_O1(ZI)AUBSURZUV"M]0G8BT56SQ$?/URR5^1:2\%/0<
MLU2?1<Q#RK!5=E(QDBS71=,GK195NY;JIJI*&(8!RHRO^'GN6G5)K76%IU#:
MSPB'$Z7@W<B[W9KJQ,K5H_C`IQFO;BJ;#U9:8.[:O>S<8DA/56YU5W(RPPTI
M:=>VN`>0D\O)ELNX_P"OK7JG2NL]<7B[#L:VTRH1$!/W48AE!_A#(L41(L]+
M',4TTTDR@)6R2[CU))^FW)(2[AU+.WKE4-PXQC`8QC`8QC`9Q\LY?,XN2=QD
M?]+239@\<,(OXM%A])/4&RJK1A\<Y*=NS^-<$3;?%KD,BV]7UE2F3(8!Y#`A
MV`A]X=8%5,%XBNRVCC?SW;/$Z2U33N,EDK--W!<'^_-76&/@K/;J[J^WPZ+-
MNP9,3/81.L[5@Y*6L+APP9Q@LI1!5(XHIJ*2P+S#T0[+`V"'V;K23UF_K.W[
M'.[&_/(JC"+K!=-R5(B[*V>1#YVE,O`:.KHU2FG;5`$:PM]$(S!2'M-?^+U1
M8.'EBG&_-1J>V5HR/*/>NGMKP:+N&D'"%;B-;Z_X^TZ2A)]$ZQDY5Y+.=.RS
MQJNR*DS1;34>BY244:.Q4U+LWP_KI=-@;=O#&U:O?H7VQ;PM$16;O4[7*0P/
M=CUKA9'UIM.*UZQ5R::.828XL2\BG:JM,1=DK$E8JI:*HN6<J9D7@3J8\DM!
MR.I7^]VFX->'TY$"^+-;*4M,6WIT$K%RY8"6;STTY61;0;N(G#!$R[.6%DZB
MI$!:2"+98IBAQ\5RGXYS=IJU)BMTZX>VNZUQG;:K`HVF-^D9RO2,4]GHR38(
MJ*D!1&4@(V1GXM(YTW,G`Q[Z:8(.(MFX=IQ/D.%>S+=PSV_QPO&R8>;L&U[Q
M(V9HO85[9L.#IE6?WVI6A/7SVX71539>U6K2.KL@V4M^Q7;RRR3B<,Q=&)`1
M47'M\-NGATSMGY-;`VD%VB9;7.S-LUO>\O"76P[FG1@[Q5-/1.J(VN(ZBC;_
M``>C+K6U%*W`3R,U=8-S+QL4:;I!XF7CGL=+1(3CUYREXZ;9.R2UKNK6UW7D
M;6-'8-ZY:HR2<O;4-2FKZWA6S9%87"SM_2*Y/6^+%-,S>6K,1(S<8N\CFBS@
MNF5?$"X^,MJ0.MI.RMV[._3^DZIJ>\1[MO/U79=CW?5=K6ZO,85U#@Y,P9L8
MW4LV@^F90R,6,@_BV15TUEC%"+M#X-<G]>#2+=7]E:D"S:LV'KZRT#64R[W3
M;]1QD96]&;BT9;#15ANT]8]LU!A8(W:S*>J^K8R=F-<:[3HS.N5\HFM$[9">
MC6GAT;?H#71;IULO6%AGM:%XMM;9Z]3M#:`L2&IM5<F]4[.7C8M62>J)(S[7
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M%PN51$MBG$'$+73.Q;EGYANXBX<7KY!5`G(VW?.EZ'=H77%TVE1*K?+%7YFV
M0E1G[-%Q4_)56NMI-Y8;,VC7CA)<U=@&L/(KSDX<I(R(2:J'D'38!3]2"7*S
MA?OO>MZN#^L;6IC"CV=?CE-QD/9_SRF9:J^T%LR'V/(U]2J4.?@J??D-B2$,
M@*-SV*E89C6YU%T:W79)J=,$-F<D^%2O(FT;ND'ES:5>+V[PVM'%ML^8Q+EU
M9:V^LUWEK8XL2;DKQB1U!*%<Q2$E!-GL<[E!CA*,@V_O5PV#<0<R^*HT!':8
M\@M3)Z^7N3'7R=L7NL,WB#7629I2K&L`LX<)*?33J"6)9&[`4056K!@LQ`&`
M[D@XC1W,K2FZ]3UC:C>W5JKM;$77I58.5M<"^D(=WMZRJUC4C)\YBW*S(SC9
MSTT<>CE1.(6).7C?H[UP<I'4A53^`>\J-:JOOR`N&JU]_5S9[NRK1=VL/(?:
MU#G:;):2?:7=1\E==H7JU;+:V>-+(NK+5G\2U8Q$'".9#6[AA*LY)6WHZZU]
MX9W(W758UQKN+V[I)Q4%)+@[8=R/T*+=8674D^(6RT[A+0^I(EE,N(FMP6P8
MEG%-H1:?>/GE`>,W+4C>R,7;-U$!9XWY>\7G;;93QIO[4SEMI]1%+92R%W@U
M24\[F=7JK4)?TW1A*#RVM7=19F;`Y*\MK1U5VQE9YNM'$UEO;Q!N+6C-*N=S
M2.W==V)G)4&]WK6];B[W6FLSM0*$FX;RL'4#/WA$3R7X1I(TU4STJ*4=;GC6
MN/P1F52L!AZ\\.3>4WI_7^IIW:.IVT=QL)IAIH.1HM7OVN;3=D-,7XUG9.-Q
M[%J5E8;!JHV:N-XV-?1>J9L&43L5)SMM!S)O`CJG'8K;/#$W<36FRJKKK86F
MVL_R.TGM;4.[W.R8_<FRVT"ZV/M:W[-1N>O[)<+K8KW8YAFC=I6#L*%TF(YI
M9[$P@]BHI03IJ\JC\+O63H'K-J\*0R9739NY*F<0$Y`71(L!#"'MYB@?RFZ]
MNP'K/JSXXYL9FP9-#F`YFS1LW,<.^CF0032,8/-T;HPD$0\WOT/O[]Y]F`QC
M&`QC&`S%;L@*]9DP*'8HD1<`'XD'"2A_XDRF',JSYWC9-XT<M%0[3<H*H'[#
MOZJI#$$>OQ`;L/?YX%'?+9T&M^1_%7=2B1PC8NS,8>973,!#&1B;.Q>KH&-\
MBE-!STH81,(%$B:@?XW5Y91`0`0^7V?;V'V"`_<(>X?B'*K>:6H7>RM+6B+9
MM#N+31G1[;"(I$$SIPK#).$)N/:^3S'!:2@E7OPX)@)E'3=F4H]F`<DCP:WD
MAO3C_5)1T\*XMM0;MZ3<TS*%,X/+0C-NFSESE$YE!1L$09C*IJF*!3.57J`&
M.HV5$`F%G$SR*KF$F&Z"9EEUXN1112+^F5559+IIIE[$`\QSF*4.Q#W$/</G
MG+9X$>@_F_*(^P!_"/M@5ZT#5^Y]:\/*]#0L[LRP[2F='Z^US&Z_M:M0&&UE
M9[%'0=8?RJ!(*N0<FBSUT62>2<E])6684^AX!9!-5V_.FX6U[,:`N-!:776B
M-*M-FUX2P:;V_4+-HI9QK:V4:9KM>7U;;3Z_"4L\\E(7R,85&D6Z0A9=[]&7
M*&M]^^J^F"(1<ENF"YE,5W._'\Y6VR=4UU69R_ZL>0LD+V1VC1J?8['KFSOT
MR+)D81[U/955<,(WTEUF2E<L=3F72R1GRR2>9S>V]V:MK-HM>VM<TZ6C6M81
MDH#\[*SOEE"W61GH2M0&LYDEM:,'"Z\_+V)BG'WB+:A#)(L9=67A8H21A9((
MSM]&[)VJE486^QM_3JCW;VQYN`O%JA*'7-R0$$ZT">&JFP[\6A(Q\0G=X79K
M-NG29A9@G9E8:+K*-L9I*@X1&3O%&$VE$0VWG.WZ\C7[C-[OM,BLHP.0\)96
M+*JT6M-+K7@*HHJW@[>:O.)UE'.P3>1`NUHAR4RK$5E<@:VSD7`L;$6T:PI5
MMDTXJ,>U-;7-K?-(E>9?S;.&>UNPEM[)"69H0Z#X+":TQC!ZUD8&.F0^A(Z7
M0CHR5R'2>T9'9D=<R2T7"M9.BWF1HK^7J<RK8:597D=$PLHZDJK-.&4>Z=-X
M]>84KDXU<M07B+3"3<0=9P+/U1#=>,9QTO*QT%%24W,/6\;$Q#!Y)RDB[4*B
MU81[!NHZ>O7*IOJIH-6R2BZIS>Q2$,.!3[S\?EV#ROXJ:ACS)N'$(^1M4J4B
MI3?#)35DCG9TW!``11.E"TAZ[Z4`/.BY1$.BF`1LPUJD964E7G7U"M2I]_Y3
MISZH!_`5`>_X,J3XVNG?(7DWN;E+)-G9(!H[7K%`3?%,)D4';1&/8I)&$A$P
M5B:@S15=I%)YF[ZRF#S><#B:Y37L>+2#^*.42J2*YW`=]=^@G^@H?CZ,!3J!
MW]BG8``#[AG>,8P*B&?[+E,_O6%_JYA\MWRHAG^RY3/[UA?ZN8?+=\!GCOK[
M_P"(1_T!GG(U<D^-T'R"JXM`GINE7:*;K!5KG7Y*29+,U3>=0(^;9,'K-.<@
M'"QO,Y8KF*Y;F$SJ,=M'7F,J$B)$?[P>==]_".NO8?\`^'5_%G4:/8">HI]?
M_E%/M#_'-^+,AW73-^:"N+JE[&E+DP=?HJL3+MK59G%=M$:0P%"3K\D=Z1-\
MU$IR`Z;'!.0C53_"R;5NL``>/_T@M^/^6/\`9@;=_"`G^/\`SA_9C\("?X_\
MX?V9J+Z06_'_`"A_LQ](+?C_`)0_V8':'X"N0=<6-<K^X@=S<^AZ$>_+=9XO
MV!^+)D]A^/\`B'^S.G'47^RK!*1-.HKF[24O*NA:0M:K$M/>N[=*B991-E&Q
M[M)(O_*.'2WD2013!5V[622*JL'8'X?<+Y;5"4?L'<MGF;;LHQ$G497U+-.2
M=6HQE40$2%27D%&=@LJ7G.DXEE4E(U@83)0R1S%&3<!8MC'RQ@,8Q@,8Q@,8
MQ@,8Q@,8Q@1/Y/[2W%19?CU1](MM9_A?O+<,SKAQ,[5:VJ1KE8AH?2.W-JN9
MU"(J$I"RDW*)O==,&",.I+Q+1ZT?O2J2T:J1%VG`K7'B([WFJ1#RVQ(+0U7L
MNX=#:"VSI1K!)[9L;*-M.X]I/]6JZYFH>.1?6K:=A5%D-OI[6HL*$256^+I4
M\]K\4P<[2+<9)5V`F7]?E):$B9.2JDFXFJQ(2$>U>/:[,.X:4KCJ4@W3A)1:
M*D7-?G)F$7>,CHN%8F6DH\ZAFKUPDIK26X[Z$GJZ6HS6EM52M7)5X:DIUU_0
M:N[A4J?79DEBK]72C5HP[1&`@K`FG.0T4DD1G%S"9))BD@\*58`J$-XAG)Y`
M+#L9\AJMG5=?\:N6DU8M;NZ99(QU/[AXZ\O(;0#*VGEGEN<3E(K<K`.#R4AK
M]TO8GL`_6D(EY999PDSEV,J[3S'VPIR6/I*DQ^FVU7@N0E[H%UN%N?6=9Q"Z
MSU?Q<X[<A+:_;-H2329J7I:2V[.5ANW?JL86(C&T3.2*+E>.?1LW+QMQHXUP
M34R;+1.F(=B$7<X`R+36],CF/T'LMC#P]_A#H(Q"#3Z)O;&#@F%MC#I_!65&
M+C499!X+1OY.0HG'WC]JM)FVUKIG4VODHN3EY9DE3:%5*S\%-VN&A:U/RJ18
MF,:"E+V2`K\!!S+\0!],Q<-%1[Y9RV8-4DPJU9<Z.3FPI-*L5!UIZMKS,QPG
MV;3[R;6>TSUF;TOR1Y)O]1RU8CXN]SU6L%U(Z@&+"5K^Y6<;KQA/-)202C]>
MP;MJPE`XN'\0/=D3#;,FJQ5M6NZ+QOF7E@W'&;#OE]E-H;"@]B\M]W:IKT;J
M"1>/GJ,,>`@*`!HE:UMY^%LEW<IZ>JL548>OHSJ=ANO=!<'[-62V/66EN-LI
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MF5=KTMFC'S=7ITM2[\\M$\C+OJS'VK15`UO&R4<]AJ93F$M67=Q>Q3J/@(=M
M(03W9,N:P7QVQ5;MB.8UQ>YL#35I71%%2RR7<C)&>./T7-6;!UKQ<I#S:'(O
M8&K]1,)^-UM:7FU=IO\`7M:?7%QK*,K*X6IO8YQ&&<V27@5*I#'8/HY51V22
MBHY")%%T@W;M"A#I+:/(.EZ(\*LM=V%7W<KN&_Z"HF^)RZ0D]<YF^5ZS<=KO
M?K+]$S,W;'$S%SLE,5@K\\_(/Y:1,\!`P'3CQ?1KN,&I?$!Y':LXW:P4VA7:
MSM>VV[C3PZNNN+#`%V#:+:ZFN0.WHO0AGFUF21%Y?8,LU<R,9L60/1V-9>34
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M?4J!4(".4N4*D<L!9FJ$5&-D5;%$-_.E"2B0'?1[8HHQRJ*)1*`4,66[<B6U
MDC=6,7W+AK$K^(EJO5P\?)/E&5EO]G79#@/MS;UAB7')AAM"3826O;_86U/V
M97*VAM5^K".*K,1#TT,]DBU5G(S:\;NE"X<1-4PE)YEK?A'J3F3<[3J*#YV*
MP.T!FJY>>.D34;/;-Z*[:1;V^*A&ENF&];K1+A*I0!;>`_0H?1SE-M/9Q&\*
M>3-VN6N['J?6FS+0G:[!,VYG>-11\FB^M^@WK;4+F>>2%A@E&LE-T]"[FJ==
MFO65>!7)>0:0S@T,9T3,R?\`##AI*UR!I,EQFX^2%7I;NQS-;K3S5M&=1%7>
MW)1@%KD8>-5B3H0RUG4@HSZ=<-4V_P!+J0['XXRYV"'I!2!3]F\C>1TQKV%K
MMBY5;KLR?AHZDFU7>EN0\;QJC:WR--N;D1JVVW^_LY'85"A+@[4M&NVD"_FH
MZ#OL%*-J8\FXZLOH6>8-I2U':.X>46L'O"[1$#*Z)E-T;EJ-XC=EW_:06LE5
M-<=1:<A;;8I.IP-/=UIW,&LMF^E53Q9EX<D963/[`B'<":%D9LP.O=94ATWE
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MEH!.W.*U)O#O/@I\T6A86<=`!)JUZ+V#"<7N-M;KB-/K^@M-0M4;EM14:Y%Z
MTI[&$3"\Q;6"N?48WB$V@_A7!L&$+8O,D89F(8LHQ^*[%HW03VS&U>MPTM8Y
MZ(@(6+G+>]82-KF(^,9LY.ROXJ(9P$8]GGS=%-S+NXZ#CF$.R</U5U6L6R:,
M$#D:MTDBASN,8P&,8P&,9H#<7)'7VEIJKU2<CMAW"ZV^+L-AA:-J?6EUVM<#
M52HKPS.SVU_`TB(EG<56X=_8Z_%*2<C\,5_,S4;#0Z<E*N2,P#?^<%:+!'U2
MMS]GEG;%A%UR$EIZ2?2;E1E',V$/'N9)ZZ?O$FSQ5JR;MFJJSMRFT='0;D46
M(V7,0$3P[LGB":"AE:U^#K3;^U&5GTO7>0C63T[I+9>S6$=J2UOIZ/@+1.FK
M,`Y=0ZK]S6+`F2ONVA;*DI$/4%H=-REZ`_"AS_T)=+#)4V@5C=>ZF2,#K*6E
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MNI2MPLA`\A#P^S*U*S=AE:K9JTJUC[.X:*BL?TQW-'DW/7ENBVKNC8G6\YMO
M77'R&6.A?9"]M+WL_@Q4N432[ORFF6M=-6*C=K">KN*DF@:6M-76)($LE:E8
M@4+#,53C7Q%MM8#5,[QAT^IK_4UADV-;J=PT?4FE"8O[7!1<O89:A,)JOE@I
M&,G4+`2-LDU!)*,Y2=0E8>56<R4:Z22V5/0>AZ&[IY;!`ZTJ[VT[.KOX$_'P
MT!&N)G;K6BN*M5G$$8[4AW%Y:ZYJR]<AGC<?I9O48,89HL2,9%;%"'#;DAR#
MBN*G!V24<ZEL?(SE>OJ>F+7JPP]BK6G:_8KCJ.U;?EK3*5.'G5)V167K]-?0
MD%3HFV0);'=Y9@W9RT!$F%NWP+A[R`W9R)Y435CND[6XBAUKBTVA5]9TR2M<
MA5B[?A>6/(#2=]V%7Y=Q-M82VU>UJ:#"2I<K.5+\((2JR<="QK]FX/<7UJFU
M3*)QGW!QZJ56@-7ZWG>.UGKL18:YKF5U["H49.%D5RVF)4&@2L42.ASI/7)9
MENV5BVKA@^.#M(B"X`<-K5+7>MZ<6/<T>D4RL)LJE`TF*6JU<A88C2CUMQ)/
MJS5(\T2S;D1J\&ZFI9W"0K7RQ<<XE)!=BW24>N#*!4#.<Z>:",;8;5#5CBZ%
M94H_.S:55:2;?;2DXTJG!?=9-=RT%856E@1CG\_MJ"DXD[&6C`CH[6LPUD'[
MB*V&R=M8AKDVR>?^X'%O=Q6JD=8GIEP3W)KBH6)6J[#F76OMMZZXE[!Y`B[M
MES?NX"@7.3@+70I.E6G4M.AGGT4U(E-.]I'DTIFGQ=H1M7:=/&D;GU_KHT2I
M&7VN)H&K%>-'J1&V9E*7V9!D)\(+92/V-/H(R5UCB@*%KET4W4RB]>)E,$:H
MN.X.6#D+*4]GI_53K?$=8+(R?S2^EH<LT2=U/KG3LU*K$N:]<`#+PVOM_:WC
MV3Y&1[>QLP]K[55P2#E6C0(Z:1YT;6E:Y$0VQB:UE;='K>&S6)"?8-9*MIVZ
M=Y@0M6>[$DF4`>;>),G,463EGU0C&"ZR'3!=1^DNS050;Z6;>)ER4;Z>TY<I
M74]+EKMMO2^X^3S.+US0=N7RLQNK-6/*/`0M`FW\;.).ZO;+S.VL[R;VY.G3
MUSJF',T2DJU<U"FD'=JK7C!Q=8SE%G6NA-(-['JJ$@876\NEK>DDF=>U^FO%
MW=7C:<^")^,J\557SMVK7V\0HS;P*SMT$<#072Y5.6LO'OCQ:*O4*A;=,:AG
MZ;K19&0HU:GJ#49*N495),2).:S$OXM:.KH`D4R?FCT6B2B("FH!TP\H!LNH
M3YK55*U9SQCN&-8J_"SIHA^HU6?10S$8UDAC7JK)9PS4=L!<BT<J-%UVRBR)
MSH*J(F(<V19K>O[6H]BN.Q:'%2AQL.J5ZBTN;=RQ=L&4:K=J^G9:X1O).TD6
M$@5Y$*IJG,Q76*U6,5HX%-STGFQ!52*(@*A`$HIE,`G*`@94?*F40$0$!./L
M0!`!,/L4!'VP/9C/2DX07%4$5DE104%%8$U"'%%8H%,9)4"F$4U2E,4QDS^4
MY0,41*`"'?NP&,8P&,8P&,8P--;%A!0=$FT2]HN_(@]#R@8A'!"`5)4X"`D\
MBZ902.!@\IE"`!O,*HAE8%2UON;B9R46O6H]9W:_:'V@GZEPK-2C/CEX)%1V
M=97X-JNJ@0[JNOW2TI6%2&*F_A'LA7A<)*)E.$MO$HY8K<*^'&WM]1D5&3UK
M@8^(@*%"S*:BL0^OEQFV-<K"DLDF'F7BHAV]4GY%J55NH^:1"C!)RW5=$6)^
M;YM?D5OG>=RD]@;=W%L>_P!OEEE574Q.6^<\J1%%3K`RB8MD]:P]?B$#J'!E
M"03"/B6"0@DU:)E`>P_5K;K%<H(N"%5(1=%-8I%T56RY2JD*H4JS=<B:Z"I0
M,`*(K$(JD<#)J$*<IBA\4TP<2L/*QC23>PKJ1C7[%M,1WH_2$4X>-%FR,DQ!
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M%'6=I-,]K[*V)M=)]3)2@PPS[J`KQJY!R[V'DGLLQ+1X2N(/;RI(UV`>I7:4
M1=2T<M$-QARQI7<L61Z"U>X3O7^PU:C/\A=HPD',SFCJK3[`QA(.PFCK/O&*
MEGS&%VJ^:\A&^OJO*4Q_$+1<]6J)?]EW&=:KMK-5J\ZKXJ."ZY9\=(\D1J)W
M+;^W(YF+OQ\LO)6_0E-I#R:;4&@0=HM-(CV#&T6'<%2KLG-3=DK93*RMN>4*
ME5^&?ME)*R+V)Y%5N0#]">;XTREJ@;<QMF[=F6&Q62KH49C:%V]/B3U^H&GH
MR>G8IG7:U`0E:D'5S4B6D?<)B6CG4A(Q!!C(X\.R.J@IN'5E%D-<U5"JN[*%
MC:QZYRPWHU.H4MC"Q())$;PD;!TF*AX5!BU4*LJB8K,%NW!R&.)")@'YY;7A
M-%I6]&A3O+#8;.S7'?+G16I"PU&E9V'L3Q?C[K??\+;;U+)[C:H4V&/'[.@:
MI-LJX-]>-Y0'$O!*3D.W4..M*[Q<<VJ_:PT3$\B[N3D)</SG9&X5)[6[6&NJ
ME7MNT,-G`YA]FM+\X&=F:52WT"ZF&5DK5%@[)-3"D'4K&^5B73E8/TQ\K)Y^
M3.]M@-8CCUJ'7-Q6KUQ<L$]A[+&"??@BVCE%2.D(`TXDFHDTC$O0^D[9)F*D
MB+9NV@&BSAT^>MR=`;D;K*P:,F*0A&[.O%@B;Y3E+8R;V"P0L=<ZXLTL,M7G
ML);8C7.VMKU5HX5&-;3<*\C+H_2E(67;&4;LGK-\W+J_6^^MVZ?MT5?-7;=V
M50[?#+IN(^>KEUL+5VD)#E4%!R@J_7CY1@L)`([B9=F_B7Z(F;OV3E`YTS!^
ME!HK3T3KVHU36-;[48PS;SRDF9,$EY-\X.#F=GG8%#HKF3>'4%(@B/HIF9M`
M$2H`.3;12302202*!$D4R))D#Y%33*!"%#\12@`!^3*X?"EY62'-'AOK[?%J
MBH^,V2_=S](V>:(9A'P\C=:%**0DC.1#`JRQ(]A9&_P5B&/2$B+%Y)NVB)`0
M02`+(L!C(^<EMF;*U/K@EIU5K9SM2T&L</%FJ[1"875+%OBO!?2GDA&SIZ!&
M(H(`8PI>B7UP]4P=E[@'_=O\V/\`F4S?_P!F;&__`"7`^AG^RY3/[UA?ZN8?
M+=\I4XX-M\[.YV$WKLG2-LUHR?T*9BI`[R$G&L`R485J/@HTA).;;,U%7,B9
M$IO0*0Q_4$_E**1#J!=7@,8Q@:LV_IG7F\Z>[I.QX!";B%S_`!#18IS-96%D
M2D.1&7@I1$/B8N30`Y@*X0$2+)&.U>(N6:JS=3K;<J^&NPN,DL+]QZULUE).
MQ0@KXS:'33;*JJ'!M#6QLF!TX6<.0`]!4##$R_0FCER.?5CFW:<SB9Z!A;1#
MR5?L45'S<',,UF$I$RC5%]'R#-P42+-G;1<IT5T3E'W(<H@`@!B^4Y2F`.EK
MFV]+Z1V)ORYMJ1KF%-)2!BIN)63<F.V@:U&&4!,\O89($U"LF91[*@B0BS^1
M6`&L:T<KB)2VK[*\*`7^UXE?6=N0@=13;MPZL;.6.H^L=*23/ZPQM8]1(Z5A
M:/"G%M$'EUT7$,*?<FM+H%3%2UC3NEM>Z)IC&CZZA$HJ*;=+/7BHE<S,[)&*
M!5YB>DQ(1:2DG'70JJ`1%LB!&;%!JR11;IAISBWP]USQF@BJQJ*=EV+),RH6
M6_R#8"/G13F*JK%P34YU2P%?35`H%8MSF<OA22<2[MZN5/T9<XQ@,8Q@,8Q@
M,8Q@,8Q@,8Q@,8Q@,8Q@5[\Y=)7#:$WHFU,-%U;E3K[7,SL8][XY7"T5JO15
MJ?72EI5ZEWQNVOR9]>SDEKJ23DTBL[,H@[BHBWS-FJ9GEIA(V)D8*USAWS#U
MNC1M;+T*"VS%VRS^%]8MC[.3VS'I0])B>)^Q*O(;HKCMA>%$+]?9!K6*ZS:4
M61+'.R;`@DG"]N?U^Q)A$3-^6,#KUU7@!NRHCQ^3K7'ZFP<SJR;GH^(7=3FF
MI[5=<59<Q+AM52Z/:H=BPONNB6O6TU$6&M;)X]6MAMR3L3!E0-MT-.OUV#D4
M_FV1P+W_`":]B1>\<J9N.8MLYHQ]K;84_LZG0\QQKB-9\L+1L_9,1%A)&4D4
M4=BU"597E!#7AE&E\L;R1HNT21$/`0;YYV'<8%-O$;AWR'U5ROGMD[(>`\C&
M,CR;<6+9;0NJH4^\F6X=JM[AJ]O*GJ46XVU;0HE6319.XW;\G&1NL)6,;5W5
MXVNKN$G\;IG;'`O=5[E.1E>4X]:WG++=%><5B<<H9/8<`O8-]4;?>L=C0.D.
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M:2@ZJTE-?5MW=).KMI:9I")Y%>(F[.`O)'88QC_7>EJ?IN@SU+W34:-H.LV?
M4]A;<<KY?K_'3<)O(LG>H^QU'5UBFX-N5Y8'W%MM.V'5%@@8=+7+.VA8;'+M
M>Q)C`KJXV\>MJZXY!7V]VV*:I5F:F.3+B.F`FX=Z]D4MB[DUQ;JF^=1\<8JC
M9S-P==EY1^D#=$D:[*#-PD@JNBED59_P\[TM0-JDINN*%5]M[EJ'BI5>[WLL
MO$LI6S?W2VQ[/8N/:-ULD:5S,S4$#%6MOTV)RR2>O#(B1O',W:*S=:[_`!@4
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MDHL&#)S\+_>1^QCC`H2K?#_DRUY*&F&^N-I0T:Q\0RZ<D4-@VODA6;+QD7TY
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M\ULZCIO*I2<XVA7+N$7>S/T<U=V;8P*`)#PZMY5W5ZU3U11ZA1I*Q\/=$U+:
M;>(L-9:M=G[BUIR5J>RKU`W!L[3D(:\RMSU4SNM(;VB]LI2LRC&T*U&ROB51
M_(MTI3ZQXI[U@N">^],-Y$],ONT)W:5AU]3GLG38"/I58LZL2+#5ITM01:6O
M]8L+<TBIIO8&NLCV>%I#^^SDM`S-B=("=6UC&!U_=S<(MX["KD"^UOQ@HNC*
M`><W:B;C!6)S2EO;1MCONN]1U>A[NE(.[IR&@:%+UZ8HUUBY%;3`/;E6:O:D
M;]74;/L&RWFMY*S07%7>.N>2\3?;F!+'7HIOM5G)WQ_:XV6G+,]L/&#P[M7Q
MUBD4?392KU_9+MQ\VL>0>NHUB\/]&M)N29,PL;)(;5L8%$]_\.?95ID]NV2N
M4.D5[9>W.4/-J5E=HNIV-)/+Z(WIP]VIJ+7K*=F6)G5A7IAMF2.NI&1UPT(Y
M)#O8Q.Y%@!EH]1\?A`XS\K[Y?'NT-I\58*9UY"/^(;.=XTV#<NMK$XWC6]/Z
M2Y$46S&ENW:^L7*U$VOM"G[&J-.O<NWJ]U85F.F).0@;8P91,1?GC`Z^5KX)
M\D72;&5;Z>J#&EL;)JN6>\>Z].ZLW7`*1T+QTF-=QL;"&Y+%;4ZS,].6=\6#
M8-KLC"IHP<M)S>NTTR5:L0;[8T/Q2Y9:\?ZSH;:CH;.B)J0\,"5ONW%]L5A%
M.FAQ&OL5,;@)-1TPUK]GN<PZ91#!:HJ5RMHQ]HB#O?I5U79>/:0TU>/C`JU\
M/SC3M3C];=EGM&O82CUF=KL&Q?/G\GK^RWBUWN+MEN?.I5'8FN6-<D]LT0(2
M82=1-]Y!5"&Y`KS$F^CY\[Q@@N^?6E8Q@,8Q@,8Q@,8Q@08\2?2>J.0'"C?>
MNMS[!A=249Q426)QM6P?"_1.NIJH2;&R5RUOBNEVQ7#-E,QS5J_CF[A!_+Q[
MYW$1RQ'[YL.=#)U3_"1KBZL.]WCS_P!E.V*AV[FXT+2FB*53IE5(?(9[7(+8
M-O6N;>)<"`JLOPB29R@('3*[:IK`?.T)^:87^PVO!_7C2M&>DHLIR#J;;9QF
M?LFHP0K-J?4QM*&((*?1BMV;1BH%.`ME)=O$%6_1`;AG17P+<M4[*\-_5,C*
M):MVSXGL:I<V["$GZR&HN'=U@+JBS=G?0T=.T&TO+/6K8O&21CR$`20KTB^B
M9$3O(<S5T=10V1J;^X',K+(3S_D-XL1K<K?I?8$[(3]!XF/II_>)>E)ZUGE[
M,C/2SA22:2>ODR4:8ITZV<55U50"!=5T8X?A\BMX>TK(1&Y[DM#U=W=Y9]I#
M8\*SJ-0V6?4&\)I"84KS67'C7L(8J8:0V\HF'![,03!VT\UDJ;.Y5]@<\@_0
M;+SOM''S5>[]NJPNT[K=T[O7=!ZCY#6:-WW8:D?>VJ=)Z-V+=X_>^D-T76B.
MH>O[#V59M)/JWL*E6^4C";1;U>/K<%/-XMVV1;+AAD+RCX)UJ9E;#`\AO$[A
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M2:_;;#.L*K$/73.#C648NHB.7;#XE\9:U=-<158UY(7&+=W^88Z^0AXNXQ`<
M@]916BK':BVI96T<@6[G=\LXNK:F6EJUT.KJ!O-1<[8-5LE&UK+7H]+T(\?-
M2ME9ZH+T/\)&1-[*3,;I:I3NSD8EG-+\%&UW:-I/1UOW%6[R\L\)=C+R-EU4
MPV8OM@['U-:5K8,VP20BG(:0O]T\+K9\NSF[KLKQ(Y%W&Q2$'$-8K3_"VH0,
M'"MW3Q^G$P%4I3VN56!CQD9&1DUVT/"LB.I.1?R+H%WKQ=<^.PNE_#'W`^3I
M6J^4O)31^P98#-JG.<N-6:O1TA*3J@D)&PMMO6H+')SNO6DJX,#(MIDX*0@X
ME51-S)`*':9HK<L:%7-9[_OE.J;*"BH%@G4I%I"UUW:'$?`+6*D5RPR,`LTN
MS^7M]=F(>3DWC*?I=CG+#+4>:3>U)U8Y\8<LJZCL`$,/E4`HIF`2J@?KR"D8
M!!0%/-]44Q()@.!OJB01`WMW@?IY^'+Q#C^$'$;5N@T9UE:IZ):R=HO-HC`5
M+$SU[ND@K8+,\A2K"*OT"V<N4HJ!45!-=Q#QS)TX227753).3*\_">D+Q*>'
M%PY?;$6EG%H6T?5`5<38N#2:\(B+QO457)W0`X.*E01@3)**]F4;BB?LP&`P
MV&8#KO\`]HA_HSQT'X_XQ_MSSC`\=!^/^$1'_2.><8P&,8P&,8P&,8P&,8P&
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MIKF@J$$0$!`1*=8Q>RB`&*/78&`!#H0`<SZG_F;:C4&M;$J=2YA[&AXO:M<;
MT^ZN4M.:G7GWM32E6\T]K<78W3=::KD+8G[)@:VLH!Y'%M36.8Q\V9XP0^&.
MQ@8$/YEITL/??+?;`]B8P]ZZH0@)C]@<PAZ_79P$0./S,`B!N^Q[\!^9:-*E
M#HO+7:Y0[*(`77-"*`"0``@@`+``"0``"=!]4``"]``=,8'\!^98](!YP#EA
MM(`4$!4`-:Z^`%!`XJ`*@>KT<04$5`\P#T<1.'UA$1\_[UETD)?(/++:8D_Q
M!UMK\2?I_4#ZHJ^7V4'U`]O93]$#Z_UL8P/Z+^9:=+$*!"<MMKID+[%(GKJA
M$(4.Q$0*4JX%#L1$1Z`.Q$1'W$<W7HO\S5\0M9W>*M^U-E;0WY&PSYL]:4&P
M-J[3Z5*+H*%432M;:MM33<_&@J4IEH@DY&1K],#-)5M(,55FRC&!V+F3)G&L
MVL?'M&S%@Q;(,V3)F@DU:,VC5(B#9JU;($31;MFZ"::*"")")(I$(FF0I"E*
;'TXQ@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@,8Q@?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g608237.jpg
<DESCRIPTION>G608237.JPG
<TEXT>
begin 644 g608237.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4$Q!4TU!7TM?3$E.12Y%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`#Z`8P!`1$`_\0`'P`!``$#!0$!````
M``````````D'"`H!`@0%!@,+_\0`31````8"`0("!`<.`P8$!P```0(#!`4&
M``<("1$2$Q05(3$6&$%14Y+1"A<B,CA987%R=Y:SN-B!D:$9(R0E,_!$4K'!
M-T)#8F=SX?_:``@!`0``/P#/XQC(Q^JCS%O_`!5X^'@>/4?$6/E[O8MNI/&V
MN32#=Y#14K5:3-[`V5N.XM'`G2+KW1>M:_.WRR+NFKIA(RZ54IZB#AY;&+5Q
M"YJ[J,]0WEKJSI#<?-1[YU_IKD/S"X?[UY7[[Y+6+1U.V(J1'3P*1=3JM4U6
ML6O:_C4+U9C'9W&1;L2.HB#1*\K;9J\*=)]2C7G6+Y^\_J7Q=JG&K8NI.+^R
MTNE]OWJ#<@;?):68[6B+[>M#;NMG'ACI^M0%PG?1:+KV^7"@3-DG)Z-4L%LA
M(.;9,X>1!Q#F)*]M?.L%SZY04-YM'BK?M1<<HSC+T>]?=37==<LVG6NW$MW;
M7L`6%_8-"(/+).QCZAZI3B*3.>K;767(7?U@]9%<28MSBHPRI>+>[&W)/C1Q
M[Y$,XP81IO;2.JMPMX4RAU1AT]E4:"N`1)E52D.J:--,&8^:8H"J"`*>\^5E
MB9F(GV)9.#E(Z9CCN'S0C^*?-9%D=U&/G,7(MBNV2R[<R["29NX]ZB"@J-'K
M5RT<%3<(*ID[+&,8QC&,8QC&,8QC&,8QC&,8Q[O?FT#%-^*8INW81["`]@'W
M#[!^7Y/GP)BAW[F*'A[>+N(!X>_N[^WV=_D[^_Y,T!1,P]BJ$,(^X`,41'Y?
M<`]_=[<W=P[]NX=Q]H!W#N(?/V]^.X=_#W#OV[]NX=^WS]O?V_3FGC)W\/B+
MXO=V\0=^_P`W;OWS=W#OV[^WVCV^7L';N/\`AW#O^L,"(``B(]@#VB(^X`^<
M<T$0#WB`>WM[1[>T?<'M^7-1$`]X]O<'M^<1[`'^(^P/TXQC&1Y<Z.F+Q6Z@
M24++[SJ]H7V+1M>[1H.KK[5]K;GUV[I37:K"/1L"CF,U3LC7[6W1SB2@Z](2
M$%9E'T=+(1!8EV3U:\>(*QDTSH.7SCCIW@>RX?<N(O6')/A7KW?NKW^VM@:=
MF]GT'<%7Y+-D0V(=]K23VXE-T->`G6K*X:ZA:W?W-0KTZF_26K[AG,/Q-UBW
MW/\`6/2VO^.T-PAY:M-(;'U?PIVUP(VO?]C:0;;4:[8U!O&\2^T[O<HRNQE_
MI:E,V5#[0LUHN%.6=3-JA6A9-E"29'C.,76EN9M?H$V5E7("C<1.6R.A:7;^
MGE3NF?R39772;+:<IL[2=4?/7([+J+^-O-#)2]TRC&<M4(_D'Z5AJYH^P"HU
MC&3J,:JGG[TUJ>IZ&T[JK2%"07:T?3NNZ'JZG-G1TU72%7H%=B:I`INEDDD$
MUG01D2V%RL5%,%G`JJ`0@'\(6:]*4>_"ZM^[_P"/'-;W``>[F[R+#W!V#[1]
MH^W)&<8QC&,8QC&,9M\9`-X1.4#?^7Q!XO\`+OW_`-,W8QC&,8QC&,MBYH\E
MX7AQQ/Y#<I)^$=V:-T/J.[;,-66*H-G-D>UF&7=Q-?3>&*H1@$W,"PC%9$Z2
MI(Y!TJ^.DH5N*9OS9=:?=@75(@^0,1L#9RVFKOI,]M]-M.@H?5<#68U.FNG:
M82<'3KX@X4V$PFXJ,!R-8FK)9[(B,MY*UCCYI@91@'Z!//SDI?*SQ;U)(\>+
M0ZH5ZY=;TXI<=]<;4>5^.DWFIX[E#L2KP,ELXM6L+.0B7UIJE`DIUY4XB>8/
MH8+\I7B3T=(1*+YBX])I_B_MCC=NZH/ZGRYVYM325QIEJA-GZLY6;%D=QW9Y
ML.*0B)"D;,TG<Y1FRGJB]61):&NV=?@\<ZS>1+J#EZ34Z2^@GAI:%[BWSUL'
M+_FG?=?S'-1PXT=U$&W)^O\`&+7&BMK4V&W#Q6-P>V%`PU`F&+:)/,VZC2/+
M[449LS<DNZM$8J<48!A$-FK7TXB2=P'#&\TO3.P^4>UN7G4?W7`U;0G4#WEQ
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MEY`7NZ7>):UU"6N,B%.@U)F/KB4\QEK-9;G;SGV#P?Z:_(^K3^GJ0ELSEUQ?
MX^\OGB5>GG%VM$J\YOU?C'>2Z::"Y<4VJU#8K^!M;V?^$;:8F(BHV`D355H^
M9(A-L\C0/_<?]!'-<8QC&,V*?BA^VG_,+D='2D_(NK?[^.:W];O(O)&L8QC&
M,8QC&,I]MG8#75&K=D;0?1CV:9:XH5ROCN'C0,,C*M:=6Y2R.(Q@4B+E0SU^
ME&':-03;KG%=9/PHJ#V(;\DRY?=.'6(L7("0WC"<HI*FQ:UH]>P^CX>KTYSI
M.&KP.#*M**K4I2ON7,U")QQPBGTU+2J]OD`$\L:Q-Y@&[UM^J]PSW\YY5<2N
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M18U1K7+!+.H10\[`;!U^]L-$V`BZ`'4M#665<MEVDF#5VA6[0?%RE:!><A'D
M'*S-E-R)Y'WODM94K.C#KI0-LOM:I%8D(2O`RCVHD@63*C1ZS$9`7DKY[Q[Z
M0^52%!-*TZ)Z=^UZ-N[?NZ=2\Z]QZY?\C-L$VEL*,+I+BE=I%VFP914+6:"6
M_P![T[/;"<T&BU>(0J]#@7UA<)5*+7?J1`H2$@^>./BVZ7\,UV[ZU3Y!;0-Q
M>#E,ZYN)\1#P-`"DI\F'-O#9H3I=C)P1-D#K%MN05-X-M4>L0CB[35%\I/*U
M!-"EI<V%Z;LTZONN@W!RVWEO_CYI7;CO>FH]#[8CZ+8I!CL0BEF<4XNS=Z.H
M9QMK<-.U0[N$TZUG6[/*LWK15I50N]AOJ54C2&]'2NE!P:U?RIU9RPU/QZT[
MJFX:CU5L;6E8K6N=0:OJ%6*]V%.TJ2^^*H6$JC.61V!586J2E*J\XTD$!CZ?
M>KE"B0[:4*1.Y;E-QLI_*OC/N[B_:9.7J5.WGK:UZSL$S3THEO.P\5;8Y2-?
M2,*228/HD))NDH*C87S!TV%0`\Y%0OX.45Y+<*IW;VSJ!OS2?(6]<7=^TG6-
MPT8[V/3J;KG8K6W:;O$O7++(5:PTW9D),0)IRJV^JQ-QUO;6?H[JJSZLRE)Q
MUHKL[*5]Q]Y'I\Z6^+)QTXHUF1M]5UKQIV5QEV=2W31_'2EGFIOC'M>J;A@1
MM\K*QJR4LO>K;5_2M@2C=FQD9-:;F7L<I&/'")T+[@]G^O\`J/?&,8QC&;%/
MQ0_;3_F%R.CI2?D75O\`?QS6_K=Y%Y(UC&,8QC&,8QD.O4VY]WW54Y1."7"B
MN0.W.HORGB91OK.I3":<E0M!ZR+_`,!<.3?(0R0.2U[6]08*OAK#"29N5+]:
MVR4-'1<VV:OXQ[$IK3[C3Z<$!.ZVM.S-J\F-E/*_#P"VR:>G:J13]>;+N+,K
M=:QNP:P5!1N]0IMC>^G`-5@;FC*1T<X0;,K4V60.LKELUBLU^EUNOT^I0T;7
M*K5(2)K5:KT,T1CX>!K\$P;Q4+"Q+!L1-NQC(N-:-F+!F@0B+9J@DBF4"$`,
M[S&,8QC&,8QC&:`(#W["`]A[#V$![#\P]OE_1FO</G#V>_\`1FG</G#_`#S7
M&,8QC&,8QC&,V*?BA^VG_,+D='2D_(NK?[^.:W];O(O)&L8QC&,8QC&1F]2?
MJ'Q_".E4>DZSHZV^^:G)&<<Z\XA<885P=.:VE?2D1&1L-B<(B4*UJ?7#)T2S
M;'M\DYC(QC$MO5H2T>Z?^GL.NZ:O3Y=\1:]?=S;ZNJ6^>>W)^08W7EER,>MA
M3//S:"0>H-6Z[:*]DZMIG5;$R5;I4!%MHMK((QZ4RYC(]((:%@90\8QC&,8Q
MC&,Z*SS[6K5Z:L3TIU&L+&NY%9),0!18K9(RA44Q,`E!18X$2()O8!C@(]P#
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MJ[1;A8`7O-$N[:P+\KZD-ZW%6D-FU>S,8:FTUP6L,8XKLBZ%:^$FS]ELMB<H
M[KRGZD>RG=%X[<[-V\6:)1]QEX7ZVH6Q:S5=6ZZL-7+;IR"X_P"MK=)WE@]O
M4S.'5I=RK#5^$'%>?`>K&TLVD^NYD<B^<>A;J\OJ6_M45N\VKD95];\,>G-!
M4JAW^>Y?ZG1M53K=AGK'<%%`W+`WBQQ4Y:+T_N-'<5W5?'*KUV&>;0B;6P2L
M$F^ZH.9?+D8XO.]+:]1=<55^I`EPE3XOI:QK_DET>;F4/`8N\D]LG.ELL^XU
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MZ^M,Y1ZRY<*"O/VA)%KZFE.1R(VKR/VMS`HO"KCSNYCQL<PO%:3Y6;-VZ75=
M0V_8IMS.[$0U!J/7$35KX*-4C*D[L+&\6_9<HW16MLG%UV!JM4EZ,O-.K,E:
MC-=1[F#=N&/3MY*:_HNF*DUWGRJXQZ`Y7S,C:;`YL%3F+%S#K?&+9T)I37+F
MC6.OV&!NE@CK@W2L=MV9!R^OJL_9/(-K=+"5&289``?^X_Z".:XQC&,9L4_%
M#]M/^87(Z.E)^1=6_P!_'-;^MWD7DC6,8QC&,8QECG/[GIJ/I\Z+<[:V,TF;
MG;K%,Q]"TAHZCIED=J;_`-P6-9-E4=7ZVKZ15W\I,2S]P@K*O&C)Z2O01'DP
MX;.5$FC!]:;TV>!^T:O=[EU#N?+B%N_44Y&031A+LHX?3Z'Q'TT!CNZOQBT<
MBZ*L:&80S5=%3:%@9NG*]RN!'IUI.823?SUEF5QC&,8QC&,8QG6340QGXF2A
M))(5H^68NH]XF!O`8[=VB=%4"'`!$AP*<3$.`")#@4P=Q#MEH[#B.T1FDEI"
MWJOH!)R"IV)(HK:2=MB'*8K1=\#M1NF*I>Z3EP@T`QR>,44T3G`4O8\M.,-8
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MSO:\;D]2M$;VCN8^R2[Z:T3[]P7PT0.@&7)`#[O3HR>GTKFI,F)43[%"FI>K
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M[PJV^)9Q:O+<0;`DWMNWP$HZM4W'(I(QDC99"2C8=9-!".-(P`=O\Q'_`#'O
MC&,L2YH\_P#6?"R0TQ39K6N\-\[FY#SMO@]+Z"XXTJ(O.V;Z77=>2M>PIR.C
MK'::56F%<H\`Y9R-BEIBSL"($>M4FJ3M90Y4K2['UT>(Z.D>+FX=5T+DGR+F
MN7K3;\AJ71.D-5QTYO=*/X]>F$WT\N=0M%PJ<+4BZF>,7$;8V[VTK.Y1^":5
M10L:*I'&?+:G7;X<477O'[86NJER&Y.)\AM!6OE1!U+CIK!A;+K1>.E`.+38
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M6\-6X1N8AWC]P51PLTCFSY\TBIX$<2=R\I]],.K/U%*@I7=RR$,]C>#_`!,E
MU_6M?X/:/L":1TIZ2;+J*M77)O;$4#.3V+9Q:,Y6KLEB5I%*)6`M>J4\H```
M`````````!V``#V```'L``#W!FN,8QC&,8QC&,8QC&,8QC&,8S03%*'<P@4/
M=W$0`.X^X.XX`Q3"(`8HB'O`!`1#]?;W9KD1?50VYL[7,?JRK-^-/*K:/'W;
M$?L>F[FY!<"EK7)\R.,$JDQ@I77TQK&IT2$?W9S";$DVKNMVNT5IZF%=C6BR
M4PS=-I)HW=8\7$O0?+W@%6NE)RKVCPWY-WNAZ@TSU%M#S6I-/ZB1O?)36U6W
MEL1YLSC59MUZJUV*JZE^V2D\?QNT+%&L"JUZ9582&QU&DZM(J.::\<.&W,SI
MDT[BSM+9O$OD?NQ;9'1KY5<,9BA\>M>OMNW'47(C<7*+8?)'7-.V/!UA=^ZJ
M5?E*[L&-JTW=G285NN66.DVTLY;I,C>/N9#AYS(X+ZDN6K)[B9R+WY8N8_05
MUEP7J[O0%!=;1A=7<KV?PWA)G5^VY2!<NV>OJO",MALI9?94TNWHSA*&ETF4
MDNJF)$<QWA)IZT<>^&/$O0UW<-W5RTKQNT3JFV.6:Q7+-:RZ_P!;U>K3IVCD
MBJQ7#4)2+=$;+E4.59$I%2F$IPRA72D_(NK?[^.:W];O(O)&L8QC&,8RG.W=
MN:TT+K2[;CW%=8#76L=<UZ0M5VNMG>E8PM>@8Q/S'3YVJ(&55.8QDVS)@T2<
M2,I(N&<7&-7<B]:-5H%N+&FMC]73D10>I?R[IU@HW$#3TTI8NF;P_N[$S*0E
M'0E(@AS<WW`*(I)/;E;6J23W2-0D1D(VFUU=M8&97"AF5@M61<``4``/<'SB
M(C^L1'N(B(^T1$1$1[B(B(YKC&,8QC&,8QC&,8QC&,8QC&,9$IU([*EKA77%
MHWYS;W-Q7XO;%V71-&J/N/KC3FEU:I<;C&6J6;7??/)#:BMDN%=US)R5>:TV
M-^\PRHDS6Y6>C)"S2,G`'E[%6.AXKT*I*VSTKA7U<[KR>B:E(P<EM;4.W-\:
M?YSUL];EG3AIXE;5#*1V]M7SLH1C+IU::2VB[IY)9HH+RAV-FP<1X3$AW^7]
M/_\`/\>WO_3F@@`]A$/:'N'Y0[^_L/O#O\O;'A+[`[![._;L';MW]_;M[N_R
M]O?CPE]GL#V!V#V>X/F_4/8.X>X>P>S`E*/O`/=V]WR?-^K]'N_1FU3\4/VT
M_P"87(Z.E)^1=6_W\<UOZW>1>2-8QC&,8SJYR;AJS#2UBL4M&0-?@8U_,SDY
M-/VL5#0T/%M5G\G+2TH^5091L9&L6Z[V0?O%D6K-H@LY<*IHI'.&-E586Q]?
MC?L3M>WLI:'Z,G&_8"KO3]"F6C^'5ZCV\*3(I(&VA?Z\^#M(\4];SK5RG1:U
M)-D$[]8VRCR:16%.:A:ODM-6K=DV0:-$$FS5JBDW;MT$DT4$$$$RI(HHHI%(
MDBDDD0B:221")I)E*FF0I"E*'WQC&,8QC&,8QC&,8QC&,8QC&,9`GUA><W'V
MDGU5Q4F.2NH])WJR;DU[([>L>P>/C'D?,:DTY,T794M$[!JFM[W3+'K61E)F
M[1=/I4E9)E&:)1*A;K#8UH8RC=-PT]'TAIOC_+6?>9=+<[M9\Q'B-?UZ:PQ-
M!X<:/XMK4)NI*6T(V0DY'4>L-?.KDE8EB/6C1C.N)5O!'AUW,>DT5DW:CB<G
M&,8S8I^*'[:?\PN1T=*3\BZM_OXYK?UN\B\D:QC&,8S01``[C^@`_2(^P`#]
M8_X?/[,QKMS6FY]=/?UGXGZ6L4S7.DYQ[NY(+F9OJJR#Z+5YL;3K#UD]?<1=
M06%F,<_3U%6W16[G=&QJZ_71L)O1H*%<ECW,*_GLBVFTZK:\J59H='K\15*;
M3("(JU4K$`Q0BX.NUR`8(1<+!P\:U*1NPBXN.:MV3%F@0J3=NBFF4/8(CZ7&
M,8QC&,8QC&,8QC&,8QC&,8QC(>^:6[*Q0=VK-8K5/5I:['BJM5G"&UN%NEMH
M[5T](,G))5RPAI2KRJ5UX^W";B%%G*4Z6;UD\L<:1PV9J3229FH(U.X"\F]Z
M;UG-@5S:-)WI$P%,@*Z\@[AO[A9LWA_<9]]+RLNT.P40L5QN&N]@.V<?')NY
MB3HK:C&BU73$'=-;M'[9R,FV,8QFQ3\4/VT_YA<CHZ4GY%U;_?QS6_K=Y%Y(
MUC&,8R+WJO=5G0G25X\,MW[EB+)>)^XV,U)U1JJFJ,FUBO\`;B1J\LZ24EI/
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MNGP<)6*4G`%V_&1<[(2,7<;KKJK4U:$74G4I**[KIC\=H+1U@V^]A^EN'3R/
M8X2D-G$\'(C7>\/OJ%BY"RK)Q(LZ/>+<M7/@@+X[_P!)D4V24I\(?):J.#LE
MRI2]XQC&;%/Q0_;3_F%R.CI2?D75O]_'-;^MWD7DC6,8QC,3+[KPX@-.1O!S
M1^Q(2V)1^W]3<B:I1-.ZW49NGCS>=GY(/X/7AM85;T42D;70SB)B[?$.G_>-
M&(K%D9NU6@O$'B%A7W/']SA\R.%_-R'YG<T6E+UJWTS6[Q%ZOUY6KY![`LEL
MN5^JDE17<]-/*>Y?UN&J<#5K!8@2;.)E><E+"M'?\J;1;)5XYSPO=C&,8QC&
M,8QC&,8QC&,8QC&,8QC&1/=3_453V10H8_(NT\2Y?C3%W:@V-MK7D[L[87%8
MB>W:H%E>UNP4_E1KO83)Q`V(Z#ETXA:M+:ULA"O(E25:2+<6YSLZ1]+FS]/"
M`OU\I?&"OP^O=KVZKPKNRQ4?S;A^7U8NT35)*9%-77=A8\DMT'\J#7DG[R42
M>5#6]J&.<H.IV#%B@T%";W/-6VY5&A0CFS7BT5VG5QD9$CR?M4Y%UV$:'<JE
M0;E=2TR[8Q[<RZQR(H%6<D,LJ8J:8&.(%SAV78="IE>;VVWW6I56K.U8]!K9
M+)982"@'"TL)0BT4)J5?LXQ962$Q0CTTG9SO?$'HH+`(#FMIV#1*.RBY*YW.
MJ5*/G))E#0SZSV2%K[.6EY$!&/BXQU,/F3=_)/@`19L6BBSIT`=T$5`]N;[+
M?:13'-?96ZX5:K/+9*D@ZNUL=AAH)S8YI0"BG#P*$J]9JS,J<#%$L=&D=/#`
M8H@@/B+W]4?\4/VT_P"87(Z.E)^1=6_W\<UOZW>1>2-8QC&!$``1'V``=Q'Y
M@#,?VZ>;U`>MU1Z`B(2_&SH_4EIMN\D`AG$#9^>._P"%<L=603HY0/'R#[1V
MI$W]V;J-782%7MTT9J_:%.\1,3(!`.P`'S``>WVC[/G'Y<UQC&,8QC&,8QC&
M,8QC*>K;7UPWFQKBUQ@TY@KGT,[0SOL5-WX@(+51WX!9)N04$$Q0.X*H"G=,
M2@<!*%0L8QC&,8QC(?\`K35FH/\`C7J38.P['Q>1H&B>5&H]RW#57,:_0>L=
M"\BHBOQ=W@4M+6*[V&OVR*A;$[D[.QO]"&3JUD@G]SH,/&V>(/674L]91,:!
MUGK+J'<B;)N;BA4NFQJF;H]YX3.Y6,XW;EU3N':>J8K4.\+1MJZ<H)JQZ:T_
M%5Z.VAL&FP;CB?KVCP5B;_";7EMNLOMJ\NZS78/6SK+F*'8.WZ^WS``B(@`?
MH*'L#]`9`]UMF?"6+=<,=B<O*CL;DK;*CMF]0_%KI_59A2[31^8.]+[2T:O'
M-=G46[5N4@W\#JU@X]>I7FP34%5=<IS;Y_,)6!Q+Q]?DH.M,\+6E#W5T<>$G
M4&0U-LW3D;QFZJ>YF&G9JVQNU-#4"\SS]&P,M2Q$K.OY2"N[WC9JJ7(>#L1B
MN3TN7--3%-F!CXEA,&LFX50T)RGIG$*G\](>`V-J+6GW.YSOOND&>Y2-)*#A
M[53N5^T=?QFQ*\6R+.48F\4K0=2I)JY;(Q*+L%<KD%#6"(<-21;-\U[=A#UO
MDIHK<=IYK1\'?;IIC[EDTYLSC&_VHJA,S%4GQ?W<T=NR@_"%S(NXS9LA;82A
M1:VQ(;T.T2IWK&(=.G+6>,U>YU'3^L]]NW`WA7<MJ+R#K9MLXI<<[)L%W+"M
MZV=W2;U/3I&R.Y0%U5ERR;N6<.G,@590ROIBRPJ]CB8`I-TI/R+JW^_CFM_6
M[R+R1K&,8RUWFMREI'"CBEOGE3L0Y!J^D=<3]U5CQ6*@K89IJ@5G4J@R5.8B
M99*YVY[!U6,*<Y"F?3"(&.4H&,%H71HXNWCCAPNKUGWB0SKE3RNMMGY>\K)E
MVEX9-QNC>SE*TNZVZ,J9PZ10UU5E*W06L>=^];,%H%\#)4J"_AR5_&,8QC&,
M8QC&,8QC&,I!=-H0C4DC5ZTJ_M%S=,7C9I#U)#UJ\CG*R"J"+N4=)*)L(A%J
MN8JJIWKM)4H$$2)B(!D:*U9L:,L:N+P<N,]YPLS1(L71WRSHPB4Q")`F8505
M.(G*X*)D%"F\_P`X4Q%3):ZBRDHZJUN/F516EF4%$M))4QP4,=\W8H).1,J!
MC>:;SB'`ROB$53`*G<?%WST6,8QC&,8R(?J-V.L[$N?'K6FKN1G%33/+[CYO
MRA\E]7UKE^C-MJ3<HY;7NUM9RC>NU\TG4'NPG;J$V'*L49/7TX^DZ#.D;R#A
MW"SK:.36])HCE5LW75Y6HG-GD1T\IJVW]U3X#1^M.'+7:3O;EDGI.5?,YI65
MH-ANFP[3.UYNV7B'035>K[6(JK)O/3MOE6,$W,\9RJ`/?_O_`+_S^7WA[,M;
MY(<).(_,!2H*\H^.6G]^GH!)PE*':]'A[H%6+9319K`$&6807+'>N1A(?UD+
M<I1=A&,@6$P-TP+2.T]*SIS7/2]:X\6/A?QX?:5IMOE;[4==):XAHZO5:WSP
MH#/S]=2BR,G<*_L!&S="P&C7C9*=:((LY9%XU232+ZW=G3FX)\C*9JC7FZ^)
MNB-ATC1;9K'Z>JT[KR""%UM#-&S!D2MT]E'-V"<+4UVD5%-7]2:>&LR;>,CT
M9*)=D9-@2^^]^G?P:Y./=6R&_>*.B=K.=*LV43JXUOUW`2"5-K\<*)F-3BVR
M;9NU-2VIFZ!T*2^0>5%,Z29RP@&+W&\1-!!JW1;-D4F[=`K=%!!!,B2***0I
MII))))@4B:2:92D33(4I"$*4A2@4``([>E)^1=6_W\<UOZW>1>2-8QC&0`=0
MLX\[>HYPOZ9,8`RNG=-+QW40YQ)H^)6.=U+6<X,1QCTY-J)$(@L79&V3JV><
MKZ\BV>+5FNL)8C)XT()B3_%#L`!\OM$>WN$1'N8?;W]XB(]OD]V:XQC&,8QC
M&,8QC&,T$0`!$1```.XB/R`'O$?T!\H^X/ERE$YMV":O58*ILWVP+.G[#PU6
M!-T@R-W``-,S9C>J8A(#=P4\YPJX*("`-A'.F"E7^]E\>Q;#\'854OX5(HSI
M9L"Q!#_HSUI,`/WW<.Q%VL85JS,/?LJ8/?5*NU6NU*/+%UN'80[$OM%%D@5,
M5C^W_>N5A\2[M<0$?$NY555-\IQSOO"7OW[!W]W?Y>WO[`/O`/T>[]&:XQC&
M,8QC&6S[Q;<1]LV:H<7>147H;:%HV1&6&Y4S0^WH2CWV1M<-2D4T[);(C7MN
M8S!G,972R*#60L248FV8KOD67IQ73@B!J:<,*AT[XF/V&[X%4/BE4FM3O%BU
M1M=+C70]:4E[7=@4F57:V"A[$8T:#A9>*L4(_`ZZD#9T$'`(.6\FT058/6KM
M>^/&,8S8I^*'[:?\PN1T=*3\BZM_OXYK?UN\B\D:QC&>&V=L6GZAUS?-K;"F
MFM;H>MJ?9;Y=+`^."32$JE1AGL_8)1PH8Q`*DQBH]TX'N8/$8A2`/B,`9#AT
M/]=VZ^ZNWAU,=S0CF)WAU.]H'WRVC90@&E:%Q@KK9>I\3]7`L?SSE80NLDBV
MTA$)!TV75N*:_P"`J00"<C&,8QC&,8QC&,8S:<Y$RF.<Q2E(43&,80*4I2@(
MF,8PB`%*``(B8P@4`#N(@&4BE=O1:KU:#H48]V+84A\M5M7CI!"1QQ'P@::L
MZW_*6)`'\9-)5RY$0\()`(@.=:77USNY06VA9?1XM3\+X"4I=S&0XD-X3`C-
MSGB++S0@'X*J*1VC(3`(E`Y1]M6(*NP=9CTHJOQ3"(CT0#P-&#9-NEW```5%
M`(`&65,`!XUEC**G'VF.(^W.YQC&,8QC&,8QD-%ZL6Q^$?-ODER'LG$[??)7
M5W*"G:&CJMMOC%0V6Y]CZ>6U!4)>JR^C[QJ]&Q1FQT-<2<VX<[6IMGU_"6F!
M4MM]NS.Y-8%TSBY*0]OQ"CMF[KYD[RYKR/'#9/$_5MUT/JS2$#6-SQU7J.Z=
M_P!CI-XNML5W%L;6M4L-B<T>)HT)/HZZUDAL>0#94E$2EE5D("IP3>(92,L&
M,8QFQ3\4/VT_YA<CHZ4GY%U;_?QS6_K=Y%Y(UC&,@8ZT<_,<DI[B?TC=>R;U
MG/\`/;9(SG(F4AEUD7](X/Z(>1UWWI)KO6_D*1#C8;]K`:UKRJDBP&76?3<6
M@+H3+(9.?7H"&JL#"UFNQC.%@*]%1T'!P\>@1LPB8:(9H1T5&,FZ?^[0:1[!
MLW9MDB`!4T4"$*'8,[C&,8QC&,8QC&,^:JR2":BRZB:**1#**JJG*FFFF0!,
M8ZBAQ*0A"@`B8YQ`H``B(AE'W^WFLDY7A]:PSS8DRD8Z2SB-.5G5(Q4!,7O*
M6AR4&/<H@!@;QWIJZ@`)2B01`<XJ>M;+<1*YVO9C2+,QO,+1JJ=S#U1(!-X@
M2DW13DE[`)`'L/I*Z#;Q%'LB<H^VKD3#1,"Q0C(6.914>V*!46;!LDU;I@``
M'<$D2E*)S>$!,H8#*'-^$<QA$1SLL8QC&,8QC&,8QD$_/5ET-%N0TFKSNWAJ
MVB\@1J%/))0%LY@[MTW*IU(C1Z-1=C2*1N"G5YN@[:*/#HRB,(F\E"!YCUTZ
M%)(Q/GTQ9CCT7E+OBM=._:-CVQP*:Z0UI*61VAMC9F[],TCE8YO=S)(06HM@
M[1LEM<IS]CU.>)GMQ4^GV24@(*19T65F(ZNV.QN`FYW,8QC-BGXH?MI_S"Y'
M1TI/R+JW^_CFM_6[R+R1K&,^+A=%J@LY<+)-T$$CJK+KG*FB@DF43J++*',4
MB:*1"F454.8I")E,<Q@*41"`CI-M#<T.5'-;J_3J:KRG;<L:O#W@VL[`ZB+3
MA_QWL3MA8;[7EC`8OJW?>ZFTW;E"><J*):X0B1@1=&`\_N,8QC&,8QC&,^#E
MRV9H*NG;A%JV;D,HNX<*IH(()E#N91994Q$TR%#VF,<Q0`/;WRCSG;9IY=:,
MU;`N;T^3.9%>;\9XNE1B@=P,+RP.$P!^=/MX_18=)THL4!`BI>X#GR0U9+VD
MR;S;-E5LP`;S4ZA"@O#4IH;Q',4B[5(Y'\\9+Q`!5I1<$S`'86Q@'VU?CXV/
MB6:$?&,FD>Q;$`C=FR;I-6J!`]Q4D$2$3('R]P+W$>XB(B/?.=C&,8QC&,8Q
MC&,8R#/J)<LN<&I-V-M>U;6Z7'3B0[I47,3_`%"F/&N]<]9"#GU@5&Q5AUH?
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M%>&I#`X"`&/ZQ53![-'3'N(MHAN8#AV$'(`/<-6FIG-@52D=K6)S=W29P61K
MR)#15(CE`'N4J,(@8IY4R0_@D=3"JPG*`"9N`Y6)HS:,&R+-BV;LVC8@)-VK
M5%-NW03+W\*:*")2))D*`]@*0I0SDXQC&,8QC&,8QC&,8S:)2F]X>WL(`(=P
M,`#[^Q@[&#O\O80RF=<TII^G["NFVJGJ[7U8VAL=A$1>PMAUZGU^%NEZCZ^X
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MF#,O-,4!5!`%!]ILM?Z4GY%U;_?QS6_K=Y%Y(UC-!'L`C[^WN#YQ^0`[_*(^
MP/TY`!QA(//WK#<DN9#GM+\?.FS"3W!#BV[]BT1.<C[6DQG.9&SX58A"^!W6
M&)JYI4CE)V^CY)B+A=OY#ALIWR`,8QC&,8QFG</^P'M_G[LX$I+1D*R7DI=^
MSC(]L43N'K]RDT:HE#O[5%UCD3`1[=BE\0G,/L*41]F4A'9\[<3':ZHK*LNV
M$YDC76S$<PM/0["!159%.0):P&*(_P#28MT41$`$R_@'N/(C]1DDW*$OLV>>
M;!E45"KH1[Q,&-/C%NY3!ZOK+<WHJQDQ`2E<R8NUCE`#"0AN^5@0;H-44F[9
M%)!!$A4T444R)(I)E#L5-)),I4TR%#L`%(4I0`.P!GVQC&,8QC&,8QC&,8QC
M&,8RUWFSQO/S`XC<C^+B=P+K]3?VFK[J=.[G@36DE4/=8)S#%GCUPLQ7S398
MTS@')HPLY$F>`040D&HF\TL=>]NE/MJ7;<"MB<7>45>TIR6X,\<I[BPRV-=-
M*??+HNU-67/5U6UU9/A!0VM^JTO!SD/*5=K?:*LRM\BQB9I9Q&3+6:8+J+9:
M^M]S_6/2VO\`CM#<(>6K32&Q]7\*=M<"-KW_`&-I!MM1KMC4&\;Q+[3N]RC*
M[&7^EJ4S94/M"S6BX4Y9U,VJ%:%DV4))D>,XQ=:6YFU^@3965<@*-Q$Y;(Z%
MI=OZ>5.Z9_)-E==)LMIRFSM)U1\]<CLNHOXV\T,E+W3*,9RU0C^0?I6&KFC[
M`*C6,9.HQJJ>?O36IZGH;3NJM(4)!=K1].Z[H>KJ<V='35=(5>@5V)JD"FZ6
M22036=!&1+87*Q44P6<"JH!"`?PA9ITI/R+JW^_CFM_6[R+R1K&1Q]5[F%*\
M).#VW=MTAF>;W=8T8?3/&JHMDBNI*Z<C=QR*=&U)!Q<>99L,FJRL$E\*I%BF
MX164@ZW*G3.!DPSV_3;X>QG!#A5H;C,W=EFK-1Z@20VC;3+'>/+UN6X.W%NV
MY='TFN7T^44GK[,SBS)Y)JN7Q8=*+:+.%2M2#E\N,8QC&,=_^_\`OWY378FR
MZY1X66.O-11;$2.>&AH11R19^]D@:J'9(^KT#'=BB=?R_-4,FFD5/Q"90A?P
M@C51V5?6TP%D+;IT\N17TLRZLBY5;K&)W4\A6/.<T>=D;N)/0_1?1RI#X$TR
M]BB$@U8U:QETXJU;#D)*]6%=LUDDF]A!,D%!+NT4W(MHNLM_^5-S-A4%$5G"
M;I83)^,#$$>P5K33(D0B:9"IIIE*0A"%`A"$*`%*0A2@!2%*```%*`%`````
M,WXQC&,8QC&,8QC&,8QC&,8QC&,9L4_%#]M/^87(Z.E)^1=6_P!_'-;^MWD7
MDC6:&,!0$QA`I0#N(B/8``/E$1S'_OIQZ@?6VH.K4A];\<>C_38S>6QD@_XB
M#LG.O?4,Z8:5K[P`3(DX?Z3U4C,;!9NV+]P:'L\T:/E&**RJ1LR``#L`!\P`
M'M]H^SYQ^7-<8QC&>>L%LK54:B]L<Y%PK?MW(>1>(MC*C_Y$$3F\]PH/8>R:
M"2AQ[>PHY34=K3%C[IZWH4[9$C`8"6&=`U1J_;OV*NBZDT_64DF'XPD9,`$Y
M.PE4[&`0#0]A6CN:];!6C6*G?S*WKM`\$T$A@#Q).;`[](G713_B*>0+(!+W
M\'A$1'/:UG7-*J`&-`5V.:.5/%YTBJF+Z6<"<HE4%Q*OC.)!;S`$?$4SCP"`
MB'A`![9YA#1.K&TX6?2JC4'A'(/4VYG+T\4D[*IYI54X@[@8\H%4_#30\@6R
M9@`2(%\)>U7<8QC&,8QC&,8QC&,8QC&,8QC&,8S8I^*'[:?\PN1T=*3\BZM_
MOXYK?UN\B\D:S!N^Z>.O'S(X0<CJ%PVX7VUMIE\AJN"VGM/;!Z;6;1;9IU=Y
M.PQ]<IE2+>(BP0$-!1,57SR\Y/,H9Q-24S*-(QE)1#>!DV\O[3[CXYY6WD?`
M<[M2;7@VTWN!QN1'EI>-YE0=&L6VK!O5R\K]G+>U``8=C)5J1ID<2ILX-*%A
MPKDHYCXZO-S0;Y^^S7<8QG7R4M%PS51]+2+*,9)`)E'<@Z09MB``"(B99P=-
M/W![@,(C\@92A7<T;*J'::]KMAV&[*($%U#M!CZXBH81``=666!LQ*3N'<3M
M"//P0'P@80[#\P@=OVS\*P6J,H$6IX?%$4E#UG.F2\7<4U[1*I@BU6[>P3QL
M<(`'?PG'O[/0U_4E%K[KUF2(]<S@B)E+#97"U@FU5!-W%3TV3,N"!Q[?^$2;
ME`.P`4`#*D@`!\GN]WZ/U?,'Z`]F:XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,V
M*?BA^VG_`#"Y'1TI1[<+:V/_`.>.:W];O(O_`#_5GWV;U;>F=IZR[!I.Q><W
M&.MW?5K&S/+S2%]MU-Y<H1:GP[J<L$,-8CI!W+2%H9,F;A).I1C=Y97LH0L(
MRBUYDY&(X[&P>D1/?='%QGNH5RJ?7+AOJ69JU?H'`JB5*G4L^Y[-Q\BK#.6%
M'<?)4;&TD%UGVRU9QW*ZWH\;-QJ=,KS\KTJC]D\2?6B=GI/]'SC%TC=66^CZ
M,<VJZW?9\E$2VU=OW]2*-;KDI7DI%&MPJ#"#91\+7:G6BR\LI"P3!%POZ7*R
M#^6EI9ZN1=&4F>GX>L1;J:GI!O&1C(I3.';DXE(7QF`B:9"E`RBRRIS`FB@B
M0ZRRABIID,80#/$U/<.O;HX=-(2P(F=LVZCQ9M((.(E46B(`*[I()%-N59%N
M`]W!TCF%`O8ZI2$$##P9+=%03=JQ=9+*7V:3,9,8VEL%)@B:@`';TJ6**<,T
M(`C_`+PZK\13[#W)W#L/`[;JMHAW&O:MBE#"/8/!;[=Y1B"``/<$:^Q4-[!'
MP^F'2-[A,("`\^,TO4$G24I9!D[[-I^$P2=U?JS0)G#VF]%BU/!#LR>+\0B+
M+\````/[/;5=%%%NDF@@DFBBD4I$DDB$323(7V%(FF0"D(4H>P"E*```!V#V
M9]<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S8I^*'[:?\PN0S\5879MDZ16[*
M]I66&!W'/%ZFT-JB<+(EAS0^R)/DURM94B3),'?Q9(A1C9%HURE*J2+).-53
M(^4<HD;F.'X\-6H>PMD[!A==TRN6"]['N%A1K=?JU:9N;+8[/:9%V9DWCHAE
M&`\<S$D^DC&*FJT!QZ0L)W?FG3\2V?N@\6Z_LRH\:./55W4^+);BK6CM30&U
MI$JZ;D)#9$-0*]'7AX#E)R\2="XLK:34,Y2<KIN3B9=-0R:A<]Y:=F4JGJ%:
MS,XW"34$2MX2/*K*SCE3V`5-")CB.'@F.(@4IE4TDO%[U`]N6[;D'8^TZH48
M?7LU#P$+(%F/!,.VR-DFO+0<-">B5AMY[A--JFZ4=B5RY!XJ``#=L<X"0]#]
M.ZIF[3=(L9NLO0K$:X4=3IIJ.=-&+A)%)8J<;X'::`NUW+KRBG;I@<I$2+'<
M>%,/"I)-'1<;$-$V,5'LHUFD'9-I'M4&;8GL`!\*#=--(._8.X^'N/RYS\8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC(C^<76!TUPCVY+:;D=*<A=[V37>A%
MN5>_WNC:W2I:'T!QP;6H]/7V;>W5RO--4DQ&30?/$JG4$9VRF@8N2G%FC9B@
MF=:4:FW.L[&IE2V!2I=M8*=>:Y7+C4YYF"H,YNM6>-8SD#+M/.(DKZ+)13]H
M\0\Q,B@)K%`Y"'`Q0Q"6.\KSRRTM0NCQQDV"XUV^ONR^96P.HSR(AW;)-+C1
MQ!E^<W(EBOKJ-F5%C,8W=_(\IQJE:A7H*R453)%S-.(GU7.>MHK))U!6-(Z@
MI&OM8\6-%Q"M:U34(;7]'?0L!%UJNUNMP48$6R9#=Y1DE+2*AD/-5E'C<7KR
M:>.G[YZX<.W[A16LX4O8-M[GOE]]31R@#XJQKKQQ*`D,4/\`<O;,[!29=@(=
MR*E:$9)F]HD,4!#/>U>B4NF)F+6X.,C55>XN'I"@XDG1C`'B,ZE'1UI!R8P^
MT15<&#N/L`,]AYB7_G)[?_N+_G[_`'_IS3QIA_\`4)_B<!_]1S7S$_I"?6+]
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M&5Z>8:QY!,GERJ2++<H3,]`#K_7"]:M3*V&V,_.O!I+-G,08P.3.%(_(BX4Z
M7GN.G#GBGQ^M;MJ_L^C^.6D=36-ZP4!5B\L&NM<5JJS+ADJ'_59*RD4Z%JI[
MU6_EJ>SQ]@L"J72$TCJB\7-347+WEIIF6VGL/8>YI:F46X\:V24E:+[<)VZ6
M>9*RL/&V>M%D;L)FQ2+>,?V:4LKR#BQ0BDY,C9L0@7`_$$V)^<KZBP?H"\<8
M``/U%#B:!2A^@H``?(&/B"[%_.5]1;^.>,/]IV/B"[%_.5]1;^.>,/\`:=CX
M@NQ?SE?46_CGC#_:=CX@NQ?SE?46_CGC#_:=GS5X%;`03,JMU+^HFDD3MXE%
M;YQ>3(7N(%#Q'/Q/*4O<P@`=Q#N(@`>T0#.,IP7NJ+5R]5ZG'4+39LTE%W;I
M387%DC9JBBF9559PN;BD"*"2213***K'(FFF4QSF*0!$.'\2:S^I?A'_`+47
MJ`_!_P!$]8>O/OE<5/4_H/A\?IOK3XJOH'H?A_"]*](]'[>WS.V=DUX'WQ\V
M;O&?4RZB#IHZ12<-G+>^\75V[ANL0JB*Z"Z7%`Z2R*J9BJ)*I'.FH0Q3D,8H
M@(_?X@NQ?SE?46_CGC#_`&G8^(+L7\Y7U%OXYXP_VG8^(+L7\Y7U%OXYXP_V
MG9H/`;8@!W'J6=18`[@'MO/&#WB(``?DG>\1$``/>(B`![<ZAMPEM#R,<3+3
MJA]0)U$M!?%=2;?9/%1>/;#&**HR(.'J7%4[5`6"J"Z3X%E2>AJ(JD<^49,X
M%T^)-9_4OPC_`-J+U`?@_P"B>L/7GWRN*GJ?T'P^/TWUI\57T#T/P_A>E>D>
MC]O;YG;-7?"6T,(?X0/>J'U`F<%Z.@[&9=;)XJ-HD&KGRP;N1DUN*J;$&Z_G
M)>0OZ1Y*WFI^4<_F$\7:I<"=@K)D61ZEW44425(51-0EZXOG(HF<H&(<AR\3
MQ*<ARB!BF*(E,40,41`0'-_Q!=B_G*^HM_'/&'^T['Q!=B_G*^HM_'/&'^T[
M'Q!=B_G*^HM_'/&'^T[.N=\&[@P=1[%[U/>H.T>2SA5I%M'6Q>+#=S(ND6YW
M:S9@@MQ3(J\<)-4U'*B#8BJI&Y#KF("1#'#[CP2O(*B@/4UZAWG%.5,R7WP.
M+?F@<P`)2"F/%'Q@80,40*)?$("`@`]P[\4G!^VJ2RL"GU/^H,>;09DD%X@F
MQN*YI1%@HIY*;U6.+Q3%ZFS45_W:;LZ!6YU/P"JB<0##?A!;74F]A6W4_P"H
M*XEXU)NM(Q:.QN*ZLBP1=E$[59ZQ3XIF=M$G)0$S=1RBD1<H=T3'#VYVGQ!=
MB_G*^HM_'/&'^T['Q!=B_G*^HM_'/&'^T['Q!=B_G*^HM_'/&'^T[/BXX&7Y
MH@LY<]3'J)-V[=)19==:^<7DD444B"HJJLJIQ/*FDDF0ICJ**&*0A"B8YBE`
M1#KB<)+2I#_"%/JA=0-2!%F,@$T39'%4\2+`I!4,^"3+Q4%@+,J8"<SL''HY
M2@)C*@`".:+<)K.WAOA$OU1.H"C`>B$?^NU=E<4TX@&*H%%-X,H?BJ5AZ(H!
MR"FY](\@X')X5!\1>^K_`(26F+BPFY+JA]0*/AQ(W5]:OMD\5&D9Y;LR96JG
MK!SQ529^!R95(K<_G^%<5"`B)_&7OVI.`^PU"E.3J6]14Q3`!BF"\\8!`2F#
MN`@(<3NP@("`@(>P0$!`1`0'-WQ!=B_G*^HM_'/&'^T['Q!=B_G*^HM_'/&'
M^T['Q!=B_G*^HM_'/&'^T[.L'@];RRI8,W4]Z@Y9D[,T@2)'8O%<),S`BH(&
M>ECQXI@\,S*L()&=E0%N500(*H']F<DO!*\F5%`O4UZAQE@.*0I%V!Q;%0%"
M_C$%,.*/C`Y>P]R>'Q!\H9Q4.$%M=2;Z&;=3_J"KR\:DW7D8M'8W%=618(NR
MB=JL]8I\4S.VB3DH"9NHY12(N4/$B8X>W#+@_;9%Y)1S#J?]09Z_AU4499DT
MV-Q7<NXM9PF*J",BU1XIJ+L%5D@%1)-XFB=5,!.F4Q0$0[3X@NQ?SE?46_CG
MC#_:=G:Q_!B_L4E$E.HIU`9$5%A5!:0NO&TZJ8"FDGY*8MN+;4@(@*8J@!B&
M/YBJHB<2"0A)!<8QC&:"4IOQBE']8`/_`*YM4'L0X]^W8AA[A[P]@^W_``]^
M8!O+Z/0=VCJO<X)-J5QSOXU];CB)J7C#>E91X.PJ3JN#FM6U^@:YI#=*0"3;
M4K8-)LEP<3]2CA3A;NF5Z^?Q[E2).=MGY$_%]_?L90/U`!S``?J+V\(?H#-^
M,8R'_KIZ]F=S].?9>B*Y=-%TVP;MV7QVH$6ER&V['Z3H%X(7>]!M\WK(MW?#
MYI9W8%;J4S78R$ARJV.<2=O65>0<R_HB"F+CLEW7*/1K;TTI?BAQRXSA5.M=
MTPM*<ZWO$*Q[#7XV;_T5R#K]UO$%%/#['E%[3!K,BU2`K6P:W-KK,CBLU%=K
M&*"H@;T2E(J2N^T^GJ,*P)T[F_W2J76Y-/%D'`:H]`5XYFV6/'/U:=\:$4UF
M;:Y%90^H0;&@T)Y8S,L<BZ522&?7[GN>OHW0O.3444HL73'';JG\VM'\:XPK
MIR]AZSHVLVJN3%?J56=KN'":U5KD]8;&RAB-#BU9IF59IF,*)A"??&,H_OK4
MJV\]46S5B.T]NZ6/;$8UJ;96B+:SHNUJXBSF&$DN:I6Q]!V)&$<2:#-2'?O$
MXI9X$4_?$CW#!\=O(-L&#4B$@XZ"_3,TI,R$O):9WKUR*YHGDGZXF'9AN&E)
M_EQNIS/P%YESN$!?P]IGJ_7B6562!1O(KCW=^`RWBSLU*14E=]I]/485@3IW
M-_NE4NMR:>+(.`U1Z`KQS-LL>.?JT[XT(IK,VUR*RA]0@V-!H3RQF98Y%TJD
MD/E>-M:B=Q\FN$_3]VO"M+KT\*QUK>LYK.BZBLSMQ+:JFZ3H34=7N?'[72S&
M0>KQ5AJ%.N5UO:E/AEDG#(':[EBT,JJB9,V1U]SFV2>F.FG7JZ\E7\Y2]7\A
M>5.I=-2TC).YQ1?3%`WE:XF@,&=@>N7:TW#5UD9U6()V5PJ@WAX5E%MQ!&/(
M`3N8QF,WU%],KU7KA]%+<:FX-W6A':6\N2T2CJ6UWE"1TIK(E,XL$:%>ZMHC
M2#C@KLQ:UG3B0N$O*2L_(RSLQ4V[B/CD46"4;&R]>QN@N?&QNHUMK0?3QYHZ
MCV3UF=<:;K6U*=NNW[`Y@:5L4HKK?7^M(BK1=3=DU-7[)HV5I9)VUZ6MR#K9
M2UE?/T9$\/6F\7-HT1UK%FK5PXH<W89LDOS^V=]TY;>XV[?V&C)NW5^F-+3,
MK?:)=]%2O9^:13U77*'#UL["G.51AZJS7;R+0C1"1`R_UZ;L<SKEAZ$7,2"1
M`O-3F1SKZC=%Y@W@DD[<WO<%+6F]IM[?7=FMP>F>6.#ULPK%-FZ^UFRNVM'=
MHQ\NR!N:0!5SGXIB)DR"/O$A1']8E`1_US?C(J^LK5.,5IX-W`_,K=U[TOQK
MJ][UE<]I-M>G37F=U1E<M3=W#\>G<"G'2<O;(G;=E/#0CJK5Q)K-3"Z#0A9%
MA&HR3E/%_L7&C9=)UKQWJNU=*3/$[@-U'>O7Q6D*GP!L\XU2:ZPXZ/Z'<7A:
M%M>KQ4BYKNO$.1MZAZ_=++H=JX<QE8=P41!G!C)G.SSS>N*A6+IR,T[T^;/#
ML)SIU5_[HOYX:P@=/2;]=YJ,:]K3C]7=C:VT*:,=/E8*6U[7MI6.U/(G7SML
M\8!-23N.,D=P5!!/B\.J;4.16]NF%P9Y`Q;/8_`ZI<UNNC4]6:MN\N_FM:WF
MLZ#BX%;2<&]&4DG#2VQ.I&EMN*^O"$5$(1$SOU>J9O&"FWR-_N<:[7"\=(SC
M:YMDU*65K69_?6O:'8IAXYDWDIJW7>^]C5#6Y"2[E54TM'0M5BF-;AGR1Q1/
M#PK!!(QRM_,/.7C-#=NP]_8'8>_ZOE_TS#0WMQ!UONWJ6SE+X,K[2W9S>IW4
M4U=RMY@=1"YRK"%JG!#5<2DV`>%M,O40TAPV(O,4Q$]5KO'6,:V)H1F^<EV1
M+$"%D/@S1K5=(B>+?/O5O-#:_'KI]\KJ;SCZQ>]-::;Y+Z)WI;MM<H];WK<5
M_NSO5,H5S!/R:?-2M40+`E.M^O$&ZMKJ3AL_<6*0B)5\FW);?PA"0HE5Z-G-
MS7S(IN?W*[D_U7*[R=MZ$@\>7G<C..AMW.)"K;)9DD"O;/!:X=T^@S%;8S1G
M#:E.T8V59"U-)%6<5TZ3%8JVH>07W.WM'2I2DV5SQXR]1.2YUW5C,.YBS;Q-
M76GWQ8BT[?D@>*N)Z7J6W$W$7"SL\*[N+5:_!HJQA8$00SL0]P=_FQC&,8QC
M&6,W?II<$=C\GX#F;>.,6L;)R8K3^N3$7M.1CI`TD>P4YL5E3K5,02,FC4;)
M<:<T30:U&Y6.O2UHJ[=JR2@I=@1DS!"^;&,8RC>_./>D^4FJ[/I+D+K*H[<U
M5<46J5AI-TBTY2'>J,':3^,?(AXDG<;+Q$@@A(PLW%.F,Q#2*"#^+?-':*:Q
M;8ZQTL.GO3^-UXXCP'%+5;?C[LN81L>P*&]CY6:5N5H:*LEHZW62XS<O(WZ7
MN4,K'1ZE?M[NU*62O'8,C0<G'BU2\/U_V6W3^^*Y\3#XK>M/BV?"KX>?>Z\B
M<\S[X/F^9]\;X:^NOOA_?)[?\/\`?$^%OPT]"_Y?Z\]`_P"&RY70''G2?%C5
M-7TAQ[UK5]3ZKIR3PE?IM29':1K162>KR4K(.5G"SJ1EIF8DG+B2FIV8?2$S
M,R+A=])OW3I4ZHUFQC`AW]_Z!_R'N'^N6<.NGUPQ?<9IOAP]X[:Y=\9K#+3<
M_*:@<1SU:KFL%@MCB]25A8F4D#2\18/ABZ6LD?.P\HPEH:8$CV&=QZJ*(D\7
M_LMNG]\5SXF'Q6]:?%L^%7P\^]UY$YYGWP?-\S[XWPU]=??#^^3V_P"'^^)\
M+?AIZ%_R_P!>>@?\-GQM72PZ?%TXTTGB!8>*NKG''C6\X-HH6OF#.9@QJ%K5
M6?KO;=7[=`S,9?(RX3"DK*&L-L;VDMAL@2<D2>DI%-\Y(I=QI_3NKN/^LZ;I
MK2U$K6L]7:^ATX&FT:H1B,17X"+(NNZ.@R9(]^ZKIZZ=R$@\7.L^DY-X\DY%
MRZ?NW+E6I.,91V_Z`TWM+8>F]L;`U]`6G8O'V;L]CTS;91)T>6U]-W.`^"]H
MD8`Z#I!!->:@`",>>EH.TS-RD%---4A5`MH5Z7'3]6Y/?'*4XJ:I-R0^$Z5Y
M'8_JR1`37Y`1.CL<]1"4"A*;+37$79-CGJIKL#T1?>O?31%P/:PW34X)U[E/
M(<UX;C'K&/Y/2<C*SCK:J$=(^L26:=8'BYVZ,:^I)GIL9?IV.5793E_C:VTN
MDPU<ND9&=<E=./-:MZ:G!/2?(RU\M-5\8]8TGD)<W%E>S6QX6.D"/49&YB8;
MG+UR#<2;BJ4R;N?F+!<9NFP$!+6H'+LL^\D"NW0+7R8QEO/)GBAQWYCZ[:ZG
MY-ZGJNY-=,[-%W)M4K@B^7B4;/"M)-C%3)4X]]'KB\8-9F31;F,N9,@/%3"F
M)_`8EKE<Z/?3.J.G-HZ`K?#C3\-J+<\K4Y[8],81TVBTG[!1?6'P-L:,D,X>
M=@+)5QEI,\#8:S*PLU&*OW2K5\FHLH8WJYCI9=/J=XPP/#:3XKZQ6XX5BS$N
M]>UXBVFF2D->RK.ES[`CKHPF6VPFNPW(OGJ;^_)VT+?(MGKQF_F7+-RLW/I?
M.EET^=E\=M:\4+AQ5U<\T%IUZI):MH,6REZN2@R;H[M25E*M9JK,0ETB)2Q*
MR#]6VR3:QE?7!5\]5M*\PH[7.>\/5^KM=:4U[4-3ZEI=;UWK:@P3*M4VE5&*
M:PM=KD''D$C6/C(UF0B*")1,HJJ<0.NY<JKNW2J[I=993WF,?]_Y9&%/=&+I
M>V?;4IO:>X8:>D]NS6Q'6V96_.6=C&POMCO;+\,'=P<.4[&FD>:<V7_FZSCR
M`(HZ_&2%'_=94*F]+7I]:]Y*R7+ZF<4M45_D1*6&=MZNQ&47(B=E<[01=.S7
M>!JSB47H]9O-C*Z=C/W6N5B*M$R=X\5D)9PJ[<**=OJSIJ\$])\C;7RTU5QC
MUC2.0ES<61[-;'A8Z0(]1D;F)AN<O7(-S)N*I3)NY^8M\,9NG0$#+6H'+LL^
M\D"NW0+./W34X)\5]P7C??'SC'K'5FVMA-I5C8KC6HZ1*Z0C9V4)-SL/4XV0
MDW\%KZ#G9A)&3G(.@159B9E^@@ZDF;E5!(Q+Y,8QC&,8QC&,8QC&,8QC&,9H
M(@4.X^[N4/\`$Q@*'^HAD8E0ZN?$*VA"31_O]5/5UEV`ZU;!<@+YQFWE4..3
MR\-]@/\`5;>)=;TE*6&N()I*;$C'E.B;%9)R'K#VQ%:Q)9I-[(QJ+N3GQE^<
M1^01`IA`![B`@)@#L'80'Q=Q#P__`#=LU\0=^WM[]^W?PF[=_P!KMX?T>_W^
MSW^S`&`1[>WO[?>4P`/;YA$``?G#L(]P[B'<`$<IM==N46@6S5=&L<L9"V[G
MM<M3]>P+1HYD)"9DZ_3K!?;"[40:$4&/@H&L5J0>S$^_]'B6+A:)C%7(2<Y$
M-'E2`4*(`/8_M^=-0!^3W@)?9[__`%^8<U\8>S\;V^WV%,/R]O:`!W#]0]A]
M_P`PY3B%VU2)W:%VTXSDUD]B4"L4BZS]>?,'K!<U0V&O9F-6LT2NZ13;S4,]
MEZ9:H)=[&JN"1TW!/HR0!LY!`J]2<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC/FK^*'_P"Q+_14@C_IF(CKC>=)N/1CV;TV*;6+YL'FMNN-YH<>JEHIAJ?9
MX25?N.ZN2V]6U>OUSLSZF-J32M?ZZ@+5&[=LU^GK-'PT/7(A)RQ>.II["Q[_
M`*WEM&1,5<^H!&;"D]O/.K/%[YU/$]*Y["R&U!NS[6K+6.EXKC]*Z#2A7BU/
M^\],;&+N9SS"5$ZL*NX/L,F\%UX]I6CD[^L2,-6NIRE+U9\PWYONU<[]Q1JK
M1]\9'2//#0D1-M+ZR1A-KP3MW:]1\@^F]08=G$!4G+$^HJ8ZU*XU[;JJK9=E
M-12L5/\`I8CMF3Y2\*5Y&S:\C^4S)+;#GJ$L*=`\LY7D;/.BZPMK79]>YY.-
MCNXS6-90C-\O*<[TK-N&\FS">A*Y7M`-%-52<P\;3J['2ES]7O0![,`C5$NG
M#R\^]:#GTGT?[Y"N_P#BR799HS_PGKH*(%*+[!"0]3J2'D`+7TT2PA<0>`>M
M;FRZ(/WV-0[!LH\D>'W(R9YQEO-BW"^)M^VUO7FH[5K)AR)2F;`*<Z:DV^?L
M#S64!=B`C4';)FRJ3./1KT<U8T<UC'ZNE]":<_VDDURA8S-/Z8>O&'`D[B=Y
M$1,LWW_5=@\HX7:2VG5ZD_9.9CF7!1<1QMCZ\RL*SB^JZP;PCB#0?5)>].BR
M>]/*6LLYM'HMR[>1=RULENA+,2W(:3EGBS^6D8V3?\'G6J)&?>/%5U'<N^OY
MMKN(=VJLJ]=`:XJME5&PR1LR,\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M=8@<YG'A,<QB]S_@F,(E]G<0]@CV]@@';YLY"AC`L4`$0`3)]P`1`![B/?N'
MN'O\OS_+FA3&\\"^(?#YIP\/<>W8$S"`=O=V`0`0_2'?-Z8B*I@$1$`\SL`C
M[`['``[![@[`(@';W`/;W98QR[:-$MX].B<2:MTYI'F!8Z\C,)HIDE$8"P\0
M^3KF?@TI`I0=IP\XY@(%Q,1A%@92:\)$*O4%U(UF9&^9(QA*V[F$?$F(F[B(
M^(?"7VC\X_I',+C[HSV[M?5_*R4B]:;/V'KN,OW3&M"%ZCJ+=;)4F-T1B=^2
ML/%HVUI`2<>WL:4;$6RTQ<>G,)O",XZRV!BW!-M,R*3G(<X>0$%#\IN2+&)A
M8F+94_C;P'H=29QT:S9-:O1XVD;>D8ZF5UNV121A*I'R#QV_95V,(UB&KUTY
5=(,TUUU5#2:XQC&,8QC&,8QC&?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g342690.jpg
<DESCRIPTION>G342690.JPG
<TEXT>
begin 644 g342690.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?2$5!3%1(65]+7TQ)3D4N15!3_]L`0P`!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!_\``"P@`S`&)`0$1`/_$`!\``0`"`04!`0$`
M```````````("0<!`@,&"@4$"__$`%$0```'``(``P0"#`T"!`(+``$"`P0%
M!@<`"`D1$A,4%2$6,1<8&4%155B!E9C3U@HB(SAA<7B1H;&XT?`D,B5"0U,:
M1"8G-#8W4E=RDL'Q_]H`"`$!```_`/?QQQRJWQ8-P[!XOEN#DZX72&I-MT#L
M5&5:X/E]"ZO9]<7^91&1Z]>[+%9HZ[;MY#+IFY.I:J5DQHM*$G;&WK2-@EV,
M8#".E'['*N6=P%IWI'U<[,TC*.S79YMM689-96T?4*1D$1LSAC=:&G8AN^@5
M&1OF6YK`'461*E86U'EW$*VFI9FG58QS7%4GC;*W3;LJX[:8>ALCO-+%D#M;
M3]YSAUGEOD(N1ME?<8GN&@XVJ%G/"*.H9C/R1Z*,M+0L3)SL;`OGR\,RL5A;
ML4YI]*?CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCF/=.R3*
MMKJZE'V3,\^UFEK/F,HM4-,I=;OM76DHQ0RT;(*U^UQDM$J/H]4YE6+LS07#
M10QCMU$S&$1[NT8LHYFTCV#1LR8,$&S1BR:()-FC-JU3(@U;-6R)"(MV[=!,
MB*"*)")(I$(FF4I"E*$`?#,``Z[Z``!Y`'=WQ'P``^H`^W\['?+EA/''''''
M'''''''-HF*7_N,4O]8@'^8\>LOEY@/J`?OE`3A^'_R@/_/+\(<H:\5?Q^>N
M_A.;3F^(:YB&]ZI8]+R\=3B7^2M**YCV4.%LGZB+!^C:K5`2/Q`KRO.W9Q;-
M%FI6:S<WMQ4%4B<R_"[\2C+?%2ZVR'9C(J'H>=5:.U"VY8M7],+6R609BH1E
M9E'K\I:M,SL:$>X1M#1-N!WI78+-W(*H$("1U+'................?,F)F
M)K\3*3L[(LH>$A(][+3$O)N4F,9%Q<:V5>2$C(/W)DVK-BR:(K.73IPJFB@@
MDHJH<I"B(1HP+NWU9[03UCJ^%[%7+]8:JU^(2\*R;3<7)?"0<I,QG(QI/Q44
MK.0)7:[=LI-PI7\:DLY:$6<)"[;>VE2`^?S^?YP$/\!`!Y@?LWK-WP[#=$U/
M.L7MG8"X4ZO/9B'RVFV3/:C+V!1H@JNNLK8M.ME-JL7$1#9)65G%U)5Q,#%M
M7*==@[#.'8PSR"4IW/[*Z?0?#YJO7*GXTQ[`]U^NZO9:QV/5F]ZF,8R'.J?F
M>3V:]/#5NHSM?N]ID)G0-KSV@TJ*-:X0&C*3E[1,2$@:OEA)C`E6\1_NEV0A
MH^"ZO8)B\%K^18'>]=[3U;:IG09.NIZ50=TV7KDEUSR&7IXU^31E;_HO6_:I
M*#UNVQDI&UJH,:6^>9Q8GME>MX>PQ_WMQJO]'Z)WWM;2YQ..WK,,2U%K%156
MD[9?&<?O"]&CJ=!$J,"DM+2]A)-7^$AW<9$H.7BCL''N39R<$T%,*5#Q6L2L
MMW@*!.8YVJS6<<[Y`]8+^OHF*'BX+%MRO<?$2^2T?3;'"V>PPOJU^(LM2DJ3
M8L^>7^ILD+C54;[.TAY.,VI]V5^+3UBV#>,]PNIUS>TD]KNVBT+K[M,WC-AB
MNOO8.:R"N7:QZFXR/4E7!V,[#4E&@6!DO+2T=`MK2LFA)9_]+JT+F?:V=^L/
MP#_A_OS?QQQS0?J_.7_,.5[^&9_-XT'^V[XC_P#K\['\L)XXXXYH(@'S$0`/
MPB(!_GS0#D'_`+3%-_\`M'U#\OZ"^8\XE7*""9U5U"H)$`!.JN/L4B`(@`"9
M17T$*'F(!YB8`\Q`/K$`Y&W0.Z73[)BK&U/M5UPS4&Y!46^GNY9=4C)D*W*Z
M,8Z<[:F*@`5J8KD?X@C[`Q5@`4Q`PPNMWCL>$C3G:C!QWGQFUODSE3]RRE2V
M[4\45.Y=,TDD6^0U:['7.L[:*M4@2$P*.#M4BB)GS/V^"+%_").AK)4A*)3.
MXNNIK&`&SNF]2]0J<6Y(9U&-"+$F]P0R&&10,:6;+"J[?-BD;D7.K[,R8$/A
MN9_A"KF94!''_#VWFQK*D,9`=5WCJ9EA/4`JM2`[CZGK&SV=N7XJB+!P1"NN
MW34J[)THU%-VD3GXEO%8\431_P#\)>@F)U!`ZXIE>6:Z=U-T<H-B2[N*4=K,
M,EZ4U"`653`S%^HR1NI4BH%7;ED3N%DP:C;3X\NG)IHM&F?Y:*PM1`V;^'Q/
M2"Z!!?QZ#PGQOM/WPSQN=1,4Y'V2[BE-B'C%V[LK,5O:*,]H]<?&ET%J9I?.
MV'<=BB\(DDNE4K+X:W6!NT]LH[8OC,'5!Z^=G;<U]"'N,DU.I8W:R)B.DT5/
M>%TU$?T)>$KVNNI?5JFS;7?4'OLCR+'7_%D[XV>-.!I%Z=\FI2^NE/ZLU`I%
M&#M1!LC&F9)I-53L"J(@)%D(#]K?`PUW().IZA@.04.\S=@@TZ/?6F.2FRSU
MM9&BGSE_!S<W8.SFX:O?+0G-)/#,)%]#62&9-',9%(O*TX4<$ES2K\-WIWX@
MV%=9XW?>E/8S#G2&N76T:1>.E&\T%;["\[.$=1M)GGT=MF>M4-:Q+;7+>ENT
M+H"L%H]&-:4V3>:IS60CIB1D;&Z1XO>;4>TU_)?$.R+0?#<V6>>)PT(YWMU$
MS75_1YT?:G5;8YW#J@K8W9R`W*@Y3B+XZRZ[E*[216J!%B*@6W1F]9R#9L]8
MN6[QF\;HNV;IJLFX;.VKA,BR#EJX1,=%RW624(HDN@=1)0ARF(<Q1`1_5QQQ
MQQQQQQQQQQ_S\'^7*]M]\.3)-SB]<%U>]Z@;)J<=:`.X0W_9'U&B)JP-5BH+
MAE*UV)0WM:9O3(JKTL\0E`.V1%F)6R!52J)UD]+O`]NN4:=,W?L-K;5S#,Z_
M*PE8B^O]]U*@V*2>2ZS9-Q*3MUB!I5@AXMNR:^85B,>R"$L[<IC,/%6L6D@]
MOHQO'*KAU15I=/D[W*Q*LR_G#.M#T6ZZ=/`\D4VJ2Z1+'?)J>FTXXA6:0M8L
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MGSMM94R-VL02S()*Q#]2,64>U!].,D[+(=C_``X>N#.EZ.SZ]^''K'9:58FT
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MPFD;[HO8*(K=FE?I$BZB9UO`:5'UU5=5L$0]LT;)(Q3Y_'^[O#V]77Q+.A6?
MF4+8^UV+>T2%4JC>OVYO<WA3H+NFRJ7N5,2L#HRQ'#-=N*)4A5%?V*($%1TU
M*M&.Y>.7X?%7'T1%_P!!T!3VGL_32<=T%=$P>]-VPJ$?6>)JD<=("N/>BG([
M-[5JBLH@"IP324CG8/X0AB+EHX<9AUJWJXB@HDB+BV6;`\QC`56*`E*JYE=5
MGI%,I1!7U*IPZZ0@0@D.<ROLT\8SOCB=BIUHF>A]7>L-*2>>964QL'>B`?%)
M_)OURJO(#.,P?+IE]U39*"3XVBF$B#^&4=)&2)(ATI_XCOB:7)PA$LMG\+_'
MUI$$S-R1.<=P]XFFY!,#D40<0+<L4Y?`FU=1ZJ18854E5%'HLQ:-$EW'5$;]
MXCFBNG439?&)FJB`-C@\9=>/"QU%X)4R-O8K+L)FS=9['($25>#Z`<MI8QVR
MR:CELX`##&H=,7ZIZ%H[216T/Q3/'-U!,B9QE(:@=<NSN/,7BBR;XX,46-&A
M*5'$2=*.GJ1TCI-FRT<DV9>;#W-(R?53^$1X?-H2^-ZKCGC.]C':[@_M"Z97
M=>G'+D?2E[1TZ9Z6_5(H`.FA%UA5.`OE"LE/=W0LD%T\Z4GPJO"LH2\>M7/!
MJ[<6APY(8J;Z>I5)CG#0'8(IH`Z7?;16'"!TR"H(JK`"K8JK@)$X&]!4YL5O
MKWUYK4F6/I_@NZJHU.#@4W]IE.O)VASN5`D7P.26CL3-)I^M\C[5,RIC@L[-
M[9("*.#&/FZ!B[%#.7H53P>*S6"HBX.T>.+9TX@SO057$Y/6>(EIMPW47532
M<.TQ46*B(`=-1RH0H&R[%ZYW1:1ITX3P_P"EUM5-02H1S_M;GD6V,!S$466]
M=6S::3324]1_3Y%]LHNGYK()D$JH_3<:7X@SQFS6B^J'7J)=*B)W;6?[;V=X
M=`@@)2I`:%Z\G;BN0X>M0Z;E=$4Q`I#"<!\N9Y,>(VX=MAC\QZ6Q;,Q2D=J/
M]HV^;=$,)Q$5T",\2@TU"$3\B^[&,4YSE,8')2B!2[$_NE*SY7VI^CT3&"41
M0*FW[`V-^F<`(!4E3&6K""Q3F%0YG!"H"D'H3!LL/J4#1O7?$@>-GR4AK?32
M%74+Z&#B(P3:9HR('*<165))[K%I"H@/LP(F*2R2X"<RGLA`"#6MXD\;XFX9
M)!9#6I(V['TU\J\N;[KEUJMU+6I$-39>'FH(I[J]UF['(_L,ZBR$T,C$MW2L
M?$/E#R"+58J#S*GAR[U+HVBFN;3%OZS3>\4+<-*AHI^U48Q]4[AY5(.JUVAJ
M$*W.F4&4/KQ(8NX5F,_DBMIQOI$:1$KUF[1)<G=Z)2-,JD]1-%J%8OM(M4>O
M$V>G7.OQ5HJMCBG1?0YC9VO3;1]$2[!P0/2LU?LUT5"^0"0?ERI!_P"%5;^M
MLB\N'A8]GKATV,9V[E775B]QTEV`Z$VIVZ5=2,BU0PNQV",MV'.IZ4.W][L7
M7W0Z2WC&Z8^RITFD)F2QIXHVE]85T:UXJ/5NS]66C=5BP#MQC#BP=BNB5@5<
M&9QZ4I/:5`UMCI/7?XM-N3MVD-O.?0T1'-RE55O\@W`SP;9\^T?/]9IT!H>7
M7>I:-0;6P2E*Q=J+8HBVU*Q1RPB"3Z$L<`\D(B4:J"4P%69/%B>HIBB(&*8`
M[GY_U_W#_MS7S_K_`+A_Y]__`#_`/'G_`%_W#_S[_P#G^`>:>8?T_P!P_P"W
M'G_7_</^W'G_`%_W#_MS7S_K_N'^G_;_`)YAQY_\\A_Y][_GF''''''`"`^?
ME]X?+\_',,[SV!R7K1GSC3MEM0U>K$FZ]5XXC&#L5NM%HMUNE4(.J4NC46EQ
M%AN]]NMFEW*+"`J-.K\W895851:1ZB+=RJC&=7Q.>GIJ+0[[%7/1;2AHVFW?
M&:[1Z5UY["W/:&NJ9I7):X:%0K;@U9R^3V>A66EU6$?6.R1UVHL`I%P1H^7<
M"$=,1#I]]#4/$FZCXO6<ZM.HW.^TU#3*-8]1B:])X%OZU_JV6TUW&L;EJ&MY
MM&YD^ON)9K3W<Q%M[5?->KM+K$`L_;DDI)`PG`DX(V3C9F-83$0_92L3*,FL
ME&2<8Z0?Q\C'OFZ;ID_8/6AU6[UD\:K).6CILHH@Y;JIK(G.F<IAYDW394$A
M2624*MZA1,10ARJ@3_O%(2B(*`3_`,XD$P$'Y'$H\WD41,<Q"&*8Z?EZRE$!
M,GZP]1?4`>8I@</XQ1,!04#^,7U!\^<O/-QXU&F6EYMO6Z@-KEVK?=?(JJ[8
M\V>L='Y3I"74H;<&+S'7N,+70W;^1>0GP=K4)N[NE*U$Q41-H%GH.U$EG*!$
M8Y>[CJ#*?&^KV!S'Q78YSXEE-,>?&.PDE0)C;Y(%X=`X/=5E,K7=9P_O:X"!
M[$ZI+A:LK/Q4-$J&:^@>2/Y"GN7U*GNS26'VO.=@=81M?7'4I;4\ET<:-%ZA
M`,9.U93H>)W&(M6=R\Y66MFB9G/M.LB;$6]C@W\+96\%-INWC-B_A96*O8KP
MKHF[^'-@G0S&;BRA0ZVAA#/-;]I[1Q.R!FF2-4Z]-OY@\`W:BE.7FH/;+#RC
MF+9-6"`6%ZDT:-&I6Y6],G2_P5K;V&2>7_2MAKT#E]?T?L_CLK!TB)=.[N]O
M."Z[=<1AK4T>6R%>UL*TXM^?25H6@G3+WU[7Y1M"N'R+Y!5X6<TYX>?;OK>9
MS(YMC_0SNO56I7`$B+_U[I.2;$LS6(_]Y22E((T/5Y1R=&4D$Q4<39A5]L4J
M$9_TL<@UZK5NT75:H3*-,[1>%+%87=7A%6JD=&4S.%SS"[KW]%R:%C=`8Y@Y
ML+5P25D`32ITG<5EDW'H;`N8&X%GQ3]/\*&SRS&-DZUB>5VZ362D6]9W#*38
M58'#XQH)1-2.;Z;7*M'S2YU*S7C)N:^_E&[DT3'BBX7*BF;DZ:_U_P"N9XNN
MN:QF><GAHI%FM6'$'$1:L4S;LYFFV-BI$K1PG9%11F\]I,J@9`YDP>5F(7+Y
M^[`!OMQ_7_%HULT:QV<U=JV8KUUTS2;LSD(W<5)*D(5M5+R6$2GAD<WHJ;$0
M'^1)5X@/(WNP^O8PZ\XI%D03C\WK#0C9@C%H%29J`"4>A'46(1:$`5Q\D4XW
M,Z$R*7ZP0JL,3S_Z41/M1Z[8@W,W,CF543,U%H+80CQ\T18&@C,Q3\U1]/NQ
MJQ7Q2\O^T8EF/_I_/:OUSPYT9P9QE]06,[%V+DRD84PK"_&>%X*@BIYC[P-H
ML(J__F&7>_\`NCY)#KEALL1=.1RZGO".H]:+<%7BB'!:/<1M]AUFBG\</4@I
M%ZAH#$Y/OM[=-D\_^L$2\DAUXQ&5;O&LCF51>-WZ]D=/$5XPIR.7%O1O*%F6
M5#UAZCS:.E7Q.0-YA[<EJF0'R]['T\BW7W%G'Q7VV:U-3XX9T:7]<:4?B!GL
MU<[$[%U_'_E!<3>AW>35\_+U/+/+J_\`S0@7<WP#&&KU.1;YO5$7R3A5VFZ)
M&E!4CE92<556*;U_)112RSYS#]\TJ\'_`-7Y?C3ZXX8D1)-/+J>0B)&Z:12Q
M90!,C0L$1L4H>T^0(EK-?*F'W@B6?_M?/<TZYX<Q]R%GE]0;_#OA/N/LHP"^
MZ_`OL<?"/8_RG\3X=]B+-/=?K]G]"J_]?N0>OG3Z^8JBZ;O4LTJA'35S'/&Z
MY8T`41=1*^=N8U<AO:?)1DODN;*MS?\`D/3(`?G[D'KXTNN^(H(Q;=+,:BFA
M"Q\3%Q*18PH$81\$2#3B&;8/:?R:$>2LP!6Q`\_9EB60>8^R#SV_:ZX>#$L:
M&8U$&)3@J5L$84$BJ!`?18%"@"GF!RUWRB`,`^8,@!,/J`>5`=E>HM6@-:T3
M$8&O5JO1/:V!<:9U1LJC<C2,S?M7C\:ZGK;C3D2+H$9YYNM=6?V5["IKMV\N
M#W7&0MEE9!M[.Q+KC%]?^R&/TS:&635B(E+>UE5KA7G<:4LI4-%1D]-BM/I\
MLG[0#HRE>NVD;##ORJ)IBJ:SS3@I?929#!FM[URPR0!^5[E]0<EE"S!9`%HP
M#@[+/AHY9D%P]H'K"2#7M,!W]7M0NU@\_+WX?1OF>NN'V(949S+Z?*_'$GK>
M8*_B4W))-"1;SC5\@^24,*;I!VWLT^BX16(9)5.6>E.006'E9&R^"5UQD+/*
M:YTXM-NZ"[N]?NYYQ8<*:Q,MA]UL+F6BYT7.P=5[BG(8U>F;F8AHR0E75=B\
M_N4@LP8"-R2]P9`AAYMK_8+I0HG%]_.@=9U'(HV2A'`=U/#RIELTNGP[6K2=
M?EJU8]IZA/UYG?\`)T*NWI4!.3EESA[N%-C)"%:*)'C6:28<J_J_\*D\%TMN
M@:M5>I?:=%Z,]#T^`DFN5XVVCB)D>Y[5(9ZW,XW=-ZA%)LLRS91`JS%.02C*
MC!IJ,"/60L^>M1CUSPV/!@#'+Z@U"+^$%CP2C"E]T"O?8X+#`A_*#Z`C?L09
MG[I]?L@I-?\`K]Q#U\P=>,2!4JX9E4@6(JBN53X87U`LW4@U45`'VG_<FI6H
M$Y!^\,4S_P#:#SVK==</<(H-ULPJ"B#:,;0R"1HLHD2BV;"6BVS$@>T^3=".
MG9AFF3_RH2+DGG_*>8:N^N^(OV3F.>9C47#%XI,*NFJL84R*ZD_#6JOS)U">
MT#S-)0MWML:['S#VC2P2:0^7O`B&]UU[Q1Z2:3=9I4UT[$A+M9PBD:!BR;>>
M>WN1F$7@>T_E22+[3;^Z=%^7M%K9-'^7O8@7[<)C^8UN<&RP5(K\7/"[=OQE
M6;($GHO'\E>IAXX%7UB/M7$GIM^?*F\OXSBV32GE_P!6(%R3QQQ_5ROC>=3[
MRY.PU70X^F]1%,>H32RV>.D;'I6VM[R\IL&V5?-PD8"OY9+1X6I^BD#1&)AY
M"0;K2:[9JU<J^U`P5,^'MW_[X;KI&L9LPK&625FN%@M.UUY'>Y?7Z3$UN$>N
M(:/DLRHC^OTFT)N(NKIJ,9"-CI06+A-H>7=(*O5#.2(>A;&W.VNJDJKOL/E\
M)>0F7Y$661V*UV>JC`%3:C&+JR5QKM8EBRZBHO0?-2QIF:)"-1;NEC**@G#[
MQ+=1L&1Y+E%JI.!&V[1C=@Z+&YY8G>)ZWOU:ZW6!Y7KL20[+VW.L+KEDU:9B
M<]J/TEA8V,I24-,6:U7&OT\]JJ$789*T1-3TUFG5T\;@6W[[8/%-N[M7:NSE
M[VCL_FV$=JNJ4HX[%:%AN09@"]TQK)<[J_:NA9Q+8_4Z]F^`R&+M'&9M5J*^
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M:6W1TQ0<JDO!.ZY=Q=%IH>UPO`K5J.N;WJ_8/*DG4?:M-LN/T&,EWK$+&X6G
MZ)2FL>_@Z@,RS]#7AYV"G6OHUU,LV?2U6FZ38,`S"9K$G2<9B.N]5<P\C5V+
MMG\$PNORT]!9*R0(J+8,_AIR8BZPJ@K&,)1^U12=*S(XYH/U?G+_`)ARO?PS
M/YO&@_VW?$?_`-?G8_EA/U_7SK%NI5/O\"^JMZJM<N=8DTP2D:Y:X2,L4"_2
M+\P3>1$NU>1[@@#\P!1N;R$`$!`0`>04M_AOY0,4_C\1N-]P%H]36%2CP+R+
MTS!7RRHB/HE^N^RQ]ZRXL>(")%6M3BJ>Z%/^*W?MC@50L,7_`$GUS$7SJ7A\
M&B)]`5/6MH_AX;-=.GFG>ZMR#[Q(2?6RTVMS@MFD'`?RRC&(M239RN!T6L""
M2A&W.TT#L3H[&=;4ZF=Y(F/O7_V=GU^\2C`0R+4##ZQ(FQ8:!35,F-97)OD"
M4I!0.B(K@8JP+.@_BFF";LAVNST"?9?Z3V2U0Z"8`YNG5G3ZEL#)SYAYE>(4
M*\)91HA&QR_QP;QT=8')0\RIBY-Z?5]VL^(=U,FI9O6;/IX8W<EQ]F:F=@ZS
M:L%L2;GS]/NB2.IP]9CI%?U?Q2_!Y2124-Y`DJIY@(S'BIB*G6#65A9)A+Q;
MU(%F<E%O&TC'ND3?,JK=ZR57:K)F#YE.FL8HA\P$>?1`0$/,!`0_"`^8?WAS
M7CCCCCCCD:NVF&.M_P`6G:E79)*NZ779"'T;%KD<!!6D[)0GI9_/[&FL3S40
M:_%VX0T\"0"=W69B;8&*=)T<AH`]1=R9PNWP]B/%'I.>=ZE+,]GZ0Z<""&,=
M_P#'4W$!OF8N2JN`38K:?#5]U98P5BIJST_1I22:MS+60@JW)_7]7''-IB@;
MR\P#S`Q1`?OAY"`CY#]8>8!Y#^$/D/RY_//_`/@R.S?V7/LD?;EX/[G]DGZ;
M?#?L?:5[U[E],/I%[E[?VGL/>?=?^G]?H]E[;_S^C^5Y_0Q`/(/SF'^\1'_^
M^:\<<<<<<<<<T\OZ_P"\?]^:\X7#A!LD99RLDW1*(>I594B*91,/D`&44,0@
M>8B```F#S'Y!\^?G*_CU&XNR/&QVI3"471'21D"F`Q2"47!%!3(/K$I!`5`\
MSB4GEZC``\RJK=($O:J$2!0Y4DO6?V0J*'\_0B4#"45%#^0^E$/4<_D/I(;R
M'R_1\O(/+ZOEY?>YI\A_`/F("'S^^`@(>7]0@`_U\A[E/07J-B6J*;-F.-1%
M9OB7TY^CZ_TBN\S6,]^R=+DGM&^Q'G=AL\OG6,_3R5(+RX?8GJ=,^DAU%TY;
MWI!PX15F'SRZ?PBRJN-(L74W-3]+:[OQK+%:NC3]KFH+LR^'(+VM=,.;.VLI
M8NLESS^5KU"@LN-H_8&\PE^LB4!>V^(1496DT;3&(K'O!\.^<?V7HCT]GI/'
M8CKZ]E>MF-/5L4K\)(UB!S'VM$AO94Z%K,SYS5;B8AN"*4=7II1Q,0C0R,;*
MNG<@V<NEIE<T$?+Y_/\`,`C_`(``CP/U!_67^C[X?>'Y\KW\,S^;QH/]MWQ'
M_P#7YV/Y83QQP(`/R$/,/P#SI-\S;/=2@'-4TJCU+0*R[`WO-?NE=B+1#+"8
M@D]9HZ::/6Q5"E$?0JFF15,?(Q#E,`"$.B]$6N<![?JEO&Q]9P2$3-:/'SA=
M<P[UJ&$RY3Y#K)["RA6JH_(R%!L-).F41]W52,!1+URQ6OMU4HAS7.QW5O->
MV^>&$PR%HZ^.8DL^XCDP]D5:=ZY[B\*U>/%2?RSEM3M,L9U!.9-G%CY`0<#Y
M]3O#*U"TNH;(9FP=1MQ7<`#NBTNUZ9TSUEE(+&$%4/L3OWM2K]H]"@"50[.I
M6F%5$!!-99)0?7*3["7=#.Q$^4]NXK3XQJ'H95#M1D<)8'BJ(?6D;3\:<YA8
M4S@'D!7TK5K*MY^1U2+^0E-P?;#]O\Y$2;%TMD;M%-!$KNY=5-3K&G)+%^8E
M<$SG24,HOJ9?2'F9K&!8G`?,I!6,)2F^Y7O$1ZH2,HVK=RT1UA]P<&]D:H=B
MJC;<&FTW'GY>[)*:;#U^"DE1-_%*,/-R2*@^7LE5`$!&9$-.PMBCFLQ`2T;.
M1+Y,%6<I#OVDI&NDA^I1N_8+.&BZ8_>.DL8H_>'GU`$!#S`0$/P@/F']X<UX
MXXX$/,!`?J'Y#REOMYA*M;V6=K,,\2J5*[JR\!/YQ<R?R+7$O$5QY@K9<AOS
M<"(`C'(;7`UMO79U5J8J\S.U16/=&55MJP+6.]6-U;]B<3J6C+1X5^V"5_5M
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MT)CE:N5C(K`G`OQ7<<>]A,IZZ8NQO_6RFGNW=#K^\<5_M/%R-KS;7&>=.+1J
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M:73:9G6@1T:AJ+^;I4KGM=J^_.K[,6M^ZT9`S>#6H42+RKR?I1]9OP_X!_MS
MR/\`\(#UWKY<-\RR@R7=6F5:W]::%/V32NHCC2>Z.>6*]S=^M^,7Z@-H][TY
MI]HGIRR7#.Z3=Z%8(=^@^L^49?J"N^Q,,#2O).E_0?X;];^B/0CIY7OIQ2=,
M^&]<LE3^R'G$_,VNC78%ZA&O`M%8M=B(E/VF)F@<^_H66;;M):?,LI+2+)B[
M=K-$)KCY^0^7U_>\_J\_Z>4*^+QEW9+9J?68.UYX>:P.C]EJ#?J6'7W"IWN]
M?K8PC,=UZ%<,.R/62QO,H:(9\G?K)`FCI/+[!LCEK+MJY(VNKPD"$I8Z].O&
MJYW"D>CG5.'K+7`NH_82-RC'T]4S^R9'9]CRS/UV-!;L[1F5,J-2W/+I"$+`
MSOP]I#NU-%M+&$C(QW!"$\HJA/(=5\*!M:&?4Z<:7>7A)^YM>W_B%-[;.UF!
M>U6N35D1[W]B4YJ5@*Q)3]KD:[#/Y`J[F-A']HL;R+:*),W$Y**HG>K64\<<
M<<<T$`'Y"`"'X!#SYC73L:R?:8(U9UO-Z1I,"(*"G%W>LQ%E;-E%`\A<,?BK
M5RK'NR>0&2=L%6KI$X%.DL0Y2F")I.DMER_VBW5#LKK>'LRG];?,[FZ+V"PY
M-,H`?W)G2M,>KW"J,E3@!/8431ZT@W2$0;M2@4I>;";KW&R(ZJ.\]7VFOUEJ
M(";3NH,[])7HHF^1'$O@FCNX*^1YP`OM'#:F6?15"B)B-TUO203Y'HG9_J9V
M;/(9PQN%.L5D\B(S^+ZE`K57069S$-[1M,Y)J,3$682I>1TU%"P3EF<?,4G"
MA#%.;K4OX>G5E20<SV>TN9P*U.!!0++UPN]PPE^13Y@*RT1GTQ#U22$P_P#<
M2:K4D@I\P42.`F\_E*8/W*SP!/D7<9#08UIZ08U+M3D==NIU4P$!%N?2LD<Y
M3;$_,`]'OLK$V5R4!]9P6,4?5PAO_<K.!]GL'3,=!BF8_P#77+JGK%=OGMB#
M_P"NGF>JH99=$OOF,RBY"R."_P#:F=<0+Z_L07B)]5'4FUKM\O4M@MN<G]D-
M4['TFX83)IK#\@02D-%AX:KR1Q$?(IX>Q2*"GUI*G*)1&9$#8H"TQC6;K4U$
MV&&?$]HSEH*293$8[3$`$%&\A&KNF:R9@$!`Z:QBB`A\_GS[`&`?J'S_`*OG
M_EY\UY@GLKAT/V+Q:\91*/#PSR>CDWE3M34/*3HU^@72,Y0[U#+D#V[:5J-K
M814TV5;G344(U6:F/[%RJ0U8?5#<9:G[Q%V6\Q[>H-NU5ADL3[`U=`WHA<R\
M17"8M.#EQ;"1LS8,H;LMFD8SL-64(4YIEU7ZTL"JSV>\U;LOKXXXXXXXXXXX
MXXYL$A1\_,3_`#_`HH']WD8/+\WES']%RG/\T<WEW1JRPKCG2KU,:5=UH_VQ
M#V"[3[6.9RT^]$ZI_P#JGJ$6S!0B7LT`.FHL1(BKAP=3(0``!Y!Y_G$3#_>8
M1'_'F,M?Q;)>P%#E<PVW.:;JF?3:S!S)U"]U^.LD"Y>Q+U&2B)$&,D@NFWE(
M>2;MY*(E&HH2,5(-T'L>Z;.DDU2X?L'17IO:L+J_66P]8<-EL`I,BE,T_(G>
M;5@]#JTVFO).33M>@2,"-H>=<KS4VK(3C#V$M)GG)L9)Z["9DP=?KT_I)U`V
MFO9;4=8ZR85H55Q%!JSR*MVO+JA+P.;Q;-I&,$8.FQ#B*&/@:X+&%A6:]:8M
MTJ^[:P\2@[C%THQB5#/UIIE0O$$>L7.KUZVUM1]!R2D!9(>/FX8\C69N-LM<
M?'C)%NX9F>0-AAHF=AG`H^UC)>,CY%F9%VS;JI]>>9!E,@YE7C[-:&\=SN@5
M?5YITZJ<$X<2VGTAK7&-.T.2668G4>W>JL:A5&==M+@RDW"M:W`H1SUNG$L"
MH5@XAX2E;R[MS"]J;5I-+NLM2+SK>E5!>M=9\FR#7+A>=7@[/33V/LAM-%4(
MMMSVGT:ZVJ"KY(:B92UG)>2;7O14+O=XMG-%N"]!?P?XC_OR@CL'X1O:^\=U
M[?V\Z_\`?RAX6VF-ZB.R55SVT]-6>T.*OJ#?IC&](9]V^N*^[T@]A@)K*D)5
MTUKZD!&(1,])(R17#U:/`7%JO27K<;I_U'ZY]73W$-!/@F/T?*U+N$`-5"UJ
M4^'0BSSQ:V,O/C!EDCI&<%BQFI068'!'WYSZ?:#*3F@@`_6`#_6'G_GP/R``
M#ZO,O^8<KW\,S^;QH/\`;=\1_P#U^=C^6$\<<<<<<<<T$`'ZP`?GY_,//YA]
M0_/[_,/:WU\Q#>(M.(V/*Z-H[1N408*VNNQ\G)Q!Q-ZO>(*;41+-P+PIOXR;
MV&D6+I(W\9)8A@`0C(/3_5,J4][ZL=I]*H<6W)_TV2;D#GLCCP)(B!V\=&GN
M$Q'Z]4F@B'L0^C^GG:-41_D8HX%!,P.R/:/(U/=NQ?5*9M4"@3^6UKJ/+K[!
M7S"(@8SF6Q^?;UO98!%%$#J.$H&.T))$0]FF\<?]X9UQ_M?UUWMPO%Y;J]3L
MEC9>T^)T=RY7KFBPQD"^I8LYG%J;0EXACH^0@H$A`(`4Q3?QA](CS.,U!05E
MCG,/88B+G8IX02.XN:CVDK'N$S%$HD<,)!%PU5(8IA`2*(F*8!$!`0$>0^G?
M#VZKO)-U8J30'V&VUR/M`MG72XV[!Y<CCS\Q<+-LTF("OR:@C\SEFH*205'S
M]LDH!A`:Q/$G\.#L9<\KC;MF'87:M[L>6."-:IF]PCZJ.@2L);I:'CYMDUT:
M@15%E+(2(6293B+&YQLPJDU;2ZZ$RU6.H#BR/PUF6>PW3W*JQ0I"=>O*@WEZ
MQIS>W^V3O,-M,7*N"ZQ!7=BZ<O'<7/Q=P5?H)QZ[E=%."^"+1CAU#KQ[I:>'
M*<>]&&L833U[`1\-3S;N,C3,AO%M9B1$<A[;4F0),]/^QA#>E11LJM9(]KE]
MKD6X-3N@)0V;U91N90`GMU)W-YOV+0EILL9]'-/K,A*YOME-,F=%:E[+1'!8
M6_0!D3D()&2LFF6=KZP>HCZL34+((G.DZ*89,<<<<<<<<<<<<<XSJD(!A,(E
M`H")C"4P%``#S$1.(`0"@`"(F$P%``$1$``1Y@/$^TF"]B7^@QF-:37[X]S"
MSKU.X(0RYU#L9!'S!-^S]9"?%ZX_63=MHJT17O=?E74?(MX^0<*,5P+G\!`0
M\P\_S@)1_N,`#_AS".^(=A5Z:R'K=:,4J5T0G6R\S*;O2[U>*>-33CY+X@@T
MC:!H&<2[.:^(#%.$95Y-N8MM'(22;B-567;.6M%5P\5WM?GN5]7YV\2?5V`D
M>V6\=C6F2ZNPZ^]I;O3[+U3PS+36&N:XQZ_4;29W<5IS6;FBC*U0T5,ST.TQ
MNR5>\3L=%N'+]HSDL_[Q]OM0:4JK].B]0NPEGK/3:"[D:OKB?V48[$-;B[Y;
M;_5<CR?K^R@[A/V.IS^E.,DTU1]=KS8;PUSA6`C64C2[.^EGK6$FR_[VXU7^
MC]$[[VMI<XG';UF&):BUBHJK2=LOC./WA>C1U.@B5&!26EI>PDFK_"0[N,B4
M'+Q1V#CW)LY.":"F%*AXK6)66[P%`G,<[59K..=\@>L%_7T3%#Q<%BVY7N/B
M)?):/IMCA;/887U:_$66I25)L6?/+_4V2%QJJ-]G:0\G&;4^[*_%IZQ;!O&>
MX74ZYO:2>UW;1:%U]VF;QFPQ77WL'-9!7+M8]3<9'J2K@[&=AJ2C0+`R7EI:
M.@6UI630DL_^EU:%S/M;._6'X!_P_P!^>4?^$(JY],=JNAM-UFP]5&V?NL?[
M;V5>M]Y^V^U=8^M[^U1,_P!?HVO2[%QUW:O-`D-BCXZ7LC6K/+,V5HB]3>7&
M'2%&V*1*@^@?H>QK,;TTZQ1],'(QJ;+$L^;5T<$OMSU'%_A","V(Q^Q?HNB)
M(WJZTCV!2_1ZR6U(D_*L/9NI,H.3GY+3CF@_5^<O^8<KW\,S^;QH/]MWQ'_]
M?G8_EA/'''''''''''-!`!\O,`$0^H?OAY_@'ZP'^D/GS!.Q=8\!W])J78,H
MIMX?1X$"(L,C%E:W&!$AA,4]<N\2I'7"NK%,/K*O"SC%4IP`P&\P#D>#]6NP
MN3*)N^LO;&XA#-!%1/(NT;%??Z"L1,1*WC(N_*OX#;ZJS31\DDU5+M;46_I(
M8(U8I/9&U'M9N^2F3;=G>J%WCX9$11<Z[UG?..P^<$(B`&<RTS48^*@-NJL>
M5,?:G*;/[*@V*!BFDU@3.ISZUI\2;I+5<R<:NZ[`4>4K#:;C:XYCH%TO,79K
M-2:X))QC_.D4"7F,?-&Y7,G*-92`9+1L4Q?/G1")MQ`V)]>>-^O-X:=_L153
MN6`Z5#P"G;:LTM<)J-G:25F@WJ/:ND-8T7"4E9LZBE&S302QA%5;AE9#.U"'
ME:@T4-99"S438X>*L,#),IB#G8UC,0TO&.4GL;*Q4FU2>QTE'O&YCH.V+YFN
MBZ:.43F2705353,)3`/,?;?D-2WS);]CUY046K%_KCV!?JMS&3?1BZH%<14_
M$K%,0[6;K<PWCY^#>$,51G+1K-RF('3`>5!=7M>MF0=@F;G5S`TE]3M,1U([
M8`F*:<=%=Q\R@&I,*W1))0XKH5CMMC*D8T+)D:-6Z]O95:+6,+E-4>7H@/F'
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M#NLUZVJ-X:Z.XIHTD(ITG..J4ZL,7`R"$@W/$3#]C+`*GN/LE,>;QD'9J&;8
MH]Z27S$\[:9#!V&DO<9V;.9"?RNWT^3@JY#T]5I;*4LQU6@3>6GK#4\(SK$L
MI5;G!2LY7+E#*NDZK9:M7E2O"S[1=8JU`GZA]F,MA]'O^$7W#NQ]IUC*+,[K
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MHT;,G68]B)RR8IT`V3,\F[=2FFM)#)XC(]1E"W6R56Q3G6Z@O)J?A]`=5F6/
M`UJ]7"@2=\A9^/6BXIQ;WTIKF[5#J)UGK'9Y['2/8F!PS,8O;7L5\'%FOI[.
MI1B5S,52NM65>77+-E=)O74"U0A7C\CIU%)@P60,;)FG[?C^+)U(^M:AGV:&
MT"VQU`H)+]<8"H#=;[,D5-"TNK#//F(3EHEQ2.$?"1OO,B[`IS(-E`(/*:6'
MBC]L+B>P9+"=8LGSOM#,>(??^CU`IN@[!-6O-JY%9ETFB.ZT[H.BW6@5<CZ8
ME)FGG=5Z'K5,BVS)C+S<6$A,KD@I4\I//)>_N>7WI7UE[FV2B:[%5_L=GF9W
M%K2,PR'6NQ=LJDO?ZB-G<PTA"X?0[I9%(.%<-)&,-=7=<BX-PHG&E<FCG\PQ
MCC],\*"RQ]SZG3EPB&\VTBK5W`\0JQ1C6RUR?IUC;,)GO?V)?M$)^I6N-A[1
M5YE)!<A)*OV.(BYR(=E58RD>T>H+($LIXXXXXXXXXXXXXXYH)0'ZP^?D(`/U
M"`#]?D(>0A^80Y5+XC_A@4[N]'0MRJ,O%9OO-7(C%Q]T?1[E[`V:JN'R:S^O
M7)C&^S?N31XF6DZ[,LS_`!%F]*>-="XB7QP9<.3]5^SO1//V="ZZ6*H=HL8:
M"]?2N*["9'-=":R$P1%>S*9KI\6G,4Q2-G)0S]ZUH-ZJC&*9%>"T"ZI@=V[<
M8=ZB=L*5@'8`G36T0&B9!GVFOI"?Z_9]M-><U2T8C;7[E5[8,`1E3N9.HW;+
MYI^LZGL(N%)M$_$L"+26:/EFSAG7$5;P@$!^K\X"`@(>?U>8#Y"'G_2`<J$\
M1#$8*,L:>P/UW$!EVY0->ZX]E9Z-,HDO1)1>R,WW5?LVD1-5J@G,X3L*\;%R
M,RNN"[>J6LJJHG9PA4R33Z>[78-HR)/[(;)O"[9EMAF<>WFNMU$CH1.LT,R#
M"P/H\4BD3/7KBT5C+W5'"0&1<UJS1ITE%/2<W)4\<<<<<<<<<<<T$?+Y_/\`
M,`C_`(``CP!@'Y?/\Y3!_B(`'->:"(!\Q_Y__OU!^$?D'S'G19W3:'6+E1<^
MG[1%Q5STSZ4_02NNU%22-G^A,0A/6OX:F5(R9_@<.Y0D'X+*(^ANH4Q/:&\R
MAWD#%'S^?EY?7Y^8?+\/S\OE^`?J'[P\>LOEY^?W_+R\A]7GY>?EZ?+U>?E\
M_+R\_+Y_5\^='^R90PT?[$7TGB_LE?0G[(_T.!149GZ#_2'Z*#9?9`D*7PP+
M$(1(J>V]H#O^**0$_C\[OYD`0^KYAY@(`(@`#\_/S#S`H&^OS$0`W]/-_/,W
MXD76WOSV%[S1$B?I#6>Q77W*\[M1^MVKY1XC^U^'[IE34T5IDC72*?I,Q1BV
MA.>GWEAK-G68MHNI(0\[0CUXRM@C92NS$58KZ.K57L-*ZYXG4K93Y3/[+7<T
MJ4/.4F;V2;["RU5DV,6BB[@I'<+(RCI_5GD<J46Z]\EV+20L9RC(.6Z:BHE#
M.CAHV=@F#EN@X!)0%4@6235]FJ7S`JB?K*;V:A?,?2H3TG+Y_(P<A?I/AX=2
MM8C-"C;AF\M[;3=W3[,V6Q5?3M5H5V:;B7+('$5[]3;[1;I7;GGLC(Y)7&&>
MS+*BSE>AYNK.)J+EHYXC89P'\I,\SRD9)0:7EV:UB(I6>YW6("E4BHU]H1A"
M5FJUB.;0\#!13-,1*W81D:T;M&R7F8P)I`*ASJ&.<T*O#,_F\:#_`&W?$?\`
M]?G8_EA/''''''''''''''''',,;W@68=D\QLV3ZM7&L_6+''.6A5/9-RS%>
MD%$A*QL=6DE45E82QPSD$GT5)-@`R3E$I'!%VBCANK4=U@JO<#$)^Y]=*9O)
M+)K>),F<FIB?9E65LV:;GCCUZLSIFPX;JD>!]+RE)\U1&IW:HO2ZC4Z'H3%P
MR)"Q\)(Q"BTM;)VNR*ZUR>Z^=Y,OL/6)[IT++T*4BM<58/\`%[VWG6BD>\99
M[V"ARGSN8<K-G2:\6SFW5-N:#OV*Q:\W=M@]$,NMNB6KK;V%9L=)E%)$5YR@
M].^R=C7<`=O8IU&-=+]"NW"CD3+(.8_;LT%7$+W+^W0(G?8"(1>J**,!#E]X
M#YAY_P#`_"`_T@/R'^GFO'''''''''`^?D/EY>?E\O/ZO/[WG_1SQG?PGS[J
M5]I/L/QW[4S[5C[8W,?L<_84^V-^VL^!_2.0^@_TM][_`/JZ][]?_P!\O@'_
M`$?J]W^#_P`IZ>>;[^#;?=(/NATQ]KG]!OLA_:WZGZ_MSOL^_8D^CGTDS;XK
M[K]!_P#QSZ7^]_"O@W_R'N?Q;WG^6]TY_3CZM_;<_8U<?;I_:Y?9@^E,S[K]
MJ]]D_P"QM]"O8QWT?]X^RU_]*?I1[Q\6^,^S_P#"?8_#O<?X_O/($^,EH$+0
MLUZ>)WK:=-P;';QWTQW/]VO>5WZUYC+CD=@S/<%K%`V2\4N1B;!5\^FI&-@T
M+W96,G&*U2N)O;:C,0#J!;S\73]&:[.5Y:0T'/=![`ZSU?Z[:+XL[+I9L=3L
M3_6=9E\`K70W(9@[K&]7U5G=D]A:9UV!D=>IV):7HTUI,=/,:<A'R$A:*_5&
MPR6-\^[*WZEQ'>:HXUV8<H9Z^ZR=(M)4DNMG<;?O$(<T&FO>W;K..^?8?--M
MV6G5^2>ZO3NN=N9V75WN'0@U++I=G5+>_CX^\+IM5<Q[5LU"K+Z@4;JYV?O6
MS^'1-=F;I6=2T?>.^&^Y/UJJ>AP_5^N66@Y!"^)?"QVY;)-9);;F^G[?98-2
MZITTF[Q+#('&@UU@Z7H,YB.LVS'[EI'7&Z>(#W'U3*\LG>A/;)SF.T47LMV-
MR1O>H6I=XYZ0ZW-)SL8Z@>O^F[==Z3E#".L60/+;48U'LPZB(W2`JM^7=-%I
MO:MNVNSF$7J\]].Q787#O$1I?0/J%>O#VRR%T#1<GG=)VR>QUS,&LU0Z]5:=
MA:MV2V_6NRWN6;]C<LN5)N84^&2:420KU1J$LH\>^H?Z5]S_`/\`2S+_`--!
M^^'*7?X0#V7W[KO>>F\GFO8$<WS925L\]?LOHG;CKGU3U;29:%T?%DT7,H_W
MNX4EY=,E;96ZU^IN6%%G$0KVL6W-['<VDE!L46O+A/#=TZ9UGH_UJLMQW7+.
MQVFL<EI56V36<=T2F:I2[#L59K\=%Z01*[Y^X<5.:F6-E2=M;`YB`;-%I@CM
MR@T;MW")1G!QS0?J_.7_`##E>_AF?S>-!_MN^(__`*_.Q_+">...........
M.......1"[9X!8]2B*IIV.R#"K]FL,D7MLQ2U/C'1BI19VW(A:LGO!DA*J[S
M;5HE`M>LK83",4^"'M;(H2,"@)^SXGJF=]NL84E9:FH%3<N9:AZ]CV@14=+R
M%$T&OJ%C[QF=Z@Y!NY8N7L)("8A%%VIV<["N8R?C_;1LJU5/4/X@W0"I83G5
MEV3K5).,GH=BCH?*^R%-?A+7G,*UB$W86[QOI%4I3V3^,4]UB]_4A=#:%H,K
M&DJK%&;LE=BVZ[6393,ENOWB0+UF!F:'W%HMPSJRXO8TL@T??XF+=W7"YNXP
ML7$+(6NQ6*NM5YG+8[0(:5A;M`RE[K\33I6(G4WT9:#D(Y:,IP57N-UDO6OM
M<)IFT42UZ8_IR%ZC8.NS;:9:2L`Y`RZ8Q%@CSN*_*2Q8X`FU:^PDEYU&OJ)S
MJD>6+-[R$F..........:"'G\OG^81#_`!`0'@"@'S^?YS&'_`1$.:\Q/IV+
MTG7)7(IFX(22SW$=7C=FHIH^25CTV]VBJ==Z*T7DTTB'"3C0@-!L22D:J)$E
M'*K1R)_4T(4V4TD$D$DT$2%3123*DFFF`$(1,I?24A"$`I2E*4/(I2@!2A\B
M@`<XDF31`"@BV02`A%$TP2233!,BQP46(F!"E!,JJ@`HJ4GI*HH`'.!C?/FG
MN#+W;W/W5O[H("46OL$O=A*)O4)!;^CV/H$WF<2>CTB<1.(>O^-SD4:MUB$3
M51253(8AR)J$*H0ATC`9,Y2'`2@=,Q0%,P!ZDQ`!()1`.%&K=51)55%-15`1
M,@H<A3J(F,'I,9$Y@$Z1C%_BG,F)3'#Y&$0``YS>0?@#^X.>;GQPHBH.MXZE
MRL',V"U[\TQ[M3`5G$F_AM6SQ,Z\_P`AN3G'X'3=:6RRF3-9E<ZL5*F5:75H
MF^NY=Y%2;&ZR=/D8A6,EY,SF;O@]]**STZZY2+FJVK5)V+WE7(-):PNR9*7#
M=&J#.G]:L9PYK%Z!FAO)Y":/,&RUQ;+V>319283$\2)?-%74.K+2MM)C%(43
M&,!2E`1$QA`````1$1$?D```"(C]X`$>0MG/$4Z30-$L&FJ=C\VG*)6-C0Z^
MS%EI,D^T6.3VEQ6&UR+FK(V?1UH6F+6C6G2<L\C85&1%@@FY3?*-W+)X@WE9
M3;A7=!J%6O=1D0EZK<Z_"VFMR@-'[$)&"GV+>4B7WN4FU8R3,'3%RBO[M(,F
MCU#U^R=-D%BG3+!WPS/YO&@_VW?$?_U^=C^6$\<<<<<<<<<<<<<<<<<<?7]?
M*Y>QM?G^K>GNN[>7P\E,4B3914-W.S2!;*NW=GSV$3%K"[]5XEN`F=:1C+%1
M0MB;HI*.;IEQ7\:?SDJY!J%G,!J/KN?")#PMYSG2JB8OJ241DZ[;Z7;X<Q#>
MA5(YD'\//0D@8`.4XIKM'7GY_,?*BO'IB:Z8=FE*9=WSES5ZT]S_`*RZY)39
MP7)<>OMYE9]#H;V/DG*JQ"NWU!F5IKJ7K4H_]L4B8U)])+"D5J(]AJW@@T*J
M=TVFYQ%_DXW"(2>1U&N9Q$OIB+O<;IA)Q66+70N3!5NX1SQC(",NWD&CY*W/
M&ZHU!VO\/3<33^^<`\O\?\?F/_/[N...................>5G^$,7=[1MV
MZ32D&TM]-LQ:-NZ;3=D>YG8WIQ2J#4930^N]7T".D;;UTJ%FFI$K6)LD?J.B
M.IYPSC:UC697*Q)QTVK$BW2O'\-6YRFB]`^GM]FI*=F)2Y=><OLSV2LUNNF@
M3SU::K31^*\I?=%7<7>[NC%7*![A9E32MG*4DVOZ0?$(60VJYU:]"3II*MM6
MCXX%9N479IPN>QF621=#@V!52O,]MP:=G.A>Z5*<]H'Q-W3?HK<4_9E"+M,<
M`G`]*^F^%9IZ5=WR/S+/NOMAC+?XE:O<[(\\1WCL9U&:TRG/.E5*ZUE=0.J=
M7ZZULV=:9"W6/M]B&%9UFZTJS56972>/8FRR02$79+2>I,Y8>H_7CK_V@VG7
M]1T7*:-FK"_[+F>T;3@EQTK0ZA3PKDY:9FX9)>Z1>YJ/GG;I^_>QUCGGJ<X^
M!E/S[5S/H).F^,O"@K4?3.ITY3XAQ-NXJJ]P/$*KL8ZLMCG[C8W+"&[W]B6#
M1>?MMKDIBT6B9500(>2L%CEY2<EW9E7TI(.WJZRY[*>.................
M..<:R*3A)1!9,BJ2I#IJIJ$*HFHFH42'(<AP,0Y#D,8IR'*8ARB)3%$HB`UK
M9^<>B>T1F'29UFW4C>K.[^UWF7*HC%X5LDXLYE9GKS(.EC`C'T30G0R%EQ)1
M51)&*GQGLZ3`Q%ZR0WS/$MQ*%GJ(S[`*5^2L##-*Y:*5OE>@`.$Y>.I=_122
MUV/C44R_]7:LL=LX7<\Z54-[Q&6JA'+'>EQ)J`I\KI?X@F/6.,J/6S8-TI4G
MV;JMAD\E%U[\<&&TC7#E2I&D5B=104K;MSJ5/5@Y_P""_%4)9.TNYB!3CO?6
MI6YK5>...................>8/Q;MC[+6WMM7,G@:KWZI?63"<>OUVV*=Z
M?=K.F'7&9OPWL,X#/-8FW^NZ\SMJV*TQY':EE]H8Z)4:/5W%M.K-PLY/HPZ[
M![?OU.BIF"ZTX7#6%ELT;.1>74YC*L.Q%LK-[W)F^;1#=)=OJ]RICI[4[->T
MC%]-AFJX[<0S]\!UX]4[8Q!Y(7CF@_5^<O\`F'*]_#,_F\:#_;=\1_\`U^=C
M^6$\<<<<<<<<<<<<<<<<<<<<QCLN043><SMV3:3$C,4^YQ9XV3016,TD&:Q%
M4W<9-0DBF`KQ-A@)1NSFJ_,-A*ZBIABS?-S`H@'G%[J]J%Q2D[=T][*OTI_<
M,M@"/(RW23-)*-['X0_6/#5W6V358ID%ITGG]$-D@4RK$A+HD9\'G#V>),;S
M89[T'J$/XMH]78W6X"&J>>7R(UVNJLP=!.2D'`KPFJ,\EB!C_-I$7^$BE2,G
M#AVNFBA`PSF=;(JR*B,63V>@'D'R^^(C]?G_`-PB(_F\Q^7]'->.........
M.........4"]A>K'=G-^S_>71,$ZG=.NY^<>(74<PK5B=]C=:=Y=,XNVHF.1
M.-2697R`>Y1I;79^N4HK&?9,84>M2-7DD+/:-";/62CF3CI9>UWI9@\_U=ZC
M=:>N5IO"VDV/#<.S/*IN]*IO42VB3H]3C(!Y+-6\BZ>OVL<NLR.6*:O7;ETU
MC$V:#A8ZJ9AY)WFSVA/(1]9/(!\A'U!Y`/X!'S\@'^@>;A^K\Y?\PY7OX9G\
MWC0?[;OB/_Z_.Q_+">.....................10[6X#.:[7:U=LLF6E,['
M8K*NKKA5X=$.,>C.JM0:SM`N)$!(XD,RU*((:J7F**<0(W686!HF,M`1YRTK
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MS-.0I%5]D5W-L*@YL=O<(E]$;6WI!443\?.:=[K_`'8L9(,_%7U*0Z&WK=:1
MG.S]I+/>L4K78>J2%7PSM?8YOL#'U:LU>4>='NJW:;L%3\8SK"Z%JS(MKL/T
M7>MJXG4X?1&[*S^D7K%L/=W0?#NZ9:V&59S>NT6AXIBMDVFL[??+3UNCF\E/
M9\A)6NQJA5,8V&0B[6]G!CG2]'/2(..9A,28%>1(Q;:'<O"@<VAYU.G'=WB(
M2`N;KM_XA3BVP59GGMJKD+9%N]_8E2:BH"SR4!5)&Q0S"0,NVC9M_5ZX\E&B
M:3QQ!Q:JQV2-E/'''''''''''''''''''''`AY@(#]0_(>5FQ?ARTB-\127[
MMD-&#%/*.#YE3@2,"C3<GQ%:S-7_`-D+860MG%(3(=$@*>]_2R2DYD?0H5%0
MUF7U?5QQQQQQQQQQQQQQQQQQQR.?VI/7/[8L.V7V*:[]L$6MFJQ=%]K+^]@Q
M/$DKAI0('XG]$PN1JHF2E#H/P#Z>#0RA1?I)]$0^"\D64H%#R*'D'S_O$1$1
M'[XB(B(B(_,1$1'Y\"`"`@(`("`@("'F`@(>0@(#]8"'R'^CGX"1,8F58A(]
MB0KCT"N4C-L4JWH-ZR>V*5("J^@_\<OM`-Z3@!B^1@`>?O$````/J`2_YARO
M?PS/YO&@_P!MWQ'_`/7YV/Y83QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ
MQQQQQQQQQQQQS0?J_.7_`##E>_AF?S>-!_MN^(__`*_.Q_+">...........
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MG^&@;U`7Q`>F1A(82'`O97(3"0X`!A(<"VP1(<"F*82&\C`4Q3>7D8!'7[J;
MX:?Y?_37]9/(_P!Z^/NIOAI_E_\`37]9/(_WKX^ZF^&G^7_TU_63R/\`>OC[
MJ;X:?Y?_`$U_63R/]Z^/NIOAI_E_]-?UD\C_`'KYH'BG^&@)C%#Q`>F0F)Z?
M60.RN0B<GJ#S+ZRA;!,3U!\R^H`]0?,OF'SYK]U-\-/\O_IK^LGD?[U\?=3?
M#3_+_P"FOZR>1_O7Q]U-\-/\O_IK^LGD?[U\?=3?#3_+_P"FOZR>1_O7Q]U-
M\-/\O_IK^LGD?[U\T^ZG^&AZA)]T!Z9>L"@<4_ME<A]H!!$2@<2?2SU`0QBF
M*4XAZ1,4Q0$1*(!K]U-\-/\`+_Z:_K)Y'^]?'W4WPT_R_P#IK^LGD?[U\?=3
M?#3_`"_^FOZR>1_O7Q]U-\-/\O\`Z:_K)Y'^]?'W4WPT_P`O_IK^LGD?[U\V
MCXI_AH`8"#X@/3,#F`QBD'LKD(',4HE`QBD^EGJ,4HF(!C``@43D`P@)B^>[
M[J;X:?Y?_37]9/(_WKX^ZF^&G^7_`--?UD\C_>OC[J;X:?Y?_37]9/(_WKX^
MZF^&G^7_`--?UD\C_>OC[J;X:?Y?_37]9/(_WKYD3*^^/27<KM'9MC/;KK7J
MVA3#24?Q-&SO;,ZN-NE&4(T-(3#J.KL#87TJ];Q3`IWLBJV:JD9,R'<N!31(
M8X2PXXXXXXXXXXXXXXXYAO8\!R3>6E/1U.BUNY.<YN$?HN=/K#$M)A6DZ'"(
MKIU^Z02#XJK-.;A%5Q79J.4'#<3`*:Z"B1SD&K#+_!WG<FHMMJ]9[X=A5;3:
M]54VF5U>>RCJ5:])M>BS47?*]=+!K4]<L+LH[,[L-9OB]?A5+\1^KFT36ZI$
MYNI68"+6A7MHO7[K[G76O!,<ZXYTSD%<YP[.Z;F=+3LS[Z03)H&D0C6"BW4M
M).44RNY9PV:^W>N6[5FV]X75(Q9LF8(-$>G=7^N+/KYG%AHDB_AK8M-[IV7U
M].31KR48FU:;YV#TK:V,`+9PN_.HK5V-[;5M=\58B,FK%'D$&C%!PDS0D3\!
MA/Q1%_HYE^PX^`PGXHB_T<R_8<?`83\41?Z.9?L./@,)^*(O]',OV'-IH"$,
M4Q?A$6'J*(>?PYE]\/+_`-CD<L`ZVM\8LG9V>D96(LY.P/96P[XP;$KY&)JJ
MUG<MR'/!K;A5PX>EE'*;G,7$NK*H$8I+$F$6HLBJ,CN'$C_@,)^*(O\`1S+]
MAQ\!A/Q1%_HYE^PX^`PGXHB_T<R_8<?`83\41?Z.9?L./@,)^*(O]',OV'(S
MY?UH3S_L5VBW!Y-1,S'=A?L$>X58*^5NI5/L-9W*44_O$@LZ<MY7XO\`$??&
MGL&+#X8@0S,WO'M/:!)CX#"?BB+_`$<R_8<?`83\41?Z.9?L./@,)^*(O]',
MOV''P&$_%$7^CF7[#CX#"?BB+_1S+]AR-T=UL08]N[EV9-*Q"L3:>MF9X(E2
M0KY"K,G5!UC5]*<60\L+@S59M*DTAK&DBRQB2K9Q#*/CO%P=IHMY(_`83\41
M?Z.9?L./@,)^*(O]',OV''P&$_%$7^CF7[#CX#"?BB+_`$<R_8<?`83\41?Z
M.9?L.1VLO7%I/]JL=[%IR$,TC<OPKL#CSFH#7DE%YIUM5WZ^6UG/I2I5TVS-
M&NHXJ_8+,%(]RK(&LJ2Z+IH1@X2>R)^`PGXHB_T<R_8<?`83\41?Z.9?L./@
M,)^*(O\`1S+]AQ\!A/Q1%_HYE^PX^`PGXHB_T<R_8<CGJ_7(NA[AU.UV-FHR
MO-^MF@ZE=GT&6"!9>VI:+A%^QPD>U?MG31.'4CG5Q:SR[E=K(%>H10QY4455
MDG2$HN.................86[(ZPM@O7C>-R;PGTF7QK&=2U=&N>\':#8%<
MZHL]<4X0'::2QVPRQX4K#W@B*IT0<"J5,YB@4:[O"X[D;]V0G-US;L/+Y'<;
M9FE`Z>[1#WK&JM,TFL.*YW"PQ374,^=5V9N5]76D,UDXV3C8VUEL"2ERITM5
MIM_"1,DJ[!S;UQQQS8<WH*)A$I0+Y"8QA`"@0!`3B(B(```0##YB/D'EYC\@
MY2MX7O=3L;OVD:1F?;A5:F:P?*ZQO5%RA+&*+5:PGC5OUO5:!7KO2-BS_L3M
MS?4(9T-.C8210N-7R&U,9)`)]K67T!862[2ZSCCCG1-.6TMO0;4MCL=1Y;3R
M1"_T(CM*FK!7:&ZGS&3*T3M4U58&SV*.A_(RAW+B'@9)Z'I(1)N'K,JGY:5?
M&K[FJ=?\)U_W#KS$S-2Z/5#N[V+KSNG6MPALP6CNF3JNYQ['W)K^Q7R]*,AV
MLS8&ESE6FB2;ZW2=`A7$$V8/Y4'7K/*/F'S_``F#_P#B80_O^7S_`*>;N..?
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MOF/D`_+GFDNG?KQ.D[UV,H.4MNOF]O*K>Z5FRDYA&72CVF]=M=L_;:D45AUW
MA=*V[:LAS[MUM[;J=,V32];J\9*Y`CB>KQ497+1)M(>P1[(ERW03>W/9?JAF
M&O25GD[98)AQH-9N$G-YA'XS-LKUFNG7/-;S69K-HC0M7A:U+TRUU*6J,D6"
MTBZP$L\A%IV"L,A$R;10)C<<<<<<<<<<<<<<<<<X'+9N];KLWB"+IJZ15;N6
MSA)-=NX;KIF260715*=)9%9(YTU4E"&343,8ARF*80'"V#]:.O\`U?K,M3>N
M^-YQBU5GK`YM,S`9M4HBI1<I8';5JP4E7S6);-R.7:<<P81;0ROJ(PBF#&+8
M)MH]FW;)YPXXXXY'K#.IO67K*\O,AU[P7)L6>Z7+)3=\<YG1H"G*VF0;N))X
MT4ES0K)K[PW9/)F9>,(\H)QK!Y,2SIDS;KR;U1>0O'''`AY_7_0/]P^8?X\B
M@^Z*]-Y)OB;20ZQX@^;=<'RTCA"#O.:VY2RAVO,MK&JI2"+,3A!D-8V3"Q>[
MM_\`I2V".C9LB!92.9.T)7@'E]7_`#_GW^....1(T'H5TMU>%AJ[I?5K";Y!
MU[2;YK\+%VS-:S.LXW2M2GG=GTRX-4I!BN"<QH<^^=2UY4\Q;VQXL92>;/\`
MTIE)+1---%,B21")))$*FFFF4I$TTR%`I"$(4`*0A"@!2E*`%*4`*4```#F_
MCCGY7K)I),W4>^;I.F3ULNS=MER@=%PV=(G;N$%2#\C)K(J'24*/R,0Y@^_R
M!D3X5_AT0='M.:173#KNRSZZ*55:R4Q+-H0U;D5Z.]EI"I+_``A5-1HR7K[N
M>G58Q:.39JMPFI=$#F0DWR2\Z(*"A:Q"0]:K<1&0%=KT5'P<#!0K!K%P\+"Q
M+1&/BXF)C&*2#*.C(UBW09L&+-!%JT:HI-VZ2:*9"!]7CCF@@`_(0\_F`_/\
M("`@/YA`!#^D.0+#PNO#Q]-^3-TVZ^*HZB1V6_ME\XA7#2T+/K?'W]R^DF;A
M-5J,J>\1,;;B3+9)O+(V-DWET'R3U,%AF!G.;T#(:-5\SRRF5C/,]I40V@:E
M2Z;"Q]=K-=AVGJ]WCHB&BT&S%DV(8ZBHD11**JZJSA8RBZRJA^Z\<<<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<H_P"X';SO]$=V]?ZS]07_`%$@H'#_``^ZCW1E
M3=D,\U6RO;[/S>M;'17E!:W.A;'08[.X92(S%JNE:)"I7-2,?2#ARXCG;,GL
MD,29S_"%<>N]FZM9P;K;MBVD=GL4R*]UN*@;%BZK0VG[%UXF-^JN90%=G]+A
M-9L,!))0$E0V&O?8W99]]-5XV%=R*3A1Z+2P;H[XDN1]^I.82Q:JW-&O5[`>
ML&W3MKGE*X6*B97M!4[#=H3(')(F8DEE-)SZOP`.-':M?>(>%<2\.U;23P[L
M!"Q7CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCE=7:+PM^J7
M;W5I+9==+M[*X6+'(SK[=TLJ[&[?BU=TC%8JS6>W(YKH]>RJ\5*.NM4<S5QL
MBK^,G4W:3M"36;J?R94_3U=3PEND</L$%O\`6:#<:?::3H^5[;5:;4-8TJN8
MS":CAF5)XQGUO8XM&69#-4I-AD31MF[DP5SV:]63.V23;/'+MZXA[_!L*I4`
M\-Q#<H*J050M':OLCV?WO1H>L-EFE7B;-)['9Z9'UNF,WSB1EHFC56K4^#A*
IK!R<U..XUHBN9>5>N'2ZY[_^...........................?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g26767.jpg
<DESCRIPTION>G26767.JPG
<TEXT>
begin 644 g26767.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?34].2T594U]+7T)!4BY%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`%9`9L!`1$`_\0`'P`!``$#!0$!````
M``````````H'"`D!`@4&"P0#_\0`:!````4$``(!"PP-!P<&#@,```0%!@<!
M`@,("1&W"A(4%189(3$X>-83%SE155AR=Y28M=,8&C(S05EYDI:7L;+14E=A
M<9'5UR(H1U-6@?`C)2=VD](F-#4V-T)$1G-TA*&TMDB"L__:``@!`0``/P"?
MP```````````"G,LK\A-E@KZQ%+'2I'D#!1,+MEH+SKS,A#4SJBMIB7FSK3J
M+-]U&D9)1R!TXNJ1HFW5DY<23,Q<F0SF<^*E+%XFV\V4DV:=D(IQ03#^,GJG
ML%#\+2<M$IM>-Q]9;\GQ1$\R+$B,U,/0R5)7U8C0EDE<;:JZL)W;S.VUJ_`X
MTW'G3[<MTC=V]U3=Y)RJ#1V4@9VE&:FH*P[,S5EQA.2C=2W4MK3::R@L6HB\
M>R)Y1T.-MK[?;6<S9CM7UM%5$I([,/$3&#']BYM7K,V60SY,<6P,,HD=R"4,
M*+'?2G);/)M%VII.F&I]3;[BSK%B2JI:;0Q@JJ*10WD()5,V+MF8*5R64NZ6
M8WCU93YJF2!%F9V"W']`$;,B59;QN=V-MMH[,:;]O=.1'SJJLMJQ$OA,$DIJ
M&'`X;*T[';R$L-H^JF2UJ^GX\G(J>[NFJ,2>*DK[8:VI:?';F:C+?YY1G",R
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MN3CY7-DN*```!8YNCMHYM2E'5I3QQTA.Z-)SVFBK6>2WLJO-2:^6%J3,?-(+
M%D/*FE6@XR;I13STP);"-$#JPT<9%?>#8.&%BU)JJ9R5(6?Q!E]3=W$SCU\Q
M_'S*>W#S.MLV73"LG++CPR>Q9"AZR88N?:MDI'Z/G8>%[%;S3*M;:9@?RJFN
MU!7<./,IX>U.)2N^3-A6(W+XL8TXOF)8JGJ141I9:Q%FDU&.*-':Z,.;%B;#
M5RK6-N+3KQYETBLH#:4:MQ(-.XVBJ%4I(L,X#)`KUF;=JXZCEESG:S'I%[QF
MJ(HJD^0"L0'Y!34I;45".&/D>1M+5RB9B6W&ED2^`R@]T!TDWU,T@$W"CFCA
M*SMHG6F>`U`W.B/:B&6$]4N18HODS+!<+2Y-<7M60F\OKL*FY;C5$D#`EO5(
MQJ>5>:Q&S$HG;$PVZ":=>=))^8Q==UV$QUE3B.TVM*DUW$]B>P$,Y6:T%M(;
M;K==TF,W"W6TON"PEF;R.OK)A9Q)Z,H.+`II9EO%E$P6O7BJFFF4BATN?*9<
MW2)ZWAU<UP:CL=LFS&Q2.!C/Z,(N=B(G.IN*+G;[_F)?3V_'C774&Q6QG4!2
M<-Y^Y:P6KMB;AQ-5-6G3FRV(2.H'L%TR>H$58B35$PX544U1*X#R>H$3&$V2
M/D3>*S.4.DC9>_(7-%#9?)C,%C.#)?ASX,F/+BONLOMK7ZP`````````````
M`````&E:<Z5I[?\`Q_\`88U=0(ZE5E;6<3I_OF+W6SV7.>QD325$#A5331.%
MWVTF1J7!$*KITB1;SI6UE%-6O6-'%B)ICL36^H'DG(FJN`M<7.W6E\6D9Z9[
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MC*WG[P([].&/6W!$:<66MD#YV4LQ:-\)`P[2^1-O2DU]HQ,TZE<LG,7#;C4R
MA)RF<1.ZF7J[9U*GNCX=\/;"Z4R3L'%FS<?Z0N-M/9'V/RLF+X,D*!8*AB.7
MRP-IF@DS:SUDV1C:3X=I-\<O6*6C+RBZUMV&49(["/%;U2S[&[I?L8G*;#7<
M6NJPDK9;JA"6MWUQ8QGXOQ*I+5YWDI93"$FGE`F\;SIGMLE/I*3C+/)Y3K^L
M(Y%$B>:]A;!EQ9<G?#&B*6("UY=T02^PCK,7V[M%N.ZT=2O7FFO(SY9LR;73
M--;)=S:RMI=5SQ1).L^0$#!G).PBVG,36L*J1-H&#`3+G3V1,```%H._.LQ7
M</3C8?7+)GN(K$DQJM%&.MX\OJ&=K2FWZX'=$;T)YZ4Z[`?9DG-]IN<CGQUL
MR83*79?CR8[J==3%)''#VVAMV!T8V*?6-N%7;-D.J^#BSIR;VOHE+TA-E\M_
M;*&2#9P44,MZAA8DYWKL(D\]N=5)V0I?E;MME4NA6_'\/$/@O:Z39.V8*1MJ
M@Y5U,.R3PO)483XB92AM+R[`H6NNR+&D252LJN%^O5%<^-^1"FICD3(G8)*K
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M)E=7:[:?R>V"QJU)2EUVX&THG+"R75XEU+(;()\DY.S&#)`F9-$LR:9,E\1D
MPG&<I7.9(9C%E,V0D8S$3!HEESE;[ZX,V0F:,E+\N.^XL8SX:V9;_M``````
M```````````6_K>TL"-S8]F:C+4B$".Q,A1LOR\SXSO27'E45J.FPI9T=<<V
M)9+HV9KE<!%1*F2W8*@NE%4S7!FRDR!C#COR4N``!IRI[5/[`Y4Y5IRIRKXZ
M<J<J_P!=`ZVVO+G2E>7@IX*>"E:<JTI[7.G@_J\`<J>U3Q<O%^#VOZ@Y4]JG
M]@=;;SI7E3G3GRKRISIS\?*OX.?X>0<J>U3^R@U`!0"6=I(%@R1H&B259#(-
M"1-FW<M,2#&T;27&?,O]UMU+++2RD$CB,C*28DWD4TX5,7FG&>1B&6XQB+X#
M>4S?;AK7ZE:74I=2O.E:4K2OMTK3G2O]@U``Y4]KQ>+^@:5I2M>=:4K7ERYU
MI3GRI7G2G]5*^'^OPARISK7E3G7QUY4YU_#X?]_A#E3VJ?V!2E*4Y4I2E/#X
M*4IR\/C\']/X0I2E/!2E*4Y<N5*?@IX*4_JI3P#4`%#MC]DH2U&AIX[!;%/T
MA&4/,"U%O=SV4TY>5B2-:XG`EM5%]53VRDKBV9J?7UI+3<5I%+-76YCF._+3
M'@MRYL=8DM3(K2:GJZ88M-IRH1**)`U9;DLL,DCY?$;*9[;,MF/+;;F+YL66
MVW)CLR6TOI2^RVZE;:?>```````IHE3-$:[)KCA=$DUA+$NL]O)[L=L9)3M0
ME%^-9L*Y_(EI*\XVJ2/9UI"2E51PYR2:=5293"?,%S&,I=FK@R]9]YB48Y*R
M6EPT8?#6Q2PM,E;DE*CB];(4>I^/VXN(K97'F6;E,U53(V4MQ.-#1#BSV/0C
MB55,H1]6N,Y*X[>K1;L/!DW'G&FQ#+4?R2>:52US@+,QTI+@RIQ4Z?5TDBJ7
M6IYG-V0AJ"NWG$C)Z^2J90SZPW'$DDU'.HH2L5)UE`````1C-O)0C6(NJ6-)
MGA*\AL:,6C@X9DX$,SHD-VH#*;F(^?DY[6$265;<J@F)>,V=OQ7V%"UYJW,8
MNQW6XK+ZV7<LW'?`M#O?KZD?.2ACTU#O@6AWOU]2/G)0QZ:AWP+0[WZ^I'SD
MH8]-0[X%H=[]?4CYR4,>FH=\"T.]^OJ1\Y*&/34.^!:'>_7U(^<E#'IJ'?`M
M#O?KZD?.2ACTU#O@6AWOU]2/G)0QZ:AWP+0[WZ^I'SDH8]-0[X%H=[]?4CYR
M4,>FH=\"T.]^OJ1\Y*&/34.^!:'>_7U(^<E#'IJ'?`M#O?KZD?.2ACTU$?\`
MXLVW6J;SXCO`<<[/V;U\=3:C[;2:5=_.!MS3&RZALA)/1XRRI%4=ZLE.8VGM
MI..&,6<N4.K1@D6,9L67#AR7Y++K:9_,7$"T/IBQTKNMJ12M,=E*TKLE#'.E
M>MIX*_\`AJ/T[X%H=[]?4CYR4,>FH=\"T.]^OJ1\Y*&/34.^!:'>_7U(^<E#
M'IJ'?`M#O?KZD?.2ACTU#O@6AWOU]2/G)0QZ:AWP+0[WZ^I'SDH8]-0[X%H=
M[]?4CYR4,>FH=\"T.]^OJ1\Y*&/34.^!:'>_7U(^<E#'IJ'?`M#O?KZD?.2A
MCTU#O@6AWOU]2/G)0QZ:AWP+0[WZ^I'SDH8]-1@SZI(W"U+E'@R[A,>,MHM=
MI$>RWC@^B,SV+-T9NYTJ_8&P\5*:AVL;[>="BK'^PDPF</G*%2F7L8B6,F\U
M+"^#-DLDB1)X8MCC_J$S/_UA*%0P``````_X_L\0BZZX41X:ZH#XU3G8,8Y%
M;,W=']9I(QQU&2`F$7#(3J+,M(<IQ)0TXIB)%5%\/M5+4(%C1NO9*HN*&#(=
M,9,E]]]<3:;L+.T@<5':Q[$]?=UV+M;-W`-VG(W)DL0RMQP>9,QX74ZWPR51
MF-10=ZN<9NO#1(-1M0A%KGQ5M6'E+A<J:7D?(]'RLJ(NNX1][WLWHX-=&38:
MN:^7J=)O8Y:JGV\T_&W[9ERY&G>L^I5IAM,UD'&4QI-QBE3-3&1<M*4Y7*M;
M<[>]D'<7*2I:;ZYH7N_`^MD1%6`F);A8\GZ])4L+RI(.%?<1I3<Y1PGD50S$
MTHXWS;<3,"1;GLQX#24<-TPTN/77W8JR4T\:'3SB;\,G6O<'=N#=B(CW5>4]
MI*\@1GK<S8W.D2$.1=<Y:X3B]E;A=9P7'UE?0317(BFRF:VQ*-8#=]Y8W3'D
ME;V5K=996OCK;;6O]=:4K4;@``$4_B!:R0'MMU1GI7$&R,6-288S.\->95XT
MS'D3S'D7,LH4H/K,C*-^#`9*Y*F4[,8RY2M],U/4[[ZW4_RNMNMR8]X*X.GX
MOC7C]'EKTA#O!7!T_%\:\?H\M>D(=X*X.GXOC7C]'EKTA#O!7!T_%\:\?H\M
M>D(=X*X.GXOC7C]'EKTA#O!7!T_%\:\?H\M>D(=X*X.GXOC7C]'EKTA#O!7!
MT_%\:\?H\M>D(=X*X.GXOC7C]'EKTA#O!7!T_%\:\?H\M>D(=X*X.GXOC7C]
M'EKTA#O!7!T_%\:\?H\M>D(=X*X.GXOC7C]'EKTA&#;B?\)CAPPYQ`.";&<9
M:@0XS6'L!M%+S2F=K(R*H8DJ1FRA,-GJ:0B.3#G53%YHB0/G#9G!BQY<-+<I
MC)6[KJ774KG&Q<`O@ZUQXZUX?.O%:ULLK6O<\M>&M;:5K7_SA]L;^\%<'3\7
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MA,S_`/6$H5#```````4.:VL^O3'E-RSDSX4B]L30]"-J8\Y:0F4@IDD/!+QV
MX+,"6ZGL5)XW&XTPI86+6D4]943I,A:6+VDL."F'%UG;_6EBWUT?7OI'#&I,
MO<-ZV'KL4:J)21Z1QV[[I>X*CUH2[HJ,[NB_Y]HVJ*/:BBQ_SEV)V7_RPZU%
MNNL$PBHN-6B*(X]C=2=M"V)P'68U4A`,*)(BHK*R02+\B>6PU+H*<M.-R+:<
MWB78R$GK;E<:P23L"DO*YHY6<1P^*?[-AU._\8F^70>R!(YQ_>\?P+?W:#>`
M``M*<VED).W<J.-[%<FY;IYBR&75!#5.EW%FP-7&PW@M'%U7PGVS0K=A.JW9
MR@;J64ZG,5V##EICNP9:X\5]EVH````````M+G[2V$]DYDU5G22R;E,/S3F0
M'+)4-9T5Q9D=**N5UHA%!5KW&F8RN>QP$;B2:3J7*9,I7U#/CNOIENLRY,5]
MV=MM+;;;:>*VE+:?U4IRI_\`8:@`````#%[OMO\`SEIX\6`V(HX<VVNZZ<\F
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M`[B*DG"8+%RI/'1*<./)<:2LEN'EDPXLEUN3+9UF2Z[0````````1P^*?[-A
MU._\8F^70>R!(YQ_>\?P+?W:#>````````````````````-*VVU\=*5_KI2O
M[1IUEG\FW\VG\!'2ZJDMMIP9YYY6TI_TH:R^*E*?Z>V13]E:_P!M1(<2++.U
M:;_DV_\`B!*GW-/%0KAI2GB_!3P4'(]99_)M_-I_`:TI2G@I2E*>U2G(:@``
M```Z_C=K6RN;.RL;D0;WB51<#D,-2U83JN7`WC1[(F%E[,@4,U5L2*84<.4A
M@5<A.TAF.8[RN(Q?GLNQTZRT9@B>0'$\6@Q).CUZ.N.U"Q)D!L-)ZMER.%C*
MN2[)9C3'BB(JH>4VPHY+L.6W&26RI$S?=BR6VXJW674IR+1DF.W^9<))BOQF
MO,XTE*J,ZBK4="&XS#96;;\^.Y(<&!&/G<B*IVWE3-MQ!2M+&J7%\]OJ778,
MU+.ZB.'Q3_9L.IW_`(Q-\N@]D"1SC^]X_@6_NT&\`&RN2VE:TK2_P>#P8LE:
M?[JTLK2O]=*UH-/5;?:R?]CE_P"X'JMOM9/^QR_]P/5;?:R?]CE_[@>JV^UD
M_P"QR_\`<'Z````````````````".CU5+[#///QH:R]/C'$AU(_\EIO_`,@2
M_P#Q<(Y$``````/^/[!&3TT8+6;75&/&"0&VF7-Q.<>IFIJLIWHAH\0/9%IV
M(C?,KJX64<6>IXJM'SYC,H542N?&:L4JU.XKZ&K:Y!:F[-;-<HIW"WRW#X=V
M:*8!S0#PTMF=68NCF%W*B(CIV;W`9K+?CZ?<C8&&@J55-:1X4*M=(:KA?JP5
MM69(G9`4U0PJG#S)N673UKA&KCU;V\O!S0&7BSX6L_>IW&Z;EXD2PUL('""!
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M()F#.>SU-'<V%/*82>+*;,UMLKG,Y<>&V\QFK;;7+FNOR5MI6[E3DP``````
M`````````1T>JI?89YY^-#67I\8XD.I'_DM-_P#D"7_XN$<B```````M?;^F
M>MS5F>3MB&]&V%*FV96Q8S)0DPJZ7U1V/5K%R)9-3D-;4<CIR>KD$0D3*8&[
MBPXL%6W0J7O0;DW+AQWVT=URX5W#VU(D>LO:Y:GQ+$TF50%EL5>K825+M_<A
MN&XI<N$+SBHK*77V*M2):A[-=94T8MMOLOSULSF+<M<(1U!UMUR5U!=A6)&P
MP54^U4I@XC:7VS-W(4>(3B<CN1(V9N)845+`Q(S1G2\'0XDF.67C0&2FK:\J
M*9-"PFS5V6ER0CA\4_V;#J=_XQ-\N@]D"1SC^]X_@6_NT%K6W.[.KFB$<HTM
M;9RXC0S';@>2?'Z.YEM(=2T5//!42%M>((F,JT$!Q*6/.82&XM';3&8EB)68
MR&2S*:LS9,&/+CH^V0N"=[_://T"F_\`PM#[9"X)WO\`://T"F__``M#[9"X
M)WO]H\_0*;_\+0^V0N"=[_://T"F_P#PM&$#<;C/<,>2.-#PAMF&3MBSE^#=
M>&;NHFS/()9J2?@3F(=DV*KV\QBZ@GGF*573U[A5^1(M5&2E*PODKZH?N*8.
M6:N;ZG5(/!.I2G^?M'GBI_[A3?\`X6C7[9"X)WO]H\_0*;_\+0^V0N"=[_:/
M/T"F_P#PM#[9"X)WO]H\_0*;_P#"T7A:>\4?0K?IS/%G:B;%-N:G(P$%-<SO
M3$-M2"B7HJ&KJ61'3S^8P\6@VR9FPPI8KRWJ)$P:,XKNMR9\&+#DQY+K_0``
M``"M:4\=:4YUY4Y_AK[7]8`````.'<+A06B@+CK=*TE-ML-E'4W`XG"NJ!5*
M1$%"126=25UE85#V7`234M+3BQD\H'S>;$5)D\&8R8RX\.*^^EB%.+1PMJTI
M=3B.Z+\KJ4NI7[*V#O#;=2E;:^%[^*M*TK3^BHU[[/PM_P`8YHO\ZZ#O3<.^
MS\+?\8YHO\ZZ#O3<.^S\+?\`&.:+_.N@[TW&!OJDWB!Z)3QPFIJCF$MS]59>
MD%4DC78XF,6,]@8J?+P42:--;15U@X0;3;=*BLG"B2EDS2BJ&2Y+)@3R6#(:
M-Y,.&WKZYUDSBR<+K$G)^/)Q&M&++[").V^R[:V#J76W4*XJ76W4[M^=MUM>
M=MUM>5UMU*VW4I=2M*?=WV?A;_C'-%_G70=Z;AWV?A;_`(QS1?YUT'>FX=]G
MX6_XQS1?YUT'>FX[2R.)?PZI,>#:CZ.=[]/'Z_'FLD6XT66S=D8A<SJ="^IY
M?44Y$;[?1G<<55A5/9O^2)IY`KG-&<G*S%BONKR%[OC\0``````".'Q3_9L.
MIW_C$WRZ#V0)'./[WC^!;^[01!NK2JUIPP8-Y5K3_/?CKQ5Y>*%)]K3^ROAI
M_2/,&]4R?ZR_\Z[^(>J9/]9?^==_$/5,G^LO_.N_B'JF3_67_G7?Q&G7WUK2
MM;[JUIXJ]=7G3GX^5>?.G,:^J9/]9?\`G7?Q#U3)_K+_`,Z[^(>J9/\`67_G
M7?Q#U3)_K+_SKOXB;UU$?===M'NSUUU:_P";_''CK6OBE`QR\?M<Z_VU]L>C
MV`````CG\1SB6;`0IM8DP'$2BRE4G%LAZ^R\Z&_#JNL.J5EZ.3K3?*B\H,V3
M17)%RTVXB;4NF\:<XF(\HJ6'[+.1G,I;.I4<*QH]C+8LT.H<P*\_ZSPK-"\N
MQ`Y5>2V$CNXZMP(YG&\(A/Y%:F;+;D8CD=Z&VG.K(V/%3&7J876^C*=I_"=+
MFDXK?A]2I<>````+/>(97EH-N_6GCIJ#LO6GZE7N(,&H<`0(MZH:QK"U!D,+
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M[/0HL^XM^#;^R@W````_#LHMV3V'4QAH;KAN,T+5RV4,5+VY+<5V>F&MU,MV
M"W+?9CKFI97%3)=;96_KZTH/C*+2.H'51-(JB<<4$3+@P+!$J>*F#B3G-%K#
MA7"IE<.6_.GYC)3)8:+XCF/!DSEKK<^*V_%6EX)ZTD*V51PI:HGJ.5(/Y$M5
MQD3I4YD3%/%BQ9\J<H6%LN6XB?Q8<^#-D)&J835F+-BR7XJ69++KN3$</BG^
MS8=3O_&)OET'L@2.<?WO'\"W]V@B"]6E^Q@P;Y[\=="D^CS!``````3?.HCO
M*CW9\W^..E`P/1\`````42EC7.%YP4(S5908J<YU&'YB94^QX<O-*B4809;C
MM,7T=EN_)E0SR9>LF$%-="X4*)J]<IHMV,]=7.G9KL)>N*L1$@23"A<@G%"Q
M$D4Q6X2Q0G@PE2Q?%;SZW'A+X+,>'%93G6M+,=EMM*UK6E/#4?6````+/>(9
MY`N[_F@[,="CW$+O3#R/M5/-QA7H[;XN6`````4%??E<<)G\J=K1]$R`)]%G
MW%OP;?V4&X!9[M[O9KAI`W6TL3H[%K$X'\>44F,HNCUENR5)CE%72BN,VI$&
M!%S!2EQV+N),Q9R=%I<N(DVNWKU!,M<*ZE7*:?0S:?KEQI=29_D1L12X6?M#
MJN_7^M6-N-4;<?6Z0]?DN27'EKUA5MLQ\.`L?CU0=*GGK830FB==::Z'$?OL
M3F^D*A^^PM=ER"M.?_'_`!_OI^'Q5\`BU0->I1=QZ>-HKL:UPN!;:VA6O[Y:
M:0X7,ZWMEO<^5H8'KC24JKF5ULZ02%!V9\IDLVDC(51"690,8DM,*V9[L5V%
MC7796?X2AWA0SC$2FO*4P;`<+[C:R'.+I+W9S;AE!\L,]*\\,E]/XY3%GSNA
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MV,&#?/?CKH4GT>8(`````";YU$=Y4>[/F_QQTH&!Z/@````LZV%WYU4U7<B(
MVIVDHXQ\BPJL]%.N/UO9-<D>L=1D%7O0&'BEB3FDS5Z/(=Q/-9LN3VR:E%S-
M(LL9N5Y/+D+5IG%3IEV9@W7U8AYO2_(*4S%Z?I5;<)Q`C&RJLH*;XDQV9,UB
M(VDLFC)ZCEPW9Z%\^8TJJ-"2(F%L.0PI*17%2EUW#OG;;7^.)318:>$@%$I^
M+!B.R>0E1)7CJ.W#\PN%;:,.IKW=2>EFFNQ5*778VU]L1>GNY71S;[<"2;2&
MYB/G:8<6:JN:26;AD=/B;MQ9F?Z@SE)_T;Y4J<-9B#035D@WJK:R:+X,A%$+
MJ*V?[6(&)5,E#3C,IK@HA8%#&VG!>F]Z```!9[Q#/(%W?\T'9CH4>XA=Z8>1
M]JIYN,*]';?%RP````"@K[\KCA,_E3M:/HF0!/HL^XM^#;^R@W`(Z/%*V/V_
M@+;A#-ZS;:<%K6'"L0`SB:U7B&24H,S8%T5H_)$,Y*M7&CJ-IWUG2F3&3M3+
M,^(F6-O7NHS8[#^4K=F*?'PY=D=Q=MYX=<,[C[A<&[;Z&CT(O1?,Q9H-(*E)
M+]*N-+><9$T5TR"DN2\[C(L5+Q*BD73U%-SE5`N\3B(9MYW%"Y@I(YMMI;;2
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ME$SYLXDM=IIZ'>((X?%/]FPZG?\`C$WRZ#V0)'./[WC^!;^[01!>K2_8P8-\
M]^.NA2?1Y@@`````)OG41WE1[L^;_''2@8'H^````MUV0G1X0,UT)Q,W62?M
MH3RPX.TAII:]XHARN5OE.U9Y1[HUJDQ2U$*'1"KG)XDGFF+:DJ]LE`E3M7V%
M4R=+8]N+2GR9*/#%EY_--C1ZVDXA&B-L)L-K=LHW#&55E".HS((4IO+7%T.^
M*Y1*H\?/ERI+0I'ZD[$Q6D1*OSX[6^AG[")PLY"G3>*@XL[O97!_=9AOJ;3,
M.?BU\/IPF&NL6>I*[<RK:/(JIE057%;;9;C4$;(;N33V.VRVS&:*Y;;;;*6T
MMM[UN=I<P['G+&Q+BD133H^F!Q:,N"7XD2VED<#]E62=*YD-/[7!C0TXK70D
M6-Q>F!^J[.CIRHQU`<558NFIM6Z<:AU57EJRCY'<B1=:9FF/`_XY;;P>R&^M
M`+=PG0745"QQT6]^Y97(3AJ-X"L*$\Y!1BS4XA8CES&5P769I3.J[^<1$LTW
M@IKR@O9ZJ5YTY_TUI_OI6M*_[N=/![=!J```L]XAGD"[O^:#LQT*/<0N],/(
M^U4\W&%>CMOBY8````!05]^5QPF?RIVM'T3(`GT6?<6_!M_90;@&`?BYP#P_
M=CE%Q,1YI^BV3B(WL**U2"<.ZN`NC)K\9[)E'*]L,2);G6JI:Q1GR+B*OMD.
MC+$2MF=S9[K\ZR?+V5M+69Z.\*GA][&1KM_GVAECA\Z"<.-IM.$))B)+9FJ1
MTD]WW-JG)+QCER%W(YW$C9LK5;K/91!A9<:)A)X2CK5CKE.%5+'VCPEL!*2T
M```".'Q3_9L.IW_C$WRZ#V0)'./[WC^!;^[01!>K2_8P8-\]^.NA2?1Y@@``
M```)OG41WE1[L^;_`!QTH&!Z/@```.ONITM9D-Q;>#V<2`TFDVDTVM.)T.E7
M34!NH".0Q79SZLM+:N9*)B4FDL%MV8V?/FBY4MBMNR9LMEE*U&,!?=G!G=$V
M*VQ#AFK1-7F%?3V>EN1W']B(G,5<Y>/,W9#!R.EOWR+5IN908YBW&89ZLOH"
MBJMG/A+YD4Z2REL%^/O\O[!<*:>.X.DQ[)Z12#ZV3V2Y'CONFV)ATWW'2&B=
M=VB>[;ZU_8.UCO1*Y,_:1PE>M5TFIDWVN-%NRS/JO>7'N3PXG<ILY7<NW>G:
MT?C]QY'>SLQ_9"'<]J`Z,C?6VM1?(EZOJA:BK@0'(NII0[FP9LY+`J'+B=V#
M-EKEIM15OAV;13:VGBTG]JQ.LZLM-2EM$R,J3HZ?[R*I3`63:JUUM00&LZ%+
M*L%8W<CL4%AEJZ\E*5L=N)T*"LUC2"KKQHT;OI```!9[Q#/(%W?\T'9CH4>X
MA=Z8>1]JIYN,*]';?%RP````"@K[\KCA,_E3M:/HF0!/HL^XM^#;^R@W`,>G
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MBK_3XJT_;2GB_#3QTI6E:^"M.>X1P^*?[-AU._\`&)OET'L@2.<?WO'\"W]V
M@B"]6E^Q@P;Y[\=="D^CS!``````3?.HCO*CW9\W^..E`P/1\```!T*4HO8$
MUQR]8DE1K)3WCB1FTK,][M!<QY<R0Y&RNE;R2LC*6+!F+YKR9\KDOP9[<6?%
M?6RZO6Y+:\JC%[7@%\'2M:UKP^=>.=?#7_P>6O2$8+^-'PF>''`#[X2B7#>H
M4.QZ1FWBI:[PU*Y9NHRB7Q/J+W7C5*.%DKU,ZL8O,(:K4OBJ;P8K\.2ZMEM<
M>7%7KJW9T.\%\'2M:UIP^->*4K==RI5O+5>5.NKRIX'!2G@IX/!2E/:I2G@%
MP>M/"UX?>G<BYI:UDU3B>&)',-I59^=W,I*4B2OE;2V:3#JJCWY#2L=PW$SI
MI&3,V:VN#KZWD\769+:=?2Z_P```%GO$,\@7=_S0=F.A1[B%WIAY'VJGFXPK
MT=M\7+`````*"OORN.$S^5.UH^B9`$^BS[BWX-O[*#<`Q]<5%\J\=:![).9&
MC."I;R49Z4WU9F;.J%B9KQ<U'B\6TSWFYYI-5R8<U8V8;5759\NLH1S850ZE
M-[.52LV)1R%LEL?3AAQ`P=F9M1=>]EX8ZG;E2&HT@"0;XX:/#C74F8)99ADM
M)\:+V7(Y,BXZ'8X$&-%E75UQ37EK$9L47(\UBTFX58^6<"H349AUEEMEMMEE
MM+++:4MMMMI2EMMM*<J6VTIX*6VTI2EM*<J4I2E*4I2E*#<.$<IFPDWUPY>N
MDVQ852%0S>XU"TI<00+,!`SEN6SMI_+@(W%$BVRJB9H<S8BM<)6^AC)CPUOO
MM\^+23;O86!G8W:OQS++2FN+.'IQ4=AX@V)3L3V=;,XTZ<9Q."5X<D)=/O`F
M65+G##)EFO:1&^9?A`X[C+/P(;;249IMU8+)RSDIX2<Y2<UMTN%_'Q-><JVU
M]PN!XB3KL+@5%I86*/6>D&5W"Y,.P#PSG\YW,KR8K46UIG+3Q4L_;1<1%Y)1
M%,\<)-IID$O/?Q`9_P"(9!OK5?8(:'-_=CNFJ\_7/[>;$,>!O6X[44;-6A4M
MW976]U'=751<=,O:[KJH]4#'V52E%+!41Q9/G_B%SEQL.!C]G?H<WM)^YJ0]
MO_6Q[1;$,:>O7'[;PB0[L.RNXRM>Y>K4[7-OU&BE7KEBC@OJ5_R4[-2DU?']
M[Q_`M_=H(@O5I?L8,&^>_'70I/H\P0`````$WSJ([RH]V?-_CCI0,#T?``=2
M?SS2(Y8[QD!P6';T)CM5QO!:L3L%AI0O26NC'EU2M(ELF8OC,'+B2?GH5P7F
M,%F7/7'CNS8K;JWVQQ4GJJC0=>2TU;1=<^(LK)"N1+*28J)>J>!23CY$WBMS
M%S1)0(R68)'"^6RZE<9DH8SE\O*MV++DLY75Y#[:3T:]['Q)?FC7_P"(H?;2
M>C7O8^)+\T:__$4/MI/1KWL?$E^:-?\`XBC$1Q4>-A`&YCPX;:]$>MV]I4EJ
M?Q#X1VDE"UY:SJ"$8,QI'EJA1>+M/$4=2O:LNC)4WC[7)!G(F%S7*_U12+=;
M3KLN_P!M):,TY_YL?$E\=>7^:/?XJUK6G^D2GX/Z*!]M)Z->]CXDOS1K_P#$
M4/MI/1KWL?$E^:-?_B*'VTGHU[V/B2_-&O\`\11??P^.,EK%Q(I-DJ)(8C_9
M"/WI%;';TA.1/GR*2<95SMQSKQIN)9A(P4=R^HG+\B@3S5NNS$"A2[!;=<7-
MF,F/-BQ9:``6>\0SR!=W_-!V8Z%'N(7>F'D?:J>;C"O1VWQ<L`````H*^_*X
MX3/Y4[6CZ)D`3Z+/N+?@V_LH-P#'#Q0X><&U^G<\ZP1&W(9E"<%I-AQX-N*)
MN5#F&.%#M+-K5=2`K2BDI!G"L'XYRF8_<-Y\C;BS)[IJ@J;8RX%#U4V0OQC<
M,;3':[3W8MV37M/I;P@=08F)P;(**:E#0EO/EDO?,L'W7&ZL4;\D*#]6<B?F
MCPPFH:LI8<)`MD,X7.E)%<F;!CS8\9J2M2M+J4NISY5I2M.=*VUY5IS\-MU*
M76U]NEU*5I7P5I2HU'%+J&D.9%5FZX$TFL(2\F*",M)*A@QFB"HDJI3,GJ2<
M>+9:78S!,\1,9RAK!DMK9EP9LF.ZG*ZHQT0WPI=5X>6X-4_47]*"3J[%LH0K
MK&SIA<J8]VM`\7S'CM2Y":;0P=SB6LN/$N,W`0CBU:E);D%R)T=$,;13E@L0
M.J]REWG6#AQZVZF/)$?L:ISM57(R8(1-78K/OIQVN;-$>N3>>RY(29#K$,43
M4X[:V[70MT-'UIU&G0^5HBA-)%678?1VF@DB=^=:4KXZ4K_6(X?%/I2G&PZG
M?Y4Y?](F^70>R!(YQ_>\?P+?W:"(+U:7[&#!OGOQUT*3Z/,$`````!-\ZB.\
MJ/=GS?XXZ4#`]'P`%ONV7DN;'_$+,G1JZ!YMNJ5UU-8]?J4NNI3UHV5X*5K[
MEV?TBOW7W_RKOSJ_Q#K[_P"5=^=7^(=??_*N_.K_`!#K[_Y5WYU?XAU]_P#*
MN_.K_$.OO_E7?G5_B'7W_P`J[\ZO\0Z^_P#E7?G5_B,I?4]%:UXGVY-:UK6O
MV%,!>&M>?^EYW":6`"SWB&>0+N_YH.S'0H]Q"[TP\C[53S<85Z.V^+E@````
M%!7WY7'"9_*G:T?1,@"?19]Q;\&W]E!N`66;=Z50%N*1;R?(RQ(4>28TK%+'
M&DTP++KL@R?8\N7,5EZIB:$@,1635?.D*EJ=A.*+0<91R,I6.)A%646V:44=
M/.DK3=?.##!<.OMMR'+.R>]V\*^Q7"GN^/$[=S:EYS4Q&"[$<Q:;1'4AQ@5*
MM6/5%RH1VRQ20%MVMYRG$!8P$UQ#[7+9`@HELPM*4IX*?\?QK7\-?'6H```(
MX?%/]FPZG?\`C$WRZ#V0)'./[WC^!;^[01!>K2_8P8-\]^.NA2?1Y@@`````
M)OG41WE1[L^;_''2@8'H^``M]VR\ES8_XA9DZ-70/-KU2\F/7_XHV5]%V"OP
M````#*9U//[)]N3YE,!=+SN$TP`%GO$,\@7=_P`T'9CH4>XA=Z8>1]JIYN,*
M]';?%RP````"@K[\KCA,_E3M:/HF0!/HL^XM^#;^R@W`,(NP&V.H&GO$UN>>
M]!QA0RH/O6"/VSJ+LO(R"8*,JPBAO24#VP\2%Y0-$#*.Q'M:IJ\=NE1)J)U'
MP.9GJ3?+%3^;,0,)^?L<(\0#6?<[B*MALZ3RT@SHEQCK1*!G:-_QT95EB+4A
M,67Q'%FO;/,NNF#$TW&_#3D]==<;6%"SJ9E!:^%^V'#A2U;M*F,RX`-.NISY
M<^=?PTISKR\'/_*Y?<\Z>+GRY_@"EU*UY4KX?'XJTYT]NG/QT_IISI_2-1'#
MXI_LV'4[_P`8F^70>R!(YQ_>\?P+?W:"(+U:7[&#!OGOQUT*3Z/,$`````!-
M\ZB.\J/=GS?XXZ4#`]'P`%ONV7DN;'_$+,G1JZ!YM>J7DQZ__%&ROHNP5^``
M```93.IY_9/MR?,I@+I>=PFF``L]XAGD"[O^:#LQT*/<0N],/(^U4\W&%>CM
MOBY8````!05]^5QPF?RIVM'T3(`GT6?<6_!M_90;@%#-A=:(`VNCLW$^R,.Q
M[-L='#Q52R-*1FRFN9+*JA2F7$56TNA_#D,(BZ2P&36(DNH^<@K$\9@QC+G,
M>/-FLOQ_\'I@LF(8$D:,DV"H;UK>B!LOLXCJ$71FQ6_&JV:CMFS8[6M"3Q>C
M>)Y\SE65)PP^69"J3=[HR&CK@25-.5BYGM>I$O5,N8#J;\>*3'C(>#]7NR.T
MC):[A=RSV)B]7-]JFRCG5Q2H5P==;ZL8J2(9Z8,774Z_+6RWGX1#ZU7XQ;E6
MHR<&U>T*',>'9_9O4W>_;_0Q),N=(4=36O'NL"1*%N"`6%'[3=I;-ADQ);;.
MM=+YD>6F`==K]JHJ*:1>9!(+-QMWU2X4NV<XDMQ.'!%SGD9_2&VMX^#,C[13
M9A?#L7'=52V81Y-7U@W,A;(O'3]6\J.!NGU1DK2<WZ):&>1R[,(53;,#.0<9
M3.'O]N-L[J=ZUGV.7#UF+>[NZJ\^Z[UIWTVV7ZV/<Y1M50^WG="A+7;'NOJM
M*M$[L7L:A7N<.^K5S5,8:61Q)3W&V=VQXV'`Q^R,X>LQ:(]PLA[@=R/KL/IM
M/3USNZ.$$^BYVC[GD-&[7=R':1*[8]ETS]E4<9&N#U+U#+7+-4Q_>\?P+?W:
M"(+U:7[&#!OGOQUT*3Z/,$`````!-\ZB.\J/=GS?XXZ4#`]'P`%ONV7DN;'_
M`!"S)T:N@>;7JEY,>O\`\4;*^B[!7X````!E,ZGG]D^W)\RF`NEYW":8`"SW
MB&>0+N_YH.S'0H]Q"[TP\C[53S<85Z.V^+E@````%!7WY7'"9_*G:T?1,@"?
M19]Q;\&W]E!N`83]_N,ADT+V!+P;DT4W2VFQGXL9<FXWGJK%])'0&_1U.*0&
M]>V7GGR&R5J(O67L?MHG%K:YZ'TI0KGNKAJ6Y9;9=%M]6?Q`>)VR)#2N'WM7
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M\N?*G/\`J$<3BG6VV\;#J=_K;;;?^D3?*G@I2G@]9!DUY>#\'.M:_P!=:U_#
M42.L?WO'\"W]V@B"]6E^Q@P;Y[\=="D^CS!``````3?.HCO*CW9\W^..E`P/
M1\`!;[MEY+FQ_P`0LR=&KH'FUZI>3'K_`/%&ROHNP5^`````93.IY_9/MR?,
MI@+I>=PFF``L]XAGD"[O^:#LQT*/<0N],/(^U4\W&%>CMOBY8````!05]^5Q
MPF?RIVM'T3(`GT6?<6_!M_90;@$?[BBOS<R69_3]0=1MT(!X<[;1(>9TQ3OL
MO)9AIFY5>-[_`'=(32CB+8@;CB.IM_8B,6C5W.1_.S"H)!PE16::.BKQ>F=9
M3SSA<.W<F(M@5;4W;3>:!>(^V7'#SHF""]@H]JU",KL,Y'[L831DV-)106T=
M5[LJ,ODY)9CB8SK.JRD=,YT9V)"HJ7THDD"L@$```$</BG^S8=3O_&)OET'L
M@2.<?WO'\"W]V@B"]6E^Q@P;Y[\=="D^CS!``````3?.HCO*CW9\W^..E`P/
M1\`!;[MEY+FQ_P`0LR=&KH'FUZI>3'K_`/%&ROHNP5^`````93.IY_9/MR?,
MI@+I>=PFF``L]XAGD"[O^:#LQT*/<0N],/(^U4\W&%>CMOBY8````!05]^5Q
MPF?RIVM'T3(`GT6?<6_!M_90;@&*K<K@Q</#B`3*6G/<&%,LPOI(CYLQDV#)
MF1Y/9!-NM)MK;O<5I$H2CUYM4H>RJ*R\E(X=.JI<\<LIA*%BN?`7LR8LMKFF
MG#ATFX=7$;(-[6C3(S!9Z3]7IH.-V<V]L*_93;+_`&FTI$@"QWQP\8^DM4/K
M#%>J0L.%H.=$4D"Y70E%#JHX,CFSG+LR,F9^``.=.?+G3GRY\OP\O;Y>T-*5
MI7Q5I7\/@K2O@\-.?]M*T_W5]H:B.'Q3_9L.IW_C$WRZ#V0)'./[WC^!;^[0
M1!>K2_8P8-\]^.NA2?1Y@@`````)OG41WE1[L^;_`!QTH&!Z/@`+?=LO)<V/
M^(69.C5T#S:]4O)CU_\`BC97T78*_`````,IG4\_LGVY/F4P%TO.X33``6>\
M0SR!=W_-!V8Z%'N(7>F'D?:J>;C"O1VWQ<L`````H*^_*XX3/Y4[6CZ)D`3Z
M+/N+?@V_LH-P#";OKP\N(!M%L323M7N*-(^AL<%(J8C-/Q\Q(S*206>SQ1'!
M(:HKO=1R*+Z:>)!-6)#B;K>PEBA0[<IX$OL@V9Q=B%<-W$:(<-/>;67:E-G?
M:GB9OS?ALD83E.+FXUG_`!<3CG+'*P_';$#FS.=#,D'T[<2O<LE8WN1E0J8)
MD<I3'C(&,!S-9D,%[<Y(#BEU<1FPBJ[C<2JFH2`@):@M+BVLGBR8D(Z.E%,Q
M]35552.9,11/34XB7,'#YXUEQERA7!F,9K[<>.ZZD69W<5:>TCB4;$N[(XB9
M?66+^")L)NQ`T`XU7'95UJC0E9/N:3\E9/P*-N6^1W\VF0<<;?:UUY!3C>)G
M>GI"D0(NX^]+K/HX7V^>Q"UMGP]H@E63WK*J!O;P@D;;V0KGFJ6K-Z1LTER8
MXE%:>#0LRV82S%:+A8YTVT34<M`JEL@C:W&6?1D!,5,#C4U[,-Q`>($Y=&/6
MJ[GM(-S]R/7,J\Z&_L1HII)GK?=R-&S7#W>\SI3M+W3]T67N:K7KZ*%4);IS
MMJ4I2Z.+)_$"<N\W&PX&/=#H_N?IOZVDA[?U*?9=152,O7"[KH1(4SU87(\=
M[==R_<YBHY:\L5"%5U$IRNJ;K6DU?'][Q_`M_=H(@O5I?L8,&^>_'70I/H\P
M0`````$WSJ([RH]V?-_CCI0,#T?``6^[9>2YL?\`$+,G1JZ!YM>J7DQZ_P#Q
M1LKZ+L%?@````&4SJ>?V3[<GS*8"Z7G<)I@`+/>(9Y`N[_F@[,="CW$+O3#R
M/M5/-QA7H[;XN6`````4%??E<<)G\J=K1]$R`)]%GW%OP;?V4&X```'`NIKM
MU\-AQLMWHJ:Y&F[D%8;#G;JR4Q'T=>;K@3C*2MHJJ1SVW8#J:JIAPT0/%,UM
MV(R5,9<.2VME]:##FTN`OP^V!N0=VK8,+1RQ6ZH:IO36(Q`3,C9K->.[<LB'
M%M/>TLE3Z/:56R4@N2-G(NQ.I'2OJ5<S*5#93LNF3)45-TTX4D<:E2E%LL&I
M%7I5<>OFH2'HUK]E6FZE-RYDP(C2"LO_`#9G/<F'CY9YRFNY#;>;2V^"1)H)
M%S;:9'"E,Q*4EUUJ*SE=K3G[?]M:?L$</BGTY<;#J=_XQ-\OPUK_`*#V1[8D
M<X_O>/X%O[M!$%ZM+]C!@WSWXZZ%)]'F"``````F^=1'>5'NSYO\<=*!@>CX
M`"WW;+R7-C_B%F3HU=`\VO5+R8]?_BC97T78*_`````,IG4\_LGVY/F4P%TO
M.X33``6>\0SR!=W_`#0=F.A1[B%WIAY'VJGFXPKT=M\7+`````*"OORN.$S^
M5.UH^B9`$^BS[BWX-O[*#<``````(X?%/]FPZG?^,3?+H/9`D<X_O>/X%O[M
M!$%ZM+]C!@WSWXZZ%)]'F"``````F^=1'>5'NSYO\<=*!@>CX`"WW;+R7-C_
M`(A9DZ-70/-KU2\F/7_XHV5]%V"OP````#*9U//[)]N3YE,!=+SN$TP`%GO$
M,\@7=_S0=F.A1[B%WIAY'VJGFXPKT=M\7+`````*"OORN.$S^5.UH^B9`$^B
MS[BWX-O[*#<````-*5I6M:4K2M:>.E*^&G]?M!2M*\^5:5Y5Y5Y5Y\J^U7VJ
MC41P^*?[-AU._P#&)OET'L@2.<?WO'\"W]V@B"]6E^Q@P;Y[\=="D^CS!```
M```3?.HCO*CW9\W^..E`P/1\`!;[MEY+FQ_Q"S)T:N@>;7JEY,>O_P`4;*^B
M[!7X````!E,ZGG]D^W)\RF`NEYW":8`"SWB&>0+N_P":#LQT*/<0N],/(^U4
M\W&%>CMOBY8````!05]^5QPF?RIVM'T3(`GT6?<6_!M_90;@```?$I54:)YZ
MJ183R*MI,U<FXU'+GP$,A^F#)4GC/9RV$R9PD[S-,5AK*7+Y\^,O7)?APY,M
M++*Q@L.Q_$JTBWOV\0YBV9([RZP0]PTY`WAEK&;AME16GZ^2NB7///'D1-$_
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M?WO'\"W]V@B"]6E^Q@P;Y[\=="D^CS!``````3?.HCO*CW9\W^..E`P/1\`!
M;[MEY+FQ_P`0LR=&KH'FUZI>3'K_`/%&ROHNP5^`````93.IY_9/MR?,I@+I
M>=PFF``L]XAGD"[O^:#LQT*/<0N],/(^U4\W&%>CMOBY8````!05]^5QPF?R
MIVM'T3(`GT6?<6_!M_90;@```?`J6*61-4+$;,1+*]Y$W:EF%,KG.IN!1N+Y
M*$<J@3*FR!HV1QFJXKS98L>)F#!>W)BPFRV6^S/CP8ZX\*7<!HOR<+MN.)'9
MM/`.QR?.9J:(%;NI<>P-5_/.;V?2.C"ZY)417J\9`6V^Q8]S9V6PF.LGU%#;
M""E,@BCT(EF2DXJU$T=X2:?JO,<*S$^Y0(RHMZL:4HNA>O5B:SL[3["BM-?R
MR]521'SV0X%VQ0D]QIAENLLQA0J)S;2DY#7E4G89S/2J8V,R]UM+N7.MU.7/
M[F^^SQ^WUMU.?B_#SY?@\=1'$XIUM+>-AU._RZ[_`-(F^5/\JZZ[_0@R:_\`
MK5KX?#7P^/ERIXJ4I21UC^]X_@6_NT$07JTOV,&#?/?CKH4GT>8(`````";Y
MU$=Y4>[/F_QQTH&!Z/@`+?=LO)<V/^(69.C5T#S:]4O)CU_^*-E?1=@K\```
M``RF=3S^R?;D^93`72\[A-,`!9[Q#/(%W?\`-!V8Z%'N(7>F'D?:J>;C"O1V
MWQ<L`````H*^_*XX3/Y4[6CZ)D`3Z+/N+?@V_LH-P``````CA\4_V;#J=_XQ
M-\N@]D"1SC^]X_@6_NT$07JTOV,&#?/?CKH4GT>8(`````";YU$=Y4>[/F_Q
MQTH&!Z/@`+?=LO)<V/\`B%F3HU=`\VO5+R8]?_BC97T78*_`````,IG4\_LG
MVY/F4P%TO.X33``6>\0SR!=W_-!V8Z%'N(7>F'D?:J>;C"O1VWQ<L`````H*
M^_*XX3/Y4[6CZ)D`3Z+/N+?@V_LH-P``````CA\4_P!FPZG?^,3?+H/9`D<X
M_O>/X%O[M!$%ZM+]C!@WSWXZZ%)]'F"``````F^=1'>5'NSYO\<=*!@>CX`"
MWW;+R7-C_B%F3HU=`\VO5+R8]?\`XHV5]%V"OP````#*9U//[)]N3YE,!=+S
MN$TP`%GO$,\@7=_S0=F.A1[B%WIAY'VJGFXPKT=M\7+`````*"OORN.$S^5.
MUH^B9`$^BS[BWX-O[*#<````*,[&S,CZYZ_3AL`X2.=408/B*2)<64PKDNPF
ME),CEG++N.)Q;+;@,UQ&#^%(N)X<OJ&:F*_/;EKCOI96VN"[AR<4:>9@V1TT
MA.?5=`=A?>GA@HF^*&;1FDFMBV,)7QR4O$'/%;7QHUEN4_%N6.S"=F0S+U..
M)ZI[C:"B;/.Y7*O$NDMW(_OUQ4],N&AZUM-MWZZ&3Z\E7E1A]S<9/V1>V56'
M1M5<G9?<0AK/:GL2CL1*X.V/8_9M#&:I3U6A0QZG%1WOX[_#>G3B<<'79..I
M3?JK$>HKRVL5YU7SD&RZD'&N0E2,&PV&;F3T%1:6%:<M5!63#>`QB;Q)1RIV
M/':8.68L62RM<RUG54G!HMLLI6>90YTMMI7_`#99[\=*4I7_`-QQ'=ZI=XSV
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M+B`MY-<V)!T1,IS.-VDG$TX\;*`N$\$<O`[A+*B:0MP&\&(X63KRYJS'DI6V
MW/@NNQ9*?Y5EU:>$5<[X?JO_`+6/+]5[V_NP.^'ZK_[6/+]5[V_NP.^'ZK_[
M6/+]5[V_NP?EEXBVJ.&N.F9XN[%7-DIBQ4R1F],=<F6[[G'CZ].MZ_)7\%EG
M.ZOX*5'Z]\/U7_VL>7ZKWM_=@=\/U7_VL>7ZKWM_=@=\/U7_`-K'E^J][?W8
M'?#]5_\`:QY?JO>W]V"^S@_\8'174?>39.;IOD)[MJ.Y#UCB2-VFJDH=DUQ'
M%%WM21E]>6T[(D-YN*:@1PE4E1+F<9\]B+$3-:WX,&>\QC]1NDM?;4O!G_GY
ME#YLL^>@X?;4O!G_`)^90^;+/GH.'VU+P9_Y^90^;+/GH.+==O\`JF'A'R[J
M9M#%+(FV25%Z29KK-\?-!/,ZY3DF%S[I><8.EMMXCG43K*Q$B&(XL*1(MD.G
M<N$F5MRUSFL^$OCR9;(UFM/%!TWCC7.`X]=KX>R>ZV+#$9,YS$"\1O\`4,!)
M?;3.2$A7*83Y1+O*G<1<\4SXL9LM??@,6VTRX;KL=UM:UM[[IHM_.&_/U,2/
M_=`=]TT6_G#?GZF)'_N@.^Z:+?SAOS]3$C_W0/RS<7O1`OCKESR0^,.*VMM*
MY,T.2)BQTK=6EMM*WY$JVVE;JUI2VE:TK6M>5.=1^O?=-%OYPWY^IB1O[H#O
MNFBW\X;\_4Q(_P#=`=]TT6_G#?GZF)'_`+H#ONFBW\X;\_4Q(_\`=`I,[.*5
MIFJ;"</M_$'T]<K8@7?*$9RDX[FB20R^1$C9F$':7<*R4*=I<QU9-E,JL1IB
M1TDL:4S5,MUQ8ME]2OI261;U5)P:*6VTK/,H<Z6TI7_-EGOQTI_U'&OVU+P9
M_P"?F4/FRSYZ#B]Z'>,SH1.T=($J1O)3O5V8YLBYB2%`W$LCHYG/D;KA5FNJ
MVY4U2;^`\5N+K**H%J6F,..[);AIEMIZGDLK7*@```IK,T4M.=HAE*$GY@,&
M6/+\=/:,'B7)Y,6$YF:[^;2FU5W&3SYL)C%@-U3%4S<4SWX,MN$S;BRUQWTL
MK;7#YH;PDG-K7.FMTU2\_F:\5'3C0)$T#A(NRB*[@L=**5D1><Z_-SSP+Q8M
M5INI;:5S:9Y*/T,^[$I%S7/-9SO-8Q+B&EM_.*8)E376=DEBYCK.NZSU?#BS
M=9UW+KNM]5LOZWKNMISZWESY4Y\^5!\W:A*]S2'R(K]2':A+]SB'R(K]2':=
M*KXTTA7_`.B*_4C3M.D^YB?\A*?4AVG2?<Q/^0E/J0[3I/N8G_(2GU(=ITGW
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M+JEIM:IQ"M>UY&GA)E:^(IAI3QXOP4IR_H\5/`.0[4)?N<0^1%?J0[4)?N<0
M^1%?J0[4)?N<0^1%?J0[4)7N:0^1%?J0[4)?N<0^1%?J0[4)?N<0^1%?J1^^
M,D3Q6TLQE"UEE.?*VPOALMIUU:W5Y6VV4MISNK6M>5/#6M:U\-:U'U``````
M````Z.LQG&SA>K0DAP,!D+DB1^76RC#?:PU$!3>C**N<K0BXBS1=)Y/SKK;P
M.`G9:46L**?)8U8M90N?M,8K:64[P````````.CO*,XWD4RTS4@,!D/DVP70
MGOECF'BU$!SF&8\TJW+8EN]J9EM//96XYTVS+FL(.!'N)*Q.W+EM+',=+[J5
M[O2ZVOW-:5]OE6E?'X?P>WXQJ```````#I$A1K'$M-DTR)583)DMG*!E/.GF
MC(#507FV3IM'/8%)*-FD!R$%-*,F$M2+EE!/,9BE^4D>P8#1:_%GQ8\EO=+/
M4[:4QX^LMMLI2VEEG6TI9;;_`)-+:6V^"VEO+K:4I2E*<N7@Y<AO````````
M`````!MONZVRZ[ESZVVZ[E[?*E:\A#?W;XJNR4:R-Q:=@6B_'<CMWAK[=<-^
M%(GBP@I]B,5R,1\KQTILPG/]K8J]IGN>F*JVI)Q1?7L69>8B8@,K.P%!HK!%
M:/K4QLKGM,E\)BREU+,^+'FLI=2E+J8\ME,F.EU*774I?2RZVE_*ZM.NI7E6
MM.51^X``````#J;[?+1C)ENN1'\X$UJ,ED-Y7=3L<JQF['2T%O()',I*ZL?S
M<JW6E2)$OF,9*66WY<E+*8L-F3-?CQW1Y=:=L=M]H>*9O/#)F7[8<:/V!<'O
M'7..\)%.<AB"[I*>B]=1_O-GFE4TV'1L"60#A1?<98Y:=;;5.&&_'2I@7$9L
MJ)EPU+X4"+N.Q=U>)9$#WVHF/;_22'WI&31@V6]B#*(X9'Q3D<;6)PSO'**^
M6\A-U,<J5%9Q3*-%\84M)3&DWG=C3F\VT5!74Q])>#/V```````_/-EMPXLF
M6^ZEMF.RZ^^^[[FRRRE;K[[N7AK2RREU]:4\-:4Y4\-:",#H#Q:4_</8MB2#
M/#PFB*FUMC*^R,<<,Z.T=.QHVL3A0-<3F)OKIN57*T',3?<@[`O++0XYLK4E
M<JB1.CHV-/0(X(WNVN=8/]SUCEV2(?X[\J:?/#=_9^460^=/+97PQ7M2Q3B>
MW'Q/G=S<>7UC4!92X\9#*1HDCZ.TXW583&X:.HYQ245-#3#CW/M!?5FE)/``
M````````````K2E:5I7PTK3E6GMTJ,/$Z\&^$)RF*>WPJ.Y728RVTE74B:-H
M(?QM]/4"TD/C3H^>.,:B`[,JB5SL9NR%@M;2;,:5B05\\Y";6+YVFLL=57G,
MI*F8:E.5.7]-:_A\=:UK7Q\_!SKX*?@IX*>"@U```````=,D2.V++;%=L92:
MTT!]Q\^T!3:SR9KI32ZPW7,W%DM>4545:2S=MY8^FJ!6^_`:*Y[+L>;%=6VZ
ME:5&(2/N"%K?KWLGL#M#J+5IZO2%+6NB9!,:X8YA6/NTFO"S;0S@<TMQRF9K
MBA,R]W62R%<:IC52UJ:8,)Q/*JVK13U=/S5:X=O#>D#14VKXW;O#L%M.U\;,
MP,Q@,F5TME(#9CG&:<E[H=B^E$F<5+5672]%3&2,.%Q+UQM9/FL:@H'#YP^M
M*)C)E4```````;;[;;[:VW4I6VZG*M*TI6E:?AMNI7P5MNISMNI7P76UK2O@
MJ,$<9\":)XK?,1*#6G)_)L8:O2SMI.>H\>$6FS[56#9*VU0$],5\^9W*U%M+
M?C2AQ=Q*CRA1M*C%23*8O*6*R15V1TU,+$\MX4)Z'N=&ER#]AMKIUP;63YK9
M%DC1)#DF6P^V85-$$>6CR%D?[Q>**U'$XD]SR4O(C71&O<L)5S29Z6CWN'*B
M,).5W4M*>?(X````````````````````````````````````````````````
M```````!6M*4YU\%*#2EU*^+G^"OAMNM\?A_]:E/]]/'3Q5\(UI6E?#2O.GM
MT`:4NI=3G3GX^7AMNMK_`&74I7E_3RY#4;*9+:UY?Y=/Z;L>2VG^^ZZVEM/Z
MZU&\`````````````````````````````%H&_K4F9^:8;*L;7:4$Z&IU>L2.
MMHQ'(JHLXFV60)!<I6Q%:^/&Y,O.]M'UU4.EVTDN,I;>I("JM$E=+QWJ1,I;
M6,SK7Q$+]>D3:EFN?1%U\/KB4ZH\/J>)8Q:Z.Y=?)W3#9Y(B0@W'8XIN9!I#
M6CB:YG>F^M^=L,N@O<M.1X-]<440U-CUL25-10;P-7>*;M`R(%X&3;FMK,27
M'[Q/4]80EV4;G@YB*JV;B$>-E](SU6TBK8P$%9=73CD.%'`UDK*EHJ'A(E,;
M?63A;+3"2_*"./))&S,'<,LZQ]>H^:6P'$KV`V)BEL-]WR"Z%F*8S8^KRH?]
M<IZK*NCM0BZ'4L*R7B1R;9:.$BWRN=26S.=07L9%'NP*=B'#8XB$W:2<-UX;
M$/!DI\HQ$6XR$RP=L@Y7')+P43^N,4/Y[QBTTN06I<90C5'0QH^65+,C9D`[
M>TO5*K"`8(6$[3"D6Q2VH%D9Q3.Q7*[G.AM0LV%62)*0HX,MY4-+Z:]XB;[O
M4FHSWP?O/%<92E7\GI9IPEBB;E4D;.W5)'-E#YK"?NMQP2XK1EPCP[>.[MJU
M):E:--D-&N))-!O6*7VO*3V2EJ.6VRWJR,1&)BZ?>XJMU>BYR)JNJM<Y'#D2
M5EJ';5C'?5%,&RY.EN7Z>^/?LKK/J+KILD]M:8^/$G;H]JOM.Y[7!(.5/<LV
M.25W,Q6?,3,BYB-#$HNB)$J-,#Q3'ICDZ4FLH1PLF%HC'Y4P07#+:R.J_P`D
M3BE2LP=QI$U%/PHRBJR^-4VKLEHJXU9Y.`G9LFM.9Y-ABG(A<)+`C&"C.>C3
M<+ALJN%VXJ/`SE:];7E@(X$_!G3[\V1;LCL?#V57%4S3%CH8K@I?;@KGI9;3
M-=AIDNOR4PW9.NKBIDNNOICK;2^M;N=1^X``````````````````````````
M`*+["P0Q]F8=>T'R1F<Q=EOXB03ULPS7*HLYTE\2:N)3A*&$%UHU^)9;JG@4
MD8EE++*.8**R??9V2F'21[&7-X;>ESAZ09(+C=#MG!3D*?W`Y-<I)U/PJ4HN
M%(LS-F"9CICLE9HMRR/FTP<6)6D#`42RCED-6QJ\D'2221)XG86+5.XSM#E#
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M8\0/,@^XQ.%6>513R18JLM=2T^]%33N$^Q<5">`YG99A8LHJ#M:5J:XY/W0B
M)_37!#736+P\2ZV2TNGC-)">^GQ*B;*T',R.79W:M:])(J+776DJI[M-J9A5
ML[!4%2QDKS6J9.6+9XME4I2E*4I3P4I3E2GM4H```````````````#%I.O%)
MCR#-MVYJJJQPZUE7/G$1$5EDFNL4IESK<@UC*R,KVSA4'45;^!&/YGB[<+NK
M*3GBMTIUS%K>Q&I(V)U-?(JY('2^F4QL!`T]'<V&@653UZ8F&'0X$=OX5%1L
M+&#MQ`CE5SI/&<.4)E#1NI4O=DSVE2^<Q=CMPX<M]GX1_(L?RPTDA_1:^6=)
M+%<&//F07HP7.AO)IK>$L9RDS&9(<;</J2,I8L!O!G*YLA([GMQ&<.;!DK;E
MQ7V6]"D+8J)(U<">RUQSU59$5[<%Z1&#*2E=^R:H%C-UF/&IVL%GD5ES$6_C
MOR8^SG4L)Z8U4G%?0RK+9$K2[/;3K9C:'#!SHUZB5JMC`_)PVGE!5C&(6>?6
M[FP@8K6>P'/*LE/UZ.+&EK9Q*9C`C]HJA\YVH1%I:6G"HM=M)I#%5<RJR7]N
MLNU31V*B-S21F3LC`68OD.7H=FQH+"C@/UC:4H&=RRS)-1LB[B+DBJRWBYQ%
MO<C7<UA).[H&0KH"^82D<R?SI)*V'7OB6HLRK^KYITQJ8C&,=Z8ZE65-1GDJ
MNC&HJSF:<5$";ORE)70*(B>GQLYWQ#Z@7F9G)B<Y'B3QM9.=2*Y%%'<#;IB5
MNVZ0;SNC=Y;?;R8T5QE35)/S+).*MA6-M)'DQ*\BJ2<NEB11*=$3,ANU-Q$L
M&V]EN=)Y!<SU4W`@%S"4DK"275CIO"EY&```````````````````````````
M``%#W5K9!+VD-'E5U1>TEM]HA=<+EELZF8K[3U7!C8>(Z;<*73K4=UJA7%&+
M$QH*PZ$]856OC;:?8V3J393+;EQH\9(DV\F+AGJ+E8=\B$D_BH:XV&&T1;J>
MYEA133L=SK:JE4Y(/78^V>*F+!@4U1'P9+\ZP12KR9<BK'*E$PU7#AXZ^*$/
MJ>[KQ)L(]#T4[*[?.&;8@A\TFEFT8;+7/PY$3"=CS,-=/RXLC&49EDYF/B4\
MS3,E4Q=2R[A(J#B();E551+3^^1[J8Z]6[#974]UH%K(5UNU8<<43<24'3F5
M3!M3KF/GT[8-.M,39D6[2IHYZBI3-GV!NH7P)Z`F5;B/@Q7%>@[K0>]%3:#A
MZ;@M1MK;X2M29+G5)DYGM8KD4W9ZUFR<(JL8*KV:[?+8\J@[%*/WBGL595FN
MCXC*\HLPPZC3>35E;3B"0=H/J/`TG1O%DPQA*<-2@GGN)MM1OU/D@J;<R,=3
M1]4VA-*8JWQNCRZ:S.[";HZ%R/49HHV0FQ"3X)D)45%1%/'"B(2M5[[=X`UB
MV,3L'"1;3^@YW%:\(+6^;TB5J$:H5R?.4HI6MN74V)V1`BFO+B,C/DE*3.,N
MR4<JRKFFZV6L7.,UIO-<;KK/+[>1KT]2(/2SVVCVW)B[7]XZCQ_+6N;58DKQ
M8]66WHI<\MS0GOBCK;\AO.,6BJJ:06=L0-$RY(T.2&HY,BL_;';<F)BDNLQD
MMQ9.970`````````````````````````````8B^+#_YQ<*?\KIK)T7;##+84
M_P#%L'_P[?V#Z!^)C[S?_P#U_>M&VG_LWP:__P"0VV?=&O\`C\%X$_O-/A7?
8M'U`````````````````````````/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g477145.jpg
<DESCRIPTION>G477145.JPG
<TEXT>
begin 644 g477145.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4%)/5$5)3E]+7T)!4BY%4%/_VP!#``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0'_P``+"`#T`8\!`1$`_\0`'P`!``$#!0$!````
M``````````D'"`H!`@0&"P4#_\0`81````4$`0$`!A(-!PD%"0```P0%!@<`
M`0(("1$2$Q0A,3D*%1@T-SA167%W>'F8L[:WN-86%QE!6')S=':QLK77&E=A
M@9&7M"(H,C-25IG5\"-'EJ'3)2DV0F:5P='A_]H`"`$!```_`,_BE*4I2E*5
M&-R$+RVC3;Q0%4A84TLJXN1\HB+Y=//FB8"VC7TIW,5+I*L$7%#P4$VZFEIJ
MA<D;Q%+=VIY(UVOMY8'/"38/_5X?B8_JM6^E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E4GF^9V5K]&3DE9_6<QAOMS%-`P2&2SW/(3X<RXO*Y!O-AI,EALQ+67
M6\7>ZG$JIB"W6Z@I9L^I*9\N%C@&#88P#2*%MSXAFPW":,FE7NQ'9/\`!2QL
M%';&E!KYL]Y#L]HK[9;,B(BVB9GE#)!?<:K3V9A-[M%0'P/)N3E*7)"*=DYP
M>4]VM*4I2E*BPY&O1TXA_?,R?T&MVZE,#_U8?XF/[-JWTI2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4JT+?%(;ZWJK*1-SN)C,U(QQ9QL9[2'.;IUF0&2*2?S6-%
M7@3V`9)<XZ(B>+;,!!JT>/A(*&Q4E^EFYW44-IXQPL-!?P<,_C$-;(3:XM;]
MA-K=O-J(S8AF*E^6MBY-=&RK!8T8'7`CNA=9T`;!MZ/FI":RU5IW&T]1-V`%
M(/Q8%!.'2Z&52A%T8WE&TI2E*4J+#D:]'3B']\S)_0:W;J4P/_5A_B8_LVK?
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2HA>3L39%Z1Y.4/%M.H`V/UL<D'Q::
M:Y:7)[QCLG*>SZGL[':&WH*>Z"8,-4NC,(9!S).T!S#.RY%TN$J18!DH;\O!
M$DST#CADGDD399(0#M%Q^ZFZ0Z^MZ'G4OL%)USEQF.S/)PHKG8R,CH1..VDL
M!EFPUKIBRX#!I:*(&9.ZH32TL8V2'-%PSTW-*50%)VGUT7]@%C59OS-'S@V)
M;C(/R,YH?0'$27'NU68FJR$B&5MV)*5D<NU0\E)S(0!,DX14U34<%$(RGD31
M3`<P%\QF;>ZVR%*A^%&=+C77)*(*LC(.#>+74@05IP0Z?04J7VZTE\XGEFR]
MG%$JHYV\G2D@,]97%B.SZRGE'>21QQ[!X_G&&X>M$SO%68493`TW8Z$A*=Z_
M8B1%/ERJ\W8]?1V,'^YF2M*)`DAR$UV'(Z>;83X<K$4G&A-%Y!V;;@4$]5&`
M+"[=?MQ=9]IQ',#`$P-:3!6@1;JRM!(?EH7$^QEXY+.#,>Z0&LIR7DY([>N;
M=<&#+D9MV5F([LD):Q;CA4[I9ZP%6(NE%AS0Q&_)L8N$N[&&ZP#9MLN8D64"
MR:OIQ-2.I7END9*10D,H(9\PGF#"(N%@1$EPI.9-=0CBBB**>H&H[^1KT=.(
M?WS,G]!K=NI3`_\`5A_B8_LVK?719.DMC0W'KSE63'$3:4?Q\W%5W/%S*`9P
M8DA-U$*YG554-!)Y4Z>$`)E0\QA,"A0P/ECC>P0(F73&\:]^<CBGM>]K[F1O
MUMWK_P#L22?J)7Y9<Z'$]@,$6SW5B[`T.&**`4S39#P-F`2]P[&!BY3)D6,&
M`2UQ0;&1@0LPBUQ@;#YAW&"[/]?NY/%/^&9&_P#]DDGZB5?AKSLG"&UD<EY:
MU]D)(DV.S2TMMXNZ$0LL%2(JRW36)):(8@KB8DG["IYK+$$;+(G8++*]KA""
M8_Y55RI2E*4I2E*4I2E*4I2E*4I2E*4I4-_-WK=K1-FG2L]-A$39=3-Q&Z&`
MI1R'IR<7_-)N9X.>3F*A($71JW$<^73GHKR8YA6^VR*0Y""J20U0<B\TO%.7
M6Z0408C>!077HEN0ZK19JCR[L-R.'763L`)>Y''Z7<;&2$%HS!'K<?#+B]/R
M"*A&W(J/U/3T9^'2HAQ3:RJPBS<4R2<,=4>U9@5[VM;K?O6KCV-%\A,@<1L,
MA@[6R$!ME:XP>.72]LA`;7N*'C>U[7[+/#''I>U^O2]NO(\/@K&G9A9.)^2I
M9B!1,4E//'^&Y`&-6+8$R^1A=%V-;>>!D^&!AV9D]W$$2%%$,!#&;D`R^65L
MB]@;5"3IDQ]F1$#@VCUO9+93:>/MP^=`.3L!AKXN!GN%$(N=%DLX\LLRXV:)
MCDN.M*2CII7+%P1%=WMHKUQ-+Z38Q4?B[C!Z2"]_(Z4<!IJW=!;.D'+@W=I&
MZ&,HI:NW(_6)-=T1N%+>0!7M*RWC?VWCR"V,>[.X#I-[)UBMLPE1*'""E80^
M/E%UL>+@UV8<NR?,ZB3TAB&$IQ7FTV2C6=,3<<FMBC)J['\-EK-99L6<VS6X
MC@4G+$I=\%K-\;".&O)#V9S/9:XA)F3IN;XON1:0MT@E*'3,>1K#^!O1K6/:
MJ)5^"RQI;:4,M/9`.26NSX1=R,X0Q4`1_P`2`Q\G*269*%F^W7PCW/E@H_:A
M%N"8JM)]@8`VYBC:;B87=@-]G7M4U37(-BBD6,O:YP##Y5+<PNE>X!HN\PW!
M%"$EKALR6(D%5,Q0S1C-%&#6QC8P'=2>GYX9$]LNP`ME:W7L0K9=/5Z8=>E8
M,'(WY+*V&TEW@V6U4;&I\+/9O0=)B@QD=U+[XD%,65LF33$D[B>4B26&(G@&
M<Q3XN&6!7L0K8!X6MC>_7/.R:_DW':.]NGF)M?\`O^I)$H6O_;8O:]OZKUM_
MEMVT/X$\!?WERI_Z-6WO3R6_L.]-I8&VB-:E0N278'B?86*4EK%W](@B.O$=
M@E6&%565U(Z,!<^6.MT6&4P),!*8W"-!K)_(UF'F6)WQN0_EMVT/X$\!?WER
MI_Z-;K>3<-HK6Z6TF@#^N2)1RO\`VY`7O_YUV9F>35-GW0[FLVQM+8#*@K[D
M0$08R%(DFB"EP5=8))PPX6`@..&0@(1G,0.V=^QOGCCV6.5NN.7HK6OUM_7E
M;^R][?\`XK6E*4I2E*4I2E*4I2E*4I2E*4I4%G+3,FX2M]DNI<2\3$D[XP#)
MT1H9U^2FQ=KVUK0I-9W*;H<'<S::QU6;AQ>+NMH8M9N/,@\4!4$#2SRLFEC1
M+H$*"=M%XGH=D:^^ZG-DE\1<I:''+:M+#(3I<<&\1/99B.8TGGX6;.:>#'31
M))[?0I&E!O,9%7GS+"OD9-2.IQN84Q01G6;<*T:R$=CHD=,Y1T-&+=F-_08F
M.92`+/E[1.=*H4J"LC`J=R5FY'[U-%3^4=++@-W32)Y^I:>:<R"WKK(;/,-]
MU'D=V-_&W<NA/!/"&VI6+6\Q]WH[V7S=+?;"[N;%DK\@AUN1E+SUQ1C+61)&
MVH!>:Y%C?D-R&G(V[YDG,,J(9!17T1/>."0(J!DA<H.*FV\6?'[8:S]?AR4'
M2WB%TA0D-424A#7'D"0,#ETQP.5+;Q-.;I9UGTK`D(ZA&ZEHS>.N&RDH(B"@
M)ALLBD-A:(8I)/062"<9Q\4D(?MW;GT6939`>(MS`5P#%Q'0$EX+PEQP<L@1
MNS4,NVA97#S[+"]\:YJ5&D=(3O79!1&$RT=^.@O@4<SU2VLA)[M<14+N;M19
M=<A0@"LJY<+N,IVL%0.F`\>Y2W3'J7`[6;T:1TT7`Y78U6$S&TZ7H8Q-O!RH
M#60D9?=AK`88Q@9<JRFD"RBNF,!S`XN(RH9-B6%&&%[+MHHF>7VD]KMI)5U]
MP)3>1$Q==8R<9="TGI)`DK.0RCIP2.DF%Y2+%PCJP.EI(`"6G#*(YD0BG``D
M2N018/`*WPV3&$;QKBNX1W'[)86+H63#C<N++::`U<7$X3=NAM>7<4%/3\5=
M:-6Z6,JJA8P>'M:UA!\K5'3R->CIQ#^^9D_H-;MU*1EYVO\`D+_%UXR'/QXX
MWD&]T(N_N%N5#[2E*542(O13C?\`3YE_*=)KWLL?!?\`&S_;RK=2E=8<#V9[
M3$*A.AU-MN"'<!A"8:\O)"-F;P+Y!X#YEL%,X5R,8`Y"A8BY`VSQ#R$#MG?&
M^>-K]=^W)$O\YT>?^.&K_P`WK6\Q1-;PR;'MNMK7MU>[6MWKVZVOWU?P7M>U
M[7^_;OVK>#+T5&!@BX$E,`8<<4,``$)ZM<0488;/$($$(/!6RS$%%$SQ###P
MQRS$SRQPPQOEE:UZBTI2E*5#CRL<C\E:3L61F_'$-/0D\SNOZ[(<1[02(Q#:
MYI4BRLF.'-/)0Y,[_;Z\3.1J[7$E%!3#24'U9JL!;6%AO(PCR+G#8I:UXVH&
MW'FM$^25A,A6<(Z9["=*:U&G)TJQX?C=F;"%<T0$XI25!:2YC0+Z5XJ$4[#`
MMUU.9MH(#D3#*6JHUSP)@W@0O(I2E*4I2E*4I5A/(\V6Q*>LCO@)1D2%&>\)
MO&0VO'[.G>2%:-6'-ZRCN9"<YZ$UY3:"^WY'.MF34M*,,MVE8['4%_!!73.0
MZ&X4K,\W5B)+C'C/<>,-UHHBO;)>U`UV*0'HW(L8P9ICK6_UZ2Y'>45B2S&1
MP28);4CY4H"A1M&ATJA,B&2J@5+G1C[F>`*8`7&^RL=1E5Y(7GKVP(?:KIFI
M4GQ&=J:^\!(%4M3FX_7CLX4E.S8<`F9B*FI'B&YCCD#+M`-PCO9#?#<7XA5F
MF&>3Y.151"-!D3$6<,L"$97E:,=MMD"$\.UKOM\M7$K+T:K^R4)ZZON=F.YD
M9BMLER`\?AU=`+P'L.U7@TFN@JJ\LME8@!].E`05=T*;/-*+19IC)9MTZ=[P
M=;_V];]?Z^O7K?[]^_6M*4I46'(UZ.G$/[YF3^@UNW4I&7G:_P"0O\77C(<_
M'CC>0;W0B[^X6Y4/M*4I51(B]%.-_P!/F7\ITFO>RQ\%_P`;/]O*MU?%<;D;
MS00U-S.M=1FRW$8KF>5UYPJA!$14HD'?'$0VI*JH8*IY$MAEGC;,P;,`@XWR
MQMEG:^5NM$/-=ZJ6\.R^OW]],9?6FK<9U`XH=H3C;4-DP^/_`&`/LXLJ$FD=
MFDWKI)YIL$UL8D862K?,/0VLBHY=5'34\91!3\BX9T4B3$,XB9E@;X4%MJ?P
M#]<?\W7B0_TL?#&VGM[?Z5O#;RORZV]6W8Y=;=[I?P5'IQM:V\+C@B&<S,N0
M5QF+*R2WVY!$5LF9!C_5LXJEHU1-MY12XR2D8PXB&1S!D)#%*H9!BD28ET(@
MUP4X%`#"2KE^SD:2=9>!M`54Q=0H&XH$9;15$BKHZNEL'44@II2JEFP3Z:I)
MQXJ3",DCY`Z7`.$S9<4,<L9!"'!$P%#PRM?S;;O5.W@V6U]MW[W[TTQC;OWO
MUO?_`.*?#>][WOZM[]:[PQ)OAF4%$XD1M+492"JIQ*RDH)K(?[1=J@13[CAE
M;'CA)O+*D9*D[F10B]C0X08%QQ`P;"=LSQQO5&E*4J*SD3XOF%NTFO>26ZO#
M,7;(MKZZH-@27W,?=+Q9<)9NQ5&/++X:\476R[33)$4DP^L-D23$E,!?:<BJ
M`02>IWQ32A>KEM4=(X(TTO+0D'H"@U<9P?(4H2&@%'$Y!V#A(1I.[G<JZP(_
M5%=2;D8I[I5AE!?56VS0$Y$L?.X@EBH">GI9(E=[2E*4I2E*4I2L1+FL:&OS
MXWM5@=EN,K?GD23TS3&,$"%%K4=LOM<:6O+J=4E3^?>RVHFVBY6V32)4<1A&
MCI31U%2P<`Q=":Y;+%+L5OF$?V^1^TMGLO8AT`/;2/D>:FX\P0L[7[L/OQR0
M,18;CHEQ3;Z[$Q(_$L3*!]34RI)M@+*\"MW0KY6<!IO--#/N-35;E$PDWYXN
M2N)6C)\!D#KNBN?Y)3X^>9-X#G]27X\8^VHCM-NA+Z$L/J$#C!6V\ZGDNIY%
M6[@<D8)BB,<?#+/KP"0@.YR)J$TUF.'7'FFX>X/:2%JKK6[]FI%D9KF%<$&$
M4_5O=22]F7@_5E6-K#L,O,V_HR^R9Q2.X7*=.FW,NO5SE\!%(SEB.I$TLN`$
M5GHBES/%YQZUG8_6$>BYTN-.LLGX[5U1*65YF`*`XQA+;SF4D`VH-\9V)Z3F
M1"=0+>4UA`(.'RR3D5=7DTF663U0Z4I2HL.1KT=.(?WS,G]!K=NI2,O.U_R%
M_BZ\9#GX\<;R#>Z$7?W"W*A]I2E*J)$7HIQO^GS+^4Z37O98^"_XV?[>5;JA
M_P"?6_3AYW\[UKVO`ZAC>V6..6.6.3I:V.6.6.5KXY8Y8WOCECE:^.5KWM>U
M[7K!H-P)!%C9JUH.ABUK&3%K6M$\?=+6L-G:UK6^QSO6M;O6M]ZN/]H6"/YC
MH8_NHC[ZN4^T+!'\QT,?W41]]7*W9P1!@E[9"0E#@F5L<,,<A(K8(F6(8>-L
M0P\;YM[*^(8>%K8!X6O;##"UL<+6QM:UMOVA8(_F.AC^ZB/OJY3[0L$?S'0Q
M_=1'WU<J9CR.VS&:R>425B++9[39I(_Q]K)P\3:390VR5.FP]G&"7#-'"Z&0
M(`FC(9?'$`,<Q@(+@#C8+'.V%K8UG#TI6E^O2_2_2_2_2][=;6O]Z][=;=>G
MJ=;=?5M4=LI0WR:+TANU8B+>/6".XU45<4RS60\-"G3)3F;2+D`!@$F++[);
MBL,JZ#N!C`P-FJ`M!`P$P&#"LGX=I[8)9'NDK<NNGNINQ.T8N\VGL@XP'$;R
ME.S'PX[WDU_LLNT$S-3N@Y..^[Z[Y164,`\PK*>*(KW+9=C?RO'M>_8W+%H*
MY>C)<N8MR*Z=X6'`!&["_&F\\NQ[<%@)?'LK;YV[+L;YWQ[+I;LNG6^.-[]C
M:O6O<7;],]^BJVRFW&OTVQUDWE,F"S8RTY<4%.0-RCF4[-*6\WLJ;02^6%3$
M\J"I@&T*S3#%4!3Y8QBKDK$,@3E[]*4I2E*4I2E40GZ9F]KO&ZG*:PT'>]Q/
MLDCAE)S/C@@WCS\>#GDF0&Y&C-0D`JYG&T$,R:&<;O3[C"*[D2R2<E8J*@*9
MP!*BXY62:@\LNKN\,YR'$D)-F83R8P5F0&PSY_<,?%2,`S4X(O,-HG+*-"$B
ME5Y4,.<=B".AMYK)D^C(*6N)RD45FJ><"9:YC&MV]^^,6<?<6->6)784WR.C
MNZ02$<)3<@&-A93>UED^VW,Z;*1IM%U=''";Y-,:BC8^JACC6*&AD\',"^)K
MM@<:D8>2(-2I7D^-XQ;>K?(.@N.5I%8L9([B?VJIYE,Q,5WTZT=I)R@[WB<=
MQD%%;Z:;5@#2J>'!-=SE`,^UEQ1>U!WR!K>#O6Z=.MNGL7Z5K2E*5%AR->CI
MQ#^^9D_H-;MU*1EYVO\`D+_%UXR'/QXXWD&]T(N_N%N5#[2E*542(O13C?\`
M3YE_*=)KWLL?!?\`&S_;RK=4/W/MXGC?SVB#_P`JFK6&`;\]F_SHS\=G7'I2
ME*EEX`?&G29[WDN?2B8=9L=*QS^=#?;<#464--(WU4DEBQEC-36V:<[Z6GE$
M23+8AK[48D(!-L@F)ZJXVU@EXBWD):S.F0C@N0W8%L<@,NUXWM"M]USY?/PN
MX2^!4S_XMT^ZY\OGX7<)?`J9_P#%NJ/[`<@')ULU"4J:^2QM?$ZA&LR,=?CM
M\$D+4)JM]9,MERE,B*J"EK0$JF1$PZ(7RRQ`.XEC%R^=^V8@Y9XXWM5P+ENY
M>00@@0]NX3[`$(('"V6EC0RO;`(/$+"U\KRWUO>V&%K7O_9:UNEK?I]USY?/
MPNX2^!4S_P"+=+\N?+Y:U[^:[A+O6Z^DK9_\6ZR6>$K;:>=RM/'#)>QSD;;N
MDEJ['S]$)AQM5ED6`EJZ)&+N`044Y9KIQ]4*IQD8OD)F/C@H&\KWRQQS,#98
M7%SF`I2E+WM;OWI3K][_`*_Z_P#YZM*4I4%'+B9Y('D0?,/0?J;HC/6D#F@X
MJ8G59W&E=RQN7Q6K+CE/N<K<RB/9L%DAKM)!1&>Y`'>,*D**"O#YJ2>M@#I8
M)@E;OP\,+9Y)F2)3,EZJ<;L-Z]L73EUH>NCPT<GIS2R-=C2#)K*=2?9*(*4H
MNI!.QQ*JLFNAV+<GIJ0L*S_>K62QUYY'#),#$?)3/!"YEQ,RP8&9T(,7(EW3
MD(&%8SD'EB%B*,#@(."`)G?'`QF#AF)8'+/L<,[],;X6,!3#LJK;XM%.(3IS
MRN7;@_*+7!EV!9BA:.,^-M&1A'LF`2L8,%DUQ'H[9NNX#;!6\X[D]A*QMWXI
M>;746P?<3R4KHZAFLX]>ENO]/3PVOTZW['K:_?M?L>G7KT[_`%[UJUI2E*BP
MY&O1TXA_?,R?T&MVZE(R\[7_`"%_BZ\9#GX\<;R#>Z$7?W"W*A]I2E*J)$7H
MIQO^GS+^4Z37O98^"_XV?[>5;JA^Y]O$\;^>T0?^535K#`-^>S?YT9^.SKCT
MI2E2R\`/C3I,][R7/I1,.LV.E8C7DDSTS_&W[5F]W^)U4J"2E*4K3+P7]B_Z
MJRL?(UOI"Y2]W5N1\Y8%9"%*4K&FYL=S=@X^<C_U)BR8X[;Z9*VN34=R$FZY
M.Z04'D>A9UHDPIIQ:F`$EAVN(<]>G&WT<!@F#;H>\1N/$\L.+RE6W6.$3:RQ
M?%I!O++.T^O^W\RN.2]*$!0C)\2@@QT@M%RR@JE]="#,9&9TFW=XS3Y3(Z5D
MJ0VRXBAQ9DXJT6VT$!/:P!P%#.CBELE$."5H<N6VPLM')I'FC5QNJ4M15K#!
MA:3Y+DN?\>)%/=J%,NP&+_FF#L!66CRJ;=$T(K4.,%GDG<F,!K9.AB/;$U/4
MG)#-0T0'-0MX/^O_`-W]GPW\/AOX;ZTI5D_(A&X<KZBRBRLT(TYQ3YN.SQ%`
M#A$+91'4U5#D]F+22&]H`'5D/"7HU+J)$N>DMD@JA124&*47S*$+BO$DSK%;
MQ/ZF[(),Z)4Q[(;AZ[2&#K%!#TU@A[5;56-W)$:##;<E1Z,E_.10F=F2.31)
M4;#L,@Q\SD]KQVYVTEI;:2$\J;1<"P?4,]D1&ABX`79&100@Q!`P;=O$##P%
M$&SL&&!:XN6.&0@^65@@P[WZB996PMX:Q.M#HMYG]5X\UE8S,F'B<1^/T],[
M246ZCL46:U&3LX=G.=[O,RS8[<CG;>#4-O%:(O-50V:;=QPUW<M'RJ:(YU97
M&2CQK+,M_3_3_9U[W_E6M*4I46'(UZ.G$/[YF3^@UNW4I&7G:_Y"_P`77C(<
M_'CC>0;W0B[^X6Y4/M*4I51(B]%.-_T^9?RG2:][+'P7_&S_`&\JW5#]S[>)
MXW\]H@_\JFK6&`;\]F_SHS\=G7'I2E*EEX`?&G29[WDN?2B8=9L=*Q&O))GI
MG^-OVK-[O\3JI4$E*4I6F7@O[%_U5E8^1K?2%RE[NK<CYRP*R$*4KY2ZN)#9
M15=QN!2)HZ$@):@M+*LH#X%B"8DI1,904E`Z8$O;``H1)%QS1D;.]L`@`A!,
MK]CC>H(=L]W.!S="'I3AJ8M[-4`T.9FFV&8]'8RIN931DHXU6F\TJ0V\B%GX
M4`'7`4@BYTL!1#21Q#25E<RH89D;]W&,LZ_D>6OA93,'>&0W>T<)XR";'4'Y
M8&1X\!S?*@92"Z`9/._+''$1UGS*$3*I!HXNW439A**@DC`HA,'$/&VTCN%P
M"$IP?<[9[KZ?J*Q(<%Q%KLN,%8F-A*T/%XU@]W.)ZQXGHL8'B@S:2#**MN(4
M0"Y4&R<3P34P5)3$P_90.J,P.NNV&M>W#977GK+.$:3HU&ROW:S@<$8NI.=B
M2CN/RL)+-T50.)H@@192\JE(@H7*YWL)W*;`%Z=B):KA:4JP?DX1E%TZ5RTR
MD%SSXTG0^U"+V0T%/5YRMMDSZ==KHEUB)3=;$8/IY.5H,YA.)YJ8X#1L^G6X
MB#=:">MGE]6"5"Q#)&48V>*9A\>VL,GP_%T7Z_VC'=#:35%V;#R6ZY$ETGLA
MLB'BQWVS&?*3'E^63!HTJA!#.E=0CK:5&L20HMD<ZU'H90DLD8:9?)6G,FJ&
M8HV$BUZ0U.#`;<H18_T4RA/%D.Q+P5D9;3!K6$MCD7O:Q@NH$S`8)Y&5$T4J
MLHRN6)*B,>(JA0J;!P7-(=/]<V-L9JS+D/\``%O$09B'-T4*#`VMG;;A466^
MVTW*04A%2)UD.%R(=D<)2:%Q[/$VR@0`@$A;20"PP0&9(:X>?ICWK=/4ZV]6
M_>O>W6][]^][_?O]^]:TI2E18<C7HZ<0_OF9/Z#6[=2D9>=K_D+_`!=>,AS\
M>.-Y!O="+O[A;E0^TI2E5$B+T4XW_3YE_*=)KWLL?!?\;/\`;RK=4/W/MXGC
M?SVB#_RJ:M88!OSV;_.C/QV=<>E*4J67@!\:=)GO>2Y]*)AUFQTK$:\DF>F?
MXV_:LWN_Q.JE024I2E:9>"_L7_565CY&M](7*7NZMR/G+`K(0K2_>M>_J6O6
M*#O3S:[VP3O)M#K5!<<:@G8]@!QQ<VDY:EY-G$X]5PT^X0CV5SYHX(QG@G(&
M)8F<>9A,)X@IY4;N8H#<?$46^8XEKU^?GE-RM>V49\>.5KVO:]KH.T-[7M?O
M7M>UWY>U[7MWKVO;I>W>O7$^[T\GO\T?'%_X4V7^N]6_RSRP<BTORIK#+*XQ
M="DE9U6E!ZRJRTE%;.P^*(Y%M\PG(D&*2<Z\#CM'-W3"C<DA4625TD<F;NO)
M:1<P,(0#,EQK@+<]')[:UK?:DXXN]_\`2FR_UWK]PN?/E'`M?$O%O'6!CE?L
MLL0&YLZ#CEETM;LLL0GUC:^72UK=;VO?I:UNO2U=>>WDB#E'93*>;T-19Q\G
M2K.:#H=IDF60]G;&3@#90E!<&*%[CR"$#8<R&0R!"N**$%83/&X@@>'7.V9K
M"+Z/RA#43R2JDR:>IR!&;!>ZB03^W]P$CSM:2.X3A0EW2*.9[D+&5(4`MV\8
M8;M`8?;11!.RSRJA5,I/CV*)V8[\A.5FNT9+8KQ;N;?D"/'01)+R2JMY?#&L
M$56T<;MF08!RY,0RG&;X@&`C9'$\FF`3A$,P!#YIKQ]:^<9>^8<?:OP!`[#B
MC9?7R97=B\2)>8%S8MMKT,OV!RN4>J+]DJ4Y!2E>)ETG*>2_B2;Z0SC@3C;R
M6$KDU<,B04`IR#9D`F6'-FA,02Q4$0P.-G?I@""!A<44;._^P$'AD)GX;]CC
M?I:]^EKX+4`Z(ZG,G;F)9_$X3-UXI@%'FR,95C+?I<W0*O`^&M*4E-M=CF8I
M#U:P<@V2&Q'&Y%!*776G`&7"KMMM*XQL\T`\P#)1-SK,;VO;O>KEU_HO:][7
MM_5?K:F5^EKW[W7O6MUZ].RO>UL;7O:U[VM>][=;]+]+=_I6/AK5R\RSM1N-
M(C*C,;0LYIY%3FF05]NTMM"(K[9-V,8>!<J*9?*KKL4!`.$B#F=K>!,IZMU,
M("6SEE/4E`[FIYX$A^+JCS?J4VN/4PX_(E3DMF[]:_[DSYK8VF-=:5).0;ZC
MOUPE+1@\P3IXTCOEURA%"**^$U5:I-J@-AX$5!@8(;K3QB#SR^WI5S1*<R->
M07IL''S5;[92-+]7]VVR>@X5R/,<F0VG=$@,EFZN+)18'SNX]@[.]H(S79HR
M2*W0)2<#GS2R3(:(R)E=2FKA-3EI9BME+$ZM]K-*65=&P5WJT&6>-*S>9ZDI
MF#!X!H%5LT9-Y.$XU$T<BWEMR%<P$QQKR<IK:.G)20?(II6P+D8RME.G$/TM
MEXS,I_I89X^#1K=K_:QMZMNGJ]_IUZ7Z2E9>=K_D+_%UXR'/QXXWD&]T(N_N
M%N5#[2E*542(O13C?]/F7\ITFO>RQ\%_QL_V\JW5#]S[>)XW\]H@_P#*IJUA
M@&_/9O\`.C/QV=<>E*4J67@!\:=)GO>2Y]*)AUFQTK$:\DF>F?XV_:LWN_Q.
MJE024I2E:9>"_L7_`%5E8^1K?2%RE[NK<CYRP*R$*TR\%_8O^JO/LY(O&P\E
M'MJ:Z?0T@FK4Z4I2J3SWZ`\Y>TO+'S?..O2/U#]*GK1[GZ%?FR:M7$U"SOUP
M<:P<CD_$Y^GN4-D6LMHD7-&*D!"A"4"L;HF",V7"^G,*IK@0C6<0ZPKG5![F
M`,#68Q4`F0(%RX8%Q!!AA-N@O!GJ[QP["&MA8%DO8UTN%9BEXQ&NH\WR:3DE
M)R0'2YF"[,3J'8-K-XRBJA1489,,87$P9+G21L4(8M84(`<*079.7)+CY2@Y
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MRML@FW5)&;IA2"=ZD5`HQQ\<0,^0?,G&`<F@)`(-GBIA+=2.D9[(SC3%,E/K
MVV(E!P$(^7VHW"!L5>;3428=6#KA>6+Y"0UE+D$\39Z(DN=%3S+T&E5=&HJD
M])S<AYLL..X+BF,TH_(<4FFFU&1;*6]PWTV7"DE]AY);J"$!Y9@:[)R@&#'9
M)T@8+3ADETN=]&<2^;%CE;&LKXHM$-L8#4I%)[,Y"($>NO4;7F"Y$9^,N*$C
MFIUV?98LG![!;;`KJ<L"J#:REI%=K?1L'"HFT26'K=/"4'NC-HPT&U<UTW8+
MCKU'U!VFXF'_``!'CI:+J5N0;%CGSZ[-\]R85%;)S2O<%5,$0T6590>Z&5,Y
MGF^EBV5RJ:"M!A@"E@E`,J</@FLB/+SM?\A?XNO&0Y^/'&\@WNA%W]PMRH?:
M4I2JB1%Z*<;_`*?,OY3I->]ECX+_`(V?[>5;JA^Y]O$\;^>T0?\`E4U:PP#?
MGLW^=&?CLZX]*4I4LO`#XTZ3/>\ESZ43#K-CI6(UY),],_QM^U9O=_B=5*@D
MI2E*TR\%_8O^JLK'R-;Z0N4O=U;D?.6!60A6F7@O[%_U5Y]G)%XV'DH]M373
MZ&D$U:G2E*52>>_0'G+VEY8^;YQUZ1^H?I4]:/<_0K\V35JXFL/#GVV936;N
M.V8_>N\F]VIGVI]7V=-&N[7TOCUQ.QO/:>G8_9D3Q'7L$;13=B2ZST(&-V8V
MDN.U<CB$I)JZ[#F*T3*&U$H<EEXXN:_7?D,?[5@B.FY+Q.8",#F)9E`P^(J<
M4;M%(/-H2-V\Z$UN*#BQ#R<8@SP?MP4\)/`L&`E)XQT<7`,0GB8O%WYU.?&U
M42M\&$YL7=;=F(8?!:7];YT04XBMA,J2T]MN-HF$UY-I0+&23QC-],]V.1EO
M]I'@3)-31U?`]D14#*45)&(BX*TLYU-@YFCXCRB[8ZNXZE1))#+E)5B'5QHB
M`KVQSMBQRD7I&Z8_UU28;3.-R/$Y[H;==[@1@%$4%R9(Q=O'FEV@U952LEC&
MW2UK>'U;].G6]^_>_2W>[]^M[^S6M*4I46'(UZ.G$/[YF3^@UNW4I&7G:_Y"
M_P`77C(<_'CC>0;W0B[^X6Y4/M*4I51(B]%.-_T^9?RG2:][+'P7_&S_`&\J
MW5#]S[>)XW\]H@_\JFK6&`;\]F_SHS\=G7'I2E*EEX`?&G29[WDN?2B8=9L=
M*Q&O))GIG^-OVK-[O\3JI4$E*4I6F7@O[%_U5E8^1K?2%RE[NK<CYRP*R$*T
MR\%_8O\`JKS[.2+QL/)1[:FNGT-()JU.E*4JD\]^@/.7M+RQ\WSCKTC]0_2I
MZT>Y^A7YLFK5Q-8\7*!NWO3KYLZ,FZ=E]-TB.H"U[9>S.SB7L8^4]DRCLNA*
MCOE)*3(%@8<P>"R*.A(8\7/I<*.13!(HQ5S.%N$!UK$.YA#6?B<5&Q/(4[]H
M,6GO9/&G.Q:'L!KZ]MEX4)ZY*C45'CJD;17=$J8Z(&=.3?1$`X>;9YKRNU,B
MKE5A7B8..1FJA/[+C@7:Q5#(P-"C`EAQ2X&1H<((00$KCF&%F9%PPOD&7P%&
MS#!#S'SM8+`07/`(/+.V8F5L,<JPWH-Y8=C'/N:Q20W*YK]++O?\O-J/%OBC
M3]!)I9#Q9B@LO4DWWY&*+,"@U2C\1'W$:59PF#,D2,=&81HPVC[A=)!/9AT,
MT2S*,;];6O[/2_7KUM:][6RMT[W3*W3*WL]*UI2E*BPY&O1TXA_?,R?T&MVZ
ME(R\[7_(7^+KQD.?CQQO(-[H1=_<+<J'VE*4JHD1>BG&_P"GS+^4Z37O98^"
M_P"-G^WE6ZH?N?;Q/&_GM$'_`)5-6L,`WY[-_G1GX[.N/2E*5++P`^-.DSWO
M)<^E$PZS8Z5B->23/3/\;?M6;W?XG52H)*4I2M,O!?V+_JK*Q\C6^D+E+W=6
MY'SE@5D(5IEX+^Q?]5>?9R1>-AY*/;4UT^AI!-6ITI2E4GGOT!YR]I>6/F^<
M=>D?J'Z5/6CW/T*_-DU:N)J!3>[5GBEV2W$>2SOWK>3>)R'M8XA7'ALS+\C!
M1M`,41ZZ'[-Y9A,"RJGRVSUH5X+:\WY$<ZZ9,-`PA)"``FG%1WD[9DTS+@Z*
MZE\;VL&[;'7]%-78_9;:G#5J:EM@[20M.2_)#!DQI,R1($*/N.G`V'&KKF))
M3*K3D9+K:#K;"HN(:ND%5@.ZP6,Y#I5YH9Q0Y@<46.]*@-]-&-Y?'3L16([G
M\R3$B,E/6BHX1D(NZF@1<+44E1"5`PA$M0S2G"F*J>`;R4D_,P9*!DC./9JI
MJUY(,3Y+U]<.QT@\9+>:22M15>>I'C]KRJO;@O".&2HI2FY60L2&;0@6Z\5Q
M[IZ/BTW$;5%PPW<"ZH87B&.1],3L;9-5NO2W7P^SU_JZW[]^G@ZW[]_#>M:4
MI2HL.1KT=.(?WS,G]!K=NI2,O.U_R%_BZ\9#GX\<;R#>Z$7?W"W*A]I2E*J)
M$7HIQO\`I\R_E.DU[V6/@O\`C9_MY5NJ'[GV\3QOY[1!_P"535K#`-^>S?YT
M9^.SKCTI2E2R\`/C3I,][R7/I1,.LV.E8C7DDSTS_&W[5F]W^)U4J"2E*4K3
M+P7]B_ZJRL?(UOI"Y2]W5N1\Y8%9"%:9>"_L7_57GV<D7C8>2CVU-=/H:035
MJ=*4I5)Y[]`><O:7ECYOG'7I'ZA^E3UH]S]"OS9-6KB:QI^7C3M/E39E%>+L
MYFS?&,W-@H=9.M:9#R8XFRC![)*;<7Y5-*MUH@YI-88#A#"(R^$T"Z?@04B8
M(:KF5.'PAUPD2SV\>.HRAIQR2(4/R5RVRCOE+35TXE8!+UMDU,N"<@&-%%^Z
M\@%WR5`3W\\4UF!K8S?;;63FXJ$D5674BY=32,!D=$-Y7R6J4I2E*5%AR->C
MIQ#^^9D_H-;MU*1EYVO^0O\`%UXR'/QXXWD&]T(N_N%N5#[2E*542(O13C?]
M/F7\ITFO>RQ\%_QL_P!O*MU0_<^WB>-_/:(/_*IJUA@&_/9O\Z,_'9UQZ4I2
MI9>`'QITF>]Y+GTHF'6;'2L1KR29Z9_C;]JS>[_$ZJ5!)2E*5IEX+^Q?]596
M/D:WTA<I>[JW(^<L"LA"M,O!?V+_`*J\^SDB\;#R4>VIKI]#2":M3I2E*I//
M?H#SE[2\L?-\XZ](_4/TJ>M'N?H5^;)JU<36*CRZQQ=Y;RO$^X^&:0.55"5-
M,HECUIO)%=Q!M(6ORJHR)L0JNY/;N"VGGBQ1^N:QUF.`5X-K-/=[?((Z.``J
ME`#X.`OQ^`6,'AKI+*C&+XXM]AM9)(D*(GH^YJWJVPDA%F.8=C)#1'#&8(S&
M"=*:VDL9HH)DPXE=VE6J$?Q)G";9)&E+!S.4DIN:V6-2E*4I2HL.1KT=.(?W
MS,G]!K=NI2,O.U_R%_BZ\9#GX\<;R#>Z$7?W"W*A]I2E*J)$7HIQO^GS+^4Z
M37O98^"_XV?[>5;JA^Y]O$\;^>T0?^535K#`-^>S?YT9^.SKCTI2E2R\`/C3
MI,][R7/I1,.LV.E8C7DDSTS_`!M^U9O=_B=5*@DI2E*TR\%_8O\`JK*Q\C6^
MD+E+W=6Y'SE@5D(5IEX+^Q?]5>?9R1>-AY*/;4UT^AI!-6ITI2E4GGOT!YR]
MI>6/F^<=>D?J'Z5/6CW/T*_-DU:N)K'HY6.2%;T"?DP.5159:,26L:W,YI:!
M:XMIM+CH8&SFQ[^<;\1W*XC7E&SE(1;<T,FPH_NLQW=TIF0;./XK(J$OJCW:
M@R3UWB9:TVZ]2U&<-;(<@4N[1[GS3KR]M@]TM<92EIL2&U]<UL9Q,0PS!XX;
M(1`)Q1">3#[W,1TM-).5\VB\P"ZHY$QL)"4U&\*#D<TI2E*4J+#D:]'3B']\
MS)_0:W;J4C+SM?\`(7^+KQD.?CQQO(-[H1=_<+<J'VE*4JHD1>BG&_Z?,OY3
MI->]ECX+_C9_MY5NJ'[GV\3QOY[1!_Y5-6L,`WY[-_G1GX[.N/2E*5++P`^-
M.DSWO)<^E$PZS8Z5B->23/3/\;?M6;W?XG52H)*4I2M,O!?V+_JK*Q\C6^D+
ME+W=6Y'SE@5D(5IEX+^Q?]5>?9R1>-AY*/;4UT^AI!-6ITI2E4GGOT!YR]I>
M6/F^<=>D?J'Z5/6CW/T*_-DU:N)K\Q`0A;X9"!X9W#R[,.^6-KWPSM:^-L\+
MW[^&=L<LK6SQZ9VM>]K7Z7O:_&"34\`P*;!(DPC0V>8HQD,J`&8%$$PP#$$$
M&P#Q%SSS###PSSSSRRRP#PQRO>V&-K<VE*4K;;/&_>M?U?O7MX/Z;VZ?TV]7
M'IE;KC>UZUME:_@Z^#KW[7MWO5[]K=ZEKVO;K:_6U18\C7HZ<0_OF9/Z#6[=
M2D9>=K_D+_%UXR'/QXXWD&]T(N_N%N5#[2E*542(O13C?]/F7\ITFO>RQ\%_
MQL_V\JW5#]S[>)XW\]H@_P#*IJUA@&_/9O\`.C/QV=<>E*4J67@!\:=)GO>2
MY]*)AUFQTK$:\DF>F?XV_:LWN_Q.JE024I2E:9>"_L7_`%5E8^1K?2%RE[NK
M<CYRP*R$*TR\%_8O^JO/LY(O&P\E'MJ:Z?0T@FK4Z4I2J3SWZ`\Y>TO+'S?.
M.O2/U#]*GK1[GZ%?FR:M7$TI2E*53N7'<I,"*Y)?2,F^7*NS&"\W8EH_0;+R
MU46VV55;()O8E\<Q\K'S9$$K?$'#,7*PU\0\,\[VQOA:<:NPVQ"I)/"&.@R0
MY+2/R3ZC<H@FS<B*0IUQC/.1VP_WY)46S`]D@R/=.7G#%;K)`(C0/FL2QAN,
M%4-QRA'$UH7)(8-\6J<1[TZ%!*C3=*^B,.5IUU>@N"44LY),+3"VW#L=!PLD
MN7<WE'>(JDKCAD&$UXP=+77E$V\BZ0_9F?N4<1I("&@'C[1'.RJ<>VXNL,GQ
M*%">IY&4%14B^`6%-D?H4X@CM5XSK%,PBO4S'4^8NU3%6!%0I-[W;+L4'.X'
M$12GFC.14,*KT8R!@LHQ<_:-L8K\L>P+XTY>V/&;%[2OJOLT5V-/)0_(/'2U
MF]`PX'FZ&1&:3.`0FGAHIC$Q,>"_BMC@J`&0#>&3_*^PBF$;)757VIY6KA7#
M^Y01SWP^PZ_='XS_`-GL>O3[07]?2L++D#\CA<O^\>YFP^V9.$H+C4K.\BGW
MX`Q#VSC6<YQKAG4]-(V2S"^5:J.651`[I^0MS8*82PRQ&Q#[3U#OGG9S_)%.
M8C_<N`/[_F[_`,GI_)%.8C_<N`/[_F[_`,GJBZGY&.Y2$G81F:RFVI"MI2?D
M/2-.2`3#FA%$1<V)%KRCEB.L<TM62K%RRF"O2DT\"*;<//,Z4'/&L10\4\;"
M]:/Y(IS$?[EP!_?\W?\`D]/Y(IS$?[EP!_?\W?\`D]=C:'D3/F':SK;3ER84
M`G<6\X$1<R)X[!MP#(WBCJI-2R*XC71!+`Y&,2MP<1L@Q,0LA+"9!YVQOA?/
MSMM9RLVZ].)^.>E[Y7M_[Q^,[=.N5[]/0#OX.O3PW]FM?-6<K/K3\<_\1^,_
MX!59UR`VY8=XM-M@M3RG&O%\:F9R8)AD@/D]R`QVZ"C:$'5DE3\L3""5A5&,
M*8>.*9D!<N$I%<[Y#8Y]LZ87M>$\;B,Y>Q1AA?,B0ECVT407L?-J,^_8]LSR
MS['K]J6W7IV73KTMUZ=>EO!7Y_<B>7S\$6$OAJ,_^$M:9<17+WCCEE?46$NF
M-KY7_P`]-G^"UNM_^Z7U*HS#^@O)I.AR8R$=ZJ12>,01-;MU^D2RKMRV$;`I
M)#)16HOKQ1(S,12)Y<(N":\T(0FL88EK&1A30.10#(MV0M9_N1/+Y^"+"7PU
M&?\`PEI]R)Y?/P182^&HS_X2U=UQ[Z3\N&C>U;HV7/Z,0_(H#BUU/0+@S4[>
M1C(!DJ,=E-OR39TYKAR(SP&8`0:)DC72,4SMN8AK$]W=A@%<OE-_YJSE9]:?
MCG_B/QG_``"IYJSE9]:?CG_B/QG_``"J(+DPU?Y;.0>4-:)(3]!XBBW'7MJ3
MTV1T93WL8CF$=>4V"Q0($>+J!*'DS!(Q;?VLA,1BPQ(]=4\N@[A#D>X,[&[!
M_N1G+Y^")"7PU6?_``DI]R,Y?/P1(2^&JS_X25T&5N-?E0A>+I)F%^:F1`38
M\3L!YR8\C29N*U%92+-1@MI3=CB'3DL&*`A5(^$CI!W,F0P%!N;,XA%^W`V$
MN+A]1B\7_*](S)9T@M;4J&S#9?;4;;S;PYW<EID#@R$ZT0BX$@0X1%B7(0F;
MR3E$M<T5RS$[G'N(%B*+CA87/M7W(SE\_!$A+X:K/_A)2_$9R^7M>WF1(2[]
MNGIU&?\`PDJ6;C.C[EEX](`=$)'N.J*I5,.6>)GFK[(D[?B/FH7(A2TY@G$$
MV[D#L,K(QH9!MAD4%5;#%@E'*]APR)6W_98R'^:LY6?6GXY_XC\9_P``J7VL
MY6;VO;[D_'/?MT\8_&?\`JQY=F.-CEUV!VVV8V?*Z80PVBVPSKCAS`,PUNRR
MSQMI8L"%V%$>9$PL@1/@76<E01DYKX9D$BG6*!*6";F`.(4R.#TD^Y&<OGX(
MD)?#59_\)*?<C.7S\$2$OAJL_P#A)5')3T#Y.(;<D&-1]:H1246-BI>P@Z,<
M$W;MK*I8[(`D=2!*>)1:,@Q4%Y2I7V(1D[#-U7,,UC90+D$[N:XBB$*'6*W$
M;R]Y6M>VHD)=+VM>W^>HS_!?OV_[I*U^Y&<OGX(D)?#59_\`"2NIO[ADY?7P
MPGTR,=4H02\GHRG:T,53/<MHG<$R[H;RD@V4<B>,5E<CF)&ZA8UD4Q,ELC-@
M;@6,`7$L+ADMP_-_*Y%43QE&6?%G&RYG'<>,ABYK07(I&R>&KB,]K)+<S4PR
M(D%&\R8:AFF9',"N9D?,O@-8'(83+"^5ZH$=I^5`<V`"=XJ8[)%!,A+#F\.1
M>-3>0&.(`N8>6);"!0LANV#8!`7MB)A?"PMQ;WO8.^.4K5*4I2M@@88N&88N
M&(@8F-\,P\\;989X96O;+#/&_6V6&6-[XYXY6OCEC>^.5KVO>U[`-=N,_5O6
M%_LI_1DWW!CG$C,EF.H%:B^M%U9G0`Q)RDX:7)2:\4I6"43.)Y-T/#,##`^Y
ME1TKK<:1(E'S45D1C`70!+C;:[1R:E&49:<14^\7+*T=H,1JQ1V#$59`;T7(
M^"P*?8302K)Q>R,WWBLKRFXWY@,8/GW<LW2K*QX5*;#52T2@6H/'/KKI4LJC
MBB8)\+"^9BJ,X$;ZQ(CKN[5!B0'#1APG(PAAF#V34ON%F-,XZELY8XJXK+U<
MAHP4'>3M<8B0CW(7Y4I2E6ZK&M[66=K(^VT'7'`$\X[@.6M?DQN`W3?L8/-J
M7I!B&0UM9/VS)9*_EZF*<.H9)*N74`4ZQ!35N["9@S<F,6N*I2E*4I6W+&V6
M.6-^];+&^-[V\/2]NE6Y:\ZTM77-0V%46NO.%<%V+V.?.RCHP7[IEPT1U/QM
ML=M**$@>5I(EE9O$RC$3AR5E+(ZI]T'#O=!T4+M`85Q]*4I2E*I3.\2HT^0A
M,<%N-25$9O3/%<AQ.NJZ)W)992T:1F@LLY444BZ@7-D+*9$BM#FB%SI0T4[K
M"![I+C`]F'E]N+F"G15&L?1DCG#RBDQVQVBQ4P^I]SW43J<SV\FMPB;/]R`E
MRO=IDJF!#F^Y@`0.Z!!.TA!A]CACWNE*4I2E6[SGKBUYX=^LSR<2XOHY[5^?
M0M@FD51;IMBC@<H412S#V**X^[R1L:Z%=#EU:4[V2Q"*CY;)J5>QRQ.QPL8N
M'QMV...-O!C:UO[+=*UI2E*4I2E*4I2E<-14"220.J:B9")D$XH9/'38^78@
ME29,`0R:,C9?_*$7+A"#"7^]AAE>W?J'74'?':7?S7F2-S=:HWAXA!IYW2(@
M:KQE)=WL1DZ=VU%[@4V:I/\`>,B)RX6:L1Y/-T(JT"SV.!'3[P*%$LM=QODM
MDLBF$*\HER`ZFJ,VFM>B$K`*,GE7J^XNP(IK5>I]N*DMQ>PTN3Y$AY`?1-NF
M&2ORXS6`LI[H7HT1G`>>!0C<^!@EC**(N$DZWM,YGN/9TQY)\D1Y,:W(R-%V
MK;\W(.E6Q$\M%C[O@*-7(L,EYO..\G4R6TF/,!N/E$.,URX)*CF&TERV-G:,
MAIP9D^7_`%3^8?25-8T++\IOQS14^IJ@&+-B4*(U>)IJ<#[LQ9376TSDY01T
MQMQJ?,.Y+2WPYR;?/KK=+&T[$@"8>>>0#+#$7</E3CRQ:])<!;8OK6]_-64)
M5U]UAV2V59;;7T)^I3#EYMZQ*#H:TC*4?/6Z4CHLDL]O2.TST>.=TQLO.`FW
ME@VFJ`V1E*4DDRIWY:T2J?G77*`9M5$HFA*<PPI%,IJ*(GCCFB".?D)AH#O.
M)1(R:M8R8*)YA8$)EAS%K#C`@X"#6L)EE:JW4I2OF+2TE-Q'55]</EDM%1$X
M\KJZF=%Q!)IR6F%!CR@?-C9?Y(18F3+CF3`F7>P!"SROUZ=*BLXVN3%L<C*B
M^WBS'%&3290:9DY8P@Q1LX1=F#\3&G6KM5G3])."@H([:;+4DDTW58=N,MG-
MM\@H1$PC8.B4@':.I,I+^2I[R;7QCR3,S62;H0AY)U@FR(-D)5C"1&`_'8ZI
M=C-MZPYM3%RO;89-,(A-DHS9D7[+4(%GIC3R."("BN)B,JNI<6@55/*](XFN
M3AZ\DCAF-S@.W3)1BAEAA8HC(AQ[3Z:V;8I]<<!O)M$)^C>9(GC1,:F(K5)&
M2XRTRC3M:ZR\"2J1;B^;34P482;.E*4I5K6[FP#EU2U&V/V9:C$2Y,58!AF1
M)AS9"P[1V.17TN.6JJNU9)Y.0LVW8.2'NEI)K(H$&AF+G35@25QR.(^1XO&U
MN-R);GPQQ^0;OM!<!00_&F-!4'S_`+!-A_R"]T-PJA&6`(]+_:DUY16TC*IA
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M*X:@GDU4B<3%$L$<(*!4P1.E!\+"`&B9L',N:+#!Y=[,$P7%$!%PO_I!YY8]
M;=>M1/:6\?4TZ!QBKZK:^3LS,-62LF.YZQ%D\8W5UN:X29L@.@^\G9%Z:L9N
M_-@2""373ZB(PWJYVRF&6X76!\',U'[FG`6.4N:7#[FTMBT^12DQE#$0-3D(
MG[DU9S',M(_D\[;`SW%8S".LMQ.P-QA)YR+FDZU9T2`F9IZ24<:N75TMD*'<
MQ1"&<*U;-`OD?-3B*/4B,5W:TFZ6Z7XJ=I.+=9/)4+&&\M'VULE,SKF3&8$S
M(]*+@():ZS3CD#;MV@;+*Z<OE2.:G9<1136)`K>OKGQCO:%MG]6]CW9.K0?X
MFNW&PE\=A]KI40K#-L[DQ(>3?=Q254M5,RH[<VDHW!:J0WS37$+.#$V5,*JC
MBXB@HY4@5M";'`>:08>R@KS11&[*BW2?>S1[6E3RCI0-+K;9F][S6%IU/Z5@
ML7J0*O1U1FS%$FQVXD(!ENHSG.IX[S5C",84`F^FSI:V1.<@77B"H-/KY9U&
MH9A^-8H%<Y1+%0R[C^UTS49GAKH:*.H*XJ3Y;A(P9_--R55+N(0QF6Q/F\0\
M1\ZUTI2NM/-IHK]:+H9#C`$--]X-U<:RZ5!,"E!3*,XDHVC*I<(T!EB.6$&(
M'C`89@'+$4#/+$4.]L\+5`E"7#5L'KUDC.N)-UD1GS1"VGT=Z":TRR+`"6ZL
MT#6QH[-!SLNFY89+@>.;;?$F+['+)<-IJDD60FXV@22T_DY,\NG3@F-FZ1&T
M7W8*[XOS;53WX9?VL'@$H()*"$73YIEG.C1T@M9SD(BC3.?EF3UQY#LQFR$O
MXS`[T)(16\FR*]!%P,T71""N!9-K5KEIZ\&A-H6V&Q+IB]][490$!K6Y9%AB
M-5&)&U(['(/X%^E72\VHL.E['LW?D?3TT,@2+N$PB-3`PYBR%GFGN`$DC2"4
MI2E*MHW+@96VFU/V-UH17:G,(WL%"\C0L,]51O&G66:J7)S64V:M+P;;*+K9
M%6CZ:D+!TRF$<EY,+B*(9:YLQD5Q&!$CKFKCCW.>VOVD$$PQO/%<&A:>L]BI
MZFOK.F:+.Q&59"B=JH[/B>1LV;(<O@(#0'8`2/\`9HW44?%WY)LD&2#L*+`9
MMK-VY6Y8_!/(.BFGV99V[,:N1,'*ZS%8V:$M:PIZTF)Q:-6FH(>QP#Y<C.D!
MK.9QG-DU\R1=I5:)YE<HG,IN"2AI2RGFCEQJZ:G:MLG4]@.UF,@N0(A2!,$J
MSFY4Q!3\41GI+SF%U&'8Y4ICMW`0;!NM$@<&P+I*5B.+>W8&#XMPQSXI<&Z&
ME*4I7'-V-9%3&)+,`,Y<`:Q7,T&(,6Q,=KR[1D8""$!%$`L+V%Q@PA0A,PNS
MQ#%#SOCGC"M!F@?))"BCLD]1N2J*'X_IJ'4WHVPSNAK8:;12I:5GJRU$RZ)/
MS0IK,OZ641-B9H7@1D(1QZHF<>L4VEFT(R.:;"83$O\`-6M6T+7H_.CW#*-1
M.D#9J44V:9=3X[13;8C<"0"D9,2,CIMG-PZ=4#A(-;(L0HX'$HJ)L94<+I5E
M=8/7#S,8`AW:TI2E*4I2E*4I2E*4I2E*4JC$^ON5HXC-8=<+P<J;$O\`)'40
MNEQ6CR"Q(Q/K1105BI)7/A/"1SJ>U"&""F#&%D4N=-8&%$,ID13\1#HP.%[`
MO-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/
MK.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#
M@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU
M/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/
MK.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#
M@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU
M/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU/-E\E/K.TC?#@TT^MU5LU^V-
MW/DJ22;6FSCM>.N#"'15H^:E!9V<UQE$B252`9;))0\FC&K@4728%7<Q1P@E
M``MD03[E<LS^8>`P5[W\4I2E*4I2E*4I2E*4I2E*4I2E*4JVK9C;.%]3F\SE
MB65U3Q6I-?*-%\2QXST!4>LFRU)3ARRLCLB.V,@@F%AP*XX>(AQ1-WP)H#;2
M`#*\ZEI#0RIA0#[-%L\MF47*\F.`W)`9;]CU)9:V\F?(#/.MX\E)DA".D-I'
M"*T7&56:["BG=FN#$4\R7.Y$]-,D!DY5-DE4,8@%1%)Y!M;G=#$=SW&*XZI@
MCJ4WW(,>LU2BAD+[U-'%N*Q)%P?YQ2))X`=T!NMNT6N[(VY%T9/2!L@$D`F9
M,FG$A`'_`-]2M^(&W6;[4>4%X22I,9_L(])4?O=TQ@[&8U7LTTIZ&8_6#2`J
MKI0#')11W25R)**"I!)RX"5')J^)`1(.%CPM)F1RWZ1O20]C8U&D!V,1:UBA
MU=V+?:E*45R+'#<<FO+7.G$IQSM%:PZ6\1PE")TM9(F$D)YM,`ZFKQKN<PU;
MKZ8<)GQ^\I_(_K>=AZ4I@$$DXMA#3R9+!?\`%H$4/-PSNF.R3D!B/*,D=,AE
MG$'*^'0;D%B26RGNUPFNG+`AIN*IP<[@0/MQTIR)R7-R,:T,34<7=:1E&1(M
MA?RT#0B)>6(ED"+9.5G`<>MX_1$!,B1_(C?D`98<KEMVEN$1T0MFK)?9.$'+
M%OABJ8=UDI2FPX683@DR2W$2:S-;09+RR53O;1+YG595)("`BII(L&,>6'"Y
MG&II3::[>2BQM9<CC5DI!121U442A47N2<>[O($3V1,Z0S.%"QG(BH`8@GB6
M9@N&/D4/!A"F`0C96^=P#6`9@8((P&(%B.)V-LKV4P;R*ZK[`.[:B/V4]E9-
M?6EBJ,E;'M-[M!Q,M9C^P`3F%S5^TK1,(%Q-J^+/<7:7,V#"NAF+I_4`Z)B9
M)Y&/D:S<ENJ6V3$BR4(H=;F#CF;G^\HIB9Y/MBN2.TE\R:PPE(PX&&EA.PJG
MJ91T7`07,(B)BTGI0CHR:;I+-O)5.("@6!O\M>U[=;7ZVOW[7MX+V]6E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*@^Y+M8IT5]Y>+WD!BQD+<WLC29\SDCS+"
M;6P33S\LQY_819F"RY'#?6UM$(NEP1T9*!G%1L)9@9X*B;W*(UT]7-DQB%[N
MYQD66)9BUT,R*H=EAC&)4<[2A,E*+C8@82@V64Y_++[9\L*L=&7`V7XFLYEM
M[)106]90,H+M7GHXBQ]"1"+;3QG>/&9QZZO;$:&RIR<ZGA0HXU;2YZ*CDV.T
M^?;&:A!!8B*^I*8>!:9]?&2PE&0G@\6T@DW082`8U#,BX-HZ"CN,>RN!BH$\
M!.T\4^K'(C#/&UH7"9)_L/4=XP:B/MM["15-.N7V\W*Z<SDRKKN2L6:]F=L,
MPV^UB9EG*ID`)5+E7V$.>62YD4L3-H)I).6O[+0'MWR#.KDK3%;C]F.&WU-F
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MF'4!GVCUNN92;K@?>*"L+B\HI,<LN7G0QY`/%%IS+.;1:Z-Y>+BVI8-PXH"1
M5)N.WCOV_DQ\1-%FQ,RQE%/D@Y2D)TJ\?.)$%;.,+(6M1K7AV-DE9R2&W<#*
M0Q9H(F\'ZV+$\4MJ%@PG*=+BA&R=Q[LC''U-CEY!(9W*8K7=,;1A))#;Z&N0
MAD.9$(`+LGPZR]C''L9J\>1&X57#`BPIR0;%0F$?62^(BZ4CCNAK'"J>(<42
M`-E<>:W[*Q5P_P"I6H;XBEXQGN*X^7.-W7%K950T,RN)7:MR%'9P]*Z8H-I6
M7R(3<9L')#L=#O5R)@<=L$B*J15R8%LL+&,RC#KV/?[_`%RSO;\7+/*^/A[]
MO\F]N]?OV\%;Z4I2E*4KJHKY9H#U(QP,Z4`)_*;857JG,P15)XN<\T4-81F\
ML.8JBW%L?'0DM=<2"D'U0,'(H545A-)C"X#G`,,^U4K2][6\-^_?P6^_?IX>
MEO#?I]_I71I#D^.8D;]W9*#Y:<?-KNTJF677BO)C=2LU$[87(HGAG50P6!&.
MF<`#`@)0++,P("7,C8AW!+CB!]K3%1,6DQ/6D=0)*R0K$BBDEJB8;`/IRDG'
MP`S1$^GG2@@Q8Z2.E1@C),T6%%`-`"AC`""!B899='8DP13*)UT)T<2.QWV?
M92CBDNXFT72BN(RVE',RH$@RBV`E'30B<**=2%@B%W3CA@*>1U<D%GF:2SX)
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M$LTF41<CA2$,X[G4<`',E&TV"JF<*F%]?,EBQDP`CI(9Q0$`+CCXE[A`B9X]
MNM>U[6O:]KVO;K:]N_:]K^"]K_?M>E*4I2E*4I6E[6RM>V5K7M?PVO:U[7]F
MU^]6G88=+6[''I:_6UNQMTM?U;6Z=Z_]-.PPZWOV./6_>O?L;=;V]2]^G?K6
MUK8VZ8VM:WJ6M:UO[+5I;##&_7'''&_@ZVQM:_3U.]:G88=CV/88]CUZ]CV-
MNQZ^'KTZ=.O6M;VM>W2]K7MWN]>UNG>\'>\'>^]7$44Y/6$\\DJI$HII:F3,
MIZBG*!8$X1/D#H&98X2.DS.`I<V4-EA12YDL8#$`,`""`C!YAYY8WZDPXQCB
M+4M00XT8+,CY&5G$MNY4264V$5K)JDZG(:L><#D/$40D1+&UU<.6L:5E8<+,
M\H&+8BFAQ<\<;V[Q;'&UNEL;6MW^]:UNG?\`#_;]_P!6ODC-]",+*>XQT5*&
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M+?;1553&BHJ1=>)->2"#/(G4A(>;:=>""EAX`!I075&>XY&/.YJ!;]+\GQJ[
M!',W@VPSXRQ56[IBHNT91(ET(BG3"P31Q[OK,RNX@$TU$V:<,7$GF9'`P*08
M`*%;L_A['W43G+[QCISD%RQ8!&!.0-SLDL()C9/-SR23=?V^4,9@Y7$#$<:9
M##FE'%OY7P!.`H2H^;DQLRN:J#5H6J;JE),X(MJ#<0GSV+P0&7RQVU`NFFC-
MUW-C,J8MER.O5VEA<Q@JB)R&F@MM.8N05@L"J"6:H17L"N1#,7KT1-P'#83A
MQ8^M[B%92$[N$[8A"?KS9.">*H($5!MO3"\"/S(,\7S0CBD@RHXU=89AY63S
MF(JPLNF^9?(NK+.(UV_'1'+YT^E_8?4*25"+)-;\:1;!LML?:EJPW'L'OURL
M>0EV6FB!%FRQ5@)J,T%R36$IQHH.-&D`D&GY2`V7B,O+2*FKX*D<59%=HH')
M;,P8](245[[%R;U&:5QW%@W4=SGD;%LO9MO#%014Q>M=,+.4OF@8YM=Q"AC&
M6@XK)CL3BYA212@`D7L7<23@;NF;PU[=\IH&3_D5[11*CA=J6TTUQJ+=>,8(
MS=)%4AL28XDPD\CI8$RV"19CR`LH5GI&*(;%3FV6'Q3T^^-[/'YJ2K:9Z]EH
MN772ENMVKBR1>[N5TQ)!!!+N]38+$;#A3;.+,LG+D@IJ,JM8P1:;N=R>G.K-
MBEVNV50OA@W2XPD5,-[A;ZC-_3?8QWS0RY&9$P<DDXZ$25`*9"[6:I8XPTK8
MS8Z'6A,K5=Z<;/O4A(4=`1$E.-S(=U$XR%2.0W",H)0;@1S+I49;]H%S;!,5
MFCC"R(3SB(PEGQ92=3`*MYW;(H:@&>)YIH<7QW)IMN1*HI`J392&67"LKCQ=
M28=")%&Y$+RS-B9EOMP,>8IB+WZ:A5WR&_'F"H*^+H,S8I/W.2RTFAMHL.GI
M3V:DEEF^IQ\)<,1&'+,Q*:S+:!`B;Q,MY`)$#?;A<?[3$T;)0[Y&4/L\Z;-R
MH[7!LH9F`R.8,9K:RCN[6*<'IMR(]Q+]HL9&RV(*LY8==U>^1JTFI[<S&N86
M0P^V2`R!="=G,.]R\N9I2O"Q#AG<A]C@K8@1YIBDWELJMIFTBB3L)<P3SN,S
MT6"DQU'"60>7V/G4<J8R,%3N&.%AT98/5P\<7D:=WS`G7.2<#M-H\"77UPG@
M:=`;74M?Y]!;8XBL<L850Q5]B%VJ;5A<S6(ZGGGB,HVS&RSQME0@_P"J"_)X
M?LVK]*4I2E*4I2E*4I2E*4I2E*4I2E*4J&ODO;J&]-P>&QF.=/R4D!;W1FHP
M;!`4EE%/`'4;1;9-01U)+66^I)*RD*B2IXEU1-4TP^5/$CY0L.`8P[#/$25V
M.H]9$6,Y'8T=-='9S21['A4]"0RF!0F$:6%(XMK2B/>W9#GE==7%%175]9/C
M&E9>7%%065@Z=4SQLV-W:]K7OU^_WN_:][7[U^MK7O;IUMUO?O7[W]%4MEF'
M(SFA"3D*3FB0=1!$60W`@B#CJ"8K-Y=Q3U%&R6&XX40XF.!O*0Z&L+*"=.HB
MH0,'T!96$(\(82%90)&?DINO4&HKJB1XHL4,5&<T&Q^XXOAU61V\02A8SCMT
M`M4LO,MF%T\(L20VZHEF<URPB82+!EPBR*3+EL0`;"X"4_(:6ZI)[5E9D%H%
MCN[/F%G'HYD9LF4:QY%<,<'1W"<$CD(@=&,`($>`'W6Z%1.8C9P1FDD*[C7%
M=*1B2FJG38U'-AM8M>6MI/+4&IT/LTW%3[(MAMNYHKQ8^Y"[D!5W(SFF`K.-
M37E!17',NM].`21&\I.536,R`K>0"HH9I(3L$S.^IH-E.9;5;3/2,SHJ4U4!
M&;:8(I&Q#Z@(GH*:522.9\\+T%.'<RI,+(T:$M80P8N(-G:V6=Z[%6P3_1M^
M.'\9C4'7"O#<6+6N.<V*3(23DF$-SN2,\EN,X85U'%%5U'=381J*+C;Z*I*1
MQ`;KK4FA?%GJ;L0DM.<BFU,+M]05#*8.:+CSD=+7MTO:W3ITZ?>Z>IT]2M.E
MK=?#W[]?#>_]G6_>MZEK=+6^]5!VGK3`K*?CJD5K16T49YNPLZ":TMEB&6>>
M11]K)=R/XLDD3`HR6V@)!<I0HYI!";1%(#?CE*%'$[L5I:*@'@^EGM*]4CT5
MQG#8T$L'"+HD;R@SHY91-.'3D=JLM>3+([F9!*R>:+&S+'=Z0&&E/9EJ)DZU
MWLFA`DG8DK)8$$/"HTE0'#4K?:TM(L<MIV8Q`[TE^Q;@I%!,0H_>Z`5S(H+M
M:81,8J$BN)"(CF22*KDL`CJ23-G2B>,6+G308U9_^O[:4I2E*4I2E*4I2E*4
*I2E*4I2E*4K_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g764620.jpg
<DESCRIPTION>G764620.JPG
<TEXT>
begin 644 g764620.jpg
M_]C_X``02D9)1@`!`0$!FP&;``#__@`\1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4T5#4D547TM?0D%2+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`3<!40$!$0#_Q``>``$``@,!``,!````
M````````!PD!"`H&`@0%`__$`$\0```&`P`!`04""@<%!`<)``(#!`4&!P`!
M"`D1$A,4(3$540H6&3=!<7:!D;87.5EA>+74(B-2F;$8*3(X)"4U5:'1\$A6
M97*"A):7U?_:``@!`0``/P#OXQC-;>M)QT'7=%S66\Q5Q6UGVRTMRM2SQZV;
M&>:RA21&G;7%6X2%R>F"$SIU=!,04Q*PJ*)6YI')=:,;?QHC?MZ<RJ0^<.I_
M*%V)XD?'K=503RJHC;W0+](G'KWKN<12KOL'G2D(E,K.3/MG1FFGIVA4*E4A
M`CC3`SI4/N%C2VI2G%V>FPL"@U];-/:<\LGD!ZKC'$'*U>6U5%?6[U7VQW70
M<=[\8:(;Y;![6YQX?A+7,B>A*EI>52`N$B<;:7/Q,2/]\O<8NB6QV0',*-,8
MKWMCO.\0/8EE=K\51FSKK2QHNZ(59=RT1:SA"FY0T1"23&D[(>X*=+XZT*3#
M36I#*VA$SOZEK"8),V.:YQ1H@E(B$Y)>N%R>?_E&B6VQGRP.=O(DWL%7'OQ4
MHDN^';<;H>61'W<QE5.9,ZD0&.%$LBE6``V]]=']L:%2=0D-^,+VI)`*[I@>
MD<C8V>0-X3PH7QJ;7A&%27HI0%*Z(B%Z8)Y01F!+.T0H+T:6$P>@&>T'0Q:U
M[6_U\8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,\_+&+\:(O(HW\5\%]OL+RR?&>
MY^(^%^UFQ4W?$^X]Z3[[W'Q/OO=>]*]Y['L>\![7MAY[I]X,;9D'C`XZ\9T*
M[>01"%<Y2LV1VX_.O/B^2Q/IUJ0R^43B.U_/:Y07A%5:.NTLAD@5LCB:B=OK
M?+!,[;\=I.-.G-2R7+_%'U7((KR/.B.R:-;^M^#[8L*3<Q6/$.)&BL*%CM*V
MC5C-5DNH"0<]0^YSM',HD3>>ZM$GCDY8QMFQHVLN.;`B*<@;]^.+B-K\??*<
M,YU(GJZUY.BD$]L&R[5<F))%UEC6C:4Q=IQ.)3^+:%:Y)6!`H=7;[/96<MP<
M!M[(VMR=2O6J@'*3-://J'6O#IY!]^HO_+S(/J,>]?\`MR.[^FQ;U^C^'R^F
M]ZRT*J/S8UW^PL._EIKR0,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*?_/M
M_4Y^0;_#S(/\\CN6@51^;&N_V%AW\M->2!C&,8QC&,8QC&,8QC&,8QC&,8QC
M&,J:Z[\A/1M?6P]\X\.^/NZ^TKJBK?'5\]E#F^,O/',E;AE;4F?&=L>;YLD@
M#3,YCIB7('U9#:];W@YO;UI!+H]-[OL;47J]$_)!Y::54`?^[_#](V^F@CV?
M(K5XKO&&]+2:`MFCPEFNK]0S>N-L.3LC:EV<ZO3C"%CDY(VQ*<:ECR]3[M&9
M?PV.*1W;D+J@,&:A<D:5>C,,3J$IAB5:G+5)QC3*RB%2<8R32Q"(4D$J"1;V
M6<46:$8`_>QC&<Z?X255G4\I\>G3D^JWJUGJJ@X5SK*]71S^LY_BD_<;N&?+
M(Z<DVAMYUD[7(:M^"0>B3U8V1["H&#9YI6AFA&1?74_KJL*ZUO?KO4$AWKOT
M]/7?XM-7KOT_1Z_7T_1D@XQC&,8QC&,8QC&,8QC&,8QC&,8QC-$^ANHK7YLL
M]G42>@'FS^;I(QMX-6!1KF;8%Z5]+4BE=J4*9+S$%&BGMGURB:S&9W*=^=U%
MFV8W@`^`>JCTRHBI**C+PCU?W:[]$%7Y,+2?;'HIQK:[V#HJ^E7:C;U#4W9M
MYO5N$/-136BZ53/2]ZY*W4\(+<F*5P271JL93%T:Y%6KG!SU[4O=`=7.,8QE
M/_GV_J<_(-_AYD'^>1W+0*H_-C7?["P[^6FO)`S&Q!U]1:U^O>M?]<QH0=_+
M0@[W]VMZ_P#GGRQC&,8QC&,8QC&,8QC&,8QC&,8SC=\PM`U]U9Y)I%6Q?5?$
MM36@LY\YVK=E-[2D-LU'=O,)K';:RXP=&^/![$WM]9VS.9FV.9L9E"1CF,:>
M8Y,((C:9$\&-`G5J,NKM[HCQ$<HV6Y=E33H+G^KK9=HXX1^3N=9VTF-F=]IE
M!9)*1'+*4I]]<7#I";-:A*47"%[K`)M.HPJ.4((FXMB1R7I%5M3:O)=&]"Y)
MRU)1#@C2K22UJ4]"K+*5IRU)8%2)4`M2D4@`:$)Z9066>G-T,DX`#`"#K7[J
MV_W?F:E91;;'1MQ]$.C"$LM'6=&L\=>)JXFJ250@.)P91)8LT-L9:1)PJ9,]
MFN"@YI;-F*TK4ZG@"B,IIC?FAN&>>/7QNW[7]!5T]]8^3*XRJ-J6K'VP))&J
M=@K[J36*B?)].Y8D8)/.5$$A\<@I#H]I8\PKY`L6/!)"``"B]!-\>P^<:[K5
MC//E$4]S=4_Y0VX^Q.JN*9=6D_N&4(^>ZPGO%S"5+;JGZJ?1F`NUB2.#+XPZ
MQ1QB")+"D#F,V1J4RI>L$Q%_;]L/C:[;3]_<G0SH15!!U5,C9)85:VE60Y`G
ME0():=3S9X@,U8D<C3)4);TTG.;.!Y8'`2-*H4,3NV[6)R5>C@Y4+YP?)[X\
M;'\9/>]&03M+FN67&ZT_*X6UUBQ6U$W";N,M029G1+8VACI*_;DJ>DJE$M*/
M;R"#%)8DBG8B]`)-&#HLJ?>MUA7>];]=;@D.WK>OIO6XTU>F_P!^2#E!GF7N
M*^>>GFIII5'3%AP$N>)'*,IJIC#+&R&/7XI;,=)'.ULG4@4N@URO<AC3&G9C
M&U03Z$C4DN"0`#DY^GGC-Z?ZBZ'ZMAT&L?KJU26UL2+IN1$UC/&9`QV4DBWN
MS9!!WA2(AJ4Q\"QH6#<DKJC3N9V]-RLHLE&H"F6!ZM-;]-:UO>_EK7KO>MZ]
M?[_G\M>N9]H/_$'^.LSG\#%*<H7L&'%%B]-;]D9I8!>F_7TWZ#$'?IOTWZ;]
M/3UUO7KZZW@"I.:+0"SBC![]=Z"`TL8O37UW[(!BWZ:_3OT]-?IS^^,8QC&,
M8QC&,8QC&,8QC&,U>ZLY>Y(Z>KI2P]@4W3=LUY'BECL$ZXH['G%!#O;)T6O?
M&:2O6DZV$JOA@:+4OC*\,JK1.O8,6:#Z:S2KC7Q[^&6@K(2R/C>D.1$MNM:=
M4\L\BB<BC=L6;'$Q7N4JYUC+W(Y9.I9%R`A6$I%B^/J&P`2U@$YQ^@*=`,MV
M^F>4G;*KD<*EL?0>XTN>XQ(6A'M2/9:?2IT9ER!/L\P(#!%DZ.4@]Z,)8]A+
M]H6@"WKV=\S\3\3O9%->.GQ$Q2$(*7G/7?BXOHZZ72M'6QGJ-UG<49?7^T2Y
MI7D>M/\`$YPW%I&Y1R9L*M@E3["5S0VNK:M3K$9I`@;51=7?B'[MH5SYQ[QB
M44HBR>TH'Y`^\>V+8YG4W$]PVM7"+=YPIJKM\JZ$W@J@#REW(ZU9HG%'4M]=
M8$E:G9>K?R"5:TIN0%OMT7B*XQL?AKC&-U+=#U%'NZ)99-Q7C;(X&<XJH,TS
MBZ;#>9PMC436.R=(XKVB,-RUJ8].2E*FVYKD*UP)(+3J"=9JSYW^?*&C_B5\
M@4N8J5J1FE9%$25V(DS56L);9`0Z*)$PJ3W(EZ1,1#F6X'GFFG'+`JM*##33
M#1F",&(>[H*H^58UWK7T_$6'?RTUY(&4H^5?D?JGKQ]KF.53!JA<X'!D*A\0
M2]]FSI')^DE#V-6WR>/F(SR#V$Z*K6U#&5R<0$:APVYH1F_&I`%[3**WJ*\/
MW<T2MF$/#C(6JI&,#N!+);!J^X-HYY'(XK*,`ZJ8[]GLY1JQ:8`!106T\>D*
M_P!K1"[8$_M&EVLA\:-ZI`[/:/)IV,C<@@]DE0X/Y+NC+]OT"=HUO.>"`G>V
M7L8"Q:/+&2/830BWL'IL7Q_Y*(@2$J#^2PZ0@T4`KV+*HZ..Y@?;$$)PPKCU
M<@5B&4203L@9VS#!FF*?>"![T1@WXI^9R#J4QR.U./KI1EA5B,2R.*2.#JS@
MEAUI*4<)D;&L&C3P@T(`B%8"R5!QI:DPT@)1P:C/($WVDSR!9:W:G([,P6#9
M$=,A$1L>I>IWPF,FR:+L*@IC=R*N,-D8E#>RIS$:QY;32V=&Y:]D"IT3N#CK
MWV.`[V\=E)NM66=8C#T=';M@C<H3RZQ/BG^24TC?Y`C=6(UQ4,T8?EZY*TKV
MM8I+0)'./:3!5$&&;1GGI0&@Z2ZB[2Y4O3X0JK+ZK:4."XPLA(PZD:5FE)QX
M];]D@$6D.VJ0B/\`]D7^Z"W"'ZZW\MYL]K>M_+]/W;UO6_E]VM^F]Z_OU\LS
MC&,8QC&,8QC&,8QC&,8RA+\(II>;WEP_5\;A]$7AU$VQWL[FF?65SA1;2Y.+
MM==2Q%^?7&PH%,ES&J)?(U#'%C]Z:7*6I*ZJ&.;$0U4-O`1LQU:M>_$;57%\
M-ZK7O%">#+LSQVSL=231(??U[1B1-,"6,2EXAYKG79"UPMN;(!OTB5$H%[:3
M]C%J-IHXX[+5I=!/)-Z<<8QC*?\`S[?U.?D&_P`/,@_SR.Y:!5'YL:[_`&%A
MW\M->2!C&,8SGD\Y/,UMV!NLKZ@S$Z2^&5O$)9'9ZW,Y?Q:Z'HE#DFD9<T-;
M0;^).8!IDJE'(W%*$_;.%N;%:TDEN$H6)_`>#CF6S6Z16%T%,8ZH9ZEFE:@@
M\2(?"P:)L4]=)VM\.D"!H.T:%;&V(EC,2)'A:06F7KW<\MG$J)2KS0V[W#XW
M^+KMV8JEE$0]H?=D[*32B`$'5U(49NA>T6L`LAYC4F5JR1^@R3'1$X!"+6O:
M`(/^SFJZCA/L7G/XEQXL[(DKM'4X3U">E>FB_P`?XT?LLL1@4+7+=$FJ&CXP
MW>RB]IVAFV$0@&*W0>]>]+^_'/)I+J:D2.O_`"!<_2KG-Y5*"4#9:\8(7SND
M9$>,S98E!+VV%+U3.4+T`9HI.LD8TP#-B<@MH"A"W]WN?RLP'E]N@#?5+/'K
MRE=CQ]1+VE<W2].5`VJ)%KS6I(\+'UB(>#794ZN:5>E;VEM]SL);:X*'!<BV
M6E(5R#X\/(HQ]OM<Q9'6'!KRT8`2V.+U'T;J<_,+U''@X](BD,?<U"%`L*"0
MXIC6YV:')/\`$(#C$)Z=6O2K-&$V78QC&,8QC&,8QC&,8QE$OX0\]V<Q\#LB
MF+/]L12D3NG.?$?<$KHLU[)MF,\2*Y2K)O!XB!L;3J7TG9(=QTJ0'(2S"@QD
MYU`ZD*F(UV3F5=^&9SY!2>3=?&_#!8G0M@^/X7*\S<^O44_57(NHJ*WV*:QW
M5*JX,JO!L;903;<@;?QL-DB-*7M$KBXEZE`:>2C<$C3V/8QC&<Z?X24H[=+\
M>G3A-)M7+:KELSG65[Z*7VB]6NBOI&/<LCH6_5+-L49UM?N'_JWV1K`SAP;M
M;5>\T0;[L``'WUU/Z_T85U[7I[7XB0[U]/7T]?Q::O7T]?GZ>OT]?GD@XQC&
M,K.Z[HCR`7,_3V+TW?E'PR@YU!]0]9"IA`5Z^5>Z>6-4T3+WTD2,SJ=H+K\4
M:-O4HU*4Q`2,!9:8!Y&U2CRO&W,O?_/+A5<"G5_T3(N<J\9EK`=!([`77<M4
MM);8Y!8TR&4+FEI5@4HWM4D6'KUB\_0T9)Z<Q$K$>'9=K?Z__K_KC/-2^&Q.
M?QMXATWCC)+(K($AB![CLA;4CNS.B0W>MB)7-RTHY,>'0P@,`(9?O"C0%FE#
M`:``P\^G8WA";%2=VG?'KAIH6E^^6FT=)W(8V-8(8C3E)4"E[FH,4L:LX>P;
M3L4I/5LZ@W8@%R!D+T$`OI^$J.555DZNJ)SV0N<2ZS6F)XFXT]-V4Z)/#)#H
MVI/=C=1[3@IV*6KW-:<4ZOH4)1)K6W(&L:9&M;!"?%?1Y]?IC&,8QC&,8QC&
M,8QC&<U7F!OV3\X6PE9G3S3%\-']&NG.40J6L$E%U!8SC3J%$\V`UV/=<K-G
M=B1%6*G9PN2(VN;316E/15TL8$99")["ZFITL:>*>\GH/=K#29WG/8O)TTRG
MGBX+`#4E0\VT'!:RABF)RZLFK4KF-@59/5SHQS#VI&>7'(N.*K4\F;E3TY.#
MNUB:&XEUZH,8QC*?_/M_4Y^0;_#S(/\`/([EH%4?FQKO]A8=_+37D@8QC&,8
MQC&,TGZ^X<J_K!F0NJLQ77]TP_0%U979$?;;IG$'A"9I8U:4JT1B12]L)#@6
M4>-K4*BE2'8CU4=<65R,VK%KMRWV/95?V8CXQ[K(3QF^2=Z35;;91>D]?="L
M0?9*;EC8[#(0HB9BK%KX?1`4R(MZ7:$VJ431+`[:7&V'6];^>O\`Z_\`EO7Z
M=?76\8QC&,8QC&,8QC&,903Y^$=0QND.=9L[\X\MVE?D_P"P>=>=:0N#J:+Z
M7570$DL-]E"E!9MMNS;I$ZN]3Q$"9]5+X&]NA\&>Y$\-JM^CL@VE`U+=+?#G
MU0J!TARC4;C37&.Y'TAQ)TK+K&L;FZD*VJ*U(K9_,G95BU@[KI@WUPP,B)OH
M6U8037Z:!M[B0%:;-X<K6F&'G*U)AO61C-#>^N\(KPI!ZF<E-93Z[[3Z&O"%
M\X4!3%;J(NUR"Q;>GB=T6,;0KE$W>&&'PR/$(V=:I>95(7("!K!\/H9)NCA#
M)T41>=FL9A3]'O-3<R7S9'4-]=&7)R=%N.R72JHK8+1>'.C8)\O5IDUD22:)
MJD11&!,NT+GN9H)(Y)'4A\9@`0(COMH+'95Q!V)6G>'-<!Z7JQKE<;C\S-DS
M,ZPV>-R9HG$$FT$E#O")U"):VHUB](F>HU*F)S;S3$BQ0B<$H4CFA.&D6D[U
MH)YZ9_!G'Q!^09I03&*K73?/\B3:;DDC9%2_:@$ACQ`T^D:=>8IV<`[U*&5[
MKW@3-;+V'0_]G+;JH_-C7?["P[^6FO)`QC&,8QC&,8S6#K'E&L^NJN75Y8"0
M21Q1B.=8).&TL(9-7\L`3Z(I`Q*]"+-]W[P!);PT[.`D>D`-IS_=*2D*U'J'
MQ5U)9L5L-=PKV*84DZ&@366=7=B#5''L_04"3E'"0/[<XJBRA+I2E;4PCENS
M-Z7O:9*O&N3)Y*Q2,@5K?U^F,8QC&,8QC&,8QC&4H^>]TM!!PJB1UES`^=FE
M2&_J;8+)YF9*"7=`'6M4RAT='";,PV]H`H?:P5(DK8F=H[<S$W.SK!I<CCP4
MJ).)V^UVO5GPR&\'5Q=,MKKDCPQ=_>/V236O'V02J\.IN=)=$HJ\L\=D#$?N
MM4MNS^T;$D(5*YV>27%FAS:)$T.P(TH<%1.E+(D]CI4QE%'G9YJN7I&K^1DD
M2IF?](4)5/8M>6_U70M*OS%$[YFU6Q%CD&FQRJ*2NLH@#LCD,9D:TL]0@A5B
M0F9NI#B24U/[>20L<$%-'-/!7<W(S)XYNN#>1KDET`X[[G\CTZB?&$2D-72[
MJBL>..UX.V1^MRG]6[S=F8;*LZ*S)K<I%+TBZQG65`:I4WD.:W>V]S''[]?"
M+R_<_+/"C/&NA(F"O;<M&Z+^Z#EE:_;#;(5%<_TSVD]RY@AKF]LYI[6X/;1&
MQLYCX)">>G2.ZI8W`/.VC$/=;7FV\1/C7JSQM]Y]$5_QW3<6NQDJB73]HLEL
M:'0,F;YDYRAJ7KY"F5*'A026X*5+DO,,,TGT#7Q1H`@"5OW>=+M3ZUJL*[UK
M7IK4$AVM:^[6HTU:UK)!QC&,8QC&,8QFD'<''C3U1`$"R.N8X+?=9*]RNCK4
M;!B0O,6EJ$PI<F;5+FE!\<"./2Q*E"X`($(QN6E(7Y(68I;Q$*OP>`^N7/I*
M!2*(6D@31+I2D'HV!7;"!ZTD6!>&PTUN(F*1N]@("&F2J$*[1A*49R5O>4B]
M*0:)O-:SE._N,8QC&,8QC&,8QC*/?P@*4WW$.%6-UIV0WU#Z]'TG1:'L"9<N
M%+Q]"Q+CE8^.15S/U4'M*52Z-\@1F?BUI<YH]E%HF`QT&[#%'Q/!8]->`>W6
MKM'R[/=@\&W%U?;O%KGR&H;>IVJZHW.X]0M=73`ET+B=%J:?0V`QL:]FM29Q
MQ*^N%CI&M/HF5(QN,D5FN!B7W$?ZC,9C>M"UZ"UK>ONWK6]?PWF/8!L/L["'
M8?\`A]G7L_P]/3_X9\M:UK7IK7IK7RUK7TUK[LI_\^W]3GY!O\/,@_SR.Y:!
M5'YL:[_86'?RTUY(&,8QC&,8QC&,94!WW4<SH6PV#R/<Z-AATZK1*4V=%09(
M(P".VZ8]E,D<UBY.5H6C'>+(""-GKA$F#(;$;9(!C]N&$E*K-:>MF%7G6<-M
MBO'33O#YPRIGIG5[#HI06`WVBE;>X)]"%M(ZM"\I4U.R,0MB2.*-21O>]`T(
M4E8QC&,8QC&,8QC&4H>>JYKLH_B>+R2J[(LRC:_?^F*(@_6/1%,M"]YM7GCD
MJ3OZ]+;MN0<IL;'-P;75E&5'6@^0-Q&W-B;WQ4M:P'.&TY(Z??`QV]/[XZ4Y
MMIZG>F+@Z6JFO^(NBF;KY#8QDNDS#";!C'9ECN7+=IN%A2]M1G.]XW!5TU+;
MY<G;%(0.L)9&(3FATHBR9!%^S'&,8SG3_"2KBZ2A_CTZ<K:N.0GFW:2GG.LK
M';G1B.[*PA3;1`B97'4J0*ZKY0:7.K%^-2>B[?XEA-&F`/1)A0A`.,)OKJ?>
M]UA76]Z]-[@D.WO7KK?IO\6FKUUZZ^6_3Z>NOEO)!QC&,8QC&,8QC/K+$:5P
M2*4*Y,G6HEB<Y*K1JR"U*54E4%B)4)E*<X(RCTZ@D8R3R30B+-*&,L8=A%O6
MZ2J:7&>-?L%UYLDR[3;R+T^Y.TYH&1NYPDK)6=D:T6.0UPI<E`])$;>KUI*W
MI_B#=`]@R&K_`&M'KY`>"[5&M2.*4A:@4IUB-26$Y.J2G%*4YY0]>H3"3R1F
M%&EB_0,L8@[]-^F_EO/LXQC&,8QC&,8QC.73N/R7]#5+V]Y"/8N6%U7S=XS_
M`!_MUND44[0^/.[OU_>?1]?21'62URD$@5$.2.$5M/3XDR::XP$29<^J0M;V
M4O%(2S6:)O$?->UN:^Q>0^>;]ZG/Z(:>]_'Y*>T[2IQX@T(B[CRY;Q+I#)`W
MF1PJ#,[.F8H5)F>8*HB)D&C;VI7)FMU7(VQ`(A`$_KDQC&,I_P#/MK7Y'3R#
M?+_[/,@_SR.Y:!5'YL:[_86'?RTUY(&,8QC&,8QC&,8SDR\Z\CLM7TO!XE(S
MG$NKF^L&QXKUL$(_3`X/CBZ/"6=.H2A!"C6/Z<:=F:UN]^_4-[/]F`U\.0Z&
MA4;6>`683QSBO0D*7.RE?6\0<Z_<(PU*W#9Y,<D4E*EFY"F9$0Q#$A;G5(TM
M:Y:G)V4@TZ$F*"$X5JMQ--Z(<8QC&,8QC&,8QE<78/BE\=/;5C0J\^N.:X':
M4^JUI3-S),7YWE4=UJ--#BJ?DC#,RHS)8\SS6)MCBJ7KD[).DSVRH]+W0L)!
M:-R7D*)+J+FCB^']/W/U;5$;@!W3=^1F)QNS;#;)D*32-S@]?L<9C4=C3*T"
MD+DUPZ*(&^,Q@+BW1)H943RM:FA<_;<%:%O,3[I8S67JWK^@>*ZW;K1Z%F:B
M*1Z03*/5Q#6QEB\KGDVL"QY<-27%J_KZ`05FD,QFLP?AHU8D#(P,ZQ3\,D5K
ME.TR%(I4E:PO?F"X%9N?J^Z/)N%XD4-M2Q7BG8%$(?55K2V[7ZWXSI4*7U;J
MA6*'++<:YU#"D*I1+F)ZB3<;'D@4JQ>:!*ZLYKCN?SOT-3G5M,0'H.@)PVV-
M45FLXWN&R]K3N*(AR2)UZQI<$ZEM>$;<\-#LSO#>X,SXR/#>A=V5X0+6QR1I
MEB8TH-<_GVW_`-SIY!OK_P"7F0?HW_[\CO\`=EH-4?FQKO\`86'?RTUY(&,8
MQC&,8QC&,8R.+,J"K+F928Y;%>0RQF-,I^-2-DSCC7(DB)9['N]K$(').>)$
MKV5O90E*01)PBA"*$,18MARG_I.&-'CFZBJ+KRJ(TBB'.5BA9Z-Z9AL3:R&V
M*QI$9LDF&SY''FHHE*B$BT5M0:<F2A"-S:%"<0]KYFJ&IN_2*TR]*F6HE!"Q
M&L()5)5:4TL],J3*"PG$*$YQ0AEG$'DC`:2:6,0#"AA&$6PBUO/L8QC&,8QC
M&,8QE`OX1U6LQM3A.N(W&ZEZ0Z"C*;LGFI^N/G[F.(2B632[:09'][7V9`'X
MR'&`?8K%EC"4-R)EQ!2M(U31NAQ"XI(4N"\M.JGAPJ#QMP;KUP>N4O#/Y,.#
M;0-IR=HS[MZPK&YHC4Y\54/D),>("2[3R\+#8QRY_5E-2YA2Z8OM$]#'GL:9
MS3%EJBU75+C.;3\(&KF0JYQXQ[_>['O&E^;Z`Z9L0?2-V<]1Y?*+'I2-6=4Y
M\4C-HH$+9$9\MCZ="X(W2&F6&EASRX5^=-B7YG"F>@MIVJAZ@MF^89*O%3Y`
M^PG.\9GQ5S'WOY-83$>D+'IV9N-J/?+]MTQ&H)R5T'?T9B4*!+'!SE,C8)0P
M$66\0HEZ=$QK2I<E1QCBTZ5]`'X/=7U@0GQT,KO.XK*(*FMKH/I^[Z\B$Q:E
MD<DC)5=H73)9%`AN,97@*4QP,@:1;E2-J&23ZMS\E7;+UM?L0JZO-1XHX_6'
MCP[POY/WIY19JL:*RF<ZU4]C=L326T2YF.<L;7#\4WJKU#&F:G*#-XG#29LC
M1ZC:=(E;VPKWI@T8#=]2]3Z]*PKK7KO?I!(=KUWOUWOTC35KUWO].]_IW^G>
M2#C&,8QC&,8QC&,9&%T5+$+VJN=U%/$?QT5GL>7,#H`.@[/2[4!":A=D.Q:V
M$MS9'(E&\-9P@BT2X(4QFPBT'8=UY^,6UY>S,]D\1W.L.'<W)3SN,H%*S0PC
ME].*C_9@$F;A&BV:J1(4)B1O`;L/H2QKXILTP9Z@[V+6\8QC&,8QC&,8SGN\
MR54PZJ('9G3-B]X^3&GD=N2'FFEZQH_B.P%!$VDEM-3U)T,4@5`0W0D:+4]N
MQ0]*-S<"US;D;\CBJ/:M2;M$E0'ZA^%E_K@'3U0N"_N3RZ65.;^X]M6XJ_HK
MO.VT%B5(<Q1/H9^H^Q6L!S,64VE=!5#(:N)='^.&D%G,$1L5.8B6.!@7L"7K
M-QF-AT+T]?7Y;]=;UO>MZ_?K>M_K^?SU\M_+,>QKT]/G]?7U]H7KO]8O7VM_
MJWO>OEK[M>F=:UK6M:]?37W[WO?[][WO>]_W[WO>\J`\^W]3GY!O\/,@_P`\
MCN6@51^;&N_V%AW\M->2!C&,8QC&,8QC&,8RG?R.1)]YZLJH/([5S6H4N]0N
M*""=`L38G+V9-:0DJP+>>I6!T5[!BR/GJQMZ=6IV9M,)S8UYAA1$=*$"V6'R
MQ@GD4CDUBKD0\1J6,;7(V!T3#",AP9WE$2X-ZLL0=[UZ')5!0Q!]?4`]B+%K
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MY8,1DL&E[6F>XO+F-SCL@:58`F$.#0[HS4*],/0M;]G9B<X?NS`^@R3M%G%B
M"86`6JI/&[+Y'1$_N+QSVBZ'+7VCEZJ8T6^KRQ$F36BY(M"N3#3&#,$4<='U
MKJF.,()--$GT[.+65ZE1P_W5P6,8QC&,8QC&,HQ\]EEK:DYHH1YA<-HP=OV3
MVOS/1]67O?U?QN?0'E*66"^R-,W]'N[?)23&PHRN4Q3J!C6.VCV-M>G\I<YH
M5Y!8T2K7?A&SNM.6O)BR<$]"=?TIY!H[=_+E@7PPVI7]%U11UM4>ZUI,HXV'
M1^PV.HC5S2LK2<@D:TN(.$@7*7`3XW)$35]FH41Z1;TK8QC&4_>?;6M^'3R#
M;^?K_P!GB0:^N]:_]N1W?TUOT]?E]?3U]/77TWO66@U1^;&N_P!A8=_+37D@
M8QC&,8QC&,8QC&,94EY-8/+JT<Z:[_JAO&X3GEEY$58+*08(HV8T;)5/P<J:
M3A!]L0RVD;@K%O82MZ0MC\\NPM^K87K+.*XL"+6K`XA9$)<BW>)S>/-4F8'`
MO8?50V.Z0M6GT<`(S/<JR-&;3+4PQ>\2K"3TYN@F%"#KVN,8QC&,8QC&4G^?
M.VA5%P9MQ=.?(9U17<NO*GX)<M!R^J+!MA78-1/+LXN,S30)+7<BC"^#VBQ)
M&0J35Y8KXZ%QV-R5H1%*=D.3@UJR-8?"Y,_#Q#;:F=3>.7C3H'G:P9U!%TOF
M4PN2A+PCJASC$6<F71D6,MFY7N4*RBR7)^0K$T+9'@EI<%B10Z!3JS6\A6'I
M.QGYCT]-$<9W60/[FA9F)B;5[P\O#HJ)0MK4U-:0Y<Y.3@M4C+3HT*%$G/5*
MU1Y@"4Z<DPXT80`$+6K#EWUQ2R\^L'5KSU30K/S=*W(]EB]VNMFQ9MK>2/29
MV=&,]F8)0M7D('EW*=F-Z0C:VT2E>$]H<_5/[M`J,*V.@D\A-H0Z-V%6\NC4
M]@<Q:$;_`!.9PY\;)+%I*QN)>CD+NQ/S.I6-;JVK"M^VG6(E1Q!H?7V1[WH6
MM55>?;>OR.GD&^>O_+S(/T__`(Y'<M!JC\V-=_L+#OY::\D#&,8QC&,8QC&,
M8QC/R']B:90Q/4:?T!#JQ2%I<6-Z:U0=B2N30[HSF]R0*0A$'8B%B)0>F-UH
M6M[`8+TWK?IO*@_'^]//*=\V[XY)^XJE#*PGN-N<M/SILT)DFJR1*CW!ZC:<
M\X>BU2Z/*A'+CR4H-[^TDLV,WL*9*0$-R>,8QC&,8QC&<?'E!O"^K;\C_2]#
MH_*1,?'-6W(7"T#O^HV""3>'5V5>=Y2O4L>QM4P62-^CRV=HQ%-K4T[A19SP
M@$@)3FI&E(K6.1[G=7XD/('#>V.,>4Y5-+MIZ5]3S*@8Q*[=@$6GD)-G)<C9
MRB6&7R=UK5E=?M>,E.#F6D=W-(%B0MC*J?DZ(DM,G-1EBM<QE*GFN=+V?ZDI
MBAZ^YSZ-OF@[OL]0B[1_[+[5%WJT2N<H,SAE#M4[.EE<VKMN;">A)/IBKJ62
M04K3#9ZN#8I"-$XNSHV)!\KGC<LF(M]$?@T,LZ%9R*JY4J7IWRH0V=3F\3(G
M&Z1?[)D3!,9=2<M;WMR>UC(5'4+L^2F`,"^8"CQY,_ALS1(FU0VMB-^7],?X
M-Z4XZ\9,?4HRCDU8.72/7#M0A84AB)H_H2<.@IFIAYD92'$D&$1=6K$_J&(.
MRPE[1'Z,2?\`H8D^M:)>:CCKR0Q+QX=X6/8'EYFEITNCK*9R!UYV5\5\PQ%K
M?(8JEC:I;J_'9K`D%.VTAJ1J&]#^,Z`\I\7::_?GB#M<J)%U+U/K>JPKK6]^
MN]02':WOTUKUW^+35Z[]-?+7K]?37RUD@XQC&,8QC&,8QC&,8RKOR<4?+WN#
MP?JJED_L7WR0_?TDQWX<.M'RB")1E*YW$%82B=GN"8;<E$ZEMYAWNE"(E^;2
MB3#GG6M[M<[WE#^D*9@-SP8\)C%.&),Y?![.`:I9'4OU2OD=<-@T'07!A=R5
MC8JUL`-&"3A4%ZV2>4(4U8QC&,8QC&,J,[TXQ\-4EF1'0GD3KOD=LELG0,\,
M169T?-&2"#>TD:(VG:&%M<)-,(X@7FM:9;[`$[>2:J+).+VHWL&RA9][Q_<A
M>'F&2=UZ!\;T#Y,6R)`T.M=OEF\V3-CGGP#8]J&Y>ZQ9V=HW+I*A1#7'L;<I
M-1+@D*S/@2QE?[L)FQ6RXSX#+`9KV3``'K>MZWH8="UO0M>@M>@M;UZ"UO>M
MZ^F];]-_+(H?:#HR45S_`$/2:FJID52[/^)%5[[7,-=J[&HTX&NVCQ0A>R*(
MQL[3H><Y:-^RM&:7FF+/;^),&:*16)B9(PS-<=C;0UL$?8T"5J96-D;T;2SM
M#8A)`G1-S8V-Y*9"WH$:<`"$J-&G)3)R0`*)*`6$(=5*>?;^IS\@W^'F0?YY
M'<M`JC\V-=_L+#OY::\D#&,8QC&,8QC&,8QC&?`TLLXL91H`&%F`$`PLP.AE
MC`,.PB`,`O\`9&`8=[",`M;"(.]A%K>M[UG,/*^M5?B9Z6Z.H6N(RSVQ4LQ?
M(S:\3@RB3+XIJGI!-4);D_QP"@IC?0J4I[3\$%&@(+`$EL+BZXU4%5]J)#[M
MN*.RX-VK52BPHHS.,2>V![,C,WA3LK3N*N./H4A#BFTE=DI2<AY9G1M5$+FI
MT"D1'&@^(3+4")<C4)P[BXQC&,8QC&<KGE3Y)NR5^0-SZ6;_`!MUKY>*=>^.
M&KF]EIF2V_7D8=^7KC22V3S@Z<&Q:S/C&M"WV3'I(R:W)HH4AER4#?I1MP:`
M%-9KYYCQ+^+>^.%>MN,%,NA5,4CN'^-R4P3H^8P">1-`^]AWK)+(32)#"EU6
MQI2C'*5/)$1)C"65WJO:5)\I=I$W%%/K\4K"J1=96,8QG/A^$>==\UU'XWNK
MN=+)N*&PZ[;UYWE(JBK=Y5JB9)/O@Y1'T"D,?(+1FIE`BE0#2A`-5$&;$48(
M(!%EF&`O.J?>MUA7>];]=;@D.WK?WZW&FK>MY(.,8QC&,8QC&,8QC&,?7.?'
MR5>*BX>@+Q<[]H9UBCNKFC4PI)G"I8]&QI:E>8TT)F!&[1UV&A7-BU&YL[>W
M$K&QP,;#D+@D&I3J5:=P$2@E?P=16&1.BK>;2EKD3<B2X71GNB'/*4#<Y0=P
MC:43%%F;X'WAAYB,Y"E=%0W,WW>CWP3ZV%EATS[$9=OC&,8QC&,9QQ>:?M>`
M^,?M27=@\H]EP)F[#/I>NXMTEX]+L:;&7U=TA5B!MD!=13N,/,>CZ=KCUO5^
M)V/<FHG\<VHQ[CJ=R;B'5D.<'6/SK]+P`V9R?U'TLK[!N+R*._:GE7N.@'I6
M^5<1'+$K^M>5J45.\/=)94-=0IQBS1$-?BU(CF!N?GA,YA;%ZL(EL68U!RM^
MF,E["\8QC*:/P@!@8UWB%[Z>%K.U*W5NYVD);>Y*FY$H<$(!2&-GB"C6G$#5
M)0B-+`9L)!Q8=F!"9O7MA"+5J]4?FQKO]A8=_+37D@8QC&,8QC&,8QC&,8QC
MZ_7*7.PXT_\`#_2\?\A-9M"U=5DU&U5YV+"V1#HWWS(M4IT;)::5$1LH`G5"
MH"C+5*A;)V)\1MQ9YVR96]GAN#B<KCLYC+!,HB\(I!%Y0T-[]'WMM,]\A=6A
MT3%K$"]*9O01;*4IC2S-!&$)A>][*-``T`P!]!C&,8QC&,YH^T.XML_<_9C*
M=S-R?*>=_&MQ!OH;JZ>W/!VZ37-:%@V/6,ME'.5452M,9%J=KCR9U:&Y/(EK
MP)8-6%S<D3<:U*$[6D>H3\1'0G8\2ZLYC@/9=9\;Z2^0KB.6=?4<\\]45%:9
ML:B$[*X0UY7TQ+P,;>F6/D3=(5*F-V*7NZER=0R),!N-?7?[*<!%]9&,^DXN
M+>T(E+DZ+4C<WHRAGJUR]20C1I2`:]1G*52DPI.G)!K_`,1IQ@"P^NM;%K>]
M>OUEK\R-K4)]<'=L0LH""5(W=8O2)6L"=1LO1"@;BH.+1!(.V:5HDX1^BC=F
M%Z+&/8P:%^F4:6<6`XD8#"C0!,+,`+0P&%C#H0!@&'>PC`,.]""(.]A$'>A!
MWO6];RH+S[?U.?D&_P`/,@_SR.Y:!5'YL:[_`&%AW\M->2!C&,8QC&,8QC&,
M8QC&,_`E46CTWC3]#Y:SH9!&).TKV)_8W,G1[>[-#HF,1N"!63O_`,9"I,:8
M4/TWH8?:T,L03`A%JFKER92'Q\]#G\)7$[KU=$66Z.$BXYLIX.]XC2;=7$1S
MC4KTX#`62G<=.BWW*4LP9>BY$<4H`7I).6P"*[36_77KK]/[M_OUOYZW]^M_
M/7Z<8QC&,8QG*IY%N3?'YWSY=JXY-=XUVLX7E-*%9'/M%_YBLK5;<ZI.>(>.
M0SBFXWUX$R.R$V5.$HES,V1^%M+*;$W=.C?HPXGR8:UNC")-LMR>9R$V^;;K
M:/2BO^E:V[38:'BD,H%FNM>A7<YK^,(0@@T96.W$B1`T-Z>.,3E)&%I66:R.
M:ES<0R#3ZHCKB(LV?(D?0KC*5O-PP\=**0HB9]P2ZT':H:[Z1A,DCG*%8L:6
M:KNW[A&WNJ*LN=G"M-HS5]E%NSF8L>4<4TN:V#:A$8[2I80U-VE*?GZKCC2U
M8?9?ADXK[AK]L9>5>H.ZO)AT.EXBDTK!/X'0T$;Z099=RURO-5GQRF.R8ZOW
M1PF,F3QK05K>A>I$I;4INUP%S<DO1_!SI(_O'C3CT=5NJY\AE7=#=45+3;JY
M.2Q\,/I>`7G*FF!($<@6J59[VT1U`)7&&%6%0:G3M#,A;$^_<-X=:T#\T[;Y
MN"O'AW@=<4L\7*KF#^C*9B?VZN81U6EO85:?C8VB9BF5VDDP-@!4Y^S=-`7-
M0O:U#!\7]I_"IO=[2'%]3%3^O]&%=>UZ>U^(D.]?3U]/7\6FKU]/7Y^GK]/7
MYY(.,8QC&,8QC&,8QC&,8QFK'8?*T*Z]I9^JZ4^[;'D._MJOYH40,QS@LV1$
MF!:9"@V0<G/,)_WAB%W0@/+"XM2E23Z@4@2'I]9>#NKYD]NKWQ[U,6*,=8TT
MF$@.&X&&B27+"&P@K3;8<7<CR2`/2L;;\.H>A$ZV-U2B*DR<`1'OK>Q6@XQC
M&,8QG,/Y!8?UEP#Y#)!Y`>-;$XLEAW9E8UC2MS\N=@WK%N?)!,)33`1M5?36
MBYK*)/%&UR6)61<!L?(\8X&&)CSEII;+(SGM`9&)FX?Y4\D-Y^0!/Y(O)=&Z
M+HI74]"R_GWFSFRB94.?FM2&Q9"V/\UL2Q9\6L>&YV4KT:(2!G;FYZ4%J?C2
ME@F>+_8^PR+H2QFJ?5'#_*/;;)$XWU71\+NYB@KNXOT2;)H2YGI&)X=4`&MP
M<40&US;=Z5*6\L"41AHC?8*UO16@;$(6X`/\//C0/Y_/Y<UQ_5*.BC;.'<Y$
M$:2I,REM-J&L3=&#Y[')$TR-'+XO)U4;:4$?6.<<D+68L9"1-2K1R(]02;N_
M3=-U;SY6$+I>E(+'*TJRO&8M@AD'B:`#:PL#6`\]6,A&F"(8QFJEJI6X."U4
M:H7N;DL6.3BJ5+U:E0;67Y]OZG/R#?X>9!_GD=RT"J/S8UW^PL._EIKR0,8Q
MC&,8QC&,8QC&,8QC&:*=K\6M73[+'YE#)`?5W255&?;%,W$T&'HW%E<DIXEY
M,=D!Z,(E2R)N*W8A#T$M0I8E9YSD@(5)U+PSO/BN+>V'2T79ZYQZ39TM5=@5
MEO;;+88MV0WH+%1)"/>E3NOM>W\*Y)')%H+HO:V@Y6G(3&A>F4:B/*`[;[(/
MK],8QC&,9PG>7LWF$ORO]C+>Y>1.A>I(H\^.^J*QY7<J[IV<6:QUG:[LDFSR
MM>$:UE>6)NCIJ=Y=`+C'1,8YKD+@<M&!*6,X_1UK_P"#_>2MAN#G;EKA.:5/
MUU'^@J4Y?;DDWG-OTF^1*L%A%8',\7(:6BP7ITTK>'(#,[1Y*SD'LI"A<D;%
MQAQH!I?4[I2QC&,I/_"#;"@4?\3'=,-?9K$6672CG:2&1J+NTE9&V12$!4BC
M:<T3&QK5Q#H[A+/&$HP3>D4!`;O10MZ,V$&[<*H^=8UWO7T_$6'?RTUY(&,8
MQC&,8QC&,8QC&,8QC&:3]B<25_U>RL[O]I+:TNV!F`<JMN^)`&CF$0<T@S%*
M)(K5(3T"YXC6EH]J1M/V@D4H%(S7!B7MBXQ08II>FWF!ZVYE<G3GJT:VJ*P+
MBJ:0*(O-;(%(7O['EZ,E$WK&I<2RQU$T$(WM8A6%*7)P"<D(V8>`HZ+-+@0M
M2[NSX=Z]C_:%))K1:X^?$7YJ?5T/F\4-7!<RF63MJ1`O&)L=-$I3')E=&QS;
MW1L5GHTBD!:DU"K("L1'B'N-C&,8SX"`$6_7>Q__`*3#`Z_@$6M?_#`0:#OU
MUL?W?[1@Q:_@(6]?O]/7/GC&,903^$7\P\\6;XR^OKUL.EJTFEQT[SO)@U59
MLFB+0\3:O/B9/'ER@4/D*Q.:X,`CE0C#C!MYI!@AFF^H]@--`.[6I]:U6%=Z
MUKTUJ"0[6M:^FM:C35Z:_=D@XQC&,8QC&,8QC&,8QC&,9C>O76];^F];U_'*
M"^[_``\3#H*\W^[J1L&%QT^P3D*^=Q6?EOB5&D?TB!O9SGZ-NT>;'DT\EV1H
M25;DS.*`D93H4>H1N@RG':9#9+PEQ^S\74>162:0?C=)GI_73*=RD*#[,2.D
MF<D;>W?#M#>,U2H1L;.UM:!K;2U:D]4HT0>Y*ME*%YB<G=#&,8QC&,8S&]ZU
M]=_7?IK^_?W:^_?ZLSK>MZ]=;UO7WZ^>LI_\^W]3GY!O\/,@_P`\CN6@51^;
M&N_V%AW\M->2!C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&4,>66:6I/\`M'Q.
M\`Q2Y[FH:JNQ[#ZFD-X3?G^=NM5VLZQ_F^E$4[B\'8+*CWNI)%VU^D3SI5(!
M,JQ(H7I&Y.E.&8F"84.5_!7T);G07`[,INZ;/MHV'3MX=$<[N%HRHXL^6V*R
MTS;+[%XE*I:I*`66MDYD3^R&Y]<]Z$I>5[6<[+33EZY2:.K?S4=B^2&6^._O
M"N+`\0TTJVEUM9S*/.O1*OM3F&6M;'#$LL;4K=8(ZS8%89VY$.B-.WK_`,6$
M!!KXBTY^X/"+:%4<'=RON_\`RZ(H)"DC?X&+%=D*>(18E$Z%>1#C)*6XI"X^
MVA3+@I3W`1Z72PC1:GX4_P!%";9NTZ@`#RS`!]?^4)\P']@19/\`S%^+?]?C
M\H3Y@/[`BR?^8OQ;_K\?E"?,!_8$63_S%^+?]?D(]%^9CR+\F5%(KWZ#\'MC
M5[5$3<H>T2&6#[ZY2DVF]PGLR8:_B2?;+$$S](%7VM+Y.Q,_O4;4H(0[7Z6N
M)B1O(4JR9O%Y"/,`$0@[\!-D;V$0@[V'R,\5C#ZA%L._9&!P$$8?76_001;"
M+7S#O>MZWO'Y0GS`?V!%D_\`,7XM_P!?D(WAYE_(QS<BK-QNKP>V+"D=QW37
M'.];&C[[Y1?A26X[<<%;57D.`3&4SR>V;D*]"J3_`&\\EM\::MEA&]/#<4:2
M,R;ORA/F`]=Z_($63\M[U\O(QQ9O7KK?IOTWI?O6]>OZ=;WK?UUOTR%;T\R?
MD;YIC47F%W>#NQH1'9G9U=4U&7`7??*$@$Z63;,A)BE?QL**+IWI>ET_R`\E
MOV\+4R=B:=F!4O3DW)-^_P`FO?D(\P`1"#^0)L?>P"$#>P^1GBL8=B`+81>R
M,#@(`P^NM^@P"$$6O001;#O6]PC"_,OY&+#NV[N<X;X/K%>KGYQ:ZK>;HA@.
M_.4$0H6VW8QN\DK%0)^<$Z2,OPI,RL+LLVGC3P\*6;:,29^);%9A)!G];6\R
M'D<I"2TG#[2\'EB161]%VB12U--P^_N3G;\<+,4QQYEI$;$J8R')%'0F1^//
M+AIZE"AEC^O@1I1.FEAA"<SX7GYE/(US7&(M,KM\'EC0F-S6S:YIR,.`N^^4
M'\3I9%M2$F*U]'`HHPG>5Z73^_J"6_;NM2IF-IV8%2].3<DW[_,7/YE?(QST
MOIQLN'P?6'#EO0%VQ3G.H2Q=_<G/@)?<TW0/SG%H<%1'"'=,R:=4,8?5`9%(
MC6F+I`H-A7/289Z8)V9+YD_(U#[QK#FV1^#VQ&VZ[FAEBV%6L*WW[R>J%)(A
M4XF4-@.NW]&0HC#.-A%(F706U]>6QU=OC@;9$3CHL[9?RK?S(^1RW;"O2JJZ
M\'EB2.?<U3./U]=C`#O[DYMW"Y?*H@WSQ@:@N3N0@:)(!?$W1O=OM**+WQJ2
M_$@1+%J=Q"-(&:?RA/F`_L"+)_YB_%O^OQ^4)\P']@19/_,7XM_U^/RA/F`_
ML"+)_P"8OQ;_`*_&_(5Y?]:WO?@(LGTUKUW_`-XOQ;]-?_O\A*F?,MY&.@UM
MS-U/>#VQ9DLY\NN6\[6^47WYR@S:B%R05O8G650[WLA3M1+]]E-\E8U&W^-&
M/$96Z7A+;WA4:2H`5-OY0GS`?V!%D_\`,7XM_P!?F=>0GS`;$$/Y`FQ];&,`
M-;%Y&>*P!]H8M`#[0QN`0`#[0M>HQB"`.O40A:#K>]0I0/F2\C?45>_TJT1X
M.[&GD!_'">P+;\'OSE".[U+*QEKI!9RU;:I6G8WG6F25LKHTZ7[;]-KGM()8
MT*UZ`92H<UZ\A'F`$((?R!-CZV,00:V+R,\5@#H0Q:"'VAC<`@`'UWKU&,00
MAUZB$+0=;WJ%*+\R?D;Z6C4HF%(^#NQIO'899UBTU)G`/??*$?$UV34TA.BE
M@1L2*4)V5>JTP2`@YOT\(DRAB=MEB4LKDXI->_Q>GF3\C?-,:B\PN[P=V-"(
M[,[.KJFHRX"[[Y0D`G2R;9D),4K^-A11=.]+TNG^0'DM^WA:F3L33LP*EZ<F
MY)OW^30=Y#/+Z0$X9G@+L?0"-'"-&'R,\6&!T$C0]F["(M>+1FM:`+8=E['H
MSTU[OV_:#ZPOSGYDO(WUI3$!Z%Y[\'MB6%3MH(5[E!ID'O[DZ,%O:)LD#K%E
MQXV28$,$B:OAWUD=$6RWEI;S!A3:6%@&A/3*3LT3YD?(WTQ&Y-+J0\'EB3:.
MPZT+#IB2N/\`V_>3HY]EV55$C-B4_CAB65$,BP\+!(236_[:2ISV!T]V-4SN
MC@CUM1J.H9YZNV["Y1DO<$/\+=BO'+<0BUMS61VEKNGF="!NC%%.TK8[6=/Q
M/<FA)/%6HHZP>5)1)$484+GG[)$<P)G1.J1&J/>-GF[[(;C^,GZU?$%/*MJ/
MN2YJ(INE[45=K<Z2](Y.=_M>Y9#W,Z)11J6RE$7_`$?I'J7F(W]%'O8TT&,"
M]8UOBI.EWT?:WZZ]?3T]?7T_5Z_+?[]>F_3ZZ]?3?SS.,8QC-&>V>!:M[?1U
M"Y2B>7%2MK<_SAPL"D;[Y]E[7"K>K)]?F!1%963'W:01N8QQ2S2^-J!,TD:'
MN,.B5<E*3#+^'4)BS<DOCSDFH>'>>*^YHH](^E0&O2'HQ.Y2QX%(YE*'^4/[
MG*Y=,9G(QID8WR4RJ3/+F]/"\*1&F^(5:2MZ%`VID:(CR_?W*(NX>-NAN32I
MR"LS+VKER@1<\'&MR\$7&N6MZT#J.-!?(T)Z"2)!H`D(7YK$;HS>]+"]@UH6
MT448=1B,1V.?$:6_8+$S,OQGN=)_BOLEL2MWQ'N/>'>Y]_\`#>]]U[TSW?M^
MQ[P?L^V+T'IK[M?PUCTU]VOX:QZ:^[7\-9X:R*OK:XX>Y5];4`AEFP1X4LZQ
MVAD^C+/+HLYJXZ]-\C8%2]@?D:YK5J&60-36^-1QZ89C>[-R%Q2B*5I230>Y
M]D/W:_3OZ:^N_GO?[]_/>/37W:_AK/"SJKZVM`F+I[)@$,GZ>$3:-V5#2)G&
M6>2E12PX<I-61*=1PMX1K`,LOC"L\Y2P2-OTG=F@\TPY`K(,&(6_=>FONU_#
M6>%G]75K:S6TLEGP"&6&SL,JC,Y9&J;1EFE#<T32%NI+Y$):V(WI&M3H9)%G
ME.0[1Y[3%EN+.Y$E+6]00H`$S7NO9#_PZ^N]_37UWOUWO]>][WO?W[^>>&9*
MOK:-3B<V;'8!#&*QK.315%8\\9XRS-LQGJ."H5C9"DLQDB1&2[R5/$FYQ7H(
MT2\*U9;(C6JTS:%,2H-`-+ZOK:P'2"OD[@$,F3S6$K!.ZW=I3&6=^<H#-2VI
MQ8BY=#5KFC4J(U)2V5W=6D#VSF)'(+:Y+D05.DZL\L>)]5U:VJUM+'9U?PNP
MV9AE,9G+&TS:,LTH;6>9PIT)?(?+&Q$](UB=#)(L\IR'6//28LIQ9G$DI:WJ
M$Z@`3-9FM7UM9)T,4V%`(9.5%<S=ILNOSY=&6:1'0BQ&%.O2,<[B1CLC5CCT
MP9TKJYIFR2-.TKNA(<5Q29666J/"/X.U65J^SR+VF\0"%NEFP=BDT9A5AN,8
M9ELUB,=F8FT<N8XW)U",QY9&B3C9VD<@;6U:F2/`FQ!M>4?M(1L&K7,W&PN=
M^B>Z[Z'80)<'M"Y*\M@N+!BNV/=<@@E.1>J=L(WG<@=M2P3H9'C'[3F%KCND
M8%H6O[/5"3"<%&\/IK[M?PUCTU]VOX:QZ:^[7\-8]D._J'7\-9X:$U?6U;'3
M137D`AD&46/-G>RK!/B,99XZ;.+$?TR!&^3J6F-*-(.0R]X2-38F=)&Z[5.Z
M].WHB5*LTM*2$'N?37W:_AK'LAW]0ZW\];^FOKK?KK?Z];UK>M_HWKUSPM=U
M?6U11W<0JJ`0RMHH)ZD4D%&H)&6>*,.Y!+GM;))4^;:6-&A0[=I)(7)P?'UQ
M]Q\6[.ZY6XKC3U:@TT7NO9#_`,.OKK?TU]=;]=;_`%ZWK6]?=OYYX6`5=6M4
MM;LR5A`(97C._2J33E[:H3&6:+MSO-)HZG/DOEKFC94:).NDDI>5![M(7M26
M8XO#D<:M<%!Z@8C-I_5U:VLUM+)9\`AEAL[#*HS.61JFT99I0W-$TA;J2^1"
M6MB-Z1K4Z&219Y3D.T>>TQ9;BSN1)2UO4$*`!,U[@198PB`,`!`'H01A$'6P
MB"/6]#T+6]>F]"T+>A:WK>A:WOU]?7>>)K>L:XIV$L%:U-`H;65>14A0EC,%
M@,:9XC$(\F5N"MU5)V2.,*1"TM9*AS7+7$\I$D)`:N5J50]"//,&+XP"KJUJ
MEK=62L8!#*\9WV52:=/;5"8RS1=N=YK,W4Y]E\M<D;*C1)UTDE#T>>[2![4E
MF.+PY'&+5Z@]0,1F_/LM!4;&ZE<Z$CU.U>QT>]-4O8GBGVB"1ENK%U9;`5NZ
M^=-#C!4C:5&EC;,ES^^+)2A4-IB9_5/#H>Z%JC5ZD1NK?6O![!TB1PJU124M
M-.1CB#L&D.H8Y%F*#)7!D?F&DH=-X:SU,S-Z%ZCB*$-1S=+DQ;>[I$KLE8D;
M*0@3QY02<`27?[6O36M?=K6OX:],SC&,8QC-<^H^L^>>,*DD]W=*6I$ZKK^+
MM#JZGKY$Z)2'-\,:40EQC%#H_HW[;FDK6EA`2TQ6,HG-]=59Q"5$B--.!K)6
MK2PHO;=<P&U8.M.<H79D*BM@1%Q4HE;:H7QB9L+?)&!:>W+RB%R`Y4TN:,\U
M$L))5I3#!$*"BSBQ@U[;&,8QC&,8QC&:Q=9]D<V\/5(_W9T[:\5JR"L+>N7%
MFOC@G^WI*>@TGV:R0B+%&[D$VDANU:8":/QE`Y.9PCR]_#A+WLS4)=,>4;C3
MDJ*4Y*[EL.2I`WU$72PJQC$(JNSK3GKY7D=B[?-9?8"J"5Q%9-)F.%0J+.:1
MYETE>V]`ULB88RSSQJ2%!)6Z59V5!+CKV$6O5\I:9O7-CQ5BF\'ES$HVJ9Y)
M%9,VIW9C>FXX0"S!)7!O5$'EA.*)4%;$(E022H+-*![C&,8QC&,8QC-0NR>[
M^5.!JQ56SU-;\:K2-@-1)VIL4G_:TXEBM<\-K(!%!Z_:=JIC-5:54Z)E#F3&
MF=QVTMA:MV<]I&Y&H4%QOU]Y0N,>&9#$8ET/9;XPR>7PUWLTI@AM7VA:SO&Z
MFCRY.VR*VYVAK*)2H^"UDQ."DI$X3*4!;6O2H"HE*-4-`OTE\GT3Y?O'[RY+
M(3$+9O31"V;5W$[BT[0B`V-:$2AE-SMZ11R%V[9\QKJ+26-5G6TI?7)`VL<L
MF;DTMR\:LE44+X`>E>]__P"D6O\`_P"_$/\`_P"3L?\`K\]EC&,8QE2_G!I2
M%7#XO^U!OE2Q>TIQ#.9KN?ZF$ZP)IF\KBDY-@CBB2O5=[6-+H[L4L-)W\&G<
MHUM(\#*%[@L_8=Z#FV_!3<O:.&^-&EU0JVQS:^4N=6YQ;5Z4]$N;UZ*GH8F6
M(EJ-264I2*TB@HQ.I3*"BSR#BQE&E@,`(.ML<8QC&,8QC&,92[Y_Z1B%O>*S
ML-Q7U'&[.L>#4A,'*IERR`M<UFT/D+FMCJ9Q7UVI.:'-^C[TXMZ0"9:JC0T:
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M9`TOK8E>?LE@<R3SS5SB28D&+=8,^AMA\1TSU90/3=;W"9<7;'@LX`YGY886
M:I["L8R57K7-5*ZOF_/S4\QIA?F]EF\'ESHTNKS'7!6U`2-:`3R3H80-`G#:
M/\CAY2/_`'BX_P#]H'?_`.GG<CC&,8QF-Z]=;UOU^?R^6]ZW^[>MZWK]>MZW
MF=:]->GW?+Y[WO?[][^>_P!>_GC&,8QC&,8QC&8WK6];UOU]-_+Y;V'?[MAW
MK>OUZWK>8V'6_3U]?EKT]="%K?I_?O6];W^_U^?S^N?+6M:UZ:^FL8QC&,8Q
MC&,9C>M"UO6_7TW]V]AW]_U#O6]?NW_=],;#H7U]?IZ?(0@_7_\`+O7[ON^?
MIZ>N\QL`=_?]/3Y"$'7I_?K6]:W^_P#1\OIF?37W:_AK,XQC&,8QC&,8QC&,
MQ[0?OU]?3U]?EZ^OIZ>OT]?7Y>GU_NQO>M?7>M?KWZ?]<;WK7UWK7K]/7>M>
MN-"#OZ"UO]6];_Z9C8@A_P#$((?EO?SWK7RU]=_/?TU^G?Z,SL0=>GJ(.O7Z
M>N]:]?3Z^GK]?3,"&`.M;$,(=;^FQ"UK6_U>N_G^[,Z$'>O:T+6P_P#%K>MZ
M_C],SK>M_/6_77WZS&MZWZ^F];]/KZ;UOT_7F=[UKY[WZ:^_>8]H/IZ^NO3[
M_77I_'Z8]H.]^FA:]?N]=>OT]?I^KY_JS.,8QC&,8QC&,8QC&,8QC&,8QD3W
MS9Y-)T?<=RJ4`W5-4M5V)9JEK+'LLQQ3P&'O4L-0%CUO6P#6@:-I@BUO6P[-
M]K6];UK>N4OCWCGR>]U<6U=Y.(=Y:>D:_P"X;V4F737]0.$J$F\?$3AQ\Y<$
MC-4;_P`_ML9D1JYHW$6PTM4]E%.1I"Y60F6,;VK2K)&OG?SK=`=SRZ0<A^/?
MBVWG>E>MI]4EY]@WC,J4D;_'ML,'YYIR1*F:'MCSLU#(M0NXKA"Z11A$X)B3
MU2Q@8-/(2@;6%"F8Z2SCRR>)/FKMJLNT.H.39A&.<K%LB<`Y9L!GAY<WMV&P
M54P3F)S\U8QN9ZYBC-FUX_C9DJ<IL5EHGI6<$PDQ4E4)]?O"O/ATOPM0'E&\
M@?E4Z$?F+HJN7^".<&ZUO%@%SQ%YVOM20(V%RAOVXVI'<B:FL58+4S;MP?G`
M8D#I*=!#LH1($GLO)]8EKSF/3ONIO\IJSD/QO0#D\N4\GRKE&SXH&3](==KE
M<E<&DB9)'6'/1MHP=<)O:8PP5;%'<X<K`C7JQ&L'LO2[<#0ZU_(7Y*KNY4Y.
ML#JF].%I3#?#M`NYKM6<[A8:TL2>=26;.#X)#$\]"YQQ[-:Z^:65`U3275>@
M2QW1KS(7^,FD-PTK6M8]59#Y..U.I.9?#;-RIAY"FHRUN>>QI9U,X^-.GXE.
MKILJ?438;92<+>#6F5,@:V8FQU<H'.I_($QBIJ3DIW18E96="I5L1`;3'+N-
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M&V.M12IX>KX2!>=!9V=!'VM7"%<03H1(B79)*WD]XTM.-TF:/=!`?2=T9Y!.
MZX?X>4G/$?Z;N5%VU5_8'3\8E]_:G;PFN&0\Z\[\V2+NTB3.DK1'EO!Y#[6M
MC4S"PN`%"1*:4:!J_P!\`DQ**VN*2:]HKVW^#[61OJWJ.1M'=M`S$CH*EI5;
MKB\T4]NM4>.MEG31*6ROO@$Q:>4R"<N*B9S!X<G)V&]R?13N`I$H!\^HO7TU
M^K69QC&,8QC&,8QC&,8QC&,8QC&?B2:-L<QCK]$Y,VIGF.2=F=(\_M"T(A(W
M5D>T"AK=FU6$`@"$F7MZM2D/"$01;*.'H(@B]-ZYAV[\'^ZFCU6*>#XOY5;(
M8O%HLFRM\WSFFI:*?T]MU<.,K-FKE2K3TK]O_;22(KG\9AQ[@!B`280H5DG1
M8],K6(E>TDT_!^^2>@^O[FZ4[(0,G2$#>ZSHZF>::'5-L]@K'S36E-1\YH$S
MD2U@M4QYL)?*5QIKR>N<$K"F;3UKF6%O7'+/C"YMX2\4I7"W.W8W*$,NXR1T
M1?\`:5VSFC8HK@JE&MYLB=T18Z-JJW*=U4W>C[#9XV86WN;<XG`BBE8I`YF+
M2-K'4]<"8>*/&]5O,W`7/G!]R)J\ZLB]%-BTD+U8U1QPZ-R%\/F,NE:*1$5Y
M*UT_;F1Q:@RU6VH3].[FL)+"><2M*TL-(#H'V7X3;COWL"ENFZ`["J'FZ%\T
M5BUU_P`X\\/_``O7=YU/2CM]I*GF2V%!X<^V1$H`VSEZ<S$!K5(RH(!WBI#6
M@):EVS$+:I0>RNSQ6=GRJQZAZII[R*,M<]OM?*;WQUT;>+MRW&7."WY6[O+5
M\V:I4WU"S3UF;ZWGT+DJW;C'5:%]?D(])DB0S:-&6L(<ON(O$IT7S31_'=6>
M.KR!3/F\WEZIY34<J8[-KA+<])W@7.7E?,9#:$DI[4KBK2P6XAL%Z?)3').D
M7.HD:!>1%%0CVI&8:O\`Y0G\'>\?.^3:&YOZ$K\OIJ6T+#[096"Z9PXS:*O:
MN47).WZTI])PQ6"SQF94J)98#\<ZL["L4O!C0V(D37]LJS=K5ZO<;Q7>.Z%^
M+SB^O>3XE)4\\<H^\2*5S^RD["Y13^DB=REZT<NE9T6<99-=1XP+"BCD="VH
M7Y0@TGCY"LLLH]6IT+C-6W0VW9XPX?R)3LJ=X-T7S?Y\JP4RF6.L31/,?@3M
MT7UOU,[T_,6=,L<RVV<Z9%#9]KO+`:8B+$:C*:U0_<JS%!?0LI\'-YV0Q>3E
MVZ&[P;K2N+R6T'3],RN;M7-+7!8W5"VHMNJ5N<8W"V:TS2W^,_9"AK:FYB6.
MS0]E[;U3H\2EY7N@_A?I6+^#VM<^NOJ2X=]1K4`>B/'ZY<>,T/456<X,5;VI
M(Z,J#GF6]*I2@64A3O3K)*VIUC9U\-*1,:PXM6;I3.%.DR?6H/GMF5@P>9;P
M8>.N(/\`()=:GCPKRZ6:W9`NBX8U'G&/S3QXZB]?O[(,UZ<]J54@U%U2US9D
?QJP<?&>!*<M6`!I6;U;!^FOU:_Z9G&,8QC&,8S__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g900575.jpg
<DESCRIPTION>G900575.JPG
<TEXT>
begin 644 g900575.jpg
M_]C_X``02D9)1@`!`0$!F0&9``#__@!"1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4D5#15!43U)?1E!/7TM?0D%2+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_``!$(`3H!D`,!(@`"$0$#$0'_Q``?``$``@$$`P$`````````````"0H!
M!@<("P($!0/_Q`!J$```!0,"`P,%!@T+#PD'!0`!`@,$!0`&!P@1"2$Q$D%1
M"A,487$5&3F!D;$6&B(R67=XE:&WT=;P%R,S0E=8<G68MM48)"8T-C<X0U)3
ME[*SP=(G-51B@I*3X?$E*"E&5G:656B&E*+_Q``6`0$!`0``````````````
M`````0+_Q``F$0$``0(%!`,!`0$``````````1'P(4%A<9$Q4;'A@:'!T0+Q
M_]H`#`,!``(1`Q$`/P"_Q2E10V+Q<]/,EK*U2:,<P&C-.][:<'%J+1,]E2_;
M3BHW,-O77&^Z#:YK)9G<H+H1[,`,@[1?K>ED4[(BD!3`-!*]2M$V!DFP,JVZ
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M1,AC"(`%4<]0F0>$UJYUM:Q<NXQXL=]\/.]&#ZS;+R;=V,<Q0S+&VJ$K2TU1
M/=]M1CJ-351E+5.4UJ33YL[?',_3_K("E,;MKOXKA]E\>Z+$G`_R)IXR-H+M
M!WIRT](:5X&V;UOJR[_P2UEG4^VL3+-L3`Q5_L6D\[<.E)=@K,MU56#OTA3=
ML)$S`0Y#`,O=0K<`:X--L[PZ+'0TJ6S>4#BBW<AY.MI&8ORXOHKN/(MR1%R*
M-[BR@ZG2M61':=]/0";02(U1%JBX(@HF54IRA-30*4I0*QN'B'R^'6H@N,W-
MY0M331&W=C2^];EHN;?G99P\B]"5AVO>F4;I>FMN14@6MS+W/&2Y8"PHZ403
M=S+Z-9&>+G%)L8Y4A$:@&PQK=UP:T<:\.73.EK>N;'5W7AH<U5:K<RY^PNRM
M)6_+LOK"<\\A,>8OO%S.P+F-C%+7)Z,CE5LRBF+F7FV3ULDZ31,5P`OE=VW#
MQ#Y:SN'C5!W%O$DXANOW".2KD3U7Y"TX7-H=X7D-JS>R6*K=LTI-1N;GEQWD
MFA-Y%;3,$Y32L!.)M!JQ7MNW18HOE'SQ^+Q,0*D;=?('$YXHVG/+&-]:&6&=
MX3&",TXNM%YBBRRN+58:<,A-[XTU1T_#LF\6V%WD&"NRS<NHR&0LIW,1D2)@
M<6L)GL/TRBT2$+Q=*B:X2^H2Q\I:19&ZW^JF3U/Y-MJ=G+JU(WS+Q\I"MK0O
MV[(U*_7]JV?:3V.9NX#%<!`/6R.-&Z"#PDI:[9O*E>.W3U8"ZFT]\9?AKZJ,
MP6Q@/`^IZW;^RW>9)M2V;-;6ED.'?2Y+=C7,Q-&;.KAM.*CMF$:S<.E?./";
MD3$J?;.)2F"3^E`'<-PZ#S"E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E
M`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E!Z<A'L99B\C)-FUD8V0;+LG[
M!\@DZ9O6;E,R+AJZ;+%.BNW72.=)9%4ATU$S&(<IBB(#2>RACK)MR\0S7YBO
MAA<,#01),<&N[+E<_7#JP@K<]+O2]9&U324:?$UHKPSHULVO)195"I/F*#.`
MF)5-PJI(-W:*B1;MM48N(M96@#)/&/D\<?1!Q'&F8L]Y4PYISSCF/3KE1YCO
M"=@7C?$2"=A8UE96)B`]T9!!BJ5^]MJ4DE#-T7IW39+L*J"+[/FBR;P;-5<%
MK!T*XZRG"X%MW3@XCIFZ[!N7&-DQ4=&V%&W?9,NI"7*]LD\.Q813ZWWTH@NH
MW<LR+`!RG25<KJ%[8RH561X&?#WT8V(N?4]I+S)K?0@\87IG#`LMI_SQE_W6
ML6W[RA)Q:W;P?/\`'<0W;0*4B=\@>4B'Y$RJF4<&>*`=?<]6;J!2E*#A;K%T
M36IK'B+283>8=0N%I2SG,J=A<NGO+-PXNF9!A.-2,Y6&GSPRH-IJ,<MR;)(O
M4%#LU3'6:J)*&$:X47?P$]!D_AS`F&[5CLLXE8Z>8J^[=M&^<590N&T<E3]L
M94%4<H6[?EYLUAE;NB[[])=FFT)154IE72R[<$E!*8)J:4$+.7^`KH'RJRQ;
M%1L-E3$4'C3"\7IR=PF&\HW+8<?DO!$3)+2R&,LIIQCDI[S@U7SIX==:2,=\
M=)Z[1!P5-<Q0Y.W;PRM+N0+]>7C?5O3-SPS33--:2K`QL^F79<=XGP[=<`VM
M:\V&.;=3."-O7!=]NLF<).7,B899:*:IL47"*!E2'D)I0_7"'1)H%PIH.LZ]
M;1Q-(7_<ZN09N'EKINC*%UNKTNF09VM;3&S+*ML9-XFF"=N67:,:RMVWHXJ7
M9:QZ'95475444-'1K:M^!@>-'P3R0D)#0X.&&O$7`Q45'QQG'9PS;XD!<[)L
M@=8I!$1(10QB)F,8Q"E,<XFGUJ"'7A\-+P2?XOUY_B8MZ@G<)]87^"7Y@KRK
MQ)]87^"7Y@KRH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4
MH%*4H%*4H%>)SD3(910Y4TR%$QSG,!2$*4-S&,8P@4I0`!$1$0``YB->5?)G
MX6.N2#F;>EVWID5.Q;^(DFGGEVWI+&1:JM':'I#91)PAYU!8Y//(*IK)=KMI
M'*<I3`&AHS,^+IG)-XXAC;TAW61\?VW;5X7E:Q#K$>P%M7@=X2V9A\NHB1B#
M.9,P>`T,DZ4,/HRHG*0``1\6V:L6/,IR^%&UZ1"N48&RH_(LO9X&<%D&%DRL
MC[DQUQKK'0*P"/>2(@T1,5V90RNX"F`<Z@0QIPF,OP&IF#S!=Z9I;%U\W]=-
ML9&PT7,%ZA'V5A^W$E"XLE8^ZTYHMQWTY!83+.+3G'!V$;Z49)'S14QW]FTN
M$OEMAJH99VGEE7.-IC+TI:$UA1/+5Y@P@=/<<DJ\M&X6MX%F!N6<?M9QJUD3
MV%(.!B4C.SMP3*B@4XA8W`0$`$!`0$-P$.8"`]!`>\!I7Y((IMT4FZ0"5)!)
M-%,HB)A*FD0"$#M&$1'8I0#<1$1ZB(B(C7ZT"E*4"J;FIOAU.==NO[60\X?N
MN?*6`[JP7GC#6:]2^/'N.U);&C;5;:-D%7LB],?SQ'*"DC?+2V&S!-ZV70]#
M8*^C%*LJ"JG8N1_I^FU4J.(4?2''\7>4Q?INUK:[M*&J;5/=F*L(ZB'>F.W8
M22P`KD.]6(L+,)D&?FVRJ,?D*2@3(IN6$45P_1:D1=J&;=E42MB?YYP3>\!Z
M-T]PV@.WHS3]>62K](URCE4N8KIS'#,[?R?*YY-=+D<I.+MB6:BZ31RI<(+J
M-$RNG8>B&(;T@QC'`LS51+\%BT])U@Z'X*P='UP9$NW']BY*RA9UZ7;EMH+'
M)5T9?MVYW$=DJ=NYJ8I/,OY*X45W*2:12MRMU"^8*`";>6B@4I2@4I2@4I2@
M5!#KP^&EX)/\7Z\_Q,6]4[U00Z\/AI>"3_%^O/\`$Q;U!.X3ZPO\$OS!7E7B
M3ZPO\$OS!7E0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0
M*4I0*4I0*QN`=1`/CK-03<3.W./-+YLMIQPP[WTR6UA$EC-TKF9YF)$J7$M?
M/IZHN5V@/H"36"/]`\T1/L.B)@H"FZ1C"4Q`G8W#Q#Y0IN'B'RA5(G55E[RL
M31YI[RGJ7RYEG1"..,06TM=EVA;,+;$M/#%-W#=LH$5&+VXP(^==MP02MP=)
MF.7M"`CM6X6*)'RNG,F,<?Y9M#+.A(+6R39UO7Q;H2<?;361"%N:,;2\:#]L
MC:[E)N[!JY3*X0(X6!%7MI><,)1H+FNX#T$!I407"P@N,/#&S,/%9NW`5T`X
M-9?ZBX81)&I@R*F2<"]?=\(^%B1_7S&@QC_/F<CNFZ$@IE'LU+[0*4I0?,FI
MF)MR(E)^?DF4-!PD>\EIB7DG*+./C(R/;J.GT@^=KF(BV:-&R2B[A=4Y4TDB
M&.<P%`1JD#J?Q9B+4UJ,U`ZJ>'?Q=='F++#MK41B75/GRR\V0S>996)J!Q`W
M):5L9)MV=:O47$C;DJU:(-G,:"!@DGS<K9!P8IR;VLN)5C#)>:M`FKO$F'8U
MQ,Y.R/@;(-FV7$M7B+!Q)S4_"K1Z,>B[<&(@@=XDLL@!E3E3'MB0P@!JH;-N
M%9Q&G]T:*IFZ."'@Z6MO2MB_Z`[\LJ-OQC:\7J;F$11=Q%X9G]Q)MHM<<C%R
MJ7NB9O)+.BO%%W#5R91J1!(I)VK%Q^S\1,9K?W`1@M/\+H)8+Z?\VSFI%A/9
M=RK<>2\YS=D2&/R9'R]-7$>0OZ>M^`DB^DA:2DNY4+;3XRK@7L7YE8[A4PCV
M9JJX$<-9WF9?2A9+3.NE3'VC*^(A[+Q)<$8M"/)8]M0;-<B<.O#(QICMD"/6
M^YUDBCN50O/??>N>]%*4I0*5LYFG4-@G3C;C2[L^9?QQARV)!^2*83N2;P@[
M0C7\DH0RA&#)S-/&A';L4RF4%NW%10I`$YB@4-ZTO>6KS2UCO'-GY?OK4/AF
MT<6Y!49HV+D"X<BVM%6E=ZT@7MLTK;G'<DFQF3KDW,!6"RQB``^=`FP[!R+I
M7'7(^KO2SA]K8K[*6HC"^/V63A0#';N[<CVI"-KW*Y.DF@K:ZSV323FFZBBR
M297+`RS?MJ$+YWM&VK4S/4/@F0RNI@IAE_'#W,J4&G<JF,&MWPB][E@54$72
M<K]#R3PT@+,[5P@[!4J([M%DW0!Y@Y5!#>2H(=>'PTO!)_B_7G^)BWJF:QME
MO&.88N;F\5WW:^08:W+LG[%G):TI=I-QL;>%JN_0+DMUP^8J*M@E81\!F<DU
M(J<S5R4Z"HE4(8H0RZ\/AI>"3_%^O/\`$Q;U!.X3ZPO\$OS!7E7B3ZPO\$OS
M!7E0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4$0`-Q$`#Q'D%:4
M@+[LNZY6ZX*VKKM^?FK%ED8&\XJ(EF4A(6K-N624BWB;@:-EE%HF168+H/4F
M;TB*YVJR2Y2"DH0PAJNE*4"E*4"N`O$IU^63PT]+-P:IK_L"\<F6[`7?8EFG
MM.PW$.VN-[(7]<"%N1:K52<<-F`IH/7"0KD,J"IR&`$@$U<^JKD^5/\`P25Z
M]0VU":7N@B`_WWX/PH.-1O*KK&*8Q3<-K6J!BF$I@$^-@$#!U`?_`&S7B/E6
M-B!UX;>M7N_;XW[QV_\`UG_TZCRJ!9XJIZ6ZV44#]?4VW54$`Y[=>UZ^G7NK
MUO.*_P"<4YC]5^N*!\GU0\PY>K??8=Z&-Q[WN,9"^)5Y01%:W=#6H[2M9G#]
MU<6E=&:+`=6C"7)<_P!`QH&'?.'K-R1Y*)QL@Y?J-2%;'`R;9+SIA,40,`;C
M6^VF7RERUL':=\'X;F>'5K'E9?%V*K&L*4E(U3'ON=(R%K6\QAW;UCZ3*(.`
M:.5VIUFY5T4UBI&*50O;*81A][:FW[(IR'N45$=N_O#?U#S]7C6154Y;J*]=
M@V44'OY?MN@[=/R4+N_CO/G]-86)]C;UJ?\`B8V_IFOQ<>5<8]:-W+MSPX-:
M2#9F@LZ=+J*8V!-!NW2,LNLH;W9V`B21#*'']J4HB-0)><4WW%54!';_`!JG
M=M_UO4'=6F[T.?Z#+RW45$1M&Y0_9%.>\,]V#Z[;NY[]=O#E1,=./>]QCV'6
MB'57;.N'2CA#5C9EKS]EVOG"SPO&%M>Z5XYS<$,S-*2,6#647B5EXY1P*D:H
MMVFBRB7FU"!VNT`A7*FH<_)]_@9>'U]HU+^=UTU,917S)F:A[<BG\[<$K&P<
M+%-E'LG+S#YM&Q<<T1#M*NGS]XHBU:-T@YJ++JD3(',Q@K9%WJITVILW*[;4
M#@]=5)HY<(I!E6QS>=,DW46(4`+.;F`XD`-B[B(#]2`B(5^.K5M@YUIDSP74
MO'-9;`#?%=YR.8(UX#XS9YC^*AG,G<B*A8Q1)^8!8-%!*#10BXG`H)F`1WJA
MK;V*,-Y:L]UJ-TU^3!)Y3T5F;2LU:>2)?/ET6]D^_;%A5795[WMVS%Y07RC)
M\R9G?QK1%BZ.LD)"HG=&[9J"XYPG-=5T<0[2PXU`W;:=LV=(%RUE*P&D;:;]
MY)0[N(L6YW,'%S"3MZ8ZJBDJT0(\4$AA0[2FR`F3[)AD0O.\+<Q]:-T7W=\H
MU@[4LVWYBZ;DF'JA$6D9!P,>XDY1^X44,4A$FK)LLJ83&#?L]D!W$`J/7A%S
M.C*Z-"6(+NT&X^3Q7I_NM&4G&./A+(A(6E>#AT"5Z6_-&E'#ETI-0\V@M'R"
MGGCHG6;B9("`8Q"[:\4#B.:4]*D0OITU-8OU,9`A=06+KNCGIL'X-N3*,,2V
M)E)Y:TNRE)B'52;1<QV'*B[5DJ(K"F";G;S8<P]O+G'`X=.#WFF=CD/,KB+<
M:L+7AKWQ21"WW;L4[*N.12B+<NZ\2D5*>U+?N"26*SB)"0(*;M8I^R`$`#C+
M0W<(.VZ#MJLFX;.44G#==(P'2606(55%5,Y1$ITU$SE.0P"(&*8!#D-=;K9S
M?ADQ^'<XX?D;XXH&2K[U$,\18IC<SY8T*7M<UQXKT_XTO6.N&'P_C@Z\QYZW
M59$6K.->W-%+-54DD4UTD1.)BCV+6-&,3%XYL&-@2RA8./LNUF,,6<362FBQ
M;2#8H1Y9=)P8[A*3!HFD#])<QE4W7G2*")P&A'2+\H+_`"@[4II'TX:<+)=Y
MYP-CK4'FS)<S<6+=+UK9/B&3ZS+8O:]8<(*:R!=<G*;Q]NVK:C%ZWD)J5[)I
M$$TR(QXI**&73KU)VCI#TS*<,BP=0F7L4ZA=%&.N'AKMLZ,R>9H2X\)R.L*[
MCK75/V[98.BKMT;J8H2DA;EB`Y!.4!!NS!F9N^<)')?YN"T+4NQ)!&Z;9M^Y
M$6QCF;)3\+&3*:!E"@50R*<DU=$2$Y0`IQ3`HF```PB'*O@/L2XLDX9C;DEC
M6P)"WXR0"6C8-]9MMNH>/E"F*<LDRC%XP[%H_*<A3@\003<=HI1%01`*),7E
MWOZHZU#$C''V,\"9(MGB*0D:W>7IP-[=M_A[1>7K5=N))A/RM\7ZNO9F,4'4
M<1U'9-7F'=M.!09[3@B=D"#D6Y@14YH:@-)V6<`S&&,FX&RW=\YK'NS1\XU8
MYGQFC9#17(NFK']L:0XG%V7+D=9-!=[<+6YKSM@2V5@S'4Q;Q/,Y*>JW$+P4
M+>,@>_;<&.<?76K"KW18MG7(O;:R;BW5I^V(.85@7"(@*3B%4D6#DT6LD)2B
MFHR%`Q!*42B`E`0^BE:%JHS4K<:5MP*=PSK!O%34Z6(8!,2\6T`P-8V2D_1_
M37T>V`QO,,7*ZK5'M&%-(HF$1']_*7<H.N`=J9A,Q:/K@Q1CS"]@XYMG2^K9
MED6@OC>_7E\6;?P7ICB(R6HYFKPD8MJ[/E5C,SSJ,S.5<C\[&^%9!4QP[7HB
M6P^?;RU&W9QH^#4.>\'6-AY-DPUSA;2MH9G+E9:>.IAN%!^1^U"R+0-!I,DB
MME$%Q-(%>J.%D0\R+81-8\MBS[2LF/4B;-M>W;2BE7CF05C+9A(R!CU'[Q05
M7CU1E%-6C8[MTJ(J.7)DA674$3JG.;G4(FO#X:7@D_Q?KS_$Q;U%3N$^L+_!
M+\P5Y5XD^L+_``2_,%>5`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E
M!MOF"T"7[C"^;2.>Y"&F;>?I-_H0N!6U+G.];$!\P1A+C1(H>'?KO6K=%%\*
M:B:7G!\\FHD)R&@ET(Z%M6>,-2Z.3L\7!E!]9V6W4CFBX(Z/R*BV&SLEVP]6
MMZV+=S,+=B0V5I"0LY*.21E6AF+,GF!!=$2$*F%B*FP>'J^+PH%*4H%*4H%5
MR?*H/@D;V^Z$TO?C?@ZL;57)\J@^"1O;[H32]^-^#H*O;S^VW.VX?KZ@<^X1
M\>7/OVZ;CMRY\OP'OW#?IR`/6/R_[NO?7L/=P>.A'J#A0?;RVY[<@Z_(&_CM
MZH\@YAL(CL&W/P[O^S\7+D/.@R.^P@/R!RWZ=!'KUVZ=>5-^G(`[@WY#MW=W
M+O#;OY[#M6._?H;IMN(]W+?;_P!.?B%9Y[^`;CUZB&_/V!X?%XT#GOZMP`-M
M]^X1W]7+;I\E:;O3^XV\^0[_`$(7,&^W+G#//T'_`,@"M1\Q]G/;K[0V$.?4
M-PV#Q[@#?3=Z`(V9>0#R#Z$;E$.77:%>[[CRVZ]X`'JH+K?D^_P,O#Z^T:E_
M.ZZ:F,J'/R??X&7A]?:-2_G==-3&4'$;7Q@F\-3NB_4YIZQ_+1\'>>9,-7MC
MVW)66560C&DE<D2JP2-(+(`99)FJ50Z#E1,IC$25,(%-L(5`)@W3MY2EITP1
MC+`=E9!X<B>/<0XZA<=P"LW;EX.Y3Z&[<BO<QNXE7B$@W27>ILB=MRX00035
M.EYT$2B8X&LC:D[7S!>V`\N6E@"^&&-,U7#8D_%8QOZ4;>F1]HWD[9F3AIQV
MU!!UYY!BY$%3E]&7Z`845-NR-80.'1Y3XHB"2_&!Q*<IT/,K)GQTQ4`X'1\T
MJ4QAL4HG[0&,'G.R41$>V!2CL`$G>8X_8E))Y/=CAIBKAZ1]GH9KQKGAZVS;
MFI_<%Y8D/,'L1M<TI>"[ZX8*']VV,<[)[ERJSE%=,C8&Q3=GS"BQ1$XRKZD+
MBN2R,#YDOZQK52O*_K)Q=?ESV3;YFR+E:6N>$MF2D85@BDJFIYTSB0;-P]'*
M43.`#S!0$RA:X0<'C0GDGAW:,('3YE[(<%E#(OT=7W?MTW;;;-VSB7TI>\R>
M8=^9*](FY54](45476.BB4RB@@FD0@`4)%\E,Y.1QU?C"%NX+`F'EG7*VB[Z
M,5N<MF2"T,\39W4<CS9H8EON#)RIRNOZW$K006_6A-177?6AQC<TV-B'4-(E
MXG[_`#7J>S#A?2E?N'+4:XTA8&5LK4Q<^9UX7*.FZ)M)>WG(LV5NVT4C.X'[
MA%%0B"Z:J1_.^9*;L1L>/YZ5L"QY2ZFX-+GD;0MI_<;4H=DK:>>0K)Q+H%#L
M$V!&04<)@'8+V>SMV0VV#KYVW$LG.'?JML6QLBV_PZ>+?E"\+I6A_P!533GC
MTL3J3A)!290;)W%>4Q$V(ZLY[,ODQ!T=O!F.N#Q!1YZ65`YG*?886Y+*3UO0
M4XJP<Q2LS#1DJI&/2B1Y'*2+)!V=B[((`)'+0RPMURB`"55,P"`#R`D?.?5]
MFE*44I2E`J"'7A\-+P2?XOUY_B8MZIWJ@AUX?#2\$G^+]>?XF+>H)W"?6%_@
ME^8*\J\2?6%_@E^8*\J!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E!'8!'P
M#>@5M=F^9R+;F&LKS^((!K=>5H3'%Z2N-;9?!VF5PWY'V[(.K2A79?2&G::R
M<ZDQ9KE]*;;I+&#TA'?SA:Y>IKRDIU@759J,TO6=P^,O9M=Z<;^)85R7S;.8
M+`MZ)E'J\1'S#5VWBIR)]+9E<-WP`5N9PY4(*0BH<HG`H;._31N0@';WIG4#
MTWY9XQ2/+PW"+V[?+ZSZ[U4I/:[F"L=[N8Y;4)\0#RL;S:?;X8>#A.*:8G'T
M(I`$_8+V_J/U83]C<VX@3MG[/,O:-MN/'J-XUGE),OJ3N32)'Z`]/SG4+:-D
M0V1KAQR2)D`D8RS;A\Y[CS:STV4PBQ;O?-G!-,CTRX"'U:9=PKFY]-&Y"$=@
MX3.H#?;?GGG%!0V'IL(QFPCX@`[@.X#S`:BTM+C`9EMSBR9>XD*O#CS&ZMK)
MFG?'V$6N+RY=QVC<$0_LH[DSBX%[@.E[F.6<AY\"HL4X\BJ`%[1E3=K<=8]H
MXC33'K'+.'>>W69Z],T@+'7YY5VJ^8I/.&1A!!FJ]9INURM`$R+0[E(KI4H!
MEPX@)$!4,!@(?L"`'\VIV>P:X?:#N=?VG;#ZZ&*<9<SVWH1W<,:CS2CYUS&-
M5I=DE]6I^MM)`[AN3ZL_U*8?5&^N&IT/E1V0@WWX3.H'EU[.>,4F#GX"6+$!
M'Q`.8!S'E3Z:.R%T]Z9U!;].>=\5`'=W^Y>VW/D/0>>W0=IC.7$4\;QS"Q3*
M?NMY+<]*KR\/[CQS.MW5596F"Y-">4].SB^K4R%<T1?=XY5L>[8HQ\>PS69?
MQ81%NQJ3Q1=XB\1335%RD5`3`H*:Q`/YNPT',`'QJ*57)\J@^"1O;[H32]^-
M^#JQM5<GRJ#X)&]ONA-+WXWX.@J^O?[<=^'GU.7CT[O9W=XC7J#N/Q[[AMTY
M;>WESY]_=W`/LO!'TQR(@/[.?IN/?X;[^K<0Z\]]NOK#L/+J`#_Z`.X"([B`
MAR]E!D`#<>8CW#T^</\`=MS[M^=![P^+J&^P@'3U\N@]>X>ZL=`V`?#;</JM
MM^NW@',`#;V5D1#U[[@`;"/40Y;@.WR=![_4`>7JVW[MP`.X?;[?7XAOIJ\_
M[C+R';K:-R[B([<_<9[R]6W3;?;H`CO6I>\1'PY=/'GU^(/FVWK3=Y_W&7E_
M]HW,'+H`>XSW8-]N7/J`CL'/NVV"ZUY/O\#+P^OM&I?SNNFIC*AS\GW^!EX?
M7VC4OYW734QE`JKYGWB(<7C*VO?53I9T'8NTK6?96D\MCQT_*ZE9XT?=5^*7
MK$EFF%WV_&GN.#7"U7)#JLF3YLU78G6:*IG=BZ$4PL"ZH<US>G?!.0LQVYB#
M(&>9FR(E*28XHQ<BQ<7S=ZBCQNU,Q@DI)PV9F7137.[5\\L4`004$`$=@JF3
MKYP;ILS]JMO?/F1^$#Q>,@9'RA;=C3ERW?BO-3*R[:V<V\T51MAK#-7YQ8#;
M0_UB]8IN561)`BZS<A?."8P6[-",WJ\N'3W!2NMY+$2&>5YB:+,(X2<^F6*2
M(3<$+#^B.0DI8BCPR/;%WV'AP*?LAV2]*W6U.W';EH:<<\W3>$`\NJU+>P_D
M>8N2V8\'GIMPPD?:$NXDX1L9@FJ\34E&A%6/GFQ#+(E7,L0HBGM7!#@PV%8>
M.-$]O6SCG3[J3TRVVC>EV.4\6:J;N->V46#IRLT,XDCSHN'`*P<B(%4C$2"D
M1$2+E!(NXB/-W4#J1TUZ?H2/3U(Y:QOC"!O@LG"QR>1IYA#,+D3*U\W+1R";
M\P)OB`S<]AXCV3%\TN!5`V.`"%%[2/K:N+1+IHU)Y@M[2CPW<2/HK"NES4UI
MWM?&]NP\W<DG9^9LO.+#<V/>&2'4S-SU[9:1MIHLX,VC56;N/?(]I6,(;SB1
M;_-A7(I>5C69=RK0T>I=-J6]<:C`P'`S(\W$,Y([0P*%*H`MSN3(CVRE/]1]
M44#;@%$?7;IWX!6CNTIO65I(F,6:A<]0V6[!E;.TYRF?G-Q8I6=W1D*/2=GA
M\8-&RK7T&TSR;F<A(Q`Z;.'42,X2*)2^;&]Q84TI<=C69<*S5NQ5GK4MZ959
M-/[4:*2<0S>G:MN11]';F6%)'<H?K1"\@Z5<+^/?O*1%,Z[W?-=64I2HI2E*
M!4$.O#X:7@D_Q?KS_$Q;U3O5!#KP^&EX)/\`%^O/\3%O4$[A/K"_P2_,%>5>
M)/K"_P`$OS!7E0*4I0*4I0*4I0*4I0*4I0*5Q8R3K@T@8=O*4Q[E34IAC'M\
MPJ;!:6M.[K^@8.>CDI-J1]'*/(U\[2<H$>LU".6QCD`JJ)RJ%$2CO6AO?+>'
M[^_)TY_Z5;4_I"@YP4K@_P"^6\/W]^1IS_TJVK_2%<A<09ZPOJ`@Y"YL)91L
M?*MO1,F:&DYFQ+BCKCCF$L1!-R:.=.XY99)%X5NLDL*!S`<$E"'V[)@&@W;I
M2E`K!N@^P?FK-8-T'V#\U!UL>J/;WUSBQ;_OEX'?U`%@P(_'N/+\-:9'U\AY
M[\NNP#SZ;B``.X?)ZZU)JD^%<XL(]P:EX#8/$?H"@?7W!X<PZ^JM.!L',=^?
MCN/R;\^[X]@H/'L[AW;#MMU';;D'A\8CML/=0=OJ>G0`Z`(#T#;?GMZQ^?:O
M(?RCUVZ\PW#EU'E\O3I6!`>6_+???;U^(`',>X.NP]1&@QOR'EXAMUV$._UA
MS#EW;<NE9Y\@$.7+EOSZ=_<(;\N??ZJSZ@[NG/J(`'?^#8>H!X4WW[N0#MUY
M#W>P>?R=V_2@D/X/GPJNE[EM_P`FNJ'XO[`;>#;E[/D$*O9%Z![`^:J)G![^
M%4TO;=/U-M46W_X%;W3U;[U>S+T#V!\U!FJY/E4'P2-[?=":7OQOP=6-JKD^
M50?!(WM]T)I>_&_!T%7U[N#QT'4?/J>KI^@!\>]>J/+??OYAL7IW[CX[#S\?
MEKVGO)XZWY[+J#RWZ[@'3<1Z"/?7J>K?D'/N#;;KW>O??8.X0YCO0`VY;;F'
M8>?,-PWVZ_-[*<Q'\(@'JY``"',1#KX`.P<JR//GW==]]]_5W[;]^P<^G.GQ
M`&VVV_(!W#V!OL/=RYAW4#J/=MRWW]NVP`/+J&WR#W5IN\]_H,O/ER^A*Y@W
MWY;>XS[<=O$/E'QK4FVWKWVVWWWW#G[>G=RZ;=XUIN\P_L,O(>_Z$;EY["`_
M\RO.\=_RATWZB`76O)]_@9>'U]HU+^=UTU,94.?D^_P,O#Z^T:E_.ZZ:F,H'
MZ?IM4,.;N-WIGP[KHQ_H.96!FG)5^7/E7'F%KWR/8]JH+XBQ%D?*0$5LRU+W
MNY\];)FGI%LJB\6BHM)T]:ME4U%4]A&IGJH?Z],8X@RIQ:<NX9TV<2NW]%.<
MYG4?A#-$_AS.V*'URV+>^J2T+6;-K#R!C2](N68I-'KB,(UC7\+.`";I\W)Z
M&<"@8HV/G6G;,OGVN/:2-6^+=9N,IG*6)BW`WA;=R1D#%,Y'73%FAYR+O#&U
MP.+<N-DZ8'44.1(KYN8[181[+AN8BI0`!V#\]3NB72AK.C+8A]4F",?9NC;+
M>O9&U6M]PQ)9.">R*22#YQ'=HY#('=I(I)K["(*%3(!@^I"H9.!/JCT'V<TO
M?APX.SG?N9-0F-[ER7D?+F2[^LQ2T(G.&1G5VJH9<NO&3L[YXC<$'$7098HI
M-CJ.&4>=)9XH8Q]PL@U!$^TX&'"/8NVCYIH)T^MW;%VU>M5TK0(11%TS<)NF
MRQ#%<`(&27134+SVW*&^X5*K'L&44P91<:V191T:T;,&#-N0$T&C-FB1NU;(
MD#D1)!!,B290Y%(4`[J]NE!M7F/..'M/5D2.2<XY,LG%%AQ(E*_NN_+BCK<A
MD53[BFW(ZD5T0<NU0`129M2K.E0*84TC`4:VUROK3TG8+QY8N6<Q:@\5XVQS
MDXL:?'MW7A=<?"Q-Y$EV2,E'J6Z=T<BTFFO'N$'HJ-D3D0;+)K.#)$.4PQ6>
M4<-])JW#?RM_5)0UNS=\+6Q?D7I@;S<3,3CY+.4K9<HA$J6U'Q22Y`G_`'.*
MY*S>O&YR,A$543I*B!A@NR)G?3U%W-PH]1&?UT+KT@>]#YTT]1DI<EDR%T6L
MPU31F,[:@)BT2P,E&/21=^NC,7]O1[]9DW<+O!(S1=!Z2!BO?KE)KEIYQXW7
M"\IZ]=%^$8_&TMEG4_A.PHS,+9![B]_<-_P31I?3!RHFDC)6VN5THG(Q9E54
MTQDTC>@$4,)#N"F*8`UI'ZKM-LMFL^G*,S;CE]G(D"G<XXP:W*P6NL\&JQ0E
M$WZ3$AS%7*>+=-Y0J"*RCD8Q9.0!'T,P+5UU&&V\+I@P7E*T]>UHRB$EJ%X(
M-LV!H;AK^QS,7:_979*7CD)13&%F-7L*]<VID)U)2D"Y.Q:D9RJPJ-')5S>:
M3*',O41HJR+B!;$[K3_D7*4IJZFM%Z^K'4?BM"UD`D=/%IVWI+C,4Y/7C\I,
MBN+Z;9,R];2@8SQ%CU9(A8>ZW<K=A'!30;=L<3-,J_\`;TC/"LQ>\Q)F[$V>
M8&:NG#E^V]D:V[>O"YK`EYZUW9I"';7A9L@>)NB"2D2ID:O74))IJ,'RC%5R
MU3=I*H`N91)0I8==>`#[])P23;#V?0->8;B`@&X88MX1#<0VW`-A$.NP@/00
MKY_`?U*.-1VCF[,1V_CVP,365IW0LK%&-[JPM(3TI;$G'75BJ%NYT*KNZHN/
M?.,K8_FYQS$Y/=*E=HO[X1>/UEO2'+A(O!*3T<9DTI<:CA&*Y8UUZA]9GT:Q
MNM9.$0SLUM5!/'Q8C#[!9V>V3VRW9@8TZ#]%&2*]14$I(UH9NJ3MK)B7:\:2
MML$^L+_!+\P5G</7\@_DKQ+]:3U@`?\`^:Z=C/O'&XM5J9US3;$%KRSVPA+=
MRUDJ#AV*-P,@19143>LXPCF:)?<[ZE%HS;HMT2!R*DD0NX[;T,Z;_5/Z[B@Q
MRE`3&$"E`-Q,;ZDH>TQM@#XQ"OR])0_SR7_BI?\`'72>Y5XQ_%!S;8DYC/)^
MMS/-UV/<A69)R`<7<M'H2";!ZA(-4U7,0DP?%3([;(JF32=)D6`GFU@42,8A
MN%W]4%GG]VS+G^DJ]/Z;H.^3])0_SR7_`(J7_'60<("(`"J8B([``*)B(CX`
M`&$1'U``C70U_P!4%GG]VS+G^DF]/Z;KZ\!J@U(6M.0URV_GO,47.V_*,)J'
MDF^2KQ\^PDXQRF\9.TO.3)TQ.@X2(<"J$.F<`$BA#$,8HAWP6X>OY!_)6=]_
M'XP$/GKI>O?Y>,!^_P#<_P#_`.0LOZ.JWIY)+Q!M:.M7,^L2%U4:C,D9OB+%
MQCC.4M*-O>30?-(*2E[KFFLD^8D1:H"FX=MFR+=4PF,`I)@4"AUH+R-*4H(A
M.+=Q5#<+NU<`33/`%R:A9W/^2IS&MO6K;5VP]HO&<C#6R:Y?23O)I!9JN5P@
MDJB5(11`@IF.=8-RE/#N/E1F8MQ*/"DS%OS`0'.6,_6`A^Q^H:UIY4Y^Q<+K
MI_A;WOU^U')?H%0&"!0$0$"AL8VW3G]48-O8'+\%$SF-(^Z_QN5JGU;Z(]:6
M;+HU#ZC^`UF:_LMWFV@VEQ7.75TC;Y'Z%NQ+:#ARA$P%P1\4V%M&-&[83MVB
M1E_-%46$Y_JJC:U:6-H\R=C".MS3!P6<K:>\CM\@67-R%]2FJ)6^&SRQHB3]
M(O"SRPK^YET$G%TQN\>A+E*"T4<?243=LH5S:[)0Y;%[@Y@'7N]H\NG7IZJ;
M``?6@([^`!XCRW\/TZ45MM&+\+M".CT'_D]^9GC])FU1>NRZT9(A73Q-`A'+
M@I`NH@$!=8IU0(!2@7M;=D-MJD]T4<8K&/#QL&Z,9Z1^"MF+%UEWG=8WM<D4
M.IBV;H-)7+[E,H7W1,]NA_*.T1",CV;;S""R:&R)3^;%0PF'@7L'+H&VVX;;
MCR[AV\?9S[NM!V#N+O\`$&_C[.>_CTH)MW_E366(Q@_E'W"JS`W81C%Y)OW)
MLX8V,1NQCVRKQXX,5-$YS$0;(JJF*F0YS%(($*8P@4;,&AS5"QUJ:2,`ZJXR
MTWMBQ^=<=Q&06=HR$BA+/8!"64<D3CW,BV210>*)@W[0K)HI%,!P`4R"`E#K
MN<A;?J>9"Y%#:P;V[N0[6O*;=/4.X!W"'J&KPG`<^!YX>?W-=E_[:2H);JP;
MH/L'YJS6#=!]@_-0=;%JC^%<XL'7GJ8@0$`_^P8'8=_5W_[JTUL/CS$=_P#<
M(!N(#T]6X!OL([UJ75'\*YQ8NF_]4O;_`';_`/R%`^'K^*M-;[AT#O$.@[C\
M7B(_[NHA0-P\-PV`.??S[M_#?GOW[=*P8=_#<!$.8==O7SZ;]>0>(5G;U;]1
M_A#X"&WCOL'4-N?6FX`(;=_X!#U!WCOMXAWT#?GSV'?D&X"'AU#O#_>(AR#>
M@<M^73?;F`COMW^L?5_ZY'IXB.W+IOL/@.^W_6W[@Y[5C?<#;AS'D.WB&_+O
MY]-A[]P`.E!(?P>]_?5=+PCWXUU0CMMT#Z`;>Y;]_/?]!J]F7H'L#YJHF<'O
MX532]L&W_)KJAY^.U@V\`^W;;KWU>S+T#V!\U!FJY/E4'P2-[?=":7OQOP=6
M-JKD^50?!(WM]T)I>_&_!T%7UY_;CK?KY]0!'OZ[]V^W+U_AKU=N>X=.FW3I
MORY[\N7=MRY]W/V'H_UVYY;;+J#R#</#;<.7/<>?=WUZW7;U;FY<^>_(-PY<
MQW^;UT&.[M<A#OWW$=M^@<@#\`;?AKRY#N&_/U\^H#R#GMRWY[>P:#W["&_,
M=@#F(AS\?EY<ZP`^S<>H=^X<@#U`/KZ<]^O('/Q[N6W?R'8=M]@Z=^X#W;#O
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M4!(AX`J;A%N\;>>3=`)S)58FEZI,5I6*_F$W]OPX!N@G4(WS!@'4Q)ZIM,^I
M'2'IOQ]J.M;#%YX.BI:.N*XLE:B+@C9?*45=?NNR;R"C2VGK1):/6=+BW4!T
M!6K5(Y3JJ7*JC]X9I,KIZ5[;3S1@?`VG*^PN"XCO\::;Y)G*8N9MSN4O1)*-
M<LC&2&0?I%`TB`F,;SJ9>>P!4@512E*4'SI&(BI<B24K&Q\FFB<544Y!DV>D
M24$HE%1,CE)4J9Q*(E$Y``PE$0WV':OG.K0M1\Q;1CVV;>>1K-R#UI'NH2,<
M,FSPIP4*[;M%FIVZ#DJ@`<%TDR*@<`-V^USK45*#X<E;%MS)X]27M^$E5(E4
MCB+/)1,>^/&KI[>;78&=-U19K$V^H4;"D<O[40KV$X.%1D'TLC$QB4K)H(M9
M*238-"2$@V;@)6[=\]!$'+M!`IC`BBX5422`P@0A0$=_J4H/F1,)#0+4S*#B
M8R&9G76<F:13!I'-C.7!Q47<&09HHI"NNH(G65$@J*G$3',81WJ#37A\-+P2
M?XOUY_B8MZIWJ@AUX?#2\$G^+]>?XF+>H)VR_6I^P/\`4&NA^U0?X2FH/[>&
M6OQ@7%7?`E^M3]@?Z@UT/VJ#_"4U!_;PRU^,"XJ)G&T^?\MBZ4I12E*4"KS_
M`)$%_?ZUX?:BQ#_/*XJHP5>?\B"_O]:\/M18A_GE<5!V+-*4H*F'E3G[%PNO
MNM[W_%')5`8.VX@.V^YM@$-_VP[_`*;]U3Y^5.?L7"Z^ZWO?\4<EM4!AOV^X
MCN!S"(].?:'IR[QY[;<AZ[43.=H\R"'=L`AMTZ<^@?-W].0@/+DY[AN._P#V
M>G7GOW>'Z;TY[].F_/U#T\>O?MMMMZ^8>O+F/AT^+<>6VW/;KOSHK'X!'F/+
MD`<]QW'?;OVW\>8=:#W>/0!#GSY;^`=P[[[>KOK._KY!N`\MNG+IX=W+OVY4
MW``V[MN8CN/4>_EW[\PWW]5!I'(/][S(([`(_0#>HAL&VX?0M*@&_AR'_<%7
M@N`Y\#SP\_N:[+_VTE5'O(8[8]R$(AO_`&`WJ'/EOO;$KOS$-N0]`#>KPG`<
M^!YX>?W-=E_[:2IES^"6ZL&Z#[!^:LU@W0?8/S4'6PZH]O?7>+%M]=_5+0'R
M?0%`]?5OX<ZTYS]6X".^_>`==MOBY?$-:DU1_"N\6'ETU+P`[AMN/]@4!R'U
M=]:;V#F(!Z@VY;\P$/5SZ;]_LH,;].?7L^(=.NVP!MOR^+U;4^<0WW#?<>\0
M#V!T#IS[^=!Y;B`;".W(/5M[>7Q!X"&XA6=AWWY]P!L&W>/4!\/FZ4`=AWW`
M=N0]/7SZ<P$>O/GSZ<A"G7ERY]>H"/+N'EOTZARVH&^^^WK#D._AS'D'KV'<
M>8U@>_8/8/+EL'+;8!$`'O#PZ<QVH)#^#V(>^JZ7@\,;:HOPV%;WAR^(.G?S
M'<;V9>@>P/FJB9P>_A5=+W+;_DVU1>K_`.0;>WY!R#U<QY5>S+T#V!\U!FJY
M/E4'P2-[?=":7OQOP=6-JKD^50?!(WM]T)I>_&_!T%7U[_;CH=_\<IW#XASV
MZ]W+_?7J[?(.V^_7KOW>L1WZ;>P-J]AX/]=NAW']G4V#?J(#T$=N>_A7KAW[
M"//V"`#XAOL.P=-O;RH,#Z^0;AU#OY==N6WKWZ\O560]7X`'H&X=1V#V!W!R
MZ<Z!MML.P=?J=P'U\]_E[J;<^_\`38?4``&W<(\]M_`0P&W+?U#N'AT#U[#S
MZ^OIRK3EY_W&WB/+E:5S"/CL$,]YAR\.F_+IOO6I.7/J(^.P;]_/I[>>W/H&
M_*M-7F&UF7EMN.]HW-UY;![C/?DV[P^:@NM^3[_`R\/K[1J7\[KIJ8RH<_)]
M_@9>'U]HU+^=UTU,90*HI<3;A<9\S;J<UU:I\L8/U)Y_)BG4SIXO?%MJV'>D
MLPBLKZ(5;8:M\JX>Q!%QLFD='(T/-MY.1>^:CS&206;JI*J+G$I+EVI[4_A;
M1UA>[-06H.[0L?%-D!&C<ER#%RTSZ![K2+>*8![GPK)_(K>??.D4=T6IP)VN
MVH)"`)@H99+XA6@?6?Q%M7EY:IN*=JTQ9I]CF>.CZ0G6G"X,F8UL`EO^Y7F[
MK@9:)B(9:1/>D9+F.H[>NHYJVDVC@BA72RS8Q2B[]K1_D^F&LGX,X=-J6=D_
M$5WX36>9,R?=%C6+DB0>/\FL,:7'<1Y&Q_U0@>'44:W.E#*(M'K<!2[(M^T9
MJW,82FF]J,'A$2.FB4T;VZ\TG:A\P:H,1*W==1F65\X7#<ESWU(S(N&HRT:Y
MD[J9,);T...*)&K8Z`)(`H<$Q^J$`D^H%*4H%*4H%*4H%00Z\/AI>"3_`!?K
MS_$Q;U3O5!#KP^&EX)/\7Z\_Q,6]03ME^M3]@?Z@UT/VJ#_"4U!_;PRU^,"X
MJ[X$OUJ?L#_4&NA^U0?X2FH/[>&6OQ@7%1,XVGS_`);%TI2BE*4H%7G_`"(+
M^_UKP^U%B'^>5Q51@J\_Y$%_?ZUX?:BQ#_/*XJ#L6:4I05,/*G/V+A=?=;WO
M^*.2J`T1W$W7F8_A_E".P]0WVZ\MJGR\J<_8N%U]UO?'XHY*H##`.X]P]L0'
MOVV.(\P\`\>O=WT3.=H\_P"CO`.F^VP>S;??J'(`Y?+UYU@`'NV[O';?8.>P
M^H>H<_'EO61\.8"(>/3;H/4=@'IOUH`=1Z#N/7GL'AW<MN[?8!]E%8Y[!ZQ_
M!X[>/[;GTV'V5GKV@[^X-@]77EMS'G\?=W-^8<@[]Q]@B'+UB(_A[QIM\?(>
M0<@]H![!YCOXASH-(9!YX]R#MWV#>P@`]-PM>5WW[]^O/\-7@^`Y\#SP\_N:
M[+_VTE5'W((A^I]D(.?]P-[!ZA_L7E>_?J'+K[!YU>"X#GP//#S^YKLO_;25
M!+=6#=!]@_-6:P;H/L'YJ#K8M48![Z[Q81__`'+P&_L^@*!$/P^'S5IL!ZCX
M#L`![0V`>>V_/QV#IXUJ/5&/_P`5WBQ?7?X2T!MMXC84!T_ZVWX`K3GX._Y.
M\>?K\`V$.>^P;@$![M^_KMW@/3X]NOQ<JQS#;KOR`=QY=>\>8]=]MOCY4'GT
M]6^W@._RAX@'7U;4V[^?+8.7(!V'PV_`'+N`:#(\N?3Q$>G4=N@[]1WZ=.7J
MK`>(AR'80\?5ON/,>FW78>\`K(![0`=N_H'@`=WAW\N@\^0!^4>X1V';V<]^
M\?\`T`*"0[@]_"JZ7@V$-L;:HMM]O_H&WA[A'QJ]F7H'L#YJHF<'SX572]W_
M`/)MJB'<.G]P5O<O:&W/XO&KV9>@>P/FH,U7)\J@^"1O;[H32]^-^#JQM5<G
MRJ#X)&]ONA-+WXWX.@J]N]_3'73;SY]NSOUW`.>_7X]^>PUZ_,0Y;[#L//P]
M0@.^X]>8]_MKV'?]MN>0_LQQY<PY#O[-QV]H;[<J]?GU\-]Q]G,-N_8=]A#G
ML`;>L0``=-@Y#MZ]MM]M_6(^S;D/A3KX]1#G\>^VWL[_``\=JP(=0Z=X;;!L
M`=.6_CSW\>\-N6=@#K[=P^+GRVVZ_)OUYB(`]8[]VX<AWW$.[Y/E[JTW>8?V
M&7D(`.P6C<_AMO[C/0Z#W<A'8/DK4G/ETZCR^(?';_SZ@(!O6F[S_N+O(1V_
MN1N7;Q_YE>[;COS\?;S"@NM>3[_`R\/K[1J7\[KIJ8RH<_)]_@9>'U]HU+^=
MUTU,90<'N)9<M^67H"U?7EBV,1ELD6C@')%RV.W6B(Z=%O<L+;KQ]&2C>*E6
M;]@\>PZR7NJR2<LW!!=,TA\T<0`HQ'\/C7#PZ[QX8F',DYQU,8$G\OM\&N%\
MSY`R!$8TA\L1.26T4_4NCTR"/;3)T6:MN5[;:'3:Q2Q'!6;,42N.V)1LBR`Q
M_H3DDJ+,(]9([=V5^*`,U45P%$Z+@'(^8.FL!Q2,FKN10#=@0$#;#`;JJX-O
M`;L^XEM0FIS"6G[#Z-S7.J^D)FZ+U+C2R+HN>1,J_>E<QR\Q'Q#QY)'.L]=M
M68)^>,8ZWFB`)AHF>E+TO5K_`,GLSIEC4/PV[&R-ER;D;NE'61\J1EK7U+P$
M5;4G?%A1MU.$+0N-_&0T=%,@=.XCS`*NR,$!<]D.T!A3$:F_K9O3ZO@I;#E@
MI::'6/7>#6%OLHS'1\5NXA[8:5O1R16C-M;SB"45C3M&Y$@3_65#F[93"J8R
M@F$=Y**4I2@4I2@4ITJ#/77QNK)T<9JR%B>VM.F5-0,1IOLNT,H:QL@V`]A6
MD%IRQM?,BTCH":E&LB<7EU3*X.@D%;<AR`^1C$E7QQ!!-10@3F5!#KP^&EX)
M/\7Z\_Q,6]4V-A7M;V2K'M#(=I/2R-K7S;$'=UNORAL#R$N*,;2T8X[',2&5
M:.DC&(/U1#]H@\PJ$_7>4P\:+@DJ`0_8]`UZ%[78-MN&&+=W#?;J`&*(^`&`
M1V`0&@G:+]:G[`_U!KH?M4'^$IJ#^WAEK\8%Q5WOY3AV4^1N@?M#_P"3[/'E
M71`ZH0$NI74*4P"!BYQRV`@(;"`AD&X@$!`>@@/(0HF<;3Y_RV*I2E%*4I0*
MO/\`D07]_K7A]J+$/\\KBJC!5Z#R(,!#.^O$^QNP7$>'RF,`"(`8]Y7()2B(
M`/,P%,(!U$"F$.@T'8L4KQ[0>!O^X?\`X:=H/`W_`'#_`/#05,O*G-_-<+K;
M]]O>_7[4<E4!NVPF#P,<-M]_VP@&^P<^77N[]N\)\O*FBF41X778(<__`+W-
M[%V`IM^T;$4D(!T`=Q`!$/$"CX#M`D+=83&#S"P<S;?K1]]NV.P[[#U'F`;C
MZ]QHF<[1YE^'3J'(._<1WY;"(]`Z!SW^+?>@C^V^IZ;`//QY;;=1VZ\OC[J]
MCT=Q_P!'5';I^MG'G_W>6W?ZAK`MU_\`,K`._P#FS\N7>`A[?CV[Z*_#<>?M
M`1]0?EZ^("`<NH`.-]N8;=>>XCOOMSZ;@`\A#I[/7^XH.-@_K9;F(AL*)^7A
MR[/7P#V^VGH[@``?,+\M^0)GVY#OU[._3F'_`%?CH-%Y"';'F0AY[_0!>O3?
M;^Y>4Z;@(?./6KP?`<^!YX>?W-=E_P"VDJI!Y!;KACW(6Z"A=K!O8.:9]]@M
M>5YB.W3;N'Y:N^<![ZG@]</(#`8!'3590_6F'D962$!Y!T$!`0\0$!Z"%!+=
M6#=!]@_-6.T'@;_N'_X:P8X=DW(W0?VA_#^#0=;'JCY\5WBP@'7^J7@!W_\`
MX%`[<]^X>>VWY*TYN/JV`=AZ]-PV#\O=\6]:HU1(K#Q7.+$((JF'^J6M[HF8
M>1[!@#$$1`.13%$#%'H)1`0Y#6G/1G'U(^86#V)GV_U=A`P[?@H/R'?NZ#X;
M!X[\QZCOTVVY]=NM8#8/#;8`'F'=OU\1V'ZKP]=?MZ.OR'S*_=_BC[_]H=NF
M^^_3GO6?1G'>W5#;8`_6C]-_X/(!Z;>WF.]!^`AOS#81WWW^/<.[?H/3E\?*
MGK'O$!Z]/\G?D`[;^H>\1K]?1W'/]96$`[O-'V'ERY`'<.P;=PB`[\ZR+9?<
M`%%;D`?XH_LY\MQ#;ZX.FW?02$\'OX572\.P!OC;5%T[]K"M[GT#?V_%W5>S
M+T#V!\U44.#Z@JGQ4M+YSIJ%*7&FJ(1$R9PV+]`=O<]A#?;<X!W\S%#J.U7K
M0,&P<C=`_:'_`.&@\ZKD^50?!(WM]T)I>_&_!U8T[0>!O^X?_AJN7Y4]N;A)
M7MV2F';4)I=W^I-RWS!!@'4.\1`/:(!U$-PJ]O1'TMSSY"NH'+J(B/+;ERV\
M>5>OX#L`>&P_^0!ML'MV]=>Z\;N!>.MT5Q_KA0!#S1PV#<`'<`#N\=^7*OQ\
MPX_S"P#RY"F???KL/U/+?].E!Z_LV[(<^_NYCML([_IRK/41$`Z\P$>FX!RY
M=?'GL%?J#9<"A^L*[CN/[&?Y=P#N#KL/JH+=P/\`B5N8@'),X;<A]0]=N@;>
MV@_$=MQ]6^X^H0'U=^X]/#<1WK3=Y@'T%WB(?_25S=G;I_S,]$._?<=N6W3I
MMU"M4^CN`ZHK]_+S1]^@[\^SX[[<MNG2M-WH@N%F7ENBN`#:%RF$12/T"%?=
M1VZ"`;COTZ^-!=6\GW^!EX?7VC4OYW734QE0Y>3\CV>#-P^@$#`/ZAB(_6&Z
M#=MT"`].@@("`]X#4Q8&`>6QOC*8/PB&U!Q5UQVQ@F\-(^H&$U-3DK:^!E,9
MW(_RA<T%+R4#.6[:\0T-*/)N%F(?>382T89HF[CEF)5'`NTTDTTU!/V#4$LL
MZHY+-B.%K+M[/,WJPTM:#;X#,6.=3FH#2C=%ZW%A7'=]PZEDQ;?5_I\O4L:X
MU`8N@V/8)!YGL)NI((+D2+)L@%-94>Q"SIA>P=1>'<DX*RG%JS6.\K6?-61=
M\8W=KL'+J$G&AVKLK5\V,5=F[3`Q5FKI$P*(.$TU2\R[5P1T:<*;#FCV][OR
M&&6,]ZA[KN3%T1@R)?:C;X;9`0LK"<&_4D8[%UMQY8F.8_0PFY,05B2B$@[<
M)I$25<&(*@&%\/TX0&G6R--NB:RK=L#-=F9]@,B7+=V:@R%C.#96MBUT^RC)
M%N%]&XQM)@NX;VG8L<N<R<#;IC@XBT#&;."%5(8!E!KCSISTJX&TEVQ<EDZ>
M\?QN,[-NF\9F^WUIP3A_]#K*X9\Y5912!B73E=I;\>X5+YTD/$)M(QN<QS-V
MJ?:&N0U`I2E`I2E`$-P$/$-JJG<0/A=:^KTU%<1132_:F'[^PWQ5<.X@Q1D:
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ME3F455.=0YC&,(C:EI054OI._A'_`/2-3_\`IBC?S,H/D=_"/#_'ZH/],,</
MS675JVHP>)98MK0V,+AU.9%UDZM=+V-L&6-*R=U1^FVZK<B$KF2])*JU,ZAI
MFSKE=3-SO':B$+!H-7+--9=V@W.`"IYTI)FD5Z_-/M60T=>2F:.\D9NUYVOJ
M$L;5#9V-L4:CDK,TMS8WRTM\M^8>&S(.24N+W26MAR6Z#!<;J3:!,-TF:`$1
M*U%#SZ*M2`?2=_"/_P"D:G_],4;^9E>OINO?4-C/4%IGN_4^_P"+3C+"^5<E
MVQ;F,+FS+G3#61L;7)=EVHN5+!LC/5CV=::-PV0QO=L(`5,SHA&<T+6+<ND'
M0*$+:U#\OST(FN5,:454OI._A'_](U/_`.F*-_,RMPL?^2E\.C$SF1>8JRSK
MEQB[F$$&TPZQYJ7D+,<RS9JH95JWDE[>MQ@H^0;*G.H@DY,H1%0YCIE*8PB-
MFNE%5X_I;G2C^^ZXG'\M:^?Z.I]+<Z4?WW7$X_EK7S_1U6'*4%;"\/)<M!N1
M`ARY!SWQ`K\+;S]24M\MZ:K9^YRP4HJ@+962A@F8-V$8_4;"+=1XS\RX.@/F
MC*"G]36F_I4#AN_NGZV_Y2#W\VZLYTH*QGTJ!PW?W3M;?\I![^;=<">(KY,Q
M@/#F$['N;2&^UOY'R5*:BL#6?<T,GFJ1NSW.Q!=-\M(O*MQGC$HA@=O[AVLH
MX>IR_GS$B52D=+MG"`*%+;TU0'NA+3;J`6LE2;2O%'"V3UK54MH7);B)<25E
MS*D*:!%F`N_=H)`B`Q?HH"X]-\P"/ZX):K(86S`'%ERCJ`D5M;O$&T@6]HYT
M\8EDH3%%IVW/8&NB%N5C8YG>3LJY23GK=D7>4%3WE#OF;*SW"QFSN,9&<E,)
M97L@&^(^2@\-P1,)<FZVRE$Y^R4=2+TP@7M#V0$WT-!VA`NP".P;]=@Z4^E0
M.&[^Z=K;_E(/?S;J9SAT9.R+F315I]R5E66E;CO2Z;+.Z>W9.VHM8TU>D4UF
MI2.M>^):T%TT5+>D+SMAI$7,ZC?,I$16DSBDF1(Q"AS7H*Q*ODG?#872507R
M5K7607240715U&NU$ED5B&35153/;0D4253,9-1,X"4Y#&*8!*(A6X-N^3+:
M+[0@XNV+2U-\1VU;9@VB<?"6Y;>L*[(2!AF"0F,DQBHB.B&[&/9IB<XIMFJ"
M2)!,82D`3#5C6E!7C^EN=*/[[KB<?RUKY_HZGTMSI1_?=<3C^6M?/]'58<I0
M5CWGDH?#@D9J:N20REK>?W%<CLLA<=P/=23YU-W`_(F5$CZ;E5K;.]E7A42$
M2*Y>K++`F4I`.!2@`>'TJ!PW?W3M;?\`*0>_FW5G.E!6,^E0.&[^Z=K;_E(/
M?P_V-\OCK@+8'DSF!)CB.:A,,74]UO1VC^T-.>'+RQ+D@<T2S4EPY?N*?FFF
M0[>"\#0IFLN$1%-8YP6&18HK1@K'57<*D50`TZ?%KUD7%H66PGG,D9FB5LI"
MR=3UMR1,5V+<60H"*R+*8ZAU\0SV3X&"2630M:-N9FX!.6D$SHL5EU>PF<%5
M=H_]-[?*&,6?#3U<V/K_`-8VHV\->^1K2BLDXCR?&/;DPO=MMW9$25S9+?6O
MC\MO,C:?H[%2;5XO$RIGI6Z[2-;Q[@3B](!@U/\`2H'#=_=.UM_RD'OYMT^E
M0.&[^Z=K;_E(/?S;JSD'/\/R;\OP5F@K/P?DK?#WMB99W%;69M>%NW#'I/&\
M?/P.J"7B9I@A(I$1D$&4HQM]%XU1?HIIHO4T5B$=)$(FL!RE*`;B?2W.E']]
MUQ./Y:U\_P!'58<I05X_I;G2C^^ZXG'\M:^?Z.K2]X>3!:',APBEM9`U$\0Z
M^[;6=,WRUO7GJVN6YH-5['+E<Q[Q2)F(5VQ.[8.2E<,G!D15:KE!5$Q%``P6
M1*4%8T?)0>&\(B(Y/UN"(CN(CJ1>B(CXB(VWN(UCZ5`X;O[IVMO^4@]_-NK.
M=>G(**I,7BB(B59-HY.D(``B"A$%#)B`&`0$0.!1V$!`=MAY4%.K7/Y,!I0Q
M7H_U%9%TRW'K=OK4#9^++DG,06B7.[ZXOH@OMFBD:%C#0)81D>7(Y5$Y#L$W
MC518NX)K%.4H&WHP_P"2M:"KDQ)BVX;_`+]UNP]]SV.;'F;VB3ZAWC(\7=\I
M:\4^N:/,R"W5`9BRFUWS;T0%%/1?->8\ZJ*?G#?5PQQ`M1'$7N_`^DK2MQ"\
M1X5S!9N(\BWMJPN\,;VQ?&9ULDVSD:9M&.QI;V-[K9QELMV\3%LB3MT2K!`Y
M4(\S11LNH+@P!,QPV<]97SCA.\&&;;KL/)&2L)9DR'@>Y<LXR:FC[*RJ\QU)
MA'C>T9&``MHEZ^*H5G<$2P45CXZX&4FU9G\RF4I1?B_B43'TJ!PW?W3M;?\`
M*0>_FW7BIY)YPVE4U$E,F:V5$E2'253/J.>'3424*)%$U"&MH2G34((E.0P"
M4Q1$!`0&K.M*"N/;7DR6BRRX*,M:S=3'$:M&V(5N#.&MNV-8%UP,!$-`.=0&
ML7#QD0V8,&P****>8:H))^<4.<"[F$1Y-Z7^"%IZTIYOLG.]F:C]=U\7'8J\
M@XCK8R[JDNR_\?R1Y&/<1JI9^U)!FBUE4T4G!UFR:RI2).B)+B4QDR@$SM*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!7`[B=M<?NM!.J(F4[,7R#8".*;@>7/:3
M&>7MJ7E8U@B#TX0$PW8R2K6Y&9D"OK=*5FJ#B9;,FYA3*H*A>>-19<7FUL^S
MFD.^9S">K2P-(<99</*7-DR_LC62SNV`=6E')MW2K=1VY5!6!,V%NLH"S5L\
M5DC*DC_,AYT#`$/>DN\M&&I;*NBF#R+Q>\V:G4\<W38]Y8%TL7OBP,9RCS)T
M9!&4L-#,L[;UCLG-Y7-8)EG9!0DY1E$K23,'3PZYB%$UM']/EJJKI?NR]<YY
M:TK!</$"G;ZLOZ/K&O2,A\9<-B7P:7)3F+C%W$1$S.8G,*(PUDRZHG=2D@H=
MG[I-R(E.N4CD2FM542+NLWR4I2BE*4H%*4H-I<^7=<E@8,S+?5FMDWEW69BO
M(-U6NU5:J/TW%PV]:DM+0Z*C!+]=>D._:(`=FE^N.2[H$^J4"JPL+>G$`T(V
MEA[B8,M3]\\2/0MF^R;0NS5AC:X,;VQ&91Q3:M[QY)61RAAAG;L+'2DA:UAR
M4@L@_L24"0D4[?8+-G!UUR@Z+;+>.&C5HZ=2"S=NQ;MEUWKAVHFDT0:(I'4<
MK.55A*BFW21*<ZZBI@3(D4QCB!0$:X:YHU8:4<+8`B;JD=0FF_#]E9,MN3@,
M'75?ETVM"XKN&=EHE^2W"1C4'+5C/V\+XR;B09Q*:B+F/!P0N_G0$1JTSPQ<
MU'U&:),,9R)=,I><7DX<@W5;5QS2!6<F_M!]DZ\"V@FZ8$32+'&C[;3C(TD;
MYLIH])H1F8.TB-<^:XQ:,H7)%OZ7\-1>7+@PI=>0T[33=7'<FG.WB6KA.;5D
M7SR1826.X%,I$V,"YBW3(Y1(0A'3L7+PA"%<`4.3M`I2E`I2E`I2E!L%J/U)
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M]%]*"5"&NXX(,Y^R(4KAV*R2*C%D5N"BR06C?T_3V4K`<OE'\(B-9H%*4H%*
M4H%>N[6]':N5Q)YP$4%E>Q_E^;2.IV?^UV>S\=>Q6!`!`0$`$!`0$!#<!`>0
M@(#R$!#J%!3_`)'/FN7#<M;7&/AM/6BO.&F*0E+SA<IV!@W%",'JNT_X797<
MYM2?E$LH-ECN\D7%%),'5P7C;RL>S!L*9XT452%*Y+.SPR=0N/M2&+\OWIA6
M1L25P&QS[>T5A.0Q[;[6WX1U9+EA"7`X5>)-RD4?W`I<\S/GN"0>$*]6E3.4
MW`"9+<><%AX>Q=B^WYZT\?6';%HVQ=%QW/=UP6]"13=I"2MQWH[._NN4=18%
M,R,M/O%%',FF5$K=RLJJ<Z/ZX?M?!PAIXPAIKM>5LG`N,;2Q/:$W=EP7S)6S
M9482'A%[KNIX:0N&93C43"U:N)1Z<SAPFT30;`H(BD@F'*@WFI2E`I2E`I2E
M`I2E`I2E`I2E`I2E`I2E`I2E`KAKQ!\16CG71EJ'Q;?=X6;CVU+IQS-)3%]Y
M!9^Z%G6<@P3"3)<\ZP%]'$?,X-=FE)"R5>)(NCMBH+><34,F;F54;_%-C\`9
M*TH7II@SCGBV,$/-5*:6'L63$ZJ=V^F\DR;ILZM>,B[9:=J1N9O[LHQ_NY&M
MT_1E(I1=!\NW1<`<0C,T,<1>^K[RSI]P+*Z\]+N08.<+&0%JKO=(N:,*RVH&
M"MJ(!%PGB*\[DNY"P75POV+,K^/0CX]V@[;HKFC8Y=,"@6RF'Z?I\]5@(\VJ
MK/\`JWTH:#-6&5]"F)YS2A=V+=2,G9&+C7.YS#G"/Q>R=IV4XQI#W'!0T)9-
MOR3H$Y2Z6EN2LI)Q#9->%,V!BJ!ZL_@&WRB/RCO1(NNT:S7<I2E%*4K\U2F.
MFH0ANP<Q#E*?_),8H@4W_9$0-\5!Y[AZ_D'\E-P]?R#^2JA-T<$#CD3%S7'+
M1''GR7#Q,I/S4E%Q"4=DHJ<5&OY-T[81J94KI!$"L&BR+0`1*1$`1`$DR)]D
M@?"]XOX['V?C)WWOR;^=-#&Y];W.%LK,E@FROB+*.+R2BD(;(^.[TL0LR1$R
MYHH;MMR1@0D00`R8K^A"_!P*(*)BJ"8D`Y1,`A5'NO"G$)+F3%]MWYP8<%:@
M[(P%IN=Z1L?R+[,]LIX/!N22(C$YEM&T)^%<S-JL)6(*W;79"N6#ZXVT>5VW
MA)A-P(*F^;[Q?QV/L_&3OO?D[\Z:Q[Q;QUOL^^3?O?DW\Z:)C<^M_KOA99T&
M8$NG3!I&P?@N]GEONKJL&U5F<VC:'NH:T8=[*S,G/'MJTSS*BLJI;-K%E"V[
M`JR*AG:L9&ME%NR<PE#EWN'K^0?R53L]XOX['V?C)WWOR=^=-/>+^.Q]GXR=
M][\F_G30QTY];W.%Q/</7\@_DIN'K^0?R53L]XOX['V?C)WWOR;^=-/>+^.Q
M]GXR=][\F_G30QTY];W.%Q/</7\@_DIN'K^0?R53L]XOX['V?C)WWOR;^=-/
M>+^.Q]GXR=][\F_G30QTY];W.%Q/</7\@_DIN'K^0?R53L]XOX['V?C)WWOR
M;^=-/>+^.Q]GXR=][\F_G30QTY];W.$SO&(X8L+Q,L%6!;30D`.4\(Y-@\EX
MT1O.>O"`L.X43/&#._K"O=S9:I)M.W[XM-%S$JR#!!Q(Q3DK9TP!,_G1'XN"
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M`0_^/QD[_P#H9._.FK(V@#`V?=-.EC'F'=3>H>5U3YEMAQ=*MT9LFF\@UD+J
M1F+GE9>%;K)2CIX_[,##/&,&DHY<JJ*I,"*B;ZO:BN9U*4H%*4H%*4H%*4H%
M*4H%*4H%*4H%0/<1HTQI]U]:1-<V0,"7?J$TRX^Q%E7$=YK6/9#K)MRZ=KZN
M><@;D@\U,[';(OW:L>^C(EW;DO.PD<O.1A4VH(J$14.`SPU@P`8!`0W`>0@/
M,!#P$!Y"'J'<![PH*UF;-1]A\3#5?H6MS1K@G(EQ3N$M2-F9NR_JSO##]VXP
MB\/XGLZ(E7,Q941>US14'*7#*Y(/(-+=<V<U.\C%FZBQY!OYQN7L64PY?*/X
M1$:\"))I!V4R$(&^^Q"E(&_CL4`#?EUVWK]*)WUN^Y2E**4I2@4I2@4I2@4I
M4(W%3U#ZM'&9=*/#\T2W,SQ5F35B[O"XKRST_BAFCX>POCI-LI=]QVY'BJD@
MXNM59TW:QA7@*MBF5`QTQ#M"`G!-S2H-],NECBTZ6M55G-KLUL-]<&CZ[X-W
M^J<^SK#1UJ9=QS<+1LH#%2Q4[7($9*QLDX.0RB#E,#I$3$%#";G7"#BRZQ]=
M;O5%<L9H/RC)6[C;A]8VBLSZJ[3@81X^4RB_G[G:L$,8O7B:*Y$S-+91?SIB
M(E*=)--4YC!V>9(Z=*3VPP_%J>E1M9GL')/$/TS8&OO3'K0R?I%;W>PMC)JE
M_P"&8:WIZ2N>"G())56UW2-TI*-DV#=XX4$RA4P7!PU[)A``'>$'A>X1XB^K
M&Y,Z7GD#B^ZG@A]+6M"\L&C9#:RL?&A<FVKC$\(^.M=#E1J5XS6NA.1.SD4(
MXQ4FR)#&1'MG#88]NWG'CKJMQTKC1J_<:EDM.N3DM(,7:,IJ)?01HS&GT=R)
MHJU8N9D5DVAIV6<@':41A&RJLD1H38[M5N1`H[G"J\3*\^(3PX-9&CC&N7^(
M%.:[I+4\A<:6:<#W38T;%+8RBK?C2R[_`")CA[;?:<0]KL'0&AA&YR*F=><3
M51.8`,6BW>ZUI2J;TSGCB@HZ5KJXV3/6',%QG;>8'EU):!RP$*IB1?3A$90'
M'+V%6N80^B`^0'$=V)AN^(H#`'QA*=N!"@`;%:O^)U<F3>(UJ.Q[=?$YU+</
M?!6*<+X$D+6@<%8;=9::.+LO:T&UT7G,WI(-[?F6]J1L*A,L"+2[X[)DX$AE
M!53*B:E^O'*5PK$3/'3OU]KRU*BXRWK?LG3'H$QMF&T\EJ:JKOO:SK.L3`UP
M,3-'$]J0RG<,4BSMQZDVB]T2.IQV!IJ>!N0B$<B#CM^:`"A6QW`<SWJFU#Z2
M;_O+6)/2DKFV.U&Y;MR=AY,[4X60SC9D!C;)CQ:AV/<ZWVBJ35MVSJ+]D!\\
M<3[T5-N(@`;B(`'B([!^&LU$SJGN6X,Z:^M+.C:"G9:#LFR[7N'5?G,T+)R$
M.[GHBVGZ=K8TM)1XQ71.I'O;J>+RTFS-NFZ18)$5#L`:M\'G$KTDL</ZJ\Z.
M+ZEBXYT7Y"N7%^?I8MJ39W-KWC:1X@DU'L(XK?TJ>2;FG(X$WD619NOYXWFS
MCYL^P<]J55'X\.MG6AB#*?#WN?0UE&YH&SKRA[IR_E&THQN0L??>)[:5MF;E
M'4RQ5:+O>Q'VT^=JF;IG;J$!<1,H!DA*;27%[XF^I$^2-#ELZ(LMRMG6=*26
M(,H:B[@M=L=-1;'N4'\$UMZ"D57C5=)-O,'>.4P;[)*@(B(K!V1`17^7RMR;
M@(B`"`B'4-PW#VAW5FH>M0F1IW2YQ`M(V4W$Y/O,9:OX!?35D&VUI!RK`0^1
M(Y)O<>-KT91RJ@LF+Y\962A)5=!--5T@*`*&,(;U,+^GR4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"H0.*OILU<
M.,VZ0M?&AZ`:Y'S5I6F+JMF[\+24RA!L\IX6R,FW2O&#CWK@2)$GD5FS=TP%
M55,FZ(%[0`8XA-_2@@TP7J+XO>>-54!,WMI&B-*>D*Q+)G'5[V]?$]"79D_*
M=YFC%W$3'VHXBG2J42S2D"(M`55`HJ`?M*;``G-P@TJ\%'+6=V.J#/NK?/FK
MO3AEC5KE*\9*]L5XHRS&04`.-#+N6EI0<ZT0BY4CI1&/5,8Y2NRF334%+;<>
MV6U52B4KUO/+LB7X-V']1&FG2B^TMZA("?:*:>,GWOCW$-W3LBRDS7]@Y&86
M?8WG$'+-0YA5:PJZ;"0])*DN+Q-4XI@!JTQP?=.N:-/</KK;9EL61L5;*6O3
M-F5+"*_<,ES7#8%S-+>3@[D:^AKK@FU?'9N`22<>:<%%(WG$2@)1-,?2BH3L
MMZ,L^:5&V8=6.G#.NL;55G!G!7H[QEIAR#EN.DL/2ET7><4XY`]O.H^-10C;
M6.J#B)35DBE:I(@F85`,)BQS<,:P];=EY0=7GK#X=^8Y[4[J'6DK8S/J]O'(
MMKW)&8VM"427;LH2PK=!^Y"UK2A45P,K&P*22SU5,3N5UA'M#;*I3U]8)3]P
MRQFM;[RIYS&EWB@GTAW/P9VFF47&'I[,REI#K3^B>!);)M-,MDX,@2DR-N`Y
M"03OE%B`1C9MY@J(.0`3;[[EY:9BLO7YI/S1J2M'%V@O%^M?!V<,*V)9>*+V
MA(:P;0O&WIJV[);V))6QGB3D$BR-Y6T\%!.:*]<'<+II"=LF!4TB;V6*4OQ_
M,OY2W?M6`Q9P3=6UOX;X>H6SK`98*R/H_LNZW@V8ACB"R58##(5_N5G[U_&1
M=P+G9%6M5J[&!A7)4S&9M4=VIR;UR]X(NE[6AICL#5)%:P[P"XY6^-4>1[RL
ME$;>A84TA#2;PIE[X(,0JJ4C>\ENS((QA^R$>4OFB$(4`+4X5*"'*\F!,3\:
M_%F0)\SE&!U,Z.;BP[:T@J90\:6_,67L2]58,@F*"#5_)6_*.7B1`/YUZ1H(
M%*;S)NS7T70U!Y7T:\?+2[IMTQ9+SUDK-O$LS19T>ZMY2$B;3A(Z4"QGTO+O
MYV6DVN[R%;17*+(V$72CM#9PF4#"-RG->GG%^?T\?_JCQ#MZ[Q=?\-DRQI6+
MD7$1+P%VP95DVSQG(M-G!$'+9=9G(M"G*B_9JG;K@8@[5HK35I'Q9I7D<^RF
M-`F@<ZC<Z79J#R![KO2O$QON\FT>UEABB%23!G&>:C6P-VH]LR8@814-O00?
MXUPMJLU9Y<X=5[:@-&]XX&M#&&`-3^G[-=KW5<EOSIX1O+6=;=L6=-G7C7*O
MGF-Z&8N%V!$?.+LO-&*Y$@"6N#>%^$MK0L'2-J:0R%95UW]G:X=5N(K<Q+&R
M-P13]RSTN8GR>@_MA6.6\\5%FPC;:3(X]&.H5P*28(@4PE`*ND4H7X_GE"OQ
M'V<GDS4EPQ-/%LMR/KF'/:>=+K:H$15?V]C[$<,W4EIY<YA$6C(TD_;QP*#L
M5PL8R91$2"`33AR^4?PB(ULTRP'C1EG.9U&!#*N\KS-BQ^-S7`_='=DB[/CY
M%25"(@FBI13B$WC]3TF2.T,0T@H1/TCM`F4*WFH%*4H%*4H%*4H%*4H%*4H%
M*4H%*4H%*4H(O]2'%PT@:8=0%D:>\BWN@WN>;EIJ-OV0*HDW98G1C[1/=D3(
MW2U=F0DG[*Y4@)'0Y[<9S!G$FH1AV0=F!&I)X^X8:4@HVY6C]`T)+QS"5CY!
M<P-$5V$F@DY8KB+OS(I`X172.4BP)J!VP*8H'^IJ._4OPPL-:H\V)9]OB^<G
MP^0(*&Q]%XZ>VQ*PC)#%[JQKP"[)"<LQ-W"NS(2]^)E+;EYKR1I!)];Y2M&B
M3-0/.C[W%PLJV[VX9>MN!N2-]/C6>G#)<^R10>/8M5I-VG;CNX+<D6;R,<,W
M31Q%S4:Q?-S(+IE[:!2*`9$QR"._TD'0FX=R\+'MY6-7?G;@\*Q1?M%7AF@F
M$H.BMDUC+F;B8!*"X$%+M!MVMZ^F8Q2%$QA`I2@(B(B```!S$1$=@``#J(B`
M!WC77'Z%S8ZCKD\G=O+2C?MY7#J[O.\;UA-3<<E>%W3[]?$:2\^K.)WO`23M
M5JRLZ/.;T=F]7:%B42`W*@][94!&ZOQ(=%66];6)X:P,4:K,BZ9G<3+'DIEO
M9B20P&3HTQ2$-:%^NF0M;J;VVN0I_/#:\O%OSBH('64(`$H.2*.K33>[S5&:
M=8O,=C3N;)-G(R!<<VY,H7%<<<QBFQW3YU/-X47R5NI))$'LA-K,5%CB5-$A
MSF`H\7M7/$BLG37FBV--UL61.9;SK,86R1J4F[,A7C"':VO@G$R!E;NNR3F9
M1=!H:6>+$.PM>W$/./IAXDIVP;(`18^RF@*Q\F:3+LAM--W\/G'6(H>592;Y
M/4UILN8EYXPNJ28-A,4]_%O1-OEBV[BG$VQU!&9>7"T6>G323>$34+V8Q>(%
M;CO#G')?:A,DK1D)B'(_"(U36+:MQW,]3B+6DK\@8D?2,=#+OU6[`;EFFPD=
MQL(BM[H2C=P(,$'"Y%"E"R-IGU28AU8:<L;ZI,2SXO\`%.3;*;7Q$2,BEZ`\
MC(\S91:28SK0YC&C92#60=-)9JL;=LNV4^J,F)#FC7QGQQ],N1LJ8TM].&N:
M&PSGK4)D'2M@;.;XC4UN9!S;C9:-:S$0:.0<*/XFWK@?2!F-F3[E(4IIPS7%
M1%LDHB<_`3@UY"M33!PL-#FA+,SJ>L_4GK9Q1J(N;"%D.[6N4PGC[E:W9<D2
MA<;X6(I6PK[G/FY&[>3,DJ0OF3N"-D%"+&@/TM82R4?3!PF]$#.WGKO49AOC
M.9BFLI6>V15&<QY;&,G<0-Q7O<T:JFG+0]I"V=-Y*%N)ZW;QDT0Z'N:X=J*%
M+1*].D3-S&NZWUDCC)P=L:H+JTS8RT8ZP]0![-R+!XLN#,.(<8!<V'HR[Y-2
M.;3#9_=Z,@5%BTLUY(&9W8\=(I(Q"S%]YX>PB)AF<;G5401472%NL=),ZR`G
M*H**IB`*B0G((D/YLXB3MD$2F[/:*(@(#5$G+VG;2Q9.>9S6%PD>(%F"2UQP
M&LR$M'*.FR1GY&?99@N:_LF))9'@)*PW,:TD8>#-%$F99U<2[)6UVD.Q<*O5
M6KPS!8EZJ'-)'B8P\R1%*7-'LC2B;81,W3D3-DA?$0$1$11(Z%4J0[\TP*//
MK17TJ4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0
M*4I0*4I0*4I0*4I0*4I0*4'D`CX<ZK*YOU9\1J,XJ,%BFSD8LV&;+NQ'&BEV
MDL#)/ZCR3;-ON;+V:TON,:L5GUUY$@(6%E6R-VVW/M+0A'+S>6:$34,6A/\`
M//XLU5Q@UGX#N+5+I<S;IVMB_P`N+Y#,UAS./7-\>X#>YE8.%N5`8Z?4:P[I
M=NW<.W,.L\9ME%50!JJN5R4#&2`!@]XC^J?B'8LUR8Z@\+F(_P`08I"V[ON1
MY;V/KZ?6A%Q&;6X8L@&F:$&31ZZR"A!7NH>ZDF6/7;1]#09"FETVA_Z^&;?5
M-J)E-(>D_)&H^Z+#G<P.\+X\^C:]K3QJ#)A+3K6$:MU;M?VTWGG:2"39B@#Z
M72:/'9ERL&YDA446+N8-G^'+H,@-!NF[%>"WDI:F3;HQ+`/;/@\PEQ_`VO>L
MG:3A^L_:Q4J]9I+R!_116,@I_P"TE$W:::)UB"8O*0JJ_P#I[\H!P[G#(&C>
M`G]-6?,,XXUSMY>-P/F3(:-L)6=-WW#+/$G=FN4HZ47DD#*BR438S1FX1KQ<
MR8(*&1536/(WKGXA6G7A\V);=YYZFIE!U?<V:U\=VK;T*^E9N];G*1-3W%CU
MTT0AXQ7S:A#&=SLC&L2@8`]($=P`.<M:3NVP[&OUJS8WS9MJ7FRCW97[!G==
MNP]QM63X@=DCUHWF&3U)L[(7ZDKE$B:Q0Y`<`K@7IBS/KQU#7M!9'OK"&+M-
M6F5RQD7+.S[INU7(VH:[BN6@'MZ27<V<Y/C:S8Q0RR+MRS3E+BD3)IF;B=(Z
MFZ<6O$%U+Y:RCQ6&V@:#NV[+-Q?C?AV9^U4`ULB;7M:9NK.T%&B?&\C)3S%5
M)ZK`6KNDLA`*JI1KZ2455E$W;7LI`%E-2WX)9Y$R*T-$K2$"FLE!OE8UDH\A
MTG*`-G"<4Z.@9>.3<-@!NL1FHB15``1.`I@!:^4TL2QX^YWUZL+.M5E>4H@#
M23NUI;L.VN:2:@"90:OY]%D25>(`"*0`BX>*$`$DP[.Q"[1)\(/7/DG57PD,
M3:LLN]B=RE#XUR"A?$@5)LR^BZY<1FG8Q],J-V94VK1:>4@@5=$;D(B5PJJJ
MF4A3@4*XNG'BIZMI:P]`'$/>Y'G9.2UD\3S)^FC,6,9=R1U9!L#RKJ&0L&S+
M9MY,J4;;[_';1)96.N)@!)62>N7)Y9P]25`I!U^5Y&+Q-BN#NAQ>T)C6P(>\
MW8N!=W;%6;;D?<[D7?\`;0N9]G&HRRWI(?VP*KLWG^BO;K<&JR=VYWU>VIY1
MSA/3+=>HZ5NO3;>6G_(^5[9Q!&VQ#VQ"6T[(V"-093#QF5:3NITU.AZ4W?R#
MP"I'4.";4FX"%FL.@>P*#-*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4
MH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%>`ID$>T)2B;M%-N)2B(&*`
M@!M]M]P`1`!WW`!$`$`&O.E!X"F0P]HQ"B/(-Q*41V`=P#<0$>0\P\!YAL/.
MH\N+5=-MV=PSM<\W=<W&V_#DTQY<CC2,J[39M1?3-HR,3%,2*J"';=R<D\:Q
M[%NF!U7+MRBBD0YS@49$*^!<]J6O>L*\MN\K;@+MMV1!,LA`7/#QT]"OBHJD
M71*\BI5L[8N@263(LF"Z!P35(10NQR@(!2[X4>AK/^NG31P4\G71D+"2&F+0
M^]N;*:)K,=RDKDJZ+N3>3$=%X^G6&Q6%OO8=5=,TT_.^5V3;@1.+*==,Q+F-
M]8\L3)UNO[1R+9UM7Q;$HBHWD("ZH6/G8IVDI]<19G(MUT1]1@*4Y1`!*8!`
M!KV[1LBR\?Q!+?L.T;8LF`365<IP=HP$5;<0FX7,!EUR1L,T9,BK+&`#*JE0
M`ZA@`3F,-:GH.`&&N'9B/3=F"/R3IXO#*V([)\U-%N/3U!7U-RN!)]S+(&3)
M(M;!N%Y)L;3?,7'FG38]J^YJ';0!,Z'FU%`-Q%UQ<-[)F1]9D+KCT]J6=)7_
M`#.D'->C3(=F7E+N;8:.+?RLQ.C;^38RX&K*3%:3LEP<Z;VWU&:0S$:"*31\
MU<$$]3<TH(3M*G#IU*:-,.Z&=)&(LN8I>Z6,7XYR):NLF%G+,?\`T99GN*]X
M22*M-6+)>?7&UVH3TFJN5N9R10R2>[P5R'%(.!&&.`%?UBS>F'`\_?=H):1]
M'>N#*.M"P7<,=Z>[<A(7<YBGF/L435LKI^8M\MA+-WK>8N;W4?I3S(6I&C)L
M<RNUJBE$I>7'1!=D#A_ZD[QXR&(^)`V/CAKC+%F*+BPB;'RUP/C7C-Q-P.5>
MU>J<D2-]S&:C8%2N0@%2J*'32%MZ6"B@G+.B`;``>`;4I12E*4"E*4"E*4"E
E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g765920.jpg
<DESCRIPTION>G765920.JPG
<TEXT>
begin 644 g765920.jpg
M_]C_X``02D9)1@`!`0$!FP&;``#__@!#1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4%)/5$5)3E],159%3%]+7T)!4BY%4%/_
MVP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``+"`$/`8H!`1$`_\0`'P`!``("
M`@,!`0````````````D*!P@!!@(%"P,$_\0`7Q````4$`0$!!@T0!P0%#0``
M`P0%!@<``0(("1$2"A,4%2$Q%ADV45)9=X&2F+?1UQ<8&C<Y05AA=GAYD;&U
MMM8D5E=QDY>A(B,RE24I--+P-3A#1D=(8F5G<X*9L__:``@!`0``/P"_Q2E*
M4I2HM-].&S0?DI?C'DG;B,'6_79'C3,,=K&T67)/8A$@W#:X8<!@M=$9[G2$
M88V,IFQQ1U7(EBJ&PK%2APX8+)R:$3U)[G;8+?AW7'=V"&194*1G`/*[OE#$
M4H*HLJ:]FU8Y8[X;9%O-XNHJYDT?,!%K"&39@P9'$,GU,\H*AT08^?-#BV`:
M4I2E*4I6'I^FENZ[0\_)J=C>D%TMN/4?!;64.+&(X),?APCDH$D\;-!9#6+F
MUY=S)>'64%`,@7$N12"B@J&+X%"(XF,;&KW+C'D\3HYH/46P>.J;MV!=[+UQ
M5X=17K*J8Z(!;L21Y()"=9Q/I2!9/U]3E1Q.Y480:7(1E$5,7:D'6[DBA'$)
M?.`3#VOUM:_EMUM:_EM>U_+Z]K^6U_7M?RVKFE*4I2E*4I7CGG8/#+/*V5[8
M8Y97MAAF)G>V-KWO;'##'+//*]K=,<,,<LLLNF.-KY7M:\#ICG3B`M,@9/..
M9'^H5>#3"L.4RC*3+;A`;1ASH%&9;7BVH6+?SDP44XQ\AY*!='B[!(R02@Q_
M!1S(VO>IWBX^)D`$QA@,'@.$&-C@8`%+#X8BAXB8XC%Q\`Q@!<;96Q%!&PP%
M"$MD&)ACGCEC;]J4I2E*4I2E*4I2E*5Q?S>_C^VU09\%OJ1Y0OTU_)!\HS:J
M<VE*7O:WEO?I;U[UX]O#V6/PK?/3MX>RQ^%;YZ=O#V6/PK?/3MX>RQ^%;YZ=
MO#V6/PK?/3MX>RQ^%;YZP[L!#Y/8&'7Y#AR197BDH_4@)',R!!C].QE*S<!#
M4B*B(89S[3"YL^W#QO$C=,.'"I<045)/*!/'L6-7$PC)U4XF46!)Y>LUFI*<
M[.L@;)O%^0DU(%D*0F0WW5`#@B%@,5*BC;U*5CQ\KL>M)#S;[CD>SN>V3@>H
M[P5/1$<D)1LJ&T!.F7MEA:UK=NU^EK6ZWRM>]^GW[WZ^6_KWKGMX>RQ^%;YZ
M=O#V6/PK?/3MX>RQ^%;YZ=O#V6/PK?/3MX>RQ^%;YZ6RQOY+98WOZUKV^>G;
MP]EC\*WST[>'LL?A6^>G;P]EC\*WST[>'LL?A6^>G;P]EC\*WST[>'LL?A6^
M>O'.^&>.6-Q.S;+'+'M89]G*W:M>W7'*U^N.5NO7&]O+:]K7MY;5`89X0$(S
M.X:Y?8N=\8Q^M]'01YIM.TDX\AN>S%YQ#?9*4P=J0^PJ%V&0C'PF-"\:8AY,
MH(B:$R"9.!Z]U^\]Y;#`N7!`[^(-WD$(+OI@;OPXO>@\0^^#"Y=+B"Y]GMBB
M7M:^8F66=[=<KU^W;P]EC\*WST[>'LL?A6^>G;P]EC\*WST[>'LL?A6^>G;P
M]EC\*WST[>'LL?A6^>O*E*4I2E*4I2E<7\WOX_MM4&?!;ZD>4+]-?R0?*,VJ
MG-I2HI>:^4)2B+CEF)T0U)#LB-^K,@:P1@3D9AFRB:]FJ@S1M1#$0O50:2L<
M)*`2(Y+LQ[+Q=%70B@AQ$4!BZF1N&;*@B8X-])4=^=\\L>9KFSQP[Z+;#&^W
M4<97QPQ$SQPMEE:`,+996QM;M96PPME?K>V&-K]FSTE)X^W.<V7QN8Y^@*GI
M*3Q]N<YLOC<QS]`5/24GC[<YS9?&YCGZ`J>DI/'VYSFR^-S'/T!4])2>/MSG
M-E\;F.?H"IZ2D\?;G.;+XW,<_0%3TE)X^W.<V7QN8Y^@*GI*3Q]N<YLOC<QS
M]`5/24GC[<YS9?&YCGZ`J>DI/'VYSFR^-S'/T!4])2>/MSG-E\;F.?H"IZ2D
M\?;G.;+XW,<_0%3TE)X^W.<V7QN8Y^@*M(-O=>-@>,>3N/.5(QY.^2:=,IGW
MXC?7!^1YM'.;*E2+E6/'[%$SN-;R%:!&*6J$870SK)2\$M1/G#H*784P=)D@
ME<%.427O^/[C?F/;S235;:"1>87F)07[/L%Q[++R1V/M2QDAF)KD?"("NJI)
MJI"C":P>24`L8-Y`IB::5E(0F6PP!L;S#QPP#W`])2>/MSG-E\;F.?H"IZ2D
M\?;G.;+XW,<_0%3TE)X^W.<V7QN8Y^@*GI*3Q]N<YLOC<QS]`5/24GC[<YS9
M?&YCGZ`J>DI/'VYSFR^-S'/T!4])2>/MSG-E\;F.?H"IZ2D\?;G.;+XW,<_0
M%3TE)X^W.<V7QN8Y^@*GI*3Q]N<YLOC<QS]`5/24GC[<YS9?&YCGZ`J>DI/'
MVYSFR^-S'/T!4])2>/MSG-E\;F.?H"K4'?\`XWICU#TEVJV@COF%YB5]^P%!
M,B2TS$9\;4L979BDY6,A#KR22=20G0FCGE9`,F2F(*FFE59-$.%L\P;F\`\A
M,!+%6OCJ77S`\+/1T';*3E=T2QJYW`HV+%"5CZVX&2A+"N<L3(`%2)6QI1.F
M3%BQ,L7*@=\[T6`!!PP#QS!2E*5@G8_8R--6(I6Y>E,PY,D!*-):0G(+'9[D
MD20'DZ%\Y@G-UG,)@,Y.5G2\'6O'L^\D$A'3QL@P`CBHHC$$5-4E(G@#2OD2
MA;>()TDF.R=@(=?#/*D5=8BS9R$7C!4B"M=4/'4I->*"DN@$1*=S4,JJ<<2S
M"NU%M9Q1%/$NGN(%'-J"8$=WUI2E*5Q?S>_C^VU09\%OJ1Y0OTU_)!\HS:J<
MVE*AOY[/N:,B_G#:#_B_]_?6K[]_)4Q@7_#?_P"X-_\`USK]*4I2E*4I2E*@
M-YY+=0.)[S>3ET@*_EO:W_L(V9\W6]NM_P`5NM_Q5MCPI_<E..?\SR"OX)3J
ME!I2E*4I2E*4J,#FJ^Y*\C/YG4\?P,I5M]J?_P":]KE[@T.?)LV*V!I2E*AV
MYD]@(EA^"V8U9G:FZ:>V9+D)O)3?G[2A-=GU4('>I`4V91W:W'0PBZZX&^[>
M\7-DDI%66N=:$AHBBXF8L9*A)04$(YK/PA/*+G\\9\4F7)/)_LHMM]HQV24-
MA.1XF\D&Z0"X%]XF!X<AYHN%`:S?1@"N#>1'N]U9MIRFJ.013;`3J6`R[?:R
M66L0TI6O:OMEK$@3T@ZM+>P$.I6Q[H1[K[=@Q0D1K%)564CP4T?#/)['&4L%
M\P$83R)]1*88DN_G4X@?/DP1R9(R.%V8I/T*GY6/0<3E)C&9=3@!ACL>`.-.
M$=1?,LD)CA.$A$K$:XWC8@W%M#<B@B8WR64]MKB(X3J>715=./F3'GZ%9*>+
MMCY@RDQG>]6**=!=;9;SC35181LDM:.-E7S,%"HV>8H**Z4Y1:BX8*7,ET1U
MIR@V%<4DO$32<%EV_F]_']MJ@SX+?4CRA?IK^2#Y1FU4YM*5UEWLMG2`A#-A
M^--M/9M&3J.I&&\[D%*<B&.HMY8(N%`/C)*T4.IXIU$7DM-6T@T(7R'3%=/(
MJ1(0`Z4+CA]FZ6MYK=//?W[WZWO[]_+?\=*4I2E*4I2E*Z@[H^83_LWK/MDM
M%ZV:+C)O!J6=K:17)9LNU/*'D\@Z&_99)'?$KB)$%12)%%M-\%4RQ10/%@36
M`)LQ@)_>TVDU6&VD)EL=LM]FL]KI1)";+4:B,FMUM-U$30<2R<CH2$CEB:6D
M)9`OA@`23T\H7*%0<,0@`0P\;8V[!2E*4I2E*4I77G8TFJ_6RO,M\MEOO-G.
ME)/(+G:;K14UQ-IQ(:F!F5449=05@L=2E=*4"PF9<ZG*!0R3-@9Y@F`1`\LL
M;^U3DY/2"!)*2B)-,2TTH63TY.3RH!(@0($@`RI,D2)E@PBY4H4+!!%RQ8`,
M,$``,,(+#`/#'&W]E*4I6N>T,_%==(RL]08S?\T.Y8<S>9$<1'&`#<R>TAOY
MS#F,$-`2%%Y+[49J"$&`245A67W0Y4A+24=*/F,!#JEXO2E#'>OV[$8SN_DN
M)20(K=E4_K/#&TAYD#+B0Y#[>8LPXFB)=+<)E#,&`T5Q-YR$3*.;)*01,%<*
MY%5QN#*1&RG@D[H4KB]K7M>U_->U[7_N^_58;D+4>-9^<ENFT2..2M<8;FS6
MK:B.=QYD=0*RU26Q\F2JLDP6;KYK,TDQ/&'DA]+4HN0^U'C("?D&.G,R-F#'
MR5@6"S>+:LD1YQDD3]C-D.MU+S/8[#E>ZFM[E]PA"8]5(-B9ZTKZRMN(R4L!
MF8#8@D&N%`/`&[D[)F#&7&YB%A@1/I@0G8^'!,E<.6.`]-)@K@:LS=(^60GL
M^1,=]R6T,#ZZL)`4BC_"S[9PDH"[`IB,2,XJG>C([M23X660ATB=PPL];1L'
MD,=;U;Q[4/8[66'&&6;0)5QH$V:T/B:'&I.ZRPH#"K*8XVQ.L7$DQ$S1A4HD
M&BC(ILT">)GCV:L,$>!+$8[>Y[2;T3H5Y#$^25M!<TBD>8+?XF_G(U4(VUFN
MX7H6>#0!<ZVVVP?55X\W$%56<#AY(03JZMFT@@.`0,JZD,7S.#3]TI2E*4I2
ME*4KQRRMCTZVROUZ_P##AGGYO7[.-^GG^_TZ_>\UZ\>^X^L)_@B_]RM>-HCF
MUA>(U;/2]'@-:GBZHA8()79E:DANQ/@BW4,+N4PK'8P05QV#*82582R(3*ER
MQ0<_GAD>.A`!7"'B]\<=TF_U`X4/\R]X_H_K#VPVPW=$&M$"39L6_HRX;U-C
MP-$\A3(\4UJ2!NH>="@UXT:BJ\5\DW"2JT49+-KIE*2#02464EA*(CG<@0C2
MB3!RR'P]W#LT=T5S?$<630T(XX9B;4EV-V+*+9)KTA[M%%TFWY!:R2[D8FME
M23+42)98*)RP6+J@!%14"01\(P&3/G2V(1H7(WCCNDS[[`X4/\R]X_H_J5'6
MHWLP8AQJB;@)4)(^P-Q%O%[D=<E:0'!$&(>"XH8MP9K*4DHB(\,LS#;LE#K)
M=4)7Q)K>9\L2-'"00!@3/'?<?6$_P1?^Y7ECE;+KTME;I[+#/#]7:QMU]ZO*
ME*4I2E*4I2E*5%]S!+NN2!HW(`^V:XWDG7]0=L8(D@D71!"WL6D.PLM/E)((
M;*RCIJ*R`],%-U.45'2T!X,AP-]WL9?$37.@KZ*;3[*974K@@BN!8[C*6U2!
M.+66N/ELNYP)0Q>09@%4`G)L<A(^:D7;;@!;LI2>_P#85B)"<`;.JJ0QWQB.
MUT4LOYB-QUN-1.*P@,^U*>?SUB(:`(+,.W)_#PS%`SYS6@7)F\A8X98CKR<)
M<4(<!=R<>:'DM7601@`!@56Y[P\(4$(0,QCF'AECVH&.8^+O8Y)1=C,\"15%
M*P0E!^@ME$">AY##\'N&C''5@1Q73*2'<H5O@G#G\R>/@Q>U@>@`-@S?CF/V
MFON=U-=C,]N.=[&03CS<:"V41'7G:;+9#YEC3G6$XB64%\R7R-&<@!U4R;%"
MR,#YX9VS&%RS[E?S>_C^VU09\%OJ1Y0OTU_)!\HS:J<VE*4I2E*4I2E4Q.ZO
MW"[RTJ\:[21']([.07$B;FJ2Z38$A.]A9*YUNI^ON:*,HCM-72A3MTZZB>L6
ML9N+8+`V9P#[&)@:V=6'P%T?VS;(_&1FC^<*>`NC^V;9'XR,T?SA3P%T?VS;
M(_&1FC^<*]<KMI2<"2IH*[*>P*TB+2><25A'5MA)>4DM52U`#,J?3E)..NL<
MF?('2PHA<V3-@#%C(`F8(X0@>>6-_P!4Y!64A/()*5+.PR:EI9(HFIJ<G[$3
M"2()Z<0+AE")`B3+.T(L4)DRH(18J5+A!`%RX08((>`>&.-O[/`71_;-LC\9
M&:/YPIX"Z/[9MD?C(S1_.%/`71_;-LC\9&:/YPJV!W)HYG@IJ/)<UW$^Y`>:
M,T)#U?P;0#^?3J?1A&Q7(R?I]6Q('74JJADO8^;#"$,]Y$#[]8N5#$[6!4OB
M'<9I2E*4I2E*4I2E02<J4I/&#W`:,N+EDBS1AOS8F0PT(`2Y5UOA-_)D1R2P
MY&-N>5)N2W/)Z@2+O0TYV5D18QIOJ@Y$",@S@#X1SH*E<M<7U/$1-+YDN8)Y
M;KKYDXZY7"C;C&+ED@%%T'1/$S=A\=PO"02`XQ]4AQ:7T=Q+CKP;^!<5.=(Z
M>MHB>CD3B07.)2X;,%Y\:4I2E<7\WOX_MM4&?!;ZD>4+]-?R0?*,VJG-I2E*
M4I2E*4I5+#NL#[?/%[^2V\_[LUQJL=2E*4I2K1_<E?JQY4?=%U+^29_U<QI2
ME*4I2E*4I2E1.<TKR!CS19XOTTT=8EXBS7Q':ZIN_<&*'I-\#0VEX+N9)1EE
MU1?'38=[Y="BBE3F;<:Q5NH8X@3E=B685Q`F\$KWO'-P3SW+3BV5V[UTEH+3
M"/WA$L;Q*NOV$=0=.7?K7=FR"L/*04$]E+"^YT9'!<SC`0$=%,M.R"9<K5<+
M!=+==S;5R^0JX5$L]WO;&W6_^EKWO?[_`$M:UKWO?I:]^EK7OTM>]?D&8`%O
MG8(4,2X>=\!.]YXYV#SMY\!+X7RL'GU\G9SOCEU\G3K7[4I2N+^;W\?VVJ#/
M@M]2/*%^FOY(/E&;53FTI2E*4I2E*4JEAW6!]OGB]_);>?\`=FN-5CJ4I2E*
M5:/[DK]6/*C[HNI?R3/^KF-*4I2E*4I2E*4J"3E7C7<MM'5C8N)N2/:&`(])
M-YDL-G:J:JZ<QQM%*$IR8*97QS&3,27.8*KBJZ'47&QR&("FTII-IOM,^Y'`
MNIB4`J'"?N.+LA,[4E=P$)[Y!)=VV=$OZHP)L0PX]F>"8CA%UL:.'XM.6Y=Q
M&"\.N%?3EM5Q4A;,5T$G4)8^UUA"L`USRNWE84WC(ILSK\PMIP4.')-DY^H\
M?#$59?>L01A)KAB5?E9+[^G)!`)WO*.EUN2N'&Z0<,F`E=N-5?;J*ZE9132+
MP45-(*V;RC`-J?KEQ69;/9LG2_4G?;0^25%8>0<$[OM_ZN[(@+8-Q1S=36'4
MCM(X\)<?3*F)`-)+9<:F(UIWB<%LOUJ)2^?;O:-8IZAA:B+XCX@`XF1`A3&(
M0=AQ0`<RP`@UL,;"B`EQ#!K,`+,3M9!@YF3&06%\0\AQKXW$R_7K;KTZVZ].
MO3KY>GFZ]//TZ_?IVL>O3K;KZW6W7]7GI;*U_->U_P"[\5^E_P"_I?R7Z>:_
MDOY:7\WOX_MM4&?!;ZD>4+]-?R0?*,VJG-I2E*4I2E*4I5+#NL#[?/%[^2V\
M_P"[-<:K'4I2E*4JT?W)7ZL>5'W1=2_DF?\`5S&E*4I2E*4I2E*5!'RR;NZ[
MMI0.Z@3CIQM9M%#F3.9$M[1RYKRV7/Z&M/V$HNU4]`,KN6066J([R;3I0#S(
M<+_QLS%9*<:"R6RIN+(<\0,9I)S7S@01=0AI(VX=N@^N$V$M7<BL<,Q`WMV+
M=3[<[OVR<[34W<1/MZ)L)$'!6$V"XH2@4\-#-E$A+S75EP"AKJ<D'T$H0ON%
MRQ31%#!484;!B!Y8EC8;(H]9!B^0H)F&#==9;@!HMY0:2`]WPU)>G-_L%$4<
MU@\X6^F&H;P#>[0E$`@(0E1H&6D3"R,8RXYM:8=CB=4O:8#3B.5F0]PXY^J2
MV>06'V1BU!7JWWV@E)!5$K8.%!W.L)&MTQ/0'O1YUNN&P5B()F=09TT95&"M
MK"(P#<]509;.2K.+-YR>,>(T6<9'`@Z;85W1<CSA`(V@)L<FG-%4:E<&PMF@
M$5OIKD<(V`SB%4<RCS<3G34]5($%%O$D48'.V>BCEFG9!B<NI!Q;J$.4;7.'
M)%V"66-IF''^R<3K''K-8S)9:N'%,:RK$C%9:X\V"ZIL#;*NYPB#CDX^HNQU
M'RH*VW4%!(*I9'ZIQ6;Z;&R+,O$FOR1(;N?)GDPUCY"I+GQ*6U]25&D0D&&I
MQ,N.*5]E-DT.(C1X18S'`5(F((K*)H".J-@XDV<1%86$5,5"\[VWVZLLZR/-
MJM6/^/W<';A-<+:R<!Y[:[IL2'VHVSN"N93?0JM9/F36@N!.#$N6"5L\0T?Q
M5FFJ)&Y)5.F\5,LF:!]SR.M2?<&<@CX668Y8X6'GR][\NI5CQZ!IX3R82DX'
M8SE4ZS':$D'5))#<S9,FA$9=#2U%03L%,F9Q)'C9:P8XE@&E*4I2E*4I2E4L
M.ZP/M\\7OY+;S_NS7&JQU*4I2E*M']R5^K'E1]T74OY)G_5S&E*4I2E*4I2E
M*5!QO-QK[X[-S5);QUVY.%33"'I,C!GQT]8B1M;F)-`+[.):&ZT!QN=8<CO<
MJ&HHF2L@.4LV0D5'"L%B52L52Y[$\8#Q+99XX]%MQ]0'0[/KD]^C.Y[%$BYB
MQW$K9O`S*U\1X3)LQ64\S"2W6M'JRIM]22UM$'02(8PI5.-(H+8*)Q>Q@D8Q
ML6R5R/:ZG)Q9K"7@M*=7M_BL8JZTL&-=]C<6BW%A3%5"Z:$67H=E!\,Y[M%J
MNXCFGY$UIIO-*2F?(B(=Q)*SR:XR(3\:X=BS:OD?E5428M:W%4KZAMTK@$WS
M<P[#;#P*K1[&B*GEPBA<RTHH@53>#OD\^0)`7`;K1333`9QP0$F54I#;J9E<
M:TP!8,4(N`$,/D9&#!"#%,YX!!9CB888XYC9A@XX`AY"YVN)E@%A@%A?*^(>
M..%K6MII(^CL;RAN)K_NRX7K)A>4M:&Q)#/C!NI2@S"\>`(4N)A1(D$!>2#3
M'.N)9,+A$D6"#-W=A41*R!P$3,2V??,A/XV7H\VD%TJJT_YJGO8%M![#F]GH
MXC^>G8V'V@0M)H^3A%3BL;+@3+1G[@PVB:<AX_'S#>#N=:$P#P2>*V`B(:6F
MA%.EZV\9&MFKDBM"0(Z+.HR#$C.F&.M?68XE1/4FG`+"GV5LYFE=L1X$"D$U
M@P`XGE8D4(*;P5W.M-=E)2<QFVHIR!=2`4I#LL<;WM>^.-[VOCTO>UKWM_M6
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M@@L6"7#0G.O.J5:=-LM7=8/0Q]<EL;!D`^C6ZO9G_5GE9CQE9U70+)^2[9NW
M>2VC^.;HUE9+NJ63O"+D+*)&YKO5C0';Z)$V_P#HO/#Y3(R@O<#6:9I$62BL
MHI[(B6;([D5TCIJ"2NH+*IFALY?6%`NEIA7L9G%,T`"1`$'+%\S%C)LL"+M[
M2E*XOYO?Q_;:H,^"WU(\H7Z:_D@^49M5.;2E*4I2E*4I2J6'=8'V^>+W\EMY
M_P!V:XU6.I2E*4I5H_N2OU8\J/NBZE_),_ZN8TI2E*4I2E*4I2H#.:O433+.
M(GQN9+.K6N$GRRA$XY8BI.6RS(FR3XXA.,B2V>"&?3Z8T&9FI%6V(SO'!_(\
MFM,NC@AJ;B++[R<R`STI=6D[!/!!).@+_DR4[\?NOT9MYOEM7M:3NQDYPC',
MG1C&.>QBF9=!QX0<5+2"<,EWH8;0XYYY(RH@@X^A%$6,FVI+3E\+)&$Z7+D'
MAC6MW0:_)OGC5."MJ%S7R+I)=;`09UCY%?B"A9YIA)87,PA%9H/Q0:R,=S;:
M.>>BXTVFN.?%N(8^2:C+IHJ51S<"7$6^(HSW8:2(C(_`))KE=#2DPT@.'B<C
M5R1].L()1%LXGU=1?QV[5.I[CA=PA^`,8Z.YG"VET-\.!FCE`7)?(X20;<E*
M4KB_F]_']MJ@SX+?4CRA?IK^2#Y1FU4YM*4I2E*4I2E*I8=U@?;YXO?R6WG_
M`'9KC58ZE*4I2E6C^Y*_5CRH^Z+J7\DS_JYC2E*4I2E*4I2E*T)Y(GJ\8[UF
M4GE'T(33L(]4-_QH9;,;0-+)Z$'N<5A'64+EUP])@`>26V&(U[BW79&.N[,)
MC699-9N\_"&]B>)&L9<8Y[?U383I5-UT74YFI:T93G%$+`U[<AA\OUGMAR!9
M+)<A-K];::VX;>;F'3#)`T3<T5M5)1G`7%\;WS,A&0;X;/[O)3R7=.]HD6.3
MKL39$5X"E=,C\^Q9-PAAXE'P?9:N5:([9EL;^CQJMX.$5.NGO<U;(HVQ^BH:
MPS+%QL;Q6\<"GR`1K+##BF=N++5O3YC.ID+(DCSI%.P\921)$F.I@M4B73%-
MU-]O$4]\.8^O+9D(RX7LYUI[G"A\]T6E')17RZD+/M2E*XOYO?Q_;:H,^"WU
M(\H7Z:_D@^49M5.;2E*4I2E*4I2J6'=8'V^>+W\EMY_W9KC58ZE*4I2E6C^Y
M*_5CRH^Z+J7\DS_JYC2E*4I2E*4I2E*TAY"=871MOK.YHE9F<1G7-X^:;Q1V
M=L,U'2_==Y'/LU7P6"K"G1D,QS-)R.6.EL?`,P:+)JSVTM?3F\XADAQET45O
M*<;?$C&VSC$V!F5N[D3_```I33#&M6NVO39U?UACZ9F''C'A6/UE[E&1+SC6
M)I:[96)377J?)+#9;3L;&"JQT=*07`FMQ4RP4CA`A(!R@Q)!DLZ23UAL*LS<
MV(X8,?NB2U9U:XN%WMZ:4$%FHAU5-&&+9GFRX[B4S9$$P0]"*\65&HX<3/@J
M^G9E,+&BD%W$Z@P^2W:9"FG:R]T,HCJS8DJ@MF1>5C)YWU\8MSZ"0,KN;7&5
ME4^0%DQX)9'%`2PS%LN_HF"R9!%R'+!WO;3J+^8=[9-C'D\T[T.QB!IYQUM#
M'>P$@!S$9?JB<=(.<(,BZV=;9./2K9()Z)WY;/(EL7`H.YQ8J26,?`"0D@X"
M&9OJTSN9<%Q3RW2"BU&FFZY/;DJG?C";C@R,*V#Z)R5"D3W>0,RJ2N.I6;!U
MBO:0D9S1V29)=`3U1$1<VV_<WLL#'E-H$?[]&.80WM7)FHB,ZF*W6FQ^0*&M
MJYIUL!2LU?T7M(AK#,XC%NSY(,**B;2G4LR%&@H<G!J[<3&D69BJE+;'$274
M4\!>&<C.Q&_NDVI;G0F5LUM5`L$.YRH>+H0FS*4F-AG+RHVKJ1I)P7R:2L'R
MYT5'%4R"@G@*-PL2A@XGGRX`P@I(WB#&3W/P\FI(T/\`(K(3$<*0[F._.8KD
M$>3,=;?.@J:"YVHYGFT5EON%#4BV69=12%E*.%5%-/%\\P#9,P"8!RR#$QO>
M?.M5YEWFTNUU=H+"GW;36R%'P.CDW""SI6FZ.&`Z!4%1'-EB"U@@NAQIBI=*
M/&"!T`F?\%L5-"DS6``HF0`ML<3^FO<8'MB6D/QI85_G.M.]O>7R,4-&90FB
M^XG$+):Z855?"0BVRO("S8I()2,&1*Y(([3&9=G9=;.FU#(\$KAJ(R=9/+@D
M<R@"A<Z9$3=%?3G]S_[:.YT?_P!M!G^4:Q5,?/KN/#C33G89=G!#(N"B_(Z8
M>+?B/DR5W\Z28LBO%)9H+J4$4@V"PA1D,X56P<4@.00:X#6:)%47S`!@N0%#
MOE;+F>W/QRRQM-/<Z&5L<\L>UCRT&[8Y=G*^/:Q[30QR[.73M8WRQQO?&]KW
MM:_DKB_,_NATOTFCN='KV<NS_P!;09O_`+72_9MTNT\;7M>_2U^N6-O_`(K>
M>TP[)Y9>/`RS6D9D/D`T!17\8;"".^$=I[>1$X6JE/`5+*YN9-;*\I.%&45M
MOD5K(Z51EA01TDZIIP18Z:3"(PV98/L_IKW&![8EI#\:6%?YSK;:)9FB*>V4
MGR3!\H1[,,>JIE0))CYC!Y-Y]M%0.))L0@JE";B;"@II1@TFG@A29\N&:N,3
M-!Y@&`PQ,;XUDJE*I8=U@?;YXO?R6WG_`'9KC58ZE*4I2E6C^Y*_5CRH^Z+J
M7\DS_JYC2E*4I2E*4I2E*A>W&EGFR:VPSA0M$-<-299@(NRV";#<VQC\<C#<
M0#^/@K^3P1VX"VG$E66&\1*EVT:S/*).PI=64CY$J:-`@B`I_M-`S7)Z\MC9
M.?W(Q`6N<.6+0DT&C%BEK@\5Q[([@$^J*YEQW$'>H.!<5SQ!22@Q6^:0R001
M<H,34E4?`<T/@8!([][C`1Z=U3V+298.OHA&J_#$BMI\BQ>`H&I+';#F;"@@
M*Z='95)+FU0T^E8LI9)+1*IQ88\9<!Y.!*AW&SPO:NYQ20'#L4[AM16/:?\`
M+MJ@Y;HDAM>%5G<Z:#,PP=(!*[.,&59GGDY,=CP38[D<JS$A2<C73SML4XRF
MM=PD$QVG3A7%(-VM:B;V!T^GF4.5;0S<UM`1P!#&J$:;+L5YE5EYK161'&I;
M`MA)04U0:S8*,D\@BIC6%2\3"Q=8>B2>/!C98)I(3(&V0^F#2X97JDS\UT18
M7&@;UD87*I//*4BK)975\'PK&9CBKQ`AP$8:UR%@R.32E-9<:XJ/?)RCD%6/
M4MMIY1/]$JVLA-_VN@'$!)6LDMZ/'I(=#25F)QKPMN!#4+.)NJBB.X9C'V>F
M(VY&\\7*WATPH68X3'AT3T-.-$$5%X1:D57/G$4R$VD,@H+<Z+WA>'Y+4"2O
M(L5QN_51.*63R"B]&(U'4?)$,C.1K(B4.KR0H&BI/(R)F8R+%Q@P;CYYC=CO
MF5\[PX<"Z4F(4>\F"&BIQ%(1D;F@Y%4M(24LF63TQ+3"#_:Y4BG)R>3"`)D2
M)(L$$7*$RH()<L`'@""%@'ACC:=ROE"]UUW_`.N(>GF^T!`/WK?U>6/Q?C_\
M=+56"ZW_`!?JM\U.M_Q?JM\U.M_Q?JM\U.M_Q?JM\U.M_P`7ZK?-3K?\7ZK?
M-3K?\7ZK?-3K?\7ZK?-7U>>Y%+]>'=F?G`3]]ZUO_6%&O][_`,?>\UK59^I2
MJ6'=8'V^>+W\EMY_W9KC58ZE*4I2E6C^Y*_5CRH^Z+J7\DS_`*N8TI2E*4I2
ME*4I2H5-[^0#=2!Y\":NL.KL23'"$+L-J2AM*ZY*FU!C.0%-$<QQQ*!QCZ]-
MA27$WQZ]FG'K447VIJ*Z054-8S44MI(Y6Z[8;$66QM2I'#R5<4-JO9LN)8R;
MY5U73459(J9P-N'C>1`BKF0"8PPA,H<-XYEB]S>(&8PX)@(/#+(L8L'@J=S"
MS),@-;6.S+BM]Q-*4=R./LFFR(JN,LH`1,=LE,DNCM-`14TR3=*D^%%P*J.;
M"6%9ND$!+2SRS91-J%DU(/:5:X<:.H^@NSC#>L:,*5G4MRB0D)@,:0I<V/E:
M:QX>5Q6YF\C3$9#-DM<5T]`0GDQ6,X\#+^+'5%[`Y-LLT%`V80G(9'PF)I2E
M<7\WOX_MM4&?!;ZD>4+]-?R0?*,VJG-KY0G==?W8AZ>X!`/\.K%5@J4I2E*5
M]7KN1/[CNS/S@)^_B!&JS]2E4L.ZP/M\\7OY+;S_`+LUQJL=2E*4I2K1_<E?
MJQY4?=%U+^29_P!7,:4I2E*4I2E*4I527F68_$VL;L6<^[/'CM9MV?:D%QJJ
M3SL?#@TQ"1=JQ%:FN/Y&B)%>*?&CX:A=057>YR;L53H6!09<())L@I7-*!#`
M--(YVX#XFULBJ0MG$V.^,.;>+&83K3BQ278PEV4I&E4"9(84UQ\BQK)*4JOX
M44)!<K>7RCO;3[9J-C;-MG3Z275CJD*8*6(2F;_Z>SIL,1C^4M0MGUK47;6%
MK.<K'DE!ME,?D=O-FO7)"'>D2S5'"P7,ICR8SA/-9N+*4>$*G%=B.A'*.-`+
M&1!#Y`]KMHQH[R$H<S)VQW)[NZV]GGW':"XF_!,20O':7%\'QBH/,E9%>,EJ
M>!!LL]7D"1U5JXC-)`/+B.`49*`O/,HFYGQ'+D(GS0TI2N+^;W\?VVJ#/@M]
M2/*%^FOY(/E&;53FU\H3NNO[L0]/<`@'^'5BJP5*4I2E*^KUW(G]QW9GYP$_
M?Q`C59^I2J6'=8'V^>+W\EMY_P!V:XU6.I2E*4I5H_N2OU8\J/NBZE_),_ZN
M8TI2E*4I2E*4I2J].Z>A2INWNA+#+CKDXV]U>7!H,B&\FP1KLUW/C&IMLCW?
M9!N.Z27FH)($>6=KUQ*K24CMG-QX.(XWFCB9LECE0N^@92XW]:'#J_MOL;'T
MH;Y[;[CRL4AN+#5TW:QNK80;58*F^7T.C.V(7H!B;8[G;;O7BBXBNLBDJ^;D
M0EQI)P;B3$\N92>^3B4I2E*XOYO?Q_;:H,^"WU(\H7Z:_D@^49M5.;7RA.ZZ
M_NQ#T]P"`?X=6*K!4I2E*4KZO7<B?W'=F?G`3]_$"-5GZE*I8=U@?;YXO?R6
MWG_=FN-5CJ4I2E*5:/[DK]6/*C[HNI?R3/\`JYC2E*4KCK;U[?KM3K;U[?KM
M3K;U[?KM3K;U[?KM7/6U_-?K2E*4JN9R;:/\D6SDMR\RM>I2T68^M4Z1U'#4
M6F?M0QW`\7XZ9);C8>J.LN>-E!NH9]0:YQNMU<2@D%51SX+G2E@!35DZZ>#_
M`+\]F#C*B;=B%=BY%C7<^9=*7T=:.M\>%(EC33]G&8U"BUF*,H/8THFGBPCJ
M`AF2*8\E,N!=GK.&%R2L9;CLL$%<X6/G#LZ=*4O?I:][^:WEO6@"[R6:Q(>V
M1'2^P\OKDU'72BLO/)K0#,+FC).<BTW";LNF*TR)#1,Q@FC(C?4"B@Z+F7/C
MBV>^W)K-RA\$<J%VJ!N0#6C9!_%(]B]WGU)1<C<DEYQBM*"(;2VM,S+AN2\H
M=E=VQ2N#Y9@N=#8<DW+-M6''!2C)X!12'4W2BXRE=-<AG=/*_P![\>/WK^RM
M4&G!;ZD>4+]-?R0?*,VJG-KY0G==?W8AZ>X!`/\`#JQ58*E*4I2E?5Z[D3^X
M[LS\X"?OX@1JL_4I5+#NL#[?/%[^2V\_[LUQJL=2E*4I2K1_<E?JQY4?=%U+
M^29_U<QI2L,3QL5!&K["%E'8F7H[A..P59,0<GG)KK2&>W<EQ9R'Q2D<)36#
M)8`=4/V*FA"I`"XAD4$H;'Q"[P5'$#TE].MXD^O3TQC3SK;_`.NC)M;X5U#L
MW]Z]=$D_F(XP'E';X:3#Y7-4(C>KC:RVBM64465(E=:M'R^HD!BJ4\$MMO+)
M3::^?;YP0)2*I+B3SZ*>&+XEU$H8*YB!917?78Q_UZ?9<[&Z^X_QI=/A7BCI
M_K7..V+`OGCA]ES,:_7/#&_6(>-##'I?*UK]1<XH[WATM>]^UE?LX^?+R6O6
MI&C?(T]=A-:&-*VR/=-[3UIF%PKDG)[DAQ0AGCS+FFTFM*4GDT&:I"!.J)\5
MO#%YLI";[V"N;_W0@3APR(=2%R_7;;Z[&/\`KT^RYV-U]Q[C2Z?"^I1V?]:W
MAU4Y0=%82;KI1]@N>#7?<A<6ETJIM]U/M8U>B,VST@%,"*&&Z23H50VFD*Y<
MX?P$51%!9`,J`(HEBA<0,MA?'/:OTZWB3Z]GTQC3SK[NC)Z?"\8]G_6L^:\\
MA&CVV;N5V#K1M=`DZ/9";PSM5VI%\EMMWKZ>V2ZB02#*^92THX,;P22RFJI9
M`R>L'D7+FE$@"-F'F;+V$W%I2J<'-P-K:L[DOPY.NI')KL7/$>:Y1>9TKF'3
M5D/9S1OJO()@:1W45>`([2?;42@)6/2:GM1==-G4VWN"98Z$U`2I+O8(I`UL
MSW/,H0YZ)=BK(\(\@)39Q\-*-Y'VMVUY$HY/QI).Q;\/K+E22J3&C=$=SL3$
MV,H_-EUS-.121C$\A$U]`3E=371@BXQ*T-2E<7Z7MTO;K:_2U[=.O7K?IY;>
MMZ_XNM5=F_KZ:&WF.3/QV;1;Q)3Q5MW'_'?(9JAL(8DU*A(W'L@DWT9D.<F6
MQ'\U6DG-P!!S)([@A*1&*IJ:`[`LFXU&\II9HR>*F=:N)+5:?FS-?#BSW&RG
M8T%GCPU5Y'H]VW)*J0LIJ8TWE)L\GFE&3*.K!@N72%@_(F`(DK,L`B940UR/
M48D_2N'B520E(W8.W%XZT/<9\-1]*>WO(!KH.U6KZ$\&WJ-M<[X%9:\%=9.K
M&*\YFPA)J@15G4%F>$3\5^]RYP5)`(IYBXP)`G<'0WN>%D!1G!/(#&Q=RO)Z
M`1]R\[[L@%Y2,XC#OD-VA-5ULU$#<S\=IL(`VZ7FNX$K*;F<1H$(PM+)DXHC
M!X"&,L;6`Z^4)W77]V(>GN`0#_#JQ58*E*4I2E?5Z[D3^X[LS\X"?OX@1JL_
M4I5+#NL#[?/%[^2V\_[LUQJL=2E*4I2K1_<E?JQY4?=%U+^29_U<QI2JV_=/
MQ7P[2W5,CXV1D#([R8:A%`UYQIR<KMU#&,9R,$`LN%(6.B2JH*4-D&H+*:J7
MLG'TTN:*G;V+"B7M7EC>/X_-!NKZUJ/6-))T]<X)+N^VRC):^44IMRHEK+6<
M7LX\C$4!>")9!7S)E4!-26:GV+E@UA85BX(0]D:,!@&LW6'JW'[&EQ>/^&8R
MWO7L8RVN'#J'WKLBJ@<9L\5')-]?"3<@>I=/;*:GM-/N7+8+2ZK$@\!</&-8
M^CXT;=6.K\>L.;':=S-XRYO)L*R6N7A!M9A88XJX,:M&R02;R_@F7+VQ`2FH
MG%6X0#!+8K+A5"(=LL$:L"/QU%TXZQ1^Q)Z?9S,T!+F[D^LIJE(&:-P<<`U@
MK'32!2"3;7L4S``*P**T"(2"``7`LL.11)8=0T<1_'XZLZ<-98_8FP\CF<C1
M:5]TIR9353]>F+WG'&RJ3CYJE4@LV5S%,`QQL`BLXCBD!`E@;+CD/$L<\0^(
MZC^/S"VZ?K:X^8^R<J',SA64MQIL8[72=<8]N6QQQ4B+":Q)'+MI:P200L@B
MR&S".9(N`7`Q6G0<3[9X8([CZ/QW`Z,-;X_8NS4NFLC).4]P9D9342-;HWR!
M#L`I$6*V$]'+M=9R22^.%@&^S21@KB7+A^.',9)]^!P\H[C^/C#E<]M=&`R-
MHYE'Q'(R;MM+S+:R+K)&5P@L@E0@R&REHQ9MJ]DH'`4$)OLL@;L&`$%BLN<8
MAW\+'=;@N18G1N:!PXQO).<P+YKCEFN\JR.EM=&:3`67H3V:@`J`DQNEMA+2
MVL&VVREVLG"!(%U,L5,BX!F%4T9RRP!O&TI5=7E6Y*'UH\Z)L18X6I1<&V4G
MQW%\6Z"ZH(T:I[C9<PRC((BHFK<]8*Y5CBK#N/QHJ&[(2^PC4@AHR&&R6]DJ
M-*UY11U?+8#B_,3-'#\=&ML];S*6[>P3.@N.9.VK)N7*,3YS6N<I#<RZ5M&;
M'5H[04(T38CA(H;CQ]!+N-.15;QR/DUUIPS60Y%36R#-52E*\>S;K>_EO>_E
M\N65[6OZ]L;WO;'_`/&UJ6QM:_6UO];WM;\5K7OTQMZ]K6M:_2WK6KF_F]_'
M]MJ@SX+?4CRA?IK^2#Y1FU4YM?*$[KK^[$/3W`(!_AU8JL%2E*4I2OJ]=R)_
M<=V9^<!/W\0(U6?J4JEAW6!]OGB]_);>?]V:XU6.I2E*4I5H_N2OU8\J/NBZ
ME_),_P"KF-*56Y[I["[_`*7ZI`>A<-\V'Y+]1`,V.**6`#>P8UY("$9V8QW'
M(D%9TAYY(/?#EO!,/&':,WL#;.]H$))[)U9;K<VC%RE!\"V+F8MXYM:K=\9;
M?+%L<?%F<K*!"Q4%9*)6&6-SBFZ1DADD0PQ!$E+5BV-PK)*O<VHMAM;3#7?S
MJ&`*#15QQ:RXY#MD@"4MVT@:55).R*AK1`B'CC<T?<.:*Q"(6(F::GJH&&8.
M22;6,GFPV=IQ/10KF0RF<3<;^L-KFD@,J#;'-)%E=22O%V"V1(Y!X9&C2P*A
M1^F_[W,D65`;"`WXDG^D"MAM;49^,S1L$O>)>-O6'J<+#E@.EDR\KJ2'X!9:
M3RM[`"GLSXJ`P$J]A12@2IA@*6RYDJ]QK-=M[4"VRP.%RWU)>-O5ZV1T52+@
M=G)/#E530?`,UL@7QR#S4,!A&_'I"V(HY;-3[`Q;/F1LKY@M=L;3"V)$3H!6
MT1\;FK_4\>62P-[8IH4I*K=LGB+1(/*P>9X,0=OQZ1OW[/(=2RP$+Y^$C_\`
M8FJV=H\[(*$=!`!B+C=U@ZGUIQE`;XV3@924VW<B,LD,+7!%42H8S?82=EB,
M-D;4!0QBXG,C];$&JVMHLO0NWCP1<*(>-_6'^GN%S@!WMFEEY15&S8@*L$["
MAXW/EBV2$PB>5QA#!X\/@.`+O]P]!2<7YDFZ4D9F1K$Y,MQ;39@P(4CL8J<%
MBQEY;4P%D33'BH$<`$XVYEHQVU$7!)*%TDH"!D"3N8SN9&JYQ2E?GD$'GGAG
MGACEF'>^0>5[6OEAE>U\;Y87\^&5\;WPROC>U\L+WPRO?&_2OYRZ<0*"BC%2
M10N,/F*(.*`6`!$&$&$[Z-F*(&'CF)F*+;O@F6>660@G^WG>^7EK^RE*4I7%
M_-[^/[;5!GP6^I'E"_37\D'RC-JIS:^4)W77]V(>GN`0#_#JQ58*E*4I2E?5
MZ[D3^X[LS\X"?OX@1JL_4I5+#NL#[?/%[^2V\_[LUQJL=2E*4I2K1_<E?JQY
M4?=%U+^29_U<QI2JV?=0@J>7TGU9,*SD4&6E%^2K4@=3>:2)D$J,U/!QDD4X
M[TX7`$SE@>:Y?$1=*9>#CVL.GX=H$7'KAE`PTL<DAA+JO"@6&G>MY[+-0D+;
MZ;>]F=AYI[\)GD94VF2<V8JL4$7.H@R6X71:YKOHF(C4;)<6^`&?#+QR2V,X
M%J"`\-2]>3N/ATD[HSK;PR>YCPRO;(949Q)UW\:!8JN=Q;ISC=%@\.^BX"M5
ML`F;8@Y&/;),9CE7M?\`#'5V!CUAE"3MW]@,?&$XRY@)?+(VI,D@[+AJ66!\
M7#/)-<#GL5)=L0,9KM@,YB&%F8V.1%HN=>UX#MK9"2AB,>E+>W86_C&:)6#O
M?+PQ18)%W7"4Q0SW8[XDN%RV3TB^60>3<;5CN&&`G#$MX"UG0X-<P\=?8=/8
M"')6WZV,ODH2W)X-LKXG%"/D]W=Y4C()VV6622ON#!+0`1.]XH+=R-A!6S\X
M_P"I)KN=PZWA_4+B@_@.<EGD!V1QLH2G)06-[^'J,>ICMR+GCP!S,(3)-6G#
M9';`&>06:"WQ3H87??RC[^C-UTN'6K'ZC<9'PQ3,M\ANR=_&,E2(!:]PSQ^.
M$]V7*'CQ<Q_Q)*VM8HK2"S[UBDH0QP,',7F/,<PD%TN/68/ZDL=*`)@W+G(A
MLM;QC(3_``,+WNH'XX377<H;4"8HP0MD]56<4=G%<\PK)**.:#"S%VXX-@XK
MSYC<U*)$N455!5N-B=3:I-LL75A%[8%>QVF@((Z^DPRM]Y/'6XEXV#14HV$G
M)*6('ED&E$;%@;CC7?J4I2E*4I2N+^;W\?VVJ#/@M]2/*%^FOY(/E&;53FU\
MH3NNO[L0]/<`@'^'5BJP5*4I2E*^KUW(G]QW9GYP$_?Q`C59^I2J6'=8'V^>
M+W\EMY_W9KC58ZE*4I2E6C^Y*_5CRH^Z+J7\DS_JYC2E5Q>Z:[+66H&H.+;(
M)*LX\N3_`$VQ;Z0OYBA(*NN7-R%9(2%P4'$04%&5%"Y<@JC!ABYA$#!@2P0E
M\>]Y0"'[X+<IV"7^WOSMXAFKYDV<BV\3:G:T'!KY6#%4A!L3#=3S2;EEA@,=
M5;KK]5[@V[R21SEL!+<*M@EJ4`2CO[>^NW*.+B,G1JV[61M5=;#`F>-@AUS,
MQ<R@$#25EECAFHN&ZX^5?$+L%TQ*-7!&KE:O@M2:6)/S+/?';-(&#-H\/-#_
M`*(U7UQ,B6#L`:<0AOPA`(FDW_ALL.JZR]%.X60!5&3!L@1ZX7^]K$F$R$CY
M9;U;8I&89I`@IB]$C5S74?.V.)8XZ1C=QD`B*GW##Q$6GADJ.TX,#WLDA)XN
M1<Q;EQ]A;DHFGRB)EO'M2D"AFV[KS'MO%6L.O0^5NR5/O(<[WQ"`'3+9`X&5
MMZYJCH/=Z["<W2V=RYBWBZKXK4DD4R6LK[M;1I0H1UK:T1EU2]9H!%QOC<B?
M?!H[81&#'3,+V#$7WUDHKIO$'O!%MENI<>WFZL,5B1$U+F/.^Z6SB9<$ZTM6
MXMQ\6ZUP+G:U@2:B^S!VXB*%=,M8`,ROOS(\M"9`]A+;`8>18>W+PRP5I#2T
MB:KY[E;,)V8!]GZG1-_T?KG!@N-@_`5%_&CE\T?OZ3A?#$1RO_(TI#A@W!3&
MQ@'D7'QWVX@C,B#<VI@"6)28+WD`GQDS,$N,&,BQ<!FP8!GM#`625'Y`:XHJ
MJ?.&BF&2LI'ERQ8^.-AAWDF6(8EK9W/:4I2E*4I2N+^;W\?VVJ#/@M]2/*%^
MFOY(/E&;53FU\H3NNO[L0]/<`@'^'5BJP5*4I2E*^KUW(G]QW9GYP$_?Q`C5
M9^I2J6'=8'V^>+W\EMY_W9KC58ZE*4I2E6C^Y*_5CRH^Z+J7\DS_`*N8TI5;
M#NHBR+?2/5ZSE"61VUZ9)J;Z(PFY8Y=QY-^P,EW6_0[9.RP4;K^*9X5DB>+\
MK'O&EBO@?4SWJUX&UOM-Z,4\F^\L="-2A1,BC9A=C7MGM+.X@ULL<"*R82+'
MEM"/+UNQX6D(OC9YFL#-P'"M%`LO"`^5/MMN,B0+MR#X_P#4D4?O"%%K.Z7V
MHGHP8QOA@54S"9906V\<<8=\+#)J59;?!COUP5M5)@9V'"X.=ML1<5!<.0?'
MWJ&,+8!)8C>MCEM9/8QG+'L`GAB7C-=;9UQ8"]['))UUU_C6,=A24"102PH0
MUVVW%@.*O</CWU!$$M@2;25;'ZZ^>S`]L/\`=G,RME-=;9]P6ROB:*%;K\A'
M`S=_#310J+WP'D2PC;BS#`S;'CTT_$%[!=-*7QMMA/9HQC>U@\KA^-%QM**_
M:]KV#"]$$B'P3?9%$*%!+=Y\O4O%G_H^/;4`4:_GZ?783Z.:];_RJNM@VX\1
MO_G\D#V-><B2$MWGQ"L*W(LSR*]GCVU`%&[0RB:M;Z[&?#1C&W7,.V=E5=;:
MDX>O3O@GHAD4^";Z@AE"HE[`^)?')M18,(G=[X^-/QA[9'%Y1O:^UT_#&;?[
M(@7?[*:ZVC;E"&O8(<S9P2&/B8M<J7)%!+X`;F\(B>@)_+RA!L>`5J!XY&XR
M)X,,?T9"8XR-)Y,7:G7W)4D9^D3`AM;(*BD>N&"0P<B@<631+M&Q;$P!`2F%
MV>E*4I2E*4J._<8CRM&WNU,]`W'H`BQU@ULK/8#;II[$.!YC/:RP;R#$;)F'
M7.B(8+7\1>`89@*1?-7LK8G!/",R8A;`")K572GG^T_3)T2HQE7B$6`-A-GY
MKVS>XKW8VY2F.GR1/"RGKCP1FU=%<+?"),M-.)P6#;3U$%56R@`HV"FOJV=P
MA`MI_$W=)?\`7[A/_P`M-XOY_JO_`,B?<TG+!R;;(J>T<^[#\>C5D%59S.9)
ME(B5+V40F?@E,DB83TLR"0=K?>RQBHF@C(@JD)FNYE1!NS<H4)A6N%?13["<
MWV_"KU`_Q9M^C&GV$YOM^%7J!_BS;]&-/L)S?;\*O4#_`!9M^C&M8]LNY/\`
M<?4:-&])SUV+UD<B4XIG@B$RJ>ULY8NH@KT^2RU8B;JL8\<,%.+62$9;=A)2
M6^]#"'?%9<UX`6-'.\%A=F_L)W?6_7IM7J!TMEEC:]Q)MZW[.5\>ODC*]O+T
MZ^2][?CO7/V$YOM^%7J!_BS;]&-/L)S?;\*O4#_%FWZ,:?83F^WX5>H'^+-O
MT8U8#X[>.#G@XR];4O5N`I>XF71'R2\7B]RZQ+#-W`77@(J/8V4.JA4<^U%5
MEHN2<5&)X63@PD$(T&&(+B;-G+][R#WH\3=TE_U^X3_\M-XOY_IXF[I+_K]P
MG_Y:;Q?S_3Q-W27_`%^X3_\`+3>+^?ZC*Y`N(GF^Y(G9!+RG6:^+)LJNO2?*
MJ:R08L:FV2*14@)@!9@#GS<P3J%>(QP8F&Q4?Q'DF&$C`MD.H7.AJ'?@/!M&
M?L8?E7_".X_/^5[&_P`L4^QA^5?\([C\_P"5[&_RQ3[&'Y5_PCN/S_E>QO\`
M+%84V4[GXY-M9-=YWV/=T[Z++[5@*'I)F9R(3<2Y^]$*R@QDT%=Y*Z4A^-$(
MDF^-SY!''*IWC`X5)>%BA7-&``+""X>\A+N=KD^G.&8DFMNS[H>D-^8(Q8$I
M(:4M)>P/CA,1Y"::0[DQ.5O%Z`:(^,B))8`*G_`S)@KX4$+X.,(%V,[Y/^QA
M^5?\([C\_P"5[&_RQ3[&'Y5_PCN/S_E>QO\`+%/L8?E7_".X_/\`E>QO\L5O
MCQZ\2W.'QJ*$^J<#S1Q7.@SL:MQVO/CZJS3VU6PDLW&;=66R@@M;!J&&9X$5
M.$5LT,KXJN2R,.<"+9DAR`&(Q<:2KQ-W27_7[A/_`,M-XOY_IXF[I+_K]PG_
M`.6F\7\_T\3=TE_U^X3_`/+3>+^?ZTUW;T#Y]-](_C..I<F/B4::9$T_19L@
MU%>,F-MXFKGH_B$RKFVL34[NU4>*0=;1@PLCB+"=9)`/&_!RN!94)!V,8F-0
M&-P5\S#-?"U*BE.W&7),N+&1G`O*DHMK:1V.QKDQ^^7#3603L53VDSD\GD)?
M,L606V3OGTL";$,%KY`9<,C@JYEVB^U>5UB=N,N4):4\A\"4FRHVMHW2XVF1
M&M?L);%3@2B6T6:GEA+]]`"0FV4%RR_W0XXI;+,#,S."KF8:[_5):7IWXRY5
ME<]D+@FR+*K:VC="XSR0N'9LF,1)*E$AH,XB%ET$PQ1&X6,YY6M@,9$!OF%F
M:/!5S+MR0U&7'%._&9*TJ&Q,L$E_RLVMHG,J,HD+VL,4]@HI0HC-!GE0NWVL
M<DAO@&Q+XVQ&.9X7$QSU%X[..[E@W8BMK<@3>E'CX=#BD5?E-O-16V,;6Q+D
M>$=AQ?*KTBE7*,Q`:0P<>-!/.+K+4%1)'0DVZIDF&B6!XX&9\+*X[=-C@JYF
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MP("%#2CDJ$%)1%`/EY0/$W=)?]?N$_\`RTWB_G^O=MI([HIP<;?R>#ZX:!6E
MBN)%W2&W8VW7#<&;;LHEKKN"#F??]R&"UDE>%V2LCW]#Q4+E[F_Z/82IK[]^
MZWZ7#Z=;].MLNO3[W7I?IU]>OTI2E*4I2E*4I2L"[%ZX1KM$Q46.Y3+K)EN(
M,HQ#+R>&A*XB*<Q>$)2.W938XHIL,`QD*G!.IKI8BH0OACBHD,1R60H-AN^X
M9YM:UK=+>O>_OY7OE?\`UO7-*4I2E*4I6+IPA]E;"0Q+4#205/'8]FJ-'S$[
MY*):B.D*9EH2&V5-IN,!.52UKF$T\*D*QO`H?!QR%*&+ACX8Y7#MC?VL6QPV
M(=C*.XD90!LJS8N8K0CIIECYT51/%FRR&\G-A!`.*`]K#GS0*4EE`S!P:W?3
M0V.8XG^V)>N^4I:]K^:_7^ZE*4I2E*XO;KY+^O:_ZKVO;_6WE_%6NNJ6K<1Z
M8P:U==H-35=(C1G*[_7$-/75TZY%0`[),ANF37+<974/Z68!S=#P6,R00G6Q
M(CD6)899XE["9[%TZVZ].OE\_3[_`$]>N.MK^:]K^_7-.MO7M7'6WKV];S_?
M]:N:4I2E*4I2E*XROTMUZ=?+:UO[\KVM;WNM_+?R]+=;]+^:H8=1]X=G>1)K
M;.3WK`%"T?P9&,H2E!FN"!++->3F=L\/*)DX,FN2,_70VY%;)&+XU<CT-@M]
MIHB`V76[""41/.=Q&S!D0%IX;5!\BNMB)+B#KZ]WO9*EHQ(<?0&Y1R#<<9J,
M4'9N1(S'E5M0`:DVQ(1HEY)<30('UA"0!E;/$7'-(0SB@6=*ZBHJABAM<R.B
MCT/$4]HOB15PPNL?9QZLWOD'2ZVR\@B:<X#B[&,QA'G@T6\2<S]C@,''(^VB
M(^61[$R5$3#AL,;M8]#COFSU"6H.UPE:4OJH14ZMGX$<^Q,81'C#<PR*]7(Q
M&8"F'W5BV`F`P5L%VJB`D+J,IFRZ)<8,\G#*"VC"*#=1U-6*Y+>?*?K.;$DQ
M@1+()58EU&0MET6,AG$R'K:,WW-FKT8?5*EJ*4ASAA(I!RNN,4LT2-/]KIBX
MEJ``!!WIJ4ICK3(>!9`S]Q_[#NG;7275;9I[HK?;KOG>"(WE1RH35P4@VVDK
M3S;A184$]##6#ZJJ8)94P8S")XJ"D>-X@VQL.:'SZB7V_I2E*]0OKJ0V$-8<
M:^I%$="0$M06EI7/BX`$4M)2B8Q]34C@V=[8!%2!$N8-F1,K]G`$$3*_DM4#
MO'9RIR+L#-?)+"LMI36/ON#ATS:75YJMISMX4L\M-I1C1#78T0QW(E%!2F#P
M;:X4+E),/*8)@5INJ2`VR/90!;6(YGJL'<Y"NXM4-<Y9D'7Q3<DTS1J=L?O2
MOQY'+M;B:AMC6O7@YX6Z%<@MNC/'-4>)_!63&8PF8*7+CNE>2%56="^QDD0,
MU?9MI<N:7,\R7AO6+5:<=@CHL2ZB["EWD@+T4,EE`P%M\B#+K.D56.R"\4%7
M3C#;)8`Y+[,`1U-S&L!#1U'+&TQ(5SQ/U4;<R[`EG7C/8=D:ZS<J)"$54TZ5
M&9B.QLWI`S\([,8:TB-*:R!5>,EF830SI5RRX^W6"85TEE0DS7"]S8"AG9)3
M57&I;GH@X_'.OKO*1BN`+4_3KLMK@@@K<@,]#C'ZK^LRX30E%C)$YFRV;!47
M!-(RD4-Z[@N2[&2I(+%E@(\LM9130R!_MS.Y6)`R>7(::>NO:L:C;4G=&/-0
M6:H,EP):C</T3I4<@*,NS(N*`1,I'L5HII^>CZ1'L*3/$(SC\MX+=.=*TGGQ
MC6.&CS3K,\/#BT3(%@WMH>]TV[@QB_?1>^$*RBQC&G#9>H;Q26R?2BAM#<B>
MY7&CDW.@O;`P7\*9*4(GAM8NY7($"@X^@_F4$9,-:_H:HU-@=L)2V!5>3E99
MKH>0>O\`#YX`/0E^N5:D-H.\-J*>+71D)%:`Z8VXU<:(FKZFZ0$PJ:<Z4BG3
M8^)6<+5385K[9ZUP3LTRTA;;[5GF*&-*Z"@N3$GBOHB:]T`FN@)"SXN,&T_-
M23/"\B1L4@:,$QA@,ABHN8(F%ZS_`%`YR`\I;@U(WUTBCPLKLP/5Y;F,GK[N
M$HCK:,(\&O(^R3(-*.M1O!"')9K:,T68:00W3(#KP'"1[);Z;R89SQ,Y@]>P
MS[R[B:Q;2<@;4EV,1"VM6A.I<&3JX7@UE<@LR&^77-2HZBJ(BH[;/72297)7
M6DQ%CMO)QE2!)E5@4ZZW*X2**>)E4[V+XYJ8ZBA0<[&DJ`Y2+S5'FY^M&E4A
MQ,QEUDO533'IMY')638'>C8<1H^U$)X,URHQD1%4PL!$1S(KI3E,EDBG$8(F
MX#W;TCE=4",SD-9I=U"F.$]D7-!S3F^/8H>#]AA8%D,BZ9[2X!'9K6=S0=RV
MU#SS:2VK%'8\2`:B*41F0)Z(\39I-P'-`=*MS;1:3E2=HK7M?9P27%#>M^T>
MR1=I!`MI3EE=0-3I),QR]&DMQ*74`E]BNV0@_%$C0L74SRJ0>\5.%(=ZJ=:N
M9H)+%ZL2Y@7)*,G<73;@R*60\&#R`2YL<W\W\CS$@NM$]`.OL+"2$84F@>)H
M26.$>5U=5#"7$]YH[8>C--1Z[6.L,@%QK"<<3^DR/STM]';^X:,T-;GTES'K
MEI/-FY3<8,I.-NMM6$;T*3(IP8YFK,S:2\E%?A][A+5F])*&S3&3C-NR)W*A
MK!961E92#3@O!S<I3IA:5`'[-F4MFBC.X5#&_KWUP8J1#)B+EP-N2ZS41XR.
MA2$H'BLC$Y4R(K_BEN1R9,WC01JBY&3:T`ZL+X9;]Z2\B2#N1+&QT,_4@>L1
M/37AL:SR$?*.M>:;C`<D>[71F?E",%8L;:1PZ42E\JDI2@G.YM#F#N"0HA`7
M3UI:*&._AZUQQLWM61Y(>4N'%)S')R96O^J&N$RZY06WF<RV<9">DC)LQ*9U
MEE%ZXY93<2P[U=HH*&$MO%V`II0,4O8$)"`#.'#/0.';9Z?Y3DC82']Q9<W#
MMLVP&A%SL5];MLM>M;H7+LAIN@^YT\:3(3=^O#>)D)CC-T.I./,TNOKZX9/H
M)EHXE,D^XZD853F>&+S`PG)$L,>&TJ-973EJ0=_]K..\@KG+M`-/3Y*U19I]
MX/)\&<RKA,',62X21+,JU,P"XCAL=S#R5T@B%:][QU:G<@>YR!L1M=H7L++^
M4B3),C9:<W<:LF*S(8"2K9P](CN<T7O1+7$AF-1N-QTF-7SS<5'XOJ2T0'.K
MJ0TG8=7S(1(9,3\NV\9.\6U&S_'YQA+[XFY6=VRFX^T,H&9)?9UKL1'.E->=
M79.E=PR4&G-QI,]#:2&GN)GQ?'\.*A\!&P.A+$P9*9(^65S)`8G9?M;+I;K?
MI?I;KTZ=.OW^G6U[].OFZUY4I2E*4I2E*XO:U[=+^O:_OVO:]K^]>UK^MZ_D
MJ*O6[CL>^E@L]1]J?.#:8.M\Z2P[IJ38X=D3&'H]X'?$CE4T&0PH??6,AHC=
M-M%0-IH2RS6M(D>ND%D+8H@ADZ[T*UV\+C5U\/C;<^R*A*>4QJ12(G!O]!/)
M:Y(OLT`!78<V3@*+_0"WR!"2+.`(H0C-S.1-:DE.9!R9)A9#64`^VD193FNX
M1"R7BJ*^#<HQ%O68TX]ES;H0-<3G)>("F)$0%6LK/`ER76,7?189;-20Z2B$
M8C3,?JU#0:$K@K-L;XJQ$M:]KXY:UOXF%;7Y_<<3V$V++/8/CPUPES69!3C4
M-`H)F269)P3=3B*N=42LFJ0+3<#51&>W"??RR8X`%\[X^/&`DT!6*)Z1T(MP
MGHY&1Q5DA/9\O&#6G'>[9:(&(-'X!M::4P;XQ>I1NZ\':[KNTOF]8]B\=TOY
MT,=NE4ML.!8,N5(2'2[#1-J8&%R3C2O6_P"L_P!3M>]7,7C>008"BEHQ24>N
M3?LU17,GLQ-P2$Y6,M[%;<>"6=,D0"]SI<):/`7-XC#`9A`B8%P=GZ4I2L33
ME$*-/45N^(W$X7DV$![D2Z4MJC"6P6ZYLDK!0)GCR855QTY5P`(K0!3)(6P+
MDA<5%$.*"8)?$`X+>^MSSX\X!>VV4=[H'O1FD35'<3N:#@S376TIN-EXQ8\\
MU,PYV=(+=36X$$[4Q2458TL%['#0(J"LXE55LB(ITD5%"UY+\+>H"5$L80\U
MU.;6@AQ+#4_ZVM5PHLG7-O3+6_98N$4E""U1PN1OKWAC&%+E$[)HG0R19[L%
M13PUUH.])7SRRJ*FS4':$Z_ZYS>[IUB$FYFJJNZ#X7UW&99=?!'CA#BK7I(N
M@Q`WVVWADS(\E9LU*&4"1,]X],F#8:H=LI7-WL4N4Q-(_$]J/(<=[`1V427O
M'A39;:QI[GR:Y(W=N"&YCL\,M78Z^BKI,RII"\C9(6*ZP4M;,-)80UE`S7%!
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M"'UYGU/S&4@IF8R=??4J.6V.R.6NSK`J63DN9%-(.1H&]VB;O@.AW+W""QPW
M]UO@)B:LP/$^NL89+EX[AAC(4=LG!R*>"TN`-=M%;$44HHJV!0CXP')$<`BE
MC>94,88($/(>XH]Q!A,V7MUMTOYK^?\`N];^Z_FO^*H]YMXTM>-B]>IOUJF<
MW(3]8$_2FI2X]U)8<*)=\$G(>=J,]"I1HN\!IA*+51F^L-Y%`:Y5,PL=;B$F
ME6XE*1=""Q(6ZN]N)[4N33<Q&Y,*25(!C875AD:ESC9T2.K'`Y08D:"&Q(^>
M3F`+%B87U66:*>,&D.0DK!,.%U7/%<&(CKN.*G7I'#Q&ZPN_,RNNQQ3"Y)(5
M]J(-W'<\Q'G@VR<CNZ:]:F<EL*"3Z\?1F.FMS-KQNV$DL116<EME+0SA@915
M%P!55%92-F=O9(U1@Z6)]UVV9?#2!5I?U9QE+&&W)D-WNS>QF-MDFH]<3)6P
M=PU*QI,3R^2;X5E>Z4?L(>)7#,"YY7T)BOA0U7AAT`O%AR1M&G+J:PMGXV0S
MX\WBF33<:^UTD82^_L$10NV`U0DN-^2K".YFNK-0'<V*H+@(\U5ZA$4L$CDM
MI<2FHC)<L/OMN)KZ1I"A;96;=JFV]VZ[`&0IJ,J;&H(35FBRRA,)$:[(":[Z
M:Y1+05%LMEJ-HJ7))@`R<*343ZX>5L'1QP-Z0QN17$@%:V%=[><NK^PVGBVW
MWQ,QI935"!ME)9/S:^6Q<P3;Z4KE5--D154UMO.DBJ%G%F8.YFW6HNM2`)'B
MN7GQQ$:NR*$-@[E^;5@R>T15>.=443<DA&5)7UJ7G(F.U;2%`Z:;1@41V**X
MCIQG-V@>#G"9<L&F)98@F8XE+9WUNT0A75F5Y=F>.U%_G7Q-T?:^QJ_3+N=!
M5;3SC9UC8YF.XGL032R&E`IA]*;!TX55CX&5\UXV;&45/$0[?`7#^,/0J*`)
MXV<V*+/F:DV2MLHE186DQ00I'NU\$ME-1)5T9CY1P:;"(C+\=N5C@.!<-MAW
M-Q=`<1574S"R=/J"GB`9!RG!^M+:A4%)4C;TD:9Y'2X\;,4"31-BPWW1+*Q'
M[3551;14%=<C=:S/(*>0:LM**FJ+`J)BON93S`470JK)XH5,`18ZV<,3/1S;
M8F*?'K):)/[;Y`=I=]$I*A^81,8N0W_.+W>J-<)*+FX_15DPAO2',F#9]MU5
M&/&4ITDEU,;3C*-U772J[(0U]#(*;*S&;TPQ="S+4.QE,421S,J\I(IZ2&RS
M)S<:0Z7P4+G`&X2;9PYXT1@+(!]2:YL9`(G%@@0MB66E/`STG3WC/UVTC3XA
M1(</26<;L#1S+T81*WGX[B3L368@3O*:',$IGB`V3=3E4TX74[FVBX&%E343
MHY1"(AH1'$L0R$PSD+I2E*4I2E*4I2E*4I2E*4I2OXE(N,;('"A<^;2QS9<4
MJ$ID,2>1Y/$,8W!Q.DL5$H?(7-E;YV'+V.D3I3OV&'A!4P#VPLZL4(N?D3G7
MB\V0;,%.F;]DYX(<F>TL5*KL,[2(.NLYA0#$<Y+141-CN=%AJ++8CQRF2+6;
M[.3"Z.R2;=3$EPK^*8E(I'&P0>]^HFWX40\14U[)J+8VD=4AZ?,G;1<F>*]R
M9BPD&>RLQZ\6>+G?L4N2;";8#0UY``/I8"$P7PW6=@CW9!E!40V[8Y@>(7ZB
M)R+*NYD?;:0BC,]X:_*[8XZM4]K4.7H]EU7!?3;6=O(_<KK))[9'1FTUSB0K
M1"91"PI%Q65CA1YCY9!*C93$ZQA//0HR_OIO&C\1^^6NKEF^:6CN=Q2R&\F5
M.VR;?<+E07_(;;*S$ST/5URX/>V>)PX'-C0?ZNOJIK`YBJ+#;A\P96`BI=XE
M\3MU*(0\PHKCG`4XIJ`OH%:.8Q]955)<5CHXS?3AQS:DLK!L\JJ9TR.*(,9/
M*!PR;,"YY"##9Y7ZUD6E*\<[WQQRRM;K?''*]K>O>UKWZ>_YJ@%UEE20-YN5
MODTC297Y(34B3C\.0)$L'P"Q)`?\5)JJHRHVG`]'5L!)1AB.%JKL@.%P9(A)
M(C8)84#+/:+6&N=1&_Z(CHKG-^^Y2Y&V(U2X^U:&=5IM>3EVGP:;^D=D2E(&
M2\\GZ?8D&N4*5'4CGEE!3C>*D^7D1%;<$-<=>+IY%=&<9XT;,%14XU8+33DM
MVT7I?XB6ARFZR3[/$9+TUI>C:*VD*.9DD!GM2-+KVPA-O30A%VXU5U(059YJ
M*BZU^-WJX5U,55+$BR48DBF$T,`?(U*HCR?KP*^MD-!6=MWLJWIG<2PZGHHJ
MJX4FQ><L'-$1F1Z>>:#&&QDQL-S1XF)9-#\,<#;4+OEP'V0JO98&:^&"DVRQ
M=+AX9+CVR@]C:R:^.G9+8&08,VUYJ2T=1:[)8E19<.S%^/<]%C\D!@-=\RH&
M*GR:A%)X>\8+;D:)I44TI]F84O@3P.I@KC4D=M8)5IJY,9ZX]=9YA3$;<^8H
M?UZ5]TVML9*>GNYC5U>VF=J+".QCWBEG/0TEN)@N\78`^RX4CT^>4&RFB)2N
M^Y$,CJ^2IX["%N#L7*/+NPI4Y!N*&((&V@7F_"/UR(<=2!'ZGG("9)DRYNG5
MQ3R8+@F@ZJ)Y`4XT<WV]VFV6RW3HJP3>,@66I)<(^:<E,93*R,\S,*SY)40-
MU9UCVGV2AG9Q/66FB:O1W"\EDXUCURRH.\4Y7=SWGP(!''$?D4LN,T];7'TG
MO=3'8K49R`M'B#>6'<XB!)1U+VK=>X,?\B,,SK-R1N';CZRD?5J+V5,^HNYK
M7;D*9K3P.ME#1W#LKIXBLU3=+NCV5)U>^+;<+P1)#+ADH]S:J89+&L<BZ8IR
M!;K<G.>H$QOJ*,88QD`-E<;VW_(!FO>C_)M"*(FJV21;"*<4NS-7;%L7QXR%
M[3UNH#7;ER^%L6LN6'RN#%UR`[C[#Q4N:'<K4;OV469K@SHOT^E;=C6(D_'*
MY(Q4M?\`<%3=K/<CS,-(`CBEK;OA(XH-JZ:X22$B"J`^:>K'RP>1'`,'.6HL
MVSM(_.9,S?>LN2H?AEY<<+!VAC>!U1VN(E',;BOJ=C+$9)X"/@SI=$+.M2AY
M+;RJZ;*:>8.%'BXW()G8$^%AD7L9TI2E*4I2E*4I2E*4I2E*4I2OP,E\#9<<
MJ)D-@&8!%`SS+&!BIC#$7#+"^8!HL($8+#X6R[0)@`4,8`2V(H0F`F&.5M#4
M_C)TV1(T+Q,VX\>34:!&?,MHTG-K3O/Z"ZT.?QAU,T?D]#?R?)X3X2EQ;'65
M81QE";A#0G+=2/V7TA1Q.&+"=MVPU:,S)I9LAJS#ZDV([5)TBV4&#@X'2E*S
MG1?&4LEE$J]%UX`%E`!Q.,XY<%M=&7U3)6NNGSZF,HYGLS=K"5C-D<4.BT>'
MG(JM.)'$DK#O@=AZT.99"G'8`PL*T*QGB$`QF6.LGI3-K&.#;2P"[83E_`_B
MZ;,LN`S!UP9LXB)@N8IAT5U3GMD3''<KQ$E.=I[#'F.I3L2!77<VS\OG(W14
M-O,@61'"TW"A.-TXMY(;+?*$P5)6%`SLCD!#01@4OCG6S+8;B4SVZB-5#P.!
M(S=2B"*E!*"HJ+9T).3"P9,D$:5UHXH*ZD,"6!""R.*1XV='MA;,P8%$O?._
MO:4I6K+\TT@1_P`QX;"&F^YV=-HC."CQ8DZ*)*D>(78[6&6-B'R#1?9Z-72V
M`GVBHIX88ZV0G<76332.#CFFL;1AQ1,\NVM#6:%V"[\'TRVF:;3C"BM+A4N,
ME.QYETDI'**L*;A3D8DV<G#FV":@$OK2LM#NDNCANY04U$V<4EXX,-EE?64#
MBAT'*ZX*.HI:"<B^MRK).,O'8D`E&9P6UG(6"N5<(:\`('(N*P1##<9(JY`T
M1/5"K=#<0&"[@DXJEKFK[=2O!\;3A$#O@>4D=4=<7/\`:8S&>B`,[WDE'7*U
M#8`1521U1TH#@27<,`LE`KDEX7%>#-+I(P?)*XYTJHGP3.H$4<3/'U!,5JL-
M0UKH@1PQE26VA/>`+>=,@Y.)$FE@8$0F3)K5>BN[55WM1V-<).`!2#[>6TX(
M``92+"%A2ZRKA'N]I7'5J(W52*55IQDHLG.&XJ<$(-!+8TDRFS6R?B9UJAA>
M<S&?[0;;U36M*:0NN(X=<BF+)*0Z50PXE!37,E&RDIJ!DSFU[:W0C(CP@I^.
M^/DI4=.M#D5G=!BB":5T@&.U];9BA'JD;2$M$4DU'-`#,U4.H0::L)ZDEE"P
M@8Q(D7.%BID'7G<3C$T:W]6&8N;>P42FL['B.K(3*"7'W*:&EMQ/7S98\N73
MD)FOEM(F"@KCD4ZRDL"IXJP<+IB63'/YE$TB`7R6U]*M=&9*+REQMLU:3G*_
MS4:*;M1,Y&DI0C)4<$.(C?;D8NP.'E-W'8J2WBSD5JMHDF.M&9Z<N"9("(>/
MG#BDDIQTMKM/?&U'&T>X*C.\^%4M]1/?3-?U81XV+KTGM!9ME)KX=BI-@CE4
M&0]&V@O!C2"R3S,0L&NZ$M9$1%YJ`N-'%33]\#&>:FUQ_P"I;6CH6(R<4V5H
MP,P<AZX'H_>3VD1_,]4AQN**DL)+55F\]W:OI:F;!55A543#L.E17DHFU`R(
MH.`UCEA@'W=&U%@!O[*.';Y)91XML0ZF"3BQ>D/)[R`9S4(W33_C9-9&36-N
MH=D%VXFJUK*R>GDVT7P)JG:40,L#F8@V>R=*4I2E?S'13`)0R*4+XFS89<;,
MJ5S'Q+8F3.(>5RY?(QG@)@!8<:V`5QLL,\0K9]\OCE;&^-X9N/7D4FS:W827
M(ND".H]0$A,2UA_$,&R_PE:\<(S674Z!5-FM5<]#1##9=`,;%QOL4D*TTI1&
M-4YIF&FC-01F*WC4FL89[V,Y6-4M8)0EZ')&%EH^_P""8)2]GY22&+#CW>Y9
MK:\G%T%OJTN&EE$)"(PK8:1O(T.Z"X)[)PD2*:HF22(I>#VP$VCD+:[7**('
M([.2-,;%9T"JJ`TW,C2>N+&!5M+B0_"Y`RR!4$6P>9U<.O`-43L6ND))(XL+
MQDZ5))B>9.#8`7Z;!6RKVGMUJ!I(UKE^-H-+-T\?0Y>F\%(C!POU=P5"`"65
M9T#J)@_+J:UCJ.*HJAETRPC16I!"EDTHE,]<+J@ZFE0Y3OS!RA&^Q>Q2HCEF
MU];YJER!Z2Z)NYI&&]F87GJF['MP,>9)3%<.0OC=+<<;.=S(1>.T!&PP;ZJC
MLMQ!N0NM&WVDGV-(AO=MT\8;FS0/5J-E`FV'OO'L`\H[-R";0RKC,,..8GBM
MQR8^E=M(RIWQOF7@KJ!1I-5%%<A561TPDN+*P,BJII/*`8Q7/'F3VH7>)_4C
M>B+VQ"2(^)+VB96K<]D'.B/%7*IBT)L(L02Z7+%J(672)`GXXNV172DEW4L.
M0HA%'&"FB!JYQ&R%-V@<,KY8WO?V8F/O8B98V_TM:O.E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I7AB&'A>^6.&.-[];7O;&UK]+Y99WMUM;KY<\LLK^OE>
M^5_]J][WJ;[5PT_]H.;;D&UEC!X,EF+<\\&+<@U9<3W17`K$FRC27-ZLWUYS
M)I5$'+Y*2VVVXO&U5)1#69=-7%',F1-K:,&$8&O9)AO6Z.XCUAB75`5-)/Z,
M8IAB/80!(/E)3%TJZFM'K01V>3S<Z.H@'4E0$52B.$:42@Q<8G<<83`,/O6&
M'3I\'Z:1-K:]%=?@]2D:/F$MH!U(,:^)[_7E;7A(4S:N650W2PHM<HJVFQ.K
ME,`3"6&E10<93(.)RB:\:-`^?!3CY&.69.'%+E+8F6W9A("(G0-L5N%J/NY,
M##&038CMM(^J#<&1QV,US@(V*0,RYM54AE+[S6U84%=:GB]\)R*06Q'JC*K%
MR"[M!=GI+<,*3=,FPT92OL-J1O#,.PNMRM>+A(Y99?7J3V@M1UCK@]\6V855
M7!03VRMAJ>$EDB2^JX+;?0"RJ0<X.!U5,8%>W"NL@\:FM7'K%LS-=(QA^?&+
ML@_97>#/63PS\D!OR^N3D[BZ0U$9=+70DEV/-PFDQ)R/.)7,--IDDXAD&X3X
M69ZT_P`5[]X.#<S@$&8R#QS,!@"9C`!CB6[8V`(P@1<04+`3++$,7,`',3"V
A.>8(>5[X8_O2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g927875.jpg
<DESCRIPTION>G927875.JPG
<TEXT>
begin 644 g927875.jpg
M_]C_X``02D9)1@`!`0$!FP&;``#__@`\1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?4U1!5$E.7TM?0D%2+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`2,!C`$!$0#_Q``?``$``00#`0$!````
M````````"08("@L!`@<%`P3_Q`!B$```!00!`0$&#PH)!@H+```#!`4&!P`!
M`@@)$3$2%!47(3D*$Q8945=9<7>6L;:WU=88-D%8<G-VF+*X(C)A@9&2E-+4
M&C<XEZ'P(R=&2%168GB9UR0I-$1D>8:3M='Q_]H`"`$!```_`,_BE*4I2E*4
MI2E*4I2E*CZWTY"(RT>:8A)<(GUZ:7W%$[._75AJ*4[$)CR])$-,`X]240'Y
MC+-I78K`=K[$!`2VB0="@347&:S%*-PDJJEBI`U5NF.\\2[HHCKPC\4Y=ZQ.
M0CA,FM-();B4F$T)->C0#<3@CMG2R:0TMERP<8"J"JMAV*C%.*19&5B&!=7#
M3C)P`M>]BE*4I2E*4JWK9W8QOZL18:EYUQW-<DMI+<361EY*@6+'%,;W0DEQ
M+`"4>>IQC-'`RYSK/9Q<;-<>!Y"3EA33$0L8-DT=3&PP*B6#Z'<HE]JWF-%#
M@C1=6GF;D/9[`O)$!-!V/[6=DQ1$\KN9H0Z-+$XFAA&@U9:F!GH@3B2XX3E1
M7<..-PSSB0&#=92T'"7VE*4I2E*4I2E*4I2E[].VO&XLV*@&<<WQA"\W1)+>
M<9+PS6D;&,Y'9[ZNPG,6N:L8;[RLUUE4]32R!<D=Q%3ECO,SAD2.8W#[HH8L
M%_:T)WA5_LYQ2$R)9CAV,-H64,W6\V^]6XJM9M!)22"OJ!A>7B:B*EI!4HWS
M)5P"FU`T7*V0315;Q&R2C)<X)43`D=@2JW"[OC5YMA^-8T:.D0'`TEM/7TG,
M\FF,RBB1N=33!@`,\GFL,RQXF+E@:)F,<@3`(>=NYJM:4I2E?D8,`%0!C)D8
M(N7+A"#CCCB8!`@@A89""BC"B98AA!!!XY9B""98X888Y9YY8XVO>U!VEB,+
MVM>TB,2]KVM>U[/%M7M>U[=;7M>RKTO:]O+:]O)>WEKGQKQC[8C%^.+:^M*>
M->,?;$8OQQ;7UI3QKQC[8C%^.+:^M*>->,?;$8OQQ;7UI4:O(_K`QMVHT<!-
M`V<R07:W83GEK1M#JS-28D:FR'+,BLO-(C=X;.QRA%U$_*Z'&#E+E%ANMU9S
M66>5&-'CJZQ7A<,NGWKG1.!(WTY:+@(C;/KKR,R"BQ8>6XK<$]`/>`81>;58
MQ=$?B7JLVG88NY8OBU[.T95=&3$'6CZ"D"9)Q-JH[32"82(%?CXUXQ]L1B_'
M%M?6E/&O&/MB,7XXMKZTIXUXQ]L1B_'%M?6E/&O&/MB,7XXMKZTIXUXQ]L1B
M_'%M?6E?W)DB,):/ETM(>K25%(W<3$J03G,A'CIG((+,83$`H44!C`UPP0Q!
M<[!!9WP#PS$RZ88Y96M_6=]M&FZKJC?<&YFJ*$O(:B>1UM$6=BX=2U='5TPT
M*24DM433KS`.)ZBGG0!RAXB;!!,E#0(I<P$&*'GA;YOKA^@?X\.G_P"LS"?V
MXIZX?H'^/#I_^LS"?VXIZX?H'^/#I_\`K,PG]N*>N'Z!_CPZ?_K,PG]N*M[V
M;GCB_P!M(M,PU*N^,`%6"JN%L+;C38ZW@8D7J#I3VXK!*8[/<#@8\F(R\<9;
MG"#S2G6WPE$J$LI8V8%QRXX9<T!8[I&Q>-O5Q^B38Z.1'4-2F0H[]CRB:)$&
MTL=1/$BO"\L2NY'U%S%D&&TJ4+L-Z.*&F^O"-QJ.TXB`J:24S`2\3:L4;K<.
MDY9O7#]`_P`>'3_]9F$_MQ3UP_0/\>'3_P#69A/[<4]</T#_`!X=/_UF83^W
M%/7#]`_QX=/_`-9F$_MQ3UP_0/\`'AT__69A/[<5^@/(3H08&"+E]W-0QQQQ
M0P```=EH5%&&&&SQ#"!"#P>]\Q!11,L0PP\+7RSSRQQQM?*]K5=]AG@)AB('
MECGAGCCGAGAE;+'+'*ULL<L<L;WQRQRQO:^.5KWM>U[7M>]KUVI2E*4I2E*5
M\5R)B.MM]<1G`$&,A*Z.II:T"*9&)!BI*@1'**0>9TN.5,$\,R0P^.9L`R6%
M+87R&#,`Y86$QPCW^F:<O!I<Y6Q'&_(.N;067WQT/Z"XHUJU9<D>8+J_$6OA
M3O:?]IGW%\4'C.,;7>II<M'\,8+Z8WW$Y6>V[/8`(R9D<B4)^$;B&I&SA[E&
MRBH082%O6Z>`L>1S+<S#R;@:0&^&>*K=1B.7@[`D)"PZ^8<_<]"V4:XY"J>5
MD+O2^607HHX9P;NV?H@I?CMC92>F-W9^.5F#H\,NDDQFU($[)^G#`'>C(Q?)
M\FI([2-KPQ2*$AQN$ZG'0&_F>**2D4,Y`Y@Y5=$W)]NLG;D:M:G;N<;"7J@!
MM]XZ4N))#:&Y,>;'!B.J$HU%E1Q);A;#6CYI#HZ2.VRHX(*UDK#C^%1B!8!*
M-%Q3IHA.1;RVM?V:4I2HQ.:484#B8Y&!`11`1+:<SUC80(3,/.V(C#5`\\;9
MX98Y=SF'GGAGCUZ9X99896OCEE:]JFN7!7Q&N[7Z#'2X]"8`5G`XX;BQ<7%0
MT@+%S2DL*S";R@IJ!FX2Z$'D8/'C!@T/GB'CW8HV>5[=;WO?V;U@GAS]SYUY
M^+ZY]H:>L$\.?N?.O/Q?7/M#3U@GAS]SYUY^+ZY]H:>L$\.?N?.O/Q?7/M#3
MU@GAS]SYUY^+ZY]H:>L$\.?N?.O/Q?7/M#3U@GAS]SYUY^+ZY]H:>L$\.?N?
M.O/Q?7/M#3U@GAS]SYUY^+ZY]H:>L$\.?N?.O/Q?7/M#3U@GAS]SYUY^+ZY]
MH:C?W)XVM%])MP^&Y^ZIZRQC!CR=7)"WV<XG$PTU03U)7:X\$3`K"H9P8TIG
M;9IXBDFDC>8-L<>Z%`P\ML;B8B5'PF\?>B$_Z3J4E3II;JC,DC*^V.[Y56?T
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MJ^6+K5#C4=[950EI`P"4V\Y$-GDEA%40PQ!0L#R:<*FL0AA@K"V#%%PSR%HG
MM:T81W:UK6M9B,ZUK6\EK6LVDOI:UOP6M7H%*4I2E*4I2OFK*,D.)(5&^OI:
M<N(2XG'D=:15<D64DE725,J*24DM43CH0Q,^G*!,<8H=)&P1BQLL,*7'"$"$
MSPOXQ%VK&LD'JBHMPMKI!,0K2XD>I]:5XOB&/8_5%=!L8"-^!%10:3=2#:@D
M=]@`F?!IL88EWP"$-Z1Z8'CE:H&?`T)1^S7%'3'B.-6BP7?BHX.IE-UD-I):
MCD!5DD%OJ1=>;Q--"25<H<;Y8LWQB:@4,%;H)4JB8@XI18`F'4<?QM'\4-HN
MSHS9378+5*&3ITNWF@AIS?1PCBD8S-J)RQ!,+EB^1P^:SS,G38F&9DV/E<4<
M43/RVAHY"?/`<!'PD\B_[EI^IS,>RWO6^2N:4I48'-5YI7D9_P"YU._S&4JN
M^U._T7M<?@&ASZ-FQ5P-*4I2E*4I4'_+?_I+<)W_`,T9L_N[S=3T/C;IQY7_
M`.]QO?V7M?\`YW4L^Q4X%*4I2E*4I4/_`#[>9TY!O^[RX/\`\VWO]_Y?P5*!
M%'^;&//T%9WS:2Z]`I2E*4I2E*4I2E09<A/G@.`CX2>1?]RT_4YF/9;WK?)7
M-*4JE7RQ65)S.<T>R.TFT_6&]$11;3O9;Q1$UR-5TMU7+YDU5"<*`KES:6L)
M"D5$$+'TY0*CE#8&>80X6>&5\;_:24E+04M-0T--(HZ,CD":4DI*84`(IJ8F
M)Q8(DGIY`D6P"+%"1$F`"5*%0`PP2Y<(,$+#`/#'&WT*4I2E*4I76^=K7Z=,
M_)[`>=[?TVQO:_\`->J$>$9QK(*HQ5Q]Q^SWFLQ@ZPWW&ZLZ6JEKRBP7L$E*
M*&$[F:=5")HPVG*&C*ZJDX+B.(44L$U2/$L3-BYL<//[;:;#69J9X%:+<1&L
MC]_*2GX*;B&10TWPBLGAU17/]X)1,H4[]5%(T94%$UZ3WP>/&!S9H04P*()E
M]_TS'V,__MB?W:YME;+LME_/CEC^U:U=J4I2E*4KXCC;3=>"&IMAV(*,YVXM
M%!"*P@.%*(+:(JDA;XW$)J22J%S:>?*B7QQOF7-EA@<[XXWRPO>UNGUP00BX
M08``08(((>`00(6&(8000>%L`PPP\+8X8!AX8XX8888VQPQQMCC:UK6M7Z4I
M2E*4O>UK=;WM:UNV]_):W\]<6O:_6UK^6W;;\-NO9UMVVZ_@Z]M<TI2E*5!E
MR$^>`X"/A)Y%_P!RT_4YF/9;WK?)7-*4I2E*4I2E69\@FT2MIEJ',6QZ`TT]
M[KT>)[:\#-E74C20D*"FZ7FW6<4S5%`B"8/`IY`1?\(F0R0.1HV&4[S!$+Y#
M]\@XK-_1.FWUKWM]SYK9?I?IU[YE6W^SU5WZ?TWKB_HG/;Z]KV^Y\UL\MNG_
M`+5*OVKJ*"6-ZG;,<EON57*4GY!<$A.A7=RPBQUR![C1^Q$M16C.1HT1:+)0
M7H&CM9`+B97P34-.Q[S3B]L2Y?H%AAC;S[[J!1_Z9MC_`.)GN[]MZ\S:6PTL
MI\@2RK.M][3KK#7U!FBQ6UP>1G<9/,L<@G-JY)WE3BL1>6"FOY.!Q]%<`9;$
M&%3@K=Y$+X%/X-_3/NH%'_I>V/\`XF>[OVWJ[34OEKEW31QNYT1HS7(_CSS0
MT]`4R>QNV&T&P**GDTU2$5`#3;2'V\!2[?51AQ+@G%(C?T\T2QQ)YVQ"[KNK
M[/\`*=-OOQ?-;/[3*OVKJKF!Z)FV;5'TS$IWZ[P,,UU=V-I'7\6XKR.G+V"4
MKK9!,/#I!M3659/P4"I<V(9*AG4\<L8&"P+C9`!BY&`LT2U^MNO\N5OZ,KVM
M_LM7-*4I2E*4I2E*59+R&C3$#JC(V4)#S0`Y\QVL"N_<SYQV%LV-'8SF3`I&
M+ZYB2UEC'.,RBM')2Q9UG'B*/F+WT&U@\GKFV[XQB\*8DPYN240PA^8S*`PV
MWW9X'F3%C#.4+2X,XR&*0+!(*+EXU"["R:@#KQ?>;QMFRS2[BU<6+E@HDW58
M3(4I2E*4J#+D)\\!P$?"3R+_`+EI^IS,>RWO6^2N:4I2E*4I2E*B+YU_-:[.
M_FXE^FV.ZUVF7;?W[_+7%*4I2E5.R/OW9'Z;LSYTI%;9?'LO^5G^WE7:E*4I
M2E*4I2E*L,WUT?'W:8S*;21LWLMJRY&*^F\\TM]ZXR*=:BF>P1E(NH")2ZW#
MUE!GK^>`Y4NI-M:5$,RMM)?)$U)'-]Z9JJ2JT#H_QSJ6H#_?\G/7=7<G<5Z/
M9FMYA)Q[:>1D5WDV.U4->4G*,4:::A-Q!"`.+*RHV&4SZB(>&P+$BA,C@3#$
M.W-R8TI2E*5!ER$^>`X"/A)Y%_W+3]3F8]EO>M\E<TI2E*4I2E*5$7SK^:UV
M=_-Q+]-L=UKM,NV_OW^6N*4I2E*J=D??NR/TW9GSI2*VR^/9?\K/]O*NU*4I
M2E*4I2E*5'MRC$S*CIE(J<"[$9LE%-PQ@DJZ:Y92DR"FQ(R,L22V$I1B1R3I
M#A%0DJ&T24`3OJ0/R*VP@0&^&I6S=)LJRAW(-A9'Q$QSR%A+*&_-G67#4":]
M1WJ?&>M4)Q'%$[Y[&JDICL1<`,I$WON24XT?:YC!ML\EFR63W@?/.94)N-QC
M.\^?[Q13-YY:4K\QA+@@BBV#S&N$'F)8(*X=A!+X8WR]+#N+F$%W>?3N</3!
M`P^ZO;N\\,>N5HG=>>4E,E47DK4I8AT]`#4XW7RJM-]G7'(#8=*FX$IM1D>D
MQQ.DV(@A8-5N%<4TL$"E)X#F<5Q`Q@QE%2)G,Q4TK::P>;B3_N+MBMZ9RU2A
M=G0O%:3'J9$9R`M^8=VVRFN69-=Z6R$*,SZE&+0)I47'$9=<[/P=QI<'6%9'
M)K"@=+-M1P0S.!B374+<''8A[;5PH[$%';,U:<3*E1#*B>V%<ZN-1<"=<>-F
M3F,^6F95"":MET9PH#C'2C*6LDK'DQS-APE`32HFXIZD:L3Y",K9<P'`1>UL
MO\Y7(O;^%CEC?_0M/?@RM:_3R]O3IV^Q?I.=CV6]ZWR5S2E*4I2E*4I41?.O
MYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4JIV1]^[(_3=F?.E(K;+X]E_P`K/]O*
MNU*4I2E*4I2E*5#ERJ[ML:*8IG"#FUM-(NH,[M*)X?GDW.34UFD">L8^B9U[
M%M.)3B@VT(FU%!DOQY.A1,GV429'AC%:20UJSP-ERJ8CCGB]I_!G(O'FJ/";
MFIJAL!NULM.CE1"TL;"2MMH'-S;"<IU5=%DP%31&$]TMDQ>BJ)M7-#!8F6&Q
M<US!%)`)SC=)X``@"-D>TI7Y#=UZ2+W&%Q,O2Q.YPQOC;+/+N+]SC:^>6&%K
MY7Z8VOEECC:][7RRM;K>T#>N6I.RT2.?F?D!WZS1I+9?<*<KS'`T+2A(K"S8
M\JH:5'I-H`,66#8*=("8T!EL\FX&\PE%N.9#"+C@!G3H8@0H@=J4W<(AB9H'
MW55==(1:6BKCVMA34A=#U$!<;0RC$CM;K--RM-2F[%0W$QEPQNV"CK0\$J&4
M]?99,4B:3CZN_P!8::*JBC)YJ1S5'0M<`?'*9+<[I2TRB_)7)R/B-&:.]@RS
MW8T-,R#4N&TK%5?D;+IDFW9%<ATV]7!Z>P72JV:R89:^9-T"KP9X%,C%D/CO
MUTT7YC.$4_!.4Q9&9(?>_*<Y?&I/\QS8#8JVM.%P\E^!"TJ/%TEFV/WPHFN_
MC*$"0,*85P`%$4T"4*A@96>/9;WK?)7-*4I2E*4I2E1%\Z_FM=G?S<2_3;'=
M:[3+MO[]_EKBE*4I2JG9'W[LC]-V9\Z4BMLOCV7_`"L_V\J[4I2E*4I2E*4I
M48'*H1V-2(&2I8@+=.$]+B40/1IO.3'KL@U$E:AL^TR;F1L`;KSA$4$1;;*@
M65,RA4@2*J1E+>_A`1F'D\`TL$58E9]Q-;,O^?9]E4"6N533;>MVI<-(0K:B
MS3UEYH*(S&X4?@N"](;T4<U99"\-FE151&J33B@I`01.$`/*0!NP:8*6R`*4
MI2E*@RY"?/`<!'PD\B_[EI^IS,>RWO6^2N:4I2E*4I2E*B+YU_-:[._FXE^F
MV.ZUVF7;?W[_`"UQ2E*4I53LC[]V1^F[,^=*16V7Q[+_`)6?[>5=J4I2E*4I
M2E*4J`CFJW*UF;;*<&F$HASPD2>[6:Q9B8<AQ_I";W5C>/E],?"N(PU]Z1NL
ME3<:ODPF+S)4E#*/WH'B`)@&EK@(A<X"FF@;2^#FT&FMU=CU?7A_S.!&)C7A
MG)Z%"LG<?S:U"NU@RLCV4U%749*3R:&M309*NY==P3%)'4+(:/F"Y`&6IK2J
M`W&X;-3_`.TTG;(LQ#0FIJ?!K?F*97L(IAI:G*+U/1C`D:)*4&3Q.O"5WRC(
M#L=1@&QM23R3=8+`:B\]7B<$."`V;[<1E]TI-DT=/KFVBYP"NC9V+^/G8"(@
M1O3%]N:>+VPT=3PV4>XX61E79Z%.))RL*8CR41[Z,#,X5UQ>L+(9;+!`5CBP
M,203LOQ8P&;+@&@;"V",`A#A6'`&+#>EC88B8>FES(81@`3N,K=V".$&,%EU
M#&##$QRPQ_>E*5!ER$^>`X"/A)Y%_P!RT_4YF/9;WK?)7-*4I2E*4I2E1%\Z
M_FM=G?S<2_3;'=:[3+MO[]_EKBE*4I2JG9'W[LC]-V9\Z4BMLOCV7_*S_;RK
MM2E*4I2E*4I2E64<@K6GIUZJR<C:U"2/A)Q\-M^FDH4?S,B:;'`RBKD3!GZW
M8AE.0D9?9#`DI6:%E8FTW,XTRP!4WF(33UMI*QX@[D*.[BHES?61903FSL["
M4H:X1M%.H3!C(F@;-S.V90V*V)EIFNI*2E>?Q45./**RW$%/0,AV^^7@>%MX
MUGBYT16.&U!00+!)4I&PCWV(C$\U'Y%$<(,W1PF`J):58H25$%LSD<`'-IHB
M6Z866G$K$8Z=JPD%0U4LIQ.]#3)%=X)HL<;$D)JVDA-1V0G<9D!3TYMT'_M,
M5F-K.V*@G%+Z1*;N^Z<W%<LVRRO+YA3R8L33]I%-W@^+]0WA#A9635)3;"2D
M)ZRV##<1$*.4E/CUV*U[Y*-*4I4&7(3YX#@(^$GD7_<M/U.9CV6]ZWR5S2E*
M4I2E*4I41?.OYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4JIV1]^[(_3=F?.E(K;
M+X]E_P`K/]O*NU*4I2E*4I2E*5B'<[<M:@(VWJ:B;837OO'[\C#6-E2+IPG:
MB$7F.SF%+RZ])BR4YA=EVP0/DE)\BK+*83:()KAR"3"S/2CV'>POAH8X2K'T
M/7*^O4OS=/LC&9HVJVOWXD^(VB\MH-A=A(\7X>8Z"WP'<"7:T)0%&B@.$F(T
M=M=Q*JZ.7NG)P!?"Q``9.*MU,5`&LEWE<UFG5MO7-JLU;OO3RYT)1D1/;4/;
MS*&R2%$[J7#=V<>.O>,E;6^;H04C\^,I"(FPFRV70?<1D\UE1R*S.R:`B,YU
MPS?ZCQ5K=JTVH=F6:)";9:7(>A]IPPYMAU1RFV0YYJ+H[53VH"BO\D4<II0F
M$947,,51@,AZ&)*<:.\5$J.T3!MWJ1M05[\RP^!HN`9#Q&PP'!#&PP,`#%3&
M&(N&(EL!RQC`,<N-A;*V(H`P>`H(EL@Q<,!,,L;?M2E*@RY"?/`<!'PD\B_[
MEI^IS,>RWO6^2N:4I2E*4I2E*B+YU_-:[._FXE^FV.ZUVF7;?W[_`"UQ2E*4
MI53LC[]V1^F[,^=*16V7Q[+_`)6?[>5=J4I2E*4I2E*4KR"6Y,9L(H&#Y7T)
MQJIAP.IAL,J08324':\'`O.]Q%6JUR0*.BAW43A(B=6,SBJI#Y8I;4;H2TY5
MLTFM]+5E`K:SJ%R/:C[T/R24371:=SS%BQ3=[6*R8H14^D&,)#+-%=;Z)((\
M+2XLH8#,DQ$;#F4FJ2<]FNMBCE\E1JK@A`9OKC=6C]8;M2%Q]I$?$HIY"7[J
M@@QK*_A'%)8^U[KBY#:[Z&:N:>.H&4-'D\^3)JZ@UAU9).744C#-1;IH^FG`
M31$P.6%RCET9UM]#NL38!#4=#B>@CMV1,8K2^T_%9+C7GB2FX&C$!C:ZX661
M//R0E./BJ<GCB`'%QM%F^"6`.A)G?N'?H!4>>_L[*5QW5NE[_@MVWZ7Z=.G7
MK:_3I>W3\-NMJX[O&]KWZW\G3KY+]?+V>3IUO?KY.EK7OW5KX].ZM>U<VO:_
M9?K_`+_)[%^R_P""H,^0GSP'`1\)/(O^Y:?J<S'LM[UODKFE*4I2E*4I2HB^
M=?S6NSOYN)?IMCNM=IEVW]^_RUQ2E*4I53LC[]V1^F[,^=*16V7Q[+_E9_MY
M5VI2E*4I2E*4I2H).8I6W#<+-?D8H.J&G,P:+&XF05^;Y*VHVW<FK`+;7RSJ
M6C2I@7>#754!1:"(V4]*:2E9]%W.VCP)Y;-)P)X0O@8#SHSAU:$R(3M1BSNU
M8T]U_AAH:B,-%UW-:H;6/R?F\>BQZ/T9ZMPZ5;3F=0Z(CH$A=PJO;QHI[8..
M&6UTJ>/NI\K)Y(P*X2)\AD'Z^OJ"7],LP:GP9M8\($BR2W-&+=G.+B4J(R*=
M%2R2NKY$DG-IOEQ$B!T1MHYYTV8+85GNL(J%DF("8KJER"88Q]^'9^P6J;O-
MA,C1=X99_7'$TI/6/#?'+I:[M;IAUY;9=M`"C*SC>1%K&$%;B%R'ATZ/3S:D
M9?3W>;=KC:2HBJ:^,BKB:4S`Z_`UC?,L8QQ$$"RR`&QL*%E;$0.^0>5K"!Y7
MQRMCGA>_=87OCE:V5K7OC>UNE\/Y&FB;H!@ST4V]8ZDR7'*_(&D]Q)T/NMXR
M,\Y!><:)EH$`[Q4&RY'8J+BNG%(V"7E)QMLKB/W@AV1RM@@PBY.U\+1MD-CI
MSUNACDFAV#G0\FC'QK1CA==X9QO+BZ6SCYU[%/5CPK/#S1%0`>YY&>,VL-3%
M+/5TEU(FOKCA3\7D9/&7/DI*QF=;0R>''%6P'./&MF<]W)!.G$],5^0Q%,5M
M4VZ5\DGO?6!OR"_XC@]A$+E@C!E1<S=]439CAN"DR0KO?RAW@2("N#(0>RU]
M[YI&Z',9PCDTO53>36ZS`?6^Y\4[N%K.Y=?4]W>J'3A=*8D6$;<"FH8.E21;
MD.^7$3*>EB)!,ZFF!^N)T+KE>8]EO>M\E6@[U;N0IQXZU/?:G8"[NRC-AGFF
MF*I9BM\)S.DZH/1SIC30R:4DF5-&)BYC*JJ7N.,=5B!4L5P&&S'OEC@$)`'_
M`)8]Q*_]6]O_`/4JS?\`S?KH+Z,?XF;!B7!;.WF0M@Q+A8B0NSL<,A+89>EX
MYY8R]E?'"^?<VRO;&][8];VMUJ$07T;CL_802P.D\!9!6$$L%D)(LGXYY!VS
MR]+RSQQ!RMCG?#N;Y6ME>ULNMK7Z5T_RW':/\2;7_P#UCRA_AZ?Y;CM'^)-K
M_P#ZQY0_P]/\MQVC_$FU_P#]8\H?X>I"M/\`T:!K6XV2YS6\$)/R,G^`[.]V
MDDZ[MW.2VR?9G@5.%\(K:J]WLU#Y%>\/9JA6Z>4)CD[)P!(Q8QD.,+@'=O\`
MY8]Q*_\`5O;_`/U*LW_S?J]_C[]$0Z"<D^PA36?7Q-GY,D<^SW2]B6<E1JAM
MINF4IGA$S"P!BJH[\<XP1_$N=#'+!&$\(L/B&*'WW@/Z4$+.Y2E1%\Z_FM=G
M?S<2_3;'=:[3+MO[]_EKBE*4I2JG9'W[LC]-V9\Z4BMLOCV7_*S_`&\J[4I2
ME*4I2E*4I5C'(S$*U-VJKQ8[53'<H//-T1FO,DTRX_BB7%-MNUMR&W5=#>2C
M$DXJB+%,GM9G&0+N-VLAU*J:866ZG*-F>I)C]`:JB5C:X?H*LU9;D1TR9R6L
M?=R;(0A]&U30858,;,J``]58I1W80<IYN/J$$=<4GF3>[C<Z&CA"N-Z$"69)
M/1<&^BGE1/P"R*RT;O)3Q7=.]HD2.CKK3I#6("EA+8)UC29A##P+/<^RU<JT
MAFU+0W_H\;+6+@%3N\'L:MD5;8W14-89EBXN-XS^/J0N2QLRC',/[,<;6O\`
MJ['JXREL9]3:Q=HV/+TA2$[F&TD\FG*[B;:?@`]G"I.!6&`&<;Z<BR]CY8X<
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M*@3=;K?;J?CED"124!#2DA+)DR1,,*HI.0FW3F`X"/A)Y%_PWO\`\RT_[-3F
M8]EO>M\E8X'HKWS*.QGP@:Y?3BS:U(]*4I2E*R??0BGGB&7\`$_?-U'K:]TI
M41?.OYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4JIV1]^[(_3=F?.E(K;+X]E_RL
M_P!O*NU*4I2E*4I2E*5%]S%I\?+6@TJMZ4BMAF,X75#*.MFU*=\=7F2E7-3"
MRLT]0E/8NR$YC4.Q/BI`E"DB.Y*0SRWFVSAMOH?>JLN%#Y2S3AHG;CT#56WJ
M]HY$6LC36RNH,9SM.:YJFI@R$VF1(2HY0VHO1-)LRF;*KC>[BR6#AM;CPR[W
M@L/(XV$=QC.1'0<BB4.LR"\H\3PA*NCT_P#C_49S0X^CZ.G9)R@OZU.-TMR;
MTKU%H1Y6&M']VL?(W<"PI%01TH-I.3`^SG!<YB6<9+O+"YPG!CQ-L5N(&[;*
M6574WGF:ZR*Q96+-22^3>3E-ZP8Q1E!"(&UK)!(!&3I8G(SQ2".+?3LU07#$
M1,Q5[%LQS9:U\<M6E*4J#+D)\\!P$?"3R+_N6GZG,Q[+>];Y*QP/17OF4=C/
MA`UR^G%FUJ1Z4I2E*5D^^A%//$,OX`)^^;J/6U[I2HB^=?S6NSOYN)?IMCNM
M=IEVW]^_RUQ2E*4I53LC[]V1^F[,^=*16V7Q[+_E9_MY5VI2E*4I2E*4I2K.
M=@=R]%8D7%F$-I]C-;(N57"RR2HI1UL!(\=LP-WL-X"KZ'B9#;TAJ9`H[&RI
M#H*ZCJ=@2JBFXC%AD]2QQR&#!%LDT/7M,4#;*2H_X^YUU5>,!O"&C$HO.%-7
MD;6*Z#%LE)LCHC92G`8<D!-E$<F28\6ZM*I%-0)*5'(.3,MQ0.-U0`)#&20$
MA^XP$>G=4]BTF6#KZ(1JOPQ(K:?(L7@*!J2QVPYFPH("NG1V522YM4-/I6+*
M622T2J<6&/&7`>3@2H=QL\+VQV.*'7V&(EW$:BN;TZY<=37/=$D-KPJM[ES*
M/+\'R`1R9Q@RK,\\GI3K>"='DC%6:D*3D:Z<=[E-,IK7<1!-=ITZ5Q2#>5S2
ME*5!ER$^>`X"/A)Y%_W+3]3F8]EO>M\E8X'HKWS*.QGP@:Y?3BS:U(]*4I2E
M*R??0BGGB&7\`$_?-U'K:]TI41?.OYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4J
MIV1]^[(_3=F?.E(K;+X]E_RL_P!O*NU*4I2E*4I2E*5&MN7J-Q</QY$IVWZC
M/5%P.`^@M^-&X^-ILH[`)$49N'7(N)K4::E(AU/)E+B*#J750Z03!LC!X<S@
M8,X9XEBWI?I.K6B^B>N2X8E_3V!X2B,1^LH%O*#@@Q`;Z"W7RU1E<DXDHR=%
M:]\DEPX$SQ6XR,JABCW!`.GP`1\P1^Y#JR=S"S),@-;6.S+BM]Q-*4=R./LF
MFR(JN,LH`1,=LE,DNCM-`14TR3=*D^%%P*J.;"6%9ND$!+2SRS91-J%DU(/6
M5:X<:.H^@NSC#>L:,*5G4MRB0D)@,:0I<V/E::QX>5Q6YF\C3$9#-DM<5T]`
M0GDQ6,X\#+^+'5%[`Y-LLT%`V80G(9'PF)I2E*@RY"?/`<!'PD\B_P"Y:?J<
MS'LM[UODK'`]%>^91V,^$#7+Z<6;6I'I2E*4I63[Z$4\\0R_@`G[YNH];7NE
M*B+YU_-:[._FXE^FV.ZUVF7;?W[_`"UQ2E*4I53LC[]V1^F[,^=*16V7Q[+_
M`)6?[>5=J4I2E*4I2E*4K''Y0M#9CV@VIL^H$A;C"V^>2'##`:#EC?D43YC6
MUC7Y(5G)(!IION.41CJ)]GGV1(BH3<AARE3K51'D>7F*;)DWBXDS,)!:EVO'
MAJ/%G'H^D/5.*);1<S*QK"S9,F;7Y+4EC)O)<N-]:0V(M[*1>Q%`ZJ!Q$TY\
M63#L(NEFIQA*::DO,9"6FLAX+)=_GSGM>_\`I[.FPQ&/Y2U"V?6M1=M86LYR
ML>24&V4Q^1V\V:]<D(=Z1+-4<+!<RF/)C.$\UFXLI1X0J<5V(Z$<HXT`L9$$
M/D#UO&C.CO(,AS&F;'<GF[S=V>?\>(;E;\%Q%#$=)4709&!YYD0T5W26I63V
MTT%F0I(5FM8RTD,ZNHI<DR&^NO$JEB*(CGSS39GZ4I2H,N0GSP'`1\)/(O\`
MN6GZG,Q[+>];Y*QP/17OF4=C/A`UR^G%FUJ1Z4I2E*5D^^A%//$,OX`)^^;J
M/6U[I2HB^=?S6NSOYN)?IMCNM=IEVW]^_P`M<4I2E*54[(^_=D?INS/G2D5M
ME\>R_P"5G^WE7:E*4I2E*4I2E*QK>8#>(IJA-KF#U]U3V\=.^`>LZ4J1=LKK
MIK;;86+KH;F4)526K!^R9,NXT-3$8Q=X()][I3?")K(K;7C2?(R"3/&0'`V'
M1X+Z'@$B<Y,4VNIRQ7R.'-[),B9)?>U6T^^[!/Q*2F(Z.]4@B49L,1^(['*G
MDV1'2M8<JD9!%TY02D(9,(&A;IIE&;+.RS*4I7P72YD-EMEPO!S*`*0VVJAJ
M[D<"J9[OO9,1$).,JJLH&/2\<\_2"1`H8,B]QCEEW`67<XY9=+7BL9?,9"2W
M#.P&P$F:V;W:P1)KRRVJ\UIX;3:M.6&"DB8/I>&;#+;D.%5I:-*$AN=RK^22
ME$2)`J5(EC;F;0:JJ)UU4.X=[FNNT3%V,'E]`0TU?:$BZ_R:-$,TQJ[?`F3E
M8;W]2K<?286,'&TL.!MKB.X68[F\XT%P-U;4TLX6/&$\88JN)"REI\8_(3>U
M^8#@(Z7Z_P#&3R+_`+EI^IS,>RWO6^2L<#T5[YE'8SX0-<OIQ9M:D>E*4I2E
M9/OH13SQ#+^`"?OFZCUM>Z4J(OG7\UKL[^;B7Z;8[K7:9=M_?O\`+7%*4I2E
M5.R/OW9'Z;LSYTI%;9?'LO\`E9_MY5VI2E*4I2E*4I2L?+E9Y(UK0-WRFJ(J
MS):I/;V@UC,;1K5ENQR"YFCLA/3W7GBB'7^=<"2QE%R.!2B(T,WP%F-0)`02
MQ)!*`GS#;5C\BM8\6]`XN!)\C:1R\![0;W*^XFTU];DR:=L&`X@8H4`]6I6>
MSX2";>8D>JD=-9NJC?:3D3PG:C+C&<ZBX`\52+T5]-P@QT%X$$,].;2E*MCW
M12V2MZG["HLDQ/+L[QZL1*\TI\0S`MU?QPRBTE%)&)N!BQ\&@.MCK1EQN5+&
M-)A4FENQ!.G@QQR9=0#S'M@)BO3%Q5RMEH]N]&.@F&S;ATWD>,M-]B("U5V)
MRD5/DID3Y$>Q-Y&FN+XO:,U%D.04(DHPXT47$PSW5C@*K2R.BHJ6K+@Y48<A
M+EH_KA-ZC,O,WL,W'&[X$(;OS(S2FKK^<T>9>JYL%HQUR2(Y`G@*)))(I]QB
M6$AJRCBWFU(",D9.@NQ+FU%,NVE=).'K#7WKKN5!/,9PCC[6<A#EWA).1];[
MEV2GN#6J$(!\7)]-TX71EU3*G(@+`&71=RE3!$D(27\Q"J19-Q,)N(8QPW<3
M*\Q[+>];Y*QP/17OF4=C/A`UR^G%FUJ1Z4I2E*5D^^A%//$,OX`)^^;J/6U[
MI2HB^=?S6NSOYN)?IMCNM=IEVW]^_P`M<4I2E*54[(^_=D?INS/G2D5ME\>R
M_P"5G^WE7:E*4I2E*4I2E*LD2GHF.#?%XL-5F5TM]=CZ`8\<C:USR<3>(-M]
MHC\<,@%5B<\6Z92+NYRBMU5;@<=8#(JX&VVT=)C&7"EF%5<;YLK5:=)Z,2W*
M4(527TA+AU9@(_*KFCL`@C9+L9&$20&TTT-QFE!**@*A1.F'%RKH0:<[#!O,
M\HQ4;46M8$N"Y`[W84I2E[6O;I>UKV]B_EM7'2W2]KVM>U^WKY>OO]>W^>EK
M6MV>_P"_?V;^S4&?(3YX#@(^$GD7_<M/U.9CV6]ZWR5C@>BO?,H[&?"!KE].
M+-K4CTI2E*4K)]]"*>>(9?P`3]\W4>MKW2E1%\Z_FM=G?S<2_3;'=:[3+MO[
M]_EKBE*4I2JG9'W[LC]-V9\Z4BMLOCV7_*S_`&\J[4I2E*4I2E*4I6+]SW1V
MA;)O>/8Q"XR);W)#@"/<YNEG96$9X1M=9<UHC=YK*ZB#HD.*Z@0/F)I?+@16
M*[W<JPSFGK28,10V\8\$!KK@25E+E@XZ>/C2OCR8!YHZI(!\%2F8JFR,\Y%?
MCH4'I+\N%$XJ4+HB\ZW,M8%SQA*0BKC`!3$1*3D9MH1Q=/#ED@!56U0V=DAI
M2E*4J#+D)\\!P$?"3R+_`+EI^IS,>RWO6^2L<#T5[YE'8SX0-<OIQ9M:D>E*
M4I2E9/OH13SQ#+^`"?OFZCUM>Z4J(OG7\UKL[^;B7Z;8[K7:9=M_?O\`+7%*
M4I2E5.R/OW9'Z;LSYTI%;9?'LO\`E9_MY5VI2E*4I2E*4I2HAMYN%34+D,FD
MI..PZI-_JG2XW;D6I2?&4ON2,40%M-Y;>#@QR4B#?QR#6E$ZHO12L,=/6OF$
M3`*DPL?2L1+YU#H5P\ZI<<<D/*2==5&8A%)^L$E'KC)2A*2[)Q:Z2DN,LY$@
M5&%7P\3"'F4,X&P!RY/.Y4Z$:"RS""$*8Y"RL4I2E*5!ER$^>`X"/A)Y%_W+
M3]3F8]EO>M\E8X'HKWS*.QGP@:Y?3BS:U(]*4I2E*R??0BGGB&7\`$_?-U'K
M:]TI41?.OYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4JIV1]^[(_3=F?.E(K;+X]
ME_RL_P!O*NU*HR1G,99<?/IXDRP!PVTV<Z'*6*&<L\2YHP@H9]5`+#Y!7L)B
M".*4P"%R#O;.P>65\+VRZ7MC4(O,ILDX'@XF$F9P\.ZF>P"DHO,GDQ'(32&<
MQ#PYXN4<3H=:@["K2;Y(T(EJPI(NK+Q93-)Z4I*H9+--(&S@5,@\XLW&&!&<
MH`*<2BLF:'>58D0*>$7/WPC*#H.GAT\H1835R6\7@YR9@0L.;Q7TQ`&;F"*'
MZHAE<)OB`J@EL$W\C7*3($ZRPVX:WJB"!"L+L!LN66XS#U1C614")B0B<;-F
M'&^I7>SHS2&^HN$F7%<`C25G.&K)*&6Q5<48HCB6.#6[EN1CF!.-"''T6Y4X
M\$;NPB^5;,'YWXZ8V#7)25#EQK@9L]GBF,'BH(]BP&:H9<PR`5;!!"S*N!06
M"B(>(J!GZV6^G-+B[Y@:>?*;"0.&OK:+.2<E<SI##)9/BJQPN,I%B3Q<(Y_"
M/4P?%#+CK"@EY/G)WI(&(.2BUBY4T7-B?P@\AO,282(.6@N4V/\`O?90^$G0
M0GB\=,:EG/)N8I,12R/(#+,F@G@`@E4L.RNI.=<0DAM)"0.25%96)$5%/'->
MS0QR5<H#"DN5UR8]_P"')KC_`%E2E.^PS1/:DQK&;/8YY3;IHTEA.>76PY"I
M`@XFUEZ0M*#10W`?7"^=BJ0X4@J84RA0>]$;FEV(+$(1/F;Q<5RV0.%2,'(Q
MJ+7R6=TC"&TZZQ8RD,<=>#>1!))H_I:NLKKA0D5#;Z68)GEY13`#Q/(?ZJ5S
M(;)J[HDIII%H>6UN&5=$09/+)[%<QQ):+D72XAU-::LY2;MR;PCGS*A9"JK;
M25@\OMX+,.Z\2211@,<\D*)7F9D:+8X?YPF"G&WNQ6F[32>6SS%+D3+A0B*J
M8*%Q1+W$$`+C&A`@<Q/^$R#QPOG_``^ZO7H-*4I2E*4I4&7(3YX#@(^$GD7_
M`'+3]3F8]EO>M\E8X'HKWS*.QGP@:Y?3BS:U(]*4I2E*R??0BGGB&7\`$_?-
MU'K:]TI41?.OYK79W\W$OTVQW6NTR[;^_?Y:XI2E*4JIV1]^[(_3=F?.E(K;
M+X]E_P`K/]O*NU*\GGK_`#'3+\%,B_,Y9K`WFJ^`K72BLW8Y&]7S*^VBB#KQ
M&'0[./(+L6."&,U8/5B92X)S"'V`"52E%>21AL4]>$/F3[M.DF6AW+F_D##R
MZ-+KFM9SQZ6W?*QYTEZ7^J>H:O\`#UJZH)]SUF"P>_KE6VMSHMMHMD-;T[(H
M;<QLIFZ'1DB12B$""[Y@"%%)J*&0"$R'^I:3*3_S,:]:]#B&S>R_,!LP;-X*
MPTT3.,K8`+9F$#*V`$[<LW:$52G(DE2[X?!=,C],9S..^HB#2=XSY(,F9*8Q
M7;\JQKX;7;86R*"Z[\6>NPI/)7\0\#W5\@D4Y+YM$"S'$$&R"45)0"$?[_S*
M(11$1!*`#),(W%D9FPHF>)O42[VPSTOTQ.CBA3QR;["F#&"Y;9#905?QP5<X
MNP/X6DBY=\`V30VZ5M*LHERJ(78[+,>E70Y,#D"5#!V8VD7VF,M#/+>[>,(0
M(O$7'I!(93%P`:P:PY+UL4A+?@J/D(=&.&QO#!'+#*691QP4CK-0BE'&0XX2
M6/#AP:(G2-K25=`(7'MH$$`,6E_>::<;8K5]HME"C@[M2]2-U$7)_$1))#Q(
M-]OBX2Q*I,-5/M9F&/MWR?\`9_S,HJ$SM<'9D%K9![Z;ZAYXXPWH!#5L/#66
MJ6J>2U<4IXRN\Q.IPYEZ<L!*XUY&D:YES&6RV4S[$9YIY=(BPJW#!K6_7(PD
MO/+4#6!8$'!F39,EB3#/R=N!L,"?P&<68RB4-`J;+2U_,)2L:<0+J=)W%>5D
M%$MG9:O?Z-L!?`S&?S/2*]VI2E*4I2E<6O:]NMKVO:_9>U^MK_SVJ#/D)\\!
MP$?"3R+_`+EI^IS,>RWO6^2L<#T5[YE'8SX0-<OIQ9M:D>E*4I2E9/OH13SQ
M#+^`"?OFZCUM>Z4J(OG7\UKL[^;B7Z;8[K7:9=M_?O\`+7%*4I2E5.R/OW9'
MZ;LSYTI%;9?'LO\`E9_MY5VI7D\]?YCIE^"F1?F<LU@8JV0N<K'[0?G9'V0+
MQ,'@_=GY1Z'(3X_-9S6*B8<LBM0DN6*M@::Y?S)+5TA'!-9#*19K`+CU44MC
MH!I.6/'P08H-10R`@F0_E+292?V8^O6O0^9LWLOR_P"RYLW@K#3/,XRM@`MF
M8/,K8`3MRR=H15)<B45+OA\%TR/TQG,X[ZR`!*Q^5Y"##D)DVW'LR;@[4;4`
M]Y#:\<6VO`Q+-9R@>"+K.8""8EPP@@"G#1HX*7-&C1<Q(TC&$]MIZ0D94^&3
MBC*+8R)EXQ=QW3P1[ACZEZH9X"&)_P"4/86QC%R!SY..3E#!5+0_@J@82&&,
M_P`,HF*R46"F.7@TUDI\?1^=]+O>0L9"E0\>E1G%MI"S.RPW)W)PR+W@GCA@
MFY>SDRUQUQR<EL4L63A4O'%4-FU3'%2-*6.,Q3%B&&&Q&(#YTH*$?)T?1&,-
M$;M'UQ'=MLM$M$LK&/'=O_-W?.+CPV<V=P<=LE7!@X*N6$DER\DX9$D\ED%,
MTS!BJ(K"81?]KY/_`-7\S**A,S7!V9!:^0>^N^@>6.,-Z`0W;#PWEJEJGDMW
M%)^,OO03NCAW+TY8"6!LI&D;(RYC+9;*92663.`9T(E2L(N$>#AW"(/QY\>8
MX@I64MRI2*BV5S&W^WYA7L,=3H]3CHUI`$$D#$8BCD1@WT^@S[A/M=KB^DL.
MY^\M2IFJV*[([`X8E$_=+;<E?,C$T+.<OT.QQI1K42->FYB(S2.G!55]IB6+
MWT0Q*A.22SIE[.$FD-_.OU>_T;8"^!F,_F>D5[M2E*4I2E1=\R6W\A:/<?$T
MSO$>9$K*@2G%D;1\KJ:846"#:<4Q2HSXRQ=XR6?ODGJ!AH);E4W(DD%(L>2C
MJVFIA56('4P8X6$\STRW:/)\H\L$,[`2(9/1YQP2ZUSI29']D0P5R,#OF`T6
M73.3]5D5,(`K9Q@K"8_NZ<&*."HCM(1!**%E-233"D=B;W6Y@^,R0N3;AEF!
MF;F0NX8T@1^[QJ,Q/%.65,1'CTA(NJAIF,@VX1!4<$<N$Y'0+BB)MPBXUA#U
M[!B7#P[K/&7.W/MPZ=+?^L&UY[+?\H%S[.U!=Z(XY9^./:WBAG*%M=]O8>EJ
M5'$]H+/(C':*PI&EQ2)-Z6VPN+9DL`:2286028DD3)XUE<:UL``<\NM\NXPS
MUK?<W]G'^OA_>IW-_9Q_KX?WJ=S?V<?Z^']ZG<W]G'^OA_>IW-[_`(<?8_C8
MV^6_^WLIW-_9Q_KX?WJ=S?V<?Z^']ZG<W]G'^OA_>K(&]#0;-0)J1R?M68-D
M93:</1F2A::4$T\WB=%)HH"RNH2:"CIV8Y8N;$L941P!`BN%@;^F9X7QM_"Z
M8WV.'K^W#G[H-KS\8%S[/4]?VX<_=!M>?C`N?9ZGK^W#G[H-KS\8%S[/5&GR
M^<S'%W.W'I/\6Q)NS"#ZD!SX1M9!:R$M*XZHJ>"979*XI=ZA"H8&&7>B4FG3
MHO7/&U@"XF5KWO:V.6$1?8:#[WO_`,:+3[;_`/O1S_`UQ]T-!_MHM/\`M1S_
M``-/NAH/]M%I_P!J.?X&GW0T'^VBT_[4<_P-<?=#0?>][>-!J>3_`.).VMY?
M8O<CTO\`S=>G9?RUS]T-!_MHM/\`M1S_``-/NAH/]M%I_P!J.?X&GW0T'^VB
MT_[4<_P-??:>Q\#D78TCQN56@`4(NUJGC8XALY8,`H2<*8:-#B7L1O>P8!<$
M47.]K7O;##*]K7OY*V0EN?7ASQOE;UP?7GR9Y]+^J!;\MN[RZ7\C?RMY;>7R
M97M[%[V\M<^O[<.?N@VO/Q@7/L]3U_;AS]T&UY^,"Y]GJ\YF#G?XA'!$LHH2
M1O[K\=55J.7PE)A(!>6\ACBBHM=5)D2H6-V_C;(4R:&"!#MUZWSSM:UKWO:U
M\.Z5]YM.W.VSPTI;$1O(NML:@(3Q3]3XR/JH<A;>SCF.%@WT*9%A32""$DP+
M&XY-%.>`%(_BF.-4%4%EV`*"&VTY!5_YLMYX3$D5-4L]QX+#VXG%HF$^0]J2
M]U<U!&@VO^)L,#*!]44!30<!W/*:AAE8I@MXI895;7`Q7V]54)`(I"1?Y8N[
MO'>GQNM(P3_0S6HD".4X?CW5$LLGE&<-_9X+K0`XDV[-KJRGX$@XP./$,)PI
MJ`^5.P[R-DKR))J0$VT1EQL)5(F_4(9OM/-7W$A3#;F?FH.7F';8,PL'(9T>
M@/!4PSR@#5))5&\,;<$B&KWPP!5,4D;!T/`(>4Y'5S"2FM5OIU"#[\:(79PQ
MDNZFT+JCKR[#'W/^EN2T;,2MN=/6*WW9?9#;)R+Y(1+(,$-X7R>B6G/U44E%
M94BXLH2(CG39)H,K&HL=VH-%DD?(UN_#U]J9Z:(@NQ&\!7->$C?4^$/"..86
ML6DS=5T(=7//4X(*+A@Z3"2'@;5<3<H/I345BZ"B)%$?=TZ&A1REJ9-=:!G7
M*#G@$1U6T1$7S@#QV(F?-<$!`VGW;=2J0,)A)L6<6(SR*(SJ4EDZ4!Q&>[O2
MU9P#-YLY5?CN9``D@K:%GO7&`>P$YM(NJ[?\@1+PZ528EB;`UD*GZE:&-8^@
MFUM-4+8YC%BSE'2`"J/G<W([H.N&0CJ(D(/UHLWDTN,(+;/HNP[!UVU[C2[A
M8NM&I2>HK1AS+)4YD=#>6QFTRP42%4(](3VL5-&F0VSRXH'D41:-N%RJ)YXK
MHF-9?&OW.OQ$M:"H:;2]OSK^FKC?BUA(JPG&5Y;P,$%1+;*:3/DQ\/4]?N12
MQD$0$2W7R9X96_!:]_7[<^O#I>]K6Y!M>;WO?I:WJ@7/+>__`-/5)3"4XQ-L
M=%C/FR$'TA23%3^(FU)G/=MC#CHC@(D%4^B'#!`4R7*CYAEU5,/D1?32X66)
M@J-CW-[8VROZM2E*4I5K&Z^I4>;S:Q2MJ[*!U82&K)R4DAX.)N=X>J)I.AJ.
M1&>S%>2%94*G4T55:3U;B"X"I-1*F$Y1[PS35$$4B<,87IK6+3=KZ^KNS$AK
MBV5D:7-O95"E:='==L@-ANJQI)8S?C5ILYLLL17<]T9D-=H-T$$JGK3B=*NH
MK*RY%936C`:F63DVXOQ3QAUM?Q=,3KCU[F_J-;/6W6W2_2_@KR=;>2_3\%<^
M*B,?:[8OQ.;7U77%XFB_*W3*.F)E;V+LULWM_1=*Z5T\446>UNP?B6V/JFGB
MBBSVMV#\2VQ]4T\446>UNP?B6V/JFGBDB[&^.6$<,*V6`@>>-[,QLXWM?`3'
M+K;+%*ME:]NG6U[7M>U^R]KU&YQA:,+&L\.3<SISCJ-LW`]-T]NYG:V)(FV'
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MPBQ5MJYL-/B374".Y`\(MVZ7W+4SR>&(N14*_=9+`%[J76W=Y=9+/%)%OM<,
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MYTF<$)8%C9847TB^>%NW/&W6UKVZY6MY+]E_+?LO^"_97XY&RN!G`GF9`Q-B
M%Q309;(8/$P(6!$!!&,8`WRL+F`$*8+A"BXXW##$'!PSRQR%#ME^U\\+=;WS
MQM:W2U[WRMY+WMUM:_E\G6WEM_)Y:\^39<BU8DERPVE2*R5&6V:WD1W.R,B;
MG1S#^;C4<HXQ5O.=::09O)=36\NFBQHHD+1HB&FJ)LJ:+%#(HY8<,/T.E*4I
M5OLH;0PK#DOZ[P5(+P*H$E[3.%^->%D`P'EW3I5XW9)M_.L'OF^6()$(FAE0
MP2XYF^(9U:4$E$+WS45,H")7N,MQMG*8L)!O)#&E@NP091-L(`WB.XR,?&G#
M=J$78H$`;9YIZ.J.(,TD)!D[<#PN<3E;!-Q-8I"ED5KLL=*'`L1RAD`T#EF(
M'B*6%P,!Y9@YY!#88B`Y9X99`BX9ABXXWO<,3#+#.V.>-[6_6PX.5NZL)A?'
MK?'NK96Z=UC?N<L>O7IW5LOX.6/7NL;^2]K7\E?D&=*#&!RH1D`0T5L'D9+!
MBX9CE\1<>["R&!QRN(%87"]LPKB8XV%QOW0=\L?+7GKMF2+6*H1PDNQ]-Q&4
MY?>@<=QBGF%$$0Z^7KFBK;DS;S:+%LAQE0\5;S;7EQ0L6PS!34E(/J!\4L5+
MYBVK0\X$),)JZBI+"6G$&^2'45XZ?/E291$3RQ3(^9/+!@R*$"EDRY'#,Z.:
M/YEP`BF&9H03$#'(2UOS*VNC62G[%;0CU(D=Z-F98',[$,2;6_'R^<@508ME
M=N)B*0-2GD"$BD7B[BKF)N-HM8</OY;:Y8ZM!9!E\2N)NY0,<`;(7`(4,3,#
M.P8V&&>.60.=\;96P%QM>]P\[XY6RMAG;'+N;VRZ=+VO?]:ZY98X8WRRO:V-
MO+>]^RUOPWO?\&-K>7*]_)CC:][WM:U[U:Y"FZ&ML_:ZJ.U\=2BW3<!(V4I9
M+DC*YP!#04$E#3G<S5D!6732B*$$DHZ,;::LI64SV8)4TWKD5XN)FFJ!483W
MULO1KO!O-1U-Q9***"^$1*<;4/8W$+>&T9;2BZXF'"18Y@7.96,I)H`]<#,O
M@9``$[HP"%?'.V-27&"M?&U\\;7SO?'#K?IW>5K7O?'#K_'RM:U[]SAW5_)>
M_3I:_3\C!TH4!%,FC(!8N#C;(8<<7`$$'&]^G=#"B98X!8];VM?(3+'&U[VM
M>]KWM77,^2#%*@"&RP8Y[$3(D#F.%@*;Q"QQS%N5#RSMF8L'AGAD)<''.V&.
M>&673'/&]_/V/,<7245>9]AOENNE/CU^N2+WDI)"B"93$"0&>,2*NIJ'5*U\
M2/A=N*!\!)6BX)@6R:M8FD8WF$J$3I0O_,Y)JC1KO@C%Z@Z"1B3E:.GG+"-'
M"3B*KO=8CY@G4%+<SF3FXGX#J`Z:4670W4,L/D&%@IK:N42DW(T<]/"!_&%Y
M?2)JB./YA(M60H[2Y";*4YRC/F%G*$<2.V@5?'J`D/5FK.=SK;7PLNYP,)9D
M87*U\PLP!1PA@1!/E['[!QOJI!TF;#2\9<A*-(E:2N]7H>:K,=+\6"#?0R8Q
MY1/!MYHI:LJYE"98`0PH*(P!9'1B>`RFNJ26DE39\"VV6N1F'XJB+7F7BT9[
M,R^5V;9J=(,9Q_KUK^]YTE?)E'68WWN9<[B8,=A+"FB(2(0=C72EU8$%,)J<
MX7"CI%S0HAX$2][K0<8;P:37=H2.X&^&Z&\B.$-!=B0.@NE$P6TPJIX)#E0S
M&0AA&7TW$U8FLI0XF8J:H@F28N=Q`,KU:9O1OI!_'C%2%-NQ!9_E8O5WLE,-
M0=C(9PKS*M)56BIXZGJ#M)$5`LJI3<S+I:CF9<`)$\G$,BM@CXA88VGAF_D3
MQR):[:_39K!K\YC+Q<\C;=K!=&APO'[:"<K>/#*`0QI&-+[L%5DMO-Y/7D\@
MN*B$;-GQ,55.;B\:*X98$;6&J5P;JLA+D*3(X;D73K)BK$3I2F0^E>-F"1<+
M;2'<K1^R9-#;UU0RY4O,53*-"0VF?4`<2MK$Q5.Q03*XX(V.-Y%*4I2E*4I2
ME8]W($DO*/.8WC&VDF@N>ST6CR-Y_CX5[J&9L[&\";4R$@KY!G2))0`)8R0:
M!9[-H9,C]I2,O8%D)#6[C$3BZ@&31+%6]3W6G;O=]:H..!G0H,+6^9-U4>,-
MX]FXT!,-H`TS6Q`;R/QMC>9@$\0FFQXKR"3:,<.:9FPJ%B"2I)9.,LW\BF#A
ME/$A45-ON3QVZ[0RHRC,FQD3R$M\+V^>PQDLTV@18[@?VP\+R@XB>ECL7@+,
M`RJH;^EZ,B+9=JRP&_ZE\WN.=-D1FR6+C&TR_I+OEG:@&5MD]E3;_P!@D275
MOT.3$DR0@IHZ2XKM`?:!-;3Q7I"26<WKM148Y1TE9*+M`^OL+O/`Z9=JJE)J
MDC'\CR:E8>CR++N[$:QII3(T@;C[''XMVJTHGN?)>DH)&:+8*1KN#'VES24H
M<A-H>HF/DU09"&K/ZT@OQ,B=T9+"K*\MM0-F*X[IM@H,5;N-XW5V=7WR<F91
MV/:JNUYK?7"GH"9F<H=;)IM$TV;Q'R^7-)37R(=Z@)R*X4D9RIRLN,\`3OMK
MV6BY,<L`#@':V292E*4O_)Y;_P!'^_\`OY+UC4\INCNXNXS?D;9*%V>;:^T^
MI6Q\./S0EFKB/'WJE=)2!%;OT=7192"E5*;S.8L]J#U?BNYVV_2I%0%+LZ-R
MCM*I^)``H%1FT&C^[>P&PFZ.P\7P*+"<F;8\/C+B".'T(](E+.:&-K6\N/R[
MWBQP.M'>-W,AN-S,IP%(\;TLL()P-45#%`&..U'()]@2]O$E<>6ZCT:<[&(S
MUXD)APT^=R>(R0XKUR0'LP(_=T>H>L,5(+<W8EY`(82"A-9ECN[(FFLLD$B.
M8LYY'58_$=Q)*.EG$17520&2^(D",=PM6')I:QVK&^JL@19,FL6]$=C'E0\D
MYPNKOS'9MJ.-N):^O&C0[U<\H$7%%BLL7#53R>UY!*E?20FZAAER5A[<TLWH
M<NXL@2>X=2IOB>-I(B?F!A]]E(\FZ*0'4KIDVG4UR0/='GA1D]P2,N'WV?!4
ME*)5UW-A%8<$N<VVVXTH_:R"VU]V+E4P]QN[<D5#CE6)9U\9TN(FJ?(_-"VZ
M72&RX;BJ1G]K(\=8FO#[`GN6XD4'K9A)SZ1W<VT-'DE&CQ4.*CM3XY:LJEV^
M[G:NJ2\H^81QH'OL_9UFY;=VISJB%HS]HWRJ:Z.))=4GQK(;5SD*6II67SKS
M>1I,.2.ZY4F1/7P%LRNH+[?B$3(,@TLBM!D,)H--L#JRS]*_'+NL4@N#&2U]
M3U]G+;>]#R[-Z2/M!3GA!1`M]W`[6LT$2/L%,P@2>(DJZJY7,T%!VDY/"'/)
MJ%X43CSB<*,MF#14I(#Q':<[#:P;-S&Y9`@]8B.-9"T-XX6.>4+N"/CJ8[ME
MH*C!<:\]GUU-:#T<"LI/0%36R1-0D-<3A`WS<H>/$7,N`AX&C.0E5JNXI.5G
M'#HT;Q"@.$^N2ZYVY%SF=S?Q;!C.)XV=IWO61Y0/ICF<3:R7"R"T`U1-*(S;
M.F76:6%M-,)1'(,D;-E,=4/C1W+BN.N<'0:.X417GJ=N;&T@3II\[2(\<1]&
M3*V=D!DAXOZ%$:.EF17(ZV,VSCM3VR>C9PFD\HQD`VURHF:TF&3N9X"E=B>/
M#>YW-Y:1XNA5?9SO?>DG'1%NHJX3<<:HI?0_82#]CT-_;*+JN<9[S4TQC'%0
MH!C+*P]HY,N*TL%D3./S)Q:6;DVZ:OHUMXL6U)6RG)D_MR->ES).DK:V7G-J
MR[%Y\%#J5A#$Y:^)L)R0Y&"@M)]*H;-<#HRLZ<U7%Y-A#<@6630<:>6"4TP@
M<2[6T/0G>F.M--68QE"%[[(S&QMI8L@1;<[+<[.)^HO2?697F]K0Y*[[CYZ2
M,SV)L"(\$9X#NAQ1])+F4&>`HO)E.Y]1^YU.-AD`QX]IMQ]<@<=)/$6MOF)7
MS9_:\MN)H2V+CF<%2-91B"T2LK;R8)%P>S(=2,^#[PA*<X`:(#(><?NAHG5!
MNSFTCC%A]?*$$5K*C+6:Q1N/7:F+()4H.3-'A5TTZN63:R4%MYM)Y0@:;V&N
M,FILLFXD?H\6J4FMEFRLU`DY_6915GSJ!BG0\N#BO$*)WEX+()YS]M$N.W;]
M@2CHI,>PVLJHO&&+PK2IIA(Q]SN.(78^(SV#:DT'W-&Q5;!5'T;4%0@N1B#D
MT([<;,/N4)&(*V*"NY,]&S.7#M.,<3^^[FU]9;'D;5!PO1TH'`1*FHI%+7)`
MA1=L@;XC[*W>,78W-JDJ72KK"(Q+GE9!E@H:/-YLAG0R19S$%?+(D!DL;7Q=
M.$C<0LVP.A,%TOG8F4M"G5"!%B^&VL&X#LMOZ!QX^$)KKH<CI3&D!@1=BD,,
MXW$:=0J?8J`<42AU5RS+X&X\)IX]F?L1KYQUQ%L=I3M(:F&(M.$&+VAL[!,Z
M(S*=>G,ZM)A,=OYIJ@DM>;41/-EW&Y&N$KIDD)B%)33PS;Z*5<-B:6.&<)>A
M<GS8GEJ:&<<,8.YP*LT;-$=R>.1#>1UJGT9`79PDB(U$*2Y@';7JA6VJ@#*S
MG2(S?CJ(I*HM(Y96$+6*!Y!&S1<OEY%`&FT^26Q=Q-;=M-9)6(11LSRG;[2F
M,O'G9$[I(I^MNTD02RWF,ZR=B4DJQPB6:"P\6?WB62B!U527/B*9((&*:VSJ
MO7A[#XX-]HO1N$\G)C26)\DG4S9PX\MGI);"Y'H2.R(+C:.UJ!("1T\1QO1%
M<3V-I$=$&^M*1!MIJ^M9KSB=ZJH!7-FNAB??02+9!C>!33CEMM>I>;I^E25]
MCYD0#!XJ?.MYVRX]%)9066>.$#)X@8,QG&($?Q=<1/.FR'I+)!Q)F1RU@A,K
MX*4I2E*4I2E*XOC:_3KU\GL7O;^;R7MUM?\`#:_DOY.MO)7'<8]G3\/7MO\`
MT=O9^#N?XMK>3ITIW%K_`(<NSN?)GG;R7_#Y,K=<O^U?^%_+3N+>SE_%[G^/
MGV?UOXW_`&OXW\M.YM>UK7Z^3L_A9=?Y[]>M[_AM>][WM>UKV\MK7KFV-K7Z
MVZ]G3IW673I;V,>O<VO_`"VMU_EKFE*4I7'2WL6_HIY+>7I__.OR?AO4<#&Y
M+8D=;WY$V<OL.18O+\:Y1J'YH7)$":*427TUU1@XI=)KS.`2W,L7LWAF8BDS
MZ:><1E%/J.2R4P%24ZX8MK^DZ4;;NC;]F+K^5M;I'@)LE1D/!GJ;\D&`Y$(2
M,65"9LTH*346("E&4T'O%!%!*IZEX55B!WP@=L6!)9=ZFL\+C<)6CU3`(8-5
MZL-S+3AQ>@+.1T][MK(9VJ[#OF`[4I'&+G3ES8[;/XX$75F2+GLFP-G?PV`6
MRPN'>,'7OF6@[8'6':#8),BB8&8Z]3WLH1W(6N[M*-(*8%%VCH20O,0JV"Z:
MX3C944Z30%C'%GK8BT73A`DY84E(4FE)HQV][6D.U+?W=U;A_:MI,Y?8C1FM
MLW>33;;L-HYMT$F\84#I`B*N^`!SJ.44#ER`QG,B14E+`N#F!84YD/D*"#=;
MTM[%OZ*=+6[+6M_-7-.EK]MNM6:;H;LQ?I6SX^4W>DN5^R1-TI-.#=?H48`*
M69D*99>>YT(DAM5OW7%%(;R(ED0A!%IWO-TJZ2V6FWBA@\?.C'1DM+4_08QE
MR2G*]U"/Y-@=?C143F*BO8L[B+N;K^C)<$5UH^B'&B@N<@70'!D[&R(1`.N$
MHMLI!3,D]91C3=57$&(IW2;:8?Y)XRV9:$W+VK3'=\ZN""MNE74%W--OJ#71
M1@W*B+R0FJLG9K2RJ8I9:(BR,J&'87=.5QS:PCI)\L@)2JLW*IIBFM*.2G[M
MP!$<K(UGEQLQDI2?/,.*LA+:VP%4BSY"@`SWDN%76CH*R:4T]`=Z@`HI[&<9
M7OXN>/D+%%PL@&%)'#/]'IR:IL7;LQIJC*NLLZQO'<T'I7;$/[6N?%B`Q(]G
MU";#4Y*D9)]3A)S')):C63VJBK0Z&_7@VT))=XJ8=4VV24&:'9W9>51]S7:[
MNYGOQZN5EO*/4Q.TR1^0"(BSF5&D`=F36ES/MQQ>V58B8,J:<@L5^G7XDMM'
M5&>[EP)-;Q23XZ45-W8V47"5;-R49[]D5C6"3-K)T@:2M9X_CRRB:3$QWNN%
MY57Y)1R2*3/EE6-1->Y'E)LNFSB6S>3-:J22<.2ZO.<J8)@)H1?(L:,5?%&Y
M@4T:,Q9NI',(R>]<YCB-B2>PX+:>374)*63LC@IUVRS[JJPKMQBI1G$TJE,5
M]UN)PHC,;"8$HN!=622,FF#-65M#FICIR:OK\VJNNTN,^7V;MZYM&7;JT[GC
M"#.?Y#8MEI=W0ZFNDR)($B,N&EI*2F/;-UAKOJS3@%0N%=+2@#BF93`5&3Z,
MYD$<L'M^:)>8ZGK9WZAF7"Z&;+KHC_%4CLD&H&BP'JN=#4<Z]'X&0Y$(FJ9&
M4MTJ":`742P.9_(QB-AAX/NYLW%<`04_9Y4XK`V?/:Q+C(?BG&$?"Q\YY69Z
MPY`\4AM.MI(KG.X!I#PLANT<\C"=^H*ZI--261V^;.!&+DS]J\U\T^ND4ZF:
ME;<M9BR1+S)V^,1G@R4!CV:11?9I62U-#:910D01P+J>EH8#>D1QH\>.`$F:
M4CN#CR4<4PLHDT91'!F**YC"E@!#0(8!G((.Y@`,6YD,$QW-K#@AF+@E[CX!
M"]WA@-Z0#Z;CC83TH/NNXQ_HM:UK=+6Z6MY+6MV6M[%*4I2E*4I2E*4I2E*4
MI2E*5Q?RVO;V?)_3_P#JH,6?ICL0B;"<TLOO#7R`)G8V])?7]2A>%Y5D4H=9
M4A!P%"@41J+)G`KE'3I(-=/?Y@D$NI@A9'?:81+#ADUZP`P`@F?OG'+H@UM0
MW'/LAQS$9?59B;)E85<I[3]MO8B\XZB26&,D.U+DQZ-`1"O=H(^<CEEAII!P
MBS\"24?3HZ1%XXF)"FK#H"-!WQI:H[=.LQQ4;<,"-HV<,)0I*'*](HZFH2V7
M1G4Z(VWV=(;E83E3VJ,T!?!Q]"LC'6LJ-H\LV4L'+D$9.W(-O#-4J^5L\2DK
MMF97IM,ACI#;<,K<;K0@N5=>4MZ%<VT]-U8R8"Y!\:36MN[U/@)A]O-B(W8Y
M4LHH9E,%0!1.AN#%!'6@0BP<D_%-KG*&HO'SJ]K+,Q5OEY)A"-RL?N<9IKMG
M(UU(VEJJJ9!54%7S(I1L=./%3P&>`:@DIIXN-B,",6OC@&./(72E*B7Y/-')
M3V6=^D6R\`*S:%G3078TE.;4CE]*@S>9<R,Q:`2D648U-NTLDKHK(=2TVTH'
M-D.\TBK".GK`.:<M$R9)5NX$.X.2UG;R1X4E1-9D1HT8.IS-IO,ADIRY*R#=
M](HKJ.^")-?PKD:@+D8Z(98C04#2I&">5-.,\Z7JFEO5'@TT43"^=B6O''W/
M^FG*!*L]0H?*O73G9[7N,6Q/3=>;K:#=DA'GZ#DHPWHQ?S):3*9378JLBBQ^
MG)K'=0A[%ON`\KKBNYS1]<[R#R.4[H#QJ[111J$[("DG8:4=3GP8V_V$V`3W
MIJ,\XA=)QT,F9U]3<*,TW&?F2#I`3B=T,95OFL$DUJDC%UM(3CB:YCR4,;(9
M59(&N&^\Q;J)!R0HCUC7=5VFQ7CK^RIN>4Q/!P[,M"+)'CL9L3=)S;B]O1\V
M(J3YOF]43D!*,.055'+LEAE,D1,2,BRP\$EP6<PSQ+["QNVVVXY4@/6[:%4U
MGXN8TXX&7KM*+U(EX?VC':VS1677E(RXKJ[#?A1B(]V0SF`:C1/=[0.*N$I9
MKA=QD&V@HB([E+VI.X7UY+B27476R6Y,T0;+X?#XF*+=5F`;B*3(PB]YR#K.
M5A=Z(!H63&+++<;Q-V.85SKESL7XEA&:2=2R.S5A,-J091!O)U*@#;_2OB5A
M371FY1_,&XD,Z]H+`;.#X=15M1.6?@.699*3U!T-ME%3IV.XQ)'0226/@U!G
M<\4-L$2JV>$7UD^X,;.V=H[-Z_J\U(DW+XTM$-D4X?9EVN9XL%#EX^['6E-Z
M4&[9;DW:0G*<U,!-S?.Q;_EQ==A]WI@*C%&28S+IJ6TW.8"[V2D;^3>34\YJ
MWZ'VG?3HF[C[@S!8QF%HT-NQQ*SDP:Y&>-GDI`@^,S;M5"N2THM:+$^1&9%Y
M-RJ1;(Q@V6L"JC%@"X6)8/\`H@C3S=]C[+[UR^\(0BW)G;7O7BV?B*BDYQ2U
M1610M2&C%;+E5IKX(S()IYHW@FL%Q&0A0A1D=>-*R"CI9P5/%6EI,M@D#@NG
MF--1'WK)KZXVN^TH[R0LK86$$)Y/81JM2"M/8ZEXU.:)"",((V5(V.YS+Z=T
M@'1KE"6:8J*"JFFU=9*@)!0&^5P3S$$*@"C`9E1A@\1A2HN8(@A80:WIN9<0
M0N(,`)F!EG<+/,`40'/+"^00F>%\<K_TTI2E*_`T:+$2Q@X<'"+%"H`QDR8&
MSQ#!`+EP\AAQA1,KVQP#""PS$$SRO;''#&^5[VM:J,C*3&%,T?,V5HN=2.^(
MZD)N)3O93O;YFYM%<C:7"N!U(6DLS?`.XY!0*B8#EA;AX=V'E:_<V[*KBV>%
M[VM;+&][]>EK96O>_3MZ6Z^7I^'V*YO>UK7O>]K6MY;WO?I:UO9O>_92V5KV
MZ]?)UZ=;VO;K?R=.G6UNMK];=+VZVO\`@O>O"XNV:@2:G(Y&C%<K,Y\.)J@&
M3JLF(*I8T*(E$G0NL<\O(HN8015SMHB]VNY62><[7'66Z2>3=76H:5`5](/I
MX':1-F(%B9[-F.9&E1GM%ZNT%(-H[?6%.P!S$@XG418;95%C,,,4JV4ATOQ3
M3F(U5ASF49*<[W/DV@@'%%QF`DS+JN;,P(VY92X,7959Z9*RN.WR11FFE/N%
M$-5=Y!QJK,0%`Q8+)+1W,]DMGNU49+76%`@XGDFM5R'VPEJQ1#4ABW*%LS`C
MFEE6@U!E5G*LJHII>3CS.**?IA_PRTTYN+#O;I,U<+%*5'2S$=X-)8>C52E$
M\Y&>DNEMJ;E2DHBN)HYCZC#V"@Z47Y(\81M+4>/^0(@L@6E1HLQVHCG6XZ'=
M(ZZ7;Y%ZE$4X=NVE55$;*[<JD*V955N$G#CBD@@;A"">P4I2E*4I2E*4KKAA
M@%AB&'ACAAA:V..&&-L<<;6[+6QQM:UK?R6M:U=J4I2E*4I2E*4KKGA@)CW`
MF&.>/7'+N<\;98]<,K9XWZ96O;KCEC;*U^G6V5K7MTO:UZ[4I2E*4I5L6X^M
MQ';/7*28+,*B"W51VIR>;9SP<C1'?B8PI!;"PGN9@R#BSP',S_5`I,5V)*4Z
M$0@.XDXK=:2R`YK(<`$0J/0FD.F3=THC]]L9#<8;U'><J.-[BO(\@"I#R4FV
M*"EMJ.&^_57)?6@GFY8[CI";L?8/4H5;`"\B-Y(%NUTDP"/<SC'05OUND>>,
M!.PGM#(TMOM3]$-3=QXKT%*8K"-MM3TN+IBR=6A5IK(C1(+PRW$R,BE'NERD
M?4+JB&5",EU(\825$P7&R0][F#O,^41HVU)E%N-1J)^*R++C&21TN.9SD5.S
M+VLF)L2["O!H3*P(M.6M<;$X"LPH.IJX^1;P5*D;W#$4K4WK.RR25K?/S<AN
M$]B=>IM5+O,LY;[/N1<?DHNJ9CD:EB#=?QJ<U:1)A0Y<1\Q;H1)*=S4D%<;R
M7BF9H`:6W1TH9"*8U_%B]?$](?%M+3H7!&-%VJG!]MPH;CK:B44<`XP0&MLQ
MF24$%_IY8B;54YR$Y&CU;%`:@Q/!SJ"DP'6$G)QPR@*I8.FN3IVJDX*G,L_X
MS<9B0&QN+QW\2#PT/--ZY_!5E!I+&R)9$22T:)QDL07#"UA+[B$&,(8!;!>1
M5IVH_A0HGG%(L!:IMEFQ-@.R.];"/C'#6Q+RYON&1_1D"6#SNJK;5!CQIGVH
M\6V#@2#R.M-J(L<O2RLM$20J.W@([>WA(4$)LK61;^O5]M3`'M-H2Q,1#XDX
MQ_SR\OCSFH`/$7%72V$:9+B6'V\%\/(MB*3:3R9$BM?-'7C9<JE+Q6162&EF
MLLW.A]\2B\9@+12^;WT0&CM`)MIZ9B<XX3`*8V\$DH2Q/XZ\.W)R#X$4FP0&
M)RRV:%R6Q<0;#V4S&=U#+OP7+NLBFE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4KKGV6_*P_V9XWK&Z]#GHJ&NQ3O*\EA`;ZB[D;E5WN*([I,H21FXT@FX7.U
M32X12UOO*RDGD%8P`"(?(DS()0S<(/$0'+'#'&V2/7%K6MUZ6M;K>][]+6MU
MO?MO?V;W_#>J*)L5D$KO/(FS6F4R?`I@=[9%6XCE[O(<P4%3QQW9<(EA=R##
MD,\R(PJSWZ(*3S$+"99`YYX9!6(QQQ628&9C3%'8@5@F,,(W$;,9E!W(`)MP
MVB)D2OFV<+IP02??%$R(XW(A!%+V[W#P#Q_M---JFW6E.\VV6\:=J0FG$I)=
M)E%31W(EI9_++,\F)JZ*5S5""<=SQQS.$2IL(J:RMW0X0E[WO<5:;5*.Q4=Y
M1LMXJ[5=-)I2LZBR*F@.142R&6(A!,4ET(M@JGD\CGE?,F2-&Q2I7*_=`!!W
MM:]OQ1&<T$13.*B*U&RCJ9K$;$TI)2`DIQ\SB.-B*-B8.DR@)D?$87'$06PH
DN=A!,<<\[996M>U7TI2E*4I2E*4I2E*4I2E*4I2E*4I2E?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g634352.jpg
<DESCRIPTION>G634352.JPG
<TEXT>
begin 644 g634352.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`\1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?345404)?2U],24Y%+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`30"H0$!$0#_Q``?``$``@$%`0$!````
M````````"`H)`0(%!@<$"P/_Q`!;$```!@(!`@(%!@D)`P<("P$!`@,$!08'
M"``)$1(A"A,4%3$6(D%18949,E=9<8&1UM<7&",X<GF8LK<DH?`E0F*2E]'4
M)C,T1%6QP=(W1U)89&5S@Y.4T^'_V@`(`0$``#\`MJ=8#+&;,%],O=++FNMF
MC:9F.@8.LEBIUMDW\'&%K1FKJ-3GYV+>6)1.))9XNK+3CNGI./6J.K6E"M6;
M=T_7:M5JOF)M;]9K_C['%]FO2U<U-)NX56IVJ7AY#;;'51=MYJ<CF$I*1;RH
M6O*3>UUIPC*.'3%:NV-!*=BU"FCY1('B2I!O/M2@5LW*5<7)2H(E*X$P'%<`
M2(`+"8!$#"J`>L$P"(")NX"(#WY]''''',0>\77/Z<?3LS.UP%M3EVTT?)CR
MDP.0F\-#XDR3=FAZO97TY'1+T9FIU^4C"++NZ]*$49'<`Z0*BF=5,I%DA-*3
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M(S*4S[`5:5BE7T;.5;'(IK/FT::20E'4>R?_`*%$:Y8O(]DZC%D'$<Y:-EV"
M[50JK9=DL@FHT6;J$,8JB"S8R2B)RB('2,0P#Y\^WCCCCGD]SP3A/(DRG8[]
MB#%UWGTVK2.)-V_'M/LTN6/9KJJM6)92;A7S\K-LJY<J(-BN"HHG<+G2(0ZJ
MAC5FO1"T46^A^VR""2:""/49SJDBBB0B22226.,+)IIIID`I$TTR%*0A"%`I
M"E`I0```.6O>................................................
M..........................8X>I`TTVV'UQV4T>V5V4Q5A@V3-<K%=;82
MQY'I-=N&/,9L)UBRC,].J[8YN-6+1:5D1E`J.)^4!I5W,JT)`OI5NH\'PU4;
M'"[';28]J^D6[GI#G21L>AK9]08'(TQB'*^-6&SN;<<XYF(>4@Z;9W#TM>C8
M*0GU:["-YB<1N,BX]L1)(S`7DR;IC,7O(E@PBXR.C8I%)O&,&+1E'((&,=%!
M@T;)-V2*1S&.8Z:35))-,YCF,8A2F$PB(B/(<<<<<VF^`?VB?YR\JD>B(?U%
M-NO[QW//^G>%^6N>............................................
M..............................8L.IE0]#,0X/V7WSVTUZKN5_D)JM8<
M19`<@T54MU[PL_MC&=9X2:N%IB,C$X^V9&?0Q&AW1VPM)1\5VH^(W352-4;S
MYF7I5X)O^/HM3T?''4S7<=:WZW;-]0.2:W:71L>G</LL[J85>J$A%X1J>]V*
MIM+S3)*7!X6KKRKB<]UEB8%"+EYME^A%#O8^2BHV0B5DW$6^8,WD:NB!RI+L
M'39)=DLD50I3E35:J(J$*<H'*4P`8`,`ASD>....54^J-Z4%2NF;N7D'4":T
MWN67WU`@,<SZU[A<QPU1929+]3HJY)MDZ^\QQ8%VONQ*3+'F6-,+@\5056*F
MV*()\K"]&_TDBH]+/`>8L*S^HMRS(ZRILS?\_-[!#97BJ6WA6=VK=(@$JRM'
M/\?V)5ZYCSU%1TI*$=-TG)7Q$B,T10,=7](W3/8]GM_JEKUM$PJ;JB,L^8CI
M.5FM->RZ4^[K*%SAD)=.%<3:$=$(RJL>5?U!WZ<8P(Y$OK"M40-X`DSQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ
MQQQQQQQQR$G4APO@W8;13:;#VRF0&V)\(7'#MJ3R#E)X\9,FN-8J$12LK/(*
MRLBHDQ5+2YJ%B[&#%VH1O)FC@C%#`#P.4IK'@[1&FT*(P/M!UM#WG,?5]R3I
MWG3,^<%];<D5EQE?0_&<;.0N$,/NQ59RB&#'&3[.VJ\I\L+[+59O#PM.ATIJ
MJJU./<*V;]">-8,XI@RC(YNFT81[5NQ9-$0$J35HS1(U:MDBB(B":""2:)/,
M?FD#S'X\^WCOY@'U_P#P_P#=^OFT3`4>P]^X_0!3&'](^$![!Y>0CV[CY!Y\
M"8`#Q>?;]`B/?ZO"`>+O\>X=NX=A[AY<U`P#W[=_+Z!`2C^P0`>WU#\![#V'
MR'GYW?I`/4)@L"=5;+F)I3",[:SH5C`2)+:WNL5",'"EDQM7WQ2DCWM`F5`%
M@1\*(E":5%T=JN8H,R%$"0(VUW*@M3IJ@PK[%<ED=S?6D^Z:#"6:*K2C`T`_
MCV)FYFKJG6=214>C(`JF*)VID01,F*3CUGC3_1&Z6UY2R;TZ-*,@HPCBMI7+
M6K$UB3@73Q.0<1!)2K,G)8]9ZE'Q2;M1L!_5F<$C6)5>WC!JB`^`)[<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
M<<<<<<<<QW]6/5C(.Z_3HVUU@Q3),(S).6,4O8JCJ2C[W7&R-FA)J%MT37)&
M4'LE&Q]L=5XE7>R#CNT9-Y<[IX4S1)8HTXYCIP=0?:W'&]DI==/<'T'93<6[
M:%:(4S!<5ES$5M8Z(:K8%K+*<MF;9%*JV6:2K<*]<80ID37:J@XA[=)NG%DG
M8.M2K!O$QLW^@E7(<M>@(2"*Z7?%A8B,B2O'787+LL8Q;L2NG`@(AZ]R#<%U
M>P_^<4-SF1[]A[#V'L/81#N`#]`B'<._;ZNX=_K#E?#:FN;95;K*]*F>ONT<
M1;]<,B9YVU88ZUNJ>&B8[+1GL%H]ER5:6._9+#(EIDLPS2;?WI'1Z+JM4^#A
M@D%)%C$C(`"I.5S)@7'_`%,>J5G[7;99W?K1K%I!JQK588C`T)DS(6-*7=,[
M;26C,LV_RQ;3XOM-2GK3(T>@8I@ZS1FTM-%CZO)RL],,8U60>)/D,?E1R-EG
M.5"UXZ4USS?F=W4W_6/W6TAR3EMOD.Q1>8LE:=Z6X\R/L5`8ML&6XM\TO7O6
MYU,V-,6V^XL7;"U3U:@)Q@ZG`6E%IE[DETVQW7]&.J+F+0?!KZX16JM^T8QI
MMWC[$=EO=VR)`X;RA%9YM^%,GHX]D<AV&RV6O5C)#!]3++(5=.;?0R5FBI:4
M8-H8SU1%]A4ROF.L[Y9AS/GJQUUK,T8V=\I4?&%2M2`V"#CX3!5OEL(QMU+7
MI\'\=%V2V)T9Q/./96B!XXDH9F`F6!90W`S./J9..XV4>UN$+/02X.Z[9F\1
M'(66M/BG(HF_KTZFU"3B'::J:2H*,7*`G.D03B(E*8MC7HP;5+[.ZBS,1,M/
M9KCJSG3*VHMR=>WN'_OY]A]]&N*O:#*/5%WI7-EQ[9ZA*29%W#CPS1Y,$E01
M]6DEEMXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXYC3ZQ:NPZ/3"W86U4-:BYW3P59STLU%!^:[%:%<1P
MW4U,")`9GY7EQ]\JQK(P8>_`F09C#?\`*@-!Y^=Q1\PZ*P%/W6P%T\+!L(MG
M/+]MZ1.1^GE6Z_%Y#=YKF-T</1N1V^?9RY34M&*,(H:M9LEV].Q("^95^0>R
MS)?&Q'<`Q7=M/U6J][Y]Q0_RB]F]_P#NN.]]^Q_^B>^/8T/>GLO_`.&]X>T^
MS_1ZGP>'YO;G,\@'LWJQ?\S;@=.+/U8EJFQI^H>5]@KUD>.FWTJVL4S$Y6UA
MR#A>OMZ:T90S^/D'[.T6N.?2Z4Q)P:"$&B[<M'+UZFE'KQ\V1UYW+P_NA,;R
MZ+TW"&8WN8=?*9KUL#@/,N2K!A1*3DL5W*V67#.:*AD>%H>1FKF1JS7(5JJ]
MVI\W!L??=3)'FKLLA,I>$(RQ/2DV:H&LV%+_`$[(F%YSJ08LWQRAU);7.R;>
MWP.OV1LN[!FO$)G7!2$NFQGK]6<72^+[S_)U5KHK#RDZV7IM8G7L`S8J.(EE
M*S3?6W:F<VWS;U!MVH#$>,,H7C"6-]8<+X'P]>9S*L5B7!]$N=DRA8'UWRO-
M5>DM+A?LAY&LQWTB%8IL'`PM<K5?;*.)=\=48^JA@K(.!HESF2IXNR;"67%[
M7:/:Y[BJX2<E&Q!+13YK8C(TPU71*]DU#G01>OGK>'D5U$ALD,FPGTD&PR(L
MF_O,OD2BPC15X^M]6\)"&$B"-E@5W3DX`(E1;H)R)SG44$/"`B!4R>9E#E(4
M1Y"QAU:MN="Y^]RE2UXMO\@TK8W619?)6MDXQEH-V,FDUCSVS+U'G:G+0A;>
M:-BXB,G+=*/XZ+F$FD8V:3SALFU22R]:.>DN0&SCV,J<79\2RU]?N$T&N-<Q
MN(S7W),ZX6,8B+6K3KRQ'Q9;'JQB&*A&P$BXG7!^R:<*8PD`V<AIU+ZM5W",
M=GC!>:\)R"Q4SD7EZRM,0:B9A`#N6SXR4&^=LO/QI.644\363^<F8_<OBDY1
M-Q]8LD>K)5LTT=1TJ`>KCIN4"JRAC^7=,D?:$X=RJ<!$`#U)%0,/XHFY)%NZ
M;NT4W#5=%RW6("B2[=0BR"A#!W*=-9(3I'*(>8&*<0$!`0$0$.?W`0'S`>X?
M6'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
M''''''''''',?W51KF:[;T]-L:_K@3,Q\\/\32AL2!K[>7V-\OA?64E$R%<&
MFW*,(:1B7!7[5,\JFQ.W=2M?++PJ+QBI)%>MZ]NL/4'ZN6$\?8TAKEZ.=D6]
M9PKM$JE'R3L3%9-J]/MV6)2`C64)(7NS/'F+;3:EIFSILB3ED++W:PJ/IMQ(
M.SOS)N2IHW#D%#JH(J*I"@HHDF=1$P^(R1SD*8Z8F```PIF$2"(``")1'L'P
MY_7CCCG\'+9L];KM'C=%TT=(JMW+9RD1=NX;KIF260715*9-9%9(YTU4E"F(
MHF8Q#E,4P@.%')W0>Z0,70<@34?H!KZSDF50N,HS<M:Y,)"T?(P,J];KMDR3
MOLZ'LSDI%6Z221$D/5IIH)ID(F4M3#T2;IZZ6;N8[W;E-K]<\<9SD<>W3`S&
ME/+U&/GZU<9V*M9,=SC>.%E(,?5I2;F)C%G15`4*H=DB(AY><Q^J)T_\R=%B
MZDW7T?;76P:%'L:+_(^(:M(2CJ^:83\XX%)Q<L5R[Q9TLYP-8GJXM9JGV9VX
M@J[*2)8"4,%>L+:2C?(:7H_TANM-3:]*.FL'I+M+?T5EZ7L#KY!158PGG*>%
M<[%RTR!@J3-&T>M9'3F#."V"O0`XYDIRQ**^[K'[0\95LO@MSUU]))Z!31RY
MP]=IK;_3*#56];"0L5-;'88CJTT/ZTC:X8/M2*V4L(,CMDBNYZ3QZO%U5BH)
MT5+X\/W,K*S5'TE+I6;/&C:EU#]/6>JU\>D0:/LQX98SEFQ([?AX$UI*2CZ2
MC%Y1I9%EU/$BQ/`Y,;M4BG&2L!2I@H-D/!VM>N6<J6UR[T]]Z[*K3'Q@,A.8
MMR7$Y,IK9Z*7KBQ,JU@).%D(I^U\0)OH:S*!*M!`Z#UDFJ4Q"^REJ_4\Q2"9
MH2]X@V'AVQ1*BQLS!.MV-PGW^!W/JJR4ZWA#N4Z]D>=^_P`[QCVYJ&^>9<<>
M%'8/3O*=5;(*>K>6BB"-K@.Q"]UEDA6;),"IE`!4*4MF<=T^_P#2")3#SV"B
M]174N\F2;ADU&GR:AQ(:,OT5)595`P#V$J\BX0<0)#?8$P/ZOAR7U<M]4N#,
M)&IV6`L\>($,#ZO3$=--!*<.Y!]HC7+I(`,'F'B,'?G8>X=Q#N'</B'?S#](
M<UXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXYCKZM>3,\X<Z;>Y.4-9)J-K><*1A"SS]%L4F]@H\M>7:*L2SL]%N;(
MNWAAM$-5E9V1IS9Z*Y7ML;0K-!E(.UV[!S34S;AW"^HVGN+]]M)^OIG[-?4`
MG)'!LU7:+9]JJ;?*IL=><AV&MMYW']HPK(3C6V5"OLTI.8DK0CF6;GX6JQ-:
ME(O(*+194[Z.OHX/V`Q#GJOK/L89@P[E>2KS6#0O08>R34,C1E8GI:.%U[O?
MN:I.S@1I'*S:1&))(+)JO6;119`RY$E%>>W<<<<<JF]4GT:R\]1[<S(FUL1U
M"[9@"'OU>QS7@Q?$8>F;<TARTFF1E.=NBS;7.-):/BS8L#RAFOR>9`V4=+MU
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M&TFH=!9Q,66`?V-PT**$9:XOUAE0ID;,^CP]9'I+WIUL%H1DJ_9PJL&NJNWR
M'JC)VFEYTC(9JN==)O?L),I%S,V./<@7_;HZFO\`*L`LW(LI-LF+1041]RT:
M],.W,PS+L<8;YX1B]FHV->A!R=SI$:TQ!L#$NV:AVTB$W66L:7'-PE67LYD"
MPGR;QM)J.DUQD9U18PB2Y;HSUQNFIU!#15?PEL/7Z_E62`B9L%9A*3%67DI(
MP"9:)C:[8W*<5=WK4@&,[''4_<6J($.*BQ/`8"Y$KU@+".3RKA>\642SKKB!
ME7TE6XWWN`^8`8LL@@WETA'S`#$>$$?/S$.1#LG3#U]6>*S&-I;)6&YP!%5H
M\HES?BW0<>+QIG%M->\'G@3-V\*;:59]@``*<O8!YUX==-^<7B8V*-LXS),8
M@4#)0.98!19RL3R`4!F%T+4Z$Q0`/"8DE'%'YWFG](-FMZ<8=BY>U!3O4<BE
MV5L.&9Y1\)DT>X*O#1+96W+`)BAZPJ2J46`CY=B`/A+VBK]3O7&0>)Q%]1R#
MB";`?`Y8W^FR"22"OT`9U!C+*$3$>X`HZ9-`\A$Y2!Y\F!1<YX<R8FB>@Y.H
M]K47(4Y6D/98IQ)$`W;L"T49RG)MS"(]A(NS3.`^1B@/ESU7N'U]NX]@[^0B
M/V`/;OS7CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCD&NI77)*VZ*;.0$5K@EMV[?XPDN^M*LU/UX^:&K61BWTA16DU5GT
M?8X^2E8YJ[/%+P:RLI[S;LTV;&36.6->4@[7D;T?K)U*IF,-(.BIDW/W46R%
M*3M1<Z76%CLK6)S`]OK#LD?;G^<+"VR(JW/6:JX]L?K!5U#+'C8UT:_/L2E3
M=N8^\3IAT\]/-`X6Z1>I6":[@]OE!S6I7(3*NSESFD)Z6J["090ZR@W"TV@[
M0L8E,RR*"<<NW14*[.=?VE0"+!-CCCCCFTWP#^T3_.7E4CT1#^HIMU_>.YY_
MT[PORUSSK]KJE:O59L%+N<!#VJHVR%E*W9ZS88YI,0-AK\VR6CIB$FHE^DNR
MDXJ48.%V4@P=HJMW3991%4ABF'E'?.6`,@^CBYML$VA5Y[9GH'[9WUG&9MPG
M,I.;C9M2+Q:7!&D78ZS[2[1?H.&*R;5.FW)F[:+W:+C65%N#QED^$QY=Y?+G
MCBTY"T7I]9V6U&NH[C=,?+#%O>FT?"S!9J;QQ`S:IE5;'`2/JR'9MVBOM"$I
M(*LV4>,DU?0>48*JV=H:U#G.P5GW%&R6/XS)&);2RL]=?^%%TD7_`&:9K\L5
M(BCF!LL.L;VV#G60*%]<S=$`%D3I/H]=[&N6KU>"V_71CZ>_4?9+O-A\&1+?
M)8$$(O.V,E$<=YKBEBD*1NJK=8=F<MM09``F91&0HNX0;5416;QJ*X^M"F+O
M%Z+9N7K81[9<!0]5ZDN#63M9[\E'!V^&-T*3$(>L41+6[:U=K1>0'$8U]6DT
M'VRWI.7Y2FC,)%*8I">"Z1]4[J,ZF6=MAO7C<5:S3U1DQ@)?IR]6AJ?'^082
M1:G00)2\99\NLE5:VHNB"RK&&@YG*&ODNZD3-VD1AF:,***EGW7CTH;6TEU8
M8-ZD^!,W=,[/9VZ!E6F9:M8Y[$<L"YBMVDE$7AG7(NT1T-+*@=RRG)ZBITLC
M(2K%O3Q#PN5+)&-,K8RS/38;(N(LA4K*%`L*`.8&[X^M$)<JG,-Q\/\`2QMA
MKSZ1B78%$P%.5)T91,_<BA"'`2AW[L'Q[>?P[_3^WXASK%GH],NK/W?<:G6[
M6Q$.PM+)!QDXW[>?EZJ3:NB!V$1$!*`"`B/80Y#Z\].+4VZJ'=(8\5I$F=0Z
MH2=`G).N*)'-Y@=&.%5]!IBF;L=,I(HA2F````+W`?)S:,Y]QP`JZ_[EY)A&
M[<0%E5\CHFM<&`#\2**`NX8)E\@#Q%JJA@#[`#FHWCJ;8J%0MEQ=B?8"&;*`
M*TG2Y,E>L+A$A>YCILQ<0PBJL!1[$1JSD05$2@0Q1*`_2TZE];JS@L=GG`V:
M\*R`^1UY.N*34,3S`OC!XJC`2"J1A[^$[>+<@/8.QC`(#R3="W+U@R3ZHE7S
M121=K%3\$;/2(U.3,HIV[(IL;0E$++K`(^$2-@7\_(!'X\DHV=-GB*;EHX1=
M-EB`HDX;*D7;JD'X&372,=(Y?M*<0'Z^?0`@/F`]P^L.................
M........................................8UMT,F8JV"DLI=+"I;/V
MK7K;O-NK\UE>`GJ36;Z>U4G#1[BWIL_D6!M\.%>J[65*Z9RT"SA_E[%6,3.3
MOR,58Y-0ZE;C8SII]$+#'35I.]VI&Q&:,)R&$KVTBJ'U%]>;)=\BYCM>3K%D
MAGCB87RC$MY:D!?(IQ=3BPF655)05JPB5X2I/6T.M*0\W=DCCF48,E#J^N.=
MHV.=7L(>L,=!,QE.Q@`P>L$1/V$`$/%Y@`]^?9QS!GO-LGFW^?U0-1&6YU=Z
M<F#0U*F=D`V`D:GA66M.<\CM<F2=!EL/4^Q[(PUCQ+"Q&(*XW@,FY(CXZ#?Y
M!E(>U0P-582!%U,-XU4;J-;JYJTRTYH6/KMC-EMAN?NOFG4C&6VK?%9U,9VS
M7_`[K,%JLF\^.<)RTRO'S1+9B#%2,M3ZI(S!J,^MEC1F/6)5(&C`9S::Y@V@
MQ5NIF3IY;6YO;;22L1KGCG;G!NP;S&E*Q)?IO'ULR1<,39!QYDJJ8V2C\>OI
MB@7*`@7<!9:M7J^,A7;2@VG&;B0:I/%<D=SSMA/'<RG7+]E_%U(GU&K21)"6
M_(5/K,N:/>+JI-7Q8N;FF+\S-RJV<IH.2MS(K';KD2.<Z2A2UFO1"UD7&A^V
MRZ"J:Z"W49SJJBLB<BJ2J2N.,+*)J)J$$Q%$U"&*<AR&$IRF`Q1$!`>6O>.=
M$R=C''V:,?7#%.5J?7[_`(YO]?DJM<Z9:8UO+U^QU^7;F;2$7*1[DIDEVRZ1
MNX"'@606(DZ:JH.T$%TZ8*@9J]%HV>=L73'(.=NASM-=TOZ=7VZX6K3G)%@5
M<(N60HF46]O179E`72;EHT_EDJ3!M[.X<94IKU"T9H+9K#,U`\!OUTF[K79>
MNY#K<3>Y7#U<?)2N)<U469;EFFLA1&A'+:/.C(-7*CMI4P<1BS%RLX/1).L3
M21H"2GKIQO;B_;>&=Q39)?'V9ZL15#(&'+,J=O98)XQ6!G(O8@'B#%Q/0#=\
M!FJ[LC)K*0KD2,+-%0[U1!-Q.,0`P=A`!`?H$`$!^G]'(([M=,_2'J'50E7V
MSU_IF3G+%JJUKUX%%U6\H5$I_&<H5;)E97B[G$-"N#E=+0H2SBNR"R202T-(
M(E%(:O>Q'0+ZANGU&7I^A^6<=]1[3%E(.Y(W3CZAU;J=T9P#10CHA$L.W2>6
MAH>JSR:;EPX+8L66G6JTHO`;N".+&[$R2F$3$KW!.$LXOX#`FP&W'HXN^",B
MDE-:_P"QLC?LBZ+WN;0423AVKC(<]')WFFT^57!9ZJZS[2\NT!E'&9EC;/-M
ME0=*6%*=UR>J7H%`0#_JM:*M]A-=I!!LYA-_M!):O7W'%BKBGS6]ME6,#(R&
M-WA)8P*N$%G<Y@]11`GA951PIV!2P#I)U9NG[U"HUHIJYLE1+G;%6)'S_%,T
M[4I.8H8A4BG>`_QE;"15H=M8]4WLSF:K[.<K9U@`6DTZ1.DJID8`P&\P$!^O
MZP^P0^(#]@]AYKP(`/D(=P^H>?*\8LI%LLS?M&SUFX(*:[5X@DZ;+)B'82*M
MUR*(J%$/(2G3,`AY"`\C+?M*M6\DBLK9,,4U)XN!Q4DJXR5J$B94Y?"*YW57
M6B165`>QN[DBY3&#N8INX@,;''36B:BX,_P#L)FS##SN8Z;1I8#SL$0P]^Y#
M,45Z^\53.(%\0.GSOOV^<!OH_@%2ZG6*13&!R#B'82';>(B3"UQQ*U8ED$A[
ME!1T5*O`=PL0/")U[*]$#CW,8W;Q"#>[->./"EL'IUE&L-6Y_"^M-!/\K8$I
M1^!R>-N5@4O?O\WY3JCV#R'OY<]<HO47U,O!DVXY*3ILF<Q"'B[]$258504,
M;PBFM(K(.8(IR&[`?M+B4._B$P%`1"7]<N%3N#/WC4K/7[0P$0`'M=F8Z;:B
M)@[@'KXQRZ3`>WGV,8!#Z0YV+N'<0[AW#XAW\P_2'->.................
M..................................4Z.J1MI)]/[KZ8SVLG-:MD<_8\
M>]+%SA4R&`,>.+<^9VVV9ZR#-,Q>O7JL=!(MV+6$`\BW]Z#)H)R#!=-@NDJ'
MBKG([K71QT'4>DS_`#(MU"YH7S6ED'^4M3"\N&*RQ*VR9<R>R'<"/RM!^6%/
M[L.7Y-"W]Z@80<BS[+C^IQ$@)8R/*8!*8K%F!BF`0,`@U2`0$!["`@/D("'<
M!\AYR''*X^X^/:'2>J)9<_[\:G9(V]U0M.I="QOJU+US62X;FXVU_P`IQ5QM
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M3JI.K%*F4>BB#Q<JQ"*+>%%+PXK_`$/:'85_I^[3046D9&-ANH9FJ*CT3JJ+
M'291N,,(L6B9EE3'55,FW02(910QE%!`3G,)A$1MF<<<\WR_B#&6?<97;#69
M:17\CXOR-7WM7NU)M#(C^$L$'(%`%VCM$1*JBJDH1%Y'R+-5O)1$FV9RT4[9
MR;)H[1IM8\N6Q7HO&ST)A#,TU;LW=$78W(KEIB7,$DD_G;)IO=+0\<2"\#9B
M,&SI5%DCW</[37V35*)R-"M'^4,>-(^^QN0*1*6*MGM(L>;7LJGL_K+D")QU
MGH(J'NN,\Z8\ETUJOD6-=QR3VMO)V6K9G*$U&2L4N@G#WF)!^]]S.DVS]"SU
MWM!CUW5?J#3XWP-6=VJ\CA?92(4;1D5-2!&\;1LL^M,+>.?PK](YH2.F9T4Q
M-'$8.U*K:7(*$K#MG)G&J,LL@"`^8?\`'V#]0_6`^8<U^/QY&#:;2[5?=BA&
MQIM1@K'F;:B05U(UI=(--S*UQTY(5)>1I]I9'96NERJB102-*U.;AY`4_P"C
M,X,GW(-:6V=!/?+ITS<QD[H:;QV:M4YW*/)NQ:+;3RP6["=L0=$'V^)AIEXQ
M?5EPX?(G4B&:EMJT!:BLU"J.,RM7*8NSX8,S3O30RSDYIBSK,=/#+G1-WF=2
MRJD/N!J?!3-7P/;;*U<)*C>"U^)1L=:78.)A5%1U:JI$912.8ZL@]R]`D,=9
MOE3Q03T@'1BB0F4M*-G<'=>S1-5`SJNDE+4QD\Z(UUN)?;&T!<$+6^LDO+,4
M2H1[5A'9.S&NU63413QO''*+/D_=3_2>="\OVT<,[:P^2>G-L7&N$(RP8UVK
M@G]<JK.:5/X563?)QXN,8PJ#?XF<Y2KN,#*=P!`CCS$+%-8M=8NL!$6NG6&#
MM=7GV2,C!62MRT?.U^;CW`"*#Z(FHIP[C)-FL`"*3EBZ71.'F4X\Y_CCCFGA
M#X`';S[^7EY_J[?_`/>>1WO`6%,FD6"^8LHEG67$PG?2=:C#R@"<!*<R<N@@
MA*HG$!_\XD](<!["!NX`(1!LO3#U[</%)C&\IDG#<X4049OJ)<W_`*ALN41$
M%`;3?O%V`=^WS&THT``#L42<ZX.N&^N,!$<3;;,,B1;<H"E`9E@5'"ZB"7FF
MU&8<(6QR<Q@_HQ43?1GEX1\:90[%VALMO?B_L&7=16U_C4$C"M8,-3JCLYTR
MCV]I&):K7!;Q``>(Z:C:.[@/<`3`!`>SUGJ>:ZO'A(C(+3(F'YL@E2=L;[37
MY4F[@1\)R"Y@_>K@A$S>1E'<<S[!\XQ"AR8%$SQAC)I$34+*-%M*J_?P,HFR
MQ:TH';MW!2(4<)2J(@`AW*JR(;S#R[>?/6/$'EY]NX]@[^7<?L[]N_ZOCS7C
MCCCCCCCCCCCCCCCCCCCCCCFT3@`]NQ_+ZDSB'[0*(#^H>8U^J+U.L(]*_`-;
MSMF9J]GD+=EO'V+:Y3XAX1I/RX6.92<7>P,43-'R[AICS';*SW=XBFR%*4=Q
M455Q>QCJQLWR.0VN6:!M]?@[76)5G/5JS0\98:].12H/8R9@IMBA)P\M'/$0
M,BZ8R4<Z;/6CA(QB*MUTSE$0-SF_&'A,;L;L4!$>Y3%'R#OY>(`[\C1CO:G'
M^2W6U3.#B+:U5U$RU,X<R.,HQBD23-E@\,XVS@Z>TX6LR[%_"J57*,"P0<3!
M81Z:>:2K8[!-BBTD7D9L%=5?7#/F>=>-=ZY#9,KEZV=T/Q]U`L7.;?"5UE`/
M<6Y$=*IQM"?OHJU3#E#+L7&M9"P2]=:,7L`$%%R;R-M,B=BNB7KP=834L)?>
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M)-/>*^S@Z4K]S@V4[&I/TFKEVBUDVJ#TK.49%<K&8R3=VS.<QT#"/`R>SVML
M+`VVTS.P.$8FLT!W7X^]V*3RS0&$%2GUL8-92K,K;,.K"E&UMW98Q\RD:^VF
M7+)>:8NVSR-3=-ETE3_VR?L=@[#L!7[#D+*F/:RA=64DYQRQF;S4(62R@ZC8
M0UA&&QLVFYR-+=IIY&>I<,6$`J]473=-%^Y&SA-<?YXDV'QCF'#=*S?"SS*`
MJEQQ;CG+J[*V2U?BINF5;*%.B[Q627M!"8>L*X_/"2R!EP7D5&!U4G!F+]ZU
M(5R?LDUFK#M<NW\FM@RMC:#R)\EY&\?(*8O56C+H%)B$U59>X_)5[+(3_P`E
M(I)!=23L7N_W0P2165=O$DTE#%\2H>^>G^0L.T'/<7L/B>$Q5E"P2]2H=MO-
MZK%!86:V0DU)0#^KQ7ROEH@7=C)(1+OU4(@*LFNU]0]2:F:N4%3^SV'.>%:C
M?J=BFUY>Q?6<H9#;B\H&-[!D"HPM]O#0IW"9W5/ITE,-;%9VY#M'1#+PD:^2
M`S9P3Q>)%4"_>GEW%*V2'&'$<F8_5RXT@4[4ZQ:E<ZTID9K5U3$(E9'%'))F
MM"$`JHJF1.95BB1QSG(!7(^,O?T3CCCCG&R\E%0D9(S<W),X>'AV#N3EI62?
MI1L9&1D>W5>/Y&1?.5D&;)BR:I+.7CQTJDW;-DE%UU4T4S'+C\Q/U8NF]G*2
MLD;BG</#=R^2F3L;89EY>/LK]K4SY/S$6X&Q93(6ZRK&/I]GF+\>A6QK5R5J
M<EFTJ_B3QS=R9^\CF[S(J`]_A_Q_Q]/''-!`!^/[0$0'Z^W<!`>WUAW[#]/'
MA+V\/8.WU=@[?'OW[?7W\^_U^?QX``#X?M$1$1_2(]Q']8\T-\`_M$_SEY5(
M]$0_J*;=?WCN>?\`3O"_+7/'''/#MD-<,,;:X6ONONP-#ALD8HR3"JPEIJ\T
MF?U:R?C*X8R<8^0,F_@[%!R"3:8KECB'#29K\TS9RL6[;NVR9^5#=?,W9K]&
M4VEBM)]OK==LM=(W/]C=.-3=FY=FXDG&LUDDY!X]E:'>08LCIM8]`5@?7NN1
M!DXX68_RRX\@T"/LBU%E:KV-U?P'O#BJ,8VQ*+G64A$(3^,\JT]Y&O9:#1G&
M2#^-L-/LC07<?,5Z::*LGJT>HI(5FR,#M7)T5%",)!MCFQUL]G[IVW*!P%O$
MI(Y`P3*.@B,2;31C21E!8L4P$&D-=R_[9*.R1[4@&>,)!1Y<ZZW2669N;S5T
MT)*,S=0,_!VF&B[%6Y>,GX";8MI.'FH9\VDXJ5CGB15FC^.D&:JS5ZS<I'*H
M@Y;JJ)*$,`E,/GSE^.>09NU_PALG0I/%N?\`$V/<RX[E_GOJ;DFI0MP@#N2I
MJ)HOV["::.TV$JT!4YV,O'"TE&"P@NR>-UBE4"LIE3T<+*.J5ZE=@.AQNKDG
M2;(;N2&9E]>,BV6;ONM%W%(H^SPST'S&RRB,<D0%"HM<EUG,C8IUR)L'E<30
M2<)0OSCU(XQLG`:O>E$=)AE#-'+]6JU3='&U"6N6*Y$3`4QIFM6FJ23RW5)V
M9H`2,PXPAE&5GP]J\*^,(+U*K!/O&$^D;9JQ6G.U'HU75^D(+'LB\4E5]=\C
M71/+FOS^850,Y6K%C*,3,*U"9(V#V5.'S!AV8O,>=P51W;(DY"O$_=X/T@;>
M'0.7C<?=;WIR9#Q-$&=MXEGMKJ^P)>\)SJAC`V;O'T6-AG*VBJX(!9%\A6\H
M+6(A%3$0QJR.!69+#^H_4+TLWMK?RGU/V-QGF5%%H5[*5^O3?L-^KC<XD*4]
MLQK/HQ&0*J!CJ`0AIZML453`/J%E2]C#,L!`0[@("'U@/</]W->....:=@^/
M;S^'?Z?V_$.=9LU)IUT9^[[A5:Y:F/8P>QV.$C)QM\X!*;LE)M71"B("(>(H
M%,`?`0Y#Z\]./4R[&.Y1QT>DR9S&,64H$U)UQ1`XF\0*(QOKGL$4Q1[^$/=(
M%`/F@`!V`/*/YBV=L<>)77_<G)E?:-S`+&K9"1&V012IAW214,#E2/(F!@`A
MC%JQ_P"C[@)#>8#J-SZF^*A.%BQKB38.':B4Z\C39,M;L3A/ZDFAUH,!4[!Y
ME1JKH1$0\/B`!Y]#7J5P54<%CL^8!S9A9_W*F=S(5Q2;@P5`0!4Q'JJ,`]50
M*`^,IVL<\\1/Q1-Y">3%"W-U?R2**=8S12O;%_""<;/2)JG)G4,`#ZI-C:$H
MA990!'MV;^N`P^13&\A&2S5VU?-T7;-R@[:N$P50<ME4W#=9,P=RG271,=%0
M@AY@8AS%$/,!$.?0`@/F`]P^L...................:&#Q%,7N(>(!#N'Q
M#N';N'VA\0Y7`VOZ`V1-E]B<O9[B^K-U`\)1^4;@YM++%&+LAR\10J.DZ9L&
M98&L,$;LP0;QJ2C,RR)$V30A3N3AZH!`3G_.*ZM,F>L;?Y4UQJFY.Q>YV*-=
MK?(T2NY(V!R/*7([V]1[./B\J/::R=V.=AXZO$MD:ZKK&3BUA4L3&NMI)==5
MNHS31SB^C[Z?6#JI8URCC>0ZK^_6N>5M=%JTA#8;QAF&Q?(A7!DI&MHFJ3E,
MC75TCSQ[6L6*/DZM8(:-:!$5]![3!;BB6;(W2O1=,GIM6CIVP&8H6R;G;+;B
M*94E:?*,I'8VS/;(^HI:G&S[!9C5E'L_.BV;6`\X1S+`F9J"RL7'>(BHH@<L
M>:?TWG-ZR5U2LBY89['5&5S)M%:+/A)KC+;78#"]2ON/U=.=>J'%6->C83S/
M3JA(.WF0J]<ZT[D;G!DL,BW@T8^6%Q66T2F?'[!Z0[SX>JFM>P..]=9>P[&Z
M8]++I)5[&%&5M-+B"W//>"YO:"A;6:V/)HEC%K&$DL*YS?LI>7*M\G%WJE?5
MB).26CS$;?=2NE;M;B"1N%NK5"2OUXP%>.DSM1`MI"PU6+:[BYJU^K^PTMNE
M"Q<_,R9F=6O=RMN=;S9:3/W1*%K2.17E*;N9B.K:3^;AYIQ(;6;![K8ERIA#
M'74:U>Q%/QV=8S8J>V2R5&1E`I-BL>ND_7L+M<3:DV3*.2:#,C2\D,X:V3=K
M;TDU"2N985DR<71C9+<M"=_NF(=E-0]O,3;E3#/,F_E=D-6;GJ=F^7HU%Q%%
MY\J#L^=PS=B;)<)BVFM<9U.UT%!"5L&-L@0U%;)W5H9A1;B>'M**,^O%>:9A
M1VSS38-;=M]@-,;19L$XEW#R/>ZOI_"UZG7C8NE8@G-;'6)L+Y[RQC8UYE\?
M9!RK6,P/K;>PH59FW5IQ!0\CU]TS;3M\H\TG'>"TC2+<C+$?K#BFH5&:TOP!
M`;D[<=1Z%CK34L=7@N!FS+((_P`S#7!_B=.W.JK&V&3L&1[ULC*T:`<2%(PU
M(UBNP+&52L\9'(1^2[I4X#SCJ+BC,>H^6&3B8H^#=@[VKK?EA*.KD%"Y1P5E
MX8_-;(8ZKP,J_/45L:9%O>1<7*UEPW8LHZ*K$$,`16$5:>JQ`/NGQF_`FMG2
MV?U3"^1:8QPK4=@IO:2FZ]8+UIV"R]$[+9EBZ26LYNEL99J;62GY%G$VL3D;
M'D]?*^E8LBTV&R"V8P+F/HDC;5X[JM9TCR;A2IS),O=/[/&VE3SKTY+'KA@G
M&$RWUUO=PUER79L[;)91MF([^2N2M$Q/@ZHY1B<JX:?QMOQJU-1L0LL3LL5'
MG%F^-*-)6#G[%@C<C$^K^QFKC+3;.F3\D[6Z"=//%%'L%'''KS&M5O&(->HO
M#^;H/*E\F+Q&-Z;+X^?QCV<0:NVCY.\M%&#*F.Y:3>J-VLLJGKF[8[1Y+H.:
M>G%:<]9.OO4EF=G:SN5(/*G$8TK6O[U2.>4*T/\`-Q)ASD0TIA['$>I@(VJJ
MM>+$W]LD:NOVJF*[=/6!.`IM4MFZ_@K!.$(72#(533KN#-R,%N)W'FLFN&5[
M_*Y&OVP=S<O<<N)/8&\$P;@S!V4*=_)Y>6>>0H=K1R(R07B9NR5$*3&0-CWP
M.M&S==E=>[#2],<\O\IV/#G3-AKUCW.N$L*Y8UTOUNU;KU!ILI-V/,#^?I^>
MM([S@>6J=LF6+Z'N%XIEO%I5,H52B7.9N=BKDC[IB#2_92)W.JT)D6D[0R,U
M6>I'FC;!]ENMXLTZHN"WF-9K(^1K11\BRFU#*M3FRUX?6O#D_3L$V[`2DJTM
MBK)&0Q\Y)6L-UB%DC6IRAV*4.W;L4`[=^_;L'P[_`$_I^GFO''',<75WU[S!
MM7TU=R-?<!JB&7<G87G(.E1X2*$0:S/VK^*FWM'+)/'+*/9#?H>*DJ4#B3>-
M(H@SX!*N48X72A:)+'$^Q&P26\.FN!^BULWKQ8MNXKID4_%99[$$QBK#6H>3
M=0(R?@LM9YL>2G$#"-#.9]S99V0@K>D[0G[FSLMBE;3(/IIXE&6']+ROL7T9
M!P\=)R*DO(L(N.9/Y58HD5DWC1D@W=R*A#'4,11\X25=G*90YBF6$#&,8!$>
M7XXXXYM-\`_M$_SEY5(]$0_J*;=?WCN>?].\+\M<\<<<<CQM3JM@S='!E[UU
MV*HD9D'%V08P6,Q#O@%%['O41%:(LM:ET>SZN6ZN/P3E*W9(M5&1AY%%-=!0
MR1G""]3G4G9[8GT=C9FH]-OJ"6.5R-TVLLV9[&Z.[I2I/!'XH;R,H*B./,ER
M!O`T@ZY$K2*!+A!NUBCC!VZ&YU@\AB.75)6;AUZH6/,TT64IE[KT%>Z);8Y-
M-_%22:4A&2+-<A'#-XU<(*>-%PD)D7T3,QCE!ZR7*WD8MZ@N1%P&%&8I.Q_2
M:G9&XXK+8=@-%Y*36DK;CI\Z%U=L,D=KBJ[F8MT)/"@R2\9E5+`W1)7)?L9"
M]QT'*&;79QD6G=[\+!JA;]M\>O5,ETFFQ3%]+U^'=L8>T1\B[E8B*7KDZRF%
M"!79Z/4ET5W#23\*:[8I'<<N^8.V3Q?'!^'OQ0(F`FON3%/"(@84[=0S@'Q_
M&$KD0#OV'MW^H>2HT[ZI=#W"RZOB.MXLN%.D4*;/7(9><L-6DV)FT$^@V*K,
M&T.NH\!=P>;2435$OJ2%04!00,=,!RG<ZA>L?T7)]5F:+DBF56_TJQ-3L;!4
M+K7HBU5><9'$!.TF*_.LW\3)-SB`"*3QHL3N`"``(`(5G-B_1E\957(CC93I
M+['91Z9^R39TM)(L*%.6"?P/9CF,#A2"E:<:33GZU!R3ONF[B64E:<?MV"BK
M(,7.VG@;%CLIUA.IGTU6X8DZ[.B"F9L`R+HU2>;RZR0D#;L<V>*>=F9'>1J`
MFS:X^?FFCJF,K&2:6%;`K'-URLL:3;PABK<ZUZ3'0SZN<;_.>Z7>>?YK&=XQ
MQ[_3ONG%I?X[L-#L3@QCMUK]K5,N:Y+8^$BZAU"?)*/Q,YE#$%PRGGS4Q5CO
MEOZ2WTGP(6[5&C]:+52N$(96T5$'U=VLAZTT.<0]K:LFJU\F9HZ":KARL[J^
MPBANY"N+,V(`F)/[2STDWII;:3"..;KD*8T\SNW=!$3.'ML633&#EO8$S`W=
M1,7?W3I3'[YR5\(,V<7,S=7M;Q02`-6;JG]27/LS?,Y!JU>L73=XS>MT7;)V
MU63<-GC5PD5=NY:.$3'1<MUT3D517044153,4Z9S%$!'ZN......!`!\A#N'
MU#SYW3-J^05:O&R#MJN04UFSI%-PW53,`@8BB"Q3I'*("("4Y!*(>0@(<C-?
MM+M7LD^N/9L,4PKM8@E/)5Y@>HR7B'S!47E65B#JJ@/GXG!5O%\#`8/+D:G/
M35A*FX-(8#V`S;A=Z8QSE:,+$I.09/\`G)HBR27K[U1`#_C%=R+T3E\0'`W?
MN/SA3^ISBH2'@,BXBV$B&PCZN-ML:2M6)PD7R]49T1"`**IR>8*+V9T/C\S"
M;S`^W^?7G/&_9+8+3C)E>:MU03>6G'JHVN!\@_I54RG;F8%3`.YR`%H6[E[A
MX^Y1'GK5%ZC6I=W,FW/DCY%R1SB08R_0TE6E$3!Y"5>2,B\@4Q`>X?.EP\P$
M!`!`>3`K5TI]S9A(U"TUVU,!*0P/*Y-1LVV\)P[D$5HQRZ(4#!\/$(#]G.S=
MP[]NX=_J^G]G''''''''''''''''(_JZGZO+JJKK:Y8&567557655PYC9155
M990RJRJJAZP8ZBJJISJ**',8ZBAC'.(F,(CVVD8-POC25<3N.\28QH<T[8*1
M3J7IF/ZA591S&++MW2L<O(0$-'/%F*KEHU<*,U%C-CKMFZQTA412,3U/FG8/
M/R#S\Q\OB/P[C]?EY<>$O;MX2]NP!V[!V[!\`_0'T!\`X[!Y^0>?Q\OC^GZ^
M:%(0OXI2E\^_S2@'GV[=_(/CV\OT<U,4I@[&*!@^HP`(?L'F@E*)?")2B7R^
M:(!X?+X>7;MY?1S4"E#MV*`=@[!V``[!]0=O@'V?#CL`"(@``(_$>WF/;R#O
M]?8.:"4HAX1*42_4(`(?L$.W`D(/;N4H^'\7N4!\/Z.X>7P#X?5P)""(")"B
M(!V`1*`B`?4`]O(/L#CPE\7B\)?%\/%V#Q=OJ[]N_P#OX\!/+YA?(1$/FAY"
M/Q$/+R$?I'XCS3U9/(?`3N7\7YH?-\^_EY>7GY^7T\U\)?%XO"7Q?#Q=@\7;
MZN_;O_OYNXXXXYC:ZP.6,V8,Z96Z>6]=K/'4O,5"P99K!3[=(R,+%?)H6SB.
M2GYV)?3ZJ,6E:(NK+SCNGIK"HJYMB4*U9-W3]9HV6K`8GUWUWR!CG&MVG/2\
MMD&\I:ZI4;3)0$EN]7*FHRF9F-82<E%KTJVYE0LU67;R;ARP5KE@:HSD2<AH
MZ32!VDJ0;SC4H%;-RE7%R4J")2N#&`YEP!(@`L)P$0,*H!ZP3`(@83=P$>_?
MGT<<<<<VF^`?VB?YR\JD>B(?U%-NO[QW//\`IWA?EKGCCCCCD4MU=+\";^:Z
MWW6/8ZJC9\=7IHB<'#)8C"S4^S1HJ+5R]4F:,BX-!V^L/5!=Q;X4'+-RDH\A
MIMA*U^5E8I[5_P!#MQL\=";:"O=)3JB9$4M>IMY`"]/7=N;35;5=A5R27NUG
MB[)$P]=N#5>NQ:SJ.ACL)=V[-A2=<,V*\F]PM8ZE8ZW<E.1L];F(<J+EJY1,
M0Y#E360706)V,4Q1`Z2J*R1^QBB!TU4S=A`Q#>>!+>#5*:TH:W;<_36Y-<2L
M`"+8Y<PZYBFDWCRPL['/,X1E(P56DVK^!`C2;EVST:O(L?=L0=1>5J#^NJ(*
MQ,E@:S?M'F/8>7I\WE*6K4E(4,'A:V>`H]9J*#8'TA&R;D'K6`9-$)/Q.XED
M<@/2J`D0JR1``CA8#YJ.EKN[L+L%L\\H>3IVF2-;)BRYV(K>!QG2ZF_]ZQLQ
M46[14TM`QK60,W*E).P5:&6%!<YTU%2F.BF);&7''/@DXJ-FH]]%2[!E*1<F
MT7824=(-6[YA(,721D'+-\R=)K-7C1PB<Z2[9RDJ@LF<Q%$S%,(#7&W!]&;T
MWRW>$M@M*+=?>FMM7$22\]`92UC?2$)21FE0$3+2&*X^;KS*`14[>K4_DLG\
M=)+>O<JRK"<!4[<\-4>H/UU.CX+>$ZF6L:/4.U-@GQFA]SM7$TE<F5VN(E)X
M9G(%=8Q44S4&.9@B0Y\BTS&P/9`SE-7+%A7\#M6=,!9>@EZ1)2$O:XG#.9<F
MC$G*M7[(W/AW<6@)MVICJ$1<1KZ"R:]AX@?"JJ]KLS=L9N7"?A.ZDD@43&&3
M[HA]4CIMNW5MZ+W47L]AQC&+*OT=)MQW+:TX_>M`-ZQS"5JQG8.*.U=OU#"B
MW<-ZGB.83133*]R&HL!W"G:J'Z2?DG52U0N'.MCH-FG1^\O7(QK7.&/JW+Y'
MUYMCA`Y2O96(!N\F)7W6V`1\88ZMN:3%$2BJ#0H^#ED'6_;K6/;^E)9#UCSK
MC+.%1,1N9W)X[MD9/KPJSHIC(L;/#(+%GJG*B4HBI$6>+B)-'L(*M""`@$B@
M$!`!`0$!\P$![@(?6`A\>:\<<<<<<<<T\(?5V[CW'MY=Q^WMV[\\EO>!<+9-
M36+?,6T6T*KE$IWTI6XQ24*!A[CZF81;HRJ!A'S\:#U,X&\P-WY$"S],+7=X
M]4F,>/\`(N'9OQ`JV>T*Y/@006*/B`2MIP)1P4@'`#E(VD6OA$`\!B```'6A
MULWRQ>(GQ+MRTR'&H$.=*OYE@5'2JI2_B-`EG25M<"(E`"@HF^BR`;X>K*;N
M74NR.^>,/"7+6H[+(<:BGX5)_#4^HY65(EYJ/#1#9:VN.YB`)@24918"8!``
M3*(`'9*SU/->';U*'R&PR-AV;[^K<LK[37Y4$%/@'B<P@R;@J?B^;ZQS&M0#
MXF*4.XA+^B9[PMDU-`]"RE1;0JN4#$8Q=DC%)0H&'L7UT0LX1E4#"/EX%V29
MP-Y"7OSUKQ!]?;N/8._EW'[._;OS7CCCFG</K#]O'</K#]H<UXXXXX_X_;\.
M1Z=[;:M,'3IB]V/P6S>L73ED]:.LKTA!RT>,UU&SMHY05FBJH.6KE)5!PBH4
MJB*R9TU"E.4P!W&AYSPME*2>PV-,M8UR!+1S$).0C*5=ZY9Y!E&BX3:`_=LX
M:1>.&[,72R38'*J9$174(D!_&8"CZISXCR+!-P#11ZT(Z,)2E;&<H`X,8X`8
MI2H"H"QC&`0$I2D$Q@$!*`]PY\DM88*!]@]]S,5$>]7[>*C/>DBRCO>$H[[^
MRQK'VU=#VR0<>$WJ&3;UKI;L/JTC=N?SGK-7:LQ))66=AZ]'*.$F9'\[*,(=
MD=VOX_4-2NI)PU;BY6]6?U3<%!64\!_`F/@-VY<%T3"F4%4_$L0RB1?&7Q*)
MD\`F.0O?Q'(4%"")B@)0`Y1$>QB]]".4%#*D35(H=`Y4UB)F!0Z)SIE5(58A
M/$9(3)G*H4%`+XB&(<.Y3E$?Z@("'</^[]H#Y@(?2`^8#Y#S7CCCCCCCCCCC
MCCD$^IMDS7C#>A.TN3=KL>!EK7^HXJEY'(N+Q(!QR(Q5>QS&&I*9Q<LTVR]H
MM+N"AV[Y9RBWCUG9'[D_J&RA34B:--:IT.H;=Y9VVZ`&J&,H;42^:`6K(V+J
M+:;=8LFX[U@W2CLERJ^4K+/FMTK"V2XTA&(QB^2IS"L55T"UGDH.WL:LZ;KO
MX+]%&'>Q\E%1LA$K)N(M\P9O(U=$#E278.FR2[)9(JA2G*FJU414(4Y0.4I@
M`P`8!#G(\<Q,;-[6;&6;;TVD>IMIP=AM]C[`,'L=LCL]L#2Y_*-.QG7\@WF9
MH&&,8T[&L%DC$2$[D+(TU4[7-R<S:;_$U^K4Z%]8TCYV?F(]HAYEE#=S?O&&
MO6O^-K-@G!T!U%-E]J9O4O%A7-GE)O5Z:CZU$7>_RFWJ,77+/*Y+1PTYPY1)
M"[M<52E@89+BYZ185.8?^K(,B[]BTYV;V?;;39IT-W76PY:LRX_PWC?9;%&9
M,$U>UX^IV7<'9"MMMQW+$L&-+C9KJ]I-^QQD.I+PTRC#W.QP<W!6"MRI2PKT
M[AHYRGG$`[!Y_C$_YIA#\<OT@';_`'\JD^B(?U%-NO[QW//^G>%^6N>.....
M.0IWZT%UUZC^NMKUOV0J99RL3932-8LT<5JVNN,[JV;.$(7(&/YIPW<>Y[-#
MBX53,51)>)GHI=_6[(PE*_*/V"U<GIL[^[!=)38RJ]&/JQRJJ],<.$Z_H#NO
M("\"E9%H2TJ$33<>6^?D%%@:L6ZCJ/K<`]DW8R>+IQ5GCBY'4J2])M:>>_JR
MF*.@>=S=P[>#'?<1\NW;*E,`0'ZA`0$!`?,!`0'S#E+LQR=Q^<7XC_S@^O\`
M3R='3RSI:-=\_N\G5?$EHS2E&8WMC&UU6EF7-8HRH/)"MJRMM9HMXV5%PE`N
MFD:#I!=LDU.@],+A\P(7VDEIS77J&:L;,BVC*/D1I`W5<P)*8YOY4*C=2.@$
M"':L63URI&V%5-3N53Y,2LP"0AX5@2/W)R;@"`_#]GP$._P[@/F'Z^:\<<VG
M(4X"!@`0$!`?M`?B`_64?@)1\C!Y"`AY<P)[V^CH=/3<V=4RO3JK-Z>;,-98
M;+"[`ZL.&V.IWY5)J%<MYRS4UB1"FV!][P*61>3T:QJU[=.0,HE=FJBAU#8V
MTLK>D3]&GU3/,]&8=9G2VONC)#DW'Y9]+;2G5-N`^K>6)JDTF;L_7:M_:9.3
M6LT!FN-3(V!L\RK7V9TED\J6G'63Z5/5MJ)L/MK720N]M(:&M&H6UE9JT-=I
M9Z3Q>U0K6F6M6;HN40(8BRAR4>7M+ELB3Q2;&*<`=L2)6QWHOVJ$K<ELZ=._
M,6:>F7L8S.H]B+5@"V65SC@[TYA751?4%:R0]@@V#I0J2`QE&OE9KC9N90IZ
MK()B#8T=`W'](KZ4W=ENAJW5NJ?K)71[.]BM8A5C<V1%?;%\2LM:JU7Z\E(.
M?<\6'M<BI9L.,V*RZ*GO#+"I14D@RL:,>D`],;?12.K=`SS'XERZ^539'P=L
M01AB7(_O8Y@2]T0BDM)N:3=I$5P4(5C2+?/R103$7,<U/W2+FF*<IOQ1`>X=
MP#X"(?7V'L/A'Z![=A\A`1`>;N...........P=^_8._U_3^WG6K)3:C<F8Q
MUNJ]>M,>8!`S*Q0T;-M3`/Q`4)-LZ3`/I\B@(#Y@/(@7OISZF7DRCDN-BTV3
M44,J$G09B2K*B1S>8&1CDUG<"F)#=CD`L0!0,'D`%$2CY-_,4SAC<!5U]W'R
M=7&S<X*,JMD)/Y6P`F#R*FJ8JXL$T0+V(/\`Y+KB(``B`]@YM&X=3G%0G)/X
MZQ%L)$-A#UDE4I(E:L3A(OGZT&IUX`HJG)\T4T*PZ'Q_`#!V$WTM^I5"U)<K
M#/FOV;<,/1$I3.7U>/.0@#^*=4KU9&O/%$?'Y$,VCWGB*)1`P]^23H6Z>KF2
M/4DK>:*8F[6(021MB?'J,B*A_($"M;0C$BLL!OFB1J=P'<0[&$!`1DTT>M'[
M=)VR<MWC5<OC1<M5DW+=4@_`R:Z!E$3E'Z!*<0'Z!YALWV0V9H60)[)D%LFQ
MQ1B:59P$?5*T?(UBBI>2FHZ$;DG&T%486LRRSQTX>`=VL=LL=`B2A7D@NR3/
MX@@+B/+^UN8;*WJ,/MI,56POUD&\*PO^39^N)6!VN(@2/B)%"#E8Q22,<"IH
MQ[UVQ<O5#E2CB/%>Z?+)F'(2ZUO%>/H#(\O[_OL/4H2.M\T,@O*C*6%JR32E
M'PR3ENT7?>T.2G4]J6;(*+=_&=(@CX0]*XXYH(B`"(!W$`$0#ZQ^@/U\Q<9?
MVZWBI.4KM4<?:`6+)='K]A&.K-]:WY.+;VV*(W9+DED61X=P5D15PLX:@F=5
M4"BW$YA$!\/*AMW=O9*[761E8L(>5D;E;9"5B#B18\1*/K')NY&).MX"^N/%
MO5EV!U?"7UIVYE/"'B[!/OIEY:S;AW+F0I[!&`'^PEDE,:I1$Q6(R=3KJT'!
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MF0J^=:)A'KBZ_P`=B?97+4)<(+6"_8KSCJZE?:15KS'QLK5LQ4/%%ICFN)=6
M(9F<U,-%3F/&-UFJ_1J9<FC"4J])U?O6*M!GV-<0Y;W*UPR2GM5;M@-79G*5
M'C-P\Q;<K_R<P%QSSL/CW*63L.-,\Y)U^ND7DC%N;:VO/DC,&6Z_4>QU2JQE
M)HU//4\KW2,MUUN>AN+)*\DDD7T3>=BZ16F<QD`<LR<7C/'.R>6Z#B:!>94%
M])#DQ2M8UK=7K9<@B_D/EBE$)SP2LR5Z$P_R5<<<<<<<<<<<<<<QT=2Z<TFN
M>!U=-=T<K0]`A-[7S36S'5=;OSCD:XWR[3,)$UAQCJ$9QD\]7EZG<)"JS7RB
M?PCFH5>0+$.K<Y;1KD$W%$N[X^TBP[MGL%J[NIUUMDLP569R)A'"NU.`:?HU
ME5A?,\1VGTDM7\2XIO&7(B3MS1_$4U,QXGWU6V<\I:"E2E'22LLTAY.*_2]C
M&[%K',&T8@DUCF[-JBP;((@W1;,DFZ:;1NB@4I0120;%2222`H>K3(4G;YO/
MNXY5OW(Q!I!AGJ]Y/V)ZG5(J$[K#L%J7A*,PI=,Z4.1OFJ\1GS#%@R+7+M3L
MCQ3Z&LF/6>6_Y/;)#3N()B_0Z8N(6P7Z$H\B%A<O&+R..,8&VX'Q?JKOS$XV
MS0CHQJGU<=G[]@>C/*-D*5N&).E]L;K[8<`QN6HO%+R)>Y:BL14G)\]9<H4^
MJ+0@SU;P=9XR7;5E"OL6<:QR;Z8Y7JF]_5;S3O7KRM,6W4[%^B>.]/*OF=U5
M+-6*AES,,YGJSYLR&EC-Y:XZ&?6RMXW@6E2A9BPL8M**-89U=DU=OTD47)_1
MM]^A=J/U$LYM-@<VY'VFJMR:46LX[3C,.9G;4&I&A*Q)S\DP=J0AZ=-JJ3"R
M]D?$>OAD`*LBBS(F@B9$YU<:7H>D.VK_`$^]I()DHY5:0W4*S3%-57BH+NE&
M\;B_"+%`[E<"D]<X.DW(9=7P%]8J)S^$OB\(6SN.......8_^I/TXM?^I[K/
M:-<\[Q7LQG/CFL;Y+B6#!U=<17]L@9.*NE17>D\)A\(C&6:!.NV8VZL.9"OR
M"[<KEL_85'9#<'J-:X84V%Z".Y$O6W6Y\K3*2RZ9>U][E*H3'VR$`PRC50K=
M-GKIEUHZI#FP.*Y!S,7CRQY"59RJMB8*8IN:Q<CLZK(6;!!O-^''Z=5QP_1]
MJ)_'](L.=QG!QLSA:AJ!=TI8*]-0$#*`\=U/'TFWAQ0DK-#HE"34;BJ5PHHG
MXB-G`IVLNAAHQUN==MUY._\`4&A*"PP0I@[(=<9NJS(:N.)$,@25@HCBNI"G
MAZ'CK>#=2/C+`90ZBAH@IDT_;BE7%EWL;[%]/C5G9H'4C>\<LH:Z+B"B61J)
MZFI7=-T4Y3INGDBP;&83ZJ8D("86:,F02*'9$43=C%A&&#NI?I>!%L!92C]P
ML.Q90$F*LL"#/(<7%MB%#V*OS#R1377,W:D%)H$1:4V_K1*#:C.#"1(?8\.]
M6/!-IL`8XS[`VS53+358K*2J^7&#J/KQ'WC*D)$+<JR8IQ[<RGC$CBV15;;F
M+X`2<KB<HCE!BY:+FX]G+0TBQEHN10(ZCY*,=MW\>^;*AXDG#-ZT46:ND%"_
M.35054(8H@(&$.<AQQS02@/Q#]`_`0^T!#S`?M`0'F'GJ`="KIS]147UFRYA
MEMC_`#4X7%^VV'P:>/QGF(LJ4"BC(6"8CXQU`9!51,D@")LB5VT.6::7:*>1
MBQO7AAT2PYZ1'T:?4'P;>HWK(Z65YX<2XJOWO5AM33*DB4AA9UU^[?2]R=JM
M4`1C8AO6+'F.*1!N*S3%<$T6%!+(]H=Z1AT^-SYMIB>\V:8TYV?0E#UJ;U[V
M@23H4PG:T3BW=057OC]-C3I]\9]_R>P@I9U4+Z]=AZD:.@J)2&DUO+T5^FYU
M$6TC([`:YU,N19),QT\VXR(GC/,:+E0@D1?O+G5T&X7'V8AA%FQR#&7&%(80
M.$<8P%,7"X'2]ZZ/2R$TKTM]YV>Z>OU?`31FF6Z1D59EG"-CA[!6*1;)2595
MQ([=NGX04JEXP"Q4.;N$&[,)4>>M84])ZQQCN\QN`^K1JAG7IKYU,9-JK,W"
MI6:XX2GP!0&H3T5.MH9K=8Z%?N^YF[]E7+S46C4!<+7YP@0ZY;)F',[87V&I
M$=DK!.5L>9AQ_*E*+"Y8TN$#=:XLH*9%3MS2U??/VK=X@"A2N6#L[=\U5\2+
MELDJ4Q`]7XXXXXXXXXXXXX$`'R$.X?4//G=-&KYNLT>-D';5PF*2[9TDFX;K
M)F#L8BJ"Q3HJ$$/(2G(8HAY"`AR--]TRU?R2*REGPO2O;%_$*DE`1YJE)G4,
M`AZU1]5E8A993S[B+CUQ3#^.4WF`QE==-*`JC@9'`>?,UX6D`%11-O'V(\U"
M$5,(B0IF:*T`^41[=B'*YD79CE`!/XA`?%AXW/8YBKF:75"S1DAWE.=HU>A&
M$':7#%.,2<UR;;>_FXI,4B%`K@SITNA).EU'3QVZ9%*N\<)M6P)1/*(E$!*<
MZ9@$#%43.9-1,Q!`Y%4U"B!TU$CE*JDJ0Q3I*$*H0Q3%*(7!]<K#8+9@/#5F
MM2BZ]CG<9TN4F73D#@X>/WD"R57?+^L^<*SX1!XJ;R`ZBYC@``8`Y[1QQQS:
M)"CY]@[]P'OV#OW*("'G^KF$NR=#C`=EL=BLCK,&:6[JQV"=L+INV''_`+,W
M<STL\EW"#?UM145]G06>G20]:HHKZHA/6*'/XC#*#3KIO8PTSO=IOM(ON0K9
M(6NH$I[QC</DL+%LR)-L9P'37W%`Q3GVL7#%-$?7+*(>I.?^B]9X3ER*@`!\
M``._Q[``=^=+K6.*'3K'D"WU:HU^OV?*L_%6K)$]$QC=E*W>QP=3@J+$3=F>
M(E*M+2<;3JQ7JRR=NC'5;PL-',"&!!JD4(^[%:(:A;9SD#9]B<`8]RI8ZY"/
M*M'SMBC72<NM3I%X$A(T6:DH=]%O++09%^!GC^B65:7I[UTLX7<PBBCER97=
MG+1+4/9"'QY!9CP#CRV,<21KF#Q<JC%KU:5QW77L6VA']7I4]2WE;G:S4Y")
M8QT?(52'DFE<?M(R+2=Q:Q8QA[-Z%1-9=?,7IXJ2QUAC&U(2P=2[9CK$*=7J
M,/"$QS2+X\KLC=JS42,&R!8>*M\E4ZY)V=!N`&GI.'92,HHZ>IBN?S#*.@&F
MF9HBP0>1]=<9V%A:<K2.<ISPPJL(^>9?FJPSI5AR,26KCR'EV5MM%/8-*M;I
M>/?M'%NKZ0Q%F&69*JHGE'5*I6:+6*]2J77X6IU"I0L76ZO5ZY&,H6OUVOPC
M)&.AX2$AXY%O'Q<3%L&Z#*/CV3=%JT:HI(()$3(4H<_QQQQQQQQQQQQQRIMN
MM?\`5G`7I'&O&7^HP2!@,-2FAL9!:7Y6RX@BOA''.SE:S3-2UNEG4K(F^35.
MN<=7GZ:\=;K`CZBLRDU5)8\C#O5ZY*L8#]9)ITU\#:X[#S^HFRM'V'ZD>XG4
M*QUM;JBYPW=,;9(SAA[.5EO-#;2Z.,;#B$'-DJ5#<UN$E(N-;VJ263LMJFXQ
M@@$I,I,56-Z.K&G#UN`-9BI$L1H6*&>(CZ@4238Q[89<B7LQCM_5ED1=%)Z@
MQD0*``D84_"/.>XY_-1)-4/"H4#E'MW*8`,4>P@8O<H]RF\)@`Q?$`^$P>(O
M8?/F_P`(=NWGV_2/?]/B[^+O]O?OS:1,B90*0H$*```%*``4`#X`4H=@*`?0
M4H``"(B`>8\U-\`_M$_SEY5(]$0_J*;=?WCN>?\`3O"_+7/'''''''',:/5(
MZ6^N_53UW?X7S0P&!N4![?.84S7!L&Z]YPW>5VZ9$YF&4.HV/+UF6.V9M;O2
M'3QO&6J,;H&*O%V*+KMAA?S(>KALAN?7\N:QZ3]0E@%HSMTR)RVT=QF-I8C6
M&:SCBFYSN-<@8QLLDY=F*62E!I%?8#%620=M9^Q04K!$O$:PNT79)"6_7"PW
MENA9ZQ/CC->+9UM9L<Y8I-:R'2)YJ8@I2E8M\2UG(=T8A#J>H<"S>IIO&BAO
M7,GJ;AFX*1=!0A?2N!`!\A#N'U#SQO,>OF%]@($U;S%CBKWV-*FHFT4FXXAI
M:)%0#>):"GVPMYV"<_/,(.8B19J@(]_$/F`XO)7INY]UK?O;7T^=E+%3&9UE
M'SK!V67@V/'LJ8"K*':LWRK%\Q145,<&[=68KIY7YPJ+6Y(P"KS[J_U0,@X-
MEX^C=0+7.X81EEU_86N5*3&NK1BR=5(<I#.VZ;=S)K))%3$BBJ=;G[@X()Q,
MO'QX!ZDN4_%^8\69JKJ5KQ1?JK?X!4">.0K$PTDP9J*`82MI-JD<'T0]`"B)
MV,JU9NT^P@=$O/2OC\...:"`&#L8`$/J$._P^`_I#Z!^CF-W?#I*:#]1^!68
M;18"K%DMQ&X-X7+]7(%)S17/`F1)N$;DB`2;S<@P;%(!DZ[:OE)5%3E(9S`K
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M?4.0CV.NFQ]27R&]32%7"V0U`QKF1JX4(*BK1K2+2JT6MGL8``/)*@/;?")&
M,0`E#>,GBRE@8IO@/P[=P^`AW^'<H]A*/V"`#S7CCCCCCCCCCCCCD(=NM(J7
MM*G%3Q9I>CY&@&1XR/M39@24924.*RCI.%L<29PR.^:M72J[B->-'S-_'*NG
M12J.6CA5F>&6+.D6WCK.QE,NY-8V:LL'*;A>JU*"?Q!I\J0E.5C*34H_<K-(
MQ<P"F_0CF/MCIL)T$I!F*IE"YHVC1JP:MF+)N@T9LVZ+5HU;)$0;-FS=,J+=
MNW13*5-%!!$A$DDB%`B:9"D*`%*`<^CCCCCCCCCCCCCCCCCCCCCCCCCCCCD<
M-H-1-9]T<;J8DVFPO1,V8^]X)3#6"N\3[8:&FD4%FB4[6IEHLRGZK/)LW3ID
M2<K<K%2H,G;IF+L6KE9%2&>J71'Z6>E&16>7-=-0*)4LG12IUX&]6.5ON4+)
M57)T3-CO*;(91L]Q&GR)VZJ[=25K2<9*';N'#<7OJ%E$S96_A\......;3?`
M/[1/\Y>52/1$/ZBFW7]X[GG_`$[PORUSQQQQQQQQR..WFS6/=-=9LV[0Y37,
MG1\)X_G+O+-43^K>3CMBB5O7JG%F%)8GOJY65U#U2$(H04U)69:%4$J8F,'X
MC>S.;,M[7;`Y@V0RS[QE<BYGR!8\@VAP1F]]E:OY]^HZ1AXM,Z9A:PE>8>QU
M^!9$'U3"%BV#-$"I($`+7?H\OI'$7HQ2J;HON_$RS?65E8)8N*L]LVDW)2F$
M/E7+.9I_5[U7TT7CJ?Q:>>?R,M'2E9;GLM'6D)%(\+9*\N@6L_I(TVZ5#(M5
MKUYH-HK]TI=MAV%@JULJLQ'S];L<%*-R.XV9@YN*<.HV5BW[90B[-^Q<KMG"
M1@,FH;S[=FXXYPEAK5=ML.^KUI@H>R0$FB+>2@Y^,93$/(("(&%%[&2*#EDZ
M3$P`(E60.'<`$.P@`\Q8Y/Z3.,B617)FJ&0[QJ5E-+QJM7F/Y.1<4EVJ)0,9
MJ\K8R#1_'L'1R@FLRAYE*$*F<XJ5]V0/4#YH&U74)TV_V/;G!J.PV+8\Y4EL
M[8,*B::9L""BF:0L4$V8LF)A33`YCFF8"B)"L(@:8==P5-/_`%XWBUEV@;-R
MXJR;#N[$LD"BU$L!RUJ]M#>'Q*$&MR:B;B331_%4?P"LQ%B;N"3Y0`[\EH`@
M/P']/UA^D/B`_8/GS'[GOJ8:PZWY.FL1Y+D;XWN$`Q@Y"02@Z%+SL:5O8(Q*
M6CA1DVARH+',S6(*Y"AW04[IF^<`\\;+UI=(S?BS&4A\P#_Z*[!]/_[O,EF,
M<B5K+N/*9DVH'>K5:^UN*M4`I)L58U^I$334CQD9Y'N!%9FX,BH7UK941.D;
MN0WF'(Y[B=/W3G?FCDH&VF`J'F*(:)K$@I:;8+QMWJ*BX^)5>E9$K[F)O-05
M6.!!=%K]@8MGY$RH2+=XW\2(UPY;HL=4KI92+N^=$G=B9R)B%M,N9Q]H)MO(
MQTO29%LX5*LZBJ=9WRD;31?2"YQ3.]31PK9RLFZ)G>1IA\4?7^W:Y^DS8XJ>
M06.M?5LUNRETT=D4W0QJLK>X"P36`;,H10&Y)R)MYF`6*MPDBZ.3V:6<QUNQ
M^U9F3?+9159G]>6S#1<@8_RM4H:]XUN=1R)1K*T]KK]RI%BAK;59]B8YB>T0
M]A@'DA$2C4QR'()VCQ=/Q%,0_8P&*&'[>;T?'IB;WKR%IN>"VN&<PNU57R6;
M]<%F.)+][W.?UX3$['Q<8ZH-UDS.BI*J2=QILS-`5,2M9=F8YE.8MCZG>D:]
M*8PO]0]E*IU8=9($QA0P%LH*T9GJ&@40[^R5JRS]C;S+Y6)C2^RQR==S$]:+
M."$%AB18!38#)/6KTH'4*Q71O@O?[%>9.F9L@T.W8SM+V+JT^&/$Y)=7V=(S
M3(9:_#R\'&+G(HM[WR)1:9`()?BV%ZB079['E&R!1,G5:'O.-[G5,@4JPMBO
M8"X4FQ0]KJTVS./9-U$6&!>2$1(MSC^*JS>+%'X=^_<.=OXXXXXXXXXXXXXX
MXXXX^'QYX78MG->ZE.RE9LV9L<0-AA'9F,O#2MKBV4C&O"IIJF;/6RRQ5&ZQ
M4UDE#)J%`P$4*80["',/6RG4\RE_*3.U[`4E68:AUJ0<1+*SK0D?:'US6:B"
M+J:;K2!W$:T@5W!#^Y$V;8[EVR*G(.G91<E9MY5ZA=16KY%JTU&;"V:D8_N=
M:69>SSKQ\VK4%<XM\54I'+-F^=J`UFXYPW43F&+111F+=PP?-2MRKK-6^0O'
M^6L9952E%\;WNK7A&$6:H2ZM9F&DN2-6?)K+,TGAFBAP0.Y20641*?L*A$CF
M+W`H\Q4;H]2G)6N>Z.#</T:BTVR:XT]QAEUO]D^:+,+36&87<'*C[7[5$]3?
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M7(R(2DY>T.$&AF3`3N`:Q%F^J=7'_L,S5*7E6K3]+8[*165]3\H:^V>.V<=Y
M`Q%A*CYRJ]<@7##(:5.K39]0;<PNC66;MLE0.3*_--V51L$'-5N>;J<CAKJZ
MX?R%7<!IVS%&>ZID#*.G=)W4R;"Q.*[#:*E@+#%IK&2)52Z9!MS3U8A!R$]B
MJQUZ@P\+%S&2,BJ3%0=5:AR"4C-C7NBYRZRU3Q?@O,^18O5;:MKE/$5?PI>S
MX,RCBPU&N$]BO.EXD*52\KLUH>>ML>E3G4C7K-$/V#AZA>ZK;&D96[Q3*RZE
M2'2D\]ZD^"HW)Y:`_JN:FU5C\CTK"5USV?&;P=?\:9YR%[E;U7"=YR($GZUI
M=UYZS5FDS\G!P,_CNCY'GHS&]ZO5;NSGW(G\^ZF[HZ=Y`PLZL\<V=88F,>[9
M90S/),*],62\PU1UQQ`PR:H]I<;&2C,CMP@D>2>3C%9A)N7D0P6)'%:NTA44
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MF[:+N!:LO-HT9V5=%TG<5H/W>J21,T,%3W$FN_2ONM`QQ=+)Z4EN:QM5HJE3
ML5@A)G=^+IDBVL<M%L'\U'2-*M8.K35W*<PL\:K5VPNWDU%B`LY!Z]<)G=KW
MZFA2%:MBIK&<)E;H@1<QP4,L0$B`14QP\C&5*`*"8/QA,)OIY]'''''-IO@'
M]HG^<O*I'HB']13;K^\=SS_IWA?EKGCCCCCCCCG\ED$7"8I.$DETC"43)K)D
M53$2F`Q1$BA3%$2F`#%$0'L8`$.P@`\^+W/$_P#LR/\`_P"BT_\`\>>19WUL
MP1LYBFX8/SUBNFY0Q7?(_P!VVBFV>(17CGZ1#@LT=MW#7V63AYF+=%3?P=AA
M'T;/0,FBWE(6282#=%R2H9;L*=0KT9>WSF5]6/EMO+T<I>;=6')^O-@DC2.7
M=5FS]V9:4M%5D4VBPL8=G[0H]7NL-%!2IY)-=IF*LUF7)$9/6M-Z/[[:N]1#
M"<1GC5C)4=?:B\%%E8(E4I8N[8^LIFY5W5.R)4EEE)&JV5F41,5NX%>,F&?J
MYFM2LY`NF<JYF/QQQS:8I3`("'<!`0'[0'X@/U@/T@/D/T@/,?\`L1TT-5MA
MG#BPOJ6;&N1#J&=-LCXI40I]A+)!ZPZ<A)L6K<]=G77M!RJJOI*)/,'*0$T9
M9MW\81.&I=4K2TP&I=CBM[<*Q@?-K=G%>+S)%1:78@(L7B[IS./ET42I(H"U
ME[X"GA'V>M,DQ$`PR[;[K6++6=;W;C8+Q=51D6D##KU[,.":!:<FUUW#UEA#
M2<;,6::ATYIR+.41?JPBKM%H[8QZC),&K0Z)44X;8_R=)8[1DF\?3\3VDLJL
MR555R9BNHY(<LA9)+(D)#N+0S=JQ*+@%S'?(LA(1ZLFW67`QT$Q"[KI1,K6'
M4G7*;<,(.+7E<.T1^K'5J$85R`9*.81NH9M#P,8FE'Q$<B(^!I'LDR-FJ0%2
M2*!``.2AXYX!L;JMKGMUCQYBG9C#&/,V4!V<RY:[D&ML9U&,?&("02U>?+$+
M+5:<23[D;3M:D(B9:@8?9WR?<>]9N_>CU[3Z*VR9S;T)MY;]KL^=RZE@G-0L
M\61]=M=[D(E*"D8WD'\;8&QQ39IGCHP<E4^XSQ/:0.ADZN'1(\+R^*_2.LL:
MGWB#U_ZY>D^2=)\A/Y)6%B=B\=5F<O&L]W,V`GKIA@5B]M,FG'H)F2]K=8TM
M>8FZ:JPK/V5<2(JV0LU8/V"P=LQC^,RG@#+&/LRXYF1,FQN..+5#VZ`.Y3*0
MSB.<O8ARY(PE6@J$3?1$D5G*,51%%XS05`2!TW9?3K5S<>EJX^VAP/C+.%5,
MBX29L[_5H^8D(([HO@6>52Q^K1LU/E/#Y)2]5F8:3;F['0=IG`#!7"O/HW.7
M]2+/,9=Z)'4`S-I;;'CPTL]P%D^Q2F2->+8Z3`WLL=(G68S+TK%N0B222N1Z
M3F5T`"8J;UF'A53ZW']<WJ;].%ZSJ/6GZ<=N7QS'N$(M3=73]NA:\:R+8IP:
MMINQ5\LE(4AL[EC"$@X;#>,93::0*$:8U15`&*>?_3'J>Z)=0&"2EM4]D<>Y
M,E0:B[DZ`$@K6,K0"::9#N#SN++6C#7MBU0.8R(RI8-Q".%$U!92CI,@J<GJ
M`@;X"`]A[#V'OV'ZA^H?L'SYKQQQQQQQQQQQQQQP(=P$!^`^0\CA:M1-:[M8
MYFW6O#E*G;)8'II&9F)!@X5>R+XZ22)G+DY79"G5%)!(@B!"AX4RAV\N8A]E
M.F-E5ED69F]?X.$L6/K"^/(QM:]_1D!*TL[HR8N88$YQ=DS?P;5P=52(=-7R
MCQO'@5D\:G5:D=/)2ZF=-FITVJR\GLA5ZE>KC85V8L:Z<RLO#TN,9D5'U"4@
MF+0C^<DG"YSRKEL4S!!NU8LV:KD2.'2V0_&6$L58:0F6V+J-`TA&PK,W$RG`
MMU&Y9!>/1709*N`567\9VR3E<B0AV``5-W`>_,3>4NB;@O8Y#>>W[)O6V1<[
M;>7*\OZGEN-^6]:7P=18RAPV/=:*M`5F,O+:OV)_@=M7(V[H3$O'>">R'(V"
M9*T8-7J#5"7,KJ-D>ZY,Z<^8,C9;A[#?M-(?)"N49%G47C!MF:ZY.UQ7PK8;
M%!(&FU?D2T6LKQ[="QKX;"<C1?W(5UZT@2(\YBS3"`I&U6X&R=I<5*[J;+VC
M`5CK<-)4IDK*XY'"F&8C%QT4Y^36D1?JS,C&GL;-Q'-8@8OUX-A*X<%,\/V[
M=+72Q[+X42IU#NT9CO*%'RAAC.V);?8:\O;JG'90P%E*K9:I+6ZUAI*0DA.4
MJ>F*LG7K8SBYF+FB0<L]>PK]O+-&9ABTRTOVCRW=\=Y:VESMBV1N%/E]ERQ]
M&Q%C.7B\>T*C9QP'6<)0=+J$U9)DESM3J'E(.7RA;+9?3K/9V=MCNL5N-J56
MA(IL/4,-=.S/%#P/?*:ZV&A:!F:V]-[771.`R7A^`LS(E`L^MQ-AXFL9DK[F
M8FV%B!:;A\NUA\ZAF3R$G*_-P4VI`VM)1W"2D9#"N]%_/T;7MG6S&QZ=XN=[
M%:MT+$Q:_BFBY\=QT/EK!^;5LP8YOE]OV4,CW7(F86-[/-V&#ODG/.X.T4V(
M952,JHV@64Q*2WJ#3HU3;;:F8RZK&::S=,R+M-&;>WN\WO!%CR+LM4[0^FJU
M?L@8=QM8['9"XT5I<UDNN+25#R58*BVNN+*S/O6,-692W14+=&^1[;3`%7OE
MXQ'GO(#N2DL::[4?9U+(F.:_CFW9,L^1JEFK$R-`FXFO5BBM9JU3+]G&H/E@
MKE?JMGG;,#H(N(C3O3$!3$-J+TOMA%^E/3\=O;Q/U#8'+67:/G/*M<SVI?ZR
MMDK">.8.,P]@S5O/;[#UJJN3JE$0.L%"PU%6:)KDV=U%7RKNX:V0UGAG]PAY
MKZ6/1@SM"8LL>-5FO3RR%4)#:&V[)PV))_`F5Z1CRLO\DXDQ_3)%KCFXU6[R
MN:<-W+%EGQ^1U6LA4:[K/<MP5ON:N1XB"EWT46)^W(71!RG.-\<6!SD/639+
M+"NK&-=:,I9%W0P[DK+[RMRN-+3E&?K68\3I%R@>1LDE$P>7)2C/J+F*6G5K
MW"T/'$K<\DNIAO;S6BPQC>DQ^-<>43'40#0(FA4RK4N+"/AHBNL2QU5@F$"R
M!E`0#5C!0;3V9@E[-#PS)I$Q:/@8QK9!DW02)W3CCCCCCF)O?7(6T\S+YNU^
MJ_3?KFX^N,MIE/9`0D;=D:L1-:RUGM'(32&8ZN3%-G$%A0:2M32)=C7!X!HL
MAVZ<;X`<$\7*T[?"^S(/$!'T.C4-N4'20B[+EW`PG1*"Q1%P`%A`,)DP_I0`
M![]R]OCR]HT`0:M@,@5J8&Z("V*("5`02(`HE$O8HE2'^C`0\A`H"'EVY]''
M(G[J;8U/3/`EDS#/P<M=[*JZ:4S$6)JP!%;KFG,EG1>)T'%5+:&\1W$S8GK1
MP[D7@)*MJS4HJRW*7!*#KDDNE`XW5)O[CIZZ%[(U'`T9D7:/J$IX7IN$,`1E
MT6J=*/E/*E&F\B3SBSW^4CIR3KN,,:4BIVZW6:P^Y):4780[6)9M?>,PW71]
MQTVW&SK?\Z9ETWW(Q#C?$6T>&\>XWS2T?82R'8,F82S%A/*LS;*Q`WR@2USJ
M-'OD`^K=TI5AI-QJURKB#E"1:L)B&D9&+E@389+3F*'8!$`'Q$\NX=_QR_1R
MJ3Z(A_44VZ_O'<\_Z=X7Y:YXXXXXXXXXXXY_%=N@Z140<))KHK$.DJDJ0JB:
MB:A134343.!B'343,9-1,Y3$43,8ARF(8Q1J?;P]$O/VH.;9OJ2]""S-<(Y\
M2!5_F32XH,V^!=BJ\9T>1FH6LU9XZCJW$R$DN91R?',B\AZLL^%*:QA/8PNL
M>Q&;R#=*#K@8'ZD!)/#%T@)+67>G&Y9&,R_JADCVV)M#>7K9C-K++XY4GF43
M(VN"CW"*QYJ"<Q[.\T82*(6J%&-*QLLOG!`0$.X#W`?,!#X"'U\<<<<T,`"`
M]P[^0C^OZ^4N.K$`_P`_K.W8!^&-OK'_`.JRG<QT@!NX=@'XA]`\LGZQY=ZG
MN&]?<,R-<UZQOL5@D^.:F\I:52G2P62HZGK1B:D1&/T?>"2[F59M!(BX,WJ,
MWZU0G<7BYS"H,D83K$8@@)%*O;'X8SQK58S+%162NM)>RT&B?X'%-\R;Q\\X
M3*/<?&G5S%$@>(!'D]<6;;:T9K3;CC#-^.+8Z=>'U,.ULS!C8^YP`2E5K,PI
M'6!$_GV$BL:4Q3=RB`&#MR0_B+]?;Z`[]P[_`*._;O\`JYNYYQE7#V*<Z4>9
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MMK`4X+M)23QXW;GH3A9-YXG;J0K<73;2\4.<1M"2@E5)`H(#TE_I.^)2`G*-
MUI]68```L--A)UW:^&KS50`,+9=55>^S$PNF0B*14YC8Q0$P,9*&9$[^":NG
MWI,_3PV%LR6(\_R-ST%V*9O2PMBQ)MG$JT:*C;"`]EXQME!RU955D5,3)I-R
M9%0QK-.UCE22A!4,0#V%8>;A[#%QTW`RL=-0TNT0?Q4O$OFLE%R;%TF"S9Y'
M2+)5=D_:+I&*JBY:+K(JIF`Y%#%$!'E...........................``
M`#L'D`<<<<<<<<<<<\\RSE3'.#,:7S,>7+9#T7&F,ZI-76]7">5.E&5^KUYD
MK(2TBY]2DNZ<`BW2,"#%BV=2$@Z.@QCVCM\Y;MU<'^$O22.G%FV%R+=&A<XX
M[QAC?,NNF%93*64,8,JW4W\OM"UR@XQ;<6[5E:9FU16.78XHG$YBT66O0QHA
M.4@7[B.&,6E7D18"`0$.X?\`'_'T"'<!#S`1`0'FO'*_V[>%NH_([KW/9JB8
M2U=SWA#$&N\Y2=7(C*.R%WQ#*X<M%^HLZAL?EQ2GP6#,F-+)E*Y1RK''%7L*
MMBB4:SC&(E8&*08JY#N#]3&3K5>,BX?T&]'7W,V;K=(QS@;5C*\!2IVVU6X2
M]Q@(#7C8W3&Y8+Q;L-FF1E*K5V>+O=>3;2QAKQ&D-9JU3&DM#2[F[F:NGY8_
M*OK7EG'.W/6RSMG[72[5;,&#,`].C&&L-ORYCN::V[&\AG/(&Q5IS0YH-<O,
M(9U4K-+TJA1$/)VDE:F9LL(XM4?'2IXR1*9HKW_??ID[=;;YS:96PEU:MJ=*
M:6A1:S4E<.8;BW#RHN9N%DY]Y(7554F2:ND$Q.H3#%B]($.)@1@V8G=N2B1-
MOC2]#TCW,5T^]I(Q[).9EW']0K-+%U+/`$'4FX9XOPBV7D7("HKV</E4CNUP
M]8?LJL</&?\`&&V=QQQQQQQQQQQQP(`("`@`@(=A`?,!`?B`A](#S!EU8NAY
MA/J*JQ6>,9V>4U:WXQE[OF</[68T4?05@4G*T7U]7B,G?)YQ'RMBAV#E%LE#
M6V.=M\A43U2"U<E7T*B^J$S!+1CK?YOUAS?$=-OKIU9G@/9-H+6*Q1MXJ#*/
MP'LC#JN@C(6?F;&S9QU5KC^96`B:-_CR1-'D)`Z\/=8;%UN9KQLI:V25373(
MLB<BB2A"G34(8#D.0Y0,0Y#%$2F(<I@,0Q1$IRB!BB)1`1_IQQQR.MZU'UCR
M=:92[Y"P/BNYV^:]C][62R4V(E9F1]WL6\8Q]L?ND#KK^RQ[1LS0\9A]6W02
M2+V*0`YU'^85I?\`_=?P?_V>0'_AN29J]6KE*KL)4:E"1E=K%;C6D/`0,.S1
M8Q4/%,$BH,H^/9HE*BU:-42E2002*!$R%`I0`.;K!6*W;(U:&M,!"V6(<?\`
MI$58(IA-1JX"`@(+,9-NZ:J`("(=C)#Y"(?#D"\J=*W2#*PN73G#4;1)MP<5
M23^+9!]17;541\7KD(N-44JYE`-\X!<5]8O?S[<CP3IO;0X7#UNIN^V3ZY'-
MEA4CZ%F!F6ZU4A?(2HG6(+Z+03$`*F84J0)O`'?X\V$SIU:\$'%/*FLF.=FJ
MPS5.1>S84G/<UG?)$_\`6"0Z!W#LYSE`3@BGCUMW,8">(H^7.T5;K'Z[H2B5
M:SM1,T:WVKQ@F\C\C4.1=QS53OX3`5U"I*SAT@,!@]>XK#4G8HB/;L(!D$QA
MLK@#,Z*"N+<Q8ZO"K@/$2/@K7$N)H@"`#V<P*KA";:G[#YIN8](X=A[E`?+G
MIUGJU7NT!+52XUZ#M58L#-6.G:W9HB/G(&;CUP`%V,O"RS9W&RC-8"@55J^:
MKH'`.QB#RM;M5Z,EKA-7\VR'39R[D?ID;3QCUQ+1-FP9*SHXED7:Y@6=1[_'
M+.<B'U3C)`4R-%8Z@6"'IZ;19R1_0)Y%3V3D9D.J_P!97I'+MZYUA-03[6:W
M1LF$:7??45M%.7#2)$Y$DIB_5..80%3(LH8R39LWN,!@"1<B1<&[BTO"E6<6
M%])>IQH[U#:L6RZH;`TK)#U!M[1.4)1RK6<JU8I`("PV;&-E3C+G&-$U3&12
MFB13JNOC)G/&3+Y$OK>3T^:<`_%,'?N'P,'<!\A#XAW`0_4(<A3M]TZ-)M\J
MZ>N[7ZXXUR^)&1V,9:9F%",R+74#`?L6K9-KRL3?ZX4#G]89")L3=HL8I2NF
MJZ7B3-7GF.@-OOT^921O71$ZCM_QU6A=+RSS4/:A\E=\.32HF%PNTBI<E?F*
MH@NY*96/9KSN,&=B*FH4[G)C50%'?.3J_I%.SVE%DB\6];SIV95UA<JO20K;
M9_`\2^R+K[9GWB!,KUNS"4GV96H)$%VZ3HF3\AS8`L4H4]D;LW"Q;JIO/J+N
M]3_ESJGL#C3-L&BBDM)MZ=8$5+/7/7^'U*%OH\D2/NM->*`<H@SM%?B5Q`P&
M*0Q1`PRN`0$.X"`@/P$![A^T.:\<<<<<<<<<<VBH0!["<@"'Q`3``A^KORN9
MZ0SUKIWI+8IPE%X2BZ-<]C\TWH'\75[NW>R4%$X=HZB*U^L$FTB)*/?-GM@D
MWL-2JHX5631!V[L$LB1XI6U6:F;+5793&^WVN6&-F\42)7V/\V8_@+[7O6*D
M.[C2R[4/>E<E?`!2)3M4G$9.KV!L`?[)-P[]L(`*7;D@?&7L)@,`@4!$?"(#
MV``[_1R-.)-N\#YOS5LGKUCNX'E\LZEV&C5O.-6<PTM%JU=]D>K_`"OJ"[1Y
M(-4&4_&2D.1P(R<,L[:-7K1TP=G1<I`0WSZJ;C:_[IXMD,SZ\70]TQQ'7V\X
MW4LKB%EZ\U<67'<T,#9`9)3K5BN[BB/_``#'3"28L)1LJDY9JJ)J!R3X&`0[
MAW^'?X#W_9V[]P^`A\0'R$`'G\1<H`J5`52>O.05"(^(/6G3*8I3*%3_`!S)
MD,<I3J%`2)F,!3F*(@`^;8NS%0<Q5B0N%%EU9"!C,A9/Q<[=OH][#G+<\09(
MM&)[S&)MY-%LLL2/NU.GHQD\2(9M+H-4Y&,4<,G2"Q_2U%T4O5^M4(GZTY4D
MO&8"^L5,!A*DGXA#UBI@*82I$\2A@*80*(`/;:9RW(J"!EDRK"F94$A,'K#)
M$$I3JE3_`!S)D,8I3J%`2$,8"G,41`!Z33LH4#(!+@I3;5$V`E`NUAQS<CL5
ME!)7;M5/8_E%7)(ZZ2)49"(]X,O;`*)T">T)^%<W<>W?`,`AW#X?H'O^SMW[
M_9V[_9SR9/-V.E<S_P`@24RNIDS^3`^7PB$XR0.Q&C)W,U`/(A-D0&)%X2T%
M-'GB`=>\B%`7)FX(!X^>J$<H*)"LFJFHD'B_I"'*<GS3"4X^,HB40(8IBG'O
MV()#@<2B0W;11TW2(1159-,BAB$3.H<I"G.J8"I$*8P@4QU3&`J10$3*B(`F
M!A$._GV7\L4G!>*\BYFR1)KPU!Q71[1D2Y2C>.?2KIA5Z="O;!/.VL5'(KR$
MFY;1<>Z72CF""SYV9/U+9%14Q2CWYJ];/4$W+93UB2B:2I1`I@,!5DDUB%.0
M0\9%/5JIF,D<`4*!B^(H=P[_`-$G"*Z8*H*IK)&$0*JD<JB9NQA*/A4()B&`
M#`)3"4P@4P&*(@("`?T`Q1^`_0(_`?@';[/M`0^L!`0\O/GEE2S3CV[7?,./
M8"867L^";#5:ODIJ[C7\>TA)BYX_KF3H!%&2>H(L9-%S3[7"/UG4>NNV9N')
MX]RHF];KHD].5=-T"$46631(H<B9#JG*F4QU!\*9"B<2@)U#>29`[F4'R(!N
M;C+HD.FF=0A5%?%ZHAC`4Z@E+XS@0HB!CB0GSS@4!$A/GG`I?/G]>8_NJCK0
MRW"Z>NU^M[[(U9Q+_*CBF1BXW(=UDDX>FUBPQ$K$6BKO;A+*C_R=4U['!14?
M97B2:[EO#/'JK1LZ=%1;+4G7&O'5)V7L&WF#<V1?3?P1B[?6JZ&89SIL$RW`
MU^LE7I6.-'69X9G9\+8QJV6;':PLMYCTV[]&)GZI'LXEVA[JC359M(FE(/\`
M0TH+FLNZ96%:9.L;-520<8U@9^,EF$ZQEHM@S18-'J$S%J*QTD"R34IE'3-0
MZ"BWK/`(`'A#M_'-IR$4(9-0I3D.4Q#D.4#%,4P"4Q3%,`E,4Q1$#%$!`0$0
M$!`><(XK%<=UY:I.H&%<59Q&*0CBMKQ4>K`+PZJ`M58E:&4;&C%8Q1L8S=2/
M4:F:'0,*1D13$2\XB@8WQ[BFM,Z9B^BTW'%/CU%U8^J4.KP5.K3!1R?UC@[*
M!KC"-BFIUU``ZQT6A#K'`#*&.(`(=R-\`_M$_P`Y>52/1$/ZBFW7]X[GG_3O
M"_+7/''''''''''''''(6[U=/[5OJ,X1E<$;38X97:L+BZ?5>P-#IQ5]QK9U
MVIVJ%SQO;2-W#RL6-H4Q04$$GD).M2&A[5"S\"X=12]7.E;!]07T:"X5O"NX
MX7+=OI"3$^RJ>'=GZ\Q<R65=86+UV"$)3KE&K*N#I14<V$&S3'TM*J0,BQ03
M7PM:V3AB^Q=RX!@C/N&MG,5U#-N`LCU;*N*[Y&)RU6NE0D2R,3(MS?-7;JE,
M5%[%R\8X!1A-P$PTCIZ`DT7$7-QD?(MEVJ?KW''''''''-!`![=P`>WP[AW[
M?H^KG5K71J7>XT\-=ZE6KC$*`8%(NU04788X_B#L/B9R[5XAYA]($`?M[\Q_
MY0Z2ND625%'[/&+C%\\=0RZ<_B>>D*BNW6[^(IV\*H,G54O";S[)P28A\"F(
M/80\13T`W6PF5,VKF_=R7B6?C]WT+.\2-L@4$`,)BM0DE26=DBF;\4PLZFP$
M._<HD\NVQ'9KJFX+$J>;=.JQGJNM`.56V8!GSI3+E-,?GO%()FM972HB0!."
M(U&$*/?S%,/(.X5'K":G3KTU2S'#Y.P)8UB'92T%EB@2(L4A6**2K5RY@B2Z
MX-#E.8JAY:&CT!3,(K)E((]L>6R?0FZ5.^]@1SOI-E6*T\VD829K57LVZ6W*
M*AP9V,1`Z<M9,0P,["1[)V505G;E_2%,8VMT^74<R,\\$RJ*D9?YV_I`G1N`
MK+=7"3#JN:;0+PR2NR^!4G+?86FU8G8$9*\PS&*+*KA'-#B\D5K_`$>2CUWI
M3,7>=03,B['-WH'UI>GCU(63!EKUG:&9Y/<IJ"\P)E`6>/,WQZR"9UW236E2
MD@LE<4&2!/6O);'4M<81J!@(YD4%P.@3*L`@;S`0'_X#\>P_4/G\!\^==ME/
MJ=\KLO4;O6:_<*I/M%8^=K%IA8VPUV;8.``%V4O!S#5[%R;18H>%5N]:+I'+
MY&((<KH[4>C!Z,90N)<V:=6?*'3?V-C'"DE7<C:M3TA"T]E,F4,H1ZOC():*
M2A6Z8B0H,L7VO&B!RD[K)..YBGBC_+KZ2;TH#"EG[#=,ZQ.KL"/@-DS"P.X'
M96$K[;N*+B<AX2MFMLB\;,2*O)566QGE%(RI.SW)B)!%T;)-I'Z1;TR-TI!A
M1?Y7E]:\XJN"1;_".T+-MBFS(V`H@W<0D/:G[Q?'5CD!?E5:,HEE:V]H<B0H
MKUIDL86Y,ZB2Z*Y$U$5"*)JD*HD<A@,15,Y0,15(Q1$JB9RF*8JA!,0P"`E,
M(#WY_7CCCCCCCFA@$2F`!["("`#\>PB'D/;Z>P^?*\>V^B'6/MN9\T9?P]UM
MVNLNOK^:E[;5<8R.L-`M,=BBC,(I!R\8/KE./FRT@SB$6,C)NI-Z9("H&4.H
M8H)B(4,Z#-.^IULWF[..]'63Q'BF8Q#`NL%X;S#L=A2+L,KFG%EB2R-5UUZG
MAB$;L*[1HDE/G):PN9!Z5U-PUHN\>O%R2EH9GLL;.+HL2V^MNV0RWTIM..LU
M#X(Q[BQSDB^Z_P!EJ.&ZGF'%V?&+2P-GURDL?.+:DTL=5=2%?=M\BGJ:KZ02
M2.G=/]F;R$9*OI*^OTYM9M]-<(+++'>7?,V\TK;).INL<RHX?K^)!QW'Q$?.
MM[)'`U@%5237RE>/X=UZUP("Q]S^%+O[6IVPL9MPCN)BW8W?K-NN6%LJN[_N
M/M[E;0LL_$TVQD9P>,-A]1]+0PUN$Y?)M&Z2V+-:<M4O-326OJ+A>$B']LFX
MI5R5=N^;D\<<ZNY#P'7:=C.;Q$-1T;Q_OWU."SE7S7IQL'N%AA=J1]B&"TQO
M%YUPPI=,=6[(%'FJ=#9:0H^2IHEPQC%7>6B)EU7W-GE*A8H+UUQKIN=7,):S
M5G$K#96<;]0G72UZ!YDMUFQO8\<6G6+&I]G+7D_"N8;]CZ7R3F*V8F@L<Z8Y
M,V&P]0GUZR#.Y,AWS37RL7Z3C;P=>"B>#VJBC5#<R6LE<UJF,?6'`6ZNC`05
MG@=2]S-@=@3:HXHMN"8&U9'QUM7695IA#!FK#K%)K=`6C!>.J]E.3M3I"ZM+
M_7E\A7N?>UCNL]B'&%?R7[9U%]:LYY,U=>-^IXEA*KQ.`<RYEA*]GS(74PV/
MNLG8R8^Q;3+-9JIE_*>N\_B>5UBS#),(EL$(QM9<>W"&F9`3R7-2FCV5,V8(
MS%9-N,*Y,RQL7C;H5ZPPF+Y2Z-K/;K1"[DP3'=&Q2TO19:*_V)[MO5)-MAQG
M.WVDG-DAA-22+>/F$X^X*A,^,[-O+H7:H^49O`5HKV9,5;8:`V:9R(TU#W0S
MQLQ,X*I$AKZGE7+-,VAK\JSPI@36Z7I\AD"(O&`\=UK)DE8YDE\CKY5$\@WB
M>/4N$ONN+_%=TR+4*WA6`Q[J_"]3_;RZ[+0=\TFSYLMAJ71N&%*--::7*\X$
MP[/8YL.;L-%=A>XV'G8R9OF(<<9!G*N_O=3&=;1+N!R>U'&NV)>AKFVB8(EL
MO+9VL6*=FQUTBK/CJ>UXRE7:-9;U=GF,<?XYHMXRAE?(&+DXW&3I.OZ[1V3L
MC/,B4ZO.<=,KDWJ$U$N*Y!XO+GAJN.'VU\YTJ-7]C\.8N7Z?.LF.Y\AM;]D,
M2Q<_*PNZ%7EME:14*+/ML0Y,NN<#:O-[2CF1EC*SP%\RK-.&#2%NHY+6?V-'
ML]?QB<*U9YDE0R7;>G`]W!U<'9;#6N^@NQ>HVO<[CBN8>S\SO%KH>K=VRCF/
M/>2*(YR],:N!MJUJ6.JK1;8G0R2"D9D0(W,,FGV/-E*Q&ZI&OF/L=ZAY1;:M
MS"VZ5AP`GM_J=MOMC3Z^^L]]K-;K>.\%Z88HE,?RF)GUT:-I6_:K6+9RP8YF
M\58XDYR"QXTKT?994U=XIAJW<MDM0LJ9@OF&<\Y#S;CKT>G!^&L,)7ZG941M
M[#;L,?;P8PSPRJE3N\>DM)[,M7I8"DN;<,=+7)M"6YI[DFW58R![QL759S!<
M6>.S>MT\M==P,<:N.=.<&U_?2@L:%GO$.2<S92C]ML'3F6J]5*QDF&J]NRMM
M0ST_A-G*[F/(N-R6*6OK:\5:GEMDS<)&MD;>WRV,$[)$;3M^FA@S-N+<<VS*
MFD)M`#,\39.P%A_$>_E92RXXS1LM'XOOV-HQSCW6"JXH/C>*V>DI7&9Z!F]R
MQO.,(*)M62+HLE*=3SK`[#8'U^T:NNOU$S!1=B]D8;8;I.Y]B\O3$VXOL=LK
MM=9G]N-M7/34@#1KD&*H6>\?Y6S)7,HU1N2OS^+LBDDJRVC:@JWB8ONNR&#"
M8'G,HXL>Z[N+EK43;C4NLU>YYJPMLOLG@R!HF$.FAC#'M.L&2\"X!3+<=GZY
M)V^!=X^AV5C>EQ74\QQD?9[Q+I6Z%JD3)1&E<=HV'4_5>+S)0+TN?"\]U-L3
MM,.;/=.'</*FK)&MOV&"RXI@DL38TN=@V`U?S<SP-8:L&HV1(]3,56QYBIY>
ML60%Q')->+'&['F6B;(WZXV62RIC+*6%\Q7O#VCB&C,,YT_V?W5V?P2*.#\8
M$L]>P%MU';#X<PU@C+.*MB$;]+9ZG\U(UF6M<89*SYIL=OQ^^85*.N1^Q3W_
M`+>2^[FW_?S&5UP8NUS728WUC*5C0<NV)WKU:TVU%*E.N%'S$KJ*5G)INUK;
MQC,/7=,@4Y.[-(]HX_Y0<UU)FY1<LUG+5>AWL%B?T=>TZ6ZR0'3RB,AYVZD5
MIONN4-`8AE1V$D+7E^R3=LK3?+M`SS#+^Y,=5^%F8EQ9(A)_A=[!S#>>/`.*
M)**P19.2):E]'^Q]3L*;0=:#`.LS:\Q6AV$-N,>X\P/6;?*6B;C:?FFO4FP1
M&U=3ITO9WL@]DH&#NT;7631^\>NY62@4:M*RCQZY?@]=V=>....;3?`/[1/\
MY>52/1$/ZBFW7]X[GG_3O"_+7/'''''''''''''''.IWJATO)]/LN/LBU2NW
MFBW*&?UVV4^VP["P5JR0,H@=K(PTY"RB#F/E(UZW.9)RS>-U452B`B7Q%*8M
M/_.739WDZ%>5[GNGT8BS>;-0+))FM.S'35LTA/691O%("F9_8<-&`LK89<\1
M&)&0B96(3D,O4UJT9M7B&7J1[T@8W/QTS>K#J9U3<2_+_7^V#'7JMM&*>6L&
M6U5JPRGB>:<`"1V\]#IJ"28K3EX55"`OD![769SU9VIEXR>:RE?C,FG'''''
M''''''-!`!\Q`.X?`?I#]`_$/U<Z/=\8XYR5'C%9#HE/O4:)#I@QM]:AK&V*
M4X"!O5IR[-WZHP]_(R0D.4>PE,40`>8]\E=(/2V].!EJS3K'ANQE,=9"=Q+:
MY&!,@Y$1%-1*&EAG()N5,XE,!(]@P-\T`(H0.>3_`,R3J$8/3*?6W?&2NL.Q
M2$&-%V#@SS;,K=(/Z&.2GG:=S*F`E`J93M(^$(4?Q3(AYAA*WPZ73G8E^]O&
MU/3-7J>9$GR4ZAN#TXK"PHF3O?35P#L]IMU-BF]YJ&0I%5PBW76D;56JW:D0
M1`(NV0BASK!"G`W5!ZQ/38N+;'C^PK]3S6:)>@BC6\]D<8PVZJD*0X`I$A:)
M>6L%@/+-`$"D">D,W1*B386T<%?15311M%:4]=;1;<21@L?2=DM.K6P,TJ+%
MOK_M1!CB>Z3$D4Y4`;T*QR2Q\?9**\7\?NUI4+2[LBZ`$6>5F.,J1(<S(&*/
MP'S\_(?(?(>WP'L/^[@2@;X@`]O@/T@/P[@/Q`?M`0$/KYC:W?Z1?3WZAC!^
M.SFMU'M%T=,_96F7:VU-1,RQ8I(E19*(9*JONZPRC>/`I3-8:T+6&NB8H`XA
MG"?<@X*U^CGUB.F*)ICH]=0A_FO"\4LJ[;:5;K'CYB%*Q2,4R4!3K2Y(6EMU
MGX@4BRT"77Y<I$R"XL+HYC&)W[%OI-"V!+K$8/ZRFD.=.GKD]TH+!+)[2K6/
M(>`;.X;F\#N9B'#5DO;$855403;+4=;,L2D`&4=6)%$IU"62<`[-:^;441GD
MW7+,N.,UT1Z"8%LN-[9$6I@S<*$%08^7+&N57<#+(@4Q74/.M8V5:*%.DZ9I
M*$,4/99*3CH:.?3$L_9QD3&,G4C)2;]RBS81\<R04=/7[UXX.FW:LV;5)5RY
M<K*$2102454.4A1'F.3IM]5G5+JGU+,%MUBDK:*.$\EN<<VZ%O,/&P4\NW62
M7=5+($2QC)R>(M0<@LF4DZJ$B_7CIA88B59S$'$OV2C8<E/''''.IWVBU'*%
M'N.-;_`1UKHN0:M/TJYUB72,O%6*JVF*=0E@@Y)$ATCJL)6*>NF+M,BJ9SH+
MG*50AA`P8J/P`W1R[`'X/K7T>P`'G"6`1[`'8.XC9!$?(/B(B(_3SU?!W1WZ
M9>MF5*CFW!FFF&<:96H;I^]J%XK43,(3D`[E(>1@'Z\>LZFW:":CJ&EI&/4,
M=NI_0.U@+X3B4Y<E@````!Y``=@#Z@#CM_[^_P"SF@E`?CW_`$@(@(?H$!`0
M#[`'MQV`.WE\/A_Q^GS_`$^?QYH)"B/<>_ZC&#]8``@`#_T@[#V\N_8>!*`]
MN_?N'T@80']'<!`1#[!\OLYN[!^CR[>7EY?9]7ZN;1(41[CW_48P?K``$``?
M^D'8>WEW[#P)0'OW[^?_`$A\O+M\WL/S?+X^'MW^GFO8.W;MY?5\>_?X]^_Q
M[_3W^/T\T\(=NWF/?ZQ$?M^(B(^7T?5]';CP%[=NP_I$1$WT_P#.$?%Y=Q[>
M?EW\N/`7L`=A\OM'S_M#W[F`?I`W<!^GOS4```[!W[?:(C_O$1'Z?U>0?``Y
MH!"AW\N_?ZQ$?M``[B/8`'S``[``_#@"@'T?4/<1$PCV^'<1$1'M]'<?+Z.>
M+V_7?#U]R]BW.UQIQ+#D["K:S(8MG)*<LRT93'-OCG,-/3D53PFBTD;8XA'T
MG!,[D\KCJV0T%,SL+"S4=%SLNT>^TB4!#MYA]781*(?H$!`0#[`\N:>`OVAY
M]_(Q@_4'80[!_P!$/+OY]N_'@*/T?J`1`!^CS`![#V#X=P'M]'-W(.]2C;"P
M:-:*;-[852CIY'L^$L8R5LKU/<F?$C9&;5D(R#BW<\,89*1"K03V81L%L,P<
M,WA:W%RGLSYBL)'B%=7#N#_20"2L%L%CS7;H38[N&0H>+MCRW5W%DY!9(&/N
M$>UF'#*7N-48OG<@_!E(>ROUFUJFV3Q8AS)2TJW.5XO;T@X6.@F(M8Z+BXDK
MET]E7S>'8MH]FO,R[I62FI$R+5%$BCN3E'+I^^>*$,Y>NUU73M55PJHH;F..
M...;3?`/[1/\Y>52/1$/ZBFW7]X[GG_3O"_+7/''''''''''''''''-!`#`(
M"'<!_5\/,!`0\P$!["`@("`@`@("'*TW4SZ$<K?LN_A#NE=DC^9?U&*@X?V5
M=[5ETJYBG81XX\*LU$Y"B4&3R&A;/:D2*-)>=<PTG2K\+A>/RQ690)$]OA>T
M]+GKM1NPN25=$.H5CI?2WJ4T=TA6)K%]S:.:Y2,U2R38ITI?$DA*KN&[29GD
M0"4CJ$M-325@C'+:9QC:+U"K+EB;&`"`AW`>X?\``#^L!\A#X@/D/->.....
M........:"4!\^WG\.X>0_M#S_W\\TR'AC$F6F1X[)^,Z)D!H=(402N%4A+`
M9(A@[#[.XDF3ATU.'_-4;+HJ$'S(<H\QPYBZ+FDV5&+MK%5>R8T%R43"RJ<[
M[ZJRC@#`=)5Q2\@-K=7O5HJ!XTT8]O&^`0`4CIB!!+"3*6$^JWT\ZZBYU.N%
MLVUP/6T>R&.8QE5;+E.KQ9"E<.$&&+\C2#!2S1"#A11)K'XNRDE/%1'P15#`
MI?5<C?A[TGVB-[2_QKL'1*M7LAU^3&!LM3?O;/KYDRO2[<4RNXV;Q=G.,:F0
MF$CF`%&9+,T`3F`J("02F-F6QAU?-)\B+-X^9ODUB::<HH*IQ>5JV]@$5"K>
M$"JIV&*/.UDS4PB)DW:LLW053#UA#>$!#F0RF9&Q_D:."7Q_=ZE>(LQ2F"1J
M-BA[(S`#@`E\2\.\>$((]_,J@D,`^0@`^7.,RCB+%6<*5+XVS)CBBY6Q_/)%
M2FJ1D2JP=SJDF0OB%/VVOV)C(1BRB1C"H@L9L#A!4"JH*IJ%*<*W&P'HONO\
M5>7.>^F)L1G+IE;!-P5<LG.(;;9Y_$DFY`YG?L4G4G-CC+A#Q<@Y*1JZBX2[
MN*<V8G.D%!?H@9HK@7ZO?4HZZ.A&NEWZ=.^$UKMDN1VHHDM6<>[;X7DVL9D:
MP8M83,7!Y/CI>HPC*LD9K6Z$DDJ0:6G<749_ZB4LWN.7MDBU=/8G&UT/MH+A
MT@]^-2,FY)EY-IJ=U`\15V$NECDX.8K-=^2]GN<I24[@5*:1\"Y\"YWJTC&2
MME:$50D:.-DE(,0BK2R.K^LP4P&*`AV'N'Q#S`?M`?I*/Q*/T@("'D/-W'''
M''''''''''''''''''''''''((=3N+PU,]/W;J+V&RO<\(80>X-NJ.4<G8[5
M(2\5JEBS3/-!5D%&C\LE-3:!/DVQ@_8G9I]69"#(V6-(`0?SP:EFWI7U6*K]
M6Q_U$?21(V%KBM7J%2H=86I<!`,5WS=L:F46#BH^[H0\*64:G:-:]#-6R*)V
M:R)HYHJV\`&_4B8=_86?<%RC[*V[E=#W<E'U"?<K@0`.ZX?!8>P=U/$/;GU\
M<QC[5=03(&*=@8G4G5;4NZ;F;*#B-'/EWJ</E7&6#L>8NQ'(6Q]1J[,WG*>2
M73ADA9[G9HR6:TVD0M>EYB480LQ-/5(J)9E=+>6+=8G'G\UM',C37S.#K8AQ
MM*OHDGI&0E,#-Q=SFA%7SW#R]A3L*^-T*XVJB*F4CY:/81IG\CYF]\'PE<IQ
M/)`:;[T6#8;(.6->\\:[6_4C:W"M>HU\N>%;5>J1E6$FL79/<V%E0LFXRRMC
MU<:W>ZK(R=5GZ[/%+'0LS4[5&.(28C"^M9/'60DXAV#S#\8G^<O*I'HB']13
M;K^\=SS_`*=X7Y:YXXXXXXXXXXXXXXXXXXYBCZI/1]U4ZJ>-FL'EZ*=47,],
M9JCAS9&AMFS7*.,9(BXOV;8'`G:$N%(-)`#F3HDZ[(Q.=5Q(UJ1JEH%I9&F$
MC6SJK[G]'/+53T0ZYC68N>'9MZ>!UMZF<&WFK-5+;#-#%18Q.7Y,&!Y:9<QK
M0S=.;G9!NGE&F=DG=^BKI6GJ.1T;>]9LU<N=?A;949Z%M-7LD4PG:[9*Y*L)
MR`GH25;)O(R8A)F+<.XV6BI)HJDZ82,>Z<,WC=0BS=91,P&'FP$!^'UB'T_1
M^G_</P'XAY<UXXXXXXXXXXXXXXYH(`(=A`!`?B`AW#]@\@9NUTR-'NH;535G
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MBV5#N<BA0`>W8"]0;<G"Q3([5:#7U.-9G*$CD#!;T;?74&Q1[*/!C$U;%'I$
M*0#*^%S<V@#V$HE2^`5>]P<@5W=G:>P[4Y&QM55K-#VDD=A!W+`TL\S0<94"
MQNG6*2L'YEWT=%3:QBC?;!&11EXN.NUAFD$U)`J(NW'1-A7CC;,:J;9\Y<_#
M11GS4P<IH-;,:J_*I1BO9BP!U6Z)XU.?7C(YQ+(MS%1>.F3=THF+DGK1M7]#
MC>EEN%K#=*!+BHEE#3C+%CUHNZ:RCQR>9KM5_I\370KMSZX5S6&@"QC94%7J
M[PMEK4\JLFBV<,3*YJ....<-/V"&J\+,V.PR+:'@J_%2,W-2S\QD(^,B(ADO
M(R<B\<F+ZM%HQ8MG#IRJ(]B(HG-Y]NPTHV?5\ZY75KREEB7Z+.!L;8ZU`Q+:
M'%4C,WYRAJB$UD&8BTT9`63R4R+).*TUE['&+,)`U$I=5EI&C0LY$+7*Y,7D
MLQ<DR#]'_K0;,9QVER;TQ^I_@N*U]WSQA`2-L@7%78J1E3RE78=HTEI5D2%)
M-V>.;6%"M2#*Y5ZQ4VQ3=%R#42RTI$%@5X4K>:LU@<H@8WS@`H=Q\1#E\@#O
MY`8H=_A]'?F*+(?4>RJSR+LS'X%TRN.QF'],;?'T'8Z\57+=*K64T;>WQ_6L
MLWF%P=@"7AWD]F%U1L=W.KRAD9*WXW=WR>>/ZGC-I;I6.*9[*NW[Y:8X[OM8
MQ5DG:'!>-,I7"JQ%U@<9Y(R75*%D)S7+`+0D&^<TRUR<388M666>I-HV.E&#
M.3?NR.FK-FX79/"(>V%S)B0S9J\+DZ@&:/LDO,-LW(6^!%NZRW'2LA!/\8ME
M@?"FM?V4U%2<0[J"9C3S>2CGS%5B5RU63)'B7Z@.I9ASW`4'.^(LJ91UVH>1
MKW?L047)=1E<@,VF,(B1D+4Q&&0D5W!%H>18%KD^Y31=-JO8'*,3831\@/L@
M\C"[U:OG2U[B;WFC%N+,E[+4.@7K&6)+UD2IQ%_FVN1(B/?P#"/A74@W=2"S
MV2?C6HERBW3:V&Q-UH>",^DP]B#L8[IZCAFN.UQ_G+8.-GB6DY:#CL1DR;43
MW]U88)-5>6K*=:)*&D2VADT;NGRM942)/FCV;Z01C563)TX1YZJ[5:UWG,=M
MU[IN>,26G.-$;O'5QQ-`WZM2M_KB4:LU0EPEJPSD5I1JO!K2$8G8&ID!=U\\
MM$EFT(\96/!SKF?:G6O722I</GG/&),.RN1)$\71X[)-_K-.>VATBNT:.1AV
MTY(LUG3-D\D(UF_DP(6+CWDI&-'KUNYD6*3CKM]W7U`Q;E:N8+R/L]@2BYFM
ML]'5>O8LMF5Z5`WZ4L4S&1LQ"0B-6D9EO+IR<Y'S,.X@FKEJ@I->]HM&*!XX
MD&B*O))[>ZMK9]4U71V#P\ML<DS4>JX12R#6U,FID1A0LJK4]0(_-+%E$ZP8
MMH4A!0":)6#%L1H\(40?<X/(FW>(:[B&2RACN^8GRJ[>8@R-FK&\`PS;B^H1
M>3*1BY!@>YV6'R!:IYM2XFDUAQ+1+.W9"F)!*GTY>4CRV228&=(D/YGGGJ/Z
MK8)O43AJ0RUC6S;!261->*&M@&%R33T\JQZ>PV5:#C6#GW%6<2!I([6"87YG
M?Y"-3;#+/*4Q7FF;8L:X;2!O9*_N'JK:\VV'6VM[$X8G,^50),+!B"+R-5GF
M0HQ:#:D?6!HO649(TB>0K;%5![98U!):1K;-RU<SS6.0<H'4XG%6\.G><8W)
MTSB'9[!.18?"[-23RQ+U/)]1EHG'L(F67,-CMDHC*`PAJN<M?GQ1M+IP2N+A
M!3(H2JGNI][/Z)A#87!FRM07OVO^6\>YDIC29>5U[9,<6N'MD2QGF"39RZAI
M!S$.G`,)--D^82(,7I6[E6,D8Z3035CI!DZ7]CXXXXY!GJ6:B*[XZ*;+ZE-;
M@TH4EF?'+B"@K?(M57D5!V6&F(BWUAY-H-Q!R>`&P5R-;SXM`.\2AEWRS--5
MRDDD>HULYK%U!;!$WZCXXS1TR["YZAF!=*\>;KVQQL?1ZR36;8O3-TE1(#.6
M%F*EP@91RB[HM:HLW'2<%#3UPB;3$'9Q-4K)JW75'5[>$:.F$1%LGTD>9>M(
MYBV=RRB2:"DHZ0:(I.9%1!(YTD3OUR*/#I)G.1,RXE*8P``CRG',)6Y>ZJE/
MVXDM4-2VNJF.-K)[#='N&P>V^S\I7*S0<'X<D;%9V.+8)>&9R=<R#L/DJ2>!
M>IK'V)DK/6Z/3T'2MIMUE8,+$:-DH0W+$>%=.L@=)C,#/8B+V%I"O4_SE:=R
M=G)6TTQ]'Y`VUVWU)RIC:KY1O#6D.W&.\;Q[>TFIU"I-<9>P0N-ZRM0ZJP='
M,L63D9O8[L<+DOK\YPFL>RT;9(/!O2UQ'B+,K^`D6LBTK65L@;37O(U%HMD-
M'JKIM;3&T*'F[&$7*'1?QD19&SAJ@"$JZ-SB.H?K?US,J;`LK5T[]_,`ZUX!
M2Q_5(IUCG)F+H"Y3ZV1&4M8U[+92R4G@K(:WNR5CGE;:MV1[%Z@BD6Y$L8S]
M:HL\Q]^AXMY=KT^-HFU@>HR,XWZA&9T)F0;)@DW?2J.+<()R3Q!(J+<J2+I\
M1==),J")2)J%*"20!ZLMM#CCCCCCCCCCCCCCCCCCCG@^RFL>!]OL/VS`NR&,
MJUEC%-T;$1G*I9FJBB(.4/$:/F8>1:*M9>MV:&6-[7`VBO/XRP0;TI747(M5
M@$QJ>%]K>_WHLDG.Y!Q(^G=X^C5.6$2/<6WJT)1^4M6;)<)/V6`*QG08+-(6
M+FK5(LF)[!`0RE!O+Y\Y:VFG46]2D3:)3@/1U_2)*1;83:;%O4MV1HV-[6\R
MW:-A<59'RW;T:S6I"&R[9'DC?,1PDG8'XM8]G0;4X;S%#K**AC-ZG8I.,C4F
M\14T4$;,?X:_I)_G&-/O^W*F?^/X_#7])/\`.,:??]N5,_\`'\?AK^DG^<8T
M^_[<J7_X_G>HWJT]+R68-))EU#]*C-'J(+MS+[,8A9K"F)C%`5&KZUMG;<_B
M(8!3<()*AY")``0$?M_"L],7\X=I+_BBPO\`OEQ^%9Z8OYP[27_%%A?]\N/P
MK/3%_.':2_XHL+_OEQ^%9Z8OYP[27_%%A?\`?+C\*STQ?SAVDO\`BBPO^^7'
MX5GIB_G#M)?\46%_WRX_"L],7\X=I+_BBPO^^7'X5GIB_G#M)?\`%%A?]\N/
MPK/3%_.':2_XHL+_`+Y<?A6>F+^<.TE_Q187_?+C\*STQ?SAVDO^*+"_[Y<?
MA6>F+^<.TE_Q187_`'RX_"L],7\X=I+_`(HL+_OEQ^%9Z8H_'J&Z2_XH<+_O
MER+VU&PO0<W;H!\9;5;,].3-E0**JD<UN.Q.%E9BN.5BE(K(4ZV1UW86ZE2J
MB902-*U.<AGYD1,B=<Z)SIFK7V'6^@].2R2>4>A7U^-2:M5%YE>Q3&C&TNWV
M$[%A:Q^L#UC^.A;+)VM>JJ/7A/\`DV.<VFLUBW(-/"97-"+XA'1II:5>EQ8"
MGK:I@OJ18V9ZQ9:AI;Y/RV8L-6!EG'6&6?`!!)*#.4F:N%AK$2]4<-R,9""?
MY9J0MQ-)/+G',RJ%0\(W\R)B;,FV&4<D8`N%&R7B2R)4=2HW7%,M#6BA3*;"
M@5J-E@@YRK*NX-V+"::2$=)ILW!SLY9J]9O"IO4'"98<E:N^X?[([^(?^JN/
MK_\`T^7B>GFS@4-,-<'<&UB41D<24M:7<Q:#-(7TVVB4H^35D56A"BYE6[MH
MLQ?J.C'>).&JC9R)543$+,_CCFA@\13%$1#Q`(=P\A#N';N`_0(?1]O*Z>Z7
MHZ6&=N<D;#YK<;G;[TB]9P&VS2-&K>>(>+P9`6&:JWN2-B2T<F/7C\]`]M;-
M%)R`/-+.W\:XE&24DV*X0,VI":'X\T(UMF<WZD=7'9;J6]/G8/#V1K"4D=@V
MZ2[+#<Y''BH<I6BE2J6+L@VIE<)!RR4E8JY((/Z+D"F2-8DXF9:>SD"0D3TS
M^F7CKJU]4+)EMUVR9U!83I]X*I[F(<[89,RC#MMDI^XA4DX:NU2OY!;U16(K
MB]FF961GFM(1AYN4KV)8XY+2YAY>SL6J=_/IS],;'/39A<LPN.L][19S2RW*
MU*7DW6S>3HW);RMK5".FHYFVJ*\=5JP,4RDR3:Z\RDX*^4>.&K`Q%44VQ4AQ
MQ;O:<9GRIE?9VQ1'3]FK#L]:E'#/3KJ):E;#T_526IT/*4N*B,>J[43#?-]!
MRW.SF!;BB^<S!4L:9XJEZQVS@F4#6#/E7U0:QLW,P9M=KQKYOE4<P8!CMDPV
M8V)TYV5L&\L98L2UNI5A>F--1,<6J(M..+!:6&7HBWXWO6*;0^P3!8XIMAI!
MJUD"&6>3E4>,K8PY,YMK_N*7)].P>36";#'53ZP^0=YIO9%7*.&@QG)X%M][
MR'E&!;U:L?+G^6!UDR/G+\RJMKJ<UC:%B8Y&OS<W`6NRI.H=NYB%7=,^H?9K
M5@]O=M?,GQ#&E8)WNPS;JXSL^A6/-5L5Y!V/PW9X*LR6JN)\'+0F1"8`D+4S
M;-7UUS%9)K-29[-!+6:@2TBYN=KK_P!&1.FON2JZS/C-]0-@KS1MJ,2:2TA>
M*P]G_4O&."*B3$^N.)L$91JFR\[DS&]^V#CV5`LE&LN4,?SVNT1D9*75M"J5
M2BJ3=1E;+*Y#U=&\O!`9%%OC^L)6.V=:W&&[97A)FJE=R.&*CE;#[]W>'3_V
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M`K_3KVTC:GU+I1S@W&+*8ZCVJ^S:%$H<#>XE1?3>_P`W)7E:FZR,9B;L[NL2
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M>VZL/,8TJ\5",?;FUJ6_\K9;&<U*5=>-<Y.9ERV].'`N6:/DW:?.F7J7LA4Y
MK,1,)TZ'D=K<PZZY#S7<X/$4-=EB3EDJ>JM288AHT7%R>0Y&LU1R?(&0[U:8
M2,!>QA4(F+K,*KEBXXXXY6,](ZZG&M^#=8]B^GY9\D9.QKLAL3JT\L6.)NJX
MZM-BJJ\+8+/,0I:[/VJN*'5A6U[+1K-1)LQ&+PT7$6()%R@Y:**-SUVL.95]
M#^5QUC`U]U"V:C\D?)"EIW!O)CLW)/T;JE$QB$Z9])U;,;6K/UU9Y-TY5=P#
M)C".05\<?&Q[4Y(UM^D<R%`6;46I1*V%L@*!3>+N5$42"B`@81-W!/P@/B$3
M=P'N(CW'GU<<B+F'0#1786ZNLD9[TTU9S9D%ZPC8IW>,M8#Q=D6VN(N&1.VB
M8Y6PVZL2\J=C&(**(L&@NO4-$U#D03(!S=^8@-(=-:GAFYZZ5/5+7.J8"R*_
M<RU]PM6,+X[K^++C+O&T4S<R]EH<17F=:F9=5M!0:(RKZ.6D2%AHD4W)#1K(
MR'8=<=5-;]0Z*MC363">-\&T=U*K3TA7L;U:.K;27G7""#1:<G%FB7MT[,J,
MVK5D:5F7;]^#)HU9E<%;-T4B>_F^`?VB?YR\JD>B(?U%-NO[QW//^G>%^6N>
M....................?G[>F+[N9`R!;,4]./#L)<9:L4<L3G'89_7J_//F
M$C<Y=@X3Q)07+N/8F(L2M5I](WZ79F.Z9+/[33EA%-_!F*G2OP+!VS%6:,79
M'NVM\QF&F4J]5FQV[%5RH=K<UC(M7BY5LXL%,F$T6#=8C6PQ!7D85R@NBNR<
M.$'J*A56Y1Y^L7AGHP=#_/.)L;9IQUH/@*1HF5J16<@U%V\K-B9/U*_;(AK-
M1B<DP7L8.(Z5;-W96DK'.BD=,)%!TS<IIKH*$+Z9^`'Z.7YOG7O[BGOWCX_`
M#]'+\WSKW]Q3W[Q\U_`$='/\WSKU]PSO[Q<?@".CG^;YUZ^X9W]XN/P!'1S_
M`#?.O7W#._O%Q^`(Z.?YOG7K[AG?WBX_`$='/\WSKU]PSO[Q<?@".CG^;YUZ
M^X9W]XN/P!'1S_-\Z]?<,[^\7'X`CHY_F^=>ON&=_>+C\`1T<_S?.O7W#._O
M%Q^`(Z.?YOG7K[AG?WBX_`$='/\`-\Z]?<,[^\7'X`CHY_F^=>ON&=_>+C\`
M1T<_S?.O7W#._O%Q^`(Z.?YOG7K[AG?WBX_`$='/\WSKU]PSO[Q<?@".CG^;
MYUZ^X9W]XN/P!'1S_-\Z]?<,[^\7/YGZ`_1R``'\'SKY_P"<3`0"#G@[E,H0
M#`'_`)1B`=RB(=^P]OCV\N?D9;".+AC+8?/>,*6YMM%@*%FK,%9BJ'!SEK:,
MJA'5W(=ECRP2#!5^9ZW1AD6H-%1?`9X'J3*OU#N3+*&\A4O^644U%E+GD--)
M("&45/9+21-,#G!,ACJ&?`0@'4,4A1,8`,<0*'<P@'/U"?0^;UDVZ=)^9;Y"
M?S$G$U#:S,E<QJ\F5G;A4U.>0&.KA+HLG+Q=91RQ2R+:;LIZXG9,DBYD4!,9
M5-7M:GXXXXY%_/VDVH&U3B)>[)ZQ8&SM(P!$48.5RMBJF7B8AVR+H'@,HR8G
MHAY*L8]1R`*+QS=Z2/<]S%<-E2**%-[1CK&>.<05&(Q_BB@TO&5$@$CH05+Q
M_5H.FU.%044%51&*KM<8QL1'IJ*F,JJ5JT3]:H85%!.<1-SO''8/J#G&3,)#
MV*.<1$_$QLW%._5`ZC)=@TDX]R"#A)T@#AD^17:K>I<H(.$O6I']6NBDL3PJ
M)D,7DNP!\``/U<U[!]7V_K^OCCCCG&,X6(CWTK)L8J-92,ZX:NYM^T8M&SV8
M=,F#>+9N91V@BFXD7#2,:-8]LL\47508MT&B1R-T4TB\GQQQV#Z@XXXXXXXY
M7YW;W)W1R#U4M:NF1HL7%U"6B,9U/<7;W-F3X9G-O6^N\?E=G6)3%^.F$E`V
M1JWGK?'M'D(ZDDX%_)&>W&&"+FJ2WA9RR%V]:?:K>GIQ'Q/O9A>-PSDC1/%2
MD+5-R<#6B'8-<DOT,@Y(@ZW7LDXTL*4$V>LY.$;2S>NIH_*UQ'(RLE'O):@V
M.+]X2L+GS@IAE88:*G8TQSQ\S&L)9@=5,R*AV4DT1?-#J)'`#)*&;.$C*)F#
MNF<3$'\7OSE>....;3?`/[1/\Y>52/1$/ZBFW7]X[GG_`$[PORUSQQQQQQQQ
MQQQQQQQQQQQQS02@/GY_J,8/]P"`<T\(?6;_`*Y__FYN``#R#_C_`+Q'Z1^(
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M_;RU2G:A$2ZT"+AT].OIU2EJO@KJDYBU0P'HZTNM3M.9<::N-G+_`"#G%E3I
MAM8XFM#(N$;&,9&K2;-`#NW]WBHR)?),[":F6F2B(M).W;'1[.)8,HR.;I,V
M$<U;,6+1$OA1:LV:*;9JV1+_`,U)NW2313#X@0A>XB/<>?;QQQQS:;X!_:)_
MG+RJ1Z(A_44VZ_O'<\_Z=X7Y:YXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXYU\+95QLSFEEL4$:X,X!
MI:G=4)+QYK*UK#^0?1+&Q.((K@95&">RL9)1K684:%CEY"/>LTG)G+99(F!G
M;KK6Y'UYS5M<QQUILYS-JQT]WV'8O=S.XYPJ]$N-.?YCB(&R)$Q#B*7@'KS)
MA*'6K'%R=A]MGZY[\?G>0D"=,[$DB\S[Q<FQFHUA+QJY74=*,FDBP<E(HF5R
MR?-TG;1<J:Q$U2`LW625`BJ9%">+PG*4P"`??QQR+6WVWV)=*<3(Y9RRE<YI
M*;N56QECS'N,JF_OF5<NY5O#I9I3,78OI,:=%S9[O9E6KU1A'BZ8LV[&/D96
M4D&$8P=.T^AZ@;XXYV\D\GT=MC;-^OF<,+JUE3*6O&RE&8T#+M3@;PE*+T.Y
ME9P5BN-/M%(NJ4),E@;13;?8([VR)D8J4-&RS4[(9OF^`?VB?YR\JD>B(?U%
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M%`JJ3UAL"S?KW<<DDE;"-G<HG94Z=-[@4C3UHK$I7H*`ND^$C=,P^)2J/T%:
M]U]I+63/:O3GO&E,!B9+;S)J&1FN=V<@M97&;"5''IK8\@C-Z=-IEJ2L*>LD
MBR'<(*@[3D1]D3*/B4SB_(WTOG\JO2Z^[97^&W'R-]+Y_*KTNONV5_AMQ\C?
M2^?RJ]+K[ME?X;<?(WTOG\JO2Z^[97^&W'R-]+Y_*KTNONV5_AMQ\C?2^?RJ
M]+K[ME?X;<?(WTOG\JO2Z^[97^&W`TWTOD`$?Y5>EUY?_ELK_#;D%,:;N>D]
MY6WMV%Z=U7R7T_4\_P"L^/JKDO(SN6HZK/'B]=N#.AOXE.LV5&JNY.3DRM\B
MP`O&KZO12*)TY$B;I86R/M4Z_D;Z7S^57I=?=LK_``VX^1OI?/Y5>EU]VRO\
M-N/D;Z7S^57I=?=LK_#;CY&^E\_E5Z77W;*_PVX^1OI?/Y5>EU]VRO\`#;CY
M&^E\_E5Z77W;*_PVX^1OI?/Y5>EU]VRO\-N/D;Z7S^57I=?=LK_#;D$LT;O^
MD\X'W-U:T4O&3>GXKFW;R+MTOBMU`T9>1HC-K2VTV[F"W&?<51C(Q"QD(!Z=
MD2-@9LK@3MDSG2.=0J,[`IWI?)@`P95Z7780`0_Y-E?@(=_R;<U^1OI?/Y5>
MEU]VRO\`#;CY&^E\_E5Z77W;*_PVX^1OI?/Y5>EU]VRO\-N/D;Z7S^57I=?=
MLK_#;CY&^E\_E5Z77W;*_P`-N/D;Z7S^57I=?=LK_#;CY&^E\_E5Z77W;*_P
MVY"K>_</TH?IV8?K>;]@,E]/9Y3;3EBCX;BT<=TM:S3@6Z_IS:L&JZ8R52KS
M9&&3+`/0D'I7ZCAN)V_J&3D#J"C-8:9Z7R!C`&5NER;PF,7N$9+@`^$PE[@!
ML:%,`#V[@!BE-V_&*`]P#3Y&^E\_E5Z77W;*_P`-N/D;Z7S^57I=?=LK_#;C
MY&^E\_E5Z77W;*_PVX^1OI?/Y5>EU]VRO\-N/D;Z7S^57I=?=LK_``VX^1OI
M?/Y5>EU]VRO\-N/D;Z7S^57I=?=LK_#;GB>R62_2OM6,!9AV/R=E'IL+8]PA
MCRS9-N2%6K;Z7LBU<J;`\E*IP<8ZHD8T?2@MDSBT:NI*/064`$S.TA,7OQ6J
MN8_2L]Q-=\1[.8CRCTWD,;YIJ#:ZU!O<*P]A+.A$.WK]BDG-Q3.C2S-D^];'
MK'.BTE'Z)4CI#[0*@J))R!^1OI?/Y5>EU]VRO\-N/D;Z7S^57I=?=LK_``VX
M^1OI?/Y5>EU]VRO\-N/D;Z7S^57I=?=LK_#;CY&^E\_E5Z77W;*_PVX^1OI?
M/Y5>EU]VRO\`#;CY&^E\_E5Z77W;*_PVYJ%,]+Y$2@.5NET'B,4O<8R7$`\1
M@+W$"XU,80#OW$"E,;M\"B/8!F9Z.UO[M!U$-0,SY4VTE:3+Y-QSMAD+"K9S
M0:HTJ$&6O5*AXQF$DO8&BJA';@)NRSA_>"@)++-3M4CIE!`O?/QQQQQQQQQQ
MQQQQQQQQQQQQQQQQQQQS'1N_TP]>=[[#C^]Y#LV=L2Y2QO`6VDP.7-:LR6;"
M62'F,\@>S?+S%5BGJ\5RC8<>6\6:/O>"DX]95/Q/`BWT<63E"O9=X(P7BS6C
M#F.,!84J3*CXIQ/5(NF4:K,5WCM*)@XE(2(%6?R+AW)R<BZ7.O(2LQ)NW<K+
MRCMY)R3MR^=+KG]<XXXYX;L9K9@_;/%%@PCL+CV'R7C2RJQSN0@)1>4C7+24
MAGB<C"6"NV.OOXBT5*TP,@DF_@;559J&L4(](#F,DVJHF$WG.IFC6M&DL->(
MS7RAOX"4RC86MLRC>[A>+WE;*62[#'LAC8N1O>4<H6.VWNREA8\RK.!CI"=/
M$0*+E\$/'LCR#\[F6X@`AY_6`_L$!_\`AY\Q[].'IOX1Z9.)<CX=P3;,FV^M
MY-S=<<\3K_*<Q5YF:9VRZQ%9A9*,BW%3J=/8HUYHSJL=[O;.X]Y)D54='=RC
MOUB8)9">......!\P$/KYCTQ7TX<'XDZA6R/4AKENR6^S9M!C:G8NO53F)FK
M.,8Q$'2F%!CHU[4XAE4V-I9R[I#'4$+]66MLTR.HM("U8M`71*AD+XXXXXXX
MYCRSITV<([!;R:E[^6ZV9/C<MZ=P]VAL;5JMR]6;8ZGFU[8S3"45NT;(U"5L
M;]=HC//31IH*T5])-0J`NTW92&*?(402>$"D,!@*`%\A`>W8.WGV^G]G-_''
M''''((=0OI\X=ZDV%:M@O-EGR-5:I4<Q4'-4?(XOE:W$V!:SX["9+$QKUS:*
MM;H\\$]3G7A)1NC&H2"@`@9G),CD,8\ZP42`?""A!$3#Y>,O?N(B/;MW[]^X
M]@#X\_IQQQQQQSP/:+7NE;:Z[9KUER%*V*&I&=,;6S%ULE*<\C&-JC8&WQ:T
M3)/(!W,14Y%M99NW6,=DM(P\DT36`HKLG!.Z8\-I_K!0=*]:<,ZKXRFK5/T3
M"5+94>K3%Z?0[^WR<6R=/7B;J>=P,+78=S(*+/E@54CH.-:B4I"IM2>$1-)7
MCCCCCCFPQB=P*)B@81`0*)@`1$!`0[`/F/<0YCXZ<G3@PCTQ,39&P[@ZV9,M
M=;R=FZXYXG'^5IBK2\VTM=TB*S"R49%+U6ITYBC7FC.JQWN]NZCWDD151T=W
M*._6)@ED)`Q3!W*(&#ZP$!#]H>7->...............................
M....8Y^J5L?E+6W5)S(8$D8.&V"S5F/`&K6"YZS1!)^!JV2]E<P5/$T7=9"$
M7'V.8^0D38)RZ,H>2`T5+R<"QC)0BC!VX3/$O%3C931+J!:P:M9.W`S+N3AK
M>#$>Q<K'2>PL3C/^4'%^Q6N<;1;S,.:58\8TBB)-\59+H-FL1F^.IZ)FD*3*
M51B>'M@GDG#*2SF<<<<<<<Z5DBZQV-L>WG(<P8I(BB4ZT7*4.83@4D=5H&0G
MGIC"FFJH!2MH]43"1)0_8!\*9Q[$-4TZ5.QF*\V):+WG.765ZB;S93-#&DW=
MY@J]Q:>/-0\K96=E2L%CU]H-[NNI4-5,CMHHT@WJ,I2Z)GVP6ET]9O6,9)IR
M*8LV%O\`#X!Y]_(/,?B/VCS7CCCCCD.]WKYMWCW"DQ.Z9XPPODG)R3:?5>*9
MRRC8\;5&FPL=5)N5):TFM8Q_>9*]R#:791[0E,%U3F[Y%RJY7M3)-N9)7%S$
M;S;$T#H$ZT;2Q-D0OVW>:<#:D46EV^^-4)1"5S]M+=,>XB@[U9&*236.D$:]
M.W]2[OHM5%&.D207NM5$S=R*"G;J"7:30?>[2_`F2=SLS[HXCWP@MA*A:'.P
MD#BQC8\8;'X2QBAFB-L^)7N+J13%8'&&1ZA!7V(=8LGRV2-ISN'A7D9:%';Y
M9)UG<^/'''''/+\T366*[C"X3.#:+4<E978QR1Z72+Y?WV+JC.R2C]F@NC.7
MR-IU_?5YJTC57TB1=M49A1VY9H1OJV@/1D&F+7I&[);'Y8PWO-<MT;!7C9-P
MQU`]J<9ST13))[-8[QK4L4PF/5FU%QY*R$5$S<K3*T@I)JQ\I,QK:9EG#M_)
MOFK9=Y[$AAUZ8&U&+-@X_33*>PO61ZB%9V#SK<XNTEP;,L6]'TRO.17E\D+#
M&:PU+*%SU(2H]R6&N'@J38:%5-@9&WR+\9>)AG43+>")B;D@?]__`!^KX?9Q
MQQQQSR[.$[DRKX8RW9<+TMMD?,%?QE?)O%6/7DI&P;.]Y(BZM*O:-3WDU,2,
M3%0[2R6A&+B'4I)2;!BP;NU7+EXV13,L2OA=6>]>C#G0;,62^H9F;/FTNT&Q
M&N6',Z:1WZ(P0ZPKD)IEF1CH[.49K93\=XQK]QQ4CKA&2+_("N3$KC9H`E8H
M3T]Z6(QLYC\_C/67?7;''>_V^^'MVLGX*::KY@VOH&EVME&J>))#7_),!IB^
MGJA8I?9%K<J9+WC(1]@KU1K=')>[[A2#XN@W4;*0!E7Z7LZ&>S5?-K;9;637
M;8IFP3BFF>L&8FS,VBDCKJ)Q:.3J%`70L:11TFDX4)'C-&9D47336.5`#J%`
MYAY[UQQQQS0>_;R^/D'T>7<>PCY^7D'GV^GMVY6[V2J._L!AO=/??8SJ&98T
M)DL)7+/T_JK@JJ&ULF-:XG#>,W#Z.P?_`"[P<I1+M9,WW+84T,A-N()KD6'M
M#%>^0E/K=>8V*.3A0C5M)O/;<H;0Z=XPV)VHW1Z>T?8NE70MMLJXKTFI-GR%
MF!;87+]ZA&+NEV&I06OVPUF3J.)ZY4\B'L$@ZIC$D,LM%DEI^'67]BF;`?3V
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M)Q=#UB`B3P-8LZRMOD(9!@Y37LX$#PAV^LQS>?Q#Q&$W;Z?AW[?JYNXXXXXY
MTS(T8^F:!=XB,;F=R,I4+/',&I#)D.X>OH&0:-$"F5.FD4RSA9-(IE#D(43@
M)SE*`F#!.&B6R=OZ!FMNJT/6&E,W#P3@K46]TZEVV9BFS)GGW5BZ8[RY$T"<
MFF3U]7D$[',41Q25Y9207A8]6;))KO"-FAG*78:3+;&]07?_`$JSC9=-MA=.
M\+:#Q>Q%WNKG9YM1("P9.V"S9BH^$8.D8GAJ1;;DO::)CZM3]WL$EE)9]%UJ
MS*O(MG&QHN$4%%<]0>0`'U<<<<<<VF#N4P!\1*(?[N8CM#]?=@L1T#J@1DU2
MZ[4KMG#J%;M9DP.7)J3>QT2U5+)D'3F^+;A:HFK3"LDZHL[+QBI9V",ZB+(O
M"MI!L+=@X7;J&QQ[#/MS^HCK)AOIQSW3;S3JMF9EDO5^9SWL"YC<75K3?`<'
M@;)U1OUPR#JU>ZYDNT3=\=6!"FKU_$V/:[76<_!Q=K597"6BF<:=_+6C2`(%
M\P[=S&-V^KQ&$W8?,0[AW\^PB'?OV\N;N....>`;5VS--&UKSO;M<:&CD_/U
M>Q->Y/"V/W2K1%E;,IH5Y]\A(:1.^D(EH:+<60T>:327EHLB[!-P@,DQ]:#E
M+`1H5$98PAD:G96S!TF>H#EW=/)B%3JF=M]<_9"T_N-GCAL;MBE=4:2U8[%R
M)\+Z]U:0D)-:"Q/ABHPC5"CQ,<S?P]BL":BSG6=8[N:=XPW]T!QAI)G;/S_:
M+-.VEYTEV`QRXQN?7BH53<U[,6R29;%W*S7!A8<6OL#7^]W5V^2E:A-_RAP;
M")1KJRAWJCI//EJ7A`-9M6=;-<@DD)K^0/`F'\+C,M@7!O,'QACZO4I651*Z
M`'!4I):%4>I$6`JA$ER%.0A@$H2#XXXXYM-W`/FAW'N4/T`)@`P^?E\THB/Z
MN50*VPVGNNQ]VV6WTZ2.[.X.4J;FN^/M5ZLUO^J;W536O%D!:';+$TSB##MU
MV,@(R0S+.5ME%6B^YIR!37V0/E.HW:U)Y686*:LQR69+VUVRP%FUGEZU]-?,
M.7L"YHUXQ"X@WFKM$QI>MQ<,9F:NIM_=,);(Q;S,\1%VBG-!G8U:E6_'DG(4
MNGSZ%H3G7[R.D@L##NG2&UKS!@##&Q%TSA3$,27;;[=38?<@F`FTU$6`FO\`
M7,SR<"G6\7/I:NK.:R^LK>*K*%INBM:<*PB5ML\NT:&.=JLH?+#QQQQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQS:4I2]_"4I>_;OX0`._;R#OV#Z`\@^KF[
MCCCCCCCN'?MW#O\`5]/-H$(`]P*4!\_,"@`^?F/F`=_,?C]?T\W<<<<<<<<`
M``'8```#X`'D`?JYM*4A>_@*4/AW\(`'P[]N_;ZO/M^OF[CCCCCC@``/@`!W
M'N/;Z1^O]/-H$(`^("E`WF/<"@`]Q^(]^W?S[!W^OF[CCCCC@0`0["`"`_$!
M\P']7-GJTP^!"?\`5+_W<U$I1$#"4HB';L(@`B'8>X=A$.X=A\P^H?/F[CCC
MCCCFSU:?_P!@G_5+_P!W-1(00`!*40#R`!*`@`=NW8`$/+R\O+Z/+FX```[`
M'8`\@`/@`?5QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQR"/4Q
MW<@.G7H_L!M].PB-I6Q-4VJU6J2[T\<A;+]:IV*IM!KKIZBFLY:1LE;9^*+-
M/&J"SIE")23QND=9`@<KU5AUZ4"]U2IO41A-E,"Y/MEOA:EFEETS(K6JI-64
MCC&\+1<I&4F+R8U;-+VE<652EF4RYK2]L),QX)OF2V0)B>9^R/\`*%U4.I?D
MW3KI'O\`;N'H$UAK:'*=5Q12,4XDOT=#3=BH&?LQ>P)KU>=C7)7D'/2F,F"-
MQG%VBK9W&SOR4336:BV?'1+#'IK;G=3?J#:/;>8#D<V8WP'U4-0-J7.',AW^
MX8BJT_5HJJ-[&TEFZ\GC>$APKBZTO&PV1<>QLBQA6Z2JM::3H*F=.3OCP@UZ
MSWZ0OL+U!MUNGW#=1O6RO7#3*#HTQ/Y"DM1*`ZK=T+>V%>>LDH.*:5096+/'
MDL*(.#R!G9%3M5/5$%(X&+<2R5>+'B/!E]R,K5I_+-MQKBJS7(U*H<2]<V?)
M-CJ%1>3(U:G0T9'23U:<N4M'^ZH%@RC'J_MLDU119+B4$350;'U4.M1J1B_4
MO?C=>@ZR1^NFU>PU8P_:M*66-LF8SV>P37LB2UC3I[YC-6YX1_.7EG`U5]-3
ME<L,9(J%]IB6;J+B_?CA[4O8\U]1_JM[&YWZFZO3L<ZL47`_2K?R%+L$-FNA
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M#`6O3:YM5']4JSEPM",+#?96,3433E5H21MM2BHME)&"$:NYU2P3J$K$U]Y!
M2L5Z^EZ0OHYG76:?S3F&G=5#73+=VBZ#L=4<5Z^4O%&0-=F4H5J#K)-+E*ZS
MJ9K76J\=P[>+2%A(DA--(@T,YJU>>S;">BIV[;==3IW:9YFLF`LIY)O%CR?C
MV(9V/+\)AW$60,NM<*UQ^DR=-9O*\S3(A]$5-`6,@SD7$<+Q_.L&#MBXD(IJ
M$E&E>>GYQZPW3TUZPMKAL9D;8&*2P7M=+&B,*Y1K5:MMOJU@619&?OEY1:OP
MKV0K",21-PUFDK!'L)"&EF;^$D6#>88NF*7\]*^KUI'OC<LOXXPI>;?"Y%P;
M!HV_(=#S'C2YX:M430G)VY&U_+&WR.C`4J9A>L#NWBRS9]#(R44YG8V+;2L:
MLZC_`(M](;Z6V8,WU#"51S9:4C9(O;S%^,,MV;$61ZE@/)6163A!F>G4[+UA
M@F%:>RCE\Y081KA_[MB91ZZCFT?).#S$-[QY[9KKY]-?5#-]UP'DO*MXEKCB
M=S%-,WRV,\-9*R=1L'.)E9NBR0RC<JC`OXB$=`=TFD]819YQ_%O`4BY)JUF$
ME(XOJNRW65Z?.I\Q@^&RWFIR5;9+%SK+^#'E$H=XR;&9.II4$E892IOZ'!SB
M4I+VY9RQ8TZ#1`9*Q/Y%@V9H@+@#%B%F'K^ZN3G3CW#W)U+GYFUY#UH;O:*Y
MQGD["^4V$W2\WS;*5_D\ALN49@E$S<+29B1B'Y96UDL,;7HY*-E64E9(B4C7
MS1MOU\]("U(#033S;;<J]*88F]AWK7&5G=,L.9=B*!'YM@ZA!VC("-?)*1T_
M)$QE&MYMNO#7D):PUV2;@X183\FZ8O")>@6?TA?IKUK$VO\`E5.\Y5M*NSD3
M?;/B#%]&PE>[CF:<I>-[K:J!9;Q*XY@V;F3JU4"PTRP)1$C8W$<M.M8V0=Q+
M-TE%3/NV&'47])"P_BK1S`FU^@<_6,T/,R[%M<3ND,AX@S$]A:E#4YLQ>9DK
MMPCHES27U&RE#M[12EJ?"6.8`;<PE'TQ48RX13!T[:SSK>]"F5.ISK%BZ@;3
M,H7#V==$7FQ,%J';-:[K7\GVTLA9+BVA\NR.4K)3V"^/TV#.&3C'F*;%*0UA
M2<1#AR]@1-)MSAU"R>D9=*.K9:EL8R6>;&M`UV_$Q79<\Q>(\DRVM=>R*=11
M`*M*9N80"U3*<JR9A4GV9GE2(T!25&P>YF[J20D-MGUC=#M+,Q5[`6<,EV=M
MERZ8D89FH-+HN+L@9,D<@569G9BMU]E25:-!33.PV>P2T#*)Q->9N/:U6316
M7<*-8@IGQ?<=%.H)J_U&L1R69=7+P^M=<KEND:#<X:PUN:IETHUVBFK-^\K5
MKJT^V;/H]Z$?(,GK9RV.^BGR"X^Q2*ZS9XBVA5ES<?-F3NLGK[T\=>[H:CXZ
MPCA&Q[>[P3K:LUF=D+E6999K3,-8&CY.S1DF:IHS=CG(>Z7&6@D&EE>03B,8
MPDW&%2E`<3[C=X]5I7`=$V>C\P0[S!.2[Q5L:T?(:4);O=U@N]TRJ&$:U!-X
MP:Z6P-EI3*(_),CI_#M(YLZ`S]Z\;0Q3205G.K9U@]X=*^L%B["6.,@UJ,TZ
MI.*]6,V;%TJ2QQ1YF3>8\R!LLUPQE&2;7>2A5[1`]H^TUPR#AG,-F\8LT*Y0
M%N"KHZOT=6GK`;NZ_=6[`6KFL60ZY5M>83)VB^&=AXN3QO2;9)3F1-J[[>;0
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M:39)9Q'6:,A9*J.(6`J869Q(.X[)W@E#F;IRR26_3O`?4!Z>G7Y=V_94D?GJ
MF=3[",NAEW,^N&#;_5,'4?+U%-XJ2[N[0&\M%U"?54HPM'DG(22#*57RTXEQ
M*19214+*[IT8DRK6/2(.M9DVRXSR#7<;WREX"0H^09RF6.)I%S7CJ]CQ.01J
MEK?QK>!L2K%1HZ2>)Q$@\.U.W7(L4AD5`+,Z4T"MVJ>?,R]1UWO=U)\\P="2
MV(SR32)WEEY<<'V%":IMZE&.)J5BB.A7;YZSKZLFW98JKS,CIQ'S476012<'
M:BFK6CUAV@G=I-LZGO%UB]5.I_ES+..\D*N=1=1<;Z.Y(5T\U:06F8Y.!O#Q
M:=DX5YD*^IKHQLJI8+!%>.-<0;2<G'=I?LZS'TZ3SC+=\Z3NPO75P/E/6#:+
M)ZN_%_R#L/IA<\,88M^6*IERP9SJ>08=2A2=BJ[95O7Y6O7"Y0T/)IND5))L
M+&;46:*F=U@T[U:D:]8TZ<^!>D%1.ICTH97:G&=`UKRJA;L^QE,M>Q<KK-FG
M+N4,B9CD,)9`UMKL9+8_L$04]QKS5K:+2G,.D;,%C2K/KE:P=9?JNF'2DVLW
M!TPW5@<"12^B6K6P?5*I^SFNVM^T./;DYJ]CUKQ22YRB=7N.'"N49-I1LA6]
MQAMR-??*HQLY'8A*T2=R-?)!2LA*;I@ZX]3NA>D![U9`V*N%'FZ\[Q/AIKG;
M*E>UZNM&QAL!%(XNK4?CJO8%FY0P0=?F,>31*U\MSMY.;]O1KD\P]F:JN@5:
M30](6U>V4M#[I\=0/5?%DQGK(738V3)F"U80JJ#B0N=^Q=.2E!F+4-1A&C=V
M_GIB->8XBV*L7"L7TXG$V!_.,&#X()PW'J4=UH-K-\]C-6\#=-33C/E`JS^^
M,;#N3FW=+7*;IM%Q-AMF9H:7@ZRNVNR<>]R$_;DETH0R\J)Y"7;Q<;$0\JW=
MS$C!P^Q]FRR=('='K-U_9[3?:3.#7>G-\]GK6+(6$\'3N8:;GJKVYA=@A\"3
M5FB&RR$'+UUS=FE=>0TR@\;1XA8%EXQ%LO7%++"VC]._;3!>F'HZ&+<LX0R`
M_M=>ZJY,XY/QRPID[<"X&QK?<H5VS13#)B$9&R;*FM6D,B:QV1&?]A;5V3F)
M*,F1;2D=)IHY.\Z:N9YR]USNJ(UH=$ND)$YTZ'5XP7CC+SVM3D5CIQEJY)4>
MO0,.CD-PR;UH\\V<]C.6B<P:29,6CIV=,B+!4R<5=#-J)EEJ+TY.E>[Z.F4L
M];.8*R_&5?.%3VCP`\J^`=<DZY=;?*2^T+7)EBI%QK8S1265.<AI!M&13]ZN
M^L#=G-/7;RM$M4'\E8)R=J;L-U8\`[(R_5^B6NW.S.8\FXKI.CV%J1DK$N\&
M*\XOIPC"%G[G:L=Y!.SO*4=95(:TM7<R>/K[99VV)%A9FYDY')!B+27(.#^I
MAZ.A5V.$=@6^,<":A;-L;1)9=C(K(<WAN4LM6S!9*M3,LY(QQ76N+H:XUYS9
MHVNQ24>>.1;+MH^,C%'3I$CEQQ2&L^P5AM_I=T/`X.RHZ>Y[J%?9X/;IT&RL
MR9BDOY,\V>O:XQ<.8QLUOCQ1X_:('0K"\HNN^D&;7P*NW[5)>/,]2L@[-:0^
MC/X^6U0V.02UGW?P=A?8RDY6U^N<6$/'XWC<9,+A;[#`R$3(%)AR7:NEO8;;
M96T;#2#5K+-9!NS5CW[5&=/56R'GNN=7&ATZV!MYK;J=):EE88]V`Z=>J-4R
MCM)G/+2]K=N'>"F^>4L59&NN-XLI5W:,=36:\576TB$39)YDV:60EIBL&,#J
MYM0UZ$VPU$+K!MG(9(H/7$A,Y3V-+3BV[3^<U<4MZ!"Q![U)1S:&!>[>*7(I
M'V"VUCWK!.)XLA('?I1P*O$L^^0:GDW;+KQZN[$4#%V<\:XLS1T5<APL9?L@
MXMMU05Q9<,CR^:2PM4R,X]C<QE-R57S3T8]DZ<YFC33106YD"K)N&JRV(JK7
M;+>'.B3E#H.6+IU[:S?4`D[?><7PL)7,#S$OAN^K6_.Q<BPVPC+,I&Y:HXJ]
M;@4D6[&U.C&;>MK\*^3F8VL%>RT+EJPQJCFS$?7:Z7C:\4.W6B%U^Z(E,P=>
M,TM*K.RV/&V6Z8WR!4YQD&0PC#0#2P2`.7`-6RDHWF7D3*I*"B9"2[+2,Z#6
M*<D8UV*ZWKZ]8XN]!B+WU/<JVJ@O;93Y^JQURJCR7NBK.R5!S,QS!M8J\Z3<
MMU&TQ#'>1JY%T3I.3E53,;KVM4<XQIZ4!U&HFZJN&S_8_1G77*^'%Y)(Z*4M
M2\<*8XQW<HZ%<N%#@O[OM$))J+M&1BIB6->+K($,V$PXU\2[`0:_10URUI)C
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ME7?(L!4*Y*.DC@FD^=NKO6I]LR>`;UB!D'39$XD%=&S+QQQQQQQQQQQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQS9ZLO?O\X?^B)SB7]'@$W@[
M?9X>P?0'-W8._?S[_I'M_P!7OV[_`&]N_`@`B`^?</J$0#]8`/8?U@/```"(
M^?G]8B(?J`1[!^H`YJ(=P$/K\O(1`?VAYA^D//FSP%^L_P#_`"*?_-S42%$>
M_P`X!^/S3F*`CY>8@4P`/D`!Y@/D';X<"0H@`>8=OAX1,40#ZNY1`>WV=^WV
M>7-0``#L'?\`6(B(_I$1$1'[1$1X[``B/GW'[1$/+Z@$>P?J`._T\"`#Y"'?
M_O#X"'U"'T"'F`_#FTI"E'N'B'ZO$<Y^WQ#N'C,;L/81#N'8>PB'-1(41[_.
M`?I\)C$[_`//PB'B\@`//OV#RYKX0\OB``/<``1*'ZP`0[A]@]P^SCL'?OY_
M#MV[CV[?V>_A[_;V[_;S:!"@/?S_`$"8PE#MYAV*(B4.W;R[`';Z.W`D*(]_
M,!^(^$QB@(_68"B`&^H>X#W#R'RYN\(>7;N'A#L``(@';X?B@(`/;Z.X#V^C
MCPAY_$>_Q[B(A^H!'L'ZNW-/"'EYF\A[A\\X_M[F\P^P>X?9P)"F'N/?O]AC
M%[_V@*(`8/L,`A\0^D>/`7MV\^W]HWE_9'OW+Y>7S>WEY?#FH%`!`?/R#MYF
M,(=OM`1$!'[1[C]O-O@+W[^?Z/$;P_\`4[^`?K_%^/G\>;NP=^_GW[=OB/;_
M`*O?MW^WMW^W@``._P`?,>_F(C^SN(]@^P.P?9R$6P^E6)\V;%:K[3R4O>Z-
MFS6.;ND93;;CJ7A(56V43*U;>U:\XMR2C+5N?"SX_E$G"<XSCVQXB9@;,S;S
M5?G8MPH]*\[MI)@2K:Q:EZ_8!I<_=+/4\48PK=.KT[D&99SEQ?14<@<[0\W*
MQD5`Q[ATBFX]E2&/AXQH@R0:M&[1%!`A`E-X0^/G\.WXQNW[._;O_P!+X_;P
M)`$/#W-V_MG[_K'Q=Q#](_H[<A3K5IABC`V<-MME(65N]VS3MYDN,L^3;MD2
M5A)F1AZW0X@E8QSB6AA#5RNIU_%F/XD'"=<AGA9B>57>KN;!9IQ9%@9G-CCC
<CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCG_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g130958.jpg
<DESCRIPTION>G130958.JPG
<TEXT>
begin 644 g130958.jpg
M_]C_X``02D9)1@`!`0$!F@&:``#__@!"1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?455%7TQ!4U]&4$]?2U],24Y%+D504__;
M`$,``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_``!$(`,<"?0,!(@`"$0$#$0'_Q``?``$``@$%`0$!````````````"0H(
M`0(%!@<+!`/_Q`!E$```!@(!`@($!@D,#`L$"P`"`P0%!@<!"``)$1(3%!4A
M,0H646%QD1<9(CA!<H&QLA@C,SE9>'FAMK?1UR0E*#(W.FF2E[C!\!HG*35"
M5W5V=[/21TA8M31%1DE28F1H@I3A_\0`%0$!`0````````````````````'_
MQ``E$0$``0(%`P4!`````````````1'P(3%189%!<:&!L<'1X?'_V@`,`P$`
M`A$#$0`_`+_''''`<<<?[_)P,`-@.IWIMK-=S/KG:EC/Q%RO,>8Y8&$P^LK*
ML1P:HY)7OXOL3P_G0:+/R1C1N3I@92<3D>0+)19BH8`I@9-YGV6:6:6`P`NX
M#`!,!G.,@SD(PX$'.0CP$0<Y#G&<X%C`L>[.,9QG'*G'4YT6VCGW48=+6UGU
M-L@=PVXMU''4?4$KW8MUC,3U_8J;EI)MSQNYJL4.+8D,:'Z'97H6IO:TTB(F
M):\)(RFY:6;G&6?621[>Z[JJQW)IK>^Z*^B1=^:B4R[:N,T3KE54\E1V)<4;
M@DT>7)[<F<^7IU;VTO:I0860L&22H3IRB"RBC!C)7=\"PQQS0.>^/_Y"Q]0L
MXQ^;FO`<<<<!QQQP''''`<<<<!QQ[N0P=1[KB:6:`PJ_F-=:T%F&U-.Q$AY9
M];%JZ3LC]*9`ZID"UA8C7Q-&'%K0`7M[@4Y#4`4GY+2@$'.`G""'`3/\<I$]
M/3X83%=C]CFJL-O::J?4VGE\3D[HJN$%D326`;Y(TITY[&R&LP82$8R7P8U*
M;!P1^),84`P6<@R+M;]UPV>H7;JLTEQZX66Q6Q6:YW=6%++XZ6Z%-ISPQF%%
M.R`('=O;%F#D1AY0#<B2A+SD>,EC'COG`>\\=\>_O[/EY']L!,IY;&QL?TN@
MU@2>DTCC23G?\WMB!*6[[()[$T3IM@[?!(D8X(UB6+#<7-Q`[.\L.3K%`D"+
M#*W)2AK5*LOSZ_++G.@>ID\<)UL)BPG%RE,5KFDK'MG"!%-&9XLUV1QT@Z;O
M*4LIGF9L(/7.$L0*@M;2:M9F@QN=S,Y#A7@)0>^/EQ]?->^,^[/?D&#;:LWV
M?T(M^2QO<&8(+=T]7WBQ/UN:_/<>:TEMNM>QET<8/*Y*T#;W9O+C\P83V24E
M,214(L)XQA$X&C`:27E-KA8\`U@H:G'O9?<&12>3;$,,-E3`Z[$36/D+U$B=
MHC'E3Q&X,6F;VLHML+7.I"GU:'"H:<U:5CSO"/&,A)3WQW[=\=_D_#QR)25.
M]\U-N;3YY6P4BMEQM9MM5_MO7X@I`UTU6-)Q6,K5T6L.,(`D+I%''I%(DK%&
M`.CP]*\V`ZO;V:4G(PW%)R<55NY.PU+UG5FT:J=+K('MS0EWV^LJ29"3!KJG
M9)6<+02N%MM6C;$:=Y2,&"'3#/(T+JJ7GR;T0+P8J2.!HL`"PKWQ\ON]_'(D
M(D[[#Q.P[8UD_5`S>:K9+KDP[(-UL2.)M,@L6!KWV8J8[.HG7$8:"FYN7I5#
M:F,45VT.85?Q5>STR80G9(`)!G<-'=A9:9JY<DLMF1364.]$R.S3/BQ9C>0V
M[(QJNHNVJ'Z&L][LA04J8BSWQA2C>,&)P@2.#6XMAOGY.PHP4$G_`'Q\O'?'
MR^_W<BQ9T-W6?HY7<\LW:]VI%#)X-(KKM^W(.E;4,W8X]("%$PA;%"GQR(.9
MHHSQ9K5MJ9]":SNS@[A;LL2,TL+BI4&8JLE[;4VC`C<N=M2FK9'K#I/$=J\K
M6%L:1N-ZR!U.M',0%<K4Z(A@1L4J@M=LD@D4*:,(#29!,G49BP@QD0)0A/QW
MQ[N_M^3COCW=_;\G()9)M->[\V33;1MGCK&&^C+CU]I1+0;4:E/JB>,5Q-E,
M+IO(IN)2A$_J)20?;9X(HX(5Z4B-$1EO+`F6C<W,T7>*JOZ[U<RURV&>+&>G
MF.[8["V!K\\42L]!Q6=<1B'K+-2Q630)04B+>P3$K-=!-D+BX*STTJ]?JRC4
MJ$#8W=@FBXY&GM!O=/Z-MB<UW!J!)LMGJ&@6_92TY:MLE!$/0H$*2/+$X1R)
MLAK$Z*'^>&DLJA>QHEBIJ8UV?[$7/#<8(L8^EL?4>G*Q3)JY?==\L6P+@_U0
MST_7@+%2.<9EP;SB4DG<%#-)PG8"P0=PCT3BCZYV(F2M$B2-8T04L=72`Q4F
MR8$L''(A)9N=<#W58+I,B*BEWC6K=*/4;L!6.)&VSQ#/82Z.T=A$@.C3DF;F
MP*LU4KG;!(X>8<%O5IBT)YB\L!V<I.2]X_VY_/P''''`<<<<!QQQP''''`<<
M<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP''(P[=ZSO2YI:)V!*I;O#KDO'
M6R-[42"(P^THE,;!4KV`\U&NCK%"&)T5/[W)A.!(VXEE0I!JLK,"`;@HLHXT
MOQ+5GX0;TH]J*X.L%LVOK>EE"%V/9W:![%R>.5#/&]04#)Q"LMHD#OZ*\-"Y
M/CSDKLQ+W)'@6!I58TJPL:?@34\=\8]^>W.H0&?P>TX;&[$K:71R>0.8-29\
MBLQB+PAD$:D3.KQG*5S9GEM.4(7%"?@(O*4I3C"AY"+&!=PYQC!NYYC>U[[`
MS/5*B+8/UM)J6N*SMBQKG;(G&)]-GL^SWN=-4/@,*C<R2K8DUM0"8"^.DSDS
MRE7N@\&M#0P-Z;SESJ2$B?&<XQ[\XQ]/(M[XN[8S3;5?T"R+(K>S+JF5O0+7
MJA[A?&]M@J)_=;66HFMEGMO1#![9&FQV@)/QID<I;X4M/9WJ/1,+TF;6[TIP
M:DGBCA=VQ^R&BU@7!6^SY5'71J2/8^*7"Z59"ZMLV#VO8="1YT,2K"2):6_^
MI(=,B4#+.6E*VJ6YU,99206=DA/E(((39]\9]V>_',`M1Y%+:OHF"S7:W<)'
M:#]=$;A$]8':T&BI:<)C^7^$L3J\1.,(XV6Q)WE`G<'`Q8$:X;BYI`'%)Q*1
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M:^.[K'_6":OH!5"\FOK%LY2RX3C7R^>JIHFF:YBBDE5MT;6',4>R)4B97%6`
M\J2GOCY<<<@`8MC]L@/V=*$NR!LVEDSW)FNMD5WI%6T`;Y8Q,L(UZ-OFP&=%
M5:-M#7;[/:[DK:?4"Z1K$F&$8W%0[#9E+LT&(0]CA>SVU6Q%G,6D4:N5'3=C
MP)RV@13O:)EKZ+2Z16,7JG9=95NU')*QD9/Q+B)MF#L,E_G1:<]Q`@RT*VF*
M":R78E<V$K%*]O,TCRG<XY`3&MT-I]I*\D-D5U83%KZ=K'KDDV%G<>00EGL5
MMO\`E*9^NYB50I\42'T%?!:Z7$4HH5X!%3OC<G62X(@R`PB.EIW;/&P=]6NK
M-,J`VSD543:7+;Y0:U)&:J:S,;7R4XF6R9,93Q^/M1[TH8TCFG:7F2$IEB\\
M2(8FY.>XY3@\L9.!6/%?1(+QR)^$=3]P>Y^@AD]U2M:KFF/70SZV7A.GJ85R
M_1BH[\F3>UO-?09"*.O"M?9[/(66115<]SF&)3(]"S9`0B>QY.1+LD]HJ_J.
M)K?LRH(DT4!;L>J#9U;-$.MFS*E7"U4%L1MAL*>9<NDRR-A=1R^#IGI*TGJ*
M^1RMD+53-N+,=RTR-&2:3D5B^]/=)QQS#+12ZI[<M*.2>X#6X^[:;M*S*&N1
M0S(BT+,MG%9R0Y$4[-H4^<H#0OT07Q1^<!M><-9#RYN:%"640D"6#,WA7F%P
M715=`P-XLZY9RP5Y`V$`1NLDD2H2=$G\>>P"P%DEGJU9X@X&9A.B3*#_`"2C
MCLEX))-&#D:ZM*O+<8<RBM)@Q31@"J$B&YL*T"Q.4K"00K]'.QC`32#1I%25
M84`XL&3D:I,J)\:<\HP43W5^=(.U!U<+F4]CU/*)9,[AK.,7'8'EO=605\LJ
MFWV*9*G4#,$1\8_C`WKE:../85K=F%O2<IW,7$D*#0C]1Z9<&JQICLNEL6V1
MK78RQ11.I*LGCM3(D[36\?9:ECBQ@@2=)%4SDZ#(DKJTFJ5\CD3LK4NKP?DE
M"684TM+<G+"4[CCC@:9"'.<9SC&<X]V<XQWQ]&??CD(77^^\@KO]_1HA_K+P
M3DWW(0>O]]Y!7?[^C1#_`%EX)P)O`^[/XP_TQ<W<VA]V?QA_IBYNX#CCC@.:
M=\?+CZ\<UY3PO%RZN)77DA&E4,ZE[A%Z9MZ(O.W+!'0U)%E39#ZHBDP,1JJ0
M,2#3"5.I[B@9U;=\9#',KPDKLK#"O2"_+$%P_CFF._;'?/?OC'X.WX,?[?;_
M`!<UX#CCC@.8P;5:@4=N)2=KT3<,63J(O<44/B$K>V-(TMTS*;S1)S"5#3)#
MFU8K1KDAB4@24\6#L%A!DO`/`+..9/\`/*['O&GZB895);*LJ%0UGA#`XR>4
MGOLC:4)[.QM:`UR6+E*`U6%=D(490S22BTPSE.<@`G+-&8`(@A4T0^#>=/CI
M\[`->QM0&6]*YLTQ:211*V6I*(Y+XIE)*$Z=,O7&LWQ20^-Q))3XPB/">$*<
M1A@\%BSG':>QH9&>/H@-K$U-K,WEC&8!"U($C<C`89GN8,*5$200$9F<8R,>
M"\"'GVBSG/(<]#^O?TY.H?9TYJ*B[.?66;PIM5OY#?:\=!7A$RC"%:0WK)##
M5KHY&IG-*F4*DPU#>J&A>2$B@E68WX)$9DJ8MG>V:0H0.;"[-CVW&#&66X-"
M](YHC#"L^$P`%:(X\@0RQ?<C"$S(@9]@L8SP/!KXUS:;F-8).QS26T[;D/+5
MHXC<E;X8RYJTLCH(&7N*K2Y"U/+'(XD\Y+*4+(Z_MJY`4Y)D;NA`E<TA2GGE
MD,T9AC;*X=/+4L:RMA)?%%$L=QJ[?61]Y8764R=K0QQ/)\PQO8T$49G&,1-(
M?&8V4Q-B!$D;W9V4*4ZIS697!Z5?N\R_7_;JN*7DT&1*:/D-/+I_9-MD.:D#
MM4[DML%K@<3>7]E$7A"=6RQT<"FF1/X%`5\?=7-G/,3'-IBHPGDX=NJ6Z6L\
M5U-"8_$,E;36_046R0BD+R;)V:K:A06DK>USB6,ANB;@2B/5J5IK@!2U*$24
M"5%X5QWBX'ITDTUJ5ZD-JOK,%U@B>YZ+=*)GT=@N&B/1MW:E9JG#5,1M*9K]
M'Q.8RW.+JR,CSD(BBVAS4)%:55@"<1/L4?INOV6#5W`E\>:I:U5C&V"-1=7,
M&EH?W)*GCS4A:$J["A:@,`0Y*4[<F,6*4127S3@X$$(`A`$.+4<ZCFNSW)G9
MC=A3N!LQ,*E5AQ2=V%$3XI$+*AL)*`?)9!`#%RKU\ZMJ,DP)J)4N8FTA["(`
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MMNQ5M1I5SPX0@]R.$O,,:$JPE2L1O*!J4B2"PJ3%GD"`,7C5W=0.65U#-[I[
M&(&P.T7U:<8?55;NJD,M?16'?\D3-Y3M&W]GB:%4]-D8B+Y)HBVNY[2C5.!A
M"Y:M3G9"0$L(>BH>GG$QL4T*D]Y[`2FPI&7#&J-W,;,F^/6;7<0K60!E,`A<
M6=HLRM"%3'FM]!A?(")"W.YLZ$,XF7C=$YN2L>LU9J)!Z[@-MQ9]D4KLZ6[`
M$+@WC:<T4-Y,TL90LC9L03C7`C:)E9&9&RQL86AB;(^W-R-L2`[$@R:(9@L,
M8+O1=<I@$#;&IVH&=W3>EPGTY6PV:&7!`(56#XQ0%XG\M,O")3QP+L9.J3-3
M`N'&6IJ(;!R,*ML-`K(2FG*0<A&=Y[_M9]2T56,"JAIV(B#G=*6U'R=.$J.I
MDU-0LECL5?3()AD/)EQYLZ=)(@,9`O(PYB2$*PYU"]'$$E'AV-)I'<-IZQZ\
MTM:5Z3>GW>A'90D7IZE*KV0Q2V&.'*3VNK!3AIG$3D:-T9V=F2,CX"/G$IPC
MD2(I2\A7"3%@YZ5.M`V.PRV!>^7A<**8KJY0T[>$VCIT-87C8JJD:EV5AAUC
MHT,8"S-I0!OCNG2O,)01U[0M[LZ-Z5:!.L$$';67>&LD^E[?NO8B!_AE>DQI
M.]REL1M:J4O;,K^-`(4K1-S<S%G+7TK,D%@IN,1D>DK$!I"H:8H>3"@>;LG4
M^H%SE2:).L0O6&+$TRB\"F;C,ZH>&1CK236'Y`ZM;YZZY4*$[699J94C5Q,M
M'EQ.PG5IQ/A32(T(,AVF3=/FII!/$[REDDUC=4KWJ#2^>Z]L2AE(JVQYY6"9
MB1U[,9+Z0TJ)6F7L":*Q0M6@9)`VM$BS&64U]1+#DYPU')0K1&N(5:[3/$TN
MG;G`X7*Y'8M44.YJV8=6539<R$Z#E<XB9)#03)35S@8^OQS<UO+ZXL<<.?G<
MUC0)!*@^5I(.H'1,>M%GK0]%9+BB?K1:J/:;28X$Z/-0K+C<CCR3ZY#.$1@T
MI;\RC($6]GFI@,Z%7GU=ZQ,<2SDI?I^O-V/]I+[IALZ86F+V'2=MO\`?&IH5
MJE*-TC!Z=)(*YG"8I7XU"!+-(DY)5X&\]2H.3*DJT.1A*$2'`=<M+3BN+9F-
MQS9_?)DB=+LUZ*UODQ#2Y(4Z)OAA+P]/871C*/;E!B61Y4O:DL2Q0:I29(*(
M#Z'@01#%C+LCI"I1$22V:18YK/+A7&T22R(T5D1:`2*"GTA&W^)QN>U6]RB/
MN,1)FX&J0+$<@:YV0X1.3,2YV;STA)AB8&94>.!#1!-&;X)H6-U5-'XMX6W?
MN`AV2VC62B0MKX\,T-;W9KF)L`0O[.A;@R*1.;W$HHA]=Q]&U-+5G"TA`G*9
M22LFS+XQV^O.?KSWXXX#CCC@....`XXXX#CCC@....`XY^-Q<6]G;USL[+D;
M6U-:-4XN;DX*24:!O;T)!BI:N7+%`RTZ5&D3%&J%*D\PLD@@L9IHP@`(6/+#
M=@Z&3IZW5'W54Q":XQDE5(H.L2(E$V@:H*P<077IACN$,R&<4(!A08]EPR,`
MP"#WP+'</7^.>>)K=JE98:VHTEF5^JM9M:P/;A6:>91T^?H&8P/B+=ED.*<1
M2%*VC#G`P+3F\"<0!8'@SPYP+/H?`<<<<!QQQP''''`<<<<!QQQP,$;NZ8^@
MNP%=6+6=@:F4(%HM!F>&B3OL5JF!P^=`&]C$H5/C+.(_'D4D9I*6N%ZR3/J)
M>!<!?C)YAAOC-"/P'2[H?]-O2"KU]90#7*"6:%Z?E$C?YO?\3AUOSMW7&%83
M)4XGF41P\AK:FU&'"9"TLB%M0A\1RI04H6J#U`Y-;$LF`5'#7ZQ+0F4;KZ"1
M=*%=(I?,7=''XXRI##RDI9[D[N1J=&E+-4GDIRLFFXR:>:647@0QA#GI=,;'
MT)L6VOKO0]Q5Q<#7&7!,U2%?7$M9Y<E9')8FRL2(70YF4J@HE*E*$2@@H_(!
M&E!$,&,X#GL'IL8BT9A,?:8G#(ZQ1*+,"(IM8HU&&AO8&!E;B._D(&EF:DZ1
MN;D1/?."DJ-,207WSX"\=\\Q:N/7";N=HE;!:ZV,RU-=JR)-U<S4Z8Q)9/ZS
MLR`M#@YNL?032'MLBB+OF1PER>7E;")2QR=J6-P'EX:W8EY:%^49.8>,]_;^
M?&<?Q9]O,*5.\%=M>[OZA]^CLH9Y@Y5=&+#B<^-3EJ8)(W5_-G1ZBO!KB.YK
M'+D3#!7&1H"G,):*0(/24[8H&XH!I#0\];]"U,_G<(GFVEHI]GB(PAL)\55=
M-*^8C*=26E/L1YE(E$.A3N>_$,<;@\$8!Q:&QEX-D;BA<7N13)1)#I"^.!QW
M-YT&@\<=]E$=1O#73M6;,:\GU!**?@\&8&B%LE@>K)1&DUTL3<V9;F]'(38E
M)<,3\U)6Y,5)O4[.N=UYZA`EP3V>C=SH[>4A1LC8P-L5,/N39VG`M\GF[4EE
M3LXZU2)-'G=]B,8)1&GRAJ=AG^L'$)"M(=%$!J(Y?Z7Z6'`/0:WW&U=MZ;3J
MNJTO2N9E,ZU+<CILQLLA3G'L:=F5#1O"PQ2:$E`M0M"H`B75>V*UR)M,[86G
MD8&#(@_6'5JE)!6%1UG;=:US=:.GHA&XO&E]F5_%Y7E*<Q1UICREX;$;^WNA
M+*L=R6A,<LP@$#OX2BA#-`07G&-5>ZH[)1':R5;!R*Z:2F[-*'H3.B;G*B)&
MCGM>T:A),"PTM6<I(MDR-19K(7@3O4CD!<,.<ID\>)4^@.(1M"5O]MA6Y]`V
MR1!WJFK6JRQXI*+"E5=.3XWSQ&@/;7N(PB335T0L[.J0"625Y);XX:O,:"?0
M/%%\+I8C6+6UO\*G^M0[RZAW[.C*TI?8BK+,FX&+,F+8(?)TKP>M8@@3&&N+
M6J3A]7NY*8"L@2P+4L6'(L#%E641Y1WEAC9'NG&0A>(I7TAL@M\U.JFQ;"N2
MHZA3QU6V3UHL6T")V5(4LQM0+^?F405A/L^?N$/9D,:8GY.J?49,BD;^B8D"
M?/'0WIQ2AI8XO$'[9"5I&77ZFYQ16F\MKB,,\,M6D8K/F-IC;C+Y))G`V21V
MP[,8HU'8]%HT\&1-CC1;2W*5[O%W.0NRUUYD#-=U(+";<V"K)Q9%Q;5K)KBB
MV#MB?+W!$U1EI+?37Y1&82F4*@Y).>W!ABKZ_.ARE4C`QHQ,.34ZDM^3GE8O
M4]U*;&D]$/>Q-QZYP^N8(O1UBS58U5WLI#+UF,RMVWGYHC<+IN4MT3C;<S5S
M*3W:3Q5$[K79_7MS$:ZJ#7$925O,4&KY_O"83TKZ5RFN?2D^=V4%%ZQSR(6Z
M_;"7K:[?;ER*JQ;*-CSM%X256\8;*K9)&*6$^LV`+S(5#W.Y)(\X>9-(#W4I
MG2GX$WQ"/1MJ.5I%&.->Z_;3I*AWDUMATF*UV<)-L19DPH'803,EGQCA65]O
M8+)D[HD:T,G8E"2<L$@>YS$"#CP,PXXF'''A$6Z+B<K1_O,ZD$@8T2FI)O0)
MT;WF-E<2@4?UB26,A?8E))-8D8ETZ@S@AOM+&B8ZFA*N&0:5.LBD"^-)W2.N
M#`Y,N(\XJAM0W+++6K9AGOV&39Q=6`RO+$IN9N]6WO`%CF!]3UY9L99VI[D#
M*@EJ9&B;9A'PM;RVNK+*FU,G3N;6M),/1-RXM6WIBUO]R]&)\?T+M!HK*G&L
MBQJ9C%J:LS]7.-9'Z"5#+VRNF$I\A3C!YBQVQ#G^V)#([+S-6V0212_24B:1
MN4C>'(I[)=0N)!YJK^S=T\I77KI%KDIB[4<8VG)5W2ML:RI=`0RZO;`.V-DT
M:F-K8Q62>1,9T:*;9/$HZZ5J6U2C^T13,G;)-F6(ESJ%7ZUGJ=]/SU+()$#;
MFCU#)&%+`D=W%),T:U.`Z3#,+:/0,I`'&/1)IA)P%:ID`XI6H1)V'<Y!Y1GA
M]CMS;K62AVV"/%P7G6M?-%F]QP)TD<G0I&Z4)`H2G,QU:UP!G)C&,EO4)U:A
M_-,*94Q"E,,]>7A03Y@8:&]--1`XL&#:\W0NK:,3VETNOU_BE$00SYZG4%`[
M3=\62Z%+#G%H102TE*VR9TE"XJ$$BA)3<_EXQ#,K65L5EY#6_I?$K%HW7V@X
MS)G6"P[7:QM:IG$C,)2I&O6,6M3ZPN<=BB]0O/(&/UTWL"5K7O61#5DY&8M"
M4:;G(,]RCNTL+DFP3'1+>E&K)G5`-NQ%76*W+TR^'S^(&R(N/O*!K4A`3GUN
MVEN4>?T1*4QP+=HX[C=0#2DHAX.R>X$=;QH$V."VTW$5C.AV+)WBK7=-0WX8
M4)84BJNHW74?S612GTW`A-TB)K_.3Y*+!:YN$]FB)1FY1%Y-P&U'H?:<%W:M
M1%TKVVZIU>T5+MA7%XE;,8K,MW78DT'?(%#X8TV+"I[)#[G51<IZ<!1B;HXW
M6[5B*@R&9HY%+'!(L3V#>.V,>[&,<)2,KU8.Z`U38E<4S*I1<,?^)UNW_=MN
M;#6-""5J)>WPMYL>2Y`SQMO/1*5X`A1PMCBI[HG,<W0Q+(5;RG"X'$%DA+SB
MXXX5'OU`IO-X?&:Q(2.:BO*9?Y6\(+YO]FB3?.I7248*83#HV[QZ..33(DQ`
MI3),DQMQE)L<?"8NE/PL,1>,XHT'&Z!3.3R8FRD#-(U5R:_-1D9,J+9:01AI
MA<RM)T6%NN)['WIF:F")IWQ%7[D0B;&J9$QAF(</3%;)D"U2Q*%AG+[KM,I?
M9'2+Q"Y!')*;1LF<+TGFO#Q/D==BM&(,2'U:S293*%)GHC,GK>4&D25N!),$
M1-\<"!H714'T</A_+HDO?+*67/L@BD;`W5G>,D:G",T[%YVW6@UPB6QDA6RS
MV6KI@V9PV))%8"X*!2Z11B!AF;$[2WN83#7%W7CX$AO'''`C@W6ZEE1:7W'J
M'0#^Q/,ZMG;ZXX]6D3C$?5)T>8G&7)Q):G>RY2L4DGE)F-L7JTJ!N;\X*5R%
M<)20@-#A`K&#%+K^N;:+2ZOFOUBWX<P;Q:'J<MHER0+AD@6S$%P$T"(1V%1@
M!8"(6,@)%W``PS'<LHP0>J;]=%%_VKVPAFW]5;:VS4<\Q;.L+Y8414*VAP@.
M:VUZ?5[VG2P%%B.JG=DFF5C@K<FS*ER%'53JX+U+NE-\160^.]?_`$XUN,KZ
MK=S3JS0&[,M>WVB,*;K5R[R`+FGC@M@X@R&-XF8#H&,F@-:G!8E&88RY/_7L
M&@.`86#."8[5[[ZTTVSPW65P^[/XP_TQ<W<VA]V?QA_I9YNX56XZJW6/WDT"
MVLK2A*DZ=X;\@UYGQ:(459)]B^HA6?;;LW*'%^KUJ:DQ9N4"YA"64#)KD).!
M2$8CP&9+\.,V$:U?93**]@\DG$3,@DR?HE'W>5PHU<0YF1.1N#6E5/4<&XIL
MY(6B9G`U0@RJ)SDL_P`CS`YSC/?E>7KH??F]"7^$*3_R8Y9/Q[ORB_/G@:\K
M,6[_`(U'J9_!G6C_`"WDW+,_*S%N_P"-1ZF?P9UH_P`MY-P+,P?=CZ,?FY^-
MR<D#.W+W9T5$H6QK1*G%P6J1X+3HT*$@Q4K5'F9]@"4Z<HPXT>?8$`!9S[N?
ML#[L?1C\W/XJDR=8E4I%9!2E*J(.3*4QY832%"<\L11Q!Q0\"`84:4,19A8\
M9",`A!%C.,YQP(ZJHZN_3/O.T8Q2M1;G4G/K5FCPIC\4@[!(%*A[?WI(2J4*
M&UL*-0$DJ519*)69Y83ONPD&9+R+MCO(YC/?'?'NS[<<J7]+[7BA63K^=8S+
M-3%8M6:G(U[=JQRWPMC2_8^=)''SA/[C#0E)`EQM8]#.-&YJ&D"4U6(P?F#\
M`Q`S;0]WNX(KUSV/?R+K;+HR=-K=60V-/[[U@A$FMJS([\7WJWTYCP@L!"),
MS89&5Y9W$ARPWI7B/I2TQC4>:VGI\&I20K$ZHG)A8Y1>.!46T,^"(:6:SVE/
M9[LQ*C=RH\N2N#)6M=3>,AC46CC8L5IE!<ADY30YX52"9IDR;"!*<E4-[*E+
M4+%6$!J@\G"6SGKGK)0NH]9(::UNK".5#5[8YNCT@AD5`L+:$SH]G`4.JTL*
M]6M4Y.7'%@&=D2@0>X<8"$.,=N>[<<#$"9:MIY[M(NNJ5K&)\KE[U8DNNDAK
MUR;!J3W84CL%IERAQ4*#<C1&->6]`<A$D&3D\*L9*DL6/+QG&(M6=-BQ*V<H
M.:._U4B^(^QVPMO-LP=&HY18&(I;%'FU%!D"MR/&:A=)Q7Y@DJ\^0+",HGM,
MV(PG)`G9-\4O/'`@&AG28MQZ6I&*W)32;;'(]#[=B*FQH$SS)ZO:WWRPFME*
M9[%L&8S=P<2&@IL>&%*YN59,)`(@>I4K5+5ZL%Y!8,CY=IOMK?JVN)3?EL4V
MU/=;(;JB[1$ZTB+]B*89K"IR05>UR;+P^J39&JDC@XNR=[?6M0:%A:6Y-ZO9
MB35HC5ALM7'`P'@&H,HA\@T5>ELW:'`&I=*RRKY*06VJRS)BY2*`Q>($.S.8
M8:(+<D2J6(]480J"(TQ.>46$6!!%CG3:BJFZX986_-=QW*Z`_9#MQIV&I6Y7
M5A;I)&7IVG\<9T\FC"]H&(1!S?%7V&)F=S1F&H7U2T/ICBA4)SRTJD,E7'`B
M./TCV%?7=QVGD,JJ<G<]%8$:L:)1=C)E!6N1(X;`)'5B"*O_`*3XYRO+?HG*
M7A:Y24@\EQ;7SU6%(0>WH3256QFT9V`JE6VWG44ZK!QV=E[G:RBWFZ?-\B'2
MF2+\DD>E$S%!$C*85*T0X$Z1U!\4RW58HQ)$(%:9[&C-5EFIY=..!'O--'!J
M]"P:80><>AJ4S;%DY$WDZ,:P)[BUV,TV$^K5"!N\C)1#@L2N*9N2$YSA"0>D
M*-,/\DPT?5[8T6F-A&W,:@L*/MWV3-DM9[R;,*V9<HPTM=%-T&1N[&M"6=_9
M2Y_-B:@U`I*S@E*!40`_`L@%G$F''`KV'U3>AM\1#52IH;*B:1@VYJ+:>4OU
ME5M(F1R;DZB9/LVEK>WVTG7FUO*(PH=7<#E"?4"(^6K$Z[$>>4B<UK4+AR>:
MEP^78G&UMU3&,NL,-NF\C<1./.I02%"BO*MC377<1F)R0S.7!N538IL7O)K:
MX!+,3I\(SB"BR%0.^:_;\/\`MS^;W<?[_7P''''`<<<<!QQQP''''`<>[CC/
MLQG/S?[_`"\#%*5;Q:GP*QI%4U@WG!JYG\86,Z)?'[&6JH$8N&^HDZYN4QI?
M+$C2U2]L$4J))5NT67.[8V+\C;7-6D7EC3ARB0."%U0I'-L6)'%N7IB5B%>A
M4D+$2U(H+":G5)%28PU.I3GE""82>28,HTL01@&(.<9Y63ZF:]9.-P$<<S7E
ME[FQN*JHE'%VK-II"*6UZBTBD>6=>BE,,M$J5P5PLE\4(SO15[<X1JQ8:2-W
M<&M]DC=Z'\7\V/*O:RV2N(*SDP!IJHEKB3`@*K1B/:%++`2TC:G)!#VI0P)T
MK(>WQX(,-:0UH3$-QA*8`D90",@#@.]\<<<"!3X0@X;>O.G1%-ZS4U9]E5[<
M1TX:ML933RR+IY_!:"C,*7/[RV1_$H=6U*4?8;@`B/NB],6XJD\72R!$G0'K
M'-(6.I!+&YM<]6ZH(O&C;&!:5N]&'52FNFJD<ZVD\P<TVS$'V/?0R@53N43;
M'=!6<P>D?Q4G(71X41EW/APO-<CBR##&Y7],@00CQD(@X%C.,XS@6,9QG&<=
MLXSC.,XSC.,]LXSCMG'LSS^84Q`0E`"46$!';R`A+`$)/8.08\K`0XP5V`(0
M,9+P'/ASD/NSVX%!BDX043U*]>JXS5\])ZE,1ZTUKW-L5/38/,/C`HT>7U,4
MF)=WVWLH,Q)ZJUT3X:T#6RIWLT@]6G4$I&\LX\0UMAJ^]MNI9KCU%]5JMG+7
MIH[:1[=[-.E(5N9&&VW3-E6)D;J;D-@X<9BK='Q'7I#@)WC3@1Y[.WN1/H8D
MJ<2(LP\2LJ=#!8,#R9@./,$'`<C[8\>0ASG(0Y%V\60AR(6<!SG(<9$+.,=\
MYY"%U5?OSNAY\OVPB4^W\'WL=N=_K]G;Z,\";X&<B`$6?>(.,Y[>[OG&,\W<
MV%_L9?X@?T<<W\!QQQP''''`<<<<!QQQP*LO4/\`@Y4FV2H&[(W4G4,WPE-C
MSQ])E$>KK9;955,M;#E@YD7(U+(^0EL@B=:!K:TIJ@J)9*5G>I%:1L,,+5`(
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MBJB>L)&Q=Z_'#+,<6Y0\.K`A%E^AS6N-:G89*M,6:/$LKIK;9W!,V/'Q'V!B
M.6W2+8[7J13_`&.MVG/B/'IK,5=2.T(K.E*9HXY$V1ZESU,2E#.GGHVH<R41
MYQ2HIOE[$E!@^V7VQ\G^^??S3MC'NQC'Y.+Y/SPA2?*>V`V!O2A[Q!J!']?6
MZN'N7QJ0CD,D@_V8WAN+UANNO6]Q=<PQZ<8@=7#;.)@PQFO4Z=<MEIR%0.1K
M$,7CP1M1?)Z^Z;7#6U<]&Z-*ZZCL;5ZFQF1I[[;VAVBQ":'/#UKJ_P`+/&A]
M5&!3R<YPG#GA.N4,/I6%!RDUW5C,+\:CDS?;'R8XX28B9KI]Q/O$(?8+&S,;
MC=5ZD'2+Q25R:_812-Y0.+6$VKE-7SJ#'4@W44K8Y<:$&#UJ4N>01:V3%$U)
MUQ;;'WMB5G&#/<P(A>`R;3^Z;J3V%/X#JRP:B%QIEUC6%4/AYKYO;KSM76S8
M2/7<X.#2.NEBF'L+0?&X\MK&N;$DJ=(_.Q<A)5R%D:&-K]'#/KE`A$N+<Q(T
MF7(I*<A*<,IR<KBT2@XE0>C+5Y!E0!*<>F3GFIPF8),.()-&`0R@"#^OMCY/
M?[^+X(BG,SS-4"4MUJV3L78TCJ*XIF01I5$+?I>7-&J[P]PHVZY/`JLJ.X:M
MDB_#NWRM56C3,7)=;AS[%XFIEYB-P9XMY3A(6QP?4Y"3-346A[/AD$VZG,Y8
MLQ&7;:W?9=YL=9+%[:K?ZZ:Y5`XU#(U%)<]M*]PCZB5C*C!3J]>HUZUG9SW3
M#60Y.&4!JTV1GMCW=O9\G'"H`-:M"+WKMET,2RBIHFU+:&Z;FR5#S+R':$*\
MQ"YK0<J\4-;*T&I##`J,R,EJD8G:1LN1-HL#5@=5@O60\*,>9TYJ-%JYB\=M
MR&U[8%C2;I$T]K.\4LZV;6+$^P:;5U'INU.!84\Y="$L[KJP9!(0QYX5U2CF
M#XF>XPU)U\->B7=C4DVA>=2D$!@TL<F)YE$,BDD>(LJRNC+J_1QG>'*.+<F%
M&Y6,*]Q1*530JR:G(,RH;S4YN3""1^/Q%@S@E^8K?*'2FXX_.5^=)&KC&9P:
M9?JOHE)[)N-O=DIB8N,H;%J:OJ3CT9":6$W`)4&9-#M@UD6X0B`QM"U>1DP2
M8Q.7-QS\I:%$2K4KRD:4I<L*3DJUI:<H"M42D\WT4I2I"#!QY:;SS_1P&C&$
MGSC?*P#S!^+]7"G'''`<<<<"'&]]3+YE%O[+1*/LS=(JZW<D%-&RBTESHE`1
M45552UL338M7/36L/R_J3+#1I5ID+S$P";,.#T[G/(VLY-E0JR:U6IZ8,5S[
M!7HZPH=/0^TFZMH/#*>4J&\UV0):=)DD?-L.0IX^J5QM"XSI*O09;4B(]6Y`
MCK2TC>5051F$:7F]W94AB<*A:WXT;/QF3GS`2:"YU@C*R7OCM+\M"PQG;)G'
MA-B^,NL4-4!`88W38]LBZY8`I,XKR2C!"QC_`*MWAOQ&E52Q+:VFE\\CEJ2=
M\B[%<$=866'61#TB!D7R-HE>QM41Y>Z0J"H7XA)E@+,A,D<AHY%DDE<RHTBH
MD\02L\<8]N,9[=N^/=\GS<<!R$'K_?>05W^_HT0_UEX)R;[D(/7^^\@KO]_1
MHA_K+P3@3>!]V?QA_IBYNYM#[L_C#_3%S=P*U_70^_-Z$O\`"%)_Y,<LGX]W
MY1?GSRMAUT/OS>A+_"%)_P"3'+!]HVK7%)0"56G;4UC=>5Y"6E:^RJ7RQU2L
MS&RM:$HP\]0K6JS"R\"R`O($Z8KS%2P\1:9(2<>8`L0=\/.*3E&'GFED$D@$
M:<<:,)91118<C--,,'G``%EEA$,8QYP$``B$+.`XSGGR^-GNNI=D>^$+@VBC
M;+4SM"Z(F[GIY%FDI0E<&%]U]43K#++'59.4CR-N/D;JK6.\A;I@D/)9VC&4
MB0U(H;TBG*FVJ"3;3]<LW!,`6SW3_I%N8U[6_P`S4)U,,VHWM9TZGT)S:88E
M&6:XTOKK(R0K$ADNRK0SB:-A@!-R5.@5GEI<,Y?I?JE!?A$^HNKL8U^JMNH(
MGI6VA&#:PS$&A5'%[7E_E;"::[$JTYQSL\*&L\],HD+@<>^G"/-4&.&5(\F\
M"W>QO#=(&=K?6E8C<&MW;TCDWKF]8F<$*M$M(+4)E"1<C-/2+$YA1@1%*4IQ
MJ<\/8PHP0!8SSDQ>[/T9_-RN>NKO9[H?*5,DH!AF^U_2;1C.=9?KJF5JY9LA
MI`U&&Y6/TFHA:ZGB<K?I1(8<K=G*LW9TS(H>C+.^+1JA($S`IQ=>]B:9VJJ&
M'7I0<^8K(K">-)+K'I*Q*<&%C":7C*AN<T9G@7,KZV'>-&\,3H0E=&I:4:E6
MIBC09QP*_P!TTOV_OKF?]D:P_P`G1<LV\K)=-+]O[ZYG_9&L/\G1<LV\!QQS
M3O\`3]6?Z.!KQQQP''''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<!QQQP''
M''`<_.K5)D252L6J2$:-(0<I5*U1Q:=,E3)RQ&GJ%!YP@%$D$%`&::::,!99
M8!#&((0YSC]'/%MD9"[1+7>^Y4P&IR'V,TO:4A9#U;>D=DI+NRP9]<FXU2U+
MR5"%R3EK$Q(SF]8G/2K"@C3*"323!@$$(M].5:BMB^GLN.=/S>=DOE2E<X=8
MM\;44G%WV@F445113%5)FY\;90Y"KB-NB=?8+&NKER8WY0KD,A`L_MZ6UNF)
MMM;(JM@U`4U#W&R\W(OC5:PYF5VIE:0Y`GYS>R(TXY40XICE)2]*[^#TA&LP
MI4C4I,D'&J3S1C-'"/KU>>ALQNNKZ[GK7TYC80]=/.E[VDTD/B.N30J47=*9
M2H8Y>B4+P$$,Z`C+42%:.+%)R3VT9HSO+*2B``-@*'_%+XJQSXA?%SXD^I&W
MXI_%#U9\5?B[Z(5ZH^+OJ7^U'J7T'R?5OJS^P?1/*]%_6?!P7?Z['QQQP''/
M"=@]GM>=4(0"R-D[GKFD8,<Y$,Z:363*6R+M:QV4A$82V(#7`XLQ>O&468=Z
M(B*//"26,X8`E`$/'GTAWVTLB@:0')-IJ(92]D\)AT,<X67%R"+7)5F@3IE,
M)/$X9)>49ZLP"$M84,*43@(+?YV%N?(P&6_(/^JI]^=T//D^V#RKY??^IBMS
MM[O9]'?\W?DF+=N!JT[W\Z:KM>P51K]CF5NR[.M*)9TPG6.A1!3A5F#/BX%F
M7`)Q*,8%BA'@O*U.D%A4>G+(S@SD9W54S_=G=#SVX]O4(E.?I_N8K<]O?Y/;
M^7OCY.!-Z7^QE_B!_1QS?S87^QE_B!_1QS?P''''`<<<<!QQQP''''`<<<<!
MQQQP''''`<<<<!QQQP''''`<<<<!QQQP''''`<<<<"$'J#UE?KQLGKW(JPV&
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MJ)@5B;#"'-B/5"+=!+$I(^4O/'''`KY]5[=3?G2VY:BL.K9AKU^IK?[6HVG,
MU1(J^F3_`"N:2*S).D;9<\VO=B50GAVN$<9FI8',#=GHM2GESJ##=D`U)H0!
M\[Z_VWFN9=953I\IM%F(V6=]NM#YRV51AOD)SJMC6-AX>ZF.9+P!G^+>"`-Z
M!:KQ@YW)/&21C`",F&E`%G?M+T>M:MM-A#;XL&6W2S-\Q+JT-]TQ#[#<6:GM
MC3*,>BY%3)UIQ?(3Q&FU^\%%J$8XZI91.I`"TSME4$(A#\4Z_+8W$:3UTK*0
M(0JP[P:')`*_0TPE9:8O9:!A`24J$5E06`(<8!C`#0YP#Q`[^$8\"NEX?>?@
M3E!]V?QA_I9YN]W-H?=G\8?Z8N;N049/A)'5DHNB^HIT]JO.ALRG$DT5NZ+[
M-W#AC5-3>E4M,FC_`/:F"1\]>(0#Y.-I$4]*5:GRVQ(!2D0C$-0(_),N6M&I
MUH=65;6>^74C<V=YUW>BV6V].^GI&G`;A4E;MZL&%$/M&_WM"%"&Z+97-(@.
MA3`X^F02)FN1J9,A4G%#*+@@^$*Z^ZG;&]?7IST"_P`2>4LHO-#7C'L^^1U\
M.;5,LAKK*%;+`D!(<'&A:WY"QM#LB5O*4E.J4M*IN+\0S41!@;[D#@\3K.%1
M.NX&Q(8S"H-'6B)Q2/-A>2D#+'H^@(:VAM2@%D0_)2(DQ)(1FC,.,R')AQAA
MHQC$'9DR9.C()2I""DR9,460G3D%@)((()!@LD@@DO`2RB2BPA+**+"$LL`0
M@`$(<8QBL];O^-1ZF?P9UH_RWDW+,_*?-X;K:D,OPHC7N2.^QM0MK#`M+["U
M]F;PLF3:2VQJ[W2?/*5OJMY79'E*@FRQ0X)"2&4\T*@1YP$XO`>+!7`N">'`
M@XP+&,XR'MG&?DSCMGZ\9SC/S9SCD#&U>@MC:>3BP>H+TN'R-5!/``?++VTU
M1D)RA%KGM[&HX@5OSVH`W!RH04W=($1#J)EL:+(D2%Q5J\%21&:`1R@V>C'N
MQV]OLQ^;YN_./>&EM?FET8WE"F<VAY;ES4ZMJPO!R1P;7%*:C7(E1(ON34RM
M*<:0>4+V#*,$'/LSP*!O15ZU-!79US=MI8YU[/*Z(ZDV:JB51)716T/V8M-J
MYCA_CCTO/:Q%EA*DQJ9:0RNK>$Y.4<2F*7%E96!$3]`/&>^,9^7'?GSOJ`Z1
M"%AZP74V6=/9R2UG?/3RF%,WCJ##[`.!(JF?':;-RYTG%13CT\A4\)HU*6U>
MYQV+OZ95ZTAYJI`J`J$%)YQ=T_07>^#;PUF]N!4>=JGOFI'W-=;,:XS3($]A
MT3;#<3C#O&'Y'G(1KV%<8`Q=#I8F`)KE#(,A8E,"H`J3$!D5L54*F_*/LZFD
MEBSFI%-D1-QBI-DUHY!9YY#!N7E@]>Q9S&$8$;LEP'."#A`$'`1C#G'86>5:
MO@R%17)*9/N-L!:^YFSMU9IC8VY=/([6]F3I=(8(M88*JC+@W6*X('%4L-#,
MS\*#$O\`8HR4:,H9V"L#P=G`;?8O=C\8'Z8>5B_@P?\`@=ZDW\*EL[_Y$3X%
MG;CCC@....`XYC;L3N'JSJ0BB[CLW?\`4]$H9JM7-T356C-&>(%2)<V)P*G!
M*T"=3R?3C42<PLY4$G`O)+&`0\X\6._<:,V"I'9JOT5JZ^VK!+DKAQ7N#6BF
MU=2-NE,;4N+4=@AR0E.K8:<G$K0G9P6J(R+!A(\XP,..^.X>P\<<<!QQQP''
M''`<<<<!QQQP''''`<<<<!QQQP'.*?C1$,CR>!H,D`R6IQ-`Q$^A^<]#+1G#
M"TE>L3"6_P`QRSC"('IQQ2/Q'X]*,`1Y@\<KQGW9[_)P*^C5LC#9*"U4$=Z$
M\_DYE-+36RQ6UBB&C[J!OF`8JFEJV&-V"IWZ._S1''W%I,<V=M$<>E.>V=$>
M9YR\H/)I]>+`B%K434%DP%@3Q2%SFN(A*8Q%DP60LJ,LKRRI%J&.^5&S3V`@
MQD)-PV'IV<XUM3GI3"$A@B2PYS$!?<9LVV[LV5==/(3*&>(P.2E0K:[#)M*I
MUM*MZS&J$,#](`,,2*JR=@R^%UD\L$;66JH?ZX#)5)J%(6[J2XO\86^6S5^3
MU?--=J3E=*1W,1J5_K&'.==Q<37ZF''HDI94HF9E-;>X\)CFU+@*0[`33P&F
ME#4`4*0G8/,#W?CCC@0X=8^:Q&O:LJN23+5BR+H0J)).8DT;#U!3T<V"LG1Z
M4S&!KV2-W]&*9?(W)E$V/*<CRVTXE`C))18)`8XG#*-(3G4\!ZN7K7>LJ.O;
M.T1O%\L;;[ID5SK[J6-DH^22U7!+\;-R)Q/'J06!DPAQSK=+9G&Y!%;@D):P
M]G2-'DGIDXDX$04A?TG<XQG';/?\F<AS]8<XS_'QD.,]N_?V>[[H6._T]L_=
M>[_I=_P_+G@43Z8UZMI%U!->M?E6IEPH-FJ>ZS]I;C7!M(JJAT(KJ0:DO55)
MT2)>1L08E`FDR%_4&H6!/#QN`S#5K3Z,-($0Q8Y)YOY!MQF3JM]*R6V]?-73
M?6"1=0&1@H>G(U4IT6L.N56-8K&R-3+;($\+"9DG\!#R4)/AM0CR:XI3PF&`
M3>0GLZ=L=^_M[^[^^%V_S>_A_+V[\A`ZJOWYW0\_A")3_JQ6Y\_^S/Y/=D)O
M2_V,O\0/Z..;^;"_V,O\0/Z..;^`XXXX#F&]K;[:S4K=4<U\L.72=KM:78;Q
M1N.M]7V9(2'HMP`4;YC<^Q^*.3$K*;R3R3WLPAP,`PIS0'/&410L"YF1S`"^
M!F8WUT'+P88$L<;VT$(O`Q8+&(,`B780@8SX1"#W]F>W?'?V9X'];AZ@4-IO
M9&):Q.M";3RZ93DDI7%93`*<6R:NGEO)2MBN1.2.5E.1!!B&%E.Z/$M.RGQE
MI,$,`@F^'&19]<CWNH0\=1#1\.!"P`56;:=PX$+`!9PT5KG'B#C/ASG'LS[<
M9S[,9_!CG\[+VXOZ$[A5YK(Q:KI)7%K):7V5L5M"NV+,91</A(HH3.W1;#%3
M,>[$KV=5*22FMJ"J&-Z`D--"H2X,#C`2&<<<<!QQQP''''`<<<<!QQQP''''
M`<<<<!QQQP''''`<<<<!QQQP,`.HDL9$M-MX':S+1@*A6]')FQHK>IVB[4T_
M4#0&>;&)G6\C9E\9D4=P3_9^$S\[1M&%<0086Z^D@*)%VC1(RZ2Z92-=N5)5
MU1)FE6H30IHK3#8S!=&4Q<O/-=Y/`(^4IC==R)<,PE8Z1IGD#Z$AP5+?2SD:
MD(T97@?4X@*JZ8(="(K.X$Y/<!KRTI[-]>[$F0X9`[&A<FACI!&:73^1D84$
M1YNJ^4.">:QM0^HSV=Q>6LTH8,')BE!/&=)R,N1M2+;.Q8,+6LLKC==0U15%
M8S,^P(+$)M5K`.+2^?F29<A:50IG;)A2![D3>G9T#>2A1,:G!CBO5+5HPEFX
MXXX#D(/7^^\@KO\`?T:(?ZR\$Y-[WQ[OZ?9]/R?EY"%U_OO(*[_?T:(?ZR\$
MX$W@?=G\8?Z8N:B]V>WLSGV=_D[^SO\`D[]^:!]V?QA_IBYCAN)>#9K5JKL/
M?KNHPE1U'3M@3D!F3@I\C<&2-N"AG2EG#S@)9ZQW]!2$"]^3CBPAQD6<8X%(
M>^<-&P/5GU\WSP),Y`G/6[:=1:H?`X&:$^I-2:J21ER.95>1Y+&SOE@/3PH4
M@(#@O+BVY$(0AA]GT",>[\HOSYY1:>J`>=;J+^"[0B5@-S/I?ND&\+*5*!@,
M5+[#O5I46;)E:LP&,8,4>=(""#!9[B[D9P+.<\O2X]WY1?GSP1?[1KS!.0],
M3I[RRSEUSR73C7M[M5SEY,^<)\XULPJ),MF:=:2Y$R94Y#(\TYY`O3D+,+1]
MS,J2@'"SDS'?F=G'`=L8]V.W-!>[/T9_-S7F@O=GZ,_FX%9/II?M_?7,_P"R
M-8L?DS'1=\?EYFUU`=&[936:S=13IZB:(EO35C.!MF$#5GY9ZYW6J%$9Z0Y4
M?<($YA*7,E*394'U;8JDD]UB[\!&C./&V&%Y182]-+]O[ZYG_9&L/\G1<LV\
M#"?1;>>IM\:=^R)`2G*(3R(.V8/?-&3$'JZT=?[=:L>5)ZTL6/G@(7-[@VKR
M5>&=V&E*;I.T%D/+4,:<X0"88?@P?^!WJ3?PJ6SO_D1/GN_5>IU?I.OE/6?U
M=DC76]K4+%$BO:FIU0\L=8[L4RG=F]JS$K',;4YN45KQ@#KYM4V,8VNKFD<P
MI&-=@QL/P$,/_P`$OZC],V=,MUM5361^A]JW%L9;VZ,%1.*@ES;'."S(<=1O
M44PX)B2,ADL*-(3'JS#""T[R@6Y4I`DC1*2>!=_XXQG&?=G&?H]O'`<<<<"N
MO\*'I2I+!Z1VQMF3BNXK*I_3#3&7FJ9<\MA:I^@#M)+"AC`^N$9</$`YN4.C
M0>8A6Y!D1:A/GRS2QXP'PRB=-JEZFHO2+6V)4Y7D6K6,.U05W,W%BB+:!L;E
MDJE4-8W*1/ZDK`S!J'1Y7F#5."PXPPY0<+(QB]V,8%_"5_VE7=K_`+KU[_.U
M!N2@Z8?>AZN?O>J;_F_8.!DOQQQP''''`JU[H]9_J9:X]2:+Z&5ITY(39:6X
MWE<JUQDZ^UE#8[6S7L62`73J78))!EM8A1Y(F=U*E&X&$F)R$(1Y+/P9CO:%
M:SUJIM;U+BCPWKU"%(>M0A.PH"C5FIBC%23!X<8"=A,>(PC!N,8P;@O`\8Q@
M6.5B^H)_C*71,]G_`+%-K?Y'S?V\M!!]V/HQ^;@:\<<<!QQQP''''`<<<<!Q
MQQP'&?=G\/'.O2YV3L,4D[XK?&V,)6://3JIDCR5@]GCR=N;5*PY\=B1*403
M6UI+)$O7E"6)`F)4YH,J2/%YH`KV[GQ",[&["WA('22Z?Z\F4">UP.6QW:A7
M:+#,-C(^S1YKG#?,W,N"7Y4#-FEG1O>7*"0Y^>XG9*E:<VS+!@?06\,;43F:
MZSTNT:'IZQ28"ZU81-*XB$C35R](@-SC"4SFR)%":-'(BR4Q:<MJ($6F2@`F
M3!]#`G%A,1XO*!6CL6^'6]IFS'3F.QG8ZZ8Q%6VP84FDG1?9)Y/TVN"E]$%A
MV=ACY-ME!)$E,.+^2-T8&=(_I[&6+$V3DD(PL-3Y.L[4Q*TDYJ6MIBAF\?LI
M))X1&GPBP(JSBCT<F1;BU)E.)&RL`W)X,8VYUR/*I,SG.B\]K`/T$Y4<:0(>
M5Y?/4U^[H]-XXXX#CF+.V6ZNL&CD!;+*VCMR/U3%7U\*C$<&YIW=W>Y3(C4Y
MBL+)%HO'&YWD<B<@)"C5:A.TM:K*5*`2A3DHKL+..<FZQG32B"'7QT?]N*R1
M-FT;4F?J6<0C?E2*1L"I^'%27]W4)&8\J$L8I44;%Q.LV$P(BY$4<SF'!6D'
M%`"3+D'_`%5/OSNA[[/_`+PB4_)_\,5N_E^?/;';V>W./9S-1FZF6BL@VO<-
M(6?9"!+=GFU8N:E%7@&[`5CD#8VX>'2*HW\UL!%7"7MC2(+BX19"]GOB-(+S
M#T0,X$#&%?54R'.YW0\[9QG/VPB59]G;/NUBMSO[OIQGW_)G.,\";TO]C+_$
M#^CCF_FPO]C+_$#^CCF_@....^,<#H[U9U;QIU]12*P(0PO?@2F>IWJ6,#4Z
M^!=G(40_5R]P3K/`K%C(4HO)[*!8S@K(\XYAM?'MWXT&SCW9C.VF<9^7&8!$
M<XSCYLX]W/$-Q];M?+!WXZ?$JG=)5;,9-(9'?")]?Y)"6%X=GE'#*56.\22N
MRU8B--<T\:<\87L1+AE26U*_U]"$@S(A"A[ZH'7LJC3?JYT%03_KW8<U<=?T
MK@Q.\B8Y;&VM$_&;.Q"'M[08TM:U$:>27%/$`Q>%4J`)QSXBDH4X<!-$-=OJ
M)^4]5U_MB6CW_A7MI]'_`#16W^^/R\_A;7;'4KU!SG/_`+NNUGX._P#];T]^
M'\';^/F^YC0F]0[1DS&!!\VI]L3,`'CPF!P-FK46`C!WSX1A[YP,/M\(L"QW
M]F>?SMG/_*5Z@_O==K/P^SV.]/>_Y?\`9P/6)3O7J]#+\;M8)'8K@@O-X,1!
M:8&"N;07J'(E=AL\#@A?&V&JXRI:$PGEL)<GDIY$U-*A86G=%B0_!A8,NN1\
M3LPS'4YUW+P,>"Q:?;)Y$#`L^#.?LGT1[<A[]LY^Y#[<X[^S'R<D'X#CCC@.
M...`XXXX#CCC@....`XXXX#CCC@....`XXXX#CCC@0_7GIY>4LM_8F.1M&QO
ME4[I2BF'6QK)=7A&F4U17E1MK(U3&J%456&&O,K0V<A0*@L)T<5MS>VJGAZ&
M]E),@+5+LG-9:;FS%=>P-]RJ)I:F;+705Q"(Q3J5T;'H]J9Z>)D3&BGKZOCZ
M@<?`\3A"YHQ)FQ$6J6-,?:F9(Z.BA8$2-#T#J)2&\8^DH5175IV91-29L5Y4
M;%7+5,#C]ER6'0E%%U)L=1*8D\1B7+<,<EE`TS8YR9D8EZR,X"4K.(&F.'D.
M)NM%P[8,^RL62-%M6_MQJU<4S)B<3G-JU6QUTIC[(S01ZD,\E;)EB@\'=Q-L
M*EC>RQP;Y,6I*BEYTJ5-+"F-/C6'%0$ZW'-,=\XQG..V<XQWQ\F?DYKP*LG5
MB^S*KW]J*!T'U`+8C.TT^<:5D%"ZX1"<ME8T'KI1L"E"95LY=6T7IKMAKM))
M9[49B,P"+.Y*21+G0937%VYT3%*E)'>^OU>MJ!@-5T#^I;MM;6"C;30Z2KMM
M"72!@IIK=0["PU4*-K&?$A'/\NIZY.G:2A%1S+<%8YI!F+2DP1#%,7;_`$Y-
M%;^M3[.%SZKTU9-O>&.`^R+*HBD<96(N(C`9&2ANPA!/&4RF%%C0%"SDLD0`
M9P#.0XY@IU^P`*T=KDLL.``#O-H<`(0X[!P`&RT#"$.,8_Z(<!QC&/=CMCA-
M?NOOEO3E-\'W9_&'^EGD'G7Q/=IYJ55.HL7/58E>\6W&N&NA"1&26><?"U-@
MML^M!0<4:866-N2P2&NX7#`\^`1!_EYSXC`XY.&'W9_&'^F+D#VPBQ5L!UY]
M'*:*)*<H7I1JY=>VTQ`$*@XE%8MR*3Z4K-.X`SG"0A:C;6YZ?V@[PC48[GX"
M,L`NQA7A76[:"&W;KH*M;.W`1M;9U`&UI;$*$G!:5&C0P\!")"E*!CP%E)T9
M``$D@QC!9)>,8QC`<8Y97Q[ORB_/GE?'J3=`6+=2#9AIV3E.[^U].+XJSQ9+
M`H%6;XVEP^NY#&4)Z$4T@Y"XX!\<D[P$[SW1T;,)UQQP?_I>2A>6&=>LX8;7
M5=06`GR:03,Z%Q&/18Z72M7A=)I.:PM25M,?Y`MQC&%3R[#397.2C&.QJL\T
M?X>_`[QQQQP'.->G=N8&=U?7A46A:65M7.SHM-P+)2-N;4IJU<J-P`(QY+3I
M2#3AX`$0LA!GPA%GMC/)<_D>02I)-3J"BCTYY1A)Y!Q8#23B30"+-*-*,"(!
MA9@!"`86,(@#`+(18R'.<<"E[TJ.HYI3-^OAU-E\6O=B=T6X2NC(GK:L+8I8
M0DM.0PB/K`R9L9E"EB*"A.0"1*/),?,-9#@64(Q":=W"$5T?&<9QC./=G'?'
MT9YXC'-9]<8?(4,MB5`4G%Y4V*35C;)H[5,#9)`WK#@F`.5(7IL8$KDD4G`-
M-":>G4EFF!-,"(><#%C/MW`\KO"EJRV+J2P*-N6*-\XJZT(VOB,UBKH$>4;N
MRN>`A-*R,H0#DZE.<`E:@6IS"U*%>F3+$QA9Y!8\4?O@_P!T9-,-@ZMWHE\D
M3V]$+;J/>JWJ(J"[JOMR6UY:=80>MB683%\59!&U:0@+FY9=E1,H4.B%Q3OR
M/!:-0F*(P,([Z8O=C\8'Z8>5B_@P?^!WJ3?PJ6SO_D1/@9$(:OZUVB!)@:LM
M&"=6FET?C&FKZ_G)IU[VQ9$(?&/"5INA$4ZUS81I)!918#I>RLS@K.'X,F!$
M(1_/6:FZXNGKY-6JF=H$EF:!;#N!A:3[$.X,-<:V3KW`8PEX*B5KX+65+,$I
MQ@O"B4-<N`<LQ]T!(''LY,KSR*YJ`H_8J(+8#?-25U<4+7E&DJ8U9,/8I@T]
MC@9`,TA,^(5F$:G`<Y\I6B$G5$B^[).`/&!<#T]N<VYW0HW1I7HW-L<$Y2MO
M<6]40M0+DJ@&#"%*-:F,-3*B#B\X&4<0:868#.!`%G&<9Y^[D"ROHWV?K*^K
M)MTL-W[AU.)\[*T.L=K*5NQ6G[L9DT!YS4E@<T<3I57*)P,!Y9JZ$/Y9[:4:
M:!M2D%=BL?Q3=4O<O45:-HZI.A4JA4#2&A)-V\TT4.^PFO\`A.''AR\3"%)4
MXK>K=#Y8!K%9CBRNZ5&7XP^;D!61Y#E_A*_[2KNU_P!UZ]_G:@W)0=,/O0]7
M/WO5-_S?L'(!>NSOOIAM)T+ML9=0.S%/V:SS1#`(U&RV"8MV'UPDA=F1-R''
M1Q1P&BE*!]`@;ERPQI<F9&M+2I3E(R<$EB,Q.SH1+HM.-)]4)-#9$S2J.N.O
ME2@0OC`X)W-K5C0PIG0+2R%B88RAFHUR90C5DYS@U,J(.3GEEG%C`$,N....
M`XXXX%7WJ"=_^$I=$SM_U)[6_@[^SXGS?ZOIY:!#[L?1C\W*OW4#[_\`"4NB
M;V_ZD]K>_P!'Q/F_?EH$/NQ]&/S<#7CCC@....`XXXX#CCC@....`YYM<T$/
MM*G[6K%*O(:E-C5M.H(G=%1`U29M/E\7=(^2O4)BQ`,4$(S'`*@X@`P#-++$
M6$81"QG'I/-,^[/;Y,_/P(*:TU+ZHM;6)&+*1O>AKJYQC3V!ZA$LAZO8-.VJ
MV>`O"Q\13DQ64U&G$N;@I5>C*&8!0R4Z<'F%+QF9[9E,U&I=YUUUCHBC9$]-
M<CD%5U?$82^/K(E5(F=U>&1K*3.2UJ2+AC6D-IZS!PD1:L8E6$WE^D9\W(^0
M\W+"&B5[-[1BVK9NI^\#;YZRE4E(=3U.UC!2RFD'"OH\H:XTR):0<VV.+IK%
MI9B89F;XL0!=5RMY:""'5R`BR4WSE4^B9FZJJY01TJ<D,**$QI*S$V<;(S[$
M*;"&E*6B+G!TO-.E)LK`G"7A^,D1ICT-QPHRY#$K\S/"1U[ZS/2,ZY3MCK7%
MZ/QQQPJ&3K/2ZS(!4U3S'7?2>5[7[3()G(V6B[)B]4I[54:@JI7&11^:W\2T
MG9`-0_M$;6B*B4:*4MQ<N?4R=`L=4*-*>(=;2P.G_L#!JIF]7ZX:,[8V7`]T
MNG'5VH57RFSH+%(?9-07U#=G938EL3_9R-NTI5@I]CG#G(5MJ,KNTK%+,-&B
M9&U'DM>22-)?FSCO\OUYQ^;FG;'^^<_Q_+^7@4M:BT@W*9MR]>M>G74*?MB*
MANL)8_4#F&Z1I<:!3<SH!_K<+.ULS-,<N.)0ZS-X<C2691#5)!BY(!I3&KT^
M$W;"/-7?RDMC85U7>E9:U@[=OMK4;8G4"D8*LUF751"XLT4@H+U@L+&5C;9#
M,J,E,TR+"!V+]'?TY)0,/0QEYR-.'(K.O;'^_P"?M[N_S^_D(/54Q_=F]#W/
M^4(E/R__``Q6[GZ/P?D^O@3>%_L9?X@?T<<W\V%_L9?X@?T<<W\!R(+>S6^D
M+'W*Z?;[-Z];I"[3BV+!B4N5GNLF1`D,:AE$61,HLRO*)I>V]N<T#)*T:20-
MY"]&H"0Z)$ZD/?(!!'+[R)OJ#WG3E*[$:$32UK.@T"CM<6;><[FBR2R9H;#6
M**(=8+4$8[J4"A4%Q,)4G%^@MH$Z4TUS=#4S8A`>M4DDC#!'JL]8;1O2/=;6
M.-VC8+VNM36YFN&>2JJ(U")BYO*\NUJ-6--5,:&0A9<Q4M=,WD:-`$T3L>%C
M(5A<7PM$FP#)V"C?T9(OMYM-KYL)U8XHLF>T&]!>P%B3J`0N>OL8BVO4!@58
M10-%T_$G"(+T9CO)*W1J_6+W+SEB@IRD`PIA)EB)!D2K":^>EK+.N-N_4.]]
MP2&4:AUKNK+)%$==8&;"@2&R%M"ZX5.4^0VXILG>7=L2,KI;OH>537%O1@C:
MF0Y,O/-48.)";<'N9$%MWEZ>K<`P1P$$+VI0A-'@(1F!25O#4X3!A#V"$1F"
M\"$$/LQG.<8QVQCA,,>^/>D?%%!7?;>GJ>=,#J;,6MK#MY;5HU'J6[M3#5EG
M797$5D4D)I2TD,&>IFW3.:.$74*)BE9(^))'ELP5KLJ2DC24H2FM)XLE@OES
M.31Z9]0G2:71)\:Y+%Y+K#L\^QZ0L:Y,Z,STS.CA3:QM<VQR2&&I5B%:D-+4
M)E!!HRS2AA$$7;FFR<.B4UWUT[C4PB\>E,?DU,;>,TB99`RMSNVOK0I8:[3*
M&MV2KDQY:Y`<0<:28D4!,)$`TP/@QXQ=Z">UMP;K=+CK`'4?K]8&Q%2Z0:W7
M@WEU6CD+0_RJMZXUILITK.97DUQY[D#$[I05(VFN#@4K`F6F((XB2IR@'HUP
M,F#*^@C//9U/-=L_)I[LG[O?_A/HKW<[T];UT^P[(MNJJZ)W\*V'D8SVH*/7
MFVET*<8^F4MB%SFB2PTL9,AQL)9'!X;V]ZE&';U6VK#LDJ#@Y+,R#R=TD\=F
M?4;U:EL2?6F31B2Z4[#/L>D+$X)71G>V5TLBAU;:Z-;BB-.2K4"U(:4>F4IS
M1E&E#"((LXYSLS$/[9]1Q?C'@`M.+RSD&!B\&<YM.K_;D/?PYS[,>W.,^['R
M8[!(5WQ\_P`GNS_1_'[N:\AW=*$3XZMT=5XNG9DN/.&N<GV&4UF5?D_+J<=@
MLULQ6&(L?$`+CZC#&0L3DK)-BH20LIIYF%(TV3`^V6$$UAPWG,=!+(T)_P`*
M1H\L87YJ$\85@+R>-+ELPKRNPH`3C)HB,D>:$K&1Y!@&._`[/QQQP''''`<<
M<<!QQQP''''`<<<<!QQQP''''`<<<<"-#J)L]N.:W6T^(0O86S*B2V1)4]]5
M[K;+#H3.WA@<8<I)ASXL?D,MA;P..Q:4@+7N;*U/99SQYY9!A)H"NV/3M*6:
M.M#+/`L%0[15,$]W:1*DVS<TDLQ='H12(X)*F*&R.PIZ-`V)0Y$4N)2FM@#%
M(P#&0>+'C#A%U/9[01$_HJ@Y!8VO]>.]R6NM56).;0G#FH<JN<FNO<_$)R-@
MK//XF:0*>X3?%1`X2`Y#%TX,F+C,"6C"J!D]TZZNKBL8W9B2O+[IR]2'5^9%
M#HNJ$W!B..GD-Z@HA"\]K%L+.%*PL0CTO]D-N,E%CS@@_P#OP!)!QQQP'(0>
MO]]Y!7?[^C1#_67@G)G9#+HK$@-)DJDL?C1;\^-T88QR!Y;F8#S(W<0P-3`U
M"<5"?#B]N8RS`-[4DR<N6"`/"<@S(!=H8NO]]Y!7?[^C1'_67@G`F[QGL'/S
MB%C&?DSDS.,9_)W[\@>Z2S@#8W;CJP;U*`*5;?+-HT6H53NBH97^"O4^+MS.
MO3HR@",$%`ILB32E:2<$8"5&19$$O)H3#!2M;:WJT:Q:O;`["OB@M,W4S45A
MV*8,XH9Q8U,7CKDY-J81)?ZX;Z6YE(TN"P?=CR=@(<>+..8<=%*@56NG3*U4
MB+VE$1-9I`Q7?8QQR3"-:LGMZ.JZTI`:X%9R(T2Q(.3)VH9J@9J@93>3@TP0
M@^P)4>...`XXXX#CCC@....!M%[L?C`_3#RL7\&#_P`#O4F_A4MG?_(B?+!.
MR$WM:MJ*M*>4=50KPMR*1!R>J^J0+XDC0I_)4F"Q((YA]79PD;/3<Y'_`&2=
MGPA\OPX^[$''*U'P<Z!=2W7*:[25#MGH:XT)5EZ7+:NVA-M.,[CSF-LGUA*X
MZD#5"5@;7IV4KVY(C0GJT;V+R3P>6<%;@7C)\(N[[K8G'''`<_D:22>6:2>4
M6<2<6,DXHT`3"S2C`Y`84:6/`@&%C`+(1@&$01!SD.<9QG..?UXX%(KX6!TA
M*D=]8C=^=?8/4]02^D703A?R*+Q9OAJBWXU+W-FCS.^+,1Q`E;WB:1=[5DX+
M6NR?TU<SN2TK+AD24@@61G2GZ-_4+ULT@U_74QU7;`J!WFD836LZTD=5D'N#
M7Z-'6"F3R1"UQU))@(Y*2<%(L3CDIZ)U2-CF[FJU")`1C&#SY$?A*_[2KNU_
MW7KW^=J#<E!TP^]#U<_>]4W_`#?L'`BJ6PGX1G5Q;D*-WKTU]I$Y./,;"K#J
M*U:3?50`FX'Z,<?"I:O9DR@PG.2<&C).(P/PFYSC'BQG^[=N7URJ\RWCN#I(
MU/:S?G.0.3CK-N)#`K<9+$$.34L<LY&VJ08.#G)I10W`T(<8\LP\(^3R\9QC
M/OQC/T\"#LSK2O$`-5I-CNF+U*J84(`B-6.$?HA)>D6)3%A[G*L2.JG]X":G
M+SD.`F%H!^8'.1!]@<XXCOPBWI-N:M.W2[8234RY''Y2'H;SHR[*I$W*PY[#
M2N*Z509(U)C2Q9\`Q>GC)QG&<^;X<=^3A^''SX[?@QG.,?5C.,?DYTZ4UU`9
MPC&W32$Q&7-X\Y$-#)XRQ/Z,0LXSC(Q)G9O6$"%G&?;G(,YS^'A(KUFOIV_>
M=E&;?WK,]/-SZ_/3-OJ+7>DGU(ZQU_:4+MNUH$W*9)"VA[N5AD35&\M;BEQ@
MR0-S(>]MI\O<6@E40TIS3\$^F*42H@N]TSNS:_-+8]LRU.Y-#PWHG1K<4AF#
MDB]N<4Q2Q"M3&A^Y-3JTIQ2@@S'L&48`6/?RA'U.NB[IG,?A"FBE4(VI^@56
M[Q1VQK3N:`0,IC8X^1(J=9'ITRDAB9,VE$1EHL'XO(4LJ2)DYN$8S7%Q9Q)U
M2_(2+ZT?8FF,,3+&V%"2V,<?:6UD9FY/XO(0-32B(;VY$1@61"P2D1IB$Y>,
MYSGP%A[YSGOGA7+\<<<!QQQP''''`<<<<!QQQP'.$DP6<<;D`)`L]7,(V1V"
M]N'K)0S>@M`D"C#DL];I%"14U>BHLGG^LDRI,H0^7Z42H),*"8'F^>;W)(7V
M(U#:LLB[$1*9-&*WG,ACL84I%2]-(WUEC#HY-#"H0(>ZU:0[N"9.WFI$?]E*
M2U`B4_ZZ,'`K![C;(:@XME>[Q':&D[+CMZ+X-"*[ML?4.O*"036U[31O$>PF
MNBL:AO&..4P@[FD9R%T1F,-+:WARF;DJ:[*>VY&<EDX[,]`HFAMI"I&]AG9-
MGLB.NH@F:K%3NASVFG"`EC1@32E,[J'%X4N:9[+P%>F7*79U4J2#BS5#DN.$
M-4;!!'0`N]FH^!M&PA$"BT,U(-VTVDV5B44HQF68L*S3R3:NI_U^9`U\(CD2
MA3@CFJF0U4\(4"EV@[=&VQS<E!I"U4;-3IW/)=:&K&OMASV,(8;,9G4<'D4B
MC+6S*(\VL[FYL:4\],W,2H`#VA"+Q!4)&T8<81D'`(+SDH`,\#)/CCC@..>-
M[`;`T_JY44XO6]YTQ5U6%>,3A()+)G]82E(+3-Z0Y7AO;4XQA4O#\Y>1E(QL
M#86I=GIQ,(;VU*H5'%EYCDFO71Z<]>-&N3Y+[3E[6W[,UE$KHB)Q553YV#!J
MEG3^3%(K8MSFLK,XIZIBCQ*5!$>2N4H/3X$Y#QC)>$V,J,!+_P`@_P"JKG^[
M.Z'F/\H1*<]^_P`FL=N?@^?O[_P=OGYD3'>K_H9*=Q%&C;-;+HIN\N8.M:HU
M(H#-"JO>K48F,B2OE5L5KC9\09UL%I852=S61Y*["-P2<662:<I&$C..W54]
MNYO0\SC'?'VPB4>W\'MUBMS./K]^/HSP)O2_V,O\0/Z..;^;"_V,O\0/Z..;
M^`Y\Y'X1-T]-AMU^OM4E+TH?`'B87UK5"I;#&>2S0AH2-+#4A,Q^.)TH`J)4
M!9LJ2H^ZJ69*40?Z^"'PIP^D#.QCZ-N<]L?5C'TYSVQ_'GE1K7-Q1;-=:B>[
MUX697-3'O)-NGE49GHPBB`PC6K4*>RB?KD.3LB.`-;9<P<DZXTKRTJTLI./`
M1#*R,03@70S&L&UW2\9!$DEY8UFP;2:%"3X$)`V[7(:+):<)1191*;`B,A3@
MP`L`2@X"``0@R$/3-G+XI&&]1;1")RZWZSC$I01W9$I;&Y!-H^T/B0V7P>+)
M(H6I;5RXE2G')%1)J5B`>`LQV4`R2W@4F?<\]MO7I[TQL+=4+OR;36_VB=U\
M`G$.(@EV3&&1=@,]",;7%2WQMH4EMZ=5(&TP3?(E!00&O"/`2%0A`QVYE,]T
M_5$E?TTKDE9U_(I2C]"]%DS]#(T\R%/EM[>KQ$O;BUJ7,L2+(<"2B`J").+[
MHG(,^W@UW^HCX8=W5[>HEH]GOCV57MI]/_--;8]GT?AYUO8.,Q^;=0+62$S!
ME;)/#I;JWM_'93%GU&0YL$A8GE54K<ZL[RUJ@&)7!N<4"D]&L2*"QDGIS1E&
M!R$7;G9+K_;$M'O_``KVT_\`E%;?G[^WG\+9_;*]0?=][KM9]/\`SO3WN_V\
M"@7L3L/N_P!+7K&K-?\`6N3[*1/2W6JXS$]>UXF@3W9[/%-5I](J\LN\8O!P
MN,:=W=SK5.I"::C2M;B:4QA0H4C>K2*/-\^W=$^J[TY[UZD>L4BK#;ZG9&BF
MNLMC0".D#?%+2Y*IY.[.K<^)PA4W/*%`K;)6[X2*B$S"Y%)7#TI,8E$1@_)8
M!R$V`46;U.M>`&``,(].ME0"P,`!X$$5FT8'(<Y$'.<AR$8@Y#W[>$0@]NPA
M8S4AVJ^#A77/NMLMM6FMEZBHQ#9TR?\`<^MC&:LU[@OJW-=3B#>0V@B8`(HH
M\/14K<"'E,6(XAF<`%*<N7@.4&`$%MUUSC/59B'M_P#<!GF.W?WYQL'",9_+
MC.,_Q\\J!K3KXFZMA,]3TS7),W.U,=+7-E9<80@?1V2?=:-@-G(UF`X\4I,9
M3!M8WW)?K/*$8TGI7D"R7RD%+^JKU=];^MB-MV$M.<6*R4G;IU*6>IJK6LT3
M%*]96>QVATGBZ(0-NC*^0B9WA.VDR0)S>Y+UR9R+"0W.YZ7!11UI*I.MQTQ+
MVZI5<H:NV>:Y*LLK6A+1$-+%`;0:,.EL/URHI(UPLX3W#6X38Y'-@!Y,.=`(
MF\A4#*,]<!5G!/`LG\<?[_5QP''''`<<TSGMC.>V<]L9SVQ[<Y[?@QC\.<_@
MYA/2V[+3=-[6'02.@MBH+)*M*2'3:26##8VSPQGP])37*(@$[MTP=U*D<R:D
MY[FPX2(%`<IBLX<AMYP@E9#-GCG\CCBDY)J@\P)1))9AQQH\^$!910!&&&#%
MGV!"``1"%G/LQC&<\Q>IG=S4S8:9O-=TE?M<69.(\C5.#Y%XH]X<'AK1HE($
M:I0M2^26(D!*@P!8O%GQ9\01!"(&<"X&4W'-,9QGY?9\N,X_/C'?\G->`XXX
MX#CCC@....`XXXX$7/46-G4(/J:PJ\B]?.B$QRGS582=V;:KQ*Y4\'UZYH:4
M0'*;&$WA=8$R6.J;WBQ42%W(7(XFC4+2P&)TYI0G3GBMF1!=:38]3B&S^NSX
MY4;H2_L<AKJ3.)MWNL?<%]X$,Z^O&]L))JU`[GM+7`$3VF`M2B0/9:+`D(0&
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M.<["Q3!2UGE&';XA$1X+WEK,/2GM`W(;4!:42>`X><YLU"``?A\80B\(L##X
M@X%X1A_O18[XSV%C\`L=LX_!G'(0^O\`?>05W^_HT0_UEX)PE,[RZ<UY=?\`
MA`ZMQGNH=3Z<QE6$,LWPVUH#6XM`$U44I4P5;-DTSM!8`23L8%(@B484%KQB
MS@H"=;^N]\"QC,Y3&SH8^S-3$UDX3MK*VH&AO(#[,$HFQ(2A2%8[>SL6G3E@
MQV[>P./9R":\%BW8?K[:BTT`"A=!]%]2;5VNE2<0\%H$]GW@]&4_6IXLE^(2
MA4B8FV2*BTQXB\DA.`J++$'/CS/;C';&,?)CMPIQQQP''''`<<<<!QQQP'-.
MV/DQ]7->.`XXXX#CCC@03_"5_P!I5W:_[KU[_.U!N2@Z8?>AZN?O>J;_`)OV
M#D7WPE?]I5W:_P"Z]>_SM0;DH.F'WH>KG[WJF_YOV#@9+\<<<!QQQP*OO4#_
M`,92Z)GL[_\`$GM;^#O_`/8Z;^WYNV?P\M`A]V/HQ^;E7WJ"?XRET3/_``4V
ML_D?-^6@@^['T8_-P->...`XXXX#CCC@....`XXXX#C/S_@]OU<<XUY7&M;0
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M!)+`*,C"_)HP,;$2XX4`:Q"28*SP5SV>B\<<<#$S=772"[)Z_P`]B<LJ^,6M
M(V")SN35*R2AL;W8ALMG%?2MAASXUIG;.6LI\2*WL9#6N7`$6@4J@K"Q$'$E
MJ"JBL@Z8G4DB^N\6J6'ZL#G+AN%TE=6M";&<5-E06.#U4M*G[0>I/*)%9B=Q
M<3QR"(&160*%2-5#C7-28]H"6SRNX@F9O.^_W\T\(?9]SC[G^]]F/9]'R?DX
M%/RJNG)ONP;9T!K\]4`V(=>-=>K%/^I&/;\-AQ8R+S>NY'`/4S%7+5`"S139
M)8!KZL6(W0A6FPW)$:5*J$I$4#(AY,=0/6F45QU5^E)?#GM!L394?MO?^2)V
M?7R?R2.N5'U`(O6*Q,B5U<QM\:;'MH5"RUG`$)T?'<`RW9RQX0"$`6;-?;'?
MOVQW^7MCO]?OY"!U5>WZL[H>?+]L(E/U?J8[;[_[."^_";TO]C+_`!`_HXYO
MYL+_`&,O\0/Z..1@[SR;;>*W;J2QT-L;%JHA=[VR&FI/'GRB8_92Y"H30&Q+
M%43!L?G62M1V%2DN(H8^%C-3%(223SW$*L:G."PA_;J`]4_7OI_1^7!M<BS"
M)4CK"4S>'GM-06!)H.]N[1'']X;F(^:LK0=&TR[S&7)[JC4.9!C8VB"M6C3$
MF`,S$WT]M'=ZZSU8Z9$JJB.:S'`B)TMW$MX=Q3*U6*P)1;>U[#.CITU921J)
M/K4G31R-6"SY9W-<N5K%JIC*;525&FP)0./CX5[U'J99!4MTZI:DMD<]9)E3
MUR7=,XRU,K5%)!1DK:Y-'IS&H]VDY3FJDL@0)U>/5!Z1"S$EGA1Y?3,X.\%W
M*MU,>65]!E<23*$<650Z+J(VD5EX)5)F`]A;S65.I*P,S!9Y#8)*4<7@P>`&
M@&'`Q8QXLB[O7N[B7X_`#S/#@SP!\?@SG(/'X<>+PY%C`LA\7?PYSC&<X[9S
MC&?9S?QQP(QKYIG>24[KTO>-5"U9Q3=.L,LC21LGR^T2+)>$%H((NFG2Q0)@
M;SXXG5,QK`9F+$%C$2J+/#ET&`>18!V>V>^>I7J#G_\`;KM;_P#.*>QC_?Y>
M2)?1R,BV:?W;D.]537M"&?6(VE:MC$QK].5*)I9R&S72-6@;!U<N>36UKA:Z
M,IGE@41946P-H'0U([%*"!KE[<+`@@#ML\_;/-=?WGNR?\Y]%<V3/]M!HW]Y
MQ>7\Z58<W3S/_*>:[>[O^H]V4[8[^_\`XSZ*[?Q>_P"?OSI4PC^W"SJ(U];K
M1K7%U]&0VN)?2:N?GW['D,B5L\[D\,E!]A)J_%%3504L?^+RMN/C1SOZU<3#
M2U"12`KV8#N+IVQU68?[`^S0*=CQW"'(O%^J"@_?.!9#X_F]@L8QW[?]+/>G
MMU$^E0GT"ZKRKJ@QV=O%I5G6]L1GJ#7S5C3#4C))H+43]?J*'S0V&GMJU6DE
M!,!4NY<E<P&-C,:..$K3<%8,2FG&6OWBYJ@*ZO42B1MJUP5*@:1S.'#C!DVC
MH9`&6J[XA2])&!L^7#TT$A4H"S%J=F$4%R-2%F*`)1$A\?/1I;%H_-NHR[0^
M6LR"0Q25]/.01N2,3H0!4V/3&]7NF;G9J<$P^X#T:Y"I.3*"A8[#*-%COC.<
M9P'[J^ZC53VA?<=H"$57L>]N<LA3#:,<LDBHS\4T\51*^WQ9M%%867WT0V$O
MA@RR&]QPA],&H,"28WE&8'@,@O/G3],CJH3O3WK#%]-U#`R[/IAEOF;:$4?(
MI/*UJ68T_1(;WDTIBS#@9*1>GF9,-<E)K8R^ME*16FCN"FX"K/HI16?HK^+'
MRX]_;W_A[]OS\#7F+T1W7U)G]I'4A"=C:<E-OIE[JVJ*U8IVQN4T(7L65&'A
M(='TZD;@4>W^B*L*0&$AR7E.=[_+%VX*([[ZASN[5VN,2NZ.O5W-KDZM*^O"
M&N4DO"1<R#4E.)9QRMA3M@"2C4:LHA9E?Z&N-3'%H%"DPL0<5SJ_Z\?2/@O5
M!VPE3[:&(HD759656M<H-I*4%>L[(J&46D58#2@6-4<4O2E<O-=FM`SG^C8!
M)%(@DIC3`DE9R$R%'V;N&LWDVLJ^R[QK*64GKS$ZXFS?%8[1`XM,WY%;S#,W
MYK9U$O%8;LG3G0X,;(1^G@:3!2'!PCCTK<(60EPE]*/X0!5.YG5BO:E677FP
MX*OV@PP)XX^NTJCSNEC)NMU=2)`YY?T:-.G&,J3$I#SD8T!IN&\[)1!X3@B$
M<&"W3'JL;]]4/J?S/505XI-?H!O3*DU=VQ/:EJQ!';70TE23'8"UAB\3='C+
MJO@C_(HFI41V02'];=$9S@)1@\@Q-Z$?,.R=&'777_8K;FSNEE)&RE=M=(04
M?:6OBN4VP_VI%I^V+JJD;M=E/V1'WY^>SS6"U4A2QB<Y`4D&XQ-R5IQHA(4`
MSD^"1=_"WZV;!40_GO*!@N2KI$XL+0\/CVTQZ>1=^=6QH8`&#>W!8UM+FL7E
M)6K!1@5YHDWA3##DLWPC[!Y!WTV^I+T_-H-W]^*[I2]8=,9)<$EB,Q@S0W1V
M1157)X+`:3C\9G[HW.2]B9L9(8W5*O`K&:L3J\EEB=4H3$YGI/($]/.L;']L
M=@MDZ:Z?VB47B6\N\A,+BT37SAH@4=J/7AGCM-'Q6_IO()-%P#E#W'F9T(=)
M*U1UK:$QDN-R@]<_VPSE`K_;HK\%A8FC8;;]JF.X5B+I'0D?'6C"LJ4+Y3*Y
M\L*W:60RA.^N,M9GE:[(H:TNC\:@=8P4B7D29I`-.YA"G,$F&58BZ:%<:Z0W
M:;J%G4M/?CE)HI:3=$:V8';8J866VML&655"Y0X)&AE>9E)2$C,;.5BX*YZ2
M-ZQ2A.P>B+5`\H:866.GVV&S]Q6#LJQ;"T]2E1P?6Z5N<!?I7#;6D<O5.<G:
MV-IEBIQ`B>8<P)444)C+N0I/<%2LM84K*.*RDR4`1@:1'3`^#]=4J@-AMMII
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MEG'@`6,S&0!%D7LY1`Z9_P`)]U5CT^W>.O\`UJ3U)%[>=K)V-8!1$H,R/D3K
MB*Q9B34BN;FZ(D$^7(2&@\Y/(W<:6.)3U:DMU*3E&8,'G[\'0ZK^L.V^RVV-
M)U!J2;1DHL"6V3LRAE2)/`2D2&OG!TB+.VUBM%&VUL<<"959XUZ$"8)C)W.4
M>6F2&A"(X+AO'''`<<<<!QQQP*[&TFWZ:F[KW28YXK8%4P8KKU+0TPU3JC5$
M^R53\H8HC]EM5&%14,<\NK*2`V1J%J_UBJ"P.(#Q!]&,"$O,S&NUM:U6NW2A
M7K@X1!>VLSBB22@42B2B*$EN"A.::APK*4,3&):8).`W)1P2U&"P8R'(P>+&
M,^#[4[ER369]<5<AUK=7ZM&],T%%7,\VW2U?0]4XNY8\F,A`9W(F]X+5)3L>
M0=@27!)HA>:#.">YF>Z:9[<,&V+).G9@A39#"X4]-C.L3-ECUW8@5"AQ0#7!
MRK.KYQ7E,RDLD(!80O&$ZP\@TI406),8`P89I\<<<!R$7K\DC4Z2ULG*QW,4
M;VZ&$%XQ[\C.V:@18<8^?(A8[?/S)K83JO:5ZP;*P?52W;#>F>SIE\4,.*UL
MAS^^0.LQV*ZB8ZW*MZ<MR4YBKDVPW@`V^'@?SR,NIP<&8R4G&`T4;?PG/9>N
MJ.Z?I7I$Y@Y5OQF]]9KK@U6NDH:VZ931MK6ZH^^J5[`PFJ/6KBWHE+6(2IP2
MHSTB7T<T1X\^#)8@]YZ4Y)5W[;=6?=Q264J*FVVXM2JX=<$'`P=6FGL?2PU2
M>W'GX_76UVG;U(CC1IA93&+V]1G./-`()<Y?(E^A[&8?'^F;K@ZQ:5QJ:N-E
MM<INFPY#%)"1*&Q1:=R2YYL>P$)SFF&87AV97V1&LKRASX!-SD@4HA%EY)\/
M)9^^/G^K/]'`UXYBO:.\>G-)3%QKVW]H*(K*=-*-`X.<0G-GQ.,R-O1.J;*Q
MM5+&AU<DRU.0N2X](2F&$A"<3^N`[A[9YD9&Y-'IC'V:5Q-[:Y)&9$V(WEA?
MV-:G=&=Y:7`@"E"Y-CBC&:E6HE:<P!R=208,HTL6!`%G&>!SG'-.^/G^K/\`
M1S$!ZZ@>CD=F3A7C]MQKLS3IJD.8FY1%SMR%HI"@DP5A;>)A5M1[L!6G=@KC
M`)!(3"PGA4B"3D&!Y[<#,#CFT(PC#@0<^((L8$$0>X@B#G&,XSC..^,XSC.,
MXSCV9QG&<>SGY7!Q0-*!:Z.:Q,WMK:C4N#@O6G`2HT*%$0-2K6*U)V0%)TR9
M.48>><:()910!F#%@(<YP'[..8B0C?S2*RIBPU[7VV>O4TG,H<A-$<B,8MF&
MO4A?70)9QV6]I:4#J<L7K/*3G&83IRAF9`48(.,X#G/,NO%C/N[_`%9_HX&O
M'.HSR?0FKX@_V!8TLC\&@\50#=)++98ZHV&.L3:6864-<[.[B:0B0I0FFE%Y
M.4&@!YA@`=_$(.,^)U-NAJ3?,J%!J5V3I*U9B!J5/@HO`+(BTI?@LZ$9):QS
MRUM#BJ5^@I1J"`*%/E>64(XO`\X\>.X9-<<T[X^?ZL_T<=\?/]6?Z.!KQS3O
MCY_JS_1QWQ\_U9_HX$%/7OU+ZA&\NJ2?5S20VA"HE:JU2V[!CN)W=&)Z#&V=
M<RR&)_$1V1MSJF2*Q/K6(+N-0A.-$DR`M/X,#,'C-GIDP?<JL]/:PKG>G[#_
M`-G"!(00P&:2/7JH=F"1A$B9H6(]0O3I!'OXVI&$;R:G3$I3%`L"*+!W$'&1
M=S;.:[ZZA817Q=U6T]B4C6EQS[)$W8(?E\&W!*&O"U!>UJ3*[*,)Q.5/H^!X
M)P:7X\X\8>_9:FNJHKXBWQXI:RX/:L.]8*VGXSU_)6J5L6'-#Y?IC?ES9E*M
M)A8EP:7D]-DS!I6#`9$'&!!SD/3N.:=\?/\`5G^CCOCY_JS_`$<#7CFG?'S_
M`%9_HX[X^?ZL_P!'`J^]03./^$I=$SO_`-2FUG\</F_;/U_7RT$'W8^C'YN4
MI.H15.T\ZZM49VVB_5UZ7M.N^IDADD)HBM[4?TJ*P*LALV0803>*6+&/BVM1
M/TG6)'9U*P<ZNPCBRU27*4]L,`$95T*.*QKH^QK37)`\FJV=K5&.[3V$UN@U
M"!.<-Q;A%Y&#*!<(>52/(!"#E,<5X19QVSD.:XYIWQ\_U9_HX[X^?ZL_T<#7
MCFG?'S_5G^CCOCY_JS_1P->.._'`<<<<!QQQP'&?9C.?DXYIGW9[>_MGMP(:
M[[Z@M_1O89375.PJ@T=>,%C277Y]67]+)5!INX7*VTH[WRUR]O*1$Y96:@5$
M99Q1D$X<\*UCQ(#G1Q;4X&J,K0*I/J+M9OO.FZPN-J87Z,-UFP:-S9%'I0A,
M;G]G3R)L3N(&]T1F8P(I2F\[)>18QX#R\%J"_P!;.#C%<;>"I8-L)M%LQ,]D
MMF-3M<)!0:QD9-9H1LMK-3$\F#Y%&V"MDL2V.WR252!IDMB5W*K!5.S8P,L9
M1.4@:#V>31L_S%3JE;S)6^FAL+>-O0B85[L*@4K[)J)CI=R>YWF'MD`(>5-R
MUHBLD<#=(:Q%Y8(]-:E+7$QB4-[.J&1A*H8#UB%L<SER;B[_`#[3KWG#/##Q
M&&>LTSSDUXXXX4XXXS[.`Y"!U5/OSNA[CV_MA$IS^#M[-8K=_+W^3M[/?W]O
M;G>6#K8:K2#>4>CY4/O-`XJ;?D^N4?V$<8`21KA*MC86SX?932##/0NYBU3-
MFE#GR\@-92FY4MQZ(E6&B^ZYA%URY(]-&Z/1K"T;5UA0?HFV$G=L$3ID@SH=
M#%.:=L1'BX73XT2)F,/B6$(ET#&@<<M\=$_.Z!3EURYDD)L!9@+_`&,O\0/Z
M..4-OA+_`%E-R='NH?0%24@74X(C44(ANR41S,H`;)7118\C;[7KER&Y+A/;
M?E0PACB]40F;4($AA3A@"T:TPT@LLNZE*+TK*EZ+46[;-L0_,.A54YL666/A
MP9&YE?(TQ1P#L[S1G3)W`:(UM>"B3%S44U*%:,X2U(D0'GX,*R*IY6#E7$TV
M$U(ZD'4$?Z=@U];Y[=HGJCZLN9UC32^4=T^8Y2MSME%PY7&94>%.VAG,F4I)
M](Y&K1)TRF22)G08<QN(CR`AURSN@]4.X\MT-V+W]ON^]@MD=VI`0MNF5Q]]
M9:[A<;AZR@I-:L4J^K(:1'5_Q.BD&4)$;(VC-4*EBU/ZR5*DZ=8N&,-T2,1]
MNB<;8(NT!.`TQQD:6%L`H-R>>!O9F],VH@''BQ@1QH4J4K!AHL8R8/`AYQC(
MNW*MW5>ZAO13I'<W7J#;6#N:?6\!KBJ]!,*&M:>-]=:[QU<>YM,<E,H1PBUH
MHRH%S@B6.85X8LR/<E^*F0GNI'JXQO+.SDVK^$+=,+2VS8'4%EV\[2-3,XA'
MY:QR^J6]!:L$31MX5+&Y&L>I5'']<-$H($W&&K4JH@3C@@PA5Y!P5`1Y)E2L
M[:5E.1W^GZL_T<Z"]VO5\:?T\4D5CP)AE"O*7"6-O4QCC4_J,KL^%%@AG7N2
M=Q.RLSG&$N"DP\J,^PGQY]G/G&]4[JY;J[`=46J7GIYR'9F-:\2'-.Q>O(W(
MB;<I^O-@'LMT+`[REW8W%4T'ME?/2IP*:B)`%,P>GL"$Z0FX$,>#<=ZZD73"
MZ_%P=3ZG]FWB#P&[K$B2:J'E@L6BHX\1+7NO%$/>SWIK@BXV89'(WPA$:$*6
M32AQ;UN7$I9X5/HZ-*0225]'?CE$[8KK_"K#J.5!4VX,<Z@6D+I&EK9']LZG
MB%KU;)*?BLD6HXV97,RKDIL8'5ZE]2O2$Y3+YJN*4)79Z9'<LMG;EZA+D)V9
MMJ_"2:M(ZF=/:OTWM#KK)];+->HLW/-KBJBPG1L@3P]#94C;"'N;CE3*A6+I
M:N4KBC)<W,&8_`C%;24_@4!(=#$P3_3+3B3RS;&+;4$;/7#'5,/8U<09JN:6
M>M#(&7!WU;&'681<\QPB*J1*"92[Q-I7JW0YU&[MXP&$-:M*GR``<YN1?SC=
MJV6+?&M-2(PS:LO$8L^&NUD,3\[;"*FRSS(=%5D5;I&016R2).&5TE7G2%8O
MAZ1`XJFQZ9V1R6J')'Z(L`G[[)MJ=A&3<V+:NH=:8TYP^6QAZL5NMT=X($)I
M5=1=YC,?D;HI@0H8<YXD"5RDA`4#$4YF)UY)/F"=4_CS@L,NC*:J$Z4_'DVK
M*X,FN7$#QF7F0:+CE&78L.`%NF9`)JR[^L2P!"`"[TSTH`0A"$W&,8YCDFZ?
M.KZ394S;<F(2?%ZFN:IS'+!V;8IB+(E@_./;\18<E%&0L>5.,*P,06O#26KQ
MA2!($[&!<X=5U!:J2;3$Z@G57M'FTU)YAJ9W+URL<VL5$9(7)FM5/RK)`VYC
M`Z_2.JQ*U*I9A5ZM)<#RTPA>(6,\RS!:-:F2G,'+L*#F33!QJ;,0!+8^.4X4
M$E^<<GS'@N.7CSRB?UTPKT/S`%?=B#@/MX2)B:TZ33U53MF.GWTU]B>IC<,%
MJ==&M=MHGZIFZ<5O?%7))@SS2![W,]T.LDQ*BE`2`1EXD1S<D3&S*/G#/1NT
M94+3`EIE@R5I,=6L_P`)&NZLM]B=>-VGO92R72OI"_TE84.UR@55S:,2V^(1
M+99%GU^AD/9H,AM%[@LG;FMC/8H@S.>)(@D)K@K&L5M@PI2[^OH2+!WI.$B?
M"CQ>9Y^$Q7G^+/W.1>9@OS?%D/<.1=^^<>S.>V>5$:1Z39,/Z_=@W.+6_4QK
M8(RD0;5M$H9;?VH6SUL/L.S[-;D=@H(\Z9#"E-MOJU$H*E\-<3!U4SH`EJ(N
M6-6(>,E0?:^=:;JU;B=6M]H^IYI$]?GC9:9BUU0R2=:TE#EU/5'"I58+]$5[
MU%%RI4<WV#&6MY=BG(;T<H1BD!Q9#ADHI(683+/T^?@[%1ZQ=8E_LAPV3LVW
MWC6N*UYL,ES-(3$T^9_-[N/M!D=1R12G,4%$@:'!I,?T:E`1A8:YG@%DPG*?
MQ9D0UVT0L^#=;>_[F>+W2OT<353!;,Q!2VA_3G`:K#FEKMK4QA5G/IQ8Q,QK
M68>J.4$'H%'FE`2(4HL&^"5^N-":PK'925[5,]H;'O5F3=N+992WRVY)#(8*
M[L"%0ZJH_'U$05I@H,,T44/3@9&$)8P@:LG8\(C?`'L&&>J$UU6<.JMODV0>
M2T(LFJN$:RIHTFC"F!BE*Q\9XW8Y5ED,AS8##BK=6Y6<F!.$[<>:L3*!$`?2
M@&%AP7('%=(-1J\DDGG<"U^JR"366,LG99%-8G%6UAD[@V2TA05(RCWM&6!7
MGUD`\X:@S(\YR//F8[9QST^.,=#)Y@H41)FJ4B>IS'$Y6?'6^%ER\DY2,7K4
MU08UDX?"S5`Q#]8#-R$9H\B]*R(61<].(=FM6>-*F<$*E07@?F)TZQ,H/!@`
ML`'XR231FAP`6<!'W!CPYSV%VSP*BG1_Z9G3`H+J=[4SC66T9/*+%I,;>Q48
MWNUFI90B''[!K?S+7=Q("&)K%+LQF3K3V0M3Z:8G:!@]&6X4+<!48GIUHT^O
MZCKBOVV9OMH7;N;_`#D3T_QHZBXE!T33+6"/(HE$WIM<&1^4K,HFB.-R1$M9
MC>Y3NH`-::I3G#SS/!NB,395HW-HC$?:G$T!A9K@VL;:A6F%G#\PX!BM(D*4
M"`:9^N&!&9X1C^Z'C(O;SD"7II4"/"0Y(#Q)2QFJ0D+4IXDY8._C,.`2<8(H
M`.V?$,80A#VSWSC@1V:F:D[/TA:^Q5@VSLU!;-:MA'D,R=&6'T:37KC'IRDC
M;-#&IW;7A3,9,4<VH8VQH@C:ES>KRJ=<#5F*@D#&F%^FFM%$U&!V@>I_>=O[
M'Q/9!)*)!;%<3F-0`UO?W9UCA;"]G,;?"(LQNPE3M%4!,=(8$2H")1CRLD)\
M+1A-QF1$;UI2?KW1K@ENUE-7-C1'.+VVQ*=1F1KV9`F'Y1ZQU1,[FL4MJ8DS
M[@TY:40``^P<Y[YY^"NMB:$MYW<&"J;IJNRGQI1>L75F@4]C$N=&M#Z3A)Z4
MYH&%R7*D!/I6<)_&K*)Q@[(0?WPL8R%<OI=]/G1&!27J"G)^GA>=),L^-LF.
MQ9TM:GK.CAKYJA)8K'4CA7\(5OKN[KLO+@]HW]1EH;@E2XXL*+)!XPX(+#S7
M0AT7T9U]NS:VQ:$UGV#IZPP3N;1FOY+=<-NR+H%>M#LOCBF)-C$=902FI:XJ
M'=M5GN0!`,DX2$Z<:T04_;O9[\0?_P`_^:9_1QC(<>[Q_EP9G\^,\#?QS;XL
M?(+_`#!_^GCQ8^07^8/_`-/`W<<V^+'R"_S!_P#IX\6/D%_F#_\`3P-W'-OB
MQ\@O\P?_`*>;L9[X[^W\N,XS]6>V>!%AU2*CJVQH163U8$O3-+O'':?QF*P8
M<"76PZ6:5:4&5PZ3LL2K!D,`_P`IG3`UC(E<0/;L"3,SNTDJ7GP-1J@P/$],
MJ'*BEMPV:_35C,F<G9ZG@4KK!OKQXJ24LAM4L+FP,=EVW7<DPF?&:T;185#>
ML=3LHL,IS0T-!+&X+DA&0)O.^HW7=NG7CK_/(#LE.VBT"Y4]@U:H.N:LJUSD
M;U*TT)4$6L)=/+"-`TI(6LA@S%TO/?!%>JT196&8659F.>E].IID**S=EG6^
M9O+'[;E[+JPVT8;.X_`FEZKZO$3=($M7((Z[UB:=#I1!'L69*ZMCD6,3RF?A
M2%O=,A]'3AP$KW&<=\9Q\N.W''`JT=1'IY[QVUM#ME!:4J6"S:ANHX_Z&R.9
M;`/4\;&!1K%G3B5@<Y:BD,"6)S'F?#F;*26;#!QU6G+2.1IA*_&?+SC,9'PI
MKI$;Y;A;3TC>VK546!?4$:J2BE6OK6RN["JS"90&=OA1)#%%C3DCRC85R-Q1
MR*2O`A+F]$I4*U:E2D3D&!Q?.Y7LZL>\>\]3;#H=?])Y#2]?*ZKT?N/?^UI+
M;T/7S<%A12IY0*-HZ78$:)0G^*QDD&A<#G&8YR<>WA.2>BE]RS?$3?KA'IC[
M5EAKTA^A_ME4.C=>P2\MU-X=1;%;I382UUI.D+=KP-=,25QDAIK8Z-)((E(L
ME*G]&6!S<\">%&1JS1#\HCOX1R:9Z15JYQG_`)6_J>>[/_M=@']7').M9[:.
MOO72AKP4M)3`JN&G*TL]4QD'94D,ZJ=PYGDREK(49^Z4$(#W(Q*2>+L,THH`
MQA"(6<8]OX5\T/J\?!S.J';N]%H3NC6BU-LJZ=8_``M-W7?:==*["DZM#$42
M%T;W(S&(WX26-<F,;6\H30E\"(!'ZZ?G.3,6A]0.C/L!#M6->HE.^I1U$:@F
M49J&$LDGJZ"V_7HX;`GM`T$EN$7C&00)<'#*T'Y$D0A].6Y"47CNJ-SG.<6-
M.V/DQ]7->"[X0M%](VU`&%C^VW=3W/@&`7;%NU_C/W(L9SVSFMAXQGV>S.0"
M[9]OAS[N4.+S^#G]6.0[_P!JI8S1UI3:$*K=<+!:=@)5-81Z7+(>OL(`2)2O
MFOI"9J.L90CSF0N#0!`4N(,"):)M$1CPF?5LY#&Y[G;C$]7RH-39%4T8JW4>
M;UQL`NBDD=79ID]C7C):J9(4ZG3=&D;1YS74$:E4E&SLZ!>8<]R-6F<%JXE(
MDPB+X'%H^D3;`4:,!G5IZG*<PM&C*,(+MVO\EDC*2DE"*+\-<9Q@LL0,@!C`
MA8P$.,>,?]_GH]L]'JZ'>JK.:&3JG=2F7/3M74W:VB*/=OUZ!EDSHXQET1M\
M>>!#KPD.&EZ5'%-CCW/3XRC5'=U!&.Y@9Y\>W&,_+C'->!\MWI[_``:_JPU[
MNSK?,[1KF:4!7L:L]L=)7=%6VC79$_KEG2IG#S9-%%/GN^`NR8S))2806E?X
M\*!]DN>_<%WO/2+M3.<Y^VW=3P/?.<]OLNU_GMW_``=\5OC&>WN]F,8^3&/=
MR:;MCY,?5CFO`J_=1WHJ[,61H[LA!*GZ@._.Q]BR>"ID,4I&U[=KO%>6&Y$R
MF/.&664X-A3*$2`M,B/<2P>MVWQ+4*7&56,9\L==/H4]`?J50S;@^S+V:]D-
M%:^35]:<2S:M9S&&0RT!O_GM:!&QEM[JDDBE5$9(("@\*\MIRF<2D!"I&N*)
MR`X7T.]EG6^66AK3<M8(U"9?L`GB2_%41^QWLV.P59+SQDIT)\H=R2S34S0V
MEG'NJHLL.!+,(0H<&D^D^<7&=T>=HMJ-BDFUS!L+:%8;+1:D;D:JZK+:VG*Z
M5UA7=K.9441+;5B4=9CU2Q%(4E1S8P^)9FC&><TO9GC`!2>H3'8*%\4OE_+[
M45:G[K?U//\`2[`/ZN./M15J?NM_4\_TNP#^KCDU''`A7^U%6I^ZW]3S_2[`
M/ZN./M15J?NM_4\_TNP#^KCDU''`H#_"%^A=OK83+04JUWL;;[J$I(63+44L
M16_.87,9)!!/SHQD-?Q)CK8RQ=Q4I700SE4A.)*<?14S>6I,$624/RLU.BET
M*MR*2U'>(EL%MGN5I;.5=K25Z*JC7ZW*\+@ZQF4MS04BE2@@$:D^2GQR&4>E
M7!RY!QY2%.+!(?%X2YQ>K39.Z%142KM#4:W:ZJM/5L6GUE6B2ZT@_P"Q-LS9
MEBK(!0Q1:L*R9UJ`@Q"K=QA%.Y,K.$.,Q_!CJ3C!:8_`\L-%;NENR>G.L]^3
MPJ$DS*WJ7@4_DQ5<O&7^$`>Y(QIG!PQ&W7.<B4-WGF"R`L0AC2&Y-1#,,$FR
M,0N[^6`WVHJU/W6_J>?Z78!_5QQ]J*M3]UOZGG^EV`?U<<FHXX$*_P!J*M3]
MUOZGG^EV`?U<<U#TB[4"((OMM_4\SX1!%_A=@'X!8S_U;YQ^#\.,X^;/NS-/
MQP/E-;Z_!T^K#*M][R(KFDK5O>%3Z?3.8Q"_IS,84XJ9HPX6E"+>K!F!9[2U
MMLR>/'YV&M6@;E:L6<#3I!`+-'B\-671^N9MK6NFQYZJ/4JBKNUP&%-;I&6:
MWJ]$T1YQ;8PU(5S&U"+KLP&6UI5)SD"#.#3O[$3D]SS\]SC."N/JOS,[K$ZJ
MZ&4<="UE'?&^P:UVMGCB8QJW$5U@IJ2V7#:;BX5#H6ZM[I'VMM9WN0NB1N.)
M4N#RGC'G!6$&IS9^\>['?W]L=^$^,+HA8^U%6I^ZW]3S_2[`/ZN./M15J?NM
M_4\_TNP#^KCDU''"H5_M15J?NM_4\_TNP#^KCC'2+M3&<=^K=U/,X[X[XQ;L
M`QG..^._M^QOGM[._M[9[>_MGW<FHYX+M/8\QJ#6J_+3KN-*YE/Z]IZQ9A"(
MJA3E*U3_`"Y@BKHXQQJ+2G&$EJ<*W@A&68G&<5@XO(R_&'(L9X&#72<BVV$`
M@NTM=[4RV]+`'`=Q+;BE%6!L`8WJYI.*";D<<%!I,0YMB)O3.S.X''.GHK@6
MD(+/.+/R446''@#*_P`KN]$7=/=O8R9736?4#F#W%MA8/6U53]7K=*]>([4;
MC%8U8:EXRV61%IG&I`])IS"9"-"8QITCB4@>F9R0'8<$I)IGE!L1<$8[=SCC
MC@....`YIGV8S]&>:\9]V>WR<"OO<LRKR2[-;(,VW-G[=P1]K&QFE%1.*(H>
M<2>NB:9=()%Y%'W*/S!KU[LY$OL=),1RLR;*6N0EJVM03%TPDI)A!.>3?U`"
M/9K2$K8NY21]9W6,,;HED<U0+&V;R8M8UI!%2":IG)G8'3$L=$X"3WP3JS-K
MEZ;XP*T28T&205^MT*9FB39:?3^Z%&P%L1C$W>U"")T=M$Y50O6:RV=5I$5B
M3%!JX:[NJG!=R:]W+&W"7IW]2A(3NT1L=U?S'Y^4L);4U3<Z;L\_CVJ>N[%:
M:Q*X6(STY`&V8+4<A,EI*E]1QY$0L.%*35SH.1J1B`'*Q\RY.&'19Z0L"M5!
M.P<,,E>...`YIGW?5GZL]_X^:\<"K''.EWO?G>"`1-]C]1H-+*?ZJMK]4Z-W
MXDGABJPY6JL9C<BFVAU-2^@A/:W1G?7MTPOF(W'U0<W>2<E)PH"(L^*KX2)T
M5K)V'ZB6I=A5);Q!:C>:>J*&+;;EGLTD;97]F,L2E4]P9%VSU4ZE0^HSHI&C
M`EQN,A4B32Y2O6X;L^N<F`OX\KQ]9FB*KMC<_HKCG\9/?12'=:4U\["+DLL9
M?28B*@[.E8FH`6!\:P)#!/[6WK\NB,*=X\*;"+#AAO.4)30J>=0WX,MU5(T_
MT5$Z,FEH[K0U'04%BC^\R2Q6QK9*PE364>D=ZMAS3)I*C-(JMD,)(41,X]`C
M++;E!9*Q.0J('R4:S?@>\AOD.L\OGG4$N9SD3!7D#C-XM%U-15LOK.VM*!`H
M50.FY.C?FI+&HY&#%#O'F!M=$[VVI@>2[$&CQ@Q(HO!L+,VQYC9F!H3Y2M+&
MTMS.UIAGJ58DS<V)"42(@2I8<H5J<DIB2B\GJCSU!V0Y,/.,-$(8N6X%8+/P
M13H^&X"-7&-B%JGRB2SE:F_'T2A4,HDLG)YV<,_@P89@O`A!+P`D'?RR2RR@
M@`'`?8SX&)0<KN6$R36&\S::I5C1,&)C6UA-,RM&53=R3/9RR0&ESU-,8O\`
M%=(X,N4[4W%MK*H.0*"S7$PP\8P%`NZ\<""%7\'TU47F$FKMFNI"K,3HT#<E
M$KWAM!6-(W-1(4[6W)#5)!IJ=`UI@`3-R0H8"$9`0ED%EAQS$:Q^BT_M.\NL
ME=P?87JBNFI<KJ*_7B^)P+>*Y5@8]8\?S$P5`TBDN78I:Q"=\.$@R6@2IQIW
MG"/'I(>R(WSK2_(2-N]SMU*NZEFA>O\`$JUCU?ZA7%>"^KYK:[^Z1R1RV\I`
MHH><6:.,0F*%EGND$B,%.CQ`7J8+U"5U?I'@#6UIO5"=:8IO&';;G^[I2-],
MYT[^==T6][_!;8%8FVL3N!JF<SG5?M)3.5(Y7=>U=[R78M\4H436G:WA!/,-
M*XME50`:107#T11YZ12F]$*7B3@)P$/7;:^".T+/MF"+&33=4_4XN6%FS-!9
MEF7))KMF(EA+2!P?'&?)7%,U$/K5E*XEL99+9ZM5$*$07@LT2/.3+CX,Y$`&
M<^_(0YS].<8SGF[D*=^9OI[ZR^='>WP?K5J#=8FJ*;I#J8M^O\,6,:.5I8^M
MLH;QM/3TTC.8:V,=:0Z5N+R5D,JL3,G%**]/>A)')K:DSN0G87Q.F1F*^*M_
MH,=7-#U3HE1]>]06X7*OW^N)7*H)MU-+AF:NPX=2C<X,:*9QYZBS7)FYZ4R`
M,J=VQ!\76%S0,$CP:F>1K6\HE06F^B@?$8JI<LO*B-,![OD\A5EU-9FTQR])
M3`P6F4^GC2B5>>G`$("#O-\PD.,!+$'&,8QB6]:%TF_;*MFUZY]NC%MLXQEM
MAJ6Z;`21%&SJ#VQ4OBQ$*(=PQXN)NBQH0K72/!28;EZHH1QY(A&#[CO3/"]7
MS]9]THNMI4_4J9*#9MJK5VI`SUSB>))XU;ER:A'BQZ(;)<S`E=8EOSQ+Y-**
MPE+S)S26DACPFD!1#D8DDR3#@D3C4%8XPBUNGQ&>K^X0O;FNNH!I_'$K876%
ME3V7[QS&3W;06RC:ZN:Z66')K/C;(:_RROEJ?U=%LC2+BQ)4`A3P7G$&F-1'
MTO56C&H2V[`['JM>*O47J%\+D@;3-CA(YCA\*\O`'/UKDS(_2@>46((L@R'Q
ME@'X?'C`N5;(3%=P@?"28N^[`:QZ76$GM^%WBR.3%6[/"I=9%`ZQL8#4E=7E
M;4J*084HIA/\Y01=*?-$F'R5M"]\AC$G`A2%FE"8N*QT_*8Y=)K1B0_R3H7Q
M+=N30-=U7MW'2K6G7)JFZ*?P[>&_9F0[W4MF2D2F+QV<14#J8_R99"#6\PJ,
M)"SR<N)XTN!%.GB3%Q#54R;W;,=7"8TAJ\S[](X3/VIU0U@BV-V.VHJF81_7
ME+ET7UM<MR64`*>?)(,<:%7+44=$ERV.#R\?%=E&J<AA--M$UQTA.EY"NOTK
MM2&R:--SY&ZX(V+CNO#;,H4F@K#LFYV`ZQE8G:HFC,`[DX9TX#)F@KHL`4S2
M]FX6`2%M*1.@!+I")Y-E/5=M"0J-9=F6FOW[7>`T,V7$\5<E1UBKEE?V=94M
M>'(,JP_F*?BBL:9`VFLCV-#@IR4G^06E`9P4C?*F<[><,U)%1TG^L5K;OA9$
MELJ9;';:Q"IX#7$[O<W5';:>16^;5U]E#Q(&MFBM<NLC<`V$\.D3=V-[5DQ5
M8G,7*DK(::A,":[@/Q)_IHAZ76X^[<[U]KOJ8]20IA4T;6$UJZ*S+=F_:[F(
M+*`LEAMR0AR624UO.',X:WIHT!UB2P9AK:H"[#:A*P$J#"+.M>5QN.@WVLR[
M997=#-U)SNO895)#HS6A+'*PTK'6LFGDB8Y&='5,*1LQB^0XF!25:S`<R@-`
MD>3`.2W`A8,KSU!T+>DA8/64V]1S)];+IBYD'C5K,6O+[:;<K8$EKW%)9THL
MHC!\9>VV;O/Q.5,.'%JC@W$)L=,?SPO(EA*5O`4*1W\:8]-(X>6:U=.#HNR'
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M&5M#)-`F^83-Q9V`XUQ^,(FA[<E,63261`=5$>;6XM$`\IW-5K#%Y77M]EYW
MXZ\HE.GVIZ`T]V/W:9,;L[B:OL3/,RW2IK.E&X4LI%#<M7H8VUM<D-,E!1R%
MQD[X;*DKFO0L$BR-^=(N:U&HDYWEJ$I/HG2BB_1>VDV(W,KZ(;D[LT`Y(;27
M2.GI&_;F/M"G714A+:@;#7G+^4H9%,CD1#XB6N*IJ?E&9""-JFI:(@1:5<(B
M5GI::(=$8&UO46#54`UTM3)<Y"D@D9E[HAMF-Q:D!0.//<T5UTR3$MR;FV,I
M9TX/C6X2=M$X+&T"(J/E/B9(D"F'YWTY^E#T+;CM+J1PEGK2E;>;2;B=V^#(
M'"Q5TO-KZERHLUN(GRL5ACJ4JC3&AE;R\$%S!`L6J"!-B%J,>1I6T!1S^Y'\
MSG&E*^N&7?630S3K1O>J5;N0JL>J)O;,W"CKQDL4@RJ#=0BTU:MEJC,79,1Z
M=91+%^4\TCY,M%)4X94(+@RKS6W#>H7Y*\K)WC?1RZ=T?W*>=WB[@ZJ.\-R_
MJ==L;4U_@L;JS<V5150JKB&.:8B%7._*8C(W=<L*L0C#H2S^`14<.&SKC4!J
ML98\$^1:!]"3I7P\KJ;3JTMKYE*8=K[/;%A,6FE>W@;73I6%&QR%M4E6SQ_6
MUM($V9NI5&ORAD/-<R#8>\>I0MX&90K<E16/[?`W->*XCMQ]0ZW(O84C=C8N
MLKRKH%'7!4WM1T@J66F/<[C-ARR.-B]67Z^7MJ-A)`D&(TB-+ECP@$,"XPPD
MH4\]\<*9]/6M<\UA7[0OKQ[/[K_JC^S\/VP.Z_=__9[?)^#C[0OKQ[/[K_JC
M^S_*!W7\W_ZGY<=_I]_L]G)Q>.6O;B+Z>^LE(RQYG[_B#K[0OKOG.,YV_P"J
M-G./\H'=GS>WV*?FQ\WS<?:&->/P;?\`5&QW_P`H'=?O^7VJ>3B\<5[<1?3W
MUDI&_,_>R"YPZ#E`D(5QR+;CJB*5A:-6-*0/J!7:()RH"4[*4L6`K2\YQE1Y
M6.WC#C.>V!=P9$'/OG18A>RE=]-Z@X9MJGM%->S`OMM#*BKD>%K_`&/EJ!<D
M]%"CI$[N"M<N6C4PD4?4H#E*D9@FTU)GPEA\)8?1.JQ>VQ6N.B-Z6AJ7#'2=
M;&(FZ-1VI65HCJ66*2)7,9<R1A,\CCBW&4KP2S$.9Z[*)2$2<XTHH*C'D>;D
M.,'13V3V9V!KK85IW!MR6R_8:G+9:(%8-0V%K]`Z&G=#+%,.;9"A9W<NMI!)
M8G.6F<MSDEET9DB!Q$(MJ-"D.!@>,\A$1&7O]WX>Z[R-]R3(U<SAUIKN55K!
M4()M&;Y<-LD^OT_KMU2MX\2.21]V!!71PA`&=(,:1Q>0/HD#@UFF%N9'HPO*
MYW7I[15V9ZZ?I$[5O&&(4S5M;R@MENV.*VEDUTMOHZDM*^R*U<1QC.7HV$O`
M6>/(BS5;<E0`$!$6E%Z3D_&G:6+L3!86V:3;MXLDRF-GJ^B=94K8=?1.2SXF
ML8@C9TIEAU6IC<98I(-B=Y)*D1DS]=.K`I:I0W'B:S70!S1AN%D7HW!W-FD%
MN3F!-;E`M5)TCKW-%5@\,QL84E.C&TKD<_M!NA*A*C45ZQ60I$SFH(F>C:SS
M3F=3)#V1K&^>`TJ1'CCC@.1E;Y=*/6GJ#2>#3:V':V(-,H?$I)5[G)Z:L!RK
MYWL"E)LL(7S6E9^H;P&8D%=256G"H7-!H2QEG&J#"#@9.'R37C@=7A$,C-<0
MR)5]"VA,P0^"QEAAT48D6,A1LT;C+6E96-J2X%G(L)V]M1)DI/B$(7@*QD0L
MBSG.>T<<<!QQQP',;)MJY7D[V:HW:MX5R(JQJ!AMK0>&HT3B`F-J6BWB&)/)
MC'IMR0(:U60%@1Y;#@'E83B&=D8#,"QVR3XX#W<<<<!QQSRZZ8S9TRK"6QFF
MK0;Z8LQW1)$\3LYTKYNM1!$5H'1`H4KU,`=GR-MTE`H;25S<%(J>T`"#%H%X
M3##$@"#0X?8NED.Q='6A1CI,YW7K5:<1<H8ZS&LGX<9G3*UO`0$N)L<?BRSA
MMBQ4BP>WFJ`%Y'Z&K4E@R`1F!AQPZ?\`H'$NGI6"RG*[NB]K.KDC#0EA$5N*
M7H)*T5>S-*=05Z@@")`SM)+,UN*E2:XN@!!4'+G`8E1QPC1"%F$O7[>7?PJB
MK#V.OC;6,2N.0_J:M/3Q;8+`M1*XCRY<<V;AP6B#+%7R%PLX["5+-&%U7$O#
M(F0*5,0PZ&.;&O>ES2E`KRP%UR)&[V096]=]/#9:R54CM#:RBJ@?V*Q->VEB
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MQ]C3!2HD^3U`S%"D\6,#/5JSS!GJU1QZ@X63#19Y%7L=UEHI0-F634S;K5;M
MN3:"[FZ_:4,L>@<@@*5VL"QMBM<Y5L##W*.%RIT9&Q"V(R(T&)N@9$\-8"%B
M_+Z-<4T(50<\/!^LFR6?NP\Z%)]>K-KNP6UQ3UC)YVZV-KLXN%>V^X5J@G"X
MO%+KK&16E.JYBXW0#<"W(=%9)`9`Y(#C$>3&,8G``3?<<P/Z<&RTWVFUB03>
MT$K(5:,$M.]*"LEQBZ(QNB<HF6OMO3"I'2:QA":L7B;VF:%Q5+)_5&%BD#`X
M.B]@+//+:PFBSPX(QB)U....!&=->D3H5--MZMW<%0\2CNPM:6.^VJHFD80%
M-"FPYH\1\]C2.]BA)[XD:F/GF%/K&<;@LQ*])2%`Q&EX&2.3'CC@....`YT.
MTJTAES5M/:DL5G!((%9D0D4%F3(8>>F"ZQF4M2IF>4'I*4PI4F$H0+#BRU*8
MTM0G,R$XDP!@`BQWSC@1SZ*=,B@]!5]@22N9+;]G3ZQ6N(Q%ULF][#=+,G+;
M65=IU*2NJK8GIT"6-L@L*3JU.&EK*!DP9YPU*L\XW`<XD8XXX#CCC@....`Y
MQ[NH7I&IS5-3=AW<TS>M/;FK*PEOPYKR4QIB-ORO4`,(186J`EILJSBQE)O-
M\\P`@`$'/(<\^MJ(NE@579D#8WH4;>IM7\SB+/(@948,8'221QR9F][!E(82
MJP-J5K25P<ICBE'<C]8,`;X18"MHW-[[+C=F-KM@NF5J-LM74\LA?-6^Z[1V
M^UNG*6K6)CCT?KN2U$KGDAK]W:D,$@DRB[CECRT.'JI,MDK]A<B0'E&J%MD:
MH$A"&JZZ1IH$Q5:G2PJ-$$5O%W%F>(Y!20-"7!438G6/)D3$Y-#$7X6]N7,Z
M1,V*DI!1Z(@M.,L.(K*ZV:,J76>+ZG2+238EQN>#U:@I-34$:I9R?*>G,C;X
M\&+%K$%TIV[[#@:]GF0"D[A)7UX3`:FQR7@DR(#V0>@/D4U-JJ3T;K/1-/S1
M]!)996U60R&R%[*-4GD+G9C94R-:)*>K--4GI"#092)#CQ^8<F3E&9"#`L`"
M&0O'''`<<Q!W@W8I?0:@I-?EU+W,3:W`5-4-AT=:G1\F%FS\QG='6/5W#FEI
M0."A0_2++4I))5*"2FIJ3%J'1W6(VY(>>&(N8?"'J^C$&U_L%LU.N.<1V9ZP
MU?N)M"XQ&2114BU!H*VI:*$1652H]=Z`;8K@8^$K%*ABB*<"XAA0*W<W``$F
MD@"QER#_`*JO?]6=T//D^V$2GZ_U,=M]OS9Y^*%]<FL)EN:QZX)]>[=141-]
MAG_4*M-S3U3".J)YL_&(L"6.U9MT9"8&6HT0T9GH#;*U1'H"YT*4)LD$EISS
MB_V=5/[K<WH>BQCN''4(E&,Y_P#PYSK#;@L!S\F<XQG/;/M^Y[^[WA-\7^QE
M_B!_1QS?S87^QE_B!_1QS?P''''`<Q8OO4R"["6IJG;4K?92TONH]P/5S01`
MP*6\AK?Y"]UQ*:S4-TJ+5H%:E0T%-$K6K22VY0WJO6"=-DQ2--YQ!F4_'`T#
MCPA"''N#C&/JQVYKQQP'''&?=GM[,_@S[^W`TSCOCM_O]'T9]V?FY#5KGT<8
MYK7NC8FZD2W.W&?)/<=@2*PKCK&2S2$JJQM18Y-LA:XLQS5"D@Z60.4<K1+(
M!A@342_)4S+EN;L8`:$D>#/!]EIYU)XGU/M<=3*^WCKB+U9MQ&-G[=CH'+3.
M%2A[I^-4(*`KVRN\.ZJTD!T_'($4R4(5<Q<"X^N0C0$JBVA6)4,M+Q#+UFYA
M7M3Q-4.AKBV\LB:S?J3'HDD)*I2FU+'!-!;M+A\X/>$TAFI4;RW-4/<!+&%P
M0NJ^3RL3*0C&P&2)^*3$$W].:?4=N4V2?6'7%)87V6DM"TXGM/UT?(\V036T
M0*G67]4`9:E[S*P-(7OUJH`:9@Y?Z;Z09Y@\B,SD6>_N7;'R8^KE>B0_"':,
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M$I2.K>T,+O"754)F/9X:W/;FWPE'@L&(TD5#+0CP+`18QTT8Z*&J.A-RNMT5
MK);DG;JWPN45=3D7M::)I/$-?*HFDHS,I37E5M:9H;#D[.\O^<*%"R1JGUV"
MEQE$2M+(.48-Y^/]6.NI(;7V&^JYB8GL/J4V)TWFM8!^CIA!,KKYIF+R;:IF
M>P,GPUZ21`T2!G)_M\7A>F$=G/EFASA@5\(28C-0:DW`4:379'H3L%83?75%
M%SFV]>*_CU@KT31+G2>/BFRIC.F>$5['8R?$E+)'5-F+HDXV8^*?186V*TR-
M4L"2D1?;ZA.!"-8-;ZSD:R85W0=-P26.*-P;U\FB%:Q"./RY"[&>:YHU;LTM
M*5<I2N!GW2P@X\9:C/[*$7/Z5]K+KI4S^KE=7413]=2=<C5-ZV0PBN(E%GM8
MA6G84K$:IT96I&M4)E1X0G*"#CAEG&!"(819#CF!M+[WS.R-O]=8*<RG(*5W
M.TJEVQM91E^;8R&QZAG5,3&`L$U8),_PF42>+2V*3EAM%I<FEZ:W)T0MCU&L
ME-+PY-4H3!12Q<*X!#%(PV#,,;8ZQ-YAR<U(:-$SMJ09J0X>3#4I@DZ4L0TY
MI@LC,('G)8QYR(819SG/.%:ZQK9C"Y@9:^A#.!Z;SVEX"U11A;L.K4JP,*EM
M<O0F\CTY`HP8/!R-3YJ<W`Q>,L7BSW[SQP,7#](]/SH;85?$ZRT:V0VV(HH@
MUDL##6D5CB*;Q!6:!0HCLDRPMS:>Z-1IY99^4B@X0,'%EFA[#`$6,>M).E%I
MWT^K=V/M[6.O4<!7['*H5AUC3<C;4T;@#%#&8+>7$J^(3(RES3&GQWR=+'MO
M5K%OI,A.RI+,+(*((*DHXX#CCC@....!CIM?J_5^Y-"S[7BWR7S,+GJ)"$UR
MBSTKCDKC;XQN:-^B\MBSZB%A0U2.+2%N;GQF5X":2!<B*"I3J$XC21^6Z.:*
M5WHU"9TR1J>6K<UBVW-SK%N>^KUE!4SN"V9=AM2,36XS"0D(&Q(<3'HZWH&!
MA0HF]*F0-J4)80#,,-&+-WC@....`XXXX#CCC@....`XXXX#CCC@....`YIG
M'?Z\9^K.,X_-QQP(WF[I::U-E+R2B4[C:`H5*=V"M]G,XV5M`WT-W%7BR;``
M1)5^(L!,7`_CS'T"?,?,0&N66#)Z'+_Z:8%S+Y*O^F1KE6TNKB:QY=9@WBKK
MSVRV$C07*6-ZM&9.]RV20,-N$NA`(XG,61],ADKAF'-I9Z90QJ`IC5C@\>4(
M!KC@>`,_1!U2BC%3\9@-H[>5='ZOKN*U1*6FI]C9+6"786`060/DCA;%L)\1
MFQB-FIL75R1Z0-3ZPF0^1A8%F(ZJ=U3*F2(B)+;5HV$V[BM#Y#EZ:W>H;)B]
MJ5](8RYX:7Q@DL8"K0B(+6#3+"U3#)8XYO,0ES&L3GHGZ,/3DWGA+.&F5IG'
M`PUA'2AU-A,-U]KW#?.97"M<6?;&/1&-3*3HGAKDS!N<L>E5S,L_*3L+>.0-
MYH7]P21DM&8SF,B3)(337$XD)^?%V#H:Z?(:]MZO9M.=J;J*M6J([1;1+[LV
M(E5@3RD:@A<U:;(@L!H63+4:4VO&B&3V.1:5LRKT9X>53M%8^-_='HAO"0-Q
MP.;A/1;U=B#NP2=RLC:"RIHS;74=N:XSNV;G^R!-9A=]`U/)J:AKG+Y$\Q82
M]T8E\0E3AF0,28;>4:O3-F&-0PM2$MJ%V&=]'_6BR=LFK;V93_9:02^+6";<
M,`K5ZNMQ?Z5K.Y\,IC.W6I7L(D+,[KHQ(&4TP;XTQ]'(Q5RG?<Y5G0=2GR))
MEQP,Z]<]?:YU:IB#435*1U30J"(%Q"15('90_P`G?WA[>'&2RN7RV0*P@52"
M8325O+U*I6^J`%G.[^[N"X997G8*![;QQP''''`<<<<!QQQP''''`<<<<!QQ
MQP''''`<<<<#3MC_`/SOGM]7NYKQQP'&?;C./E^3W\<<".=\T($E=-S)\V7M
M?UH2C9N"SEKB%8WA:*J8T=1\H?XO(V9L54O$%#6+%:)\FO>6]:J:#5"HME&<
ME+R,&<@'`C(^A9OFEI:L*AKNP==$+?>'3JU^Z?&Z:F7*IDX+*Q9J2L%PFN;-
MH@UI;4A$U<GEJ>G:.Y8924RITZP9#L!5D`0DE.."_-;V9#UST:MNXGM]5+,Z
M692I^A5#=0*7]2&`/B9/)A[&OUDRJ%XC:6H9"TC3EPQ-%VET4.#BHE25:-<M
M1J,$%H`&@*P3+8IZ5FE"[;5OW?7UK(G#8QHG9UE-,K<+5M)>P-,T4Q8<,/>6
MJ`+)<?!6XP<?,&CR0BCY"?Q9\_!6#ON^..!(EC&,8QC'LQC&,8Q\V/9CFO''
M`<<<<!QQQP''''`<<<<#&*=:F5?86TU!;>ORF6`M77&#W%7]?I6]X1IHB>QW
M@3%T\R,D;,:TJ%KDX$EQ)K]2*$KPVE(A#5B5)E^3"?(QECO2<U>C(&`#<X6L
M+$;0[V-[?Z3,&HS(D_4-E1,POK*GRXJ3@XQ$ZD@!7YF,`S'$G<IR^,)N<'X<
M<#@Y)T>M3)0@;4JYQN5"Y1W5C735"%2I@L?XN3.OHQJM*%,RI:S()*F1A0O,
M9NF-2!4:K/FJ%3AO<DPU#4KC8FI>Y(EF76L6K4/U>K-QK9GGMTW$9(I"[2J9
M6#L9:+]<EDS5^>D:)N7*GZ0R'!2).@$W-Z1$GCD=9F&+HR0'#2,I*A:N.4N.
M!CHAZ6.M+>N>5B9RM?R733RX-%D;:HG"98ACFO5R3]78+G'&`2N/G+R'*'+%
M88]7SHX+G+$<B*)O8STCH%&4IQY19'1/U`L]XCQCW)MCF>"8KNFZQN"E8?><
MABE*[21VA&IL8JR/V6K]H1$(;%=V9F:&]H<%J)3&P2-I2IVN0IW)N3)DQ+C@
M<PGZ-^K*'91'LJV3/8]K7-.R_P"J[C]+HKH<@ZZ1F^U[$]1^6SF/U$>SJ&EN
M73Q(^K#I2(*T9V5.`X8%#"C4."1;N7='G7+&F5(Z01&T]I:PK:@#'T,$F=9W
M69$[,5MDH5O:N1Q^:+B(RH@LYC[R)\/+/:Y-`'`E'A(A/:LMZTLY4H<<%\/;
M-4^F[K%IJ\0YWI5DE2+['%!LVMM;-DDE2J1--?UDFF3G8\N3Q9(I3$C1OMJV
M$Y`F5H/RD]8LDKJSQU(1ZL8H\TM"3/7CC@....`XXXX#CCC@....`XXXX'__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g828095.jpg
<DESCRIPTION>G828095.JPG
<TEXT>
begin 644 g828095.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!!1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?0TA/3$535%]&4$]?2U]"05(N15!3_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!_]L`0P$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M_\``$0@`]P$F`P$B``(1`0,1`?_$`!\``0`"`@,!`0$!```````````)"@$(
M!08'"P0#`O_$`&\0```%`P(#`P0+"08,#14```$#!`4&``('"!$)(3$205$3
M4F'1"A05%AE9<8&1DI<7(C4Y=7>AM-<:-UBQN-08(R<H.':5M<'5X?`D*3(V
M1E165WB6M];Q)28S-$1%1TA3569S>8*&F*6SML+$_\0`%@$!`0$`````````
M``````````$"_\0`)Q$!``$"!00"`P$!``````````$1,2%!47'P88&1H<'Q
M`K'1X2+_V@`,`P$``A$#$0`_`+_%*5%;K)XKV(M'^H?#FF19C+*V7,G9:]KF
MFH\;M"92WPE*]MTH4PB^1KW`TDF]=/W.'OS!$V=`)SFYNR*\@@@T1[(!*E2M
M>-*&I.$:O=/.+M1N/$3TU17)[":[)622)K$4BCSDW.:]@D,;?DA=]]B=XCLA
M:G1E<BK+QML6(30#;H&P]`I2E!%3JFU^9.PI.\V78\Q!&)QA[2-$H/-=4DID
M$P6Q^5M;3.41,D3I<8LJ-"M;'M>R0<5$F=[I2XQ]'>!((41QQU]MUTGL??4,
MD8620M]UP('YH;7I%Y;L6&^TW5$0O2^5MMOOMM,\@H+[86WW6A=OV;A#81A(
MUKZ:M5,GG6L3&&(L0-^1<7<1?'V-8%,<IW3!B8"M/YL3B)>+I&YR5B=G5$]2
M-"OB9I[TRV0]O>%MCD582N*)+'88]./7A76GI.T]S/6M@'B<ZIL2,T65Z6<3
ML^FV"'-33B]HM>'F`X7?W]L=`.%X+5.AAZJ9'$WI>R8\*3DYU]Q!EHEA;9[=
MGG6_6#UT[=GG6_6#UU7*;^#'KR7(42P>/WQ"RQ5)$RD2P:(;<%@J""SAL"[W
M5MW"T;QM`1`!$`Y@'2OU_`LZ\>7^G^\0SN#\#0P.H@'7W5_306*NW9YUOU@]
M=.W9YUOU@]=?(KU]<3_BRZ/-8>?],T=XF^K29LF&Y\OAS?*'J;6MCH]D(B$Y
MGMY8A0%&I$IIEQMW])(,OLMM"T.U<.XCJ!\.MQ@/C#]3_P!H:G^;4(FMGVD^
MW9YUOU@]=.W9YUOU@]=?%K^'5XO_`,8?J@^T15_-J?#J\7_XQ#5!]HBK^;4'
MVE.W9YUOU@]=.W9YUOU@]=?%K^'5XO\`\8?J@^T15_-J?#J\7_XP_5!]HBK^
M;4'VE.W9YUOU@]=.W9YUOU@]=?%L^'5XO_QA^I_[0U/\VK'PZO%_^,0U0?:(
MJ_FU!]I3MV>=;]8/73MV>=;]8/77Q:_AU>+_`/&(:H/M$5?S:K%?`4D/$XXP
M:_/J&?\`&"UKX7'#K?$U[<=$'AJDX/7OB6KT9Q2PM[,1"F%+[2"\N\B^_MB8
M-M]@=G<7P?+Z-/;L\ZWZP>NG;L\ZWZP>NJZWP+.O+X_WB&?W&AG^-:Q\"SKQ
M^/\`N(9X?@:&?XU_3UH+%7;L\ZWZP>NG;L\ZWZP>NJZOP+.O'X_[B&>'X&AG
M^-?T]:?`LZ\?C_N(9_<:&?XVH+%7;L\ZWZP>NG;L\ZWZP>NOG7:DWGB58)S[
ME[#3?Q@-<,A18SG3O$4KXL?V-"J=26T$XVK5"(@H\I,8;Y<0$DHXRRSLAM=X
M>(AG'B:;@'PM.MCO_P!E31N`]-MQ3#\W7Q#QH/I?]NSSK?K!ZZ=NSSK?K!ZZ
M^:!]W#B:[?C9];/?R]]31OW<O^UMP_3RY[;]<!G'B:[@`\6C6R'_`,4M(<M^
MN_M;O^?GR\*#Z8';L\ZWZP>NG;L\ZWZP>NOF@?=QXFG0.+1K8WZ_ZZF@>77_
M`&KN([=P;@/=W[9'.'$UY[<6C6SU_P!U31X;_P"U0Y<P_3L`T'TONW9YUOU@
M]=.W9YUOU@]=?-!^[AQ-?C:-;`<A'G*FC;IZ$W(`_P"CQH&<.)K\;1K8Y_\`
MI2T<N[O2^GT;]P4'TONW9YUOU@]=.W9YUOU@]=?-`^[CQ-1$0^%HUL=_+WU-
M&_H_[E]/7IU[@`:ENX;NDCB'ZZX;DZ4/W&ZUZX].@$P98PF2-!T8?2G(ETCM
MCY>K.-6'HKR#"C+_`&O:79;?;=9;V[KM[@``NH]NSSK?K!ZZR%UH\@N`1\`$
M!JNI\"SKQ^/^XAG]QH9_C:MBM*_#'UA:><V17*<]XPFK[4M$F.Q>G>\/9=C<
M150J4HW`HLHRQ9<0XG'(5J8"_*-[FF)O5H3;KC$]UEUUW:":*E*4"JCGL@%O
MX:MNHW#+KGO6?J8TEZF6R,QN26JM,,'EF19`[PN*O3]=CYUD[;'DYQ<:,9G=
MWFI45?[KBUEQSD\6)1"XF[>W$(@',?$`^<1``_2-4>^+%KV48_USQ_/FG?5Q
M+],KS+<##C!X9W;AX/FH9>^H\:9DRA$'%:I?SW$$"-%[Y&IY%E06I?*V(!)>
M+30+=2K+$7CGQ/Z%H3A:&:;3=!&G(S2,Y3!ZT_WQ9\&"ON0&=[8)H_G>_22!
M+W^1L\B(3/"%S>YL$B=3BUA-G:]MVFD#>FO*OND!J/3A4Y@EF>M`FG?+4XRB
M=F>4S!AE*IVR8HQ"&!SI28@G\K:"%-^*`NNMB0HDB`AL!/9=V'&U$#Q8`6N`
M`$A=`I2E!C8!V$0`1#H.W3Y/"J^'LGS\49EC\]FD[^4;CZK"%5[_`&3Y^*,R
MQ^>S2=_*-Q]03],/X$:/R6W?J1%<L(;_`$@/T#O7$L/X$:/R6W?J1%<M05%M
M8?L1O3UK"U-9EU,R35_F:'O>9)FMF3C&&6`P-P:F10M+)+N0H5JY06L4IRP)
M`;#5-H&CVA[8W;`-:T_N(?2__#CSS]FF.OYW\O\`GUN_TH1%+*0'[B'TO_PX
M\\_9ICK^=UD?80^E_NUQYZ^?&F.1_P#ZPJ[]2@^:?Q6/8O&!>'AIJ:LZQ/5)
MEW([HXY<QKCBYAD,+A3,@*0S=_(:5KD"IL-.4W*D))HFIB1M`DPP``X>QN%2
M*17V%!IAD49CK^9K<SPFO?&)G>+TUF-\=F6D7N;<F6W$V&7*K;K[2KCQLMON
MM`;K;0$0`1&I=/9-OXO2+?\`"DT_?_FB3Y]MM]PZ#T&I\<9_O<0#^TJ*?W@;
MZ"EO^XA]+_\`#CSS]FF.OYY6?W$/I?\`X<>>OLTQS_.ZN_4H*0'[B'TO_P`.
M///V:8Z_G=3:\'K@<XNX/J_,:_'.=I_F.[,*".('$F:QF-1^QEMCBQ<L)-0W
M,)AIBF]5<MN+-M47!87:7:)=NXC4Y5*'P4I2@4I2@H"\0W^SEU6;"(?U:Y4`
M]/,0CN'IV_0`[<]JTW#J._3EU[QZ[]VVXCX=0]%;D<0T/Z^;5:.X[_=JE0B&
M^V^UB';8>H!Z?E"M-P[N6V^W_0(==@Y=_P![N`<P`:!T`-N@=>>P^.W/IW=1
MZ<AH&_+]/=OW[[`/CMOR[Z=-]O`!Y;;;?-S^3]`#TK`]X@(<_DWZAN.^_H\0
MVY=!"@R/3T<N6^P^`AOOS^<>8_-3KN`>`[^(\Q]&WI]`#T#<!H(]P\N_EUZ[
M=V_7EMMZ:#S`>X=@W^;GU`.[??EZ.Z@>GERZ_)MSY=P]![QY`&]8`.[?;LAZ
M-N?0?T;COW]^U-A$>7(-MN_Z-NGARY@/4-N>S?8!$=^GS`(=P;>(^GT#MRH,
M[CX?_J/H#KOUY==MQVY\ZM1>QZ=_N2ZD=^0_=8B/_)^G#Y_E\>G*JKO<&]W+
MT^/@.P\^6X;<^>XCOTJU%['I_>EU(?G8B/R?O?I^GH[OEWH+$%*4H%*4H`AO
MXAS`>7H'?Z!Z#Z*I'\233ZQ8:UR1'#$>UO\`&6G^0=0DQ53![C.+=3K/%<88
M51Y653MUQE%(ZG6PYSO!)*I'$)!$HC&"@(!*6A+&Y:?=V]KN%5;N.GCCA8SW
M,4.<=5^5-5^)\[8UQ.=E,QWTB+CT$J>(-%)!8@A,?D!JE`O;SI&[/TAD2'%[
M:W>T7YS5*)42A<"#++0OL3,3>F5;X)/G&/6/GTESX1S[&9)P[-,CQ$YUG#([
M6IBD@+42G4C)$LPS:9($<ZE**6,D_DR),C2O+K$I2G>(HF6$I4]E[6RH;?(V
M#:(!(]6D7#@'34.B33V&D*U[MT]EPY23`K90G7)99;>3('@F6!+TSB`+$\N"
M:62$)22:``4_>W["@`FTL`W=J7(M%K96[="E*44JO?[)\_%&98_/9I._E&X^
MJ4;4/Q`M(VE2;Q_&^=LLC#IS*8R?,62,M\"R?.G-5&$SM:QG/)Q6/(5++&Y'
M:ZWVHK;G(Q&8:;<%Q1=Y8]NHKO9-JY*Y\'_)CDB,$Y&X9BTBK4AMQ1I%QJ97
MJ&QVH3F7$GEE'E#>499<)1Q99I8CV#+++PNM`+`K#^!&C\EMWZD17+5Q+#^!
M&C\EMWZD17+4"E*4"E*4%=CV38`_!Z1?GTU2:?AZ;AO[]$FV_P#GTWJ>_&7[
MW$`_M)BG]X&^H$/9-GXO2+_\*/3_`/3[]$FP[>O8.?4*GPQG^]Q`/[28I_>!
MOH.[TI2@4I2@4I2@4I2@H"<0T/Z^;58/4?NU2KD'HM0B&_A\O+EML/4!TW\`
M'?;D/R[[\A`-NGASY!TK<CB'?V<NJWTYJE?/;<1'LH>77GRY\M@Y<]^=:<`/
MR[;<Q'?<.7AMM\_0=N\>H`\.OS]!#GX`(!TV'TAL`!M3<1WV[MN6_/QY\PV\
M!Y#S\0#:@[#OT'?D'/EZ`W`/G`-^\?EIMN'R]-O3OXARZB/?X;]`$,;[>CNW
MVZ<@Y#U`.?/;D'7<>Z@[<_H[_D#?H.P^//?;KR`*SOL'T>(\A'Z=_F#P[AIS
MYCZ1]`;<@_R[[#WARH'7QZ]P^D.H?/Z0VY[\PK'+?Y-PYCN`^C<1V$1Y<NO(
M0&L]0V_C#H'HY;#L.P\N7@(!M6!NY@(#RY[^'4`_CZ#TY>&X@&>?,0[^G/8`
M#O'?Q[]]N7I[[47L>D=\2ZD.@_U5XCS`=_\`8`GZ^FJK@AN/+EW[]0Z[[!\H
M\]PY<OEJU%['IY8EU(AMM_58B/CS_J?I^?.@L0TI2@4I2@51E]D/W9/OXE.$
M1T^XUR[D^1MV/,).688I&WN(1V&O;@3+,K7:7BK7A\)//3/3/D:R52"].MLM
M:5BEL:2#!$RZW:\T([=?0'TCL'Z:K3\0;4#P,,SS'/B;4[JP5P2;X\;H_IQS
M/;CF7O\`&GY*XJ7@]\@AJ:YJCKNM=)%CUYN>U+#)8U<I1Q-4[O9;WO<=;8GL
M;5Z<Z^Z).].52`\$<%OP7^E:]XC3[$I*<Q9`43-EDTE9Y<^VSQ3EN>'SQR<W
MQ@2HFD]2_3`QZ?;TB5/;[D^Z(-)]YRA$:<9*O6HF@S&FG'$6D7!\!TD/9DFT
M\-$64+,:20^1F2U8_MDA?'61N;TXR(X+3G1U=)`ZNRUU//+*/M<3E))Q))A=
MQ5FW=3G+J5Y/FS)CQB''CO.F+$F4,X.36I:$Y..L.H8JXSUWM='1*W'*FI)-
M)9"8^8F:"E%[HZW*Y"D,+;4JF](4K4VEIC?6*P(!<&P@`AX"`"'T#05N]=+T
MKQ)J2U!:LL?ZV9)C[4=$\%X@MQ3H@4MD8:AR8ML(2O)..7M*_-#D^9'33QYV
M1*T^(I(BMB[T(6O+A<87:-^B?LDS57K%>M+,YP&]:#94VZ:7*5Z,).Y:S0R3
M&R8JBE3A-\<3)PB-N,#R+Y8!B:<G7X^M5W+;RR59(KE`"3<6(V[I)B/%,QE$
M>F\NQGCZ4S.)=GWJRZ1PN-/DGC79/!5;[WW]T;%3LR]E2`*+?<U8E[)X`<&Q
M@!=4&/LGP`^"-RP.P;CFS2;N.P;_`-D9C_O^<?I'QH)^V'\"-'Y+;OU(BN6K
MB6'\"-'Y+;OU(BN6H%*4H%*4H*Z_LFW\7G&!\-4>G_YA]^B38>8AW]W/?PJ?
M#&7[W$`_M)BG]X&^H#_9-N_P><7`/X4FGX1'P`)HDW_CZ]U3XXS'?'$`'QA,
M4'_Z`WT'=Z4I0*4I0*4I0*4I04!N(9_9RZK?#[M4JY]X#V4/(`Y_+\_3K6FN
MP^'I$-P#F._/8.H=?2(#SWVK<GB&_P!G-JM_/5*MAWY;]E!U`.7T\QZ!W;:;
MASVW#GRWWY=.@AMN&X<^7(1]`4#</H#??QW#KR^7N$!$=P#H-8#Y>[Z-QY<A
MW`!VY;=WIWK(AOOSY\^6X\_E\0YAN`!R^>L!M_'OU$.74/G'F(<Q'O\`2#;;
MIX[;^D>H\Q#?GT#<>?CML&>?0/#J(CUW`=A[_#KS$.7C3H`<_$?T#N'B`!TZ
M<NG4:;["`<QWYCR'_#^D>?/??F-!@=]_EW^C8-N0^(CMML'7T`-9V#K\H<PY
M`'SARY<A[NX=QK&PATYCW[]1V#8!YCX[^C;YJSS\!\-^_<=N>_(!#](;=`#H
M#O#TA_%MW]=AY=.0]=AWWJU%['IV^Y+J1V_WV(CX_P"X!/WCOO\`+55WT#N'
MI]/0!WZ#OZ>\`Y!5J+V/3O\`<EU([]V6(C_R?I]N??R[QYT%B"E*4"E*4'^;
M@W#_`-ZT?HN`1_15&QXQ)Q4L3:H(E*(IP3<>9ZA^`<G:W18IG)LB8T1F9^9-
M263C)-&)G+DCE8X')%4(:"!2QDA62N.M1NB@!%M.M`*O*U7&XI&M[6+BC5W'
M<!X.UA:%]"L`*PNT9&OR-K/1VJD&59.\2%\:G*(Q(]0%J5"KB+>TH7-6`F@8
MNL>R[;;;KB`MNL7M$])KK&DQMMY28KVY3TD&X/6*LO86X=V`,?9XQI?AS*S<
M=EIZE>+KW%N=@@IDTS9D6:-4=(<6E0J;E21O8W]M*17I3A+M1@18-A-]MQ-D
MF=:@Z"YOD/(VDO#LTRMG;!VIB?OC2^GR'.&FX"0PK/3D\L?D:1=!O:X^1%&V
MMR=(QN5Q86VW/;8Y#V;1$;0V^J3><NFBE*4H%5[_`&3Y^*,RQ^>S2=_*-Q]5
MA"J]_LGS\49EC\]FD[^4;CZ@GZ8?P(T?DMN_4B*Y:N)8?P(S_DMN_4B*Y:@4
MI2@P-UH=1`/E$`_CK';L\ZWZP>NHE.)EHVUZ:J7?$*W1CKVD>C!!"VV9I9^@
M8T3LLLGZM\5QXZ.*U`-H=FRZ.$-KN05Y8=[K7:\+`V"X:BW'A`\='NXZF0/[
MBR@/\`_Y:#8SV39<'P>D6$+K1_KI=/W+<.>TU1CMN/(`Z;\PY5/AC.ZT,<P#
M>ZT/^LF*=X?^8&_ISZ>'HJHWG7V/WQ:]3$+3X\SIQE)%D>&)9`SRHF/R*-R9
M8WV2"/JK5K*Y@3?:-HJ&Y79:H37B']+-MM$-PW`?8$7!VXX[<C2($7'-GB9&
MA2IT:1.4QR>THA,E*L(()+M```+"BB[++`[K;0#E0[<_S=:[[=GG6_6#UU_H
M!`>8#N'B%52O@@>.CL/^GJ9`Y@/_`'EE'(1#D/3GL/R59*TX0/)&,,$8HQ[E
M_)"O,&3X?!V%@G64%UAQ:R=R5O1V$NDE4V*-C[3G11;<HOM-#R@#=]]SH/:Z
M4I0*4I0*4I04!>(=M_1RZK!$`_?JE8=-^?90\QZ?('AOUY\M-^?R#W[;]WAN
M`[]X\O0'IK<CB&CMKFU6?GJE0CT#EV4(=>74?$>[T!6G'+U;_P"#Z=@#Z`VH
M,"'^I#8._NZ<A'QY#OMT'NZT`0Z\QWY\OT!R]`;>'(=^_=W>(>C?O]&^X;<A
MY=W0`IR^8>G+ERWV`=A\1Y`/+;EMO0.R'=RW'?\`B'O#EL(>G;GX\FP\^>V_
MCSVZ]W(`[M^H#W[]1!SWY]=^@]_=W;AMMTWY`'/>L=?1O=T'8>>WAOR\-N>W
MHH,\PVY\N_?Z.>^PAZ-M]^H[][GON.P<N?R"/>.X=/G#D/C3N';F.W+GS'EU
M#T;B.VW+PZU@?D'8?HVY;[!Z0$>FX\_EV#._,0'QY==QW'?Y@#IX?Q5:C]CU
M"`XEU([=V6(B'S^\!/55OET'Q#?TB([[<NO=M][T`0W#NM1^QZ0VQ+J1].6(
MB//;_>_3^'IH+$%*4H%*4H%52^+]HGU594UWM.=,6\-G1]KPQFLT\PW'=ZG5
MCDMHCZ")RIEE\M=E941C[K+&"Y$N,2.R(5[HD(.%U)N3I#C/]`EA5K2JG_'!
MTW99R_JP@\CENDK4UKSTXH,,H&B%X;TP9N7X^?\`$F:S7UZO4Y0F$?:7I&KN
M9WE)?'DK<[J47M43HZM$%-WM,PNVQSKCS.!/'PXX)-\9Z+\'0C(^G3%&DV:,
M3-(BGS3[A!Q*=<6XZ-5S21N"9%$W`EQ=BE*9X0JTTC77V.*NVUU=UUGE1[.P
M;NUH7PQ,>9WQ3H2T[0#4JH>SLR1V*.I$F(DK\=)Y"T-RN62!PAL=>WX]2L.<
M72,0E7'H\M.,4FW6J&V\H;@\GV0WTJ!2@B``(B.P!S$1Z`'B-0L\:B=:GG7A
M[Y=E^AC,<7@M\28YM*LK9AC$LNOD\4@F/(HZ2-V9X`[1=>::DF<A=T3?&KU!
M)UBQD2N)SAVTEY`'V(QF(U$TNX?Y@/Z1Z!\]5\/9/GXHS+'Y[-)W\HW'U>9:
MC)QF.50G5UJ&19[SE"WSA[Z8=-^0<61*#Y$D<?A<ZDTFP@SYGECAEJ--R\EM
MR<>_K;3H[<5*2'$HE`J.N)M!0-AEOX_9'658M)^#Q)6Q?+HJ&07V=:)Y$OB)
M;ZSER.PUXS-C*0'FVQRU9[JE$>USC5E@BCML!&'E[1]KVC>`YX64V#\!L_Y+
M;OU(BN6KB6'\"-'Y+;OU(BN6H%*4H%*4H%*4H%*4H%*4H%*4H%*4H*`O$-$?
MZ.75;^>N5;?-8A$?'F(;]W\85IMW]V_(1Z[[]`#J(!UVZ]!VZ<ZW)XANP:Y=
M5@B'_AJE7/Y+4(\_HY#S'PV[]-P#;EOW=W=Z.?4.NVX;ASH,`',1V'GS[PZ]
MP@(\]N?/H//PVK/R!UVVZ`._/<.[;8`Y#Z>0CRK'7?H/+8.X-O3MU^8-@$!`
M-N=?K0HECFL2M[>E/6KUR@M*B1I2[CE*E2?<%A)!!5GWQAQQEUMA=H6B-PW`
M`@&XT'Y1VY[@'=OX`.X;?*([^CEL`@%8^D.O>(!OUV'GS[Q&[EO\M;$2W2EG
MR$3^"8KD./EY&1<BLS6^QF&)%*1>^BA>%9J)*#LD3&W6,ZJPXHVY8E6&VWHB
M++CCK@LVKL!.C//!F39UB0YBCB&9XW-;4TM+<)@S(V5"Y/:$M>S,R9^ONN0.
M#R[$WA8WMR2ZXY0HL-)MN"XHP:#5CY0[_1SY;#R'?D/0-N8[\]MZR&_?U^7N
M\>@!N/S<OHKT.3XKFD,8$$DE3<G8T;L[N;0T(W!>G)>G<QF4&(W1R;&<1%6J
M8T"XF]O.>+0M2"M#R!=QHA==;YWS\0Y]^_=MW#R[N?H'?N'<`<^?+QV\!Y[[
M[;]=_DWZ\NZU%['IW^Y)J0`1W$,L1'GZ/N?I]M_3_D^4:K@!W"(CS_1S\1Z"
M'AW^.W*U%['I_>EU(]`_JL1'I_:`G]([?)R^2@L0TI2@4I2@P([?2`?2(!_A
MJCCJ]XC41R5K[R%DS`/%RQ5PRLCPW&5FG_+F.<V8+690(>5^,,R90:$?M:3#
M=>VF.BDBPB3@QV,"<]G:'QJ5>ZKA[<N`B\?5?[6@KX*NF761'!U"Z6\;9'U0
M:HX^G:U+8W:?XIE$H&V,%2N5-LKE30\)"V-BD$J-22!`GE*9.IE,P.:2FA::
M>G;TH6HY]9["2'AOSR09-T5X,G$JU/PW68_OS-(SG'4KC^)VP>(Y1,2S:2("
MG%GBMI"4&BQE(2E1A44"<GRZYE4JQL`3ZW@K6+1G.=.V3-,6'Y_I/CD<A^GZ
M6QBY[QS%HK$&R`L\?;UCDOO=&FV&LY"9NCKBBD'NJ0]MB8D`(>K%_E+S3KC#
M;]G:#%UMMP#;<`76W`("`@`@("`@("`\A`0$0$.\!VK4O(>BS!4JTO9KTFP&
M&1G`V,LXQ*?1J2)L,0^)PVQ"NR,V&-DBEB%F0M!<?/DRJV^Q0>O<&U3<M/)*
MN6^7"W:MM:4$7>8.%["LJR)O6),WY@@,*?X'C?'.>L914R*71/43&<6HF]JB
MQ$^N=6-:Z,ZBQF06LC@IAJQD-<&@XYO4B8F,O*OC`]DT:8M.3+PW<FYQ;<$8
M@2YM0Y3T@QY+F0O',2^ZN4Q-^:L>1!(TAD6YINEXH"HO99'_`&H+OY"]GLL;
M[R[DMEA=MH.J]_LGS\49EC\]FD[^4;CZ@GZ8?P(T?DMN_4B*Y:N)8?P(T?DM
MN_4B*Y:@4I2@4I2@4I2@4I2@4I2@4I2@4I2@H"\0T=M<NJW8.8YKE0;CML/W
MB'EX_P"7EOM6FXB/</?S'KMMU#PW'EL`!W].^K">K;@]ZP\S:F\Z98A96*!B
M>0LD/DICUSO/E;>YBU.`)03^WT-D85VI%/\`2K^V38H/"SEL9=N-:\?`8:ZM
MP'R&%_M+6_\`-#GU'D/(.[J-!#F(^D`#?D/+<0]'4.NW/P[@ZU[7%D&.'PZ%
MMD5>Y'CN?6K23G^<9!F\=:,=(+2;R[C%#.:Q1;WSLQX%B8*4Q<O<+Q,V`.R/
M,9(0X&&NKO(PORZ?U2ENW+OV]Z'(?T=.8!3X##75_P"1PQM^<I;O\N_O1Z[[
M_3OUH.K3UQA4FUD8P>4FIC%5F*(&SXW:KIQ9DI^3JU<1C9;6?*&I<X@Q^Z:E
M\>74AV,.;S1&UP2*K+SE&QPV!PUFHFS'.HC4)E]=D^!S.*2"4^W$<.APMLN'
M(`76JV^&W-"N0L5OO>0QQE."Q^D#;:E?4%GE&UK.L.46JB_!]9.@S/VA:!PC
M(V="X5[WL@Y:Q_A:.A"929)'(9IDEW!DCMZ](K:F2Q,R%*[_`"CHXVJ#SDB:
MVZ\E"L.&PB_;H>!AKIWO"TO"]VQE]O;MR4O[-PV7W6#=;VX?9?V1&T1M[=EM
MW9':ZVT>0!KUKAF.$)U;"I/CQ?'G:5.2<KVXIC$G?G8I%'2F5E.L:7Z-.P@V
M09Q;WU2](&]C8/*$*T2.][=%*EV<5)U\>X;@.W41#<?FWVWY=/3S$>7SS&CP
M,-=8B&Y.%Q[OWREH\M^@;Q``_1S#O`:?`8:ZN?\`2<,?+]TI;_%[T-@'Y.0C
MUVH(<O3OSZ<^X`';?QW^<-_FVJU'['I_>DU(<]_ZK$1\/][]/UV$>?R\ZCI^
M`PUU!T(POO\`G*6[<^8_[$/'T5./PEM&&:=&D"S#',SV1&QQF\[8)"QA$I";
M(4_N<W10IG4^W#CFIJ%,>"RR[R90%G!>3M?Y2T?O`"6^E*4"E*4"JA7'S8M%
MJ;5?B"8R?BI)N'AJC8HQC^6+T#KC.9Y,126'0=_E]^,9(U)HU$'!.RO;([R&
M?E$*5+VH`\5I9AK3;:EM,.MZU6WXM.G#+)NJ"-:@L1Y^X8,*<I?AM+B!]Q_Q
M(4[1>VELS0\/+@=*,8W'%&+[G@\N1')UXW""8OVFAL"XKRAE]6+QO'[TI-?$
M[)-,\.]/;>K@]Y<T,R72/"\*Z(-2S3J4BV"DBIIETJ#W50R91*9>^O,RD+X\
MLKZPQIT1IG^3O;XL;C/<KVK:3<"*U8J4)3S+I7J@RX0_#X/THK#\Q->8L&9C
MC&2--F,L;K9;@DI`$3E,_A.5\RR^429J7,9%S(ZL2=-.VN&-"_W16.XDQ04K
MG:1<F+L"<VISEB+?S[DI2E%*KW^R?/Q1F6/SV:3OY1N/JL(57O\`9/GXHS+'
MY[-)W\HW'U!/TP_@1G_);=^I$5RU<2P_@1H_);=^I$5RU`I2E`I2E`I2E`I2
ME`I2E`I2E`I2E`I2E`I7CN3]0^`<(J&U+F;.&(,2*7DDQ0SI\G9,A,!/=4Y5
MXE&GMI,L?&@Q<269;<68:EM-LLOM&RZX+@$*\I_H_M"7\-/27_\`,AAK_GK5
MI.DB'SV3#_8GZ4__`&AVD?\`Y0+?\G^>U6-RO]2/_K#O_NWU5&]D4:M-*^3=
M+NF1LQOJ7T^Y`<V?7OI6D+JVPG-6-)4XMK"U3H%#H^+D##)UZM*SMA`"<XNA
MY):!`5L8K4$V"%PV`K-?FA.T+K;M:6DP!`TX!`=1^&P'_LM_<,T`0^<`&E)T
MG[MY&W=*U'_H_M"7\-/27RYC_7(8:Z!U'_7KW5M"PO[%*F5KD<8>FF11Y[1)
MW)F?6)R1/#,[-RJP#4J]L=&X]2A7HE)8@80J2'G$'6"%Y9EUH@-0<O2E*!2E
M*!2E*!5+SCVXY5(N('"\J3S03IRUH8R>-.$9AT=*U*:OHII[8XW+&B7RMQ>;
MH<Q/4[BC@M=11.+;<\N*=*J3K$PH2+S2[TH;W0ZIS>R`=.N&%FJ!+GK+I>E2
M<2`W`T'##./=267H-CQM6R/#,UDS]*8'>AF+PV'F(,UM$Y2-A3FU%FIDJF&>
M4=E*+R:'VQ?QOKI&,5QC"L3%,!/[PDKV0SAY:;;X[@O&FFMFOC\LN0X3P_DQ
M#F+',%L'(<N$Q'&LDMSS(4<H)<S_`"KXN5$/*X$CFY+6V\RV]%<47(Y467!3
MC2>)<,72NS)#\/FI0CLW<TQ&!9`V2K%#40^Y3G#X5'XI(V90K;'JR-EN-K"[
MN"-2<6I?FYS,N,N,&[:4VI-YRZ:)%HVY8K2W7KKPP3P[-/K_`*A\]N2^R/-B
MM,T,,88+$:J73:2K@ON11R+MRQ4D*5KS"BS5*@TTXI(WH23URX\A(28=9NA=
MVNS=V`M&_8>R%PB%O:V'L]H0`1`-]MQ`!$`W$`$>51$ZY,-YRSSPW=5;7G_"
MF'YKJ(:L59[^XK&<%6S'*]A2UY@CI'HHLB@S2'Q^3%Y'>&]Q7-:M$SLQMA5Z
MFU.UKU/EK[@1>%>F9<XB#S#,DP;%F'](6H+4Y*99A9CS@]E8G<<2MJ6`QR1+
MD*-I:Y4HR'D"(E@^*[5Y2LI(UW+[3$EMYUE]UEHW5H?[)L4G+.#]DM6H1'MJ
MA5F'2(I/;E5Q-ZI`<?J&QV:8B47)C3D]QZ6^ZX@ZX@XTFXPN\2C#"^S>/ENK
M;3/!%JE_DT6TI:I%6OR1::<`QK3EGQAATW?\=PK(D5A;,ULQJ:4QD@UCP^?"
M7PH"Y^7/U#48[EDGG(;#2M[Q\A]DDXKU5I>'C,\@R?5(F487(FNB]M>]-@X5
MAQRJ^7$Y1QLT/+X.<;7CWVG^6FMITL]I@T"FOM$68#`1W>6NNGOEOT<YR5K9
MA_`C/^2V[]2(KEJXEA_`C1^2V[]2(KEJ@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@C[UH\+K1%Q!7>&ONK'"S9E)U@+:K:(JM6.SPUG-C<N57K526P6I6E\H
M48ION.$#.UM</+H%:/\`[FBX,W\$%C_XW3#_`!O4\E*"!L?8T7!F'_Q06/YI
M=,0_B=PI^YHN#-_!!8_^-TP_QO4\E*"!O]S1<&;G_6@L8;@(<I=,-^8;<O\`
MJO4T^+<90K#..H5BC'#*3'('CV-M<3B3$G,--(:6%F36)&Y`48==><98G(LM
ML"\V^Z^[;>ZX1$1KOM*!2E*!2E*!2E*#`B(!R\0ZCMRW#<?F#<?FVJEEJXPO
MKOU,ZX]0&HG('"<X?^K2`87CRO`9*/,NJ"*/;1"(W`W-ZR`TS9V9G0E1;!)F
M]PJ4M;Y)6DU"!R9K,0%G'@)5MXW3;M]N7C:/S!<`C^@*J=PKB-Z7^&F?JQT<
M:N<`:@!SOEW/V>);<5%<733(;%JX;<NJW$R$JV"7-"8QO0BMA+E'L5WE&F>3
M;KF*^_M"!%Q=MBN7SWM,9$TS]IY>&ZSKV/1)@!&XX#PYIB./BKB[)\):?Y$V
M2S#\-;'Z3OCVSWP>1,UEC8ZMDE:G!'+#U"0!+]T7Q87==??9?<.\%1U\)S%6
M1,*\/G3?CK*3,ZQB7M$=E#E?$7Q4>K>(5')5/Y7+(/!W(U2`'V+(5"GM@BQZ
M8T+;D9C2*3LV@3V0D4J!2E*#`AO_`-([?1TJOA[)\_%&98_/9I._E&X^JPA5
M>_V3Y^*,RQ^>S2=_*-Q]03],'X#9_P`EMWZD17+5Q+#^!&?\EMWZD17+4"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"NDS)1C
MQA2>^J?'PUG0MMQ5HR*7&L#<D07C?VB`%X?+B24MPWV]HH/;)8C>&]@=H-P[
MJ/(.\.8=/2(`'S#T'T547U&94?M=N59WHGALXR_G*'-N5YUE]DC\_P`=XOA\
ML1N.`'U8BF<;Q))EMD_@.2XM'%CP>A;8!G/#"*^6G^T4Y+\:264NL"VNSO#1
M(&U&\L+FW/+0X%`>@=&E<E<FY:0-PV@<D7(3CTBDH;K;@`P@XRP1`0[6X"%<
ME6E_#SQE$L.:.<*8W@S+EN.QF,M$@(0,N=69GCN5&\]?,I$ZN9$J88]?>P,Y
MGNJN6WM;:R`6THF2]M3MR=,DL*3E[H4"E*ZC+I_!8"F2+)S,XG#4BX_VJB4R
MN2,L<3K%.P#[72GO2Y"4H/V$!\B3?>9L(?>\Z#MU5[_9/GXHS+'Y[-)W\HW'
MU3NN>18`RN+`T/$WB#4ZRNVRZ,-CE)F-`X2*PRZRPN]B1*EY*EYMOO,+LL%M
M*5!=??;;;O=<`#!%[)\_%&98_/9I._E&X^H)^F'\"-'Y+;OU(BN6KB6'\"-'
MY+;OU(BN6H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%>01?3[@>$3V193AF%L41/)LO$\97D.-8]B;'.),*D;14#()4VM29\
M>!/&VT31<%R@3!`.UOL%>OTH%*4H,77!9;==<.UMH#<([".P``B([``CT#N#
M<>@<Z@7UZ9XT/9TP[$<[QC!]FN',*I^R!IMTTX@DV.L@WMKUDU\6L?OO7N&.
MIU'F<M"U0XQL;7)PRP?'KK8ZW6*2X[(;;G`XE1/36H^H_0KI9U:O\)E6?<7W
M3>28Y;9$SPM\23C(L)=&)KEBAK52)"0N@,LBZA0F=3V5KO4EK#%-O^A++2^Q
M9<9;>%<:7Z>%,$TMZYTVH@YAR!JJT.:.=-#?@F?NRH%,B@,ZNQ8HR.H5XU6.
M1ECFU'K,GG(VI2X-(I5+N:@M:C#C2#1(,]MXWKYJ,U3Z$G+1IA717J_S%DQZ
M,TC9"MRO%8##U6%GPN,2;'V4IBG2S!PR&@?S'MO1-Z]K4)#HF79?)++T(*O(
M`*P9J7+ARZ+GI7B)>]8,97E;@QD:8YC96\22<.JEK8V)Q]UF9M?3G"3*3)XF
M:W$`6(;9]=)A3'??%#;M6Z]A)1=EA991=A9=MMEEEEEMMEEE@!;999:``%ME
MEH!;;:`!;;:``````%!$ZV\369(FY`D,X7O%)N,2HDB<P;,#8H&P3"$Y15XV
MB.>MQM&^P1M$0`1#8=@WV#]OPGTO^*\XI?V"XG_;W4J_8L\VWZH>JG8L\VWZ
MH>J@BH^$^E_Q7G%+^P7$_P"WNGPGTO\`BO.*7]@N)_V]U*OV+/-M^J'JIV+/
M-M^J'JH(J/A/I?\`%><4O[!<3_M[I\)]+_BO.*7]@N)_V]U*OV+/-M^J'JIV
M+/-M^J'JH(;<B<8UNQ,QH)+DGAT<36',+I*X=!F]S>,%8K*3*Y=D&2-\0A;"
M2)6=CKQ72*3.S:RM]HV`5<M6D6&F%6W]L.]CQ/I>`B'P7O%*'81`=L#8F$-P
M$0'80SV("&X=0$0'J`[5O!J&T[P74O"6&!3]5($3+'LJ8?R\A-C*Y(W+S)/A
M3)$=RA$DZDY8WN)1C0ID49;R'M+:06>L:S%29,K1G&V*2_=PLL#?[VT=Q$1W
M`-]Q$1'N\1H(J/A/I?\`%><4O[!<3_M[I\)]+_BO.*7]@N)_V]U*OV+/-M^J
M'JIV+/-M^J'JH(J/A/I?\5YQ2_L%Q/\`M[I\)]+_`(KSBE_8+B?]O=2K]BSS
M;?JAZJ=BSS;?JAZJ"*CX3Z7_`!7G%+^P7$_[>Z?"?2_XKSBE_8+B?]O=2K]B
MSS;?JAZJ=BSS;?JAZJ"*CX3Z7_%><4O[!<3_`+>Z?"?2_P"*\XI?V"XG_;W4
MJ_8L\VWZH>JG8L\VWZH>J@BH^$^E_P`5YQ2_L%Q/^WNGPGTO^*\XI?V"XG_;
MW4J_8L\VWZH>JG8L\VWZH>J@BH^$^E_Q7G%+^P7$_P"WNGPGTO\`BO.*7]@N
M)_V]U*OV+/-M^J'JIV+/-M^J'JH(:YYQCVS&`0T<@<.GB:1,,A3V.8NA7NM@
MK%97ODR#+[E=L9B;;Y/.QOE'9ZN0J[411GDRKQ(O[9MFP;]]^$^E_P`5YQ2_
ML%Q/^WNMWL[Z=('J%##@3A3($@80SUCG43$/>\N2(/;,ZQA>ZWQU*]^VF]?[
M<CQUSNJ]TT"?VFJ4A:2!*]-V;NW[SV+/-M[QZ!W\Q[J"*CX3Z7_%><4O[!<3
M_M[I\)]+_BO.*7]@N)_V]U*OV+/-M^J'JIV+/-M^J'JH(J/A/I?\5YQ2_L%Q
M/^WNGPGTO^*\XI?V"XG_`&]U*OV+/-M^J'JIV+/-M^J'JH(J/A/I?\5YQ2_L
M%Q/^WNN[8VXALHR'/HA!E7#OXB^.TTL?T#$=.LC88QJRP.)EKC?)W/LN=FW-
M#RX-S"@#^FKU:-I<5!1?,M(==][4D/8L\VWZH>JOSJS12)5*DM(<L,3ISS[$
MB6TH5*F\DJ\RU.G`TPDH3S[K0*)`PTLL3+[0O,LMWN`/U4KJD%DJV8Q"/2AR
MB4F@:Y\:TKBJATR*:B93'#E!87WM3Z4QNKVT%N*41\FIM;W9P2@8`@4I,M^^
MI0=KI2E`I2E`I2E`I2E`I2E`KC'IZ9XVT.;_`"!U;F-B94*IT=WEW6IVYK:V
MU"3>I6KW%>K,*2HT21.68>I4J#2R2";+S#+[;+1$.3K4S7E;;=HJU76W`%UH
MZ>\NA<%P`(#;[Q7SM`(#R'<-^5(O&23-(F=(J_&FU^Z+7>'9%G40U/X1R,P8
MHA[M/9_]RW(\6R8[1R)LJ6Y8XO*QBA#F]O`I2"+>T'DD=]QHW66%VW77V@/O
MV*\I0C-&-X+EG';Q[MP7)$599I#W<Q(L;;W2.R%$4X-2X6]R)2KT@J4AUA@I
MU:<E04(C8:79>`VA2IPKH-RS(N&_&-;<\0:>L90C%'#*S3"8"QX&)DED\RZ$
MT9EIMTASTH=8O'6N]R8@;C4S4F:7"0E^14#<:LM$+2BM<)3Q%M2&-\?Z>(;A
M/.D@P<HP'AKA_P`;)A3[G)8P*<OMN1BXZ@D+GCK3X&/75EGD<*;+E25^DKC-
M&HPD%!2DHKVQ845<*Q2)G"MMZ5H^A)V[-^SVK>T',;>T&^WCMOO7F>8\PX_P
M)BR>9FR@^#'\>8UCCA*Y@]E(5[M>UL;65Y58KM;6E.K<5EQ5G,$Z-,<>8/WM
MA=PU53BVNK5"]MFO;*A^J;(C7KDQ)+LZL&%]!!;8SO,%68WB\`,=(=)R<-"Q
M#+U`I5=QKV5D,QV-1.ZA$0S"GNN6V`.ML7S-JDR_H2UARV=Z_P#3EGW'LLT*
MSF23S!#5J/?<W9XB$]/L[!4B.BSQC>#WXA;FH^T6=ZA5BM[2$'")X+3#+B[*
ML8S$:S!,X5B,IG2W2:3]+JF-LC1#+<"B62X&Z>[,.F["@DL;=+DJI#<N9G,K
MRR-5<C7$IUB83+.8DJ22CBQ`;;[+1#:N[6WV7;]FZV[;KV;@';Y=A&J,>!M9
M>JC!D%<(CI#U&9:U.QN+<-^R>9-8)@C;\@)=,V=$SX4VIF=B1L\?0JX:Y-,6
MO+=2,?R(U>K*)O!>;=>1?:%DK'#4U!SN4:Z2,48EUG9+UPZ9UVD-LR-E:9SV
M7Q?*B3&NH)0^-*9-%VJ=1-B9D#`H<FA0I5*8(IN4K$=O;4"-I90]F4Y6.9\I
M*1^5<IWIA\_SJLC4I2C12E*!2E*#Q#4EGR$:7,%91U`Y'O5A"\41!UF#\4W^
MU!<E:1K($P$+;8M4)$IK@M-["=(4<H*LO.OM"Z\`K4S2SJSU,Y@A#!FW,FFZ
M%8FP;/<=.^2XH\,.7EDOG438D#>J>6]/EJ-.L)BS,QKGAK27&)_>;))JE3'J
M4Q:Q005Y8TK9+5WIIB6L'3=E_39.'!>T1O+<.<HHM>6NVR]Q9S%=@7)'1&6:
M(%&G(55A1]I1HA8:%HV7"`#N$4UFDCBUNND1RT?.66](44C[1B>W$+!E:&+<
MIJ,@S9B4WE,*IUDZ!T@B5D@#NWQ,Q2L171,Z0E+WXI.D5W)FTXTXH.U:)>*[
MD[6T\Y?@,6P#",?9(38_;,RZ9TTXRI(+(?F;#KRXI6MOF$D>&C';B^0TP%JL
MLA8B98[+K"#-[;5)HVC7H6@'7AJHU@97SO$9O@3`>-H3IQR8\8AR&_Q?.N0)
MI)W&9(F\5J!7#X^ZX4BK2X1I0-AI2M:\R)D<DWWEQ#4JWO`OR'#G"`F&E351
MI&S[I^U&9-F,=Q#B]^P#EJ':B\DKYLG-PBO3MBMEC>)$;-!VQ.U&L$C2*71$
ME>E99%HF$B*T;K;[1]8TT\+YMBR;73$=3Z3'^7<9:KM1I^8V:*-*Z6I[43'[
M0/3I&^3'%V1U60\$'G>4[+0X*4@6[C[9O$`MHD5\8;VQM'K"[U3B%ZR=0.CC
M'4QS3`=/4-R5B3$T<9Y5DE]F.6%D%?'E&[R9M8/<#$["R0V9>^25-Y2PQ<J2
MRI7#FPX#$)"!S5FFJ`3ZZ9DXLL^32Q\A^FW3LSY!=\7:5F#5YG!'EC)*[&*R
M*X_E#4H?&F(1E,Q0Z<7/N1+6UJ>+EK<\#'60A06A*M>KK5)MY'G6LOAQ:O<@
MS/3YC#30DTH)]`6GVUFEC7I;R?/\X0CWYY28'F]ZCKG.)%"H;.7)]A<8<`M7
M(8DH=!2N:HY0#D/D@LMK^FH3AQ:S)-FC)^?,%R33(T2S5GI?:=..IB*9`=<D
M!%8':B1.#:;*<&+F*&*W&0W$HY`[@E:)JCCZ(TU"U"=<38>JL)N'-[3V^R:X
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M(766W0*&QZ)72=\N"]X?Q86U.W"[.5P7F`*Q<)'M@\.W?M?>(=N_;M#Z/12E
M*4#ITI2E`I2E`I2E`I2E`I2E`I2E`K^"E,G6)STBL@E4E4E&$*$R@HL\@\DV
MP;#2CB3;;RC2C++KK+RS++K+[1&VZT;1$*_O2@XNQD9BFD&$MI;2V0$MR(&>
MQ`DL:P1WVC;<E!NM)!&":ZVZZVXCR'D;K1$!L$!$!ZVJQGCE<K1KEL"A:M:W
M)DJ-`K4Q2/J%2)(B[/M-,C4'-UYR5.E[-OM<@B\LHCLAY&RS8-N\4H.N60Z)
ME/I\H*C$>+DBE/<D42`MD:['L]+?:%EZ<YVM2`XFD76`%MQ)BFXJZT`M&P0`
M`KAF[%N-6B]Q,:L?0=MO=TQJ-UO;XC'45[DD/N[9R9PN3-I5RU.;?]^80J$T
MHR[[Z^RX:[Y2@ZTUPR(L8N8LT7CK2+T(W/`MC&U-XNMPE@2(N0HTA`KQ$H`*
M$5?EMRP[`_>@`5B-PR(0XI43$XM'(P2M-M.6%1YB:F0M4=9;V+35);6C26'F
M6V?>VF&A??;;]Z`@'*NS4H%*4H%>`ZH]1,)TGX#R7J"R&!YL6QLP7.ZM"D/3
M)ESNN4*4[:RL:`Y9=8E+7O;RM0-2.]1=:38H5EWG"!5MXA[]4.''KCK](.&3
MF\UD3JUA4:D&(I?(4*,HT\U3%HSEF&.TA[1)5MPF$)FQ,H6*0OM$JQ.G-,-V
MLL$0$VG"O37H]=;N*;@DQVA<'=,?:CCLO23$6-LR2+%>-]/&7,X/&/(WE!IL
M=XZ3+WS$T3DT=1*?(77VJ+P7>1+$N^ZX;``0#NF?.)GI,TV24N(Y/E<V3R!%
M$&N>S5OBV)LD3B_$\->A2>YDAS(;$XXZDXH;5EJL#"CYQ>SAY)*O-$`L0J;B
MX3-;L4A<^1MV;])&/N)\EU>Y&TY8&;<49,TL->76'3)(T@MK49`D\^F$7MMQ
MZNCT?1KSKY18['7I4;?:HM/*Y@`^=9[POK1Q7-]>K3D[3WE_/,^X@>D+#F+X
M3.,%0ATR%`V++4=A;C#I@V9/D2!/[4QNPIW^2$KT[\Z6>Y:MM3.KBGL\DF[-
M6(KG3[HDSA6(KMM6/.'3%//F7BDZ-\&N:9!+)Y*'M+;!8[DR1R/&^+\AY0B&
M/H%+13W1J59-E<%C[VQ8[:'M,I*7MZF6K6NT]N[:^T/:MEQ@;T-,SBCY%V6:
M-<A:%<4D+:VN[*_V+TMC6XMSN04H;5298:;81>6L*.*N)#M]J\;PL`.WO;50
M5XTV:I=*F*=8VF61:<,XYKENLG2=@_'&))AA:`/60L;1N61V!7P!]C64)FC(
MN18X2L;RX@K]T7G=`>S)%#HFLM+MMM&1#7OI)S2LX0.GW3$S0:2Y&R-$)CH^
M9)I',=)')[7VM4:R;$U$Y5DBWV^V[FEE:+%YSHX@`$D(DZA3>-I("()CKRD3
M\T[)$URG_9FU-L9T3U%36('@4),ICAH'G@F)$I^:3`.4B&X)RAL67`8<(<P*
ML[1@AS[.U?H72J,MBP&]QD+&@77=CLHUKPVI%8^4V$O9,H5%GCVPNM&S8L>U
MN'9WW"J4.H;A;S>-G<4J[!VD;(+03#)OIKDVB)%!H<]E-[0^^X3$=D23X02(
MK>Q8\%N%RY+)'1E$#K+/;"-3>%@WVUXQE\<19,XA&09%JM(+)QQ#=4NE#W7S
MB_X*R'EB:QM^@6.V=K7X.+R4VJRL>P3'<TDR99?/6N1)3'RU4F!0G)56D7WV
MJ<CM?S3=:])O3X[:[4V7&LOZT(/BK4_IXTG)XS(IOE#4`CEK^01&S$`)8'"(
M84@,=YI+!5F676,XW+;BDMB8;E*DQ*IM)LO&S:N,Q1Q$-*&;=2N0M)N-,B+)
M+F;&+:<[RAJ3Q"5IXV#>F-!.K4LLY4M141D5J-8!K>L!D=EMR9P3*D9P6*$Q
MI=L7^EW'^1=9^<>(?KAQQ*FZ,+WMCE&C719)I$4<[1R-16%M@-[SD-*F;;?;
MJ5*JGJR06E)VX1O4(TJ4WMW#:%ENM?#NT,:X=*?%`A2?)&/<.J,4Q/1HCA$H
MS/BQES*5#YC)5<KDS\\K['J:IP0CE21R5S6R"3MAQMS62C<2`;K_`"EHA4*S
MAA6)F\:>=<[46GKWIG+N,M,=&ZRXI64@-MO7I+1+6G6]LE(8%QP#8J-M^^+3
MW`!YEOWUA=P<Z_,XR:.M"4]<ZOK,VHDRL$"A6X.K>B2D+AM[0(SE"I2424J&
MWF"8R^T\0`1`O8!&JQ6N/AN:L)[JWSTLPO$)`KPG/I%BG71%I0PS*/QXA-JH
MT[QM+%&7$1[<O=B'*XK**4M0O6.)J"Z.%FWV^Z+@GONO"O(LP<,_6SE?#&F_
M*\[@.17B59"U(ZC-26L#3'!)7@5XES`_9\;&$B#(&A-GE+*\`R4<.)H^:R'B
M?[84$%.HJ(LMW$^^A.W*Q]]EM!QE,::$Z!6Z/[(W)72^TMM4+W=N1$.!E]MM
MUA:$Y4J**6&7VW6C;8FO-NN"ZT0`0N`1\'AFJC&TVU!9STXH"WIOFF`6K%[M
M+G5W3HD47<B<LM"MYC1$==+EPF."HI,C-+<"34R<2CQLL(%1;=VJK1ZB^%#J
M`?F[1NG;(1J]RC@2#Z7)QBV18DOR3I&D.H;%63WB:JI(V2=U=,P-;KA>P?>\
ML&--LHQ,<WRR.W-[?:W+B4:<OL<K)^&MK`CFN:#9W1XNR+FW3%`'?1^VR+"D
M_P`B00Z6952PG%CI&#<G25U1OK8V2><X(?U"8Q:S/BQ/%7RX3'!B1N*FVP\;
M3;SSF-L2N-LZ6G3:F>U\\%D#4IJRQ=I=@Z7(,\N=WF/69)QIC>2WPXE$^KH0
M?E&5(8>RRB6H+%Q2IKBK<[N2(7M>)9AZ)(=[9M2FEEF#;LW;=;?:%UHA=;<`
M#;=:("%UHAN%P"&X"%P"`@(#L("`AR&J2F2=+NJ#3=A[B`L65\2FML-U,Y=P
MG#</9/GTF;IOGW(67\D9LA]C;$R%L8<75(\XVC-Z1>^QYQ=&AK?4/E"4RDL"
M4IMPW58\A4-C"RMJLWRZIO:6U"I.W`?+*$B(A.<;O;;;:/E#2[[M[;;0'?<+
M0#8*BN8I2E`I2E`I2E`I2E`I2E`I2E`I2E`K&^P@'/GZ!$/G$`V#YQK-5\.*
MC(=2;-KET>NNG:>2UI=<8X'U#YP=L:-[R_61#*S;`9EB4B0QV1Q5K7I4<C=?
M>4\288I:K).-(?11VDB%AII9@6#ZP(@'7?Y@$?X@&JPT'XA,_;</ZA,W8PU.
M89@3!.=>.3T$0>]2\`SUG:/)H2;$(NY(83$6C##G>ZQ<QC6F*BC$JH2V-,<2
ML))(*47CVN@S#*&9M4KG!<EZB5V?]5&FMNQGD)K:)3PKV#49A&/Q;.""5H#2
M'#)$/D4Z@>3CP;X4*KR+F[R!P@AP7$@#2"SRBFT+7%*CZX5N2,AY<X?VF/(6
M4WJ022:R+'X'N<CEB8M%)WY.E>G9`UNC^B*M"U*ZGMJ5*6K*&XR\3"?*F''&
M&W&W2"T"E*4"N$DL;C\QC[U%)4S-DBC4B;%K*^L3RC(<6EW:7).8D7MSBA4V
M&$*T:Q,::0H(-LN+-*ONLN`0$:YNE!UJ'PZ*X_BT?@\(C[1$X?%&A"PQJ,Q]
M"0U,C$RMA%B9O:VIN26EID2%$GLL)3)B++2BB[;;++0``"NR[?Y[C2E`V^7Z
M1I2E!C;KU^D?T;?X.M:B2G0+HGG&5C,Z2_2M@>2YB.<4;L;DM[QE&7":&NC>
MGM2(G`U]4H+UUZQ*FMM()4WF"984`6A=M6P>3E*A'CB?*TAQR=4FA4L4)E"<
MV\@\D\B/N)I)Q)Q5UIA1I1MEAA1I=UMY=]MM]EP76@(5`M+>HS49C?3QH5PO
MEW-$_D*[.&H#2+G#"^0WJ82=1*IGCV5N3VFS)C&525:[F+Y-;'I)>6I,8;S#
M4WO1,;O;J<X32KA"WWC?&&.\/1)!`\60J,X^A;4:L/;HO$6=&Q,2$U>I-6+3
M4S:@+*3$WJE1QJA1=98`FG&7F7B-UPC7>NHCUY<N\`^;?D/RA5?:%\0;.TOU
M6D81/UF:(U4<=<H/,%MA$6TM:OVS+R="*M:W)6MLG,D4J<6E3%N$"KK'IR2G
M1,Y>G\I>0:A,\C?[%@VV68=D?%`9I'J(R0Z>]%&6[-V7<L/*F1C#GETQ0G5)
MY.B8&]*CC+*C9%9R-2#%$&!G;E@MX'7(+URI4H.":;[VX>G/;;<;1#EX;B`<
MO16=@VVV#;PV#;Z*JJ\)>19A9-5V'B\J-.H+"#?EO33,Y0D3YMSSD#-[!K.D
M%TD8+DV9H6P2U[<6[`2AC0VGOA6.&Q+;8LCF06-66I+)3%)0M5T2)K%<>\3$
M^)I+`VVB``(`(!T`0#8/DIL'@'=W!W=/H[O"LTHK\2UM;G*TBUP0(EUJ542M
M36K$J=5:G6)K_*)U1('EF`4I(O#MDGEA::5=]\7?;=SK]M*4"E*4"E*4"E*4
M"E*4"E*4"E*4"E*4"O)'_!>+I1EN&9S?8N2OR=C^'S"!Q.2&+7&P6N*SU6RK
M94U^YQ:JQK5V.JF/M1EYRQ&>H(!+V$QI5AIMMZE!U#3?I0P'I(BTHA6GO'S?
MC>+3&<ON1W]E:EKHI1*9?)/("\.9!;BL5^T+%0IRA]HH13H21`1)3V#?=OT+
M4EH,TWZLY1%);F^/S>0.4-:E#*T(V++^5X+'5#8K7@Y*4C_%H3,6".R8L]2&
MQOO@;'(;TXBD$?:PB4*E"D:-JHQ%X["H\S1.),K;'8U'FY*TLC&SHR$#8UMR
M,L"DR-&D3V%DD$E6!RMLL#>X;K[M[[[KAYVE*!2E*!2E*!2E*!2E*#CW5K0O
M;6XLSF0"EN=D"QL7IQOO+`]$O3&I%9(WEW6&6`:G.,+&ZRZV^WM=JVZVX`$-
M.G#AXZ0'6/Z98PX8=:E31H]>6U_T[6&.\A%9CES:@2VI#4#G[J>Z+@5LC2^V
M$KNJ7)E?D"_;)1H6@%*4&Y#@WIG-"M;E8&W)7!(J1*;25*A,:)"P@Q.>!2A.
M84>G,$HV\+#B#"SB;Q`PJ^PRVVX(]<5\*G19AN?S#)D+@<Z,E,_8Y/'9F,MS
MCFJ>L<D:I>BN;GHAVC$TGC['5AAB*X4R%2<V7*6DL+0;#4HV6=E2@[;ITX;N
MD/2Q.5&2,/XZ>D$RN:5+"VO$OR3DG)5T79%AI)JMGA27(4JDJ.%-BFY,FM/1
=18AI3&E)DQ-Y8E$%66;U4I0*4I0*4I0*4I0?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g894296.jpg
<DESCRIPTION>G894296.JPG
<TEXT>
begin 644 g894296.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`\1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?3$5614Q?2U],24Y%+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`1<`]P$!$0#_Q``?``$``@("`P$!````
M````````"`D'"@$$`@4&`PO_Q`!6$```!@("`0`&!`8-"`4-`0`"`P0%!@<!
M"``)$0H2%!4A,1,6%U$T06%T@;0B(S4Y4U9Q=7:1E[C6&#)BE:&QTO`E)CIS
M>1DD*"DX0D-(5%AC<GBS_]H`"`$!```_`-_CCCCCCCCCCCCCCCCCCCCCCCE:
M3%VP:=/.SFW&LJBR6F/N^E4`C<WO";2(Y4TQ!A.6E3!SG+.%P4-X2!$5-&XZ
MS/E@R(:H+&U_6M*W$GGJ620"09-BG91H;/D4A7P#:ZDY^5&#JD1N9$#FB*:N
M!KM?)3F?3<=9FJ,!=722RNR2V=T%$8C&D3Q)W;*%0`EHP,L0<>RF_8?I-7=:
MP.WY5LK5:2NK-BK_`#R"21O?Q2(F2P6(X3?76;MZ",I7EX^IT#&M2$6!*5+:
MG8H&I4DI)@O9%1@2,XO?>TS4INW$H72UDL)GF%DWY2SC?4<=XPO][Q1-`%V(
MW]F"M.]-J1<WR-7<87Q<O@I#"M5%FL<=<'EP/2D.,=+>>XW]M?6HZN<?:&S=
MK75P7RI+,3XZ!'8K4I(>5,!"`4L8T"TKUD)\K:@F%#S#<*<2U<`TH;6R+@FE
M9'E=FWUT]DE*P/8:-;!5W)JBM%X<XY7$LC;HID&9S)F,B0*Y!%HI'F="MECY
M*8XAB<J<9+&6]@/?8XUQB1.CVWH&]D<U2;T=@]CNBE6-T2=I]M724;;[`J-1
M?-?J5<W;E`9_3J1L/>5-BP0#?[89,XN2U)5#@-PC('3PD),.^C]0.<XPY:_;
MGI355T:C4PJM9@DJW<&"R:WH',HROP[P5LI9DA+])F:SE\B;DZY&O9YN]M":
M(Q%"V#-7N*Q4X.AH4[<R*LGV=<<<<<<<<<<<<<<<<<<<<<<\1X]8(@X_]X.<
M?UXSCFM?+>MK;ILO#T@J01^*P*50CL_USB<;H-]364D9G=KG+'KY-Z@%%IG&
MWAG(PTA^LDL+=%,A"\&M">,)!*4(W%Y/]P$X^F/5=M#$=`>GU%5-7PYRV2ZZ
M)_2LWNRC(S:#94QEZH(K$I3!9VEBMX1M>R-Z"<HLRV02>!2)_>VQ*`$JE8UJ
MU&Z.:QL<_6;N=7FRL_KND*=U$U&IRJ*T7ZX]@$6FRTN_B2+IJR?;+H)@]1BO
MW6[9>@F\S<JEL*92]9+[IA52K!-LRFZQXB#E,6RJ#G)RE_T6A76ENAKKMGUD
M['3N`P8$=HWI_8-"+QBZ>U&=1*8%9D/L5UF_OA!AO;G%@FK0]M*I*W-8(\]"
M3$/V#R'AU;FA.4_*XDZI].&]=0#ZK!3*L(7C&H?89MQL]<@6RSX(X_25_=>8
M-F#*(UZS@G#(90BPS+,.B`[V#W=EM3Y2KU'TZ;)?7H+J`[!M>:GZ\)\*LVN>
M6)I?NUNS8UB4)!]CT=9/5E4?N<P,L642R`V\S2.+-C78%<M*5PSF.O4GBH'M
M*Y/31[V.;5ZA,X29V+ZB[R7WEJ:\:UT)`*THRB>MS?#6I-7[=<1;T5`["V;K
M:WV6`11B=YVN%)9`T-+[-6]/*)2>84@08<5IC$0I9T!24/0U/ZLMX-=[4Z4+
MI7P6MY&JT:U%V#UQO>$YMMM:%K=)9TFF.(M(XV]DL;ZU22-.&'P@@S"#`7E`
MH^@PN;"DN3U23:XXXXXXXXXXXY$[:_=&C],6BJWB[5TN1DW1<U>4'7I46@TE
ME8'2RK.>RV.+,[H[MB',;B:=4;E4LRX2Q\9$ZA&VN.&OWDN3X0F89V.[0M8M
M8)]:D`L$V>.2B@*YK*W=B9!#XRB>H_1-96[.QP"$3*<X5/[5(79O6.B=>ZNZ
M*N(_/'N+15O42>2M;6U'(#%OUB3L5UJ7;"EZZ)7Q\.?SKP?]7R)V!K1"K([9
MN+U`AOE_H($A"[Y=@V`V54X$2,\\R.`AF7'!T(+EHY^2.+8G/]*5_"%_'_3#
M^/\`3S].........<9SXQG.?/P^/PQG.?T8QC.<_R8QG//BK%G376E?SBQ7A
M$Z.#1`H?)IHZ(&<A,8[K6V*LJY]<$K64Y+&Q`:Y'HV\\"(E:XH$QBC)8#UB8
ML0C@8:TXVQK'>/6FI]JZ;22Q#6EQL;B_Q1).6A"QRHA&UR-ZBZHMY:VQW?V]
M&IPYL*[)9:5Y7EC2Y(/P=C)@@`DSZV/]+Y>?B$6/A^3SCXY_)CX_+X?'''KA
M^?QQ\?'Q"+'R^.<_'&/AC\8O\W\O/+&?././Q_HS^G&?CC/WXS\<?CXXXXXX
MXXXXXXY2#WFU/;-RU'I>P4[5EAVJ]0'L?U(O.8MT!BKE(3H]5M2R5^=YU*'$
MQ,`*4HMK1K4OLS:`\;P[G'8):F]9DI0(BLSMUT9VDV.W4MV\J@I>5MUO5S76
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M#[68C_"N/^K#_P#BX^UF(_PKC_JP_P#XN/M9B/\`"N/^K#_^+C[68C_"N/\`
MJP__`(N/M9B/\*X_ZL/_`.+C[68C_"N/^K#_`/BY]7'90UR<E2>UB4"+2&@)
M.^G3C3YP,9?T@?5P/.<BQZOSSCQC&?A\^?1<@/VI*5"'K0[`')$I4H7%GTVV
M1>VIP1*3T2]L>&2I94[,[JW+4IA*M"XM;FC2.#>N2G$JD:U,0I3FEG%`'C4D
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M?SBE_4L<S5G.,8\YSXQ\/Z\Y\8Q^7.<YQC&/GG.<8Q\>1QGS'1^[5`W-42.P
M&B=U79K'9=!V2[51-F%T4(_:"7"#V9#`R-F$^I&*4-6#G.//B49>'F/KA'E#
M*1.!)1A7O=;-?8)JO1%5ZZUB;(#*ZIN%L]?P<N3.I;T]HHK'R<I&1M6.Q2)N
MRX";4."T12T]-A:>025E8>I48&>/.&`8QXSY%\/A\1CS\_/SQD6<9^?SS\<?
M#Q\L<8!C'XQ?+Q_GCS\//GSYR+Y_Z7^=C'PQGQ\.<>H'QX_9?/SY]<?K>?\`
M]_6];'W?/Y?#Y?#GGC'CX?\`/_/Y>...............45^DE?O/&RW]/M1/
M[Y-!\G:M_#5WYZL_63>=;CCCCCD(+/W0MVG.R3K:U#@PH@GJW:5KV\G5_N<B
M8!K7=HBE"56WR.(*XU(A/S6BC?TLD$L32%0L;7D`VLPL00)!Y`HQ7-MSV([.
M=R%Y3'K1Z:)5F,4G%SB67=OLE0C,,A$6AKQ@;8\0.BGI$(H]Z=7H@3JA0/L;
M<$<CGBMO5E0=SCE?M[[9"O8`Z[^O37;K-UMCFM>N3"K21]`L.D4RF#^8F63>
MSY\X(T2-ZGDW<TJ=(F4O+@0WHD25$WI43,PLR%N8F5"E;T!013HXXXXXYU%[
M@A:D2MR<E:9`WH4QZQ:N6GDI4:-(F+$<I5*U2@9:=,F3E`$:>H/,+))+#D9@
MPAQG/,9U]>])6RM=6ZK+@JVRG!A&:4^(:_L*'S18RFDF`)/*=DL:>710W&$&
MFE%'!6%D_1&&``/U1"#C.5^...........45^DE?O/&RW]/M1/[Y-!\G:M_#
M5WYZL_63>=;CCCCCFL_WA]4O8YV$7Y1]@Z5CBK=":]H"=4Y8+DLN<JJ)*[$6
MC,GE5.X9@0TJTU1&91`SD3*ZC`F,1NB-Q=&AW2N+?@Y"=9QU=UEV2ZB!IG5D
M_KBTKUMTSCZE]+EDBJ7:62V!9;>K6L[@NS-W9,^Q["NR9?()$E:44B<W=84O
M.0J@81J&]J96]K(V%\>?&//PSXQYQCXXQG\?QY'W:#:2DM-Z>?KZV%E+I#JO
MC+C'6IY?6>$3NPUZ=?*WQ%'&(@F+5O&Y9+%V%CPX)$HS4#(I)1@-RJ7&)TA9
MIX(KZ:=O&@/8!83U5NJ%T/EF3./1%UG+LB5TI>T`:D\;9'UEC3JI+E%CUM$X
MLK7HGN0-:$]B1O)[Z`9QYF6WZ%`O,365\<<<A%M3H93.[3W'V[9\Z56;1\6:
MBS&_7'$KE,0J61SH3Q[>*?6DUPI^8%ELJ&A"D;&J&P^:J5\$BXQO[Z*.NTA>
M$#DPU7S3JQZZJ>VEI"JZ\Z]7'7=YM9PEH*(WJU4MI;7,QJFU8-5\JLI0W/25
M!*FB7,3DM8XQ(,1Q$H8;3J^:$-ZUKL!M(1*@L+AL(QA`\M<<8&V1OF)/(&]E
M:T3Y)`M:5D"_NZ1"00Y/6&9$8<C:,.JPLY?[L2&FI4&5&4J88B"B^>\XXXXX
MXXY^"A2G2%9/5'E)R0Y#@1QY@"2@Y&,)8,#-,$$L&1F#`6#`A8]<P80!\B%C
M&?P<7-N:$:AQ=5R-M0)"\FJER]20C1I2L9P')BE4I&4G3E^MG`?7.,`'ULX#
MY\YQCGXA>V<;MAB`ZMPGK+:%YPT!7)<N>6@2CV0+IAOP=E9EM$J_\V"OP1[&
M)1^T8.R=^PY1_P"DE?O/&RW]/M1/[Y-!\G:M_#5WYZL_63>=;CCCCCDA:7_<
MU\_G%+^I8YFOCGYFX\AQ_P!X3GYYQ_\`%!]W^[Y<I&]'VQ_ZO<[Y_P#M>;Y?
MCS_]W=L_E_)_O^_/F[WCCCE!W9NB[-B=F8XZZ3=A&FNFU<*:*C*"5Q':D<,=
M%TUG"*P;$49E$/97^$2IQ;D;7'ES8S.SH2M;D+FH/2I,HERAJ]I11[TWCW:H
M][M:O.^XO:#H'M14<0>[=>@TUK:=#8_8#C*%U#6-&&:5^P,E?1Q=(FF)E/Z[
M#BAP\%D("GH+L:WKS$B<U#LZ\<XSY\?#/C/G'SQY^'G'G'Z<><8S^+.?/-9-
M^G_<T7VCH-#FS>C6)+'Y%J],-SVZ3J-*RE)K5`F'8AHJ5+4RA/\`:H6J7OHV
MI\3*A3?VI*3D:4P'N$9QP%6-FW'G\?WY_J\_#_9QQQQS7T](9:TAE0=>SUG*
MP#@C[:-$F@H9#BY)TYC:\3YW4N*-6WIU93>XDJ%#0V'X`O2*OH3T*<U/]$:6
M$>(/=GVZ]X4MOON+<+S$8%9=+=7.L^HUM5YK5:OUG*C5KG[.V]B&VM>\)PSO
M*)GS<<'3FD5W74MFD8L./PDU`^(8\SL#_+G=W.P57MB7^[[G0NSU[<_H[R=O
M2@[NHIP&[(@DS1NTY#HK%\-=8.!P31+`UU'Z2]GEQ,9]L/C29[1BEB5$:ZAP
MK%GWTA#8'L&>M,=I:EFO7K%X7J0FNG7IJ;MO"-Q:^D[\Y11DVKIU=")8/75%
M`TDN1GSE[1LS(JCYTJRLBH'@YT6GKT[886=?ZM_#5OYZK_6#>=;CCCCCDA:7
M_<U\_G%+^I8YFOCGYF_YN/\`O"?_`/4'*1O1]LXSU['>,XS_`.EYOE\L^?\`
MYN[:S_NSC/\`)G&>7>\<<<HY[;>LO5;?-EL*2KZ1K#8K>"!T5'T-1UW-;C?*
M]=S*];+&=90Y,+/ABD"4B%+[,+5SF'QFU)/&WICCTM-9EZC(F]@<DAM7G6=I
M:)L[!-?[@J3H@>NKV,TFEN-3;-XV;LB[V*MES%-*MD\$8*XKR`8?!)G=^<9:
MZ,[TLFQQ;@TL<59GY#D(U$E;CL[A./EC_G_?QQRC%Y_[27`?_!/LO^_'`.7G
M<<<<<PW<&N]#[!HX\W7K3M:W"W1%[3R:+-]F0QAFJ"-R9%GR@DS$BD*)>E:I
M&W9R++:_(2B'9N$,S*)8GR8/(O6V#K#KS:\PA]@V52]:SJ<0(EL2Q.5RJ(M#
MV_LZ)DD""7,C<4YKTQRE4ULDP:FF9,S6X#6-S3,&ILE;<E32%O2.1/M?\GVD
M,V^&_LU1`<W0!`<W`L[,8:LS,)"EH31U0<%\RG]J"X'QI&CC!SO@6'<V+I$T
M:,7B8B"FX&O5Z4,_;@)-!;.9:VKRBGK5E:HUK56I.);/Y>S7&QV$GVUK`R'L
M\.A;9&EL7>HLXNR>&IGYU=)"W.*!`Y/ZE&C4'M:(M58[0;OL>]U_[?M9!Z?K
MRXAR:3%.48HR;R6PJ]3L!2TK$>6(Y-+&YK>3W584)9EV2&HP)T@RD_LXLX.&
M`O.`$JLP.!EI%9H,^?`RDJ@P`O&?&?5&`L0<^,XSC/C.?&<9QGXXSCGXB"(`
MA`&$0!ASD(@#"(`PBQ\PB`+&!!%C\>!8QG'X\<XXXXY(6E_W-?/YQ2_J6.9K
MXY3_`-\.V=]:1=6^R^QFM:I$SVW$$U>,T?EBUL:7P$'3SRS8E!W>9)&-\3+6
M=U=F%N?SSF9.Z(7!N)=34B]<W+TJ(U(;K!^AO[R;=6K;FR.J,]>W*>ZWQ2NI
M+?B%W<V9N$=7=SSRW&LYW0ERI`V)E9@+>-DTWDZF.O:]:`3I$U[Q&$S<1B1!
M5[_G'''*O.T^IM93==ISLC<&F[3M;8E,,3)FOFF'MS@P;&.![K,V=B0PNE[3
M@B9/;3!*'=QDYPHU'H:_(#9!)#DK85@A2X^V$T\1O?.RM9X92EH4DS]G+VZV
M5NA7FD39UF]DF8=&ID?+KUC\S?*EGK7L?:<1F5XP^O!QZ*/#TVR1QL6Y(^X.
MT;<H0_(F`#<[25!L_P!-V@RW35<`M:/IU*%JGL59Y*2V+C$AS@S'."4(U[$Y
M&MYZIO-<F)Q"L9W$UN5K&\Q:A/,0JU*01)YF2^<9S@./.?OQC](LX#C'Z<YQ
MC]/QYHWOG?[HP3Z1@R3Y0;8B>GHQJ],.MQQMLQD9L17%M/6T<?FN;'"F]_9>
M/L6;UK$='%,IRBP^F&&8D)$7%'"\KA[Q12D@\`3"3`G%BSG&!E?MH,Y#GQG'
MKE^N#X9_TN?KD8,9\9&'&?NSG&,_U9\9YY<<<<<<HK])*_>>-EOZ?:B?WR:#
MY.U;^&KOSU9^LF\UW^TG4B-/6V^A,L07CN#"3MP=VXK1]QQRN-J;1@4&Q`&^
MCI,N+202&QY8E:(,ZJ5T09US@ZMP5`URT;FJ.(^G<CQXO:JR`--4UM!*S876
M6OK+`HJT15J>9[*'&;39U0-*?!*==*Y@[?\`2<F?E`<Y&X/2_&%2XW]L-QC/
MC&,D%H'`T`3"FYQ.+'CR`PE`L-+'CY>0&%DB`/'G&<>0BSCSC.//.J((@B$$
M81`$'.0B`,.0C"(.<X$$018P((@YQG`@BQC(<XSC.,9QSCCDA:7_`'-?/YQ2
M_J6.9KYT7-S;F5N7N[NN1MC4UHU+@Y.3@J(1(&]`B(,4K%RY:I,*3(T:-,4:
MI5JE!I9"9.48><8`HL8\:W5?H7;O7VF:;WDI:X74%I_9QAFOD)<T1A#)V";)
M0=V$VKKSEK0Y)QD/^M]1O"9P::[CZ]*:W3B1A6+7@(@`DD<;L\^CNQ6,QOK[
M=3H]'6)B.==O=X,NAK,SMK48Y99=I;/86?*\3>F3969:F-O0LS;[1])[`U(T
MK:D^A1)B""[VN...0>[(Y!0\6TAV&?-EDMGK*=1PU$"0$4EE[#<^7Q;*H\WU
MZ;4)L=6('=):::R5<04UZO3+4I;=+B6A:L/+0$*A<U5=3:XU?W(NS7'7I=%O
M2,HA<,<M"<7LT;<[ON`(Z@2W'6=42X^G)I+U\M!8,.<I;1Q1;TVT3#FV)LD=
M-/DTO(L`$T97IWC[IN?4Q5,:HRIZZI^(&N2F.5M#F"'-:][4$*WUU(8V\E$8
M]/ZU,F1D+G][4EGO#XN*2)BUKNN6J@)R`G8*!DWG&<8%CQG[\9_2'.!8_P!N
M,><?C^7-!F9>CA:<OWI!".B7*63PW76<:V3+L0>*C`2UE`RYMVR+#7[C0X)4
M6(+B"KWIRD*IT&O(1DR]!&<?5!*[X5B!+2-AT7H[O6I&S#U=&QG8K5IT4'C4
MY<M;-P-EJU]G4#"<#Z5"SCLA^C:#U,*%.0%I&4HO(E*G)@!Y4'9'^)/4#LG7
M18LZ]]UG9U#S@&'&HDU[2VG=LF1$,>#\DEY16I6B1U7)"C1)QF$N#XJ./`6H
M`)0`2DLQ+XE:U]^57EXS!^R_339@PCZ3*=/LSHPXU88IQ@162"'1YUULU-](
M+("<X4K4+.B]<Q4J,*1EAPC*2^(;S](,K!.$4YT/Z]]GSB"<Y,#KIN%8U)*5
MX@Y)P')"*_:R>$B0X831F#(&XGDARG4%EJA^4F5/D+MEW+KI,(_8CH\["HN(
M@G!BW.NKYKWMLE(S^W>N,C,!L>..*PDL`4YAGLZ`Q3C!B@`$I@DY6%?Z"](6
MT#B0,"V$CVY6I!H<EA4)]E](-DX/A`:8(T.2G)QC\$F;.@P3E.JRH4J7`M&0
M!(J,&HP6G-$&2%:=U'4Y;6$N(=V$ZH84+<DA1MTNN",UN\*3#PDC*(*9;)4Q
M%U$IS@\&!)O8_IRQ@/+-+`8E4A)L`A%JUE9:+#G75AP:?-HL!$%PA4OCLK1"
M"/'D&0JH^YN)(L#Q\09P/.!8^..4/>D]W+5->]3]LPJ<V'$(G,;2L;6]-7$4
M?GQ$W26<F039^E9Q-A11A.,PZOI,1B+4ND$D4-R100SMI0#EQI(E*0!]AD3G
ML'LZ.,UA5Q,(S/8'-40)'#YG#WMOD,8D[`YF&G('AC>FP]0A<4"H'GU#B#1>
MH8`U.<$I22<275=V9K$:/8OIC$L6(T81]F[,,`EBM,D",`*+L=.,8!*32L#`
M!0J2IS!ASD`%"I*0,6#E2<!MN``YP4$`PB#G!>`#"+`@#"+`?5$$0<XP(`PY
M\X%C.,""+&<9QC..:VG87HM1DG[/>NQL7/%_(&K>"U]PCMB6B-;+W3%F:1YK
M/6]-.(<5%6EBE2)OKY*VR0@M:<EBB9$0N)]9$J`-*+)?-BV'Q=I@\1BL*8?>
M'N*'1E@B;)[V=%SXZX9XTT(V1KPYO;F:H<WEQP@0I_;W9Q//7N:OZ9:M.-4G
MFF"^BXY(*EC2\MSWC!@,YRY)<8\##GSG*+'C'S^>?Q8_'S-V<^,><_B_3G]&
M,?'.?NQCXY_%S71W'L>9=N&S,NZK=<I"_P`;U!IQT;`]IFRD05G(#7HH1@UB
M/1*I9*1ZI1LSG`$F?MR>FPT\F(1;VB.+S5!P7Z+/U^M>US!JAK^&U=64598/
M7M?1YAA\+B$<0E-K%&HS'TR9M9F5I1$XP!.A;T*<I.2#]D,6`Y,.,-.&8:.G
MST??][V._P#Z\WR_O>6UR[SCCCE9G<A(G.*]8^Y;\TS)Z@*ANIY<:LE,7BR*
M9RY`PFO[`EDJ:%,+B(M$.</,=/=&.%.R@](7&Y4Y-$D]N0B:`K$^NMU([&5I
M8O8-KY$XQVB=M^T[HI2VVI(IK;NKWV)4VI3H*7G)Y[O)'USE>4ZJ01PH(5##
M@MND)JI\_;`%)BS#'E+NN?/Y<<<HQ>?^TEP'_P`$^R_[\<`Y>=QQQSQ^C!Y\
M^H'S]_JX\_U^///$9)9F!!&'UPBQD(@#R(8!8S^+)8LY!G'Y,ASCD;[0TTU$
MNX*@%S:MZZVT%6+UU.+*I*LYN(\?K>MD9IDCC#B:8+.?\X0C,Y%CS@6<XR+&
M:_IYZ/KT[V`M"Z+-&JPACL4;D]([4V]V/13BA.R`HO)B,^GIM"@IOV!00Y`4
M2$K(3%(1%B"L5X/U/_26NAI\H>JZ_P!LM7IY94QH.JB&V`697%Z;!6!:<CKI
MUM&T8]&82^U:NM-Y>SLQ*1RJ6MC++8ZB=TJYL=O=\H&2[H%+TL8K&]`.GCL&
MU0U)KNI&_M5MK7::-:N325[J&N*CHZ]*0@<BE,B4N+FTLCA9+82\2#)R+)*F
M0>R*4T9^N2ET<F$*U'G"]QUM.]K07M(!NM4@;;F=F[TI;;2PZI=:;?B]8LD,
MS)Y.F;%#DNJ0JL*]4*8Y"K);U1+D].1#62D)FS?C$\*4'9]Z@:MI#6'LQF>E
M5(T/0?;E1^PNL,\AL$AU=&[:RY%]NVMUMN3622R-+[)+MJTR4CA,Q<4.&\N1
M-\P2N."5Z98O<)"#`U.2<?;R[_Z0J.S?I>?$&UM%O,>@\RVJE,TD\>GK7)8I
M$8Y>&MY$$J9YD\JC^7..L**<2HT#6VY<W-,<W@%ATD)+,S?])8V1B\AQDO(L
M>N#&09&$`\?LP><9%@!@<B#X&#SZA@<B#G`@C#D0<XSG7W8Y]VW']C[KI0X;
MIZMJ6"-ZSQ+;URDR?2Q&E,=(0_WTOJI15:4K$R&N0R$#8V'*@S02@U+@:@&`
M-H5!65(M@%R(RM2N25*I5-F5J9Q2I5B498ES9[80H(3+$IAH!%"7-N32U*8P
MTL10E2<L1A8B\B!FCW26B-L5_:1L#KU)NT[>^;U=J?76F-^-S#)WRI!D6LLM
M=QF#I+X#992>N!X/A"Q+"R&?Z*-G,+T8@='(1SJ-3[*8583V;;DW*Y6'!NL3
MK^>TX-\-D6!0^RFS`)\.D>TEUK"I`W3+9*?_`$1@0D2<TDXUEIF,&F$*GR6'
MI'`)I2@,912*?^DVF]/:':Z077"E6]6".10A0X2"4O9@%LSLR?/8BU<TM"P7
MG`0FODWFSN$;F\KS<_0IP81L[84E9FMN1I_LMFHGL--:B?&#5RVH325R*'*-
MJ8_8=A5H9;<6:T"!]1+)"C70<J118QR->&4E8V(U('M()M5*2UX?I<D8+%6Y
MU1]?NZF@*%ZK2X-O:COB@E2NW)JRP>(:Y+JPE[;;%P6EBS7^3JIRLL65971X
ME6[2U&FBV&@C!079N&%P^C:`EJ+HN...0.W"@N\@5;+:>CL]IARE;2T!89CK
MKM"W2DVE+,;4KP!Z:9#&YU`C/KG4%JQTTQP3(I`4TS"'RU`J;VV61M*KC\?D
MK5""!23ORNV0I8E9-/:"Z9P;*\PN1W&SV'/MF;4:V4].>D-<:8KP93%`RYS@
MHXTEJ>[1<S(PS^UY<'.'RLA,?&G.[2,LGU:CC#'?>ST_>X69K9O?<D<!.TA>
M/=B$A%[T?7411(G)Y<,D>V.B\1)65:XX]1@HK!F"P>\YQG.<8^&//QQCQYQC
MX9SC&<_'[L><^/GGQXQ\<\U:Y!(^VW_RM+=O.W=/$P<H!&M2III(D9@[N:H)
M5;VSOFRS':B&[REBA]"I0M>8XP@\P)2QY?PGK@EC<L&)S"C=I7'G\>/'QS_5
MY^&?TX^/Y/EQQQQRI'MWVWOS3VO=2Y31CO!VO[8]]-7-:[!^M4,4REW%`[AF
M"M$_J(@M'(VYFC[T6@9CT&5KO&Y7@Q.Z&FH2FA>C3K1?(]I._ML:WE5)"-;T
MK`HE#EMKIC55Z3M]3)G1KKF$["W4QQE/"F-O4IUB!TM.>10IW7#1*BA8@=?*
M"Y>OR@>I76QCE$&/]N]RNVV;;[1EM(H]S[L;9Z>L5<!@:#!%-5?4$U/S;=Q<
MN]B!+<3UQO<Y60L;S',<%+JHTIF*BP923]<QXD](<[)M&)YHEM'II$MF*R?=
MHVZXM<H@NI-O<7$R;)I+`MLJ9?IDSC1F-923*N.M+&[+G'`%HRBR$"G(31C+
MP`5YRW\-6_GJO]9-Y45V5XQG8WIF\XQGSV<,F,_EQ]@MG_#/WX^.?A\OCG[\
M\M;6MK>\,RUE=D"!U9GA`)`[L[JA2.C.[(CR<E&HW9I<"5+<Z(S2Q"`:D7IE
M"8P`A`&4((LXS_/;[2.@:S,]I=8P/7AYI2#5+V'6C:[I2[1X61%FI=3`X,19
MMN15[B+`P*"$<=CK.8X+J_\`JBG5I9`G.11["%B7)C0`V6:KWXN#KTC-::\]
MI])+*P@<*C\(J2N^P&EC)):^J5BH8LP-45CZ^WLB2*+'H:9N2%"W9=PRII<6
MQP=?>C@2E9F@H*HS%]8;MZA6/Z0/)`P#9*GIF1,.LVO:%B#I&YBA=8_+;H1[
M,O5D'UC%I.FP*-R*8_4IR2/9#6T.RS"WUS&A`<JD"=0TD[&`23AB"$!)PA#$
M$(`A*,R(0AYP$`0XP'SD0A9Q@.,8\YSG&,8\YYJ_)^VNE:,[0NRIZUF6-&VN
MQUQ4=HQK/JK3-9G.#XEM79&*G6JPR9B521$E*8B(55#B\H7FTY$2]`;DK*D7
M)FIS4*,'J$6Q?UD]?QVFD!G%C7)+QW1O!M&_I+3W"V`<?!ZJ93\U+ZC9!(:,
MPHLQEIZJ$!V8I6T92EI&],WISW,AO;BER1J:[/N......17W<N^9ZWZJ7;=]
M?,T7>I;74.&^-GUY*FI\"CY0W5L;72=V`GKAADL\55_6[.O<+`G*.'LJV2+(
MI&7A,SX(6&EJT]+'7UW9M^R]U:DZHIKCIW:F^K!D6YR/9-]UW@<NCM95W7%/
M/<Y=:4N]H7OBM:6Q1.<M[-#X2WQ9[=I"^/N)TRR94Z,JY$6AE>R?QQSCQC[L
M?U8YSQQQQROWL'T6QOG#:/A:RU5U6(J1V2JC9UL6M,,;Y8M?)M3*]>Z0YG7^
M]']I3)8R<M<CS'Y.F(&YN!9:<E(YM@`G^T1\WEZ2=*=ZI(FLB>0-LBURK[;I
M>S9Y:D=1N9S[8#=4BMC)40=Y;U<E*:4K-,(LP-\.<7-$0%[;V9,D&F5*%:4L
MW/O6SJ2J%HV<17@AF#B77:#=29]B*>E1QM`80#;F<T8VT2\2\,Z]Z!7@@8&]
MOS8J2!XCV5Y-I*37G$QQ%BR8<"*_I)356C3U2;''900=NG#C/M3W-*<-+'4<
MJ7!SN%1P5[@2<(LIY58RG+5X6K`",SDH"CZ<WZ()_BQHMT:W@:Q<SNC6\(A.
M"\H"UG<V]W0C-*4F8-*`M;%*M((TH6<!-+"=DPK.<8,"'.<>:*^Q%D[*+-V@
MU?=J"T+@MHU+ICLY&=CHC8SQN/5]<.-V"Q4SM%7F'*X+(V`;Q6H6I\ECDE*?
ME1\FRXDL!:HAH`G=RS$MS=4OD]DM9P*0VI`4=564\Q1G<IY6J"8-U@H8'*5*
M?`W:*I)TT)$+5+D[0?\`M!<@;D:5&XX\FDD`#\,U-[W26-D=I723]/)(TG]Q
MVEOSA\PHD;$GRQB4:C%DIPO>#G$&642@T02DX77V,1YN<%$X&9G`<W'KFYAD
M[(M:'IO:9-%I(V#;GIH7IVY[8))'W$G`53>O1+"ES.\M3BD-%CZ%8G6MRDLP
M!F2CB\ASG^<_`O1W[V;^WPO4<RZ(O&(!!HVP;B"N*!2!U8IV@UU/N57$XT.%
M-13<4NC=YXD36%F0HL*1,L0<R@3(E_<VE&D+7;<:OIA@JPI62/L3[A@@6%*R
M1Y-[")LNP$"PLTH>323HB26NP$)N<FD'")+6AP,HT90#A"#K.]5O0!LS7_=F
MUP.3VQ7J.*Z!S.A=J9C/(J^/9CK/X'(I`[R6H&*+L0F=,K0R&<BB1[9/6U]5
M-Z"&M8WP)3C(S#&E,\?TXL><8QY^?X_'R\_D_)]WY.<\<<<<<<BKNV]W9&M7
M+=D&O!,U/MEF9&EQ8`5I%83.[)"TI)5'SIN?7,&L?Q!IO8"6`!E*F%0R3&)6
MR5R8IK835[<->6M(H4ZRW+L84[A)[KL^G$VK]";.VA:#&W:=QS3FNXHY5S3$
M!KJ5N[!?NUNQ-=0%F<X;LI8EC-L.1(JTF3Z%/+L2:8.B.&Q6/9@1#3M*X^6/
M^?\`?QQQQQQQQQQQS6@])^U(UNL7KQMG9Z;T_#Y+?E7K]9H#`+1<TJLR41>&
M2W;BJ6F2QUL4%+24Y;>\MTQDR-6$Q,8;DAZ7A+-+$:`1=BE*:]4AJ_",U)KU
M6,6J&LVZ1R)]0PF&DN"=C2O#\L+,>7`DMS<'17A0XC2)1*/65B+_`&@L)190
M`^KS+?.,XQG&<9QYQG&<9Q]^,_#..5^6IU2]<%X6'+K9MW32E+"LJ>O"F03.
M:R-OE)KY)'I6240I<G(U%*D*7*DXD@D`\IDJ<O\`88&$O!F1#%.B+1A@AD:C
M<+B30D88M$F%DB<68&T!H4#+'H\VI&1@96\LTP\X*-L:T2-O1@-..-P004$9
MI@_(Q40,&SNM!O?/.I05L;0)L9<>JBM:U;Y&5=-9&,"^QR]RI$I,KU$]`E.6
MU7.P)E"=0.')U1DD"0>2:)LP6:6(5_@L9`(01XR$0!"`,(L9"(`@9R$81!SX
MR$018R$0<XQD.<9QG&,XSRO'2`8,]VG9IG`PYQG3SKHQC.!8SC.?9[EQXQGS
M]^<8_ESC'SSCE_O'''''''(D[VP2U;,U&O6#4JB=WBQI!"AI6>,QZSC:5D4W
M;"79K6RZNXW<!*!Q,JR26/"TLB@D?L7V7((6[R)'(334I2`:M/K==/6GBBJ=
MS669Z_\`55M_UO1)A234G9*P-C-P'Z>1.UVU3&'QK9JLB-0.3@[?:OZ\_=(S
M-6>XT9[>RQ,F(N&0.JU5(4S.[;??'''''''''''**_22OWGC9;^GVHG]\F@^
M3M6_AJ[\]6?K)O.MQQSD(LA$$0<Y"((L""+&?&0B#G`@BQG'QQD.<8SC./CC
M.,9Q\>0N2]<'7HA>4TB1:*:?I)`C>"I$D>TVN=4$.R60$+0N)#XG7EQ<*DEW
M)<``6E.19@58%0`'A.P8'`L3(<23EZ1P3A6JD2E>D7D!<DH@97(U*Y.>2%R3
M#."87E<C..PN3#."8#*LDL1P1@R,(JWM5.GB7UYLBOVP+[.M^9A8;DYT\V6@
MFE;E2(FRY(-3RY0[Q6N;!&BK+WDJB6$[B\-"D#.O9W3#:\N!9*_!YA:@K89X
MXXXXXXY#W?VGY!?NG.P%/QE[CS&ZSN!*&?\`ZW3.4UU$)$V`=&MP?H#+Y]"%
M227PJ)68PHG*NI/*XT,U[C[%*5[HW(W!0F`@4TI:5&=B5F;B:8L=QT?K%H-J
M/IC`[,KBKZO@&VT9VBMW8Q$X4VIKV)UVAE#=(7>0J*TA\?C+19[F7+FMJDRQ
MUKAC?'HYW<41)C'LW\<<<<<<<<<<<HK])*_>>-EOZ?:B?WR:#Y.U;^&KOSU9
M^LF\ZW''''')"TO^YKY_.*7]2QS-?'''''''(-]E%?J[6T=V.KE!KVLVM6S"
M`>Y4VNJ*?.%5F6^:JD+#ZD*-LAL4(ED*1N60?2.4C3N#88UMR=6IRZ-8`C<4
MVMCU;]9UPTKV%Z_7@EZ4ZOZU(A72:Y2)_;6=_I-LX[39HG%3RB*LD(AU?N4_
ME($DF^LRAM>#'XU,!`DB2>4$'9$L/;C"=S+^7CCCCCCCCD'=X]ZX)HI'Z0?I
M[`+&FZ:^=B*FUIBQ\%21L;9'YU;\@`R1QPFC@_R%G/;8\`LET6'J&-LDCB++
M?[+[N)RJ(/YAC=SLY0Z-V94C+8&K^P$KHN?VG6=+R[9R($P(==5S8MQ.(FV!
MLAT5=)6CLZ:I/7"`^5R.)Q$^+1X2M"P(WQ^FYYL23^;;VL46Z[,$4,D97X<5
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M;99%\D*F=<3B-_57[."?K5B5X<CB6`S%?I"O7+5<'TKVFW#07)MPZSQQNG7F
M7'5U)-G[0D&OI*Z=;74ZQN:!)1[BY&0=,Q-)#VH519F"B$ECCDG;E[;]">VI
M?5OR6_AJW\]5_K)O.MQQQQQR0M+_`+FOG\XI?U+',U\<<<<<<<I-[#-@MK>O
M6ZC]P:@U`FN[6O=GU-"JOO:#TNJ'B]Z<E%1R6QI#!+)CT>)8GT^=U[*&6TY'
M'Y@U%HBS(H[,#+(,NS8@<5Y+C@+13<_8CM0N^D9HRZ`6EI+J'K;-I_>\BGU]
M%"8I7=EURZ!V/7L>AU61(F.,2<Z/DJ+@G5D69/PY=R75[2-C3[2UNBM8%UV+
M\?#&,?=QQQQQQQQQQQRBOTDK]YXV6_I]J)_?)H/D[5OX:N_/5GZR;SK<<<<<
M<D+2_P"YKY_.*7]2QS-?'''''''.,XQGX9Q_)^+.,_+SC./CC/QS\<9QGG`0
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M:`<B5;9R_8Y@L0NPLO+YAS(9D=0Q=ZC9D/#'PQP:%2M5%O(W<QZ+/("C*0F&
M12]\^DE_Q!Z3_P"TO>+_``!Q[Y])+_B#TG_VE[Q?X`X]\^DE_P`0>D_^TO>+
M_`'(LUANKW_6SM)M-J-&JJZA4ME:B,5!2"RWEYG&Y::$O*38V+2.70@B$N22
M.KGIR5-3;%W)/*@O4?CY")>-(6TJ'I.:-27*;WSZ27_$'I/_`+2]XO\``''O
MGTDO^(/2?_:7O%_@#G.'GTDK(@XS`^DX&!""'(Q67O)D(?6%@/K"P"OA#R$/
MGR+U`B%XQGU0BSXQF*^ENZW?_O9KG"]G:@JCJ&C\`G3U9#$SM-BSG<EHER=7
M5UERZJI`:XH(]'Y0T$IE<CA;JK9QIWM4:H9CD"E82A5G'(4\I_?/I)?\0>D_
M^TO>+_`''OGTDO\`B#TG_P!I>\7^`.5-=X"_O&6=:EXIMIH?U8MU(FS36H,J
M5T).ML':TBW/.SM/YA.&!#/X:VQ4U`;.\1LF5"<%I2@B*&/2AI`>[$HB1V)G
MU]Z10:>H-^H_2UG)B@\S.06;O-@&<C.&+.08,@H1X!G.<^IZX0C]7QZV,"\X
MQ^7V=^D4?Q&Z7/[3MX_\#<?9WZ11_$;I<_M.WC_P-R,%VWAWN4'<>J5(3.LN
MHY=+=PK+F-5UFOCD\W.61]A?X17#S:#LOG:M>P-K@WLBB/L2Y(W'1]MD;@:[
M_0D*6Y*C'E:&3P:\](G$'`L0;I<\"QC./-G;Q^?&<>?C_P!1N<_9WZ11_$;I
M<_M.WC_P-Q]G?I%'\1NES^T[>/\`P-S!]0[3=^#MM/L%II%JOZARK,H2NZ5M
MJ<O;Q.MS2H0YL=W8E*:(M\5<T\=6/BMY;/J@[?60AUC[,WIO61Y:W%WR:/Z*
M8_OGTDO^(/2?_:7O%_@#CWSZ27_$'I/_`+2]XO\``'&'KTDKU@8%`^DX&!#`
M#(Q67O)D(/I!A!ZPL`KX0\A#D7K"]0(A^KC/JA$+P',7M0=S_2`=UJ<S=]45
M7U!L<4Q8]N5?ENGTYW+:I%A_IFQ7^LI0MRE88[)&WW.X2"-N"E@/PZY7*6D2
M8]Q0-:HP:(N4`GGTDWU1>K`>D[`O5%ZF<V7O'D.!^KGU/6QB`ASD/K>/6Q@0
M<YQYQC.,_'EW[5ETRV-V7L*$#QE"CRZ@:QJ#&T+EE,5E>%`-4$"D:(*OZ;"0
M2@(3Q)\%"."$S(L8]AQQQQQQQQRMW9ZV=*^M5TLC<Z?QE0R6IM;-M=:6EJV'
MB7/4^N:2,KJ"LZB:$;"]R-%&$**!-<U=%SN[)\QY&D8?:SG14Z/)[&A760A%
M@6/.//\`G"#\?O"+(<_H\XSX_)]W.><9\>/CCS\<?#'W^<>/]OCY_#[_`(<I
MLU&W(TOH[8J+]4E,Z\;`:W)QLMR6-KXX3ZMWEDI:[T#5-9%-+D=J=ETBF<DF
M[N01*WJ420:N8,$:;75&<)PBYQ[`X1<3K<IQRNWL6G>JZBOH'K+LS63K?O\`
ME02]8BK_`%[CBY.UR&R'77MC5;,OKR0ZKIE7[:SM-:--7%31P<'*7-254Y)&
M&-%`<U\B1M2N6=`7G6VS-*59L#3SYF25C<<%CEB0AY,2'MZE9'I0W$N2'"]M
M5X"L:G1+@X:)V:5@`+&MS3*V]4`!Z8P.,O\`'*;M_MQ],:$V;T_%M)KQL+*%
MD&NV/,U3[4QNMY`LH'7N[KWC;Q7K`T3:7)IC'3')ZEL0=ER92C:H;8[1'$#B
MA7.X6E[.;2PW'AR'QCU?ECR''S^'JYR'./C]V<9Q^7Q]W/+CE;BNV]+*D[,6
MJHF2-JSMX=NZ+5/LXD<?-<'!$DJ'68LY5#4]@8<I*6RQ]0H/GKX5#TL9CJA^
M>"PK%LG&F:"V!:ILCXYZUY=FE@:7-]?W-N96-E0+'=X>'=:F;6II:VQ.8N7N
M;FXK#2$:!O;TB<Y6M6JSBDR5,2:H4&EDEC'B$/7RZ:YN%'D*=/:GE4!UCDDF
MG-CUO+GU*\,[';:JS)H]S65V9`6:;2!TL@<%FLD>7*21F0R9GB[1)6EP2O,$
M;%$'61]R6SPXXXXXXXXXY'S9FNKWM&KU$5USV+_R7+),?F!P3VK]D,,N_P!F
M8VY8(]]C_P!19XN;F`[ZPI,X1>]AJ<+&CU?:48!FYSCFO/V@==7:O:M0D_5&
M^*/VXDQ;QI5'1_6/6M3`K:)S4]Y1&Q+"G$;5QN^HO4D+AS],VQ!9=J11IAJV
M32^-PM@B""6)!QN)B;-I!`!66C3`7FIU"X))>%AZ1,8C2GJ_4Q[4<E2'*UYR
M5,<H^D,3IC5RPT@@191JI08`1P^WR%NT](;?VQ(ZX<]9]WO\D^/QKWABP8U_
MDT5=?'VF>U.S$K;_`"]6`[MJZ%X;&Q`]-.?<9:G*S#]E>=C"EJ2`'774SSL_
M;O:^X7/;'7;=4,@<,C\\U]UYO^Q)Y3Q5<U?1WL^9=85AIH%&YS(K`7VKLS8$
M;C;`B.<&1N##:U:(@S&X;%2VP</5\W\O'*6^S/6>TYCMAUR;EP")2FQXQJ*?
MNW$[-@,$1D/<Y4,FTFJLEK6'RN-1H]4WC?PLMCM478'Y(@6&.*!IEV9")&)E
M97Q:@D1U%ZNS[2_K:T_UIM3Z`NRJRJ)N3SU`G7)G,EBE\H>'F<2&+E.:$9J!
MQ+B;G)U$9"N;SU*!7EI$H0JE20PE2;8YQRA_LI>=F;+V@UWK&,]=UV[/ZVT=
M,X9?RZ3L4]IN"5Q,MD61>`-.@F(I;-4<V<*GH4;DNLR4-K/&E(YC8*:,(/9U
M3)#71!*+W2\"P`.!^,CQCP/(0Y`$0\?`0PAR,S(0C%Y$'`AC%C&<8$+(O.>>
M?.,X\X\?EQY_+CSC.<?IQYQ^GFM-7&AW8]7W:]I?=]H2^B+DJ.'PC>-?;=U0
M*F)3`9,-VNY3#5#<TV(;([\DYC_/)""/PZ.P%ZB<69H)7]?UZ.&$PL+67&<-
M>RUCSXQY\>?'Q\?+S^/Q\_A^GCD'.R^@K)VET`W!UWIYS(:[.N+7RRX%"1K%
MX&I`Y/[['E)*...3H:,!#8URSU1Q5S<5&<ID*!Z4*E(1IRC0"K=Z?-:=DJ8O
M"^)D^P>S*$U=E&MFE4-CNO\`9LA6K@-.T->U0E9=A9+7\55/\@11>+MZPI!$
M7:2QSW5%K3D*4V11O$@9&EO?S]@7CCCCCCCCCCG&<8S\\8S^/XX\_''RS^CG
M//BCK)KU.>ZI3YS#B5+$%2)Z3FRE@+/:`HU92%6)S)&XA,;PIEIY*11E8$C!
M"HXI.;D!Q@`"[!4^@YS86]%3&*F-!SH4QE.A<C91MQCR=D."6DM<!<)(-S-R
M,&"V\!PEAF1AP`G.18\_5X`#&?.`AQGX_'`<8S^7XXQ_7SU#A(V!I7M;6Z/;
M0W.3V:(AG;U[F@1K74\`BP#);4BE04H7FA&:4$1:0HX81&`#D.,C#C/N><9P
M'.,X%C&<?CQG&,X_3C/PY\H@GD(='.4,K9,(LX.\(P3]<FI%(696Y1+VA.8K
M3_69`G6F*X_].D*,4D^]R47TB<L9P/6+`(6/G`W93H@!,#:M;"+&?[*`89[$
ML@$J_P#I@BP\Y"(__P##C.3/]'F30#`8`)A8@C`,(1@&`6!!$$6,""((@YR$
M01!SC(18SG&<9QG&<XSQD`,Y\Y`'.?OR'&<_U^//.<YQCY_R??\`/^3G/'./
M&//GQCSCX8SX^.,9^>//.<YQCY\<<XP$(<>`AP''GSXQC&,>?O\`&/Q\YXXX
MXXXXXXXXXSCSC.,_+/PSS47W@AS%U^]UB:VE%0IK(UP[I=:YKJE:%?(8N0Z)
MI)MM%6I,F@#2L(;TQYZ`FX$PX=&W%8<06C/5R*:S)Y&=E@.6HX<:37I-]!--
M-[-`[FKQ/:3UTC71:6T9Z4<;6HX5:-=$),6EIRA,=5[:N4M8Y=L'(";7.<33
ME#\RUG!S#49JLU&!,JM-L'M7WJU[UA%<UMTG$W&.WC->O6&ZL7:6VPYLC;L[
M;?H1&W>9(:W8KPD2\Z/4N-O4NU5/D@ED,;YZDET6C\ID`EL<D;^[PR[/;MV*
M8[*ZBK/W1I]SA[Y0O;S9^(H;!V-IE<VN77>"Q=CF%?V0BK6MI58YL<G\PB^,
ML;[729Z">IF4:4O2!K9XX],Z=)LMZ!;$*MK-2ZKV9%/X-9#/<[*JGT875Q&7
M2.-$?C2]<L`@@+DB=GY_<W">00"4R)6$X'Y9`+9XTOV$,6C;?A(UIZ+M9^['
M9:_91H)+548KE@K'LOOK>[7V`Q(F#OJZ7:ZJ==LC0TA.WAVQ-4Y5G'NBM&L4
MW0Q*TT30F$JDZF%*XJ2PK$C[Z7T:/66NKQZKU-NW1'HQ-;+V-2;<4).[*(8W
M!FL]]IF:WC8*^:PF8S4V1NY\L&\SA[E,N1/66YG7-/OHML$%Q-0"=EOIDNF6
MJDL](UN+6EVU\J#["W7I*9V0VM$5=1%#$T13A>K-"QKVIH3LP4+4^D1HS+8A
M?T1)+PC(*)`G6@"0`(?65GV\]A$?U-WTVY<8?J@X:Y]:-Y[4:N*8"V1:W4MO
M6^OJELAD%U]?,O2J?OD<C38TRZ51QVN-?C*E7)(X"19C*&,*DJ#!LTY=OAV)
MUO3#I,9M!*:C<1E]ZZ8Q:FKZFPHRVR"R*GV/AX#;;1U-KC7-IV?([1OZ"V23
MF/4-6Z5P1"MZ/2MA/&G>%\-EC@ZU637MNWLVDU1Z^EC=+(51U@V+WB1_1*XG
MI@K1Z3AFT;K&=QZ80]R=8@*SS5L7:7`Y,V(+DKABFX\S?*!<R-<ZB<9<'1G<
MI"[Z=SV_FM%D]N;)`"=8E\+ZP6K1&9M())4EAJY3<"/:!UKMDEL4>'!'=21G
MBZ-"LF3LY-4@;FE<YMB)I;6<:-S4K5K\D^DLSO&VMUH([=&:V8A2%CR72B/Z
M`2:DWF)QB602+E+=[VR'A]R62@=K`?ULCC-0NDU1G@D*-^A;G-4S*J2K@14V
M0I1QW.VUO8YV1ZFP.G#9-5-4-+I;?:?0VFU936U8LWJ4]KZW7W#E+R3:*R$4
M_?3NHKZQ()-6=^AR@"UV"QRQH);I(U1DK"D_!5>6PG:OO=<NGD2:TL_K.M+"
M9O2#63K!L2>U_6DD:T]AUG")BWS*.R(AA4VFK<8BF>E;0D9[(BS1*CE,QC03
MX\CEL<2.;V-TW1F4IU(:&PA]7(7-[)0I27AR:VT]F;7!U*(`6XKFYG5.CXI:
M4*Q8$Y0C;%#T[G-Z8PI(:Z.!A(EAWL^..............8WGE0UI9SS6,AGT
M-9)4]4S/@6C5[B[)LGJ89/RXG*8.7*&<6!AP6Y`BTTDK2`1P3B0%N8E`2L+$
MR)0F^66ZU40YNMZO+K5T1=EVS49C\,OOWLVA<TEJQ2+19VA3#'IBWK1'H71I
M015]=V,"(Q.$HU`O4%GX,R+`@QB:NJC0YKU?EVFAU&_637&:-3*PNE>SRR+;
ML03:PQ9V6OL-8X?+)S/)!-H`SP1Z<5[O`6R"R*.HH0Z+5;A&26U8I4'&_9*.
MNK4)P!KV)]K!TE+CJW8Y-OTK(9A:-O2Z5QVT2$C,WD3R02R1SUSD5CR4ELCS
M*TDK[+<I?@AG;DS0044V`]DSDW6K4C7S4",2R%:YU^"M(A-9Y(+-?XPADTS?
M&(<XE1P%$C?&EKE<B?D<:$\J"BE"YMC)3.SF'E%G!;@&`P+F,X7UW:>5U9B"
MVX?42-BF+$Z70^PC*:4S3$=K&0[%^S9O61U+#39&.)U;(K4RD)^MKU!&9B7J
M<&N($1R`#T]`<<JZPZK4%IG5#;1>M<`35A530\2!_:88B?Y5($+<Z2AQ,>)`
MH0JY@_2)W(+<W4Y0Y*$A;AA&%:I5*24Y1BD\1GHD.F.N3=M(X;IHX&M*V:=8
M']EKA:`IY8QRI56^%93B7!1QDZ6F0C$6(<R"'=,SEQD"5.\DE.Y(0.0?:L_.
MUOH)J#5-8WW2\*I9@)JS9V5SF;W[!)"]2Z<QZS9=9B`#9/WV1H9Q(I'X6RU$
M402\X;QH"5(DJ4X)):A*0:7ATWJ.T$5T;`=<7*F'E[JJJK#K:T:X;)!=5\R"
M4P:7T^!U)JXV+V2\6:MLEB88&B?7ILB\0;)8DB;0TO#HVHV4I*X*@F]AGZC^
MO%AK(-.M>MD>35TFV3.V\9H_B764,44V).$G]>R8.\9FF'^#+<%)2$066(NK
M-&L-@1-8F8:`PQ.+VEF]5.A%QN6Q;K8]!(Y(JVU0UDU[%%CL"V&M!:353"EH
M5U4UO;4R3QL;$+;`3V%F^K2&/I&9*A*;4J?Z(Q.#)0O<./6-HT]+]BW.04*S
MRA9MI7L,JS8H<LE=A2HJTH17#.V,->MCXCD,O<D2);!FMF:R8E(6%,T21@4(
M4[@VNZ=Q+]KSUS^L/2IPK.HJC?JJ?I7"J)L^#7-5Y4QN2\9=)(]9M8-)#!6T
MM4SF0V2XS:1K8`P)RF&&(Y/('AGC3&'W0T-B1`(9`O7G=5.@BFOYE5ZG7EG5
MPF>['@V]D;6LFMGJE8]F0JL+!72R/YTX'(XG.#S<?1*W&).[&2L0B,;5*8UO
M..3#L`;T"-K0HFQO3E(T#<D3(4*0@/J$I4B0D"=,G)!YSZA1))8"RP^<^`AQ
MCX\[?'''''''''''''''''''*J.W.,[GRK7Z&M.@-\.=#;1.-H)6ZO7(1,66
MP^;FD06>2]57TV13&/R)F)02D4,3-32_#2IAQ]X5IU:U7AC-=R#H5:&=L@=T
M6!DM:6);`KO8+5"C-D6+=[2E/+(+6Y31?E62>F6)M<5Y%QO\)C["QO9,BG9\
M)=YG9$0B+0O,=(U.7L]S@V%R>:L![/T5GS>*UPQ:[RN-O<W>TL89Y`_;2]:D
ML9&9T=`FDM[B\1BK-ZYI9C\UIU>"1+VJ!1"32U6E^E`RLBY7ZI>(AZ=N'8+7
M7;[L7KA.=M)3N%K&SZ=0"X[.DL\@$#B[?0VTMC3`])#JL@J6OFIH)96I^@C"
M_3E#7RM<>H10%P87)]<W!\PDE,H^^ZA-EMD[WV-[=(-L+;1MI)M;=XU-)58!
M/%F2%L47@<<CCB6E;&:.LF#0I\JS$Y2UT6N3F\.KDX?2*U;B/U@%%7J\<<<<
M<<<<<<<<<<<<<<<<<<<<<PK;-9R>P9!3#NP2YDC"*K[21V*^('6(+9,IEB-)
M%97%/J\VKTLNC1<6.-3R]<MR]J&^4!`H1HRL,XBA*,F1O3=<6M[?NO:.[S?$
MFHJ=7UKNJUYOR'+&%D=(/;K83+(?((_,)6T+T9Z=9*&UGBYD,>#51"M+*(X:
MRDN903XZ2:NS8BU*UMC2LB0P'7O7J'3AE&)RB,L04=7A2R-R1.49EH?$QC,T
M,+O@QM6B*4Y"VO;0M-+`,E.Y(AFX4%UXZ0=9FUFJES2.R[/[,[+V3ALL?[4L
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MDUD.U+%A&_TY>*ZIF1PVKI$]-\:E$<0O:B2(KA,)]7-;!C[A'7IC=AN`5HTZ
M]K=G$!9L89'R0-N2MM=^*1TRE6ND,MEOL=QD.TUEF4_3S?7T).FA[W8HD:18
MW1M8G1N*14VGO`5I)+>M-3F-N#?I<N"Q`028>&/E8]R>GER5'K39U:F67)Y#
MMK;DZHNEJ.!%&=INAZL^K0NJBSX^\-#[+&R$QM%7K6TF/$HE;M/28@E;U[)A
M(^K5SZU(E,>I]WH5"ZS'K(8]9JYL2\6'L/L6S6=&](8IAM<H5&J.9WU-;T45
MQM\D4=<4MR1.<8C30\1ISR6S,L9R_P`IRYNX,1I"^V#[8;[4MJ#*Z3KB=M\X
MF=J[#CLK[(:NK1IC[M,YL144722Z?F,*:52N&-#JYMC6XM9#'#&MZ76#/7IT
M0QZO(E*WLPU"3!.P.U:GZ!V\VW4WGLRYQN@=?-(J9V">*3<=;SD"^)9GTP8&
M=KG[9<3;(7-_FS[83E.XI7K;4RN+M1C9(Q8$`Y$6A5N;WD1^[K=6(=&-MI1/
M8)L)!"M((A2TUV.:'Z`Q%:]0AGV#2QATJC"8F+V3(44D5R=AEC<_8)8%ZXIN
M0)W4AR4)G9I6-@,);"]SE&RW6+L`7TQ9MK:RVQI]`Z+E,KGUC:V)9XY0>*;)
M(XM(JBMZ/U"]2]N+L**25A?TR83:Y+&N11X]R(='N(F)2$Z9?@>9[[[BWUVL
MUOHI0MLOE05I%=!JDW)=+1;->(#.@7,].4U@\CEA,QBTVFB%3%:LG%9&/E4Q
MM/$Y5'Y+#;AE9;BM=WQN8V\\F0VG_;I52W3S72Q+#N6=[@6OL(^[;*:T+K36
M]NINQ++C&LBV;S6SU3?42Z<9C;&VTY`VANC:UV73-*LG3\*/-L?0/$PEK<V+
MLH6_WJ:*4Y%F^<NZ^VY'#B:'H#9JP'^,UH>7]CU';-3!J@E1SNQ6"6O43EN2
MWJ2O+>D=(S!H_-YE&TJ@AS?8^B;5*12H]CL]W<:::GV%==;6(@NY]?=?ZFK&
M][*65Y6&);'FJF[6E$4B$?L5._XD;<@4LB)YFC$!V1"$1(/HCS?<S,\GE?0"
M]K"^TAILSM$5=?U>U3,I)#X_JG&MA)%=:-`B-8SU%F.4.<JX<&O!C\E/3UM]
M37=>G>7]6UJ'U7.WAE8D;&A;6=S=7")'9SO)M%%.QC4#KZH6SU^L4:NZA;]N
M:9[*%5=75ID1AT@#&]+(PO>62R'A"PF557N8LZR.Y491S#(%K*Y-V&B0)BD:
MA.NF-3'<-J3<"=B)9UME)%$RUHL/:ZH7"3U\7$T^PM(U$_/D7G\XJ=N521:L
M3*TCA'E#TDK^?_4J>J(HYM4E2,2IA$L<TF1-'>SN@.P8*9TU[AVP9T%<*S16
M:SVQ/:.ET"J>0)CYN_P%SB$:GCUCW+(YU&GR.K!2-B9#5Z9`C,`,IT5*DCLC
M;<46WW1ZA5/8M@5P)!;\^/K#8ZK=0)I+:\A+(\0UGV?N)M>W2$4Q[:]S.-/#
MA(#RF%6C?9`W,:F`Q=Y/1L#_`"]`]*/8@06UU[CW&J+-[)P[MV"_26L*9[4(
MWHWKL*)UK&#7B-I+!02(4/99%F)((VH>$`%K$<%?*7G+J[)\!`$W*@)W@-C*
M?MVT_/-O9MR[3PB4T+MU"=%G>%JH@6FDL[V?LB0?5J"5I6)9CW[IE"B2N(3C
MB'M6[,C`U,Z-QD,@<6AC;'!>F[#=VPZSO372:-C8;D=+<V`M2^Z9KC78<"1L
M5TN$\U?2OJZ_4:QOE4F88(E9:R1L1AKO+"Y^IB[H>Y,K=&75[=70A`'XQG[I
M]*9PGU^'3[I8EWN&QU-2&_X7':SAZ)3*VVJH;/"ZRF[Z\QB6R.(O;H]0F<DO
MK+*Z^@".<V,RI8=-I.IB?U/BCQ($^70=GVJAM\DT*GD3\I<#=FEVEXK$);6O
M-9D;8M]8#MU30ISJ-^!)OK<&'E&EX>2HB;`OK:4;`!R\$V*-8@6&XSC.,9Q\
M<9QC.,_DS\<<YXXXXXXYJY]BI%G+_2#^L)OIEQ@;=91VE>[1<<'93?(%L-,4
MJ8M-"<%O(XRI3O"(GU`FJ"UB(ER&28EP48V*0*?()WZ:]:^P&A6MN@&L>NVU
MS$U06@[(FTTV^.DE0-SZNV>:+"/D\LD$:AYBUW5'U,D23:0"]R'-BLQR(:DS
M2N7NBTQI<F"5Y9W^T&ENXMW]>5LQ^R8W!DFD6T+9L>[,CW'G5Z56/EJ)9T9<
M0;5[>Y("(OE0F2+3#'Q4D?<%*#$@0-)A19^3*WM<^A^?:W1+2.1--[P&>79H
MCMSL]L/`E#K%)3%*XL&$;91Y$R6%6LD)1.LDD,5?F-:VLCQ&)R@*E*,7N8UL
M<(CD#Z:N:OIZ8Z%'&A$?5D^P+8YF.L;0&Y]H;FG[M(ZN<G"*7,_[?)4)5DAC
M["BL%N<X*"(E-36V0).J?'Y,H0("5DD"H<3%GMDT.VGKF7]D%41>I!$4;EE:
MFNQ!))#9\:F0[$K*R'YOC:&LKGI*PH$[M3W%)-62]"[O+[$7(IPA]MMQJ*'2
M8EI("DD;)51V*=:\PHZ+[W;ARVV('?;7;O7OK+U_$02ZX9*'ETE4M0VO0T%:
M;5LF7LTC)/\`?<TE&%3LJ>HXV%O-?2-P:9ZTJ'YPCPFQP^>9M)]@=FH!V/\`
M6Y8]&T%K9:&UM':]6G--PX%?]T[8*GY+!)]'ZUK6$V8FNUIKZQ7-Q8*\J=<A
M@),2/1P=C:DB\]_+)EC\K4/N:[2Z$K4LEH[*VP>R==M(NP77/1NARSPUS*%0
M:K.TZBM810^3F$YE1.9@5/DT$<%9#0$V.#CI[HB+,<7DM$HRLFC2O6)9-4=@
M#/NZHMR!/1#9UM0/0T5=DQ21HCSG:#JX[(0V8&3&/"@!;<YOS$8C%%\LHU:-
MF5`/P^*5Q`B3X+4KT-['ZN5'UWN%";:U4GV<Z[[2V@>HM+9O4TU64U;]3;9N
M^76PZ[GD+9;`1REI6M.3U)#*\,DC/RJ+$,P_V!:-O6L^1NT#IEVU['C+$9Y?
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MJ\X.+NH:CR"I)[O4I_>K@688C]I*/``_"8C6[NEJM1#M5O7M[$M,M6-CZ7I+
ML<K^2JXL\[`7G1LUD-Y43#JSK"&2DBDT<?D6ODKMN/2&QY&;';2G<C11^2N;
MDCDDQCS4LC$:7MDN;EZ$+6LR,;N'-&Q==M4QV-[)*M[&:W3.T`DQD;AT@K=Q
ME0,5+/E""2#<WMI<VB1X"9,(R4V+$[JC']&Q&HCP"*XE_0;=4PB.W3P?MO!V
M*^[B[%ZL[.Z+L&+U+(&V)U%?%:`EA*:+2*)N4[?7*40L]#+W)N0N*:0IG9$8
M%(ZKD+L,@UN4SNMKK\V,N"X]$=V9K;-).>X>FJN_4ZIC8H1/89KI-XAL35JJ
MN7Z(MJ=7+)]9$>.A3EE!,H_*'!=(54@48?8\YM+.VN;,IC$`'KT=0274_4/4
MR+6Q6F5.L[?B2Q?:I5#)M$]GJCV!DU]AN:PKGH60Q.8";$<;=VPU=$&ZD9N>
MXQC"]/$)R.1H)-$E)TFG9K-U=3/6'<S:"U8Q+*`EVO6R>RKEN*!KGE+&239&
MK+EE9*8=@QV!V8O>#F))!Y2](TKX@>!M@)#%"_;&UF;<.+@=)R[J\?#&/Y/Y
(/]GXN..?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g769326.jpg
<DESCRIPTION>G769326.JPG
<TEXT>
begin 644 g769326.jpg
M_]C_X``02D9)1@`!`0$!KP&O``#__@`\1$E32S$R,CI;,31:1$@Q+C$T6D1(
M,34R,#$N3U544%5473(V-34R7S%?5%))1TQ97TM?0D%2+D504__;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_```L(`0P!5P$!$0#_Q``?``$``@$$`P$`````
M````````"0H(`08'"P(#!`7_Q`!?$```!00!`0,%"0@,"`L)```#!`4&!P`!
M`@@)$0H2(1,4%3%X%AHY05&1F+?6(CA866&TT=<7&2-)4W%W@8B3R-(8,C54
M=':4MB0F*3=2EYFAL<'3-$)$1TAH@K+P_]H`"`$!```_`+_%*5\*F;%3TX\>
M`('%4<H4,&`$M.N3LH*0P(6681`C=1.)R?B<."8XERV1]0($<1A,+FSI0O80
M<.%:)^;6*'UI1O[O&^X9?\0Q_H;-TP0>XF,XW`TUR17FYHI263@$GX!-TP;9
MS><+M?;V),%)2R[L="&5/8EE4=V&2!O/S;\YY\V\;0O&>ZBG.47'V_-&F#?U
M=<*U%;+>!=TH\FA;G(+:-P$08[Y5F^V!0C0CO<)EBR0.J-7`JS!4$V[BUUQO
MJ*=A?]EY\S<?1DV=B6R^X[P"V6UZV^@72@[$2`\\3K6?4K;/XMM2A)QMB0E%
MN)QPC'JRV%I<<#H.KC.*N1MVCQ\IQ-OKPP#>,+V;.ENY[7V]39^22Z%FT).U
M8V1D_5J;VC@I77$DC(<:'"N>*\SET0@D'5]BO-MJB,Y&VI**$B*A?(VHH"JF
M`JB$<S&S3QSQROTM;/\`_(,3&WSY8VM_WUYTI2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*5\IXQB4*&#601@;`L'D8S"*%Q39H3`#]USP+E0,<QS(^6.-[!``X9BC
M9WQ##PRSRQQO3PCCBYVTF?B7YL-177$SGB*7]H][9YVEUW2'R;:Y$E(+94'E
M%DG1@1R64U>6$9`-O-2C$RU3Y1PGTDRV#*L1/KEB:=WS6.W-I>)7:K<-.Y,M
MBFM&KH:#GD9E<9J5KA$;]%06D]9/5=.6^R''.B>HD5)3N2:V9Q3++$>QH<7E
M9+2W6[D`ZK6/`Q^HM]X*^XI]XF-DIVD_<W>EN,9V$#KRY4N/O;6)H372R6@2
M<_8'TT:HS%D-;#;BNHE+(#E<P4DOM?8[-=*@@N=7(QV7+CI)-0=J"4,2W<8>
ME+XC@]R?RM,J(X&<2W_W=G.5V:RCAL9OO%(@=3)FF:QEU=]&&0UEEO![D#B\
MZ`4,4P5<K21CC8Q6BZ$[<59&2L-V7IA$FA?-3H0P=?'!.)5H2WJGNZMOQOR1
ML+,TQ):NK,+]B,FUCP1&3'FY2B:,F%U]2QQ]&@%<!<Q0Q1<,A@`A+6=*4]7K
MJ(F:^0D@N;E.'2&*9CA.#,X?2(V4=D9XF-=:N!I&>4S`FU*(=<($8CL<K92W
MQ-[Q;)`=\N9P+0JVUXU:IQJE;,Q]N9Z`)S=V1R8<@IS5-\:VZVH&U<#ZLR'+
M"<JN17V&VRA60)%A\9-0+DFNB,P\:8*[&+!9#XDMSGE)?`77>^6PUT)`8SA*
M@IHIQ=0`</W]HMIYFU]5^/2!),V%C:,3>T8D@-63=U$^*4T.-1I@9;1;+C8<
M4Q\V7DZW$QHW5I_'6'6?8R[)*^\DT-(C=0:R866'8[4M61\M]`YNE6?M?L'S
M+1!(,*9&3I@8S0DEO-U09+;GN,6!(R\THXG]N,185EU39R)+382R;E()8JTJ
MIA_`6[D:AXPS5YNYU\+OY+]!F(IKB0ZMM8-23C7D\C#;J[[X3C15J20H`HXH
M3:=2@G^=I[:%+B.%!(J:FN&B"&C*RREHJPJD%@\6(B<K1/M[K-.DBR%$L139
M'S_DB+"Q%0?#/;JZ$<64E(43IE+*KY<'+`()=;62P2.(8KF;@RPWRR\3-(9I
M3!5BXI+'9[;W\TR=CW9\<HFR,4F'C)(09F+$<RY0DO*7B(BT8;EU2'#ZN"02
MI=1P5XJ*D&UF-3[I2B2CY(J;.`"CE\1?`+8I*;[VVC?TEOUKL'7.`,&#'@SA
M<IU&248"10D3W:20NG'`9QQ,CEL2\CQ9'J.CAF,N^[TA?2B)4ZN'PRN$/3BY
M0YH="GSE.:$9B8#M9.A&H\-;!:^E#,0F$R[:?1N,-C7](<:RXC.(XD/964#1
MZ+FP05`U3)EJZ.DJ1,TEHJ:(/D;5YIM)WY($K:CZVRW*:\EN%_RY!\52JZ3J
M$W0&H@EEB16&WW@>2T)""/JHI%'2S*P*23\3RLJJ&8`.(AM0,"Y7O;*&E*4I
M2E*4I2E*4I2E*VL]GRRXU:B\^Y#=K:8C):R<.KN9X/%=2VRUVZDEK6N94UQ?
M6C1))24\"U[>6.'S8!?#KC:XG>RQM>+AI\\7$`]9`#C)`Y`-?!'4,HX)1?-5
M<*LVFH</"C8%P`4^0W,AH\>J%C(P@8988FZ!BQG//&P`PEK]:EI+&2YPN`;*
M#@F2ID((<N8+BX#`#@#88B@C`C!99ABA"A9X"!"AY9!B!Y8YX99896O?W^OU
MUXVQQQZ]W'&W7U]+6MU_CZ6\:UMCC:W2V-K6^2UK6MX^OPMX4[N-K=VV-K8_
M)TMT^;U4M:UK=+6M:UO5:UNEK?S6J$#9KX=KB_\`8_Y#OSJ"*G`I7CGCWL,L
M>O3O8Y8]?DZVO;K_`#56:DW6HS'+[YKH4EW5U^SLF\BM[RIK,]VI$2E*";(B
MJ[]>TB*LH0<CY2V\IH<)NF');:*>Z&JLRFXF:T4IM+J3(:`YBAA`<.23FT7?
M:5%^O<7<<>UVM&SFV[Q)Z2P^RY%<Z%KF[I6U[V2>1!B$V*^64-,@00\>M9XJ
M#@;QE95CTTJL;(Z606D=SW=>0N)@8EB\[M/7C&VI_&?IMN2T'-L?I@P83?L;
M;DH[):#TF4Q>5T5@MDOK($X4AA-Y>EM=B&/3`TC(R6\FBV@AT.2&_"KX<%D`
MBGES)'/OBECN>(HU<5HWF9U2<]6JT)GEQ"U=<<Z%%$C/)[4LDO`@0@',Y9<+
M$G$$\RB;BK$R-G.G(SH]PX#0NY4!N+-SB`F10SC#DI.76[M*Z"CP%-2HZ=F7
M^J80*F@09)(BQ-)8SJ1#T5-XW'P631L9=J43D]L.HB&I)OG*<CV!$<PQ@FBJ
M156-Y(.2/5D;D4AMYJT2RZ3@M.X0YN@MZ.Q.8;F8360G8Y9!A5[ID8F9`<"6
MWV4Q7C=ALUXF28#D7$,FTCY$,FLF48\*"6$PQT=?L?M=1XNU/8M(VU9KBT0U
MC=NOL#MI?X\=I8L270\)KC:/V*VF/)<^K:"M0LY7<*QV`CQPP49CK15H3/+"
MF3=B*JDE559\?D\Y-P87V":>G>C<FMZ-7G+#F@K>J$=ZMQH;CI"R<,CO]"5E
MN0W],">Q&87&".2`Z8EDB2$!],QDELLU=9PBI&(H0&:JG)1.^&DPI\GS$\.T
M&.]CZR;5XMG;_C(@B,=>%QP:URNU3\P22W8+V89!AL)+776V2?95QC*\I-!/
M\P=+91SZ64+G3;CP1$PF1-'I--6MI'#&>GVF\)(NLVV2M.23#^KT'*K;=&K<
M^,%E,EUEF2RV6]'%(,F.Q@H[*0F)'&9%;6'0N%5TZ(?))5BC4`75!3303$P-
MKWO;K>W3U_-U\/7TO:][=+WM\5_"M:4I2E*4I2E*4I2E*5B#L=I-".W;J8QK
M99#O,<61V7-*2!KX\;8GH259!-G,/)23(+(M?!-DU?;J*&(A,E)?`2PTVE@L
M.1:)H)AQ*I-52,&=ZH`TGU5A@U)(G$=K1L+"383\Q)A36!#&MJ8[V$RR69,#
M!UD60[F4D%7HWD#'/`\N@(KM).%&3"8BDG(JUB5%P"D1UDUB8NIK.5XLB(ZO
M)T-`KPJM&T7*JJ?74.&TPZ4+X*S%CM16#A];3XYS6P3CB;C..GCJ>QQUE40&
MGFF,T)`;:#DG2E*5!_LU\.UQ?^Q_R'?G4$5.!2E:7QM?UVM?XO&WKM;QM:_R
MVM>_6UK_`!^/KI?'&_KM:_7IUZV]?3U=?EZ?%U]7Q4O:U_7\7C;\E_5UM?XO
M"][>'Q7O:M;6M;PM:UK>/A;P]=^M_GOXW_+6G2WCX6\?7X6\?X_EKCF7XECZ
M>(MD*%I6;P;LC25&:X6`_&T*?54K!>:3I31TA=2<E-#/)BRGV/)YD8#SQ+4"
M1\M?.PQ0T`-A@)CC!#^@\;Q0O(*VJRUM#.!=F*)17CYM[%;$R#,;58RHG!9@
M(ZLF(3C-X%W"O((.?5NN>0LWJYF^;QQ54=8)+.-E&LY>[CTMCTMW;6M:UNGA
M:UO5T_BZ6Z?)T\*T[N-K]>[;K>U[7OTMUZ7\;VZ_)>_C?Y;^-_&M>[CX?<V\
M/5X6\.GJZ5K2E*4I2E*4I:]K^-K];?+:E*4I2E*@<Y09QYJHKV#8:9Q7ZR1%
MLDRE.%[GY<*3,JHJ*C,YUA2`M%6J9;1M5FV'!1U5=1+*P*R4*W<`?F24F#FL
M4W,(KD;B7FN?^U@2]$<CQ=+7&OJ6UXM?[25&I)#D8SN9Q]Y(3`6,,"KT5&L1
M'W"<H9M=*-G)4$3@+-Q?'S'[OF:.H';%BV=TG"_7&V5KVO;+KEC>WJOCE>]\
M;V_)?&]KUY4O>UO&]^EOEO7C;*U[=>O3IXWM>U[7M;QM:][7M:_C>U^GAX]/
M"M>];IU^+\MKVOU^3I>W7K?K;I;IUOUMT]=J6O:]NMO_`#M?^*]K^-K_`"VO
MXU"!LU\.UQ?^Q_R'?G4$5.!2E*TOUO;POTOUMX].OA:]KWM_/;K;K\77K\50
MFN;3#FE4G(X5%L\UD>MIN*"\M'V^W#'&%"RZ.WD(ZJ&S2,@BK8\NE#"QFB)H
MQ5+R53)8`RI7*>>F0\!QQ+6_$_P(^<#\>-&__96PC^N:M@RKJ[S>QA&,C22)
MS:1RM81^PGF][H^'%Q"!#)6NT6RJN+%+\_O+YNQ&RCDFV)9'?-#=R>(]S-BA
MNX5BPO$6ET9\WFX&IFN6T@7,M',?8[`0XQ9:NQLN,N$'1[D;O9%`6;-^SDM*
M"!Z>LFX&,`+JMT)&N<RMD)Z-+8],;Y-_X$?.!^/&C?\`[*V$?US5IEI%S@WQ
MRM;G'CC&]\<K8Y6XK80ZXY7QO;'*ULIERQO?&][96ME:]K].E[7M>]JG`2BY
M\JF)Q94/X*JD7(DP%!3P)AI^"@>!+!!FSV!$(04(GB<,XBF<2H8@@9:PM@,,
M\\0[97^^E*4I2E*4I6"6\VV4D:B(<8/I"U^5)=B!:>)YOSY(J#)$?M9=U[9X
MZ/GDC282CQ]'T,:9B@*YG8-:9K4<28YBR.3.*":663/FZ6/'GPY;_P"T6SC,
MAB+9'9@FP!9I0NXUG8W?&SNC^.T%0FX9\J0S2C%GZ]!(B#)"R4"9)X@179`.
MM)AM\FL(0P)5/5\#P*F;GYI2E*4I4!O,[J/NI+R4K[&Z]<CL]:5QEK9KA)CP
M=L=P*@NMUN&8W&WLEA[C99HZ%(;%+%CI!NH8",E&L2CG5C6:F8#*)X>!'S55
MK"R(N.IE0EA*:/VN)PS\\""<Q7"%KRTC,A+SDDE2,+;>-J4=-YLDYJ,OE055
M8.YY*14MPL=!#5CUR"4]PV6E*BNH(_8S%\KY@AYY=>]GC;/+J'F%?O96[V74
M(3+(0*]LKWM<'/++(&]KA9997POE?W5'?RSN:5&;QN[DNB$IG;.ODIH<'.I0
M9TNNQSE&6F-)2!R)^6N3=IW(,)MN=>3KGFNR5L,4(VFO-;0#)`4,_@5$PI_6
MY-MC&MIIR6'F*Y)QU6D]#7.-76-<U1DUY22KS;JK)\@WLT-F9W9S@D,0\X&J
MUYM328J.SU%&7[N8N],3$HN!+:#P64M3=V3.R7()L!"\P[P:%,5ZOQ)BQ(Y?
MN-#7%AKI5UN(1VQW`NV;04)`FB+VN_QU,5X(Z,M*<6*B:D>16,E!O(DC.A)0
M#Z40LEER4SW$]M-(2\K\LD.O@9Z2"T-&M^9Z8$+%2X9YX/4I"]TX=ZMJ(D+,
MT.*N.LPSCY1=1&,34U`VI`HRNVV>6-XIB.E`E\0F;NRF;G<X?'JKINLNYFMN
M+(U(WK+"D-P=>'!`"FZ?='^P\9Q,L<HNJ2E[IR:+DD"%'$:)"V"2CIQ.+B9"
M9&\;X6EZ4I2E*Q^VQ^]>V._D&F/ZMG/6(/"K\$KQS>QU!'^XR;4G]*4I2E*4
MI6E[VM:][^JWR6O>_P#-:W6][W^*UK7O?XJ7O:WC>_3]-_5:WRWO\5K>-[^J
MM._:UK7^Z\?5;N9WOX?+CW>MOX[VM\7RVK6V5LO5U_GQRQ__`&M:L7MB=,M;
M-K7!"SKGV+$&2U[79[G9+AD9S"JAY'9S_-I5DH%T#-+T@&T78<3<`BAY)*O1
M#<*<EJQ$DK)Y0LI%@C6.)>AG$]!^FZ=!T@.TR7G3<:(H6=D"+&WBBE++)>\D
MQVYGX=>0"2\6P1=ZVA+@K?)V06N@K3G%<SE2D)`+D$U<))QC-.#E6K3K;KT^
M/IUZ?DIWK6Z^OPZ=?N<K^OY.EONOR]WKT^/I2U[7MUMU_GM?&_S96M?_`+JU
MI2E80[1,;><VYDN1-2]A8%:2*@LTXEN2!=DH25W?&SX6/21D_9UVE^.WXS).
MC)1!21,4@SG9)D5JV)E0SPC0R.7-#CPZ,B&M>M8)K([#;&\!+3C^1R2\27TW
M:S0QI,G=*'T]:,8X'C<DID=-A!CS8*/#1<?&ZQ@Y$?6)5.IOE!E#!S"FA!S@
MMD5I/%IOU!).ADN5!=S;4O+^CUYM*Z>NHQVY8<0L9L54TLR;)#Y%S(0I<S@&
M/D(7,!"EQ\0QPQ`\=R5C/N'JC%N[VM\G:P3+[H0F!*"<C`'U-I*@2*[&ZMM9
MS(KV9KM;"H8)*1,HX&B\FV@N1)]))BHCF3B8$36DI423!P@8PN>O#[KW-:9M
MH>V,=+[F&4-R65#[!DR6+A-)B.%M(,`&D];AX>-45I-X!L-U=:;W2R<AF%I9
M37.87W4$$35<!&.1268G?J+?$?KN\V).:8_EMWNB7-@MCHPVT>L^8EVFDOU(
MG:#[M<*&'`RTPJWQ6J@MZ.$YIE41):9M*6"2FCKKT+KYM3'=JD:ME7JEJ/'.
MI:#*I9FFE9PO&>IPD;8^;7^X<4X-<?TNRBH`G'`KYE$DF23$1!24\DE-=GMI
M-`\V06PC)Q4<TJJXBJMJ<=.S-O\`EVN+_P!C_D.^.]__`(J"/EJ<"E*4I2L?
MML?O7MCOY!IC^K9SUB#PJ_!*\<WL=01_N,FU)_2E*4I2E*57TY\9JEPWH?NX
MS8#=SKCA+@R#,WY.4O,\[Z)60%Y05FL98.O346BXX*@067LC*(KUEQ821@%5
MIQ?9LMTO<`],1!8;^ZMXMJY'>&Z$::"QNU=AW'&;&UE-;B[>VU<Q34^:Y#:!
MES&6%#VNK4?*H]HZ$CD@_EY"=COD56:KM1I(=;:;:/'C$648T[E44SS>@P5J
M+R9ZWZX25$LK3NR]6D9(?2@T6)!4JRSK`H#O(RN"-9U!2L<9+@:\CXNB+G"W
MW>W%!EJRR5))SO/.M0<.+@.62S1+W\-4;DVIJRZY)0W7+3F86P\^R_,,,@3)
M*TG3"Z6_K_DX,8_@LL7=DJNAV.3-,=T<L5(E>Q7)4$`"/2,=L'UQQPMCMB8>
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MXEUV.AUO!V-LLLN!PK[B<JBJK*FHJ"@;&$S%-GA,2X/D213`N1+%BP,H-*4K
M'S;-%<KCU=V+;[-;QMVNM=@R649NM5.L5NI.585F$OIQ%!2\3U\"`BLKBF;$
M$D)0%`3QE,P4!/&"Y3,8;"A/$\Z1:R]7.1A$T,='.),+37M,I;U^GI*VZ999
M_)$2;#N-NH#`UY2T`G&=SCLCZ2`LPGNP7J(63SK6065F`&X3*3@EM8WG9%[/
MJFQZU8+5(VB%C*T<MF*8'TPCV>6<;8KJCT)!W];\2N4#<!+<""YDM'RSE,CA
ME$!>5SY4H(*:<N!?TH<-J`8HEK"U*4I4'^S7P[7%_P"Q_P`AWYU!%3@4I2E*
M5C]MC]Z]L=_(-,?U;.>L0>%7X)7CF]CJ"/\`<9-J3^E*4I2E*5I>UKVO:]NM
MKVO:]OEM?PO:H.>2;@XU3W.AS:0U&\-Q0S-N9[15`XD3DZ3C]!+$)%.&$##W
M7KQ9"4E0#,;)+1`R(PI)L&LQ,<"V.983`.][<HY<?[LUCV=B?9+1IJQ-9N-[
M4I/TPD3761'H\8_:YJ/F3(!R3X>?;!D9)94M+*8Z&&YG`\4)P(+B;2H1=S-<
MX619825IK)P:IO)FZ-R7"O')(VID.OEJ!39*9*<E-Q2>:!7&LUDB1=J9+=;X
ME]X-)-(XN%62"#(QDATWBI$$\N/E9MM(BN*`(YE45@I%6`Q6Q&##9D:LA*+H
M3,CYIMQC-!$*V[I5&:[21B3?;Z46QZ6MB`GI">3*!8VM:UL`;6MTM4-TB\>.
MR;R2^<1/)*4(E<^4-G);.B`4T]GW?&/P2NJ*1JN94Y*L%%(F6`MB25:0"Y!J
MV<6.9D;)I"'@L,,7+E^RZ==)6@.6M6-R)%5(G(0WH;QJ3I#<U73%*0GB[CQX
M\VXE=CC=;)8Z;'!+W8-UO`0-D&40AG`@NAV!.3,N53TPZG@@*<8^AC@<L4_X
M$BBVVGQR[/9-4CDPX)$@3D+E9^R(PP]D%`D')#SA;4Y1B%P1Q&+=;Y14S4I9
M;Z3**DG1##C>>;8CIV)S33,&PNR[;*\?$DREI;`,61G(S40-G]89HA;;F.7R
M]`%]7B]Y;.1<\5&1G9C(A=)"*NG*/I:<[K?Z>N'DHKFO()1SEUTJE*9M)LD&
M^+4C3S>UT;#[H;%2*0U1;9C:K16-]8$>-V;)DNN4%EO5B"3'F&JJDAK,.-OT
MPUQ!Y<43HR@3CXFK&0"Q%(+()<0@;7%K<FL6O')/K=I+K_ILV`-.T=1B&)8S
MA`U/127IJ<*P1;S:Q36\YY`:\6G-=6ZFFWH&T0U(ZS4!;D$!OE7C9+,KJB>0
MRYM.,S)@AW""#"[^8GD\,<+9B9Y9B9VPM;''(3/*]\LQ,L;6N)G>_7/.^67Q
MU[*4KA79)4EI$UYG99@,F@*,Y),.R8IPVGNLP1*-@]*9!EK1M@$W":4S9!,+
MHIET@I8*D,I'R*>$4S%S/G"I.PXX=$]L;0;[/)';[N4.U1:49*#G(HZZI1!9
M`8K'=5SRIYL<4X\Q+I49%G&V5ZYD4TV"UB"2`K$3OD,B14+/$O;'L%@\,<+9
M7QQMC?/++/*UK6M?O7]?>[OA?.UK6MEEUO?*]NM\KW\:]E*4I4'^S7P[7%_[
M'_(=^=014X%*J]\YW:%GEQ`;!Q)"3<U?;,YE)+AFTJF'`MRJLL(PD&,GVZ&?
M9&!3DUD.@(X#8)NXGO/<S0`EQ#60'F^.(.(@L(OOX64OQ>,?_20=7ZH:>_A9
M2_%XQ_\`20=7ZH:>_A92_%XQ_P#20=7ZH:>_A92_%XQ_])!U?JAK8LH=M-DN
M38UD..#6@+$22[_8CQ9(JJ!L2YC8R9@[6TJ-ZZD&5%B0(,UF0])>>6*YC`6,
MW!\AYP7N)Y</B;3GM?,B:AZJZ\ZO)NC3*?!&`HA8\3EGB>GMQ(1MS@,I&`1P
MELPBE8N4@$H4^&!B,(0#4E#`OG?+#`V+AW>F2?OX64OQ>,?_`$D'5^J&GOX6
M4OQ>,?\`TD'5^J&GOX64OQ>,?_20=7ZH:>_A92_%XQ_])!U?JAJ9?@^[1H].
M77:I^ZY.+59KP>29L$.28PG4BRTM/PT?,H+ZCUGXH.:2HL5L@EP#(3W%/Y*&
M)X40+-/#+XE1,3.8@-J>E*4I2E?'DHD<,LL,SA3'/#*^.6.1D#'+'+&_2^.6
M.0EKVO:]NE[7M:]K^%[5X^DT[_/B?^UE_P#U:>DT[_/B?^UE_P#U:T])IN>/
M@?)98WM>W6QLM>U[>J_2]A?_``KCIHQE"[`6UURL9@1DS'$Z!,AG*O--J-!M
MK+A%S%N/F*NJJ*GD3ZN)F-?RV>:B8,Y9"_NF5[Y_=5R-Z33O\^)_[67_`/5K
M[<<L<\<<L;VRQRM;+'+&]KXY8WMUM>U[7O:]KVOUM>U[VO;QM?I6M*4I6,.Z
M[5L_M.MLF'@V7`^!GAK1.C9Q8[153**['?=PQ>ZTH!KMM6)$U$XEKKC&'LD(
MQ\LG*`Q90,@BAD3MP\BPM#EAP#/R&U68BN/LF,>DW:CH382UN8R;T?A?,JNI
MQ5/*'I&`9Z<,86`A2IH`1RW02CG'/W,A9E0EG,3.P]NQ@PSPRZX8YXY986M?
M*ULL;Y6ME?+NYY6QZ=+"=W*]K]+6O>V5K?XM[6]E?(H*!%*(G%-3.%4Y.3RI
M@\?/GC`)0D2)%`<S!HX<-&,PP"Q4J7#$',F1Q`P0``Q!A<\`\,LK8,8<D>JU
MX(E7:O-W+X.K,4)GI$SL0.RW"#&$@W]-XM@("%S@I7!Q3$"IN<<@VFNNL%MK
M+3?*^I$$EB.)S'![AX>PWR.:NHT6RM)KJ=:RT1X2EINP%)T9KK=-Y2XVYQ>R
M@UDZ/8L#8J.*KF5]S2**^&@98YEL'EIM.!*70EHLX,$E-7#B5SSK_L9%^RK6
M=#FC)7,&A&!)+YAJ2FTK%;)KJC:6XT5?0SYCIYI.(YH-.<2":S*F;9%#B@CK
M:&I(SG;:LLMI<2%8[%ILS>U^=KB_Z7_^C_D._.H(J<"E=:-VV/[_`&U4]D`+
MZ[9.JF!2E*4I2E*M^]BT^$^G+V()%^NN`J[/NE*4I2G_`/?-4.\F<`G$+,<C
MOZ6Y*TL93ID23WDY)`?;F-/R:"9IPO!WJYI=<:V8*)<ED$PL.J*QTT<%+IY(
MF2"S&RP+%0`;8!X['][>\)_X!S#_`.L6=OUK5\I[LX/"D"2-BAZ'L3$0,J9S
MPRM(DZ]<<\`!,L,K=95O;[G*UK^-O'ITJ+#A!X0N+/:OBRU$V`V`U&:<DS!(
M[0>JB]GNJOB7D]07SR5+DAMP@8,DT"0TA(!S+(B,F)^%B:<6QR"*!YB8YBY"
M"9RL^]O>$_\``.8?_6+.WZUJTR[-YPGY8Y8WT.8G3/'+#+I(T\8W[N>-\<K6
MRQE>V6-[XWO:V6-[96]=KVOTO4R[%9+6C1DL^.6.D`H#+8+6;S*:"$7'-F0$
M5KM5()H+?20#!\P;/#@IJ2GDR88QTT9-BX`8B&3`PV68F6ZJ4I2L%=RM8)KE
M\NBR7J?LFKZK[,LA*/(S?>0S00I,BF0VJ>-A*!F.9QBQP@Y%76V<3P8Y]JN9
M!/(C\C=:4E94:ZN,G+CG;;BB<16)VI1;>`S2<LP\2C&8V(MBXLM-J.IH=CG#
M(@YE[65D5@*P1$D;6AP^^)=+6ADQ*Q&L8"L=+X>:C5-QJ[K\KP`P3":^I=>>
MPDQ.]3NZ9?G60"#>1'#(3O%*`$;9)C3:)!,:,>,)N)Y<!#8,;M,B"B-5"`M<
MP977,I.1T+V2M1$<\S.G20.(K>5GZY)B\N2BMQ#@7!0FL6.G7(O,0!WM@Y+B
M$AIR<&,>55!9BDL\D[!()@#G%<`P83"8`QHV$%G5[V2OLU/FH'(?">OCLDG8
M+0+6M`XF)Q@\^*7P=GN23DQ"CMY3]#3#<K>12(CI;D4MSS*075'@F2TI1($T
M"25YHEJ)RY`_NG:J`IJDG8/D#W)CZZ@X-5TSFYXHI*,N]`%&4VBX8ZU\8AME
MS;)J*9("#`.!CQNZ)48I9U.Q'!44`A[G7,<-*6`#%7!4R<GAXBN4A75S-2HF
M+I]HL'93DHV,7-='X$0*+:4K$$-+NQ3DS,P@HWS0W2VAW<"$31U+]T1'8*Q3
M%@3!Y%\V-"XXLV!-M8*YP^/4EM9O8O[OJ:_J1O6*SU==UYAR`,F`62_V'@UX
MF6)1$`$`Y<7,;/)YP0POB&#*19)"*$!?(&1\;6EZ5UHW;8_O]M5/9`"^NV3J
MI@4I2E*4I2K?O8M/A/IR]B"1?KK@*NS[I2E*4I2E?"I_Y./?Z&;_`#<6H3>S
M>_`GZ'?ZAR+]>TK5.!2E*4I2N(M@);)0%!4RSDI(2FZ$Z'(L?\HGVXC"EBZL
MO$V$U55T&$=/,GLL"!0VHA)>10(ZH"!)Y&XMSAX4,J`-G:OBG\Z;QA+7'9:9
M]S5O2%)D:,9@A+&'X)ULG#]EH_+4/2ZU(W<]V@RGOZ>RRDB9$5/=CB.CNAIM
M`&.+"H)8$P2+-TT8=92S0'G83#'.W7IEC;*W>QSPRZ96MECWL!,<<\,N[>W>
MPSQMEA?KCE;K:O.M+VM>W2_Z/FO;QM>WQ7MXVOXVKT@E2Q8.X1<`(`++,42X
M8&&(6'E!A,AAA.Z';'&P@PN>8HN=K6S$%RR$SOEGE?*_@"1)ERN)(`J7!)XA
MW"P*@@AA%L`KVO:X6`&&.(6`5[996N%CA8.]LLK7QO;++K[0``2H(1<N$&`7
M`#P"!`!PQ#"!"#QM@&$$'A;'`,(/#''`,/#''###&V.&-L;6M:$39KX=KB_]
MC_D._.H(J<"E=:-VV/[_`&U4]D`+Z[9.JF!2E*4I2E*M^]BT^$^G+V()%^NN
M`J[/NE*4I2E*5\*G_DX]_H9O\W%J$WLWOP)^AW^H<B_7M*U3@4I2E*4J$OE(
MY--HM(WRTF/`?&;*6][378H<DBR@[F.[%AM-R+TM-7#2($FN_,O$S_1;$EA+
M(K2L(9559*[J>FG;7(&B81HT7JH-YX1W%,E-[<4CV1F2(G6@G6RWDF2<Y9$G
M%5AZ/SKC<R`$D/@E!ZG$21%J3Z',*)-50BA9%;9!(5L21HL80<L//"W8P!Y6
MRPME:W2V76]K7QRQOTO>]_NL<[8Y8Y^/W>.5K98Y]ZV5K7M>O.E*4J#_`&:^
M':XO_8_Y#OSJ"*G`I76C=MC^_P!M5/9`"^NV3JI@4I2E*4I2K?O8M/A/IR]B
M"1?KK@*NS[I2E*4I2E?"I_Y./?Z&;_-Q:A-[-[\"?H=_J'(OU[2M4X%*4I2E
M*CVW2VCT>01')I-M#+@31<NQ6LVPSN'9"82>=W:JP6PH]=!^8'0A+;70%0%%
M56ZT$QT+:"%YZ`Y5(PW%0RU$U6-(IL(*DD7V:U0DYV`1=,W:F=M)XU'<QI*;
MJWKX#JWLJUYEEAFFS10F'%;OE\XWK)@@3N+BV;KN<JD6%!<1$Z;NMI*>`=-"
M)_8Y`AX!!8!AX]T,/'$/##_H8X6MACA\?6V&.-L;7ZWZVMUOEE?QO[*4I2H/
M]FOAVN+_`-C_`)#OSJ"*G`I76C=MC^_VU4]D`+Z[9.JF!2E*4I2E*M^]BT^$
M^G+V()%^NN`J[/NE*4K'^<]L-7]8O<S_`(1^Q4'P)[M+J]F?^S)*;*C7W4W;
M]DZZ[9O>[!:2/3-T:RNE75/1_G'F%E(C<UY+SL#OX_\`[:]Q@?C$M(?I2PK]
MLZ?MKW&!^,2TA^E+"OVSI^VO<8'XQ+2'Z4L*_;.G[:]Q@?C$M(?I2PK]LZ^-
M0Y7.,(0B=PPY$=(LL\BAJV...TD*WRRRN7%MCCC;W9];Y97Z8XXVZY997MCC
M:^5[6O$+P#\B&@\-<0NE4;2WNOJA&4AMADOTNY6*_M@HJ:3P;QDW-4FJ10LN
M-M<=))723!E..$U`N`?*%Q1B!PH<#PR+&0!1)AOVU[C`_&):0_2EA7[9T_;7
MN,#\8EI#]*6%?MG3]M>XP/QB6D/TI85^V=/VU[C`_&):0_2EA7[9UR/$^_VC
M$\/A,C*$MQ]7I>D9:*JAU(8<9SO&3X>*H31"0BDLFT]MMMRJ2N<+)2>$*>41
MBY00,D3#S,F,@PL<L[9<TI6(FZ3-8^>OD^2LHMJ&L)`C[6C8,LTI*EV.@GTC
M,A'6(V6S+E+K^"6EGWL9CA6#3"@DB-1K"9&'8A$1$_).5!_-BHE774?EL[.N
ML:V0BB[(I.H*SM(88#40Y5(LSCC.LT)9EL0H5)JH+-]S\+FV^EE#:^.&4;J^
M0<2&G9]PNX?-F8`)=,1KH>'3NX]+7MX=.E[];VO;PO:]^M^]>U^O7+K?K?K?
MK?KUOY5LJ1I#:$3L5U20_EH!OL]F(AY?<"L.$9,^:IY`*X@F)8B2!,*"HHFA
M/)DDE'3"QM5650R224LH:43I4L+5CD;F]VNCF#>7.4W8QVFS'[`.W&O.JVJT
M7+:837BL;#S4@-4H&M2D?1_1YEUNQ()*ZO(CK;8RODC$'4G91RE*^2&%BJF]
MWS9S1S'![JVYU#]+$7+.44\D^DVE43S8O--"N>RC/=%'*O;)[O)H-].0F(MR
M'&;>:<L(B0934EMM9;/Y,%46FB9L1<!-?E`XY=[%N?S/(#&TSK*2$X-!MRYI
MU_4Y(4`DIMEW;$37QNYV!(;VN0*HS31W05;-U9&?9A"3T1M&335S=A-&;A-;
MNBIV$SFVIUCV@YSN-]0ULV)@[8$BTM1=^R[J.0I*[&E$LV#*V+"PR,6<(S)7
M%L-$,*P":?,)H"GD5&/%R9D<M@*"%GG:QW2NM&[;']_MJI[(`7UVR=5,"E*4
MI2E*5;][%I\)].7L02+]=<!5V?=*4I5`/MR%_@U?Z6GQ6_\`MXJ@)UO^3YK?
MHIUO^3YK?HIUO^3YK?HIUO\`D^:WZ*=;_D^:WZ*=?XOFM^BG6_Y/FM^BG6_Y
M/FM^BG6_Y/FM^BG6_P"3YK?HJR!V4*__`"UVN?J_YO\`8WXK6_\`D<\ODM7;
M;TI6/^V#O;<?ZO;%OAY,`25VBT(-E=RNF,`\@\,I$;J*Q%Y06V1D(,`:!"!=
M*87-(AH8<L8``*G1QQBXX0>8.=19/W=TGA'7'962MKX0X0'W,3(F6$\8$A#2
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MW)A9Z/<@WFT(159`3SR2S#P#*P*.20+1+0PCJX#N([7\;;;QD3>+:F7]E982
MTXL,JLMO)L@#72&M$B0:74U,..Y`:+-!L25W`M-Y$R=B^M.51P;B&C'""&2P
M`D+7^!X%YS^-4C!L*1)#))?U"W^%7B<41NS(Z*K8J2+"("6*KEV>BHP*D(F@
M'#8"?F<P&R)@F3`9:X6(XML[#E*ZT;ML?W^VJGL@!?7;)U4P*4I2E*4I5OWL
M6GPGTY>Q!(OUUP%79]TI2E4`^W(_O:W]+3^SQ5`.E*4I2E*59`[*%\-=KG_)
M_L;]1SRKMN*4KA;9"5A8*U\G&:P&L9?`\1Q%(\E@LPF+YN9=8S'9ZPY0FZ$9
M\@:L4NL9IN)$0W<J9Q*`C"&<BX^(5PLZ<?NOXD]/-961R%2W`W$2XN3<S(S<
M>#;@W2^1;38R'@869A1\$(I#D:(S_=[=:4B6C0X"M%9)3&Z,TV=)18%PDQ12
M9O!,%O`A9V$#P$MCEA;/&V=L<\<L,\;96[UK9X9VME@):U^@F&5K98YVRQOX
MVO7LI2E*@_V:^':XO_8_Y#OSJ"*G`I76C=MC^_VU4]D`+Z[9.JF!2E*4I2E*
MM^]BT^$^G+V()%^NN`J[/NE*4J@'VY'][6_I:?V>*H!TI2E*4I2K('90OAKM
M<_Y/]C?J.>5=MQ2E;!E50<Z3&$C*C)%:`+R36([C[2'D$X*GL(%S$V^H&$$5
M[GR^6(Y)H!JH93-S&P,L1RR)8\,#?RN&%53`75V?O2?==BA[-ZZ:-Q-NFL.@
MFIH;JUH65_8Z,FW)80Q<0J=-Q6VD6Q_7EXCN(0(VU@5N&RUR1R^*FG.[,R!D
MIU;`8LA,634`)T1X[FZ]&\*8')V6&RKD5DB&?*]RQU.,CD1AK$U0@()B$HI9
MRP"BGCWN`>*EQK7PK>-*4I4'^S7P[7%_['_(=^=014X%*ZT;ML?W^VJGL@!?
M7;)U4P*4I2E*4I5OWL6GPGTY>Q!(OUUP%79]TI2E4`^W(_O:W]+3^SQ5`.E*
M4I2E*59`[*%\-=KG_)_L;]1SRKMN*4K&[<@@@*VHVTB4Z_27N74]<YP3W)=&
M/$$M7L@'(O=1=9NEJ:J24DM.4O1HAFQ`^I)Y]/)F[@F3I(V6"%+BUA.+':SA
M+U;A/8I]:O:,3'KY*FL6K#HV4<RYL'$IW&;YU8#$:R,:?QV)YH=YA:5UE)(.
M=;;C<6$TH!&Z,&8<J*Y2S')(!@Q=.E"X6'H<FA*V)VF?K>GJ/ICW%4(8VC4X
MKE^;FI.+194&RHR%L[KGG"ZTTF-'@:`QS+8)N5OF6XZFT"^D)3:/N?7%%<3D
M9"6E"<JOSEA826\DJB^O*:>BH:(G'5=9658Z634I)2DTL*<45-343HH!,@GD
M"@(QHZ=-C@E2I8(4<P*&$'GG;B*/-E]=)<C9:F2*IYAJ2HC;=EB[AE%AR<RG
M;'B%BWBOGR_DLO-"6SS=2L44E>QU5R4%$MBGD[XFS5PBV6(N7ZR?/$*JT<*,
MP)TL1V<BM'Q4;J\B@O%`NRTFZ0;]'JN"JY,C^*4FC)I__@)\N>-`&"AV^)0<
M+`QG@'EO!EO=GR,V4QYL)SH+R::UB9S27&V58BMHJA8D=,II[$JHIPY@J**1
M4B9Q-/@6$\N1429L@<#`.%1P0X9]FOAVN+_V/^0[\Z@BIP*5UHW;8_O]M5/9
M`"^NV3JI@4I2E*4I2K?O8M/A/IR]B"1?KK@*NS[I2E*H!]N1_>UOZ6G]GBJ`
M=*4I2E*4JR!V4+X:[7/^3_8WZCGE7;<4I4?.Y^UFF+5&<&F&Q,WBQR^Y]UKV
M"?:>WF^2=N;XM$$<,%S*THOQKK+?;BT11W`SFTD.)RMD`<Q@OJAUK*([:25D
M9%.@!TESFW&LT^QM.,6;'=IBD:9W!)++<,"P1@D\?\GF$A*BJ71T9$DQ-DQF
MN6)6C9T25)C:3$-HI3E37TWAXT-W6%TH]CQ=?5RH%T?CJTEDC3=M.-O27,*#
M+N*,Q(,UWAPZ@,89BCH.M>L347FS$*<^R^:VM%'!*Y\P\W@LR`YT/%&;2B<.
M)X"$A)Q0G?#*2>N'=@&Q"[LAU_IFQ)!GJ<'E4`PXI0)2'<I>/A6<TA`G4KYO
MPNI9X(Z@RRP*-8VYTI=Q,-]61RYI/721]*,&B8]%792,(B8W'/RJ3[J&ZXV1
M&-N[N9I=(KNUDA9TM9:2=>-12TUDVHQU*0VXQE0RA1@ZMB':9.O)X1ED$%BU
M&<X$F.51/#S074G)6XMS'%/17<7D39;>*K.6NBMSY<,^;V+ERXUVN*=6XZ`4
MWH$?`Q%Q3A0E1V-37TRX[F"@WEE8!F9'!+#F"7?G4X=%R6R\E\Z)1&2,UYJM
MSE7V8-P\D+"D*DMX^_U!LI2R]6X46,L#@:,FGW)=IG%P8H1S`(JKA5ED4`VI
M'#]L^!FI)&[LB<XG'F/NCK1$VN"JF:D;VX,0C%D_"3L`ZB9S*'\W(9636;&9
M=FV,C&P$DL1+8>E\50,Z:&\Y+^9V!SM'TKK1NVQ_?[:J>R`%]=LG53`I2E*4
MI2E6_>Q:?"?3E[$$B_77`5=GW2E*50#[<C^]K?TM/[/%4`Z4I2E*4I5D#LH7
MPUVN?\G^QOU'/*NVXI2L0]TV<Q<]?I[E12;D,X2$P-:-A"S1DB7H[!?*.R4=
M7C9<,N8NO!I:6>>QJ.%8),*"2(U&KGD8=:$1$3\DY4'L7*YU=M1^6SLZZQK9
M"*+LBDZ@K.TAA@-1#E4BS..,ZS0EF6Q"A4FJ@LWW/PN;;Z64-KXX91NKY!Q(
M:=GW"[A\V9@`ETQ&NAX=.[CTM>WATZ7OUO:]O"]KWZW[U[7Z]<NM^M^M^M^O
M6_E7&TNP_&,]QVY(EF5CMV28S>)<H3=C%=R?@KMAR$B2@552Y%<21LK%50A@
MH$2AK,D<P%*#"%PO+@B8X]VN`XOX]M'86C^58IBC4Z`6!&DY)A=&F)AM>,&N
MEM.34HF14TTJGO="!(W3W$3+$5I5+``*((V`(:@;\E;#,;+*^_">I>MY**7E
M"5H<9!V,9&7S3ND%L+*7DO!OMY&SJ0I"/=YJRX.HK[H?(2BWFX?)/5;5CSJ3
MCC;;AE.5RHR`D9DN18OB:.87:N++B]H(S,;EUEP.0V02`,\1%9T.Y9..-VNM
M?430IE5<3L=CA43Z^Z72O'E)P.-;/&U5:4CQ\P*/E$'LU\.UQ?\`L?\`(=^=
M014X%*ZT;ML?W^VJGL@!?7;)U4P*4I2E*4I5OWL6GPGTY>Q!(OUUP%79]TI2
ME4`^W(_O:W]+3^SQ5`.E*4I2E*59`[*%\-=KG_)_L;]1SRKMN*4JMWRQ\CNK
M.CNZD6H6\TKSRFZZO_4Q\%TJ"HU2E%P1E*SO79(-M1X&9A;B**04'"GIS"$"
M14A$4%+%M'RZVM^ED\\8`3[!1\&.=3LSBL3$16;J$Q%QT*(824UD(MH5&+7$
M45TZ($00B`+AR2R>+>MFH#%,;+(9D`5(#PN>*Y^<E@,,KI&'^)C:]NE[6Z7M
M:]\K=ZWAE]UE]UEXVO\`=9?=9>O+QO>O.E*4J#_9KX=KB_\`8_Y#OSJ"*G`I
M76C=MC^_VU4]D`+Z[9.JF!2E*4I2E*M^]BT^$^G+V()%^NN`J[/NE*4J@'VY
M'][6_I:?V>*H!TI2E*4I2K('90OAKM<_Y/\`8WZCGE7;<4I6`$O:>J\E;DQ]
ML(H%H(?,6DH3/0S(482]$^#V<5_^/XSZ17I&KN-FC*6V5,GF:.)*TC*C<4B+
MB*"E!1#B<83"8MN;5/3G4Y833R2HZTP*,14B@Y$X#A#\=ELQ"YD/((7$,P6;
M8)DN);'*^01@N,$8+BVP&`%#&#PSQR1M:V-K8VZ]+6M:W6]\K^'RY97OEE?Y
M;WO>][^-[WO6M*4I4'^S7P[7%_['_(=^=014X%*ZT;ML?W^VJGL@!?7;)U4P
M*4I2E*4I5OWL6GPGTY>Q!(OUUP%79]TI2E4`^W(_O:W]+3^SQ5`.E*4I2E*5
M9`[*%\-=KG_)_L;]1SRKMN*4I2E*4K!_?W=1OZ-0RU9"/MS!Y/"4YPAO7"(V
M<86+MY/<<JS>\2C4;@2ROX)RN,D-Y`(767>XS91)4C^2(WCI1.)BJ!LMW?GT
M>W51-O2.Q;<,((32E;4K9F4-5IH;Q)0$54$P\HY-%ADYYLQ0,`%%(TRWXV5)
M+7DD%7(E%9%4KKC7.W4A$&RVJ82[,YVOSL\7]^F73_`^Y#K^.&=K_P#M4$_%
M?'KU\+^'3KZO#[K'K-]Y7'Y!/ZD7^Y3RN/R"?U(O]RNM)[;%>V6^NJE[=?O0
M`_7CEC?_`)[I.MZLK6O;U?';U>/JO:J8-*4I2E*4JWYV+6]K<GTY=>OWD$B^
MJU[^J:X#O\5K_)X?+?PMUO>UJ[/CRN/R"?U(O]RGE<?D$_J1?[E/*X_()_4B
M_P!RGE<?D$_J1?[E/*X_()_4B_W*H"]N/RME^UJ].]ZMM+^..6/QZ\V_]ZUO
M'P]7KZ=+^J]KWH"TI2E*4I2K'_90[].:W72_CX1_L;?PM>]_"#GE?U6M>]_X
MK6ZWOX6\:[;7RN/R"?U(O]RGE<?D$_J1?[E/*8_()_5"_P!RO92E*4J(OF1T
MUD;<&"-?C$3)V;C?>K6[.LVW">QRYU+35!_H,2.PT5?3313RX>3$8!Q"LAS+
MJTVP511(E%1:12B)F<*YJ@1@/;'&AHZ]XJ'Y+I1FI)5VB-R"[HSA,:`P[JX9
M%VM2#UTH99[!$<2@VE$QDVGVZ4<TLNLRFIJJ(IM`FJM]//C$'205B1#81CLZ
M'&H;7D=TFT;:(TYF\FJ*.A.(QNYM4*NHR6L8@8JZ<E*^<HW4$TBJV*E_29,B
M8+EC_D`O.@A?)!]W]SWOOQ[_`,-MY]/+;S];5/>^_'O_``VWGT\MO/UM5QB^
M>S&<2TG*!-6D>+YS?RHG$O1I!1>NVVR#L/D4[S@8WY@3.."0E$R6)>=&!S/F
MH`H9?S@84;R?E1,\LMD^]0N%'\'20/I&SC]LJ>]0N%'\'20/I&SC]LJ>]0N%
M'\'20/I&SC]LJ>]0N%'\'20/I&SC]LJX]EOLJ'$(F17):A'.M4AG9!)1Z^#;
M%*![!34?%,/,NUE<5JA!$C3TQ*G!<U_!.Q"*FN\4,"7Q!-!B%\Q`\N&-'.RR
M<:+MT\UF<VU>KTEH>R:["<?*DYI*A.$OMD\GRB>0BYAX%#C>1G@$D(IDNJYC
M`BIJ8``2)WP\B"#C;&]\LJ?>H7"C^#I('TC9Q^V5/>H7"C^#I('TC9Q^V5/>
MH7"C^#I('TC9Q^V5/>H7"C^#I('TC9Q^V5;R9'9AN(^-%4PNQU%4WL-:-D!4
MHTKLO;/8UJJAA,&'+FADX=00)!3C@Q$4R4*F!"8@V180<N`+F%<0$++#E+WO
MOQ[_`,-MY]/+;S];5/>^_'O_``VWGT\MO/UM4][[\>_\-MY]/+;S];5/>^_'
MO_#;>?3RV\_6U3WOOQ[_`,-MY]/+;S];5<>OOLSG%)*/HO\`9*CR?I!]">>>
MAO=QM_LL[O1/I'S?S_T9[HI&4O,//?-"OG?FGD?.?-B_E_*>1"[G'OO4+A1_
M!TD#Z1LX_;*GO4+A1_!TD#Z1LX_;*GO4+A1_!TD#Z1LX_;*GO4+A1_!TD#Z1
MLX_;*O09[*)PKXES&0&N<@W&L`/<&UMBYPRO<:P.=PK=V[SM:_[IW/"_AU]=
MLK=<;X-\9W9;M!GQHUKZZ=Z=6).;>UZLWG*+,:,IS/*;//DED&07>50\3+;:
M[PP0$O,1G`-L7$),##"&"$#-"XW-#F,\\Z_>H7"C^#I('TC9Q^V5/>H7"C^#
MI('TC9Q^V5/>H7"C^#I('TC9Q^V5/>H7"C^#I('TC9Q^V5;F:/9=N(%@+A9S
ML6'9D9CD)A&P"B^U-JMAFVME0#Q?,H=!+JR*_2*@`$<*BB%C081G#`P7$S!&
MQS"SRPOR][WWX]_X;;SZ>6WGZVJ>]]^/?^&V\^GEMY^MJON3>`?C_2CH"@4%
MVVN8+7$N'YQO5MJ:!ZB@"E\^^`8E<0+/]S&S[O>PO?'+IECTRQM>IKJ4I2E/
M7ZZ6M:UNEK6M:WJM;PM;^:E*4I2E*>OUUI:UK6M:UK6M;PM:UNEK6^2UK>JM
M:4I2E*4I2E*4I6EK6QM:V-K6M;U6M:UK6_BM;PK6E*4I2E*4I2E*4I2E*Q+W
MRF!_Z]:8;23_`!<,VL'[!<"RK,;:+/)#/.-K*JE&C*6GB"B+R4F+S84Q4Q9N
MD>C30Z<NIQTH&8N:+BYB!6!$KE1/SL;@K)F&4!P(>LLM*FQ7%1+._P`"J0^S
MWP@&]4)#C.+'Y()=G3PV#LPR*&Y(M=BPTT=H-Y>Q6(T=AA8<7F%ROE@2Q@W)
M9K#S.P<;T3U4V,W.?C48$O39K.I[*OEC1''LI/0-LQTU%PRB/N3[L=I$Y/>;
M6BAJF;D@E9U.,Z:3B`N9R^:F8P(G\B>9\P<F.C\$D&LKR5/K82D)V1BQIM*N
M%)370[6^APK)KM0V%'DPO59:*$N)[$BYY/5RHC:;[Z=XZ,WU!1-F+A'?-$I:
M-)V\E_>76%$F4/7L[+"<0DXW(;?A?'JA.0XT4J:WHPSTF,R(EI^@I&;"2I3<
MS!3S+P0(_5'(3<*ND^C\02EC:VBE5"+;BAYJVUMC$D6%]N7"QHQV&FS8B?X0
MB9+9\82\TXH?IZ(UHN$DMA)D%S^[&/\`"4%-NF`U01FF)*!75F^6.:*WPO+%
MR8LF,>\ANGTIRPBPNQYE2%E[NUS2TRF#E=%=*>TI.>4#9$\9H:<7/]20RC'D
M=QQE8\"*[4EG.!7-$BX*H:+8'"J$NC)N:E*4I2E*5M9\O1MQPRW=(3R5`41H
ML5L.!XNE9,XB9%TAN-=(.+JZJ&,0L<A,@4]*(&S8N.&-\\L`;XXVOE>UJA7T
M`W#WGY-H6<N[,2J4$P#K^ZG5)[?U0AR08N=4A/216RP5=29I9^3Y)"-*K9Q9
MHSI>:*KDRC3C1I&O<:G%,SIQ=?V5P2YGGS?_`'JEK1#C47-HW'%:<\=F4*)V
MJI&(<;7I17;N<I6;!5R2F%@;3\AE+]CN,$1*?[U<*]Y:]RK*:!HZ*:\L*'GG
MQ5MWO'L>2T?=7(SIL[]?AM;VUHXH[4-M,E&,7C(#PDAYC)XCK2&:,?:TS1T1
M83?2&L!9/<X@R4Y5S)U'LRI:Y#%#/E3?,7&!/6XNT$!PCLKL"IP.HQ]L1K/$
MLPMM'BB-GFP'!'TB.[)14'8SU<RY9<DPN\FI@WS3>';:T6(M92*GRBX"J@'0
MSB=YKBM.NZW)?KIR4Z9Q2\8UUF>.HF[DTR1"C,8;#P?AG9B,D5@M^SHM+KX=
MIU=LQUH"S8".OQVHC8;!I!:3<)F6H*KFUT`FZU;@^#.<)Y2%*^M[[<R,Q"NK
MNW&]^V.DC`3R*>JDWDPDV"$8L8B>7E9SCJ)LJY3TG+R<N%'JT[HJ0FMQ(=#3
MS;RAD>9Z\*^?KTYYL),GI]\>J^ZV4SOV-.5++D&*P(SD\HHMUPP\L:</@\1B
MM'=CS,*"^7>.4S,1*/V>*@*W4(%KOPPF#-\OBW+&DD3)W3'<_<I[<F>T>D>P
M#DTYE)D1/KZP9Q#=FM)A>0'3#+Y?3W/-@MKW)#8=\AN]?=2\00TE1<2B[BZ(
MV,$XGBV%5>26WG)#?:"3-S2E*4I2E*4I2E*4K$O?&'W]L-IAM)`$7@MK-^3I
M`LJ0XVC+Q7#K=:R4I26REEG!+:\J)B"YU,),1KJ_I(T`G(2@=.!E[E2X08@M
MA@\*=:^/Q[PAQ%&=)\6;"+=V*.Z;.;7)SNQCF\BS'?;_`#L6K,>)KZ7WF`P$
M%VJ*8>-*8"JH&EIHG%\B`&8`P*J1C`(4S$/(?"9R%.+3S5K4D@IZD&42*^.+
M8'5N0ELN]7FTG'E.+R6E,PP7$GR>APK>2Y!@\-+,D#8L-JJ@P&,*]LQW?(*`
M\Q6PU20N2<#<8&^6M,VZQ2ZUT74N8VJN<9NM.@FW4,2Y(#V#;35=.MZ>D%FG
M+L9K!>&W*')""%=+N?/L!90&<*HJIE1*@KI,-3).EN\X0UQ=RE$V_FT$DNJ-
M=:Y]UTV!VPCW>:/)(DISO(*7==YK;H"6"Z4U`B3%I*S2=*H7,I]QX>D`%_-H
MY'@8ES:D"OY8BH)C#C5W@[VF:#-T0@F:7-$B5'NI/(6_^1-V2#'KT<Z\NN]5
M5<!E:.H=;#=46:UQB)LDYU-0"?[O4U`JEET%/(&FI@N**L;3TG?6I/"+/,)2
M)QTLAXO=E#PEQL['[N3X@R,B.=6-OV=2NQBF&>B)MCLX=KDBS%/-H,ZI92^*
MH+RT1.9)Q9-99M:+.0XIMRT5CC;'''&WC;'&V-KW]?2UNGC7E2E*4I2ME22P
M&W*\>/N+GD5%/-"2&:Z&$ZR((^188ZVGBA'VXO%`C.%KYEQ3*4I&P0Q\+7R!
M$SQ%QME?#NWA8XWM0=\.,.`<M&V@AP1L7"['>,C*FN\]N*671&3G;C-?SC5'
MC9N39$9>*74(?5VRYUE8.%U.-'T?(NPB?"3Q"[*S+^D+Y?3?J.^=I)C\VG)2
M4$Z"VG!)YC-4W#LNNB/G&]GS)]KI\]8OMCE&[F$49#@::6U6JS"HDCNPV1(Y
MO?%1*EKK18T+%CK_`,5^]\.<1V[G%JMN*#G@@/HG.+#TI>1V57T(*RX?FPZK
M&2K6FWSF)A!4Q381]1/N`(5B@N\@L".`\AE<$HNEE5`WF-KQQ+M_'471^']F
MGC+R3*VI,#LF&CH^M6U^P,61JX3;/N0S&6Q4U@KD9A.\JHFD\,8KF\&P$IE4
M\01(%Q\VO>U]EX:_\P*WR5Y[(K-N/!+UGLX4*.&T8.KD]OC9B+=5DQQE'.]F
MO&A<9J->(422)Z6D9+/RLN'R:R/<@`V6V0<AQ+CAKYB8W0EP;O5@2GK3'CC6
MV0;U7U(WQVPW99"L26UH9^/M(G-#+!1)$2FV\TDN70%*-W$>617Z[,E\ZGN)
M";;8R;96RD[UPLR/R=;>%/8+7T]HPC(KGB173^*)N<D*IJ@XW6ONLRG3M)VW
M3F4E/7X686TWVXGK#!:$7-Y3,`R[Z!6UY667,`3LQPSZ,(8/!9UP%HE(+OWN
M8?)'L)$<+Z[3XT-9G?`+Y;>OS[47^F3B[7DYD!3-2*\G0>8,>CB-MH(Z":3F
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M&;%+0-DTA<E-_'#!HH4;#-NZ%1'9J$,9$&5W6ZE+).;22IET1U'D#`2#^7Z-
MYL?LF)(FI>]D00?%T?2Q+*CN3-VO^+"U+=$8Q*)Y0\^&#)PKK/GW>BN]%MDZ
MV)@E-L1176H$.MBD2)8`7N_1'7,EJLZ68_7N_BSVA=/:&E#2Y&DI-?1%$/KC
MQTS?5ET)MR>BD&<M.'`%Q8J:%BA+D;'3.#H2EMQM$B7]*W7;"%.?M2]^8SVM
M>+^B\BV'?&,N1W'\*2^N1N_/00JP+$VQ#1N\HI>B>IME56D$_B;*@J3<=R,5
M41E%FO)&/)1VQU'/-EQN+.<0<$*W>$$PPQOGB';+/*V.-Q,\K88AVROTQOGE
MG>V&.'7O997MCC:^5[6NP'"$N)C@)CGD%E;`7'&_>R#SOC;.V&>-NN6&=\<L
M<NYE:V?=RMEW>E[7OM!YR"TF"PG?)CF629%E,9K.5YN5>\K@,036ZT4H^M+Z
MB*.%EF'<%.3TPZ,8OCE>^%P,\,NF6-[6P$ECE)@6#H^T0<\GH;V;;ZY!I"@"
M.(8AG,!%'D1*5YV&;'?47J7]*`I20A1F4=*>(_U$N>.6!4<P$!!"6%H^2*"R
M6>4PZWM?*UKVZ];?'TM>]KWZ?]&U[7ZW]5NE^M[=*]`YXF5#L*9-%P`KB!`V
M%&&#"#N,.)B"`%;//+'&X@XN6(0.'7OBBY8AAVRSO;&X8\4`%!`&,@A#F;"W
M+@9B88C&/(8>5'\@#E>P@UP`OW0:P6.=P@^F8EL<;VO?"C6'?2+-J)RW*@!F
MM606R]=(I3;L32@>>)-L`-QR+;I2%I=2%6/SR$Z%Q04D3-,1#`QH1Q)384RP
M@H06:9E;$80/+UQN&Z(BN!234E0=:JA)!M4":C?&2O="M"@%1S11)2@U=224
MS%36+E\RJ3Z54TM.,&\L,!U$J!84P%LB"9QC/9*)F5-L/.0)UQV_DT=005?`
MJ;3S.`J>HG4-=1%E)4`2ZF@N9K.-+5VP[&VK%BJPVW,CJJ$K%"R@0,`X<MTI
M2E*4I2E*4I2JNNX>CJ7N-SYH#7G2%IA>NFCIXO5)DR$LHP,SLB%G-,A*8U]Q
M(#-=TD1^9;2"<=9)K72W&FHIQSX'+9I#?'L&(.E)Y8*)/DF@?:<EL%S+LID:
MY[.NH:5]P^**8H`'BN&)6>[7-QC'[5?168'FUW,R6^J-Q-)IBFK)J4[RR>HX
M+XRF9,W5DW,%.5SB?]'*KK%LD_-AN<R18NURV0=B\=?'%:\=.'2QH;F-8!4G
M@RU1J?LV/"#32"VQDM1<;6"+J7NW<K5\LI(Q896R.GRX"DHY&K%F\D;\@3KU
MFY`E%7E>()2@5^ZC;-DH1@&,]7)*([(>ZYVQ:J`PHE8OH"3W)BY7<EN@TG8F
M@D:*4A15EC(N(GDV\8!M<G7>>^K>PL@H7%0B/76_8ET)C/X)-N8QF=+68=E\
MZ11)QOK[*"?&D<2D4%;OFX4BF)#+%K,UE.X/);-N;-(.I"6,=,I!@6U)PNIT
MJHO%GH^WYM1Y!;LJ-B"&VU'FW941G&W9!0%1KG51""1G0ANXF0<B8>34PBGE
M`0%8F"/D0")BA>5+9@BYR?TI2E*5`(SDM40.:[E`QEA-=;D19*XVM87%"Z`U
MP5,=ZKT,L53E=IS$U(R-)8Z<J67PY17,LQ$M!52BF"XGHUCWG)(RII9FT7C(
MXRF\^XUF%'XBS&V4$:U[1:,[B0GL5IOMJ2GEFM1AS0MQH33M>_0J-L#T/MZ3
MA9&%,MYYJ2$XWRBAQZ$K*1=TE$%5+D'=C>[^.+;#<&,E8:.(Q?[648;[-1KY
MHXN(#S:KAC]8<.XC3E-*DQQZXI1=W$D`-774-+B\PEN0\2%-MM'6W8R"QY3P
M`7,#(,PG%K`LGK/([-VXAUHO=G0\7XY=&]6$D1^-%R,<ZZ)<;+0;;FDY*3D-
MS$$Q4%&B`=!+-!WFQB&!1/>*ZH-8L:'5T!R%$V)KENU4F^5=J>=-S-76V>)`
MP7-3])A-65EK0_*SD1G%.+1?D+9O50A0RB-XVAN"4FLE%US)45FA<ZZD%+]T
ME[&BA(PO>5VE)\-2U%A#FT,Y7V8U/A&4.+[1=UCSBB15,6*(XIR:[3B(&:U!
M87!B!`PZW@MJRTY&ELDOA*JK(J:UG)(:^Y`5,^E*983F?4"VM&QZINNU-49I
M@F37IOO)6B6MCEA+5`@_3*/JUJ8QV2UFQM?(YA?D.&877`VC-36CV0L'$:0&
M,DLLB]7#&2.N+1Y_NT/&_,?+1J#RR+^P^N<F,=E:QS&SS'+)JB_H:5V>U]DW
M+)D/1M$UGP##:3/1!!2QF7'VLL=677,X9=6&'Y$X;?;MS<^2KF*<)ETOY.0O
MB^VF?>Q'*;'\()S@38-G_6Z-^1F+7"V@CV0R'R`:_#/%IEX<8PQE,,EPAYL'
M$4W@\B(0^>61=31P2X802RI6R_9VBA[8<X\^-5Z[,Q9)2'KYM#%6U"QNZEP9
M"+TGU/A7<O;V-D`N@N60HJ;:$Y'0..RVGD##D=R%BU%BT<+:,L'0,TLPMG1E
M?\8;6*=!-YGE!^P[QWR$CY9URXVU/CXV+1X2M)\QIRYJ;B56Y`9[CEPBV7"P
M]=IJ><BV-KLZGW4>::%(;2/+0;X7@RUT*PW"]VGMK"/(KR#SFL:>R?.6ECFY
M5M>'1,L9%M=Y?<\A2W'Q6.I);C'G6"0R*6(ERO'^OLGV*O-_(+=1%\HNCEVM
M@<5@$/SK`;.G2Z,9AC[FMEEU(38=TX0)-#TV_D5:E*7H.DN(ISU)<QA1;"."
MT@Y@6DI-9NQNJ<TC)*"1US1`%UU"MM.;UAD1MQN=CMZ8.W-+@?2'6!#.]#O.
MBF!8IE#E>Y`)`UR$OW[I!B&#LMXH02DU^O4+%M+$B(#_`%%.L4RR)C##'3A>
M]K&LNLY5*4I2E*4I2E*4IT\>OC\]^GS>JM.[;KUZ>/\`'?Y[6Z]+7O\`'>WC
M?U7ITM^7Y[_IK7I\7_G?_P`?76G2WY?GO^FM:4I2E*5QZYXICYXO%A2&X6LF
M'GW&`R[FPWCB'F4<K:*NHF6(.M&(+1,0N?NW'65(IN+G;)@8=OKXR0AG%1-,
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M_IK\1QMY-=2"L-M7L=NEKR:=2%&R>J*2.>R(J``A4V&554@V15$T84N*(%B<
M33A0Z!;.^98R");'/'Y66RVC'+2;3"8+90F8R6<AIC::;3;"420VZVV\C%`B
M"2B(B.G`ER*8EII(`(J2)%`0@"X(>.&&%K6\=S4I2E*4I2E*4I2E*4I2E*5Q
MM)\R1%"2&6<\RRG',2MHZH!I)1PR:]VPPD(TJC!"C@IA=8=:HDIPR@,``.,"
M2#,Y&10@1A`PLL`L[X_:JRE&:$M,AMKDA,A&<,F"#!1RA*KK04]9?PI8C=3,
MA,I,-GPCKJ$+)MKJ)@-!`4,@"%KG1;8%;7&MORMFEI%C\X^E.,"CW:)F245O
M$':L1^7<B,.]DIJJAT1-3'(I-0([FO)Z"HJ((Q`@KG"`!`Z<!%+%3`PP0F&.
MR8^V/U\EE[/Z-8MG.'Y(D2*CN29)S$8<E,QWO&.E+`UF2S3WPVF^M*"RU3H9
MT,0F(67"9(8(X&(4%P#,X9!6YHI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6`W
M)-`D8[2ZS":[3,@Y.6+ICE^!F(]$@$T.GG14A8EQJ87-IBF4OB:2U9+-8%U-
M*4`<O^#*!,OD.$9*W'*CU^]''3N7IULPT^'+9`%\RHO:ZLV?9NX[-K$I`:ZT
M=E#6TM!$@LA`8=RCZ6F^VS$FQ:Z'.@-].0G0ZDM"3RV5V6XU=)8A-G.-8D.C
MES<J8S\C\)X@;RV:PKQ9V#KNX=7>)Q(1+-_-=3,7!==5&;ONXW6E)-DRYRZL
MH-%!<#C3R5C)ENHZPJ@DB)G'[3UJL&/NT5\Q!=&1FZQVN9U#U3=#E$3`RK83
M+&EIOH"H[7.J'RN1#`N>/B9FU9;<(Y@$X(8N85#9VQBPABWNC^+"FO':%(G<
M"!JY""%"NSW'W(\?ZU2OK6>-(1=';,,.9L2-)+EGMM);=3VZY%UU&'1'+1;+
ML*GU%*+H9UBX):TL*RDL%TFS52E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2N.I&
MC!@R@5;9-_MHFYRK4=R$^FX`>'/A!I#Q;!K$^W'(4L1-E>ZK(1_#`\DF\[YY
MD#F&!HMY,?#$2WW+L=,1R/!COY>::&K/6.;.?!B.DZ0!&7&F&\TH%&=@*(HW
MQ\Y)%G&F%2A18*AB>;'\"1',P%F*1*"`[V[MODM\5_5\GC:L7D_3O5M/DJ39
M;+P3'64F3.U3S&E][G$3%1<$I,D\FA)!AG2$>41363P:WHH`!-`;Z_B?229`
M$,H3*``88X6\M<M/]9=62`R?K[#30B\IZ/NAE@T()0,YI3<NIF5S%IH!A:/J
FAEMLT%:.&U@NS4`9-:Q94-#J`"0&<%R&OE!2E*4I2E*4I2E?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
